PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Reginato, MJ; Zhang, JS; Lazar, MA				Reginato, MJ; Zhang, JS; Lazar, MA			DNA-independent and DNA-dependent mechanisms regulate the differential heterodimerization of the isoforms of the thyroid hormone receptor with retinoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET GENE SPECIFICITY; AMINO-TERMINAL DOMAINS; NUCLEAR RECEPTOR; RESPONSE ELEMENT; BINDING DOMAIN; ACID RECEPTORS; ORPHAN RECEPTORS; ZINC FINGER; DEOXYRIBONUCLEIC-ACID; MONOMER-BINDING	Thyroid hormone receptors (TRs) require heterodimerization with retinoid X receptor (RXR) for maximum DNA binding affinity. Interaction with RXR occurs via two dimerization interfaces, one in the DNA-binding domain and one in the C-terminal ''ninth heptad'' of the receptors. We studied the relative importance of these two dimerization domains in naturally occurring C-terminal TR variants. TR alpha 1 has a conserved ninth heptad and formed stable heterodimers with RXR in solution. TR alpha 1 . RXR heterodimers bound similarly to direct repeat 4 (DR4) sites with different 5'-flanking and spacer sequences. In contrast, TR alpha 2, which contains a highly divergent ninth heptad, did not interact with RXR in solution and bound as a heterodimer with RXR only to specific DR4 sequences in which the downstream half-site was the preferred octameric binding site of TR (TNAGGTCA). Although the ninth heptad of TR alpha 2 was insufficient for interaction with RXR off DNA, this region was required for DNA-dependent heterodimerization with RXR. TR alpha 3, another naturally occurring TR alpha isoform whose ninth heptad differs from those of both TR alpha 1 and TR alpha 2, displayed intermediate behavior in heterodimerization with RXR. Thus, in the absence of a strong ninth heptad interaction an octameric downstream half-site allosterically promotes RXR heterodimerization with TR alpha 2. Differential dependence upon DNA-binding for heterodimerization with RXR may influence transcriptional regulation by TR alpha isoforms.	UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,DIV ENDOCRINOL DIABET & METAB,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Reginato, Mauricio/I-6155-2013; Lazar, Mitchell A/AAF-3738-2019	Reginato, Mauricio/0000-0002-7541-4094; Zhang, Jinsong/0000-0002-8798-7316	NIDDK NIH HHS [DK43806] Funding Source: Medline; NIGMS NIH HHS [GM15677] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043806, R37DK043806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM015677] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN HW, 1995, P NATL ACAD SCI USA, V92, P422, DOI 10.1073/pnas.92.2.422; DANIELSEN M, 1989, CELL, V57, P1131, DOI 10.1016/0092-8674(89)90050-0; DARLING DS, 1993, J BIOL CHEM, V268, P10221; DAVIS KD, 1994, MOL CELL BIOL, V14, P7105, DOI 10.1128/MCB.14.11.7105; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KATZ D, 1993, J BIOL CHEM, V268, P20904; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1990, MOL ENDOCRINOL, V4, P1627, DOI 10.1210/mend-4-11-1627; LAZAR MA, 1991, MOL CELL BIOL, V11, P5005, DOI 10.1128/MCB.11.10.5005; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; MITSUHASHI T, 1989, J BIOL CHEM, V264, P8900; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; ONATE SA, 1995, SCIENCE, V270, P1354; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; RASTINEJAD F, 1995, NATURE, V203, P375; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SHULEMOVICH K, 1995, NUCLEIC ACIDS RES, V23, P811, DOI 10.1093/nar/23.5.811; SJOBERG M, 1995, MOL CELL BIOL, V15, P4718; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILLS KN, 1991, MOL ENDOCRINOL, V5, P1109, DOI 10.1210/mend-5-8-1109; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WONG CW, 1995, MOL ENDOCRINOL, V9, P551, DOI 10.1210/me.9.5.551; YEN PM, 1994, ENDOCRINOLOGY, V134, P1075, DOI 10.1210/en.134.3.1075; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909	64	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28199	28205		10.1074/jbc.271.45.28199	http://dx.doi.org/10.1074/jbc.271.45.28199			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910436	hybrid			2022-12-27	WOS:A1996VU03300036
J	Simm, M; Pekarskaya, O; Volsky, DJ				Simm, M; Pekarskaya, O; Volsky, DJ			Synthesis of full-length viral DNA in CD4-positive membrane vesicles exposed to HIV-1 - A model for studies of early stages of the HIV-1 life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 REVERSE TRANSCRIPTION; ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; SOR GENE; T-CELLS; INFECTION; RNA; EXPRESSION; INVITRO	CD4-positive membrane vesicles (MV) were isolated under isotonic conditions from human T lymphoblastoid cells MT-2 and CEM and tested for their ability to support reverse transcription of viral RNA upon exposure to human immunodeficiency virus, type 1 (HIV-1), MV contained cytoplasms as confirmed by the presence of mitochondrial DNA but were devoid of chromosomal DNA. Virus binding and vesicle lysis assays revealed that 4-19% (depending upon virus dose) of MV-bound HIV-1 entered the vesicles, HIV-1 internalized in MV was able to initiate and complete viral DNA synthesis as determined by the detection of products of reverse transcription using polymerase chain reaction amplification of viral DNA using regions present in early (strong stop) transcripts and full-length double-stranded molecules, Viral DNA was undetectable in MV exposed to HIV-1 at 0 degrees C, in MV exposed to UV-inactivated virus at 37 degrees C, or after exposure to intact virus at 37 degrees C in the presence of reverse transcriptase inhibitors 2',3'-dideoxycytidine and a tetrahydroimidazo[4,5,1-jh](1,4)-benzodiazepin-2-(1H)-thione derivative, indicating that viral DNA detected in HIV-1-exposed MV was synthesized de novo. Kinetic studies revealed that HIV-1 DNA synthesis in MV was very rapid; full-length viral DNA was detected within 15 min of exposure at 37 degrees C, and the DNA levels increased 90-fold after 1 h and declined thereafter, Strong stop viral DNA was 10-fold more abundant than full-length DNA after 1 h at 37 degrees C, indicating that 10% of input viral genomes are fully transcribed in MV within this time frame, This system preserves the critical features of intact CD4-bearing cells to permit studies of HIV-1 entry, uncoating, and reverse transcription of viral RNA.	COLUMBIA UNIV, ST LUKES ROOSEVELT HOSP CTR, MOL VIROL LAB, NEW YORK, NY 10019 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10019 USA	Columbia University; Mount Sinai St. Luke's; Mount Sinai West; Columbia University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035466] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43628] Funding Source: Medline; NIAID NIH HHS [AI35466] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BALTIMORE D, 1970, NATURE, V226, P1209, DOI 10.1038/2261209a0; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BENZAIR AB, 1993, J VIROL METHODS, V45, P319, DOI 10.1016/0166-0934(93)90116-9; BORROTOESODA K, 1994, ANTIVIR RES, V23, P235, DOI 10.1016/0166-3542(94)90021-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIMITROV DS, 1991, AIDS RES HUM RETROV, V7, P799, DOI 10.1089/aid.1991.7.799; DREXLER HG, 1994, ATLAS HUMAN TUMOR CE, P213; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FOLKS TM, 1986, J EXP MED, V164, P280, DOI 10.1084/jem.164.1.280; GREWE C, 1990, J ACQ IMMUN DEF SYND, V3, P965; HAROUSE JM, 1991, J LEUKOCYTE BIOL, V49, P605, DOI 10.1002/jlb.49.6.605; HEINZINGER N, 1995, VIROLOGY, V206, P731, DOI 10.1016/S0042-6822(95)80097-2; HOGLUND S, 1994, VIROLOGY, V201, P349, DOI 10.1006/viro.1994.1300; INIS MA, 1990, PCR PROTOCOLS; JUNGHANS RP, 1975, P NATL ACAD SCI USA, V72, P4895, DOI 10.1073/pnas.72.12.4895; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KINNESAFFRAN E, 1989, METHOD ENZYMOL, V172, P3; LORI F, 1992, J VIROL, V66, P5067, DOI 10.1128/JVI.66.8.5067-5074.1992; LUCIW PA, 1992, RETROVIRIDAE, V1, P159; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MCCLURE MO, 1988, EMBO J, V7, P513, DOI 10.1002/j.1460-2075.1988.tb02839.x; MICHAELS FH, 1993, AIDS RES HUM RETROV, V9, P1025, DOI 10.1089/aid.1993.9.1025; MONNERON A, 1978, J CELL BIOL, V77, P211, DOI 10.1083/jcb.77.1.211; NAGY K, 1994, J VIROL, V68, P757, DOI 10.1128/JVI.68.2.757-765.1994; OBRIEN WA, 1994, J VIROL, V68, P1258, DOI 10.1128/JVI.68.2.1258-1263.1994; PAUWELS R, 1990, NATURE, V343, P470, DOI 10.1038/343470a0; PAUZA CD, 1988, J CELL BIOL, V107, P959, DOI 10.1083/jcb.107.3.959; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PELLEGRINO MG, 1991, J BIOL CHEM, V266, P1783; POTASH MJ, 1993, DNA CELL BIOL, V12, P685, DOI 10.1089/dna.1993.12.685; PURI A, 1992, J ACQ IMMUN DEF SYND, V5, P915; ROTHENBERG E, 1976, J VIROL, V17, P168, DOI 10.1128/JVI.17.1.168-174.1976; RUIZ MC, 1994, J VIROL, V68, P4009, DOI 10.1128/JVI.68.6.4009-4016.1994; SAID HM, 1993, P SOC EXP BIOL MED, V202, P428, DOI 10.3181/00379727-202-43554; SAKAI K, 1991, J VIROL, V65, P5765, DOI 10.1128/JVI.65.11.5765-5773.1991; SINANGIL F, 1988, FEBS LETT, V239, P88, DOI 10.1016/0014-5793(88)80551-9; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; STAMATATOS L, 1993, J GEN VIROL, V74, P1043, DOI 10.1099/0022-1317-74-6-1043; STEIN BS, 1987, CELL, V49, P659, DOI 10.1016/0092-8674(87)90542-3; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STREBEL K, 1987, NATURE, V328, P728, DOI 10.1038/328728a0; TEMIN HM, 1970, NATURE, V226, P1211, DOI 10.1038/2261211a0; TRONO D, 1992, J VIROL, V66, P4893, DOI 10.1128/JVI.66.8.4893-4900.1992; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VERMA IM, 1978, J VIROL, V26, P615, DOI 10.1128/JVI.26.3.615-629.1978; VOLSKY DJ, 1980, P NATL ACAD SCI-BIOL, V77, P5453, DOI 10.1073/pnas.77.9.5453; VOLSKY DJ, 1979, P NATL ACAD SCI USA, V76, P5440, DOI 10.1073/pnas.76.11.5440; WEBB NR, 1989, P NATL ACAD SCI USA, V86, P7731, DOI 10.1073/pnas.86.20.7731; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZHANG H, 1995, J VIROL, V69, P3675, DOI 10.1128/JVI.69.6.3675-3682.1995	51	5	5	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28266	28270		10.1074/jbc.271.45.28266	http://dx.doi.org/10.1074/jbc.271.45.28266			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910445	hybrid			2022-12-27	WOS:A1996VU03300045
J	Wang, ZG; Kiehn, J; Yang, Q; Brown, AM; Wible, BA				Wang, ZG; Kiehn, J; Yang, Q; Brown, AM; Wible, BA			Comparison of binding and block produced by alternatively spliced Kv beta 1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL BETA-SUBUNIT; HETEROMULTIMERIC K+ CHANNELS; FUNCTIONAL EXPRESSION; POTASSIUM CHANNELS; RAT-BRAIN; INACTIVATION	Voltage-gated K+ (Kv) channels consist of alpha subunits complexed with cytoplasmic Kv beta subunits. Kv beta 1 subunits enhance the inactivation of currents expressed by the Kv1 alpha subunit subfamily. Binding has been demonstrated between the C terminus of Kv beta 1.1 and a conserved segment of the N terminus of Kv1.4, Kv1.5, and Shaher alpha subunits. Here we have examined the interaction and functional properties of two alternatively spliced human Kv beta subunits, 1.2 and 1.3, with Kv alpha subunits 1.1, 1.2, 1.4, and 1.5. In the yeast two hybrid assay, we found that both Kv beta subunits interact specifically through their conserved C-terminal domains with the N termini of each Kv alpha subunit. In functional experiments, we found differences in modulation of Kv1 alpha subunit currents that we attribute to the unique N-terminal domains of the two Kv beta subunits. Both Kv beta subunits act as open channel blockers at physiological membrane potentials, but hKv beta 1.2 is a more potent blocker than hKv beta 1.3 of Kv1.1, Kv1.2, Kv1.4, and Kv1.5. Moreover, hKv beta 1.2 is sensitive to redox conditions, whereas hKv beta 1.3 is not. We suggest that different Kv beta subunits extend the range over which distinct Kv1 alpha subunits are modulated and may provide a variable mechanism for adjusting K+ currents in response to alterations in cellular conditions.	METROHLTH MED CTR, RAMMELKAMP CTR RES, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, DEPT BIOCHEM, CLEVELAND, OH 44109 USA	MetroHealth System; Case Western Reserve University			Wang, Zhiguo/GRS-4339-2022	Wang, Zhiguo/0000-0002-0811-2045	NHLBI NIH HHS [HL36030] Funding Source: Medline; NINDS NIH HHS [NS23877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023877] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KIEHN J, 1995, CIRC RES, V77, P1151, DOI 10.1161/01.RES.77.6.1151; KIRSCH GE, 1992, NEURON, V8, P499, DOI 10.1016/0896-6273(92)90278-L; KOLB HA, 1990, REV PHYSIOL BIOCH P, V115, P51; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	23	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28311	28317		10.1074/jbc.271.45.28311	http://dx.doi.org/10.1074/jbc.271.45.28311			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910452	hybrid			2022-12-27	WOS:A1996VU03300052
J	Marcus, SL; Winrow, CJ; Capone, JP; Rachubinski, RA				Marcus, SL; Winrow, CJ; Capone, JP; Rachubinski, RA			A p56(lck) ligand serves as a coactivator of an orphan nuclear hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; THYROID-HORMONE; COUP-TF; X-RECEPTOR; TRANSCRIPTIONAL ACTIVATION; PROTEIN; SUPERFAMILY; REPRESSOR; PROMOTER; GENE	Chicken ovalbumin upstream promoter transcription factor II (COUP-TFII), an orphan member of the nuclear hormone receptor superfamily, acts as a transcriptional repressor by antagonizing the functions of other nuclear hormone receptors and by actively silencing transcription. However, in certain contexts, COUP-TFII stimulates transcription directly. A cellular factor, isolated by interaction cloning, bound COUP-TFII in vitro and allowed COUP-TFII to function as a transcriptional activator in mammalian cells. This factor is identical to a recently described ligand of the tyrosine kinase signaling molecule p56(lch), suggesting that it mediates cross-talk between mitogenic and nuclear hormone receptor signal transduction pathways.	UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA; MCMASTER UNIV,DEPT BIOCHEM,HAMILTON,ON L8N 3Z5,CANADA	University of Alberta; McMaster University			Winrow, Christopher/K-1864-2014	Winrow, Christopher/0000-0001-8248-4157				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Ausubel FM, 1988, MOL REPROD DEV; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BEGEMANN G, 1995, DEVELOPMENT, V121, P225; BURRIS TP, 1995, P NATL ACAD SCI USA, V92, P9525, DOI 10.1073/pnas.92.21.9525; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Devergne O, 1996, J VIROL, V70, P1143, DOI 10.1128/JVI.70.2.1143-1153.1996; GAUDET F, 1995, J BIOL CHEM, V270, P29916; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ING NH, 1992, J BIOL CHEM, V267, P17617; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRAMER S, 1995, DEVELOPMENT, V121, P1361; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Leng X, 1996, MOL CELL BIOL, V16, P2332; LU XP, 1994, MOL ENDOCRINOL, V8, P1744; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marcus SL, 1996, MOL CELL ENDOCRINOL, V120, P31, DOI 10.1016/0303-7207(96)03813-0; MARCUS SL, 1993, P NATL ACAD SCI USA, V90, P5723, DOI 10.1073/pnas.90.12.5723; Miyata KS, 1996, J BIOL CHEM, V271, P9189, DOI 10.1074/jbc.271.16.9189; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; ONATE SA, 1995, SCIENCE, V270, P1354; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Power SC, 1996, MOL CELL BIOL, V16, P778; QUI Y, 1996, J STEROID BIOCHEM, V56, P81; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Wayne ML, 1996, MOL BIOL EVOL, V13, P191, DOI 10.1093/oxfordjournals.molbev.a025555; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	41	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27197	27200		10.1074/jbc.271.44.27197	http://dx.doi.org/10.1074/jbc.271.44.27197			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910285	hybrid			2022-12-27	WOS:A1996VQ67900003
J	Thyagarajan, B; Padua, RA; Campbell, C				Thyagarajan, B; Padua, RA; Campbell, C			Mammalian mitochondria possess homologous DNA recombination activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; STRAND-BREAK REPAIR; HUMAN CELL-EXTRACTS; MOUSE L-CELLS; SACCHAROMYCES-CEREVISIAE; GENETIC-RECOMBINATION; MULTIPLE DELETIONS; ANTICANCER AGENTS; ATP HYDROLYSIS; RINR-38 CELLS	Mitochondrial protein extracts from normal and immortalized mammalian somatic cells catalyze homologous recombination of plasmid DNA substrates, Mitochondrial homologous recombination activity required exogenous adenosine triphosphate, although substantial activity remained when non-hydrolyzable analogs were used instead, There was no requirement for added nucleoside triphosphates, and the reaction was not inhibited by dideoxyadenosine triphosphate or aphidicolin, The majority of recombinant plasmid molecules result from a conservative process, indicating that nuclease-mediated strand-annealing is not responsible for the mitochondrial homologous recombination activity. Affinity-purified anti-recA antibodies inhibited the reaction, suggesting that activity is dependent on a mammalian mitochondrial homolog of the bacterial strand-transferase protein, The presence of homologous recombination activity within mammalian mitochondrial extracts suggests that this process is involved in mitochondrial DNA repair.	UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								ABE H, 1994, ANTICANCER RES, V14, P1807; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BERTRAND H, 1993, MOL CELL BIOL, V13, P6778, DOI 10.1128/MCB.13.11.6778; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BLUME H, 1979, ARCH PHARM, V312, P561, DOI 10.1002/ardp.19793120702; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL CR, 1989, MUTAT RES, V211, P181, DOI 10.1016/0027-5107(89)90118-8; CERUTTI H, 1995, MOL CELL BIOL, V15, P3003; CERUTTI H, 1993, PLANT PHYSIOL, V102, P155, DOI 10.1104/pp.102.1.155; CERUTTI H, 1993, PLANT PHYSIOL, V102, P145, DOI 10.1104/pp.102.1.155; CERUTTI H, 1992, P NATL ACAD SCI USA, V89, P8068, DOI 10.1073/pnas.89.17.8068; CLAYTON DA, 1974, P NATL ACAD SCI USA, V71, P2777, DOI 10.1073/pnas.71.7.2777; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; Darley-Usmar V. M., 1987, MITOCHONDRIA PRACTIC; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FRIEDBERG EC, 1995, DNA REPAIR; GANEA D, 1987, MOL CELL BIOL, V7, P3124, DOI 10.1128/MCB.7.9.3124; HINO O, 1991, P NATL ACAD SCI USA, V88, P9248, DOI 10.1073/pnas.88.20.9248; HOWE CJ, 1988, TRENDS GENET, V4, P150, DOI 10.1016/0168-9525(88)90017-0; HOWELL N, 1993, MAMM GENOME, V4, P271, DOI 10.1007/BF00417434; JEONGYU SJ, 1992, MOL CELL BIOL, V12, P112, DOI 10.1128/MCB.12.1.112; JESSBERGER R, 1993, J BIOL CHEM, V268, P15070; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; KALINOWSKI DP, 1992, NUCLEIC ACIDS RES, V20, P3485, DOI 10.1093/nar/20.13.3485; KUCHERLAPATI R, 1988, GENETIC RECOMBINATIO; KUCHERLAPATI RS, 1985, MOL CELL BIOL, V5, P714, DOI 10.1128/MCB.5.4.714; LEDOUX SP, 1993, CARCINOGENESIS, V14, P913, DOI 10.1093/carcin/14.5.913; LEDOUX SP, 1992, CARCINOGENESIS, V13, P1967, DOI 10.1093/carcin/13.11.1967; LESTIENNE P, 1988, LANCET, V1, P885; LIM LO, 1987, BIOCHEM PHARMACOL, V36, P2769, DOI 10.1016/0006-2952(87)90263-2; LIN FLM, 1990, MOL CELL BIOL, V10, P103, DOI 10.1128/MCB.10.1.103; LIN FLM, 1990, MOL CELL BIOL, V10, P113, DOI 10.1128/MCB.10.1.113; LING F, 1995, EMBO J, V14, P4090, DOI 10.1002/j.1460-2075.1995.tb00081.x; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P5643, DOI 10.1093/nar/15.14.5643; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MIQUEL J, 1992, MUTAT RES, V275, P209, DOI 10.1016/0921-8734(92)90024-J; MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099; NAGLEY P, 1992, ANN NY ACAD SCI, V673, P92, DOI 10.1111/j.1749-6632.1992.tb27440.x; OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; RAUTH S, 1986, P NATL ACAD SCI USA, V83, P5587, DOI 10.1073/pnas.83.15.5587; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P975; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; ROTIG A, 1989, LANCET, V1, P902; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; Sambrook J., 2002, MOL CLONING LAB MANU; SEIDMAN MM, 1987, MOL CELL BIOL, V7, P3561, DOI 10.1128/MCB.7.10.3561; SELVA EM, 1995, GENETICS, V139, P1175; SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053; SHEN CC, 1995, MUTAT RES-DNA REPAIR, V337, P19, DOI 10.1016/0921-8777(95)00008-8; SINDEN RR, 1978, P NATL ACAD SCI USA, V75, P2373, DOI 10.1073/pnas.75.5.2373; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; SINGH G, 1992, PHARMACOL THERAPEUT, V54, P217, DOI 10.1016/0163-7258(92)90033-V; SMITH L, 1955, METHOD BIOCHEM ANAL, P427; SYMINGTON LS, 1983, CELL, V35, P805, DOI 10.1016/0092-8674(83)90113-7; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Thyagarajan B, 1996, SOMAT CELL MOLEC GEN, V22, P31, DOI 10.1007/BF02374374; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U; WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4; ZEVIANI M, 1990, AM J HUM GENET, V47, P904; Zeviani M, 1991, Neuromuscul Disord, V1, P165, DOI 10.1016/0960-8966(91)90020-S; ZUCKERMAN SH, 1984, SOMAT CELL MOLEC GEN, V10, P85, DOI 10.1007/BF01534475	71	220	233	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27536	27543		10.1074/jbc.271.44.27536	http://dx.doi.org/10.1074/jbc.271.44.27536			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910339	hybrid			2022-12-27	WOS:A1996VQ67900057
J	Villemain, JL; Giedroc, DP				Villemain, JL; Giedroc, DP			Characterization of a cooperativity domain mutant Lys(3)->Ala (K3A) T4 gene 32 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; NUCLEIC-ACID INTERACTIONS; DIMENSIONAL HOMOGENEOUS LATTICE; SODIUM-CHLORIDE CONCENTRATION; BINDING-PROTEIN; CRYSTAL-STRUCTURE; REPLICATION FORK; SSDNA COMPLEX; LARGE LIGANDS; V PROTEIN	The N-terminal ''B'' domain of T4 gene 32 protein contains a Lys(3)-Arg(4)-Lys(5) sequence that has been postulated to provide a major determinant for cooperative binding, In this report, the equilibrium binding properties of a Lys(3) --> Ala substitution mutant of gp32 (K3A gp32) and described and compared to a set of substitution mutants of Arg(4) previously described (Villemain, J, L., and Giedroc, D, P, (1993) Biochemistry 32, 11235-11246) and further characterized here. K3A gp32 exhibits binding behavior which mirrors that of R4Q gp32, Despite an 6-8-fold decrease in overall binding affinity (K-app = K-int x omega) at pH 8.1, 0.20 M NaCl, 20 degrees C, the magnitude of the cooperativity parameter is at most 2-3-fold smaller than that of the wild-type protein, The magnitude of omega is independent of salt concentration and type over the range in [NaCl] from 0.125 to 0.225 M and [NaF] between 0.20 and 0.32 M (log omega = 2.86 +/- 0.19), For comparison, log omega for wild-type gp32 is 2.91 (+/- 0.21) resolved at 0.275 M NaCl and 3.39 +/- 0.11 in [NaF] between 0.40 and 0.45 M. In contrast to omega, the [NaCl] dependence of K-app is large and markedly nonlinear for both wild-type and K3A gp32s over a [NaCl] range extending from 0.05 M to 0.40 M NaCl. Modeling of the complete salt dependence of K-app for wild-type, K3A, and R4T gp32s in NaCl and NaF with a simple ion-exchange model suggests that substitutions within the basic Lys(3)-Arg(4)-Lys(5) sequence do not strongly modulate the net displacement of cations and anions upon poly(A) complex formation by gp32.	TEXAS A&M UNIV,INST BIOSCI & TECHNOL,CTR MACROMOL DESIGN,DEPT BIOCHEM & BIOPHYS,COLLEGE STN,TX 77843	Texas A&M University System; Texas A&M University College Station			Giedroc, David/A-8608-2018	Giedroc, David/0000-0002-2342-1620	NIGMS NIH HHS [GM42569] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM042569, R01GM042569] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUJALOWSKI W, 1987, BIOCHEMISTRY-US, V26, P3099, DOI 10.1021/bi00385a023; BUJALOWSKI W, 1989, BIOPOLYMERS, V28, P1637, DOI 10.1002/bip.360280912; CARROLL RB, 1975, J MOL BIOL, V91, P275, DOI 10.1016/0022-2836(75)90380-0; CASASFINET JR, 1992, P NATL ACAD SCI USA, V89, P1050, DOI 10.1073/pnas.89.3.1050; FOLMER RHA, 1994, J MOL BIOL, V240, P341, DOI 10.1006/jmbi.1994.1449; FRIED MG, 1993, EUR J BIOCHEM, V218, P469, DOI 10.1111/j.1432-1033.1993.tb18398.x; GIEDROC DP, 1991, BIOCHEMISTRY-US, V30, P8230, DOI 10.1021/bi00247a020; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIEDROC DP, 1990, J BIOL CHEM, V265, P11444; GUAN Y, 1995, PROTEIN SCI, V4, P187; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HURLEY JM, 1993, J MOL BIOL, V229, P398, DOI 10.1006/jmbi.1993.1042; JIANG H, 1993, J BIOL CHEM, V268, P7904; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; Karpel R.L., 1990, BIOL NONSPECIFIC DNA, P103; KHAN R, 1992, J BIOL CHEM, V267, P6689; KNIGHT KL, 1989, J BIOL CHEM, V264, P13706; KOWALCZYKOWSKI SC, 1981, J MOL BIOL, V145, P75, DOI 10.1016/0022-2836(81)90335-1; KOWALCZYKOWSKI SC, 1986, BIOCHEMISTRY-US, V25, P1226, DOI 10.1021/bi00354a006; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4656, DOI 10.1021/bi00315a022; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LOHMAN TM, 1981, J MOL BIOL, V152, P67, DOI 10.1016/0022-2836(81)90096-6; LOHMAN TM, 1984, BIOCHEMISTRY-US, V23, P4665, DOI 10.1021/bi00315a023; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; NEWPORT JW, 1981, J MOL BIOL, V145, P105, DOI 10.1016/0022-2836(81)90336-3; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; OVERMAN LB, 1994, J MOL BIOL, V236, P165, DOI 10.1006/jmbi.1994.1126; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; QIU HW, 1994, J BIOL CHEM, V269, P2773; QIU HW, 1994, BIOCHEMISTRY-US, V33, P8139, DOI 10.1021/bi00192a019; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SPICER EK, 1979, J BIOL CHEM, V254, P6433; STASSEN APM, 1992, EUR J BIOCHEM, V206, P605, DOI 10.1111/j.1432-1033.1992.tb16965.x; TERWILLIGER TC, 1994, J MOL BIOL, V236, P556, DOI 10.1006/jmbi.1994.1165; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VILLEMAIN JL, 1993, BIOCHEMISTRY-US, V32, P11235, DOI 10.1021/bi00092a038; WILLIAMS KR, 1978, J BIOL CHEM, V253, P2463; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	44	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27623	27629		10.1074/jbc.271.44.27623	http://dx.doi.org/10.1074/jbc.271.44.27623			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910351	hybrid			2022-12-27	WOS:A1996VQ67900069
J	Higashi, S; Matsumoto, N; Iwanaga, S				Higashi, S; Matsumoto, N; Iwanaga, S			Molecular mechanism of tissue factor-mediated acceleration of factor VIIa activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-VII; CARBOXYGLUTAMIC ACID DOMAIN; EXTRINSIC PATHWAY; CRYSTAL-STRUCTURE; COMPLEX; BINDING; PURIFICATION; IDENTIFICATION; ACTIVATION; ASSOCIATION	The mechanism of the acceleration of the catalytic activity of factor VIIa (VIIa) in the presence of tissue factor (TF) was investigated, To explore the VIIa's site(s) that correlates with TF-mediated acceleration, zymogen VII, VIIa, and active site-modified VIIa were prepared, and dissociation constants (K-d) for their bindings to TF or soluble TF in solution were determined. We found that conversion of zymogen VII to VIIa led to an increase in affinity (Delta Delta G = 4.3-4.4 kJ/mol) for TFs., Dansyl-Glu-Gly-Arg chloromethyl ketone (DNS-EGRck) treatment of VIIa led to a further increase in the affinity (Delta Delta G = 7.3-12 kJ/mol), Neither removal of the Gla domain from VIIa nor truncation of the COOH-terminal membrane and cytoplasmic regions of TF affected the affinity enhanced after DNS-EGRck treatment of VIIa. Treatment of VIIa with (p-amidinophenyl)methanesulfonyl fluoride also enhanced its affinity for soluble TF, whereas treatment with 4-(2-aminoethyl)benzenesulfonyl fluoride, phenylmethylsulfonyl fluoride, or diisopropyl fluorophosphate had a slight effect on the affinity, On the other hand, DNS-EGRck and (p-amidinophenyl)methanesulfonyl fluoride treatments, but not diisopropyl fluorophosphate treatment, of VIIa led to protection of its alpha-amino group of Ile-153 from carbamylation, Protection of the alpha-amino group was consistent with formation of a critical salt bridge between Ile-153 and Asp-343 in the protease domain of VIIa, Therefore, TF may preferentially bind to the active conformational state of VIIa. When one assumes that free VIIa exists in equilibrium between minor active and dominant zymogen-like inactive conformational states, preferential binding of TF to the active state leads to a shift in equilibrium, We speculate that TF traps the active conformational state of VIIa and converts its zymogen-like state into an active state, thereby accelerating the VIIa activity.	KYUSHU UNIV 33,DEPT MOL BIOL,GRAD SCH MED SCI,FUKUOKA 81281,JAPAN; KYUSHU UNIV 33,FAC SCI,DEPT BIOL,FUKUOKA 81281,JAPAN	Kyushu University; Kyushu University								BACH R, 1981, J BIOL CHEM, V256, P8324; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1976, J MOL BIOL, V106, P325, DOI 10.1016/0022-2836(76)90089-9; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BROZE GJ, 1985, J BIOL CHEM, V260, P917; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; HIGASHI S, 1990, J BIOCHEM-TOKYO, V108, P654, DOI 10.1093/oxfordjournals.jbchem.a123258; KAZAMA Y, 1993, J BIOL CHEM, V268, P16231; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OBRIEN DP, 1991, BLOOD, V78, P132; OPPENHEIMER HL, 1966, J BIOL CHEM, V241, P2720; PEDERSEN AH, 1990, J BIOL CHEM, V265, P16786; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I. H., 1975, ENZYME KINETICS, P320; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; SILVERBERG SA, 1977, J BIOL CHEM, V252, P8481; TAKAYENOKI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1145, DOI 10.1016/0006-291X(91)92058-R; TAKEYA H, 1988, J BIOL CHEM, V263, P14868; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	33	86	103	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26569	26574		10.1074/jbc.271.43.26569	http://dx.doi.org/10.1074/jbc.271.43.26569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900128	hybrid			2022-12-27	WOS:A1996VP23300022
J	Kato, K; Ito, H; Inaguma, Y; Okamoto, K; Saga, S				Kato, K; Ito, H; Inaguma, Y; Okamoto, K; Saga, S			Synthesis and accumulation of alpha B crystallin in C6 glioma cells is induced by agents that promote the disassembly of microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-LENTICULAR TISSUES; HEAT-SHOCK PROTEIN; STRESS PROTEINS; EXPRESSION; HSP27; CYCLE; HYBRIDIZATION; STAUROSPORINE; SUPPRESSION; INVOLVEMENT	When C6 cells in culture were exposed at 37 degrees C to 1 mu M colchicine or to 1 mu M colcemid, a tubulin-binding anti-mitotic alkaloid, levels of alpha B crystallin in cells began to increase after about 10 h, reaching a maximum of more than 1 mu g/mg protein after 24 h, The level of alpha B crystallin returned to near the control level within two subsequent days of culture in the normal medium, Northern blot analysis showed that the accumulation of alpha B crystallin was preceded by an increase in the level of the mRNA for alpha B crystallin, Nuclear run-off transcription assays showed that colchicine induced new synthesis of mRNA for alpha B crystallin, Immunofluorescence staining revealed that alpha B crystallin accumulated in the peripheral areas of cells, as did the depolymerized tubulin, after several hours of treatment with colcemid, and then it gradually became more conspicuous in the cytoplasm, Vinblastine and nocodazole, which also promote the disassembly of microtubules by binding to tubulins, also induced the synthesis of alpha B crystallin. Furthermore, induction of alpha B crystallin by these drugs was observed in quiescent cells that had been cultured in serum-free medium. However, taxol, a microtubule-stabilizing anti-mitotic agent, did not stimulate the synthesis of alpha B crystallin, but rather, it suppressed the induction of synthesis of alpha B crystallin by the microtubule-disrupting drugs. Induction of alpha B crystallin by colchicine or by other drugs that promote the disassembly of microtubules was sensitive to staurosporine, an inhibitor of protein kinases, and the induction was completely suppressed in the presence of 10 nM staurosporine. These results suggest that the expression of alpha B crystallin is stimulated, via phosphorylation reactions that are sensitive to staurosporine, when the depolymerization of microtubules is enhanced.	AICHI HUMAN SERV CTR, INST DEV RES, DEPT MORPHOL, KASUGAI, AICHI 48003, JAPAN		Kato, K (corresponding author), AICHI HUMAN SERV CTR, INST DEV RES, DEPT BIOCHEM, KASUGAI, AICHI 48003, JAPAN.			Ito, Hidenori/0000-0002-6527-477X				AOYAMA A, 1993, MOL CELL BIOL, V13, P1824, DOI 10.1128/MCB.13.3.1824; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BANERJEE AC, 1979, FEBS LETT, V99, P333, DOI 10.1016/0014-5793(79)80985-0; BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3; CROSSIN KL, 1981, CELL, V23, P61, DOI 10.1016/0092-8674(81)90270-1; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEBRABANDER MJ, 1976, CANCER RES, V36, P905; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; DUGUID JR, 1988, P NATL ACAD SCI USA, V85, P5738, DOI 10.1073/pnas.85.15.5738; HEAD MW, 1994, J CELL PHYSIOL, V159, P41, DOI 10.1002/jcp.1041590107; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; INAGUMA Y, 1992, BIOCHEM BIOPH RES CO, V182, P844, DOI 10.1016/0006-291X(92)91809-5; INAGUMA Y, 1995, J BIOCHEM-TOKYO, V117, P1238, DOI 10.1093/oxfordjournals.jbchem.a124850; INAGUMA Y, 1993, J BIOCHEM-TOKYO, V114, P378, DOI 10.1093/oxfordjournals.jbchem.a124184; ITO H, 1995, J BIOCHEM-TOKYO, V118, P629, DOI 10.1093/oxfordjournals.jbchem.a124956; IWAKI T, 1990, J HISTOCHEM CYTOCHEM, V38, P31, DOI 10.1177/38.1.2294148; IWAKI T, 1992, AM J PATHOL, V140, P345; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JEROME V, 1993, EXP CELL RES, V205, P44, DOI 10.1006/excr.1993.1056; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1992, J BIOL CHEM, V267, P7718; KIM SH, 1993, BIOCHEM BIOPH RES CO, V193, P759, DOI 10.1006/bbrc.1993.1690; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONGONI S, 1990, MOL CELL BIOCHEM, V97, P113, DOI 10.1007/BF00221052; LOWE J, 1990, LANCET, V336, P515, DOI 10.1016/0140-6736(90)92075-S; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; QUAXJEUKEN Y, 1985, P NATL ACAD SCI USA, V82, P5819, DOI 10.1073/pnas.82.17.5819; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHINOHARA H, 1993, J NEUROL SCI, V119, P203, DOI 10.1016/0022-510X(93)90135-L; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683	34	60	61	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26989	26994		10.1074/jbc.271.43.26989	http://dx.doi.org/10.1074/jbc.271.43.26989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900185	hybrid			2022-12-27	WOS:A1996VP23300079
J	Kita, N; Boyd, CM; Garrett, MR; Jurnak, F; Keen, NT				Kita, N; Boyd, CM; Garrett, MR; Jurnak, F; Keen, NT			Differential effect of site-directed mutations in pelC on pectate lyase activity, plant tissue maceration, and elicitor activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERWINIA-CHRYSANTHEMI EC16; GRAM-NEGATIVE BACTERIA; PARALLEL BETA-HELIX; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; ASPERGILLUS-NIGER; VIRULENCE FACTOR; MAJOR ALLERGEN; EXPRESSION; GENES	Oligonucleotide site-directed mutations were introduced into the pelC gene of Erwinia chrysanthemi EC16 that directed single or double amino acid changes affecting disulfide linkages, calcium binding, catalysis, and protein folding, Subsequent characterization of the purified PelC mutant proteins demonstrated that pectinolytic function involves amino acids located near the calcium binding site rather than those surrounding an invariant vWiDH sequence. Wild-type PelC and the tested mutant proteins generally macerated plant tissue in proportion to their specific pectinolytic activity in vitro., However, some mutants gave higher maceration activity in plant tissue and elicited greater production of the phytoalexin, glyceollin, in soybean cotyledons than predicted by their in vitro pectinolytic activity, Most notable in this regard were three different mutations at lysine 172 with greatly reduced pectinolytic activity but as much elicitor activity as the wild-type protein, Pelf macerated plant tissue 10 times more efficiently than PelC, as observed previously, but surprisingly showed equal activity in the elicitor assay. The results indicate that factors other than pectinolytic activity per se are involved in plant tissue maceration and elicitor activity.	UNIV CALIF RIVERSIDE,DEPT PLANT PATHOL,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								AYERS AR, 1976, PLANT PHYSIOL, V57, P751, DOI 10.1104/pp.57.5.751; BARRAS F, 1994, ANNU REV PHYTOPATHOL, V32, P201, DOI 10.1146/annurev.py.32.090194.001221; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDELIER KA, 1990, MOL GEN GENET, V224, P183, DOI 10.1007/BF00271551; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; CROWE JS, 1991, NUCLEIC ACIDS RES, V19, P184, DOI 10.1093/nar/19.1.184; DELORENZO G, 1991, PHYSIOL MOL PLANT P, V39, P335, DOI 10.1016/0885-5765(91)90015-A; Emsley P, 1996, NATURE, V381, P90, DOI 10.1038/381090a0; GYSLER C, 1990, GENE, V89, P101, DOI 10.1016/0378-1119(90)90211-9; HEFFRON S, 1995, MOL PLANT MICROBE IN, V8, P331, DOI 10.1094/MPMI-8-0331; HENRISSAT B, 1995, PLANT PHYSIOL, V107, P963, DOI 10.1104/pp.107.3.963; KEEN NT, 1983, PLANT PHYSIOL, V71, P466, DOI 10.1104/pp.71.3.466; KEEN NT, 1986, J BACTERIOL, V168, P595, DOI 10.1128/jb.168.2.595-606.1986; KEEN NT, 1984, J BACTERIOL, V159, P825, DOI 10.1128/JB.159.3.825-831.1984; KOTOUJANSKY A, 1987, ANNU REV PHYTOPATHOL, V25, P405, DOI 10.1146/annurev.py.25.090187.002201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIETZKE SE, 1994, PLANT PHYSIOL, V106, P849, DOI 10.1104/pp.106.3.849; LINDEBERG M, 1992, J BACTERIOL, V174, P7385, DOI 10.1128/jb.174.22.7385-7397.1992; Maniatis T., 1982, MOL CLONING; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MUSSELL HW, 1969, ANAL BIOCHEM, V28, P353, DOI 10.1016/0003-2697(69)90190-0; PICKERSGILL R, 1994, NAT STRUCT BIOL, V1, P717, DOI 10.1038/nsb1094-717; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; ROGERS HJ, 1992, PLANT MOL BIOL, V20, P493, DOI 10.1007/BF00040608; SCHOEPFER R, 1993, GENE, V124, P83, DOI 10.1016/0378-1119(93)90764-T; SOMEREN MAK, 1991, CURR GENET, V20, P293, DOI 10.1007/BF00318518; Someren MAK, 1992, MOL GEN GENET, V234, P113; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAMAKI SJ, 1988, J BACTERIOL, V170, P3468, DOI 10.1128/jb.170.8.3468-3478.1988; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; Wing R. A., 1989, Plant Molecular Biology, V14, P17, DOI 10.1007/BF00015651; WITHOLT B, 1976, ANAL BIOCHEM, V74, P160, DOI 10.1016/0003-2697(76)90320-1; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YODER MD, 1995, PLANT PHYSIOL, V107, P349, DOI 10.1104/pp.107.2.349; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YODER MD, 1995, FASEB J, V9, P35; YUCEL I, 1994, MOL PLANT MICROBE IN, V7, P1440	42	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26529	26535		10.1074/jbc.271.43.26529	http://dx.doi.org/10.1074/jbc.271.43.26529			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900122	hybrid			2022-12-27	WOS:A1996VP23300016
J	Rosenberg, AH; Griffin, M; Washington, MT; Patel, SS; Studier, FW				Rosenberg, AH; Griffin, M; Washington, MT; Patel, SS; Studier, FW			Selection, identification, and genetic analysis of random mutants in the cloned primase/helicase gene of bacteriophage T7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE-PRIMASE; RNA-POLYMERASE; DNA; PROTEINS; RECOMBINATION; EXPRESSION; FRAGMENTS; SEQUENCE; REGION	T7 gene 4 specifies two overlapping proteins 4A, a 566-amino acid primase/helicase, and 4B, a 503-amino acid helicase whose initiation codon is the 64th codon of the 4A protein, The 4A' gene, which has a leucine codon replacing the 4B initiation codon, specifies a single 566-amino acid protein that can provide the primase and helicase functions required for normal T7 growth, We selected N-methyl-N'-nitro-N-nitrosoguanidine mutants in the cloned 4A' gene that no longer support the growth of a phage that completely lacks gene 4, Genetic mapping of the 76 mutations found them to be distributed throughout the protein, including both the N-terminal and C-terminal halves of the molecule thought to represent primase and helicase domains, respectively, Complementation tests with partially and completely defective phage showed that all but five of the mutants lacked helicase function but retained primase function, The other five, which lacked both functions, all made short proteins, including one missing only 60 amino acids. No mutations lacked only primase function, and none mapped within the first 105 amino acids, which includes the 63-amino acid region unique to 4A that contains elements required to recognize primase sites, Forty-six mutations were sequenced and included 27 missense mutations affecting 25 amino acids, Many mutations in the N-terminal half of the protein affected its solubility in cell extracts. Mutations in the C-terminal half clustered in or near five helicase consensus sequences, Biochemical analysis of nine of the mutant proteins is described in the accompanying paper (Washington, M. T., Rosenberg, A. H., Griffin, K., Studier, F. W., and Patel, S. S. (1996) J. Biol. Chem. 271, 26825-26834).	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210	Ohio State University	Rosenberg, AH (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.			Washington, Todd/0000-0001-8680-2992				BECK PJ, 1989, J MOL BIOL, V210, P687, DOI 10.1016/0022-2836(89)90102-2; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; CAMPBELL JL, 1978, P NATL ACAD SCI USA, V75, P2276, DOI 10.1073/pnas.75.5.2276; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; DUNN JJ, 1983, J MOL BIOL, V166, P477, DOI 10.1016/S0022-2836(83)80282-4; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KERR C, 1975, VIROLOGY, V65, P281, DOI 10.1016/0042-6822(75)90031-8; MENDELMAN LV, 1994, EMBO J, V13, P3909, DOI 10.1002/j.1460-2075.1994.tb06702.x; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; POWLING A, 1974, MOL GEN GENET, V134, P173, DOI 10.1007/BF00268418; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; STUDIER FW, 1972, SCIENCE, V176, P367, DOI 10.1126/science.176.4033.367; STUDIER FW, 1981, J MOL BIOL, V153, P503, DOI 10.1016/0022-2836(81)90405-8; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, 1969, VIROLOGY, V39, P562, DOI 10.1016/0042-6822(69)90104-4; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825; ZHANG X, 1995, J MOL BIOL, V250, P156, DOI 10.1006/jmbi.1995.0367	26	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26819	26824		10.1074/jbc.271.43.26819	http://dx.doi.org/10.1074/jbc.271.43.26819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900163	hybrid			2022-12-27	WOS:A1996VP23300057
J	Sato, R; Inoue, J; Kawabe, Y; Kodama, T; Takano, T; Maeda, M				Sato, R; Inoue, J; Kawabe, Y; Kodama, T; Takano, T; Maeda, M			Sterol-dependent transcriptional regulation of sterol regulatory element-binding protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LEUCINE ZIPPER PROTEIN; CULTURED HUMAN-CELLS; NF-Y; GENE; PROMOTER; SEQUENCE; SREBP-1; ACID; ACTIVATION	We show in this manuscript that expression of the mRNA for sterol regulatory element-binding protein-a (SREBP-2) is regulated by the cellular sterol level in cultured HeLa cells. We have cloned the 5'-flanking region of the gene encoding human SREBP-2. Characterization of this region shows the minimum 50-base pair segment, which contains a 10-base pair sterol regulatory element 1 (SRE-1) identical to the one in the human LDL receptor promoter, confers sterol responsiveness when fused to the luciferase reporter gene. Enforced expression of the truncated SREBP-2 protein (amino acid residues 1-481) also shows that this upstream segment contains the information required for transcriptional activation. The luciferase assays using mutant versions of the reporter genes reveal that the sterol dependent transcriptional regulation is mediated by two nearby motifs, the SRE-1 and the NF-Y binding site (the inverted CCAAT box, ATTGGC); the latter is reported to play a critical role in sterol dependent regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase and farnesyl diphosphate synthase genes (Jackson, S. M., Ericsson, J., Osborne, T. F., and Edwards, P. A. (1995) J. Biol. Chem. 270, 21445-21448), Gel mobility shift assays demonstrate that the transcription factor NF-Y truly binds to the ATTGGC sequence, These findings suggest that the activity of SREBP-2 is controlled not only post-translationally by proteolytic activation of the precursor protein but also transcriptionally by itself together with NF-Y.	UNIV TOKYO,DEPT MOL BIOL & MED,ADV SCI & TECHNOL RES CTR,TOKYO 153,JAPAN; TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOL PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN	University of Tokyo; Teikyo University	Sato, R (corresponding author), OSAKA UNIV,FAC PHARMACEUT SCI,BIOCHEM LAB,1-6 YAMADA OKA,SUITA,OSAKA 565,JAPAN.		INOUE, Jun/O-7352-2016	INOUE, Jun/0000-0003-4145-3754; Kawabe, Yoshiki/0000-0002-6465-7146				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; KAWABE Y, 1995, BIOCHEM BIOPH RES CO, V208, P405, DOI 10.1006/bbrc.1995.1352; KAWABE Y, 1994, BIOCHEM BIOPH RES CO, V202, P1460, DOI 10.1006/bbrc.1994.2095; Kawabe Y, 1996, BIOCHEM BIOPH RES CO, V219, P515, DOI 10.1006/bbrc.1996.0265; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SUDHOF TC, 1987, J BIOL CHEM, V262, P10773; TAMURA S, 1992, FEBS LETT, V298, P137, DOI 10.1016/0014-5793(92)80040-N; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	23	223	228	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26461	26464		10.1074/jbc.271.43.26461	http://dx.doi.org/10.1074/jbc.271.43.26461			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900111	hybrid			2022-12-27	WOS:A1996VP23300005
J	Chen, HC; Appeddu, PA; Isoda, H; Guan, JL				Chen, HC; Appeddu, PA; Isoda, H; Guan, JL			Phosphorylation of tyrosine 397 in focal adhesion kinase is required for binding phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTORS; SRC SH2 DOMAIN; SIGNAL-TRANSDUCTION; PHOSPHOINOSITIDE 3-KINASE; CELL-ADHESION; RAS PATHWAY; P85 SUBUNIT; ASSOCIATION; PP125(FAK)	We have shown previously that cell adhesion or platelet-derived growth factor (PDGF) promotes the in vivo association of focal adhesion kinase (FAK) with phosphatidylinositol (PI) 3-kinase. In vitro experiments indicated that this interaction was mediated by the p85 subunit of PI 3-kinase and dependent on the tyrosine phosphorylation of FAK. Here we report data suggesting that the major autophosphorylation site of FAK (Tyr-397) is the binding site for the SH2 domains of p85 in vitro and is also required for the association of FAK with PI 3-kinase in vivo. We also show that Tyr-397 is responsible for the increased FAK:PI 3-kinase association upon PDGF stimulation, implying that no additional site of FAK was involved in its binding to PI 3-kinase after PDGF stimulation, Finally, me present evidence that the interaction of PI 3-kinase with Tyr-397 of FAK stimulates its activity, Together, these results suggest that FAK activation and autophosphorylation at Tyr-397 may lead to its association with PI 3-kinase through the SH2 domains of p85, which can subsequently activate PI 3-kinase during cell adhesion.	CORNELL UNIV, COLL VET MED, DEPT PATHOL, CANC BIOL LABS, ITHACA, NY 14853 USA	Cornell University				Isoda, Hiroko/0000-0002-1399-9541	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048050, R01GM052890] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52890, GM48050] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BJORGE JD, 1990, P NATL ACAD SCI USA, V87, P3816, DOI 10.1073/pnas.87.10.3816; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; Cary LA, 1996, J CELL SCI, V109, P1787; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CUNNINGHAM SA, 1995, J BIOL CHEM, V270, P20254, DOI 10.1074/jbc.270.35.20254; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FURUTA Y, 1995, ONCOGENE, V11, P1989; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ILLC D, 1995, NATURE, V377, P539; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; LEV S, 1992, P NATL ACAD SCI USA, V89, P678, DOI 10.1073/pnas.89.2.678; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TOKER A, 1994, J BIOL CHEM, V269, P32358; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	52	445	454	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26329	26334		10.1074/jbc.271.42.26329	http://dx.doi.org/10.1074/jbc.271.42.26329			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824286	hybrid			2022-12-27	WOS:A1996VN18000092
J	Sasahara, Y; Kobayashi, T; Onodera, H; Onoda, M; Ohnishi, M; Kato, S; Kusuda, K; Shima, H; Nagao, M; Abe, H; Yanagawa, Y; Hiraga, A; Tamura, S				Sasahara, Y; Kobayashi, T; Onodera, H; Onoda, M; Ohnishi, M; Kato, S; Kusuda, K; Shima, H; Nagao, M; Abe, H; Yanagawa, Y; Hiraga, A; Tamura, S			Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN PHOSPHATASE; MESSENGER-RNA; MOLECULAR-CLONING; TYROSINE PHOSPHORYLATION; CATALYTIC SUBUNIT; CYCLOSPORINE-A; RAT-LIVER; CALCINEURIN; GROWTH; DEPHOSPHORYLATION	Mouse P19 embryonal carcinoma cells in aggregation culture in the presence of 10(-6) M retinoic acid followed by monolayer culture differentiate into nerve and glial cells, In this study, we demonstrated that the neurofilament-L (NF-L) mRNA and protein levels of these cells were enhanced in accordance with their retinoic acid-induced neural differentiation. Okadaic acid (OA) treat ment of the cells markedly suppressed this differentiation-dependent NF-L gene expression increase and neurite outgrowth of the cells, Similar results were obtained when tautomycin was used instead of OA, suggesting that inhibition of protein phosphatase(s) is involved in the suppression of neural differentiation. OA treatment did not affect the NF-L gene transcription level, determined by the nuclear run-on transcription assay, but it did reduce the stability of both the 3.5- and 2.3-kilobase NF-L mRNAs, The expression and activity levels of protein phosphatase 2A (PP2A) and 2B (PP2B) but not protein phosphatase 1 (PP1) in P19 cells increased in accordance with the enhanced NF-L gene expression, The presence of OA in the culture medium during the course of the neural differentiation caused a reduced PP2A activity but not PP1 and PP2B activities of the cell extracts, On the other hand, both PP1 and PP2B activities but not PP2A activity of cell extracts were suppressed by the addition of cyclosporin A or FK506 in the culture medium, However, both cyclosporin A and FK506 treatments affected neither NF-L gene expression nor neurite outgrowth. These results demonstrate that the OA treatment inhibits the differentiation-dependent increase in NF-L gene expression by destabilizing its mRNAs and suggest that PP2A plays key roles in the differentiation-dependent enhanced expression of the NF-L gene and is the point of the action of OA.	TOHOKU UNIV, INST DEV AGING & CANC, DEPT BIOCHEM, AOBA KU, SENDAI, MIYAGI 980, JAPAN; TOHOKU UNIV, INST DEV AGING & CANC, DEPT PEDIAT ONCOL, AOBA KU, SENDAI, MIYAGI 980, JAPAN; NATL CANC CTR, RES INST, DIV CARCINOGENESIS, TOKYO 104, JAPAN; TOKAI UNIV, SCH MED, DEPT MORPHOL, DIV HUMAN STRUCT & FUNCT, ISEHARA, KANAGAWA 25911, JAPAN	Tohoku University; Tohoku University; National Cancer Center - Japan; Tokai University			Kato, Shunsuke/F-7607-2014					BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BALLOU LM, 1986, ENZYMES, V17, P311; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DELFRANCO AF, 1993, BIOCHIM BIOPHYS ACTA, V1171, P323; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HORI M, 1991, FEBS LETT, V285, P145, DOI 10.1016/0014-5793(91)80745-O; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKENAKA K, 1990, J BIOL CHEM, V265, P19782; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JULIEN JP, 1986, MOL BRAIN RES, V1, P243, DOI 10.1016/0169-328X(86)90030-6; KATO S, 1995, ARCH BIOCHEM BIOPHYS, V318, P387, DOI 10.1006/abbi.1995.1244; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1989, J BIOL CHEM, V264, P12800; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAIR APK, 1994, NATURE, V369, P239, DOI 10.1038/369239a0; NAKAHIRA K, 1990, J BIOL CHEM, V265, P19786; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; PSHENICHKIN SP, 1995, J BIOL CHEM, V270, P5994, DOI 10.1074/jbc.270.11.5994; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SACHER MG, 1994, J BIOL CHEM, V269, P18480; SACHER MG, 1992, BIOCHEM BIOPH RES CO, V186, P524, DOI 10.1016/S0006-291X(05)80839-3; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; SCHWARTZ ML, 1995, J BIOL CHEM, V270, P26364, DOI 10.1074/jbc.270.44.26364; SHIMA H, 1994, P NATL ACAD SCI USA, V91, P9267, DOI 10.1073/pnas.91.20.9267; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; TAMURA S, 1978, BIOCHIM BIOPHYS ACTA, V524, P349, DOI 10.1016/0005-2744(78)90171-7; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598	49	21	21	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25950	25957		10.1074/jbc.271.42.25950	http://dx.doi.org/10.1074/jbc.271.42.25950			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824230	hybrid			2022-12-27	WOS:A1996VN18000036
J	Steinert, PM; Kim, SY; Chung, SI; Marekov, LN				Steinert, PM; Kim, SY; Chung, SI; Marekov, LN			The transglutaminase 1 enzyme is variably acylated by myristate and palmitate during differentiation in epidermal keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECESSIVE LAMELLAR ICHTHYOSIS; CORNIFIED CELL-ENVELOPE; CROSS-LINKING ENZYMES; MEMBRANE ANCHORAGE; ALPHA-SUBUNIT; PROTEIN; EXPRESSION; PALMITOYLATION; SUBSTRATE; BINDING	The transglutaminase 1 (TGase 1) enzyme is involved in the formation of a cornified cell envelope in terminally differentiating epidermal keratinocytes. The enzyme is present in proliferating cells but is more abundantly expressed in differentiating cells and exists in several intact or proteolytically processed cytosolic or membrane-anchored forms, We show here that the equilibrium partitioning of TGase 1 between the cytosol and membranes is controlled by variable modification by myristate and palmitate, During synthesis, it is constitutively N-myristoylated. Later, it is modified by an average of two S-myristoyl adducts in proliferating cells or one S-palmitoyl adduct in differentiating cells. The three myristoyl adducts of the former provide more robust anchorage to membranes than the one myristoyl and one palmitoyl adduct of the latter, The half-lives of the S-myristoyl and especially the S-palmitoyl adducts are less than that of the TGase 1 protein, suggesting a mechanism for cycling off membranes. In in vitro overlay assays, the S-acylated 10-kDa anchorage fragment facilitates binding of TGase 1 forms, supporting a mechanism of cycling back onto membranes in vivo. We conclude that differential acylation increases the repertoire of functional TGase 1 forms, depending on the differentiation state of epidermal keratinocytes.	PACIFIC RES & DEV CORP,KIHEUNG EUP 449900,SOUTH KOREA; GREEN CROSS CO,KYOUNGGI DO 449900,SOUTH KOREA	Green Cross Corporation	Steinert, PM (corresponding author), NIAMSD,SKIN BIOL LAB,NIH,BLDG 6,ROOM 425,BETHESDA,MD 20892, USA.							AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; CANDI E, 1995, J BIOL CHEM, V270, P26382, DOI 10.1074/jbc.270.44.26382; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; DEGTYAREV MY, 1994, J BIOL CHEM, V269, P30898; DUVIC M, 1994, J INVEST DERMATOL, V102, P462, DOI 10.1111/1523-1747.ep12373021; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; GALBIATI F, 1994, BIOCHEM J, V303, P697, DOI 10.1042/bj3030697; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HUBER M, 1995, SCIENCE, V267, P525, DOI 10.1126/science.7824952; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KIM SY, 1995, J BIOL CHEM, V270, P18026, DOI 10.1074/jbc.270.30.18026; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; KIM SY, 1994, J BIOL CHEM, V269, P27979; KWONG J, 1995, BIOCHEM BIOPH RES CO, V207, P868, DOI 10.1006/bbrc.1995.1266; MERDES A, 1991, J CELL BIOL, V115, P397, DOI 10.1083/jcb.115.2.397; MICHEL S, 1992, J INVEST DERMATOL, V98, P364, DOI 10.1111/1523-1747.ep12499806; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; PARMENTIER L, 1995, HUM MOL GENET, V4, P1391, DOI 10.1093/hmg/4.8.1391; PHILLIPS MA, 1993, BIOCHEMISTRY-US, V32, P11057, DOI 10.1021/bi00092a015; POUMAY Y, 1995, J INVEST DERMATOL, V104, P271, DOI 10.1111/1523-1747.ep12612810; Reichert Uwe, 1993, P107; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RISINGER MA, 1992, J BIOL CHEM, V267, P5680; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; RUSSELL LJ, 1994, AM J HUM GENET, V55, P1146; RUSSELL LJ, 1995, NAT GENET, V9, P279, DOI 10.1038/ng0395-279; SCHMIDT R, 1988, J INVEST DERMATOL, V90, P475, DOI 10.1111/1523-1747.ep12460936; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHROEDER WT, 1992, J INVEST DERMATOL, V99, P27; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Steinert PM, 1996, BIOCHEM BIOPH RES CO, V221, P101, DOI 10.1006/bbrc.1996.0552; STEINERT PM, 1995, CELL DEATH DIFFER, V2, P31; STOFFEL W, 1962, ANGEW CHEM INT EDIT, V74, P905, DOI 10.1002/ange.19620742218; THACHER SM, 1989, J INVEST DERMATOL, V92, P578; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; TRAUPE H, 1989, ICHTHYOSES, P111	40	77	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26242	26250		10.1074/jbc.271.42.26242	http://dx.doi.org/10.1074/jbc.271.42.26242			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824274				2022-12-27	WOS:A1996VN18000080
J	Hart, MJ; Sharma, S; elMasry, N; Qiu, RG; McCabe, P; Polakis, P; Bollag, G				Hart, MJ; Sharma, S; elMasry, N; Qiu, RG; McCabe, P; Polakis, P; Bollag, G			Identification of a novel guanine nucleotide exchange factor for the Rho GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; DBL ONCOGENE PRODUCT; BINDING-PROTEIN; RAS TRANSFORMATION; SIGNALING PATHWAY; MOLECULAR-CLONING; CDC42 GTPASES; KINASE; ACTIVATION; EXPRESSION	The Rho GTPase promotes proliferation and cytoskeletal rearrangements in mammalian cells. To understand the regulation of Rho, it is important to characterize guanine nucleotide exchange factors (GEFs), which stimulate the dissociation of GDP and subsequent binding of GTP. Using Rho as an affinity ligand, we have isolated a 115-kDa protein (p115-RhoGEF) that binds specifically to the nucleotide-depleted state. A full-length cDNA encoding p115-RhoGEF was isolated, and its protein product, which exhibited sequence homology to Dbl and Lbc, catalyzed the exchange of GDP for GTP specifically on Rho and not on the Rac, Cdc42, or Ras GTPases, p115-RhoGEF is capable of regulating cell proliferation, as determined by its ability to induce the transformation of NIH 3T3 cells. Northern and Western analysis suggests that p115-RhoGEF is ubiquitously expressed. These results indicate that pll5-RhoGEF may be a general regulator of Rho and its associated cellular phenotypes.			Hart, MJ (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.			Hart, Matthew/0000-0002-2683-480X				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CERIONE RA, 1996, IN PRESS CURR OPIN C; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PASTERIS NG, 1994, CELL, V79, P669; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388	46	145	152	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25452	25458		10.1074/jbc.271.41.25452	http://dx.doi.org/10.1074/jbc.271.41.25452			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810315	hybrid			2022-12-27	WOS:A1996VL69300059
J	Pearman, AT; Chou, WY; Bergman, KD; Pulumati, MR; Partridge, NC				Pearman, AT; Chou, WY; Bergman, KD; Pulumati, MR; Partridge, NC			Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE; TRANSGENIC MICE; 5'-FLANKING REGION; EXPRESSION; TRANSCRIPTION; COLLAGENASE; SEQUENCE; GENE; AMP; IDENTIFICATION	Many parathyroid hormone (PTH)-mediated events in osteoblasts are thought to require immediate early gene expression, PTH induces the immediate early gene, c-fos, in this cell type through a cAMP-dependent pathway, The present work investigated the nuclear mechanisms involved in PTH regulation of c-fos in the osteoblastic cell line, UMR 106-01. By transiently transfecting c-fos promoter 5' deletion constructs into UMR cells, we demonstrated that PTH induction of the c-fos promoter requires the major cAMP response element (CRE). Point mutations created in the major CRE within the largest construct inhibited both PTH-stimulated and basal expression, This element, therefore, performs concerted basal and PTH-responsive cis-acting functions, Gel retardation and Western blotting techniques revealed that CRE-binding protein (CREB) constitutively binds the major CRE but becomes phosphorylated at its cAMP-dependent protein kinase consensus recognition site following PTH treatment, CREB was functionally implicated in c-fos regulation by coexpressing a dominant CREB repressor, KCREB (killer CREB), with the c-fos promoter constructs. KCREB suppressed both basal and PTH-mediated c-fos induction. We conclude that PTH activates c-fos in osteoblasts through cAMP-dependent protein kinase-phosphorylated CREB interaction with the major CRE in the promoter region of the c-fos gene.	ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104	Saint Louis University				Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039743] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109, R56DK047420, R01DK047420] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39743] Funding Source: Medline; NIDDK NIH HHS [DK48109, DK47420] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRISANI OM, 1988, MOL CELL BIOL, V8, P1947, DOI 10.1128/MCB.8.5.1947; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASE LR, 1970, J BIOL CHEM, V245, P1520; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; GACK S, 1994, J BIOL CHEM, V269, P10363; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HOYLAND J, 1994, J BONE MINER RES, V9, P1191; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; OMURA TH, 1994, J BIOL CHEM, V269, P24994; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P220, DOI 10.1210/endo-108-1-220; REID IR, 1987, AM J PHYSIOL, V253, pE45, DOI 10.1152/ajpendo.1987.253.1.E45; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANG WW, 1994, GENE, V143, P261, DOI 10.1016/0378-1119(94)90107-4; WU JX, 1990, ONCOGENE, V59, P89; XING LP, 1993, MOL ENDOCRINOL, V7, P1484, DOI 10.1210/me.7.11.1484; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	33	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25715	25721		10.1074/jbc.271.41.25715	http://dx.doi.org/10.1074/jbc.271.41.25715			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810350	hybrid			2022-12-27	WOS:A1996VL69300094
J	Shtrom, SS; Hall, ZW				Shtrom, SS; Hall, ZW			Formation of a ligand-binding site for the acetylcholine receptor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DISULFIDE ISOMERASE; TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; ALPHA-SUBUNIT; DELTA-SUBUNIT; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; TORPEDO-CALIFORNICA; MOLECULAR CHAPERONE; SECRETORY PROTEINS	Investigation of the mechanisms by which the subunits of ligand-gated ion channels fold and associate to form oligomers has been hampered by the lack of an in vitro system in which these reactions occur. We have established conditions in a rabbit reticulocyte translation system supplemented with canine pancreatic microsomes under which the alpha and delta subunits of the nicotinic acetylcholine receptor (AChR) fold and assemble to form a heterodimer with a cholinergic binding site comparable with that found in the intact AChR. Folding of the alpha subunit was followed by its ability to bind alpha-bungarotoxin. Folding efficiency was highly sensitive to changes in the redox potential of the translation medium and was favored by an oxidizing environment. Acquisition of the toxin binding conformation required N-Linked core glycosylation but not oligosaccharide trimming, suggesting that oligosaccharide-dependent interaction of chaperones with the alpha subunit is not essential for correct subunit folding. The conformationally mature alpha subunit specifically associated with the delta subunit but not the beta subunit to form a heterodimer with a high affinity ligand-binding site. These data demonstrate, for the first time, correct folding and assembly of the AChR subunits in an in vitro system.	NIMH, CELL BIOL LAB, SECT SYNAPT MECH, BETHESDA, MD 20892 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of California System; University of California San Francisco								ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BIJLMAKERS MJJE, 1994, EMBO J, V13, P2699, DOI 10.1002/j.1460-2075.1994.tb06560.x; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BLOUNT P, 1991, J CELL BIOL, V113, P1125, DOI 10.1083/jcb.113.5.1125; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CHAVEZ R, 1992, THESIS U CALIFORNIA; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CREIGHTON TE, 1978, PROG BIOPHYS MOL BIO, V33, P231; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KADERBHAI MA, 1985, EUR J BIOCHEM, V153, P167, DOI 10.1111/j.1432-1033.1985.tb09283.x; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LANG K, 1987, NATURE, V329, P268, DOI 10.1038/329268a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1981, J BIOL CHEM, V256, P3605; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OLSON EN, 1984, J BIOL CHEM, V259, P5364; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; RIBAUDO RK, 1992, J IMMUNOL, V149, P2935; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHEELE G, 1983, J BIOL CHEM, V258, P2005; SEBBANE R, 1983, J BIOL CHEM, V258, P3294; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1986, J BIOL CHEM, V261, P4825; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WELPLY JK, 1983, J BIOL CHEM, V258, P1856; WILLIAMS DB, 1995, BIOCHEM CELL BIOL, V73, P123, DOI 10.1139/o95-015; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU L, 1986, NUCLEIC ACIDS RES, V14, P3539, DOI 10.1093/nar/14.8.3539	63	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25506	25514		10.1074/jbc.271.41.25506	http://dx.doi.org/10.1074/jbc.271.41.25506			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810322	hybrid			2022-12-27	WOS:A1996VL69300066
J	Geier, BM; Wiech, H; Schiebel, E				Geier, BM; Wiech, H; Schiebel, E			Binding of centrins and yeast calmodulin to synthetic peptides corresponding to binding sites in the spindle pole body components Kar1p and Spc110p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; HIGH-LEVEL EXPRESSION; EF-HAND PROTEIN; SACCHAROMYCES-CEREVISIAE; GAMMA-TUBULIN; CHLAMYDOMONAS-REINHARDTII; MUTATIONAL ANALYSIS; MOLECULAR-CLONING; HALF-BRIDGE; CELL-CYCLE	Centrins contain four potential Ca2+ binding sites, known as EF-hands, and have essential functions in centrosome duplication and filament contraction. Here we report that centrins hom yeast, green algae, and humans bound with high affinity to a peptide of the yeast centrosomal component Kar1p, Interestingly, centrin binding was regulated by physiological relevant changes in [Ca2+], and this Ca2+ dependence was influenced by acidic amino acids within the Kar1p peptide, which also prevented efficient binding of the related yeast calmodulin, However, a hybrid protein with the third and fourth EF-hands from the yeast centrin Cdc31p and the amino-terminal half from yeast calmodulin behaved more Like Cdc31p, indicating that the carboxyl-terminal half of Cdc31p influences binding specificity, Besides Kar1p, centrins bound to a yeast calmodulin binding site, explaining the dosage-dependent suppression of a calmodulin mutant by CDC31. Consistent with an essential role of Ca2+ for centrin functions, mutations in the first or the fourth EF-hands of Cdc31p, impairing the Ca2+-induced conformational change of Cdc31p, resulted in nonfunctional proteins in vice, Our results suggest that centrins are involved in Ca2+ signaling likely by influencing the properties of target proteins in response to changes in [Ca2+].	MAX PLANCK INST BIOCHEM, GENZENTRUM, D-82152 MARTINSRIED, GERMANY	Max Planck Society								ANAND S, 1987, BIOCHEM INT, V14, P963; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; Baron Andre T., 1992, P167; BAUM P, 1986, P NATL ACAD SCI USA, V83, P5512, DOI 10.1073/pnas.83.15.5512; BHATTACHARYA D, 1993, PLANT MOL BIOL, V23, P1243, DOI 10.1007/BF00042357; BIGGINS S, 1994, J CELL BIOL, V125, P843, DOI 10.1083/jcb.125.4.843; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS B, 1981, CYTOLOGY YEAST LIFE; BYERS B, 1981, A BENZON S, V16, P119; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; COHEN P, 1988, CALMODULIN MOL ASPEC, P91; DAVIS TN, 1992, CELL CALCIUM, V13, P435, DOI 10.1016/0143-4160(92)90056-X; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; ERRABOLU R, 1994, J CELL SCI, V107, P9; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; GEISER JR, 1993, MOL CELL BIOL, V13, P7913, DOI 10.1128/MCB.13.12.7913; Geissler S, 1996, EMBO J, V15, P3899, DOI 10.1002/j.1460-2075.1996.tb00764.x; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HAIECH J, 1991, J BIOL CHEM, V266, P3427; HORIO T, 1991, J CELL SCI, V99, P693; HUANG B, 1988, J CELL BIOL, V107, P121, DOI 10.1083/jcb.107.1.121; IIDA H, 1990, J BIOL CHEM, V265, P13391; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KILMARTIN JV, 1993, J CELL BIOL, V123, P1175, DOI 10.1083/jcb.123.5.1175; Kretsinger RH, 1996, NAT STRUCT BIOL, V3, P12, DOI 10.1038/nsb0196-12; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE VD, 1993, P NATL ACAD SCI USA, V90, P11039, DOI 10.1073/pnas.90.23.11039; Levy YY, 1996, CELL MOTIL CYTOSKEL, V33, P298; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1994, SCIENCE, V263, P963, DOI 10.1126/science.8310294; ONEIL KT, 1987, SCIENCE, V236, P1454, DOI 10.1126/science.3589665; PAINTRAND M, 1992, J STRUCT BIOL, V108, P107, DOI 10.1016/1047-8477(92)90011-X; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROUT MP, 1990, J CELL BIOL, V111, P1913, DOI 10.1083/jcb.111.5.1913; SALISBURY JL, 1984, J CELL BIOL, V99, P962, DOI 10.1083/jcb.99.3.962; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIEBEL E, 1995, TRENDS CELL BIOL, V5, P197, DOI 10.1016/S0962-8924(00)88999-0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Spang A, 1996, J CELL SCI, V109, P2229; SPANG A, 1993, J CELL BIOL, V123, P405, DOI 10.1083/jcb.123.2.405; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; STIRLING DA, 1994, EMBO J, V13, P4329, DOI 10.1002/j.1460-2075.1994.tb06753.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Sundberg HA, 1996, J CELL BIOL, V133, P111, DOI 10.1083/jcb.133.1.111; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAILLON BE, 1992, J CELL BIOL, V119, P1613, DOI 10.1083/jcb.119.6.1613; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1989, METHOD CELL BIOL, V30, P127; VALLEN EA, 1994, GENETICS, V137, P407; WEBER C, 1994, J BIOL CHEM, V269, P15795; Wiech H, 1996, J BIOL CHEM, V271, P22453, DOI 10.1074/jbc.271.37.22453; WRIGHT RL, 1985, J CELL BIOL, V101, P1903, DOI 10.1083/jcb.101.5.1903; ZHENG YX, 1991, CELL, V65, P817, DOI 10.1016/0092-8674(91)90389-G; ZHU JK, 1992, PLANT PHYSIOL, V99, P1734, DOI 10.1104/pp.99.4.1734	65	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28366	28374		10.1074/jbc.271.45.28366	http://dx.doi.org/10.1074/jbc.271.45.28366			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910460	hybrid			2022-12-27	WOS:A1996VU03300060
J	MagnierGaubil, C; Herbert, JM; Quarck, R; Papp, B; Corvazier, E; Wuytack, F; LevyToledano, S; Enouf, J				MagnierGaubil, C; Herbert, JM; Quarck, R; Papp, B; Corvazier, E; Wuytack, F; LevyToledano, S; Enouf, J			Smooth muscle cell cycle and proliferation - Relationship between calcium influx and sarco-endoplasmic reticulum Ca2+ ATPse regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; INOSITOL TRISPHOSPHATE; EXPRESSION; THAPSIGARGIN; ENTRY; INHIBITION; RECEPTOR; RELEASE; ISOFORM; STORES	The role of Ca2+ influx in the regulation of the sarco-endoplasmic reticulum Ca2+ ATPases (SERCA) associated with intracellular Ca2+ pools was investigated during smooth muscle cell (SMC) proliferation induced by platelet-derived growth factor (PDGF). We first; defined that the previously described up-regulation of the SERCA2a isoform found in vascular SMC after a 24-h stimulation with PDGF (Magnier, C., Papp, E., Corvazier, E., Bredoux, R., Wuytack, F., Eggermont, F., Maclouf, J., and Enouf, J. (1992) J. Biol. Chem. 267, 15808-15815) was precisely associated with SMC entry into S phase as it appeared linked with [H-3]thymidine incorporation, This was further confirmed by testing the effect of transforming growth factor-beta(1), which inhibited both aortic SMC proliferation associated with G(1) cell cycle arrest and PDGF-induced SERCA2a up-stimulation, Then, we tested the role of Ca2+ influx by using SR 33805, a nem Ca2+ channel blocker, which was characterized with regard to the voltage Ca2+ channel blocker nifedipine and the capacitative entry Ca2+ blocker SKF 96865, SR 33805 was found to be the most potent inhibitor of both PDGF-induced SMC proliferation and the associated rise in intracellular Ca2+ concentration with IC50 values of 0.2 +/- 0.1 and 0.51 +/- 0.04 mu M, respectively, Finally, by examining in parallel both SERCA2a and SERCA2b isoforms, in terms of activity and expression we could determine that PDGF-induced stimulation of total SERCA activity (detected by formation of the phosphorylated intermediate, E similar to P) and of SERCA2a expression (Western blotting) were abolished when extracellular Ca2+ entry was prevented by SR 33805, This study demonstrates that SERCA2a up-regulation is: 1) related to the G(1)/S transition step of cell cycle and 2) dependent on Ca2+ entry during PDGF-induced SMC proliferation.	HOP LARIBOISIERE, INSERM U348, IFR CIRCULAT LARIBOISIERE, F-75010 PARIS, FRANCE; SANOFI RECH, CTR TOULOUSE, F-31036 TOULOUSE, FRANCE; CATHOLIC UNIV LEUVEN, PHYSIOL LAB, B-3000 LOUVAIN, BELGIUM	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Sanofi-Aventis; Sanofi France; KU Leuven			Quarck, Rozenn/J-8067-2018	Quarck, Rozenn/0000-0002-8293-6261; Papp, Bela/0000-0002-5025-3087				AMRANI Y, 1995, BRIT J PHARMACOL, V115, P1204, DOI 10.1111/j.1476-5381.1995.tb15026.x; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4, DOI 10.1111/j.1476-5381.1995.tb14896.x; BAFFY G, 1995, BIOCHEM BIOPH RES CO, V210, P378, DOI 10.1006/bbrc.1995.1672; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CHATELAIN P, 1993, EUR J PHARM-MOLEC PH, V246, P181, DOI 10.1016/0922-4106(93)90030-D; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DOL F, 1995, EUR J PHARMACOL, V280, P135, DOI 10.1016/0014-2999(95)00196-R; EGGERMONT JA, 1990, BIOCHEM J, V271, P649, DOI 10.1042/bj2710649; FONTENAY M, 1992, J CELL PHYSIOL, V152, P507, DOI 10.1002/jcp.1041520310; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GILL DL, 1989, NATURE, V342, P16, DOI 10.1038/342016a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOSEY MM, 1988, J MEMBRANE BIOL, V104, P81, DOI 10.1007/BF01870922; KOBAYASHI S, 1994, J BIOL CHEM, V269, P9011; KOBAYASHI S, 1992, JPN J PHARM P, V412; LAPIDOT SA, 1995, ARTERIOSCL THROM VAS, V15, P44, DOI 10.1161/01.ATV.15.1.44; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LYTTON J, 1992, J BIOL CHEM, V267, P14483; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MEANS AR, 1988, CELL CALCIUM, V9, P313, DOI 10.1016/0143-4160(88)90012-7; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MOGAMI H, 1993, BIOCHEM BIOPH RES CO, V196, P650, DOI 10.1006/bbrc.1993.2299; PAPP B, 1991, J BIOL CHEM, V266, P14593; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; REDDY GPV, 1994, J CELL BIOCHEM, V54, P379, DOI 10.1002/jcb.240540404; REDDY KB, 1993, J CELL PHYSIOL, V156, P48, DOI 10.1002/jcp.1041560108; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; THASTRUP O, 1987, BIOCHIM BIOPHYS ACTA, V927, P65, DOI 10.1016/0167-4889(87)90066-8; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; VANBREEMEN C, 1989, ANNU REV PHYSIOL, V51, P315, DOI 10.1146/annurev.physiol.51.1.315; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; WHITFIELD J F, 1992, Critical Reviews in Oncogenesis, V3, P55; WUYTACK F, 1989, BIOCHEM J, V264, P765, DOI 10.1042/bj2640765	50	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27788	27794		10.1074/jbc.271.44.27788	http://dx.doi.org/10.1074/jbc.271.44.27788			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910375	hybrid			2022-12-27	WOS:A1996VQ67900093
J	RodriguezFernandez, JL; Rozengurt, E				RodriguezFernandez, JL; Rozengurt, E			Bombesin, bradykinin, vasopressin, and phorbol esters rapidly and transiently activate Src family tyrosine kinases in Swiss 3T3 cells - Dissociation from tyrosine phosphorylation of p125 focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; PROTEIN-PHOSPHORYLATION; ACTIN CYTOSKELETON; ANGIOTENSIN-II; TUMOR PROMOTER; DNA-SYNTHESIS; C SUBSTRATE; CROSS-TALK; STIMULATION; ENDOTHELIN	Treatment of quiescent Swiss 3T3 cells with bombesin induces a rapid (less than or equal to 40 s) and transient increase in the kinase activity of the Src family of tyrosine kinases, as determined by autophosphorylation in immune complex kinase assays (4.6 +/- 0.2-fold stimulation, n = 44) and phosphorylation of exogenous substrates. Phorbol 12,13-dibutyrate increased the activity of Src family kinases with similar kinetics but was less effective than bombesin. However, Src family kinase activation by bombesin is not dependent either on protein kinase C or Ca2+. Bombesin stimulation of Src family kinase activity could also be dissociated from p125 focal adhesion kinase tyrosine phosphorylation. Neither treatment with cytochalasin D nor placement of the cells in suspension prevented the stimulation of Src family kinase activity induced by bombesin, but both abolished bombesin-induced tyrosine phosphorylation of p125 focal adhesion kinase. The stimulation of the Src family kinase activity by bombesin was completely prevented by treatment with vanadate, a potent inhibitor of protein-tyrosine phosphatases. Bradykinin and vasopressin also stimulated Src family kinase activity transiently, and this stimulation was also inhibited by vanadate. Our results dissect two separate pathways that lead to protein tyrosine phosphorylation in neuropeptide-stimulated Swiss 3T3 cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Rodriguez-Fernandez, Jose Luis/Q-5021-2019	Rodriguez-Fernandez, Jose Luis/0000-0001-8874-1425				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; Dent P, 1996, J BIOL CHEM, V271, P3119, DOI 10.1074/jbc.271.6.3119; ERUSALIMSKY JD, 1988, J BIOL CHEM, V263, P19188; ERUSALIMSKY JD, 1991, J BIOL CHEM, V266, P7073; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LAU KHW, 1989, BIOCHEM J, V257, P23, DOI 10.1042/bj2570023; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIU XQ, 1993, ONCOGENE, V8, P1119; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHENOY S, 1992, P NATL ACAD SCI USA, V89, P7237, DOI 10.1073/pnas.89.15.7237; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	61	113	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27895	27901		10.1074/jbc.271.44.27895	http://dx.doi.org/10.1074/jbc.271.44.27895			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910389	hybrid			2022-12-27	WOS:A1996VQ67900107
J	Sakharov, DV; Lijnen, HR; Rijken, DC				Sakharov, DV; Lijnen, HR; Rijken, DC			Interactions between staphylokinase, plasmin(ogen), and fibrin - Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; FLUORESCENCE ANISOTROPY; PLASMA CLOT; ACTIVATION; MECHANISM; ALPHA-2-ANTIPLASMIN; STREPTOKINASE; COMPLEX; CONFORMATION; FRAGMENT	Staphylokinase (STA), a protein of bacterial ori,bin, induces highly fibrin-specific thrombolysis both in human plasma in vitro and in pilot clinical trials. Using fluorescence microscopy, we investigated the spatial distribution of fluorescein isothiocyanate (FITC)-labeled STA during lysis of a plasma clot and its binding to purified fibrin clots in the presence or in the absence of plasmin(ogen), STA highly accumulated in a thin superficial layer of the lysing plasma clot following the distribution of plasminogen (Pg) during lysis. Experiments with purified fibrin clots revealed that STA binds to Pg bound to partially degraded fibrin but not to Pg bound to intact fibrin, Binding of FITC-labeled STA to various forms of plasmin(ogen) in a buffer solution was studied by measuring fluorescence anisotropy. The binding constant for Glu-Pg was estimated as 7.4 mu M and for Lys-Pg as 0.28 mu M; for active-site blocked plasmin the binding constant was less than 0.05 mu M. The much lower affinity of STA for Glu-Pg compared with that for active site-blocked plasmin was mainly due to a lower association rate constant, as assessed by real time biospecific interaction analysis. Gel filtration of a mixture of STA with a molar excess of Glu-Pp demonstrated that STA migrated as an unbound 18-kDa protein when activation of Pg into plasmin was precluded by inhibitors of plasmin. When gel-filtered under the same conditions with plasmin, STA migrated in complex with plasmin with an apparent molecular mass of 100 kDa. Confocal fluorescence microscopy finally demonstrated that when FITC-labeled STA was added to plasma before clotting, it did not bind to fibrin fibers during the first minutes (lag phase), although Pg bound to the fibers moderately. Then, both Pg and STA started to accumulate on the fibers progressively, followed by complete lysis of the clot. In conclusion, our results imply that, when STA is added to plasma, only a small percentage associates with Pg. In contrast, STA binds strongly to plasmin and to Pg, which is bound to partially degraded fibrin. These findings add a new mechanism to the known explanations for the inefficient Pg activation by STA in plasma and specify the mechanism for fibrin-dependent activation of Pg.	CATHOLIC UNIV LEUVEN,CTR MOL & VASC BIOL,B-3000 LOUVAIN,BELGIUM	KU Leuven	Sakharov, DV (corresponding author), TNO,GAUBIUS LAB,PREVENT & HLTH,POB 2215,NL-2301 CE LEIDEN,NETHERLANDS.		Lijnen, Roger/AAA-4085-2020					Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; CEDERHOLMWILLIAMS SA, 1979, EUR J BIOCHEM, V100, P125, DOI 10.1111/j.1432-1033.1979.tb02040.x; COLLEN D, 1994, BLOOD, V84, P680, DOI 10.1182/blood.V84.3.680.680; COLLEN D, 1992, FIBRINOLYSIS, V6, P203, DOI 10.1016/0268-9499(92)90073-Q; COLLEN D, 1993, J BIOL CHEM, V268, P8284; COLLEN D, 1996, IN PRESS CIRCULATION; FLEURY V, 1993, J BIOL CHEM, V268, P18554; HUFF S, 1994, J BIOL CHEM, V269, P15563; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KOWALSKALOTH B, 1975, ACTA BIOCHIM POL, V22, P327; LIJNEN HR, 1991, J BIOL CHEM, V266, P11826; LIJNEN HR, 1992, BIOCHIM BIOPHYS ACTA, V1118, P144, DOI 10.1016/0167-4838(92)90142-Z; LIJNEN HR, 1994, EUR J BIOCHEM, V224, P143, DOI 10.1111/j.1432-1033.1994.tb20005.x; LIU JN, 1992, BIOCHEMISTRY-US, V31, P6311, DOI 10.1021/bi00142a021; MANGEL WF, 1990, SCIENCE, V248, P69, DOI 10.1126/science.2108500; Markus G, 1996, FIBRINOLYSIS, V10, P75, DOI 10.1016/S0268-9499(96)80082-8; MATSUO O, 1990, BLOOD, V76, P925; MCCANCE SG, 1995, BIOCHEMISTRY-US, V34, P9581, DOI 10.1021/bi00029a035; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; NORRMAN B, 1985, EUR J BIOCHEM, V149, P193, DOI 10.1111/j.1432-1033.1985.tb08911.x; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; RAMAKRISHNAN V, 1991, BIOCHEMISTRY-US, V30, P3963, DOI 10.1021/bi00230a023; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; SAKHAROV DV, 1994, FIBRINOLYSIS, V8, P116, DOI 10.1016/0268-9499(94)90268-2; SAKHAROV DV, 1996, FIBRINOLYSIS S3, V10, P75; SCHICK LA, 1974, BIOCHEM BIOPH RES CO, V57, P47, DOI 10.1016/S0006-291X(74)80355-4; SILENCE K, 1995, J BIOL CHEM, V270, P27192, DOI 10.1074/jbc.270.45.27192; SILENCE K, 1993, J BIOL CHEM, V268, P9811; SILENCE K, 1993, BLOOD, V82, P1175, DOI 10.1182/blood.V82.4.1175.bloodjournal8241175; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; URANO T, 1987, J BIOL CHEM, V262, P15959; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2050, DOI 10.1161/01.CIR.92.8.2050; VANDERSCHUEREN SMF, 1995, FIBRINOLYSIS, V9, P87, DOI 10.1016/S0268-9499(08)80019-7; WEISEL JW, 1994, J MOL BIOL, V235, P1117, DOI 10.1006/jmbi.1994.1061	37	43	49	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27912	27918		10.1074/jbc.271.44.27912	http://dx.doi.org/10.1074/jbc.271.44.27912			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910391	hybrid			2022-12-27	WOS:A1996VQ67900109
J	WeberNordt, RM; Riley, JK; Greenlund, AC; Moore, KW; Darnell, JE; Schreiber, BD				WeberNordt, RM; Riley, JK; Greenlund, AC; Moore, KW; Darnell, JE; Schreiber, BD			Stat-3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; IFN-GAMMA RECEPTOR; CYTOKINE RECEPTORS; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; BINDING PROTEIN; T-CELLS; ACTIVATION; IL-10	Recent work has shown that IL-10 induces activation of the JAK-STAT signaling pathway. To define the mechanism underlying signal transducer and activator of transcription (STAT) protein recruitment to the interleukin 10 (IL-10) receptor, the STAT proteins activated by IL-10 in different cell populations were first defined using electrophoretic mobility shift assays. In all cells tested, IL-10 activated Stat1 and Stat3 and induced the formation of three distinct DNA binding complexes that contained different combinations of these two transcription factors. IL-10 also activated Stat5 in Ba/F3 cells that stably expressed the murine IL-10 receptor. Using a structure-function mutagenesis approach, two tyrosine residues (Tyr(427) and Tyr(477)) in the intracellular domain of the murine IL-10 receptor were found to be redundantly required for receptor function and for activation of Stat3 beat not for Stat1 car Stat5. Twelve amino acid peptides encompassing either of these two tyrosine residues in phosphorylated form coprecipitated Stat3 hut not Stat1 and blocked IL-10-induced Stat3 phosphorylation in a cell-free system. In contrast, tyrosine-phosphorylated peptides containing Tyr(374) or Tyr(396) did not interact with Stat3 or block Stat3 activation. These data demonstrate that Stat3 but not Stat1 or Stat5 is directly recruited to the ligand-activated IL-10 receptor by binding to specific beat redundant receptor intracellular domain sequences containing phosphotyrosine. This study thus supports the concept that utilization of distinct STAT proteins by different cytokine receptors is dependent on the expression of particular ligand-activatable, tyrosine-containing STAT docking sites in receptor intracellular domains.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110; DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304; ROCKEFELLER UNIV,MOL CELL BIOL LAB,NEW YORK,NY 10021	Washington University (WUSTL); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Rockefeller University			Schreiber, Robert D/A-1276-2013	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341	NATIONAL CANCER INSTITUTE [R01CA043059, R37CA043059] Funding Source: NIH RePORTER; NCI NIH HHS [CA43059] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1992, SCIENCE, V257, P813, DOI 10.1126/science.1496402; DIGHE AS, 1993, J BIOL CHEM, V268, P10645; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FOUNTOULAKIS M, 1992, EUR J BIOCHEM, V208, P781, DOI 10.1111/j.1432-1033.1992.tb17248.x; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1992, IMMUNOL TODAY, V13, P198, DOI 10.1016/0167-5699(92)90153-X; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEHMANN J, 1994, J IMMUNOL, V153, P165; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; LIU Y, 1994, J IMMUNOL, V152, P1821; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.iy.11.040193.001121; MOORE KW, 1990, SCIENCE, V248, P1230, DOI 10.1126/science.2161559; MOSMANN TR, 1991, INT ARCH ALLER A IMM, V94, P110, DOI 10.1159/000235340; OGARRA A, 1990, INT IMMUNOL, V2, P821, DOI 10.1093/intimm/2.9.821; OSWALD IP, 1992, P NATL ACAD SCI USA, V89, P8676, DOI 10.1073/pnas.89.18.8676; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA K, 1993, BLOOD, V81, P2964; TAN JC, 1993, J BIOL CHEM, V268, P21053; WANG HY, 1996, IMMUNITY, V4, P331; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	43	165	168	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27954	27961		10.1074/jbc.271.44.27954	http://dx.doi.org/10.1074/jbc.271.44.27954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910398	hybrid			2022-12-27	WOS:A1996VQ67900116
J	Chien, AJ; Carr, KM; Shirokov, RE; Rios, E; Hosey, MM				Chien, AJ; Carr, KM; Shirokov, RE; Rios, E; Hosey, MM			Identification of palmitoylation sites within the L-type calcium channel beta(2a) subunit and effects on channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; CLONING	The hydrophilic beta(2a) subunit of the L-type calcium channel was recently shown to be a membrane-localized, post-translationally modified protein (Chien, A. J., Zhao, X. L., Shirokov, R. E., Purl, T. S., Chang, C. F., Sun, D. D., Rios, E., and Hosey, M. M. (1995) J. Biol, Chem, 270, 30036-30044), In this study, we demonstrate that the rat beta(2a) subunit was palmitoylated through a hydroxylamine sensitive thioester linkage, Palmitoylation required a pair of cysteines in the N terminus, Cys(3) and Cys(4); mutation of these residues to serines resulted in mutant beta(2a) subunits that were unable to incorporate palmitic acid, Interestingly, a palmitoylation-deficient beta(2a) mutant still localized to membrane particulate fractions and was still able to target functional channel complexes to the plasma membrane similar to wild-type beta(2a). However, channels formed with a palmitoylation-deficient beta(2a) subunit exhibited a dramatic decrease in ionic current per channel, indicating that although mutations eliminating palmitoylation did not affect channel targeting by the beta(2a) subunit, they were important determinants of channel modulation by the beta(2a) subunit, Three other known beta subunits that were analyzed were not palmitoylated, suggesting that palmitoylation could provide a basis for the regulation of L-type channels through modification of a specific beta isoform.	NORTHWESTERN UNIV,SCH MED,DEPT MOL PHARMACOL & BIOL CHEM S215,CHICAGO,IL 60611; UKRAINIAN ACAD SCI,AA BOGOMOLETZ INST PHYSIOL,UA-252024 KIEV,UKRAINE; RUSH UNIV,DEPT PHYSIOL,CHICAGO,IL 60612	Northwestern University; National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of Physiology; Rush University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL023306, R01HL023306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F30MH010770] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23306] Funding Source: Medline; NIAMS NIH HHS [AR43113] Funding Source: Medline; NIMH NIH HHS [1 F30 MH10770] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; CMAP LA, 1995, J BIOL CHEM, V269, P23212; GERHARDSTEIN B, 1996, BIOPHYS J, V70, P186; Josephson IR, 1996, BIOPHYS J, V70, P1285, DOI 10.1016/S0006-3495(96)79685-6; Kamp TJ, 1996, J PHYSIOL-LONDON, V492, P89, DOI 10.1113/jphysiol.1996.sp021291; LINDER ME, 1995, METHOD ENZYMOL, V250, P314; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SHIROKOV R, 1996, BIOPHYS J, V70, P183; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6	17	159	162	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26465	26468		10.1074/jbc.271.43.26465	http://dx.doi.org/10.1074/jbc.271.43.26465			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900112	hybrid			2022-12-27	WOS:A1996VP23300006
J	Shworak, NW; Fritze, LMS; Liu, J; Butler, LD; Rosenberg, RD				Shworak, NW; Fritze, LMS; Liu, J; Butler, LD; Rosenberg, RD			Cell-free synthesis of anticoagulant heparan sulfate reveals a limiting converting activity that modifies an excess precursor pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-BINDING SEQUENCE; ENDOTHELIAL-CELLS; HIGH-AFFINITY; PROTEOGLYCANS; BIOSYNTHESIS; EXPRESSION; RESIDUES; PROTEINS; SITES	LTA cells synthesize a minor population of heparan sulfate proteoglycans (HSPG(act)) bearing anticoagulant heparan sulfate (HSact) with a specific monosaccharide sequence that accelerates the action of antithrombin (AT), LTA cells also synthesize a major population of heparan sulfate proteoglycans endowed with nonanticoagulant heparan sulfate (HSinact) lacking the AT-binding site. To investigate the pathway specific features of HSPG(act) generation, we established a novel detergent-containing cell-free system with unlabeled and labeled microsomes from wild-type and variant LTA cells, respectively, The unlabeled microsomes provide ''HSact conversion activity'' that requires 3'-phosphoadenosine 5'-phosphosulfate to convert [S-35]HSPG(inact) into [S-35] HSPG(act), presumably by sulfation, The reaction kinetics demonstrate that the rate of HSact synthesis is constant over the first 4 h of incubation, During this time, the rate of HSact production is linearly dependent on the amount of unlabeled LTA microsomal protein over a range of 10 to 50 mu g as well as on the level of [S-35]HS substrate over a range of 0.4 to 4.0 mu g, microsomal protein, Compared with labeled microsomes, equivalent or slightly greater levels of HSact were generated from S-35-labeled HSPG, microsomal HS, or cell surface HS, which demonstrates that HSinact is the minimal substrate and that large amounts of HSact precursor exit the Golgi apparatus, Indeed, extensive modification of wild-type LTA cell surface [S-35]HS elevated HSact content from 9 to 35%, The hypothesis that microsomal HSact conversion activity predicts the cellular rate of HSact generation was tested with wild-type or variant LTA cells in which production of HSact has been significantly altered by mutagenesis or overexpression of core protein or growth conditions, The data demonstrate that microsomal HSact conversion activity accurately reflects the cellular rate of HSact synthesis over a very wide range of conditions, The possibility that the reduced HSact generation is due to an inhibitor was excluded by mixing experiments, The possibility that reduced HSact generation is caused by decreased levels of HSact precursor was excluded as equivalent levels of HSact were formed from wild-type and variant [S-35]HS, Based upon the above data, the LTA cell microsomal HSact conversion activity contains one or more limiting components that kinetically regulate the rate of cellular HSact generation and the levels of HSact precursor in HS greatly exceed HSact production.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [HL-33014, HL-41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DEAGOSTINI AL, 1990, P NATL ACAD SCI USA, V87, P9784, DOI 10.1073/pnas.87.24.9784; DEBENHAM PG, 1982, MOL CELL BIOL, V2, P881, DOI 10.1128/MCB.2.8.881; FLEISCHER B, 1970, Biochimica et Biophysica Acta, V219, P301, DOI 10.1016/0005-2736(70)90209-9; KIT S, 1963, EXP CELL RES, V31, P297, DOI 10.1016/0014-4827(63)90007-7; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KOJIMA T, 1992, J BIOL CHEM, V267, P4870; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LITTLEFIELD JW, 1963, P NATL ACAD SCI USA, V50, P568, DOI 10.1073/pnas.50.3.568; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1989, HEPARIN, P275; MERTENS G, 1992, J BIOL CHEM, V267, P20435; PEJLER G, 1987, J BIOL CHEM, V262, P5036; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; RICE LI, 1967, ARCH BIOCHEM BIOPHYS, V118, P374, DOI 10.1016/0003-9861(67)90363-3; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; SILBERT JE, 1967, J BIOL CHEM, V242, P2301	34	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27063	27071		10.1074/jbc.271.43.27063	http://dx.doi.org/10.1074/jbc.271.43.27063			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900197	hybrid			2022-12-27	WOS:A1996VP23300091
J	Clotet, J; Posas, F; deNadal, E; Arino, J				Clotet, J; Posas, F; deNadal, E; Arino, J			The NH2-terminal extension of protein phosphatase PPZ1 has an essential functional role	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; SALT TOLERANCE; GENE; MYRISTOYLATION; CALCINEURIN; EXPRESSION; ISOFORMS; SUBUNIT; CELLS	Deletion of the yeast Ser/Thr protein phosphatase PPZ1 results in increased tolerance to sodium and Lithium. PPZ1 is also important for cell integrity, as ppz1 Delta cells undergo lysis under caffeine stress and PPZ1 over-expression overrides the lytic defect of mutants in the protein kinase C/mitogen-activated protein (MAP) kinase pathway. The PPZ1 protein can be dissected in two halves. The COOH-terminal half is related to type 1 phosphatases, whereas the NH2-terminal half is unrelated to phosphatases and contains a consensus site for N-myristoylation. Several mutated versions of PPZ1 have been constructed and tested for complementation of ppz1 Delta mutants. me show that PPZ1 can be myristoylated in vivo and that change of Gly-2 to Ala results in lack of myristoylation and loss of complementation of salt tolerance, Removal of the entire NH2-terminal half results in complete loss of function, although it does not abolish the phosphatase activity of the protein expressed in Escherichia coli. The deletion of a large region of the NH2-terminal half (residues 17-193) does not affect the ability to complement the salt tolerance phenotype but abolish complementation of caffeine sensitivity, whereas the opposite behavior is observed upon removal of residues from 241 to 318. Mutation of Arg-451 to Leu results in both complete loss of function and of phosphatase activity. These results indicates that the NH2-terminal half of the protein contains structural determinants that are specific for certain functions and that the phosphatase activity is required but not sufficient for full PPZ1 function.	UNIV AUTONOMA BARCELONA,FAC VET,DEPT BIOQUIM & BIOL MOL,BELLATERRA 08193,BARCELONA,SPAIN	Autonomous University of Barcelona			Arino, Joaquin/D-3756-2011; de Nadal, Eulàlia/J-8178-2014; Posas, Francesc/K-1364-2013	Arino, Joaquin/0000-0002-6774-2987; de Nadal, Eulàlia/0000-0003-0039-5607; Posas, Francesc/0000-0002-4164-7076; Arino Carmona, Joaquin/0000-0002-0390-4270				BLACK S, 1995, YEAST, V11, P747, DOI 10.1002/yea.320110806; BREUDER T, 1994, P NATL ACAD SCI USA, V91, P5372, DOI 10.1073/pnas.91.12.5372; CANNON JF, 1995, ADV PROTEIN PHOSPHAT, V9, P211; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1993, ADV PROTEIN PHOSPHAT, V7, P429; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HUGHES V, 1993, EUR J BIOCHEM, V216, P269, DOI 10.1111/j.1432-1033.1993.tb18142.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENNY TF, 1995, PROTEINS, V21, P1, DOI 10.1002/prot.340210102; JOHNSON DR, 1994, P NATL ACAD SCI USA, V91, P10158, DOI 10.1073/pnas.91.21.10158; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LIU HP, 1992, GENETICS, V132, P665; LOHR D, 1988, YEAST PRACTICAL APPR, P125; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; POSAS F, 1993, FEBS LETT, V318, P282, DOI 10.1016/0014-5793(93)80529-4; POSAS F, 1995, FEBS LETT, V368, P39, DOI 10.1016/0014-5793(95)00593-X; POSAS F, 1992, J BIOL CHEM, V267, P11734; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; ZHANG SR, 1995, MOL CELL BIOL, V15, P2037; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	39	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26349	26355		10.1074/jbc.271.42.26349	http://dx.doi.org/10.1074/jbc.271.42.26349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824289	hybrid			2022-12-27	WOS:A1996VN18000095
J	Heiska, L; Kantor, C; Parr, T; Critchley, DR; Vilja, P; Gahmberg, CG; Carpen, O				Heiska, L; Kantor, C; Parr, T; Critchley, DR; Vilja, P; Gahmberg, CG; Carpen, O			Binding of the cytoplasmic domain of intercellular adhesion molecule-2 (ICAM-2) to alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; CYTOSKELETAL PROTEINS; MEMBRANE INTERACTIONS; LFA-1; VINCULIN; CELL; EXPRESSION; CLONING; LIGAND; GLYCOPROTEIN	Intercellular adhesion molecule-2 (ICAM-2) functions as a ligand for lymphocyte function-associated antigen-1 (LFA-1) and is involved in leukocyte adhesion, We studied intracellular associations of ICAM-2 using a peptide encompassing the cytoplasmic amino acids 231-254 as an affinity matrix, Among the proteins from placental lysates that bound to the peptide was alpha-actinin as demonstrated by immunoblotting. Purified, I-125-labeled alpha-actinin also bound to the peptide. Confocal microscopic analysis of Eahy926 cells demonstrated a colocalization of ICAM-2 and alpha-actinin. Of overlapping octapeptides covering the entire ICAM-2 cytoplasmic amino acids, ICAM-2(241-248) bound alpha-actinin most avidly and effectively competed with the longer cytoplasmic peptide for binding. The site of interaction in alpha-actinin was studied using bacterially expressed alpha-actinin fusion proteins, Several constructs covering nonoverlapping regions of alpha-actinin bound to the ICAM-2 cytoplasmic peptide suggesting that multiple regions in alpha-actinin can mediate the interaction, These results, together with previously demonstrated interactions between alpha-actinin and the adhesion proteins ICARS-1, L-selectin, beta(1)- and beta(2)-integrins emphasize the role of alpha-actinin as a linker between cell surface adhesion molecules and the actin containing cytoskeleton.	UNIV HELSINKI,DEPT BIOSCI,DIV BIOCHEM,FIN-00014 HELSINKI,FINLAND; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV TAMPERE,SCH MED,FIN-33101 TAMPERE,FINLAND	University of Helsinki; University of Leicester; Tampere University	Heiska, L (corresponding author), UNIV HELSINKI,DEPT PATHOL,DIV BIOCHEM,HAARTMANINK 3,POB 21,FIN-00014 HELSINKI,FINLAND.		Gahmberg, Carl/AAE-1876-2019	Gahmberg, Carl/0000-0001-9892-9296				ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; BELKIN AM, 1987, FEBS LETT, V220, P291, DOI 10.1016/0014-5793(87)80832-3; CAMPANERO MR, 1994, J CELL BIOL, V127, P867, DOI 10.1083/jcb.127.3.867; CAMPANERO MR, 1993, J CELL BIOL, V123, P1007, DOI 10.1083/jcb.123.4.1007; CARPEN O, 1991, J CELL BIOL, V115, P861, DOI 10.1083/jcb.115.3.861; CARPEN O, 1983, J IMMUNOL, V131, P2695; CARPEN O, 1992, J CELL BIOL, V118, P1223, DOI 10.1083/jcb.118.5.1223; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DEFOUGEROLLES AR, 1993, J EXP MED, V177, P1187, DOI 10.1084/jem.177.4.1187; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DIACOVO TG, 1994, J CLIN INVEST, V94, P1243, DOI 10.1172/JCI117442; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Gilmore A. P., 1994, Molecular Biology of the Cell, V5, p45A; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; GILMORE AP, 1994, EUR J BIOCHEM, V225, P235, DOI 10.1111/j.1432-1033.1994.00235.x; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; NORTAMO P, 1991, EUR J IMMUNOL, V21, P2629, DOI 10.1002/eji.1830211049; NORTAMO P, 1991, J IMMUNOL, V146, P2530; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTTO JJ, 1983, J CELL BIOL, V97, P1283, DOI 10.1083/jcb.97.4.1283; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; RENKONEN R, 1992, AM J PATHOL, V140, P763; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; WACHSSTOCK DH, 1987, BIOCHEM BIOPH RES CO, V146, P554, DOI 10.1016/0006-291X(87)90564-X; YOSHIHARA Y, 1994, NEURON, V12, P541, DOI 10.1016/0896-6273(94)90211-9	38	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26214	26219		10.1074/jbc.271.42.26214	http://dx.doi.org/10.1074/jbc.271.42.26214			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824270	hybrid			2022-12-27	WOS:A1996VN18000076
J	Kan, M; Wang, F; Kan, M; To, B; Gabriel, JL; McKeehan, WL				Kan, M; Wang, F; Kan, M; To, B; Gabriel, JL; McKeehan, WL			Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; CELL-ADHESION; LIGAND-BINDING; ACTIVATION; AFFINITY; KINASE; FGF; IDENTIFICATION; MECHANISM; PROTECTS	Polypeptides of the fibroblast growth factor (FGF) family are ubiquitous bioregulators within tissues whose activity is controlled by heparan sulfates within the pericellular matrix. FGF and the ectodomain of their transmembrane tyrosine kinase receptors (FGFR) exhibit heparin-binding domains that when juxtaposed in a FGF . FGFR complex can accommodate a single, potentially bivalent, decameric polysaccharide chain in a ternary complex. Here we show that the interaction of heparin with FGF ligands is not affected by divalent cations. In contrast, the high affinity interaction (apparent K-d = 10 nM) Of heparin with FGFR requires Ca2+ or Mg2+ at physiological concentrations. Divalent cations maintain FGFR in a heparan sulfate-dependent state in respect to FGF binding and an FGF- and heparan sulfate-dependent state in respect to autophosphorylation. A model is proposed where divalent cations and heparan sulfate cooperate to maintain FGFR in a conformation that restricts trans-phosphorylation between intracellular kinase domains. The restriction is overcome by FGF or constitutively as a common consequence of diverse mutations in FGFR associated with skeletal and craniofacial abnormalities.	TEXAS A&M UNIV, ALBERT B ALKEK INST BIOSCI & TECHNOL, DEPT BIOCHEM & BIOPHYS, CTR CANC BIOL & NUTR, HOUSTON, TX 77030 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Texas A&M University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK47039, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICKMAN YG, 1995, J BIOL CHEM, V270, P24941, DOI 10.1074/jbc.270.42.24941; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELISSER HM, 1993, J BIOL CHEM, V268, P16037; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HOU JZ, 1992, J BIOL CHEM, V267, P17804; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LUO Y, 1996, IN PRESS J BIOL CHEM, V271; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; Matsuzaki K, 1996, IN VITRO CELL DEV-AN, V32, P345, DOI 10.1007/BF02722961; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MUENKE M, 1995, TRENDS GENET, V11, P308, DOI 10.1016/S0168-9525(00)89088-5; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; NEILSON KM, 1995, J BIOL CHEM, V270, P26037, DOI 10.1074/jbc.270.44.26037; NORGARDSUMNICHT KE, 1993, SCIENCE, V261, P480, DOI 10.1126/science.7687382; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; Patstone G, 1996, J BIOL CHEM, V271, P3343; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; Wang F., 1995, Molecular Biology of the Cell, V6, p123A; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; XU JM, 1992, J BIOL CHEM, V267, P17792; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	43	89	97	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26143	26148		10.1074/jbc.271.42.26143	http://dx.doi.org/10.1074/jbc.271.42.26143			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824259	hybrid			2022-12-27	WOS:A1996VN18000065
J	Krishna, MC; Russo, A; Mitchell, JB; Goldstein, S; Dafni, H; Samuni, A				Krishna, MC; Russo, A; Mitchell, JB; Goldstein, S; Dafni, H; Samuni, A			Do nitroxide antioxidants act as scavengers of O-2(.-) or as SOD mimics?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE ACTIVITY; HYDROGEN-PEROXIDE; CYTOCHROME-C; PHARMACOKINETIC PROPERTIES; POLYETHYLENE-GLYCOL; OXIDATIVE DAMAGE; ANION; DESFERRIOXAMINE; CARDIOMYOCYTES; COMPLEXES	Stable nitroxide radicals were reported to act as SOD mimics and catalyze the dismutation of O-2-radical-anion through two different catalytic pathways including reducive and oxidative reaction mechanisms (Samuni, A., Krishna, C. M., Riesz, P., Finkelstein, E, & Russo, A. (1988) J. Biol Chem. 263, 17921-17924). Recent studies directly monitoring O-2-radical-anion and employing kinetics analysis did not reveal SOD activity of nitroxides (Weiss, R. H., Flickinger, A. G., Rivers, W. J., Hardy, M. M., Aston, K. W., Ryan, U. S. & Riley, D. P. (1993) J. Biol. Chen. 268, 23049-23054). Such discrepancy may result in cases where distinction of stoichiometric scavengers from catalytic detoxifiers of O-2-radical-anion is not readily feasible. Nitroxides are effective antioxidants that protect against oxidative injury in various pathological processes. The distinction of their SOD mimic activity from O-2-radical-anion scavenging was established by examining the validity of direct and indirect methods employed to assay SOD-like catalytic activity. Kinetics analysis along with direct EPR monitoring were used to study the mechanism underlying nitroxide reactions with O-2-radical-anion. The nitroxide EPR signal decayed in the presence of NADH but otherwise did not decrease with time, thus substantiating its catalytic role in O-2-radical-anion dismutation. The catalytic rate constants for O-2-radical-anion dismutation, determined for the nitroxides tested, were found to increase with [H+], indicating that (OOH)-O-. rather than O-2-radical-anion is oxidizing the nitroxide. The results demonstrate the limitations associated with direct kinetics analysis in evaluating SOD mimic activity, underscoring the need for independent assays for valid discrimination of SOD mimics from stoichiometric scavengers of O-2-radical-anion.	HEBREW UNIV JERUSALEM, DEPT MOL BIOL, IL-91120 JERUSALEM, ISRAEL; HEBREW UNIV JERUSALEM, DEPT PHYS CHEM, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem; Hebrew University of Jerusalem			Dafni, Hagit/I-1873-2019					BARR DP, 1995, J BIOL CHEM, V270, P12709, DOI 10.1074/jbc.270.21.12709; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BEYER WF, 1989, ARCH BIOCHEM BIOPHYS, V271, P149, DOI 10.1016/0003-9861(89)90265-8; BOCCU E, 1982, PHARMACOL RES COMMUN, V14, P113, DOI 10.1016/S0031-6989(82)80092-1; BRAWN K, 1980, ACTA PHYSIOL SCAND, P9; BRIGELIUS R, 1975, H-S Z PHYSIOL CHEM, V356, P739, DOI 10.1515/bchm2.1975.356.s1.739; BUTLER J, 1975, BIOCHIM BIOPHYS ACTA, V408, P215, DOI 10.1016/0005-2728(75)90124-3; BUTLER J, 1982, J BIOL CHEM, V257, P747; Czapski G, 1988, Free Radic Res Commun, V4, P231, DOI 10.3109/10715768809055147; DARR D, 1987, ARCH BIOCHEM BIOPHYS, V258, P351, DOI 10.1016/0003-9861(87)90354-7; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GOLDFRIED MR, 1991, J PSYCHOTHERAPY INTE, V1, P5; GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0; GOLDSTEIN S, 1986, Journal of Free Radicals in Biology and Medicine, V2, P3, DOI 10.1016/0748-5514(86)90117-0; HAHN SM, 1991, ARCH BIOCHEM BIOPHYS, V288, P215, DOI 10.1016/0003-9861(91)90186-M; HUBER KR, 1987, BIOCHIM BIOPHYS ACTA, V915, P267, DOI 10.1016/0167-4838(87)90309-8; KOPPENOL WH, 1986, ARCH BIOCHEM BIOPHYS, V251, P594, DOI 10.1016/0003-9861(86)90368-1; KORCHERGINSKI N, 1995, NITROXIDE SPIN LABEL, P27; KRISHNA MC, 1994, METHOD ENZYMOL, V234, P580; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; Krishna MC, 1996, J BIOL CHEM, V271, P26018, DOI 10.1074/jbc.271.42.26018; LENGFELDER E, 1978, H-S Z PHYSIOL CHEM, V359, P751; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MIURA Y, 1993, ARCH BIOCHEM BIOPHYS, V300, P148, DOI 10.1006/abbi.1993.1021; MOHSEN M, 1995, MOL CELL BIOCHEM, V145, P103, DOI 10.1007/BF00935482; NAGANO T, 1989, J BIOL CHEM, V264, P9243; RABINOWITCH HD, 1989, FREE RADICAL BIO MED, V6, P45, DOI 10.1016/0891-5849(89)90158-5; RACHMILEWITZ D, 1994, GUT, V35, P1181, DOI 10.1136/gut.35.9.1181; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; ROBERTSON P, 1980, ARCH BIOCHEM BIOPHYS, V203, P830, DOI 10.1016/0003-9861(80)90246-5; SAMUNI A, 1991, BIOCHEMISTRY-US, V30, P555, DOI 10.1021/bi00216a033; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; SAMUNI A, 1990, ADV EXP MED BIOL, V264, P85; SAWYER DT, 1981, ACCOUNTS CHEM RES, V14, P393, DOI 10.1021/ar00072a005; TURRENS JF, 1988, FEBS LETT, V227, P43, DOI 10.1016/0014-5793(88)81410-8; VERONESE FM, 1983, J PHARM PHARMACOL, V35, P757, DOI 10.1111/j.2042-7158.1983.tb02888.x; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WESER U, 1980, BIOCHIM BIOPHYS ACTA, V631, P232, DOI 10.1016/0304-4165(80)90298-6	41	328	344	1	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26026	26031		10.1074/jbc.271.42.26026	http://dx.doi.org/10.1074/jbc.271.42.26026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824242				2022-12-27	WOS:A1996VN18000048
J	Ohnishi, H; Kubota, R; Ohtake, A; Sato, K; Sano, SI				Ohnishi, H; Kubota, R; Ohtake, A; Sato, K; Sano, SI			Activation of protein-tyrosine phosphatase SH-PTP2 by a tyrosine-based activation motif of a novel brain molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; CELL ANTIGEN RECEPTOR; SH2 DOMAINS; SIGNAL TRANSDUCTION; SEQUENCE SIMILARITY; CONTAINING PEPTIDES; SYP PHOSPHATASE; KINASE; INSULIN	BIT (a brain Immunoglobulin-like molecule with tyrosine-based activation motifs) is a brain-specific membrane protein which has two cytoplasmic TAMs (tyrosine-based activation motifs). Using the Far Western blotting technique, we detected association of a 70-kDa protein with the tyrosine-phosphorylated TAMs of BIT. A mouse brain cDNA library in lambda gt11 was screened for this association, and two positive clones encoding tyrosine phosphatase SH-PTP2 were isolated. SH-PTP2 has two SH2 domains and is believed to function as a positive mediator in receptor tyrosine kinase signaling. SH-PTP2 and BIT were coimmunoprecipitated from phosphorylated rat brain lysate, and BIT was a major tyrosine-phosphorylated protein associated with SH-PTP2 in this lysate. This interaction was also observed in Jurkat T cells transfected with BIT cDNA depending on tyrosine phosphorylation of BIT. Bisphosphotyrosyl peptides corresponding to BIT-TAMs stimulated SH-PTP2 activity 33-35-fold in vitro, indicating that two SH2 domains of SH-PTP2 simultaneously interact with two phosphotyrosines of BIT-TAM. Our findings suggest that the tyrosine phosphorylation of BIT results in stimulation of the signal transduction pathway promoted by SH-PTP2 and that BIT is probably a major receptor molecule in the brain located just upstream of SH-PTP2.	MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN									ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CAMBIER JC, 1992, FASEB J, V6, P3207, DOI 10.1096/fasebj.6.13.1397843; CELENZA JL, 1991, METHOD ENZYMOL, V200, P423; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIRAGA A, 1992, EUR J BIOCHEM, V209, P195, DOI 10.1111/j.1432-1033.1992.tb17277.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KORETZKY GA, 1993, FASEB J, V7, P420, DOI 10.1096/fasebj.7.5.8462784; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PENG ZY, 1995, ONCOGENE, V11, P1955; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANO S, 1989, J BIOCHEM-TOKYO, V105, P457, DOI 10.1093/oxfordjournals.jbchem.a122686; SANO S, 1990, J NEUROCHEM, V55, P1252, DOI 10.1111/j.1471-4159.1990.tb03132.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUZUKI T, 1995, BIOCHEM BIOPH RES CO, V211, P950, DOI 10.1006/bbrc.1995.1904; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAGI T, 1994, DEV GROWTH DIFFER, V36, P543; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	46	88	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25569	25574		10.1074/jbc.271.41.25569	http://dx.doi.org/10.1074/jbc.271.41.25569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810330	hybrid			2022-12-27	WOS:A1996VL69300074
J	Klinman, JP				Klinman, JP			New quinocofactors in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							COPPER AMINE OXIDASES; BACTERIAL MONOAMINE-OXIDASE; ACTIVE-SITE; TOPA QUINONE; LYSYL OXIDASE; MECHANISM; COFACTOR; OXIDATION; MODEL; TOPAQUINONE		UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	Klinman, JP (corresponding author), UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM39296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTON G, 1995, ARCH BIOCHEM BIOPHYS, V316, P353, DOI 10.1006/abbi.1995.1047; BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BROWN DE, 1991, J BIOL CHEM, V266, P4049; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; DAVIDSON VL, 1990, PRINCIPLES APPL QUIN, P3; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; DUINE JA, 1989, ANNU REV BIOCHEM, V58, P403; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P4605, DOI 10.1021/bi00232a035; HARTMANN C, 1987, J BIOL CHEM, V262, P962; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KAGAN HM, 1986, BIOL EXTRACELLULAR M, V1, P321; KILLGORE J, 1989, SCIENCE, V245, P850, DOI 10.1126/science.2549636; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KLINMAN JP, 1996, IN PRESS CHEM REV; LEE Y, 1995, J AM CHEM SOC, V117, P11823, DOI 10.1021/ja00153a001; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MATSUZAKI R, 1995, BIOCHEMISTRY-US, V34, P4524, DOI 10.1021/bi00014a004; MCCRACKEN J, 1992, J AM CHEM SOC, V114, P3715, DOI 10.1021/ja00036a021; MU D, 1994, J BIOL CHEM, V269, P9926; MU D, 1992, J BIOL CHEM, V267, P7979; MU D, 1993, THESIS U CALIFORNIA; MURE M, 1995, J AM CHEM SOC, V117, P8698, DOI 10.1021/ja00139a002; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; Nakamura N, 1996, J BIOL CHEM, V271, P4718; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; PAZ MA, 1991, J BIOL CHEM, V266, P689; RIUS FX, 1984, BIOCHEM J, V220, P767, DOI 10.1042/bj2200767; SEAMAN CH, 1992, BIOCHEMISTRY-US, V31, P6829; SHAH MA, 1993, J BIOL CHEM, V268, P11573; TIPPING AJ, 1995, J BIOL CHEM, V270, P16939, DOI 10.1074/jbc.270.28.16939; TRACKMAN PC, 1990, BIOCHEMISTRY-US, V29, P4863, DOI 10.1021/bi00472a016; TUR SS, 1988, FEBS LETT, V238, P74, DOI 10.1016/0014-5793(88)80228-X; Wang SX, 1996, SCIENCE, V273, P1078, DOI 10.1126/science.273.5278.1078; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P6302	39	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27189	27192		10.1074/jbc.271.44.27189	http://dx.doi.org/10.1074/jbc.271.44.27189			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910283	hybrid			2022-12-27	WOS:A1996VQ67900001
J	McGuire, TF; Qian, YM; Vogt, A; Hamilton, AD; Sebti, SM				McGuire, TF; Qian, YM; Vogt, A; Hamilton, AD; Sebti, SM			Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GERANYLGERANYLTRANSFERASE-I; MEMBRANE ASSOCIATION; SIGNAL TRANSDUCTION; MITOGENIC ACTIVITY; RAS FARNESYLATION; FARNESYLTRANSFERASE; INHIBITORS; CELLS; TRANSFERASE	We have used specific inhibitors for farnesyltransferase (FTase) and geranylgeranyltransferase (GGTase) I as well as combinations of lovastatin with geranylgeraniol (GGOH) or farnesol (FOR) to investigate the role of protein prenylation in platelet-derived growth factor (PDGF)-induced PDGF receptor tyrosine phosphorylation, NIH-3T3 cells treated with the highly specific FTase inhibitor FTI-277 had no effect on PDGF receptor tyrosine phosphorylation or PDGF activation of mitogen-activated protein kinase (MAPK) at doses that completely inhibit FTase-dependent processing. In contrast, treatment of these cells with GGTase I inhibitor GGTI-298 strongly inhibited receptor tyrosine phosphorylation, and co-treatment with FTI-277 had no additional effect, Interestingly, the inhibitory effect of GGTI-298 on PDGF activation of MAPK was only partial, Furthermore, although lovastatin, which inhibits both protein geranylgeranylation and protein farnesylation, blocked PDGF receptor tyrosine phosphorylation, co-treatment with GGOH, but mat FOH, reversed the lovastatin block, In addition, although lovastatin was observed to block MAPK activation by PDGF, co-treatment with GGOH, but not FOH, Pestered its activation, Further investigations indicated that inhibition of receptor tyrosine phosphorylation was blot: due to decreased expression of the receptor or to inhibition of GGTase II, Thus, these results demonstrate that PDGF receptor tyrosine phosphorylation requires protein geranylgeranylation but not protein farnesylation and that the tyrosine phosphorylation levels of the receptor are modulated by a protein that is a substrate for GGTase I.	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [U19-CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1992, J LIPID RES, V33, P1731; CRICK DC, 1995, BIOCHEM BIOPH RES CO, V211, P590, DOI 10.1006/bbrc.1995.1854; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GRAHAM SL, 1994, J MED CHEM, V37, P725, DOI 10.1021/jm00032a004; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGUIRE TF, 1995, BIOCHEM BIOPH RES CO, V214, P295, DOI 10.1006/bbrc.1995.2287; MCGUIRE TF, 1994, BIOCHEM BIOPH RES CO, V204, P399, DOI 10.1006/bbrc.1994.2472; MCGUIRE TF, 1993, J BIOL CHEM, V268, P22227; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PATEL DV, 1995, J MED CHEM, V38, P435, DOI 10.1021/jm00003a006; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SUN JZ, 1995, CANCER RES, V55, P4243; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	35	105	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27402	27407		10.1074/jbc.271.44.27402	http://dx.doi.org/10.1074/jbc.271.44.27402			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910319	hybrid			2022-12-27	WOS:A1996VQ67900037
J	Tonetti, M; Sturla, L; Bisso, A; Benatti, U; DeFlora, A				Tonetti, M; Sturla, L; Bisso, A; Benatti, U; DeFlora, A			Synthesis of GDP-L-fucose by the human FX protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GALACTOSIDE ALPHA-2-L-FUCOSYL-TRANSFERASE; ADENINE-DINUCLEOTIDE PHOSPHATE; HUMAN-ERYTHROCYTES; D-MANNOSE; GENE; CONVERSION; IDENTIFICATION; TRANSFERASE; METABOLISM; EXPRESSION	FX is a homodimeric NADP(H)-binding protein of 65 kDa, first identified in human erythrocytes, from which it was purified to humogeneity. Its function has been unrecognized despite partial structural and genetic characterization. Recently, on the basis of partial amino acid sequence, it proved to be the human homolog of the murine protein P35B, a tumor rejection antigen, In order to address the biochemical role of FX, its primary structure was completed by cDNA sequencing, This sequence revealed a significant homology with many proteins from different organisms, Specifically, FX showed a remarkable similarity with a putative Escherichia coli protein, named Yefb, whose gene maps in a region of E. coli chromosome coding for enzymes involved in synthesis and utilization of GDP-D-mannose. Accordingly, a possible role of FX ir, this metabolism was investigated The data obtained indicate FX as the enzyme responsible or the Last step of the major metabolic pathway resulting in GDP-L-fucose synthesis from GDP-D-mannose in procaryotic and eucaryotic cells, Specifically, purified FX apparently catalyzes a combined epimerase and NADPH-depsndent reductase reaction, converting GDP 4-keto-6-D-deoxymannose to GDP-L-fucose. This is the substrate of several fucosyltranferases involved in the correct expression of many glyconjugates, including blood groups and developmental antigens.	ADV BIOTECHNOL CTR,I-16132 GENOA,ITALY		Tonetti, M (corresponding author), UNIV GENOA,INST BIOCHEM,VIALE BENEDETTO XV 1,I-16132 GENOA,ITALY.		TONETTI, MICHELA/AAF-3404-2021; Tonetti, Michela/F-3039-2018	TONETTI, MICHELA/0000-0002-8829-7173; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AOYAMA K, 1994, MOL BIOL EVOL, V11, P829; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BROSCHAT KO, 1985, EUR J BIOCHEM, V153, P397, DOI 10.1111/j.1432-1033.1985.tb09315.x; BULET P, 1984, EUR J BIOCHEM, V144, P255, DOI 10.1111/j.1432-1033.1984.tb08458.x; CAMARDELLA L, 1995, BLOOD, V85, P264, DOI 10.1182/blood.V85.1.264.bloodjournal851264; CHANG S, 1988, J BIOL CHEM, V263, P1693; DEFLORA A, 1977, BIOCHIM BIOPHYS ACTA, V500, P109, DOI 10.1016/0304-4165(77)90051-4; FEIZI T, 1990, TRENDS BIOCHEM SCI, V15, P330, DOI 10.1016/0968-0004(90)90066-K; FEIZI T, 1987, BIOCHEM J, V245, P1; FOSTER DW, 1961, BIOCHIM BIOPHYS ACTA, V54, P376, DOI 10.1016/0006-3002(61)90386-9; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GABRIEL O, 1978, TRENDS BIOCHEM SCI, V3, P193, DOI 10.1016/S0968-0004(78)91666-3; GABRIEL O, 1972, METHOD ENZYMOL, V28, P454; GAUGLER RW, 1973, J BIOL CHEM, V248, P6041; GINSBURG V, 1960, J BIOL CHEM, V235, P2196; GINSBURG V, 1961, J BIOL CHEM, V236, P2389; GOETHALS K, 1992, MOL PLANT MICROBE IN, V5, P405, DOI 10.1094/MPMI-5-405; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HOLMES EH, 1995, J BIOL CHEM, V270, P8145, DOI 10.1074/jbc.270.14.8145; ISHIHARA H, 1972, METHOD ENZYMOL, V28, P399; ISHIHARA H, 1972, METHOD ENZYMOL, V28, P403; KONG RKM, 1993, ARCH BIOCHEM BIOPHYS, V300, P677, DOI 10.1006/abbi.1993.1094; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZERINI L, 1981, BLOOD, V57, P209; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MARTIN A, 1989, J CHROMATOGR-BIOMED, V497, P319, DOI 10.1016/0378-4347(89)80036-2; MORELLI A, 1977, ARCH BIOCHEM BIOPHYS, V179, P698, DOI 10.1016/0003-9861(77)90159-X; MORELLI A, 1977, FEBS LETT, V80, P1, DOI 10.1016/0014-5793(77)80393-1; PRICE TH, 1994, BLOOD, V84, P1635; REITMAN ML, 1980, J BIOL CHEM, V255, P9900; RIJCKEN WRP, 1995, BIOCHEM J, V305, P865, DOI 10.1042/bj3050865; RIPKA J, 1986, ARCH BIOCHEM BIOPHYS, V249, P533, DOI 10.1016/0003-9861(86)90031-7; RUGGIEROLOPEZ D, 1991, BIOCHEM J, V279, P801, DOI 10.1042/bj2790801; SHIRAHAMA T, 1993, CANCER, V72, P1329, DOI 10.1002/1097-0142(19930815)72:4<1329::AID-CNCR2820720430>3.0.CO;2-6; STOKLOSA JT, 1975, ANAL BIOCHEM, V68, P358, DOI 10.1016/0003-2697(75)90633-8; SUN J, 1995, P NATL ACAD SCI USA, V92, P5724, DOI 10.1073/pnas.92.12.5724; SUZUKI J, 1992, CLIN CHEM, V38, P752; SZIKORA JP, 1990, EMBO J, V9, P1041, DOI 10.1002/j.1460-2075.1990.tb08208.x; THURIN J, 1995, J BIOL CHEM, V270, P26577, DOI 10.1074/jbc.270.44.26577; WALTZ G, 1990, SCIENCE, V250, P1132; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; YURCHENCO PD, 1977, BIOCHEMISTRY-US, V16, P944, DOI 10.1021/bi00624a021	48	134	150	4	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27274	27279		10.1074/jbc.271.44.27274	http://dx.doi.org/10.1074/jbc.271.44.27274			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910301	hybrid			2022-12-27	WOS:A1996VQ67900019
J	Kalabokis, VN; Vibert, P; York, ML; SzentGyorgyi, AG				Kalabokis, VN; Vibert, P; York, ML; SzentGyorgyi, AG			Single-headed scallop myosin and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; CALCIUM-BINDING; HEAVY-MEROMYOSIN; GIZZARD MYOSIN; ACTIN; DOMAINS; PAPAIN; ATPASE	Single-headed scallop myosin (shM) was prepared by papain digestion of filamentous scallop myosin and purified by hydrophobic interaction chromatography. The shM preparation consisted of equimolar amounts of polypeptides corresponding to an intact heavy chain, rod chain, essential light chain, and regulatory light chain, In electron micrographs the shape of shM showed the presence of a single head domain to which a normal looking rod was attached, Myosin and shM bound Ca2+ with association constants of 5 x 10(6) and 11 x 10(6) M(-1), respectively. The ATPase activity of shM was activated about 3-fold by Ca2+, Both heads of myosin and shM had comparable ATPase activities in the presence of Ca2+. The activation of the ATPase activity of single-headed scallop myosin by Ca2+ paralleled closely the Ca2+ binding, in sharp contrast to the activation of intact myosin by Ca2+, which is highly cooperative. Single turnover experiments of myosin with radioactive ATP gave a half-life for the ATPase cycle of similar to 3 min in the presence of EGTA, whereas that of single headed myosin was shorter than similar to 30 s, which was the resolution time of these measurements. The results suggest that the presence of two heads, as well as the attachment of the head to the coiled coil rod, contribute to the regulation of scallop myosin by Ca2+.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254	Brandeis University; Brandeis University					NIAMS NIH HHS [AR41803, AR15963] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041803, R01AR015963, R37AR015963] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BERGMEYER HU, 1965, METHOD ENZYMAT AN, P10; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; CHANTLER PD, 1981, BIOCHEMISTRY-US, V20, P473; COOKE R, 1978, J MOL BIOL, V120, P361, DOI 10.1016/0022-2836(78)90424-2; CREMO CR, 1995, J BIOL CHEM, V270, P2171, DOI 10.1074/jbc.270.5.2171; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; FROMHERZ S, 1995, P NATL ACAD SCI USA, V92, P7652, DOI 10.1073/pnas.92.17.7652; FUNK MO, 1979, INT J PEPT PROT RES, V13, P296; JACKSON AP, 1988, BIOCHEM J, V251, P527, DOI 10.1042/bj2510527; JANCSO A, 1994, P NATL ACAD SCI USA, V91, P8762, DOI 10.1073/pnas.91.19.8762; KALABOKIS VN, 1994, J MUSCLE RES CELL M, V15, P547, DOI 10.1007/BF00121160; KWON H, 1990, P NATL ACAD SCI USA, V87, P4771, DOI 10.1073/pnas.87.12.4771; KWON H, 1992, J MUSCLE RES CELL M, V13, P315, DOI 10.1007/BF01766459; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; SEIDEL JC, 1980, J BIOL CHEM, V255, P4355; SELLERS JR, 1980, J MOL BIOL, V144, P223, DOI 10.1016/0022-2836(80)90088-1; STAFFORD WF, 1979, BIOCHEMISTRY-US, V18, P5273, DOI 10.1021/bi00591a002; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; TAUSSKY HM, 1952, J BIOL CHEM, V202, P675; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; WELLS C, 1984, FEBS LETT, V168, P260, DOI 10.1016/0014-5793(84)80258-6; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	24	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26779	26782		10.1074/jbc.271.43.26779	http://dx.doi.org/10.1074/jbc.271.43.26779			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900158	hybrid			2022-12-27	WOS:A1996VP23300052
J	Marriott, I; Mason, MJ				Marriott, I; Mason, MJ			Evidence for a phorbol ester-insensitive phosphorylation step in capacitative calcium entry in rat thymic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTRACELLULAR CA2+ STORES; PLASMA-MEMBRANE; NA+/H+ EXCHANGE; MYRISTATE ACETATE; HUMAN NEUTROPHILS; XENOPUS OOCYTES; CONCANAVALIN-A; OKADAIC ACID; K+ CHANNELS	Experiments were undertaken to investigate the regulation of capacitative Ca2+ entry by phorbol ester-sensitive protein kinase C and serine(threonine protein phosphatase activity, The thapsigargin-activated Ca2+ entry pathway was probed in control cells and cells treated with phosphatase type 1/2A inhibitors, okadaic acid and calyculin A, or with the phorbol ester, phorbol 12-myristate 13-acetate. The permeability state of this pathway was monitored in the presence or absence of these agents using fluorometric measurements of intracellular Ca2+ concentration, unidirectional Mn2+ entry, and membrane potential and unidirectional measurements of Ca2+ uptake using Ca-45(2+). The results of these studies demonstrate that modification of the phosphorylation state of target protein(s) on serine/threonine amino acid residues by inhibition of phosphatase type 1/2A inhibits the capacitative Ca2+ entry pathway in rat thymic lymphocytes, Importantly, the capacitative Ca2+ entry pathway in rat thymic lymphocytes is not modulated by activation of phorbol ester-sensitive protein kinase C.	TULANE UNIV,SCH MED,DEPT PHYSIOL,NEW ORLEANS,LA 70112	Tulane University								BALASUBRAMANYAM M, 1993, AM J PHYSIOL, V265, pC321, DOI 10.1152/ajpcell.1993.265.2.C321; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BODE HP, 1994, FEBS LETT, V339, P307, DOI 10.1016/0014-5793(94)80436-2; GRINSTEIN S, 1987, J BIOL CHEM, V262, P15277; GRINSTEIN S, 1984, J GEN PHYSIOL, V84, P565, DOI 10.1085/jgp.84.4.565; GRINSTEIN S, 1985, J CELL BIOL, V101, P269, DOI 10.1083/jcb.101.1.269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KANDASAMY RK, 1995, J BIOL CHEM, V270, P29209, DOI 10.1074/jbc.270.49.29209; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; MACDOUGALL SL, 1988, J CLIN INVEST, V81, P449, DOI 10.1172/JCI113340; MAHAUTSMITH MP, 1991, J PHYSIOL-LONDON, V439, P513, DOI 10.1113/jphysiol.1991.sp018679; MARRIOTT I, 1994, J CELL PHYSIOL, V161, P441, DOI 10.1002/jcp.1041610307; MARRIOTT L, 1995, AM J PHYSIOL, V269, pC766; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1990, J MEMBRANE BIOL, V116, P139, DOI 10.1007/BF01868672; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MONTERO M, 1993, J BIOL CHEM, V268, P13055; MONTERO M, 1990, BIOCHEM J, V271, P535, DOI 10.1042/bj2710535; MONTERO M, 1994, J BIOL CHEM, V269, P3963; MURPHY TJ, 1996, BIOCHEM J, V313, P83; NISHIWAKI S, 1990, CARCINOGENESIS, V11, P1837, DOI 10.1093/carcin/11.10.1837; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; RINK TJ, 1980, BIOCHIM BIOPHYS ACTA, V595, P65; SARKADI B, 1990, MOL IMMUNOL, V27, P1297, DOI 10.1016/0161-5890(90)90034-W; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; WILSON OI, 1994, J MEMBRANE BIOL, V137, P159	35	14	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26732	26738		10.1074/jbc.271.43.26732	http://dx.doi.org/10.1074/jbc.271.43.26732			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900152	hybrid			2022-12-27	WOS:A1996VP23300046
J	Yamaguchi, T; Pang, J; Reddy, KS; Witkowska, HE; Surrey, S; Adachi, K				Yamaguchi, T; Pang, J; Reddy, KS; Witkowska, HE; Surrey, S; Adachi, K			Expression of soluble human beta-globin chains in bacteria and assembly in vitro with alpha-globin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC PROTEOLYSIS; ESCHERICHIA-COLI; HUMAN HEMOGLOBIN; PROTEINS; BINDING	Authentic soluble human beta-globin chains were produced in Escherichia coli using an expression plasmid (pHE2 beta) containing full-length cDNAs coding for human beta-globin chain and methionine aminopeptidase. Spectral properties of the purified beta-globin were identical to those of authentic beta-globin. Soluble beta-globin showed low (16 kDa) and high molecular mass (32 kDa) forms that could be separated by gel filtration chromatography, SDS-polyacrylamide gel electrophoresis and electrospray mass spectrometry revealed the 32-kDa species was dimeric beta-globin formed by an intermolecular disulfide bond, while the 16-kDa species was authentic monomeric beta-globin. Monomeric forms of beta-globin, like authentic native beta-globin, formed tetrameric hemoglobin (Hb) A (alpha(2) beta(2)) in vitro upon incubation with alpha-globin, while dimeric forms did not, When beta-globin dimers, however, were converted to monomers by incubation with dithiothreitol, the beta-globin chain monomers assembled with alpha-globin and formed hemoglobin tetramers. alpha-Globin was more thermally unstable than beta-globin, while assembled tetramers promoted higher stability. Disulfide-bonded beta-globin dimers showed a slight increase in thermal stability compared with beta-globin; however, dimers were still more unstable than tetrameric Hb A. These results indicate that presence of alpha chains favors assembly with beta-globin, beta-beta dimers cannot bind alpha chains, and that Hb A tetramer formation results in the most thermally stable species.	UNIV PENN,CHILDRENS HOSP PHILADELPHIA,SCH MED,DIV HEMATOL,ABRAMSON CTR,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOPHYS,PHILADELPHIA,PA 19104; CHILDRENS HOSP OAKLAND,RES INST,OAKLAND,CA 94609	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland					NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR006505] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL020985, P60HL038632] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06505] Funding Source: Medline; NHLBI NIH HHS [HL20985, HL38632] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ASAKURA T, 1974, BIOCHEM BIOPH RES CO, V57, P780, DOI 10.1016/0006-291X(74)90614-7; Ascoli F, 1981, Methods Enzymol, V76, P72; BALDWIN R. L., 1987, PROTEIN ENG, P127; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; Di Iorio E E, 1981, Methods Enzymol, V76, P57; FERRIGE AG, 1992, RAPID COMMUN MASS SP, V6, P707, DOI 10.1002/rcm.1290061115; FRANCHI D, 1982, BIOCHEMISTRY-US, V21, P6181, DOI 10.1021/bi00267a024; FRIEND SH, 1981, BIOCHEMISTRY-US, V20, P580, DOI 10.1021/bi00506a021; FRONTICELLI C, 1991, J PROTEIN CHEM, V10, P495, DOI 10.1007/BF01025477; GROEBE DR, 1992, PROTEIN EXPRES PURIF, V3, P134, DOI 10.1016/S1046-5928(05)80030-0; HERNAN RA, 1992, BIOCHEMISTRY-US, V31, P8619, DOI 10.1021/bi00151a032; HOFFMAN SJ, 1990, P NATL ACAD SCI USA, V87, P8521, DOI 10.1073/pnas.87.21.8521; Ikeda-Saito M, 1981, Methods Enzymol, V76, P113; KLIBANOV AM, 1987, PROTEIN ENG, P213; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGHTWAHL KJ, 1993, J MASS SPECTROM, V30, P1663; NAGAI K, 1987, METHOD ENZYMOL, V153, P461; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; Nakanishi T, 1995, J MASS SPECTROM, V30, P1663, DOI 10.1002/jms.1190301205; PERUTZ MF, 1974, NATURE, V247, P341, DOI 10.1038/247341a0; PHILO JS, 1988, J BIOL CHEM, V263, P682; Schroeder W. A., 1984, CRC HDB HPLC SEPARAT, VII, P287; SCHWARTZ E, 1991, HEMATOLOGY BASIC PRI, P368; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SHEN TJ, 1993, P NATL ACAD SCI USA, V90, P8108, DOI 10.1073/pnas.90.17.8108; VALDES R, 1977, J BIOL CHEM, V252, P74; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WITKOWSKA HE, 1993, HEMOGLOBIN, V17, P227, DOI 10.3109/03630269308998897	31	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26677	26683		10.1074/jbc.271.43.26677	http://dx.doi.org/10.1074/jbc.271.43.26677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900144	hybrid			2022-12-27	WOS:A1996VP23300038
J	Kage, R; Leeman, SE; Krause, JE; Costello, CE; Boyd, ND				Kage, R; Leeman, SE; Krause, JE; Costello, CE; Boyd, ND			Identification of methionine as the site of covalent attachment of a p-benzoyl-phenylalanine-containing analogue of substance P on the substance P (NK-1) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHARACTERIZATION; FUNCTIONAL CDNA; BINDING DOMAINS; CELLS; LOCALIZATION	Previously we have been able to restrict the site of covalent attachment of a photolabile and radiolabeled derivative of substance P (SP), p-benzoylphenylalanine(8)-SP (Bpa(8).SP), to residues 178-183 located on the second extracellular loop (E2) of the SP (NK-1) receptor (Boyd, N. D., Rage, R., Dumas, J. J., Krause, J. E., and Leeman, S. E. (1996) Proc, Natl, Acad, Sci, U. S. A. 93, 433-437), To ascertain the specific amino acid in this sequence that serves as the site of covalent attachment for I-125-Bolton-Hunter reagent (EH)-Bpa(8)-SP, we have employed here a novel solid-phase approach to cyanogen bromide cleavage of the photolabeled receptor followed by mass spectrometric analysis of a purified labeled fragment. SP receptors on transfected Chinese hamster ovary cells were photolabeled with isotopically diluted I-125-BH-Bpa(8)-SP. A membrane preparation of the photolabeled receptors was adsorbed onto C-18-derivatized silica gel and cleaved with cyanogen bromide, A single radiolabeled fragment containing 63% of the photoincorporated radioactivity was generated and purified by high performance liquid chromatography. Mass spectrometric analysis identified a single molecular ion with a molecular mass of 1751.4 +/- 2, establishing that upon irradiation the bound photoligand forms a covalent link with the methyl group of a methionine residue at the peptide binding site, In view of our previous findings, this methionine is Met-181 on the primary sequence of the SP receptor.	WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA; BOSTON UNIV, SCH MED, DEPT BIOPHYS, BOSTON, MA 02118 USA	Washington University (WUSTL); Boston University	Kage, R (corresponding author), BOSTON UNIV, SCH MED, DEPT PHARMACOL & EXPT THERAPEUT, BOSTON, MA 02118 USA.			Leeman, Susan/0000-0002-0951-5364; Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031346] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00317] Funding Source: Medline; NINDS NIH HHS [NS31346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BOYD ND, 1991, BIOCHEMISTRY-US, V30, P336, DOI 10.1021/bi00216a005; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FONG TM, 1992, J BIOL CHEM, V267, P25664; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KAGE R, 1995, J NEUROCHEM, V64, P316; KEUTMANN HT, 1993, ENDOCRINOLOGY, V132, P1305, DOI 10.1210/en.132.3.1305; Krause J.E., 1994, TACHYKININ RECEPTORS; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; MAHMOOD R, 1989, BIOCHEMISTRY-US, V28, P3989, DOI 10.1021/bi00435a054; MILLER WT, 1991, METHOD ENZYMOL, V200, P500; ONEIL KT, 1989, PROTEINS, V6, P284, DOI 10.1002/prot.340060311; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	20	76	76	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25797	25800		10.1074/jbc.271.42.25797	http://dx.doi.org/10.1074/jbc.271.42.25797			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824208	hybrid			2022-12-27	WOS:A1996VN18000014
J	Sakaki, T; Kominami, S; Hayashi, K; AkiyoshiShibata, M; Yabusaki, Y				Sakaki, T; Kominami, S; Hayashi, K; AkiyoshiShibata, M; Yabusaki, Y			Molecular engineering study on electron transfer from NADPH-P450 reductase to rat mitochondrial P450c27 in yeast microsomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NADPH-CYTOCHROME-P450 REDUCTASE; FUSED ENZYME; ESCHERICHIA-COLI; CYTOCHROME; EXPRESSION; GENE; MONOOXYGENASE; STEROIDOGENESIS; FLAVOPROTEINS	We have reported the localization on yeast microsomes for a modified P450c27 (mic-P450c27) that contains the microsomal targeting signal of bovine P450c17 in front of the mature form of rat mitochondrial P450c27 (Sakaki, T., Akiyoshi-Shibata, M., Yabusaki, Y., and Ohkawa, H. (1992) J. Biol. Chem. 267, 16497-16502). In this study, we found that mic-P450c27 could be reduced by NADPH in the yeast microsomes without supplement of its physiological redox partners, adrenodoxin and NADPH-adrenodoxin reductase. In order to elucidate the direct electron transfer from NADPH-P450 reductase to mic-P450c27, we carried out simultaneous expression of mic-P450c27 and yeast P450 reductase. The reduction rate of mic-P450c27 was increased by overproduction of yeast P450 reductase, roughly in proportion to the reductase content in the microsomes. In addition, we constructed a fused enzyme between mic-P450c27 and yeast P450 reductase. The reduction rate of heme iron in the fused enzyme was too rapid to be measured. These recombinant yeast microsomes showed a notable 27-hydroxylation activity toward 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol in the absence of adrenodoxin and adrenodoxin reductase. Finally, we purified mic-P450c27 from the recombinant yeast microsomes and reconstituted the hydroxylation system in liposomal membranes using the purified mic-P450c27 and yeast NADPH-P450 reductase. Mic-P450c27 was reduced by NADPH and showed its monooxygenase activity on the reconstituted system. Therefore, yeast NADPH-P450 reductase alone was found to transfer two electrons from NADPH to mic-P450c27. These results clearly show that mic-P450c27 not only localizes on the microsomes but also functions as a microsomal cytochrome P450 that accepts electrons from NADPH-P450 reductase.	SUMITOMO CHEM CO LTD,BIOTECHNOL LAB,TAKARAZUKA,HYOGO 665,JAPAN; HIROSHIMA UNIV,FAC INTEGRATED ARTS & SCI,HIGASHIHIROSHIMA,HIROSHIMA 724,JAPAN	Sumitomo Chem Co Ltd; Hiroshima University								AOYAMA Y, 1978, ARCH BIOCHEM BIOPHYS, V185, P362, DOI 10.1016/0003-9861(78)90178-9; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BERNHARDT R, 1992, BIOCHEM BIOPH RES CO, V187, P310, DOI 10.1016/S0006-291X(05)81494-9; BLACK SM, 1994, P NATL ACAD SCI USA, V91, P7247, DOI 10.1073/pnas.91.15.7247; COGHLAN VM, 1991, J BIOL CHEM, V266, P18606; Dong MS, 1996, ARCH BIOCHEM BIOPHYS, V327, P11, DOI 10.1006/abbi.1996.0086; FULCO AJ, 1987, LIFE SCI, V40, P1769, DOI 10.1016/0024-3205(87)90087-7; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; JENKINS CM, 1994, J BIOL CHEM, V269, P27401; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; LAMBETH JD, 1983, J BIOL CHEM, V258, P5596; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURAKAMI H, 1987, DNA-J MOLEC CELL BIO, V6, P189, DOI 10.1089/dna.1987.6.189; MURAKAMI H, 1990, J BIOCHEM, V108, P859, DOI 10.1093/oxfordjournals.jbchem.a123293; MURAKAMI H, 1987, DNA CELL BIOL, V5, P1; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OKUDA K, 1988, J BIOL CHEM, V263, P18138; OMURA T, 1964, J BIOL CHEM, V239, P2370; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; SAKAKI T, 1990, DNA CELL BIOL, V9, P603, DOI 10.1089/dna.1990.9.603; SAKAKI T, 1992, J BIOL CHEM, V267, P16497; SAKAKI T, 1987, DNA-J MOLEC CELL BIO, V6, P31, DOI 10.1089/dna.1987.6.31; SAKAKI T, 1994, BIOCHEMISTRY-US, V33, P4933, DOI 10.1021/bi00182a023; SHIBATA M, 1990, DNA CELL BIOL, V9, P27, DOI 10.1089/dna.1990.9.27; YABUSAKI Y, 1988, J BIOCHEM-TOKYO, V103, P1004, DOI 10.1093/oxfordjournals.jbchem.a122370; YABUSAKI Y, 1988, DNA-J MOLEC CELL BIO, V7, P701, DOI 10.1089/dna.1988.7.701; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020	32	34	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26209	26213		10.1074/jbc.271.42.26209	http://dx.doi.org/10.1074/jbc.271.42.26209			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824269	hybrid			2022-12-27	WOS:A1996VN18000075
J	Teramoto, H; Crespo, P; Coso, OA; Igishi, T; Xu, NZ; Gutkind, JS				Teramoto, H; Crespo, P; Coso, OA; Igishi, T; Xu, NZ; Gutkind, JS			The small GTP-binding protein Rho activates c-Jun N-terminal kinases stress-activated protein kinases in human kidney 293T cells - Evidence for a Pak-independent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; MAP KINASE; SACCHAROMYCES-CEREVISIAE; GTPASES; RAS; HOMOLOG; CDC42; RAC1	Work from a number of laboratories has established a role for certain small GTP-binding proteins in controlling the enzymatic activity of a family of serine-threonine kinases known as mitogen-activated protein kinases (MAPKs). MAPKs have been classified into three subfamilies: extracellular signal-regulated kinases (ERKs), also known as MAPKs; c-Jun N-terminal kinases (JNKs); and p38 kinase. Whereas Ras controls the activation of MAPKs, we and others have recently observed that in certain cells, the small GTP-binding proteins Rad and Cdc42 but not Rho regulate the activity of JNKs. Furthermore, because Rad and Cdc42 but not Rho bind and activate a kinase known as Pak1, it has been suggested that Pak1 is the most upstream component of the pathway linking these GTPases to JNK. However, in both yeast and mammalian cells, Rho1p, a Rho homologue, and RhoA, respectively, directly interact with a number of proteins, including kinases related to protein kinase C. In addition, in yeast, Rho1p controls the activity of a MAPK cascade involved in bud formation. Considering this diversity of target molecules for small GTP-binding proteins, their likely tissue specific distribution, and the potential role for Rho in signaling to a kinase cascade, we decided to extend our initial analysis, exploring the ability of Ras and Rho-related GTP-binding proteins to activate MAPK or JNK in a variety of cell lines. We found that in the human kidney epithelial cell line, 293T, Cdc42 and all Rho proteins, RhoA, RhoB, and RhoC, but not Rac or Ras can induce activation of JNK. Furthermore, we provide evidence that signaling from Rho proteins to JNK in 293T cells does not involve Pak1. Taken together these findings demonstrate that Rho signals to JNK in a cell type-specific manner and suggest the existence of a novel, Pak1-independent signaling route communicating the Rho family of small GTP-binding proteins to the JNK pathway.	NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Crespo, Piero/M-3273-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Crespo, Piero/0000-0003-2825-7783				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCormick Frank, 1994, Trends in Cell Biology, V4, P347, DOI 10.1016/0962-8924(94)90075-2; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	28	164	165	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25731	25734		10.1074/jbc.271.42.25731	http://dx.doi.org/10.1074/jbc.271.42.25731			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824197	hybrid			2022-12-27	WOS:A1996VN18000003
J	He, ZG; Wong, JMS; Maniar, HS; Brill, SJ; Ingles, CJ				He, ZG; Wong, JMS; Maniar, HS; Brill, SJ; Ingles, CJ			Assessing the requirements for nucleotide excision repair proteins of Saccharomyces cerevisiae in an in vitro system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; TRANSCRIPTION FACTOR TFIIH; CELL NUCLEAR ANTIGEN; REPLICATION FACTOR-A; SIMIAN VIRUS-40 DNA; PIGMENTOSUM GROUP-F; XERODERMA-PIGMENTOSUM; COMPLEX-FORMATION; MAMMALIAN-CELLS; MULTIPLE STAGES	Nucleotide excision repair (NER) is the primary mechanism by which both Saccharomyces cerevisiae and human cells remove the DNA lesions caused by ultraviolet light and other mutagens. This complex process involves the coordinated actions of more than 20 polypeptides. To facilitate biochemical studies of NER in yeast, we have established a simple protocol for preparing whole cell extracts which perform NER in vitro, As expected, this assay of in vitro repair was dependent on the products of RAD genes such as RAD14, RAD4 and RAD2. Interestingly, it was also dependent upon proteins encoded by the RAD7, RAD16, and RAD23 genes whose precise roles in NER are uncertain, but not the RAD26 gene whose product is believed to participate in coupling NER to transcription, Replication protein A (RPA/Rpa), known to be required for NER in human cell extracts, was also shown by antibody inhibition and immunodepletion experiments to be required for NER in our yeast cell extracts. Moreover, yeast cells with temperature sensitive mutations in the RFA2 gene, which encodes the 34-kDa subunit of Rpa, had increased sensitivity to UV and yielded extracts defective in NER in vitro, These data indicate that Rpa is an essential component of the NER machinery in S. cerevisiae as it is in mammalian cells.	UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 1L6,CANADA; RUTGERS STATE UNIV,DEPT MOL BIOL & BIOCHEM,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08855	University of Toronto; University of Toronto; Rutgers State University New Brunswick					NIAID NIH HHS [AI 20460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABOUSSEKHRA A, 1994, CURR OPIN GENET DEV, V4, P212, DOI 10.1016/S0959-437X(05)80047-4; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADACHI Y, 1994, EMBO J, V13, P4153, DOI 10.1002/j.1460-2075.1994.tb06733.x; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BANKMANN M, 1992, NATURE, V355, P555, DOI 10.1038/355555a0; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BUDD ME, 1995, MOL CELL BIOL, V15, P2173; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FRIEDBERG EC, 1995, DNA REPAIR; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HABRAKEN Y, 1993, NATURE, V366, P365, DOI 10.1038/366365a0; HANSSON J, 1989, J BIOL CHEM, V264, P21788; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1989, BIOCHEMISTRY-US, V28, P2856, DOI 10.1021/bi00433a017; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LEHMANN AR, 1995, TRENDS BIOCHEM SCI, V20, P402, DOI 10.1016/S0968-0004(00)89088-X; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, pU3559; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; PAETKAU DW, 1994, GENE DEV, V8, P2035, DOI 10.1101/gad.8.17.2035; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; PRAKASH S, 1993, ANNU REV GENET, V27, P33, DOI 10.1146/annurev.ge.27.120193.000341; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUNG P, 1993, J BIOL CHEM, V268, P26391; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; TOMKINSON AE, 1993, NATURE, V362, P860, DOI 10.1038/362860a0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Verhage RA, 1996, MOL CELL BIOL, V16, P496; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6	56	40	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28243	28249		10.1074/jbc.271.45.28243	http://dx.doi.org/10.1074/jbc.271.45.28243			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910442	hybrid			2022-12-27	WOS:A1996VU03300042
J	Skerlavaj, B; Gennaro, R; Bagella, L; Merluzzi, L; Risso, A; Zanetti, M				Skerlavaj, B; Gennaro, R; Bagella, L; Merluzzi, L; Risso, A; Zanetti, M			Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; PIG MYELOID CELLS; BOVINE NEUTROPHILS; ANTIBACTERIAL PEPTIDE; CHEMICAL SYNTHESIS; MOLECULAR-CLONING; CDNA CLONING; BONE-MARROW; ANTIBIOTIC DODECAPEPTIDE; PROLINE-RICH	Cathelicidins are a family of myeloid antimicrobial peptide precursors that have been identified in several mammalian species (Zanetti, M., Gennaro, R., and Romeo, D. (1995) FEBS Lett, 374, 1-5), Two novel bovine congeners have been deduced from cDNA, Their C-terminal sequences of 27 and 28 residues correspond to putative antimicrobial peptides with a cationic N-terminal region predicted to assume an amphipathic alpha-helical conformation followed by a hydrophobic C-terminal tail, Peptides corresponding to these sequences have been chemically synthesized and shown to exert a potent antimicrobial activity against Gram-negative and Gram positive bacteria, including methicillin-resistant Staphylococcus aureus, and fungi, Both peptides are also cytotoxic to human erythrocytes and neutrophils, although at higher than microbicidal concentrations, The target selectivity has been improved by synthesizing truncated analogues, comprising only the 18 N-terminal residues, which show a great reduction in cytotoxic, but not in antimicrobial activity, The involvement of the C-terminal hydrophobic tail in the cytotoxic activity has been further demonstrated by inducing a major loss of activity in an analogue after replacing highly hydrophobic residues with more hydrophilic ones.	LAB NAZL CONSORZIO INTERUNIV BIOTECNOL, I-34012 TRIESTE, ITALY; UNIV UDINE, DIPARTIMENTO SCI & TECNOL BIOMED, I-33100 UDINE, ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine			Gennaro, Renato/AAJ-2511-2021	Gennaro, Renato/0000-0003-1331-3885; SKERLAVAJ, Barbara/0000-0003-0437-802X; BAGELLA, Luigi/0000-0003-2815-037X				AGERBERTH B, 1995, P NATL ACAD SCI USA, V92, P195, DOI 10.1073/pnas.92.1.195; ALVAREZBRAVO J, 1994, BIOCHEM J, V302, P535, DOI 10.1042/bj3020535; BAGELLA L, 1995, FEBS LETT, V376, P225, DOI 10.1016/0014-5793(95)01285-3; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1994, CIBA FDN S, V186; BUCK MA, 1989, ANAL BIOCHEM, V182, P295, DOI 10.1016/0003-2697(89)90597-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COWLAND JB, 1995, FEBS LETT, V368, P173, DOI 10.1016/0014-5793(95)00634-L; DELSAL G, 1992, BIOCHEM BIOPH RES CO, V187, P467, DOI 10.1016/S0006-291X(05)81517-7; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DOIG AJ, 1995, PROTEIN SCI, V4, P1325, DOI 10.1002/pro.5560040708; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FRANK RW, 1990, J BIOL CHEM, V265, P18871; GAHAY JE, 1994, SCIENCE, V264, P373; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GENNARO R, 1989, INFECT IMMUN, V57, P3142, DOI 10.1128/IAI.57.10.3142-3146.1989; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; LARRICK JW, 1991, BIOCHEM BIOPH RES CO, V179, P170, DOI 10.1016/0006-291X(91)91350-L; LARRICK JW, 1995, INFECT IMMUN, V63, P1291, DOI 10.1128/IAI.63.4.1291-1297.1995; LEE JY, 1989, P NATL ACAD SCI USA, V86, P9159, DOI 10.1073/pnas.86.23.9159; LEVY O, 1993, J BIOL CHEM, V268, P6058; Mahoney MM, 1995, FEBS LETT, V377, P519, DOI 10.1016/0014-5793(95)01390-3; PUNGERCAR J, 1993, FEBS LETT, V336, P284, DOI 10.1016/0014-5793(93)80821-B; ROMEO D, 1988, J BIOL CHEM, V263, P9573; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; SCOCCHI M, 1994, FEBS LETT, V352, P197, DOI 10.1016/0014-5793(94)00954-6; SCOCCHI M, 1992, EUR J BIOCHEM, V209, P589, DOI 10.1111/j.1432-1033.1992.tb17324.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1992, J BIOL CHEM, V267, P4292; SKERLAVAJ B, 1990, INFECT IMMUN, V58, P3724, DOI 10.1128/IAI.58.11.3724-3730.1990; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1363, DOI 10.1006/bbrc.1993.2403; STORICI P, 1994, FEBS LETT, V337, P303, DOI 10.1016/0014-5793(94)80214-9; STORICI P, 1992, FEBS LETT, V314, P187, DOI 10.1016/0014-5793(92)80971-I; STORICI P, 1993, BIOCHEM BIOPH RES CO, V196, P1058, DOI 10.1006/bbrc.1993.2358; TORICI P, 1996, EUR J BIOCHEM, V238, P769; TOSSI A, 1994, FEBS LETT, V339, P108, DOI 10.1016/0014-5793(94)80395-1; TOSSI A, 1995, EUR J BIOCHEM, V228, P941, DOI 10.1111/j.1432-1033.1995.tb20344.x; ZANETTI M, 1990, J CELL BIOL, V111, P1363, DOI 10.1083/jcb.111.4.1363; ZANETTI M, 1993, J BIOL CHEM, V268, P522; ZANETTI M, 1994, J BIOL CHEM, V269, P7855; ZANETTI M, 1995, FEBS LETT, V374, P1, DOI 10.1016/0014-5793(95)01050-O; ZHANG L, 1993, 3 INT S INN PERSP SO; ZHAO CQ, 1994, FEBS LETT, V346, P285, DOI 10.1016/0014-5793(94)00493-5	47	207	228	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28375	28381		10.1074/jbc.271.45.28375	http://dx.doi.org/10.1074/jbc.271.45.28375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910461	hybrid			2022-12-27	WOS:A1996VU03300061
J	Bufe, A; Betzel, C; Schramm, G; Petersen, A; Becker, WM; Schlaak, M; Perbandt, M; Dauter, Z; Weber, W				Bufe, A; Betzel, C; Schramm, G; Petersen, A; Becker, WM; Schlaak, M; Perbandt, M; Dauter, Z; Weber, W			Crystallization and preliminary diffraction data of a major pollen allergen - Crystal growth separates a low molecular weight form with elevated biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; MAGNETIC-RESONANCE SPECTROSCOPY; PHL-P-V; TIMOTHY-GRASS; EPITOPES; RECEPTOR; ASTHMA; RNASE; GENE	Group V major allergen Phl p 5b of timothy grass pollen induces allergic rhinitis and bronchial asthma in 90% of grass pollen-allergic patients, In addition to its allergenicity ribonuclease activity has recently been attributed to this 29-kDa protein, The allergen was expressed in Escherichia coli and subsequently purified, Spontaneous conversion of these preparations to a mixture of various forms with molecular sizes between 10 and 29 kDa was consistently observed, Surprisingly, crystals could be grown from this heterogenous preparation, Single crystals, redissolved and analyzed by SDS-polyacrylamide gel electrophoresis and immunoblot, yielded one distinct low molecular weight protein, which was identified by amino acid sequencing as the C-terminal 13-kDa portion of the allergen, Histamine release assays with single crystal solutions using basophils of an allergic patient demonstrated allergenicity comparable with that of the holo allergen, By contrast, RNase activity of the crystallized C terminal form was 23 times higher than that of the full-length parent allergen, Crystals were used to collect preliminary diffraction data; the space group was evaluated to I4(1)22 with cell dimensions of a = 87.7 Angstrom, b = 87.7 Angstrom, and c = 59.6 Angstrom. We conclude that preferential crystal growth of the 13-kDa form is indicative of a compact conformation of this particular C-terminal portion of the allergen, Thus, we show here that protein crystallization is not only a prerequisite for structural analyses, but it also can provide a unique separation technique to localize the functional domain of a major allergen.	UNIV HAMBURG,HOSP EPPENDORF,INST PHYSIOL CHEM,ARBEITSGRP MAKROMOL STRUKTURANAL,D-20246 HAMBURG,GERMANY; UNIV HAMBURG,INST CHEM & LEBENSMITTELCHEM,D-20146 HAMBURG,GERMANY; DESY,EMBL,D-22603 HAMBURG,GERMANY	University of Hamburg; University of Hamburg; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Bufe, A (corresponding author), FORSCHUNGSZENTRUM BORSTEL,LAB GRP ALLERGOL,PARKALLEE 22,D-23845 BORSTEL,GERMANY.		Perbandt, Markus/K-7603-2018; Betzel, Christian/G-8105-2018	Betzel, Christian/0000-0002-3879-5019; Bufe, Albrecht/0000-0001-7335-9362				BALL T, 1994, J BIOL CHEM, V269, P28323; BARNA B, 1989, PHYSIOL MOL PLANT P, V35, P151, DOI 10.1016/0885-5765(89)90085-4; BARNES PJ, 1991, TRENDS BIOCHEM SCI, V16, P365, DOI 10.1016/0968-0004(91)90152-L; BAUR X, 1989, SCIENCE, V233, P351; BECKER WM, 1988, BIOCH ENG, P440; Bufe A, 1996, PLANTA, V199, P413, DOI 10.1007/BF00195733; BUFE A, 1994, J ALLERGY CLIN IMMUN, V94, P173, DOI 10.1016/0091-6749(94)90037-X; BUFE A, 1995, FEBS LETT, V363, P6, DOI 10.1016/0014-5793(95)00259-C; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; FASLER S, 1988, ANAL BIOCHEM, V174, P593, DOI 10.1016/0003-2697(88)90061-9; GUNTHER N, 1990, J BIOL CHEM, V265, P22082; HAMPEL A, 1996, SCIENCE, V162, P1384; HENDRICKSON WA, 1995, MACROMOLECULAR STRUC; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224, DOI 10.1159/000236761; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Matousek J, 1995, BIOL CHEM H-S, V376, P715, DOI 10.1515/bchm3.1995.376.12.715; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; MCPHERSON A, 1982, PREPARATION ANAL PRO, P118; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5117, DOI 10.1021/bi00137a005; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P8697, DOI 10.1021/bi00152a003; ONG EK, 1995, MOL IMMUNOL, V32, P295, DOI 10.1016/0161-5890(94)00127-M; OTWINOWSKI Z, 1991, DEN20 FILM PROCESSIN; PETERSEN A, 1994, CLIN EXP ALLERGY, V24, P250, DOI 10.1111/j.1365-2222.1994.tb00227.x; SCHRAMM G, 1995, THESIS U BAYREUTH GE; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5	28	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27193	27196		10.1074/jbc.271.44.27193	http://dx.doi.org/10.1074/jbc.271.44.27193			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910284	hybrid			2022-12-27	WOS:A1996VQ67900002
J	Faris, M; Kokot, N; Lee, L; Nel, AE				Faris, M; Kokot, N; Lee, L; Nel, AE			Regulation of interleukin-2 transcription by inducible stable expression of dominant negative and dominant active mitogen-activated protein kinase kinase kinase in Jurkat T cells - Evidence for the importance of Ras in a pathway that is controlled by dual receptor stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY MOLECULE CD28; C-JUN; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; IL-2 GENE; MAMMALIAN-CELLS; JNK; INDUCTION; P21(RAS); PROMOTER	Engagement of the T cell receptor induces the activation of several mitogen-activated protein kinase modules, including the extracellular signal-regulated kinase and c-Jun N-terminal kinase (JNK) cascades. Whereas extracellular signal-regulated kinase is activated by T cell receptor/CD3 ligation alone, activation of JNK requires co-stimulation by the, CD28 receptor, Activation of MEKK-1, which acts as a mitogen-activated protein kinase kinase kinase in the JNK pathway, was also induced by CD3 plus CD28 (CD3/CD28) ligation in Jurkat cells, To study She significance of the JNK: cascade in T lymphocytes, we established stable Jurkat cell lines that inducibly express dominant active (DA) or dominant negative (DN) MEKK-1. Whereas expression of DA-MEKK-1 resulted in the constitutive activation of JNK along with the transcriptional activation of the minimal interleukin-2 (IL-2) promoter, DN-MEKK-1 inhibited JNK responsiveness during CD3/CD28 co-stimulation, In addition to inhibiting CD3/CD28-induced IL-2 mRNA expression, DN-MEKK-1 abrogated the transcriptional activation of the IL-2 promoter and the distal nuclear factor of activated T cells (NFAT)-activating protein 1 (AP-I) response element in that promoter, A c-Jun mutant lacking activation sites for JNK also interfered with the activation of the distal NFAT/AP-1 complex, suggesting that the JNK pathway functions by controlling AP-1 response elements in the IL-2 promoter, Using inducible stable expression of DA- and DN-Ras in Jurkat cells, we found that nas regulates JNK activation in these cells, Our results suggest that the dual ligation of CD3 and CD28 in T cells triggers a cascade of events that involve Ras, the JNK cascade, and one or more AP-I response elements in the IL-2 promoter.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,DIV CLIN IMMUNOL & ALLERGY,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Kokot, Niels/ABB-5847-2020; Nel, Andre E/J-2808-2012	Kokot, Niels/0000-0001-7388-6373; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI034567, U01AI034567] Funding Source: NIH RePORTER; NCI NIH HHS [CA-09120-21] Funding Source: Medline; NIAID NIH HHS [AI-34567] Funding Source: Medline; NIGMS NIH HHS [GM41576] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNERIAH Y, 1995, RES IMMUNOL, V146, P150; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOISE LH, 1995, CURR OPIN IMMUNOL, V7, P620, DOI 10.1016/0952-7915(95)80067-0; BOUSSIOTIS VA, 1994, CURR OPIN IMMUNOL, V6, P797, DOI 10.1016/0952-7915(94)90087-6; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOWNWARD J, 1992, IMMUNOL TODAY, V13, P89, DOI 10.1016/0167-5699(92)90148-Z; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; FARIS M, 1996, AIDS, V10, P370; FRASER JD, 1992, MOL CELL BIOL, V12, P4357, DOI 10.1128/MCB.12.10.4357; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; GUPTA S, 1994, J BIOL CHEM, V269, P17349; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUELLER DL, 1995, CURR OPIN IMMUNOL, V7, P375, DOI 10.1016/0952-7915(95)80113-8; NEL AE, 1991, J IMMUNOL, V147, P1933; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; NUNES JA, 1994, J EXP MED, V180, P1067, DOI 10.1084/jem.180.3.1067; PETRAK D, 1994, J IMMUNOL, V153, P2046; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITEHURST CE, 1992, J IMMUNOL, V148, P3230; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	55	61	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27366	27373		10.1074/jbc.271.44.27366	http://dx.doi.org/10.1074/jbc.271.44.27366			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910314	hybrid			2022-12-27	WOS:A1996VQ67900032
J	GarciaFuentes, L; CamaraArtigas, A; LopezMayorga, O; Baron, C				GarciaFuentes, L; CamaraArtigas, A; LopezMayorga, O; Baron, C			Thermodynamic characterization of 5'-AMP binding to bovine liver glycogen phosphorylase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HEAT-CAPACITY; PROTEINS; AMP; SURFACE; CRYSTALLIZATION; TEMPERATURES; PURIFICATION; ACTIVATION; MECHANISM	The binding of adenosine 5'-monophosphate to liver glycogen phosphorylase a (EC 2.4.1.1) has been studied by size exclusion high performance liquid chromatography and isothermal titration microcalorimetry at pH 6.9 over a temperature range of 25 to 35 degrees C. The results are compared with those of the binding of the same nucleotide to the muscle isozyme and to liver phosphorylase b. Calorimetric measurements in various buffer systems with different ionization heats suggest that protons are released during the binding of the nucleotide. The dimer of liver glycogen phosphorylase a has been shown to have two equal and independent sites for 5'-AMP, which would correspond to the activator sites identified in the muscle isozyme. The binding constants as well as the changes in Gibbs energy, enthalpy, and entropy per site for 5'-AMP binding were calculated at each temperature. The results show that the major contribution to the negative value of Delta G(0) stems from the value of Delta H in the range of 25 to 35 degrees C. The enthalpy change of binding is strongly temperature-dependent, arising from a large negative Delta C-p of binding equal to -1.45 +/- 0.02 kJ K-1 (mol of 5'-AMP bound)(-1), which suggests significant changes in the polar and apolar surfaces accessible to the solvent.	UNIV ALMERIA,FAC CIENCIAS EXPT,DEPT QUIM FIS BIOQUIM & QUIM INORGAN,ALMERIA 04120,SPAIN; UNIV GRANADA,INST BIOTECHNOL,GRANADA,SPAIN	Universidad de Almeria; University of Granada			Camara-Artigas, Ana/M-2252-2019; Garcia Fuentes, Luis Sebastian/D-1125-2016	Camara-Artigas, Ana/0000-0003-2197-726X; Garcia Fuentes, Luis Sebastian/0000-0003-2471-8052				APPLEMAN MM, 1966, BIOCHEMISTRY-US, V5, P2101, DOI 10.1021/bi00870a043; BARFORD D, 1989, NATURE, V340, P609, DOI 10.1038/340609a0; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BARFORD D, 1992, PROTEIN SCI, V1, P472; BARON C, 1989, J BIOL CHEM, V264, P12872; BUC MH, 1968, 1967 FEBS S REG ENZ, P109; CAMARAARTIGAS A, 1994, PROTEIN EXPRES PURIF, V5, P157; CHRISTENSEN JJ, 1976, HDB PROTON IONIZATIO, P93; COHEN P, 1983, METHOD ENZYMOL, V99, P243; COHEN WE, 1955, NUCL ACIDS, V1, P513; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FLETTERICK RJ, 1979, CAN J BIOCHEM CELL B, V57, P789, DOI 10.1139/o79-098; FLETTERICK RJ, 1980, ANNU REV BIOCHEM, V49, P31, DOI 10.1146/annurev.bi.49.070180.000335; Freire E., 1990, ANAL CHEM, V62, P950; GarciaFuentes L, 1996, BBA-PROTEIN STRUCT M, V1294, P83, DOI 10.1016/0167-4838(95)00272-3; GARCIAFUENTES L, 1995, EUR J BIOCHEM, V232, P641, DOI 10.1111/j.1432-1033.1995.tb20855.x; HEDRICK JL, 1965, BIOCHEMISTRY-US, V4, P1337, DOI 10.1021/bi00883a018; HERS HG, 1976, ANNU REV BIOCHEM, V45, P167, DOI 10.1146/annurev.bi.45.070176.001123; HUANG CY, 1970, BIOCHEMISTRY-US, V9, P660, DOI 10.1021/bi00805a028; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; HWANG P, 1984, BIOCHIM BIOPHYS ACTA, V791, P252, DOI 10.1016/0167-4838(84)90016-5; Johnson L. N., 1989, ALLOSTERIC ENZYMES, P81; JOHNSON LN, 1979, J MOL BIOL, V134, P639, DOI 10.1016/0022-2836(79)90371-1; JOHNSON LN, 1993, ANNU REV BIOPH BIOM, V22, P199, DOI 10.1146/annurev.bb.22.060193.001215; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; JOHNSON LN, 1994, PROTEIN SCI, V3, P1726, DOI 10.1002/pro.5560031011; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KASVINSKY PJ, 1978, J BIOL CHEM, V253, P3343; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LEDERER B, 1976, BIOCHEM J, V159, P689, DOI 10.1042/bj1590689; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; MADSEN NB, 1986, ENZYMES, V17, P366; MATEO PL, 1984, J BIOL CHEM, V259, P9384; MATEO PL, 1986, J BIOL CHEM, V261, P7067; MCKINNON IR, 1984, ANAL BIOCHEM, V139, P134, DOI 10.1016/0003-2697(84)90398-1; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; OIKONOMAKOS NG, 1985, BIOCHIM BIOPHYS ACTA, V832, P248, DOI 10.1016/0167-4838(85)90257-2; PRESS WH, 1988, NUMERICAL RECIPES C, P683; PRIVALOV PL, 1990, J MOL BIOL, V213, P385, DOI 10.1016/S0022-2836(05)80198-6; SANSOM MSP, 1985, J MOL STRUCT, V123, P3; SCHIEBEL K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P349, DOI 10.1016/0167-4781(92)90453-7; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; SPRANG SR, 1991, SCIENCE, V254, P1367, DOI 10.1126/science.1962195; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STALMANS W, 1974, EUR J BIOCHEM, V49, P415, DOI 10.1111/j.1432-1033.1974.tb03847.x; STALMANS W, 1981, BIOCHEM J, V20, P327; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; TITANI K, 1977, P NATL ACAD SCI USA, V74, P4762, DOI 10.1073/pnas.74.11.4762; Wang J. H, 1972, ENZYMES, V7, P435; WOLF DP, 1970, BIOCHEMISTRY-US, V9, P1923, DOI 10.1021/bi00811a010	55	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27569	27574		10.1074/jbc.271.44.27569	http://dx.doi.org/10.1074/jbc.271.44.27569			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910343	hybrid			2022-12-27	WOS:A1996VQ67900061
J	Itoh, T; Miura, K; Miki, H; Takenawa, T				Itoh, T; Miura, K; Miki, H; Takenawa, T			beta-tubulin binds Src homology 2 domains through a region different from the tyrosine-phosphorylated protein-recognizing site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT EMBRYO FIBROBLASTS; SH3 DOMAINS; PHOSPHOLIPASE-C; SIGNAL TRANSDUCTION; CRYSTAL-STRUCTURE; ASSOCIATION; RECEPTOR; GRB2; KINASES; INSULIN	Src homology 2 (SH2) domains have been demonstrated to bind tyrosine phosphorylated proteins that participate in signaling by growth factors and oncogenes by recognizing amino acid sequences containing phosphotyrosine residue. We found that SH2 domains such as Ash/Grb2, the 85-kDa subunit of phosphatidylinositol 3-kinase, and phospholipase C gamma 1 also bind beta-tubulin through a different region that recognizes phosphotyrosine in vitro and in vivo. Furthermore, binding occurs even when the SH2 domain is occupied by tyrosine-phosphorylated epidermal growth factor receptors. Using deleted constructs of Ash/Grba SH2, we found that carboxyl-terminal beta strands E and F, and alpha helix B (region ''c'') are required for binding. A synthetic peptide (FLWVVKFNSLNELVDYH) composed of region c inhibited the binding of beta-tubulin to the SH2 domains of Ash/Grb2, phosphatidylinositol 3-kinase, and phospholipase C gamma 1. The co-localization of SH2 proteins and microtubules is also confirmed by immunostaining. These data suggest that microtubules play important roles in the assembly of signaling molecules complexes containing SH2 proteins.	UNIV TOKYO, INST MED SCI, DEPT BIOCHEM, MINATO KU, TOKYO 108, JAPAN	University of Tokyo								ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN S, 1982, J BIOL CHEM, V257, P1523; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1993, MOL CELL BIOL, V13, P6052, DOI 10.1128/MCB.13.10.6052; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MIKI H, 1994, J BIOL CHEM, V269, P5489; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHIBASAKI F, 1993, BIOCHEM J, V289, P227, DOI 10.1042/bj2890227; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TOBE K, 1993, J BIOL CHEM, V268, P11167; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27931	27935		10.1074/jbc.271.44.27931	http://dx.doi.org/10.1074/jbc.271.44.27931			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910394	hybrid			2022-12-27	WOS:A1996VQ67900112
J	Wilson, KP; Fitzgibbon, MJ; Caron, PN; Griffith, JP; Chen, WY; McCaffrey, PG; Chambers, SP; Su, MSS				Wilson, KP; Fitzgibbon, MJ; Caron, PN; Griffith, JP; Chen, WY; McCaffrey, PG; Chambers, SP; Su, MSS			Crystal structure of p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; PHOSPHORYLATION; THREONINE; STRESS; CELLS	p38 mitogen-activated protein kinase is activated by environmental stress and cytokines and plays a role in transcriptional regulation and inflammatory responses, The crystal structure of the ape, unphosphorylated form of p38 kinase has been solved at 2.3 Angstrom resolution. The fold and topology of p38 is similar to ERK2 (Zhang, F., Strand, A,, Robbins, D., Cobb, MI H., and Goldsmith, E. J. (1994) Nature 367, 704-711), The relative orientation of the two domains of p38 kinase is different from that observed in the active form of cAMP-dependent protein kinase, The twist results in a misalignment of the active site of p38, suggesting that the orientation of the domains would have to change before catalysis could proceed, The residues that are phosphorylated upon activation of p38 are located on a surface loop that occupies the peptide binding channel, Occlusion of the active site by the loop, and misalignment of catalytic residues, may account for the low enzymatic activity of unphosphorylated p38 kinase.	VERTEX PHARMACEUT INC,CAMBRIDGE,MA 02139	Vertex Pharmaceuticals								Bokemeyer D, 1996, KIDNEY INT, V49, P1187, DOI 10.1038/ki.1996.172; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Brunger AT, 1992, XPLOR VERSION 3 1 MA; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423	31	202	217	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27696	27700		10.1074/jbc.271.44.27696	http://dx.doi.org/10.1074/jbc.271.44.27696			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910361	hybrid			2022-12-27	WOS:A1996VQ67900079
J	Cippitelli, M; Ye, JP; Viggiano, V; Sica, A; Ghosh, P; Gulino, A; Santoni, A; Young, HA				Cippitelli, M; Ye, JP; Viggiano, V; Sica, A; Ghosh, P; Gulino, A; Santoni, A; Young, HA			Retinoic acid-induced transcriptional modulation of the human interferon-gamma promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A-DEFICIENCY; IMMUNODEFICIENCY-VIRUS TYPE-1; NEGATIVE REGULATORY ELEMENT; LOOP-HELIX PROTEIN; NF-KAPPA-B; GLUCOCORTICOID RECEPTOR; DNA-BINDING; THYROID-HORMONE; FACTOR USF; MAMMALIAN-CELLS	Disregulation of vitamin A metabolism is able to generate different immunological effects, including altered response to infection, reduced IgG production, and differential regulation of cytokine gene expression (including interleukin-2 and -4 and interferon-gamma (IFN-gamma)). In particular, IFN-gamma gene expression is significantly affected by vitamin A and/or its derivatives (e.g. retinoic acid (RA)), Here, we analyze the effect of retinoic acid on IFN-gamma transcription. Transient transfection assays in the human T lymphoblastoid cell line Jurkat demonstrated that the activation of the IFN-gamma promoter was significantly down-regulated in the presence of RA, Surprisingly, two different AP-1/CREB-ATF-binding elements situated in the initial 108 base pairs of the IFN-gamma promoter and previously shown to be critical for tran scriptional activity were unaffected by Rk Utilizing promoter deletions and electrophoretic mobility shift analysis, we identified a USF/EGR-1-binding element cooperating in the modulation of IFN-gamma promoter activity by RA, This element was found to be situated in a position of the IFN-gamma promoter close to a silencer element previously identified in our laboratory, These results suggest that direct modulation of IFN-gamma promoter activity is one of the possible mechanisms involved in the inhibitory effect of retinoids on IFN-gamma gene expression.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP FREDERICK,INTRAMURAL RES SUPPORT PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,DIV BASIC SCI,EXPT IMMUNOL LAB,FREDERICK,MD 21702; UNIV AQUILA,DEPT EXPT MED,I-67100 LAQUILA,ITALY; UNIV ROMA LA SAPIENZA,DEPT EXPT MED & PATHOL,I-00158 ROME,ITALY; REGINA ELENA INST CANC RES,LAB PATHOPHYSIOL,I-00158 ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of L'Aquila; Sapienza University Rome; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Cippitelli, Marco/AAF-4857-2021; Sica, Antonio/AAB-9546-2020; Ye, Jianping/N-1998-2017	Cippitelli, Marco/0000-0002-9620-538X; Ye, Jianping/0000-0003-3875-365X				ABB J, 1982, IMMUNOPHARMACOLOGY, V4, P303, DOI 10.1016/0162-3109(82)90051-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEATO M, 1991, FASEB J, V5, P2044, DOI 10.1096/fasebj.5.7.2010057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAZSEK I, 1991, BIOMED PHARMACOTHER, V45, P157, DOI 10.1016/0753-3322(91)90103-Z; BROCKERS JP, 1989, NEURON, V2, P1235; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; BROWN DA, 1991, EUR J IMMUNOL, V21, P1879, DOI 10.1002/eji.1830210815; Cantorna MT, 1996, J IMMUNOL, V156, P2674; CANTORNA MT, 1994, J IMMUNOL, V152, P1515; CANTORNA MT, 1995, EUR J IMMUNOL, V25, P1673, DOI 10.1002/eji.1830250629; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CARMAN JA, 1992, J EXP MED, V175, P111, DOI 10.1084/jem.175.1.111; CARMAN JA, 1991, J IMMUNOL, V147, P1247; CARMAN JA, 1989, J IMMUNOL, V142, P388; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CHIRIVIA JC, 1990, J EXP MED, V172, P661; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CICCARONE VC, 1990, J IMMUNOL, V144, P725; CIPPITELLI M, 1995, J BIOL CHEM, V270, P12548, DOI 10.1074/jbc.270.21.12548; COHEN M, 1987, AM J DIS CHILD, V141, P263, DOI 10.1001/archpedi.1987.04460030041020; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; DE LUCA LM, 1991, FASEB J, V5, P2924; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GARBE A, 1992, J EXP MED, V176, P109, DOI 10.1084/jem.176.1.109; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HONG D, 1993, EMBO J, V12, P501; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JANOT C, 1990, CELL, V62, P1189; JIAYANG C, 1995, EMBO J, V14, P1187; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; LANIGAN TM, 1993, MOL CELL BIOL, V13, P6079, DOI 10.1128/MCB.13.10.6079; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIN Q, 1994, J BIOL CHEM, V269, P23894; LIPKIN SM, 1992, P NATL ACAD SCI USA, V89, P1209, DOI 10.1073/pnas.89.4.1209; LOTAN R, 1991, BIOMED PHARMACOTHER, V45, P145, DOI 10.1016/0753-3322(91)90102-Y; LU YC, 1990, J VIROL, V64, P5226, DOI 10.1128/JVI.64.10.5226-5229.1990; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MASSACESI L, 1991, J CLIN INVEST, V88, P1331, DOI 10.1172/JCI115438; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RACKE MK, 1995, J IMMUNOL, V154, P450; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; ROBERTS AB, 1984, RETINOIDS, V2, P209; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2; SHENEFELT RE, 1972, TERATOLOGY, V5, P103, DOI 10.1002/tera.1420050115; SIDELL N, 1993, CELL IMMUNOL, V146, P28, DOI 10.1006/cimm.1993.1003; SIDELL N, 1988, CELL IMMUNOL, V115, P299, DOI 10.1016/0008-8749(88)90183-9; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; SMITH SM, 1987, P NATL ACAD SCI USA, V84, P5878, DOI 10.1073/pnas.84.16.5878; SMITH SM, 1987, J NUTR, V117, P857, DOI 10.1093/jn/117.5.857; STAUBER C, 1992, NEW BIOL, V4, P527; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STROMSTEDT PE, 1991, MOL CELL BIOL, V11, P3379, DOI 10.1128/MCB.11.6.3379; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; ULLMAN KS, 1993, GENE DEV, V7, P188, DOI 10.1101/gad.7.2.188; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YE JP, 1994, J BIOL CHEM, V269, P25728; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q; YOUNG HA, 1994, J IMMUNOL, V153, P3603; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1991, J BIOL CHEM, V266, P8248; ZITNIK RJ, 1994, J IMMUNOL, V152, P1419	93	41	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26783	26793		10.1074/jbc.271.43.26783	http://dx.doi.org/10.1074/jbc.271.43.26783			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900159	hybrid			2022-12-27	WOS:A1996VP23300053
J	Mougey, EB; Pape, LK; SollnerWebb, B				Mougey, EB; Pape, LK; SollnerWebb, B			Virtually the entire Xenopus laevis rDNA multikilobase intergenic spacer serves to stimulate polymerase I transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; DROSOPHILA-MELANOGASTER; SEQUENCE ORGANIZATION; X-LAEVIS; NONTRANSCRIBED SPACER; NUCLEOTIDE-SEQUENCES; RESTRICTION ANALYSIS; MOLECULAR-BASIS; FACTOR XUBF; DNA	The promoter-distal half of the spacer separating the tandem Xenopus laevis rRNA genes consists of ''0'' and ''1'' repetitive elements that have been considered unimportant in polymerase I transcriptional activation, Utilizing oocyte microinjection, we now demonstrate that the 0/1 region, as well as its component 0 and 1 repeats, substantially stimulate transcription from a ribosomal promoter in cis and inhibit transcription when located in trans. Both the cis and trans responses increase linearly with increasing numbers of 0 or 1 repeats until saturation is approached, The 0/1 block and its component elements stimulate transcription in both orientations, over distances, and when placed downstream of the initiation site, properties for which the 60/81-base pair (bp) repeats have been defined as polymerase I enhancers, In their natural promoter-distal rDNA location, the 0/1 repeats can stimulate transcription from the rRNA gene promoter, above the level afforded by the intervening 60/81-bp repeats and spacer promoter, In addition, as with the 60/81-bp repeats, the 0/1 repeats bind a factor in common with the rDNA promoter. Thus, the entire X. laevis rDNA intergenic spacer (the 0 repeats, 1 repeats, spacer promoter repeats, and 60/ 81-bp repeats) acts together to enhance ribosomal transcription.			Mougey, EB (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205, USA.			Mougey, Edward/0000-0003-1190-6660				ARNHEIM N, 1980, CELL, V22, P179, DOI 10.1016/0092-8674(80)90166-X; BACH R, 1981, NUCLEIC ACIDS RES, V9, P5311, DOI 10.1093/nar/9.20.5311; BECKMANN H, 1995, SCIENCE, V270, P1506, DOI 10.1126/science.270.5241.1506; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BOSELEY P, 1979, CELL, V17, P19, DOI 10.1016/0092-8674(79)90291-5; BOTCHAN P, 1977, CELL, V11, P599, DOI 10.1016/0092-8674(77)90077-0; BUSBY SJ, 1983, CELL, V34, P989, DOI 10.1016/0092-8674(83)90556-1; CASSIDY BG, 1986, MOL CELL BIOL, V6, P2766, DOI 10.1128/MCB.6.8.2766; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DEWINTER RFJ, 1987, J MOL BIOL, V196, P813, DOI 10.1016/0022-2836(87)90407-4; DEWINTER RFJ, 1986, CELL, V44, P313, DOI 10.1016/0092-8674(86)90765-8; DOELLING JH, 1993, P NATL ACAD SCI USA, V90, P7528, DOI 10.1073/pnas.90.16.7528; ERICKSON JM, 1985, AM J HUM GENET, V37, P311; GERLACH WL, 1979, NUCLEIC ACIDS RES, V7, P1869, DOI 10.1093/nar/7.7.1869; GONZALEZ IL, 1995, GENOMICS, V27, P320, DOI 10.1006/geno.1995.1049; GRIMALDI G, 1990, MOL CELL BIOL, V10, P4667, DOI 10.1128/MCB.10.9.4667; GRIMALDI G, 1988, P NATL ACAD SCI USA, V85, P5502, DOI 10.1073/pnas.85.15.5502; HU CH, 1994, MOL CELL BIOL, V14, P2871, DOI 10.1128/MCB.14.5.2871; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KOMINAMI R, 1981, NUCLEIC ACIDS RES, V9, P3219, DOI 10.1093/nar/9.14.3219; KUHN A, 1990, P NATL ACAD SCI USA, V87, P7527, DOI 10.1073/pnas.87.19.7527; LABHART P, 1984, CELL, V37, P285, DOI 10.1016/0092-8674(84)90324-6; LABHART P, 1987, NUCLEIC ACIDS RES, V15, P3623, DOI 10.1093/nar/15.8.3623; LABHART P, 1987, MOL CELL BIOL, V7, P1900, DOI 10.1128/MCB.7.5.1900; LABHART P, 1985, NUCLEIC ACIDS RES, V13, P8999, DOI 10.1093/nar/13.24.8999; LEBLANC B, 1993, EMBO J, V12, P513, DOI 10.1002/j.1460-2075.1993.tb05683.x; LONG EO, 1979, NUCLEIC ACIDS RES, V7, P205, DOI 10.1093/nar/7.1.205; LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455; MCSTAY B, 1991, EMBO J, V10, P2297, DOI 10.1002/j.1460-2075.1991.tb07766.x; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; Moss T, 1985, Oxf Surv Eukaryot Genes, V2, P207; MOSS T, 1980, NUCLEIC ACIDS RES, V8, P467, DOI 10.1093/nar/8.3.467; PAALMAN MH, 1995, MOL CELL BIOL, V15, P4648; PAPE LK, 1990, GENE DEV, V4, P52, DOI 10.1101/gad.4.1.52; PAPE LK, 1989, MOL CELL BIOL, V9, P5093, DOI 10.1128/MCB.9.11.5093; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PIKAARD CS, 1990, MOL CELL BIOL, V10, P4816, DOI 10.1128/MCB.10.9.4816; PIKAARD CS, 1989, GENE DEV, V3, P1779, DOI 10.1101/gad.3.11.1779; PIKAARD CS, 1988, MOL CELL BIOL, V8, P4282, DOI 10.1128/MCB.8.10.4282; PIKAARD CS, 1994, P NATL ACAD SCI USA, V91, P464, DOI 10.1073/pnas.91.2.464; PROBST E, 1979, J MOL BIOL, V135, P709, DOI 10.1016/0022-2836(79)90173-6; PUTNAM CD, 1994, MOL CELL BIOL, V14, P6476, DOI 10.1128/MCB.14.10.6476; PUTNAM CD, 1992, MOL CELL BIOL, V12, P4970, DOI 10.1128/MCB.12.11.4970; REEDER RH, 1984, CELL, V38, P349, DOI 10.1016/0092-8674(84)90489-6; REEDER RH, 1983, CELL, V35, P449, DOI 10.1016/0092-8674(83)90178-2; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAMBROOK J, 1989, MOL CLONINGG LAB MAN; SIMEONE A, 1985, NUCLEIC ACIDS RES, V13, P1089, DOI 10.1093/nar/13.4.1089; SKRYABIN KG, 1984, NUCLEIC ACIDS RES, V12, P2955, DOI 10.1093/nar/12.6.2955; SOLLNERWEBB B, 1979, CELL, V18, P485, DOI 10.1016/0092-8674(79)90066-7; SOLLNERWEBB B, 1982, NUCLEIC ACIDS RES, V10, P3391, DOI 10.1093/nar/10.11.3391; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SYLVESTER JE, 1986, HUM GENET, V73, P193, DOI 10.1007/BF00401226; TAUTZ D, 1987, J MOL BIOL, V195, P525, DOI 10.1016/0022-2836(87)90181-1; TOWER J, 1986, MOL CELL BIOL, V6, P3451, DOI 10.1128/MCB.6.10.3451; WELLAUER PK, 1976, J MOL BIOL, V105, P461, DOI 10.1016/0022-2836(76)90229-1; WELLAUER PK, 1974, P NATL ACAD SCI USA, V71, P2823, DOI 10.1073/pnas.71.7.2823; WINDLE J, 1986, MOL CELL BIOL, V6, P1228, DOI 10.1128/MCB.6.4.1228; WINDLE JJ, 1986, MOL CELL BIOL, V6, P4585, DOI 10.1128/MCB.6.12.4585; YANG Q, 1994, NUCLEIC ACIDS RES, V22, P4798, DOI 10.1093/nar/22.22.4798	62	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27138	27145		10.1074/jbc.271.43.27138	http://dx.doi.org/10.1074/jbc.271.43.27138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900206	hybrid			2022-12-27	WOS:A1996VP23300100
J	Song, JS; Gomez, J; Stancato, LF; Rivera, J				Song, JS; Gomez, J; Stancato, LF; Rivera, J			Association of a p95 Vav-containing signaling complex with the Fc epsilon RI gamma chain in the RBL-2H3 mast cell line - Evidence for a constitutive in vivo association of Vav with Grb2, Raf-1, and ERK2 in an active complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; AFFINITY IGE RECEPTOR; BASOPHILIC LEUKEMIA-CELLS; T-CELL; IMMUNOGLOBULIN-E; HISTAMINE-RELEASE; EXCHANGE ACTIVITY; CROSS-LINKING; SH2 DOMAIN; B-CELLS	Aggregation of the high affinity receptor for IgE (Fc epsilon RI) on the mucosal mast cell line, RBL-2H3, results in the rapid and persistent tyrosine phosphorylation of Vav. Immunoprecipitation of Vav from activated cells revealed co-immunoprecipitated phosphoproteins of molecular weights identical to the Fc epsilon RI beta and gamma chains, and the former was reactive with antibody to the Fc epsilon RI beta chain. Conversely, Western blots revealed the presence of p95 Vav in Fc epsilon RI immunoprecipitates. The association of Vav and of Grb2 with the receptor was found to be regulated by aggregation of the receptor, and the interaction of Vav with the Fc epsilon RI was localized to the gamma chain. To gain insight on the signaling pathway in which Vav participates, we investigated the in vivo associations of Vav with other molecules. A reducible chemical cross-linking agent was used to covalently maintain protein interactions under nonreducing conditions. A fraction of Vav increased in mass to form a complex of > 300 kDa in molecular mass. Under reducing conditions the cross-linked Vav immunoprecipitates showed the presence of Grb2, Raf-1, and p42(mapk) (ERK2). In vitro kinase assays of Raf-1 activity associated with Vav revealed that this complex had an activity greater than that of Raf-1 derived from nonactivated cells, and aggregation of the Fc epsilon RI did not modulate this activity. In contrast, aggregation of the Fc epsilon RI increased the total Raf-1 activity by 2-5-fold. These results demonstrate that Vav associates constitutively with components of the mitogen-activated protein kinase pathway to form an active multimeric signaling complex whose in vitro activity and associations may be directed by aggregation of the Fc epsilon RI. The findings of this study may also be relevant to other members of the immune recognition receptor family that share the T-cell antigen receptor zeta/gamma chains.	NIAMSD,SECT CHEM IMMUNOL,NIH,BETHESDA,MD 20892; NIAMSD,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)								ADAMS JM, 1992, ONCOGENE, V7, P611; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; EISEMAN E, 1992, NATURE, V355, P78; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FURUICHI K, 1984, J IMMUNOL, V133, P1513; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, J IMMUNOL, V152, P2123; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOLOWKA D, 1982, MOL IMMUNOL, V19, P219, DOI 10.1016/0161-5890(82)90334-0; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LIU FT, 1980, J IMMUNOL, V124, P2728; MAO SY, 1995, BIOCHEMISTRY-US, V34, P1968, DOI 10.1021/bi00006a018; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MORISHIMAKAWASH, 1996, MOL BIOL CELL, V7, P893; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PRIBLUDA VS, 1992, P NATL ACAD SCI USA, V89, P11446, DOI 10.1073/pnas.89.23.11446; QUARTO R, 1986, MOL IMMUNOL, V11, P1215; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1995, MOL CELL BIOL, V15, P4337; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	45	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26962	26970		10.1074/jbc.271.43.26962	http://dx.doi.org/10.1074/jbc.271.43.26962			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900182	hybrid			2022-12-27	WOS:A1996VP23300076
J	Akbarali, Y; Oettgen, P; Boltax, J; Libermann, TA				Akbarali, Y; Oettgen, P; Boltax, J; Libermann, TA			ELF-1 interacts with and transactivates the IgH enhancer pi site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN GENE-EXPRESSION; PROTEIN-BINDING-SITES; PU.1 REGULATES EXPRESSION; TRANSCRIPTION FACTOR PU.1; ETS-RELATED PROTEIN; RESTRICTED EXPRESSION; NUCLEAR FACTOR; RECEPTOR-BETA; DNA-BINDING; 3' ENHANCER	We previously identified a B-cell-specific regulatory element in the immunoglobulin heavy chain (IgH) enhancer, pi, with striking similarity to binding sites for ets-related transcription factors. Whereas the ability of ets-related factors to bind to and transactivate the pi site has been substantiated, the identification of the particular member of the ets family responsible for B-cell-specific regulation of the pi site has remained controversial. We have used antibodies specific for individual members of the ets family to evaluate which ets-related factor in B-cell nuclear extracts interacts with the IgH pi site. We present strong evidence that ELF-1 is highly expressed in B-cells and is one of two major factors specifically interacting with the murine IgH enhancer pi site in B-cell nuclear extracts. Binding of ELF-1 correlates with activity of the pi site, since mutations abolishing function of pi also inhibit binding of ELF-1. Furthermore, we demonstrate that ELF-1 can transactivate the IgH enhancer in HeLa cells, suggesting a role for ELF-1 in B-cell-specific IgH gene expression.	BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School			Oettgen, Peter/AAF-5026-2021; Libermann, Towia/F-9866-2010	Libermann, Towia/0000-0002-4006-8179	NIAID NIH HHS [AI/CA33211-03] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033211] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; GRANT PA, 1992, NUCLEIC ACIDS RES, V20, P4401, DOI 10.1093/nar/20.17.4401; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HROMAS R, 1993, BLOOD, V82, P2998; JABRANEFERRAT N, 1994, MOL CELL BIOL, V14, P7314, DOI 10.1128/MCB.14.11.7314; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LEUNG S, 1993, ONCOGENE, V8, P989; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LIBERMANN TA, 1990, MOL ASPECTS CELL REG, V6, P399; LIEBERSON R, 1991, NUCLEIC ACIDS RES, V19, P933, DOI 10.1093/nar/19.4.933; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MOREAU GF, 1994, BIOCHIM BIOPHYS ACTA, V1198, P149; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PIERCE JW, 1988, P NATL ACAD SCI USA, V85, P1482, DOI 10.1073/pnas.85.5.1482; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WOTTON D, 1993, LEUKEMIA BALTIMORE, pS55; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452	52	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26007	26012		10.1074/jbc.271.42.26007	http://dx.doi.org/10.1074/jbc.271.42.26007			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824239				2022-12-27	WOS:A1996VN18000045
J	Elgersma, Y; Vos, A; vandenBerg, M; vanRoermund, CWT; vanderSluijs, P; Distel, B; Tabak, HF				Elgersma, Y; Vos, A; vandenBerg, M; vanRoermund, CWT; vanderSluijs, P; Distel, B; Tabak, HF			Analysis of the carboxyl-terminal peroxisomal targeting signal 1 in a homologous context in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSITIVE SELECTION PROCEDURE; FIREFLY LUCIFERASE; TRYPANOSOMA-BRUCEI; PROTEIN IMPORT; 3-KETOACYL-COA THIOLASE; MALATE-DEHYDROGENASE; ASSEMBLY MUTANTS; SINGLE-GENE; IN-VIVO; YEAST	Most peroxisomal matrix proteins contain a carboxyl-terminal tripeptide that directs them to peroxisomes. Within limits, these amino acids may be varied, without loss of function, The specificity of this peroxisomal targeting signal (PTS1) is remarkable considering its small size and its relaxed consensus sequence. Moreover, several peroxisomal proteins have a PTS1-like signal that does not fit the reported consensus sequence. Because many of these PTS1 variants seem to be functional in a species-dependent or protein context-dependent manner, me investigated the PTS1 requirements in a homologous context, using Saccharomyces cerevisiae and endogenous peroxisomal malate dehydrogenase (MDH3). Peroxisomal import of the MDH3-PTS1 variants was tested qualitatively by the ability to complement the Delta mdh3 mutant and quantitatively by subcellular fractionation. We observed efficient import of MDH3 into peroxisomes with a large variety of PTS1 tripeptides. Many of these variants do not fit the observed PTS1 requirements for heterologously expressed proteins, which suggests that additional domains in the protein may be of decisive importance whether or not a certain PTS1 variant is recognized by the components of the peroxisomal import machinery. Because we show that dimerization of MDH3 precedes import into the organelle, these domains are most likely conformational domains.	UNIV AMSTERDAM,ACAD MED CTR,DEPT BIOCHEM,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT PEDIAT,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN BIOCHEM,NL-1105 AZ AMSTERDAM,NETHERLANDS; UNIV UTRECHT,SCH MED,DEPT CELL BIOL,NL-3584 CX UTRECHT,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University			Elgersma, Ype/F-5164-2013	Elgersma, Ype/0000-0002-3758-1297				BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; DEHOOP MJ, 1992, BIOCHEM J, V286, P657, DOI 10.1042/bj2860657; DISTEL B, 1992, NEW BIOL, V4, P157; DISTEL B, 1996, IN PRESS J CELL BIOL; ELERSMA Y, 1996, IN PRESS J CELL BIOL; ELGERSMA Y, 1995, EMBO J, V14, P3472, DOI 10.1002/j.1460-2075.1995.tb07353.x; ELGERSMA Y, 1993, GENETICS, V135, P731; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; GOULD SJ, 1990, EMBO J, V9, P85, DOI 10.1002/j.1460-2075.1990.tb08083.x; HANSEN H, 1992, MOL GEN GENET, V235, P269, DOI 10.1007/BF00279370; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KRAGLER F, 1993, J CELL BIOL, V120, P665, DOI 10.1083/jcb.120.3.665; LUMB MJ, 1994, EUR J BIOCHEM, V221, P53, DOI 10.1111/j.1432-1033.1994.tb18714.x; MARZIOCH M, 1994, EMBO J, V13, P4908, DOI 10.1002/j.1460-2075.1994.tb06818.x; MCALISTERHENN L, 1995, J BIOL CHEM, V270, P21220, DOI 10.1074/jbc.270.36.21220; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; MOTLEY A, 1995, J CELL BIOL, V131, P95, DOI 10.1083/jcb.131.1.95; ODA T, 1990, J BIOL CHEM, V265, P7513; OSINGA KA, 1985, EMBO J, V4, P3811, DOI 10.1002/j.1460-2075.1985.tb04152.x; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V181, P947, DOI 10.1016/0006-291X(91)92028-I; QUAN F, 1986, NUCLEIC ACIDS RES, V14, P5321, DOI 10.1093/nar/14.13.5321; ROGGENKAMP R, 1992, CELL BIOCHEM FUNCT, V10, P193, DOI 10.1002/cbf.290100309; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; SOMMER JM, 1994, FEBS LETT, V350, P125, DOI 10.1016/0014-5793(94)00747-0; STEFFAN JS, 1992, J BIOL CHEM, V267, P24708; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SWINKELS B, 1989, THESIS U AMSTERDAM N; SWINKELS BW, 1992, FEBS LETT, V305, P133, DOI 10.1016/0014-5793(92)80880-P; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; SZILARD RK, 1995, J CELL BIOL, V131, P1453, DOI 10.1083/jcb.131.6.1453; Tabak HF, 1995, COLD SPRING HARB SYM, V60, P649, DOI 10.1101/SQB.1995.060.01.069; VANDERLEIJ I, 1992, J CELL BIOL, V119, P153, DOI 10.1083/jcb.119.1.153; VANDERLEIJ I, 1993, J CELL BIOL, V90, P11782; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; vanRoermund CWT, 1995, BBA-GEN SUBJECTS, V1245, P348, DOI 10.1016/0304-4165(95)00099-2; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; ZHANG JW, 1995, J CELL BIOL, V129, P65, DOI 10.1083/jcb.129.1.65	43	135	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26375	26382		10.1074/jbc.271.42.26375	http://dx.doi.org/10.1074/jbc.271.42.26375			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824293	hybrid			2022-12-27	WOS:A1996VN18000099
J	Hiasa, H; Yousef, DO; Marians, KJ				Hiasa, H; Yousef, DO; Marians, KJ			DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone-DNA ternary complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IN-VITRO; GYRASE; IV; ACID; PURIFICATION; INHIBITORS; MECHANISM; BINDING; POISONS	The formation of a topoisomerase-quinolone-DNA ternary complex leads to cell death, We show here that an active strand breakage and reunion activity is required for formation of a norfloxacin-topoisomerase IV-DNA ternary complex that can arrest the progression of replication forks in vitro, Mutant topoisomerases containing either an active site mutation, a quinolone resistance-conferring mutation, or both, could all bind DNA as well as the wild type, but unlike the wild-type, could not halt replication fork progression, The collision between the replication fork and the frozen topoisomerase converted the cleavable complex to a nonreversible form but did not generate a double-stranded break. Thus, the cytotoxicity of this class of topoisomerase inhibitors likely results from a two-step process: (i) conversion of the frozen topoisomerase-quinolone-DNA ternary complex to an unreversible form; and (ii) generation of a double-strand break by subsequent denaturation of the topoisomerase, perhaps by an aborted repair attempt.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM BIOCHEM,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM STRUCT BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,PROGRAM MOL BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University; Cornell University; Cornell University					NIGMS NIH HHS [GM34558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Champoux JJ, 1980, MECH STUDIES DNA REP, P809; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P16371; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; HOLM C, 1989, CANCER RES, V49, P6365; HOWARD MT, 1994, P NATL ACAD SCI USA, V91, P12031, DOI 10.1073/pnas.91.25.12031; HSIANG YH, 1989, J BIOL CHEM, V264, P9713; HSIUNG YC, 1995, J BIOL CHEM, V270, P20359, DOI 10.1074/jbc.270.35.20359; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P8571; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; LYNN R, 1986, SCIENCE, V233, P647, DOI 10.1126/science.3014661; MADDEN KR, 1995, EMBO J, V14, P5399, DOI 10.1002/j.1460-2075.1995.tb00224.x; MORTON RM, 1989, GENE, V77, P61; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; PENG H, 1995, J BIOL CHEM, V270, P25286, DOI 10.1074/jbc.270.42.25286; PENG H, 1993, J BIOL CHEM, V268, P24481; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; SUGINO A, 1977, P NATL ACAD SCI USA, V74, P4767, DOI 10.1073/pnas.74.11.4767; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; TSAO YP, 1993, CANCER RES, V53, P5908; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665	27	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26424	26429		10.1074/jbc.271.42.26424	http://dx.doi.org/10.1074/jbc.271.42.26424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824300	hybrid			2022-12-27	WOS:A1996VN18000106
J	Li, FZ; Baykal, D; Horaist, C; Yan, CN; Carr, BN; Rao, GN; Runge, MS				Li, FZ; Baykal, D; Horaist, C; Yan, CN; Carr, BN; Rao, GN; Runge, MS			Cloning and identification thrombin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; PROTEINASE-ACTIVATED RECEPTOR-2; RNA-POLYMERASE-II; MOLECULAR-CLONING; CORONARY-ARTERIES; FUNCTIONAL EXPRESSION; GROWTH-FACTOR; TRANSCRIPTION; ANGIOPLASTY	Thrombin, via activation of vascular endothelial and smooth muscle cell thrombin receptors, modulates vascular wall healing. To understand the mechanisms that regulate human thrombin receptor (HTR) expression, we cloned and characterized the HTR gene. The HTR gene consists of Exon I, which contains the 5'-regulatory region and 85 nucleotides of coding sequence; a similar to 15-kb intron; and Exon II, which contains the remainder of the coding sequence and the entire 3'-untranslated region, Multiple transcription initiation sites were identified by S1 mapping and ribonuclease protection assay. DNA sequence analysis indicated the presence of two SP-1-AP-2 consensus binding sequences, near or within the transcription initiation sites, and consensus binding sequences for numerous regulatory proteins that potentially modulate HTR expression. Functional analysis of the HTR promoter was performed by transfecting human microvascular endothelial cells with HTR promoter region-luciferase constructs. The highest level of expression was obtained with a 0.7-kb promoter sequence and was progressively less with fragments of 0.54, 1.16, 1.6, and similar to 3.2 kb. The data presented in this report provide a foundation for further characterization of the HTR gene and the mechanisms that regulate its expression within the blood vessel wall.	UNIV TEXAS,MED BRANCH,DIV CARDIOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,SEALY CTR MOL CARDIOL,GALVESTON,TX 77555; EMORY UNIV,SCH MED,DIV CARDIOL,ATLANTA,GA 30326; UNIV TEXAS,MED BRANCH,SEALY CTR MOL CARDIOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Emory University; University of Texas System; University of Texas Medical Branch Galveston					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48667] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1994, J BIOL CHEM, V269, P26381; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAHOU WF, 1993, BLOOD, V82, P1532, DOI 10.1182/blood.V82.5.1532.bloodjournal8251532; CHAIKOF EL, 1995, J BIOL CHEM, V270, P7431, DOI 10.1074/jbc.270.13.7431; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; CHOW CW, 1995, NUCLEIC ACIDS RES, V23, P3132, DOI 10.1093/nar/23.16.3132; COLOTTA F, 1994, AM J PATHOL, V144, P975; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; Davis R.W., 1971, METHODS ENZYMOL, V21, P413; FERGUSON J, 1978, J MOL BIOL, V123, P417, DOI 10.1016/0022-2836(78)90088-8; GELEHRTER TD, 1986, J CLIN INVEST, V77, P165, DOI 10.1172/JCI112271; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; IP JH, 1991, J AM COLL CARDIOL, V17, pB77; JONES PL, 1995, GENE, V153, P155, DOI 10.1016/0378-1119(94)00666-G; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; MARI B, 1994, J BIOL CHEM, V269, P8517; MARMUR JD, 1994, J AM COLL CARDIOL, V24, P1484, DOI 10.1016/0735-1097(94)90144-9; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; NELKEN NA, 1992, J CLIN INVEST, V90, P1614, DOI 10.1172/JCI116031; NGAIZA JR, 1991, BIOCHEM BIOPH RES CO, V179, P1656, DOI 10.1016/0006-291X(91)91765-5; NOREN CJ, 1990, NUCLEIC ACIDS RES, V18, P83, DOI 10.1093/nar/18.1.83; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OZAKI H, 1992, CIRC RES, V71, P1285; PALLANSCH L, 1990, ANAL BIOCHEM, V185, P57, DOI 10.1016/0003-2697(90)90254-7; PANACCIO M, 1993, BIOTECHNIQUES, V14, P238; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; RAO GN, 1995, J CLIN INVEST, V96, P842, DOI 10.1172/JCI118130; RASSMUSSEN UB, 1991, FEBS LETT, V288, P123; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Schmidt VA, 1996, J BIOL CHEM, V271, P9307, DOI 10.1074/jbc.271.16.9307; SHAMMAS NW, 1994, THROMB HAEMOSTASIS, V72, P672; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SOIFER SJ, 1994, AM J PATHOL, V144, P60; TESFAMARIAM B, 1993, AM J PHYSIOL, V265, pH1744, DOI 10.1152/ajpheart.1993.265.5.H1744; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILCOX JN, 1994, CIRC RES, V75, P1029, DOI 10.1161/01.RES.75.6.1029; YAO SK, 1992, CIRCULATION, V86, P1993, DOI 10.1161/01.CIR.86.6.1993; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHONG CZ, 1992, J BIOL CHEM, V267, P16975	48	39	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26320	26328		10.1074/jbc.271.42.26320	http://dx.doi.org/10.1074/jbc.271.42.26320			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824285	hybrid			2022-12-27	WOS:A1996VN18000091
J	Acharya, S; Karnik, SS				Acharya, S; Karnik, SS			Modulation of GDP release from transducin by the conserved Glu(134)-Arg(135) sequence in rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; CARBOXYLIC-ACID GROUP; BOVINE RHODOPSIN; ACTIVATION; MUTATIONS; BINDING; INTERACT; CASCADE	A superfamily of seven-transmembrane helix receptors catalyzes GDP release from heterotrimeric guanine nucleotide-binding proteins (G proteins) to initiate the intracellular signaling cascade, The photoreceptor rhodopsin is a prototypical member of the superfamily that activates the retinal G protein transducin (G(t)), The cytoplasmic domain of rhodopsin binds and activates G(t), but residues that stimulate GDP release from G(t) have not been identified until now, We show here that the abnormal signal transduction phenotypes of several different mutations affecting the highly conserved Glu(134)-Arg(135) charge pair result from alteration of the GDP release step in the G(t) activation cascade, We propose that Glu(134) and Arg(135) constitute the site that directly provides the signal from rhodopsin to activate GDP release from G(t), Because the Glu/Asp-Arg sequence occurs at a topologically identical location in most of the seven-transmembrane helix receptors, we propose that these residues constitute a switch for signal transfer.	CLEVELAND CLIN FDN,RES INST,DEPT MOL CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Karnik, Sadashiva/Y-2477-2019	Karnik, Sadashiva/0000-0003-0746-2753	NEI NIH HHS [P30 EY025585] Funding Source: Medline; NHLBI NIH HHS [R01 HL057470] Funding Source: Medline; PHS HHS [9704] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNIS S, 1994, J BIOL CHEM, V269, P23879; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; ERNST OP, 1995, J BIOL CHEM, V270, P10580, DOI 10.1074/jbc.270.18.10580; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; FRASER CM, 1989, MOL PHARMACOL, V36, P840; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLMAN AG, 1984, CELL, V36, P577; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MIN KC, 1993, J BIOL CHEM, V268, P9400; MORTON RA, 1955, BIOCHEM J, V59, P128, DOI 10.1042/bj0590128; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; SUNG CH, 1993, J BIOL CHEM, V268, P26645; WANG CD, 1991, MOL PHARMACOL, V40, P168; WEISS ER, 1987, J BIOL CHEM, V262, P4319; ZHU SZ, 1994, MOL PHARMACOL, V45, P517	30	96	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25406	25411		10.1074/jbc.271.41.25406	http://dx.doi.org/10.1074/jbc.271.41.25406			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810308	hybrid			2022-12-27	WOS:A1996VL69300052
J	Akasawa, A; Hsieh, LS; Martin, BM; Liu, T; Lin, Y				Akasawa, A; Hsieh, LS; Martin, BM; Liu, T; Lin, Y			A novel acidic allergen, Hev b 5, in latex - Purification, cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTACT URTICARIA; CROSS-REACTIVITY; GLOVES; RUBBER; BRASILIENSIS; PROTEINS	Latex allergy is recognized as a serious health problem among health care workers and children with spina bifida, A number of IgE-reactive proteins have been identified in natural and processed latex products. One of the most acidic proteins in the cytoplasm of lacticifer cells of rubber trees (Hevea brasiliensis) is demonstrated to be a potent allergen in eliciting allergic reactions in humans, This protein, with pI = 3.5, has a molecular mass of 16 kDa with a blocked N terminus and an unusual amino acid composition, This acidic protein was found in extracts prepared from latex gloves, which were shown to be allergenic, The purified protein elicits histamine release from human basophils passively sensitized with serum from latex-allergic individuals in a dose dependent manner. From a latex cDNA library, the cDNA coding for this protein was isolated and sequenced. The deduced amino acid sequence shows a high degree of homology to another acidic protein identified in kiwifruit (Actinidia deliciosa var. deliciosa). The sequence homology (47% sequence identity) between these two acidic proteins suggests a molecular explanation for the high frequency of fruit hypersensitivity in latex-allergic patients.	US FDA,DIV ALLERGEN PROD & PARASITOL,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20852; NIMH,CLIN NEUROSCI BRANCH,UNIT MOL STRUCT,BETHESDA,MD 20892	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)			Moussa, Luciana/M-2257-2013					AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Akasawa A, 1996, J ALLERGY CLIN IMMUN, V97, P1116, DOI 10.1016/S0091-6749(96)70266-X; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BLANCO C, 1994, ANN ALLERGY, V73, P309; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; CARRILLO T, 1986, CONTACT DERMATITIS, V15, P69, DOI 10.1111/j.1600-0536.1986.tb01279.x; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; FORTESDIAS CL, 1994, J BIOL CHEM, V269, P15646; HARMANN CP, 1994, ALLERGY PROC, V15, P17; JONES WB, 1994, PHYSICA D, V73, P227, DOI 10.1016/0167-2789(94)90159-7; KURUP VP, 1994, ALLERGY PROC, V15, P211, DOI 10.2500/108854194778702711; LEDGER SE, 1994, PLANT MOL BIOL, V25, P877, DOI 10.1007/BF00028882; LIU TY, 1989, ANAL BIOCHEM, V182, P383, DOI 10.1016/0003-2697(89)90612-X; MACDONALD SM, 1987, J IMMUNOL, V139, P506; MOLALES C, 1989, CLIN EXP ALLERGY, V19, P425; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V90, P279, DOI 10.1016/S0091-6749(05)80003-X; SLATER JE, 1990, ANN ALLERGY, V65, P411; SPACKMAN DH, 1967, METHOD ENZYMOL, V11, P3; TOMAZIC VJ, 1992, CLIN IMMUNOL IMMUNOP, V64, P89, DOI 10.1016/0090-1229(92)90185-Q; TOMAZIC VJ, 1995, J ALLERGY CLIN IMMUN, V96, P635, DOI 10.1016/S0091-6749(95)70262-8; TURJANMAA K, 1988, CONTACT DERMATITIS, V19, P362, DOI 10.1111/j.1600-0536.1988.tb02953.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	23	81	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25389	25393		10.1074/jbc.271.41.25389	http://dx.doi.org/10.1074/jbc.271.41.25389			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810305	hybrid			2022-12-27	WOS:A1996VL69300049
J	Apasov, SG; Smith, PT; Jelonek, MT; Margulies, DH; Sitkovsky, MV				Apasov, SG; Smith, PT; Jelonek, MT; Margulies, DH; Sitkovsky, MV			Phosphorylation of extracellular domains of T-lymphocyte surface proteins - Constitutive serine and threonine phosphorylation of the T cell antigen receptor ectodomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; CRYSTAL-STRUCTURE; ATP; DEPHOSPHORYLATION; CYTOTOXICITY; SPECIFICITY; ACTIVATION; RESIDUES; SUBUNIT; LYSIS	The extracellular accumulation of ATP after activation of T-lymphocytes, as well as the presence of ectoprotein kinases in these cells, led us to propose that T cell surface receptors could be regulated through the reversible phosphorylation of their extracellular domains (ectodomains). Here, in a model system, we used T cell transfectants which express T cell antigen receptor chains lacking intracellular and transmembrane protein domains and P-32(i) metabolic labeling of cells to definitively demonstrate phosphorylation of ectodomains of T cell surface proteins, We show that alpha beta TCR ectodomains were phosphorylated intracellularly and constitutively on serine and threonine residues and were then expressed on the T cell surface in phosphorylated form, TCR ectodomains also could be phosphorylated at the cell surface when extracellular [gamma-P-32]ATP or [gamma-P-32]GTP were used as phosphate donors with the same cells, Consensus phosphorylation sites for serine and threonine protein kinases were found to be strongly evolutionary conserved in both a and beta TCR chains constant regions, These results are consistent with the hypothesis, where T cell surface proteins which are phosphorylated intracellularly on their ectodomains, could subsequently be expressed at the cell surface and then be reversibly modified by ectoprotein phosphatase(s) and by ectokinase(s), Such modifications may change T cells cognate interactions by, e.g. affecting TCR-multimolecular complex formation and antigen binding affinity. It is suggested that alpha beta TCR ectodomain phosphorylation could serve as a potential mechanism for regulation of alpha beta TCR-mediated T-lymphocytes response.	NIAID,IMMUNOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Margulies, David/0000-0001-8530-7375				APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; APASOV S, 1995, IMMUNOL REV, V146, P5, DOI 10.1111/j.1600-065X.1995.tb00680.x; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Ehrlich YH, 1996, SCIENCE, V271, P278, DOI 10.1126/science.271.5247.278; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; FILIPPINI A, 1990, P NATL ACAD SCI USA, V87, P8257; HARINDRANATH N, 1989, IMMUNOGENETICS, V30, P465, DOI 10.1007/BF02421179; Hedrick Stephen M., 1993, P383; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KREBS EG, 1993, BIOSCIENCE REP, V113, P127; KUHLER DW, 1982, J BIOL CHEM, V257, P322; LAUTENBERG D, 1995, J EXP MED, V183, P249; MARCHE PN, 1986, P NATL ACAD SCI USA, V83, P2190, DOI 10.1073/pnas.83.7.2190; MEGGIO F, 1994, BIOCHEMISTRY-US, V33, P4336, DOI 10.1021/bi00180a030; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; PLOEGH H, 1993, NATURE, V364, P16, DOI 10.1038/364016d0; REDEGELD F, 1991, J IMMUNOL, V147, P3638; SAKIHAMA T, 1995, IMMUNOL TODAY, V16, P581, DOI 10.1016/0167-5699(95)80081-6; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SAMELSON LE, 1991, CURRENT PROTOCOLS IM, V2; SIEGEL JN, 1992, CURRENT PROTOCOLS IM, V3; SKUBITZ KM, 1994, J IMMUNOL, V152, P5902; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; VIGNALI DAA, 1994, J EXP MED, V179, P1945, DOI 10.1084/jem.179.6.1945; Walter J, 1996, J BIOL CHEM, V271, P111, DOI 10.1074/jbc.271.1.111; Weiss Arthur, 1993, P467; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67	31	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25677	25683		10.1074/jbc.271.41.25677	http://dx.doi.org/10.1074/jbc.271.41.25677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810345	hybrid			2022-12-27	WOS:A1996VL69300089
J	Martin, ME; Chinenov, Y; Yu, M; Schmidt, TK; Yang, XY				Martin, ME; Chinenov, Y; Yu, M; Schmidt, TK; Yang, XY			Redox regulation of GA-binding protein-alpha DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT-IV GENE; NF-KAPPA-B; MITOCHONDRIAL TRANSCRIPTION FACTOR; ETS-RELATED PROTEINS; SECONDARY STRUCTURE; E4TF1 SUBUNITS; MURINE ETS-1; IN-VITRO; ACTIVATION; DOMAIN	We have investigated the reduction/oxidation (redox) regulation of the heteromeric transcription factor GA-binding protein (GABP), GABP, also known as nuclear respiratory factor 2, regulates the expression of nuclear encoded mitochondrial proteins involved in oxidative phosphorylation, including cytochrome c oxidase subunits IV and Vb, as well as the expression of mitochondrial transcription factor 1. GABP is composed of two subunits, the Ets-related GABP-alpha, which mediates specific DNA binding, and GABP-beta, which forms heterodimers and heterotetramers on DNA sequences containing the PEA3/Ets motif ((C/A)GGA(A/T)(G/A)). We demonstrate here that GABP DNA binding activity and GABP-dependent gene expression in 3T3 cells are inhibited by pro oxidant conditions. DNA binding of recombinant GABP-alpha was activated by chemical reduction (dithiothreitol) and by thioredoxin; however, GSSG inhibited GABP DNA binding activity, Treatment of GABP-alpha, but not GABP-beta(1), with sulfhydryl-alkylating agents also inhibited GABP DNA binding activity, Our results suggest that GABP DNA binding activity is redox-regulated in vivo, possibly by thioredoxin-mediated reduction and by GSSG-mediated oxidation of the GABP-alpha subunit. The regulation of GABP (nuclear respiratory factor 2) DNA binding activity by cellular redox changes provides an important link between mitochondrial and nuclear gene expression and the redox state of the cell.			Martin, ME (corresponding author), UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212, USA.				NICHD NIH HHS [HD27200] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027200, R55HD027200] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; BANNISTER AJ, 1991, ONCOGENE, V6, P1243; BASU A, 1993, J BIOL CHEM, V268, P4188; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; DROGE W, 1994, FASEB J, V8, P1131; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; HAYASHI T, 1993, J BIOL CHEM, V268, P1180; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; Kadonaga JT, 1990, CURR OPIN CELL BIOL, V2, P496, DOI 10.1016/0955-0674(90)90133-Y; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUBAL G, 1995, CHEM RES TOXICOL, V8, P780, DOI 10.1021/tx00047a019; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAMARCO KL, 1989, GENE DEV, V3, P1372, DOI 10.1101/gad.3.9.1372; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MARTIN ME, 1992, MOL CELL BIOL, V12, P2213, DOI 10.1128/MCB.12.5.2213; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NG L, 1993, NUCLEIC ACIDS RES, V21, P5831, DOI 10.1093/nar/21.25.5831; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Plummer J L, 1981, Methods Enzymol, V77, P50; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REMACLE J, 1995, MUTAT RES-DNAGING G, V316, P103, DOI 10.1016/0921-8734(95)90004-7; RIORDAN JF, 1966, METHOD ENZYMOL, V11, P541; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; Sambrook J., 2002, MOL CLONING LAB MANU; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMINAGA K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P217, DOI 10.1016/0167-4781(92)90082-B; TORRONI A, 1990, J BIOL CHEM, V265, P20589; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; VOS O, 1984, INT J RADIAT ONCOL, V10, P1249, DOI 10.1016/0360-3016(84)90327-4; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; White T.J., 1990, PCR PROTOCOLS GUIDE, V18, P315; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; YOO W, 1991, J VIROL, V66, P5391	61	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25617	25623		10.1074/jbc.271.41.25617	http://dx.doi.org/10.1074/jbc.271.41.25617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810337	hybrid			2022-12-27	WOS:A1996VL69300081
J	Jarnagin, K; Bhakta, S; Zuppan, P; Yee, C; Ho, T; Phan, T; Tahilramani, R; Pease, JHB; Miller, A; Freedman, R				Jarnagin, K; Bhakta, S; Zuppan, P; Yee, C; Ho, T; Phan, T; Tahilramani, R; Pease, JHB; Miller, A; Freedman, R			Mutations in the B-2 bradykinin receptor reveal a different pattern of contacts for peptidic agonists and peptidic antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; PHARMACOLOGICAL CHARACTERIZATION; CONFORMATIONAL-ANALYSIS; EXPRESSION CLONING; MAGNETIC-RESONANCE; BOVINE RHODOPSIN; BINDING-SITES; HOE-140; PROTEIN; MUTAGENESIS	The B-2 bradykinin receptor, a seven-helix transmembrane receptor, binds the inflammatory mediator bradykinin (BK) and the structurally related peptide antagonist HOE-140, The binding of HOE-140 and the binding of bradykinin are mutually exclusive and competitive. Fifty-four site-specific receptor mutations were made, BK's affinity is reduced 2200-fold by F261A, 490-fold by T265A, 60-fold by D286A, and 3-10-fold by N200A, D268A, and Q290A, In contrast, HOE-140 affinity is reduced less than 7-fold by F254A, F261A, Y297A, and Q262A. The almost complete discordance of mutations that affect BK binding versus HOE-140 binding is surprising, but it was paralleled by the effect of single changes in BK and HOE-140. [Ala(9)]BK and [Ala(6)]BK are reduced in receptor binding affinity 27,000- and 150-fold, respectively, while [Ala(9)]HOE-140 affinity is reduced 7-fold and [Ala(6)]HOE-140 affinity is unchanged. NMR spectroscopy of all of the peptidic analogs of BK or HOE-140 revealed a beta-turn at the C terminus. Models of the receptor-ligand complex suggested that bradykinin is bound partially inside the helical bundle of the receptor with the amino terminus emerging from the extracellular side of helical bundle, In these models a salt bridge occurs between Arg(9) and Asp(286); the models also place Phe(8) in a hydrophobic pocket midway through the transmembrane region. Models of HOE-140 binding to the receptor place its beta-turn one alpha-helical turn deeper and closer to helix 7 and helix 1 as compared with bradykinin-receptor complex models.	ROCHE BIOSCI,MED CHEM,PALO ALTO,CA 94304; ROCHE BIOSCI,MOL STRUCT GRP,INFLAMMATORY DIS UNIT,PALO ALTO,CA 94304	Roche Holding; Roche Holding	Jarnagin, K (corresponding author), ROCHE BIOSCI,MOL PHARMACOL,S3-1,3401 HILLVIEW AVE,PALO ALTO,CA 94304, USA.			BHAKTA, SUNIL/0000-0002-1554-7098				Abd Alla S., 1996, J BIOL CHEM, V271, P1748; ALLEN MC, 1981, J CHEM SOC PERK T 1, P2040, DOI 10.1039/p19810002040; ARIENS EJ, 1971, DRUG DESIGN, P176; AUSTIN CE, 1994, BRIT J PHARMACOL, V111, P969, DOI 10.1111/j.1476-5381.1994.tb14835.x; CANN JR, 1987, INT J PEPT PROT RES, V29, P486; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; COSTELLO AH, 1989, EUR J PHARMACOL, V171, P259, DOI 10.1016/0014-2999(89)90118-0; CUTHBERT AW, 1992, BRIT J PHARMACOL, V107, P797, DOI 10.1111/j.1476-5381.1992.tb14526.x; DAUGAARD H, 1994, EXP NEPHROL, V2, P240; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; DENYS L, 1982, BIOCHEMISTRY-US, V21, P6531, DOI 10.1021/bi00268a032; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; EVANS EA, 1974, TRITIUM ITS COMPOUND, P326; FRESHNEY RI, 1983, CULTURE ANIMAL CELLS; GETHER U, 1993, REGUL PEPTIDES, V46, P49, DOI 10.1016/0167-0115(93)90011-V; GRIESBACHER T, 1994, BRIT J PHARMACOL, V112, P1004, DOI 10.1111/j.1476-5381.1994.tb13182.x; GUBA W, 1994, J AM CHEM SOC, V116, P7532, DOI 10.1021/ja00096a009; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HEAPY CG, 1993, BRIT J PHARMACOL, V108, P209, DOI 10.1111/j.1476-5381.1993.tb13464.x; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HENKE S, 1989, Patent No. 370453; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KRSTENANSKY JL, 1994, LETT PEPT SCI, V1, P523; KYLE DJ, 1994, BRAZ J MED BIOL RES, V27, P1757; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; KYLE DJ, 1990, BRADYKININ ANTAGONIS, P131; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LEE SC, 1990, INT J PEPT PROT RES, V35, P367; LINTNER K, 1979, BIOCHEM BIOPH RES CO, V91, P803, DOI 10.1016/0006-291X(79)91951-X; MARTINA YC, 1990, COMPREHENSIVE MED CH, P349; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MIRMIRA SR, 1990, MAGN RESON CHEM, V28, P587, DOI 10.1002/mrc.1260280706; MULUTIS F, 1985, INT J PEPT PROT RES, V26, P460; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; NAKAYAMA TA, 1991, J BIOL CHEM, V266, P4269; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; OTTER A, 1993, BIOPOLYMERS, V33, P769, DOI 10.1002/bip.360330506; PARK J, 1994, BRAZ J MED BIOL RES, V27, P1707; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; PROUD D, 1994, BRAZ J MED BIOL RES, V27, P2021; RHALEB NE, 1992, EUR J PHARMACOL, V210, P115, DOI 10.1016/0014-2999(92)90661-M; Sambrook J., 2002, MOL CLONING LAB MANU; SAWUTZ DG, 1994, BIOCHEMISTRY-US, V33, P2373, DOI 10.1021/bi00175a004; SCHAMBYE HT, 1994, P NATL ACAD SCI USA, V91, P7046, DOI 10.1073/pnas.91.15.7046; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SRIVASTAVA S, 1991, PROTEINS : STRUCTURE, DYNAMICS AND DESIGN, P57; STERANKA LR, 1987, EUR J PHARMACOL, V136, P261, DOI 10.1016/0014-2999(87)90723-0; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; STRADER CD, 1989, J BIOL CHEM, V264, P13572; STRADER CD, 1989, J BIOL CHEM, V264, P16470; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VILLARREAL XC, 1991, ANAL BIOCHEM, V197, P362, DOI 10.1016/0003-2697(91)90405-I; WEIPERT J, 1988, BRIT J PHARMACOL, V94, P282, DOI 10.1111/j.1476-5381.1988.tb11526.x; WHALLEY ET, 1992, AGENT ACTION SUPPL, V38, P413; WILSON DD, 1989, CIRC SHOCK, V27, P93; YOUNG JK, 1994, BIOPOLYMERS, V34, P611, DOI 10.1002/bip.360340504; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	68	62	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28277	28286		10.1074/jbc.271.45.28277	http://dx.doi.org/10.1074/jbc.271.45.28277			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910447	hybrid			2022-12-27	WOS:A1996VU03300047
J	Murai, N; Makino, Y; Yoshida, M				Murai, N; Makino, Y; Yoshida, M			GroEL locked in a closed conformation by an interdomain cross-link can bind ATP and polypeptide but cannot process further reaction steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHAPERONIN GROEL; THERMUS-THERMOPHILUS; PROTEIN; COOPERATIVITY; PURIFICATION; MUTAGENESIS; HYDROLYSIS; STABILITY; BACTERIUM	It has been believed that when GroEL binds to GroES its apical domain moves upward and outward, To inhibit this ''opening'' movement, its equatorial and apical domains were cross-linked through a disulfide bond between mutationally introduced cysteine residues at the positions of Asp-83 and Lys-327. To avoid possible undesired cross-linking, we at first prepared a mutant GroEL (GroEL(NC); Cys-138 --> Ser, Cys-458 --> Ser, Cys-519 --> Ser) in which all cysteine residues in wild-type GroEL were replaced by serine residues, GroEL(NC) was fully functional as a chaperonin, We then introduced the above two point mutations into GroEL(NC), to generate a mutant (GroEL(AEX); Cys-138 --> Ser, Cys-458 --> Ser, Cys-519 --> Ser and Asp-83 --> Cys, Lys 327 --> Cys). Oxidized GroEL(AEX), which is locked in a ''closed'' conformation by an interdomain disulfide bond, can bind 6-7 mol of ATP, which remain bound without hydrolysis, This ATP-bound, oxidized GroEL(AEX) can bind the stably nonnative substrate protein isopropylmalate dehydrogenase, whereas the nucleotide-free oxidized GroEL(AEX) binds it with a weaker affinity, However, oxidized GroEL(AEX) fails to process further reaction steps such as ATP hydrolysis, binding of GroES, dissociation of substrate protein from GroEL, and facilitating protein folding, When disulfide bonds in oxidized GroEL(AEX) are reduced, GroEL(AEX) exerts the ability to process all the reactions just as GroEL(NC) and wild-type GroEL. Indications from these results are: hydrolysis of ATP may require opening movement of the apical domain; GroES binds to an open form of GroEL; and substrate polypeptide is released from GroEL coupled with either ATP hydrolysis or opening movement of the apical domain.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			MURAI, NORIYUKI/V-5747-2018	MURAI, NORIYUKI/0000-0002-1552-5104				BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BOCHKAREVA ES, 1994, J BIOL CHEM, V269, P44; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; DATE T, 1990, GENE, V90, P141, DOI 10.1016/0378-1119(90)90450-6; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GETHING MJH, 1972, EUR J BIOCHEM, V30, P352; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; ISHII N, 1994, J MOL BIOL, V236, P691, DOI 10.1006/jmbi.1994.1181; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KUBO T, 1993, J BIOL CHEM, V268, P19346; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHIDA M, 1975, CHEM PHARM BULL, V23, P1385, DOI 10.1248/cpb.23.1385; MACHIDA M, 1977, CHEM PHARM BULL, V25, P1285; Mande SC, 1996, SCIENCE, V271, P203, DOI 10.1126/science.271.5246.203; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; Penefsky H S, 1979, Methods Enzymol, V56, P527; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; TAGUCHI H, 1991, J BIOL CHEM, V266, P22411; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; TODD MJ, 1995, J BIOL CHEM, V270, P5388, DOI 10.1074/jbc.270.10.5388; VIITANEN PV, 1992, PROTEIN SCI, V1, P361; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YAMADA T, 1990, J BIOCHEM-TOKYO, V108, P449, DOI 10.1093/oxfordjournals.jbchem.a123220; YIFRACH O, 1995, BIOCHEMISTRY-US, V34, P5303, DOI 10.1021/bi00016a001	41	45	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28229	28234		10.1074/jbc.271.45.28229	http://dx.doi.org/10.1074/jbc.271.45.28229			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910440	hybrid			2022-12-27	WOS:A1996VU03300040
J	RomeroGraillet, C; Aberdam, E; Biagoli, N; Massabni, W; Ortonne, JP; Ballotti, R				RomeroGraillet, C; Aberdam, E; Biagoli, N; Massabni, W; Ortonne, JP; Ballotti, R			Ultraviolet B radiation acts through the nitric oxide and cGMP signal transduction pathway to stimulate melanogenesis in human melanocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN MELANOCYTES; PROTEIN-KINASE-C; MELANOMA-CELLS; SEQUENCE-ANALYSIS; CHOLERA-TOXIN; PHORBOL ESTER; TYROSINASE; EXPRESSION; HORMONE; DIFFERENTIATION	Ultraviolet B (UVB) radiation is the main physiological stimulus for human skin pigmentation; however, the molecular mechanisms underlying this process are still unclear. Recently, nitric oxide (NO) and cGMP have been involved in mediation of skin erythema induced by UVB. Therefore, we investigated the role of NO and cGMP in UVB-induced melanogenesis. In this study, we demonstrated that UVB stimulation of melanogenesis was mimicked by exogenous NO donors. Additionally, me showed that NO stimulated cGMP synthesis and that cGMP was also a potent stimulator of melanogenesis, Furthermore, the inhibition of the melanogenic effect of NO by guanylate cyclase inhibitor demonstrated that NO mediated its effect through the activation of guanylyl cyclase. Interestingly, 1 min after WE irradiation, we observed a significant increase in cGMP content in melanocytes. The effects of UVB on cGMP production and on melanogenesis were blocked by both guanylate cyclase and NO synthase inhibitors. Additionally, inhibition of cGMP-dependent kinase also prevented the stimulation of melanogenesis by UVB and NO. Therefore, we concluded that NO and cGMP production is required for UVB-induced melanogenesis and that cGMP mediated its melanogenic effects mainly through the activation of cGMP-dependent kinase.			RomeroGraillet, C (corresponding author), FAC MED NICE, INSERM, U385, AVE VALOMBROSE, F-06107 NICE 02, FRANCE.		BALLOTTI, Robert/F-8825-2013	BALLOTTI, Robert/0000-0002-7322-4908				ABDELMALEK ZA, 1992, PIGM CELL RES, P43; ABERDAM E, 1993, J CELL SCI, V106, P1015; AGIN PP, 1991, PHOTODERMATOL PHOTO, V8, P51; BRECHLER V, 1992, J BIOL CHEM, V267, P15496; CARSBERG CJ, 1994, J CELL SCI, V107, P2591; DELICONSTANTINOS G, 1995, BRIT J PHARMACOL, V114, P1257, DOI 10.1111/j.1476-5381.1995.tb13341.x; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; FRIEDMANN PS, 1990, J CELL PHYSIOL, V142, P334, DOI 10.1002/jcp.1041420216; FULLER BB, 1987, J BIOL CHEM, V262, P4024; FULLER BB, 1981, J NATL CANCER I, V66, P799; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GORDON PR, 1989, J INVEST DERMATOL, V93, P700, DOI 10.1111/1523-1747.ep12319900; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HUNT G, 1994, J CELL SCI, V107, P205; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; LIBOW LF, 1988, PIGM CELL RES, V1, P397, DOI 10.1111/j.1600-0749.1988.tb00142.x; LOTAN R, 1980, CANCER RES, V40, P3345; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; MURAD F, 1993, ADV SEC MESS PHOSPH, V28, P101; NAEYAERT JM, 1991, BRIT J DERMATOL, V125, P297, DOI 10.1111/j.1365-2133.1991.tb14161.x; OIKAWA A, 1972, ARCH BIOCHEM BIOPHYS, V148, P548, DOI 10.1016/0003-9861(72)90173-7; OKEEFE E, 1974, P NATL ACAD SCI USA, V71, P2500, DOI 10.1073/pnas.71.6.2500; PARK HY, 1993, J BIOL CHEM, V268, P11742; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; POMERANTZ SH, 1969, SCIENCE, V164, P838, DOI 10.1126/science.164.3881.838; PONNAZHAGAN S, 1994, J INVEST DERMATOL, V102, P744, DOI 10.1111/1523-1747.ep12376924; RAMIREZBOSCA A, 1992, ARCH DERMATOL RES, V284, P358, DOI 10.1007/BF00372040; ROMERO C, 1994, J CELL SCI, V107, P1095; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TOMITA Y, 1988, J INVEST DERMATOL, V90, P882, DOI 10.1111/1523-1747.ep12462151; WARREN JB, 1994, FASEB J, V8, P247, DOI 10.1096/fasebj.8.2.7509761; YAU KW, 1994, P NATL ACAD SCI USA, V91, P3481, DOI 10.1073/pnas.91.9.3481	36	143	155	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28052	28056		10.1074/jbc.271.45.28052	http://dx.doi.org/10.1074/jbc.271.45.28052			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910416	hybrid			2022-12-27	WOS:A1996VU03300016
J	Tang, KC; Wu, HJ; Mahata, SK; Taupenot, L; Rozansky, DJ; Parmer, RJ; OConnor, DT				Tang, KC; Wu, HJ; Mahata, SK; Taupenot, L; Rozansky, DJ; Parmer, RJ; OConnor, DT			Stimulus-transcription coupling in pheochromocytoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE GENE; CHROMOGRANIN-A GENE; CHROMAFFIN CELLS; MESSENGER-RNA; DIFFERENTIAL REGULATION; CATECHOLAMINE RELEASE; NUCLEOTIDE-SEQUENCE; 2ND MESSENGERS; EXPRESSION; RAT	To explore stimulus-transcription coupling in pheochromocytoma cells, we studied the biosynthetic response of chromogranin A, the major soluble protein co-stored and co-released with catecholamines, to chromaffin cells' physiologic nicotinic cholinergic secretory stimulation. Chromogranin A mRNA showed a time-dependent 3.87-fold response to nicotinic stimulation, and a nuclear run-off experiment indicated that the response occurred at a transcriptional level, Transfected chromogranin A promoter/luciferase reporter constructs were activated by nicotinic stimulation, in time- and dose-dependent fashions, in both rat PC12 pheochromocytoma cells and bovine chromaffin cells. Cholinergic subtype agents indicated that nicotinic stimulation was required, Promoter deletions established both positive and negative nicotinic response domains. Transfer of candidate promoter domains to a heterologous (thymidine kinase) promoter conferred region-specific nicotinic responses onto that promoter. A proximal promoter domain (from -93 to -62 base pairs) was activated in copy number- and distance-dependent fashion, and thus displayed features of a promoter element, Its activation was sufficient to account for the overall positive response to nicotine, Within this proximal region, a cAMP response element (CRE) was implicated as a major nicotinic response element, since a CRE point-gap mutation decreased nicotinic induction, transfer of CRE to a thymidine kinase promoter augmented the promoter's response to nicotine, and nicotine activated the CRE-binding protein CREB through phosphorylation at serine 133. We conclude that secretory stimulation of pheochromocytoma cells also activates the biosynthesis of the major secreted protein (chromogranin A), that the activation is transcriptional, and that a small proximal domain, including the CRE box, is, at least in part, both necessary and sufficient to account for the positive response to nicotine.	UNIV CALIF SAN DIEGO,DEPT MED 9111H,SAN DIEGO,CA 92161; UNIV CALIF SAN DIEGO,CTR MOL GENET,SAN DIEGO,CA 92161; DEPT VET AFFAIRS MED CTR,SAN DIEGO,CA 92161	University of California System; University of California San Diego; University of California System; University of California San Diego			Mahata, Sushil/AAF-8781-2021	Taupenot, Laurent/0000-0003-2316-3825				ABMAYR SB, 1989, CURRENT PROTOCOLS MO; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BARBOSA JA, 1991, ENDOCRINOLOGY, V128, P174, DOI 10.1210/endo-128-1-174; BAUER JW, 1993, J BIOL CHEM, V268, P1586; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOCK AE, 1994, J NEUROCHEM, V62, P1863; CHODOSH LA, 1989, CURRENT PROTOCOLS MO; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COKER GT, 1988, BIOCHEM BIOPH RES CO, V157, P1341, DOI 10.1016/S0006-291X(88)81022-2; DEWET JR, 1986, MOL CELL BIOL, V6, P1663; EIDEN LE, 1987, J NEUROCHEM, V49, P65, DOI 10.1111/j.1471-4159.1987.tb03395.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FORSSPETTER S, 1989, J MOL NEUROSCI, V1, P63, DOI 10.1007/BF02918892; GAETANO C, 1995, EUR J CANCER, V31A, P447, DOI 10.1016/0959-8049(95)00038-K; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1989, CURRENT PROTOCOLS MO; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; HIREMAGALUR B, 1993, J BIOL CHEM, V268, P23704; IACANGELO AL, 1991, MOL ENDOCRINOL, V5, P1651, DOI 10.1210/mend-5-11-1651; IACANGELO AL, 1995, REGUL PEPTIDES, V58, P65, DOI 10.1016/0167-0115(95)00069-N; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ICARDLIEPKALNS C, 1993, J PHYSIOLOGY-PARIS, V87, P153, DOI 10.1016/0928-4257(93)90026-P; KILBOURNE EJ, 1992, J BIOL CHEM, V267, P7563; LASLOP A, 1989, REGUL PEPTIDES, V26, P191, DOI 10.1016/0167-0115(89)90187-0; LIVETT BG, 1987, STIMULUS SECRETION C, P118; MCKNIGHT SL, 1982, BIOL MED PARIS, V4, P81; MOULAND AJ, 1994, J BIOL CHEM, V269, P6918; NANKOVA B, 1993, J NEUROCHEM, V61, P776; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1989, HYPERTENSION, V14, P434; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROZANSKY DJ, 1994, J CLIN INVEST, V94, P2357, DOI 10.1172/JCI117601; SERCKHANSSEN G, 1984, J BIOL CHEM, V259, P1597; SIMON JP, 1988, P NATL ACAD SCI USA, V85, P1712, DOI 10.1073/pnas.85.5.1712; SIMON JP, 1989, BIOCHEM J, V260, P915, DOI 10.1042/bj2600915; STACHOWIAK MK, 1990, BRAIN RES, V510, P277, DOI 10.1016/0006-8993(90)91378-T; Tabor S, 1989, CURRENT PROTOCOLS MO; TAKIYYUDDIN MA, 1990, CIRCULATION, V81, P185, DOI 10.1161/01.CIR.81.1.185; TAKIYYUDDIN MA, 1990, HYPERTENSION, V15, P237, DOI 10.1161/01.HYP.15.3.237; TAKIYYUDDIN MA, 1991, J CLIN ENDOCR METAB, V72, P616, DOI 10.1210/jcem-72-3-616; TANG K, 1993, ENDOCRINOLOGY, V123, P2518; TSCHERNITZ C, 1995, MOL BRAIN RES, V31, P131, DOI 10.1016/0169-328X(95)00045-T; WAN DC, 1991, MOL BRAIN RES, V9, P103, DOI 10.1016/0169-328X(91)90135-K; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1991, J BIOL CHEM, V266, P13130; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YOUDIM MBH, 1986, NEUROSCIENCE, V19, P1311, DOI 10.1016/0306-4522(86)90145-4	52	54	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28382	28390		10.1074/jbc.271.45.28382	http://dx.doi.org/10.1074/jbc.271.45.28382			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910462	hybrid			2022-12-27	WOS:A1996VU03300062
J	Endo, T; Matsumoto, K; Hama, T; Ohtsuka, Y; Katsura, G; Obinata, T				Endo, T; Matsumoto, K; Hama, T; Ohtsuka, Y; Katsura, G; Obinata, T			Distinct troponin T genes are expressed in embryonic larval tail striated muscle and adult body wall smooth muscle of ascidian	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; HEAVY-CHAIN GENE; SKELETAL-MUSCLE; MOLECULAR ARRANGEMENT; RELATIVE REACTIVITIES; TRANSLATIONAL CONTROL; HALOCYNTHIA-RORETZI; ACETIC-ANHYDRIDE; ALPHA-ACTININ; THIN FILAMENT	During development of the ascidian Halocynthia roretzi, the tadpole larva hatched from the tailbud embryo metamorphoses to the sessile adult with a body wall muscle. Although the adult body wall muscle is morphologically nonsarcomeric smooth muscle, it contains troponin complex consisting of three subunits (T, I, and C) as do vertebrate striated muscles. Different from vertebrate troponins, however, the smooth muscle troponin promotes actomyosin Mg2+-ATPase activity in the presence of high concentration of Ca2+, and this promoting property is attributable to troponin T. To address whether the embryonic/larval tail striated muscle and the adult smooth muscle utilize identical or different regulatory machinery, we cloned troponin T cDNAs from each cDNA library. The embryonic and the adult troponin Ts were encoded by distinct genes and shared only <60% identity with each other. Northern blotting and whole mount in situ hybridization revealed that these isoforms were specifically expressed in the embryonic/larval tail striated muscle and the adult smooth muscle, respectively. These results may imply that these isoforms regulate actin-myosin interaction in different manners. The adult troponin T under forced expression in mouse fibroblasts was unexpectedly located in the nuclei. However, a truncated protein with a deletion including a cluster of basic amino acids colocalized with tropomyosin on actin filaments. Thus, complex formation with troponin I and C immediately after the synthesis is likely to be essential for the protein to properly localize on the thin filaments.			Endo, T (corresponding author), CHIBA UNIV,FAC SCI,DEPT BIOL,INAGE KU,CHIBA 263,JAPAN.		Ohtsuka, Yukio/L-7008-2018	Ohtsuka, Yukio/0000-0001-9977-9349				ABE H, 1986, DEV BIOL, V118, P42, DOI 10.1016/0012-1606(86)90071-0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BREITBART RE, 1985, CELL, V41, P67, DOI 10.1016/0092-8674(85)90062-5; BREITBART RE, 1986, J MOL BIOL, V188, P313, DOI 10.1016/0022-2836(86)90157-9; BULLARD B, 1988, J MOL BIOL, V204, P621, DOI 10.1016/0022-2836(88)90360-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER TA, 1985, J BIOL CHEM, V260, P1140; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; EBASHI S, 1980, PROC R SOC SER B-BIO, V207, P259, DOI 10.1098/rspb.1980.0024; EBASHI S, 1973, COLD SPRING HARB SYM, V37, P215, DOI 10.1101/SQB.1973.037.01.031; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P321, DOI 10.1093/oxfordjournals.jbchem.a123899; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; ENDO T, 1981, J BIOCHEM, V89, P1599, DOI 10.1093/oxfordjournals.jbchem.a133355; ENDO T, 1982, J BIOCHEM, V92, P1457, DOI 10.1093/oxfordjournals.jbchem.a134070; FYRBERG E, 1990, J MOL BIOL, V216, P657, DOI 10.1016/0022-2836(90)90390-8; GAHLMANN R, 1987, J BIOL CHEM, V262, P16122; GARFINKEL LI, 1982, J BIOL CHEM, V257, P1078; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HASTINGS KEM, 1985, J BIOL CHEM, V260, P3699; HITCHCOCK SE, 1981, J MOL BIOL, V147, P125, DOI 10.1016/0022-2836(81)90082-6; HITCHCOCKDEGREGORI SE, 1982, J BIOL CHEM, V257, P7372; IMAI H, 1986, J BIOCHEM, V99, P923, DOI 10.1093/oxfordjournals.jbchem.a135554; JACKSON P, 1975, BIOCHEM J, V151, P85, DOI 10.1042/bj1510085; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUSAKABE T, 1991, DEV GROWTH DIFFER, V33, P227; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEHMAN W, 1975, J GEN PHYSIOL, V66, P1, DOI 10.1085/jgp.66.1.1; LEHMAN W, 1991, J MUSCLE RES CELL M, V12, P221, DOI 10.1007/BF01745110; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MAKABE KW, 1990, ROUX ARCH DEV BIOL, V199, P307, DOI 10.1007/BF01709509; MAKABE KW, 1989, DEV GROWTH DIFFER, V31, P71; MEEDEL TH, 1993, J BIOL CHEM, V268, P6755; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; Myers CD, 1996, J CELL BIOL, V132, P1061, DOI 10.1083/jcb.132.6.1061; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OBINATA T, 1983, COMP BIOCHEM PHYS B, V76, P437, DOI 10.1016/0305-0491(83)90272-9; OBINATA T, 1993, INT REV CYTOL, V143, P153; OBINATA T, 1985, ZOOL SCI, V2, P833; OHSHIMA S, 1988, COMP BIOCHEM PHYS B, V90, P779, DOI 10.1016/0305-0491(88)90334-3; OHTSUKI I, 1979, J BIOCHEM, V86, P491, DOI 10.1093/oxfordjournals.jbchem.a132549; OHTSUKI I, 1982, ADV BIOPHYS, V15, P93, DOI 10.1016/0065-227X(82)90006-5; OJIMA T, 1986, J BIOL CHEM, V261, P6749; PAN BS, 1992, J BIOL CHEM, V267, P23052; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PEARLSTONE JR, 1977, J BIOL CHEM, V252, P983; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Sellers JR, 1991, CURR OPIN CELL BIOL, V3, P98, DOI 10.1016/0955-0674(91)90171-T; SMILLIE LB, 1988, J BIOL CHEM, V263, P18816; Sneath P.H.A., 1973, NUMERICAL TAXONOMY; SOBUE K, 1991, J BIOL CHEM, V266, P12115; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANOKURA M, 1982, J BIOCHEM, V91, P1257, DOI 10.1093/oxfordjournals.jbchem.a133810; TERAKADO K, 1987, CELL TISSUE RES, V247, P85, DOI 10.1007/BF00216550; TOKUUE Y, 1991, EXP CELL RES, V197, P158, DOI 10.1016/0014-4827(91)90418-T; TOYOTA N, 1979, COMP BIOCHEM PHYS B, V62, P433, DOI 10.1016/0305-0491(79)90114-7	65	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27855	27862		10.1074/jbc.271.44.27855	http://dx.doi.org/10.1074/jbc.271.44.27855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910384	hybrid			2022-12-27	WOS:A1996VQ67900102
J	Saenko, EL; Shima, M; Gilbert, M; Scandella, D				Saenko, EL; Shima, M; Gilbert, M; Scandella, D			Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; PORCINE FACTOR-VIII; SURFACE-PLASMON RESONANCE; COAGULATION FACTOR-VIII; VONWILLEBRAND-FACTOR; LIGHT-CHAIN; BINDING-SITE; DOMAIN; PHOSPHATIDYLSERINE; INACTIVATION	The anti-factor VIII (fVIII) C2 domain monoclonal antibody ESH8 inhibits fVIII activity only when fVIII is bound to von Willebrand factor (vWf). However, ESH8 binds with similar affinity to fVIII and fVIII . vWf complex, and it does not affect the kinetics of thrombin cleavage at positions 372 and 740 within the fVIII heavy chain and at 1689 within the light chain, The latter is required for fVIII release from vWf. We showed that ESH8 reduced the initial rate of thrombin-activated fVIII (fVIIIa) release from vWf by 4.3-fold compared to that in the absence of antibody. The complex of vWf . fVIII . ESH8 was activated, and the rate constant determined for fVIIIa dissociation from vWf was 4 x 10(-3) s(-1). We constructed a mathematical. model incorporating the measured rates for fVIIIa release from vWf and for inactivation of heterotrimeric fVIIIa due to the spontaneous loss of the A2 subunit and found that the decreased release rate is sufficient to explain our experimentally observed inhibition of Nm activity by ESH8. We hypothesize that the slowed rate of fVIIIa release from vWf in the presence of ESH8 allows time for inactivation of unstable fVIIIa prior its participation in the formation of the factor Xase complex, The relevance of these findings is illustrated by our observation that reduction of fVIIIa release from vWf represents an additional mechanism of MII inhibition by an anti-C2 domain antibody (epitope 2218-2307) from a hemophilia A patient. This rare antibody binds to a more amino-terminal epitope than other human anti-Ca inhibitors, resulting in its lack of inhibition of fVIII binding to vWf but not to phospholipid. These two MII ligands therefore bind to C2 sites which do not overlap completely.	AMER RED CROSS,HOLLAND LAB,ROCKVILLE,MD 20855; NARA MED UNIV,DEPT PEDIAT,NARA,JAPAN; BRIGHAM & WOMENS HOSP,BROCKTON W ROXBURY VET AFFAIRS MED CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	American Red Cross; Nara Medical University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [R01-HL36094, HL02587, P50-HL44336] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL044336, K08HL002587] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BOWIE EJW, 1984, DISORDERS HEMOSTASIS, P43; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GIRMA JP, 1986, BIOCHEMISTRY-US, V25, P3156, DOI 10.1021/bi00359a013; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOYER LW, 1982, METHOD ENZYMOL, V84, P51; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1994, J CLIN INVEST, V93, P2497, DOI 10.1172/JCI117259; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; NISHINO M, 1989, BLOOD, V74, P1591; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCANDELLA D, 1989, BLOOD, V74, P1618; SCANDELLA D, 1992, THROMB HAEMOSTASIS, V67, P665; SCANDELLA D, 1988, P NATL ACAD SCI USA, V85, P6152, DOI 10.1073/pnas.85.16.6152; SCNADELLA D, 1995, BLOOD, V86, P1811; SHIMA M, 1995, BRIT J HAEMATOL, V91, P714, DOI 10.1111/j.1365-2141.1995.tb05374.x; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0	45	122	129	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27424	27431		10.1074/jbc.271.44.27424	http://dx.doi.org/10.1074/jbc.271.44.27424			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910322	hybrid			2022-12-27	WOS:A1996VQ67900040
J	Gamby, C; Waage, MC; Allen, RG; Baizer, L				Gamby, C; Waage, MC; Allen, RG; Baizer, L			Analysis of the role of calmodulin binding and sequestration in neuromodulin (GA1-43) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-ASSOCIATED PROTEIN; KINASE-C SUBSTRATE; BRAIN POLYPHOSPHOINOSITIDE METABOLISM; MEMBRANE TARGETING DOMAIN; LONG-TERM POTENTIATION; B-50 GAP-43; NEURITE OUTGROWTH; NERVOUS-SYSTEM; RAT-BRAIN; ADULT-RAT	We demonstrated previously that forced expression of the neuronal phosphoprotein neuromodulin (also known as GAP-43, F1, B-50, and p57) in mouse anterior pituitary AtT-20 cells enhances depolarization mediated. secretion and alters cellular morphology. Here we analyze the role of calmodulin binding by neuromodulin in these responses, In cells expressing mild-type neuromodulin, a complex with calmodulin that is sensitive to intracellular calcium and phosphorylation is localized to the plasma membrane, Transfection of several mutant forms of neuromodulin shows that the effects of this protein on secretion are dependent on both calmodulin binding and association with the plasma membrane, In contrast, the morphological changes depend only oh membrane association. Thus, the multitude of effects of neuromodulin noted in previous studies may result from divergent properties of this protein.	GOOD SAMARITAN HOSP, RS DOW NEUROL SCI INST, PORTLAND, OR 97209 USA; OREGON HLTH SCI UNIV, CTR RES OCCUPAT & ENVIRONM TOXICOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS026806] Funding Source: NIH RePORTER; NINDS NIH HHS [NS26806] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AIGNER L, 1993, J CELL BIOL, V123, P417, DOI 10.1083/jcb.123.2.417; AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALLSOPP TE, 1989, J NEUROSCI, V9, P13; ANDREASEN TJ, 1981, P NATL ACAD SCI-BIOL, V78, P2782, DOI 10.1073/pnas.78.5.2782; ANDREASEN TJ, 1983, BIOCHEMISTRY-US, V22, P4615, DOI 10.1021/bi00289a001; Apel E D, 1992, Perspect Dev Neurobiol, V1, P3; Baetge E E, 1992, Perspect Dev Neurobiol, V1, P21; BAETGE EE, 1991, NEURON, V6, P21, DOI 10.1016/0896-6273(91)90118-J; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BENOWITZ LI, 1989, J NEUROSCI, V9, P990; BENOWITZ LI, 1987, TRENDS NEUROSCI, V10, P527, DOI 10.1016/0166-2236(87)90135-4; BENOWITZ LI, 1988, J NEUROSCI, V8, P339; BIFFO S, 1990, EUR J NEUROSCI, V2, P487, DOI 10.1111/j.1460-9568.1990.tb00440.x; BURNS ME, 1995, CELL, V83, P187, DOI 10.1016/0092-8674(95)90160-4; BURRY RW, 1991, J NEUROCYTOL, V20, P133, DOI 10.1007/BF01279617; CAMPAGNE MV, 1989, J NEUROCYTOL, V18, P479, DOI 10.1007/BF01474544; CHAN SY, 1986, J NEUROSCI, V6, P3618; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHAPMAN ER, 1992, J BIOL CHEM, V267, P25233; CIMLER BM, 1985, J BIOL CHEM, V260, P784; COGGINS PJ, 1993, J NEUROCHEM, V60, P368, DOI 10.1111/j.1471-4159.1993.tb05862.x; DEGRAAN PNE, 1990, J NEUROCHEM, V55, P2139; DEGRAAN PNE, 1985, NEUROSCI LETT, V61, P235, DOI 10.1016/0304-3940(85)90470-7; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DEKKER LV, 1989, J NEUROCHEM, V52, P24, DOI 10.1111/j.1471-4159.1989.tb10893.x; DEKKER LV, 1989, NATURE, V342, P74, DOI 10.1038/342074a0; DELAMONTE SM, 1989, DEV BRAIN RES, V46, P161, DOI 10.1016/0165-3806(89)90279-4; ESTEP RP, 1990, CURR TOP CELL REGUL, V30, P161; Gamby C, 1996, J BIOL CHEM, V271, P10023, DOI 10.1074/jbc.271.17.10023; GIANOTTI C, 1992, NEURON, V8, P843, DOI 10.1016/0896-6273(92)90198-M; GISPEN WH, 1985, BRAIN RES, V328, P381, DOI 10.1016/0006-8993(85)91054-6; GORGELS TGMF, 1989, J NEUROSCI, V9, P3861; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; GOSLIN K, 1990, J NEUROSCI, V10, P588; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATFIELD JM, 1988, DEV BIOL, V126, P164, DOI 10.1016/0012-1606(88)90250-3; HENS JJH, 1993, J NEUROCHEM, V61, P602; HENS JJH, 1995, J NEUROCHEM, V64, P1127; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; ITOH H, 1984, J BIOCHEM-TOKYO, V96, P1721, DOI 10.1093/oxfordjournals.jbchem.a135004; IVINS KJ, 1993, J NEUROCHEM, V60, P626, DOI 10.1111/j.1471-4159.1993.tb03194.x; JACOBSON RD, 1986, J NEUROSCI, V6, P1843; JOLLES J, 1980, NATURE, V286, P623, DOI 10.1038/286623a0; KALIL K, 1986, J NEUROSCI, V6, P2563; KUMAGAI C, 1992, J NEUROCHEM, V59, P41, DOI 10.1111/j.1471-4159.1992.tb08873.x; KUMAGAITOHDA C, 1993, J NEUROCHEM, V61, P526; LABATE ME, 1989, NEURON, V3, P299, DOI 10.1016/0896-6273(89)90254-7; LIU YC, 1991, NEURON, V6, P411, DOI 10.1016/0896-6273(91)90249-Y; LIU YC, 1993, BIOCHEMISTRY-US, V32, P10714, DOI 10.1021/bi00091a023; LIU YC, 1994, J NEUROSCI, V14, P5807; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; LOVINGER DM, 1985, BRAIN RES, V343, P137, DOI 10.1016/0006-8993(85)91167-9; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; MASSOM L, 1990, BIOCHEMISTRY-US, V29, P671, DOI 10.1021/bi00455a012; Meiri KF, 1996, J NEUROBIOL, V29, P213, DOI 10.1002/(SICI)1097-4695(199602)29:2<213::AID-NEU7>3.0.CO;2-D; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MEIRI KF, 1990, J NEUROSCI, V10, P256; MORTON AJ, 1992, EUR J NEUROSCI, V4, P910, DOI 10.1111/j.1460-9568.1992.tb00117.x; MOSS DJ, 1990, J NEUROCHEM, V54, P729, DOI 10.1111/j.1471-4159.1990.tb02312.x; MOYA KL, 1987, DEV BRAIN RES, V31, P183, DOI 10.1016/0165-3806(87)90116-7; NEVE RL, 1991, MOL NEUROBIOL, V5, P131, DOI 10.1007/BF02935542; NEVE RL, 1988, P NATL ACAD SCI USA, V85, P3638, DOI 10.1073/pnas.85.10.3638; NEVE RL, 1987, MOL BRAIN RES, V2, P177, DOI 10.1016/0169-328X(87)90012-X; ROUTTENBERG A, 1985, BEHAV NEURAL BIOL, V43, P3, DOI 10.1016/S0163-1047(85)91426-8; SHAO S, 1994, SOC NEUR ABSTR, V20, P659; SHEA TB, 1991, J NEUROSCI, V11, P1685; SILVER PJ, 1986, BIOCHEM PHARMACOL, V35, P2545, DOI 10.1016/0006-2952(86)90052-3; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SKENE JHP, 1981, J CELL BIOL, V89, P96, DOI 10.1083/jcb.89.1.96; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; STRITTMATTER SM, 1994, J NEUROSCI, V14, P5503; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1992, J NEUROBIOL, V23, P507, DOI 10.1002/neu.480230506; STRITTMATTER SM, 1994, J CELL SCI, V107, P195; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; STRITTMATTER SM, 1993, P NATL ACAD SCI USA, V90, P5327, DOI 10.1073/pnas.90.11.5327; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; WIDMER F, 1993, J CELL BIOL, V120, P503, DOI 10.1083/jcb.120.2.503; YANKNER BA, 1990, MOL BRAIN RES, V7, P39, DOI 10.1016/0169-328X(90)90071-K; ZUBER MX, 1989, SCIENCE, V244, P1193, DOI 10.1126/science.2658062; ZUBER MX, 1989, NATURE, V341, P345, DOI 10.1038/341345a0	85	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26698	26705		10.1074/jbc.271.43.26698	http://dx.doi.org/10.1074/jbc.271.43.26698			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900147	hybrid			2022-12-27	WOS:A1996VP23300041
J	Nicholson, SE; Starr, R; Novak, U; Hilton, DJ; Layton, JE				Nicholson, SE; Starr, R; Novak, U; Hilton, DJ; Layton, JE			Tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor mediate G-CSF induced differentiation of murine myeloid leukemic (M1) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; CYTOKINE RECEPTORS; KINASE JAK1; ACTIVATION; BINDING; PHOSPHORYLATION; PROLIFERATION	The cytoplasmic tyrosine residues of many growth factor receptors have been shown to be important for receptor signal transduction via the recruitment of proteins containing phosphotyrosine-binding domains. This study demonstrates the importance of specific tyrosine residues in the granulocyte colony-stimulating factor (G-CSF) receptor cytoplasmic domain in G-CSF-induced macrophage cell differentiation. Site-directed mutagenesis was used to generate a series of G-CSF receptor (G-CSF-R) mutants in which the tyrosine residues were replaced with phenylalanine either singly or in combination, The mouse myeloid leukemic cell line (M1) transfected with G-CSF-R cDNA can be induced to differentiate into macrophages in response to G-CSF. The effect of the tyrosine mutations on this differentiation response was assessed by examining cell morphology and differentiation in soft agar colony assays. Although three of the four cytoplasmic tyrosine residues appeared to contribute to the differentiation response, mutation of a single residue (Tyr(744)) significantly reduced the ability of the M1 cells to differentiate. The STAT family of signaling molecules (Stat1, Stat3, and Stat5) were activated by G-CSF in M1 cells expressing those G-CSF-R tyrosine mutants unable to mediate G-CSF-induced differentiation. Furthermore, activation of STAT proteins was shown to occur in the absence of all four cytoplasmic tyrosine residues, suggesting an alternative mechanism for STAT activation other than direct interaction with receptor phosphotyrosines.	UNIV MELBOURNE,LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; UNIV MELBOURNE,DEPT MED,PARKVILLE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; University of Melbourne; University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne			Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392; , Sandra/0000-0002-1314-2134	NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-22556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVALOS BR, 1995, BLOOD, V85, P3117, DOI 10.1182/blood.V85.11.3117.bloodjournal85113117; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; deKoning JP, 1996, BLOOD, V87, P132; deKoning JP, 1996, BLOOD, V87, P1335, DOI 10.1182/blood.V87.4.1335.bloodjournal8741335; DEMETRI GD, 1991, BLOOD, V78, P2791; DONG F, 1994, P NATL ACAD SCI USA, V91, P4480, DOI 10.1073/pnas.91.10.4480; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; FUKUNAGA R, 1993, CELL, V74, P1; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HACKETT RH, 1995, J BIOL CHEM, V270, P21326, DOI 10.1074/jbc.270.36.21326; HIRAOKA O, 1994, J BIOL CHEM, V269, P22412; INHORN RC, 1995, P NATL ACAD SCI USA, V92, P8665, DOI 10.1073/pnas.92.19.8665; Isfort RJ, 1990, GROWTH FACTORS, V2, P213, DOI 10.3109/08977199009071507; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIESCHKE GJ, 1994, BLOOD, V84, P1737; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; METCALF D, 1984, CLONAL CULTURE HEMOP, P19; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NICOLA NA, 1990, COLONY STIMULATING F, P77; NICOLSON SE, 1995, BLOOD, V86, P3698; NOVAK U, 1996, IN PRESS GROWTH FACT, V13; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PAN CX, 1993, J BIOL CHEM, V268, P25818; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SOLER C, 1994, J BIOL CHEM, V269, P12320; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGAWA T, 1995, BLOOD, V85, P379; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TIAN SS, 1994, BLOOD, V84, P1760; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILKS AF, 1994, BIOESSAYS, V16, P313, DOI 10.1002/bies.950160505; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	59	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26947	26953		10.1074/jbc.271.43.26947	http://dx.doi.org/10.1074/jbc.271.43.26947			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900180	hybrid			2022-12-27	WOS:A1996VP23300074
J	Gonzalez, CI; Martin, CE				Gonzalez, CI; Martin, CE			Fatty acid-responsive control of mRNA stability - Unsaturated fatty acid-induced degradation of the Saccharomyces OLE1 transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; 5'->3' EXORIBONUCLEASE; YEAST-CELLS; CEREVISIAE; GENE; DESATURASE; TURNOVER; STABILIZATION; MECHANISM; PROTEIN	The Saccharomyces cerevisiae OLE1 gene encodes the Delta-9 fatty acid desaturase, a highly regulated integral membrane enzyme involved in the formation of unsaturated fatty acids from saturated acyl-coenzyme A precursors, The mRNA levels of the OLE1 gene are regulated by at least two independent control systems that respond to nutrient fatty acids, One involves the unsaturated fatty acid repression of OLE1 transcription; the second, described in this report, involves unsaturated fatty acid-responsive changes in the half-life of the OLE1 mRNA. Measurements of OLE1 mRNA half-life indicate that it is a moderately stable species (t(1/2) = 10 +/- 1.5 min) in cells grown in medium without exogenous fatty acids, Its half-life is drastically reduced (t(1/2) < 2.5 min), in a time-dependent manner, following the addition of unsaturated fatty acids to the growth medium, Saturated fatty acids that have previously been shown to increase activation of OLE1 transcription do not regulate its mRNA stability. Inhibition of translation, by the addition of cycloheximide, slows the nucleolytic degradation of the OLE1 mRNA and blocks the unsaturated fatty acid-triggered reduction in its half-life. This suggests an intimate link between the two processes of mRNA decay and protein synthesis, A chimeric mRNA, produced by replacing the upstream activation and fatty acid-regulated regions of the OLE1 promoter with the GAL1 promoter sequences is destabilized by exogenous unsaturated fatty acids. A similar chimera under GAL1 control that replaces the OLE1 mRNA 5'-untranslated region with GAL1 sequences is not regulated by unsaturated fatty acids, These results suggest that the 5'-untranslated region of the OLE1 mRNA contains sequence elements required for fatty acid-triggered destabilization. Disruption of the XRN1 gene, which encodes a 5' --> 3'-exoribonuclease, results in an approximate g-fold increase in OLE1 mRNA half-life in the absence of fatty acids, Its half-life is reduced when those cells are exposed to unsaturated fatty acids, indicating that the 5'-exoribonuclease encoded by the XRN1 gene is required for the rapid degradation of the OLE1 transcript but is not required for fatty acid-induced destabilization.	BUR BIOL RES,NELSON LABS,PISCATAWAY,NJ 08855						NIGMS NIH HHS [GM45768] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045768] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BLOOMFIELD DK, 1960, J BIOL CHEM, V235, P337; BOSSIE MA, 1989, J BACTERIOL, V171, P6409, DOI 10.1128/jb.171.12.6409-6413.1989; CEREGHINO GP, 1995, MOL BIOL CELL, V6, P1125, DOI 10.1091/mbc.6.9.1125; Choi JY, 1996, J BIOL CHEM, V271, P3581; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HSU CL, 1993, MOL CELL BIOL, V13, P4826, DOI 10.1128/MCB.13.8.4826; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON RM, 1993, OVEREXPRESSION OLE 1; LARIMER FW, 1992, GENE, V120, P51, DOI 10.1016/0378-1119(92)90008-D; LARIMER FW, 1990, GENE, V95, P85, DOI 10.1016/0378-1119(90)90417-P; LOMBARDO A, 1992, MOL CELL BIOL, V12, P2941, DOI 10.1128/MCB.12.7.2941; Maniatis T, 1989, DECONTAMINATION DILU; MCDONOUGH VM, 1992, J BIOL CHEM, V267, P5931; MITCHELL AG, 1995, J BIOL CHEM, V270, P29766; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PARKER R, 1991, METHODS ENZYMOLOGY M, P415; PELTZ SW, 1992, MOL CELL BIOL, V12, P5778, DOI 10.1128/MCB.12.12.5778; PELTZ SW, 1993, CONTROL MRNA STABILI, P291; PIERRAT B, 1993, GENE, V131, P43, DOI 10.1016/0378-1119(93)90667-R; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; TISHKOFF DX, 1991, MOL CELL BIOL, V11, P2593, DOI 10.1128/MCB.11.5.2593; WYNE KL, 1989, J BIOL CHEM, V264, P16530	31	77	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25801	25809		10.1074/jbc.271.42.25801	http://dx.doi.org/10.1074/jbc.271.42.25801			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824209	hybrid			2022-12-27	WOS:A1996VN18000015
J	Hoang, B; Moos, M; Vukicevic, S; Luyten, FP				Hoang, B; Moos, M; Vukicevic, S; Luyten, FP			Primary structure and tissue distribution of FRZB, a novel protein related to Drosophila frizzled, suggest a role in skeletal morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; POLARITY GENE; EXPRESSION; OSTEOGENIN; CLEAVAGE; SITES	Articular cartilage extracts were prepared to characterize protein fractions with in vivo chondrogenic activity (Chang, S., Hoang, B., Thomas, J. T., Vukicevic, S., Luyten, F. P., Ryba, N. J. P., Kozak, C. A., Reddi, A. H., and Woos, M. (1994) J. Biol. Chem. 269, 28227-28234). Trypsin digestion of highly purified chondrogenic protein fractions allowed the identification of several unique peptides by amino acid sequencing. We discovered a novel cDNA encoding a deduced 36-kDa protein by using degenerate oligonucleotide primers derived from a 30-residue peptide in reverse transcription polymerase chain reactions. Its N-terminal domain showed similar to 50%, amino acid identity to the corresponding region of the Drosophila gene frizzled, which has been implicated in the specification of hair polarity during development. Hydropathy and structural analyses of the open reading frame revealed the presence of a signal peptide and a hydrophobic domain followed by multiple potential serine/threonine phosphorylation sites and a serine-rich C terminus. Cell fractionation studies of primary bovine articular chondrocytes and transfected COS cells suggested that the protein is membrane-associated. In situ hybridization and immunostaining of human embryonic sections demonstrated predominant expression surrounding the chondrifying bone primordia and subsequently in the chondrocytes of the epiphyses in a graded distribution that decreased toward the primary ossification center. Transcripts were present in the craniofacial structures but not in the vertebral bodies. Because it is expressed primarily in the cartilaginous cores of developing long bones during embryonic and fetal development (6-13 weeks) and is homologous to the polarity-determining gene frizzled, we believe that this gene, which we named frzb, is involved in morphogenesis of the mammalian skeleton.	NIDR,BONE RES BRANCH,NIH,BETHESDA,MD 20892; US FDA,CTR BIOL EVALUAT & RES,DEV BIOL LAB,BETHESDA,MD 20892; MED SCH ZAGREB,DEPT ANAT,ZAGREB 41000,CROATIA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); US Food & Drug Administration (FDA); University of Zagreb			Moos, Malcolm C/F-3673-2011; Vukicevic, Slobodan/AEG-2646-2022; Luyten, Frank/GPS-7793-2022	Moos, Malcolm C/0000-0002-9575-9938; Vukicevic, Slobodan/0000-0003-4076-0285; 				ADLER PN, 1990, GENETICS, V126, P401; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; CARLSON BM, 1994, HUMAN EMBRYOLOGY DEV, P182; CHAN SDH, 1992, J BIOL CHEM, V267, P25202; CHANG SC, 1994, J BIOL CHEM, V269, P28227; EPIFANO O, 1995, DEVELOPMENT, V121, P1947; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUYTEN FP, 1988, ARCH BIOCHEM BIOPHYS, V267, P416, DOI 10.1016/0003-9861(88)90047-1; LUYTEN FP, 1989, J BIOL CHEM, V264, P13377; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; MOOS M, 1988, J BIOL CHEM, V263, P6005; NARDI JB, 1976, J EMBRYOL EXP MORPH, V36, P489; PELTON RW, 1989, DEVELOPMENT, V106, P759; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; Thomas JT, 1996, NAT GENET, V12, P315, DOI 10.1038/ng0396-315; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VUKICEVIC S, 1994, J HISTOCHEM CYTOCHEM, V42, P869, DOI 10.1177/42.7.8014470; Wang YS, 1996, J BIOL CHEM, V271, P4468; ZHAO ZY, 1995, GENOMICS, V27, P370, DOI 10.1006/geno.1995.1060; ZHENG L, 1995, DEVELOPMENT, V121, P3045	29	207	246	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26131	26137		10.1074/jbc.271.42.26131	http://dx.doi.org/10.1074/jbc.271.42.26131			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824257				2022-12-27	WOS:A1996VN18000063
J	Maurer, F; Medcalf, RL				Maurer, F; Medcalf, RL			Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events - Identification of a functional nonameric AU-rich motif in the 3'-untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; 3' UNTRANSLATED REGION; FACTOR-ALPHA; SEQUENCE; CELLS; ELEMENTS; EXPRESSION; FIBROBLASTS; STABILITY; POLY(A)	Plasminogen activator inhibitor type 2 (PAI-2) mRNA and antigen levels are synergistically induced in HT-1080 fibrosarcoma cells when treated with a combination of tumor necrosis factor (TNF) and phorbol 12-myristate 13-acetate (PMA). Here we demonstrate that this effect is not fully reflected at the level of gene transcription, suggesting a contribution of post transcriptional events in this induction. Insertion of the 8'-untranslated region (3'-UTR) of PAI-2 mRNA into the 3'-UTR of a rabbit beta-globin reporter gene reduces beta-globin-PAI-2 chimeric mRNA expression in stably transfected cells. The region within the PAI-2 3'-UTR responsible for this effect is located within the 368-nucieotide sequence preceding the poly(A) tail, a segment that includes a nonameric UUAUUUAUU motif. Mutagenesis of this element abolishes the PAI-2 3'-UTR destabilizing effect, revealing a functional role for this motif. TNF and PMA co-treatment of transfected cells increases beta-globin-PAI-2 chimeric mRNA expression 3-4-fold, indicating that the inherently unstable 3'-UTR of PAI-2 mRNA can become stabilized in response to TNF and PMA. Our results indicate that induction of PAI-2 gene expression by TNF and PMA involves both direct transcription as well as mRNA stabilization, the latter involving an AU-rich nonameric motif in the 3'-UTR.	MONASH UNIV,DEPT MED,BOX HILL HOSP,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital; Monash University			Medcalf, Robert L/E-9632-2011					BACHMANN F, 1995, THROMB HAEMOSTASIS, V74, P172; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; CAJOT JF, 1989, J CELL BIOL, V109, P915, DOI 10.1083/jcb.109.2.915; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUSIN E, 1991, NUCLEIC ACIDS RES, V19, P3881, DOI 10.1093/nar/19.14.3881; Dear AE, 1995, FIBRINOLYSIS, V9, P321, DOI 10.1016/S0268-9499(95)80079-4; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; FISHER R, 1985, J BIOL CHEM, V260, P1223; GAN HX, 1995, J IMMUNOL, V155, P1304; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; MEDCALF RL, 1986, EMBO J, V5, P2217, DOI 10.1002/j.1460-2075.1986.tb04487.x; MEDCALF RL, 1992, J BIOL CHEM, V267, P12220; MEDCALF RL, 1988, J EXP MED, V168, P751, DOI 10.1084/jem.168.2.751; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; Mikus P, 1996, J BIOL CHEM, V271, P10048, DOI 10.1074/jbc.271.17.10048; MINTY AJ, 1983, J MOL BIOL, V167, P77, DOI 10.1016/S0022-2836(83)80035-7; NANBU R, 1994, MOL CELL BIOL, V14, P4920, DOI 10.1128/MCB.14.7.4920; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PYTEL BA, 1990, J CELL PHYSIOL, V144, P416, DOI 10.1002/jcp.1041440308; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SCHLEUNING WD, 1987, MOL CELL BIOL, V7, P4564, DOI 10.1128/MCB.7.12.4564; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; WEBB AC, 1987, J EXP MED, V166, P77, DOI 10.1084/jem.166.1.77; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	37	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26074	26080		10.1074/jbc.271.42.26074	http://dx.doi.org/10.1074/jbc.271.42.26074			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824249	hybrid			2022-12-27	WOS:A1996VN18000055
J	Soejima, A; Inoue, K; Takai, D; Kaneko, M; Ishihara, H; Oka, Y; Hayashi, J				Soejima, A; Inoue, K; Takai, D; Kaneko, M; Ishihara, H; Oka, Y; Hayashi, J			Mitochondrial DNA is required for regulation of glucose-stimulated insulin secretion in a mouse pancreatic beta cell line, MIN6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROKE-LIKE EPISODES; TRANSFER RNA(LEU(UUR)) GENE; TRANSFER RNALEU(UUR) GENE; DIABETES-MELLITUS; PROTEIN-SYNTHESIS; LACTIC-ACIDOSIS; POINT MUTATION; MYOPATHY; DELETION; MELAS	To determine whether mtDNA and mitochondrial respiratory function in pancreatic beta cells are necessary for the phenotypic expression of glucose-stimulated in sulin secretion, we used a cultured mouse pancreatic beta cell line, MIN6, and two derivative lines, mtDNA knockout MIN6 (rho(0) MIN6) and mtDNA repopulated cybrid MIN6. The MIN6 cells retain the property of glucose-stimulated insulin secretion, but their mtDNA knockout induced the loss of mitochondrial transcription, translation, and respiration activity, without inhibition of transcription of the insulin gene or loss of succinate dehydrogenase activity, indicating that the observed mitochondrial dysfunction in rho(0) MIN6 cells was not due to a cytotoxic side effect derived from the mtDNA knockout. Moreover, the mtDNA depletion also inhibited both the glucose-stimulated increase in the intracellular free Ca2+ content and the elevation of insulin secretion. The possibility of the involvement of nuclear genome encoded factors in this process was excluded by the observation that the missing sensitivity to extracellular glucose stimulation in rho(0) MIN6 cells was restored reversibly by repopulation with foreign mtDNA and isolating cybrid MIN6 clones. Therefore, these findings provide unambiguous evidence for the involvement of the mitochondrial dysfunction induced by mtDNA impairment in developing pathogeneses of some forms of diabetes mellitus.	UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN; NATL CANC CTR,RES INST,DIV BIOPHYS,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN; YAMAGUCHI UNIV,SCH MED,DEPT INTERNAL MED 3,UBE,YAMAGUCHI 755,JAPAN	University of Tsukuba; National Cancer Center - Japan; University of Tokyo; Yamaguchi University								ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619; ERIZIRIK DL, 1991, BIOCHEM PHARMACOL, V42, P2275; FROGUEL P, 1993, NEW ENGL J MED, V328, P697, DOI 10.1056/NEJM199303113281005; GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HANNA MG, 1995, AM J HUM GENET, V56, P1026; HAO HL, 1995, AM J HUM GENET, V56, P1017; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1982, SOMAT CELL GENET, V8, P67, DOI 10.1007/BF01538651; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HAYASHI JI, 1984, CANCER RES, V44, P3957; HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; ISHIHARA H, 1994, J BIOL CHEM, V269, P3081; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; KADOWAKI T, 1988, SCIENCE, V240, P787, DOI 10.1126/science.2834824; Kaneko M, 1996, FREE RADICAL RES, V24, P299, DOI 10.3109/10715769609088027; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5; LUDER A, 1994, J INHERIT METAB DIS, V17, P298, DOI 10.1007/BF00711812; MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V; MIYABAYASHI S, 1991, J INHERIT METAB DIS, V14, P805, DOI 10.1007/BF01799954; MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MORAES CT, 1991, AM J HUM GENET, V48, P492; ODAWARA M, 1989, SCIENCE, V245, P66, DOI 10.1126/science.2544998; OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7; ORAHILLY SP, 1986, LANCET, V2, P360; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; ROTIG A, 1992, AM J HUM GENET, V50, P364; SERRADAS P, 1995, ENDOCRINOLOGY, V136, P5623, DOI 10.1210/en.136.12.5623; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; STEINER DF, 1990, DIABETES CARE, V13, P600, DOI 10.2337/diacare.13.6.600; SUZUKI S, 1994, DIABETES CARE, V17, P1428, DOI 10.2337/diacare.17.12.1428; TANAKA M, 1991, BIOCHEM BIOPH RES CO, V174, P861, DOI 10.1016/0006-291X(91)91497-Z; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; YADA T, 1993, ENDOCRINOLOGY, V133, P1685, DOI 10.1210/en.133.4.1685	48	128	130	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26194	26199		10.1074/jbc.271.42.26194	http://dx.doi.org/10.1074/jbc.271.42.26194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824267	hybrid			2022-12-27	WOS:A1996VN18000073
J	Torpey, J; deMontellano, PRO				Torpey, J; deMontellano, PRO			Oxidation of the meso-methylmesoheme regioisomers by heme oxygenase - Electronic control of the reaction regiospecificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIVERDIN-IX-ALPHA; CARBON-MONOXIDE; PORPHYRINS; MESSENGER; CLEAVAGE	The oxidation of heme by heme oxygenase (HO-1) results in highly regiospecific extrusion of the alpha-meso-carbon as CO and the formation of biliverdin IX alpha. The first step in the accepted mechanism for this process is alpha-meso-hydroxylation of the heme. To define further the reaction mechanism, the oxidations of the four isomers of meso-methylmesoheme by human truncated HO-1 supported by NADPH-cytochrome P450 reductase, H2O2, or ascorbate have been examined. Surprisingly, the results establish that (a) HO-1 can oxidize an alpha-meso-methyl-substituted heme to biliverdin IX alpha without proceeding via the alpha-meso-hydroxy intermediate; (b) the normal HO-1 alpha-regiospecificity is inverted in favor of the substituted gamma-position by introduction of a gamma-meso methyl group; and (c) the beta- and delta-meso-methylmesohemes are oxidized less regiospecifically to mixtures of methyl-substituted and -unsubstituted mesobiliverdins. The results indicate that electronic rather than steric effects primarily control the regiospecificity of heme cleavage by HO-1.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR LIVER,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK26743, DK30297] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONNETT R, 1987, J CHEM SOC PERK T 1, P1063, DOI 10.1039/p19870001063; BONNETT R, 1973, J CHEM SOC PERK T 1, P881, DOI 10.1039/p19730000881; BROWN SB, 1981, NATURE, V289, P93, DOI 10.1038/289093a0; FURHOP HH, 1975, PORPHYRINS METALLOPO, P836; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; ISHIKAWA K, 1992, BIOCHEM BIOPH RES CO, V182, P981, DOI 10.1016/0006-291X(92)91828-E; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; JACKSON AH, 1968, J CHEM SOC C, P302, DOI 10.1039/j39680000302; LAGARIAS JC, 1982, BIOCHIM BIOPHYS ACTA, V717, P12, DOI 10.1016/0304-4165(82)90373-7; Lemberg R, 1941, BIOCHEM J, V35, P363, DOI 10.1042/bj0350363; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P453; Lin Q., 1992, INORG CHEM, V31, P4216; MAINES MD, 1986, J BIOL CHEM, V261, P411; MAINES MD, 1992, HEME OXYGENASE CLIN, P109; MAINES MD, 1992, HEME OXYGENASE CLIN, P203; MARKS GS, 1994, CELL MOL BIOL, V40, P863; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; MEDFORTH CJ, 1992, J AM CHEM SOC, V114, P9859, DOI 10.1021/ja00051a019; MORELL DB, 1961, BIOCHEM J, V78, P793, DOI 10.1042/bj0780793; MORISHIMA I, 1986, J AM CHEM SOC, V108, P3858, DOI 10.1021/ja00273a067; SAITO S, 1982, P NATL ACAD SCI-BIOL, V79, P1393, DOI 10.1073/pnas.79.5.1393; SAITO S, 1986, J CHEM SOC PERK T 1, P1, DOI 10.1039/p19860000001; SANO S, 1986, P NATL ACAD SCI USA, V83, P531, DOI 10.1073/pnas.83.3.531; Schmid R., 1979, PORPHYRINS, V6, P258; SENGE MO, 1995, J CHEM SOC CHEM COMM, P733, DOI 10.1039/c39950000733; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; TAN HM, 1994, J AM CHEM SOC, V116, P5784, DOI 10.1021/ja00092a032; TENHUNEN R, 1972, BIOCHEMISTRY-US, V11, P1716, DOI 10.1021/bi00759a029; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TORPEY JW, 1995, J ORG CHEM, V60, P2195, DOI 10.1021/jo00112a045; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WILKS A, 1994, J BIOL CHEM, V269, P29553; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1981, J BIOCHEM-TOKYO, V90, P125, DOI 10.1093/oxfordjournals.jbchem.a133441; YOSHIDA T, 1984, J BIOCHEM-TOKYO, V96, P563, DOI 10.1093/oxfordjournals.jbchem.a134868; YOSHIDA T, 1988, EUR J BIOCHEM, V171, P457, DOI 10.1111/j.1432-1033.1988.tb13811.x; YOSHINAGA T, 1990, BIOCHEM J, V270, P659, DOI 10.1042/bj2700659	38	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26067	26073		10.1074/jbc.271.42.26067	http://dx.doi.org/10.1074/jbc.271.42.26067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824248	hybrid			2022-12-27	WOS:A1996VN18000054
J	Levy, AP; Levy, NS; Goldberg, MA				Levy, AP; Levy, NS; Goldberg, MA			Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel Lindau protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; AU-RICH ELEMENTS; UNTRANSLATED REGIONS; STABILITY; SEQUENCE; CELLS; AUUUA; GENE; STABILIZATION; VEGF	Hypoxia induces an increase in the stability of the mRNA encoding vascular endothelial growth factor (VEGF). We have previously demonstrated that a 500-base region of the 3'-untranslated region of VEGF mRNA that is critical for stabilization of VEGF mRNA in an in vitro degradation assay forms a RNA-protein complex in a hypoxia-inducible fashion. We report here the identification of three adenylate-uridylate-rich RNA elements within this region that form an identical or closely related hypoxia-inducible RNA-protein complex. This complex is constitutively elevated in a tumor cell line lacking the wild type von Hippel-Lindau tumor suppressor gene and in which VEGF mRNA is constitutively stabilized, Furthermore, the glucose transporter-1 mRNA, which is also stabilized by hypoxia, forms a hypoxia-inducible RNA-protein complex with similar sequence and protein binding characteristics to that described for VEGF mRNA. Finally, RNA affinity purification and UV cross linking were used to identify three proteins of 32, 28, and 17 kDa that are derived from this hypoxia-inducible RNA-protein complex.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BOSTON UNIV,SCH MED,EVANS DEPT MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02118	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003405, F32HL008838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045098] Funding Source: NIH RePORTER; NHLBI NIH HHS [1K08HL03405-01, 1F32HL08838-02] Funding Source: Medline; NIDDK NIH HHS [DK45098] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; HAMILTON BJ, 1993, J BIOL CHEM, V268, P8881; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; KATZ DA, 1994, NUCLEIC ACIDS RES, V22, P238, DOI 10.1093/nar/22.2.238; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MYER VE, 1995, RNA, V1, P171; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; RATNER L, 1985, NUCLEIC ACIDS RES, V13, P5007, DOI 10.1093/nar/13.14.5007; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Sharma H S, 1992, EXS, V61, P255; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; SHARMA HS, 1992, J MOL CELL CARDIOL, V24, pS10, DOI 10.1016/0022-2828(92)91543-E; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SKOOG DA, 1988, ANAL CHEM, P74; STEIN I, 1995, MOL CELL BIOL, V15, P5363; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WANG XM, 1995, MOL CELL BIOL, V15, P1769; White FC, 1995, GROWTH FACTORS, V12, P289, DOI 10.3109/08977199509028967; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	42	189	196	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25492	25497		10.1074/jbc.271.41.25492	http://dx.doi.org/10.1074/jbc.271.41.25492			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810320	hybrid			2022-12-27	WOS:A1996VL69300064
J	Holt, EH; Broadus, AE; Brines, ML				Holt, EH; Broadus, AE; Brines, ML			Parathyroid hormone-related peptide is produced by cultured cerebellar granule cells in response to L-type voltage-sensitive Ca2+ channel flux via a Ca2+/calmodulin-dependent kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALCIUM CHANNELS; GENE-EXPRESSION; MALIGNANT HYPERCALCEMIA; MEMBRANE DEPOLARIZATION; CALMODULIN ANTAGONISTS; HIPPOCAMPAL-NEURONS; GANGLION CELLS; CA-2+ CHANNELS; RAT-BRAIN	Parathyroid hormone (PTH) related peptide (PTHrP) is expressed in the adult mammalian brain, but its function is unknown. Here we show that PTHrP and the PTH/PTHrP receptor are products of cerebellar granule cells in primary culture. Granule cells maintained under depolarizing conditions (25 mM K+) make and release PTHrP. Further, PTHrP-(1-36) stimulates cAMP accumulation in granule neurons in a dose-dependent manner with half-maximal activation at similar to 16 nM. Granule cell PTHrP mRNA is activity-dependent, and the pathway of regulation depends absolutely on the flux of Ca2+ ions through the L-type voltage-sensitive Ca2+ channel and the Ca2+/calmodulin kinase cascade. PTHrP is therefore a neuropeptide whose regulation depends upon L-type voltage-sensitive Ca2+ channel activity, and the gene is expressed under conditions that promote granule cell survival.	YALE UNIV,SCH MED,DEPT INTERNAL MED,ENDOCRINOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06520	Yale University; Yale University			Brinesd, Michael/AAE-6072-2020	Brines, Michael/0000-0003-4151-4449				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ARMSTRONG D, 1987, P NATL ACAD SCI USA, V84, P2518, DOI 10.1073/pnas.84.8.2518; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS LF, METHOD ENZYMOL, V169, P371; BROADUS AE, 1994, PARATHYROIDS; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; CARTER CJ, 1987, NEUROSCI LETT, V82, P201, DOI 10.1016/0304-3940(87)90130-3; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; COLLINS F, 1989, BRAIN RES, V502, P99, DOI 10.1016/0006-8993(89)90465-4; COLLINS F, 1991, J NEUROSCI, V11, P2582; DAIFOTIS AG, 1992, J BIOL CHEM, V267, P23455; DEERAUSQUIN GA, 1990, P NATL ACAD SCI USA, V87, P8017, DOI 10.1073/pnas.87.20.8017; DeKoninck P, 1995, J NEUROSCI, V15, P7966; DIDIER M, 1993, EUR J PHARM-MOLEC PH, V244, P57, DOI 10.1016/0922-4106(93)90059-I; DOROSHENKO PA, 1988, NEUROSCIENCE, V27, P1073, DOI 10.1016/0306-4522(88)90211-4; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; GALLO V, 1987, J NEUROSCI, V7, P2203; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GREENBERG DA, 1987, BRAIN RES, V404, P401, DOI 10.1016/0006-8993(87)91403-X; HACK N, 1993, NEUROSCIENCE, V57, P9, DOI 10.1016/0306-4522(93)90108-R; HARVEY S, 1993, J ENDOCRINOL, V139, P353, DOI 10.1677/joe.0.1390353; HASHIMOTO H, 1994, BIOCHEM BIOPH RES CO, V200, P1042, DOI 10.1006/bbrc.1994.1555; HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384; HOLT EH, 1994, J NEUROCHEM, V62, P1239; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KARAPLIS AC, 1990, MOL ENDOCRINOL, V4, P441, DOI 10.1210/mend-4-3-441; KINGSBURY A, 1987, EUR J PHARMACOL, V140, P275, DOI 10.1016/0014-2999(87)90284-6; KINGSBURY AE, 1985, DEV BRAIN RES, V17, P17, DOI 10.1016/0165-3806(85)90128-2; KOIKE T, 1989, P NATL ACAD SCI USA, V86, P6421, DOI 10.1073/pnas.86.16.6421; LEE KC, 1995, ENDOCRINOLOGY, V136, P453, DOI 10.1210/en.136.2.453; LI GD, 1992, MOL PHARMACOL, V42, P489; LUCHOWSKI EM, 1984, J PHARMACOL EXP THER, V230, P607; MARTIN TJ, 1990, Q J MED, V76, P771; MCDONOUGH PM, 1994, J BIOL CHEM, V269, P9466; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NISSENSON RA, 1992, PARATHYROID HORMONE, P145; NUTLEY MT, 1995, ENDOCRINOLOGY, V136, P5600, DOI 10.1210/en.136.12.5600; ORLOFF JJ, 1991, J BONE MINER RES, V6, P279; PAUWELS PJ, 1990, J PHARMACOL EXP THER, V255, P1117; Schousboe A., 1989, DISSECTION TISSUE CU, P203; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SKEEN GA, 1993, MOL PHARMACOL, V44, P443; STREWLER GJ, 1990, WESTERN J MED, V153, P635; STRUCKHOFF G, 1995, BRAIN RES, V676, P1, DOI 10.1016/0006-8993(95)00088-8; SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618; TANAKA S, 1995, DEV BIOL, V168, P166, DOI 10.1006/dbio.1995.1069; THIEDE MA, 1991, ENDOCRINOLOGY, V129, P1958, DOI 10.1210/endo-129-4-1958; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TRENKNER E, 1991, CULTURING NERVE CELL, P283; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WEAVER DR, 1995, MOL BRAIN RES, V28, P296, DOI 10.1016/0169-328X(94)00222-Z; WEIR EC, 1990, P NATL ACAD SCI USA, V87, P108, DOI 10.1073/pnas.87.1.108; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; YAMAMOTO M, 1992, P NATL ACAD SCI USA, V89, P5326, DOI 10.1073/pnas.89.12.5326; YATANI A, 1985, CIRC RES, V57, P868	62	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28105	28111		10.1074/jbc.271.45.28105	http://dx.doi.org/10.1074/jbc.271.45.28105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910424	hybrid			2022-12-27	WOS:A1996VU03300024
J	Lin, XY; Tombler, E; Nelson, PJ; Ross, M; Gelman, IH				Lin, XY; Tombler, E; Nelson, PJ; Ross, M; Gelman, IH			A novel src- and ras-suppressed protein kinase c substrate associated with cytoskeletal architecture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE INTERACTIONS; SECONDARY-STRUCTURE; PLASMA-MEMBRANE; FOCAL ADHESION; V-SRC; FIBROBLASTS; CELLS; EXPRESSION; CALMODULIN; ONCOGENES	We previously identified a novel src- and ras-suppressed gene, 322, encoding a mitogenic regulatory function (Lin, X., Nelson, P. J., Frankfort, B., Tombler, E., Johnson, R., and Gelman, I. H. (1995) Mol. Cell. Biol. 15, 2754-2762). Here, we characterize the 322 gene product as an in vivo and in vitro substrate of protein kinase C (PKC). Hence, we named this product SSeCKS (pronounced essex) for Src Suppressed C Kinase Substrate. Rabbit polyclonal sera raised against glutathione S-transferase (GST)-SSeCKS recognized a myristylated 280/290-kDa doublet in Rat-6 fibroblasts. SSeCKS levels in src- and ras-transformed Rat-6 cells were 15- and 8-fold less, respectively, than those in untransformed cells. Short-term addition of phorbol ester resulted in a Ei-fold increase in SSeCKS phosphorylation a which was inhibited by bis-indolylmaleimide. In vitro phosphorylation of GST-SSeCKS by purified rabbit brain PKC-alpha was enhanced by phosphatidylserine and blocked by excess PKC pseudosubstrate inhibitor peptide. GST-SSeCKS bound purified PKC-alpha or PKC from Rat-6 lysates in a phosphatidylserine-dependent manner. Four SSeCKS domains containing Lys/Arg-rich moths similar to the PHC phosphorylation site in MARCKS were phosphorylated in vitro by PKC. Immunofluorescence analysis showed SSeCKS present throughout the cytoplasm with enrichment in podosomes and at the cell edge. Short-term addition of phorbol esters caused the movement of SSeCKS from plasma membrane sites to the perinucleus coincident with a loss of actin stress fibers. These data suggest a role for SSeCKS in the control of cellular cytoskeletal architecture.	MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R29CA065787] Funding Source: NIH RePORTER; NCI NIH HHS [CA-65787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BORNER C, 1992, J BIOL CHEM, V267, P12900; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; Chapline C, 1996, J BIOL CHEM, V271, P6417, DOI 10.1074/jbc.271.11.6417; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEHBI M, 1993, BIOCH CELL BIOL, V70, P980; DEVEREUX J, 1993, GCG SEQUENCE ANAL SO; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FRANKFORT BJ, 1995, BIOCHEM BIOPH RES CO, V206, P916, DOI 10.1006/bbrc.1995.1130; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GELMAN IH, 1993, ONCOGENE, V8, P2995; GELMAN IH, 1987, J VIROL, V61, P2286, DOI 10.1128/JVI.61.7.2286-2296.1987; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HERGET T, 1993, P NATL ACAD SCI USA, V90, P2945, DOI 10.1073/pnas.90.7.2945; HOLTZ RW, 1994, PROTEIN KINASE C, P269; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYATT SL, 1994, CELL GROWTH DIFFER, V5, P495; HYATT SL, 1990, MOL CARCINOGEN, V3, P45, DOI 10.1002/mc.2940030202; JAHNER D, 1991, ONCOGENE, V6, P1259; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIN XY, 1995, MOL CELL BIOL, V15, P2754; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MAEKAWA S, 1993, J BIOL CHEM, V268, P13703; MAHONEY CW, 1994, PROTEIN KINASE C, P16; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; NEEL VA, 1994, DEVELOPMENT, V120, P2235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEARSON RB, 1991, METHOD ENZYMOL, V200, P63; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Sambrook J., 2002, MOL CLONING LAB MANU; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	42	120	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28430	28438		10.1074/jbc.271.45.28430	http://dx.doi.org/10.1074/jbc.271.45.28430			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910468	hybrid			2022-12-27	WOS:A1996VU03300068
J	Petrovic, N; Comi, A; Ettinger, MJ				Petrovic, N; Comi, A; Ettinger, MJ			Copper incorporation into superoxide dismutase in menkes lymphoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; S-ADENOSYLHOMOCYSTEINE HYDROLASE; CANDIDATE GENE; STAPHYLOCOCCUS-AUREUS; BINDING-PROTEIN; CLONING; CADMIUM; PLASMID; EFFLUX; ATPASE	The incorporation of copper into Cu,Zn-superoxide dismutase (SOD) was examined in Menkes lymphoblasts that express a genetic defect of copper metabolism, SOD activity was approximate to 40% higher in Menkes than normal lymphoblasts, Since Menkes lymphoblasts contain elevated copper levels, the higher SOD activity is most likely due to near copper saturation of an apoSOD pool that is in normal lymphoblasts. Cycloheximide markedly inhibited Cu-64(II) incorporation into SOD in Menkes lymphoblasts under conditions in which no significant, de novo synthesis of SOD protein was detected with normal lymphoblasts, The maximal amount of Cu-64 incorporation into newly synthesized SOD in Menkes lymphoblasts was approximately equal to the maximal amount of Cu-64 that could be incorporated into the apoSOD pool in normal lymphoblasts. The increased synthesis of SOD in Menkes lymphoblasts may play a protective role against copper toxicity in Menkes lymphoblasts. The protonophore, CCCP markedly inhibited Cu-64 incorporation into SOD in both normal and Menkes lymphoblasts, which is consistent with Cu-64 incorporation into SOD within a membrane-bounded compartment in both cell types, When Cu-64-incorporation into SOD was blocked with CCCP, copper accumulated in a Superose column fraction that contains S-adenosylhomocysteine hydrolase (SAHH), which has a high affinity for copper, SAHH may play a role in delivering copper to SOD.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								ANDERSON MLM, 1991, J BIOCHEM BIOPH METH, V22, P207, DOI 10.1016/0165-022X(91)90069-9; BETHIN KE, 1995, J BIOL CHEM, V270, P20703, DOI 10.1074/jbc.270.35.20703; BETHIN KE, 1995, J BIOL CHEM, V270, P20698, DOI 10.1074/jbc.270.35.20698; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; Danks D. M., 1989, METABOLIC BASIS INHE; DAS S, 1994, AM J HUM GENET, V55, P883; ETTINGER MJ, 1984, LIFE CHEM REPORTS, V5, P169; HERD SM, 1987, BIOCHEM J, V247, P341, DOI 10.1042/bj2470341; HUNT DM, 1982, LIFE SCI, V31, P417, DOI 10.1016/0024-3205(82)90326-5; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; LEONE A, 1985, CELL, V40, P301, DOI 10.1016/0092-8674(85)90144-8; MENKES JH, 1962, PEDIATRICS, V29, P764; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PACKMAN S, 1983, J INORG BIOCHEM, V19, P203, DOI 10.1016/0162-0134(83)85025-9; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Petrovic N, 1996, J BIOL CHEM, V271, P28331, DOI 10.1074/jbc.271.45.28331; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; RIORDAN JR, 1982, J BIOL CHEM, V257, P4639; SCHMIDT CJ, 1983, GENE, V24, P137, DOI 10.1016/0378-1119(83)90139-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TYNECKA Z, 1981, J BACTERIOL, V147, P313, DOI 10.1128/JB.147.2.313-319.1981; VOLPE C, 1993, NAT GENET, V3, P7; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471	31	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28335	28340		10.1074/jbc.271.45.28335	http://dx.doi.org/10.1074/jbc.271.45.28335			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910456	hybrid			2022-12-27	WOS:A1996VU03300056
J	Krosl, J; Damen, JE; Krystal, G; Humphries, RK				Krosl, J; Damen, JE; Krystal, G; Humphries, RK			Interleukin-3 (IL-3) inhibits erythropoietin-induced differentiation in Ba/F3 cells via the IL-3 receptor alpha subonit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GROWTH SIGNAL-TRANSDUCTION; ERYTHROID PROGENITOR CELLS; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAIN; GENE-EXPRESSION; BETA-SUBUNIT; LINE; PROLIFERATION; HEMOGLOBIN	Introduction of erythropoietin receptors (EpoRs) into the interleukin-3 (IL-3)-dependent murine hemopoietic cell line, Ba/F3, enables these cells to not only proliferate, after an initial lag in G(1), but also to increase beta-globin mRNA levels in response to erythropoietin (Epo), With IL-3 and Epo costimulation, IL-3-induced signaling appears to be dominant since no increase in beta-globin mRNA occurs, Differentiation and proliferation signals may be uncoupled since EpoRs lacking all eight intracellular tyrosines were compromised in proliferative signaling but retained erythroid differentiation ability, intriguingly, a chimeric receptor of the extracellular domain of the EpoR and the transmembrane and intracellular domains of IL-3R beta(IL-3) chain (EpoR/IL-3R beta(IL-3)) was capable of Epo-induced proliferative and differentiating signaling suggesting either the existence of a second EpoR subunit responsible for differentiation or that the a! subunit of the IL-3 receptor (IL-3R) prevents it. Arguing against the former, a truncated EpoR lacking an intracellular domain was incapable of promoting proliferation or differentiation. An EpoR/IL-3R alpha chimera, in contrast, was capable of transmitting a weak Epo-induced proliferative signal but failed to stimulate accumulation of beta-globin mRNA, Most significantly, coexpression of the EpoR/IL-3R alpha chimera with either EpoR/IL-3R beta or wild-type EpoRs suppressed Epo-induced beta-globin mRNA accumulation, Taken together, these results suggest an active role for the IL-3R alpha subunit in inhibiting EpoR-specific differentiating signals.	BRITISH COLUMBIA CANC RES CTR, TERRY FOX LAB, VANCOUVER, BC V5Z 1L3, CANADA; UNIV BRITISH COLUMBIA, DEPT PATHOL, VANCOUVER, BC V6T 1Z1, CANADA; UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z1, CANADA	British Columbia Cancer Agency; University of British Columbia; University of British Columbia				Krystal, Gerald/0000-0002-1961-6281; Humphries, Richard/0000-0003-0540-7005				BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; CARROLL M, 1995, P NATL ACAD SCI USA, V92, P2869, DOI 10.1073/pnas.92.7.2869; CARROLL M, 1994, P SOC EXP BIOL MED, V206, P289; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; EDER M, 1994, J BIOL CHEM, V269, P30173; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KITAMURA T, 1992, BLOOD, V80, P84; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1986, J CELL PHYSIOL, V126, P259, DOI 10.1002/jcp.1041260216; KRANTZ SB, 1991, BLOOD, V77, P419; KROSL J, 1995, BLOOD, V85, P50, DOI 10.1182/blood.V85.1.50.bloodjournal85150; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARUYAMA K, 1994, J BIOL CHEM, V269, P5976; MINEGISHI N, 1994, J BIOL CHEM, V269, P27700; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MIYAJIMA A, 1993, BLOOD, V82, P1960; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SAWADA K, 1990, J CELL PHYSIOL, V142, P219, DOI 10.1002/jcp.1041420202; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; WEISS M, 1993, BLOOD, V82, P3298; WICKREMA A, 1992, BLOOD, V80, P1940, DOI 10.1182/blood.V80.8.1940.1940; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; WOGNUM AW, 1990, BLOOD, V76, P697	33	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27432	27437		10.1074/jbc.271.44.27432	http://dx.doi.org/10.1074/jbc.271.44.27432			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910323	hybrid			2022-12-27	WOS:A1996VQ67900041
J	Satoh, T; Yamada, M; Iwasaki, T; Mori, M				Satoh, T; Yamada, M; Iwasaki, T; Mori, M			Negative regulation of the gene for the preprothyrotropin-releasing hormone from the mouse by thyroid hormone requires additional factors in conjunction with thyroid hormone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT GENE; MESSENGER-RNA; RETINOIC ACID; PARAVENTRICULAR NUCLEUS; RESPONSE ELEMENTS; PROMOTER ACTIVITY; RAT HYPOTHALAMUS; C-ERBA; TRANSCRIPTION; BINDING	To gain additional insights into the negative gene regulatory action by triiodothyronine (T-3), we isolated a 2-kilobase pair 5'-flanking region of the mouse preprothyrotropin-releasing hormone (ppTRH) gene and characterized the DNA elements mediating inhibitory regulation by T-3 in the promoter region. In GH(4)C(1) cells, the expression of the 2-kilobase pair mouse ppTRH 5'-flanking region fused to the luciferase reporter gene occurred by transfection and was significantly suppressed by T-3. In contrast, T-3 suppression was not observed in T-3 receptor (T(3)R)-deficient CV-1 cells, suggesting that T(3)Rs were required for the negative regulation. Cotransfected mouse T(3)R alpha 1, beta 1, and beta 2 possessed indistinguish able potency for the negative regulation. Deletion analysis localized the element mediating the negative regulation to the region between -83 and +46, and the sequence downstream of the transcription start site (TSS) between +12 and +46 was found to be essential for the inhibitory regulation. In mobility shift assays, only T(3)R monomers bound to the element containing a T-3 response element half-site at -57. No apparent T(3)R binding was observed to the element downstream of TSS. Neither the T-3 response element half-site nor the element downstream of the TSS confer T-3 suppression individually in heterologous promoters. These results indicate that the negative regulation of murine ppTRH gene by T-3 might be mediated by the cooperation of T(3)R monomers with unknown factor(s) interacting with the element downstream of the TSS.			Satoh, T (corresponding author), GUNMA UNIV, SCH MED, DEPT INTERNAL MED 1, 3-39-15 SHOWA MACHI, MAEBASHI, GUMMA 371, JAPAN.							AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BODENNER DL, 1991, J BIOL CHEM, V266, P21666; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNSIDE J, 1989, J BIOL CHEM, V264, P6886; CARR FE, 1992, J BIOL CHEM, V267, P18689; CARR FE, 1989, MOL ENDOCRINOL, V3, P709, DOI 10.1210/mend-3-4-709; COOK CB, 1992, ENDOCRINOLOGY, V130, P1077, DOI 10.1210/en.130.2.1077; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FENG P, 1994, BIOCHEM BIOPH RES CO, V200, P171, DOI 10.1006/bbrc.1994.1430; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HODIN RA, 1990, J CLIN INVEST, V85, P101, DOI 10.1172/JCI114398; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; HOLLENBERG AN, 1995, MOL ENDOCRINOL, V9, P540, DOI 10.1210/me.9.5.540; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JACKSON IMD, 1982, NEW ENGL J MED, V306, P145, DOI 10.1056/NEJM198201213060305; KOLLER KJ, 1987, P NATL ACAD SCI USA, V84, P7329, DOI 10.1073/pnas.84.20.7329; KRISHNA V, 1989, P NATL ACAD SCI USA, V86, P9114; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LECHAN RM, 1986, SCIENCE, V231, P159, DOI 10.1126/science.3079917; LEE SL, 1988, J BIOL CHEM, V263, P16604; LEZOUALCH F, 1992, MOL ENDOCRINOL, V6, P1797, DOI 10.1210/me.6.11.1797; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; NG L, 1995, MOL ENDOCRINOL, V9, P1202, DOI 10.1210/me.9.9.1202; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OPPENHEIMER JH, 1987, ENDOCR REV, V8, P288, DOI 10.1210/edrv-8-3-288; PARK HY, 1993, MOL ENDOCRINOL, V7, P319, DOI 10.1210/me.7.3.319; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SATOH T, 1992, MOL BRAIN RES, V14, P131, DOI 10.1016/0169-328X(92)90020-C; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SEGERSON TP, 1987, SCIENCE, V238, P78, DOI 10.1126/science.3116669; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; THOMPSON KL, 1992, MOL ENDOCRINOL, V6, P627, DOI 10.1210/me.6.4.627; UMEDA PK, 1990, J BIOL CHEM, V264, P10672; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WOOD WM, 1991, MOL ENDOCRINOL, V5, P1049, DOI 10.1210/mend-5-8-1049; WOOD WM, 1989, J BIOL CHEM, V264, P14840; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAMADA M, 1990, MOL ENDOCRINOL, V4, P551, DOI 10.1210/mend-4-4-551	49	73	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27919	27926		10.1074/jbc.271.44.27919	http://dx.doi.org/10.1074/jbc.271.44.27919			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910392	hybrid			2022-12-27	WOS:A1996VQ67900110
J	Guzov, VM; Houston, HL; Murataliev, MB; Walker, FA; Feyereisen, R				Guzov, VM; Houston, HL; Murataliev, MB; Walker, FA; Feyereisen, R			Molecular cloning, overexpression in Escherichia coli, structural and functional characterization of house fly cytochrome b(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER MITOCHONDRIAL-MEMBRANE; OXIDATION REDUCTION EQUILIBRIUM; PROTON MAGNETIC-RESONANCE; TOTAL ENZYMIC-SYNTHESIS; AMINO-ACID-RESIDUES; BACTERIAL EXPRESSION; MUSCA-DOMESTICA; P450 REDUCTASE; PROTEIN; PURIFICATION	A microsomal cytochrome b(5) cDNA from the house fly, Musca domestica, was cloned and sequenced, The deduced amino acid sequence of the full-length house fly cytochrome b(5) (134 residues) is 48% identical to that of rat microsomal cytochrome b(5). The house fly cyto chrome b(5) protein was overexpressed in Escherichia coli, purified, and characterized. Absorption and EPR spectroscopy reveal properties very similar to cytochromes b(5) from vertebrates, NMR spectra indicate that the orientation of the heme in the protein relative to its alpha,gamma meso axis is about 1:1. A redox potential of -26 mV versus standard hydrogen electrode was measured by cyclic voltammetry on a modified gold electrode in the presence of hexamminechromium(III) chloride. The cytochrome b(5) is reduced by house fly cytochrome P450 reductase in a reconstituted system at a high rate (5.5 s(-1)), and it stimulates heptachlor epoxidation when res constituted with house fly cytochrome P450 reductase, cytochrome P450 6A1, phospholipid, and detergent. Cytochrome b(5) decreases the apparent K-m for P450 reductase and increases the V-max for heptachlor epoxidation at constant cytochrome P450 6A1 concentrations. The results indicate that cytochrome b(5) stimulates a step following the first electron transfer during cytochrome P450 6A1 turnover.	UNIV ARIZONA,DEPT ENTOMOL,TUCSON,AZ 85721; UNIV ARIZONA,DEPT CHEM,TUCSON,AZ 85721	University of Arizona; University of Arizona			Feyereisen, René/Y-7514-2019; Walker, Frances A/O-4395-2016; Feyereisen, René/I-3140-2012	Feyereisen, René/0000-0002-9560-571X; Feyereisen, René/0000-0002-9560-571X	NIDDK NIH HHS [DK 31038] Funding Source: Medline; NIEHS NIH HHS [ES 06694] Funding Source: Medline; NIGMS NIH HHS [GM 39014] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031038, R56DK031038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039014] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN JF, 1994, BIOCHEMISTRY-US, V33, P2171, DOI 10.1021/bi00174a025; BAUER S, 1974, BIOTECHNOL BIOENG, V16, P933, DOI 10.1002/bit.260160707; BLACK SD, 1994, ARCH BIOCHEM BIOPHYS, V310, P126, DOI 10.1006/abbi.1994.1148; BOISPOLTORATSKY R, 1967, EUR J BIOCHEM, V2, P361, DOI 10.1111/j.1432-1033.1967.tb00146.x; BURCH AM, 1990, SCIENCE, V247, P831, DOI 10.1126/science.2154849; ENOCH HG, 1979, J BIOL CHEM, V254, P8976; FEYEREISEN R, 1989, P NATL ACAD SCI USA, V86, P1465, DOI 10.1073/pnas.86.5.1465; FEYEREISEN R, 1993, HDB EXPT PHARM, V105, P311; FUKUSHIMA H, 1981, J BIOL CHEM, V256, P4822; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P5500, DOI 10.1021/bi00475a013; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; GOLLY I, 1988, ARCH BIOCHEM BIOPHYS, V260, P232, DOI 10.1016/0003-9861(88)90445-6; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GRINSTEAD GF, 1982, J BIOL CHEM, V257, P3937; GRUENKE LD, 1995, J BIOL CHEM, V270, P24707, DOI 10.1074/jbc.270.42.24707; HEGESH E, 1986, NEW ENGL J MED, V314, P757, DOI 10.1056/NEJM198603203141206; HEWSON R, 1993, PROTEIN ENG, V6, P953, DOI 10.1093/protein/6.8.953; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; Hodgson E, 1985, COMPREHENSIVE INSECT, P225; HOLMANS PL, 1994, ARCH BIOCHEM BIOPHYS, V312, P554, DOI 10.1006/abbi.1994.1345; ITO A, 1980, J BIOCHEM, V87, P63, DOI 10.1093/oxfordjournals.jbchem.a132753; KATAGIRI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P343, DOI 10.1006/abbi.1995.1173; KAWANO T, 1994, J BIOL CHEM, V269, P9024; KELLER RM, 1972, BIOCHIM BIOPHYS ACTA, V285, P326, DOI 10.1016/0005-2795(72)90317-0; KELLER RM, 1980, BIOCHIM BIOPHYS ACTA, V621, P204, DOI 10.1016/0005-2795(80)90172-5; KOENER JF, 1993, INSECT BIOCHEM MOLEC, V23, P439, DOI 10.1016/0965-1748(93)90051-S; KULA ME, 1995, J MOL EVOL, V41, P430, DOI 10.1007/BF00160314; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; LAMAR GN, 1981, J BIOL CHEM, V256, P6075; LEE KB, 1991, J AM CHEM SOC, V113, P3576, DOI 10.1021/ja00009a054; LEE KB, 1990, BIOCHEMISTRY-US, V29, P9623, DOI 10.1021/bi00493a017; LEVIN RJ, 1989, NUCLEIC ACIDS RES, V13, P631; LLOYD E, 1994, BIOCHEMISTRY-US, V33, P11432, DOI 10.1021/bi00204a005; LOOMAN AC, 1987, EMBO J, V6, P2489, DOI 10.1002/j.1460-2075.1987.tb02530.x; MATHEWS FS, 1985, PROG BIOPHYS MOL BIO, V45, P1, DOI 10.1016/0079-6107(85)90004-5; MATHEWS FS, 1979, PORPHYRINS, V7, P107; MCFADDEN KA, 1979, INSECT BIOCHEM, V9, P301, DOI 10.1016/0020-1790(79)90010-6; MCLACHLAN SJ, 1988, BIOCHIM BIOPHYS ACTA, V957, P430, DOI 10.1016/0167-4838(88)90234-8; NOSHIRO M, 1981, EUR J BIOCHEM, V116, P521, DOI 10.1111/j.1432-1033.1981.tb05367.x; OKADA Y, 1969, J BIOCHEM-TOKYO, V65, P581, DOI 10.1093/oxfordjournals.jbchem.a129051; OMURA T, 1964, J BIOL CHEM, V239, P2370; PALTAUF F, 1974, J BIOL CHEM, V249, P2661; PASSON PG, 1972, BIOCHIM BIOPHYS ACTA, V275, P51, DOI 10.1016/0005-2728(72)90023-0; PEISACH J, 1973, ANN NY ACAD SCI, V206, P310, DOI 10.1111/j.1749-6632.1973.tb43219.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POMPON D, 1984, J BIOL CHEM, V259, P5377; REID LS, 1982, J AM CHEM SOC, V104, P841, DOI 10.1021/ja00367a032; REID LS, 1982, J AM CHEM SOC, V104, P7516, DOI 10.1021/ja00390a021; RIVERA M, 1994, BIOCHEMISTRY-US, V33, P2161, DOI 10.1021/bi00174a024; RIVERA M, 1992, BIOCHEMISTRY-US, V31, P12233, DOI 10.1021/bi00163a037; RODGERS KK, 1991, J AM CHEM SOC, V113, P9419, DOI 10.1021/ja00024a087; Sambrook J., 2002, MOL CLONING LAB MANU; SANBORN RC, 1950, J GEN PHYSIOL, V33, P579, DOI 10.1085/jgp.33.5.579; Sanders J., 1993, MODERN NMR SPECTROSC, P163; SATTERLEE JD, 1986, MET IONS BIOL SYST, V21, P121; SHICHI H, 1962, J BIOL CHEM, V237, P2959; SHINZAWA K, 1985, BIOCHIM BIOPHYS ACTA, V833, P151; SMITH MA, 1994, BIOCHEM J, V303, P73, DOI 10.1042/bj3030073; SPATZ L, 1971, P NATL ACAD SCI USA, V68, P1042, DOI 10.1073/pnas.68.5.1042; STRITTMATTER P, 1956, J BIOL CHEM, V221, P253; TAMBURINI PP, 1986, BIOCHEM BIOPH RES CO, V134, P519, DOI 10.1016/S0006-291X(86)80451-X; VERGERES G, 1995, BIOCHIMIE, V77, P604, DOI 10.1016/0300-9084(96)88176-4; VONBODMAN SB, 1986, P NATL ACAD SCI USA, V83, P9443; WALKER FA, 1988, J AM CHEM SOC, V110, P6234, DOI 10.1021/ja00226a045; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WHEELOCK GD, 1989, INSECT BIOCHEM, V19, P481, DOI 10.1016/0020-1790(89)90030-9; Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022; YOSHIDA Y, 1974, J BIOCHEM, V75, P1211, DOI 10.1093/oxfordjournals.jbchem.a130504; ZHANG ML, 1994, ARCH INSECT BIOCHEM, V27, P205, DOI 10.1002/arch.940270306	71	61	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26637	26645		10.1074/jbc.271.43.26637	http://dx.doi.org/10.1074/jbc.271.43.26637			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900138				2022-12-27	WOS:A1996VP23300032
J	Lim, BL; Reid, KBM; Ghebrehiwet, B; Peerschke, EIB; Leigh, LAE; Preissner, KT				Lim, BL; Reid, KBM; Ghebrehiwet, B; Peerschke, EIB; Leigh, LAE; Preissner, KT			The binding protein for globular heads of complement C1q, gC1qR - Functional expression and characterization as a novel vitronectin binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PROTEIN; ALPHA(V)BETA(5) INTEGRIN; RECEPTOR; IDENTIFICATION; LOCALIZATION; ASSOCIATION; COMPLEXES; SURFACE; SYSTEM; CELLS	A binding protein for the globular head domains of complement component C1q, designated gC1qR, recently described to be present on vascular and blood cells (Ghebrehiwet, B., Lim, B,-L., Peerschke, E. I. B., Willis, A. C., and Reid, K. B. M. (1994) J. Exp. Med. 179, 1809-1821 was expressed in recombinant form in bacteria to investigate its functional and structural properties. The recombinant gC1qR was found to be functional because tetramerization of the 24.3-kDa polypeptide occurred as described for the native protein, and the binding of the ligand C1q by recombinant gC1qR was indistinguishable from binding shown by gC1qR isolated from Raji cells, Recombinant gC1qR immobilized to microspheres was used to search for additional binding proteins unrelated to C1q. Surprisingly, it was found that vitronectin or complexes containing vitronectin were retained from plasma or serum, and subsequent analysis revealed the specific binding of the ternary vitronectin-thrombin-antithrombin complex to gC1qR. Because the thrombin antithrombin complex was unable to interact with gC1qR, direct binding with vitronectin was investigated in a purified system. The heparin binding multimeric form of vitronectin but not the plasma form of vitronectin was found to bind specifically to gC1qR isolated from Raji cell membrane as well as to recombinant gC1qR. This interaction was saturable (K-D similar to 20 nM) and inhibitable by glycosaminoglycans such as heparin but not by chondroitin sulfate. C1q and vitronectin did not compete with each other for binding to gC1qR, and both ligands seem to interact with different parts of the gC1qR because a truncated version of recombinant gC1qR lacking the N-terminal 22-amino acid portion hardly interacted with vitronectin but bound C1q as well as the intact gC1qR. These findings establish gC1qR as a novel vitronectin-binding protein that may participate in the clearance of vitronectin containing complexes or opsonized particles or cooperate with vitronectin in the inhibition of complement-mediated cytolysis.	MAX PLANCK INST, KERCKHOFF KLIN, HAEMOSTASIS RES UNIT, D-61231 BAD NAUHEIM, GERMANY; UNIV HONG KONG, DEPT ZOOL, HONG KONG, HONG KONG; UNIV OXFORD, DEPT BIOCHEM, MED RES CTR, IMMUNOCHEM UNIT, OXFORD OX1 3QU, ENGLAND; SUNY STONY BROOK, DEPT MED, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	Kerckhoff Clinic; Max Planck Society; University of Hong Kong; University of Oxford; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Lim, Boon Leong/D-3104-2009	Lim, Boon Leong/0000-0002-2720-2353				DEBOER HC, 1992, J BIOL CHEM, V267, P2264; DEBOER HC, 1993, J BIOL CHEM, V268, P1279; DEITCH EA, 1993, ARCH SURG-CHICAGO, V128, P1222; EGGLETON P, 1995, J CLIN INVEST, V95, P1569, DOI 10.1172/JCI117830; ERDEI A, 1988, BIOCHEM J, V255, P493; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; Kanse SM, 1996, EXP CELL RES, V224, P344, DOI 10.1006/excr.1996.0144; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DA, 1987, J BIOL CHEM, V262, P16343; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PARKER CJ, 1988, BLOOD, V71, P86; Preissner K.T., 1993, NATURAL IMMUNE SYSTE, P281; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; Reid K B, 1989, Behring Inst Mitt, P8; REID KBM, 1981, METHOD ENZYMOL, V80, P16; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SCHREIBER RD, 1984, SPRINGER SEMIN IMMUN, V7, P221, DOI 10.1007/BF01893021; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENBERG RH, 1996, MOL IMMUNOL S1, V33, P21; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; WALPORT MJ, 1988, ARTHRITIS RHEUM, V31, P153, DOI 10.1002/art.1780310201; WEI Y, 1994, J BIOL CHEM, V269, P32380	28	92	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26739	26744		10.1074/jbc.271.43.26739	http://dx.doi.org/10.1074/jbc.271.43.26739			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900153	hybrid			2022-12-27	WOS:A1996VP23300047
J	Rhee, KY; Parekh, BS; Hatfield, GW				Rhee, KY; Parekh, BS; Hatfield, GW			Leucine-responsive regulatory protein-DNA interactions in the leader region of the ilvGMEDA operon of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SYNTHASE ISOZYMES; GLOBAL REGULATOR; RNA-POLYMERASE; ILVIH OPERON; LRP; TRANSCRIPTION; BINDING; K-12; SEQUENCE; PROMOTER	The leucine-responsive regulatory protein (Lrp) regulates the expression of many operons in Escherichia coli including several involved in the metabolism of the branched-chain amino acids, L-isoleucine, L-valine, and L-leucine. The ilvGMEDA operon contains the genes for four of the five enzymes of the common pathway for the biosynthesis of these amino acids, A high affinity, consensus-like Lrp-DNA binding site has been identified at an unusual position in the leader region of this operon 226 base pairs downstream of the transcriptional initiation site between the attenuator and the ilvG gene, Binding to this site facilitates the cooperative binding of a second Lrp protomer to an adjacent, upstream, secondary site, At higher Lrp concentrations, binding to a third site is observed, Chemical, enzymatic, and alkylation protection and interference footprinting experiments demonstrate that the Lrp homodimer contacts the DNA helix at symmetrical half-sites present in adjacent major grooves and that the primary and secondary binding sites are separated by one helical turn and aligned along the same face of the DNA helix, In vivo, Lrp represses transcription through the leader-attenuator region of the ilvGMEDA operon, Lrp-dependent production of attenuated RNA transcripts is also observed in vitro. No transcriptional effects are observed, in vivo or in vitro, in the absence of an intact Lrp primary binding site, A possible physiological role for Lrp in the regulation of ilvGMEDA operon expression is discussed.	UNIV CALIF IRVINE, DEPT MICROBIOL & MOL GENET, COLL MED, IRVINE, CA 92697 USA	University of California System; University of California Irvine					NIGMS NIH HHS [GM49388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JJ, 1976, J BACTERIOL, V126, P80, DOI 10.1128/JB.126.1.80-90.1976; BARAK Z, 1987, J BACTERIOL, V169, P3750, DOI 10.1128/jb.169.8.3750-3756.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; COLE JR, 1986, P NATL ACAD SCI USA, V83, P4129, DOI 10.1073/pnas.83.12.4129; CUI YH, 1995, J BACTERIOL, V177, P4872, DOI 10.1128/jb.177.17.4872-4880.1995; Cui YH, 1996, J BIOL CHEM, V271, P6611, DOI 10.1074/jbc.271.12.6611; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDBERG D, 1995, J BACTERIOL, V177, P1624, DOI 10.1128/jb.177.6.1624-1626.1995; HANEY SA, 1992, J BACTERIOL, V174, P108, DOI 10.1128/jb.174.1.108-115.1992; HAUSER CA, 1985, J BIOL CHEM, V260, P1765; Hildebrand F. B., 1974, INTRO NUMERICAL ANAL; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; LAWTHER RP, 1981, P NATL ACAD SCI-BIOL, V78, P922, DOI 10.1073/pnas.78.2.922; LAWTHER RP, 1980, P NATL ACAD SCI-BIOL, V77, P1862, DOI 10.1073/pnas.77.4.1862; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2132; LIN RT, 1992, J BACTERIOL, V174, P1948, DOI 10.1128/jb.174.6.1948-1955.1992; LIN RT, 1990, J BACTERIOL, V172, P4529; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller J.H., 1972, EXPT MOL GENETICS; NEWMAN EB, 1995, ANNU REV MICROBIOL, V49, P747, DOI 10.1146/annurev.mi.49.100195.003531; PAGEL JM, 1991, J BIOL CHEM, V266, P1985; Parekh BS, 1996, P NATL ACAD SCI USA, V93, P1173, DOI 10.1073/pnas.93.3.1173; PLATKO JV, 1990, J BACTERIOL, V172, P4563, DOI 10.1128/jb.172.8.4563-4570.1990; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; RICCA E, 1989, J BACTERIOL, V171, P1658, DOI 10.1128/jb.171.3.1658-1664.1989; Sambrook J., 2002, MOL CLONING LAB MANU; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; Umbarger HE, 1987, ESCHERICHIA COLI SAL, P352; WANG Q, 1993, J MOL BIOL, V229, P306, DOI 10.1006/jmbi.1993.1036; WANG Q, 1993, EMBO J, V12, P2495, DOI 10.1002/j.1460-2075.1993.tb05904.x; WEK RC, 1986, NUCLEIC ACIDS RES, V14, P2763, DOI 10.1093/nar/14.6.2763; WEK RC, 1988, J MOL BIOL, V203, P643, DOI 10.1016/0022-2836(88)90199-4; WEK RC, 1985, NUCLEIC ACIDS RES, V13, P3995, DOI 10.1093/nar/13.11.3995; WILLINS DA, 1991, J BIOL CHEM, V266, P10768; WINKELMAN JW, 1990, J BIOL CHEM, V265, P10055; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365	42	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26499	26507		10.1074/jbc.271.43.26499	http://dx.doi.org/10.1074/jbc.271.43.26499			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900118	hybrid			2022-12-27	WOS:A1996VP23300012
J	Chen, AP; Beno, DWA; Davis, BH				Chen, AP; Beno, DWA; Davis, BH			Suppression of stellate cell type I collagen gene expression involves AP-2 transmodulation of nuclear factor-1-dependent gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) PROMOTER; TRANSGENIC MICE	The regulation of collagen gene expression was studied in culture-activated rat hepatic stellate cells, the fibrogenic effector cell involved in hepatic fibrogenesis, Treatment of cells with a 5-lipoxygenase-specific inhibitor caused a reduction in alpha I(I) collagen mRNA transcript abundance, which suggested that leukotriene production was involved in maintaining the activated cell's high level of collagen mRNA production. The underlying mechanism involved a decrease in collagen gene transcription, Suppression of gene transcription was localized to an nuclear factor-1 (NF-1) binding domain in the proximal promoter and an AP-2 binding domain adjacent to it, Gel retardation assays demonstrated that an increase in AP-2 binding adjacent to the NF-1 site was likely to be the transmodulator responsible for the suppression of the NF-1-dependent gene expression. The data suggest that post translational alterations in AP-2 activity are responsible for this unappreciated mechanism of regulating the collagen gene.	UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637	University of Chicago					NIDDK NIH HHS [DK 02022, DK 40223, DK 42086] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK040223, P30DK042086, K08DK002022] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENO DWA, 1995, AM J PHYSIOL-CELL PH, V268, pC604, DOI 10.1152/ajpcell.1995.268.3.C604; BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; COURTOIS SJ, 1990, NUCLEIC ACIDS RES, V18, P57, DOI 10.1093/nar/18.1.57; Davis BH, 1996, J BIOL CHEM, V271, P11039, DOI 10.1074/jbc.271.19.11039; DAVIS BH, 1990, J CLIN INVEST, V86, P2062, DOI 10.1172/JCI114943; DUFAU ML, 1995, J STEROID BIOCHEM, V53, P283, DOI 10.1016/0960-0760(95)00115-G; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; LASKIN DL, 1990, SEMIN LIVER DIS, V10, P293, DOI 10.1055/s-2008-1040485; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; RITZENTHALER JD, 1993, J BIOL CHEM, V268, P13625; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066	15	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25994	25998		10.1074/jbc.271.42.25994	http://dx.doi.org/10.1074/jbc.271.42.25994			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824237	hybrid			2022-12-27	WOS:A1996VN18000043
J	Bunnell, SC; Henry, PA; Kolluri, R; Kirchhausen, T; Rickles, RJ; Berg, LJ				Bunnell, SC; Henry, PA; Kolluri, R; Kirchhausen, T; Rickles, RJ; Berg, LJ			Identification of Itk/Tsk Src homology 3 domain ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; WISKOTT-ALDRICH SYNDROME; CELL ANTIGEN RECEPTOR; C-CBL PROTOONCOGENE; SH3 DOMAINS; T-CELLS; PROTEIN PRODUCT; K-PROTEIN; B-CELLS	The tyrosine kinase Itk/Tsk is a T cell specific analog of Btk, the tyrosine kinase defective in the human immunodeficiency X-Linked agammaglobulinemia and in xid mice. T lymphocytes from Itk-deficient mice are refractory to mitogenic stimuli delivered through the T cell receptor (TCR). To gain insights into the biochemical role of Itk, the binding properties of the Itk SH3 domain were examined. An optimal Itk SH3 binding motif was derived by screening biased phage display libraries; peptides based on this motif bound with high affinity and selectivity to the Itk SH3 domain. Initial studies with T cell lysates indicated that the Itk SH3 domain bound Cbl, Fyn, and other tyrosine phosphoproteins from TCR-stimulated jurkat cells. Under conditions of increased detergent stringency Sam 68, Wiskott-Aldrich Syndrome protein, and hnRNP-K, but not Cbl and Fyn, were bound to the Itk SH3 domain. By examining the ability of different SH3 domains to interact with deletion variants of Sam 68 and WASP, we demonstrated that the Itk-SH3 domain and the SH3 domains of Src family kinases bind to overlapping but distinct sets of proline-rich regions in Sam 68 and WASP.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138; ARIAD PHARMACEUT INC,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Takeda Pharmaceutical Company Ltd; Takeda Oncology; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)				Bunnell, Stephen/0000-0001-6887-0828	NIAID NIH HHS [AI37584] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037584] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gibson S, 1996, J IMMUNOL, V156, P2716; GIBSON S, 1993, BLOOD, V82, P1561; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASBOLD J, 1994, EUR J IMMUNOL, V24, P152, DOI 10.1002/eji.1830240123; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOBERT O, 1994, J BIOL CHEM, V269, P20225; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; LIM H, 1994, PROTEIN SCI, V3735, P2233; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; MACHIDE M, 1995, ONCOGENE, V11, P619; MAHAJAN S, 1995, MOL CELL BIOL, V15, P5304; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PARSEY MV, 1993, J IMMUNOL, V151, P1881; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Ribon V, 1996, MOL CELL BIOL, V16, P45; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANAKA N, 1993, FEBS LETT, V324, P1, DOI 10.1016/0014-5793(93)81520-A; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEISS A, 1984, J IMMUNOL, V133, P123; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; WIJFFELS GL, 1992, EXP PARASITOL, V74, P87, DOI 10.1016/0014-4894(92)90142-W; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YANG WY, 1995, J BIOL CHEM, V270, P20832, DOI 10.1074/jbc.270.35.20832; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	77	148	148	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25646	25656		10.1074/jbc.271.41.25646	http://dx.doi.org/10.1074/jbc.271.41.25646			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810341	hybrid			2022-12-27	WOS:A1996VL69300085
J	Griac, P; Swede, MJ; Henry, SA				Griac, P; Swede, MJ; Henry, SA			The role of phosphatidylcholine biosynthesis in the regulation of the INO1 gene of yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-PATHWAY REGULATION; SACCHAROMYCES-CEREVISIAE; PHOSPHOLIPID BIOSYNTHESIS; INOSITOL SYNTHESIS; CHOLINE KINASE; MUTANTS; METHYLATION; EXPRESSION; DEFICIENT; GROWTH	In yeast, as in other eukaryotes, phosphatidylcholine (PC) can be synthesized via methylation of phosphatidylethanolamine or from free choline via the CDP-choline pathway, In yeast, PC biosynthesis is required for the repression of the phospholipid biosynthetic genes, including the INO1 gene, in response to inositol. In this study, we analyzed the effect of mutations in genes encoding enzymes involved in PC biosynthesis on the transcriptional regulation of phospholipid biosynthetic genes. We report that repression of INO1 transcription in response to inositol is clearly dependent on ongoing PC biosynthesis, but it is independent of the route of synthesis. Our results also suggest that intermediates in the phosphatidylethanolamine methylation and CDP-choline pathways are not responsible for generating the regulatory signal that results in repression of INO1 and other coregulated genes of phospholipid biosynthesis. Furthermore, repression of INO1 is not tightly correlated to the proportion of PC in the total cellular phospholipids, Rather, we report that when the rate of synthesis of PC becomes growth limiting, the addition of inositol fails to repress the phospholipid biosynthetic genes, but when the rate of PC synthesis is sufficient to sustain normal growth, the addition of inositol to the growth medium has the effect of repressing INO1 and other phospholipid biosynthetic genes.	CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213	Carnegie Mellon University			Swede, Marci/AAD-3921-2021; , Peter/ABA-9227-2020; Henry, Susan/K-5464-2014	Swede, Marci/0000-0002-3003-4258; , Peter/0000-0003-3538-0405; 	NIGMS NIH HHS [GM-19629] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM019629] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BJORNSTAD P, 1966, J LIPID RES, V7, P38; BREMER J, 1960, BIOCHIM BIOPHYS ACTA, V37, P173, DOI 10.1016/0006-3002(60)90104-9; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; GRIAC P, 1996, NATO ASI SER, P339; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HUDAK KA, 1994, GENETICS, V136, P475; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; LAMPING E, 1995, GENETICS, V137, P55; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; LI ZY, 1993, MOL GEN GENET, V241, P680, DOI 10.1007/BF00279911; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sherman F., 1978, METHODS YEAST GENETI; STEINER MR, 1972, BIOCHIM BIOPHYS ACTA, V260, P222, DOI 10.1016/0005-2760(72)90035-5; SUMMERS E, 1989, THESIS A EINSTEIN CO; SUMMERS EF, 1988, GENETICS, V120, P909; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1	30	61	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25692	25698		10.1074/jbc.271.41.25692	http://dx.doi.org/10.1074/jbc.271.41.25692			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810347	hybrid			2022-12-27	WOS:A1996VL69300091
J	Raveh, T; Hovanessian, AG; Meurs, EF; Sonenberg, N; Kimchi, A				Raveh, T; Hovanessian, AG; Meurs, EF; Sonenberg, N; Kimchi, A			Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; NF-KAPPA-B; MONOCLONAL-ANTIBODIES; GENE-TRANSFER; HELA-CELLS; P68 KINASE; BINDING; PKR; EXPRESSION; ACTIVATION	The antiproliferative functions of interferons result from specific effects that these cytokines exert on several cell cycle-controlling genes. The possible coupling between the interferon-responsive genes that are directly transactivated by the interferon signaling and the genes that constitute the basic machinery of the cell cycle is not clear yet, We report in this work that interferon-induced double-stranded RNA-activated kinase (PKR) is one of the specific mediators of the antiproliferative effects of the cytokine. Transfections of M1 myeloid leukemia cells with two catalytically inactive mutant forms of PKR abrogated the ability of interferon to suppress c-Myc without interfering with the pRB/cyclin D responses. As a consequence, these genetically manipulated cells displayed a small but significant reduction in their growth sensitivity to interferons, a phenotype that characterizes a single pathway disruption. Transfection of the parental M1 cells with the functional wildtype human PKR restricted their proliferation in the absence of interferons. This PKR-mediated growth inhibition could be efficiently rescued by the ectopic expression of deregulated c-myc. Taken together these results prove the existence of direct or indirect links between PKR and c-Myc suppression, thereby placing this gene along one of the complementary growth suppressive pathways that are triggered by interferons.	WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL; INST PASTEUR,CNRS,UA 1157,UNIT VIROL CELLULAR IMMUNOL,F-75015 PARIS,FRANCE; MCGILL UNIV,CTR CANC,FAC MED,MONTREAL,PQ H3G 1Y6,CANADA	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; McGill University								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DEBENEDETTI A, 1984, NATURE, V311, P79, DOI 10.1038/311079a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; ICHIKAWA Y, 1969, CELL PHYSL, V74, P233; KADEREIT S, 1994, J INTERFERON RES, V14, P251, DOI 10.1089/jir.1994.14.251; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KLEIN E, 1968, CANCER RES, V28, P1300; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MEURS EF, 1992, J VIROL, V66, P5804; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RESNITZKY D, 1991, CELL GROWTH DIFFER, V2, P33; RICE AP, 1985, J VIROL, V54, P894, DOI 10.1128/JVI.54.3.894-898.1985; RICE AP, 1989, J BIOL CHEM, V264, P20632; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SAMUEL CE, 1984, J BIOL CHEM, V259, P3451; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; YARDEN A, 1986, SCIENCE, V234, P1419, DOI 10.1126/science.3097823	41	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25479	25484		10.1074/jbc.271.41.25479	http://dx.doi.org/10.1074/jbc.271.41.25479			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810318	hybrid			2022-12-27	WOS:A1996VL69300062
J	Wang, GF; Tamas, MJ; Hall, MJ; PascualAhuir, A; Perlin, DS				Wang, GF; Tamas, MJ; Hall, MJ; PascualAhuir, A; Perlin, DS			Probing conserved regions of the cytoplasmic LOOP1 segment linking transmembrane segments 2 and 3 of the Saccharomyces cerevisiae plasma membrane H+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANT PMA1 MUTANTS; SARCOPLASMIC-RETICULUM; DIRECTED MUTAGENESIS; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; SCHIZOSACCHAROMYCES-POMBE; YEAST; SITES; MUTATIONS; CA-2+-ATPASE	Genetic probing was used to examine conserved amino acid clusters in the first cytoplasmic loop domain (LOOP1) linking transmembrane segments 2 and 3 of the plasma membrane H+-ATPase from Saccharomyces cerevisiae. Deletion of the LOOP1 region in PMA1 resulted in a defective enzyme. Scanning alanine mutagenesis of conserved residues produced lethal cell phenotypes in 14 of 26 amino acids, suggesting major enzyme defects. Most viable mutants showed growth characteristics that were comparable to wild type. Two mutations, I183A and D185A, produced reduced growth rates, hygromycin B resistance, and low pH sensitivity, which are phenotypes associated with defects in the H+-ATPase. However, both mutant enzymes displayed near-normal kinetics for ATP hydrolysis in vitro. Localized random mutagenesis was also performed at sites Glu(195), Val(196) and Ile(210), which all showed lethal phenotypes upon conversion to alanine. Amino acids with polar side groups could substitute for Glu(195), while Val(196) could not tolerate polar side group moieties, Nine mutations at Ile(210) proved lethal, including K, R, E, P, H, N, V, G, and A, while functional enzyme was obtained with S, C, M, and L. Normal rates and extents of pH gradient formation were observed for all mutant enzymes, except I183A and D185A. Detailed analysis of the I183A enzyme indicated that it hydrolyzed ATP like wild type, but it appeared to inefficiently couple ATP hydrolysis to proton transport. In total, these results affirm that conserved amino acids in LOOP1 are important to H+-ATPase function, and purturbations in this region can alter the efficiency of energy coupling.	PUBL HLTH RES INST,NEW YORK,NY 10016				Perlin, David S/K-4013-2015; Pascual-ahuir, Amparo/K-1338-2014; Tamas, Markus J/E-8183-2010	Tamas, Markus J/0000-0002-0762-7848; PASCUAL-AHUIR, AMPARO/0000-0001-6173-1526	NIGMS NIH HHS [GM 38225] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038225] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BANDELL M, 1995, BIOCHIM BIOPHYS ACTA, V1280, P81; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; GHISLAIN M, 1987, J BIOL CHEM, V262, P17549; GHISLAIN M, 1992, EUR J BIOCHEM, V209, P275, DOI 10.1111/j.1432-1033.1992.tb17286.x; GOFFEAU A, 1990, J BIOL CHEM, V265, P15508; HARRIS S, 1993, GENETICS, V135, P55; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HARRIS SL, 1991, J BIOL CHEM, V266, P24439; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCUSKER JH, 1987, MOL CELL BIOL, V7, P4082, DOI 10.1128/MCB.7.11.4082; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; NA SQ, 1993, J BIOL CHEM, V268, P11792; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PERLIN DS, 1988, J BIOL CHEM, V263, P18118; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; RAO R, 1992, BIOPHYS J, V62, P228, DOI 10.1016/S0006-3495(92)81808-8; RESTALL CJ, 1989, BIOCHEM SOC T, V17, P509, DOI 10.1042/bst0170509; SACHS G, 1995, ANNU REV PHARMACOL, V35, P277, DOI 10.1146/annurev.pa.35.040195.001425; SCOTT TL, 1982, J MEMBRANE BIOL, V64, P137, DOI 10.1007/BF01870879; SERRANO R, 1989, BIOCHEM SOC T, V17, P973, DOI 10.1042/bst0170973; SERRANO R, 1990, BIOCHIM BIOPHYS ACTA, V1018, P195, DOI 10.1016/0005-2728(90)90247-2; SETOYOUNG D, 1994, J BIOL CHEM, V269, P23988; SetoYoung D, 1996, J BIOL CHEM, V271, P581, DOI 10.1074/jbc.271.1.581; SETOYOUNG D, 1991, J BIOL CHEM, V266, P1383; TAYLOR WR, 1989, EUR J BIOCHEM, V179, P241, DOI 10.1111/j.1432-1033.1989.tb14547.x; TOROK K, 1988, EUR J BIOCHEM, V173, P361, DOI 10.1111/j.1432-1033.1988.tb14006.x; WACH A, 1992, J BIOENERG BIOMEMBR, V24, P309; Wach A, 1996, BIOCHEMISTRY-US, V35, P883, DOI 10.1021/bi951998r; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	44	27	27	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25438	25445		10.1074/jbc.271.41.25438	http://dx.doi.org/10.1074/jbc.271.41.25438			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810313	hybrid			2022-12-27	WOS:A1996VL69300057
J	Chen, G; Oh, S; Monia, BP; Stacey, DW				Chen, G; Oh, S; Monia, BP; Stacey, DW			Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POINT MUTATION; GENE FAMILY; CELL-PROLIFERATION; ONCOGENE PROTEINS; MESSENGER-RNA; NUDE-MICE; EXPRESSION; INHIBITION; GROWTH; REQUIREMENT	Although members of the RAS protein family (Ha-, Ki-, and N-RAS) are known to play a key role in normal cell proliferation and to be frequently mutated in naturally occurring tumors, it remains unclear which of these proteins functions to regulate growth in normal cells, Gene-specific oligonucleotides (oligos) against c-Ki-RAS (ISIS 6957), c-Ha-RAS (ISIS 2503), and oncogenic Ha-RAS (ISIS 2570) were used to analyze the requirement for individual RAS proteins in the proliferation of diploid human lung fibroblasts (MRC-5), and human bladder carcinoma cell lines with (T24) or without (J-82) a RAS mutation. The oncogenic Ha RAS oligo substantially inhibited T24 cell proliferation, whereas the c-Ki-RAS and control (ISIS 1966) oligos had little effect, Interestingly, in MRC-5 cells the c-Ki-RAS but not c-Ha-RAS oligo was effective in inhibiting cell proliferation, No inhibition was seen in the J-82 cells with either oligo, In Western analysis, p21 RAS protein was decreased following treatment with the oncogenic Ha-RAS oligo in T24 cells or the c-Ki-RAS oligo in MRC-B cells, whereas no reductions were observed in J-82 cells with either oligo, The specificity of these oligos was demonstrated in Northern analyses in which both Ha-RAS and Hi-RAS oligo treatment resulted in reduced levels of their respective mRNAs in all three cell lines, whereas the mutant Ha-RAS mRNA in T24 cells was most effectively reduced with the oncogenic Ha-RAS oligo, These results demonstrate that oncogenic Ha-RAS plays an important role in the proliferation of T24 cells, whereas c-Ki-RAS contributes predominantly to the proliferation of normal MRC 5 cells.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195; ISIS PHARMACEUT,CARLSBAD,CA 92008	Cleveland Clinic Foundation; Isis Pharmaceuticals Inc					NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT CF, 1996, ANTISENSE THERAPEUTI; BIZUB D, 1987, ONCOGENE, V1, P131; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FOX PL, 1994, ONCOGENE, V9, P3519; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GRAY GD, 1993, CANCER RES, V53, P577; HELENE C, 1994, EUR J CANCER, V30A, P1721, DOI 10.1016/0959-8049(93)E0352-Q; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; LOWRY DR, 1991, TRENDS GENET, V7, P346; LOWY DR, 1986, CANCER SURV, V5, P275; MARSHALL CJ, 1991, TRENDS GENET, V7, P791; MIZUKAMI Y, 1988, CANCER, V61, P873, DOI 10.1002/1097-0142(19880301)61:5<873::AID-CNCR2820610504>3.0.CO;2-W; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; Sambrook J., 1989, MOL CLONING; SHIMIZU M, 1990, HUM PATHOL, V21, P607, DOI 10.1016/S0046-8177(96)90006-4; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SHWAB G, 1994, P NATL ACAD SCI USA, V91, P10460; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STACEY DW, 1987, EXP CELL RES, V171, P232, DOI 10.1016/0014-4827(87)90266-7; STACEY DW, 1988, COLD SPRING HARB SYM, V3, P871; WILLUMSEN BM, 1992, RAS TRANSFORMING PRO	42	62	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28259	28265		10.1074/jbc.271.45.28259	http://dx.doi.org/10.1074/jbc.271.45.28259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910444	hybrid			2022-12-27	WOS:A1996VU03300044
J	Lee, K; Du, C; Horn, M; Rabinow, L				Lee, K; Du, C; Horn, M; Rabinow, L			Activity and autophosphorylation of LAMMER protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; DROSOPHILA-MELANOGASTER; CONSERVED FEATURES; FAMILY; IDENTIFICATION; LOCUS; PHOSPHORYLATION; REGULATORS; THREONINE; MEMBERS	Clk/STY, the murine homologue of the recently described LAMMER family of protein kinases, autophosphorylates on serine/threonine and tyrosine residues in vitro and in, vivo, LAMMER kinases are found throughout eukaryotes and possess virtually complete amino acid identity in many domains critical for kinase function, leading to the question of whether other family members also possess dual specificity. We report here that the Drosophila family member DOA, human SK-G1, and the Saccharomyces cerevisiae KNS1, all possess protein kinase activity and autophosphorylate with dual specificity in vitro, suggesting that the entire family possesses this activity. Although the LAMMER kinases are closely related to the mitogen-activated protein kinase family, they possess different substrate specificity in vitro, based on phosphorylation of peptide and protein substrates and sequencing of a phosphorylation site in a common substrate.	UNIV NEBRASKA, MED CTR, DEPT BIOCHEM & MOL BIOL, OMAHA, NE 68198 USA; RUTGERS STATE UNIV, WAKSMAN INST, PISCATAWAY, NJ 08855 USA	University of Nebraska System; University of Nebraska Medical Center; Rutgers State University New Brunswick			Du, Cheng/F-1569-2013	Du, Cheng/0000-0002-8882-2513				Ausubel FM, 1988, MOL REPROD DEV; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DOUVILLE E, 1994, CANCER METAST REV, V13, P1, DOI 10.1007/BF00690414; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; FERRELL JE, 1989, J BIOL CHEM, V264, P20723; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MCCLELLAND M, 1994, NUCLEIC ACIDS RES, V22, P4419, DOI 10.1093/nar/22.21.4419; PADMANABHA R, 1991, MOL GEN GENET, V229, P1; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RABINOW L, 1989, EMBO J, V8, P879, DOI 10.1002/j.1460-2075.1989.tb03449.x; RABINOW L, 1993, GENETICS, V134, P1175; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; WETTENHALL REH, 1991, METHOD ENZYMOL, V201, P186; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	29	49	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27299	27303		10.1074/jbc.271.44.27299	http://dx.doi.org/10.1074/jbc.271.44.27299			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910305	hybrid			2022-12-27	WOS:A1996VQ67900023
J	Sun, JR; Bird, CH; Sutton, V; McDonald, L; Coughlin, PB; DeJong, TA; Trapani, JA; Bird, PI				Sun, JR; Bird, CH; Sutton, V; McDonald, L; Coughlin, PB; DeJong, TA; Trapani, JA; Bird, PI			A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier a is present in cytotoxic lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEINASE-INHIBITOR; PLASMINOGEN-ACTIVATOR INHIBITOR; INTERLEUKIN-1-BETA CONVERTING-ENZYME; NEUTROPHIL ELASTASE INHIBITOR; CELL CARCINOMA ANTIGEN; MOLECULAR-CLONING; MEDIATED APOPTOSIS; OVALBUMIN FAMILY; CRMA GENE; SERPIN	Using a polymerase chain reaction strategy we identified a serine proteinase inhibitor (serpin) in human bone marrow that is related to the cellular serpin proteinase inhibitor 6 (PI-6) and the viral serpin cytokine response modifier A (CrmA). This serpin, proteinase inhibitor 9 (PI-9), has an unusual reactive center P-1 (Glu)-P-1 '(Cys), which suggests that it inhibits serine proteinases that cleave after acidic residues. The only known serine proteinase with this specificity is granzyme B, a granule cytotoxin produced by cytotoxic lymphocytes. To test the interaction of PI-9 with granzyme B we prepared recombinant hexa-histidine tagged PI-9 in a yeast expression system. Addition of the recombinant protein to native granzyme B resulted in an SDS-resistant complex typical of serpin-serine proteinase interactions. Further analysis showed that complex formation followed bimolecular kinetics with a second order rate constant of 1.7 plus-minus 0.3 times 10(6) M(-1) S-1, which is in the range for a physiologically significant serpin-proteinase interaction. Recombinant PI-9 also completely abrogated granzyme B and perforin-mediated cytotoxicity in vitro. Examination of PI-9 mRNA distribution demonstrated that it it expressed in immune tissue, primarily in lymphocytes. The highest levels of PI-9 mRNA and protein were observed in natural killer cell leukemia cell lines and in interleukin-2 stimulated peripheral blood mononuclear cells, which also produce granzyme B. Like PI-6, PI-9 was shown to be a cytosolic protein that is not secreted. Fractionation of natural killer cells and stimulated peripheral blood mononuclear cells demonstrated that PI-9 is in a separate subcellular compartment to granzyme B. These results suggest that PI-9 serves to inactivate misdirected granzyme B following cytotoxic cell degranulation. This may explain why cytotoxic cells are not damaged by their own granzyme B during destruction of abnormal cells.	MONASH UNIV SCH MED,DEPT MED,BOX HILL HOSP,HEIDELBERG,VIC 3084,AUSTRALIA; AUSTIN RES INST,CELLULAR CYTOTOXIC LAB,HEIDELBERG,VIC 3084,AUSTRALIA	Box Hill Hospital; Monash University; Austin Research Institute				Trapani, Joseph/0000-0003-0983-1532; Bird, Phillip/0000-0002-6695-606X				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEATTY K, 1980, J BIOL CHEM, V255, P3931; BELIN D, 1993, THROMB HAEMOSTASIS, V70, P144; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; COUGHLIN PB, 1993, J BIOL CHEM, V268, P9541; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Dear AE, 1995, FIBRINOLYSIS, V9, P321, DOI 10.1016/S0268-9499(95)80079-4; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Harlow E., 1988, ANTIBODIES LAB MANUA; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KORZENIEWSKI C, 1983, J IMMUNOL METHODS, V64, P313, DOI 10.1016/0022-1759(83)90438-6; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MORGENSTERN KA, 1993, J BIOL CHEM, V268, P21560; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; POE M, 1991, J BIOL CHEM, V266, P98; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REMOLDODONNELL E, 1992, P NATL ACAD SCI USA, V89, P5635, DOI 10.1073/pnas.89.12.5635; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; RIEWALD M, 1995, J BIOL CHEM, V270, P26754, DOI 10.1074/jbc.270.45.26754; Sambrook J., 2002, MOL CLONING LAB MANU; SARIN A, 1995, J IMMUNOL, V154, P5806; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Scott FL, 1996, J BIOL CHEM, V271, P1605, DOI 10.1074/jbc.271.3.1605; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMORI T, 1995, AM J RESP CELL MOL, V13, P314, DOI 10.1165/ajrcmb.13.3.7654387; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; SUN JR, 1995, BBA-PROTEIN STRUCT M, V1252, P28, DOI 10.1016/0167-4838(95)00108-7; SUN JR, 1995, J BIOL CHEM, V270, P16089, DOI 10.1074/jbc.270.27.16089; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; TRAPANI JA, 1988, P NATL ACAD SCI USA, V85, P6924, DOI 10.1073/pnas.85.18.6924; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WOHLWEND A, 1987, J EXP MED, V165, P320, DOI 10.1084/jem.165.2.320; YE RD, 1987, J BIOL CHEM, V262, P3718; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	50	247	260	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27802	27809		10.1074/jbc.271.44.27802	http://dx.doi.org/10.1074/jbc.271.44.27802			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910377	hybrid			2022-12-27	WOS:A1996VQ67900095
J	Bergwitz, C; Gardella, TJ; Flannery, MR; Potts, JT; Kronenberg, HM; Goldring, SR; Juppner, H				Bergwitz, C; Gardella, TJ; Flannery, MR; Potts, JT; Kronenberg, HM; Goldring, SR; Juppner, H			Full activation of chimeric receptors by hybrids between parathyroid hormone and calcitonin - Evidence for a common pattern of ligand-receptor interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDE RECEPTOR; EXPRESSION CLONING; MOLECULAR-CLONING; HUMORAL HYPERCALCEMIA; SECRETIN RECEPTOR; SALMON-CALCITONIN; BINDING; GLUCAGON; GENE; MUTAGENESIS	Calcitonin (CT) and parathyroid hormone (PTH), whose receptors belong to the same family of G protein-coupled receptors, share no amino acid sequence homology and selectively activate either CT or PTH receptors. We now show, however, that reciprocal hybrid ligands (CT/PTH and PTH/CT), which do not activate the ''wild-type'' receptors, activate PTH/CT and CT/PTH receptor chimeras, respectively, Our findings indicate that PTH and CT share a similar architecture with at least two functional, receptor-specific domains, These domains are sufficiently independent to permit synthetic hybrid ligands to efficiently activate appropriate receptor chimeras. Therefore, both ligands follow, despite their very different primary sequences, a common pattern of ligand-receptor interaction.	MASSACHUSETTS GEN HOSP, ENDOCRINE UNIT, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, ARTHRITIS UNIT, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, CHILDRENS SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Fitzsimons, Chris/B-4171-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK011794] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK11794-28] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ALBRANDT K, 1995, ENDOCRINOLOGY, V136, P5377, DOI 10.1210/en.136.12.5377; BARDEN JA, 1989, EUR J BIOCHEM, V184, P379, DOI 10.1111/j.1432-1033.1989.tb15030.x; BARNAY G, 1979, PEPTIDES, V2, P1; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; CHOREVV M, 1994, PARATHYROIDS, V1, P139; EPAND RM, 1985, BIOPHYS CHEM, V23, P39, DOI 10.1016/0301-4622(85)80062-4; FEYEN JHM, 1992, BIOCHEM BIOPH RES CO, V187, P8, DOI 10.1016/S0006-291X(05)81450-0; GARDELLA TJ, 1994, ENDOCRINOLOGY, V135, P1186, DOI 10.1210/en.135.3.1186; Gardella TJ, 1996, J BIOL CHEM, V271, P12820, DOI 10.1074/jbc.271.22.12820; GARDELLA TJ, 1993, ENDOCRINOLOGY, V132, P2024, DOI 10.1210/en.132.5.2024; HJORTH SA, 1994, J BIOL CHEM, V269, P30121; Holtmann MH, 1996, J BIOL CHEM, V271, P14944, DOI 10.1074/jbc.271.25.14944; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1995, MOL PHARMACOL, V47, P798; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; LIN SC, 1993, NATURE, V364, P208, DOI 10.1038/364208a0; MAGET B, 1994, FEBS LETT, V351, P271, DOI 10.1016/0014-5793(94)00875-2; MCCUAIG KA, 1994, P NATL ACAD SCI USA, V91, P5051, DOI 10.1073/pnas.91.11.5051; MEYER JP, 1991, BIOPOLYMERS, V31, P233, DOI 10.1002/bip.360310210; MORELLI MAC, 1992, J BIOMOL NMR, V2, P335, DOI 10.1007/BF01874812; NUSSBAUM SR, 1980, J BIOL CHEM, V255, P183; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; REAGAN JD, 1994, J BIOL CHEM, V269, P9; Rosenblatt M, 1981, Pathobiol Annu, V11, P53; SCHIPANI E, 1995, J CLIN ENDOCR METAB, V80, P1611, DOI 10.1210/jc.80.5.1611; STROOP SD, 1995, BIOCHEMISTRY-US, V34, P1050, DOI 10.1021/bi00003a040; Turner PR, 1996, J BIOL CHEM, V271, P9205, DOI 10.1074/jbc.271.16.9205; WRAY V, 1994, BIOCHEMISTRY-US, V33, P1684, DOI 10.1021/bi00173a010; WRAY V, 1993, BIOCHEMISTRY-US, V32, P5832, DOI 10.1021/bi00073a016; ZAIDI M, 1990, CRIT REV CL LAB SCI, V28, P109, DOI 10.3109/10408369009105900; ZOLNIEROWICZ S, 1994, J BIOL CHEM, V269, P19530	43	132	143	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26469	26472		10.1074/jbc.271.43.26469	http://dx.doi.org/10.1074/jbc.271.43.26469			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900113				2022-12-27	WOS:A1996VP23300007
J	Luo, YD; Gabriel, JL; Wang, F; Zhan, X; Maciag, T; Kan, M; Mckeehan, WL				Luo, YD; Gabriel, JL; Wang, F; Zhan, X; Maciag, T; Kan, M; Mckeehan, WL			Molecular modeling and deletion mutagenesis implicate the nuclear translocation sequence in structural integrity of fibroblast growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; FACTOR RECEPTOR; 3-DIMENSIONAL STRUCTURE; MITOGENIC ACTIVITY; FACTOR-I; IDENTIFICATION; FGF-1; MECHANISM; AFFINITY; COMPLEX	The sequence NYKKPKL in the NH2 terminus of fibroblast growth factor (FGF)-1 has been proposed to affect the long term activities of FGF-1 through its function as a nuclear translocation signal or its role in stabilization of the structure required to sustain binding and activation of the transmembrane receptor kinase. A dynamic molecular model of FGF-1 docked into a duplex of the FGF receptor ectodomain and a hexadecameric heparin chain suggests that the NYKKPKL sequence does not directly interact with heparin or the receptor, but rather the lysine-leucine residues within the sequence indirectly stabilize a major receptor-binding domain, Concurrent with a marked increase in dependence on exogenous heparin for optimal activity, sequential deletion of residues in the NYKKPKL sequence in FGF-1 resulted in a progressive loss of thermal stability, resistance to protease, mitogenic activity, and affinity for the transmembrane receptor. The largest change resulted from deletion of the entire sequence through the lysine-leucine residues. In the presence of sufficiently high concentrations of heparin, the deletion mutants exhibited mitogenic activity equal to wild-type FGF-1. The results confirm that a primary role of the NYKKPKL sequence domain is to maintain the structural integrity of FGF-1 required for optimal binding to and activation of the heparan sulfate-transmembrane receptor complex.	TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, ALBERT B ALKEK INST BIOSCI & TECHNOL, CTR CANC BIOL & NUTR, HOUSTON, TX 77030 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; AMER RED CROSS, JEROME H HOLLAND LAB BIOMED SCI, DEPT EXPT PATHOL, ROCKVILLE, MD 20855 USA; AMER RED CROSS, JEROME H HOLLAND LAB BIOMED SCI, DEPT MOL BIOL, ROCKVILLE, MD 20855 USA	Texas A&M University System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; American Red Cross; American Red Cross					NATIONAL CANCER INSTITUTE [R01CA059971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038639, R01DK035310] Funding Source: NIH RePORTER; NCI NIH HHS [CA59971] Funding Source: Medline; NIDDK NIH HHS [DK38639, DK35310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CRABB JW, 1986, BIOCHEMISTRY-US, V25, P4988, DOI 10.1021/bi00366a003; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; ERIKSSON AE, 1993, PROTEIN SCI, V2, P1274, DOI 10.1002/pro.5560020810; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Feng SJ, 1996, BBA-MOL CELL RES, V1310, P67, DOI 10.1016/0167-4889(95)00146-8; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; GABRIEL JL, 1993, P NATL ACAD SCI USA, V90, P4186, DOI 10.1073/pnas.90.9.4186; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1995, BBA-MOL CELL RES, V1266, P124, DOI 10.1016/0167-4889(95)00009-H; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1991, METHOD ENZYMOL, V198, P158; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; Prudovsky IA, 1996, J BIOL CHEM, V271, P14198, DOI 10.1074/jbc.271.24.14198; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; ROSENGART TK, 1988, BIOCHEM BIOPH RES CO, V152, P432, DOI 10.1016/S0006-291X(88)80732-0; SHI E, 1991, J BIOL CHEM, V266, P5774; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; XU J, 1992, J BIOL CHEM, V267, P11792; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU HY, 1995, J BIOL CHEM, V270, P21869, DOI 10.1074/jbc.270.37.21869; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	33	27	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26876	26883		10.1074/jbc.271.43.26876	http://dx.doi.org/10.1074/jbc.271.43.26876			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900171	hybrid			2022-12-27	WOS:A1996VP23300065
J	RuizArguello, MB; Basanez, G; Goni, FM; Alonso, A				RuizArguello, MB; Basanez, G; Goni, FM; Alonso, A			Different effects of enzyme-generated ceramides and diacylglycerols in phospholipid membrane fusion and leakage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; LIPOSOME FUSION; PROTEIN-KINASE; CHOLESTEROL; MECHANISM; VESICLES; SPHINGOMYELINASE; SPHINGOLIPIDS; MEDIATOR; RELEASE	When large unilamellar vesicles consisting of sphingomyelin:phosphatidylethanolamine:cholesterol (2:1:1 molar ratio) are treated with sphingomyelinase, production of ceramides in the bilayer is accompanied by leakage of vesicle aqueous contents and by vesicle aggregation in the absence of lipid mixing or vesicle fusion, This is in contrast to the situation of phosphatidylcholine:phosphatidylethanolamine:cholesterol (2:1:1 molar ratio) liposomes when treated with phospholipase C. In that case, in situ generation of diacylglycerol leads to vesicle aggregation followed by vesicle fusion in the absence of leakage (Nieva, J. L., Goni, F. M., and Alonso, A, (1989) Biochemistry 28, 7364-7367). Moreover, when ceramides (5-10 mol %) are included in the formulation of the phosphatidylcholine-containing vesicles, they reduce the lag time of phospholipase C-induced fusion, although they are less active than diacylglycerols in this respect. P-31 NMR studies of aqueous lipid dispersions show that diacylglycerols as well as ceramides induce a thermotropic lamellar to non-lamellar phase transition in both phospholipid:cholesterol mixtures under study although sphingomyelin-containing bilayers are more stable than those containing phosphatidylcholine, and ceramide is less active than diacylglycerol in promoting non-lamellar phase formation. These observations are relevant to both the physiological role of ceramides and the current views on the mechanism of membrane fusion.	UNIV BASQUE COUNTRY, DEPT BIOQUIM,COSEJO SUPER INVES CIENT, UNIDAD ASOCIADA,GRP BIOMEMBRANAS, E-48080 BILBAO, SPAIN	University of Basque Country			Goni, Felix M/M-5425-2015; Basanez, Gorka/L-9509-2014; Alonso, Alicia/E-5310-2012	Goni, Felix M/0000-0001-6270-9216; Basanez, Gorka/0000-0002-7475-7861; Alonso, Alicia/0000-0002-2730-7470				BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Bottcher C, 1961, ANAL CHIM ACTA, V1061, P297; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1995, CURR OPIN STRUC BIOL, V5, P541, DOI 10.1016/0959-440X(95)80041-7; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; ELLENS H, 1986, BIOCHEMISTRY-US, V25, P4141, DOI 10.1021/bi00362a023; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GONI FM, 1994, BIOCHEM SOC T, V22, P839, DOI 10.1042/bst0220839; GONI FM, 1992, LIPOSOME TECHNOLOGY, V2, P261; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Huang HW, 1996, BIOCHEM BIOPH RES CO, V220, P834, DOI 10.1006/bbrc.1996.0490; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Maulik PR, 1996, BIOPHYS J, V70, P2256, DOI 10.1016/S0006-3495(96)79791-6; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; MONCK JR, 1994, NEURON, V12, P707, DOI 10.1016/0896-6273(94)90325-5; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; NIEVA JL, 1993, BIOCHEMISTRY-US, V32, P1054, DOI 10.1021/bi00055a009; NIEVA JL, 1995, FEBS LETT, V368, P143, DOI 10.1016/0014-5793(95)00631-I; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBEID LM, 1995, J CELL BIOCHEM, V58, P191, DOI 10.1002/jcb.240580208; REQUERO MA, 1995, BIOCHEMISTRY-US, V34, P10400, DOI 10.1021/bi00033a011; RUIZ J, 1988, BIOCHIM BIOPHYS ACTA, V937, P127, DOI 10.1016/0005-2736(88)90234-9; SIEGEL DP, 1994, BIOPHYS J, V66, P402, DOI 10.1016/S0006-3495(94)80790-8; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Steck T L, 1974, Methods Enzymol, V31, P172; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TOMITA M, 1987, ARCH BIOCHEM BIOPHYS, V255, P127, DOI 10.1016/0003-9861(87)90302-X; VIGUERA AR, 1993, BIOCHEMISTRY-US, V32, P3708, DOI 10.1021/bi00065a024	37	134	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26616	26621		10.1074/jbc.271.43.26616	http://dx.doi.org/10.1074/jbc.271.43.26616			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900135	hybrid			2022-12-27	WOS:A1996VP23300029
J	Sienaert, I; DeSmedt, H; Parys, JB; Missiaen, L; Vanlingen, S; Sipma, H; Casteels, R				Sienaert, I; DeSmedt, H; Parys, JB; Missiaen, L; Vanlingen, S; Sipma, H; Casteels, R			Characterization of a cytosolic and a luminal Ca2+ binding site in the type I inositol 1,4,5-trisphosphate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; CHANNEL RYANODINE RECEPTOR; DYE STAINS-ALL; ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; DROSOPHILA-MELANOGASTER; CA-2+-BINDING PROTEINS; INSP3 RECEPTOR; LIGAND-BINDING; RUTHENIUM RED	To study the Ca2+ regulation of the inositol 1,4,5-trisphosphate receptor (InsP(3)R) at the molecular level, we expressed various cytosolic and luminal regions of the mouse type I InsP(3)R as glutathione S-transferase fusion proteins. Ca-45(2+) and ruthenium red overlay studies and Stains-all spectra and staining revealed both a cytosolic and a luminal Ca2+ binding site, The luminal Ca2+ binding site was mapped to the nonconserved acidic subregion of the luminal loop between amino acids 2463 and 2528, A K-0.5 of 0.3 mu M and a Hill coefficient of 1.1 were determined by Ca-45(2+) overlay by quantification of Ca-45(2+) binding on blots, The cytosolic Ca2+ binding site was localized in a region just preceding the transmembrane domain M1. The Ca2+ binding was mapped to a 23-amino acid stretch between amino acids 2124 and 2146, This cytosolic region showed a single high affinity site for Ca2+, with a K-0.5, of 0.8 mu M and a Hill coefficient of 1.0, Neither of the identified Ca2+ binding regions contained an EF-hand motif, We conclude that the type I InsP(3)R has at least two quite distinct types of Ca2+ binding sites, which are localized in different structural regions of the protein.			Sienaert, I (corresponding author), KATHOLIEKE UNIV LEUVEN, FYSIOL LAB, CAMPUS GASTHUISBERG O-N, HERESTR 49, B-3000 LOUVAIN, BELGIUM.			Parys, Jan/0000-0002-3591-4967				BAKSH S, 1991, J BIOL CHEM, V266, P21458; BEAN RC, 1965, J PHYS CHEM-US, V69, P4368, DOI 10.1021/j100782a050; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; BOOTMAN MD, 1995, BIOCHEM J, V306, P445, DOI 10.1042/bj3060445; CADAY CG, 1985, J BIOL CHEM, V260, P5985; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; CHARUK JHM, 1990, ANAL BIOCHEM, V188, P123, DOI 10.1016/0003-2697(90)90539-L; CHEN SRW, 1992, J BIOL CHEM, V267, P23318; CHEN SRW, 1994, J BIOL CHEM, V269, P22698; Combettes L, 1996, EMBO J, V15, P2086, DOI 10.1002/j.1460-2075.1996.tb00562.x; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; FURUICHI T, 1995, J NEUROCHEM, V64, P953, DOI 10.1046/j.1471-4159.1995.64030953.x; Furuichi Teiichi, 1994, Current Opinion in Neurobiology, V4, P294, DOI 10.1016/0959-4388(94)90089-2; GAMBERUCCI A, 1995, CELL CALCIUM, V17, P431, DOI 10.1016/0143-4160(95)90089-6; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Joseph SK, 1996, CELL SIGNAL, V8, P1, DOI 10.1016/0898-6568(95)02012-8; KAY RE, 1964, J PHYS CHEM-US, V68, P1896, DOI 10.1021/j100789a040; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LOIRAND G, 1994, J PHYSIOL-LONDON, V479, P41, DOI 10.1113/jphysiol.1994.sp020276; LOOMISHUSSELBEE JW, 1993, BIOCHEM J, V289, P861, DOI 10.1042/bj2890861; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARANTO AR, 1994, J BIOL CHEM, V269, P1222; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIGNERY GA, 1992, J BIOL CHEM, V267, P7450; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MISSIAEN L, 1994, J BIOL CHEM, V269, P7238; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; NUNN DL, 1992, MOL PHARMACOL, V41, P115; OLDERSHAW KA, 1993, BIOCHEM J, V292, P631, DOI 10.1042/bj2920631; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PARYS JB, 1993, J BIOL CHEM, V268, P25206; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1995, AM J PHYSIOL-CELL PH, V269, pC813, DOI 10.1152/ajpcell.1995.269.3.C813; TAKESHIMA H, 1994, FEBS LETT, V337, P81, DOI 10.1016/0014-5793(94)80634-9; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; YAMADA N, 1994, BIOCHEM J, V302, P781, DOI 10.1042/bj3020781; YAMAMOTOHINO M, 1992, RECEPTOR CHANNEL, V2, P2; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YOSHIKAWA S, 1992, J BIOL CHEM, V267, P16613; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	55	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27005	27012		10.1074/jbc.271.43.27005	http://dx.doi.org/10.1074/jbc.271.43.27005			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900188				2022-12-27	WOS:A1996VP23300082
J	Srinivasula, SM; FernandesAlnemri, T; Zangrilli, J; Robertson, N; Armstrong, RC; Wang, LJ; Trapani, JA; Tomaselli, KJ; Litwack, G; Alnemri, ES				Srinivasula, SM; FernandesAlnemri, T; Zangrilli, J; Robertson, N; Armstrong, RC; Wang, LJ; Trapani, JA; Tomaselli, KJ; Litwack, G; Alnemri, ES			The Ced-3/interleukin 1 beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for the apoptotic mediator CPP32	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEATH GENE CED-3; CELL-DEATH; INTERLEUKIN-1-BETA-CONVERTING ENZYME; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASES; MOLECULAR-CLONING; IDENTIFICATION; EXPRESSION; PROTEINASE; INDUCTION	Recent evidence suggests that CPP32 is an essential component of an aspartate-specific cysteine protease (ASCP) cascade responsible for apoptosis execution in mammalian cells, Activation of CPP32 could lead to activation of other downstream ASCPs, resulting in late morphological changes such as lamin cleavage and DNA fragmentation, observed in cells undergoing apoptosis, Here we describe the identification and cloning of a novel human ASCP named Mch6 from Jurkat T lymphocytes. We demonstrate that the pro-enzymes of Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for mature CPP32, Site-directed mutagenesis revealed that CPP32 processes pro-Mch6 preferentially at Asp(330) to generate two subunits of molecular masses 37 kDa (p37) and 10 kDa (p10), However, CPP32 processes pro-Mch2 alpha at three aspartate processing sites (Asp(23), Asp(179), and Asp(193)) to produce the large (p18) and small (p11) subunits of the mature Mch2 alpha enzyme. The CPP32-processed Mch2 alpha is capable of cleaving the VEIDN lamin cleavage site, indicating that CPP32 can, in fact, activate pro-Mch2 alpha. Granzyme B at a concentration that allows processing and activation of CPP32 failed to process pro-Mch2 alpha. However, incubation of pro-Mch2 alpha with granzyme B in the presence of a cellular extract containing pro-CPP32 resulted in activation of pro CPP32 and subsequent processing of pro-Mch2 alpha. Interestingly, granzyme B can also process pro-Mch6 but at a site N-terminal to that cleaved by CPP32, These data suggest that Mch2 alpha and Mch6 are downstream proteases activated in CPP32- and granzyme B-mediated apoptosis, This is the first demonstration of a protease cascade involving granzyme B, CPP32, Mch2 alpha, and Mch6 and evidence that the lamin-cleaving enzyme Mch2 is a target of mature CPP32.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MOL PHARMACOL & BIOCHEM,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,PHILADELPHIA,PA 19107; AUSTIN RES INST,CELLULAR CYTOTOXIC LAB,HEIDELBERG,VIC,AUSTRALIA; IDUN PHARMACEUT,SAN DIEGO,CA 92121	Jefferson University; Jefferson University; Austin Research Institute				Trapani, Joseph/0000-0003-0983-1532	NIAID NIH HHS [AI 35035] Funding Source: Medline; NIA NIH HHS [AG 13487] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; ALNEMRI ES, 1996, IN PRESS J CELL BIOC, V62; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; HARVEY NL, 1996, IN PRESS GENES CELLS, V1; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; SHI L, 1991, J EXP MED, V175, P553; SMYTH MJ, 1995, IMMUNOL TODAY, V16, P202, DOI 10.1016/0167-5699(95)80122-7; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; TAKAHASHI A, 1995, P NATL ACAD SCI USA, V93, P8395; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TRAPANI JA, 1993, BIOCHEM BIOPH RES CO, V195, P910, DOI 10.1006/bbrc.1993.2131; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0	33	268	301	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27099	27106		10.1074/jbc.271.43.27099	http://dx.doi.org/10.1074/jbc.271.43.27099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900201	hybrid			2022-12-27	WOS:A1996VP23300095
J	Winegarden, NA; Wong, KS; Sopta, M; Westwood, JT				Winegarden, NA; Wong, KS; Sopta, M; Westwood, JT			Sodium salicylate decreases intracellular ATP, induces both heat shock factor binding and chromosomal puffing, but does not induce hsp 70 gene transcription in Drosophila	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENATURED PROTEIN INDUCERS; XENOPUS-LAEVIS OOCYTES; DNA-BINDING; STRESS RESPONSE; ACTIVATION; YEAST; GLUE; OLIGOMERIZATION; PHOSPHORYLATION; INHIBITION	Sodium salicylate has long been known to be an inducer of the heat shock puffs and presumably heat shock gene transcription in the polytene chromosomes of drosophila salivary gland cells. Stress induced transcription of the heat shock genes is mediated by the transcription factor known as Heat Shock Factor (HSF). In yeast, sodium salicylate has been reported to induce the DNA binding of HSF but not heat shock gene transcription itself, and similar findings have been reported in human cells. This apparent discrepancy in the induction of certain aspects of the heat shock response between these organisms prompted us to carefully reexamine the induction of the heat shock response in Drosophila salivary gland cells of third instar larvae and Drosophila tissue culture (SL2) cells. Sodium salicylate (3-30 mM) decreases intracellular ATP levels in SL2 cells and induces HSF binding activity in SL2 and salivary gland cells in a dose dependent manner, Despite the induction of HSF binding and heat shock puffs in polytene chromosomes, we found no evidence for increased hsp 70 gene transcription suggesting that chromosomal puffing and gene transcription may be separable events. Salicylate did not induce the HSF hyperphosphorylation that is normally associated with HSF activation. Furthermore, salicylate (30 mM) prevented heat-induced hyperphosphorylation of HSF and hsp 70 gene transcription indicating that salicylate's inhibitory effect on hsp 70 transcription may be independent of its effect on HSF binding activity. We propose that the reduction in intracellular ATP caused by the addition of salicylate likely plays a role in the activation of HSF binding and the inhibition of both HSF hyperphosphorylation and hsp 70 gene transcription.	UNIV TORONTO, ERINDALE COLL, DEPT ZOOL, MISSISSAUGA, ON L5L 1C6, CANADA	University of Toronto; University Toronto Mississauga				Winegarden, Neil/0000-0001-5964-5899				ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ASHBURNER M, 1970, CHROMOSOMA, V31, P356, DOI 10.1007/BF00321231; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BEHNEL J, 1975, EXP CELL RES, V91, P119, DOI 10.1016/0014-4827(75)90149-4; BERENDES HD, 1968, CHROMOSOMA, V24, P418; BONNER JJ, 1981, DEV BIOL, V86, P409, DOI 10.1016/0012-1606(81)90199-8; CROSBY MA, 1986, DEV BIOL, V118, P593, DOI 10.1016/0012-1606(86)90029-1; CROWLEY TE, 1984, CELL, V39, P149, DOI 10.1016/0092-8674(84)90200-9; DELANEY TP, 1994, SCIENCE, V266, P1247, DOI 10.1126/science.266.5188.1247; Fernandes M., 1994, BIOL HEAT SHOCK PROT, P375; FIRESTONE GL, 1990, METHOD ENZYMOL, V182, P688; FRYDMAN J, 1994, BIOL HEAT SHOCK PROT, P251; GIARDINA C, 1995, J BIOL CHEM, V270, P10369, DOI 10.1074/jbc.270.18.10369; HOJ A, 1994, EMBO J, V13, P2617; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; JURIVICH DA, 1995, J BIOL CHEM, V270, P24489, DOI 10.1074/jbc.270.41.24489; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEENDERS HJ, 1974, EXP CELL RES, V86, P25, DOI 10.1016/0014-4827(74)90642-9; LEENDERS HJ, 1972, CHROMOSOMA, V37, P433; LI N, 1992, PLANT MOL BIOL, V18, P477, DOI 10.1007/BF00040664; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; LIVAK KJ, 1978, P NATL ACAD SCI USA, V75, P5613, DOI 10.1073/pnas.75.11.5613; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; MEYEROWITZ EM, 1987, TRENDS GENET, V3, P288, DOI 10.1016/0168-9525(87)90270-8; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15718; Moore DD, 1995, GLOB MOB SURV; MYOHARA M, 1991, DEV BIOL, V122, P396; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; NOVER L., 1991, HEAT SHOCK RESPONSE; OLSON JE, 1992, METAB BRAIN DIS, V7, P183, DOI 10.1007/BF01000245; RENSING L, 1973, CELL DIFFER DEV, V2, P221, DOI 10.1016/0045-6039(73)90010-9; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Ritossa F, 1963, DROSOPHILA INFORMATI, V37, P122, DOI 10.1016/0014-4827(64)90147-8; RITOSSA FM, 1964, EXP CELL RES, V35, P601, DOI 10.1016/0014-4827(64)90147-8; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SORGER PK, 1987, NATURE, V329, P81, DOI 10.1038/329081a0; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; WU C, 1994, BIOL HEAT SHOCK PROT, P365; ZIMARINO V, 1990, MOL CELL BIOL, V10, P752, DOI 10.1128/MCB.10.2.752; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	48	56	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26971	26980		10.1074/jbc.271.43.26971	http://dx.doi.org/10.1074/jbc.271.43.26971			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900183	hybrid			2022-12-27	WOS:A1996VP23300077
J	Boisset, N; Taveau, JC; Pochon, F; Lamy, J				Boisset, N; Taveau, JC; Pochon, F; Lamy, J			Similar architectures of native and transformed human alpha(2)-macroglobulin suggest the transformation mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN; 3-DIMENSIONAL RECONSTRUCTION; ELECTRON-MICROSCOPY; CRYOELECTRON MICROSCOPY; MONOMALEIMIDO NANOGOLD; CONFORMATIONAL-CHANGES; SINGLE PARTICLES; HUMAN-PLASMA; TILT SERIES; METHYLAMINE	The refined three-dimensional structure of native human alpha(2)-macroglobulin (alpha(2)M) has been determined by cryoelectron microscopy and three-dimensional reconstruction, New features corresponding to ''sigmoid arches,'' ''basal bodies,'' and ''apical connections'' were observed in the molecule, Since similar elements are found in the architecture of transformed alpha(2)M, the 2 volumes were aligned in three dimensions. In their common orientations, they show many similarities except near the openings of the central chamber, In the native conformation, these apertures are fully opened, allowing the proteases to access the central chamber of the molecule, while in the transformed structure, they are partially closed. These structures suggest that alpha(2)M conformational change involves a strong lateral compression and a vertical stretching of the native particle seen in its four-petaled flower view to produce the H view of the transformed form. A model of structural transformation, in which all the parts of the alpha(2)M molecule seem involved in the entrapment of the proteinases is proposed.	UNIV TOURS,GRP ANAL STRUCT ANTIGEN,F-37032 TOURS,FRANCE; CNRS,EP JO117,F-37032 TOURS,FRANCE; UNIV PARIS 11,INST CURIE BIOL,INSERM,U350,F-91405 ORSAY,FRANCE	Universite de Tours; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay								ADRIAN M, 1984, NATURE, V308, P32, DOI 10.1038/308032a0; ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BJORK I, 1982, BIOCHEM J, V207, P347; BOISSET N, 1992, J STRUCT BIOL, V109, P39, DOI 10.1016/1047-8477(92)90065-I; BOISSET N, 1993, J MOL BIOL, V232, P522, DOI 10.1006/jmbi.1993.1408; BOISSET N, 1989, J BIOL CHEM, V264, P12046; BOISSET N, 1994, ANN NY ACAD SCI, V737, P229, DOI 10.1111/j.1749-6632.1994.tb44315.x; BRETAUDIERE JP, 1988, P NATL ACAD SCI USA, V85, P1437, DOI 10.1073/pnas.85.5.1437; DELAIN E, 1992, ELECTRON MICROSC REV, V5, P231, DOI 10.1016/0892-0354(92)90012-F; FELDMAN SR, 1985, P NATL ACAD SCI USA, V82, P5700, DOI 10.1073/pnas.82.17.5700; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GONIAS SL, 1989, J BIOL CHEM, V264, P9565; GONIAS SL, 1988, J BIOL CHEM, V263, P10903; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; HARAUZ G, 1986, OPTIK, V73, P146; HERTZ J, 1988, EMBO J, V7, P4119; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; IKAI A, 1983, J BIOCHEM, V93, P121, DOI 10.1093/oxfordjournals.jbchem.a134145; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KURECKI T, 1979, ANAL BIOCHEM, V99, P415, DOI 10.1016/S0003-2697(79)80026-3; LARQUET E, 1994, J STRUCT BIOL, V113, P87, DOI 10.1006/jsbi.1994.1034; MARSHALL LB, 1992, J BIOL CHEM, V267, P6347; PENCZEK P, 1992, ULTRAMICROSCOPY, V40, P33, DOI 10.1016/0304-3991(92)90233-A; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; RADERMACHER M, 1987, J MICROSC-OXFORD, V146, P113, DOI 10.1111/j.1365-2818.1987.tb01333.x; SCHRAMM HJ, 1982, H-S Z PHYSIOL CHEM, V363, P803, DOI 10.1515/bchm2.1982.363.2.803; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P11539; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; STOOPS JK, 1991, J STRUCT BIOL, V106, P172, DOI 10.1016/1047-8477(91)90086-C; STOOPS JK, 1989, BIOCHEM BIOPH RES CO, V161, P216, DOI 10.1016/0006-291X(89)91583-0; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAPONBRETAUDIERE J, 1985, EMBO J, V4, P85, DOI 10.1002/j.1460-2075.1985.tb02321.x; Taveau JC, 1996, J STRUCT BIOL, V116, P223, DOI 10.1006/jsbi.1996.0034; VANLEUVEN F, 1986, J BIOL CHEM, V261, P6933; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; ZHAO BL, 1988, BIOCHEMISTRY-US, V27, P5304, DOI 10.1021/bi00414a053	41	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25762	25769		10.1074/jbc.271.42.25762	http://dx.doi.org/10.1074/jbc.271.42.25762			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824204	hybrid			2022-12-27	WOS:A1996VN18000010
J	Sartipy, P; Johansen, B; Camejo, G; Rosengren, B; Bondjers, G; HurtCamejo, E				Sartipy, P; Johansen, B; Camejo, G; Rosengren, B; Bondjers, G; HurtCamejo, E			Binding of human phospholipase A(2) type II to proteoglycans - Differential effect of glycosaminoglycans on enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE CELLS; ARTERIAL PROTEOGLYCANS; PANCREATIC PHOSPHOLIPASE-A2; ENDOTHELIAL-CELLS; HUMAN MACROPHAGES; CULTURED HUMAN; SERUM-ALBUMIN; FATTY-ACIDS; HUMAN AORTA	Phospholipase A(2) acting on low density lipoproteins in the extracellular arterial intima may form proinflammatory lipid mediators. Human nonpancreatic secretory phospholipase A(2) has three regions that may associate with sulfated glycosaminoglycans. The apoB-100 molecule in low density lipoproteins also has glycosaminoglycan binding regions that could mediate its retention in the arterial intima. Here we report that human nonpancreatic phospholipase A(2) isolated from a transfected cell line binds to glycosaminoglycans secreted by cultured human arterial smooth muscle cells. A gel mobility shift assay showed that the affinity of phospholipase A(2) for glycosaminoglycans from a heparan sulfate/chondroitin sulfate proteoglycan was higher than for chondroitin sulfate glycosaminoglycans from a larger versican-like proteoglycan. Affinity chromatography confirmed these results. All glycosaminoglycans tested, at concentrations up to 100 mu M, increased the activity of phospholipase A(2) toward phosphatidylcholine liposomes. Above this concentration, heparan sulfate and heparin inhibited the enzyme. Heparin and chondroitin 6-sulfate increased phospholipase A(2) activity on ion, density lipoproteins up to 4-fold at 100 mu M, whereas heparan sulfate had no effect. The results indicate that human nonpancreatic secretory phospholipase A(2) interacts with proteoglycans via their glycosaminoglycan moiety and that the enzyme activity may be modulated by the association of the enzyme and its substrate to the sulfated polysaccharides.	NORWEGIAN UNIV SCI & TECHNOL,DEPT BOT,UNIGEN CTR MOL BIOL,N-7035 TRONDHEIM,NORWAY; ASTRA HASSLE AB,DEPT BIOCHEM,PRECLIN RES LABS,S-43183 MOLNDAL,SWEDEN	Norwegian University of Science & Technology (NTNU)	Sartipy, P (corresponding author), GOTHENBURG UNIV,SAHLGRENS UNIV HOSP,WALLENBERG LAB CARDIOVASC RES,DEPT HEART & LUNG DIS,S-41345 GOTHENBURG,SWEDEN.							AMRI EZ, 1994, J LIPID RES, V35, P930; ANDERSEN S, 1994, PROSTAG LEUKOTR ESS, V51, P19, DOI 10.1016/0952-3278(94)90173-2; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BROWN SD, 1993, BIOCHIM BIOPHYS ACTA, V1168, P13, DOI 10.1016/0005-2760(93)90260-G; BYRNE CD, 1992, BIOCHEM J, V288, P101, DOI 10.1042/bj2880101; CAMEJO G, 1993, J BIOL CHEM, V268, P14131; CAMEJO G, 1988, ARTERIOSCLEROSIS, V8, P368, DOI 10.1161/01.ATV.8.4.368; CAMEJO G, 1985, BIOMED BIOCHIM ACTA, V44, P389; CAMEJO G, 1983, ATHEROSCLEROSIS, V49, P241, DOI 10.1016/0021-9150(83)90136-3; CAMEJO G, 1989, ATHEROSCLEROSIS, V79, P121, DOI 10.1016/0021-9150(89)90116-0; Camejo German, 1993, Current Opinion in Lipidology, V4, P385, DOI 10.1097/00041433-199310000-00007; CARDOSO LEM, 1994, ARTERIOSCLER THROMB, V14, P115, DOI 10.1161/01.ATV.14.1.115; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DUA R, 1994, EUR J BIOCHEM, V221, P481, DOI 10.1111/j.1432-1033.1994.tb18761.x; EPPS DE, 1995, ANAL BIOCHEM, V227, P342, DOI 10.1006/abio.1995.1290; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FAGER G, 1989, IN VITRO CELL DEV B, V25, P511; FAGER G, 1995, J CELL PHYSIOL, V163, P380, DOI 10.1002/jcp.1041630218; FENSKE DB, 1990, CHEM PHYS LIPIDS, V54, P9, DOI 10.1016/0009-3084(90)90054-U; GOLDBERG RL, 1990, CONNECT TISSUE RES, V24, P265, DOI 10.3109/03008209009152154; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HURTCAMEJO E, 1992, ARTERIOSCLER THROMB, V12, P569, DOI 10.1161/01.ATV.12.5.569; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; HURTCAMEJO E, 1996, IN PRESS ARTERIOSCLE; HURTCAMEJO E, 1995, ARTERIOSCLER THROMB, V15, P1456; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; JOHANSEN B, 1992, BIOCHEM BIOPH RES CO, V187, P544, DOI 10.1016/S0006-291X(05)81528-1; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; MARCUS AJ, 1993, J LIPID RES, V34, P2017; MORISAKI N, 1994, BIOCHEM J, V303, P247, DOI 10.1042/bj3030247; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEILHAMER JJ, 1986, DNA-J MOLEC CELL BIO, V5, P519, DOI 10.1089/dna.1.1986.5.519; SMITH EB, 1972, LANCET, V1, P463; SMITH EB, 1980, ATHEROSCLEROSIS, V37, P579, DOI 10.1016/0021-9150(80)90065-9; Spector A., 1986, BIOCH BIOL PLASMA LI, P247; SRINIVASAN SR, 1993, BIOCHIM BIOPHYS ACTA, V1168, P158, DOI 10.1016/0005-2760(93)90120-X; TAILLEUX A, 1993, J LIPID RES, V34, P719; VANDENBERG JJM, 1993, BIOCHEMISTRY-US, V32, P4962, DOI 10.1021/bi00069a035; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WIGHT TN, 1995, CURR OPIN LIPIDOL, V6, P326, DOI 10.1097/00041433-199510000-00013; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551	50	78	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26307	26314		10.1074/jbc.271.42.26307	http://dx.doi.org/10.1074/jbc.271.42.26307			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824283	hybrid			2022-12-27	WOS:A1996VN18000089
J	Schreyer, SA; Peschon, JJ; LeBoeuf, RC				Schreyer, SA; Peschon, JJ; LeBoeuf, RC			Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; LIPOPROTEIN-LIPASE; TNF-ALPHA; MONOCYTE-MACROPHAGES; SCAVENGER RECEPTOR; ENDOTHELIAL-CELLS; APOLIPOPROTEIN-E; ENDOTOXIC-SHOCK; GENETIC-CONTROL; INBRED MICE	TNF-alpha (TNF) is produced primarily from macrophages and promotes numerous inflammatory reactions associated with atherosclerosis including the induction of vascular adhesion molecules and the recruitment and proliferation of monocyte/macrophages. There are two receptors known to elicit TNF responses, termed p55 and p75. Since p55 is thought to play the primary role in inflammatory processes, we postulated that the absence of p55 in mice would protect against atherosclerosis. In contrast, C57BL/6 mice lacking p55 had aortic sinus lesion sizes 2.3 fold larger than C57BL/6 wild type mice when fed an atherogenic diet (37,123 +/- 3485 mu m(2) versus 16, 688 +/- 2887 mu m(2), respectively, p < 0.0004). Plasma lipid levels were not different between strains. A 3-fold increase in the uptake and degradation of acetylated low density lipoprotein for p55-null as compared with wild type mice was demonstrated in cultured peritoneal macrophages. Immunohistochemical staining for scavenger receptor protein in the aortic sinus was more intense in lesions from the p55 null mice as compared with wild type controls. Our results support the concept that increased scavenger receptor activity contributes to excessive fatty streak formation. We conclude that TNF p55 receptors protect against atherosclerotic lesion development in the mouse.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; IMMUNEX RES & DEV CORP,SEATTLE,WA 98101	University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL50367, HL07247] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL007247, R01HL050367] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBRECHT H, 1995, J INFLAMM, V45, P64; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254, DOI 10.1161/01.ATV.11.2.254; BONET B, 1995, ATHEROSCLEROSIS, V112, P125, DOI 10.1016/0021-9150(94)05404-7; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; COTRAN RS, 1990, J AM SOC NEPHROL, V1, P225; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; FEINGOLD KR, 1989, ENDOCRINOLOGY, V124, P2336, DOI 10.1210/endo-124-5-2336; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; HUGHES DA, 1994, IMMUNOL LETT, V43, P7, DOI 10.1016/0165-2478(94)00143-X; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KIRK EA, 1995, J LIPID RES, V36, P1522; KOEFFLER HP, 1988, MOL CELL BIOL, V8, P3432, DOI 10.1128/MCB.8.8.3432; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; LEBOEUF RC, 1994, J LIPID RES, V35, P121; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LUSIS AJ, 1987, J BIOL CHEM, V262, P7594; MACKAY F, 1994, J IMMUNOL, V153, P5274; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARUCHA PT, 1991, J IMMUNOL, V147, P2603; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; OBRIEN KD, 1994, AM J PATHOL, V144, P538; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; POBER JS, 1991, LAB INVEST, V64, P301; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; RUTLEDGE JC, 1994, J LIPID RES, V35, P1152; SHIBANO T, 1993, AM J PHYSIOL, V264, pH403, DOI 10.1152/ajpheart.1993.264.2.H403; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STOLPEN AH, 1986, AM J PATHOL, V123, P16; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TIPPING PG, 1993, AM J PATHOL, V142, P1721; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	43	148	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26174	26178		10.1074/jbc.271.42.26174	http://dx.doi.org/10.1074/jbc.271.42.26174			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824264	hybrid			2022-12-27	WOS:A1996VN18000070
J	Yang, MZ; Hayashi, K; Hayashi, M; Fujii, JT; Kurkinen, M				Yang, MZ; Hayashi, K; Hayashi, M; Fujii, JT; Kurkinen, M			Cloning and developmental expression of a membrane-type matrix metalloproteinase from chicken	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN STROMELYSIN GENE; IN-SITU HYBRIDIZATION; IV COLLAGENASE; MOLECULAR-CLONING; EXTRACELLULAR-MATRIX; TRANSMEMBRANE DOMAIN; TISSUE INHIBITORS; BREAST CARCINOMAS; CYSTEINE SWITCH; MESSENGER-RNAS	We have cloned a novel matrix metalloproteinase (MMP) from cultured chicken embryo fibroblasts. The cDNA-derived protein sequence contains 608 amino acids including a C-terminal hydrophobic transmembrane domain of 24 amino acids and a cytoplasmic domain of 20 amino acids. This chicken MMP is 72% similar to a recently described membrane-type MMP (MT-MMP) from human placenta (Sato, H., Takino, T., Okada, Y., Cao, J., Shinagawa, A., Yamamoto, E., and Seiki, M. (1994) Nature 370, 61-65). Accordingly, we name this novel MMP chicken MT-MMP. As shown by Northern blotting, two MT-MMP mRNAs of 6 and 10 kilobases are constitutively expressed but only modestly regulated by growth factors and cytokines in cultured chicken embryo fibroblasts. Both mRNAs are abundant in the head and body of 8- and 9-day-old chicken embryos. As shown by in situ mRNA hybridization, MT-MMP is expressed in embryonic neural tube, spinal ganglia, and respiratory epithelium, as web as in developing cartilage and muscle. Using reverse transcription-polymerase chain reaction, we have found MT-MMP mRNA in a-day-old chicken embryos and extraembryonic membranes. In addition, a strong correlation was observed between the mRNA expression of MT-MMP and 72-kDa type IV collagenase. Collectively, the early MT-MMP mRNA expression and its co-localization in several tissues with 72-kDa type IV collagenase mRNA suggest that the MT-MMP plays an important role in early development.	WAYNE STATE UNIV, SCH MED, CTR MOL MED & GENET, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, DEPT ANAT & CELL BIOL, DETROIT, MI 48202 USA; UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT PATHOL, PISCATAWAY, NJ 08854 USA	Wayne State University; Wayne State University; Wayne State University; Rutgers State University New Brunswick; Rutgers State University Medical Center					NICHD NIH HHS [HD 24442] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024442] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; AMES RT, 1994, BIOCHEM J, V300, P729, DOI 10.1042/bj3000729; APTE AN, 1993, BIOTECHNIQUES, V15, P890; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BONASSAR LJ, 1995, ARTHRITIS RHEUM, V38, P173, DOI 10.1002/art.1780380205; BRAUNHUT SJ, 1994, J BIOL CHEM, V269, P13472; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; FRISCH SM, 1987, J BIOL CHEM, V262, P16300; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; IYAMA K, 1994, HISTOCHEM J, V26, P844, DOI 10.1007/BF00162929; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KNAUPER V, 1993, BIOCHEM J, V295, P581; LEPAGE T, 1990, EMBO J, V9, P3003, DOI 10.1002/j.1460-2075.1990.tb07493.x; LOAKES D, 1995, NUCLEIC ACIDS RES, V23, P2361, DOI 10.1093/nar/23.13.2361; Matrisian L.M., 1990, Current Topics in Developmental Biology, V24, P219, DOI 10.1016/S0070-2153(08)60089-7; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NEWMAN KM, 1994, J VASC SURG, V20, P814, DOI 10.1016/S0741-5214(94)70169-5; NICHOLS R, 1994, NATURE, V369, P492, DOI 10.1038/369492a0; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; OGATA Y, 1992, J BIOL CHEM, V267, P3581; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Puente XS, 1996, CANCER RES, V56, P944; QUINONES S, 1994, BIOCHEM J, V302, P471, DOI 10.1042/bj3020471; REPONEN P, 1992, J BIOL CHEM, V267, P7856; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; SHAPIRO SD, 1992, J BIOL CHEM, V267, P4664; SIRUMCONNOLLY K, 1991, NUCLEIC ACIDS RES, V19, P335, DOI 10.1093/nar/19.2.335; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VINCENTI MP, 1994, ARTHRITIS RHEUM, V37, P1115, DOI 10.1002/art.1780370802; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERB Z, 1994, TXB RHEUMATOLOGY, P248; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLY JP, 1995, CANCER RES, V55, P1401; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YANG MZ, 1994, EUR J BIOCHEM, V222, P651, DOI 10.1111/j.1432-1033.1994.tb18909.x	57	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25548	25554		10.1074/jbc.271.41.25548	http://dx.doi.org/10.1074/jbc.271.41.25548			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810327	hybrid			2022-12-27	WOS:A1996VL69300071
J	Jiang, HB; Wang, Y; Huang, YL; Mulnix, AB; Kadel, J; Cole, K; Kanost, MR				Jiang, HB; Wang, Y; Huang, YL; Mulnix, AB; Kadel, J; Cole, K; Kanost, MR			Organization of serpin gene-1 from Manduca sexta - Evolution of a family of alternate exons encoding the reactive site loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATOR INHIBITOR-1 GENE; PROTEINASE-INHIBITORS; TOBACCO HORNWORM; DROSOPHILA; SUPERFAMILY; DIVERGENCE; EXPRESSION; SEQUENCES; ISOFORMS; CLONING	Manduca sexta serpin gene-1 encodes a family of serpins whose amino acid sequences are identical in their amino terminal 336 residues but variable in their carboxyl-terminal 39-46 residues, which includes the reactive site loop (Jiang, H., Wang, Y., and Kanost, M.R. (1994) J. Biol. Chem, 269, 55-58). Here, we report the gene's complete nucleotide sequence and exon-intron structure. A unique characteristic of this gene is its exon 9, which is present in 12 alternate forms between exons 8 and 10. Isolation and characterization of cDNA clones containing exons 9C, 9H, and 9I, which were not found previously, indicate that all 12 alternate forms of exon 9 can be utilized to generate 12 different serpins. The splicing pathway apparently allows inclusion of only one exon 9 per molecule of mature serpin-1 mRNA. Analysis of exon-intron border sequences reveals unique features that may be involved in regulation of RNA splicing. The exon 9 region has apparently evolved through rounds of exon duplication and sequence divergence. The exons near the center of the region may have evolved recently, whereas the outermost exons are the most ancient. Exons 9G and 9H were duplicated as a pair from exons 9E and 9F, an event that may have occurred more than once in the history of this gene.	KANSAS STATE UNIV, DEPT BIOCHEM, MANHATTAN, KS 66506 USA; EARLHAM COLL, DEPT BIOL, RICHMOND, IN 47374 USA; NATL INST STAND & TECHNOL, DIV BIOTECHNOL, GAITHERSBURG, MD 20899 USA	Kansas State University; Earlham College; National Institute of Standards & Technology (NIST) - USA				Kanost, Michael/0000-0002-6827-0061; Jiang, Haobo/0000-0003-1357-1315	NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R29GM041247] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONIEWSKI C, 1993, INSECT BIOCHEM MOLEC, V23, P105, DOI 10.1016/0965-1748(93)90088-A; BARBAS JA, 1993, MOL CELL BIOL, V13, P1433, DOI 10.1128/MCB.13.3.1433; BENSON S A, 1984, Biotechniques, V2, P126; BILLINGSLEY GD, 1993, AM J HUM GENET, V52, P343; BORRIELLO F, 1991, P NATL ACAD SCI USA, V88, P9417, DOI 10.1073/pnas.88.21.9417; BOSMA PJ, 1988, J BIOL CHEM, V263, P9129; BRADFIELD JY, 1983, CHROMOSOMA, V88, P190, DOI 10.1007/BF00285619; BRUZDZINSKI CJ, 1990, J BIOL CHEM, V265, P2078; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; COLE KD, 1990, INSECT BIOCHEM, V20, P381, DOI 10.1016/0020-1790(90)90058-3; *GEN COMP GROUP, 1991, PROGR MAN GCG PACK V; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HORODYSKI FM, 1989, P NATL ACAD SCI USA, V86, P8123, DOI 10.1073/pnas.86.20.8123; HWANG SR, 1994, P NATL ACAD SCI USA, V91, P9579, DOI 10.1073/pnas.91.20.9579; Jiang H, 1995, INSECT BIOCHEM MOLEC, V25, P1093, DOI 10.1016/0965-1748(95)00042-9; JIANG HB, 1994, J BIOL CHEM, V269, P55; KANOST MR, 1989, J BIOL CHEM, V264, P965; KANOST MR, 1995, INSECT BIOCHEM MOLEC, V25, P285, DOI 10.1016/0965-1748(94)00067-R; KANOST MR, 1996, IN PRESS SOS PUBLICA; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; REBERS JE, 1988, J MOL BIOL, V203, P411, DOI 10.1016/0022-2836(88)90009-5; RHEAUME C, 1994, J MOL EVOL, V38, P121, DOI 10.1007/BF00166159; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; Sugumaran Manickam, 1993, P317; WANG XY, 1989, GENE, V80, P259, DOI 10.1016/0378-1119(89)90290-4; WILLOTT E, 1989, J BIOL CHEM, V264, P19052; WRIGHT HT, 1993, J MOL EVOL, V36, P136, DOI 10.1007/BF00166249	33	74	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28017	28023		10.1074/jbc.271.45.28017	http://dx.doi.org/10.1074/jbc.271.45.28017			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910411	hybrid			2022-12-27	WOS:A1996VU03300011
J	Krovat, BC; Jantsch, MF				Krovat, BC; Jantsch, MF			Comparative mutational analysis of the double-stranded RNA binding domains of Xenopus laevis RNA-binding protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DAI PKR; MESSENGER-RNA; DROSOPHILA STAUFEN; INTERFERON ACTION; ESCHERICHIA-COLI; MOTIF; IDENTIFICATION; LOCALIZATION; MECHANISM	Xenopus laevis RNA-binding protein A is a ubiquitously expressed, double-stranded RNA-binding protein that is associated with the majority of cellular RNAs, ribosomal RNAs, and hnRNAs, X. laevis RNA-binding protein A contains three copies of the double-stranded RNA-binding domain (dsRBD) in tandem arrangement, Two of them, xl1 and xl2, belong to the type A group of dsRBDs that show strong homologies to the entire length of a defined consensus sequence. The xl3 domain, in contrast, is a type B dsRBD which only matches the basic C-terminal end of the dsRBD consensus sequence, Here we show that only xl2 but neither xl1 nor xl3 are able to bind double-stranded RNA substrates in vitro, suggesting that different dsRBD copies have varying RNA binding activities. By fine mapping mutagenesis of the isolated xl2 domain, we identified at least two central aromatic amino acids and a C-terminal alpha-helix that are indispensable for dsRNA binding. Furthermore, we show that different charge distributions within the C-terminal alpha-helices of xl1 and xl2 seem responsible for the different RNA binding behaviors of these two dsRBDs. Analyses of the RNA binding properties of constructs containing various combinations of different dsRBDs reveal that type A dsRBDs exhibit a cooperative binding effect, whereas type B dsRBDs show a rather low binding activity, thus contributing only to a minor extent to a stable RNA-protein interaction.	UNIV VIENNA,INST BOT,DEPT CYTOL & GENET,A-1030 VIENNA,AUSTRIA	University of Vienna			Jantsch, Michael/N-7873-2019; Jantsch, Michael/E-9122-2015	Jantsch, Michael/0000-0003-1747-0853; Jantsch, Michael/0000-0003-1747-0853				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; BASS BL, 1993, RNA WORLD, P383; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; CLARKE PA, 1994, NUCLEIC ACIDS RES, V22, P4364, DOI 10.1093/nar/22.21.4364; CLARKE PA, 1995, RNA, V1, P7; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; IZAURRALDE E, 1995, CELL, V81, P153, DOI 10.1016/0092-8674(95)90323-2; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEITZ TA, 1993, RNA WORLD, P219; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13	31	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28112	28119		10.1074/jbc.271.45.28112	http://dx.doi.org/10.1074/jbc.271.45.28112			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910425	hybrid			2022-12-27	WOS:A1996VU03300025
J	Sexton, DJ; Carver, TE; Berdis, AJ; Benkovic, SJ				Sexton, DJ; Carver, TE; Berdis, AJ; Benkovic, SJ			Protein-protein and protein-DNA interactions at the bacteriophage T4 DNA replication fork - Characterization of a fluorescently labeled DNA polymerase sliding clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE HOLOENZYME PARTICLE; ACCESSORY PROTEINS; ESCHERICHIA-COLI; III HOLOENZYME; PRIMER-TEMPLATE; ATP HYDROLYSIS; COMPLEX; PURIFICATION; MACHINE; LOADER	The T4 DNA polymerase holoenzyme is composed of the polymerase enzyme complexed to the sliding clamp (the 45 protein), which is loaded onto DNA by an ATP-dependent clamp loader (the 44/62 complex). This paper describes a new method to directly investigate the mechanism of holoenzyme assembly using a fluorescently labeled cysteine mutant of the 45 protein. This protein possessed unaltered function yet produced substantial changes in probe fluorescence intensity upon interacting with other components of the holoenzyme. These fluorescence changes provide insight into the role of ATP hydrolysis in holoenzyme assembly. Using either ATP or the non-hydrolyzable ATP analog, adenosine 5'O-(3-thiophosphate), events in holoenzyme assembly were assigned as either dependent or independent of ATP hydrolysis. A holoenzyme assembly mechanism is proposed in which the 44/62 complex mediates the association of the 45 protein with DNA in an ATP-dependent manner not requiring ATP hydrolysis. Upon ATP hydrolysis, the 44/62 complex triggers a conformational change in the 45 protein that may be attributed to the clamp loading onto DNA.	PENN STATE UNIV, DEPT CHEM, DAVEY LAB 152, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park				Sexton, Daniel J/0000-0001-9604-5948	NIGMS NIH HHS [GM13306] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berdis AJ, 1996, BIOCHEMISTRY-US, V35, P9253, DOI 10.1021/bi952569w; CAPSON TL, 1992, BIOCHEMISTRY-US, V31, P10984, DOI 10.1021/bi00160a007; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREY MW, 1993, P NATL ACAD SCI USA, V90, P2579, DOI 10.1073/pnas.90.7.2579; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; Kaboord BF, 1996, BIOCHEMISTRY-US, V35, P1084, DOI 10.1021/bi9520747; KABOORD BF, 1995, CURR BIOL, V5, P149, DOI 10.1016/S0960-9822(95)00036-4; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, VSecond, P113; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; MUNN MM, 1991, J BIOL CHEM, V266, P20024; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOSSAL NG, 1979, J BIOL CHEM, V254, P6026; NOSSAL NG, 1992, FASEB J, V6, P871, DOI 10.1096/fasebj.6.3.1310946; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1991, J BIOL CHEM, V266, P21681; PIPERNO JR, 1978, J BIOL CHEM, V253, P5174; RUSH J, 1989, J BIOL CHEM, V264, P10943; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; XIAO H, 1995, J BIOL CHEM, V270, P13378, DOI 10.1074/jbc.270.22.13378; YODER BL, 1991, J BIOL CHEM, V266, P22689; YOUNG MC, 1992, BIOCHEMISTRY-US, V31, P8675, DOI 10.1021/bi00152a001	25	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28045	28051		10.1074/jbc.271.45.28045	http://dx.doi.org/10.1074/jbc.271.45.28045			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910415	hybrid			2022-12-27	WOS:A1996VU03300015
J	Su, J; Yang, LT; Sap, J				Su, J; Yang, LT; Sap, J			Association between receptor protein-tyrosine phosphatase RPTP alpha and the Grb2 adaptor - Dual Src homology (SH)2/SH3 domain requirement and functional consequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; BINDING-SITE; SH3 DOMAINS; PHOSPHOTYROSINE PHOSPHATASE; SIGNAL-TRANSDUCTION; T-CELLS; KINASE ACTIVATION; RAS PATHWAY; PHOSPHORYLATION; DIFFERENTIATION	Receptor protein-tyrosine phosphatase RPTP alpha is found associated in vivo with the adaptor protein Grb2. Formation of this complex, which contains no detectable levels of Sos, is known to depend on a C-terminal phosphorylated tyrosine residue (Tyr(798)) in RPTP alpha and on the Src homology (SH) 2 domain in Grb2 (1, 2). We show here that association of Grb2 with RPTP alpha also involves a critical function for the C-terminal SH3 domain of Grb2. Furthermore, Grb2 SH3 binding peptides interfere with RPTP alpha-Grb2 association in vitro, and the RPTP alpha protein can dissociate the Grb2-Sos complex in vivo. These observations constitute a novel mode of Grb2 association and suggest a model in which association with a tyrosine-phosphorylated protein restricts the repertoire of SH3 binding proteins with which Grb2 can simultaneously interact. The function of the Tyr(798) tyrosine phosphorylation/Grb2 binding site in RPTP alpha was studied further by expression of wild type or mutant RPTP alpha proteins in PC12 cells. In these cells, wild type RPTP alpha interferes with acidic fibroblast growth factor-induced neurite outgrowth; this effect requires both the catalytic activity and the Grb2 binding Tyr(798) residue in RPTP alpha. In contrast, expression of catalytically active RPTP alpha containing a mutated tyrosine phosphorylation/Grb2 association site enhances neurite outgrowth. Our observations associate a functional effect with tyrosine phosphorylation of, and ensuing association of signaling proteins with, a receptor protein-tyrosine phosphatase and raise the possibility that RPTP alpha association may modulate Grb2 function and vice versa.	NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University					NATIONAL CANCER INSTITUTE [R29CA068365] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA68365-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BELLOT F, 1990, J CELL BIOL, V110, P491, DOI 10.1083/jcb.110.2.491; BENJAMIN CW, 1994, J BIOL CHEM, V269, P31346; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOULTER CA, 1988, ONCOGENE, V2, P207; Brady-Kalnay Susann, 1994, Trends in Cell Biology, V4, P73, DOI 10.1016/0962-8924(94)90172-4; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DENHERTOG J, 1995, CELL GROWTH DIFFER, V6, P303; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEMMON MA, 1994, J BIOL CHEM, V269, P31653; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MIKI H, 1994, J BIOL CHEM, V269, P5489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REIF K, 1994, J BIOL CHEM, V269, P14081; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMIDT JW, 1992, J CELL BIOL, V116, P1019, DOI 10.1083/jcb.116.4.1019; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STOCKSCHLAEDER MAR, 1991, HUM GENE THER, V2, P33, DOI 10.1089/hum.1991.2.1-33; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; SU J, 1994, J BIOL CHEM, V269, P18731; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU M, 1995, THESIS NEW YORK U; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	74	53	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28086	28096		10.1074/jbc.271.45.28086	http://dx.doi.org/10.1074/jbc.271.45.28086			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910422	hybrid			2022-12-27	WOS:A1996VU03300022
J	Noguchi, T; Matozaki, T; Fujioka, Y; Yamao, T; Tsuda, M; Takada, T; Kasuga, M				Noguchi, T; Matozaki, T; Fujioka, Y; Yamao, T; Tsuda, M; Takada, T; Kasuga, M			Characterization of a 115-kDa protein that binds to SH-PTP2, a protein-tyrosine phosphatase with Src homology 2 domains, in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; SIGNAL-TRANSDUCTION; MITOGENIC SIGNAL; SYP PHOSPHATASE; KINASE; SHPTP2; IDENTIFICATION; ACTIVATION; EXPRESSION	SN-PTP2, a non-transmembrane-type protein-tyrosine phosphatase with two Src homology 2 domains, was previously shown to play a positive signaling role in the insulin-induced activation of Ras and mitogen-activated protein kinase, SH-PTP2 was shown to associate with a 115-kDa tyrosine phosphorylated protein (pp115), as well as with insulin receptor substrate 1, in insulin-stimulated Chinese hamster ovary cells that overexpress human insulin receptors (CHO-IR cells). In vivo and in vitro binding experiments revealed that SH-PTP2 bound to pp115 through one or both of its SH2 domains. The pp115 protein was partially purified from insulin stimulated CHO-TR. cells that; overexpress a catalytically inactive SH-PTP2 by a combination of immunoaffinity and lectin-affinity chromatography, A monoclonal antibody to pp115 was then generated by injecting the partially purified protein into mice, Experiments with this monoclonal antibody revealed that pp115 is a transmembrane protein with a domain exposed on the cell surface and that it binds to SH-PTP2 in response to insulin. The insulin receptor kinase appeared to phosphorylate pp115 on tyrosine residues both in vivo and in vitro, The extent of tyrosine phosphorylation of pp115 associated with SH-PTP2 was greatly increased in CHO-IR cells that overexpress catalytically inactive SH-PTP2 compared with that observed in CHO-Ln cells overexpressing wild-type SH-PTP2, Furthermore, recombinant SH-PTP2 preferentially dephosphorylated pp115 in vitro, indicating that SH-PTP2 may catalyze the dephosphorylation of phosphotyrosine residues in pp115 after it binds to this protein. These results suggest that pp115 may act as a transmembrane anchor to which SH-PTP2 binds in response to insulin. Furthermore, pp115 may be a physiological substrate for both the insulin receptor kinase and SH-PTP2.	KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Kobe University								ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KASUGA M, 1983, P NATL ACAD SCI-BIOL, V80, P2137, DOI 10.1073/pnas.80.8.2137; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; MATOZAKI T, 1992, CANCER RES, V52, P1; MATOZAKI T, 1995, ADV PROTEIN PHOSPHAT, V9, P319; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1993, CELL, V74, P219, DOI 10.1016/0092-8674(93)90412-J; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	34	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27652	27658		10.1074/jbc.271.44.27652	http://dx.doi.org/10.1074/jbc.271.44.27652			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910355	hybrid			2022-12-27	WOS:A1996VQ67900073
J	Trieber, CA; Rothery, RA; Weiner, JH				Trieber, CA; Rothery, RA; Weiner, JH			Consequences of removal of a molybdenum ligand (DmsA-Ser-176) of Escherichia coli dimethyl sulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAMAGNETIC-RESONANCE SPECTROSCOPY; MOLYBDOPTERIN GUANINE DINUCLEOTIDE; PERIPLASMIC NITRATE REDUCTASE; IRON-SULFUR MOLYBDOENZYME; F-SP DENITRIFICANS; X-RAY-ABSORPTION; NUCLEOTIDE-SEQUENCE; FORMATE DEHYDROGENASE; DIMETHYLSULFOXIDE REDUCTASE; METHANOBACTERIUM-FORMICICUM	We have used site-directed mutagenesis and EPR spectroscopy to examine the consequences of altering the molybdenum ligand in Escherichia coli dimethyl sulfoxide (Me(2)SO) reductase (DmsABC), Mutagenesis of DmsA-Ser-176 to Ala, Cys, or His abolishes both respiratory growth on Me,SO and in vitro benzyl viologen: Me,SO oxidoreductase activity. EPR spectroscopy reveals changes in the line shape and the g(av) of the Mo(V) signals of the S176A and S176C enzymes. The midpoint potentials (E(m,7)) of the Mo(VI)/Mo(V) and Mo(V)/Mo(IV) couples in DmsABC are -15 and -175 mV. The E(m,7) the Mo(V)/Mo(IV) couple in the S176A mutant is 35 mV; however, the Mo(V) species could not be further oxidized with ferricyanide. Titration of the S176C mutant produced several overlapping Mo(V) species occurring at E(h) > -150 mV, suggesting heterogeneity in the molybdenum environment. A Mo(V) spectrum was not visible in S176H membranes poised between -435 to 350 mV or oxidized with 200 mu M ferricyanide. No differences were detected in the EPR spectra of the reduced [4Fe-4S] clusters of DmsABC and the S176A and S176H mutant enzymes; however, the S176C mutation altered the EPR line shape of one of the reduced [4Fe-4S] clusters.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA; UNIV ALBERTA, MRC, MOL BIOL MEMBRANES GRP, EDMONTON, AB T6G 2H7, CANADA	University of Alberta; University of Alberta				Trieber, Catharine/0000-0002-1336-1126; Rothery, Richard/0000-0003-3265-1783				BARBER MJ, 1976, BIOCHEM J, V153, P297, DOI 10.1042/bj1530297; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P3561, DOI 10.1021/bi00258a006; BARBER MJ, 1983, J BIOL CHEM, V258, P839; BARBER MJ, 1995, ARCH BIOCHEM BIOPHYS, V320, P266, DOI 10.1016/0003-9861(95)90009-8; BASTIAN NR, 1991, J BIOL CHEM, V266, P45; BERG BL, 1991, J BIOL CHEM, V266, P22380; BERKS BC, 1995, BIOCHEM J, V309, P983, DOI 10.1042/bj3090983; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BILOUS PT, 1988, MOL MICROBIOL, V2, P785, DOI 10.1111/j.1365-2958.1988.tb00090.x; BILOUS PT, 1985, J BACTERIOL, V162, P1151, DOI 10.1128/JB.162.3.1151-1155.1985; BLASCO F, 1989, MOL GEN GENET, V218, P249, DOI 10.1007/BF00331275; BLASCO F, 1990, MOL GEN GENET, V222, P104, DOI 10.1007/BF00283030; BOKRANZ M, 1991, ARCH MICROBIOL, V156, P119, DOI 10.1007/BF00290984; CAMMACK R, 1990, BIOCHEMISTRY-US, V29, P8410, DOI 10.1021/bi00488a030; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1979, BIOCHEM BIOPH RES CO, V91, P434, DOI 10.1016/0006-291X(79)91540-7; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; GEORGE GN, 1989, BIOCHEM J, V259, P693, DOI 10.1042/bj2590693; GEORGE GN, 1989, BIOCHEMISTRY-US, V28, P5075, DOI 10.1021/bi00438a026; GLADYSHEV VN, 1994, P NATL ACAD SCI USA, V91, P7708, DOI 10.1073/pnas.91.16.7708; HEINZINGER NK, 1995, J BACTERIOL, V177, P2813, DOI 10.1128/jb.177.10.2813-2820.1995; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; Hilton JC, 1996, ARCH BIOCHEM BIOPHYS, V325, P139, DOI 10.1006/abbi.1996.0017; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; KRAFFT T, 1992, EUR J BIOCHEM, V206, P503, DOI 10.1111/j.1432-1033.1992.tb16953.x; LIN JT, 1993, J BACTERIOL, V175, P2370, DOI 10.1128/JB.175.8.2370-2378.1993; MANADORI A, 1992, BIOCHEMISTRY-US, V31, P2703; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEJEAN V, 1994, MOL MICROBIOL, V11, P1169, DOI 10.1111/j.1365-2958.1994.tb00393.x; OGAWA KI, 1995, J BACTERIOL, V177, P1409, DOI 10.1128/jb.177.5.1409-1413.1995; PAULSEN KE, 1993, METHOD ENZYMOL, V227, P396; PIERSON DE, 1990, J BACTERIOL, V172, P2194, DOI 10.1128/jb.172.4.2194-2198.1990; PLUNKETT G, 1993, NUCLEIC ACIDS RES, V21, P3391, DOI 10.1093/nar/21.15.3391; POLLOCK VV, 1995, ARCH BIOCHEM BIOPHYS, V318, P322, DOI 10.1006/abbi.1995.1236; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROTHERY RA, 1995, J BACTERIOL, V177, P2057, DOI 10.1128/jb.177.8.2057-2063.1995; Rothery RA, 1996, BIOCHEMISTRY-US, V35, P3247, DOI 10.1021/bi951584y; ROTHERY RA, 1993, BIOCHEMISTRY-US, V32, P5855, DOI 10.1021/bi00073a019; ROTHERY RA, 1991, BIOCHEMISTRY-US, V30, P8296, DOI 10.1021/bi00098a003; SAMBASIVARAO D, 1991, J BACTERIOL, V173, P5935, DOI 10.1128/jb.173.19.5935-5943.1991; SAMBASIVARAO D, 1990, J BACTERIOL, V172, P5938, DOI 10.1128/jb.172.10.5938-5948.1990; Sambrook J., 2002, MOL CLONING LAB MANU; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SHUBER AP, 1986, J BIOL CHEM, V261, P2942; SIDDIQUI RA, 1993, J BACTERIOL, V175, P5867, DOI 10.1128/JB.175.18.5867-5876.1993; Trieber CA, 1996, J BIOL CHEM, V271, P4620; TRIEBER CA, 1994, J BIOL CHEM, V269, P7103; VINCENT SP, 1979, BIOCHEM J, V177, P757, DOI 10.1042/bj1770757; VINCENT SP, 1978, BIOCHEM J, V171, P639, DOI 10.1042/bj1710639; WEINER JH, 1992, BIOCHIM BIOPHYS ACTA, V1102, P1, DOI 10.1016/0167-4838(92)90493-W; WEINER JH, 1988, J BACTERIOL, V170, P1505, DOI 10.1128/jb.170.4.1505-1510.1988; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; YAMAMOTO I, 1995, BIOSCI BIOTECH BIOCH, V59, P1850, DOI 10.1271/bbb.59.1850; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	56	27	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27339	27345		10.1074/jbc.271.44.27339	http://dx.doi.org/10.1074/jbc.271.44.27339			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910310	hybrid			2022-12-27	WOS:A1996VQ67900028
J	Quimby, BB; Wells, L; Wilkinson, KD; FridovichKeil, JL				Quimby, BB; Wells, L; Wilkinson, KD; FridovichKeil, JL			Functional requirements of the active site position 185 in the human enzyme galactose-1-phosphate uridylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; YEAST; GALACTOSEMIA; MUTAGENESIS	The active site of galactose-1-phosphate uridylyltransferase (GALT) includes a HPH sequence that has been conserved in all species examined from Escherichia coli to humans, The crystal structure of the E. coli enzyme suggests that this proline is important in positioning the active site histidine (His-166) near the substrate, To examine the role of this proline in the homologous human sequence, we have performed saturating mutagenesis at Pro 185 within human GALT and characterized each resultant mutant enzyme using a yeast expression system, Activity analyses in crude lysates indicated that only proline at position 185 produced wild type levels of activity, although five other amino acids, Ala, Gly, Ser, Gln, and Glu, all produced partially active enzymes, Western blot analyses of the GALT proteins in these lysates demonstrated that abundance varied from 9-118% of wild-type and was independent of activity, All five active mutant proteins were purified and characterized with regard to specific activity, apparent K-m for both substrates, and temperature-dependence of activity, Finally, modeling of these mutations onto the conserved E. coli active site structure was performed, Together, these results provide functional evidence demonstrating the critical role of Pro-185 in facilitating the transferase reaction.	EMORY UNIV,SCH MED,DEPT MOL & MED GENET,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM GENET & MOL BIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,GRAD PROGRAM BIOCHEM & MOL BIOL,ATLANTA,GA 30322	Emory University; Emory University; Emory University; Emory University			Wells, Lance/H-3118-2013	Wells, Lance/0000-0003-4956-5363	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046403, R29DK046403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030308] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46403] Funding Source: Medline; NIGMS NIH HHS [GM30308] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANROQUES J, 1981, BIOCHIM BIOPHYS ACTA, V657, P374, DOI 10.1016/0005-2744(81)90323-5; BANROQUES J, 1983, BIOCHIMIE, V65, P7, DOI 10.1016/S0300-9084(83)80023-6; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BEUTLER D, 1966, J LAB CLIN MED, V67, P947; Cornish-Bowden A., 1981, FUNDAMENTALS ENZYME; ELSAS LJ, 1995, AM J HUM GENET, V56, P630; Elsas LJ, 1993, INT PEDIATR, V8, P101; Elsevier JP, 1996, P NATL ACAD SCI USA, V93, P7166, DOI 10.1073/pnas.93.14.7166; FIELD TL, 1989, BIOCHEMISTRY-US, V28, P2094, DOI 10.1021/bi00431a019; FREDOVICHKEIL JL, 1995, BIOCHEM MOL MED, V56, P121; FREY PA, 1982, METHOD ENZYMOL, V87, P20; FRIDOVICHKEIL JL, 1993, P NATL ACAD SCI USA, V90, P398, DOI 10.1073/pnas.90.2.398; HELMER GR, 1981, ARCH BIOCHEM BIOPHYS, V210, P573, DOI 10.1016/0003-9861(81)90223-X; MARKUS HB, 1977, J BIOL CHEM, V252, P5363; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MUCKE M, 1994, BIOCHEMISTRY-US, V33, P14608; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REICHARDT JKV, 1991, P NATL ACAD SCI USA, V88, P2633, DOI 10.1073/pnas.88.7.2633; Sambrook J., 2002, MOL CLONING LAB MANU; Segal S, 1995, METABOLIC MOL BASIS, P967; WEDEKIND JE, 1995, BIOCHEMISTRY-US, V34, P11049, DOI 10.1021/bi00035a010; WILLIAMS VP, 1978, ARCH BIOCHEM BIOPHYS, V191, P182, DOI 10.1016/0003-9861(78)90080-2; WONG LJ, 1974, J BIOL CHEM, V249, P2322; WONG LJ, 1977, BIOCHEMISTRY-US, V16, P1010, DOI 10.1021/bi00624a032; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P961, DOI 10.1002/pro.5560010801	25	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26835	26842		10.1074/jbc.271.43.26835	http://dx.doi.org/10.1074/jbc.271.43.26835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900165	hybrid			2022-12-27	WOS:A1996VP23300059
J	Resnick, D; Chatterton, JE; Schwartz, K; Slayter, H; Krieger, M				Resnick, D; Chatterton, JE; Schwartz, K; Slayter, H; Krieger, M			Structure of class A macrophage scavenger receptors - Electron microscopic study of flexible, multidomain, fibrous proteins and determination of the disulfide bond pattern of the scavenger receptor cysteine-rich domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; MACROMOLECULES; CONTAINS; EXPRESSION; CLONING; GENE	Structures of secreted forms of the human type I and II class A macrophage scavenger receptors were studied using biochemical and biophysical methods. Proteolytic analysis was used to determine the intramolecular disulfide bonds in the type I-specific scavenger receptor cysteine-rich (SRCR) domain: Cys(2)-Cys(7), Cys(3)-Cys(8), and Cys(5)-Cys(6). This pattern is likely to be shared by the highly homologous domains in the many other members of the SRCR domain superfamily. Electron microscopy using rotary shadowing and negative staining showed that the type I and II receptors are extended molecules whose contour lengths are similar to 440 Angstrom. They comprised two adjacent fibrous segments, an alpha-helical coiled-coil (similar to 230 Angstrom, including a contribution from the N-terminal spacer domain) and a collagenous triple helix (similar to 210 Angstrom). The type I molecules also contained a C-terminal globular structure (similar to 58 x 76 Angstrom) composed of three SRCR domains. The fibrous domains were joined by an extremely flexible hinge. The angle between these domains varied from 0 to 180 degrees and depended on the conditions of sample preparation. Unexpectedly, at physiologic pH, the prevalent angle seen using rotary shadowing was 0 degrees, resulting in a structure that is significantly more compact than previously suggested. The apparent juxtaposition of the fibrous domains at neutral pH provides a frame-work for future structure-function studies of these unusual multiligand receptors.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; ARRIS PHARMACEUT CORP, San Francisco, CA 94080 USA; DANA FARBER CANC INST, BOSTON, MA 02115 USA	Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute			Krieger, Marco/AAE-8611-2020		NHLBI NIH HHS [HL 52212, HL 33014, HL 41484] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; ASHKENAS J, 1993, J LIPID RES, V34, P983; BELLA J, 1994, SCIENCE, V266, P75, DOI 10.1126/science.7695699; BICKEL PE, 1992, J CLIN INVEST, V90, P1450, DOI 10.1172/JCI116012; Cheng H, 1996, ANAT REC, V244, P327; ELOMAA O, 1995, CELL, V80, P603, DOI 10.1016/0092-8674(95)90514-6; EMI M, 1993, J BIOL CHEM, V268, P2120; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KOZARSKY KF, 1986, J CELL BIOL, V102, P1567, DOI 10.1083/jcb.102.5.1567; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LI XJ, 1995, J BIOL CHEM, V270, P17674, DOI 10.1074/jbc.270.30.17674; Lu J, 1993, Behring Inst Mitt, P6; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAITO M, 1991, AM J PATHOL, V139, P1411; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; RESNICK D, 1993, J BIOL CHEM, V268, P3538; RESNICK D, 1994, TRENDS BIOCHEM SCI, V19, P5, DOI 10.1016/0968-0004(94)90165-1; RESNICK D, 1996, THESIS MIT; ROHRER L, 1990, NATURE, V343, P570, DOI 10.1038/343570a0; SCHUMAKER VN, 1981, J MOL BIOL, V148, P191, DOI 10.1016/0022-2836(81)90511-8; SLAYTER HS, 1983, ANN NY ACAD SCI, V408, P131, DOI 10.1111/j.1749-6632.1983.tb23241.x; SLAYTER HS, 1976, ULTRAMICROSCOPY, V1, P341, DOI 10.1016/0304-3991(76)90050-4; SLAYTER HS, 1989, METHOD ENZYMOL, V169, P326; SLAYTER HS, 1991, ELECTRON MICROS, P151; SMITH CA, 1984, J ULTRA MOL STRUCT R, V89, P111, DOI 10.1016/S0022-5320(84)80008-8; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; VALENTINE RC, 1968, BIOCHEMISTRY-US, V7, P2143, DOI 10.1021/bi00846a017; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187	33	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26924	26930		10.1074/jbc.271.43.26924	http://dx.doi.org/10.1074/jbc.271.43.26924			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900177	hybrid			2022-12-27	WOS:A1996VP23300071
J	Bagarozzi, DA; Pike, R; Potempa, J; Travis, J				Bagarozzi, DA; Pike, R; Potempa, J; Travis, J			Purification and characterization of a novel endopeptidase in ragweed (Ambrosia artemisiifolia) pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL PEPTIDE; NEUROGENIC INFLAMMATION; SEQUENCE; NEUROPEPTIDES; ASTHMA; VIP; DEGRADATION; REACTIVITY; ALLERGENS; RESPONSES	Ragweed (Ambrosia artemisiifolia), the major cause of late summer hay fever (allergic rhinitis) in the United States and Canada, is clinically the most important source of the seasonal aeroallergens. A novel endopeptidase was extracted from the pollen of this plant and purified by a series of column chromatographic steps. It has a molecular mass of 82 kDa according to gel filtration and SDS-polyacrylamide gel electrophoresis and a pH optimum near 9.0, and its activity is unaffected by chelating or reducing agents. A 17-amino acid aminoterminal sequence of this protein showed no similarity with any other proteases. The enzyme was inhibited by diisopropyl fluorophosphate, a general serine class inhibitor, and more specifically N-p-tosyl-L-phenylalanine chloromethyl ketone, a chymotrypsin-like proteinase inhibitor. Various synthetic substrates were efficiently cleaved with a strong preference for Phe in the P-1 and P-3 position and Pro in the P-2 position. This specificity was confirmed through inhibition studies with both peptidyl chloromethyl ketone and organophosphate inhibitors. In addition to synthetic substrates, the neuropeptides, vasoactive intestinal peptide and substance P, which are required for normalized lung functions, were also rapidly hydrolyzed. Activity toward protein substrates was not detected with the exception of the inactivation of alpha-1-proteinase inhibitor, which occurred through cleavage within the reactive site loop. These results indicate that the purified enzyme is a novel endopeptidase, which may be involved in both the degradation of neuropeptides and the inactivation of protective proteinase inhibitors during pollen-initiated allergic reactions.	UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30605; UNIV CAMBRIDGE,CTR MRC,DEPT HAEMATOL,CAMBRIDGE CB2 2QH,ENGLAND; JAGIELLONIAN UNIV,INST MOL BIOL,PL-31120 KRAKOW,POLAND	University System of Georgia; University of Georgia; University of Cambridge; Jagiellonian University				Pike, Robert/0000-0002-2083-0269				BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1984, AM REV RESPIR DIS, V130, P162; BARNES PJ, 1991, INT ARCH ALLER A IMM, V94, P303, DOI 10.1159/000235392; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTRAND C, 1993, J IMMUNOL, V150, P1479; BLANCHARD GC, 1976, ANN ALLERGY, V36, P410; BODANSZKY M, 1973, P NATL ACAD SCI USA, V70, P382, DOI 10.1073/pnas.70.2.382; BOOMSMA JD, 1992, CHEST, V101, P5389; BOUSQUET J, 1978, REV FR ALLERGOL, V18, P131, DOI 10.1016/S0335-7457(78)80014-8; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P76, DOI 10.1016/S0091-6749(05)80043-0; BUNNETT NW, 1987, AM REV RESPIR DIS, V136, P527; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; GASHI AA, 1986, AM J PHYSIOL, V251, pC223, DOI 10.1152/ajpcell.1986.251.2.C223; GOYAL RK, 1980, NATURE, V288, P378, DOI 10.1038/288378a0; KING TP, 1976, ADV IMMUNOL, V23, P77, DOI 10.1016/S0065-2776(08)60319-3; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KNOX RB, 1973, J CELL SCI, V12, P421; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILLY CM, 1994, J CLIN INVEST, V93, P2667, DOI 10.1172/JCI117280; LUNDBERG JM, 1984, PEPTIDES, V5, P593, DOI 10.1016/0196-9781(84)90090-1; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; MATHESON N, 1995, AM J RESP CELL MOL, V12, P441, DOI 10.1165/ajrcmb.12.4.7695924; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCCORMICK S, 1991, TRENDS GENET, V7, P298, DOI 10.1016/0168-9525(91)90312-E; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; MIDDLETON E, 1993, ALLERGY PRINCIPLES P, V1, P650; MIDDLETON EF, 1993, ALLERGY PRINCIPLES P, V2, P1173; NADEL JA, 1991, AM REV RESPIR DIS, V143, P533; PATON JB, 1919, P SOC EXP BIOL MED, V17, P60; RICHARDSON J, 1976, J APPL PHYSIOL, V41, P764, DOI 10.1152/jappl.1976.41.5.764; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROGERS BL, 1993, GENE, V133, P219, DOI 10.1016/0378-1119(93)90641-F; ROGERS BL, 1991, J IMMUNOL, V147, P2547; SAID SI, 1984, PEPTIDES, V5, P143, DOI 10.1016/0196-9781(84)90197-9; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRAVIS J, 1989, LUNG CELL BIOL, P1227; WANNER A, 1985, J ALLERGY CLIN IMMUN, V76, P177, DOI 10.1016/0091-6749(85)90698-0; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WODEHOUSE RP, 1971, HAYFEVER PLANTS, P116	42	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26227	26232		10.1074/jbc.271.42.26227	http://dx.doi.org/10.1074/jbc.271.42.26227			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824272	hybrid			2022-12-27	WOS:A1996VN18000078
J	Bokoch, GM; Wang, Y; Bohl, BP; Sells, MA; Quilliam, LA; Knaus, UG				Bokoch, GM; Wang, Y; Bohl, BP; Sells, MA; Quilliam, LA; Knaus, UG			Interaction of the Nck adapter protein with p21-activated kinase (PAK1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SH3 DOMAINS; PHOSPHORYLATION; RECEPTORS; ACTIVATION; CDC42; SITE	The p21-activated kinases (PAKs) link G protein-coupled receptors and growth factor receptors (S. Dharmawardhane, R. H. Daniels, and G. M. Bokoch, submitted for publication) to activation of MAP kinase cascades and to cytoskeletal reorganization (M. A. Sells, U. G. Knaus, D. Ambrose, S. Bagrodia, G. M. Bokoch, and J. Chernoff, submitted for publication), The proteins that interact with PAK to mediate its cellular effects and to couple it to upstream receptors are unknown, We describe here a specific interaction of the Nck adapter molecule with PAK1 both in vitro and in vivo. PAK1 and Nck associate in COS-7 and Swiss 3T3 cells constitutively, but this interaction is strengthened upon platelet-derived growth factor receptor stimulation. We show that Nck binds to PAK1 through its second Src homology 3 (SH3) domain, while PAK1 interacts with Nck via the first proline-rich SH3 binding motif at its amino terminus. The interaction of active PAK1 with Nck leads to the phosphorylation of Nck at multiple sites, Association of Nck with PAK1 may serve to link this important regulatory kinase to cell activation by growth factor receptors.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA; INDIANA UNIV, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Scripps Research Institute; Fox Chase Cancer Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Bokoch, GM (corresponding author), SCRIPPS RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.		Quilliam, Lawrence/Q-4987-2019; Quilliam, Lawrence/B-6447-2015		NATIONAL CANCER INSTITUTE [R29CA063139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER; NCI NIH HHS [CA63139] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIGMS NIH HHS [GM39434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; HU QJ, 1995, MOL CELL BIOL, V15, P1169; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; YU H, 1996, CELL, V76, P933; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	24	265	269	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25746	25749		10.1074/jbc.271.42.25746	http://dx.doi.org/10.1074/jbc.271.42.25746			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824201	hybrid			2022-12-27	WOS:A1996VN18000007
J	Cherradi, N; Rossier, MF; Vallotton, MB; Capponi, AM				Cherradi, N; Rossier, MF; Vallotton, MB; Capponi, AM			Calcium stimulates intramitochondrial cholesterol transfer in bovine adrenal glomerulosa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; MITOCHONDRIAL CONTACT SITES; ATRIAL-NATRIURETIC-PEPTIDE; ACUTE REGULATORY PROTEIN; LEYDIG TUMOR-CELLS; ANGIOTENSIN-II; ALDOSTERONE PRODUCTION; ADRENOCORTICAL MITOCHONDRIA; STEROIDOGENESIS; POTASSIUM	In adrenal glomerulosa cells, angiotensin II (Ang II) stimulates aldosterone synthesis through rises of cytosolic calcium ([Ca2+](c)). The rate-limiting step in this process is the transfer of cholesterol to the inner mitochondrial membrane, where it is converted to pregnenolone by the P450 side chain cleavage enzyme. The aim of the present study was to examine the effect of changes in [Ca2+](c) and of Ang II on intramitochondrial cholesterol distribution, Freshly prepared bovine zona glomerulosa cells were submitted to a cytosolic Ca2+ clamp (600 nM) or stimulated with Ang II (10 nm). Mitochondria were isolated and subfractionated into outer membranes (OM), inner membranes (IM), and contact sites (CS), Cholesterol content was determined by the cholesterol oxidase assay, Stimulation of intact cells with Ca2+ led to a marked decrease in cholesterol content of OM (to 54 +/- 24% of controls, n = 5) and to a concomitant increase of cholesterol in CS and IM (to 145 +/- 14%, n = 5), When glomerulosa cells mere exposed to Ang II, a marked increase of cholesterol in CS occurred (to 172 +/- 16% of controls, n = 5), No significant changes were detected in OM cholesterol, suggesting a stimulation of cholesterol supply to the mitochondria in response to Ang II, Cycloheximide specifically and significantly reduced Ca2+-activated cholesterol transfer to CS and IM. In conclusion, our data indicate that one of the main functions of the Ca2+ messenger is to increase cholesterol supply to the P450 side chain cleavage enzyme by enhancing endogenous intermembrane cholesterol transfer to a mitochondrial site containing the enzymes responsible for the initial steps of the steroidogenic cascade.	FAC MED,DEPT MED,DIV ENDOCRINOL & DIABETOL,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva			Cherradi, Nadia/K-9695-2016; Rossier, Michel/AAW-2895-2021	Cherradi, Nadia/0000-0002-4292-774X; 				ADAMS V, 1989, BIOCHIM BIOPHYS ACTA, V981, P213, DOI 10.1016/0005-2736(89)90031-X; AMBROZ C, 1992, ENDOCRINOLOGY, V131, P408, DOI 10.1210/en.131.1.408; APPELMANS F, 1955, BIOCHEM J, V59, P438, DOI 10.1042/bj0590438; ARDAIL D, 1993, J BIOL CHEM, V268, P25985; BAKKER A, 1994, BBA-MOL CELL RES, V1224, P583, DOI 10.1016/0167-4889(94)90297-6; BAKKER A, 1993, EUR J MORPHOL, V31, P46; BARRETT PQ, 1989, ENDOCR REV, V10, P496, DOI 10.1210/edrv-10-4-496; BARRETT PQ, 1991, AM J PHYSIOL, V261, pF706, DOI 10.1152/ajprenal.1991.261.4.F706; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; BURNAY MM, 1994, ENDOCRINOLOGY, V135, P751, DOI 10.1210/en.135.2.751; CAPPONI AM, 1984, J BIOL CHEM, V259, P8863; CAPPONI AM, 1988, J BIOL CHEM, V263, P16113; CHENG B, 1983, LIPIDS, V18, P577, DOI 10.1007/BF02534665; CHENG B, 1985, MOL CELL ENDOCRINOL, V40, P233, DOI 10.1016/0303-7207(85)90179-0; CHERRADI N, 1994, ENDOCRINOLOGY, V134, P1358, DOI 10.1210/en.134.3.1358; Clark BJ, 1995, MOL CELL ENDOCRINOL, V115, P215, DOI 10.1016/0303-7207(95)03683-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; ELLIOTT ME, 1984, BIOCHEM PHARMACOL, V33, P1519, DOI 10.1016/0006-2952(84)90422-2; ELLIOTT ME, 1993, ENDOCRINOLOGY, V133, P1669, DOI 10.1210/en.133.4.1669; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; FAKUNDING JL, 1979, ENDOCRINOLOGY, V105, P327, DOI 10.1210/endo-105-2-327; GAMBLE W, 1978, J LIPID RES, V19, P1068; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; KING SR, 1995, ENDOCRINOLOGY, V136, P5165, DOI 10.1210/en.136.11.5165; KOWLURU R, 1995, MOL CELL ENDOCRINOL, V107, P181, DOI 10.1016/0303-7207(94)03441-U; LAMBETH JD, 1981, J BIOL CHEM, V256, P4757; LANG U, 1987, J BIOL CHEM, V262, P8047; Muller J., 1988, REGULATION ALDOSTERO; OTSUKA S, 1964, BIOCHEM PHARMACOL, V13, P995, DOI 10.1016/0006-2952(64)90096-6; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; PRIVALLE CT, 1987, MOL CELL ENDOCRINOL, V53, P87, DOI 10.1016/0303-7207(87)90195-X; PYTHON CP, 1995, BIOCHEM J, V305, P569, DOI 10.1042/bj3050569; PYTHON CP, 1993, ENDOCRINOLOGY, V132, P1489, DOI 10.1210/en.132.4.1489; QUINN SJ, 1988, AM J PHYSIOL, V255, pE488, DOI 10.1152/ajpendo.1988.255.4.E488; ROSSIER MF, 1987, J BIOL CHEM, V262, P4053; SCHWAIGER M, 1987, J CELL BIOL, V105, P235, DOI 10.1083/jcb.105.1.235; SPAT A, 1989, J ENDOCRINOL, V122, P361, DOI 10.1677/joe.0.1220361; SPAT A, 1991, EXP PHYSIOL, V76, P859, DOI 10.1113/expphysiol.1991.sp003550; STEVENS VL, 1992, ENDOCRINOLOGY, V130, P1557, DOI 10.1210/en.130.3.1557; STOCCO DM, 1992, J STEROID BIOCHEM, V43, P319, DOI 10.1016/0960-0760(92)90167-H	40	49	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25971	25975		10.1074/jbc.271.42.25971	http://dx.doi.org/10.1074/jbc.271.42.25971			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824233	hybrid			2022-12-27	WOS:A1996VN18000039
J	Davies, SR; Cole, AA; Schmid, TM				Davies, SR; Cole, AA; Schmid, TM			Doxycycline inhibits type X collagen synthesis in avian hypertrophic chondrocyte cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHMID METAPHYSEAL CHONDRODYSPLASIA; MOLECULAR WEIGHT COLLAGEN; CARTILAGE COLLAGEN; GROWTH PLATE; TETRACYCLINES; LOCALIZATION; MUTATION; CHAIN; OSTEOARTHRITIS; PROTEOGLYCAN	Doxycycline, a member of the tetracycline family, has been shown to reduce a type X collagen epitope as detected by immunohistochemistry with a monoclonal antibody in an avian explant culture system (1). It was also shown to decrease collagenase and gelatinase activities and thus matrix degradation, This study investigates the effect of doxycycline on type X collagen synthesis in monolayer cultures of hypertrophic chondrocytes. Protein synthesis was evaluated by radioisotopic labeling during doxycycline, tetracycline, or minocycline treatment, Radiolabeled proteins were analyzed by gel electrophoresis, and total collagen was quantitated by hydroxyproline analysis, Additionally, the synthesis of type X collagen was measured by immunoprecipitation, Doxycycline was found to inhibit type X production more effectively than either of the other tetracyclines at comparable dose levels, Furthermore, type X collagen was inhibited more than other collagens, non-collagenous proteins and proteoglycans, with maximal inhibition at 80 mu g/ml and an IC50 of 7 mu g/ml. This inhibition by doxycycline was specific for type X collagen at 10 mu g/ml, and the pattern was distinct from cycloheximide, a recognized inhibitor of protein translation, This suppression of type X collagen could not be overcome by excess extracellular calcium, conditions that have been demonstrated to induce synthesis of this protein (2).	RUSH PRESBYTERIAN ST LUKES MED CTR, RUSH MED COLL, DEPT BIOCHEM, CHICAGO, IL 60612 USA	Rush University				Davies, Sherri/0000-0002-7141-8354	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P50AR039239] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR39239] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBERT A, 1956, NATURE, V177, P433, DOI 10.1038/177433a0; BAX CMR, 1993, BIOSCIENCE REP, V13, P169, DOI 10.1007/BF01149961; Blackwood R. K., 1985, TETRACYCLINES, P59; BLAIR HC, 1989, CONNECT TISSUE RES, V23, P65, DOI 10.3109/03008208909103904; BONEN DK, 1991, J CELL BIOL, V115, P1171, DOI 10.1083/jcb.115.4.1171; CASWELL AH, 1971, BIOCHEM BIOPH RES CO, V43, P625, DOI 10.1016/0006-291X(71)90660-7; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; CHOPRA I, 1985, TETRACYCLINES, P317; CLARK CC, 1994, J ORTHOPAED RES, V12, P601, DOI 10.1002/jor.1100120502; COLE AA, 1994, ARTHRITIS RHEUM, V37, P1727, DOI 10.1002/art.1780371204; COLE AA, 1993, DEV BIOL, V159, P528, DOI 10.1006/dbio.1993.1261; DEAN DD, 1989, MATRIX, V9, P366, DOI 10.1016/S0934-8832(89)80041-1; DEAN DD, 1985, J CLIN INVEST, V76, P716, DOI 10.1172/JCI112026; FRANKLIN T. J., 1966, SYMP SOC GEN MICROBIOL, V16, P192; GABLER WL, 1991, J PERIODONTAL RES, V26, P52, DOI 10.1111/j.1600-0765.1991.tb01626.x; GIBSON GJ, 1986, COLLAGEN REL RES, V6, P163; Golub L M, 1992, Curr Opin Dent, V2, P80; GOLUB LM, 1983, J PERIODONTAL RES, V18, P516, DOI 10.1111/j.1600-0765.1983.tb00388.x; GOLUB LM, 1991, CRIT REV ORAL BIOL M, V2, P297, DOI 10.1177/10454411910020030201; GREENWALD RA, 1992, J RHEUMATOL, V19, P927; GREENWALD RA, 1987, J RHEUMATOL, V14, P28; GUERIN C, 1992, BIOCHEM BIOPH RES CO, V188, P740, DOI 10.1016/0006-291X(92)91118-A; GULBIS J, 1975, J AM CHEM SOC, V97, P21; IGARASHI K, 1970, EUR J BIOCHEM, V14, P41, DOI 10.1111/j.1432-1033.1970.tb00258.x; INGMAN T, 1993, J PERIODONTOL, V64, P82, DOI 10.1902/jop.1993.64.2.82; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; JOHNSON R H, 1964, J Oral Ther Pharmacol, V1, P190; KANEKO H, 1990, ANAT REC, V227, P427, DOI 10.1002/ar.1092270406; KIMURA JH, 1980, J BIOL CHEM, V255, P7134; KIRSCH T, 1991, FEBS LETT, V294, P149, DOI 10.1016/0014-5793(91)81363-D; LACHMAN RS, 1988, PEDIATR RADIOL, V18, P93, DOI 10.1007/BF02387549; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUDA K, 1994, ANAL BIOCHEM, V217, P167, DOI 10.1006/abio.1994.1105; MOLLENHAUER J, 1994, ORTHOP RES SOC T, V19, P363; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SASAKI T, 1991, ANAT REC, V231, P25, DOI 10.1002/ar.1092310105; Schach Von Wittenau M., 1971, CHEMOTHERAPY, V16, P217, DOI [10.1159/000220730, DOI 10.1159/000220730]; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; SCHMID TM, 1982, J BIOL CHEM, V257, P2451; SCHMID TM, 1982, J BIOL CHEM, V257, P2444; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; SCHMID TM, 1987, STRUCTURE FUNCTION C, P223; SOLURSH M, 1986, DEV BIOL, V117, P90, DOI 10.1016/0012-1606(86)90351-9; UITTO VJ, 1994, ANN NY ACAD SCI, V732, P140, DOI 10.1111/j.1749-6632.1994.tb24731.x; VALCAVI U, 1981, NEW TRENDS ANTIBIOTI, P3; VONDERMARK K, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P221; VONDERMARK K, 1992, ARTHRITIS RHEUM-US, V35, P806, DOI 10.1002/art.1780350715; WALKER GD, 1995, J ORTHOPAED RES, V13, P4, DOI 10.1002/jor.1100130104; WALLIS GA, 1994, AM J HUM GENET, V54, P169; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WILLIAMS DN, 1986, ANTIMICROBIAL AGENTS, P188; WILLIAMSON DE, 1975, J AM CHEM SOC, V97, P2397, DOI 10.1021/ja00842a015; YU LP, 1992, ARTHRITIS RHEUM, V35, P1150, DOI 10.1002/art.1780351007; ZAIDI M, 1983, BIOSCIENCE REP, V13, P175	54	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25966	25970		10.1074/jbc.271.42.25966	http://dx.doi.org/10.1074/jbc.271.42.25966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824232	hybrid			2022-12-27	WOS:A1996VN18000038
J	Gu, YQ; Chao, WS; Walling, LL				Gu, YQ; Chao, WS; Walling, LL			Localization and post-translational processing of the wound-induced leucine aminopeptidase proteins of tomato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYCOPERSICON-ESCULENTUM TOMATO; GEL-ELECTROPHORESIS; THYLAKOID MEMBRANE; SEQUENCE-ANALYSIS; EXPRESSION; GENES; PURIFICATION; INHIBITOR; ENZYME; POLYPEPTIDE	Leucine aminopeptidase (LAP) is induced by Rounding and bacterial pathogen infection in tomato. DNA blot analysis of XbaI-digested lambda Lap genomic clones demonstrated that LapA1 and LapA2 cDNAs were encoded by two different LapA genes in the tomato genome. The coding and untranslated regions of LapA1 and LapA2 mRNAs shared more than 93% identity, The deduced amino acid sequences of LapA cDNA clones and in vitro translation of LapA1 mRNA indicated that LAP-A was synthesized as a 60-kDa precursor protein. The processing of a 60-kDa preLAP-A into the mature 55-kDa LAP-A was demonstrated in vivo by expression of the full length LapA1 cDNA in insect cells. Sequencing of a single LAP-A form isolated from a two-dimensional poly acrylamide gel indicated that LAP-A proteins had two different N termini that were separated by two residues. The LAP-A presequence had features similar to chloroplast transit peptides. Comparison of LAP-A levels in chloroplast and total protein extracts from methyl jasmonate-treated leaves indicated that a small proportion of the LAP-A proteins was detected in the plastids. Inspection of the LAP-A presequence indicated the presence of a dibasic protease (Kex2/furin) processing site motif 6-8 residues upstream from the LAP-A N termini. Its potential role in LAP-A precursor biogenesis is discussed.	UNIV CALIF RIVERSIDE,DEPT BOT & PLANT SCI,RIVERSIDE,CA 92521; UNIV CALIF RIVERSIDE,GRAD GENET GRP,RIVERSIDE,CA 92521	University of California System; University of California Riverside; University of California System; University of California Riverside								BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BARTLING D, 1992, EUR J BIOCHEM, V205, P425, DOI 10.1111/j.1432-1033.1992.tb16796.x; BARTLING D, 1994, PLANT SCI, V9, P199; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CHAO WS, 1995, PLANT PHYSIOL, V107, P253, DOI 10.1104/pp.107.1.253; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; CUYPERS HT, 1982, J BIOL CHEM, V257, P7077; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLIE DR, 1993, ANNU REV PLANT PHYS, V44, P77, DOI 10.1146/annurev.pp.44.060193.000453; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Gu YQ, 1996, PLANT PHYSIOL, V110, P1257, DOI 10.1104/pp.110.4.1257; GU YQ, 1994, THESIS U CALIFORNIA; HANSON H, 1976, METHODS ENZYMOLOGY B, V45, P504; HARRIS CA, 1992, J BIOL CHEM, V267, P6865; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERBERS K, 1994, PLANTA, V194, P230, DOI 10.1007/BF01101682; HILDMANN T, 1992, PLANT CELL, V4, P1157, DOI 10.1105/tpc.4.9.1157; HURKMAN WJ, 1986, PLANT PHYSIOL, V81, P802, DOI 10.1104/pp.81.3.802; KANNO T, 1984, AM J CLIN PATHOL, V82, P700, DOI 10.1093/ajcp/82.6.700; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KESSLER SW, 1975, J IMMUNOL, V115, P1617; Linderstrom-Lang K, 1929, H-S Z PHYSIOL CHEM, V182, P151; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MANFIOLETTI G, 1988, NUCLEIC ACIDS RES, V16, P2873, DOI 10.1093/nar/16.7.2873; MCDONALD JK, 1986, MAMMALIAN PROTEASESE, V2; MCGURL B, 1992, SCIENCE, V255, P1570, DOI 10.1126/science.1549783; MIKKONEN A, 1992, PHYSIOL PLANTARUM, V84, P393, DOI 10.1111/j.1399-3054.1992.tb04681.x; Mikola L, 1986, PLANT PROTEOLYTIC EN, V1, P97; MILLIGAN SB, 1995, PLANT MOL BIOL, V28, P691, DOI 10.1007/BF00021194; Mireau H, 1996, PLANT CELL, V8, P1027, DOI 10.1105/tpc.8.6.1027; PAUTOT V, 1993, P NATL ACAD SCI USA, V90, P9906, DOI 10.1073/pnas.90.21.9906; PAUTOT V, 1991, MOL PLANT MICROBE IN, V4, P284, DOI 10.1094/MPMI-4-284; PAYAN LA, 1991, J CELL BIOL, V112, P603, DOI 10.1083/jcb.112.4.603; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PICHERSKY E, 1987, PLANT MOL BIOL, V9, P205, DOI 10.1007/BF00166457; RENDUELES PS, 1988, FEMS MICROBIOL LETT, V54, P17; SANDERINK GJ, 1988, J CLIN CHEM CLIN BIO, V26, P795; SCHALLER A, 1995, PLANT CELL, V7, P1893, DOI 10.1105/tpc.7.11.1893; SCHALLER A, 1994, P NATL ACAD SCI USA, V91, P11802, DOI 10.1073/pnas.91.25.11802; SMITH EL, 1980, ENZYMES, V4, P37; SOPANEN T, 1975, PLANT PHYSIOL, V55, P809, DOI 10.1104/pp.55.5.809; SUGITA M, 1987, MOL GEN GENET, V209, P247, DOI 10.1007/BF00329650; SUMMERS MD, 1985, TEX AGR EXP STN B, V1555; TAYLOR A, 1982, CURR EYE RES, V2, P47, DOI 10.3109/02713688208998379; TAYLOR A, 1993, FASEB J, V7, P290, DOI 10.1096/fasebj.7.2.8440407; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V205, P168; Walling L. L., 1996, AMINOPEPTIDASES, P173; WALLING LL, 1988, NUCLEIC ACIDS RES, V16, P10477, DOI 10.1093/nar/16.22.10477; WALLNER BP, 1993, BIOCHEMISTRY-US, V32, P9296, DOI 10.1021/bi00087a006; WANG CS, 1992, PLANT PHYSIOL, V99, P822, DOI 10.1104/pp.99.3.822; WANG JL, 1996, IN PRESS PLANTA; Wendel J. F., 1989, Isozymes in plant biology., P5; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	54	39	41	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25880	25887		10.1074/jbc.271.42.25880	http://dx.doi.org/10.1074/jbc.271.42.25880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824220	hybrid			2022-12-27	WOS:A1996VN18000026
J	Gulbins, E; Coggeshall, KM; Brenner, B; Schlottmann, K; Linderkamp, O; Lang, F				Gulbins, E; Coggeshall, KM; Brenner, B; Schlottmann, K; Linderkamp, O; Lang, F			Fas-induced apoptosis is mediated by activation of a Ras and Rac protein-regulated signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; GTP-BINDING PROTEINS; GROWTH-FACTOR DEPRIVATION; LYMPHOPROLIFERATIVE SYNDROME; ACIDIC SPHINGOMYELINASE; RECEPTOR SUPERFAMILY; TRANSCRIPTION FACTOR; SURFACE ANTIGEN; T-LYMPHOCYTES; C-MYC	Fas induces apoptosis in lymphocytes via a poorly defined intracellular signaling mechanism. We and others have previously demonstrated the involvement and significance of a signaling cascade from the Fas receptor via sphingomyelinases and ceramide to Ras in apoptosis (Gulbins, E., Bissonette, R., Mahboubi, A., Nishioka, W., Brunner, T., Baier G., Baier-Bitterlich, G., Byrd, C., Lang, F., Kolesnick, R., Altman, A., and Green, D. (1995) Immunity 2, 341; Cifone, M. G., DeMaria, R., Roncali, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., and Testi, R. (1994) J. Exp. Med. 180, 1547-1552; Gill, B. M., Nishikata, H., Chan, G., Delovitch, T. L., and Ochi, A. (1994) Immunol. Rev. 142, 113-126). Here, we demonstrate an activation of the small G-proteins Rac 1 and Rac 2 after Fas receptor triggering. Expression of a transdominant inhibitory Ras mutant (N17Ras) prevents Rac 1 and Rac 2 stimulation, suggesting a signaling cascade from the Fas receptor via Ras to Rac 1 and Rac 2. Genetic and pharmacological inhibition of Ras or Rac 1 and Rac 2 stimulation blocks Fas-induced apoptosis, pointing to an important function of a Ras and Rac protein-regulated signaling pathway in Fas-mediated programmed cell death.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210; UNIV HEIDELBERG,DEPT PEDIAT,D-69120 HEIDELBERG,GERMANY	University System of Ohio; Ohio State University; Ruprecht Karls University Heidelberg	Gulbins, E (corresponding author), UNIV TUBINGEN,DEPT PHYSIOL,GEMLINSTR 5,D-72076 TUBINGEN,GERMANY.		Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342	NATIONAL CANCER INSTITUTE [R01CA064268, R29CA064268] Funding Source: NIH RePORTER; NCI NIH HHS [CA64268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; BERGLUND DL, 1991, CYTOMETRY, V12, P64, DOI 10.1002/cyto.990120109; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, CURR OPIN CELL BIOL, V6, P212, DOI 10.1016/0955-0674(94)90138-4; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OEHM A, 1992, J BIOL CHEM, V267, P10709; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STEVENSON MA, 1994, CANCER RES, V54, P12; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WU JG, 1994, P NATL ACAD SCI USA, V91, P2344, DOI 10.1073/pnas.91.6.2344; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1987, BRIT J CANCER, V56, P251, DOI 10.1038/bjc.1987.186; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	57	91	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26389	26394		10.1074/jbc.271.42.26389	http://dx.doi.org/10.1074/jbc.271.42.26389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824295	hybrid			2022-12-27	WOS:A1996VN18000101
J	Lassota, P; Singh, G; Kramer, R				Lassota, P; Singh, G; Kramer, R			Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DRUG-INTERACTION DOMAINS; MEDIATED DNA CLEAVAGE; BIS(2,6-DIOXOPIPERAZINE) DERIVATIVES; ANTICANCER DRUGS; POTENT INHIBITOR; ENZYME; APOPTOSIS; ETOPOSIDE; AGENTS; INDUCTION	Topoisomerase II is an essential enzyme for proliferation of eukaryotic cells, It is also a target for many antineoplastic drugs that promote stabilization of covalent complexes between topoisomerase II and DNA. Topoisomerase II and protein kinases both catalyze the transfer of phosphoester bonds from nucleotides to proteins. This similarity suggests that inhibitors may affect both classes of enzymes. In the present study, we have examined the mechanism of topoisomerase II inhibition by three different classes of protein kinase inhibitors, We report that staurosporine inhibited the catalytic activity of topoisomerase II by blocking the transfer of phosphodiester bonds from DNA to the active tyrosine site, a mechanism of inhibition not previously reported for this enzyme. In contrast, other kinase inhibitors, such as methyl 2,5-dihydroxycinnamate, most likely inactivated topoisomerase II by alkylation of essential amino acids, whereas the mechanism of inhibition of bis-indolylmaleimide possibly involved a direct interaction with DNA.			Lassota, P (corresponding author), WYETH AYERST RES, DIV ONCOL IMMUNOL CLIN RES, BLDG 200, RM 4618, 401 N MIDDLETOWN RD, PEARL RIVER, NY 10965 USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSEN AH, 1994, ADV PHARM A, V29, P89; BENCHOKROUN Y, 1995, BIOCHEM PHARMACOL, V49, P305, DOI 10.1016/0006-2952(94)00465-X; BORITZKI TJ, 1988, BIOCHEM PHARMACOL, V37, P4063, DOI 10.1016/0006-2952(88)90096-2; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DRAKE FH, 1989, CANCER RES, V49, P2578; Drolet M, 1994, Adv Pharmacol, V29A, P135; ENGLUND PT, 1978, CELL, V14, P157, DOI 10.1016/0092-8674(78)90310-0; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; ISHIDA R, 1991, CANCER RES, V51, P4909; JENSEN PB, 1990, CANCER RES, V50, P3311; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KUPCHAN SM, 1970, SCIENCE, V168, P376, DOI 10.1126/science.168.3929.376; LINDSLEY JE, 1991, P NATL ACAD SCI USA, V88, P10485, DOI 10.1073/pnas.88.23.10485; MARKOVITS J, 1989, CANCER RES, V49, P5111; MARKOVITS J, 1994, BIOCHEM PHARMACOL, V48, P549, DOI 10.1016/0006-2952(94)90285-2; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; OHNO R, 1993, CANCER, V71, P2217, DOI 10.1002/1097-0142(19930401)71:7<2217::AID-CNCR2820710709>3.0.CO;2-8; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; ROBINSON MJ, 1993, BIOCHEMISTRY-US, V32, P3638, DOI 10.1021/bi00065a016; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAHAI BM, 1986, ANAL BIOCHEM, V156, P364, DOI 10.1016/0003-2697(86)90267-8; SANDER M, 1984, P NATL ACAD SCI-BIOL, V81, P6938, DOI 10.1073/pnas.81.22.6938; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANABE K, 1991, CANCER RES, V51, P4903; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; UMEZAWA K, 1990, FEBS LETT, V260, P198, DOI 10.1016/0014-5793(90)80102-O; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WARD NE, 1992, MOL PHARMACOL, V41, P387	37	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26418	26423		10.1074/jbc.271.42.26418	http://dx.doi.org/10.1074/jbc.271.42.26418			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824299	hybrid			2022-12-27	WOS:A1996VN18000105
J	Ghadessy, FJ; Chen, DS; Kini, RM; Chung, MCM; Jeyaseelan, K; Khoo, HE; Yuen, R				Ghadessy, FJ; Chen, DS; Kini, RM; Chung, MCM; Jeyaseelan, K; Khoo, HE; Yuen, R			Stonustoxin is a novel lethal factor from stonefish (Synanceja horrida) venom - cDNA cloning and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; MESSENGER-RNA DEGRADATION; GEL-ELECTROPHORESIS; PROTEINS; PURIFICATION; SEQUENCE; REGION; MEMBRANES; ACID; DNA	Stonustoxin (SNTX) is a multifunctional lethal protein isolated from venom elaborated by the stonefish, Synanceja horrida, It comprises two subunits, termed alpha and beta, which have respective molecular masses of 71 and 79 bDa, SNTX elicits an array of biological responses both in vitro and in vivo, particularly a potent hypotension that appears to be mediated by the nitric oxide pathway. As a prelude to structure function studies, we have isolated and sequenced cDNA clones encoding the alpha- and beta-subunits of SNTX from a venom gland cDNA library, The deduced amino acid sequence of neither subunit shows significant homology with any known protein. Protein sequence alignment does, however, show the subunits to be 50% homologous to each other and implies that they may have arisen from a common ancestor, The subunits of this novel toxin lack typical N-terminal signal sequences commonly found in proteins that are secreted via the endoplasmic reticulum-Golgi apparatus pathway, indicating the possibility of its being secreted by a non-classical pathway, which is not clearly understood, The SNTX subunits have been expressed in Escherichia coli as cleavable fusion proteins that cross-react with antibodies raised against the native toxin, To the best of our knowledge, this is the first complete sequence of a fish-derived protein toxin to be reported.	NATL UNIV SINGAPORE, FAC MED, DEPT BIOCHEM, SINGAPORE 119260, SINGAPORE; NATL UNIV SINGAPORE, FAC SCI, BIOSCI CTR, SINGAPORE 117548, SINGAPORE; NATL UNIV SINGAPORE, CTR BIOPROC TECHNOL, SINGAPORE 117548, SINGAPORE	National University of Singapore; National University of Singapore; National University of Singapore			Chung, Maxey C.M./C-3817-2014; Kini, Manjunatha/H-8029-2012	Kini, Manjunatha/0000-0002-6100-3251				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUSTIN L, 1965, AUST J EXP BIOL MED, V43, P79, DOI 10.1038/icb.1965.6; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOISSEL JP, 1985, P NATL ACAD SCI USA, V82, P8448, DOI 10.1073/pnas.82.24.8448; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARLSSON SR, 1993, GLYCOBIOLOGY PRACTIC, P14; CHANG JY, 1985, EUR J BIOCHEM, V151, P217, DOI 10.1111/j.1432-1033.1985.tb09091.x; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEAKINS DE, 1967, TOXICON, V4, P257, DOI 10.1016/0041-0101(67)90053-0; DUCANCEL F, 1989, PROTEIN ENG, V3, P139, DOI 10.1093/protein/3.2.139; EHRENSTEIN G, 1977, Q REV BIOPHYS, V10, P1, DOI 10.1017/S0033583500000123; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARNIER P, 1995, TOXICON, V33, P143, DOI 10.1016/0041-0101(94)00151-W; GHADESSY FJ, 1994, TOXICON, V32, P1684, DOI 10.1016/0041-0101(94)90329-8; GOPALAKRISHNAKONE P, 1993, TOXICON, V31, P979, DOI 10.1016/0041-0101(93)90257-J; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HABERMAN.E, 1972, SCIENCE, V177, P314, DOI 10.1126/science.177.4046.314; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; HALSTEAD BW, 1956, T AM MICROSCOP SEC, V74, P381; HALSTEAD BW, 1970, POISONOUS VENOMOUS M, P758; HELMS C, 1985, DNA-J MOLEC CELL BIO, V4, P39, DOI 10.1089/dna.1985.4.39; KHOO HE, 1992, NAT TOXINS, V1, P1; KINI RM, 1989, INT J PEPT PROT RES, V34, P277; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREGER AS, 1991, TOXICON, V29, P733, DOI 10.1016/0041-0101(91)90065-Y; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LOW KSY, 1994, TOXICON, V32, P573, DOI 10.1016/0041-0101(94)90205-4; LOW KSY, 1993, TOXICON, V31, P1471, DOI 10.1016/0041-0101(93)90212-2; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; PEACH MJ, 1987, AM J CARDIOL, V59, pA35, DOI 10.1016/0002-9149(87)90174-3; PERSSON B, 1985, EUR J BIOCHEM, V152, P523, DOI 10.1111/j.1432-1033.1985.tb09227.x; POH CH, 1991, COMP BIOCHEM PHYS B, V99, P793, DOI 10.1016/0305-0491(91)90143-2; POH CH, 1992, COMP BIOCHEM PHYS B, V101, P159, DOI 10.1016/0305-0491(92)90172-N; RAPOPORT RM, 1989, CIRC RES, V64, P463, DOI 10.1161/01.RES.64.3.463; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS PAUL R., 1959, PROC WESTERN PHARMACOL SOC, V2, P47; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIOMI K, 1993, NIPPON SUISAN GAKK, V59, P1099, DOI 10.2331/suisan.59.1099; SMITH JLB, 1951, COPEIA, P207; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; WALTER P, 1985, CELL, V38, P5	49	66	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25575	25581		10.1074/jbc.271.41.25575	http://dx.doi.org/10.1074/jbc.271.41.25575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810331	hybrid			2022-12-27	WOS:A1996VL69300075
J	Kolodziej, SJ; Penczek, PA; Schroeter, JP; Stoops, JK				Kolodziej, SJ; Penczek, PA; Schroeter, JP; Stoops, JK			Structure-function relationships of the Saccharomyces cerevisiae fatty acid synthase - Three-dimensional structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYOELECTRON MICROSCOPY; RIBOSOMAL-SUBUNITS; ESCHERICHIA-COLI; 3-DIMENSIONAL RECONSTRUCTION; NUCLEOTIDE-SEQUENCE; NEGATIVE-STAIN; LOW-RESOLUTION; FAS1 GENE; YEAST; SYNTHETASE	The three-dimensional structure of the Saccharomyces cerevisie fatty acid synthase was computed from electron microscopy of stain images. The barrel-shaped structure (point group symmetry 32) has major and minor axes of similar to 245 x 220 Angstrom respectively, and consists of two different subunits organized in an alpha(6) beta(6) complex (M(r) = 2.5 x 10(6)). Two sets of three beta subunits form triangle-shaped caps that enclose the ends of the barrel. The wall of the barrel appears to consist of three N-shaped alpha subunit pairs each with an over and underlying arch-shaped beta subunit. Inside the molecule there are three major interconnected cavities that are tilted similar to 20 degrees with respect to its major axis. An axle-shaped structure extends the length of the cavity on the 3-fold axis and is connected to the two ends of the barrel, The cavities are partially divided on the equator of the molecule by three spokes that extend hom the axle on the 2-fold axis to the exterior wall. We propose that these six cavities constitute the six equivalent sites of fatty acid synthesis resulting in an extraordinary structure-function relationship with the 42 catalytic sites involved in fatty acid synthesis inside the molecule. The six cavities each have two funnel-shaped openings (similar to 20 Angstrom in diameter) which may serve to permit the diffusion of substrates and products in and out of these functional units. The subunits appear to be arranged in a manner that affords extensive intermolecular interactions contributing to the stability of this macromolecular complex.	UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL & LAB MED, HOUSTON, TX 77030 USA; NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, ALBANY, NY 12201 USA	University of Texas System; University of Texas Health Science Center Houston; State University of New York (SUNY) System; Wadsworth Center					NIGMS NIH HHS [GM 29169, GM 46278] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029169, R01GM029169, R01GM046278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CARAZO JM, 1989, BIOPHYS J, V55, P465, DOI 10.1016/S0006-3495(89)82840-1; CHIRALA SS, 1987, J BIOL CHEM, V262, P4231; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; FRANK J, 1981, SCIENCE, V214, P1353, DOI 10.1126/science.7313694; Frank J., 1996, 3 DIMENSIONAL ELECT, Ved, ppp 54; FRANK J, 1985, NEW METHODOLOGIES ST, P36; HACKENJOS WA, 1987, BIOL CHEM H-S, V368, P19, DOI 10.1515/bchm3.1987.368.1.19; HESSLER D, 1992, MICROSCOPY KEY RES T, P73; HOPPE W, 1976, Z NATURFORSCH A, V31, P1380; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; LYNEN F, 1980, EUR J BIOCHEM, V112, P431; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; RADERMACHER M, 1988, J ELECTRON MICR TECH, V9, P359, DOI 10.1002/jemt.1060090405; Schroeter JP, 1996, J STRUCT BIOL, V116, P131, DOI 10.1006/jsbi.1996.0021; SCHWEIZER E, 1987, FETT WISS TECHNOL, V89, P570; SCHWEIZER E, 1984, NEW COMPR BIOCH, V7, P59; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SINGH N, 1985, BIOCHEMISTRY-US, V24, P6598, DOI 10.1021/bi00344a044; STOFFLERMEILICKE M, 1988, METHOD ENZYMOL, V164, P503; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; STOOPS JK, 1978, BIOCHEM BIOPH RES CO, V84, P225, DOI 10.1016/0006-291X(78)90286-3; STOOPS JK, 1981, J BIOL CHEM, V256, P8364; STOOPS JK, 1980, P NATL ACAD SCI-BIOL, V77, P4544, DOI 10.1073/pnas.77.8.4544; STOOPS JK, 1992, P NATL ACAD SCI USA, V89, P6585, DOI 10.1073/pnas.89.14.6585; STOOPS JK, 1990, J BIOL CHEM, V265, P16971; STOOPS JK, 1978, J BIOL CHEM, V253, P4464; STOOPS JK, 1979, J BIOL CHEM, V254, P7418; STOOPS JK, 1991, J ELECTRON MICR TECH, V18, P157, DOI 10.1002/jemt.1060180210; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; VANHEEL M, 1985, EMBO J, V4, P2389, DOI 10.1002/j.1460-2075.1985.tb03944.x; WIELAND F, 1978, P NATL ACAD SCI USA, V75, P5792, DOI 10.1073/pnas.75.12.5792; WIELAND F, 1979, EUR J BIOCHEM, V94, P189, DOI 10.1111/j.1432-1033.1979.tb12885.x	34	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28422	28429		10.1074/jbc.271.45.28422	http://dx.doi.org/10.1074/jbc.271.45.28422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910467	hybrid			2022-12-27	WOS:A1996VU03300067
J	AbdAlla, S; Jarnagin, K; MullerEsterl, W; Quitterer, U				AbdAlla, S; Jarnagin, K; MullerEsterl, W; Quitterer, U			The N-terminal amino group of [Tyr(8)]bradykinin is bound adjacent to analogous amino acids of the human and rat B-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST BINDING-SITE; NEUROKININ-1 RECEPTOR; EXTRACELLULAR DOMAIN; BRADYKININ RECEPTOR; B2 RECEPTOR; IDENTIFICATION; ANTAGONIST; RESIDUES; AFFINITY; POLYACRYLAMIDE	To obtain data of the bradykinin B-2 receptor's agonist binding site, Ne used a combined approach of affinity labeling and ''immunoidentification'' of receptor fragments generated by cyanogen bromide cleavage. Domain-specific antibodies to the various extracellular receptor domains mere applied to detect receptor fragments with covalently attached [I-125-Tyr(8)]bradykinin, As a cross-linker we used the homobifunctional reagent disuccinimidyl tartarate (DST), which reacts preferentially with primary amines, With this technique a [I-125-Tyr(8)]bradykinin-labeled receptor fragment derived from the third extracellular domain was identified. The epsilon-amino group of lysine (Lys(172)) of the human B-2 receptor provides the only primary amino group within this receptor fragment. This strongly suggests that DST attached the N-terminal amino group of [Tyr(8)]bradykinin to Lys(172) of the human B-2 receptor, Next me asked whether DST attaches [Tyr(8)]bradykinin to the analogous residue, Lys(174) of the rat B-2 receptor, which is 81% identical to the human B-2 receptor, and we attempted to label the wild-type rat B-2 receptor and a rat B-2 receptor mutant where Lys(174) had been exchanged for alanine. Affinity labeling of the wild-type rat B-2 receptor worked efficiently, whereas DST did not attach detectable amounts of [I-125-Tyr(8)]bradykinin to the K174A rat B-2 receptor mutant, Taken together these observations indicate that the N-terminal amino group of [Tyr(8)]bradykinin is bound to analogous positions of the rat and of the human B-2 receptor, i.e. [Tyr(8)]bradykinin's N terminus is bound adjacent to Lys(172) of the human and Lys(174) of the rat B-2 receptor.	UNIV WURZBURG,INST PHARMACOL & TOXICOL,D-97078 WURZBURG,GERMANY; UNIV MAINZ,INST PHYSIOL CHEM & PATHOBIOCHEM,D-55099 MAINZ,GERMANY; ROCHE BIOSCI,INFLAMMATORY DIS UNIT,PALO ALTO,CA 94304	University of Wurzburg; Johannes Gutenberg University of Mainz; Roche Holding								Abd Alla S., 1996, J BIOL CHEM, V271, P1748; AbdAlla S, 1996, BIOCHEMISTRY-US, V35, P7514, DOI 10.1021/bi9601060; ABDALLA S, 1993, J BIOL CHEM, V268, P17277; BURCH RM, 1993, MOL BIOL PHARM BRADY, P81; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GALZI JL, 1990, J BIOL CHEM, V265, P10430; HERWALD H, 1993, J BIOL CHEM, V268, P14527; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HJORTH SA, 1994, J BIOL CHEM, V269, P30953; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KOJRO E, 1993, BIOCHEMISTRY-US, V32, P13537, DOI 10.1021/bi00212a020; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONG SR, 1994, J BIOL CHEM, V269, P19343; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x; ZHAO LJ, 1993, METHOD ENZYMOL, V217, P218	30	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27382	27387		10.1074/jbc.271.44.27382	http://dx.doi.org/10.1074/jbc.271.44.27382			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910316	hybrid			2022-12-27	WOS:A1996VQ67900034
J	Araujo, F; Tan, S; Ruano, D; Schoemaker, H; Benavides, J; Vitorica, J				Araujo, F; Tan, S; Ruano, D; Schoemaker, H; Benavides, J; Vitorica, J			Molecular and pharmacological characterization of native cortical gamma-aminobutyric acid(A) receptors containing both alpha(1) and alpha(3) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA-A RECEPTORS; RAT CEREBRAL-CORTEX; BENZODIAZEPINE RECEPTORS; MONOCLONAL-ANTIBODIES; ALCOHOL ANTAGONIST; MESSENGER-RNAS; BINDING-SITES; BRAIN; SUBTYPES; COMPLEX	We have investigated the existence, molecular composition, and benzodiazepine binding properties of native cortical alpha(1)-alpha(3) gamma-aminobutyric acid(A) (GABA(A)) receptors using subunit-specific antibodies. The co-existence of alpha(1) and alpha(3) subunits in native GABA(A) receptors was demonstrated by immunoblot analysis of the anti-alpha(1)- or anti-alpha(3)-immunopurified receptors and by immunoprecipitation experiments of the [H-3]zolpidem binding activity. Furthermore, immunodepletion experiments indicated that the alpha(1)-alpha(3) GABA(A) receptors represented 54.7 +/- 5.0 and 23.6 +/- 3.3% of the alpha(3) and alpha(1) populations, respectively. Therefore, alpha(1) and alpha(3) subunits are associated in the same native GABA(A) receptor complex, but, on the other hand, these alpha(1)-alpha(3) GABA(A) receptors from the cortex constitute a large proportion of the total alpha(3) population and a relatively minor component of the alpha(1) population. The pharmacological analysis of the alpha(1)- or alpha(3)-immunopurified receptors demonstrated the presence of two different benzodiazepine binding sites in each receptor population with high (type I binding sites) and low (type II binding sites) affinities for zolpidem and CI 218,872. These results indicate the existence of native GABA(A) receptors possessing both alpha(1) and alpha(3) subunits, with alpha(1) and ag subunits expressing their characteristic benzodiazepine pharmacology. The molecular characterization of the anti-alpha(1)-anti-alpha(3) double-immunopurified receptors demonstrated the presence of stoichiometric amounts of alpha(1) and alpha(3) subunits, associated with beta(2/3), and gamma(2) subunits. The pharmacological analysis of alpha(1)-alpha(3) GABA(A) receptors demonstrated that, despite the fact that each alpha subunit retained its benzodiazepine binding properties, the relative proportion between type I and II binding sites or between 51- and 59-61-kDa [H-3]Ro15-4513-photolabeled peptides was 70:30. Therefore, the alpha(1) subunit is pharmacologically predominant over the alpha(3) subunit. These results indicate the existence of active and nonactive alpha subunits in the native alpha(1)-alpha(3) GABA(A) receptors from rat cortex.	UNIV SEVILLA,FAC FARM,DEPT BIOQUIM BROMATOL & TOXICOL,SEVILLE 41012,SPAIN; SYNTHELABO RECH,CENT NERVOUS SYST RES DEPT,F-92225 BAGNEUX,FRANCE	University of Sevilla; Sanofi-Aventis; Sanofi France			Araujo, Francisco/ABC-6873-2020; IBIS, ALZHEIMER/O-9867-2015; CABALLERO, DIEGO RUANO/I-4471-2014	CABALLERO, DIEGO RUANO/0000-0001-6131-3033; Vitorica Ferrandez, Javier/0000-0002-0641-7902; Araujo, Francisco/0000-0001-5737-2938				ARBILLA S, 1986, EUR J PHARMACOL, V130, P257, DOI 10.1016/0014-2999(86)90276-1; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; BENAVIDES J, 1993, BRAIN RES, V604, P240, DOI 10.1016/0006-8993(93)90375-W; BENAVIDES J, 1988, J PHARMACOL EXP THER, V245, P1033; BENKE D, 1994, J BIOL CHEM, V269, P27100; BURT DR, 1991, FASEB J, V5, P2916, DOI 10.1096/fasebj.5.14.1661244; Connolly CN, 1996, J BIOL CHEM, V271, P89, DOI 10.1074/jbc.271.1.89; DUGGAN MJ, 1991, J BIOL CHEM, V266, P24778; DUGGAN MJ, 1992, J NEUROCHEM, V58, P72, DOI 10.1111/j.1471-4159.1992.tb09278.x; EBERT B, 1994, MOL PHARMACOL, V46, P957; ENDO S, 1993, J NEUROCHEM, V60, P1388, DOI 10.1111/j.1471-4159.1993.tb03300.x; EWERT M, 1992, BRAIN RES, V569, P57, DOI 10.1016/0006-8993(92)90368-J; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; IM WB, 1995, J BIOL CHEM, V270, P26063, DOI 10.1074/jbc.270.44.26063; ITEM C, 1994, J NEUROCHEM, V63, P1119; KHAN ZU, 1994, J NEUROCHEM, V63, P1466; Khan ZU, 1996, J NEUROCHEM, V66, P685; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER SZ, 1988, PHARMACOL BIOCHEM BE, V29, P763, DOI 10.1016/0091-3057(88)90202-X; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDDENS H, 1990, NATURE, V346, P648, DOI 10.1038/346648a0; MCKERNAN RM, 1991, NEURON, V7, P667, DOI 10.1016/0896-6273(91)90379-E; MERTENS S, 1993, J BIOL CHEM, V268, P5965; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NIELSEN M, 1980, NATURE, V286, P606, DOI 10.1038/286606a0; OLSEN RW, 1990, FASEB J, V4, P1469, DOI 10.1096/fasebj.4.5.2155149; PARK D, 1991, J NEUROCHEM, V56, P1962, DOI 10.1111/j.1471-4159.1991.tb03454.x; POLLARD S, 1995, J BIOL CHEM, V270, P21285, DOI 10.1074/jbc.270.36.21285; POLLARD S, 1993, J BIOL CHEM, V268, P3753; PRITCHETT DB, 1990, J NEUROCHEM, V54, P1802, DOI 10.1111/j.1471-4159.1990.tb01237.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QUIRK K, 1994, J BIOL CHEM, V269, P16020; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; RUANO D, 1991, J PHARMACOL EXP THER, V256, P902; RUANO D, 1993, EUR J PHARM-MOLEC PH, V246, P81, DOI 10.1016/0922-4106(93)90013-Y; RUANO D, 1994, EUR J PHARM-MOLEC PH, V267, P123, DOI 10.1016/0922-4106(94)90233-X; RUANO D, 1994, MOL BRAIN RES, V25, P225, DOI 10.1016/0169-328X(94)90157-0; RUANO D, 1993, BRAIN RES, V600, P134, DOI 10.1016/0006-8993(93)90411-F; RUANO D, 1992, J NEUROCHEM, V58, P485, DOI 10.1111/j.1471-4159.1992.tb09747.x; SIEGHART W, 1995, PHARMACOL REV, V47, P181; SIEGHART W, 1987, J NEUROCHEM, V48, P46, DOI 10.1111/j.1471-4159.1987.tb13125.x; SQUIRES RF, 1984, HDB NEUROCHEMISTRY, V6, P261; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TALLMAN JF, 1985, ANNU REV NEUROSCI, V8, P21, DOI 10.1146/annurev.ne.08.030185.000321; TURNER DM, 1991, J PHARMACOL EXP THER, V257, P1236; VERDOORN TA, 1994, MOL PHARMACOL, V45, P475; VITORICA J, 1990, J NEUROCHEM, V54, P187, DOI 10.1111/j.1471-4159.1990.tb13300.x; VITORICA J, 1988, J NEUROSCI, V8, P615; WISDEN W, 1992, J NEUROSCI, V12, P1040	51	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27902	27911		10.1074/jbc.271.44.27902	http://dx.doi.org/10.1074/jbc.271.44.27902			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910390	hybrid			2022-12-27	WOS:A1996VQ67900108
J	Cai, K; Schirch, V				Cai, K; Schirch, V			Structural studies on folding intermediates of serine hydroxymethyltransferase using fluorescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; PYRIDOXAL 5'-PHOSPHATE; REACTION SPECIFICITY; TRYPTOPHAN SYNTHASE; RESIDUE; ENZYMES; ORIGIN	Previous studies have demonstrated that the in vitro folding pathway of Escherichia coli serine hydroxymethyltransferase has both monomer and dimer intermediates that are stable for periods of minutes to hours at 4 degrees C (Cai K., Schirch, D., and Schirch, V. (1995) J. Biol. Chem, 270, 19294-19299), Single Trp mutant enzymes were constructed and used in combination with other methods to show that on the folding pathway of this enzyme two domains rapidly fold to form a monomer in which the amino-terminal 55 amino acid residues and a segment around the active site region of Lys(229) remain in a largely disordered form, This partially folded enzyme can form dimers and slowly undergoes a rate-determining conformational change in which the unstructured segments assume their native state (Cai, K., and Schirch, V. (1996) J. Biol. Chem. 271, 2987-2994), To further assess the kinetics and structural details of the intermediates during folding, fluorescence energy transfer and fluorescence anisotropy measurements were made of the three Trp residues and pyridoxal 5'-phosphate, attached covalently to the active site by reduction to a secondary amine by sodium cyanoborohydride, These studies confirmed that the basic kinetic folding pathway remained the same in the reduced enzyme as compared to the earlier studies with the apoenzyme, Both equilibrium and kinetic intermediates were identified and their structural characteristics determined, The results show that the active site Lys(229)-bound pyridoxyl 5'-phosphate remains more than 50 angstroms from any Trp residues until the final rate-determining conformational change when it approaches each Trp residue at the same rate, The environment of each Trp residue and the pyridoxyl phosphate in both an equilibrium folding intermediate and a kinetic folding intermediate are described.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOL BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028143] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28143] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER FW, 1994, EUR J BIOCHEM, V219, P953, DOI 10.1111/j.1432-1033.1994.tb18577.x; ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; BLOND S, 1986, Proteins Structure Function and Genetics, V1, P247, DOI 10.1002/prot.340010307; Cai K, 1996, J BIOL CHEM, V271, P2987, DOI 10.1074/jbc.271.6.2987; CAI K, 1995, J BIOL CHEM, V270, P19294, DOI 10.1074/jbc.270.33.19294; CHAFFOTTE AF, 1983, BIOCHEMISTRY-US, V22, P2708, DOI 10.1021/bi00280a019; CHEN R F, 1967, Analytical Letters, V1, P35; CUPO JF, 1983, BIOCHEMISTRY-US, V22, P2654, DOI 10.1021/bi00280a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; HEROLD M, 1991, BIOCHEMISTRY-US, V30, P3612, DOI 10.1021/bi00229a004; LAKOWICZ JR, 1994, PROTEIN SCI, V3, P628; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; MATTHEWS CR, 1981, BIOCHEMISTRY-US, V20, P784, DOI 10.1021/bi00507a021; NATH U, 1995, BIOCHEMISTRY-US, V34, P1702, DOI 10.1021/bi00005a027; PACE CN, 1975, CRIT REV BIOCH, V3, P11; PASCARELLA S, 1993, FEBS LETT, V331, P145, DOI 10.1016/0014-5793(93)80314-K; PLAMANN MD, 1983, NUCLEIC ACIDS RES, V11, P2065, DOI 10.1093/nar/11.7.2065; SCHIRCH LVG, 1963, J BIOL CHEM, V238, P1032; SCHIRCH V, 1985, J BACTERIOL, V163, P1; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SCHMID XF, 1992, PROTEIN FOLDING, P203; SELVIN PR, 1995, METHOD ENZYMOL, V246, P300; STOVER P, 1992, J BIOL CHEM, V267, P17679; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; T Forster, 1965, MODERN QUANTUM CHEMI, VIII, P93; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134	26	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27311	27320		10.1074/jbc.271.44.27311	http://dx.doi.org/10.1074/jbc.271.44.27311			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910307	hybrid			2022-12-27	WOS:A1996VQ67900025
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Inhibition of oxidative cross-linking between engineered cysteine residues at positions 332 in predicted transmembrane segments (TM) 6 and 975 in predicted TM12 of human P-glycoprotein by drug substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG TRANSPORTER; FUNCTIONAL CONSEQUENCES; SENSORY RECEPTOR; ESCHERICHIA-COLI; ATPASE ACTIVITY; BINDING-SITE; INSECT CELLS; RESISTANCE; DOMAIN; RECONSTITUTION	Each homologous half of P-glycoprotein consists of a transmembrane domain with six potential transmembrane segments and an ATP-binding domain. Labeling studies with photoactive drug analogs show that labeling occurs within or close Co predicted transmembrane segments (TM) 6 (residues 331-351) and TM12 (residues 974-994), To test if these segments ape in near-proximity we generated 42 different P-glycoprotein mutants in which we re introduced a pair of cysteine residues into a Cys-less P-glycoprotein, one within TM6 (residues 332-338) and one within TM12 (residues 975-980) and assayed for cross-linking between the cysteines, All the mutants retained verapamil-stimulated ATPase activity, We found that only the mutant containing Cys-332 and Cys-975 was cross-linked in the presence of oxidant, as judged by its decreased mobility an SDS gels. Similar results were obtained when the same mutations were introduced into Cys-less NH2-terminal and COOH-terminal half-molecules of P-glycoprotein followed by coexpression and treatment with oxidant, Cross-linking between Cys-332 and Cys-975, however, was inhibited by verapamil or vinblastine but not by colchicine, These results suggest that residues Cys-332 and Cys-975, which occupy equivalent positions when TMS and TM12 are aligned, are close to each other in the tertiary structure of P-glycoprotein.	UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHERVITZ SA, 1995, J BIOL CHEM, V270, P24043, DOI 10.1074/jbc.270.41.24043; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FALKE JJ, 1987, SCIENCE, V237, P1596, DOI 10.1126/science.2820061; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GOTTESMAN MM, 1994, CURR TOP MEMBR, V41, P3, DOI 10.1016/S0070-2161(08)60451-7; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; KATZ BA, 1986, J BIOL CHEM, V261, P5480; LEE GF, 1994, J BIOL CHEM, V269, P29920; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1993, J BIOL CHEM, V268, P19965; LYNCH BA, 1991, P NATL ACAD SCI USA, V88, P10402, DOI 10.1073/pnas.88.23.10402; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MORRIS DI, 1991, BIOCHEMISTRY-US, V30, P8371, DOI 10.1021/bi00098a014; PAKULA AA, 1992, P NATL ACAD SCI USA, V89, P4144, DOI 10.1073/pnas.89.9.4144; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; Voss J, 1995, P NATL ACAD SCI USA, V92, P12300, DOI 10.1073/pnas.92.26.12300; WU JH, 1995, P NATL ACAD SCI USA, V92, P9186, DOI 10.1073/pnas.92.20.9186; YU HB, 1995, BIOCHEMISTRY-US, V34, P14963, DOI 10.1021/bi00046a002; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	43	88	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27482	27487		10.1074/jbc.271.44.27482	http://dx.doi.org/10.1074/jbc.271.44.27482			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910331	hybrid			2022-12-27	WOS:A1996VQ67900049
J	PedrazaAlva, G; Merida, LB; Burakoff, SJ; Rosenstein, Y				PedrazaAlva, G; Merida, LB; Burakoff, SJ; Rosenstein, Y			CD43-specific activation of T cells induces association of CD43 to Fyn kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; PHOSPHATIDYLINOSITOL 3-KINASE; SURFACE SIALOGLYCOPROTEIN; SIALOPHORIN; ANTIGEN; RECEPTOR; BINDING; DOMAIN; PHOSPHORYLATION; PROLIFERATION	CD43, the most abundant membrane protein of T lymphocytes, is able to initiate signal transduction pathways that lead to Ca2+ mobilization and interleukin-2 production, yet the molecular events involved in CD43's signal transduction pathway are poorly understood. In the present report we show that: activation of both purified T lymphocytes and Jurkat cells, through CD43 cross-linking with the anti-CD43 L10 monclonal antibody, induced CD43 association to Fyn kinase, This association is mediated by the Sre Homology 3 (SH3) domain of Fyn, since a glutathione S-transferase-Fyn SH3 fusion protein was able to precipitate CD43 from lysates of CD43-activated T cells. A synthetic peptide containing the SH3 binding sites of p85, located within the amino acid sequence (300)ERQPAPALPPKPPKP(314) was able to inhibit binding of CD43 to Fyn as well as to the glutathione S-transferase-Fyn SH3 fusion protein. We also provide evidence that upon CD48 cross-linking Fyn is tyrosine-phosphorylated in a time-dependent manner. Our results suggest that CD43 cross-linking on the T cell surface induces the interaction between CD43 and Fyn, presumably through the Fyn SH3 domain and a putative SH3 binding site in CD43, leading to Fyn tyrosine phosphorylation and signal propagation.	UNIV NACL AUTONOMA MEXICO, INST BIOTECHNOL, CUERNAVACA 62250, MORELOS, MEXICO; DANA FARBER CANC INST, BOSTON, MA 02115 USA	Universidad Nacional Autonoma de Mexico; Harvard University; Dana-Farber Cancer Institute								ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; AXELSSON B, 1985, EUR J IMMUNOL, V15, P427, DOI 10.1002/eji.1830150503; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BORCHE L, 1987, EUR J IMMUNOL, V17, P1523, DOI 10.1002/eji.1830171023; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEREZ L, 1995, VIROLOGY, V208, P26, DOI 10.1006/viro.1995.1126; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; PILLER F, 1988, J BIOL CHEM, V263, P15146; PILLER V, 1989, J BIOL CHEM, V264, P18824; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REMOLDODONNELL E, 1987, BLOOD, V70, P104; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; Rosenstein Yvonne, 1993, P249; SHIOTA J, 1994, CELL IMMUNOL, V155, P402, DOI 10.1006/cimm.1994.1133; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; TOMLINSON JA, 1994, J IMMUNOL, V153, P3426; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WONG RCK, 1990, J IMMUNOL, V144, P1455; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	60	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27564	27568		10.1074/jbc.271.44.27564	http://dx.doi.org/10.1074/jbc.271.44.27564			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910342	hybrid			2022-12-27	WOS:A1996VQ67900060
J	Yogalingam, G; Litjens, T; Bielicki, J; Crawley, AC; Muller, V; Anson, DS; Hopwood, JJ				Yogalingam, G; Litjens, T; Bielicki, J; Crawley, AC; Muller, V; Anson, DS; Hopwood, JJ			Feline mucopolysaccharidosis type VI - Characterization of recombinant N-acetylgalactosamine 4-sulfatase and identification of a mutation causing the disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ARYLSULFATASE-B; FULL-LENGTH CDNA; ENZYME; N-ACETYLGALACTOSAMINE-4-SULFATASE; PURIFICATION; FIBROBLASTS; EXPRESSION; DIAGNOSIS; SULFATASE; THERAPY	Mucopolysaccharidosis type VI (RIPS VI) is an autosomal recessive disease caused by a deficiency of N-acetylgalactosamine 4-sulfatase (4S) leading to the lysosomal accumulation and urinary excretion of dermatan sulfate, RIPS VI has also been described in the Siamese cat, As an initial step toward enzyme replacement therapy with recombinant feline 4S (rf4S) in RIPS VI cats, the feline 4S cDNA was isolated and expressed in CHO-KI cells and rf4S was immunopurified from the culture medium. SDS-polyacrylamide gel electrophoresis analysis showed that the precursor form of immunopurified rf4S was a 66-kDa polypeptide that underwent maturation to a 43-44-kDa polypeptide. Endocytosis of rf4S by cultured feline RIPS VI myoblasts was predominantly mediated by a mannose g-phosphate receptor and resulted in the correction of dermatan sulfate storage, The mutation causing feline MPS VI was identified as a base substitution at codon 476, altering a leucine codon to a proline (L476P), The L476P allele displayed no detectable 45 activity when expressed in CHO-KI. cells and was observed only as a ''precursor'' polypeptide that was not secreted into the medium, Identification of the mutation has allowed the development of a rapid PCR-based screening method to genotype individuals within the cat colony.	WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,LYSOSOMAL DIS RES UNIT,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia								ANSON DS, 1992, BIOCHEM J, V284, P789, DOI 10.1042/bj2840789; BAUDHUIN P, 1964, LAB INVEST, V13, P1139; BIELICKI J, 1991, BIOCHEM J, V279, P515, DOI 10.1042/bj2790515; BOUGHARIOS G, 1993, HISTOCHEM J, V25, P593, DOI 10.1007/BF00157873; BROOKS DA, 1990, J INHERIT METAB DIS, V13, P108, DOI 10.1007/BF01799338; BROOKS DA, 1991, J INHERIT METAB DIS, V14, P5, DOI 10.1007/BF01804381; BROOKS DA, 1994, BIOCHEM MED METAB B, V53, P58, DOI 10.1006/bmmb.1994.1058; BROOKS DA, 1991, AM J HUM GENET, V48, P710; CHANG PL, 1988, EXP CELL RES, V176, P258, DOI 10.1016/0014-4827(88)90329-1; Crawley AC, 1996, J CLIN INVEST, V97, P1864, DOI 10.1172/JCI118617; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FRIEDMANN T, 1972, SCIENCE, V175, P949, DOI 10.1126/science.175.4025.949; GIBSON GJ, 1987, BIOCHEM J, V248, P755, DOI 10.1042/bj2480755; HASKINS ME, 1979, PEDIATR RES, V13, P1203, DOI 10.1203/00006450-197911000-00001; HOPWOOD JJ, 1986, BIOCHEM J, V234, P507, DOI 10.1042/bj2340507; HOPWOOD JJ, 1990, MOL BIOL MED, V7, P381; HUARD J, 1994, HUM GENE THER, V5, P949, DOI 10.1089/hum.1994.5.8-949; JACKSON CE, 1992, GENOMICS, V14, P403, DOI 10.1016/S0888-7543(05)80233-2; KAMPINE JP, 1966, SCIENCE, V155, P86; KOBAYASHI T, 1992, BIOCHIM BIOPHYS ACTA, V1159, P243, DOI 10.1016/0167-4838(92)90051-E; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEABACK DH, 1961, BIOCHEM J, V78, P151, DOI 10.1042/bj0780151; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCEWEN JE, 1994, AM J HUM GENET, V55, P196; MCGOVERN MM, 1982, J BIOL CHEM, V257, P2605; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; PETERS C, 1990, J BIOL CHEM, V265, P3374; SCHUCHMAN EH, 1990, GENOMICS, V6, P149, DOI 10.1016/0888-7543(90)90460-C; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; UNGER EG, 1994, BIOCHEM J, V304, P43, DOI 10.1042/bj3040043; VINE DT, 1981, AM J HUM GENET, V33, P916	32	59	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27259	27265		10.1074/jbc.271.44.27259	http://dx.doi.org/10.1074/jbc.271.44.27259			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910299	hybrid			2022-12-27	WOS:A1996VQ67900017
J	Keely, PJ; Parise, LV				Keely, PJ; Parise, LV			The alpha(2)beta(1) integrin is a necessary co-receptor for collagen-induced activation of Syk and the subsequent phosphorylation of phospholipase C gamma 2 in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE P72(SYK); MEDIATED CELL-ADHESION; GLYCOPROTEIN-IIB-IIIA; FC-GAMMA-RII; SIGNAL-TRANSDUCTION; DEPENDENT ADHESION; CA2+ MOBILIZATION; EXTRACELLULAR-MATRIX; INDUCED AGGREGATION; PHENYLARSINE OXIDE	Although there are multiple potential collagen-binding proteins on platelets, the contribution of each to collagen-induced signaling events and platelet activation is unclear. We investigated which early platelet signaling events, if any, could be attributed specifically to the binding of calf ages to one of its receptors, the alpha(2) beta(1) integrin. Treatment of platelets with collagen induced a rapid activation of the non-receptor tyrosine kinase, Syk, as measured by an increase in phosphorylation and kinase activity, Collagen also induced the rapid phosphorylation of phospholipase C gamma 2 (PLC gamma 2). The phosphorylation of bath Syk and PLC gamma 2, as well as platelet aggregation, was blocked by an anti-alpha(2) beta(1) integrin monoclonal antibody (P1E6), demonstrating that collagen binding to alpha(2) beta(1) is necessary for signaling, Gross-linking of the alpha(2) beta(1) integrin with stimulatory monoclonal antibody against either the beta(1) or alpha(2) subunit stimulated the phosphorylation of bath Syk and PLC gamma 2. However, antibody stimulation was dependent on co-stimulation of the Fc gamma II receptor (CD32) since specific F(ab')(2) fragments did not induce Syk and PLC gamma 2 phosphorylation. Thus, these results suggest that occupancy of alpha(2) beta(1) by collagen is necessary, but that a co-receptor, in addition to alpha(2) beta(1), is required for these collagen-induced signaling events, Moreover, the P1E6 antibody did not inhibit all collagen-induced tyrosine phosphorylation events, demonstrating that collagen also induces phosphorylation events that are, independent of the alpha(2) beta(1) integrin. In addition to Syk and PLC gamma 2, we identified the Fc gamma II receptor (Fc gamma RII) as being rapidly phosphorylated in response to collagen stimulation even in the absence of antibodies. Finally, to determine if Syk activation precedes and directly contributes to the phosphorylation of PLC gamma 2, platelets were preincubated with the Syk-selective kinase inhibitor, piceatannol. A concentration of piceatannol that inhibited the phosphorylation and kinase activity of Syk, but had no effect on Src kinase activity, blocked the collagen-induced phosphorylation of PLC gamma 2 and also inhibited collagen-induced platelet aggregation. Our results begin to delineate a signaling pathway whereby occupancy of the alpha(2) beta(1) integrin is required, but not sufficient, for collagen-induced activation of Syk and the subsequent phosphorylation of PLC gamma 2. These events are. necessary for platelet activation and aggregation in response to collagen.			Keely, PJ (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, 1106 FLOB, CHAPEL HILL, NC 27599 USA.				NHLBI NIH HHS [F32-HL09399-01, 1-P01-HL45100] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009399, P01HL045100] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; BEXDITCHEVSKI F, 1996, MOL BIOL CELL, V7, P193; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; CHIANG TM, 1982, J BIOL CHEM, V257, P7581; CHIANG TM, 1987, J IMMUNOL, V139, P887; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1989, BLOOD, V74, P182; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; GEAHLEN RL, 1994, ROLE SYK CELL SIGNAL, P103; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GREENWALT DE, 1994, BRIT J HAEMATOL, V88, P830, DOI 10.1111/j.1365-2141.1994.tb05124.x; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; JEWELL K, 1995, J CELL SCI, V108, P1165; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KARNIGUIAN A, 1990, BIOCHEM J, V268, P325, DOI 10.1042/bj2680325; KATZ DA, 1995, SURGERY, V118, P154, DOI 10.1016/S0039-6060(05)80318-6; KEELY PJ, 1995, J CELL SCI, V108, P595; KEHREL B, 1993, BLOOD, V82, P3364; KEHREL B, 1988, BLOOD, V71, P1074; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; KURODA K, 1995, J IMMUNOL, V155, P4427; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAEDA H, 1993, BIOCHEM BIOPH RES CO, V197, P62, DOI 10.1006/bbrc.1993.2441; MCKEOWN L, 1994, BLOOD, V83, P2866, DOI 10.1182/blood.V83.10.2866.2866; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; OZAKI Y, 1995, J BIOL CHEM, V270, P15119, DOI 10.1074/jbc.270.25.15119; PATCH LA, 1995, J CELL SCI, V108, P1371; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; RIILKONEN T, 1995, J BIOL CHEM, V270, P13548; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; SAELMAN EUM, 1994, BLOOD, V83, P3240, DOI 10.1182/blood.V83.11.3240.bloodjournal83113240; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANTORO SA, 1991, CELL REGUL, V2, P905, DOI 10.1091/mbc.2.11.905; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SMITH JB, 1992, BIOCHEM J, V283, P889, DOI 10.1042/bj2830889; SMITH JB, 1992, BIOCHEM J, V288, P925, DOI 10.1042/bj2880925; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TATE BF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P281, DOI 10.1016/0167-4889(93)90205-4; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TOBYAMA Y, 1994, J BIOL CHEM, V269, P32796; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; WORTHINGTON RE, 1990, BRIT J HAEMATOL, V74, P216, DOI 10.1111/j.1365-2141.1990.tb02568.x; YAMAMOTO N, 1990, BLOOD, V76, P1698; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; YANAGA F, 1995, FEBS LETT, V368, P377, DOI 10.1016/0014-5793(95)00670-5; YANAGI S, 1994, EUR J BIOCHEM, V224, P329, DOI 10.1111/j.1432-1033.1994.00329.x	85	135	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26668	26676		10.1074/jbc.271.43.26668	http://dx.doi.org/10.1074/jbc.271.43.26668			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900143	hybrid			2022-12-27	WOS:A1996VP23300037
J	Rarick, HM; Opgenorth, TJ; vonGeldern, TW; WuWong, JSR; Solaro, RJ				Rarick, HM; Opgenorth, TJ; vonGeldern, TW; WuWong, JSR; Solaro, RJ			An essential myosin light chain peptide induces supramaximal stimulation of cardiac myofibrillar ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE-FIBERS; TROPONIN-C; 3-DIMENSIONAL STRUCTURE; SHORTENING VELOCITY; MOLECULAR MOTOR; BINDING-SITES; THIN FILAMENT; HEAD COMPLEX; ACTIN; ISOFORMS	The N-terminal region of skeletal myosin light chain-1 (MLC-1) binds to the C terminus of actin, yet the functional significance of this interaction is unclear. We studied a fragment (MLC-pep; residues 5-14) of the ventricular MLC-1. When added to rat cardiac myofibrils, 10 nM MLC-pep induced a supramaximal increase in the MgATPase activity at submaximal Ca2+ levels with no effect at low and maximal Ca2+ levels. A nonsense, scrambled sequence peptide had no effect at any pCa value. MLC-pep did not affect myosin KEDTA and CaATPase activities or actin-activated MgATPase activities in the absence or presence of tropomyosin, The MLC-pep did not alter the ability of troponin I to inhibit MgATPase activity. Moreover, when troponin I and troponin C were extracted from the myofibrils, the MLC-pep lost its ability to stimulate the ATPase rate, This effect was fully restored upon reconstitution of the extracted myofibrils with troponin I-troponin C complex, Thus, activation of MgATPase activity by the peptide required a full complement of thin filament regulatory proteins. Interestingly, the stimulatory effect occurred at a ratio of 4 peptides to 1 thin filament, suggesting that the peptide engages in a highly cooperative process that may involve activation of the entire thin filament.	UNIV ILLINOIS, COLL MED MC 901, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; ABBOTT LABS, ABBOTT PK, IL 60064 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Abbott Laboratories					NHLBI NIH HHS [R01-HL-49934, R01-HL-22231, F32-HL-09009] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049934, F32HL009009, R01HL022231] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTON PJR, 1985, BIOCHEM J, V231, P249, DOI 10.1042/bj2310249; BOTTINELLI R, 1994, J MUSCLE RES CELL M, V15, P413, DOI 10.1007/BF00122115; BRANDT PW, 1984, J MOL BIOL, V180, P379, DOI 10.1016/S0022-2836(84)80010-8; CHANTLER PD, 1975, EUR J BIOCHEM, V60, P67, DOI 10.1111/j.1432-1033.1975.tb20976.x; CHAUSSEPIED P, 1989, NATURE, V342, P950, DOI 10.1038/342950a0; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GREASER ML, 1988, J PHYSIOL-LONDON, V406, P85, DOI 10.1113/jphysiol.1988.sp017370; GUO XD, 1994, J BIOL CHEM, V269, P15210; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; HENRY GD, 1985, BIOCHIM BIOPHYS ACTA, V830, P233, DOI 10.1016/0167-4838(85)90279-1; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; LABBE JP, 1986, BIOCHEMISTRY-US, V25, P8325, DOI 10.1021/bi00373a029; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LHEUREUX K, 1993, BIOCHEMISTRY-US, V32, P10005, DOI 10.1021/bi00089a016; LOWEY S, 1993, J BIOL CHEM, V268, P20414; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; MORNET D, 1981, NATURE, V292, P301, DOI 10.1038/292301a0; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PAGANI ED, 1984, METHOD PHARMACOL, V5, P49; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; PRINCE HP, 1981, EUR J BIOCHEM, V121, P213, DOI 10.1111/j.1432-1033.1981.tb06451.x; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1994, TRENDS BIOCHEM SCI, V19, P129, DOI 10.1016/0968-0004(94)90206-2; SHETERLINE P, 1983, MECH CELL MOTILITY M, P36; SHIVERICK KT, 1975, BIOCHIM BIOPHYS ACTA, V393, P124, DOI 10.1016/0005-2795(75)90222-6; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SWEENEY HL, 1995, BIOPHYS J, V68, pS112; SWEENEY HL, 1988, J BIOL CHEM, V263, P9034; TRAYER HR, 1985, FEBS LETT, V180, P170, DOI 10.1016/0014-5793(85)81065-6; TRAYER IP, 1987, EUR J BIOCHEM, V164, P259, DOI 10.1111/j.1432-1033.1987.tb11019.x; WHITE HD, 1982, METHOD ENZYMOL, V85, P698; Winstanley MA, 1979, BIOCHEM SOC T, V7, P703, DOI 10.1042/bst0070703	37	53	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27039	27043		10.1074/jbc.271.43.27039	http://dx.doi.org/10.1074/jbc.271.43.27039			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900193				2022-12-27	WOS:A1996VP23300087
J	Yuan, YP; Schoenwaelder, SM; Salem, HH; Jackson, SP				Yuan, YP; Schoenwaelder, SM; Salem, HH; Jackson, SP			The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LYMPHOCYTE-T ACTIVATION; ENDOTHELIAL-CELLS; SIGNAL-TRANSDUCTION; HUMAN-PLATELETS; CULTURED HUMAN; NITRIC-OXIDE; FATTY-ACIDS; RECEPTOR; IDENTIFICATION	The naturally occurring phospholipid, lysophosphatidylcholine (lyso-PC), regulates a broad range of cell processes, including gene transcription, mitogenesis, monocyte chemotaxis, smooth muscle relaxation, and platelet activation, Despite the growing list of cellular effects attributable to lyso-PC, the mechanism(s) by which it alters cell function have not been elucidated, In this report, we have examined the effects of exogenous lyso-PC on signal transduction processes within a variety of lyso-PC-responsive cells, including: human platelets, monocyte-like THP-1 cells, and the megakaryoblastic cell line, MEG-01. Pretreatment. of each of these cells with increasing concentrations of lyso-PC (25-150 mu g/ml) was associated with a progressive increase in the cytosolic concentration of cAMP, The accumulation of cAMP in platelets correlated closely with the ability of lyso-PC to inhibit multiple platelet processes, including platelet aggregation, agonist-induced protein kinase C activation, thromboxane A(2) generation, and the tyrosine phosphorylation of platelet proteins. In each of the cell types examined, the ability of lyso-PC to increase the cellular levels of cAMP was synergistically enhanced by pretreating the cells with the cAMP phosphodiesterase inhibitor, theophylline (5 mM), and was specifically inhibited by the P-site inhibitor of adenylyl cyclase, 2,5-dideoxyadenosine. A role for the stimulatory G-protein, Gs, in the lyso-PC-induced activation of adenylyl cyclase was suggested by the ability of the GTPase inhibitor, guanylyl 5'-thiophosphate (0.2 mM), to inhibit the lyso-PC-stimulated increase in cAMP, and also by the ability of cholera toxin to inhibit increases in membrane GTPase activity in response to lyso-PC. The functional significance of lyso-PC-induced activation of adenylyl cyclase was investigated in MEG-01 cells, Treatment of these cells with either lyso-PC or dibutyryl cAMP for 36-40 h resulted in a 3-5-fold increase in the surface expression of the natural anticoagulant protein, thrombomodulin (TM). The ability of lyso-PC to increase TM expression was abolished by pretreating these cells with the adenylyl cyclase inhibitor, 2,5-dideoxyadenosine, whereas the dibutyryl cAMP-induced increase in TM remained insensitive to adenylyl cyclase inhibition. These studies define an important role for the adenylyl cyclase signaling system in mediating cellular effects induced by lyso-PC.	BOX HILL HOSP,DEPT PATHOL,BOX HILL,VIC 3128,AUSTRALIA	Box Hill Hospital	Yuan, YP (corresponding author), MONASH UNIV SCH MED,BOX HILL HOSP,DEPT MED,BOX HILL,VIC 3128,AUSTRALIA.		Jackson, Shaun P/E-9633-2011; Yuan, Yuan/GVS-5120-2022; Schoenwaelder, Simone/E-9506-2011	Schoenwaelder, Simone/0000-0003-0465-5840; Jackson, Shaun/0000-0002-4750-1991				ASAOKA Y, 1992, P NATL ACAD SCI USA, V89, P6447, DOI 10.1073/pnas.89.14.6447; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; Baenziger N L, 1974, Methods Enzymol, V31, P149; BENTON AM, 1982, BLOOD, V60, P642; BRASS LF, 1988, PLATELET MEMBRANE RE, P441; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; DUTTAROY AK, 1987, J BIOL CHEM, V262, P12685; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HOLMSEN H, 1987, PLATELET RESPONSES M, V3, P52; HOUSLAY MD, 1986, BIOCHEM J, V234, P737, DOI 10.1042/bj2340737; INSEL PA, 1982, J BIOL CHEM, V257, P7485; ITO T, 1990, THROMB RES, V58, P615, DOI 10.1016/0049-3848(90)90307-X; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KROLL MH, 1989, BLOOD, V74, P1181; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NGWENYA BZ, 1990, P SOC EXP BIOL MED, V193, P118; PARTHASARATHY S, 1985, P NATL ACAD SCI USA, V82, P3000, DOI 10.1073/pnas.82.9.3000; PORTMAN OW, 1969, J LIPID RES, V10, P158; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RESNICK RJ, 1994, J BIOL CHEM, V269, P32336; SAITO T, 1988, P NATL ACAD SCI USA, V85, P8246, DOI 10.1073/pnas.85.21.8246; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SCHRODER T, 1980, SCAND J GASTROENTERO, V15, P633, DOI 10.3109/00365528009182227; SEAMON K, 1981, J BIOL CHEM, V256, P9799; SEAMON KB, 1981, P NATL ACAD SCI-BIOL, V78, P3363, DOI 10.1073/pnas.78.6.3363; SHIER WT, 1976, P NATL ACAD SCI USA, V73, P1586, DOI 10.1073/pnas.73.5.1586; SHIER WT, 1977, BIOCHEM BIOPH RES CO, V78, P1168, DOI 10.1016/0006-291X(77)91416-4; STEER ML, 1979, J BIOL CHEM, V254, P791; SWEATT JD, 1986, J BIOL CHEM, V261, P8667; SWEATT JD, 1986, J BIOL CHEM, V261, P8660; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TETSUTARO S, 1991, P NATL ACAD SCI USA, V88, P5149; TSAI SC, 1985, P NATL ACAD SCI USA, V82, P8310, DOI 10.1073/pnas.82.24.8310; Ulrich K. H., 1981, PHARMACOL REV, V33, P17; VADAS P, 1986, LAB INVEST, V55, P391; VALONE FH, 1988, PLATELET MEMBRANE RE, P319; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WELTZIEN HU, 1979, BIOCHIM BIOPHYS ACTA, V559, P259, DOI 10.1016/0304-4157(79)90004-2; YAMAMOTO N, 1991, J IMMUNOL, V147, P273; YUAN YP, 1995, BLOOD, V86, P4166, DOI 10.1182/blood.V86.11.4166.bloodjournal86114166; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211; ZEMBOWICZ A, 1995, J BIOL CHEM, V270, P17006, DOI 10.1074/jbc.270.28.17006	52	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27090	27098		10.1074/jbc.271.43.27090	http://dx.doi.org/10.1074/jbc.271.43.27090			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900200	hybrid			2022-12-27	WOS:A1996VP23300094
J	Blancher, C; Omri, B; Bidou, L; Pessac, B; Crisanti, P				Blancher, C; Omri, B; Bidou, L; Pessac, B; Crisanti, P			Nectinepsin: A new extracellular matrix protein of the pexin family - Characterization of a novel cDNA encoding a protein with an RGD cell binding motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; AMINO-ACID SEQUENCE; MESSENGER-RNA; S-PROTEIN; HUMAN HEMOPEXIN; SOMATOMEDIN-B; VITRONECTIN; INTEGRINS; ADHESION; SERUM	We report the isolation and characterization of a novel cDNA from quail neuroretina encoding a putative protein named nectinepsin. The nectinepsin cDNA identifies a major 2,2-kilobase mRNA that is detected from ED 5 in neuroretina and is increasingly abundant during embryonic development. A nectinepsin mRNA is also found in quail liver, brain, and intestine and in mouse retina. The deduced nectinepsin amino acid sequence contains the RGD cell binding motif of integrin ligands. Furthermore, nectinepsin shares substantial homologies with vitronectin and structural protein similarities with most of the matricial metalloproteases. However, the presence of a specific sequence and the lack of heparin and collagen binding domains of the vitronectin indicate that nectinepsin is a new extracellular matrix protein. Furthermore, genomic Southern blot studies suggest that nectinepsin and vitronectin are encoded by different genes. Western blot analysis with an anti-human vitronectin antiserum revealed, in addition to the 65- and 70-kDa vitronectin bands, an immunoreactive protein of about 54 kDa in all tissues containing nectinepsin mRNA. It seems likely that the form of vitronectin found in chick egg yolk plasma by Nagano et al. ((1992) J. Biol. Chem. 267, 24863-24870) is the protein that corresponds to the nectinepsin cDNA. This new protein could be an important molecule involved in the early steps of the development.	UNIV PARIS 06, CNRS 9035, DEV & IMMUN SYST NERVEUX CENT, FAC MED BROUSSAIS HOTEL DIEU, F-75270 PARIS 06, FRANCE	UDICE-French Research Universities; Sorbonne Universite								ALTRUDA F, 1985, NUCLEIC ACIDS RES, V13, P3841, DOI 10.1093/nar/13.11.3841; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIAMBRONE GJ, 1990, J CELL BIOL, V111, P2183, DOI 10.1083/jcb.111.5.2183; CRISANTICOMBES P, 1977, CELL TISSUE RES, V185, P159; DELANNET M, 1994, DEVELOPMENT, V120, P2687; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; FRYKLUND L, 1978, FEBS LETT, V87, P55, DOI 10.1016/0014-5793(78)80132-X; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HAYMAN EG, 1985, J CELL BIOL, V100, P1948, DOI 10.1083/jcb.100.6.1948; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; HEWITT AT, 1986, RETINA MODEL CELL 2, P169; HOLMES R, 1967, J CELL BIOL, V32, P297, DOI 10.1083/jcb.32.2.297; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JENNE D, 1989, EUR J BIOCHEM, V185, P391, DOI 10.1111/j.1432-1033.1989.tb15127.x; JENNE D, 1985, EMBO J, V4, P3153, DOI 10.1002/j.1460-2075.1985.tb04058.x; JENNE D, 1987, BIOCHEMISTRY-US, V26, P6735, DOI 10.1021/bi00395a024; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; MANIATIS JM, 1989, BIOCHEMISTRY; Maniatis T, 1989, MOL CLONING; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; NAGANO Y, 1992, J BIOL CHEM, V267, P24863; NEUGEBAUER KM, 1991, NEURON, V6, P345, DOI 10.1016/0896-6273(91)90244-T; PESSAC B, 1972, SCIENCE, V175, P898, DOI 10.1126/science.175.4024.898; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SANES JR, 1989, ANNU REV NEUROSCI, V12, P491, DOI 10.1146/annurev.ne.12.030189.002423; SATO R, 1990, J BIOL CHEM, V265, P21232; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; SEIFFERT D, 1991, P NATL ACAD SCI USA, V88, P9402, DOI 10.1073/pnas.88.21.9402; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P73, DOI 10.1073/pnas.82.1.73; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; Zheng XX, 1995, P NATL ACAD SCI USA, V92, P12426, DOI 10.1073/pnas.92.26.12426	51	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26220	26226		10.1074/jbc.271.42.26220	http://dx.doi.org/10.1074/jbc.271.42.26220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824271	hybrid			2022-12-27	WOS:A1996VN18000077
J	Finan, PM; Soames, CJ; Wilson, L; Nelson, DL; Stewart, DM; Truong, O; Hsuan, JJ; Kellie, S				Finan, PM; Soames, CJ; Wilson, L; Nelson, DL; Stewart, DM; Truong, O; Hsuan, JJ; Kellie, S			Identification of regions of the Wiskott-Aldrich syndrome protein responsible for association with selected Src homology 3 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PEPTIDES; PHAGOCYTE NADPH OXIDASE; SH3 DOMAIN; TYROSINE KINASES; CRYSTAL-STRUCTURES; FOCAL ADHESION; BINDING MOTIF; HIGH-AFFINITY; GENE; SPECIFICITY	Src homology 3 (SH3) domains have been shown to mediate selected interactions between signaling molecules and are essential for the activation of a number of receptor-driven pathways. The Wiskott-Aldrich syndrome protein was identified as a protein that associated selectively with the SH3 domains derived from c-Src, p85 alpha, phospholipase C gamma 1, and c-Fgr. Significantly reduced association was detected to the N-terminal SH3 domain and the tandem SH3 domains of p47(phox), and no binding was detected to the SH3 domain of n-Src, the C-terminal SH3 domain of p47(phox), or either of the SH3 domains of p67(phox). Three peptides corresponding to potential Wiskott-Aldrich syndrome protein SH3 domain binding moths were found to inhibit its association with c-Src, Fgr, and phospholipase C gamma 1 SH3 domains, but not the p85 alpha SH3 domain. These peptides have the sequences MRRQEPLPPPPPPSRG, TGRSGPLPPPPPGA, and KGRSGPLPPVPLGI and show homology with other SH3 domain binding motifs. It is possible that the intracellular association of Wiskott-Aldrich syndrome protein with other signaling proteins is mediated by its SH3 domain-binding regions, and this may play a role in its putative function as a regulatory molecule in immune cells.	LITTLEMORE HOSP, YAMANOUCHI RES INST, OXFORD OX4 4XN, ENGLAND; NCI, METAB BRANCH, NIH, BETHESDA, MD 20892 USA; UCL, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; UCL, DEPT BIOCHEM & MOL BIOL, LONDON W1E 6BT, ENGLAND	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London			Hsuan, Justin/C-8825-2009; Kellie, Stuart/A-6036-2010	Hsuan, Justin/0000-0001-6083-7564; Kellie, Stuart/0000-0002-8163-1474				Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; BLAESE RM, 1968, LANCET, V1, P1056; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; DERRY JMJ, 1995, GENOMICS, V29, P471, DOI 10.1006/geno.1995.9979; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; DERRY JMJ, 1994, CELL, V79, P923; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FINAN P, 1994, J BIOL CHEM, V269, P13752; Finan PM, 1996, FEBS LETT, V389, P141, DOI 10.1016/0014-5793(96)00552-2; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HAFFNER C, 1995, EMBO J, V14, P19, DOI 10.1002/j.1460-2075.1995.tb06971.x; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KARLSSON T, 1995, ONCOGENE, V10, P1475; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KENNEY D, 1986, BLOOD, V68, P1329; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; Lee CH, 1996, CELL, V85, P931, DOI 10.1016/S0092-8674(00)81276-3; LUI X, 1993, MOL CELL BIOL, V13, P5223; MCPHAIL LC, 1994, J EXP MED, V180, P2011, DOI 10.1084/jem.180.6.2011; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OCHS HD, 1980, BLOOD, V55, P243; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Stewart DM, 1996, J CLIN INVEST, V97, P2627, DOI 10.1172/JCI118712; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU QL, 1995, BLOOD, V86, P3797, DOI 10.1182/blood.V86.10.3797.bloodjournal86103797	54	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26291	26295		10.1074/jbc.271.42.26291	http://dx.doi.org/10.1074/jbc.271.42.26291			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824280	hybrid			2022-12-27	WOS:A1996VN18000086
J	Jaskiewicz, E; Zhu, GF; Bassi, R; Darling, DS; Young, WW				Jaskiewicz, E; Zhu, GF; Bassi, R; Darling, DS; Young, WW			beta 1,4-N-acetylgalactosaminyltransferase (G(M2) synthase) is released from Golgi membranes as a neuraminidase-sensitive, disulfide-bonded dimer by a cathepsin D-like protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; SUCCESSIVE COMPARTMENTS; EXPRESSION CLONING; MOLECULAR-CLONING; BREFELDIN-A; CDNA CLONE; IN-VITRO; CELLS; RAT; BETA-1,4-GALACTOSYLTRANSFERASE	Many Golgi membrane-bound glycosyltransferases are released from cells in a soluble form. To characterize this release process, we stably transfected Chinese hamster ovary cells with three myc epitope-tagged forms of cloned beta 1,4-N-acetylgalactosaminyltransferase (GalNAcT); two of these forms resided in the Golgi, while the third was retained in the ER, GalNAcT was released into the culture medium from cells transfected with the Golgi forms but not with the ER form of the enzyme. The medium from cells transfected with the Golgi forms contained disulfide-bonded dimers of GalNAcT, which carried neuraminidase sensitive, complex N-linked carbohydrate chains. This soluble species represented the major degradation product of cellular GalNAcT, which turned over with a half-time of about 1.7 h. The soluble species consisted of a mixture of truncated GalNAcT molecules, the major form of which was produced by cleavage near the boundary between the transmembrane and lumenal domains between Leu-23 and Tyr-24. This cleavage site fits the sequence pattern for sites cleaved by cathepsin D (van Noort, J.M., and van der Drift, A.C.M. (1989) J. Biol. Chem. 264, 14159-14164), These findings suggest that GalNAcT is converted from a membrane-bound to a soluble form as a result of cleavage by a cathepsin D-like protease in a compartment late in the Golgi secretory pathway.	UNIV LOUISVILLE,SCH DENT,DEPT BIOCHEM & BIOPHYS SCI,LOUISVILLE,KY 40292; UNIV LOUISVILLE,DEPT BIOCHEM,HLTH SCI CTR,LOUISVILLE,KY 40292	University of Louisville; University of Louisville			Darling, Douglas S/D-4573-2009	Darling, Douglas/0000-0002-9039-1169; BASSI, ROSARIA/0000-0001-7409-4730	NIDDK NIH HHS [DK44332] Funding Source: Medline; NIGMS NIH HHS [GM42698] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044332] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Cho SK, 1996, J BIOL CHEM, V271, P3238, DOI 10.1074/jbc.271.6.3238; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; HARE JF, 1990, BIOCHIM BIOPHYS ACTA, V1031, P71, DOI 10.1016/0304-4157(90)90003-U; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HIDARI KIPJ, 1994, BIOCHEM J, V303, P957, DOI 10.1042/bj3030957; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Jaskiewicz E, 1996, GLYCOCONJUGATE J, V13, P213, DOI 10.1007/BF00731496; KOZAK M, 1983, MICROBIOL REV, V47, P1; LAMMERS G, 1989, BIOCHEM J, V261, P389, DOI 10.1042/bj2610389; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LATALLO JFK, 1990, GENE DEV, V4, P1288; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MCCAFFREY G, 1993, COMP BIOCHEM PHYS B, V104, P91, DOI 10.1016/0305-0491(93)90342-3; MUNRO S, 1995, BIOCHEM SOC T, V23, P527, DOI 10.1042/bst0230527; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; NAGATA Y, 1994, J BIOL CHEM, V269, P7045; NAGATA Y, 1992, J BIOL CHEM, V267, P29227; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; RICHARDSON K, 1995, COMP BIOCHEM PHYS B, V110, P445, DOI 10.1016/0305-0491(94)00149-O; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SCHWEIZER A, 1994, J CELL BIOL, V126, P25, DOI 10.1083/jcb.126.1.25; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SLUSAREWICZ P, 1994, J CELL BIOL, V124, P405, DOI 10.1083/jcb.124.4.405; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; VANNOORT JM, 1989, J BIOL CHEM, V264, P14159; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WARNOCK DE, 1993, J BIOL CHEM, V268, P10145; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMAGUCHI N, 1995, J BIOL CHEM, V270, P12170, DOI 10.1074/jbc.270.20.12170; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149; YOUNG WW, 1990, P NATL ACAD SCI USA, V87, P6838, DOI 10.1073/pnas.87.17.6838; YOUNG WW, 1986, J BIOL CHEM, V261, P2279; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	52	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26395	26403		10.1074/jbc.271.42.26395	http://dx.doi.org/10.1074/jbc.271.42.26395			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824296	hybrid			2022-12-27	WOS:A1996VN18000102
J	Keller, ET; Chang, CS; Ershler, WB				Keller, ET; Chang, CS; Ershler, WB			Inhibition of NF kappa B activity through maintenance of I kappa B alpha levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; ANDROGEN RESPONSE ELEMENTS; RECEPTOR MESSENGER-RNA; GROWTH-FACTOR; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; GENE-EXPRESSION; C-FOS; MOLECULAR MECHANISMS; NEGATIVE REGULATION	Androgens repress expression of many genes, yet the mechanism of this activity has remained elusive. The cytokine, interleukin-6, is active in a variety of biological systems, and its expression is repressed by androgens. Accordingly we dissected the mechanism of androgen's ability to inhibit interleukin-6 expression at the molecular level. In a series of co-transfection assays, we found that 5 alpha-dihydrotestosterone, through the androgen receptor, repressed activation of the interleukin-6 promoter, in part, by inhibiting NF kappa B activity. It did not appear that 5 alpha-dihydrotestosterone inhibited NF kappa B by activating the androgen receptor to compete for the NF kappa B response element as we could not detect androgen receptor binding to the IL-6 promoter by DNase I footprinting assay. However, by electrophoretic mobility shift assay we found that 5 alpha-dihydrotestosterone repressed formation of NF kappa B . NF kappa B response element complex formation. In LNCaP prostate carcinoma cells, 5 alpha-dihydrotestosterone achieved this effect through maintenance of I kappa B alpha protein levels in the face of phorbol ester, a stimulus that results in I kappa B alpha degradation. Finally, we confirmed that I kappa B alpha inhibits NF kappa B-mediated activation of the interleukin-6 promoter. These data suggest that maintenance of I kappa B alpha levels may represent the first identified mechanism for androgen-mediated repression of a natural androgen-regulated gene.	UNIV WISCONSIN, INST AGING, DEPT MED, MADISON, WI 53706 USA; MADISON VET ADM, GRECC, MADISON, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison; Geriatric Research Education & Clinical Center			Keller, Evan T/M-1446-2016	Keller, Evan T/0000-0002-7592-7535	NATIONAL INSTITUTE ON AGING [R01AG011970] Funding Source: NIH RePORTER; NIA NIH HHS [AG00451, AG11970, AG00213] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; BINGAMAN EW, 1994, NEUROENDOCRINOLOGY, V59, P228, DOI 10.1159/000126663; BODINE PVN, 1995, J STEROID BIOCHEM, V52, P149, DOI 10.1016/0960-0760(94)00165-I; BRIEHL MM, 1991, MOL ENDOCRINOL, V5, P1381, DOI 10.1210/mend-5-10-1381; BURCIN M, 1994, SEMIN CANCER BIOL, V5, P337; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CHANG CS, 1992, P NATL ACAD SCI USA, V89, P5946, DOI 10.1073/pnas.89.13.5946; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; CLARK AR, 1993, BIOCHEM J, V296, P521, DOI 10.1042/bj2960521; CLAY CM, 1993, J BIOL CHEM, V268, P13556; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; DABBS JM, 1990, CHRONOBIOL INT, V7, P245, DOI 10.3109/07420529009056982; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAY ML, 1993, CANCER RES, V53, P5597; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; DEVOS P, 1991, J BIOL CHEM, V266, P3439; ERIKSSON S, 1995, CALCIFIED TISSUE INT, V57, P97, DOI 10.1007/BF00298427; ERSHLER WB, 1994, DRUG AGING, V5, P358, DOI 10.2165/00002512-199405050-00005; Galien R, 1996, MOL ENDOCRINOL, V10, P713, DOI 10.1210/me.10.6.713; GUMERLOCK PH, 1992, P ANN M AM ASS CANC, V33, pA2170; GUMERLOCK PH, 1993, P ANN M AM ASS CANC, V34, pA2950; HARRIS SE, 1990, ENDOCRINOLOGY S, V126, P93; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JACKSON ME, 1991, J CELL SCI, V100, P1; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KELLER ET, 1995, J IMMUNOL, V154, P4091; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD59; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEPPA S, 1991, CELL REGUL, V2, P1; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LINDZEY J, 1994, VITAM HORM, V49, P383; LINDZEY J, 1993, MOL ENDOCRINOL, V7, P1530, DOI 10.1210/me.7.12.1530; MANCINI MA, 1991, J HISTOCHEM CYTOCHEM, V39, P401, DOI 10.1177/39.4.1706374; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; METSIS M, 1992, GENE, V121, P247, DOI 10.1016/0378-1119(92)90128-C; MIYAMOTO S, 1995, ADV CANCER RES, V7, P2064; MIZOKAMI A, 1992, ENDOCRINOL JAPON, V39, P235; MONTPETIT ML, 1986, PROSTATE, V8, P25, DOI 10.1002/pros.2990080105; MORIMOTO R I, 1992, Current Opinion in Cell Biology, V4, P480, DOI 10.1016/0955-0674(92)90015-5; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; NAHOUL K, 1990, J STEROID BIOCHEM, V35, P293, DOI 10.1016/0022-4731(90)90287-3; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PERSSON H, 1990, SCIENCE, V247, P704, DOI 10.1126/science.2154035; POTTRATZ ST, 1994, J CLIN INVEST, V93, P944, DOI 10.1172/JCI117100; QUARMBY VE, 1987, MOL ENDOCRINOL, V1, P865, DOI 10.1210/mend-1-12-865; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; RAY A, 1989, MOL CELL BIOL, V9, P5537, DOI 10.1128/MCB.9.12.5537; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; RENKAWITZ R, 1993, ANN NY ACAD SCI, V684, P1, DOI 10.1111/j.1749-6632.1993.tb32266.x; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROCHE PJ, 1992, MOL ENDOCRINOL, V6, P2229, DOI 10.1210/me.6.12.2229; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SERVE H, 1991, CANCER RES, V51, P3862; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; TABIBZADEH SS, 1989, J IMMUNOL, V142, P3134; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; URBAN MB, 1991, NEW BIOL, V3, P279; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEI J, 1992, LIFE SCI, V51, P1953, DOI 10.1016/0024-3205(92)90112-3; WILDING G, 1989, PROSTATE, V14, P103, DOI 10.1002/pros.2990140204; WISHART JM, 1995, CLIN ENDOCRINOL, V42, P141, DOI 10.1111/j.1365-2265.1995.tb01854.x; WOLF DA, 1992, BRIT J CANCER, V65, P376, DOI 10.1038/bjc.1992.76; WONG P, 1993, J BIOL CHEM, V268, P5021; YASUKAWA K, 1987, EMBO J, V6, P2939, DOI 10.1002/j.1460-2075.1987.tb02598.x; YEN PM, 1994, MOL ENDOCRINOL, V8, P1450, DOI 10.1210/me.8.11.1450; ZHANG J, 1996, AM GER SOC ANN M CHI, P128; ZHANG YH, 1994, P NATL ACAD SCI USA, V91, P2225, DOI 10.1073/pnas.91.6.2225	84	147	152	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26267	26275		10.1074/jbc.271.42.26267	http://dx.doi.org/10.1074/jbc.271.42.26267			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824277	hybrid			2022-12-27	WOS:A1996VN18000083
J	Puttaraju, M; Been, MD				Puttaraju, M; Been, MD			Circular ribozymes generated in Escherichia coli using group I self-splicing permuted intron-exon sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-DELTA-VIRUS; RIBONUCLEASE-P RNA; MESSENGER-RNA; THERAPEUTIC AGENTS; CATALYTIC ACTIVITY; RIBONUCLEOPROTEIN ENZYME; HAMMERHEAD RIBOZYMES; VITRO TRANSCRIPTION; SECONDARY STRUCTURE; CELLS	A circularly permuted self-splicing group I intron from Anabaena was used to generate covalently closed circular trans-acting ribozymes in Escherichia coli. The RNA component of Bacillus subtilis RNaseP and an artificial trans-acting hepatitis delta virus ribozyme were expressed as the exon portion of the permuted intron. RNA isolated from these cells contained circular forms of the ribozymes, indicating that circles were generated from precursors expressed in these cells. Total RNA isolated from cells producing the circular RNA contained ribozyme activity. In contrast, a linear form of the delta virus ribozyme expressed as part of an unprocessed transcript yielded no detectable activity. These data extend previous in vitro and in vivo studies on splicing-mediated RNA circularization by demonstrating the intracellular production of circular ribozymes. These results have implications for the development of systems expressing therapeutic forms of small RNAs such as ribozymes and decoy-type competitors. Circular RNAs generated by splicing are devoid of flanking sequences that could potentially interfere with function. Also, because circular RNAs are not primary substrates for exonucleases, they may have increased in vivo half-lives relative to linear molecules with similar sequences.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University					NIGMS NIH HHS [GM47233, GM40689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040689, R55GM047233, R01GM047233] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1994, TRENDS BIOCHEM SCI, V19, P251, DOI 10.1016/0968-0004(94)90151-1; BEEN MD, 1992, BIOCHEMISTRY-US, V31, P11843, DOI 10.1021/bi00162a024; BEIGELMAN L, 1995, J BIOL CHEM, V270, P25702, DOI 10.1074/jbc.270.43.25702; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CAPEL B, 1993, CELL, V73, P1019, DOI 10.1016/0092-8674(93)90279-Y; CECH TR, 1988, JAMA-J AM MED ASSOC, V260, P3030; CHAN WKY, 1988, GENE, V73, P295, DOI 10.1016/0378-1119(88)90494-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCQUERELLE C, 1993, FASEB J, V7, P155, DOI 10.1096/fasebj.7.1.7678559; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; DIENER TO, 1989, P NATL ACAD SCI USA, V86, P9370, DOI 10.1073/pnas.86.23.9370; FORD E, 1994, P NATL ACAD SCI USA, V91, P3117, DOI 10.1073/pnas.91.8.3117; GOLD L, 1995, J BIOL CHEM, V270, P13581, DOI 10.1074/jbc.270.23.13581; GOODCHILD J, 1992, NUCLEIC ACIDS RES, V20, P4607, DOI 10.1093/nar/20.17.4607; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HARLAND R, 1988, DEVELOPMENT, V102, P837; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1995, NUCLEIC ACIDS RES, V23, P2223, DOI 10.1093/nar/23.12.2223; HERRIN DL, 1990, J BIOL CHEM, V265, P21134; JAMES BD, 1988, CELL, V52, P19, DOI 10.1016/0092-8674(88)90527-2; JARRELL KA, 1993, P NATL ACAD SCI USA, V90, P8624, DOI 10.1073/pnas.90.18.8624; KIM HG, 1995, BIOCHEMISTRY-US, V34, P8165, DOI 10.1021/bi00025a023; KOS A, 1986, NATURE, V323, P558, DOI 10.1038/323558a0; LAZINSKI DW, 1995, RNA, V1, P225; LEE SW, 1995, GENE THER, V2, P377; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MAO JR, 1995, J BIOL CHEM, V270, P19684, DOI 10.1074/jbc.270.34.19684; MAYFIELD C, 1994, J BIOL CHEM, V269, P18232; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PAN T, 1993, GENE, V125, P111, DOI 10.1016/0378-1119(93)90317-V; PAOLELLA G, 1992, EMBO J, V11, P1913, DOI 10.1002/j.1460-2075.1992.tb05244.x; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRICE JV, 1987, J MOL BIOL, V196, P49, DOI 10.1016/0022-2836(87)90510-9; PUTTARAJU M, 1993, NUCLEIC ACIDS RES, V21, P4253, DOI 10.1093/nar/21.18.4253; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5357, DOI 10.1093/nar/20.20.5357; PUTTARAJU M, 1995, NUCLEIC ACIDS S SER, V33, P92; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROSSI JJ, 1991, PHARMACOL THERAPEUT, V50, P245, DOI 10.1016/0163-7258(91)90016-F; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SIOUD M, 1992, J MOL BIOL, V223, P831, DOI 10.1016/0022-2836(92)90244-E; SIOUD M, 1991, P NATL ACAD SCI USA, V88, P7303, DOI 10.1073/pnas.88.16.7303; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; SULLENGER BA, 1990, CELL, V63, P601, DOI 10.1016/0092-8674(90)90455-N; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; TABAK HF, 1984, CELL, V39, P623, DOI 10.1016/0092-8674(84)90469-0; TAYLOR NR, 1992, NUCLEIC ACIDS RES, V20, P4559, DOI 10.1093/nar/20.17.4559; WANG SH, 1994, NUCLEIC ACIDS RES, V22, P2326, DOI 10.1093/nar/22.12.2326; WAUGH DS, 1993, FASEB J, V7, P188, DOI 10.1096/fasebj.7.1.7678561; WAUGH DS, 1989, SCIENCE, V244, P1569, DOI 10.1126/science.2472671; WEINTRAUB H, 1985, TRENDS GENET, V1, P22, DOI 10.1016/0168-9525(85)90010-1; ZAUG AJ, 1983, NATURE, V301, P578, DOI 10.1038/301578a0; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	59	13	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26081	26087		10.1074/jbc.271.42.26081	http://dx.doi.org/10.1074/jbc.271.42.26081			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824250	hybrid			2022-12-27	WOS:A1996VN18000056
J	Warshawsky, I; Herz, J; Broze, GJ; Schwartz, AL				Warshawsky, I; Herz, J; Broze, GJ; Schwartz, AL			The low density lipoprotein receptor-related protein can function independently from heparan sulfate proteoglycans in tissue factor pathway inhibitor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS EXOTOXIN-A; RAT HEPATOMA-CELLS; ALPHA-2-MACROGLOBULIN RECEPTOR; PLASMINOGEN-ACTIVATOR; CELLULAR DEGRADATION; 39-KDA PROTEIN; BINDING; IDENTIFICATION; LIGANDS; COMPLEXES	Tissue factor pathway inhibitor (TFPI) is a plasma serine protease inhibitor that directly inhibits coagulation factor Xa and regulates blood coagulation via inhibition of factor VIIa-tissue factor enzymatic activity. We previously demonstrated that >90% of TFPI bound to a single population of low affinity binding sites on hepatoma cells (2 x 10(6) sites/cell, K-d = 30 nM), and, that following binding, the low density lipoprotein receptor-related protein (LRP) mediated TFPI uptake and degradation. We subsequently reported heparan sulfate proteoglycans (HSPGs) constitute a second receptor system involved in TFPI catabolism, In the present study, mouse embryonic fibroblasts heterozygous and homozygous-negative for disruption of the LRP gene were used to further examine the roles of LRP and HSPGs in TFPI endocytosis. We demonstrate that LRP is absolutely required for degrading I-125-TFPI. LRP heterozygous and homozygous-negative cells bind I-125-TFPI similarly, and the 39-kDa protein, an inhibitor of all known ligand interactions with LRP, does not alter I-125-TFPI binding to these cells, TFPI can be cross-linked to LRP on [S-35]cysteine-labeled hepatoma and LRP-heterozygous cells but not LRP-negative cells, When HSPGs are blocked with protamine, I-125-TFPI binds in a 39-kDa protein-inhibitable manner to 41,000 high affinity sites/ hepatoma cell (K-d = 2.3 nM), Blockade of HSPGs with protamine results in significantly more I-125-TFPI degradation by LRP-positive cells, TFPI can be cross-linked to LRP in the absence and presence of protamine, However, in the presence of protamine, relative to the total pool of cross-linked proteins, 5-fold more TFPI is cross-linked to LRP. Finally, we show TFPI inhibits I-125-alpha(2)-macroglobulin-methylamine binding to hepatoma cells and that carboxyl-terminal residues 115-319 of the 39-kDa protein inhibit both I-125-TFPI degradation and binding when binding conditions contain protamine, Together, our results suggest that while the majority of TFPI binds to cell surface HSPGs, LRP can function independently from HSPGs in the binding and uptake of TFPI.	WASHINGTON UNIV,SCH MED,JEWISH HOSP,EDWARD MALLINCKRODT DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,JEWISH HOSP,DEPT MOL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,JEWISH HOSP,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,JEWISH HOSP,DIV HEMATOL ONCOL,ST LOUIS,MO 63110; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235	Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); Barnes-Jewish Hospital; Washington University (WUSTL); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034462, R01HL052040, R01HL053280] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52040, HL34462, HL53280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BREGENGAARD C, 1993, THROMB HAEMOSTASIS, V70, P454; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; BU GJ, 1992, J BIOL CHEM, V267, P15595; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; BU GJ, 1993, J BIOL CHEM, V268, P13002; DIAZCOLLIER JA, 1994, THROMB HAEMOSTASIS, V71, P339; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; HARENBERG J, 1993, THROMB HAEMOSTASIS, V70, P942; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; Holtzman E, 1989, LYSOSOMES; IADONATO SP, 1993, BIOCHEM J, V296, P867, DOI 10.1042/bj2960867; JI ZS, 1993, J BIOL CHEM, V268, P10160; Kounnas MZ, 1996, J BIOL CHEM, V271, P6523, DOI 10.1074/jbc.271.11.6523; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; SANDSET PM, 1988, THROMB RES, V50, P803, DOI 10.1016/0049-3848(88)90340-4; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, P NATL ACAD SCI USA, V91, P6664, DOI 10.1073/pnas.91.14.6664; WESSELSCHMIDT R, 1992, BLOOD, V79, P2004; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1994, J CELL SCI, V107, P719; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172	32	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25873	25879		10.1074/jbc.271.42.25873	http://dx.doi.org/10.1074/jbc.271.42.25873			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824219	hybrid			2022-12-27	WOS:A1996VN18000025
J	Ritchie, ME				Ritchie, ME			Characterization of human B creatine kinase gene regulation in the heart in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C GENE; RAT-HEART; VOLUME OVERLOAD; PROMOTER REGION; MOLECULAR-BASIS; MESSENGER-RNAS; EXPRESSION; PROTEIN; ELEMENTS; MUSCLE	During cardiogenesis, genes indicative of the adult phenotype are transcriptionally activated while genes characteristic of the embryonic phenotype are down-regulated. The regulation of embryonic genes such as the brain isoform of creatine kinase (BCK) during cardiac development has not been characterized. Accordingly, the transcriptional regulation of BCK in the developing heart was determined. In vitro and in vivo promoter analyses of the human BCK gene identified an element between +25 and +57 that functioned as an enhancer. Electromobility shift assays using adult and neonatal nuclear extracts identified a specific complex binding this element, the abundance of which correlated with the developmental level of endogenous cardiac BCK expression. Mutations at +47 and +53 led to a loss of activity in transfected cells and obviated binding in electromobility shift assays. These data show that a nuclear factor in cardiocytes interacts with an enhancer element (+25 and +57), via nucleotides +47 and +53, to drive BCK expression in the heart and suggest that developmental BCK expression is via abundance of this factor. The nuclear factor has not been identified but as described previously binding sites are not present in the enhancer, it is either a known factor interacting with a new recognition site or a new factor.	UNIV CINCINNATI, COLL MED, CARDIOVASC RES CTR, CINCINNATI, OH 45267 USA; VET ADM MED CTR, DIV CARDIOL, CINCINNATI, OH 45220 USA	University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Ritchie, ME (corresponding author), UNIV CINCINNATI, COLL MED, DIV CARDIOL, 231 BETHESDA AVE, CINCINNATI, OH 45267 USA.							ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; AUSUABEL FM, 1994, CURRENT PROTOCOLS MO; BENFIELD PA, 1988, GENE, V63, P227, DOI 10.1016/0378-1119(88)90527-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTRICK PM, 1994, J MOL CELL CARDIOL, V26, P61, DOI 10.1006/jmcc.1994.1008; BUTTRICK PM, 1993, CIRC RES, V72, P1211, DOI 10.1161/01.RES.72.6.1211; CARRIER L, 1992, CIRC RES, V70, P999, DOI 10.1161/01.RES.70.5.999; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ERLICH HA, 1993, PCR TECHNOLOGY, P171; FONTANET HL, 1991, CIRC RES, V68, P1007, DOI 10.1161/01.RES.68.4.1007; HAWKER KJ, 1993, BIOTECHNIQUES, V14, P764; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; IMAMURA T, 1994, CIRC RES, V75, P418, DOI 10.1161/01.RES.75.3.418; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LEE KJ, 1994, MOL CELL BIOL, V14, P1220, DOI 10.1128/MCB.14.2.1220; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIN H, 1990, CIRCULATION, V82, P2217, DOI 10.1161/01.CIR.82.6.2217; LOMPRE AM, 1991, INT REV CYTOL, V124, P137; MARIMAN E, 1991, GENE, V102, P205, DOI 10.1016/0378-1119(91)90079-Q; MEHTA HB, 1988, CIRC RES, V63, P512, DOI 10.1161/01.RES.63.3.512; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAVANKASATTUSAS S, 1992, MOL CELL BIOL, V12, P1469, DOI 10.1128/MCB.12.4.1469; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARMACEK MS, 1994, MOL CELL BIOL, V14, P1870, DOI 10.1128/MCB.14.3.1870; PARMACEK MS, 1992, MOL CELL BIOL, V12, P1967, DOI 10.1128/MCB.12.5.1967; Ritchie ME, 1996, BIOCHEM BIOPH RES CO, V223, P762, DOI 10.1006/bbrc.1996.0970; RITCHIE ME, 1991, NUCLEIC ACIDS RES, V19, P6231, DOI 10.1093/nar/19.22.6231; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; SCHWARTZ K, 1992, AM J PHYSIOL, V262, pR364, DOI 10.1152/ajpregu.1992.262.3.R364; TRASK RV, 1988, J BIOL CHEM, V263, P17142; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WESSELS A, 1990, ANAT RECORD, V228, P163, DOI 10.1002/ar.1092280208; WILLIAMS RE, 1994, CIRC RES, V75, P615, DOI 10.1161/01.RES.75.4.615; ZHANG JN, 1995, J BIOL CHEM, V270, P16134, DOI 10.1074/jbc.270.27.16134; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	39	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25485	25491						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810319				2022-12-27	WOS:A1996VL69300063
J	Seaman, MNJ; Sowerby, PJ; Robinson, MS				Seaman, MNJ; Sowerby, PJ; Robinson, MS			Cytosolic and membrane-associated proteins involved in the recruitment of AP-1 adaptors onto the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; FACTOR-II RECEPTOR; COATED VESICLES; PHOSPHOLIPASE-D; BINDING; CLATHRIN; ADAPTERS; COMPLEXES; SIGNALS; CELLS	The AP-1 adaptor complex is recruited from the cytosol onto the trans-Golgi network membrane, where it co-assembles with clathrin into a coat that drives vesicle budding. The GTPase ARF1 has been shown to be required for AP-1 recruitment, and here we demonstrate that we can reconstitute full GTP gamma S-dependent recruitment of adaptors onto an enriched trans-Golgi network membrane fraction by adding purified AP-1 and recombinant myristylated ARF1, indicating that these are the only soluble proteins required for binding. To identify some of the membrane proteins involved in recruitment, we have incubated permeabilized metabolically labeled cells with cytosol under conditions that promote adaptor binding, then cross-linked the samples with 3,3'-dithiobis(sulfosuccinimidylproprionate), denatured by boiling in SDS, and immunoprecipitated with antibodies against the various subunits. Under these conditions, the adaptor subunits co-precipitate not only with each other and with clathrin, but also with three novel proteins: p75, which is specifically cross-linked to gamma-adaptin; p80, which is specifically cross-linked to beta'-adaptin; and p60, which is specifically cross-linked to AP47. These proteins are all candidates for components of the adaptor docking site on the trans-Golgi network membrane.	UNIV CAMBRIDGE,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	University of Cambridge					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DITTIE AS, 1986, J CELL BIOL, P523; ESPENSHADE P, 1995, J CELL BIOL, V131, P311, DOI 10.1083/jcb.131.2.311; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; KLUMPERMAN J, 1993, J CELL BIOL, V121, P997, DOI 10.1083/jcb.121.5.997; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PAGE LJ, 1995, J CELL BIOL, V131, P619, DOI 10.1083/jcb.131.3.619; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1986, J CELL BIOL, V102, P48, DOI 10.1083/jcb.102.1.48; ROBINSON MS, 1993, J CELL BIOL, V123, P67, DOI 10.1083/jcb.123.1.67; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; Simpson F, 1996, J CELL BIOL, V133, P749, DOI 10.1083/jcb.133.4.749; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WEISS O, 1989, J BIOL CHEM, V264, P21066; WHITNEY JA, 1995, CELL, V83, P703; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	29	66	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25446	25451		10.1074/jbc.271.41.25446	http://dx.doi.org/10.1074/jbc.271.41.25446			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810314	hybrid			2022-12-27	WOS:A1996VL69300058
J	Petrovic, N; Comi, A; Ettinger, MJ				Petrovic, N; Comi, A; Ettinger, MJ			Identification of an apo-superoxide dismutase (Cu,Zn) pool in human lymphoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; HUMAN K562 CELLS; COPPER-DEFICIENT; CU,ZN-SUPEROXIDE DISMUTASE; PROTEIN; ENZYME; ACTIVATION; BINDING; LIVER; DIFFERENTIATION	Copper incorporation (Cu-64(II)) into Cu,Zn-superoxide dismutase (SOD) was studied in human lymphoblasts, Rapid incorporation of copper with a proportionate increase in SOD activity was detected, No copper incorporation or SOD activation was detected when Cu-64(II) was added to cell cytosols rather than to intact cells, Thus, incorporation of Cu-64 was not due to isotopic exchange. Cycloheximide had no significant effect on copper incorporation and activation of SOD when the data were corrected for total cell copper, Thus, the data were consistent with copper incorporation into a preexisting apoSOD pool rather than newly synthesized SOD, and no new SOD synthesis was detected over a 15-h incubation period, The size of the apoSOD pool was estimated to be approximate to 35% of the total SOD in lymphoblasts, When cells were preincubated for 15 h with excess copper (15 mu M Cu(II)), the size of the apo pool markedly decreased but was not eliminated, suggesting that the apoSOD was not due to copper deficiency, These experiments also indicated that newly arrived copper was preferentially incorporated into the apoSOD pool, while the function(s) of an apoSOD pool remains unknown, Copper binding to apoSOD may provide a rapid protective response against copper toxicity.	SUNY BUFFALO,DEPT BIOCHEM,BUFFALO,NY 14214	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo								AUWERX JH, 1989, BLOOD, V74, P1807; BETHIN KE, 1995, J BIOL CHEM, V270, P20703, DOI 10.1074/jbc.270.35.20703; BETHIN KE, 1995, J BIOL CHEM, V270, P20698, DOI 10.1074/jbc.270.35.20698; CHANG LY, 1988, J CELL BIOL, V107, P2169, DOI 10.1083/jcb.107.6.2169; CHUNG K, 1988, J NUTR, V118, P859, DOI 10.1093/jn/118.7.859; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; DAMERON CT, 1987, BIOCHEM J, V248, P663, DOI 10.1042/bj2480663; DAMERON CT, 1987, BIOCHEM J, V248, P669, DOI 10.1042/bj2480669; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DISILVESTRO RA, 1989, ARCH BIOCHEM BIOPHYS, V274, P298, DOI 10.1016/0003-9861(89)90442-6; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; HARRIS ED, 1992, J NUTR, V122, P636, DOI 10.1093/jn/122.suppl_3.636; KELLER GA, 1991, P NATL ACAD SCI USA, V88, P7381, DOI 10.1073/pnas.88.16.7381; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; PERCIVAL SS, 1991, BIOCHEM J, V274, P153, DOI 10.1042/bj2740153; PERCIVAL SS, 1992, J NUTR, V122, P2424, DOI 10.1093/jn/122.12.2424; Petrovic N, 1996, J BIOL CHEM, V271, P28335, DOI 10.1074/jbc.271.45.28335; ROSSI L, 1994, BIOCHEM BIOPH RES CO, V203, P1028, DOI 10.1006/bbrc.1994.2285; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINKUHLER C, 1994, BIOCHEM J, V302, P687, DOI 10.1042/bj3020687; STEINKUHLER C, 1991, J BIOL CHEM, V266, P24580	22	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28331	28334		10.1074/jbc.271.45.28331	http://dx.doi.org/10.1074/jbc.271.45.28331			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910455	hybrid			2022-12-27	WOS:A1996VU03300055
J	Sung, P; Stratton, SA				Sung, P; Stratton, SA			Yeast Rad51 recombinase mediates polar DNA strand exchange in the absence of ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FILAMENT; BREAKS; SITE	Saccharomyces cerevisiae RAD51 gene is required for genetic recombination and recombinational repair of DNA strand breaks. Rad51 protein has a DNA-dependent ATPase activity, and it catalyzes ATP-dependent pairing and strand exchange between homologous DNA molecules. We show here that the rad51 Arg-191 protein, which is devoid of ATPase activity, mediates the pairing and strand exchange reaction upon binding ATP. In addition, the wild type Rad51 protein can catalyze pairing and strand exchange in the presence of the nonhydrolyzable ATP analogues adenylyl-imidodiphosphate and adenosine 5'-O-thiotriphosphate. Thus, homologous pairing and the unidirectional transfer of greater than 5 kilobases of DNA can occur efficiently without the need for nucleotide hydrolysis. Consistent with the results from the biochemical analyses, expression of the rad51 Arg-191 protein in a rad51 null mutant confers normal cellular resistance to the DNA damaging agent methylmethane sulfonate, suggesting that nucleotide binding by Rad51 is sufficient for biological function.			Sung, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		CameriniOtero RD, 1995, ANNU REV GENET, V29, P509, DOI 10.1146/annurev.genet.29.1.509; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1987, ANNU REV BIOCHEM, V56, P229, DOI 10.1146/annurev.bi.56.070187.001305; HONIGBERG SM, 1985, J BIOL CHEM, V260, P1845; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PRAKASH L, 1977, GENETICS, V86, P33; RADDING CM, 1991, J BIOL CHEM, V266, P5355; RATTRAY AJ, 1994, GENETICS, V138, P587; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x	22	148	149	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27983	27986		10.1074/jbc.271.45.27983	http://dx.doi.org/10.1074/jbc.271.45.27983			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910403	hybrid			2022-12-27	WOS:A1996VU03300003
J	Chu, RY; Lin, YL; Rao, MS; Reddy, JK				Chu, RY; Lin, YL; Rao, MS; Reddy, JK			Cloning and identification of rat deoxyuridine triphosphatase as an inhibitor of peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE RECEPTORS; ACYL-COA OXIDASE; THYROID-HORMONE; BETA-OXIDATION; SIGNALING PATHWAYS; PROTEIN; SEQUENCE; FAMILY; LIVER; DNA	Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily that transcriptionally regulate responsive genes by binding to the peroxisome proliferator response elements, Protein(s) interacting with PPAR, isoforms (alpha, delta, and gamma) may modulate the PPAR-mediated transcriptional activation, Using a yeast two-hybrid system to screen a rat liver cDNA library, we have identified rat deoxyuridine-triphosphatase (dUTPase, EC 3.6.1.23) as a PPAR alpha-interacting protein, This cDNA encodes a polypeptide of 203 amino acids; the C-terminal 141-amino acid segment of this protein corresponds to the full-length human enzyme, which exhibits 92% identity with human dUTPase; the N-terminal extra Ga-amino acid residue region is arginine-rich, In vitro binding assays indicate that rat dUTPase interacts with all three isoforms of mouse PPAR, but not with retinoid X receptor and thyroid hormone receptor, Interaction of PPAR alpha with dUTPase is with the N-terminal fia-amino acid segment of rat dUTPase, Full-length rat dUTPase prevents PPAR-retinoid X receptor heterodimerization resulting in an inhibition of PPAR activity in a ligand-independent manner. Immunostaining of human kidney tsA201 cells, transiently expressing dUTPase showed that this protein is present predominantly in the cytoplasm but translocates into the nucleus with PPAR alpha when PPAR alpha is coexpressed with dUTPase, Northern blot hybridization shows that rat dUTPase is encoded by an abundant 1-kilobase mRNA species present in all rat tissues, The identification of dUTPase as a PPAR-interacting protein suggests a possible link between tumorigenic peroxisome proliferators and the enzyme system involved in the maintenance of DNA fidelity.	NORTHWESTERN UNIV, SCH MED, DEPT PATHOL, CHICAGO, IL 60611 USA	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM 23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHU RY, 1995, P NATL ACAD SCI USA, V92, P11593, DOI 10.1073/pnas.92.25.11593; CHU S, 1995, P NATL ACAD SCI USA, V92, P7080, DOI 10.1073/pnas.92.15.7080; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; GARVEY JS, 1977, METHOD IMMUNOL, P7; GIBSON GM, 1993, P SOC PHOTO-OPT INS, V2204, P119; GRAFSTROM RH, 1978, CELL, V15, P131, DOI 10.1016/0092-8674(78)90089-2; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG Q, 1994, J BIOL CHEM, V269, P8493; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LUNBERG LG, 1983, GENE, V23, P115; LUNDBERG LG, 1983, EMBO J, V2, P967, DOI 10.1002/j.1460-2075.1983.tb01529.x; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; MCINTOSH EM, 1992, P NATL ACAD SCI USA, V89, P8020, DOI 10.1073/pnas.89.17.8020; MERCER AA, 1989, VIROLOGY, V172, P665, DOI 10.1016/0042-6822(89)90212-2; NATION MD, 1989, BIOCHEM J, V259, P593, DOI 10.1042/bj2590593; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, NATURE, V377, P387; PRIHADASH A, 1992, PLANT CELL, V4, P149, DOI 10.1105/tpc.4.2.149; PYLES RB, 1994, J VIROL, V68, P4514, DOI 10.1128/JVI.68.7.4514-4524.1994; RAO MS, 1994, PHARMACOL TOXICOL, P175; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; TYE BK, 1977, J MOL BIOL, V117, P293, DOI 10.1016/0022-2836(77)90128-0; WHEELER L, 1992, J BIOL CHEM, V267, P7664; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	55	33	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27670	27676		10.1074/jbc.271.44.27670	http://dx.doi.org/10.1074/jbc.271.44.27670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910358	hybrid			2022-12-27	WOS:A1996VQ67900076
J	Haugeto, O; Ullensvang, K; Levy, LM; Chaudhry, FA; Honore, T; Nielsen, M; Lehre, KP; Danbolt, NC				Haugeto, O; Ullensvang, K; Levy, LM; Chaudhry, FA; Honore, T; Nielsen, M; Lehre, KP; Danbolt, NC			Brain glutamate transporter proteins form homomultimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCITATORY SYNAPTIC TRANSMISSION; RADIATION TARGET ANALYSIS; RAT-BRAIN; ASPARTATE TRANSPORTER; RNA-POLYMERASE; DIFFERENTIAL EXPRESSION; BENZODIAZEPINE RECEPTOR; OLIGOMERIC STRUCTURE; CHLORIDE CHANNEL; AMINO-ACIDS	Removal of excitatory amino acids from the extracellular fluid is essential for synaptic transmission and for avoiding excitotoxicity, The removal is accomplished by glutamate transporters located in the plasma membranes of both neurons and astroglia. The uptake system consists of several different transporter proteins that are carefully regulated, indicating more refined functions than simple transmitter inactivation, Here we show by chemical cross-linking, followed by electrophoresis and immunoblotting, that three rat brain glutamate transporter proteins (GLAST, GLT and EAAC) form homomultimers. The multimers exist not only in intact brain membranes but also after solubilization and after reconstitution in liposomes, Increasing the crosslinker concentration increased the immunoreactivity of the bands corresponding to trimers at the expense of the dimer and monomer bands. However, the immunoreactivities of the dimer bands did not disappear, indicating a mixture of dimers and trimers. GLT and GLAST do not complex with each other, but as demonstrated by double labeling post-embedding electron microscopic immunocytochemistry, they co-exist side by side in the same astrocytic cell membranes, The oligomers are held together noncovalently in vivo. In vitro, oxidation induces formation of covalent bonds (presumably -S-S-) between the subunits of the oligomers leading to the appearance of oligomer bands on SDS-polyacrylamide gel electrophoresis. Immunoprecipitation experiments suggest that GLT is the quantitatively dominant glutamate transporter in the brain. Radiation inactivation analysis gives a molecular target size of the functional complex corresponding to oligomeric structure. We postulate that the glutamate transporters operate as homomultimeric complexes.	UNIV OSLO,INST BASIC MED SCI,DEPT ANAT,N-0317 OSLO,NORWAY; NOVO NORDISK AS,DK-2760 MALOV,DENMARK; ST HANS HOSP,DK-4000 ROSKILDE,DENMARK	University of Oslo; Novo Nordisk			Danbolt, Niels Christian/A-1907-2014	Danbolt, Niels Christian/0000-0003-4227-4520				BARBOUR B, 1994, NEURON, V12, P1331, DOI 10.1016/0896-6273(94)90448-0; BELIVEAU R, 1988, BIOCHEM J, V252, P807, DOI 10.1042/bj2520807; BELIVEAU R, 1990, BIOCHEM J, V268, P195, DOI 10.1042/bj2680195; BERGER SP, 1994, MOL PHARMACOL, V46, P726; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bjoras M, 1996, MOL BRAIN RES, V36, P163, DOI 10.1016/0169-328X(95)00279-2; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHAUDHRY FA, 1995, NEURON, V15, P711, DOI 10.1016/0896-6273(95)90158-2; CONRADT M, 1995, EUR J BIOCHEM, V229, P682, DOI 10.1111/j.1432-1033.1995.tb20514.x; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DANBOLT NC, 1990, BIOCHEMISTRY-US, V29, P6734, DOI 10.1021/bi00480a025; DEAS J, 1992, BRAIN RES, V575, P251, DOI 10.1016/0006-8993(92)90087-P; EISENTHAL R, 1974, BIOCHEM J, V139, P715, DOI 10.1042/bj1390715; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KEMPNER ES, 1993, TRENDS BIOCHEM SCI, V18, P236, DOI 10.1016/0968-0004(93)90169-N; KEMPNER ES, 1986, ANAL BIOCHEM, V156, P140, DOI 10.1016/0003-2697(86)90165-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRE KP, 1995, J NEUROSCI, V15, P1835; LEVY LM, 1993, FEBS LETT, V317, P79, DOI 10.1016/0014-5793(93)81495-L; LEVY LM, 1995, EUR J NEUROSCI, V7, P2036, DOI 10.1111/j.1460-9568.1995.tb00626.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAKI R, 1994, J NEUROSCI, V14, P6754; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; NIELSEN M, 1984, LIFE SCI, V35, P325, DOI 10.1016/0024-3205(84)90116-4; NIELSEN M, 1985, BIOCHEM PHARMACOL, V34, P3633, DOI 10.1016/0006-2952(85)90223-0; NIELSEN M, 1988, J BIOL CHEM, V263, P11900; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SCHULTE S, 1995, EUR J BIOCHEM, V233, P947, DOI 10.1111/j.1432-1033.1995.947_3.x; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TAKAHASHI M, 1995, J NEUROSCI, V15, P5693; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TORP R, 1994, EUR J NEUROSCI, V6, P936, DOI 10.1111/j.1460-9568.1994.tb00587.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; TROTTI D, 1995, J BIOL CHEM, V270, P9890, DOI 10.1074/jbc.270.17.9890; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WANG BL, 1985, HISTOCHEMISTRY, V83, P47, DOI 10.1007/BF00495299; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; ZAFRA F, 1995, J NEUROSCI, V15, P3952	54	402	406	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27715	27722		10.1074/jbc.271.44.27715	http://dx.doi.org/10.1074/jbc.271.44.27715			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910364	hybrid			2022-12-27	WOS:A1996VQ67900082
J	Puthalakath, H; Burke, J; Gleeson, PA				Puthalakath, H; Burke, J; Gleeson, PA			Glycosylation defect in Lec1 Chinese hamster ovary mutant is due to a point mutation in N-acetylglucosaminyltransferase I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-3-D-MANNOSIDE BETA-1,2-N-ACETYLGLUCOSAMINYLTRANSFERASE-I GENE; ASPARAGINE-LINKED OLIGOSACCHARIDES; MOLECULAR-CLONING; CELLS; COMPLEX; EXPRESSION; LOCALIZATION; DEFICIENT; PROTEIN; HYBRID	The Lec1 Chinese hamster ovary (CHO) mutant is a leuco-phytohemagglutinin resistant cell line unable to synthesize complex and hybrid N-glycans due to the lack of N-acetylglucosaminyltransferase I (GnTI) activity. Here we have identified the lec1 mutation, Using specific antibodies to GnTI we demonstrate that Led cells synthesize an inactive GnTI protein identical in size to the wild-type CHO enzyme, We have cloned and sequenced the gene coding GnTI from parental CHO and Led mutant cells, Comparison of GnTI sequences detected three mutations within the luminal domain of Led GnTI, each resulting in an amino acid substitution, The effect of each mutation an enzyme activity was analyzed bg site-directed mutagenesis of wild-type rabbit GnTI and transient expression in COS cells. One of the three mutations (Cys(123)-->Arg(123)) resulted in complete loss of activity, whereas the other two mutations had no apparent effect on enzyme activity. This conclusion was confirmed by expression of GnTI mutants in the GnTI null background of Saccharomyces cerevisiae. Both Led GnTI and the GnTI mutant (Cys(123)-->Arg(123)) are correctly localized to the Golgi apparatus, indicating that the inactive GnTI molecules are sufficiently well folded for efficient transport from the endoplasmic reticulum. These results demonstrate that the Zed mutation is a point mutation and that Cys(123) is a critical residue for GnTI activity.	MONASH UNIV, DEPT PATHOL & IMMUNOL, SCH MED, PRAHRAN, VIC 3181, AUSTRALIA	Monash University			Puthalakath, Hamsa/B-8541-2011	Gleeson, Paul/0000-0002-5336-6503; Puthalakath, Hamsa/0000-0001-5178-1175				BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BRILES EB, 1982, INT REV CYTOL, V75, P101, DOI 10.1016/S0074-7696(08)61003-7; BURKE J, 1992, J BIOL CHEM, V267, P24433; BURKE J, 1994, J BIOL CHEM, V269, P12049; FUKADA T, 1994, BIOSCI BIOTECH BIOCH, V58, P200, DOI 10.1271/bbb.58.200; GOTTLIEB C, 1975, J BIOL CHEM, V250, P3303; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; IOFFE E, 1994, P NATL ACAD SCI USA, V91, P728, DOI 10.1073/pnas.91.2.728; KOOY J, 1992, J BIOL CHEM, V267, P20255; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREZDORN CM, 1994, EUR J BIOCHEM, V225, P1229; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KUMAR R, 1992, GLYCOBIOLOGY, V2, P383, DOI 10.1093/glycob/2.4.383; MEAGER A, 1976, BIOCHEM J, V154, P113, DOI 10.1042/bj1540113; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; Narasimhan S., 1993, Glycobiology, V3, P531; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; POWNALL S, 1992, GENOMICS, V12, P699, DOI 10.1016/0888-7543(92)90297-6; ROBERTSON MA, 1978, CELL, V13, P515, DOI 10.1016/0092-8674(78)90325-2; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHACHTER H, 1983, METHOD ENZYMOL, V98, P98; SCHWIENTEK T, 1996, J BIOL CHEM, V271, P3393; STANLEY P, 1984, ANNU REV GENET, V18, P525, DOI 10.1146/annurev.ge.18.120184.002521; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; STANLEY P, 1987, TRENDS GENET, V3, P77, DOI 10.1016/0168-9525(87)90180-6; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; VISCHER P, 1981, EUR J BIOCHEM, V117, P275, DOI 10.1111/j.1432-1033.1981.tb06334.x; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; Warren Charles E., 1992, Glycobiology, V2, P488	35	54	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27818	27822		10.1074/jbc.271.44.27818	http://dx.doi.org/10.1074/jbc.271.44.27818			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910379	hybrid			2022-12-27	WOS:A1996VQ67900097
J	Rao, GN; Glasgow, WC; Eling, TE; Runge, MS				Rao, GN; Glasgow, WC; Eling, TE; Runge, MS			Role of hydroperoxyeicosatetraenoic acids in oxidative stress-induced activating protein 1 (AP-1) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LOW-DENSITY-LIPOPROTEIN; OXYGEN FREE-RADICALS; ARACHIDONIC-ACID; HYDROGEN-PEROXIDE; MESSENGER-RNA; GENE-EXPRESSION; C-FOS; GROWTH; ATHEROSCLEROSIS	We have previously reported that hydrogen peroxide, an active oxygen species and a cellular oxidant, induces c-Fos and c-Jun mRNA expression and DNA synthesis in vascular smooth muscle cells and that these events require arachidonic acid release and metabolism through the lipoxygenase pathway. Here we have identified the eicosanoids that mediate the hydrogen peroxide-induced growth-related events in these cells. Hydrogen peroxide stimulated the production of 12- and 15-hydroperoxyeicosatetraenoic acids in vascular smooth muscle cells, Both 12- and 15-hydroperoxyeicosatetraenoic acids induced the expression of c-Fos and c-Jun protein and increased activating protein 1 (AP-1) activity, as measured by AP-1-DNA binding and AP-1-dependent human collagenase promoter-driven chloramphenicol acetyltransferase reporter gene transcription. Hydrogen peroxide and arachidonic acid also induced the expression of c-Fos and c-dun protein and AP-1 activity, Nordihydroguaiaretic acid, an inhibitor of the lipoxygenase pathway, significantly inhibited both hydrogen peroxide and arachidonic acid-stimulated c-Fos and c-Jun protein expression and AP-1 activity. Together, these findings suggest that hydrogen peroxide induces the production of eicosanoids and that the eicosanoids are potential mediators of the oxidative stress-stimulated growth-related events in vascular smooth muscle cells.	NIEHS,MOL BIOPHYS LAB,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Rao, GN (corresponding author), UNIV TEXAS,MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064,301 UNIV BLVD,GALVESTON,TX 77555, USA.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; ESTERBAUER H, 1986, BIOCHIM BIOPHYS ACTA, V876, P154, DOI 10.1016/0005-2760(86)90329-2; FANTONE JC, 1982, AM J PATHOL, V107, P394; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADA T, 1994, BBA-LIPID LIPID MET, V1211, P221, DOI 10.1016/0005-2760(94)90272-0; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HENRIKSSON P, 1985, BIOCHIM BIOPHYS ACTA, V834, P272, DOI 10.1016/0005-2760(85)90166-3; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; NATARAJAN R, 1993, P NATL ACAD SCI USA, V90, P4947, DOI 10.1073/pnas.90.11.4947; POSTOAK D, 1990, AM J PHYSIOL, V259, pC849, DOI 10.1152/ajpcell.1990.259.6.C849; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; WANG T, 1991, BIOCHIM BIOPHYS ACTA, V1084, P129, DOI 10.1016/0005-2760(91)90211-Y; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	40	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27760	27764		10.1074/jbc.271.44.27760	http://dx.doi.org/10.1074/jbc.271.44.27760			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910370	hybrid			2022-12-27	WOS:A1996VQ67900088
J	Xu, WF; Chung, DW; Davie, EW				Xu, WF; Chung, DW; Davie, EW			The assembly of human fibrinogen - The role of the amino-terminal and coiled-coil regions of the three chains in the formation of the alpha gamma and beta gamma heterodimers and alpha beta gamma half-molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN FIBRINOGEN; GCN4 LEUCINE-ZIPPER; FIBROUS PROTEINS; SECRETION; DNA; MICROSCOPY; FRAGMENTS; SEQUENCE; MODEL	Fibrinogen is a plasma protein consisting of six polypeptide chains which are linked by disulfide bonds. During protein synthesis, assembly of the molecule proceeds through the formation of alpha gamma and beta gamma heterodimers followed by the generation of alpha beta gamma half-molecules and dimerizing to generate the mature six-chain molecule. In the present study, sequences required for the formation of the alpha gamma and beta gamma heterodimers were examined in stably transfected baby hamster kidney cells expressing combinations of normal as web as modified polypeptide chains. Deletion of the amino terminus and the proximal first half of the coiled-coil region of the three fibrinogen chains had little or no effect on heterodimer and half-molecule formation. These deletions, however, did prevent half-molecules from forming the six-chain molecule. Deletion of the distal second half of the coiled-coil region of each chain completely prevented the assembly process. Point mutations ill the second half of the coiled-coil region also indicated that hydrophilic residues that form ion pahs between interacting chains were not critical in the formation of the heterodimeric complexes. These results suggest that the initial formation of the alpha gamma and beta gamma complexes depends primarily on hydrophobic interactions of amino acids located in the second half of the coiled-coil region of the molecule. These interactions occur in the rough endoplasmic reticulum in the presence of various chaperones such as BiP.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle			Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056				BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENRY I, 1984, AM J HUM GENET, V36, P760; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HUANG SM, 1993, J BIOL CHEM, V268, P8919; JOHN M, 1994, J BIOL CHEM, V269, P16247; KANT JA, 1985, P NATL ACAD SCI USA, V82, P2344, DOI 10.1073/pnas.82.8.2344; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; Medved L V, 1990, Blood Coagul Fibrinolysis, V1, P439, DOI 10.1097/00001721-199010000-00012; MULVIHILL E, 1988, Patent No. 39944; NORTON PA, 1981, P NATL ACAD SCI-BIOL, V78, P1661, DOI 10.1073/pnas.78.3.1661; RAO SPS, 1991, J MOL BIOL, V222, P89, DOI 10.1016/0022-2836(91)90739-S; ROY SN, 1995, J BIOL CHEM, V270, P23761, DOI 10.1074/jbc.270.40.23761; ROY SN, 1991, J BIOL CHEM, V266, P4758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VEKLICH YI, 1993, J BIOL CHEM, V268, P13577; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	27	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27948	27953		10.1074/jbc.271.44.27948	http://dx.doi.org/10.1074/jbc.271.44.27948			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910397	hybrid			2022-12-27	WOS:A1996VQ67900115
J	Kang, R; Saito, H; Ihara, Y; Miyoshi, E; Koyama, N; Sheng, Y; Taniguchi, N				Kang, R; Saito, H; Ihara, Y; Miyoshi, E; Koyama, N; Sheng, Y; Taniguchi, N			Transcriptional regulation of the N-acetylglucosaminyltransferase V gene in human bile duct carcinoma cells (HuCC-T1) is mediated by Ets-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER-KIDNEY CELLS; ASN-LINKED OLIGOSACCHARIDES; SEQUENCE-SPECIFIC BINDING; PROTEINS COOPERATE; STRUCTURAL-CHANGES; RESPONSE ELEMENT; MESSENGER-RNA; C-JUN; EXPRESSION; PROMOTER	N-Acetylglucosaminyltransferase V (GnT-V) catalyzes the transfer of N-acetylglucosamine from UDP-N-acetyl-glucosamine to alpha-6-D-mannoside to produce the beta 1-6 linked branching of N-glycan oligosaccharides, which controls the polylactosamine content, The expression of N-acetylglucosaminyltransferase V, which contains 17 exons and spans 155 kilobase pairs, is expressed in a tissue- and cell type-specific manner and is regulated at the level of transcription by multiple promoters (Saito, H., Gu, J., Nishikawa, A., Ihara, Y., Fujii, J., Kohgo, Y., and Taniguchi, N. (1995) Eur. J. Biochem. 233, 18-26). To elucidate the mechanism by which the GnT-V gene is expressed in a cell- and tissue-specific manner, cell-restricted expression was analyzed using the 5'-upstream regions of the human GnT-V gene spanning base pairs -2760 to +23 in a human bile duct carcinoma cell line, HuCC-T1. We characterized two cis-acting elements that are potentially important in HuCC-T1 cell-specific expression, The two elements each contain an Ets-1 binding site, 5'-GGA-3'. Specific binding of Ets-1 to the respective elements was demonstrated by competition analysis as well as by antibody supershift experiments. Cotransfection of an Ets-1 expression plasmid along with a GnT-V promoter-luciferase reporter plasmid revealed the participation of Ets-1 in the regulation of the GnT-V gene transcription. These data indicated that the transcriptional regulation of the GnT-V gene was mediated by transcription factor Ets-1.	OSAKA UNIV, SCH MED, DEPT BIOCHEM, SUITA, OSAKA 565, JAPAN	Osaka University			Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, ONCOGENE, V4, P853; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; FERNANDES B, 1991, CANCER RES, V51, P718; FISHER RJ, 1992, J BIOL CHEM, V267, P17957; GU J, 1993, J BIOCH, V113, P111; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Kaya M, 1996, ONCOGENE, V12, P221; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LIAHAKK NB, 1996, CANCER RES, V56, P190; LU Y, 1993, MOL CELL BIOCHEM, V122, P85, DOI 10.1007/BF00925741; MIYAGIWA M, 1989, IN VITRO CELL DEV B, V25, P503; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; MIYOSHI E, 1993, CANCER RES, V53, P3899; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; PIERCE M, 1986, J BIOL CHEM, V261, P772; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; SAITO H, 1995, EUR J BIOCHEM, V233, P18, DOI 10.1111/j.1432-1033.1995.018_1.x; SALMON P, 1993, P NATL ACAD SCI USA, V90, P7739, DOI 10.1073/pnas.90.16.7739; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SETH A, 1994, ONCOGENE, V9, P469; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHOREIBAH MG, 1992, J BIOL CHEM, V267, P2920; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; SUZUKI H, 1995, P NATL ACAD SCI USA, V92, P4442, DOI 10.1073/pnas.92.10.4442; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; TREIER M, 1995, CELL, V83, P753, DOI 10.1016/0092-8674(95)90188-4; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNERT N, 1992, AM J PATHOL, V140, P119; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; YAGEL S, 1989, INT J CANCER, V37, P607; YAMAMOTO K, 1984, EUR J BIOCHEM, V143, P133, DOI 10.1111/j.1432-1033.1984.tb08352.x; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	54	105	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26706	26712		10.1074/jbc.271.43.26706	http://dx.doi.org/10.1074/jbc.271.43.26706			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900148				2022-12-27	WOS:A1996VP23300042
J	Ohsuga, H; Su, SN; Takahashi, N; Yang, SY; Nakagawa, H; Shimada, I; Arata, Y; Lee, YC				Ohsuga, H; Su, SN; Takahashi, N; Yang, SY; Nakagawa, H; Shimada, I; Arata, Y; Lee, YC			The carbohydrate moiety of the Bermuda grass antigen BG60 - New oligosaccharides of plant origin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; ACER-PSEUDOPLATANUS L; CYNODON-DACTYLON POLLEN; SUBSTRATE-SPECIFICITY; SYCAMORE CELLS; XYLOSE; GLYCOPROTEINS; ALLERGENS; PATHWAY; LECTINS	BG60 is an important allergen of Bermuda grass (Cynodon dactylon) pollen, which causes allergic responses in human. It was suggested that its carbohydrate moiety may be relevant to allergic reaction (Su, S. N., Lau, G. X., Shu, P., Yang, S. Y., Huang, S. W., and Lee, Y. C. (1996) J. Allergy Clin. Immunol., in press). Therefore, the structure of the carbohydrate moiety in BG60 was investigated. The N-linked oligosaccharides were released from the glycopeptides of BG60 by digesting with a glycoamidase from sweet almond and reductively aminated with a fluorescent reagent, 2-aminopyridine. The mixture of pyridylaminated oligosaccharides were separated by high-performance liquid chromatography (HPLC) using an octadecylsilyl (ODS) column. Five oligosaccharide fractions were isolated, and each fraction was found to be homogeneous by HPLC on an amide-silica column. The structure of each of the oligosaccharides was analyzed by the two dimensional mapping technique (Tomiya, N., Awaya, J., Kurono, RI., Endo, S., Arata, Y., and Takahashi, N. (1988) Anal. Biochem. 171, 73-90), in tandem with sequential exoglycosidase digestion. The two most abundant oligosaccharides, A and B, have an unusual structural feature, i.e. the presence of an L-Fuc alpha-(1,3)-linked to Asn-linked GlcNAc without a Xyl beta-(1,2) linked to the branching Man (see below). To the best of our knowledge, these are the first such oligosaccharides found in plant glycoproteins.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA; NAKANO VINEGAR CO LTD, NAKANO CENT RES INST, GLYCOLAB, HANDA 475, JAPAN; VET GEN HOSP, DEPT MED RES, TAIPEI 11217, TAIWAN; UNIV TOKYO, FAC PHARMACEUT SCI, TOKYO 113, JAPAN	Johns Hopkins University; Johns Hopkins University; University of Tokyo					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK09970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTMANN F, 1995, GLYCOCONJUGATE J, V12, P84, DOI 10.1007/BF00731873; ASHFORD D, 1987, EUR J BIOCHEM, V166, P311, DOI 10.1111/j.1432-1033.1987.tb13516.x; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang HN, 1984, CLIN MED J, V34, P376; DANDREA G, 1988, GLYCOCONJUGATE J, V5, P151, DOI 10.1007/BF01061204; FORD SA, 1987, J ALLERGY CLIN IMMUN, V79, P711, DOI 10.1016/0091-6749(87)90201-6; FOURNET B, 1987, EUR J BIOCHEM, V166, P321, DOI 10.1111/j.1432-1033.1987.tb13517.x; FRANCOIS C, 1962, BIOCHEM J, V83, P335, DOI 10.1042/bj0830335; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HASE S, 1986, J BIOCHEM-TOKYO, V100, P1; HAYASHI M, 1990, EUR J BIOCHEM, V191, P287, DOI 10.1111/j.1432-1033.1990.tb19122.x; HIJIKATA A, 1994, INT ARCH ALLERGY IMM, V105, P198, DOI 10.1159/000236826; KIMURA Y, 1987, J BIOCHEM-TOKYO, V101, P1051, DOI 10.1093/oxfordjournals.jbchem.a121947; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1964, BIOCHEMISTRY-US, V3, P458, DOI 10.1021/bi00891a026; KITAGAKIOGAWA H, 1986, EUR J BIOCHEM, V161, P779, DOI 10.1111/j.1432-1033.1986.tb10507.x; KOBTA A, 1993, GLYCOBIOLOGY PRACTIC, V123, P165; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; LEE YC, 1990, ANAL BIOCHEM, V188, P259, DOI 10.1016/0003-2697(90)90603-7; MATTHIESEN F, 1989, J ALLERGY CLIN IMMUN, V83, P1124, DOI 10.1016/0091-6749(89)90456-9; ORREN A, 1975, INT ARCH ALLER A IMM, V49, P814, DOI 10.1159/000231465; SHEN HD, 1988, CLIN ALLERGY, V18, P401, DOI 10.1111/j.1365-2222.1988.tb02888.x; STRUM A, 1987, J BIOL CHEM, V262, P13392; SU S-N, 1986, Chinese Journal of Microbiology and Immunology (Taipei), V19, P263; SU S-N, 1990, Proceedings of the National Science Council Republic of China Part B Life Sciences, V14, P85; SU SN, 1991, CLIN EXP ALLERGY, V21, P449, DOI 10.1111/j.1365-2222.1991.tb01685.x; SU SN, 1996, IN PRESS J ALLERGY C; TAKAHASHI N, 1986, BIOCHEMISTRY-US, V25, P388, DOI 10.1021/bi00350a018; TAKAHASHI N, 1993, ANAL BIOCHEM, V208, P96, DOI 10.1006/abio.1993.1013; TAKAHASHI N, 1992, HDB ENDOGLYCOSIDASES, P199; TAKAYAMA S, 1986, AGR BIOL CHEM TOKYO, V50, P1673, DOI 10.1080/00021369.1986.10867633; TEZUKA K, 1992, EUR J BIOCHEM, V203, P401, DOI 10.1111/j.1432-1033.1992.tb16564.x; TEZUKA K, 1993, BIOCHEM MOL BIOL INT, V29, P395; TEZUKA K, 1993, ANAL BIOCHEM, V211, P205, DOI 10.1006/abio.1993.1258; TOMIYA N, 1991, ANAL BIOCHEM, V193, P90, DOI 10.1016/0003-2697(91)90047-W; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; TRINCA J C, 1962, Med J Aust, V49(1), P969; YASUDA Y, 1970, BIOCHEMISTRY-US, V9, P25, DOI 10.1021/bi00803a004	42	44	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26653	26658		10.1074/jbc.271.43.26653	http://dx.doi.org/10.1074/jbc.271.43.26653			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900140	hybrid			2022-12-27	WOS:A1996VP23300034
J	Schleiff, E; Schmitz, A; McIlhinney, RAJ; Manenti, S; Vergeres, G				Schleiff, E; Schmitz, A; McIlhinney, RAJ; Manenti, S; Vergeres, G			Myristoylation does not modulate the properties of MARCKS-related protein (MRP) in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; LIGHT-CHAIN KINASE; MEMBRANE ASSOCIATION; MAJOR SUBSTRATE; CALMODULIN-BINDING; DEPENDENT BINDING; BOVINE BRAIN; RAT-BRAIN; PHOSPHORYLATION; PEPTIDES	The members of the myristoylated alanine-rich C kinase Substrate (MARCKS) family ape proteins essential for brain development and phagocytosis. MARCKS proteins bind to actin filaments and calmodulin (CaM) and are phosphorylated by protein kinase C. In order to investigate how these interactions are regulated, we have characterized the properties of both the myristoylated (myr) and unmyristoylated (unmyr) forms of recombinant MARCKS-related protein (MRP), a 20-kDa member of the MARCKS family. Ultracentrifugation and circular dichroic spectroscopy reveal that MRP is an elongated protein, with an axis ratio estimated between 7 and 12 and with an apparent random coil conformation, MRP binds to CaM with high affinity (K-d,K-myr = 4 nM; K-d,K-unmyr = 7 nM) and with a second order rate constant, k(+1, unmyr), of 1.6 x 10(8) M(-1) s(-1). In contrast to classical ligands such as the myosine light chain kinase, binding of MRP to CaM does not induce the formation of an alpha-helix in MRP. The catalytic subunit of protein kinase C (PKM) phosphorylates myr MRP with high affinity ([S](0.5) = 3.5 mu M), positive cooperativity (n(H) = 2.5) and a turnover number of 130 min(-1). CaM inhibits the phosphorylation of myr MRP with a half-maximum rate of phosphorylation at a [CaM]/[MRP] ratio of 0.7, indicating that CaM might efficiently regulate the phosphorylation of MRP in vivo. Interestingly, Ca2+ inhibits the binding of MRP to CaM as well as its phosphorylation by PKM in the millimolar concentration range, suggesting that MRP has a weak affinity for Ca2+. Finally, unmyr MRP can be stoichiometrically myristoylated by N-myristoyl transferase in vitro. Since neither binding of CaM nor phosphorylation by PKM inhibits myristoylation, the N terminus of unmyr MRP is exposed on the surface of the protein and is well separated from the effector domain, In view of the observations that unmyr and myr MRP do not exhibit significant differences in their properties in solution, the function of myristoylation is most probably to modulate. the interactions of MRP with membranes.	UNIV BASEL, BIOCTR, DEPT BIOPHYS CHEM, CH-4056 BASEL, SWITZERLAND; UNIV OXFORD, DEPT PHARMACOL, MRC, ANAT NEUROPHARMACOL UNIT, OXFORD OX1 3TH, ENGLAND; HOP PURPAN, INSERM, CJF 9510, F-31059 TOULOUSE, FRANCE	University of Basel; University of Oxford; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Schleiff, Enrico/C-5105-2017; manenti, stephane/P-1518-2014	Schleiff, Enrico/0000-0002-0518-3489; manenti, stephane/0000-0002-4793-3196; Schmitz, Arndt/0000-0002-7104-6191				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ADEREM AA, 1988, NATURE, V332, P362, DOI 10.1038/332362a0; ADEREM AA, 1986, P NATL ACAD SCI USA, V83, P5817, DOI 10.1073/pnas.83.16.5817; ALBERT KA, 1984, P NATL ACAD SCI-BIOL, V81, P3622, DOI 10.1073/pnas.81.12.3622; Alberts B. D., 1989, MOL BIOL CELL, P301; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS CL, 1993, J AM CHEM SOC, V115, P11034, DOI 10.1021/ja00076a089; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; BYERS DM, 1982, BIOCHEMISTRY-US, V21, P229, DOI 10.1021/bi00531a005; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P24911, DOI 10.1074/jbc.270.42.24911; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Creighton T. E., 1993, PROTEINS STRUCTURES; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUANG KP, 1986, BIOCHEM BIOPH RES CO, V139, P320, DOI 10.1016/S0006-291X(86)80116-4; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSON JD, 1983, BIOCHEM J, V211, P473, DOI 10.1042/bj2110473; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MANENTI S, 1994, J BIOL CHEM, V269, P8309; MANENTI S, 1993, J BIOL CHEM, V268, P6878; MANENTI S, 1992, J BIOL CHEM, V267, P22310; MCILHINNEY RAJ, 1990, BIOCHEM J, V271, P681, DOI 10.1042/bj2710681; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MELLHINNEY RAJ, 1994, EUR J BIOCHEM, V222, P137; NELSON J W, 1986, Proteins Structure Function and Genetics, V1, P211, DOI 10.1002/prot.340010303; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PATEL J, 1987, J BIOL CHEM, V262, P16686; PAUL C, 1980, ANAL BIOCHEM, V101, P442, DOI 10.1016/0003-2697(80)90211-0; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; ROSEN A, 1989, J BIOL CHEM, V264, P9118; Segel I. H., 1975, ENZYME KINETICS, P360; SOBIESZEK A, 1995, BIOCHEMISTRY-US, V34, P11855, DOI 10.1021/bi00037a025; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; TANIGUCHI H, 1994, J BIOL CHEM, V269, P18299; TOROK K, 1994, BIOCHEMISTRY-US, V33, P12807, DOI 10.1021/bi00209a012; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VANHOLDE KE, 1958, J PHYS CHEM-US, V62, P734, DOI 10.1021/j150564a025; VERGERES G, 1995, J BIOL CHEM, V270, P19879, DOI 10.1074/jbc.270.34.19879; VERGERES G, 1995, SIGNALING MECH TRANS, P125; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WALKER JM, 1990, J BIOL CHEM, V265, P8016; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; YAMAMOTO H, 1995, J NEUROCHEM, V65, P802; ZHAO D, 1991, BIOCHEM J, V277, P445, DOI 10.1042/bj2770445; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	71	38	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26794	26802		10.1074/jbc.271.43.26794	http://dx.doi.org/10.1074/jbc.271.43.26794			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900160	hybrid			2022-12-27	WOS:A1996VP23300054
J	Sheu, JJ; Yu, TS; Tong, WF; Yu, SM				Sheu, JJ; Yu, TS; Tong, WF; Yu, SM			Carbohydrate starvation stimulates differential expression of rice alpha-amylase genes that is modulated through complicated transcriptional and posttranscriptional processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; COMPLETE NUCLEOTIDE-SEQUENCE; BARLEY ALEURONE CELLS; SACCHAROMYCES-CEREVISIAE; METABOLIC REPRESSION; GLUCOSE REPRESSION; SUGAR UTILIZATION; CULTURED-CELLS; MESSENGER-RNAS; HIGHER-PLANTS	Expression of alpha-amylase genes in cultured rice suspension cells is induced by sucrose starvation, To study the mechanism of sugar metabolite regulation on the expression of individual alpha-amylase genes, DNA fragments specific to each of eight rice alpha-amylase genes were synthesized and used as gene-specific probes, Comparison of the relative abundance of mRNA revealed that expression of the eight alpha-amylase genes in rice cells was differentially regulated by sucrose starvation. Accumulation of all the alpha-amylase mRNAs increased in response to sucrose starvation; however, levels of the alpha Amy3 and alpha Amy8 mRNAs were distinctly higher and constituted 90% of total alpha-amylase mRNAs, RNA gel blot and nuclear run-on transcription analyses demonstrated a positive correlation between the increased transcription rates and the elevated steady-state levels of alpha-amylase mRNAs induced by sucrose starvation, The half-lives of alpha Amy3, alpha Amy7, and alpha Amy8 were prolonged by sucrose-starvation; however, the stability of the three mRNAs seems controlled by different mechanisms, The translation inhibitors cycloheximide and anisomycin preferentially blocked the sucrose-suppressed expression of alpha Amy3 but mot that of alpha Amy7 and alpha Amy8. These inhibitors also enhanced the sucrose starvation-induced accumulation of alpha Amy3 mRNA but not that of alpha Amy7 or alpha Amy8 mRNAs. Cycloheximide did mot significantly alter the transcription rates of alpha-amylase genes, suggesting that labile proteins may selectively stabilize the alpha Amy7 and alpha Amy8 mRNAs but destabilize the alpha Amy3 mRNA.	ACAD SINICA,INST MOL BIOL,TAIPEI 11529,TAIWAN; NATL DEF MED CTR,GRAD INST LIFE SCI,TAIPEI,TAIWAN; NATL TAIWAN NORMAL UNIV,DEPT BIOL,TAIPEI 11718,TAIWAN	Academia Sinica - Taiwan; National Defense Medical Center; National Taiwan Normal University			Yu, Su-May/ABB-6950-2021	Yu, Su-May/0000-0001-8744-9246				ATWATER JA, 1990, ANNU REV GENET, V24, P519; BELANGER FC, 1986, P NATL ACAD SCI USA, V83, P1354, DOI 10.1073/pnas.83.5.1354; BRODL MR, 1991, PLANT PHYSIOL, V96, P1048, DOI 10.1104/pp.96.4.1048; CARLSON M, 1987, J BACTERIOL, V169, P4873, DOI 10.1128/jb.169.11.4873-4877.1987; CHAN MT, 1993, PLANT MOL BIOL, V22, P491, DOI 10.1007/BF00015978; CHAN MT, 1994, J BIOL CHEM, V269, P17635; CHAO YC, 1992, J VIROL, V66, P1442, DOI 10.1128/JVI.66.3.1442-1448.1992; CHEN MH, 1994, PLANT J, V6, P625, DOI 10.1046/j.1365-313X.1994.6050625.x; ENTIAN KD, 1992, TRENDS BIOCHEM SCI, V17, P506, DOI 10.1016/0968-0004(92)90341-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALLING G, 1982, ENCY PLANT PHYSL B, V14, P663; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GRAHAM IA, 1994, PLANT CELL, V6, P761, DOI 10.1105/tpc.6.5.761; HUANG N, 1990, NUCLEIC ACIDS RES, V18, P7007, DOI 10.1093/nar/18.23.7007; HUANG N, 1993, PLANT MOL BIOL, V23, P737, DOI 10.1007/BF00021529; Jacobsen J. V., 1987, Plant hormones and their role in plant growth and development, P164; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; KARRER EE, 1992, PLANT J, V2, P517; MAGOULAS C, 1993, GENETICS, V134, P507; MCELROY D, 1990, PLANT CELL, V2, P163, DOI 10.1105/tpc.2.2.163; MCGRANE MM, 1992, TRENDS BIOCHEM SCI, V17, P40, DOI 10.1016/0968-0004(92)90426-A; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAIER MH, 1991, NEW BIOL, V3, P1137; Sambrook J., 2002, MOL CLONING LAB MANU; SANO Y, 1990, GENOME, V33, P209, DOI 10.1139/g90-033; SCHUSTER JR, 1989, YEAST GENETIC ENG, P83; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHEEN J, 1994, PHOTOSYNTH RES, V39, P427, DOI 10.1007/BF00014596; SHEU JJ, 1994, PLANT J, V5, P655, DOI 10.1111/j.1365-313X.1994.00655.x; SHIRLEY BW, 1990, NUCLEIC ACIDS RES, V18, P3377, DOI 10.1093/nar/18.11.3377; TAKAIWA F, 1985, GENE, V37, P255; TAKAIWA F, 1984, NUCLEIC ACIDS RES, V12, P5441, DOI 10.1093/nar/12.13.5441; THOMAS BR, 1994, PLANT PHYSIOL, V106, P1235, DOI 10.1104/pp.106.4.1235; THOMPSON DM, 1990, NUCLEIC ACIDS RES, V18, P3621, DOI 10.1093/nar/18.12.3621; TRUMBLY RJ, 1992, MOL MICROBIOL, V6, P15, DOI 10.1111/j.1365-2958.1992.tb00832.x; TSUCHIYA K, 1992, BIOSCI BIOTECH BIOCH, V56, P1849, DOI 10.1271/bbb.56.1849; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; WATSON JC, 1986, METHOD ENZYMOL, V118, P57; YU SM, 1992, GENE, V122, P247, DOI 10.1016/0378-1119(92)90212-8; YU SM, 1991, J BIOL CHEM, V266, P21131; Yu SM, 1996, PLANT MOL BIOL, V30, P1277, DOI 10.1007/BF00019558	42	84	87	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26998	27004		10.1074/jbc.271.43.26998	http://dx.doi.org/10.1074/jbc.271.43.26998			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900187				2022-12-27	WOS:A1996VP23300081
J	Solomon, V; Goldberg, AL				Solomon, V; Goldberg, AL			Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEOLYTIC SYSTEM; RAT SKELETAL-MUSCLE; RED-BLOOD-CELLS; OXIDANT-DAMAGED HEMOGLOBIN; ALPHA-ACETYLATED PROTEINS; DENERVATION ATROPHY; MULTICATALYTIC PROTEINASE; ABNORMAL PROTEINS; MAMMALIAN-CELLS; MESSENGER-RNA	Recent studies have suggested that activation of the ubiquitin-proteasome pathway is primarily responsible for the rapid loss of muscle proteins in various types of atrophy. The present studies were undertaken to test if different. classes of muscle proteins are degraded by this pathway. In extracts of rabbit psoas muscle, the complete degradation of soluble proteins to amino acids was stimulated up to 6-fold by ATP. Peptide aldehyde inhibitors of the proteasome or the removal of proteasomes markedly inhibited only the ATP-dependent process. Addition of purified myosin, actin, troponin, or tropomyosin to these extracts showed that these proteins served as substrates for the ubiquitin-proteasome pathway. By contrast, degradation of myoglobin did not require ATP, proteasomes, or any known proteases in muscles. When myosin, actin, and troponin were added as actomyosin complexes or as intact myofibrils to these extracts, they were not hydrolyzed at a, significant rate, probably because in these multicomponent complexes, these proteins are protected from degradation Accordingly, actin (but not albumin or troponin) inhibited the degradation of I-125-myosin, and actin was found to selectively inhibit ubiquitin conjugation to I-125-myosin. Also, the presence of tropomyosin inhibited the degradation of I-125-troponin. However, neither actin nor tropomyosin inhibited the degradation of I-125-lysozyme or soluble muscle proteins. Thus, specific interactions between the myofibrillar proteins appear to protect them from ubiquitin-dependent degradation, and the rate-limiting step in their degradation is probably their dissociation from the myofibril.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								BAILEY JL, 1996, IN PRESS J CLIN INVE; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN JL, 1976, J BIOL CHEM, V251, P1009; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COUX O, 1995, IN PRESS ANN REV BIO; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; DEMARTINO GN, 1981, ENZYME, V26, P1; DHAESE J, 1987, BIOCHEM J, V248, P397, DOI 10.1042/bj2480397; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DRISCOLL J, 1989, P NATL ACAD SCI USA, V86, P787, DOI 10.1073/pnas.86.3.787; ETLINGER JD, 1977, P NATL ACAD SCI USA, V74, P54, DOI 10.1073/pnas.74.1.54; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FAGAN JM, 1992, J BIOL CHEM, V267, P23015; FAGAN JM, 1987, BIOCHEM J, V243, P335, DOI 10.1042/bj2430335; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FISHER M, 1994, FEBS LETT, V355, P69; FULKS RM, 1975, J BIOL CHEM, V250, P290; FUNATSU T, 1994, J MUSCLE RES CELL M, V15, P158, DOI 10.1007/BF00130426; FURUNO K, 1986, BIOCHEM J, V237, P859, DOI 10.1042/bj2370859; FURUNO K, 1990, J BIOL CHEM, V265, P8550; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Goll DE, 1989, ANIMAL GROWTH REGULA, P141; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GONEN H, 1991, J BIOL CHEM, V266, P19221; GOODMAN MN, 1987, BIOCHEM J, V241, P121, DOI 10.1042/bj2410121; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1986, PROG NUCLEIC ACID RE, V33, P19, DOI 10.1016/S0079-6603(08)60019-7; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KETTELHUT IC, 1988, DIABETES METAB REV, V4, P751, DOI 10.1002/dmr.5610040805; KIRSCHNER RJ, 1983, J BIOL CHEM, V258, P967; LARDEUX BR, 1987, J BIOL CHEM, V262, P14514; LIBBY P, 1980, BIOCHEM J, V188, P213, DOI 10.1042/bj1880213; LOWELL BB, 1986, BIOCHEM J, V234, P237, DOI 10.1042/bj2340237; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P195, DOI 10.1016/0304-4165(88)90009-8; MEDINA R, 1991, BIOMED BIOCHIM ACTA, V50, P347; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MEYER A, 1989, SCIENCE, V244, P1480; MILLWARD DJ, 1981, ACTA BIOL MED GER, V40, P1309; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; PERRY SV, 1958, BIOCHEM J, V68, P5, DOI 10.1042/bj0680005; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; TEMPARIS S, 1994, CANCER RES, V54, P568; TIAO G, 1994, J CLIN INVEST, V94, P2255, DOI 10.1172/JCI117588; VANDERWESTHUYZEN DR, 1981, J BIOL CHEM, V256, P1791; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639; WING SS, 1993, AM J PHYSIOL, V264, pE688	59	321	329	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26690	26697		10.1074/jbc.271.43.26690	http://dx.doi.org/10.1074/jbc.271.43.26690			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900146	hybrid			2022-12-27	WOS:A1996VP23300040
J	Uribe, JM; Keely, SJ; TraynorKaplan, AE; Barrett, KE				Uribe, JM; Keely, SJ; TraynorKaplan, AE; Barrett, KE			Phosphatidylinositol 3-kinase mediates the inhibitory effect of epidermal growth factor on calcium-dependent chloride secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELLS; CL SECRETION; BINDING-SITE; P85 SUBUNIT; T84 CELLS; ACTIVATION; PROTEIN; KINASE; RECEPTOR; WORTMANNIN	Epidermal growth factor (EGF) and carbachol both inhibit calcium-activated chloride secretion by the human colonic epithelial cell line, T-84. Although the inhibitory mechanism for the carbachol effect involves the 3,4,5,6-isomer of inositol tetrakisphosphate, the mechanisms responsible for the EGF effect have not yet, been fully elucidated, Here, we studied the Pole of phosphatidylinositol 3-kinase (PI 3-kinase) in the inhibitory effect of EGF, The PI 3-kinase inhibitor, wortmannin, slightly increased basal chloride secretion and potentiated the secretory response to thapsigargin. Wortmannin also partially reversed EGF-induced, but not carbachol-induced, inhibition of thapsigargin-stimulated chloride secretion. Wortmannin alone had no effect on carbacholor histamine-induced chloride secretion and completely reversed EGF-induced inhibition of the secretory response to these agonists, EGF, carbachol, histamine, and thapsigargin all increased levels of the 85-kDa regulatory subunit of PI 3-kinase in antiphosphotyrosine immunoprecipitates. However, only EGF significantly increased levels of the 110-kDa catalytic subunit. Furthermore, only EGF increased PI 3-kinase activity in an in vitro kinase assay. High levels of phosphatidylinositol (3)-monophosphate were present in unstimulated cells and significantly reduced by wortmannin. EGF, but not carbachol, rapidly increased levels of phosphatidylinositol (3,4)-bisphosphate and phosphatidylinositol (3,4,5)-trisphosphate. Production of these lipids was also sensitive to wortmannin. Our data suggest that EGF activates PI 3-kinase and that its lipid products may mediate the inhibitory effect of EGF on calcium-dependent chloride secretion. Our data also suggest that a phosphatidylinositol-specific 3-kinase activity is present in unstimulated TS, cells and may regulate production of phosphatidylinositol (3)-monophosphate and basal secretory tone.	UNIV CALIF SAN DIEGO,MED CTR,SCH MED,DEPT MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego			Barrett, Kim/AAE-2794-2022; Barrett, Kim Elaine/AAE-7762-2019	Barrett, Kim Elaine/0000-0002-6704-998X; Keely, Stephen/0000-0002-6315-3587	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047240, R01DK028305, T32DK007202] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07202, DK28305, DK47240] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1995, J BIOL CHEM, V270, P23816, DOI 10.1074/jbc.270.40.23816; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; BARRETT KE, 1993, AM J PHYSIOL, V264, pC446, DOI 10.1152/ajpcell.1993.264.2.C446; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; CARTWRIGHT CA, 1985, J CLIN INVEST, V76, P1837, DOI 10.1172/JCI112176; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DHARMSATHAPHORN K, 1989, AM J PHYSIOL, V256, pC1224, DOI 10.1152/ajpcell.1989.256.6.C1224; DHARMSATHAPHORN K, 1984, AM J PHYSIOL, V246, pG204, DOI 10.1152/ajpgi.1984.246.2.G204; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; ISMAILOV II, 1996, IN PRESS P NATL ACAD; KACHINTORN U, 1993, BRIT J PHARMACOL, V109, P510, DOI 10.1111/j.1476-5381.1993.tb13599.x; KACHINTORN U, 1993, AM J PHYSIOL, V264, pC671, DOI 10.1152/ajpcell.1993.264.3.C671; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Keely SJ, 1996, GASTROENTEROLOGY, V110, pA336; KHURANA S, 1996, GASTROENTEROLOGY, V101, pA337; MA YH, 1994, J BIOL CHEM, V269, P30734; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MATTHEWS JB, 1992, J CLIN INVEST, V90, P1608, DOI 10.1172/JCI116030; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; OKADA T, 1994, J BIOL CHEM, V269, P3568; REENSTRA WW, 1993, AM J PHYSIOL, V264, pC161, DOI 10.1152/ajpcell.1993.264.1.C161; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SEYNAEVE CM, 1994, MOL PHARMACOL, V45, P1207; SMITH JA, 1996, GASTROENTEROLOGY S, V110, pA362; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; STOYANOV B, 1995, SCIENCE, V269, P689; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; URIBE JM, 1996, IN PRESS AM J PHYSL; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; VAJANAPHANICH M, 1993, AM J PHYSIOL, V264, pC1210, DOI 10.1152/ajpcell.1993.264.5.C1210; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WENNSTROM S, 1994, ONCOGENE, V9, P651; WINITZ S, 1993, J BIOL CHEM, V268, P19196	44	71	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26588	26595		10.1074/jbc.271.43.26588	http://dx.doi.org/10.1074/jbc.271.43.26588			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900131				2022-12-27	WOS:A1996VP23300025
J	Burg, MA; Tillet, E; Timpl, R; Stallcup, WB				Burg, MA; Tillet, E; Timpl, R; Stallcup, WB			Binding of the NG2 proteoglycan to type VI collagen and other extracellular matrix molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; CELL-ADHESION; INTIMA COLLAGEN; HUMAN-PLACENTA; ALPHA-3 CHAIN; MESSENGER-RNA; CORE PROTEIN; HUMAN-SKIN; DECORIN; EXPRESSION	Previous studies have suggested that the NG2 proteoglycan interacts with type VI collagen. We have further characterized this interaction using a solid phase binding assay in which purified NG2 was shown to bind to pepsin-solubilized type VI collagen. In addition, NG2 bound a recombinant alpha 2 (VI) collagen chain but did not appreciably bind to the recombinant alpha 1 (VI) chain or the N-terminal domain of alpha 3 (VI) (N9-N2), Binding of NG2 to type VI collagen was shown to be concentration-dependent and saturable and to depend mainly on the NC2 core protein, since chondroitinase-treated NG2 bound the collagen as web as undigested samples. In addition, the binding studies revealed several other possible ligands for NG2, including type II collagen, type V collagen, tenascin, and laminin. Binding of the proteoglycan to these molecules was also shown to be mediated by domains contained within the NG2 core protein. The ability of NG2 to bind to these extracellular matrix molecules was compared with that of the chondroitin sulfate proteoglycan decorin, revealing an almost identical binding pattern of the two proteoglycans to the different collagen types. In addition, decorin was found to effectively inhibit the ability of NG2 to bind to collagen, thus suggesting that the two proteoglycans may bind to some of the same regions on the collagen substrates. In contrast, decorin did not bind tenascin and was ineffective in inhibiting the binding of NG2 to tenascin or laminin, indicating that NG2 may bind these two molecules using a separate domain that is distinct from its collagen binding region.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society	Burg, MA (corresponding author), BURNHAM INST, LA JOLLA CANC RES CTR, 10901 N TORREY PINES RD, LA JOLLA, CA 92037 USA.			Tillet, Emmanuelle/0000-0002-0076-8007	NINDS NIH HHS [R01 NS21990] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021990] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BROWN JC, 1993, J CELL BIOL, V120, P557, DOI 10.1083/jcb.120.2.557; DOANE KJ, 1992, EXP CELL RES, V200, P490, DOI 10.1016/0014-4827(92)90200-R; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; FLEISCHMAJER R, 1993, J HISTOCHEM CYTOCHEM, V41, P1359, DOI 10.1177/41.9.7689083; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; GRUMET M, 1994, J BIOL CHEM, V269, P12142; HANEMANN CO, 1993, J HISTOCHEM CYTOCHEM, V41, P1383, DOI 10.1177/41.9.8354878; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HESSLE H, 1984, J BIOL CHEM, V259, P3955; KAMEI A, 1992, PEDIATR NEUROL, V8, P183, DOI 10.1016/0887-8994(92)90065-7; KEENE DR, 1988, J CELL BIOL, V107, P1995, DOI 10.1083/jcb.107.5.1995; KIELTY CM, 1992, J CELL BIOL, V118, P979, DOI 10.1083/jcb.118.4.979; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KODA JE, 1985, J BIOL CHEM, V260, P8157; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LEVINE JM, 1987, J NEUROSCI, V7, P2721; MCDEVITT CA, 1991, FEBS LETT, V294, P167, DOI 10.1016/0014-5793(91)80660-U; MUONA P, 1993, AM J PATHOL, V142, P1586; NISHIYAMA A, 1993, MOL BIOL CELL, V4, P1097, DOI 10.1091/mbc.4.11.1097; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; NISHIYAMA A, 1991, DEVELOPMENT, V111, P933; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PELTONEN J, 1990, LAB INVEST, V62, P487; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; POOLE AR, 1986, J HISTOCHEM CYTOCHEM, V34, P619, DOI 10.1177/34.5.3701029; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; RIESSEN R, 1994, AM J PATHOL, V144, P962; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAUNDERS S, 1988, J CELL BIOL, V106, P423, DOI 10.1083/jcb.106.2.423; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOGEL KG, 1994, EXTRACELLULAR MATRIX, P243; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	53	169	180	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26110	26116		10.1074/jbc.271.42.26110	http://dx.doi.org/10.1074/jbc.271.42.26110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824254	hybrid			2022-12-27	WOS:A1996VN18000060
J	delArco, PG; MartinezMartinez, S; Calvo, V; Armesilla, AL; Redondo, JM				delArco, PG; MartinezMartinez, S; Calvo, V; Armesilla, AL; Redondo, JM			JNK (c-Jun NH2-terminal kinase) is a target for antioxidants in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION PATHWAYS; SERUM RESPONSE ELEMENT; TRANSCRIPTION FACTOR; REGULATED KINASE; INTACT-CELLS; FOS; AP-1; PHOSPHORYLATION	AP-1 has been shown to behave as a redox-sensitive transcription factor that can be activated by both oxidant and antioxidant stimuli. However, the mechanisms involved in the activation of AP-1 by antioxidants are largely unknown. In this study we show that the structurally unrelated antioxidant agents pyrrolidine dithiocarbamate (PDTC), butylated hydroxyanisole, and N-acetylcysteine activated JNK (c-Jun NH2-terminal kinase) in Jurkat T cells. This activation differed substantially from that mediated by phorbol 12-myristate 13-acetate (PMA) and Ca2+ ionophore or produced by costimulation with antibodies against the T cell receptor-CD3 complex and to CD28. The activation of JNK by classical T cell stimuli was transient, whereas that mediated by PDTC and butylated hydroxyanisole (but not N-acetylcysteine) was sustained. The kinetics of JNK activation correlated with the expression of c-jun which was transient after stimulation with PMA plus ionophore and prolonged in response to PDTC, which also transiently induced c-fos. In addition, JNK activation by PMA plus ionophore was sensitive to inhibitors of signaling pathways involving Ca2+, protein kinase C, and tyrosine phosphorylation, which failed to inhibit the activation mediated by PDTC. Transfection of transdominant negative expression vectors of ras and raf, together with AP-l-dependent reporter constructs, as web as Western blot analysis using anti-ERR (extracellular signal-regulated kinase) antibodies, indicated that the Ras/Raf/ERK pathway did not appear to mediate the effect of the antioxidant. However, the combined treatment with PDTC and PMA, two agents that synergize on AP-1 activation, resulted in the persistent phosphorylation of ERR-2. In conclusion, our results identify JNK as a target of antioxidant agents which can be regulated differentially under oxidant and antioxidant conditions.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOL,HOSP PRINCESA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,CSIC,SERV IMMUNOL,HOSP PRINCESA,E-28049 MADRID,SPAIN; UNIV AUTONOMA MADRID,CSIC,CTR INVEST BIOMED,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Hospital de La Princesa; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Hospital de La Princesa; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)			Gomez-del Arco, Pablo/L-2728-2013; Redondo, Juan Miguel/H-6351-2015; Calvo, Victor/L-5024-2014	Gomez-del Arco, Pablo/0000-0001-6748-7157; Redondo, Juan Miguel/0000-0001-5779-9122; Calvo, Victor/0000-0002-5913-7058; Armesilla, Angel/0000-0003-3546-5580				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aragones J, 1996, J BIOL CHEM, V271, P10924, DOI 10.1074/jbc.271.18.10924; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; BUSCHER M, 1988, ONCOGENE, V3, P301; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LISBONA C, 1994, EUR J IMMUNOL, V24, P2746, DOI 10.1002/eji.1830241126; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUNOZ E, 1992, EUR J IMMUNOL, V22, P2101, DOI 10.1002/eji.1830220821; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1995, METHOD ENZYMOL, V252, P253; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; SPITS H, 1985, EUR J IMMUNOL, V15, P88, DOI 10.1002/eji.1830150117; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	49	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26335	26340						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824287				2022-12-27	WOS:A1996VN18000093
J	Dixit, RB; Chen, A; Chen, J; Sheppard, D				Dixit, RB; Chen, A; Chen, J; Sheppard, D			Identification of a sequence within the integrin beta 6 subunit cytoplasmic domain that is required to support the specific effect of alpha v beta 6 on proliferation in three-dimensional culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; FIBRONECTIN; BINDING; PAXILLIN; PROTEIN; ATTACHMENT; EXPRESSION; RECEPTOR	The integrin alpha v beta 6 augments the proliferation of epithelial cells in collagen gels and in vivo. This effect depends on the presence of a unique carboxyl-terminal region of the beta 6 subunit cytoplasmic domain. In the present study, we have utilized deletional and alanine substitution mutagenesis within this region to map the amino acids responsible for alpha v beta 6-mediated proliferation in more detail, Replacement or deletion of any of 6 amino acids (glutamic acid 778, lysine 779, lysine 781, valine 782, aspartic acid 783, and leucine 784) largely abolished the proliferative effects of alpha v beta 6, but none of the mutants examined interfered with alpha v beta 6-mediated cell adhesion or with localization of alpha v beta 6 to focal adhesions, These findings suggest that residues contained within the sequence EKXKVDL are critical for the effects of alpha v beta 6 on proliferation in collagen gels and that pathways initiated by interaction with this sequence are distinct from those required for integrin-mediated cell attachment or focal adhesion formation.	UNIV CALIF SAN FRANCISCO,DEPT MED,LUNG BIOL CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL053949, R01HL047412, R01HL053949] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47412, HL/A 133259, HL53949] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547; BREUSS JM, 1995, J CELL SCI, V108, P2241; BREUSS JM, 1993, J HISTOCHEM CYTOCHEM, V41, P1521, DOI 10.1177/41.10.8245410; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSK M, 1992, J BIOL CHEM, V267, P5790; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONE RI, 1994, CELL ADHES COMMUN, V2, P101, DOI 10.3109/15419069409004430; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; OTEY CA, 1993, J BIOL CHEM, V268, P21193; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; SAMBROOK J, 1989, TRANSFECTION COPRECI; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHLAEPFER DD, 1994, NATURE, V372, P786; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WEINACKER A, 1994, J BIOL CHEM, V269, P6940	21	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25976	25980		10.1074/jbc.271.42.25976	http://dx.doi.org/10.1074/jbc.271.42.25976			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824234	hybrid			2022-12-27	WOS:A1996VN18000040
J	Engh, RA; Girod, A; Kinzel, V; Huber, R; Bossemeyer, D				Engh, RA; Girod, A; Kinzel, V; Huber, R; Bossemeyer, D			Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89 - Structural implications for selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-KINASE; NUCLEOTIDE BINDING; PEPTIDE INHIBITOR; C-ALPHA; DOMAIN; EXPRESSION; APOPTOSIS; POTENT; SITE; DEPHOSPHORYLATION	The discovery of several hundred different protein kinases involved in highly diverse cellular signaling pathways is in stark contrast to the much smaller number of known modulators of cell signaling, Of these, the H series protein kinase inhibitors (1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7), N-[2-(methylamino)-ethyl]-5-isoquinolinesulfonamide (H8) N-[2-(p-Bromo-cinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89)) are frequently used to block signaling pathways in studies of cellular regulation. To elucidate inhibition mechanisms at atomic resolution and to enable structure-based drug design of potential therapeutic modulators of signaling pathways, we determined the crystal structures of corresponding complexes with the cAPK catalytic subunit. Complexes with H7 and H8 (2.2 Angstrom) and with H89 (2.3 Angstrom) define the binding mode of the isoquinoline-sulfonamide derivatives in the ATP-binding site while demonstrating effects of ligand-induced structural change. Specific interactions between the enzyme and the inhibitors include the isoquinoline ring nitrogen ligating to backbone amide of Val-123 and an inhibitor side chain amide bonding to the backbone carbonyl of Glu-170. The conservation of the ATP-binding site of protein kinases allows evaluation of factors governing general selectivity of these inhibitors among kinases. These results should assist efforts in the design of protein kinase inhibitors with specific properties.	GERMAN CANC RES CTR, DEPT PATHOCHEM 0210, D-69120 HEIDELBERG, GERMANY; MAX PLANCK INST BIOCHEM, ABT STRUKTURFORSCH 2, D-82152 MARTINSRIED, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Max Planck Society				Engh, Richard/0000-0002-6207-0560				ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BHATNAGAR D, 1984, BIOCHEMISTRY-US, V23, P4350, DOI 10.1021/bi00314a016; BHATNAGAR D, 1985, BIOCHEMISTRY-US, V24, P1122, DOI 10.1021/bi00326a009; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DENISENKO N, 1994, J CELL SCI, V107, P969; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; ELLIOTT LH, 1990, BIOCHEM BIOPH RES CO, V171, P148, DOI 10.1016/0006-291X(90)91369-4; FELIPO V, 1994, EUR J CANCER, V30A, P525, DOI 10.1016/0959-8049(94)90431-6; FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103; GOLDSMITH EJ, 1994, CURR OPIN STRUC BIOL, V4, P833, DOI 10.1016/0959-440X(94)90264-X; GUIZOUARN H, 1993, J BIOL CHEM, V268, P8632; HAGIWARA M, 1987, MOL PHARMACOL, V31, P523; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTL FT, 1983, BIOCHEMISTRY-US, V22, P2347, DOI 10.1021/bi00279a007; HERBERG FW, 1993, PROTEIN ENG, V6, P771, DOI 10.1093/protein/6.7.771; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HONMA Y, 1991, CANCER RES, V51, P4649; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM SH, 1993, CANCER LETT, V74, P37, DOI 10.1016/0304-3835(93)90041-7; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P362; KONDA Y, 1994, J BIOL CHEM, V269, P13162; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE JH, 1992, BIOCHEMISTRY-US, V31, P10616, DOI 10.1021/bi00158a026; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAY WS, 1994, J BIOL CHEM, V269, P26865; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TRAGANOS F, 1993, INT J ONCOL, V2, P47; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WIEMANN S, 1992, BIOCHIM BIOPHYS ACTA, V1171, P93, DOI 10.1016/0167-4781(92)90144-O; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	48	241	251	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26157	26164		10.1074/jbc.271.42.26157	http://dx.doi.org/10.1074/jbc.271.42.26157			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824261	hybrid			2022-12-27	WOS:A1996VN18000067
J	Hayes, JJ; Kaplan, R; Ura, K; Pruss, D; Wolffe, A				Hayes, JJ; Kaplan, R; Ura, K; Pruss, D; Wolffe, A			A putative DNA binding surface in the globular domain of a linker histone is not essential for specific binding to the nucleosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENE; COOPERATIVE BINDING; CHROMATIN; H5; TRANSCRIPTION; CORE; EXPRESSION; H1; TEMPLATES; CONTACTS	A fundamental step in the assembly of native chromatin is the specific recognition and binding of linker histones to the nucleoprotein subunit known as the nucleosome. A first step in defining this important interaction is the determination of residues within Linker histones that are important for the structure-specific recognition of the nucleosome core. By combining in vitro assays for the native binding activity of linker histones and site-directed mutagenesis, we have examined a cluster of basic residues within the globular domain of H1(0), a somatic Linker histone variant from Xenopus laevis. We show that these residues, which comprise a putative DNA binding surface within the globular domain, do not play an essential role in the structure-specific binding of a linker histone to the nucleosome.	NICHHD,MOL EMBRYOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Hayes, JJ (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052426] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM52426] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; BALDWIN JP, 1992, CURRENT OPINION STRU, V2, P78; BIRKENMEIER EH, 1978, CELL, V15, P1077, DOI 10.1016/0092-8674(78)90291-X; BOULIKAS T, 1980, P NATL ACAD SCI USA, V77, P121; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; CLARK DJ, 1986, J MOL BIOL, V187, P569, DOI 10.1016/0022-2836(86)90335-9; CLARK DJ, 1988, THESIS CAMBRIDGE U; DRAVES PH, 1992, J MOL BIOL, V225, P1105, DOI 10.1016/0022-2836(92)90108-V; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FREEMAN L A, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P165; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; KHOCHBIN S, 1993, GENE, V128, P173, DOI 10.1016/0378-1119(93)90560-P; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; RUTLEDGE RG, 1988, GENE, V70, P117, DOI 10.1016/0378-1119(88)90110-2; SHWED PS, 1992, BIOCHIM BIOPHYS ACTA, V1131, P152, DOI 10.1016/0167-4781(92)90070-G; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1986, EMBO J, V5, P3531, DOI 10.1002/j.1460-2075.1986.tb04679.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; URA K, 1994, J BIOL CHEM, V269, P27171; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; URA K, 1996, IN PRESS EMBO J, V15; van Holde KE., 1989, SPRINGER SERIES MOL; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; WOLFFE A, 1992, CHROMATIN STRUCTURE; WOLFFE AP, 1993, METH MOL G, V2, P314	38	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25817	25822		10.1074/jbc.271.42.25817	http://dx.doi.org/10.1074/jbc.271.42.25817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824211	hybrid			2022-12-27	WOS:A1996VN18000017
J	Isidoro, C; Maggioni, C; Demoz, M; Pizzagalli, A; Fra, AM; Sitia, R				Isidoro, C; Maggioni, C; Demoz, M; Pizzagalli, A; Fra, AM; Sitia, R			Exposed thiols confer localization in the endoplasmic reticulum by retention rather than retrieval	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; LYSOSOMAL-ENZYMES; RECOGNITION MARKER; SECRETORY PROTEIN; GOLGI-APPARATUS; QUALITY-CONTROL; CATHEPSIN-D; CELLS; PHOSPHORYLATION; GLYCOPROTEIN	The cysteine present in the Ig mu chain tailpiece (mu tp) prevents the secretion of unpolymerized IgM intermediates and causes their accumulation in the endoplasmic reticulum (ER). In principle, this can be the consequence of actual retention in this organelle or of retrieval from the Golgi. To determine which of the two mechanisms underlies the cysteine dependent ER localization, we analyze here the post-translational modifications of suitably engineered cathepsin D (CD) molecules. The glycans of this protease are phosphorylated by post-ER phosphotransferases and further modified in the trans-Golgi to generate a mannose 6-phosphate lysosome targeting signal. Only trace amounts of the mu tp-tagged CD (CDM mu tpCys) are phosphorylated, unless retention is reversed by exogenous reducing agents or the critical cysteine mutated (CDM mu tpSer). In contrast, a KDEL-tagged CD, that is retrieved from the Golgi into the ER, acquires phosphates, though mainly resistant to alkaline phosphatase. Similarly to CDM mu tpSer, the few CDM mu tpCys molecules that escape retention and acquire phosphates in the cis-Golgi are transported beyond the KDEL retrieval compartment, as indicated by their sensitivity to alkaline phosphatase. These results demonstrate that the thiol-dependent ER localization arises primarily from true retention, without recycling through the Golgi.	SAN RAFFAELE SCI INST, DIBIT, I-20132 MILAN, ITALY; UNIV TURIN, DIPARTIMENTO MED & ONCOL SPERIMENTALE, SEZ PATOL GEN, I-10125 TURIN, ITALY	University of Turin			Fra, Annamaria/I-5532-2012; Sitia, Roberto/AAB-5005-2019; Isidoro, Ciro/J-6063-2016	Fra, Annamaria/0000-0002-4327-3004; Sitia, Roberto/0000-0001-7086-4152; Isidoro, Ciro/0000-0002-5494-3034				ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; Cals MM, 1996, MOL IMMUNOL, V33, P15, DOI 10.1016/0161-5890(95)00132-8; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HASILIK A, 1992, EXPERIENTIA, V48, P130, DOI 10.1007/BF01923507; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Isidoro C, 1995, INT J CANCER, V63, P866, DOI 10.1002/ijc.2910630619; ISIDORO C, 1991, EUR J CLIN CHEM CLIN, V29, P165; ISIDORO C, 1991, BIOCHEM J, V273, P363, DOI 10.1042/bj2730363; ISIDORO C, 1990, EUR J BIOCHEM, V191, P591, DOI 10.1111/j.1432-1033.1990.tb19162.x; KEREM A, 1993, J BIOL CHEM, V268, P180; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAZZARINO DA, 1988, J BIOL CHEM, V263, P10118; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MAZZARELLA RA, 1990, J BIOL CHEM, V265, P1094; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIZUNO M, 1993, P NATL ACAD SCI USA, V90, P5732, DOI 10.1073/pnas.90.12.5732; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; RADONS J, 1990, BIOL CHEM H-S, V371, P567, DOI 10.1515/bchm3.1990.371.2.567; Reddy P, 1996, EMBO J, V15, P2077, DOI 10.1002/j.1460-2075.1996.tb00561.x; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	44	38	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26138	26142		10.1074/jbc.271.42.26138	http://dx.doi.org/10.1074/jbc.271.42.26138			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824258	hybrid			2022-12-27	WOS:A1996VN18000064
J	McIntosh, DB; Woolley, DG; Vilsen, B; Andersen, JP				McIntosh, DB; Woolley, DG; Vilsen, B; Andersen, JP			Mutagenesis of segment (487)Phe-Ser-Arg-Asp-Arg-Lys(492) of sarcoplasmic reticulum Ca2+-ATPase produces pumps defective in ATP binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; ACTIVE-SITE; CATALYTIC SITE; AMINO-ACID; FUNCTIONAL CONSEQUENCES; CONFORMATIONAL CHANGE; NUCLEOTIDE-BINDING; STOPPED-FLOW; CA-ATPASE; PHOSPHOENZYME ISOMERIZATION	The lysine residue Lys(492) located in the large cytoplasmic domain of sarcoplasmic reticulum Ca2+-ATPase is implicated in nucleotide binding through affinity labeling, The contribution of segment (487)Phe-Ser Arg-Asp-Arg Lys(492) to, ATP binding and pump function has been investigated through the introduction of 11 site-directed amino acid mutations, ATP binding was measured through competitive inhibition of [gamma-P-32]2',3'-O-(2,4,6-trinitrophenyl)-8-azido-adenosine triphosphate photolabeling of Lys(492) or its substitute. Mutations F487S and positional swap F487S/S488F produced pumps that were severely defective in ATP binding (K-D > 1 mM), and mutant F487S, together with F487E, exhibited low ATPase activity and low ATP-supported calcium transport and phosphorylation and failed to show CrATP-dependent Ca2+ occlusion. Mutations F487L, R489L, and K492Y were less inhibitory to ATP binding (K-D = 8-49 mu M) and, together with K492L and R489D/D490R, produced correspondingly smaller changes in ATP-mediated activities, The ATP dependence of ATPase activity of these five mutants showed deviations from the wild type profile in the low, intermediate, and high concentration ranges, suggesting defects in ATP-dependent conformational changes, Mutations S488A and D490A had no effect on ATP binding (K-D = 0.4 mu M) or ATP-mediated activities, None of the mutations significantly affected phosphorylation from P-i or acetyl phosphate-supported Ca2+ transport. Mutations F487L and F487S, and not those at residue 492, increased the K-0.5, for Ca2+ activation of transport 2- and 8-fold, respectively, The results implicate Phe(487), Arg(489) and Lys(492) in binding ATP in both a catalytic and a regulatory mode.	UNIV AARHUS,DEPT PHYSIOL,DK-8000 AARHUS C,DENMARK	Aarhus University	McIntosh, DB (corresponding author), UNIV CAPE TOWN,SCH MED,DEPT CHEM PATHOL,ZA-7925 CAPE TOWN,SOUTH AFRICA.			Vilsen, Bente/0000-0002-4727-9382; Andersen, Jens Peter/0000-0003-0654-4300				ANDERSEN JP, 1995, J BIOL CHEM, V270, P908, DOI 10.1074/jbc.270.2.908; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; CHAMPEIL P, 1986, BIOCHEMISTRY-US, V25, P7623, DOI 10.1021/bi00371a053; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLORE GM, 1982, EUR J BIOCHEM, V128, P113; COAN CR, 1977, J BIOL CHEM, V252, P3044; DAIHO T, 1994, J BIOL CHEM, V269, P11060; de Meis L, 1973, J Biol Chem, V248, P3691; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; GREEN NM, 1989, BIOCHEM SOC T, V17, P972, DOI 10.1042/bst0170972; GUILLAIN F, 1981, J BIOL CHEM, V256, P6140; INESI G, 1980, J BIOL CHEM, V255, P3025; INESI G, 1967, J BIOL CHEM, V242, P4637; KAYA SJ, 1994, J BIOL CHEM, V269, P7419; KIMURA M, 1993, J CELL SCI, V104, P1129; KOTZYBAHIBERT F, 1995, ANGEW CHEM INT EDIT, V34, P1296, DOI 10.1002/anie.199512961; KRISHNA S, 1993, J CELL BIOL, V120, P385, DOI 10.1083/jcb.120.2.385; LACAPERE JJ, 1990, J BIOL CHEM, V265, P348; LACAPERE JJ, 1993, BIOCHEMISTRY-US, V32, P3414, DOI 10.1021/bi00064a027; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAHANEY JE, 1995, BIOCHEMISTRY-US, V34, P4864, DOI 10.1021/bi00014a044; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; ROSS DC, 1991, J BIOL CHEM, V266, P4613; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1442; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STEFANOVA HI, 1993, BIOCHEMISTRY-US, V32, P356, DOI 10.1021/bi00052a044; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1994, BIOCHEMISTRY-US, V33, P8240, DOI 10.1021/bi00193a010; TRAN CM, 1994, J BIOL CHEM, V269, P6558; TRAN CM, 1994, BIOCHEMISTRY-US, V33, P4140, DOI 10.1021/bi00180a006; VERJOVSKIALMEIDA S, 1978, BIOCHEMISTRY-US, V17, P5006, DOI 10.1021/bi00616a023; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1987, BIOCHIM BIOPHYS ACTA, V898, P313, DOI 10.1016/0005-2736(87)90072-1; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1987, EUR J BIOCHEM, V170, P421, DOI 10.1111/j.1432-1033.1987.tb13716.x; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WANG K, 1992, J BIOL CHEM, V267, P3577; WAWRZYNOW A, 1993, BIOCHEMISTRY-US, V32, P10803, DOI 10.1021/bi00091a035; YAMAGATA K, 1993, J BIOL CHEM, V268, P20930; YAMAMOTO H, 1989, J BIOCHEM-TOKYO, V106, P1121, DOI 10.1093/oxfordjournals.jbchem.a122976; YAMAMOTO T, 1967, J BIOCHEM-TOKYO, V62, P558, DOI 10.1093/oxfordjournals.jbchem.a128706; YAMASAKI K, 1994, J BIOL CHEM, V269, P4129	66	71	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25778	25789		10.1074/jbc.271.42.25778	http://dx.doi.org/10.1074/jbc.271.42.25778			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824206	hybrid			2022-12-27	WOS:A1996VN18000012
J	Millar, DG; Shore, GC				Millar, DG; Shore, GC			Signal anchor sequence insertion into the outer mitochondrial membrane - Comparison with porin and the matrix protein targeting pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR COMPLEX; PRECURSOR PROTEINS; IMPORT RECEPTOR; SYNTHETIC PRESEQUENCE; YEAST MITOCHONDRIA; NEUROSPORA-CRASSA; INNER MEMBRANE; CELL VIABILITY; CROSS-LINKING; IDENTIFICATION	We have addressed the question of overlap between the pathways for protein insertion into the outer mitochondrial membrane and import to the matrix compartment, using competition studies in vitro. A synthetic peptide corresponding to the matrix-targeting signal of pre-ornithine carbamyl transferase competed for outer membrane insertion of porin but did not compete for membrane insertion of outer membrane signal anchor-containing proteins. Conversely, however, a synthetic peptide corresponding to the signal anchor sequence of Tom70 competed for import of all proteins examined. Both peptides competed for a step beyond receptor binding. Import of all precursors examined was inhibited by antibodies raised against the import receptor Tom20. Following binding to the surface of the organelle, outer membrane integration of porin was sensitive to depletion of nucleoside triphosphates by apyrase, whereas signal anchor protein insertion was not. The results demonstrate that outer membrane signal anchor insertion overlaps with a general insertion pathway. However, it exhibits both properties and steps that differ from the pathway followed by porin and matrix-targeted protein.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University				Millar, Douglas/0000-0002-8640-7148				BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; CYR DM, 1991, J BIOL CHEM, V266, P21700; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; GAIKWAD AS, 1994, J BIOL CHEM, V269, P6437; GILLESPIE LL, 1987, J BIOL CHEM, V262, P7939; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; GOPING IS, 1995, FEBS LETT, V373, P45; HACHIYA N, 1994, EMBO J, V13, P5146, DOI 10.1002/j.1460-2075.1994.tb06844.x; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HANSON B, 1995, EUR J BIOCHEM, V235, P750; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; KEIL P, 1993, FEBS LETT, V321, P197, DOI 10.1016/0014-5793(93)80107-6; KEIL P, 1993, J BIOL CHEM, V268, P19177; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KIEBLER M, 1993, J MEMBRANE BIOL, V135, P191; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LI JM, 1992, BIOCHIM BIOPHYS ACTA, V1106, P233, DOI 10.1016/0005-2736(92)90001-3; Lill R, 1996, TRENDS CELL BIOL, V6, P56, DOI 10.1016/0962-8924(96)81015-4; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LITHGOW T, 1995, J BIOL CHEM, V270, P14267, DOI 10.1074/jbc.270.24.14267; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MILLAR DG, 1993, J BIOL CHEM, V268, P18403; MILLAR DG, 1994, J BIOL CHEM, V269, P12229; MILLAR DG, 1996, IN PRESS MOL BIOL IN; MOCZKO M, 1992, FEBS LETT, V310, P265, DOI 10.1016/0014-5793(92)81345-M; NARGANG FE, 1995, EMBO J, V14, P1099, DOI 10.1002/j.1460-2075.1995.tb07093.x; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; ONO H, 1988, J BIOL CHEM, V263, P3188; PAK YK, 1990, J BIOL CHEM, V265, P14298; PFALLER R, 1988, J CELL BIOL, V107, P2483, DOI 10.1083/jcb.107.6.2483; PFALLER R, 1987, EMBO J, V6, P2635, DOI 10.1002/j.1460-2075.1987.tb02554.x; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1988, J BIOL CHEM, V263, P4049; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; PFANNER N, 1988, EUR J BIOCHEM, V175, P205, DOI 10.1111/j.1432-1033.1988.tb14185.x; SCHLOSSMANN J, 1995, J BIOL CHEM, V270, P27116, DOI 10.1074/jbc.270.45.27116; SCHNEIDER H, 1991, SCIENCE, V254, P1659, DOI 10.1126/science.1661031; SEKI N, 1995, FEBS LETT, V375, P307, DOI 10.1016/0014-5793(95)01229-8; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SHORE GC, 1992, MEMBRANE BIOGENESIS, P253; SKERJANC IS, 1990, J BIOL CHEM, V265, P9444; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; Steenaart NAE, 1996, BIOCHEMISTRY-US, V35, P3764, DOI 10.1021/bi9528053; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x	57	32	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25823	25829		10.1074/jbc.271.42.25823	http://dx.doi.org/10.1074/jbc.271.42.25823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824212	hybrid			2022-12-27	WOS:A1996VN18000018
J	Kalb, A; Bluethmann, H; Moore, MW; Lesslauer, W				Kalb, A; Bluethmann, H; Moore, MW; Lesslauer, W			Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and activate the mitogen-activated protein kinase pathway with differential kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HEAT-SHOCK PROTEIN; FACTOR INCREASE PHOSPHORYLATION; MAP KINASE; FACTOR-ALPHA; CYTOPLASMIC DOMAIN; TYROSINE PHOSPHORYLATION; PROLONGED ACTIVATION; MOLECULAR-CLONING; VIRAL-PROTEINS	To dissect tumor necrosis factor receptor (Tnfr)-1 (CD120a) and Tnfr2 (CD120b)-dependent signal transduction pathways, primary fibroblasts isolated from inguinal adipose tissue of wild type (wt), tnfr1 degrees, tnfr2 degrees, and tnfr1 degrees/tnfr2 degrees mice were studied. The mitogen-activated protein kinases Erk1 and Erk2 were found to be tyrosine-phosphorylated and activated by Tnf treatment in all wt, tnfr1 degrees, and tnfr2 degrees fibroblasts; the activation was down-regulated 60 min after the start of steady state Tnf treatment. Distinct kinetics of Erk1 and Erk2 activation were detected; the Tnfr1-mediated activation of Erk1 and Erk2 started more slowly and persisted for more prolonged times as compared with Tnfr2 activation. Raf-1, Raf-B, Mek-1, Mek kinase, and p90(rsh) kinases were also shown to be activated independently in a distinct time-dependent pattern through the two Tnf receptors. In addition, both Tnfr1 and Tnfr2 mediated independently the activation of the transcription factor Ap-1 albeit with parallel activation kinetics. In contrast, Tnfr1 exclusively mediated activation of NF-kappa B and fibroblast proliferation; however, Tnfr2 enhanced proliferation triggered through Tnfr1 These findings indicate distinct but also overlapping roles of Tnfr1 and Tnfr2 in primary mouse fibroblasts and suggest different regulation mechanisms of signal transduction pathways under the control of both Tnf receptors.	HOFFMANN LA ROCHE AG, DEPT NERVOUS SYST DIS PRPN, CH-4070 BASEL, SWITZERLAND; HOFFMANN LA ROCHE AG, DEPT GENE TECHNOL PRPG, CH-4070 BASEL, SWITZERLAND; GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Roche Holding; Roche Holding; Genentech								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Bazzoni F, 1995, J INFLAMM, V45, P221; BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEUTLER BE, 1992, TUMOR NECROSIS FACTO; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CATLING AD, 1994, J BIOL CHEM, V269, P30014; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DARNAY BG, 1994, J BIOL CHEM, V269, P20299; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DEMBIC Z, 1990, Cytokine, V2, P231, DOI 10.1016/1043-4666(90)90022-L; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; EVANS TJ, 1994, J EXP MED, V180, P2173, DOI 10.1084/jem.180.6.2173; GEHR G, 1992, J IMMUNOL, V149, P911; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; GUY GR, 1991, J BIOL CHEM, V266, P14343; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HELLER RA, 1993, CELL, V73, P216, DOI 10.1016/0092-8674(93)90223-D; HOHMANN HP, 1990, J BIOL CHEM, V265, P22409; HOHMANN HP, 1990, J BIOL CHEM, V265, P15183; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KAUR P, 1989, FEBS LETT, V258, P269, DOI 10.1016/0014-5793(89)81671-0; KAUR P, 1988, FEBS LETT, V241, P6, DOI 10.1016/0014-5793(88)81019-6; KOHNO M, 1990, BIOCHEM J, V267, P91, DOI 10.1042/bj2670091; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; LOETSCHER H, 1990, J BIOL CHEM, V265, P20131; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; LOETSCHER H, 1993, INT CONGR SER, V1020, P455; MACKAY F, 1994, J IMMUNOL, V153, P5274; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MOSIALOS G, 1995, CELL, V80, P1; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; SAKLATVALA J, 1991, BIOCHEM J, V277, P635, DOI 10.1042/bj2770635; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1990, J IMMUNOL, V144, P2604; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; STORM SM, 1990, ONCOGENE, V5, P345; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WIEGMANN K, 1992, J BIOL CHEM, V267, P24069; WONG GHW, 1992, J IMMUNOL, V149, P3350; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5	75	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28097	28104		10.1074/jbc.271.45.28097	http://dx.doi.org/10.1074/jbc.271.45.28097			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910423	hybrid			2022-12-27	WOS:A1996VU03300023
J	Li, Y; Zhang, YL; Yan, HG				Li, Y; Zhang, YL; Yan, HG			Kinetic and thermodynamic characterizations of yeast guanylate kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR SUPPRESSOR GENE; AMINO-ACID SEQUENCE; ADENYLATE KINASE; SUBSTRATE GMP; X-RAY; PROTEIN; EXPRESSION; MECHANISM; DIFFUSION; PHOSPHORYLATION	Yeast guanylate kinase was expressed at high level in Escherichia coli using pET-17b vector. It was purified to homogeneity by a simple two-column procedure with an average yield of similar to 100 mg/liter. The steady-state kinetic parameters for both forward and reverse reactions were determined by initial velocity measurements. The turnover numbers (k(cat)) were 394 s(-1) for the forward reaction (formation of ADP and GDP) and 90 s(-1) for the reverse reaction (formation of ATP and GMP). K-m values were 0.20, 0.091, 0.017, and 0.097 mM for MgATP, GMP, MgADP, and GDP, respectively. Analysis of the initial velocity patterns indicated a sequential mechanism. GMP was found to have partial substrate inhibition. The substrate inhibition was not competitive with MgATP and could be attributed to formation of the abortive complex guanylate kinase . MgADP . GMP. The equilibrium constant of the reaction was measured under various conditions by NMR and a radiometric assay. The results showed that the steady-state kinetic parameters were consistent with the thermodynamic constant. NMR titration and equilibrium dialysis showed that both substrates and products could bind to free guanylate kinase, The dissociation constants were 0.090, 0.18, 0.029, 0.084, and 0.12 mM for MgATP, ATP, GMP, MgADP, and GDP, respectively, Viscosity-dependent kinetics was used to identify the rate-limiting steps of the reaction. The results indicated that the reaction rate is largely controlled by the chemical step.	MICHIGAN STATE UNIV, DEPT BIOCHEM, E LANSING, MI 48824 USA	Michigan State University					NIGMS NIH HHS [GM51901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051901] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Agarwal K C, 1978, Methods Enzymol, V51, P483; BERGER A, 1989, EUR J BIOCHEM, V184, P433, DOI 10.1111/j.1432-1033.1989.tb15035.x; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BOEHME RE, 1984, J BIOL CHEM, V259, P2346; BROUWER AC, 1982, BIOCHEMISTRY-US, V21, P1302, DOI 10.1021/bi00535a030; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7438, DOI 10.1021/bi00244a010; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Cleland W. W., 1986, INVESTIGATIONS RATES, V6, P791; CLELAND WW, 1975, BIOCHEMISTRY-US, V14, P3220, DOI 10.1021/bi00685a029; GAIDAROV IO, 1993, FEBS LETT, V335, P81, DOI 10.1016/0014-5793(93)80444-Y; GENTRY D, 1993, J BIOL CHEM, V268, P14316; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GLICKMAN MH, 1995, BIOCHEMISTRY-US, V34, P14077, DOI 10.1021/bi00043a013; HALL SW, 1986, EUR J BIOCHEM, V161, P551, DOI 10.1111/j.1432-1033.1986.tb10477.x; HARDY LW, 1984, BIOCHEMISTRY-US, V23, P1282, DOI 10.1021/bi00301a041; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KONRAD M, 1992, J BIOL CHEM, V267, P25652; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LIANG P, 1991, PROTEINS, V9, P28, DOI 10.1002/prot.340090105; MILLER WH, 1980, J BIOL CHEM, V255, P7204; MORIGUCHI M, 1980, BIOCHIM BIOPHYS ACTA, V662, P165; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; STEHLE T, 1992, J MOL BIOL, V224, P1127, DOI 10.1016/0022-2836(92)90474-X; STEHLE T, 1990, J MOL BIOL, V211, P249, DOI 10.1016/0022-2836(90)90024-G; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU S, 1968, J BIOL CHEM, V243, P3826; TIAN G, 1990, BIOCHEMISTRY-US, V29, P4296, DOI 10.1021/bi00470a006; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZSCHOCKE PD, 1993, EUR J BIOCHEM, V213, P263, DOI 10.1111/j.1432-1033.1993.tb17757.x	34	47	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28038	28044		10.1074/jbc.271.45.28038	http://dx.doi.org/10.1074/jbc.271.45.28038			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910414	hybrid			2022-12-27	WOS:A1996VU03300014
J	McCallum, CD; Hapak, RC; Neuenschwander, PF; Morrissey, JH; Johnson, AE				McCallum, CD; Hapak, RC; Neuenschwander, PF; Morrissey, JH; Johnson, AE			The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor - A fluorescence energy transfer study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND IMMUNOGLOBULIN-E; FACTOR-X; PHOSPHOLIPID SURFACE; CONFORMATIONAL SENSITIVITY; ORIENTATION FACTOR; COFACTOR FUNCTION; PROTEASE DOMAIN; BINDING-SITE; FACTOR-IXA; FACTOR-VA	The topography of membrane-bound blood coagulation factor VIIa (fVIIa) was examined by positioning a fluorescein dye in the active site of fVIIa via a tripeptide tether to yield fluorescein-D-phenylalanyI-L-prolyl-L-arginy-L-fVIIa (FI-FPR-fVIIa). The location of the active-site probe relative to the membrane surface was determined, both in the presence and absence of tissue factor (TF), using fluorescence energy transfer between the fluorescein dye and octadecylrhodamine (OR) at the phospholipid vesicle surface. When FI-FPR-fVIIa was titrated with phospholipid vesicles containing OR, the magnitude of OR-, calcium ion-, and phosphatidylserine-dependent fluorescence energy transfer revealed that the average distance of closest approach between fluorescein in the active site of fVIIa and OR at the vesicle surface is 82 Angstrom assuming a random orientation of donor and acceptor dyes (kappa(2) = 2/3; the orientational uncertainty totals similar to 10%). The active site of fVIIa is therefore located far above the membrane surface, and the elongated fVIIa molecule must bind at one end to the membrane and project approximately perpendicularly out of the membrane. When FI-FPR-fVIIa was titrated with vesicles that contained TF, the efficiency of energy transfer was increased by a TF-dependent translational and/or rotational movement of the fVIIa protease domain relative to the membrane surface. if this movement was solely translational, the height of the active site of fVIIa was lowered by an average of 6 Angstrom after binding to TF. The association of fVIIa with TF on the membrane surface therefore causes a significant reorientation of the active site relative to the membrane surface. This cofactor-dependent realignment of the active-site groove presumably facilitates and optimizes fVIIa cleavage of its membrane-bound substrates.	TEXAS A&M UNIV, HLTH SCI CTR, COLL MED, DEPT MED BIOCHEM & GENET, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT CHEM, COLLEGE STN, TX 77843 USA; TEXAS A&M UNIV, DEPT BIOCHEM & BIOPHYS, COLLEGE STN, TX 77843 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV OKLAHOMA, DEPT CHEM & BIOCHEM, NORMAN, OK 73019 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma - Norman			Morrissey, James H/H-4933-2011; Johnson, Arthur E/G-3457-2012; Morrissey, James H./GLR-5645-2022	Morrissey, James H/0000-0002-1570-1569; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032934, T32HL007207, R01HL047014] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 32934, R01 HL 47014, T32 HL 07207] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; ASHTON AW, 1995, FEBS LETT, V374, P141, DOI 10.1016/0014-5793(95)01093-T; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOCK PE, 1988, BIOCHEMISTRY-US, V27, P6633, DOI 10.1021/bi00417a063; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; DELL VA, 1990, BIOCHEMISTRY-US, V29, P1757, DOI 10.1021/bi00459a014; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FUNG BKK, 1978, BIOCHEMISTRY-US, V17, P5241, DOI 10.1021/bi00617a025; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HOLOWKA D, 1983, BIOCHEMISTRY-US, V22, P3466, DOI 10.1021/bi00283a025; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; LU RL, 1989, J BIOL CHEM, V264, P12956; Muller YA, 1996, J MOL BIOL, V256, P144, DOI 10.1006/jmbi.1996.0073; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; MUTUCUMARANA VP, 1992, J BIOL CHEM, V267, P17012; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; NEUENSCHWANDER PF, 1992, J BIOL CHEM, V267, P14477; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NEUENSCHWANDER PF, 1993, J BIOL CHEM, V268, P21489; NEUENSCHWANDER PF, 1995, BIOCHEMISTRY-US, V34, P13988, DOI 10.1021/bi00043a004; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; Payne MA, 1996, BIOCHEMISTRY-US, V35, P7100, DOI 10.1021/bi9529770; RADCLIFFE R, 1976, J BIOL CHEM, V251, P4797; Reinhart G D, 1991, J Fluoresc, V1, P153, DOI 10.1007/BF00865362; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1991, J BIOL CHEM, V266, P15719; RUF W, 1991, J BIOL CHEM, V266, P16256; SABHARWAL AK, 1995, J BIOL CHEM, V270, P15523, DOI 10.1074/jbc.270.26.15523; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WILDGOOSE P, 1993, BIOCHEMISTRY-US, V32, P114, DOI 10.1021/bi00052a016; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027; YE J, 1991, J BIOL CHEM, V266, P23016	44	64	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28168	28175		10.1074/jbc.271.45.28168	http://dx.doi.org/10.1074/jbc.271.45.28168			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910432	hybrid			2022-12-27	WOS:A1996VU03300032
J	Bullock, ED; Johnson, EM				Bullock, ED; Johnson, EM			Nerve growth factor induces the expression of certain cytokine genes and bcl-2 in mast cells - Potential role in survival promotion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; MEDIATED ACTIVATION; CYCLOSPORINE-A; SUBSTANCE-P; KIT-LIGAND; TNF-ALPHA; RAT; MOUSE	Nerve growth factor (NGF) promotes mast cell survival in vitro (Horigome, K., Bullock, E. D., and Johnson, E. M., Jr. (1994) J. Biol. Chem, 269, 2695-2702). NGF survival promotion is cell density-dependent, and conditioned medium experiments have shown that NGF increases the production of an autocrine mast cell survival activity. Cytokines are potential candidates for autocrine survival factors, In rat peritoneal mast cells (RPMC), NGF caused an increase in the messenger RNAs for interleukin (IL)-3, IL-4, IL-10, tumor necrosis factor-alpha, and granulocyte-macrophage colony-stimulating factor, This induction was NGF dose-dependent, was blocked bg NGF-neutralizing antibodies, and was not observed in the non-mast peritoneal cell population. The immunosuppressive agent, cyclosporin A, blocked both cytokine induction and NGF-activated survival promotion but not survival promotion activated by IL-3 or stem cell factor, suggesting that NGF enhanced RPMC survival by increasing cytokine production, me also examine the effects of NGF on the expression levels of some members of the bcl-2 family and the interleukin-1 beta-converting enzyme-like cysteine protease families. NGF markedly increased bcl-2 expression but had little or no effect on the other genes studied. The induction of bcl-2 mRNA by NGF was not blocked by cyclosporin A. These data suggest that induced cytokine gene expression but not increased expression of bcl-2 mediates NGF-survival promotion in RPMC.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024679] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL07275] Funding Source: Medline; NIA NIH HHS [R01-AG12947] Funding Source: Medline; NINDS NIH HHS [R01-NS24679] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALOE L, 1986, P NATL ACAD SCI USA, V83, P6184, DOI 10.1073/pnas.83.16.6184; ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ANSEL JC, 1993, J IMMUNOL, V150, P4478; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BRUNI A, 1982, FEBS LETT, V138, P190, DOI 10.1016/0014-5793(82)80438-9; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLAMAN HN, 1985, IMMUNOL TODAY, V6, P192, DOI 10.1016/0167-5699(85)90115-X; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COHEN DR, 1986, NUCLEIC ACIDS RES, V14, P3641, DOI 10.1093/nar/14.9.3641; CREEDON D, 1991, HYPERTENSION, V18, P730, DOI 10.1161/01.HYP.18.6.730; DIMARCO E, 1991, J BIOL CHEM, V266, P21718; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P10984, DOI 10.1073/pnas.90.23.10984; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; ESTUS S, 1996, IN PRESS NEUROMETHOD; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GALLI SJ, 1990, LAB INVEST, V62, P5; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GETCHELL ML, 1995, NEUROREPORT, V6, P1261, DOI 10.1097/00001756-199506090-00008; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GURISH MF, 1991, J IMMUNOL, V146, P1527; HAIG DM, 1994, BLOOD, V83, P72; HAMAGUCHI Y, 1987, J EXP MED, V165, P268, DOI 10.1084/jem.165.1.268; HATTORI A, 1993, J BIOL CHEM, V268, P2577; HEFTI F, 1994, J NEUROBIOL, V25, P1418, DOI 10.1002/neu.480251109; HEFTI F, 1986, J NEUROSCI, V6, P2155; HORIGOME K, 1993, J BIOL CHEM, V268, P14881; HORIGOME K, 1994, J BIOL CHEM, V269, P2695; KANNAN Y, 1991, BLOOD, V77, P1320; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; LAFFERTY KJ, 1980, AUST J EXP BIOL MED, V58, P533, DOI 10.1038/icb.1980.55; LEVIMONTALCINI R, 1995, J NEUROL SCI, V130, P119, DOI 10.1016/0022-510X(95)00007-O; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LINDHOLM D, 1988, J BIOL CHEM, V263, P16348; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; OTTEN U, 1984, EUR J PHARMACOL, V106, P199, DOI 10.1016/0014-2999(84)90697-6; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; PEARCE FL, 1986, J PHYSIOL-LONDON, V372, P379, DOI 10.1113/jphysiol.1986.sp016014; PLANT M, 1989, NATURE, V339, P64; RAZIN E, 1991, J IMMUNOL, V146, P981; SCULLY JL, 1995, CELL BIOL INT, V19, P459, DOI 10.1006/cbir.1995.1089; SHANAHAN F, 1985, J IMMUNOL, V135, P1331; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; SULLIVAN TJ, 1975, J IMMUNOL, V114, P1473; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; TSUJI K, 1990, BLOOD, V75, P421; VALENT P, 1991, Progress in Growth Factor Research, V3, P27, DOI 10.1016/0955-2235(91)90011-R; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1995, J IMMUNOL, V154, P1391; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YAN Q, 1991, CLIN SCI, V80, P565, DOI 10.1042/cs0800565; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	65	76	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27500	27508		10.1074/jbc.271.44.27500	http://dx.doi.org/10.1074/jbc.271.44.27500			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910334	hybrid			2022-12-27	WOS:A1996VQ67900052
J	Chen, LM; Ma, JX; Liang, YM; Chao, L; Chao, J				Chen, LM; Ma, JX; Liang, YM; Chao, L; Chao, J			Tissue kallikrein-binding protein reduces blood pressure in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; URINARY KALLIKREIN; INHIBITOR; GENE; KALLISTATIN; IDENTIFICATION; HYPOTENSION; EXPRESSION; SEQUENCE; KININS	The kallikrein-kinin system participates in blood pressure regulation. One of the kallikrein-kinin system components, krallikrein-binding protein, binds to tissue kallikrein and inhibits its activity in vitro. To investigate potential roles of rat kallikrein-binding protein (RKBP) in vivo, we have developed transgenic mice that express an RKBP gene under the control of the mouse metallothionein metal-responsive promoter. Expression of the transgene, RKBP, was detected in the liver, kidney, lung, heart, pancreas, salivary glands, spleen, brain, testis, and adrenal gland at the mRNA and protein levels, Systolic blood pressures of homozygous transgenic mice were 85.5 +/- 0.8 mm Hg (mean +/- S.E., n = 19, P < 0./001 for one line and 88.8 +/- 1.6 mm Hg (mean +/- S.E., n = 19, P < 0.001) for another, as compared with 100.5 +/- 0.8 mm Ng (mean +/- S.E., n = 18) for control mice, Direct blood pressure measurements of these transgenic mice through an arterial cannula showed similar reductions of blood pressure, Intravenous injection of purified RB;EP into mice via a catheter produced a dose-dependent reduction of the mean arterial blood pressure, Our findings suggest that RKBP may function as vasodilator in vivo, independent of regulating the activity of tissue kallikrein.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOL BIOL,CHARLESTON,SC 29425	Medical University of South Carolina					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRY TD, 1989, HYPERTENSION, V13, P3, DOI 10.1161/01.HYP.13.1.3; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CHAI KX, 1993, J BIOL CHEM, V268, P24498; CHAI KX, 1991, J BIOL CHEM, V266, P16029; CHAI KX, 1991, BIOCHIM BIOPHYS ACTA, V1129, P127, DOI 10.1016/0167-4781(91)90227-D; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHAO J, 1990, J BIOL CHEM, V265, P1694; Chao JL, 1996, J LAB CLIN MED, V127, P612, DOI 10.1016/S0022-2143(96)90152-3; CHEN LM, 1995, KIDNEY INT, V48, P690, DOI 10.1038/ki.1995.339; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; ECKE S, 1992, J BIOL CHEM, V267, P7048; GEIGER R, 1981, H-S Z PHYSIOL CHEM, V362, P317, DOI 10.1515/bchm2.1981.362.1.317; GUESDON JL, 1979, J HISTOCHEM CYTOCHEM, V27, P1131, DOI 10.1177/27.8.90074; LINDPAINTNER K, 1996, IN PRESS J CLIN INVE; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA JX, 1995, J BIOL CHEM, V270, P451, DOI 10.1074/jbc.270.1.451; MA JX, 1996, IN PRESS BIOCH BIOPH; Maniatis T., 1982, MOL CLONING; MARGOLIUS HS, 1989, ANNU REV PHARMACOL, V29, P343; MURRAY SR, 1990, J CADIOVASC PHARM S6, V15, P7; PAGES G, 1990, EUR J BIOCHEM, V190, P385, DOI 10.1111/j.1432-1033.1990.tb15587.x; SERVEAU C, 1992, FEBS LETT, V309, P405, DOI 10.1016/0014-5793(92)80817-Z; SERVEAU C, 1992, FEBS LETT, V312, P269; WANG J, 1994, HYPERTENSION, V23, P236, DOI 10.1161/01.HYP.23.2.236; ZHOU GX, 1992, J BIOL CHEM, V267, P25873	26	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27590	27594		10.1074/jbc.271.44.27590	http://dx.doi.org/10.1074/jbc.271.44.27590			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910346	hybrid			2022-12-27	WOS:A1996VQ67900064
J	GarciaCardena, G; Fan, R; Stern, DF; Liu, JW; Sessa, WC				GarciaCardena, G; Fan, R; Stern, DF; Liu, JW; Sessa, WC			Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; CALMODULIN; CELLS	The regulation of endothelial nitric oxide synthase (eNOS) by phosphorylation is poorly understood. Here, we demonstrate that eNOS is tyrosine-phosphorylated in bovine aortic endothelial cells (BAEC) using P-32 metabolic labeling followed by phosphoamino acid analysis and by phosphotyrosine specific Western blotting. Treatment of BAEC with hydrogen peroxide and the protein tyrosine phosphatase inhibitor, sodium orthovanadate, increases eNOS tyrosine phosphorylation. Utilizing a novel immunoNOS assay, the increase in tyrosine phosphorylation is associated with a 50% decrease in the specific activity of the enzyme. Because eNOS is localized in plasmalemma caveolae, we examined if tyrosine phosphorylated eNOS interacts with caveolin-1, the coat protein of caveolae, Immunoprecipitation of eNOS from bovine lung microvascular endothelial cells resulted in the co-precipitation of caveolin-1. Conversely, immunoprecipitation of caveolin-1 resulted in the co-precipitation of tyrosine-phosphorylated eNOS. Thus, tyrosine phosphorylation is a novel regulatory mechanism for eNOS and caveolin-1 is the first eNOS-associated protein. Collectively, these observations provide a novel regulatory mechanism for eNOS and suggest that tyrosine phosphorylation may influence its activity, subcellular trafficking, and interaction with other caveolin-interacting proteins in caveolae.	YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PHARMACOL, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, BOYER CTR MOL MED, MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Yale University; Yale University; Yale University			Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009224, R29HL051948] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA-45708] Funding Source: Medline; NHLBI NIH HHS [F32-HL09224, HL 51948] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DELVECCHIO PJ, 1992, IN VITRO CELL DEV-AN, V28A, P711; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gibbons GH, 1996, SCIENCE, V272, P689, DOI 10.1126/science.272.5262.689; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIRATA K, 1995, HYPERTENSION, V25, P180, DOI 10.1161/01.HYP.25.2.180; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTENSEN TM, 1982, J BIOL CHEM, V257, P9648; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONCADA S, 1991, PHARMACOL REV, V43, P109; OHARA Y, 1995, HYPERTENSION, V25, P415, DOI 10.1161/01.HYP.25.3.415; ONEILL WC, 1995, AM J PHYSIOL-CELL PH, V269, pC863, DOI 10.1152/ajpcell.1995.269.4.C863; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TSUKAHARA H, 1994, KIDNEY INT, V45, P598, DOI 10.1038/ki.1994.78	29	427	434	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27237	27240		10.1074/jbc.271.44.27237	http://dx.doi.org/10.1074/jbc.271.44.27237			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910295	hybrid			2022-12-27	WOS:A1996VQ67900013
J	Ueno, H; Sasaki, K; Kozutsumi, H; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H				Ueno, H; Sasaki, K; Kozutsumi, H; Miyagawa, K; Mitani, K; Yazaki, Y; Hirai, H			Growth and survival signals transmitted via two distinct NPXY motifs within leukocyte tyrosine kinase, an insulin receptor-related tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE INTERACTION DOMAIN; PHOSPHATIDYLINOSITOL 3'-KINASE; FACTOR-I; HUMAN LTK; C-MYC; SUBSTRATE-1; PROTEIN; SHC; CELLS; IRS-1	Leukocyte tyrosine kinase (LTK) is a receptor tyrosine kinase, which belongs to the insulin receptor family and is mainly expressed in pre-B cells and brain. In this study, we show that LTK utilizes insulin receptor substrate-1 (IRS-1) and She as major two substrates and possesses two NPXY motifs for them separately, tyrosine 485 of one NPXY motif at the juxtamembrane domain for IRS-1 and tyrosine 862 of another NPXY motif at the carboxyl terminal domain for She. By using Ba/F3 cells expressing epidermal growth factor receptor-LTK chimeric receptors containing a mutation at each NPXY site, we showed that while both NPXY motifs equally contribute to activation of the Ras pathway and generation of mitogenic signals, only tyrosine 485 of LTK transmits cell survival signals. These data suggest that IRS-1 possesses anti-apoptotic function at least in LTK signaling, Moreover, our data indicate that the survival signaling pathway of LTK is distinct from the Ras pathway and the p70(S6) kinase pathway, Our results provide a useful insight in understanding the distinctive roles of She and IRS-1 in the signal transduction system of the insulin receptor family, and this anti-apoptotic function of IRS-1 may explain the survival effects of insulin, IGF-1, and interleukin 4.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN DI, 1995, MOL CELL BIOL, V15, P4711; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOZUTSUMI H, 1994, ONCOGENE, V9, P2991; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; MARU Y, 1990, ONCOGENE RES, V5, P199; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PARRY SL, 1994, J IMMUNOL, V152, P2821; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SHI YF, 1995, CANCER RES, V55, P1982; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TOBE K, 1991, J BIOL CHEM, V266, P24793; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	44	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27707	27714		10.1074/jbc.271.44.27707	http://dx.doi.org/10.1074/jbc.271.44.27707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910363	hybrid			2022-12-27	WOS:A1996VQ67900081
J	Black, BL; Ligon, KL; Zhang, Y; Olson, EN				Black, BL; Ligon, KL; Zhang, Y; Olson, EN			Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; ACHAETE-SCUTE HOMOLOG-1; DNA-BINDING; MYOGENIC LINEAGE; CARCINOMA-CELLS; NERVOUS-SYSTEM; MRF4 PROMOTER; GENE; EXPRESSION; MYOD	Establishment of skeletal muscle and neural cell types is controlled by families of myogenic and neurogenic basic helix-loop-helix (bHLH) proteins, respectively, Myogenic bHLH proteins have been shown to activate skeletal muscle transcription in collaboration with members of the myocyte enhancer factor-2 (MEF2) family of MCM1-agamous-deficiens serum response factor (MADS)-box transcription factors, which are expressed in differentiated myocytes and neurons, Here, we show that the neurogenic bHLH protein MASH1 interacts with members of the MEF2 family and that this interaction, mediated by the DNA binding and dimerization domains of these factors, results in synergistic activation of transcription through either the MASH1 or the MEF2 DNA binding site, Consistent with their involve ment in activation of neuronal gene expression, members of the MEF2 family are expressed in p19 embryonal carcinoma cells that have been induced to form neurons following treatment with retinoic acid. These results suggest that members of the MEF2 family perform similar roles in synergistic activation of transcription in myogenic and neurogenic lineages by serving as cofactors for cell type-specific bHLH proteins.	UNIV TEXAS,SW MED CTR,HAMON CTR BASIC CANC RES,DEPT MOL BIOL & ONCOL,DALLAS,TX 75235; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77030	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center				Black, Brian/0000-0002-6664-8913				BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BLACK BL, 1995, J BIOL CHEM, V270, P2889, DOI 10.1074/jbc.270.7.2889; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FIRULLI AB, 1996, CIRC RES, V78, P1196; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEIFER D, 1994, NEUROSCIENCE, V63, P1067, DOI 10.1016/0306-4522(94)90573-8; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MARTINEZ C, 1993, MOL CELL BIOL, V13, P3514, DOI 10.1128/MCB.13.6.3514; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NAIDU PS, 1995, MOL CELL BIOL, V15, P2707; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Schulz RA, 1996, ONCOGENE, V12, P1827; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	42	63	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26659	26663		10.1074/jbc.271.43.26659	http://dx.doi.org/10.1074/jbc.271.43.26659			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900141	hybrid			2022-12-27	WOS:A1996VP23300035
J	Dabrowski, A; VanderKuur, JA; CarterSu, C; Williams, JA				Dabrowski, A; VanderKuur, JA; CarterSu, C; Williams, JA			Cholecystokinin stimulates formation of Shc-Grb2 complex in rat pancreatic acinar cells through a protein kinase C-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GROWTH-HORMONE RECEPTOR; SHC ADAPTER PROTEIN; TYROSINE-KINASE; MAP KINASE; SIGNALING PATHWAYS; COUPLED RECEPTORS; ACTIVATION; PHOSPHORYLATION; ASSOCIATION	Cholecystokinin (CCK) has recently been shown to activate the mitogen activated protein kinase (MAPK) cascade (Ras-Raf-MAPK kinase-MAPK) in pancreatic acini, The mechanism by which the G(q) protein-coupled CCK receptor activates Ras, however, is currently unknown, Growth factor receptors are known to activate Ras by means of adaptor proteins that bind to phosphotyrosine domains, We therefore compared the effects of CCK and epidermal growth factor (EGF) on Tyr phosphorylation of the adaptor proteins Shc and its association with Grb2 and the guanine nucleotide exchange factor SOS. Three major isoforms of Shc (p46, p52, p66) were detected in isolated rat pancreatic acini with p52 Shc being the predominant form, CCK and EGF increased tyrosyl phosphorylation of Shc (251 and 337% of control, respectively), CCK-stimulated tyrosyl phosphorylation of Shc as well as Shc-Grb2 complex formation was significant at 2.5 min, maximal at 5 min, and persisted for at least 30 min, Finally, SOS was found to be associated with Grb2 as assessed by probing of anti-Grb2 immunoprecipitates with anti-SOS, Since MAPK in pancreatic acini is activated via protein kinase C (PKC), we studied the effect of phorbol esters on Shc phosphorylation and found 12-O-tetradecanoylphorbol-13-acetate to be as potent as CCK. Furthermore, GF-109203X, a PKC inhibitor, abolished the effect of 12-O-tetradecanoylphorbol-13-acetate and also the effect of CCK but not the effect of EGF on Shc tyrosyl phosphorylation, CCK-induced tyrosyl phosphorylation of Shc was found to be phosphatidylinositol 3-kinase-independent, and CCK did not cause EGF receptor activation, These results suggest that formation of an Shc-Grb2-SOS complex via a PKC-dependent mechanism may provide the link between G(q) protein-coupled CCK receptor stimulation and Ras activation in these cells.	UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan			; Dabrowski, Andrzej/T-8656-2018	Williams, John/0000-0002-6063-7615; Dabrowski, Andrzej/0000-0002-5996-394X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041122, R01DK041225, P30DK034933, R37DK041122, R37DK034171, R01DK034171] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK041122, DK41225, R01 DK034171, P30 DK034933, DK34171, DK41122] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BRAGADO MJ, 1996, IN PRESS AM J PHYSL; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FOSTER CM, 1988, BIOCHEMISTRY-US, V27, P326, DOI 10.1021/bi00401a049; GARCIA LJ, 1996, GASTROENTEROLOGY, V110, P390; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOWE LR, 1993, J BIOL CHEM, V268, P20717; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOGSDON CD, 1986, AM J PHYSIOL, V250, pG440, DOI 10.1152/ajpgi.1986.250.4.G440; LU L, 1992, AM J PHYSIOL, V263, pG327, DOI 10.1152/ajpgi.1992.263.3.G327; LUTZ MP, 1993, J BIOL CHEM, V268, P11119; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SCHICK J, 1984, J CELL BIOL, V99, P1559; SOLOMON TE, 1983, AM J PHYSIOL, V245, pG99, DOI 10.1152/ajpgi.1983.245.1.G99; SOLOMON TE, 1994, PHYSL GASTROINTESTIN, V2, P1499; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; WILLIAMS JA, 1993, EXOCRINE PANCREAS, P167; WINITZ S, 1993, J BIOL CHEM, V268, P19196	46	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27125	27129		10.1074/jbc.271.43.27125	http://dx.doi.org/10.1074/jbc.271.43.27125			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900204	hybrid			2022-12-27	WOS:A1996VP23300098
J	Hanson, DA; Eyre, DR				Hanson, DA; Eyre, DR			Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE ARTICULAR-CARTILAGE; EHRLICH CHROMOGEN; LOCATION; PROCOLLAGEN; CHAIN; GENE; IDENTIFICATION; CROSSLINKING; PEPTIDES; CONFIRMS	Compared with soft tissue collagens, bone type I collagen displays a distinctive pattern of covalent cross-linking with evidence of preferred sites of molecular interaction and a prominence of both immature, divalent crosslinks and mature, trivalent cross-links in the adult tissue. In this study the she-specificity of the mature cross-links in human bone collagen was examined. Peptides containing fluorescent pyridinoline cross-links and Ehrlich's-reactive pyrrole cross-links were isolated from a bacterial collagenase digest of demineralized bone matrix. The digest was fractionated by molecular sieve chromatography, monitoring for peptide absorbance, pyridinoline fluorescence, pyrroles by Ehrlich's reagent, and immunoassay for crosslinked N-telopeptides. Individual cross-linked peptides were resolved by ion-exchange and reverse-phase HPLC. Structures were established by NK2-terminal microsequencing, cross link analysis, electrospray mass spectrometry, and immunoassay. Two, about equally occupied sites of pyridinoline cross-linking were identified, N-teIopeptide to helix and C-telopeptide to helix, Pyrroles were alternative cross-linking products at the same sites, but concentrated (85%) at the N-telopeptide end. Only one combination of chains was cross-linked by pyridinolines at the C-telopeptide to helix site, [alpha 1(I)(c)1(2) alpha 1(I)(helix). Several peptide combinations arose from the N-telopeptide to helix site, but the main source of pyridinolines was from the locus, alpha 1(I))(N) alpha 2(I)(N) alpha 1(I)helix. Pyridinolines Linking two alpha 1(N) telopeptides were a minor component. Pyrroles were concentrated at the locus, alpha 1(I)(N) alpha 2(I)(N) alpha 2(I)(helix). The cross-link ratio of hydroxylysylpyridinoline to lysylpyridinoline differed between N-telopeptide and C-telopeptide sites, and between the individual interchain combinations. Cross linked N-telopeptides accounted for two-thirds of the total lysylpyridinoline in bone, N-telopeptide pyridinoline fluorescence was quenched on chromatography, so that reliance on peptide fluorescence alone can underestimate the level of N-telopeptide pyridinoline cross-linking.	UNIV WASHINGTON,ORTHOPAED RES LABS,DEPT ORTHOPAED,SEATTLE,WA 98195; UNIV WASHINGTON,ORTHOPAED RES LABS,DEPT BIOCHEM,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NIAMS NIH HHS [R37 AR037318, AR37318, R01 AR036794] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036794, R37AR037318, R01AR037318] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAILEY AJ, 1974, NATURE, V251, P105, DOI 10.1038/251105a0; BARNES MJ, 1971, BIOCHEM J, V125, P433, DOI 10.1042/bj1250433; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; DALESSIO M, 1988, GENE, V67, P105, DOI 10.1016/0378-1119(88)90013-3; EYRE D, 1987, METHOD ENZYMOL, V144, P115; EYRE DR, 1973, BIOCHEM BIOPH RES CO, V52, P663, DOI 10.1016/0006-291X(73)90764-X; Eyre DR, 1995, ACTA ORTHOP SCAND, V66, P166, DOI 10.3109/17453679509157685; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; EYRE DR, 1980, BIOCHEM BIOPH RES CO, V92, P403, DOI 10.1016/0006-291X(80)90347-2; EYRE DR, 1981, DEV BIOCHEM, V22, P51; EYRE DR, 1988, BIOCHEM J, V175, P1; FUJIMOTO D, 1977, BIOCHEM BIOPH RES CO, V76, P1124, DOI 10.1016/0006-291X(77)90972-X; FUJIMOTO D, 1980, BIOCHEM BIOPH RES CO, V93, P948, DOI 10.1016/0006-291X(80)91167-5; HANSON DA, 1992, J BONE MINER RES, V7, P1251; HENKEL W, 1976, EUR J BIOCHEM, V69, P223, DOI 10.1111/j.1432-1033.1976.tb10877.x; HENKEL W, 1987, EUR J BIOCHEM, V165, P427, DOI 10.1111/j.1432-1033.1987.tb11456.x; HORGAN DJ, 1990, ARCH BIOCHEM BIOPHYS, V281, P21, DOI 10.1016/0003-9861(90)90407-P; KANG AH, 1972, BIOCHEMISTRY-US, V11, P1828, DOI 10.1021/bi00760a015; KEMP PD, 1988, BIOCHEM J, V252, P387, DOI 10.1042/bj2520387; KUBOKI Y, 1981, CONNECT TISSUE RES, V9, P107, DOI 10.3109/03008208109160248; KUBOKI Y, 1981, BIOCHEM BIOPH RES CO, V102, P119, DOI 10.1016/0006-291X(81)91497-2; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUYPERS R, 1994, MEAT SCI, V37, P67, DOI 10.1016/0309-1740(94)90146-5; KUYPERS R, 1992, BIOCHEM J, V283, P129, DOI 10.1042/bj2830129; LIGHT N, 1985, FEBS LETT, V182, P503, DOI 10.1016/0014-5793(85)80363-X; MECHANIC GL, 1987, BIOCHEMISTRY-US, V26, P3500, DOI 10.1021/bi00386a038; MILLER EJ, 1973, BIOCHEM BIOPH RES CO, V54, P432, DOI 10.1016/0006-291X(73)90940-6; OGAWA T, 1982, BIOCHEM BIOPH RES CO, V107, P1252, DOI 10.1016/S0006-291X(82)80132-0; PINNELL SR, 1971, BIOCHIM BIOPHYS ACTA, V229, P119, DOI 10.1016/0005-2795(71)90325-4; Risteli J., 1994, J BONE MINER RES, V9, pS186; ROBINS SP, 1983, BIOCHEM J, V215, P175, DOI 10.1042/bj2150175; ROBINS SP, 1987, BIOCHIM BIOPHYS ACTA, V914, P233, DOI 10.1016/0167-4838(87)90282-2; ROBINS SP, 1973, BIOCHEM J, V131, P771, DOI 10.1042/bj1310771; SCOTT JE, 1981, BIOSCIENCE REP, V1, P611, DOI 10.1007/BF01116276; SCOTT JE, 1983, BIOCHEM J, V209, P263, DOI 10.1042/bj2090263; TANZER ML, 1973, SCIENCE, V180, P561, DOI 10.1126/science.180.4086.561; VEIS A, 1993, J BONE MINER RES S2, V8, P3493; WU JJ, 1984, BIOCHEMISTRY-US, V23, P1850, DOI 10.1021/bi00303a041; Yamauchi M, 1989, Connect Tissue Res, V21, P159, DOI 10.3109/03008208909050006; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4907, DOI 10.1021/bi00365a027; YAMAUCHI M, 1993, CONNECT TISSUE RES, V29, P82	42	141	158	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26508	26516		10.1074/jbc.271.43.26508	http://dx.doi.org/10.1074/jbc.271.43.26508			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900119	hybrid			2022-12-27	WOS:A1996VP23300013
J	Pike, LJ; Casey, L				Pike, LJ; Casey, L			Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; ANCHORED PROTEINS; EGF RECEPTOR; CELLS; COMPLEX; EXPRESSION; TRANSPORT; MOLECULES; COMPONENT	Caveolae are small, plasma membrane invaginations that have been implicated in cell signaling. In A431 cells, approximately half of the total cellular phosphatidylinositol 4,5-bisphosphate (PtdIns 4,5-P-2) was found to be localized in low density, Triton-insoluble membrane domains enriched in caveolin. Treatment of cells with either epidermal growth factor or bradykinin for 5 min at 37 degrees C resulted in approximately a 50% decrease in this caveolar PtdIns 4,5-P-2 with no change in the levels of plasma membrane PtdIns 4,5-P-2. These data suggest that the PtdIns 4,5-P-2 present in cells is largely compartmentalized and that the caveolar PtdIns 4,5-P-2 is subject to hydrolysis by hormone-stimulated phospholipase C. As growth factor receptors, seven transmembrane domain receptors, heterotrimeric G proteins, and the inositol trisphosphate receptor have all been shown to be enriched in caveolae, these findings suggest that both the generation and response to inositol trisphosphate is highly compartmentalized within the cell.			Pike, LJ (corresponding author), WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,660 SO EUCLID,BOX 8231,ST LOUIS,MO 63110, USA.				NICHD NIH HHS [P01 HD20805208A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020805] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; AUGERT G, 1989, J BIOL CHEM, V264, P2574; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; Hope HR, 1996, MOL BIOL CELL, V7, P843, DOI 10.1091/mbc.7.6.843; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHUH SM, 1994, MOL BIOL CELL, V5, P739, DOI 10.1091/mbc.5.7.739; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; TILLY BC, 1988, BIOCHEM J, V252, P857, DOI 10.1042/bj2520857; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; WAHL MI, 1987, BIOCHEM BIOPH RES CO, V142, P688, DOI 10.1016/0006-291X(87)91469-0; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	26	325	328	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26453	26456		10.1074/jbc.271.43.26453	http://dx.doi.org/10.1074/jbc.271.43.26453			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900109	hybrid			2022-12-27	WOS:A1996VP23300003
J	Shimizu, K; Kawabe, H; Minami, S; Honda, T; Takaishi, K; Shirataki, H; Takai, Y				Shimizu, K; Kawabe, H; Minami, S; Honda, T; Takaishi, K; Shirataki, H; Takai, Y			SMAP, an Smg GDS-associating protein having Arm repeats and phosphorylated by Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP/GTP EXCHANGE PROTEIN; GTP-BINDING PROTEINS; CELL-CELL-ADHESION; MOLECULAR-CLONING; BETA-CATENIN; MEMBRANE; GENE; TRANSLOCATION; SUPPRESSOR; CYTOPLASM	Smg GDS is a regulator having two activities on a group of small G proteins including the Rho and Rap1 family members and Ki-Ras; one is to stimulate their GDP/GTP exchange reactions, and the other is to inhibit their interactions with membranes. Structurally, it has 11 Arm repeats, a protein interaction motif, found in the Drosophila Armadillo protein, a homolog of mammalian beta-catenin. We have isolated here an Smg GDS-interacting protein from a human brain cDNA library by use of the yeast two-hybrid method and named it SMAP (Smg GDS-associated protein). SMAP was a protein with a M(r) of 91,189 and 792 amino acids. SMAP had 9 Arm repeats. Recombinant SMAP interacted with recombinant Smg GDS but did not affect the two activities of Smg GDS on RhoA. SMAP was tyrosine phosphorylated by v-Src, and this phosphorylation reduced the affinity of SMAP for Smg GDS. Tissue and subcellular distribution analyses indicated that SMAP was ubiquitously expressed and highly concentrated at the endoplasmic reticulum area, Searches for sequence homology to SMAP revealed that SMAP was significantly homologous to sea urchin SpKAP115, suggesting that SMAP is a mammalian counterpart of SpKAP115 or its related protein. SpKAP115 is an accessory subunit of sea urchin kinesin II, an ATPase motor that transports vesicles along microtubules. These results suggest that SMAP serves as an adaptor for both Smg GDS and kinesin II or its related protein and links them with both the Smg GDS-regulated small G protein and Src tyrosine kinase signalings.	OSAKA UNIV,SCH MED,DEPT MOL BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696				BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUAN C, 1987, GENE, V67, P21; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATO M, 1994, BIOCHEM BIOPH RES CO, V205, P1776, DOI 10.1006/bbrc.1994.2875; KAWAMURA M, 1993, BIOCHEM BIOPH RES CO, V190, P832, DOI 10.1006/bbrc.1993.1124; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Komuro R, 1996, BIOCHEM BIOPH RES CO, V219, P435, DOI 10.1006/bbrc.1996.0251; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nomanbhoy TK, 1996, J BIOL CHEM, V271, P10004, DOI 10.1074/jbc.271.17.10004; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Sambrook J., 2002, MOL CLONING LAB MANU; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1995, ONCOGENE, V11, P39; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wedaman KP, 1996, J CELL BIOL, V132, P371, DOI 10.1083/jcb.132.3.371; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; Yamazaki H, 1996, P NATL ACAD SCI USA, V93, P8443, DOI 10.1073/pnas.93.16.8443; YAMAZAKI H, 1995, J CELL BIOL, V130, P1387, DOI 10.1083/jcb.130.6.1387; YANO R, 1992, MOL CELL BIOL, V12, P5640, DOI 10.1128/MCB.12.12.5640	41	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27013	27017		10.1074/jbc.271.43.27013	http://dx.doi.org/10.1074/jbc.271.43.27013			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900189	hybrid			2022-12-27	WOS:A1996VP23300083
J	Hateboer, G; Hijmans, EM; Nooij, JBD; Schlenker, S; Jentsch, S; Bernards, R				Hateboer, G; Hijmans, EM; Nooij, JBD; Schlenker, S; Jentsch, S; Bernards, R			mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYME; E1A PROTEINS; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; E1A-ASSOCIATED PROTEIN; NEGATIVE MODULATION; MOLECULAR-CLONING; TERMINAL DOMAIN; DEGRADATION	Adenovirus E1A encodes two nuclear phosphoproteins that can transform primary rodent fibroblasts in culture, Transformation by E1A is mediated at least in part through binding to several cellular proteins, including the three members of the retinoblastoma family of growth inhibitory proteins, We report here the cloning of a novel murine cDNA whose encoded protein interacts with both adenovirus type 5 and type 12 E1A proteins. The novel E1A-interacting protein shares significant sequence homology with ubiquitin-conjugating enzymes, a family of related proteins that is involved in the proteasome-mediated proteolysis of short-lived proteins. Highest homology was seen with a Saccharomyces cerevisiae protein named UBC9. importantly, the murine E1A-interacting protein complements a cell cycle defect of a S, cerevisiae mutant which harbors a temperature-sensitive mutation in UBC9, me therefore named this novel E1A-interacting protein mUBC9. We mapped the region of E1A that is required for mUBC9 binding and found that the transformation-relevant conserved region 2 of E1A is required for interaction.	NETHERLANDS CANC INST, DIV MOL CARCINOGENESIS, NL-1066 CX AMSTERDAM, NETHERLANDS; UNIV HEIDELBERG, ZENTRUM MOL BIOL, D-69120 HEIDELBERG, GERMANY	Netherlands Cancer Institute; Ruprecht Karls University Heidelberg				Bernards, Rene/0000-0001-8677-3423				ALKHODAIRY F, 1995, J CELL SCI, V108, P475; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRANTON PE, 1985, J VIROL, V56, P633, DOI 10.1128/JVI.56.2.633-638.1985; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GEISBERG JV, 1995, MOL CELL BIOL, V15, P6283; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; ISHIOKA C, 1995, ONCOGENE, V10, P841; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHENK T, 1991, ADV CANCER RES, V57, P47; SIMON R, 1990, MOL CELL BIOL, V10, P5609, DOI 10.1128/MCB.10.11.5609; SLAVICEK JM, 1988, EMBO J, V7, P3171, DOI 10.1002/j.1460-2075.1988.tb03184.x; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TSURUMI C, 1995, MOL CELL BIOL, V15, P5682; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Watanabe TK, 1996, CYTOGENET CELL GENET, V72, P86, DOI 10.1159/000134169; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	61	66	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25906	25911		10.1074/jbc.271.42.25906	http://dx.doi.org/10.1074/jbc.271.42.25906			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824223	Green Published, hybrid			2022-12-27	WOS:A1996VN18000029
J	Johansson, M; vonHeijne, G				Johansson, M; vonHeijne, G			Membrane topology of Kch, a putative K+ channel from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; PROTEIN TOPOLOGY; LEADER PEPTIDASE; FUSIONS; HYDROPHOBICITY	We have mapped the topology of the C-terminal half of the putative potassium channel protein Kch in the inner membrane of Escherichia coli using PhoA fusions. Our results are consistent with the widely assumed six-transmembrane helix model for eukaryotic voltage-gated ion channels and place both ends of the proposed channel-lining P-segment on the periplasmic side of the inner membrane. The rather hydrophobic P-segment is found to translocate only slowly across the inner membrane and seems to be near a threshold for stop-transfer function.	UNIV STOCKHOLM, DEPT BIOCHEM, S-10691 STOCKHOLM, SWEDEN	Stockholm University			von Heijne, Gunnar/AAH-9389-2019; von Heijne, Gunnar/F-5576-2011	von Heijne, Gunnar/0000-0002-4490-8569				BEZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819, DOI 10.1146/annurev.bb.23.060194.004131; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DALBEY RE, 1986, J BIOL CHEM, V261, P3844; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; HENNESSEY ES, 1993, CURR OPIN STRUC BIOL, V3, P524, DOI 10.1016/0959-440X(93)90078-Y; HENNESSEY ES, 1993, FEBS LETT, V331, P159, DOI 10.1016/0014-5793(93)80317-N; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; LEE E, 1994, J BIOL CHEM, V269, P28822; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; MONTAL M, 1995, ANNU REV BIOPH BIOM, V24, P31, DOI 10.1146/annurev.bb.24.060195.000335; RUSCH SL, 1994, J CELL BIOCHEM, V55, P209, DOI 10.1002/jcb.240550208; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WHITLEY P, 1994, NAT STRUCT BIOL, V1, P858, DOI 10.1038/nsb1294-858	19	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25912	25915		10.1074/jbc.271.42.25912	http://dx.doi.org/10.1074/jbc.271.42.25912			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824224	hybrid			2022-12-27	WOS:A1996VN18000030
J	Brucker, EA; Olson, JS; Phillips, GN; Dou, Y; IkedaSaito, M				Brucker, EA; Olson, JS; Phillips, GN; Dou, Y; IkedaSaito, M			High resolution crystal structures of the deoxy, oxy, and aquomet forms of cobalt myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTAL HISTIDINE MUTANTS; SPERM WHALE MYOGLOBIN; REVERSIBLE OXYGENATION; HEME POCKET; HEMOGLOBINS; REFINEMENT; STEREOCHEMISTRY; PORPHYRINS; ROTATION	The structures of the deoxy, oxy, and aquomet forms of native sperm whale myoglobin reconstituted with cobalt protoporphyrin IX have been determined by x-ray crystallography, As expected, cobalt myoglobin closely resembles native iron myoglobin in overall structure, especially in their respective aquomet forms, In the cobalt oxymyoglobin structure, the N-epsilon of distal histidine 64 lies within hydrogen bonding distance to both the oxygen atom directly bonded to the cobalt and the terminal oxygen atom, in agreement with previous EPR and resonance Raman studies, The metal atom in cobaltous myoglobin does show a small 0.06-Angstrom out-of-porphyrin plane displacement when moving from the oxy to deoxy state, In the case of the native iron-containing myoglobin, the oxy to deoxy transition results in a larger 0.16-Angstrom displacement of the metal farther out of the porphyrin plane, attributed to an increase in spin from S = 0 to S = 2. The small displacement in cobalt myoglobin is due to a change in coordination geometry, not spin state (S = 1/2 for both cobalt deoxy- and oxymyoglobin). The small out of-porphyrin plane movement of cobalt which accompanies deoxygenation of myoglobin also occurs in cobalt hemoglobin and serves to explain why cooperativity, although reduced, is still preserved when iron is replaced by cobalt in human hemoglobin.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77005; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106	Rice University; Case Western Reserve University			Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008	Olson, John/0000-0002-0760-5403	NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM51588, GM35649/HL47020] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588, R01GM035649] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANG H, 1992, J AM CHEM SOC, V114, P2843, DOI 10.1021/ja00034a014; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CHIEN JCW, 1972, P NATL ACAD SCI USA, V60, P2783; DICKINSON LC, 1980, P NATL ACAD SCI USA, V77, P1235, DOI 10.1073/pnas.77.3.1235; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERMI G, 1982, J MOL BIOL, V155, P495, DOI 10.1016/0022-2836(82)90483-1; FRAUENFELDER H, 1985, SCIENCE, V229, P337, DOI 10.1126/science.4012322; HOFFMAN BM, 1971, COLD SPRING HARB SYM, V36, P343; HOFFMAN BM, 1970, P NATL ACAD SCI USA, V67, P627; IKEDASAITO M, 1991, J BIOL CHEM, V266, P23641; IKEDASAITO M, 1977, J BIOL CHEM, V252, P4882; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; IMAI K, 1977, J MOL BIOL, V109, P83, DOI 10.1016/S0022-2836(77)80047-8; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KENDREW JC, 1960, NATURE, V185, P422, DOI 10.1038/185422a0; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; LEE HC, 1994, BIOCHEMISTRY-US, V33, P7609, DOI 10.1021/bi00190a014; PADLAN EA, 1975, J BIOL CHEM, V250, P7069; PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0; PETRICH JW, 1991, BIOCHEMISTRY-US, V30, P3975, DOI 10.1021/bi00230a025; PETSKO GA, 1978, FRONTIERS BIOL ENERG, P1011; PHILLIPS GN, 1990, BIOPHYS J, V57, P381, DOI 10.1016/S0006-3495(90)82540-6; PHILLIPS SEV, 1980, J MOL BIOL, V142, P531, DOI 10.1016/0022-2836(80)90262-4; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; QUILLIN ML, 1993, J MOL BIOL, V234, P140, DOI 10.1006/jmbi.1993.1569; SCHEIDT WR, 1974, J AM CHEM SOC, V96, P90, DOI 10.1021/ja00808a014; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123; YONETANI T, 1974, J BIOL CHEM, V249, P682; YONETANI T, 1974, J BIOL CHEM, V249, P2168	31	51	52	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25419	25422		10.1074/jbc.271.41.25419	http://dx.doi.org/10.1074/jbc.271.41.25419			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810310	hybrid			2022-12-27	WOS:A1996VL69300054
J	Lia, F; Rajotte, D; Clark, SC; Hoang, T				Lia, F; Rajotte, D; Clark, SC; Hoang, T			A dominant negative granulocyte-macrophage colony-stimulating factor receptor alpha chain reveals the multimeric structure of the receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; ACUTE MYELOBLASTIC-LEUKEMIA; SIGNAL-TRANSDUCTION; 2 DISTINCT; TYROSINE PHOSPHORYLATION; CYTOPLASMIC DOMAINS; EXPRESSION CLONING; IL-5 RECEPTORS; BLAST CELLS	The receptor for the hemopoietic growth factor granulocyte-macrophage colony-stimulating factor (GM-CSF) is composed of two chains, both of which belong to the superfamily of cytokine receptors. The alpha chain confers low affinity binding only, whereas the beta chain (beta(c)) confers high affinity binding when associated with alpha. Ectopic expression of both chains of the receptor in murine NIH-3T3 fibroblasts results in signal transduction, mitogenesis, and morphologic transformation. The cytoplasmic domain of the GM-CSF receptor alpha subunit (GMR-alpha) comprises 54 amino acids that have been shown to be important for signal transduction through the beta chain. The present study was designed to address the possibility of receptor oligomerization and its functional implication Cross-linking studies with I-125-GM-CSF on NIH-3T3 transfectants is consistent with the presence of alpha and beta(c) dimers and of receptor oligomers. We have, therefore, generated an inert alpha chain through polymerase chain reaction-mediated truncation of 47 amino acids of the COOH-terminal domain of alpha (alpha(t)), and coexpressed alpha(t), alpha, and beta(c) in NIH-3T3. In cells in which alpha(t) and alpha are present in stoichiometric proportion within the GM-CSF-binding complex, we provide evidence that alpha(t) is dominant negative over wild type alpha on the basis of two different functional assays: cell proliferation and foci formation. Hence, our results suggest the requirement for at least two functional alpha chains for signal transduction. Together with the cross-linking studies, our data indicate that the functional GMR is an oligomer that contains at least two alpha chains.	CLIN RES INST MONTREAL, HEMOPOIESIS & LEUKEMIA LAB, MONTREAL, PQ H2W 1R7, CANADA; UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT BIOCHEM, MONTREAL, PQ H3C 3J7, CANADA; UNIV MONTREAL, DEPT MOL BIOL, MONTREAL, PQ H3C 3J7, CANADA; GENET INST INC, CAMBRIDGE, MA 02140 USA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal								ARECES LB, 1993, P NATL ACAD SCI USA, V90, P3963, DOI 10.1073/pnas.90.9.3963; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN CB, 1995, BLOOD, V85, P1488, DOI 10.1182/blood.V85.6.1488.bloodjournal8561488; BUDEL LM, 1993, J BIOL CHEM, V268, P10154; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; D'Andrea AD, 1990, CURR OPIN CELL BIOL, V2, P648, DOI 10.1016/0955-0674(90)90106-O; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; EDER M, 1994, J BIOL CHEM, V269, P30173; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GASSON JC, 1991, BLOOD, V77, P1131, DOI 10.1182/blood.V77.6.1131.1131; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOANG T, 1993, J BIOL CHEM, V268, P11881; JENKINS BJ, 1995, EMBO J, V14, P4276, DOI 10.1002/j.1460-2075.1995.tb00102.x; KAWAHARA A, 1994, MOL CELL BIOL, V14, P5433, DOI 10.1128/MCB.14.8.5433; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; MELOCHE S, 1986, J BIOL CHEM, V261, P1525; METCALF D, 1993, BLOOD, V82, P3515; MIYAJIMA A, 1993, BLOOD, V82, P1960; Muto A, 1996, J EXP MED, V183, P1911, DOI 10.1084/jem.183.4.1911; NAKAMURA Y, 1994, SCIENCE, V264, P588, DOI 10.1126/science.8160019; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; ONETTOPOTHIER N, 1990, BLOOD, V75, P59; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RAJOTTE D, 1996, IN PRESS BLOOD, V88; RODRIGUEZCIMADEVILLA JC, 1990, BLOOD, V76, P1481; RONCO LV, 1994, J BIOL CHEM, V269, P277; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SASAKI K, 1993, J BIOL CHEM, V268, P13697; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; VALLANCE SJ, 1990, BIOCHEM J, V265, P359, DOI 10.1042/bj2650359; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEISS M, 1993, BLOOD, V82, P3298; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	44	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28287	28293		10.1074/jbc.271.45.28287	http://dx.doi.org/10.1074/jbc.271.45.28287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910448	hybrid			2022-12-27	WOS:A1996VU03300048
J	Pimental, RA; Julian, J; Gendler, SJ; Carson, DD				Pimental, RA; Julian, J; Gendler, SJ; Carson, DD			Synthesis and intracellular trafficking of Muc-1 and mucins by polarized mouse uterine epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOMA-ASSOCIATED MUCIN; TUMOR-ASSOCIATED MUCIN; O-GLYCOSYLATION; ENDOPLASMIC-RETICULUM; SURFACE EXPRESSION; MOLECULAR-CLONING; GLYCOPROTEINS; EPISIALIN; SIALOMUCIN; PROTEINS	Mucins function as a protective layer rendering the apical surface of epithelial cells nonadhesive to a variety of microorganisms and macromolecules. Muc-1 is a transmembrane mucin expressed at the apical cell surface of mouse uterine epithelial cells (UEC) that disappears as UEC become receptive for embryo implantation (Surveyor, G. A., Gendler, S. J., Pemberton, L., Das, S. K. Chakraborty, I., Julian, J., Pimental, R. A., Wegner, C. W., Dey, S. H., and Carson, D. D. (1995) Endocrinology 136, 3639-3647). In the present study, the kinetics of Muc-1 assembly, cell surface expression, release, and degradation were examined in polarized mouse UEC in vitro. Mucins were identified as the predominant glycoconjugates synthesized, apically expressed, and vectorially released in both wild-type and Muc-1 null mice. When mucins were released, greater than 95% were directed to the apical compartment. Approximately half of the cell-associated mucins lost during a 24-h period were found in the apical compartment. Vectorial biotinylation detected apically disposed, cell-surface mucin and indicated that at least 34% of these mucins are released apically within 24 h. This suggests that release of mucin ectodomains is part of the mechanism of mucin removal from the apical cell surface of UEC. The half-lives of total cell-associated mucins and Muc-1 were 19.5 +/- 1 and 16.5 +/- 0.8 h, respectively. Muc-1 represented approximately 10% of the [H-3]glucosamine-labeled, cell-associated mucins. Studies of the kinetics of intracellular transport of Muc-1 indicated transit times of 21 +/- 15 min from the rough endoplasmic reticulum to Golgi apparatus and 111 +/- 28 min from the Golgi apparatus to the cell surface. Collectively, these studies provide the first comprehensive description of Muc-1 and mucin maturation, metabolism, and release by polarized cells, as well as defining a major metabolic fate for mucins expressed by UEC. Normal metabolic processing appears to be sufficient to account for the removal of Muc-1 protein during the transition of UEC to a receptive state.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT BIOCHEM & MOL BIOL, HOUSTON, TX 77030 USA; MAYO CLIN, SCOTTSDALE, AZ 85259 USA	University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; Mayo Clinic Phoenix					NCI NIH HHS [CA-16672] Funding Source: Medline; NICHD NIH HHS [HD-29963] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029963, U01HD029963] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1994, J BIOL CHEM, V269, P14430; BANSIL R, 1995, ANNU REV PHYSIOL, V57, P635, DOI 10.1146/annurev.ph.57.030195.003223; BARND DL, 1989, P NATL ACAD SCI USA, V86, P7159, DOI 10.1073/pnas.86.18.7159; BAYER EA, 1988, ANAL BIOCHEM, V170, P371; BRAGA VMM, 1993, J CELL SCI, V105, P397; CARSON DD, 1990, J BIOL CHEM, V265, P2947; DEVINE PL, 1992, BIOESSAYS, V14, P619, DOI 10.1002/bies.950140909; DOHI DF, 1993, J BIOL CHEM, V268, P10133; DUTT A, 1990, J BIOL CHEM, V265, P430; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HANSKI C, 1993, CANCER RES, V53, P4082; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; Ho S B, 1991, Semin Cancer Biol, V2, P389; HO SB, 1993, CANCER RES, V53, P641; JACOBS AL, 1990, ENDOCRINOLOGY, V126, P2125, DOI 10.1210/endo-126-4-2125; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KAIFU R, 1979, CARBOHYD RES, V69, P79, DOI 10.1016/S0008-6215(00)85753-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; LINSLEY PS, 1988, J BIOL CHEM, V263, P8390; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORELL AG, 1971, J BIOL CHEM, V246, P1461; MORRIS JE, 1988, J BIOL CHEM, V263, P4172; NARASIMHAN S, 1986, CARBOHYD RES, V149, P65, DOI 10.1016/S0008-6215(00)90370-7; ODONNELL ER, 1987, BIOCHEMISTRY-US, V26, P3908; PLANTNER JJ, 1972, METHOD ENZYMOL, V28, P46; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; PSYCHOYOS A, 1986, ANN NY ACAD SCI, V476, P36, DOI 10.1111/j.1749-6632.1986.tb20920.x; ROTH J, 1994, P NATL ACAD SCI USA, V91, P8935, DOI 10.1073/pnas.91.19.8935; SCHLAFKE S, 1975, BIOL REPROD, V12, P41, DOI 10.1095/biolreprod12.1.41; SCHWEIZER A, 1994, J BIOL CHEM, V269, P4035; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPIELMAN J, 1987, J BIOL CHEM, V262, P269; STROUS GJ, 1992, CRIT REV BIOCHEM MOL, V27, P57, DOI 10.3109/10409239209082559; SURVEYOR GA, 1995, ENDOCRINOLOGY, V136, P3639, DOI 10.1210/en.136.8.3639; TANG JP, 1987, J BIOL CHEM, V262, P12832; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; WEBER W, 1985, BIOCHEM BIOPH RES CO, V126, P630, DOI 10.1016/0006-291X(85)90652-7; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	46	47	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28128	28137		10.1074/jbc.271.45.28128	http://dx.doi.org/10.1074/jbc.271.45.28128			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910427	hybrid			2022-12-27	WOS:A1996VU03300027
J	Datta, B; Li, B; Choubey, D; Nallur, G; Lengyel, P				Datta, B; Li, B; Choubey, D; Nallur, G; Lengyel, P			p202, An interferon-inducible modulator of transcription, inhibits transcriptional activation by the p53 tumor suppressor protein, and a segment from the p53-binding protein 1 that binds to p202 overcomes this inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR DIFFERENTIATION ANTIGEN; RETINOBLASTOMA PROTEIN; WILD-TYPE; MURINE CHROMOSOME-1; GENE ACTIVATORS; 2-HYBRID SYSTEM; CELL-CYCLE; DNA-DAMAGE; EXPRESSION; CLUSTER	p202, an intel feron-inducible murine protein, is a member of the ''200 family'' of proteins and is primarily nuclear. p202 is a modulator of transcription; it binds several transcription factors, including NF-kappa B p50 and p65, AP-1 c-Fos and c-Jun, and E2F1, and inhibits their transcriptional activity, p202 also binds pRb, the retinoblastoma protein, and if overexpressed it retards cell proliferation, Here we report that using the yeast two-hybrid assay we found that p202 bound the murine homolog of the human p53-binding protein 1 (53BP1), a protein shown to interact with the DNA binding domain of the p53 tumor suppressor protein. p202 bound a 98-amino acid segment from 53BP1. This binding was inhibited by the replacement ill p202 of a histidine (from the M(F/L)HATVA(T/S) sequence that is conserved among all of the 200 family proteins) by phenylalanine. me also report that overexpression of p202 inhibited the p53-dependent expression of reporter genes containing p53-activable segments from the mdm2 and p21 genes, whereas a decrease in the p202 level (in consequence of the expression of 202 antisense RNA) resulted in an increase in the p53-dependent expression of these reporters. Expression of the 53BP1 segment binding to p202 overcame the inhibition by overexpressed p202 of the transcription of reporters mediated by the p53 or the AP-1 transcription factors and of the proliferation of yeast.	YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; SUNY STONY BROOK,DEPT BIOCHEM & CELL BIOL,STONY BROOK,NY 11794; YALE UNIV,SCH MED,BOYER CTR MOL MED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06520	Yale University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Yale University; Yale University			Choubey, Divaker/A-4771-2008		NCI NIH HHS [5PO1-CA28146] Funding Source: Medline; NIAID NIH HHS [R37-AI12320] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI012320] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, V2; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BRIGGS JA, 1992, J CELL BIOCHEM, V49, P82, DOI 10.1002/jcb.240490114; BRIGGS RC, 1994, BLOOD, V83, P2153; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOUBEY D, 1992, J CELL BIOL, V116, P1333, DOI 10.1083/jcb.116.6.1333; CHOUBEY D, 1989, J BIOL CHEM, V264, P17182; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1991, ONCOGENE, V6, P873; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; DEMAEYER E, 1988, INTERFERONS OTHER RE, P488; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1566; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIGGE J, 1993, PROTEIN SCI, V2, P155; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GETZ MJ, 1976, CELL, V7, P255, DOI 10.1016/0092-8674(76)90025-8; HARPER JW, 1993, CELL, V75, P805; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JIANG HP, 1995, ONCOGENE, V10, P1855; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; Min W, 1996, MOL CELL BIOL, V16, P359; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OPDENAKKER G, 1989, VIROLOGY, V171, P568, DOI 10.1016/0042-6822(89)90626-0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RESNIKOFF CA, 1973, CANCER RES, V33, P3231; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAMBROOK J, 1992, MOL CLONING LAB MANU; SEN GC, 1992, J BIOL CHEM, V267, P5017; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANNENBAUM CS, 1993, J LEUKOCYTE BIOL, V53, P563, DOI 10.1002/jlb.53.5.563; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; VASAVADA HA, 1991, P NATL ACAD SCI USA, V88, P10686, DOI 10.1073/pnas.88.23.10686; VILCEK J, 1990, PEPTIDE GROWTH FACTO, P3; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamada H, 1995, MOL CELL BIOCHEM, V152, P149, DOI 10.1007/BF01076077; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1994, GENE DEV, V8, P1739; ZHANG W, 1995, CANCER RES, V55, P668	67	99	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27544	27555		10.1074/jbc.271.44.27544	http://dx.doi.org/10.1074/jbc.271.44.27544			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910340	hybrid			2022-12-27	WOS:A1996VQ67900058
J	Gu, MX; Majerus, PW				Gu, MX; Majerus, PW			The properties of the protein tyrosine phosphatase PTPMEG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; PHOSPHOTYROSINE PHOSPHATASE; CA-2+-DEPENDENT PROTEASE; SEQUENCE HOMOLOGY; BINDING PROTEIN; PHOSPHORYLATION; MEMBRANE; DOMAINS; IDENTIFICATION; ACTIVATION	We previously cloned a cDNA encoding a protein tyrosine phosphatase (PTP) containing sequence homology to protein 4.1, designated PTPMEG. Recombinant protein and amino- and carboxyl-terminal peptides were used to obtain polyclonal antibodies against PTPMEG to identify endogenous PTPMEG in A172 cells and to show that the enzyme is primarily localized to the membrane and cytoskeletal fractions of these cells. We prepared recombinant protein in Sf9 and COS-7 cells to further characterize it. The protein was phosphorylated in both cell types on serine and threonine residues. The multiple sites of phosphorylation were all within the intermediate domain of the protein between amino acids 386 and 503. This region also contains two PEST sequences and two proline-rich motifs that may confer binding to Src homology 3 domains. The recombinant protein was cleaved by trypsin and calpain in this region and thereby activated 4-8-fold as assayed using Raytide as substrate. We immunoprecipitated the protein from human platelets with both amino- and carboxyl-terminal antipeptide antibodies to assess the state of the enzyme in these cells. The full-length molecule was found in extracts from unstimulated platelets, whereas extracts from both calcium ionophore and thrombin-treated platelets contained proteolyzed and activated forms of the enzyme, indicating that proteolysis by calpain is evoked in response to thrombin. Prior incubation of platelets with calpeptin, an inhibitor of calpain, blocked the agonist induced proteolysis.	WASHINGTON UNIV, SCH MED, DIV HEMATOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NHLBI NIH HHS [HL 07088, HL 14147, HL 16634] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016634, P50HL014147, R37HL016634, T32HL007088] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ANDERSON RA, 1984, NATURE, V307, P655, DOI 10.1038/307655a0; Baenziger N L, 1974, Methods Enzymol, V31, P149; BERNATOWICZ MS, 1986, ANAL BIOCHEM, V155, P95, DOI 10.1016/0003-2697(86)90231-9; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; COOL DE, 1990, P NATL ACAD SCI USA, V87, P7280, DOI 10.1073/pnas.87.18.7280; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1991, J BIOL CHEM, V266, P13289; FOX JEB, 1993, MECHANISMS PLATELET; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LANG TL, 1995, CELL, V80, P473; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MOLLER NPH, 1994, P NATL ACAD SCI USA, V91, P7477, DOI 10.1073/pnas.91.16.7477; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; STONE RL, 1994, J BIOL CHEM, V269, P31323; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG SH, 1995, J BIOL CHEM, V270, P20067, DOI 10.1074/jbc.270.34.20067; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHAO ZZ, 1994, J BIOL CHEM, V269, P8780; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27751	27759		10.1074/jbc.271.44.27751	http://dx.doi.org/10.1074/jbc.271.44.27751			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910369	hybrid			2022-12-27	WOS:A1996VQ67900087
J	Parsell, DA; Mak, JY; Amento, EP; Unemori, EN				Parsell, DA; Mak, JY; Amento, EP; Unemori, EN			Relaxin binds to and elicits a response from cells of the human monocytic cell line, THP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT HUMAN RELAXIN; LABELED HUMAN RELAXIN; IN-VITRO; RECEPTORS; INSULIN; LOCALIZATION; EXPRESSION; PLATELETS; COLLAGEN; PEPTIDE	Relaxin is a 6-kDa peptide of the insulin family that is present at increased levels in the circulation during pregnancy. Its functions at that time are thought to include maintenance of myometrial quiescence, regulation of plasma volume, and release of neuropeptides, such as oxytocin and vasopressin. The protein also promotes connective tissue remodeling, which allows cervical ripening and separation of the pelvic symphysis in various mammalian species. In this report, we provide evidence for a novel target of relaxin, the human monocytic cell line, THP-1. Relaxin bound with high affinity (K-d = 102 pM) to a specific receptor on THP-1 cells. Receptor density was low (similar to 275 receptors/cell), but binding of relaxin triggered intracelluar signaling events. Receptor density was not modulated by pretreatment with estrogen, progesterone, or a number of other agents known to induce differentiation of THP-I cells. Cross-linking studies showed radiolabeled relaxin bound primarily to cell surface proteins with an apparent molecular mass of >200 kDa. Other members of the insulin-like family of proteins (insulin, insulin-like growth factors I and II, and relaxin-like factor) were unable to displace the binding of relaxin to THP-1 cells, suggesting that a distinct receptor for relaxin exists on this monocyte/macrophage cell line.	CONNECT THERAPEUT INC,PALO ALTO,CA 94303									ADHAM IM, 1993, J BIOL CHEM, V268, P26668; BANI D, 1995, PLATELETS, V6, P330, DOI 10.3109/09537109509078467; BANI D, 1995, LAB INVEST, V73, P709; BENNETT AE, 1986, HORM METAB RES, V18, P49, DOI 10.1055/s-2007-1012223; BULLESBACH EE, 1995, J BIOL CHEM, V270, P16011, DOI 10.1074/jbc.270.27.16011; CARRELL DT, 1995, ENDOCR RES, V21, P697, DOI 10.1080/07435809509030484; EIGENBROT C, 1991, J MOL BIOL, V221, P15, DOI 10.1016/0022-2836(91)90796-9; FEI DTW, 1990, BIOCHEM BIOPH RES CO, V170, P214, DOI 10.1016/0006-291X(90)91262-Q; GARIBAYTUPAS JL, 1995, J ENDOCRINOL, V145, P441, DOI 10.1677/joe.0.1450441; GEDDES BJ, 1995, J NEUROENDOCRINOL, V7, P411, DOI 10.1111/j.1365-2826.1995.tb00777.x; GOLDSMITH LT, 1995, ENDOCRIN METAB CLIN, V24, P171, DOI 10.1016/S0889-8529(18)30058-6; GUNNERSEN JM, 1995, MOL CELL ENDOCRINOL, V110, P55, DOI 10.1016/0303-7207(95)03516-A; KRAMER SM, 1990, IN VITRO CELL DEV B, V26, P647; MASINI E, 1994, J CLIN INVEST, V94, P1974, DOI 10.1172/JCI117549; McConnell HM, 1991, CURR OPIN STRUC BIOL, V1, P647, DOI 10.1016/S0959-440X(05)80091-0; NAKANE PK, 1967, J CELL BIOL, V33, P307, DOI 10.1083/jcb.33.2.307; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; OSHEROFF PL, 1990, J BIOL CHEM, V265, P9396; OSHEROFF PL, 1992, P NATL ACAD SCI USA, V89, P2384, DOI 10.1073/pnas.89.6.2384; OSHEROFF PL, 1991, P NATL ACAD SCI USA, V88, P6413, DOI 10.1073/pnas.88.15.6413; OSHEROFF PL, 1995, ENDOCRINOLOGY, V136, P4377, DOI 10.1210/en.136.10.4377; OWICKI JC, 1990, P NATL ACAD SCI USA, V87, P4007, DOI 10.1073/pnas.87.10.4007; PITCHFORD S, 1995, AM J PHYSIOL-CELL PH, V268, pC936, DOI 10.1152/ajpcell.1995.268.4.C936; RECHLER MM, 1985, ANNU REV PHYSIOL, V47, P425; SCHWABE C, 1994, FASEB J, V8, P1152, DOI 10.1096/fasebj.8.14.7958621; SHIRE SJ, 1991, BIOCHEMISTRY-US, V30, P7703, DOI 10.1021/bi00245a006; Siddle Kenneth, 1992, Progress in Growth Factor Research, V4, P301, DOI 10.1016/0955-2235(92)90013-8; TAYLOR MJ, 1994, J ENDOCRINOL, V143, pR5, DOI 10.1677/joe.0.143R005; UNEMORI E, 1996, J INVEST MED, V44, P315; UNEMORI EN, 1993, J INVEST DERMATOL, V101, P280, DOI 10.1111/1523-1747.ep12365206; UNEMORI EN, 1990, J BIOL CHEM, V265, P10681; WADA HG, 1993, J CELL PHYSIOL, V154, P129, DOI 10.1002/jcp.1041540116; YANG S, 1992, ENDOCRINOLOGY, V130, P179, DOI 10.1210/en.130.1.179	33	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27936	27941		10.1074/jbc.271.44.27936	http://dx.doi.org/10.1074/jbc.271.44.27936			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910395	hybrid			2022-12-27	WOS:A1996VQ67900113
J	Schivell, AE; Batchelor, RH; Bajjalieh, SM				Schivell, AE; Batchelor, RH; Bajjalieh, SM			Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL EXPRESSION; BINDING-PROTEIN; C2 DOMAIN; MEMBRANE; SYNAPTOPHYSIN; IDENTIFICATION; TRANSPORTER; CHANNEL; RELEASE; NEUREXINS	The identification and functional characterization of proteins localized to synaptic vesicles has contributed significantly to our understanding of neurotransmission, Studies of synaptic vesicle protein interactions have both led to the identification of novel synaptic proteins and suggested hypotheses of protein function, Synaptic vesicle protein 2 (SV2), is an integral membrane glycoprotein present in all synaptic vesicles. There are two characterized isoforms, SV2A and SV2B. Despite their homology to transporter proteins, the function of the SV2s remains unknown, In an effort to determine SV2 function and identify cofactors required for SV2 activity, we examined the protein interactions of SV2 using a combination of cross-linking, immunoprecipitation, and recombinant protein affinity chromatography, We report that SV2 is part of a large protein complex that contains the synaptic vesicle protein synaptotagmin, The interaction between SV2 and synaptotagmin is direct, specific to SV2A, and inhibited by calcium with an EC(50) of approximately 10 mu M. Interaction is mediated by the cytoplasmic amino terminus of SV2A and the C2B domain of synaptotagmin, Our observations suggest a regulatory relationship between these two proteins.	UNIV WASHINGTON,DEPT PHARMACOL,SCH MED,SEATTLE,WA 98195; UNIV WASHINGTON,GRAD PROGRAM NEUROBIOL & BEHAV,SCH MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 T32 GM07270-21] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BAJJALIEH SM, 1993, P NATL ACAD SCI USA, V90, P2150, DOI 10.1073/pnas.90.6.2150; BAJJALIEH SM, 1994, J NEUROSCI, V14, P5223, DOI 10.1523/jneurosci.14-09-05223.1994; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GINGRICH JA, 1992, FEBS LETT, V312, P115, DOI 10.1016/0014-5793(92)80917-6; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HUTTNER WB, 1983, J CELL BIOL, V96, P1373; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Kee Y, 1996, J NEUROSCI, V16, P1975; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LINIAL M, 1993, TRENDS BIOCHEM SCI, V18, P248, DOI 10.1016/0968-0004(93)90173-K; MARTIN KC, 1995, P NATL ACAD SCI USA, V92, P11307, DOI 10.1073/pnas.92.24.11307; MORIMOTO T, 1995, NEURON, V15, P689, DOI 10.1016/0896-6273(95)90156-6; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OREGAN S, 1995, MOL BRAIN RES, V32, P135, DOI 10.1016/0169-328X(95)00071-Y; PERIN MS, 1994, J BIOL CHEM, V269, P8576; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; RIORDAN JR, 1992, BIOCHIM BIOPHYS ACTA, V1101, P221, DOI 10.1016/0005-2728(92)90230-Y; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sugita S, 1996, J BIOL CHEM, V271, P1262, DOI 10.1074/jbc.271.3.1262; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; WIEDENMANN B, 1985, J CELL BIOL, V101, P12, DOI 10.1083/jcb.101.1.12; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	39	116	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27770	27775		10.1074/jbc.271.44.27770	http://dx.doi.org/10.1074/jbc.271.44.27770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910372	hybrid			2022-12-27	WOS:A1996VQ67900090
J	Brzeska, H; Martin, BM; Korn, ED				Brzeska, H; Martin, BM; Korn, ED			The catalytic domain of Acanthamoeba myosin I heavy chain kinase .1. Identification and characterization following tryptic cleavage of the native enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYLATION SITES; ACTIN-FILAMENTS; AUTOPHOSPHORYLATION; ACTIVATION; PURIFICATION; FAMILY; LOCALIZATION; CASTELLANII; SUBSTRATE	The actin-activated Mg2+-ATPase activities of the myosin I isoenzymes from Acanthamoeba castellanii are greatly increased by phosphorylation catalyzed by myosin I heavy chain kinase (MIHC kinase), a monomeric 97-kDa protein whose activity is greatly enhanced by acidic phospholipids and by autophosphorylation of multiple sites, In this paper, we show that the 35-kDa COOH-terminal fragment obtained by trypsin cleavage of maximally activated, autophosphorylated kinase retains the full activity and two to three of the autophosphorylation sites of the native enzyme, Other autophosphorylation sites occur in the middle third of the native enzyme, A trypsin cleavage site within the 35-kDa region is protected in phosphorylated kinase but is readily cleaved in unphosphorylated kinase producing catalytically inactive 25 and 11-kDa fragments from the NH2- and COOH-terminal ends, respectively, of the 35-kDa peptide, This implies that the conformation around the ''25/11'' cleavage site changes upon phosphorylation of the native enzyme, The position of this site corresponds to the activation loop of protein kinase A (see the accompanying paper: Brzeska, H., Szczepanowska, J., Hoey, J., and Korn, E. D. (1996) J. Biol. Chem. 271, 27056-27062), Exogenously added MIHC kinase phosphorylates the 11-kDa fragment, but not the 25-kDa fragment, indicating that the phosphorylation sites of the 35-kDa catalytic fragment are located within the COOH-terminal 11 kDa, The accompanying paper describes the cloning, sequencing, and expression of a fully active 35-kDa catalytic domain.	NIMH,NIH,CLIN NEUROSCI BRANCH,BETHESDA,MD 20892; NHLBI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Korn, Edward/0000-0003-3867-6295				ADAMS RJ, 1986, NATURE, V322, P754, DOI 10.1038/322754a0; ALBANESI JP, 1985, J BIOL CHEM, V260, P8649; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1989, J BIOL CHEM, V264, P10243; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; COTE GP, 1985, J BIOL CHEM, V260, P4543; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JUNG G, 1993, J BIOL CHEM, V268, P14981; KULESZALIPKA D, 1993, J BIOL CHEM, V268, P17995; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; LYNCH TJ, 1990, METHOD ENZYMOL, V196, P12; LYNCH TJ, 1990, BIOPHYS J, V57, pA335; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PINES J, 1995, NATURE, V376, P294, DOI 10.1038/376294a0; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TITUS MA, 1989, CELL REGUL, V1, P65; WANG ZY, 1995, J BIOL CHEM, V270, P27969, DOI 10.1074/jbc.270.46.27969; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	38	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27049	27055		10.1074/jbc.271.43.27049	http://dx.doi.org/10.1074/jbc.271.43.27049			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900195				2022-12-27	WOS:A1996VP23300089
J	Corradi, N; Borgonovo, B; Clementi, E; Bassetti, M; Racchetti, G; Consalez, GG; Huttner, WB; Meldolesi, J; Rosa, P				Corradi, N; Borgonovo, B; Clementi, E; Bassetti, M; Racchetti, G; Consalez, GG; Huttner, WB; Meldolesi, J; Rosa, P			Overall lack of regulated secretion in a PC12 variant cell clone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; NERVE GROWTH-FACTOR; I CHROMOGRANIN-B; MEMBRANE-PROTEIN; SECRETOGRANIN-I; CHROMAFFIN GRANULES; SYNAPTIC VESICLES; AGGREGATION; EXPRESSION; COMPLEX	A stable clone of PC12 neuroendocrine cells, named 27, known from previous studies to exhibit a defect of regulated secretion (lack of regulated secretory proteins, of synaptophysin, of dense granules and of catecholamine uptake and release; Clementi, E., Racchetti, G., Zacchetti, D., Panzeri, M. C., and Meldolesi, J. (1992) Eur. J. Neurosci. 4, 944-953) was characterized in detail to clarify the nature of its phenotype and the mechanisms of its establishment, The neuroendocrine nature of the PC12-27 phenotype was documented by specific markers: synapsins, neurofilament subunit H, neuronal kinesin, and alpha-latrotoxin receptor. Moreover, various intracellular membrane systems of PC12-27, including the endoplasmic reticulum and the Golgi complex, appeared similar to control PC12 in both morphology and marker expression. In contrast, all the investigated markers located either in dense granules (dopamine-beta-hydroxylase), in synaptic-like microvesicles (the acetylcholine transporter) or in both these regulated secretory organelles (VAMP2/synaptobrevin-2, synaptotagmin) were missing in PC12-27 cells, and the same was true also for the cytosolic and plasmalemma proteins involved in regulated exocytosis (Rab3, SNAP25, syntaxin). Pulse labeling and in vitro translation experiments revealed the defect to consist in a protein synthesis blockade that mRNA studies (reverse transcription-polymerase chain reaction, Northern blotting and actinomycin D experiments) revealed to take place primarily at the transcriptional level. The secretion defect of PC12-27 cells was modified neither by various types of long term stimulation nor by nerve growth factor treatment. Moreover, when one of the missing regulated secretory proteins, chromogranin B, was expressed by cDNA transfection, it was secreted, however via the constitutive pathway. Our results demonstrate that PC12-27 cells are fully incompetent for both branches of regulated secretion, those of dense granules and synaptic-like microvesicles, possibly because of the impairment of a general expression control system that appears to operate independently of neuroendocrine cell differentiation.	UNIV MILAN, CNR, CELLULAR & MOL PHARMACOL CTR, DEPT PHARMACOL, I-20129 MILAN, ITALY; UNIV REGGIO CALABRIA, FAC PHARM, DEPT PHARMACOL, I-88100 CATANZARO, ITALY; UNIV HEIDELBERG, INST NEUROBIOL, D-6900 HEIDELBERG, GERMANY; SAN RAFFAELE SCI INST, DEPT BIOL & TECHNOL RES, I-20132 MILAN, ITALY; SAN RAFFAELE SCI INST, B CECCARELLI NEUROBIOL CTR, I-20132 MILAN, ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Milan; Universita Mediterranea di Reggio Calabria; Ruprecht Karls University Heidelberg; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			Huttner, Wieland B./P-4080-2018; racchetti, Gabriella/ABG-7347-2020; Bassetti, Matteo/L-3081-2019; Consalez, Giacomo/AAA-2146-2019	Consalez, Giacomo/0000-0003-4594-6273; Rosa, Patrizia/0000-0002-2590-6955; Racchetti, Gabriella/0000-0003-0062-8300				Barr FA, 1996, FEBS LETT, V384, P65, DOI 10.1016/0014-5793(96)00285-2; BASSETTI M, 1995, ENDOCRINOLOGY, V136, P1168, DOI 10.1210/en.136.3.1168; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BERRARD S, 1995, J NEUROCHEM, V65, P939; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; Chen YG, 1996, J BIOL CHEM, V271, P5297, DOI 10.1074/jbc.271.10.5297; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEMENTI E, 1992, EUR J NEUROSCI, V4, P944, DOI 10.1111/j.1460-9568.1992.tb00121.x; CORRADI A, 1996, IN PRESS GENOMICS; DARCHEN F, 1990, P NATL ACAD SCI USA, V87, P5692, DOI 10.1073/pnas.87.15.5692; DAY R, 1995, DNA CELL BIOL, V14, P175, DOI 10.1089/dna.1995.14.175; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1990, ANNU REV PHYSIOL, V52, P625, DOI 10.1146/annurev.ph.52.030190.003205; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRONTALI N, 1976, J CELL BIOL, V68, P462, DOI 10.1083/jcb.68.3.462; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; Gratzl M, 1991, MARKERS NEURAL ENDOC; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALBAN PA, 1994, BIOCHEM J, V299, P1; HASHIMOTO S, 1987, J CELL BIOL, V105, P1579, DOI 10.1083/jcb.105.4.1579; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; HUNTER A, 1989, EXP CELL RES, V182, P445, DOI 10.1016/0014-4827(89)90249-8; Huttner WB, 1995, COLD SPRING HARB SYM, V60, P315, DOI 10.1101/SQB.1995.060.01.036; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; KEHLENBACH RH, 1994, NATURE, V372, P804; LEDOUARIN NM, 1988, CELL, V53, P169, DOI 10.1016/0092-8674(88)90375-3; LINDENBAUM MH, 1987, J BIOL CHEM, V262, P605; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; LOWE AW, 1988, J CELL BIOL, V106, P51, DOI 10.1083/jcb.106.1.51; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; MALGAROLI A, 1995, SCIENCE, V268, P1624, DOI 10.1126/science.7777862; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; OBENDORF D, 1988, J NEUROCHEM, V51, P1573, DOI 10.1111/j.1471-4159.1988.tb01127.x; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; PAPINI E, 1995, J BIOL CHEM, V270, P1332, DOI 10.1074/jbc.270.3.1332; PEARSE AGE, 1979, FED PROC, V38, P2288; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; ROSA P, 1992, J HISTOCHEM CYTOCHEM, V40, P523, DOI 10.1177/40.4.1552186; ROSA P, 1992, J BIOL CHEM, V267, P12227; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1995, J BIOL CHEM, V270, P10566, DOI 10.1074/jbc.270.18.10566; SHENNAN KIJ, 1994, J BIOL CHEM, V269, P18646; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1993, MECHANISMS INTRACELL, P157; TSCHERNITZ C, 1995, MOL BRAIN RES, V31, P131, DOI 10.1016/0169-328X(95)00045-T; VALTORTA F, 1992, J BIOL CHEM, V267, P7195; VELASCO A, 1991, Journal of Cell Biology, V115, p410A; Vignali G, 1996, EUR J NEUROSCI, V8, P536, DOI 10.1111/j.1460-9568.1996.tb01238.x; WINKLER H, 1987, ANN NY ACAD SCI, V493, P3, DOI 10.1111/j.1749-6632.1987.tb27176.x; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N	66	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27116	27124		10.1074/jbc.271.43.27116	http://dx.doi.org/10.1074/jbc.271.43.27116			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900203	hybrid			2022-12-27	WOS:A1996VP23300097
J	Cravchik, A; Sibley, DR; Gejman, PV				Cravchik, A; Sibley, DR; Gejman, PV			Functional analysis of the human D-2 dopamine receptor missense variants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D2 RECEPTOR; STRUCTURAL POLYMORPHISM; MOLECULAR VARIANT; GENE; SCHIZOPHRENIA; ASSOCIATION; ALCOHOLISM; IDENTIFICATION; MUTATIONS; DISEASE	The human dopamine D-2 receptor gene (DRD2) has three poly-morphic variants that predict the amino acid substitutions Val(96) --> Ala, Pro(310) --> Ser, and Ser(311) --> Cys in the receptor protein. We have investigated the ligand binding and signal transduction properties of these human D-2 receptor variants by stably expressing them in cultured mammalian cells. The Cys(311) and Ser(310) variants of the human D-2 receptor, which involve substitutions located in the third cytoplasmic loop, were markedly less effective in inhibiting cAMP synthesis than the most prevalent form (Pro(310), Ser(311)). Despite this difference, the Cys(311) and Ser(310) variants couple to G proteins in CHO-K1 (Chinese hamster ovary) cells. The impairment of the Cys(311) and Ser(310) variants to inhibit cAMP levels thus appears to result from a reduced ability of those variant receptors to activate the appropriate G(i)-like protein. The demonstration of substantial functional differences between DRD2 gene variants found in the human population might have important pharmacological implications given the widespread use of D-2 receptor blocking drugs in the treatment of schizophrenia and other psychiatric disorders.	NIMH,UNIT MOL CLIN INVEST,CLIN NEUROGENET BRANCH,BETHESDA,MD 20892; NINCDS,MOL NEUROPHARMACOL SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)			Sibley, David/AAC-3591-2019					ARINAMI T, 1994, LANCET, V343, P703, DOI 10.1016/S0140-6736(94)91581-4; ASGHARI V, 1994, MOL PHARMACOL, V46, P364; ASGHARI V, 1995, J NEUROCHEM, V65, P1157, DOI 10.1046/j.1471-4159.1995.65031157.x; ASHERSON P, 1994, LANCET, V343, P1045; Benjamin J, 1996, NAT GENET, V12, P81, DOI 10.1038/ng0196-81; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CIVELLI O, 1993, ANN REV PHARM TOXICO, V32, P281; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Ebstein RP, 1996, NAT GENET, V12, P78, DOI 10.1038/ng0196-78; ERESHEFSKY L, 1993, CAN J PSYCHIAT, V38, pS80; GEJMAN PV, 1994, JAMA-J AM MED ASSOC, V271, P204, DOI 10.1001/jama.271.3.204; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HIGUCHI S, 1994, BIOCHEM BIOPH RES CO, V204, P1199, DOI 10.1006/bbrc.1994.2590; HOLDEN C, 1994, SCIENCE, V264, P1696, DOI 10.1126/science.8209249; ITOKAWA M, 1993, BIOCHEM BIOPH RES CO, V196, P1369, DOI 10.1006/bbrc.1993.2404; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; Lannfelt L., 1992, Psychiatric Genetics, V2, P249, DOI 10.1097/00041444-199210000-00003; LICHTER JB, 1993, HUM MOL GENET, V2, P767, DOI 10.1093/hmg/2.6.767; LIU Q, 1995, AM J MED GENET, V60, P165, DOI 10.1002/ajmg.1320600216; MONSMA FJ, 1989, NATURE, V342, P926, DOI 10.1038/342926a0; NANKO S, 1994, LANCET, V343, P1044, DOI 10.1016/S0140-6736(94)90167-8; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NAYLOR L, 1995, BIOCHEM SOC T, V23, P87, DOI 10.1042/bst0230087; NOTHEN MM, 1994, LANCET, V343, P1301, DOI 10.1016/S0140-6736(94)92194-6; RAM A, 1995, AM J MED GENET, V60, P228, DOI 10.1002/ajmg.1320600311; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334, DOI 10.1165/ajrcmb/8.3.334; ROBINSON SW, 1994, MOL PHARMACOL, V46, P352; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SHAIKH S, 1994, LANCET, V343, P1045; SHENKER A, 1995, BAILLIERE CLIN ENDOC, V9, P427, DOI 10.1016/S0950-351X(95)80519-2; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SMITH SS, 1992, ARCH GEN PSYCHIAT, V49, P723; SNYDER SH, 1974, SCIENCE, V184, P1243, DOI 10.1126/science.184.4143.1243; SOBELL JL, 1995, HUM MOL GENET, V4, P507, DOI 10.1093/hmg/4.4.507	36	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26013	26017		10.1074/jbc.271.42.26013	http://dx.doi.org/10.1074/jbc.271.42.26013			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824240	hybrid			2022-12-27	WOS:A1996VN18000046
J	Macheroux, P; Bornemann, S; Ghisla, S; Thorneley, RNF				Macheroux, P; Bornemann, S; Ghisla, S; Thorneley, RNF			Studies with flavin analogs provide evidence that a protonated reduced FMN is the substrate-induced transient intermediate in the reaction of Escherichia coli chorismate synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE PROBES; MONONUCLEOTIDE; IDENTIFICATION; FLAVOPROTEINS; FLAVODOXINS; DERIVATIVES; REDUCTION; MECHANISM; KINETICS; BINDING	Chorismate synthase catalyzes the 1,4-elimination of phosphate and the C-(6-pro-R) hydrogen from 5-enolpyruvylshikimate S-phosphate (EPSP) to generate chorismate, Although this reaction does not involve an overall change in redox state, the enzyme requires reduced FMN. To investigate the role of the flavin in catalysis we have employed chemically modified flavins: 1- and 5-deaza-, 2- and 4-thio-, 6-hydroxy-, 8-nor-6-methyl-, 8-methyl-sulfonyl-, 8-chloro-, 8-fluoro-, 8-nor-methyl-, 8-S-methyl-, 8-methoxy, 8-mercapto- and 8-amino-FMN. Photoreduction of 4-thio-FMN in the presence of chorismate synthase at pH 7.5 produced a reduced flavin species with an absorbance maximum at lambda = 410 nm indicative of monoanionic, reduced 4-thio-FMN. Binding of 8-mercapto- and 6-hydroxy-FMN to chorismate synthase in the presence of EPSP or (6R)-6-fluoro-EPSP resulted in an increase of the flavin analogs' pK(a) values by 4 and 1 pH units, respectively, On the basis of these findings it is concluded that chorismate synthase preferentially binds neutral flavin species, including the protonated reduced form, rather than anionic flavin species in the presence of EPSP or the 6-fluoro-substrate analog, Further support for this conclusion was obtained using 5-deaza- and 4-thio-FMN, Addition of EPSP to enzyme bound, reduced 5-deaza-FMN produced spectral changes consistent with protonation of the flavin, Photoreduction of 4-thio-FMN in the presence of enzyme and the (6R)-6-fluoro-EPSP generated a reduced flavin species with absorbance properties of a neutral, reduced 4-thio-flavin. These results and their implications for the nature and kinetic properties of an observed flavin intermediate are discussed in the context of a possible role of reduced flavin as an electron donor to bound EPSP.	UNIV KONSTANZ,FAC BIOL,D-78434 CONSTANCE,GERMANY	University of Konstanz	Macheroux, P (corresponding author), JOHN INNES CTR PLANT SCI RES,NITROGEN FIXAT LAB,NORWICH RES PK,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Macheroux, Peter/AAB-5157-2019; Bornemann, Stephen/K-2938-2012	Macheroux, Peter/0000-0002-0242-454X; Bornemann, Stephen/0000-0001-5930-9473				ASHTON W T, 1977, Tetrahedron Letters, V30, P2551; BORNEMANN S, 1995, BIOCHEM J, V305, P707, DOI 10.1042/bj3050707; BORNEMANN S, 1995, J BIOL CHEM, V270, P22811, DOI 10.1074/jbc.270.39.22811; Bornemann S, 1996, BIOCHEMISTRY-US, V35, P9907, DOI 10.1021/bi952958q; Bornemann S, 1994, FLAVINS AND FLAVOPROTEINS 1993, P843; Bornemann S, 1995, PERSPECTIVES PROTEIN, P134; CHOONG YS, 1981, J BIOL CHEM, V256, P8671; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; DUDLEY KH, 1965, HELV CHIM ACTA, V47, P1354; ECKSTEIN JW, 1993, BIOCHEMISTRY-US, V32, P404, DOI 10.1021/bi00053a004; FRITZ BJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P113, DOI 10.1111/j.1751-1097.1987.tb08411.x; GHISLA S, 1980, BIOCHEMISTRY-US, V19, P2537, DOI 10.1021/bi00553a001; GHISLA S, 1986, BIOCHEM J, V239, P1; HALEY EE, 1954, J AM CHEM SOC, V76, P5093, DOI 10.1021/ja01649a025; KASAI S, 1983, J BIOCHEM-TOKYO, V93, P397, DOI 10.1093/oxfordjournals.jbchem.a134193; KASAI S, 1987, B CHEM SOC JPN, V60, P3041, DOI 10.1246/bcsj.60.3041; KASAI S, 1979, J NUTR SCI VITAMINOL, V25, P289; KNOWLES PF, 1970, METHOD ENZYMOL, V17, P360; KURFURST M, 1982, EUR J BIOCHEM, V123, P355, DOI 10.1111/j.1432-1033.1982.tb19775.x; LAUHON CT, 1994, BIOCHEMISTRY-US, V33, P14100, DOI 10.1021/bi00251a019; LUDWIG ML, 1990, BIOCHEMISTRY-US, V29, P10364, DOI 10.1021/bi00497a011; Macheroux P, 1996, BIOCHEMISTRY-US, V35, P1643, DOI 10.1021/bi951705u; MASSEY V, 1979, J BIOL CHEM, V254, P9640; MASSEY V, 1984, J BIOL CHEM, V259, P9667; MASSEY V, 1966, BIOCHEMISTRY-US, V5, P3181, DOI 10.1021/bi00874a016; Massey V., 1991, FLAVINS FLAVOPROTEIN, P581; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; MAYHEW SG, 1971, BIOCHIM BIOPHYS ACTA, V235, P289, DOI 10.1016/0005-2744(71)90207-5; MCCORMICK DB, 1964, BIOCHEM BIOPH RES CO, V14, P493, DOI 10.1016/0006-291X(64)90257-8; MCCORMICK DB, 1963, J BIOL CHEM, V238, P3095; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MOORE EG, 1978, J BIOL CHEM, V253, P6413; MULLER F, 1966, HELV CHIM ACTA, V49, P2352, DOI 10.1002/hlca.660490740; MULLER F, 1969, J BIOL CHEM, V244, P4007; RAMJEE MK, 1994, ANAL BIOCHEM, V220, P137, DOI 10.1006/abio.1994.1309; RAMJEE MK, 1993, BIOORG MED CHEM LETT, V3, P1409, DOI 10.1016/S0960-894X(01)80421-2; RAMJEE MN, 1991, J AM CHEM SOC, V113, P8566, DOI 10.1021/ja00022a078; SCHOLLNHAMMER G, 1974, EUR J BIOCHEM, V44, P561, DOI 10.1111/j.1432-1033.1974.tb03514.x; SCHOPFER LM, 1981, J BIOL CHEM, V256, P7329; SPENCER R, 1977, BIOCHEMISTRY-US, V16, P3586, DOI 10.1021/bi00635a014; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; STEWART RC, 1985, J BIOL CHEM, V260, P3639; THORNELEY RNF, 1983, BIOCHEM J, V215, P393, DOI 10.1042/bj2150393; WELCH GR, 1974, ARCH BIOCHEM BIOPHYS, V165, P505, DOI 10.1016/0003-9861(74)90276-8	44	41	43	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25850	25858		10.1074/jbc.271.42.25850	http://dx.doi.org/10.1074/jbc.271.42.25850			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824216	hybrid, Green Published, Green Submitted			2022-12-27	WOS:A1996VN18000022
J	Nakamuta, M; Chang, BHJ; Zsigmond, E; Kobayashi, K; Lei, H; Ishida, BY; Oka, K; Li, E; Chan, L				Nakamuta, M; Chang, BHJ; Zsigmond, E; Kobayashi, K; Lei, H; Ishida, BY; Oka, K; Li, E; Chan, L			Complete phenotypic characterization of apobec-1 knockout mice with a wild-type genetic background and a human apolipoprotein B transgenic: Background, and restoration of apolipoprotein B mRNA editing by somatic gene transfer of apobec-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; HUMAN ADENOVIRUS TYPE-5; MESSENGER-RNA; MOLECULAR-CLONING; PROTEIN; EXPRESSION; MOUSE; B-48; REGION; B-100	We have produced gene knockout mice by targeted disruption of the apobec-1 gene. As recently reported by Hirano et al. (Hirano, K.-I., Young, S. G., Farese, R. V., Jr., Ng, J., Sande, E., Warburton, C., Powell-Braxton, L. M., and Davidson, N. O. (1996) J. Biol. Chem. 271, 9887-9890), these animals do not edit apolipoprotein (ape) B mRNA or produce apoB-48. In this study we have performed a detailed analysis of the lipoprotein phenotypic effects of apobec-1 gene disruption that were not examined in the previous study. We first analyzed the plasma lipoproteins in knockout animals with a wild-type genetic background. Although there was no difference in plasma cholesterol between apobec-1(-/-), (+/-) (+/+) mice, there Or was a marked (176%) increase in plasma apoB-100, from 1.8 +/- 1.2 mg/dl in apobec-1(+/+) mice to 2.7 +/- 0.6 mg/dl in apobec-1(+/-) and 5.0 +/- 1.4 mg/dl in apobec-1(-/-) mice. Plasma apoE was similar in these animals. By fast protein liquid chromatography (FPLC) analysis, there was a significant decrease in plasma high density lipoprotein (HDL) cholesterol in apobec-1(-/-) mice. We further fractionated the plasma lipoproteins into d < 1.006, 1.006-1.02, 1.02-1.05, 1.05-1.08, 1.08-1.10, and 1.10-1.21 g/ml classes, and found a marked (30-40%) reduction in the cholesterol and protein content in the (d 1.08-1.10 and 1.10-1.21) HDL fractions, corroborating the FPLC data. SDS-gel analysis revealed an absence of apoB-48, an increase in apoB-100 in the very low density Lipoprotein (VLDL) and low density lipoprotein (LDL) fractions, and a small decrease in apoA-I in the HDL fractions in the apobec-1(-/-) samples. We next raised the basal plasma apoB levels in the apobec-1(-/-) animals by crossbreeding them with human apoB transgenic (TgB) mice. The plasma apoB-100 was 3-fold higher in apobec-1(-/-)/TgB(+/-) mice (26.6 +/- 18.3 mg/dl) than in apobec-1(+/+)/TgB(+/-) mice (9.8 +/- 3.9 mg/dl, p < 0.05). The apobec-1(-/-)/TgB(+/-) mice had a plasma cholesterol levels of 170 +/- 28 mg/dl and triglyceride levels of 106 +/- 31 mg/dl, which are 80% and 58% higher, respectively, than the corresponding values of 94 +/- 21 mg/dl and 67 +/- 11 mg/dl in apobec(+/+)/TgB(+/-) mice. By FPLC, the apobec-1(-/-)/TgB(+/-) animals developed markedly elevated plasma LDL cholesterol (518.5 +/- 329.5 mu g/ml) that is 373% that of apobec-1(+/+)/TgB(+/-) mice (139.0 +/- 87.0 mu g/ml) (p < 0.05). The elevated plasma triglyceride was accounted for mainly by a 97% increase in VLDL triglyceride in the apobec-1(-/-)/TgB(+/-) mice. We conclude that apobec-1(-/-) animals have a distinctive lipoprotein phenotype characterized by significant hyperapoB-100 and HDL deficiency in mice with a wild-type genetic background. Furthermore, the abolition of apoB mRNA editing elevates plasma total cholesterol and LDL cholesterol in apobec-1(-/-) animals with a TgB background. Finally, to exclude the possibility that absence of apoB mRNA editing was a secondary effect of chronic Apobec-1 deficiency, we treated apobec-1(-/-) mice with a replication-defective mouse Apobec-1 adenoviral vector and found that we could acutely restore apoB mRNA editing in the Liver. These experiments indicate that Apobec-1 is an essential component of the apoB mRNA editing machinery and absence of editing in the knockout animals is a direct consequence of the absence of functional Apobec-1.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; CHILDRENS NUTR RES CTR,USDA ARS,HOUSTON,TX 77030; MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,CHARLESTOWN,MA 02129; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	Baylor College of Medicine; United States Department of Agriculture (USDA); Harvard University; Massachusetts General Hospital; University of California System; University of California San Francisco	Nakamuta, M (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NHLBI NIH HHS [HL56668, HL51586, HL16512] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R01HL056668, R37HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHAN L, 1993, BIOESSAYS, V15, P33, DOI 10.1002/bies.950150106; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHAN L, 1995, SCI MED, V2, P68; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DESILVA HV, 1994, J LIPID RES, V35, P1297; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEVE J, 1993, J LIPID RES, V34, P1367; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; Hughes SD, 1996, HUM GENE THER, V7, P39, DOI 10.1089/hum.1996.7.1-39; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; ISHIDA BY, 1992, J LIPID RES, V33, P1073; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAKAMUTA M, 1995, 68 SCI SESS AM HEART, P54; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; Paigen Beverly, 1994, Current Opinion in Lipidology, V5, P258, DOI 10.1097/00041433-199408000-00003; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; VANTHOOFT FM, 1982, P NATL ACAD SCI-BIOL, V79, P179; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435	34	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25981	25988		10.1074/jbc.271.42.25981	http://dx.doi.org/10.1074/jbc.271.42.25981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824235				2022-12-27	WOS:A1996VN18000041
J	Nebl, G; Meuer, SC; Samstag, Y				Nebl, G; Meuer, SC; Samstag, Y			Dephosphorylation of serine 3 regulates nuclear translocation of cofilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; PORCINE BRAIN; ACTIN-BINDING; SEQUENCE; ACTIVATION; SIGNAL; CELLS; IDENTIFICATION; TRANSPORT; YEAST	Signal transduction processes in T-cells and other cell types alter the phosphorylation state of cofilin, an actin-binding phosphoprotein. Whether reversible phosphorylation is responsible for the regulation of the functional activities of cofilin is not clear at present. Here we have identified the phosphoacceptor site of cofilin and analyzed the role of cofilin phosphorylation with respect to its subcellular localization. Site-directed mutagenesis studies show that phosphorylation occurs exclusively on Ser-3. Expression of non-phosphorylatable mutant cofilin proteins in NIH3T3 cells and determination of their subcellular localization by confocal laser scanning microscopy reveal that non phosphorylated cofilin accumulates within nuclei. This analysis shows that the subcellular localization of cofilin depends on the phosphorylation state of Ser-3.	UNIV HEIDELBERG,INST IMMUNOL,D-69120 HEIDELBERG,GERMANY	Ruprecht Karls University Heidelberg								ABE H, 1990, BIOCHEMISTRY-US, V29, P7420, DOI 10.1021/bi00484a010; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; ADDISON C, 1990, ONCOGENE, V5, P423; DAVIDSON MML, 1994, BIOCHEM J, V301, P41, DOI 10.1042/bj3010041; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; IIDA K, 1993, GENE, V124, P115; IIDA K, 1992, CELL STRUCT FUNCT, V17, P39, DOI 10.1247/csf.17.39; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; MATSUZAKI F, 1988, J BIOL CHEM, V263, P11564; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; NEBL G, 1994, J BIOL CHEM, V269, P7371; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NISHIDA E, 1987, P NATL ACAD SCI USA, V84, P5262, DOI 10.1073/pnas.84.15.5262; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OGAWA K, 1990, NUCLEIC ACIDS RES, V18, P7169, DOI 10.1093/nar/18.23.7169; OHTA Y, 1989, J BIOL CHEM, V264, P16143; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; RITTNER K, 1991, Methods in Molecular and Cellular Biology, V2, P176; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1991, J IMMUNOL, V147, P788; SAMSTAG Y, 1992, INT IMMUNOL, V4, P1255, DOI 10.1093/intimm/4.11.1255; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; Samstag Y, 1996, J IMMUNOL, V156, P4167; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551	25	100	107	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26276	26280		10.1074/jbc.271.42.26276	http://dx.doi.org/10.1074/jbc.271.42.26276			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824278				2022-12-27	WOS:A1996VN18000084
J	Thomas, CP; Doggett, NA; Fisher, R; Stokes, JB				Thomas, CP; Doggett, NA; Fisher, R; Stokes, JB			Genomic organization and the 5' flanking region of the gamma subunit of the human amiloride-sensitive epithelial sodium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ CHANNEL; DNA METHYLATION; HOMOLOGOUS SUBUNITS; MEMBRANE TOPOLOGY; LIDDLES SYNDROME; EXPRESSION; CLONING; GENE; ALDOSTERONE; MUTATIONS	The amiloride sensitive epithelial sodium channel (ENaC) complex is made up of at least three different subunits alpha, beta, and gamma, which are developmentally regulated, selectively expressed, and variously up-regulated by steroid hormones. To understand mechanisms involved in regulation of the gamma subunit, we have determined the structure of the human gamma ENaC gene. By 5' rapid amplification of cDNA ends, primer extension analysis, and nuclease protection assay, we identified transcription start sites in human brain, kidney, and lung. A human genomic library was screened and overlapping cosmid clones that span similar to 50 kilobases and con tain the h gamma ENaC gene were identified. The 5'-untranslated region is 141 bases long, and the translation start codon is contained within the second exon, The human gene spans at least 35 kilobases. The 5' end of the gene including portions of 5' flanking genomic DNA and the first intron are G + C rich and contain several CPG dinucleotides, consistent with a CpG island. The 5' flanking region contains no CCAAT or TATA-like elements but does contain two GC boxes as well as several putative transcription factor binding sites including AP-2, Sp1, CRE, PEA-3, and NF-IL6. This is the first description of the structural organization and the 5' flanking region of a member of the epithelial sodium channel complex.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA USA; VET AFFAIRS MED CTR, IOWA CITY, IA 52242 USA; LOS ALAMOS NATL LAB, DIV LIFE SCI, LOS ALAMOS, NM USA	University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; United States Department of Energy (DOE); Los Alamos National Laboratory	Thomas, CP (corresponding author), UNIV IOWA HOSP & CLIN, DEPT INTERNAL MED, DIV NEPHROL, 200 HAWKINS DR, IOWA CITY, IA 52242 USA.			Fisher, Rory/0000-0003-3108-4836; Thomas, Christie/0000-0002-5989-9685	NIDDK NIH HHS [DK 25231] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025231] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GARTY H, 1994, FASEB J, V8, P522, DOI 10.1096/fasebj.8.8.8181670; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HECK GL, 1984, SCIENCE, V223, P403, DOI 10.1126/science.6691151; Lehman I R, 1974, Methods Enzymol, V29, P46; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; LONGMIRE JL, 1993, GENET ANAL-BIOMOL E, V10, P69, DOI 10.1016/1050-3862(93)90037-J; MASON PJ, 1993, GENE TRANSCRIPTION P, P5; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RENARD S, 1994, J BIOL CHEM, V269, P12981; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; STALLINGS RL, 1990, P NATL ACAD SCI USA, V87, P6218, DOI 10.1073/pnas.87.16.6218; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; THOMAS CP, 1995, J AM SOC NEPHROL, V6, P353; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; Volk KA, 1995, J CLIN INVEST, V96, P2748, DOI 10.1172/JCI118344; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	39	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26062	26066		10.1074/jbc.271.42.26062	http://dx.doi.org/10.1074/jbc.271.42.26062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824247	hybrid			2022-12-27	WOS:A1996VN18000053
J	Hembrough, TA; Li, L; Gonias, SL				Hembrough, TA; Li, L; Gonias, SL			Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL CELLS; UROKINASE RECEPTOR; TUMOR INVASION; ANNEXIN-II; BINDING; EXPRESSION; CARCINOMA; METASTASIS; FIBRIN; IDENTIFICATION	Cytokeratin 8 (CK 8) has been identified on the external surfaces of viable, unpermeabilized epithelial cells (Hembrough, T. A., Vasudevan, J., Allietta, M. M., Glass, W.F., and Gonias, S. L. (1995) J. Cell Sci. 108, 1071-1082). In this study, we demonstrated that CK 8 is the major plasminogen-binding protein in plasma membrane fractions isolated from three breast cancer cell lines, BT20, MCF-7, and MDA-MB-157. To assess the function of CK 8 as a plasminogen receptor, monoclonal antibody 1E8 was raised against the carboxyl-terminal 12 amino acids of CK 8. The 1E8 epitope was present on the external surfaces of breast cancer cells, as determined by immunofluorescence microscopy. I-125-1E8 bound to MCF-7 cells; the maximum binding capacity (1.5 x 10(6) sites per cell) was comparable with that determined for plasminogen. When MCF-7 cells were incubated with Fab fragments of 1E8, specific I-125-plasminogen binding was decreased up to 82%. Specific plasminogen binding was decreased up to 67%, even when the unbound 1E8 Feb was removed by washing the cells prior to adding I-125-plasminogen. Preincubation with 1E8 Fab decreased plasminogen binding to BT20 and MDA-MB-157 cells, although to a lesser extent than with MCF-7 cells. Plasminogen activation by tissue-type plasminogen activator was greatly accelerated, due to a large decrease in K-m, when the plasminogen was bound to MCF-7 cells. Pretreatment with 1E8 Fab decreased the rate of plasminogen activation by up to 83%, implicating CK 8 in the MCF-7 cell-accelerated reaction. These studies identify cell-surface CR 8 as a major plasminogen receptor in breast cancer cells and as a required component for the rapid activation of cell-associated plasminogen by tissue-type plasminogen activator.	UNIV VIRGINIA, HLTH SCI CTR, DEPT PATHOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT BIOCHEM, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia								ACHTSTAETTER T, 1986, METHOD ENZYMOL, V134, P355; ALIZADEH H, 1995, CURR EYE RES, V14, P449, DOI 10.3109/02713689509003755; AZUMI N, 1987, AM J CLIN PATHOL, V88, P286, DOI 10.1093/ajcp/88.3.286; BEHRENDT N, 1990, J BIOL CHEM, V265, P6453; BIANCHI E, 1994, CANCER RES, V54, P861; BURTON DR, 1987, MOL GENETICS IMMUNOG, P11; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHAN R, 1985, MONOCLONAL ANTIBODIE, P165; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; CHU YW, 1993, P NATL ACAD SCI USA, V90, P4261, DOI 10.1073/pnas.90.9.4261; CORREC P, 1990, INT J CANCER, V46, P745, DOI 10.1002/ijc.2910460432; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DUFFY MJ, 1990, CANCER RES, V50, P6827; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1992, FIBRINOLYSIS, V6, P27; EVANS DM, 1995, AM SURGEON, V61, P692; FLEISCHER S, 1986, METHOD ENZYMOL, V31, P6; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; GODFROID E, 1991, J CELL SCI, V99, P595; GONIAS SL, 1992, EXP HEMATOL, V20, P302; HAJJAR KA, 1987, J CLIN INVEST, V80, P1712, DOI 10.1172/JCI113262; HAJJAR KA, 1986, J BIOL CHEM, V261, P1656; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; HALL SW, 1990, J CELL BIOCHEM, V43, P213, DOI 10.1002/jcb.240430303; HEMBROUGH TA, 1995, J CELL SCI, V108, P1071; Hembrough TA, 1996, BIOCHEM J, V317, P763, DOI 10.1042/bj3170763; HENDRIX MJC, 1992, JNCI-J NATL CANCER I, V84, P165, DOI 10.1093/jnci/84.3.165; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KOBAYASHI H, 1994, CANCER RES, V54, P844; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1981, CANCER RES, V41, P4629; LIU JN, 1993, J BIOL CHEM, V268, P12257; MIETTINEN M, 1989, LAB INVEST, V61, P623; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; PLOW EF, 1995, FASEB J, V9, P939, DOI 10.1096/fasebj.9.10.7615163; REDLITZ A, 1995, EUR J BIOCHEM, V227, P407, DOI 10.1111/j.1432-1033.1995.tb20403.x; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SCHAAFSMA HE, 1991, AM J PATHOL, V139, P1389; SCHAAFSMA HE, 1993, J PATHOL, V170, P77, DOI 10.1002/path.1711700113; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; URANO T, 1988, BIOCHEMISTRY-US, V27, P6522, DOI 10.1021/bi00417a049	47	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25684	25691		10.1074/jbc.271.41.25684	http://dx.doi.org/10.1074/jbc.271.41.25684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810346	hybrid			2022-12-27	WOS:A1996VL69300090
J	Imamura, R; Yamanaka, K; Ogura, T; Hiraga, S; Fujita, N; Ishihama, A; Niki, H				Imamura, R; Yamanaka, K; Ogura, T; Hiraga, S; Fujita, N; Ishihama, A; Niki, H			Identification of the cpdA gene encoding cyclic 3',5'-adenosine monophosphate phosphodiesterase in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE GENE; RNA-POLYMERASE; TRANSCRIPTION ACTIVATION; CELL-DIVISION; FUNCTIONAL MAP; ALPHA-SUBUNIT; PROTEIN; CHROMOSOME; DNA; EXPRESSION	We have identified a gene, cpdA, located at 66.2 min of the chromosome of Escherichia coli that encodes cyclic 3',5'-adenosine monophosphate phosphodiesterase (cAMP phosphodiesterase, EC 3.1.4.17). The expression of beta-galactosidase, which is a product of the lacZ gene, was repressed in cells that harbored multiple copies of the plasmid carrying the cpdA gene. Northern blotting showed that the transcription of the lacZ gene was inhibited in these cells. Multiple copies of the cpdA gene decreased the intracellular concentration of GAMP, which is a positive regulator for transcription of the lacZ gene, We found that the purified CpdA protein repressed in vitro transcription from the lacP1 promoter by decreasing cAMP, In addition, we showed that the CpdA protein hydrolyzed cAMP to 5'-adenosine monophosphate and that its activity was activated by iron. Our results suggested that regulation of intracellular concentration of cAMP is dependent not only on synthesis of cAMP but also on hydrolysis of cAMP by cAMP phosphodiesterase.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,DEPT MOL CELL BIOL,KUMAMOTO 862,JAPAN; NATL INST GENET,DEPT MOL GENET,MISHIMA,SHIZUOKA 411,JAPAN	Kumamoto University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan			IMAMURA, Ryu/D-8433-2015	Ogura, Teru/0000-0003-3784-0970; Niki, Hironori/0000-0002-5391-6595				AIBA H, 1981, J BIOL CHEM, V256, P1905; AIBA H, 1985, J BIOL CHEM, V260, P3063; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BARTLETT DH, 1988, J BACTERIOL, V170, P1575, DOI 10.1128/jb.170.4.1575-1581.1988; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRANA H, 1965, FOLIA MICROBIOL, V11, P43; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DARI R, 1988, J BACTERIOL, V170, P65, DOI 10.1128/jb.170.1.65-70.1988; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GILBERT I, 1989, CURR MICROBIOL, V20, P83; HIRAGA S, 1989, J BACTERIOL, V171, P1496, DOI 10.1128/jb.171.3.1496-1505.1989; HUGHES P, 1988, CELL, V55, P343, DOI 10.1016/0092-8674(88)90057-8; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; IMAMURA R, 1992, RES MICROBIOL, V143, P743, DOI 10.1016/0923-2508(92)90102-T; JAFFE A, 1986, J BACTERIOL, V165, P66, DOI 10.1128/jb.165.1.66-71.1986; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P3873, DOI 10.1093/nar/11.12.3873; KATO J, 1990, CELL, V63, P393, DOI 10.1016/0092-8674(90)90172-B; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; KOMANO T, 1991, RES MICROBIOL, V142, P269, DOI 10.1016/0923-2508(91)90040-H; Miller J.H., 1972, EXPT MOL GENETICS; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MORI K, 1985, J BIOL CHEM, V260, P4838; Nakajima E, 1991, ANAL SCI, V7, P667, DOI 10.2116/analsci.7.Supple_667; NIELSEN LD, 1973, J BACTERIOL, V116, P857, DOI 10.1128/JB.116.2.857-866.1973; NIKI H, 1991, EMBO J, V10, P183, DOI 10.1002/j.1460-2075.1991.tb07935.x; REDDY P, 1985, P NATL ACAD SCI USA, V82, P8300, DOI 10.1073/pnas.82.24.8300; REDDY P, 1985, P NATL ACAD SCI USA, V82, P5656, DOI 10.1073/pnas.82.17.5656; REZNIKOFF WS, 1992, J BACTERIOL, V174, P655, DOI 10.1128/jb.174.3.655-658.1992; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIER MH, 1989, MICROBIOL REV, V53, P109, DOI 10.1128/MMBR.53.1.109-120.1989; Sambrook J., 2002, MOL CLONING LAB MANU; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STAHL FW, 1986, GENETICS, V113, P215; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; XING XF, 1991, J BACTERIOL, V173, P4570	41	83	88	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25423	25429		10.1074/jbc.271.41.25423	http://dx.doi.org/10.1074/jbc.271.41.25423			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810311	hybrid			2022-12-27	WOS:A1996VL69300055
J	Gilbert, M; Watson, DC; Cunningham, AM; Jennings, MP; Young, NM; Wakarchuk, WW				Gilbert, M; Watson, DC; Cunningham, AM; Jennings, MP; Young, NM; Wakarchuk, WW			Cloning of the lipooligosaccharide alpha-2,3-sialyltransferase from the bacterial pathogens Neisseria meningitidis and Neisseria gonorrhoeae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYLTRANSFERASE; EXPRESSION; GENES; LIPOPOLYSACCHARIDE; SYSTEM	The genes encoding the alpha-2,3-sialyltransferases involved in lipooligosaccharide biosynthesis from Neisseria meningitidis and Neisseria gonorrhoeae have been cloned and expressed in Escherichia coli, A high sensitivity enzyme assay using a synthetic fluorescent glycosyltransferase acceptor and capillary electrophoresis was used to screen a genomic library of N. meningitidis MC58 L3 in a ''divide and conquer'' strategy, The gene, denoted 1st, was found on a 2.0 kilobase fragment of DNA, and its sequence was determined and then used to design probes to amplify and subsequently clone the corresponding Ist genes from N. meningitidis 406Y L3, N. meningitidis M982B L7, and N. gonorrhoeae F62, Functional sialyltransferase was produced from the genes derived from both L3 N. meningitidis strains and the N. gonorrhoeae F62, However, the N. meningitidis M982B L7 gene contained a frameshift mutation that renders it inactive, The expression of the 1st gene was easily detected using the enzyme assay, and the protein expression could be detected when an immunodetection tag was added to the COOH-terminal end of the protein, Using the synthetic acceptor N-acetyllactosamineaminophenyl-(6-(5-(fluorescein-carboxamido)-hexanoic acid amide), the alpha-2,3 specificity of the enzyme was confirmed by NMR examination of the reaction product. The enzyme could also use synthetic accepters with lactose or galactose as the saccharide portion, This study is the first example of the cloning, expression, and examination of alpha-2,5-sialyltransferase activity from a bacterial source.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA,ON K1A 0R6,CANADA; JOHN RADCLIFFE HOSP,INST MOL MED,DEPT PAEDIAT,HEADINGTON OX3 9DU,OXFORD,ENGLAND	National Research Council Canada; University of Oxford			Wakarchuk, Warren/Q-9514-2017; Jennings, Michael P/G-4822-2013; Wakarchuk, Warren/AAO-2774-2020	Wakarchuk, Warren/0000-0002-1539-1679; Jennings, Michael P/0000-0002-1027-4684; Wakarchuk, Warren/0000-0002-1539-1679; Gilbert, Michel/0000-0002-0204-4408	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ASPINALL GO, 1994, BIOCHEMISTRY-US, V33, P241, DOI 10.1021/bi00167a032; BRAMLEY J, 1995, MICROB PATHOGENESIS, V18, P187, DOI 10.1016/S0882-4010(95)90040-3; GANGULI S, 1994, J BACTERIOL, V176, P4583, DOI 10.1128/JB.176.15.4583-4589.1994; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; MACKENZIE CR, 1994, BIO-TECHNOL, V12, P390, DOI 10.1038/nbt0494-390; MANDRELL RE, 1993, MICROB PATHOGENESIS, V14, P315, DOI 10.1006/mpat.1993.1031; MANDRELL RE, 1993, MICROB PATHOGENESIS, V14, P307, DOI 10.1006/mpat.1993.1030; MCLAUGHLIN R, 1992, J BACTERIOL, V174, P6455, DOI 10.1128/JB.174.20.6455-6459.1992; NAKAI K, 1991, PROTEINS, V11, P95, DOI 10.1002/prot.340110203; PAVLIAK V, 1993, J BIOL CHEM, V268, P14146; Rest RF, 1995, MICROB PATHOGENESIS, V19, P379, DOI 10.1006/mpat.1995.0073; Sambrook J., 2002, MOL CLONING LAB MANU; Smith H, 1995, MICROB PATHOGENESIS, V19, P365, DOI 10.1006/mpat.1995.0071; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Wakarchuk W, 1996, J BIOL CHEM, V271, P19166, DOI 10.1074/jbc.271.32.19166; WILLIAMS MA, 1995, GLYCOCONJUGATE J, V12, P755, DOI 10.1007/BF00731235; ZHAO JY, 1994, GLYCOBIOLOGY, V4, P239, DOI 10.1093/glycob/4.2.239	18	139	161	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28271	28276		10.1074/jbc.271.45.28271	http://dx.doi.org/10.1074/jbc.271.45.28271			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910446	hybrid			2022-12-27	WOS:A1996VU03300046
J	Inoue, G; Cheatham, B; Kahn, CR				Inoue, G; Cheatham, B; Kahn, CR			Different pathways of postreceptor desensitization following chronic insulin treatment and in cells overexpressing constitutively active insulin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR-I; DOWN-REGULATION; TRANSMEMBRANE DOMAIN; SOS-GRB2 COMPLEX; RAS ACTIVATION; S6 KINASE; SIGNAL; SHC; DISASSOCIATION	We have reported previously that substitution of the transmembrane domain of the insulin receptor with that of the erbB-2 oncogene (IR(erbV-->E)) results in constitutive activation of the insulin receptor kinase. Compared to NIH3T3 cells overexpressing wild-type insulin receptors (IR(wt)), cells overexpressing IR(erbV-->E) displayed a decrease in IRS-1 protein content by 55%, but basal tyrosine phosphorylation of IRS-1 was increased. This resulted in an increased association of IRS-1 with the p85 subunit of phosphatidylinositol 3-kinase, increased phosphatidylinositol 3-kinase activity in anti-IRS-1 immunoprecipitates, constitutive activation of p70 S6 protein kinase, and an increased association of Grb2 with She in the absence of Ligand. However, Grb2 association with IRS-1 could not be detected in the basal or insulin-stimulated states, and mitogen-activated protein kinase (MAPK) activity could not be stimulated by insulin, epidermal growth factor, or platelet-derived growth factor. In contrast to IR(erbV-->E), the insulin receptor content and its tyrosine phosphorylation were significantly decreased in IR(wt) cells chronically stimulated (>24 h) with insulin, With decreased IRS-1 content, tyrosine phosphorylation of IRS-1 was decreased by over 75%, leading to decreased IRS-1-associated PI 3-kinase and Grb2. In addition, Grb2 association with She and activation of MAPK and the p70 S6 kinase were insensitive to insulin stimulation, By contrast, association of Grb2 with She and activation of MAPK; but not the p70 S6 kinase, could be stimulated by epidermal growth factor or platelet-derived growth factor. These data suggest that there are multiple levels of postreceptor desensitization to insulin action. These are used somewhat differently in these two different models, probably due in part to the difference in receptor down-regulation.	BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228	NIDDK NIH HHS [DK 36836, DK 31036] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R37DK031036, R01DK031036] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; CHEATHAM B, 1993, P NATL ACAD SCI USA, V90, P7336, DOI 10.1073/pnas.90.15.7336; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GARVEY WT, 1985, J CLIN INVEST, V76, P22, DOI 10.1172/JCI111950; HOSOMI Y, 1994, J BIOL CHEM, V269, P11498; KENNER KA, 1993, J BIOL CHEM, V268, P25455; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; KNUTSON VP, 1991, J BIOL CHEM, V266, P15656; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MAEGAWA H, 1995, J BIOL CHEM, V270, P7724, DOI 10.1074/jbc.270.13.7724; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PILLAY TS, 1995, J BIOL CHEM, V270, P991, DOI 10.1074/jbc.270.3.991; REED DK, 1989, J BIOL CHEM, V264, P12673; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; RICE KM, 1992, J BIOL CHEM, V267, P10163; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; TAKAHASHI K, 1995, J BIOL CHEM, V270, P19041, DOI 10.1074/jbc.270.32.19041; UEKI K, 1994, J BIOL CHEM, V269, P15756; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WAY BA, 1993, J BIOL CHEM, V268, P26409; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMADA K, 1992, J BIOL CHEM, V267, P12452; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107	35	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28206	28211		10.1074/jbc.271.45.28206	http://dx.doi.org/10.1074/jbc.271.45.28206			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910437	hybrid			2022-12-27	WOS:A1996VU03300037
J	Ohtsu, H; Kuramasu, A; Suzuki, S; Igarashi, K; Ohuchi, Y; Sato, M; Tanaka, S; Nakagawa, S; Shirato, K; Yamamoto, M; Ichikawa, A; Watanabe, T				Ohtsu, H; Kuramasu, A; Suzuki, S; Igarashi, K; Ohuchi, Y; Sato, M; Tanaka, S; Nakagawa, S; Shirato, K; Yamamoto, M; Ichikawa, A; Watanabe, T			Histidine decarboxylase expression in mouse mast cell line P815 is induced by mouse peritoneal cavity incubation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONNECTIVE-TISSUE-TYPE; BINDING TRANSCRIPTION FACTORS; MASTOCYTOMA P-815 CELLS; LEUCINE ZIPPER PROTEIN; EMBRYONIC STEM-CELLS; C-KIT LIGAND; CARBOXYPEPTIDASE-A; FACTOR NF-E2; BONE-MARROW; ERYTHROID DEVELOPMENT	Phenotype of P815 mouse mast cells changes markedly during culture in the peritoneal cavity of syngenic BDF1 mice. The cells, cultured for 1 week in the peritoneal cavity of syngenic BDF1 mice, proliferate and express high levels of L-histidine decarboxylase (HDC) and mouse mast cell protease (MMCP)-6 mRNAs, indicating the ability of P815 cells to differentiate toward mature connective tissue mast cells. Peritoneal fluid aspirated from P815-inoculated BDF1 mouse and added to cultured P815 cells in vitro was also found to induce HDC mRNA expression, suggesting that at least some of the humoral factors in the peritoneal fluid induce HDC mRNA transcription, Among the erythroid transcription factors, P815 cells expressed GATA-2 but not GATA-1 mRNA before and after the intraperitoneal incubation. In contrast, the expression of NF-E2 subunit p45 disappeared, while expression of subunit mafK was markedly reduced after incubation. Cotransfection assays using HDC-luciferase reporter and p45 and/or mafK expression constructs showed that NF-E2 affects the transactivation of HDC gene, These results suggest that NF-E2 is also an important transcription factor in mast cell differentiation.	TOHOKU UNIV,SCH MED,DEPT INTERNAL MED 1,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; UNIV TSUKUBA,CTR TSUKUBA ADV RES ALLIANCE,DIV MOL & DEV BIOL,TSUKUBA,IBARAKI 305,JAPAN; KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 60601,JAPAN	Tohoku University; University of Tsukuba; Kyoto University	Ohtsu, H (corresponding author), TOHOKU UNIV,SCH MED,DEPT PHARMACOL 1,AOBA KU,2-1 SEIRYO MACHI,SENDAI,MIYAGI 98077,JAPAN.		Tanaka, Satoshi/H-6800-2019; TANAKA, Satoshi/B-1624-2011; Yamamoto, Masayuki/A-4873-2010	Tanaka, Satoshi/0000-0002-3468-7694; TANAKA, Satoshi/0000-0002-3468-7694; Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DENBURG JA, 1992, BLOOD, V79, P846; DUNN TB, 1957, J NATL CANCER I, V18, P587; EKLUND KK, 1993, J IMMUNOL, V151, P4266; GHILDYAL N, 1992, J IMMUNOL, V149, P2123; GHILDYAL N, 1993, J IMMUNOL, V151, P3206; GURISH MF, 1992, J EXP MED, V175, P1003, DOI 10.1084/jem.175.4.1003; HARA T, 1994, BLOOD, V84, P189; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; IHLE JN, 1983, J IMMUNOL, V131, P282; KASUGAI T, 1993, AM J PATHOL, V143, P1337; KITAMURA Y, 1979, NATURE, V281, P154, DOI 10.1038/281154a0; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.iy.07.040189.000423; KOBAYASHI T, 1986, J IMMUNOL, V136, P1378; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MCNEIL HP, 1992, J IMMUNOL, V149, P2466; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MORII E, 1994, BIOCHEM BIOPH RES CO, V205, P1299, DOI 10.1006/bbrc.1994.2806; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; OHGOH M, 1993, BIOCHEM BIOPH RES CO, V196, P1113, DOI 10.1006/bbrc.1993.2366; OHMORI E, 1990, J BIOCHEM, V107, P834, DOI 10.1093/oxfordjournals.jbchem.a123134; OHTANI H, 1992, J HISTOCHEM CYTOCHEM, V40, P1139, DOI 10.1177/40.8.1619278; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PEVNY L, 1995, DEVELOPMENT, V121, P163; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; Sambrook J., 2002, MOL CLONING LAB MANU; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1987, J IMMUNOL, V139, P3771; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; VALENT P, 1992, BLOOD, V80, P2237; Weiss DL, 1996, MOL CELL BIOL, V16, P228; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; YAMATODANI A, 1985, J CHROMATOGR, V344, P115, DOI 10.1016/S0378-4347(00)82012-5; ZON LI, 1991, J BIOL CHEM, V266, P22948	44	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28439	28444		10.1074/jbc.271.45.28439	http://dx.doi.org/10.1074/jbc.271.45.28439			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910469	hybrid			2022-12-27	WOS:A1996VU03300069
J	Kramer, RM; Roberts, EF; Um, SL; BorschHaubold, AG; Watson, SP; Fisher, MJ; Jakubowski, JA				Kramer, RM; Roberts, EF; Um, SL; BorschHaubold, AG; Watson, SP; Fisher, MJ; Jakubowski, JA			p38 Mitogen-activated protein kinase phosphorylates cytosolic phospholipase A(2) (cPLA(2)) in thrombin-stimulated platelets - Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR AGONIST PEPTIDE; MAP KINASE; PHOSPHATIDIC-ACID; RELEASE; METABOLISM; INHIBITOR; PHOSPHATIDYLINOSITOL; INTERLEUKIN-1; LIBERATION; COLLAGEN	The Ca2+-sensitive 85-kDa cytosolic phospholipase A(2) (cPLA(2)) is responsible for thrombin-stimulated mobilization of arachidonic acid for the synthesis of thromboxane A(2) in human platelets, We have previously shown that thrombin activates p38 kinase, a recently discovered new member of the mitogen activated protein kinase family (Kramer, R. M., Roberts, E. F., Strifler, B. A., and Johnstone, E. M. (1995) J. Biol. Chem. 270, 27395-27398) and also induces phosphorylation of cPLA(2), thereby increasing its intrinsic catalytic activity, In the present study we have examined the role of p38 kinase in the phosphorylation and activation of cPLA(2) in stimulated platelets, We have observed that activation of p38 kinase accompanies receptor-mediated events in platelets and coincides with cPLA(2) phosphorylation, Furthermore, in the presence of inhibitors of p38 kinase, the proline-directed phosphorylation of cPLA(2) was completely blocked in platelets stimulated with the thrombin receptor agonist peptide SFLLRN and was suppressed during the early (up to 2 min) phase of platelet stimulation caused by thrombin, Unexpectedly, we found that prevention of proline-directed phosphorylation of cPLA(2) in stimulated platelets did not attenuate its ability to release arachidonic acid from platelet phospholipids, We conclude that: 1) cPLA(2) is a physiological target of p38 kinase; 2) p38 kinase is involved in the early phosphorylation of cPLA(2) in stimulated platelets; and 3) proline-directed phosphorylation of cPLA(2) is not required for its receptor-mediated activation.	UNIV OXFORD,OXFORD OX1 3QT,ENGLAND	University of Oxford	Kramer, RM (corresponding author), ELI LILLY & CO,LILLY RES LABS,CARDIOVASC RES,INDIANAPOLIS,IN 46285, USA.		Watson, Stephen P/Q-6292-2016	Watson, Stephen P/0000-0002-7846-7423				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ADAMS JL, 1993, Patent No. 9314081; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BEST LC, 1979, BIOCHIM BIOPHYS ACTA, V583, P344, DOI 10.1016/0304-4165(79)90458-6; BorschHaubold AG, 1996, BIOCHEM J, V318, P207; BORSCHHAUBOLD AG, 1995, J BIOL CHEM, V270, P25885, DOI 10.1074/jbc.270.43.25885; BROEKMAN MJ, 1986, J LIPID RES, V27, P884; BROEKMAN MJ, 1980, J CLIN INVEST, V66, P275, DOI 10.1172/JCI109854; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; HUI KY, 1992, BIOCHEM BIOPH RES CO, V184, P790, DOI 10.1016/0006-291X(92)90659-9; JAKUBOWSKI JA, 1985, BRIT J HAEMATOL, V60, P635, DOI 10.1111/j.1365-2141.1985.tb07467.x; KEHREL B, 1995, PLATELETS, V6, P11, DOI 10.3109/09537109509013256; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRAMER RM, 1995, J BIOL CHEM, V270, P14816, DOI 10.1074/jbc.270.24.14816; KRAMER RM, 1994, SIGNAL ACTIVATED PHO, P13; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lundblad R L, 1976, Methods Enzymol, V45, P156; MCKEAN ML, 1981, J BIOL CHEM, V256, P1522; NEUFELD EJ, 1983, J BIOL CHEM, V258, P2461; PURDON AD, 1987, BIOCHIM BIOPHYS ACTA, V920, P205, DOI 10.1016/0005-2760(87)90096-8; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; RITTENHOUSE SE, 1982, J CLIN INVEST, V70, P1216, DOI 10.1172/JCI110720; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SMITH JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P344, DOI 10.1016/0005-2760(85)90290-5	39	418	427	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27723	27729		10.1074/jbc.271.44.27723	http://dx.doi.org/10.1074/jbc.271.44.27723			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910365	hybrid			2022-12-27	WOS:A1996VQ67900083
J	Nagahara, N; Nishino, T				Nagahara, N; Nishino, T			Role of amino acid residues in the active site of rat liver mercaptopyruvate sulfurtransferase - cDNA cloning, overexpression, and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODANESE; BOVINE; SEQUENCE; EXPRESSION; PROTEIN; SULFUR; CATALYSIS; COVALENT	A complete amino acid structure of rat liver mercaptopyruvate sulfurtransferase (MST, EC 2.8.1.2) was determined by sequence analysis of cDNA and purified enzyme. The enzyme consists of 296 amino acid residues with a calculated molecular mass of 32,808 Da, Sequence identity in cDNA and the deduced amino acid sequence are 65 and 60% respectively, between rat MST and rhodanese. By their entire sequence similarity MST and rhodanese are confirmed to be evolutionarily related enzymes (Nagahara, N., Okazaki, T., and Nishino, T. (1995) J. Biol. Chem, 270, 16230-16235), The conversion of MST to rhodanese was attempted, and the role of amino acid residues was studied by site-directed mutagenesis with the isolated cDNA of rat liver MST, There is a strong possibility that Cys(247) is a catalytic site of MST. Arg(187) is suggested to be a binding site of both mercaptopyruvate and thiosulfate in MST. Arg(196), which is missed in rhodanese, is important for catalysis in MST, On the other hand, the substitution of Arg for Gly(248) Or Lys for Ser(249) facilitates catalysis of thiosulfate in MST. It is concluded that Arg(187) and Arg(196) of rat MST are critical residues in determining substrate specificity for mercaptopyruvate. On the other hand, Arg(185), Arg(247), and Lys(248) of rat rhodanese are critical residues in determining substrate specificity for thiosulfate.			Nagahara, N (corresponding author), NIPPON MED COLL, DEPT BIOCHEM & MOL BIOL, BUNKYO KU, 1-1-5 SENDAGI, TOKYO 113, JAPAN.							CANNELLA C, 1975, EUR J BIOCHEM, V56, P283, DOI 10.1111/j.1432-1033.1975.tb02231.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cleland W. W, 1970, ENZYMES, V2, P1; DOOLEY TP, 1995, BIOCHEM BIOPH RES CO, V216, P1101, DOI 10.1006/bbrc.1995.2734; DUVE CD, 1955, BIOCHEM J, V60, P604, DOI 10.1042/bj0600604; HAMA H, 1994, J BIOCHEM-TOKYO, V115, P1135, DOI 10.1093/oxfordjournals.jbchem.a124469; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HOROWITZ P, 1970, J BIOL CHEM, V245, P984; JARABAK R, 1978, ARCH BIOCHEM BIOPHYS, V185, P458, DOI 10.1016/0003-9861(78)90189-3; KOHANSKI RA, 1990, J PROTEIN CHEM, V9, P369, DOI 10.1007/BF01024612; KOJ, 1968, ACTA BIOCHIM POL, V15, P161; KUN E, 1959, BIOCHIM BIOPHYS ACTA, V33, P26, DOI 10.1016/0006-3002(59)90493-7; KUN E, 1957, BIOCHIM BIOPHYS ACTA, V25, P135, DOI 10.1016/0006-3002(57)90429-8; KUN E, 1959, BIOCHIM BIOPHYS ACTA, V32, P338, DOI 10.1016/0006-3002(59)90605-5; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang K, 1933, BIOCHEM Z, V259, P243; LUDEWIG S, 1950, ARCH BIOCHEM, V29, P441; LUO GX, 1994, J BIOL CHEM, V269, P8220; MEISTER A, 1954, J BIOL CHEM, V206, P561; Meister A., 1953, FED PROC, V12, P245; MILLER DM, 1992, BIOCHIM BIOPHYS ACTA, V1121, P286, DOI 10.1016/0167-4838(92)90158-A; MILLER DM, 1991, J BIOL CHEM, V266, P4686; NAGAHARA N, 1995, J BIOL CHEM, V270, P16230, DOI 10.1074/jbc.270.27.16230; Nishino T, 1986, Adv Exp Med Biol, V195 Pt B, P259; PALLINI R, 1991, BIOCHEM BIOPH RES CO, V180, P887, DOI 10.1016/S0006-291X(05)81148-9; PLOEGMAN JH, 1978, J MOL BIOL, V123, P557, DOI 10.1016/0022-2836(78)90207-3; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; RUSSELL J, 1978, J BIOL CHEM, V253, P8102; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHLESINGER P, 1974, J BIOL CHEM, V249, P780; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SORBO B, 1954, ACTA CHEM SCAND, V8, P694, DOI 10.3891/acta.chem.scand.08-0694; SORBO B, 1957, ACTA CHEM SCAND, V11, P628, DOI 10.3891/acta.chem.scand.11-0628; SORBO B, 1957, BIOCHIM BIOPHYS ACTA, V24, P324, DOI 10.1016/0006-3002(57)90201-9; SORBO B, 1960, BIOCHIM BIOPHYS ACTA, V38, P349, DOI 10.1016/0006-3002(60)91255-5; Sorbo B., 1975, METABOLIC PATHWAYS, VVII, P433; SORBO BH, 1951, ACTA CHEM SCAND, V5, P724, DOI 10.3891/acta.chem.scand.05-0724; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1137, DOI 10.3891/acta.chem.scand.07-1137; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TANIGUCHI T, 1974, BIOCHIM BIOPHYS ACTA, V364, P284, DOI 10.1016/0005-2744(74)90014-X; TREVINO RJ, 1995, PROTEIN EXPRES PURIF, V6, P693, DOI 10.1006/prep.1995.1091; VACHEK H, 1972, BIOCHIM BIOPHYS ACTA, V258, P133, DOI 10.1016/0005-2744(72)90973-4; VILLAREJO M, 1963, J BIOL CHEM, V238, P1185; WASYLEWSKI Z, 1979, B ACAD POL SCI BIOL, V27, P807; WEILAND KL, 1991, BIOCHEM J, V275, P227, DOI 10.1042/bj2750227; WENG L, 1978, J BIOL CHEM, V253, P8109; WESTLEY J, 1971, J BIOL CHEM, V246, P1468; WOOD JL, 1953, J BIOL CHEM, V205, P231	50	88	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27395	27401		10.1074/jbc.271.44.27395	http://dx.doi.org/10.1074/jbc.271.44.27395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910318	hybrid			2022-12-27	WOS:A1996VQ67900036
J	Trombetta, ES; Simons, JF; Helenius, A				Trombetta, ES; Simons, JF; Helenius, A			Endoplasmic reticulum glucosidase II is composed of a catalytic subunit, conserved from yeast to mammals, and a tightly bound noncatalytic HDEL-containing subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE ISOMERASE; TRYPANOSOMATID PROTOZOA; MOLECULAR CHAPERONE; BINDING PROTEINS; GLYCOPROTEIN; OLIGOSACCHARIDE; CALRETICULIN; CALNEXIN; SEQUENCE; GLYCOSYLATION	Trimming of glucoses from N-linked core glycans on newly synthesized glycoproteins occurs sequentially through the action of glucosidases I and II in the endoplasmic reticulum (ER), We isolated enzymatically active glucosidase II from rat liver and found that, in contrast with previous reports, it contains two subunits (alpha and beta), Sequence analysis of peptides derived from them allowed us to identify their corresponding human cDNA sequences, The sequence of the alpha subunit predicted a soluble protein (104 kDa) devoid of known signals for residence in the ER, It showed homology with several other glucosidases but not with glucosidase I. Among the homologues, we identified a Saccharomyces cerevisiae gene, which we showed by gene disruption experiments to be the functional catalytic subunit of glucosidase II. The disrupted yeast strains had no detectable growth defect, The sequence of the beta subunit (58 kDa) showed no sequence homology with other known proteins, It encoded a soluble protein rich in glutamic and aspartic acid with a putative ER retention signal (HDEL) at the C terminus, This suggested that the beta subunit is responsible for the ER localization of the enzyme.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06520 USA	Yale University					NIGMS NIH HHS [GM 55972] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM055972] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOSCH M, 1988, J BIOL CHEM, V263, P17360; BRADA D, 1984, EUR J BIOCHEM, V141, P149, DOI 10.1111/j.1432-1033.1984.tb08169.x; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BURNS DM, 1982, J BIOL CHEM, V257, P9991; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ESMON B, 1984, J BIOL CHEM, V259, P322; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; Fleischer S, 1974, Methods Enzymol, V31, P6; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HERSCOVICS A, 1987, ANAL BIOCHEM, V166, P85, DOI 10.1016/0003-2697(87)90550-1; HINO Y, 1985, BIOCHEMISTRY-US, V24, P800, DOI 10.1021/bi00324a040; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; KALZFULLER B, 1995, EUR J BIOCHEM, V231, P344, DOI 10.1111/j.1432-1033.1995.tb20706.x; KAUSHAL GP, 1990, J BIOL CHEM, V265, P16271; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kreibich G, 1974, Methods Enzymol, V31, P215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; RAY MK, 1991, J BIOL CHEM, V266, P22818; REITMAN ML, 1982, J BIOL CHEM, V257, P357; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA I, 1995, J BIOL CHEM, V270, P20298, DOI 10.1074/jbc.270.35.20298	49	193	201	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27509	27516		10.1074/jbc.271.44.27509	http://dx.doi.org/10.1074/jbc.271.44.27509			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910335	hybrid			2022-12-27	WOS:A1996VQ67900053
J	Winitz, D; Shachar, I; Elkabetz, Y; Amitay, R; Samuelov, M; BarNun, S				Winitz, D; Shachar, I; Elkabetz, Y; Amitay, R; Samuelov, M; BarNun, S			Degradation of distinct assembly forms of immunoglobulin M occurs in multiple sites in permeabilized B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASIALOGLYCOPROTEIN RECEPTOR SUBUNITS; LIVER ENDOPLASMIC-RETICULUM; RETINOL-BINDING PROTEIN; PRE-GOLGI COMPARTMENT; SECRETORY PATHWAY; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE; INTRACELLULAR DEGRADATION; CYSTEINE PROTEASE; APOLIPOPROTEIN-B; LYMPHOCYTES-B	Protein degradation is essential for quality control which retains and eliminates abnormal, unfolded, or partially assembled subunits of oligomeric proteins, The localization of this nonlysosomal pre-Golgi degradation to the endoplasmic reticulum (ER) has been mostly deduced from kinetic studies and carbohydrate analyses, while direct evidence for degradation within the ER has been provided by in vitro reconstitution of this process. In this article, we took advantage of the transport incompetence of permeabilized cells to directly demonstrate that the selective degradation of secretory IgM (sIgM) in B lymphocytes is transport-dependent, We show that, upon permeabilization of the plasma membrane with either streptolysin O or digitonin, sIgM is not degraded unless transport is allowed, Nevertheless, upon complete reduction of interchain disulfide bonds with thiols, the free mu heavy chains are degraded by a transport-independent quality control mechanism within the ER. This latter degradation is nonselective to the secretory heavy chain mu s, and the membrane heavy chain mu m, which is normally displayed on the surface of the B cell, is also eliminated. Moreover, the degradation of free mu s is no longer restricted to B lymphocytes, and it takes place also in the ER of plasma cells which normally secrete polymers of sIgM, Conversely, when assembled with the light chain, the degradation is selective to sIgM, is restricted to B lymphocytes, and is a transport-dependent post-ER event.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University								ADELI K, 1994, J BIOL CHEM, V269, P9166; ALBERINI CM, 1990, NATURE, V347, P485, DOI 10.1038/347485a0; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; AMITAY R, 1991, J BIOL CHEM, V266, P12568; AMITAY R, 1992, J BIOL CHEM, V267, P20694; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BREWER JW, 1994, J BIOL CHEM, V269, P17338; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; DULIS BH, 1982, J BIOL CHEM, V257, P4369; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GUENZI S, 1994, EUR J IMMUNOL, V24, P2477, DOI 10.1002/eji.1830241033; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HAYASHI SI, 1995, BIOCHEM J, V306, P1; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; INOUE S, 1991, J BIOL CHEM, V266, P13311; KAJI EH, 1993, J BIOL CHEM, V268, P22195; KAJI EH, 1993, J BIOL CHEM, V268, P22188; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LE A, 1990, J BIOL CHEM, V265, P14001; LODISH HF, 1993, J BIOL CHEM, V268, P20598; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; MELNICK J, 1992, J BIOL CHEM, V267, P21303; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PLUNTER H, 1992, J CELL BIOL, V119, P1097; RABINOVICH E, 1993, J BIOL CHEM, V268, P24145; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHIMKE RT, 1973, ADV ENZYMOL RAMB, V37, P135; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SHACHAR I, 1994, J BIOL CHEM, V269, P27344; SIDMAN C, 1981, CELL, V23, P379, DOI 10.1016/0092-8674(81)90133-1; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; STAFFORD FJ, 1991, J CELL BIOL, V115, P1225, DOI 10.1083/jcb.115.5.1225; TAN A, 1992, J CELL BIOL, V116, P1357, DOI 10.1083/jcb.116.6.1357; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; TSAO YS, 1992, J CELL BIOL, V116, P57, DOI 10.1083/jcb.116.1.57; URADE R, 1992, J BIOL CHEM, V267, P15152; URADE R, 1993, J BIOL CHEM, V268, P22004; VALETTI C, 1994, MOL BIOL CELL, V5, P1311, DOI 10.1091/mbc.5.12.1311; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILEMAN T, 1991, CELL REGUL, V2, P753, DOI 10.1091/mbc.2.9.753; YE SQ, 1993, J BIOL CHEM, V268, P8497	63	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27645	27651		10.1074/jbc.271.44.27645	http://dx.doi.org/10.1074/jbc.271.44.27645			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910354	hybrid			2022-12-27	WOS:A1996VQ67900072
J	Crawford, LE; Milliken, EE; Irani, K; Zweier, JL; Becker, LC; Johnson, TM; Eissa, NT; Crystal, RG; Finkel, T; GoldschmidtClermont, PJ				Crawford, LE; Milliken, EE; Irani, K; Zweier, JL; Becker, LC; Johnson, TM; Eissa, NT; Crystal, RG; Finkel, T; GoldschmidtClermont, PJ			Superoxide mediated actin response in post-hypoxic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; TYROSINE KINASE; STRESS FIBERS; PROTEIN; RECEPTOR; REOXYGENATION; ANGIOGENESIS; STIMULATION; GENERATION; MECHANISM	The mechanism leading to changes in the superstructure of endothelial cells exposed to ischemia and reperfusion remains uncharacterized, We show that in posthypoxic endothelial cells, the simple re-addition of oxygen induces a profound reorganization of the actin cytoskeleton. The total filamentous actin pool increases by 41% and translocation of actin filaments to the submembranous network is observed, Concurrent with the actin polymerization, increased tyrosine phosphorylation of endothelial cell substrates is detected on Western blots. Overexpression of superoxide dismutase using replication incompetent adenovirus inhibits the actin and tyrosine phosphorylation responses to reoxygenation. Inhibition of tyrosine kinases with the isoflavone genistein also suppressed the actin polymerization response to reoxygenation, but unlike superoxide dis mutase, genistein also induced the collapse of the superstructure of endothelial cells upon reoxygenation. These experiments support the concept that reoxygenation following a period of hypoxia can induce the remodeling of the actin cytoskeleton in endothelial cells, Such a response requires the intact coupling of superoxide producing pathway(s) with tyrosine kinase pathway(s).	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205; NHLBI,CARDIOL BRANCH,NIH,BETHESDA,MD 20892; NHLBI,PULM & CRIT CARE BRANCH,NIH,BETHESDA,MD 20892; CORNELL UNIV,MED CTR,PULM & CRIT CARE BRANCH,NEW YORK,NY 10021	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Cornell University				Irani, Kaikobad/0000-0001-9194-7387	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52315] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FINKEL T, 1994, P NATL ACAD SCI USA, V91, P1510, DOI 10.1073/pnas.91.4.1510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FURMAN MI, 1994, CIRC RES, V75, P172, DOI 10.1161/01.RES.75.1.172; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HEINTZ D, 1994, EUR J BIOCHEM, V223, P345, DOI 10.1111/j.1432-1033.1994.tb19000.x; HELDMAN AW, 1996, IN PRESS CIRC RES, V78; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JONOS N, 1979, CELL, V17, P683; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LI J, 1995, CIRCULATION, V92, P713; LUM H, 1992, CIRC RES, V70, P991, DOI 10.1161/01.RES.70.5.991; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OMANN GM, 1994, ARCH BIOCHEM BIOPHYS, V308, P407, DOI 10.1006/abbi.1994.1057; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SULCINER DJ, 1996, BIOCHEM J, V318, P379; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; WALTENBERGER J, 1995, CIRCULATION, V92, P749; ZWEIER JL, 1994, J BIOL CHEM, V269, P24156	29	80	80	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26863	26867		10.1074/jbc.271.43.26863	http://dx.doi.org/10.1074/jbc.271.43.26863			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900169	hybrid			2022-12-27	WOS:A1996VP23300063
J	Harant, H; deMartin, R; Andrew, PJ; Foglar, E; Dittrich, C; Lindley, IJD				Harant, H; deMartin, R; Andrew, PJ; Foglar, E; Dittrich, C; Lindley, IJD			Synergistic activation of interleukin-8 gene transcription by all-trans-retinoic acid and tumor necrosis factor-alpha involves the transcription factor NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR MECHANISM; ENDOTHELIAL-CELLS; IL-8 EXPRESSION; OCTAMER MOTIF; MESSENGER-RNA; RECEPTOR; BINDING; FIBROBLASTS; INDUCTION; PROMOTER	Induction of interleukin-8 (IL-8) by IL-1 or tumor necrosis factor (TNF), and repression by interferons or glucocorticoids have been shown to involve sequences between nucleotides -94 and -71 of the 5'-flanking region, and the transcription factors NF-IL-6 and NF-kappa B. The A3 cell line was derived from the human melanoma cell line G-361 by stable transfection with part of the IL-8 promoter (nucleotides -101 to +40 from transcription start) fused to the luciferase coding region. These regulatory sequences were sufficient for transcriptional activation by all-trans-retinoic acid (ATRA), 9-cis-retinoic acid, IL-1 beta, or TNF-alpha. Simultaneous treatment of A3 cells with ATRA and TNF-alpha resulted in a dose- and time-dependent synergistic increase in luciferase expression and IL-8 mRNA levels. Transient transfections of the parental cell line demonstrated that the NF-kappa B binding site is essential for this synergistic transactivation. Electrophoretic mobility shift assays with nuclear extracts of A3 cells showed that stimulation with ATRA and TNF-alpha for more than 16 h resulted in enhanced NF-kappa B binding compared to that induced by TNF-alpha alone. The simultaneous treatment with ATRA and TNF-alpha also resulted in changes in the composition of NF-kappa B complexes bound to the IL-8 NF-kappa B site, preventing the formation of two TNF-alpha-inducible binding activities. We suggest that these complexes consist of repressive factors which, when removed, allow enhanced binding of NF-kappa B to its cognate site.	KAISER FRANZ JOSEF HOSP,LUDWIG BOLTZMANN INST APPL CANC RES,A-1100 VIENNA,AUSTRIA; VIENNA INT RES COOPERAT CTR,DEPT VASC BIOL & THROMBOSIS RES,A-1235 VIENNA,AUSTRIA	Kaiser-Franz-Josef Hospital; Ludwig Boltzmann Institute	Harant, H (corresponding author), SANDOZ GMBH,RES INST,DEPT GEN DERMATOL,BRUNNER STR 59,A-1235 VIENNA,AUSTRIA.		Hanna, Harant/AAA-7120-2022	Hanna, Harant/0000-0003-3842-0249				ANDREW PJ, 1995, BIOCHEM BIOPH RES CO, V214, P949, DOI 10.1006/bbrc.1995.2378; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ATKINS KB, 1995, BLOOD, V86, P2475; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; BENBROOK D, 1988, NATURE, V333, P669, DOI 10.1038/333669a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRABTREE JE, 1994, J CLIN PATHOL, V47, P61, DOI 10.1136/jcp.47.1.61; DEGRAZIA U, 1994, J EXP MED, V180, P1485, DOI 10.1084/jem.180.4.1485; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; FELLI MP, 1991, MOL CELL BIOL, V11, P4771, DOI 10.1128/MCB.11.9.4771; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HARANT H, 1995, BIOCHEM BIOPH RES CO, V210, P898, DOI 10.1006/bbrc.1995.1742; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; KUNSCH C, 1994, J IMMUNOL, V153, P153; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; LINDLEY IJD, 1993, IMMUNOL TODAY, V14, P24; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; Mangelsdorf David J., 1994, P319; MIELKE V, 1990, J IMMUNOL, V144, P153; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; OKAMOTO S, 1993, ADV EXP MED BIOL, V351, P87; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; TAKASHIBA S, 1992, INFECT IMMUN, V60, P5253, DOI 10.1128/IAI.60.12.5253-5258.1992; VANDAMME J, 1991, CYTOKINE HDB IMMUNOL, P201; YANG KD, 1993, PEDIATR RES, V34, P720, DOI 10.1203/00006450-199312000-00005; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG QY, 1992, J IMMUNOL, V149, P1402	46	90	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26954	26961		10.1074/jbc.271.43.26954	http://dx.doi.org/10.1074/jbc.271.43.26954			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900181				2022-12-27	WOS:A1996VP23300075
J	Lee, SF; Egelhoff, TT; Mahasneh, A; Cote, GP				Lee, SF; Egelhoff, TT; Mahasneh, A; Cote, GP			Cloning and characterization of a Dictyostelium myosin I heavy chain kinase activated by Cdc42 and Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ACANTHAMOEBA-CASTELLANII; SUBCELLULAR-LOCALIZATION; CELL-GROWTH; RHO-FAMILY; PHOSPHORYLATION; PURIFICATION; GTPASES; YEAST; DISCOIDEUM	The motile activities of the small, single-headed class I myosins (myosin I) from the lower eukaryotes Acanthamoeba and Dictyostelium are activated by phosphorylation of a single serine or threonine residue in the head domain of the heavy chain, Recently, we purified a myosin I heavy chain kinase (MIHCK) from Dictyostelium based on its ability to activate the Dictyostelium myosin ID isozyme (Lee, S.-F., and Cote, G. P. (1995) J. Biol. Chem. 270, 11776-11782). The complete sequence of the Dictyostelium MIHCK has now been determined, revealing a protein of 98 kDa that is composed of an amino-terminal domain rich in proline, glutamine, and serine, a putative Cdc42/Rac binding motif, and a carboxyl-terminal kinase catalytic domain, MIHCK shares significant sequence identity with the Saccharomyces cerevisiae Ste20p kinase and the mammalian p21-activated kinase, Gel overlay assays and affinity chromatography experiments showed that MIHCK interacted with GTP gamma S (guanosine 5'-3-O-(thiotriphosphate))-labeled Cdc42 and Rac1 but not RhoA, In the presence of GTP gamma S-Rac1 MIHCK autophosphorylation increased from 1 to 9 mol of phosphate/mol, and the rate of Dictyostelium myosin ID phosphorylation was stimulated 10-fold, MIHCK may therefore provide a direct link between Cdc42/Rac signaling pathways and motile processes driven by myosin I molecules.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; CASE WESTERN RESERVE UNIV, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Queens University - Canada; Case Western Reserve University			Mahasneh, Amjad/AAA-1732-2022	Mahasneh, Amjad/0000-0002-4931-8699	NIGMS NIH HHS [GM50009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050009, R29GM050009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; BUSH J, 1993, GENE, V136, P61, DOI 10.1016/0378-1119(93)90448-C; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COTE GP, 1985, J BIOL CHEM, V260, P4543; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Drouin G, 1995, J MOL EVOL, V41, P841, DOI 10.1007/BF00173163; FUJISAKI H, 1985, J BIOL CHEM, V260, P1183; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HAMMER JA, 1984, J BIOL CHEM, V259, P3224; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HATZ P, 1994, J BIOL CHEM, V269, P16802; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMA K, 1995, J MOL EVOL, V41, P238; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1995, MOL BIOL CELL, V6, P863; LEE SF, 1993, J BIOL CHEM, V268, P20923; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MANSER E, 1996, METHOD ENZYMOL, V256, P215; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RUPPERT C, 1995, J CELL SCI, V108, P3775; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZOT HG, 1992, J CELL BIOL, V116, P367, DOI 10.1083/jcb.116.2.367	50	77	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27044	27048		10.1074/jbc.271.43.27044	http://dx.doi.org/10.1074/jbc.271.43.27044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900194	hybrid			2022-12-27	WOS:A1996VP23300088
J	Yuan, ZM; Huang, YY; Fan, MM; Sawyers, C; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Fan, MM; Sawyers, C; Kharbanda, S; Kufe, D			Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; 1-BETA-D-ARABINOFURANOSYLCYTOSINE INCORPORATION; DNA; BINDING; PHOSPHORYLATION; GROWTH; ONCOPROTEIN; ACTIVATION; ELONGATION; INHIBITION	The function of the c-Abl protein tyrosine kinase is unknown. The present studies demonstrate that the antimetabolite 1-beta-D-arabinofuranosylcytosine (ara-C) induces binding of c-Abl and p53. Ara-C treatment of cells that express wild type or a dominant negative, kinase-inactive c-Abl(K-R) was associated with formation of c-Abl-p53 complexes and increased expression of the cyclin dependent kinase (Cdk) inhibitor p21. However, down-regulation of Cdk2 by ara-C was found in cells expressing wild type c-Abl and not in cells expressing c-Abl(K-R) or those deficient in p53. Similar findings were obtained following treatment of cells with the alkylating agent methyl methanesulfonate (RIMS). Cells that express the c-Abl dominant negative or are null for c-Abl exhibited partial abrogation of Cdk2 down-regulation and G1 arrest in response to RIMS exposure, Cells lacking the c-abl gene also responded to ara-C and RIMS with increases in p53 levels and induction of p21. These findings indicate that the cellular response to certain genotoxic drugs involves binding of c-Abl to p53 and down-regulation of Cdk2 by a c-Abl kinase/p53-dependent mechanism.	UNIV CALIF LOS ANGELES,INST MOL BIOL,DEPT MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles	Yuan, ZM (corresponding author), HARVARD UNIV,SCH MED,DIV CANC PHARMACOL,DANA FARBER CANC INST,BOSTON,MA 02115, USA.		Sawyers, Charles/G-5327-2016		NCI NIH HHS [CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GOGA A, 1995, ONCOGENE, V11, P791; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HIRANO Y, 1995, ONCOGENE, V10, P1879; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MATTIONI T, 1995, ONCOGENE, V10, P1325; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; OHNO Y, 1988, CANCER RES, V48, P1494; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	33	65	66	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26457	26460		10.1074/jbc.271.43.26457	http://dx.doi.org/10.1074/jbc.271.43.26457			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900110	hybrid			2022-12-27	WOS:A1996VP23300004
J	Braun, JEA; Wilbanks, SM; Scheller, RH				Braun, JEA; Wilbanks, SM; Scheller, RH			The cysteine string secretory vesicle protein activates hsc70 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; LAMBDA-DNA-REPLICATION; NUCLEOPROTEIN STRUCTURES; BACTERIOPHAGE-LAMBDA; MOLECULAR CHAPERONE; UNFOLDED PROTEINS; UNCOATING ATPASE; PEPTIDE BINDING; CLATHRIN COATS; HUMAN HOMOLOG	Cysteine string protein (CSP) is a 34 kDa secretory vesicle protein bearing a ''J-domain'' as well as a palmitoylated cysteine-rich ''string'' region used for membrane attachment. Mutation of the CSP gene causes impaired presynaptic neuromuscular transmission in Drosophila melanogaster, implicating CSP as part of the exocytotic protein machinery. The J-domain of CSP shares homology with the universally conserved DnaJ family, a group of proteins that act as co-chaperones with Hsc70 and its homologs. Hsc70 is an abundant neural protein with coupled protein binding and ATPase activities. We have investigated the CSP modulation of Hsc70 ATPase activity. Here we demonstrated that CSP enhances Hsc70 ATPase activity in a dose-dependent manner. CSP activation of Hsc70 was maximal (similar to 12 times) at 1:1 stoichiometry and above. We show that a J-domain-containing fragment (amino acids 1-82) of CSP is sufficient for the activation of Hsc70. Neither CSP nor the amino-terminal fragment stimulate the activity of the isolated Hsc70 ATPase domain (amino acids 1-386). CSP does not significantly increase the activity of N-ethylmaleimide-sensitive fusion protein, another ATPase required for transport vesicle function. Our results suggest that CSP, a DnaJ family member associated with the secretory vesicle cycle regulates Hsc70 functions. Hsc70 may function within the biochemical pathways of exo- and endocytosis to promote the formation or dissociation of multimeric complexes or to regulate conformational changes.	STANFORD UNIV,MED CTR,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University	Braun, JEA (corresponding author), STANFORD UNIV,MED CTR,DEPT MOL & CELLULAR PHYSIOL,HOWARD HUGHES MED INST,STANFORD,CA 94305, USA.			Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039928] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-39928] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ALFANO C, 1989, J BIOL CHEM, V264, P10709; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRAELL WA, 1984, J CELL BIOL, V99, P734, DOI 10.1083/jcb.99.2.734; BRAUN JEA, 1995, NEUROPHARMACOLOGY, V34, P1361, DOI 10.1016/0028-3908(95)00114-L; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHELLAIAH A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P111, DOI 10.1016/0167-4781(93)90103-K; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CYR DM, 1992, J BIOL CHEM, V267, P20927; CYR DM, 1994, J BIOL CHEM, V269, P9798; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; DODSON M, 1989, J BIOL CHEM, V264, P10719; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FOURIE AM, 1994, J BIOL CHEM, V269, P30470; GAO BC, 1994, BIOCHEMISTRY-US, V33, P2048, DOI 10.1021/bi00174a010; HA JH, 1994, BIOCHEMISTRY-US, V33, P14625, DOI 10.1021/bi00252a031; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; Kee Y, 1996, J NEUROSCI, V16, P1975; KOHAN SA, 1995, J NEUROSCI, V15, P6230; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MORGAN A, 1994, J BIOL CHEM, V269, P29347; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OBRIEN MC, 1993, J BIOL CHEM, V268, P24323; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERSNER J, 1994, NEURON, V13, P353; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHELLER RH, 1995, NEURON, V14, P893; SCHLOSSMAN DM, 1984, J CELL BIOL, V99, P723, DOI 10.1083/jcb.99.2.723; SUGITO K, 1995, FEBS LETT, V358, P161, DOI 10.1016/0014-5793(94)01417-Y; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Takeda S, 1996, BIOCHEMISTRY-US, V35, P4636, DOI 10.1021/bi952903o; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZYLICZ M, 1988, BIOCHIM BIOPHYS ACTA, V951, P344, DOI 10.1016/0167-4781(88)90105-4; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	47	124	126	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25989	25993		10.1074/jbc.271.42.25989	http://dx.doi.org/10.1074/jbc.271.42.25989			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824236	hybrid			2022-12-27	WOS:A1996VN18000042
J	Artemyev, NO; Surendran, R; Lee, JC; Hamm, HE				Artemyev, NO; Surendran, R; Lee, JC; Hamm, HE			Subunit structure of rod cGMP-phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; BETA-SUBUNIT; GMP PHOSPHODIESTERASE; OUTER SEGMENTS; RETINAL DEGENERATION; PHOTORECEPTOR CELLS; BINDING DOMAIN; HIGH-AFFINITY; CDNA CLONE; RD MOUSE	The rod cGMP phosphodiesterase (PDE) is the G-protein-activated effector enzyme that regulates the level of cGMP in vertebrate photoreceptor cells. Rod cGMP PDE is generally viewed as a heterotrimeric protein composed of catalytic alpha and beta subunits (similar to 90 kDa each) and two copies of the inhibitory subunit gamma (similar to 10 kDa). However, the possibility that rod PDE could exist as distinct isoforms, such as alpha alpha gamma(2) and beta beta gamma(2) has not been ruled out. We have studied this question using cross-linking of PDE subunits with maleimidobenzoyl-N-hydroxysuccinimide ester and para-phenyldimaleimide. The cross-linking resulted in major products with molecular mass of 100 and 150 kDa, a doublet at similar to 180-190 kDa, and a doublet at similar to 210-220 kDa, Cross-linked products were analyzed using polyclonal-specific anti-PDE alpha beta, anti-PDE alpha, anti-PDE beta, or anti-PDE gamma antibodies. The anti-PDE alpha and anti-PDE alpha beta antibodies recognized all the cross-linked products, whereas anti-PDE beta and anti-PDE gamma antibodies did not interact with the 150-kDa band, indicating that the composition of this band is most likely alpha alpha. Similar analysis of cross-linked products of trypsin-treated PDE preparations revealed bands that are likely formed by PDE beta subunit. The molecular size of holo-PDE and trypsin-activated PDE were studied using analytical ultracentrifugation in order to determine if oligomerization of PDE could account for the cross-linking of identical PDE subunits. The sedimentation analysis of both holo-PDE and ta-PDE revealed homogeneous samples with molecular masses of similar to 220 and similar to 150 kDa, respectively. These results indicate that PDE is likely a mixture of the major species alpha beta gamma(2), minor species alpha alpha gamma(2), and possibly beta beta gamma(2). Our data are consistent with the detection of low PDE activity in the rd mouse, which lacks any functional PDE beta subunit.	UNIV TEXAS, MED BRANCH, DEPT HUMAN BIOL CHEM & GENET, GALVESTON, TX 77555 USA; UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Artemyev, NO (corresponding author), UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, 5-660 BOWEN SCI BLDG, IOWA CITY, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NATIONAL EYE INSTITUTE [R01EY006062, R01EY010843] Funding Source: NIH RePORTER; NEI NIH HHS [EY-06062, EY-10843] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; ARTEMYEV NO, 1992, BIOCHEM J, V283, P273, DOI 10.1042/bj2830273; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOWES C, 1993, P NATL ACAD SCI USA, V90, P2955, DOI 10.1073/pnas.90.7.2955; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATTY P, 1991, EUR J BIOCHEM, V199, P263, DOI 10.1111/j.1432-1033.1991.tb16119.x; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; FARBER DB, 1977, J NEUROCHEM, V28, P1089, DOI 10.1111/j.1471-4159.1977.tb10673.x; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEM J, 1992, P NATL ACAD SCI USA, V89, P4422, DOI 10.1073/pnas.89.10.4422; LI T, 1990, P NATL ACAD SCI USA, V87, P293, DOI 10.1073/pnas.87.1.293; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MARTINS TJ, 1982, J BIOL CHEM, V257, P1973; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MURADOV KG, 1990, BIOL MEMBRANY, V7, P565; ONG OC, 1989, P NATL ACAD SCI USA, V86, P9238, DOI 10.1073/pnas.86.23.9238; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; QIN N, 1994, J BIOL CHEM, V269, P3265; SHABB JB, 1992, J BIOL CHEM, V267, P5723; STROOP SD, 1991, J BIOL CHEM, V266, P23802; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	43	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25382	25388		10.1074/jbc.271.41.25382	http://dx.doi.org/10.1074/jbc.271.41.25382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810304	hybrid			2022-12-27	WOS:A1996VL69300048
J	Okada, S; Pessin, JE				Okada, S; Pessin, JE			Interactions between Src homology (SH) 2/SH3 adapter proteins and the guanylnucleotide exchange factor SOS are differentially regulated by insulin and epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; MAP KINASE PHOSPHORYLATION; RECEPTOR TYROSINE KINASES; GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; PC12 CELLS; V-CRK; SOS-GRB2 COMPLEX; RAS ACTIVATION; OF-SEVENLESS	Co-immunoprecipitation of whole cell extracts demonstrated that the guanylnucleotide exchange factor SOS was associated with the small adapter proteins Grb2, CrkII, and Nck. In vitro binding indicated a similar binding affinity of SOS for all three adapter proteins but with a slightly lower K-d for GrbB (similar to 2.5-fold) compared with Nck and CrkII. Insulin stimulation resulted in co-immunoprecipitation of tyrosine-phosphorylate d IRS1 with Grb2 and to a lesser extent CrkII. Although Grb2 also associated with tyrosine-phosphorylated Shc, there was no detectable interaction of CrkII with Shc. In contrast, EGF stimulation resulted in the predominant co-immunoprecipitation of Grb2 with the EGF receptor, whereas CrkII primarily associated with an unidentified 120-130-kDa protein. Similar to the ability of insulin to induce the dissociation of the Grb2-SOS complex, there was a concomitant time-dependent dissociation of the CrkII-SOS and Nck-SOS complexes. However, EGF stimulation had no effect on the association state of the Grb2-SOS or the Nck-SOS complexes but did result in a time dependent dissociation of the CrkII from SOS. Together, these data demonstrate that different cellular pools of SOS associate with different adapter proteins forming various signaling complexes, each undergoing distinct patterns of assembly/disassembly following growth factor stimulation.	UNIV IOWA, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA	University of Iowa					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295, R37DK033823, R01DK033823] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK25295, DK33823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, ONCOGENE, V11, P1327; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KHARLUND JK, 1995, J BIOL CHEM, V270, P23421; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; Ribon V, 1996, MOL CELL BIOL, V16, P45; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SALCINI AE, 1994, ONCOGENE, V9, P2827; SALTIEL AR, 1994, FASEB J, V8, P1034, DOI 10.1096/fasebj.8.13.7926368; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25533	25538		10.1074/jbc.271.41.25533	http://dx.doi.org/10.1074/jbc.271.41.25533			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810325	hybrid			2022-12-27	WOS:A1996VL69300069
J	Tinti, C; Conti, B; Cubells, JF; Kim, KS; Baker, H; Joh, TH				Tinti, C; Conti, B; Cubells, JF; Kim, KS; Baker, H; Joh, TH			Inducible cAMP early repressor can modulate tyrosine hydroxylase gene expression after stimulation of cAMP synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RESPONSE ELEMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PHEOCHROMOCYTOMA CELL-LINE; DEPENDENT PROTEIN-KINASE; LEUCINE ZIPPER STRUCTURE; NERVE GROWTH-FACTOR; CYCLIC-AMP; TRANSCRIPTION FACTOR; TRANSGENIC MICE; MESSENGER-RNA	Members of the CREB/CREM/ATF family of transcription factors either enhance or repress transcription after binding to the cAMP response elements (CREs) of numerous genes, The rat gene for tyrosine hydroxylase (TH) bears a canonical CRE, at base pairs -38 through -45 from the transcription initiation site, that is essential for basal and cAMP-stimulated transcription (Kim, K.-S., Lee, M. K., Carroll, J., and Job, T.H. (1993) J. Biol. Chem, 268, 15689-15695; Lazaroff, M., Patankar, S., Yoon, S. O., and Chikaraishi, D. M. (1995) J. Biol. Chem. 270, 21579-21589). The current study identifies CRE-binding proteins induced in pharmacological paradigms characterized by TH activation. PC12- and rat adrenal gland-derived nuclear proteins retarded a TH-CRE oligonucleotide in gel mobility shift assays with virtually identical patterns, These differed substantially from patterns exhibited by extracts from locus ceruleus or from neuroblastoma (SK-N-BE(2)C) and locus ceruleus-derived (CATH.a) cell lines, Forskolin stimulation of PC12 cells and reserpine treatment of rats increased, in nuclear extracts derived from cells and adrenal glands, respectively, the amount of a fast moving CRE/protein complex that was supershifted by an anti-CREM antibody, Subsequent Western, Northern, and polymerase chain reaction analyses indicated that a specific member of the CREM family, the inducible cAMP early repressor (ICER), was strongly induced in both systems, Cotransfection of PC12 cells with TH2400CAT plasmid and the expression vector pCMV-ICER-Ib demonstrated that ICER efficiently represses the transcriptional activity of the TH gene promoter, In addition, PKA-stimulated transcriptional activity of the promoter was effectively suppressed by ICER. These results suggest that ICER can modulate cAMP-stimulated transcription of the TH gene and provide a model accounting for rapid reversal of increased TH transcription following elevations in cAMP.	CORNELL UNIV,COLL MED,BURKE MED RES INST,MOL NEUROBIOL LAB,WHITE PLAINS,NY 10605; UNIV BRESCIA,FAC MED & CHIRURG,I-25124 BRESCIA,ITALY	Cornell University; University of Brescia			Cubells, Joe F./V-2543-2018	Conti, Bruno/0000-0002-9185-5201	NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH024285, R01MH024285] Funding Source: NIH RePORTER; NIMH NIH HHS [MH24285] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANERJEE SA, 1992, J NEUROSCI, V12, P4460; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOSHART M, 1990, CELL, V61, P905, DOI 10.1016/0092-8674(90)90201-O; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; CARROLL JM, 1991, J MOL NEUROSCI, V3, P65, DOI 10.1007/BF02885527; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; FADER D, 1990, MOL BRAIN RES, V8, P25, DOI 10.1016/0169-328X(90)90005-X; FAUCONBIGUET N, 1986, EMBO J, V5, P287; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FUNG BP, 1992, J NEUROCHEM, V58, P2044, DOI 10.1111/j.1471-4159.1992.tb10945.x; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUIDOTTI A, 1976, N-S ARCH PHARMACOL, V295, P135, DOI 10.1007/BF00499445; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1990, MOL ENDOCRINOL, V4, P920, DOI 10.1210/mend-4-6-920; HUANG ZM, 1991, MOL BRAIN RES, V11, P309, DOI 10.1016/0169-328X(91)90040-5; HURST HC, 1991, NUCLEIC ACIDS RES, V19, P4601, DOI 10.1093/nar/19.17.4601; ICARDLIEPKALNS C, 1992, J NEUROSCI RES, V32, P290, DOI 10.1002/jnr.490320219; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; IUVONE PM, 1978, MOL PHARMACOL, V14, P1212; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KANEDA N, 1991, NEURON, V6, P583, DOI 10.1016/0896-6273(91)90061-4; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KILBOURNE EJ, 1990, MOL BRAIN RES, V8, P121, DOI 10.1016/0169-328X(90)90056-J; KIM KS, 1994, J NEUROCHEM, V63, P834; KIM KS, 1993, P NATL ACAD SCI USA, V90, P3471, DOI 10.1073/pnas.90.8.3471; KIM KS, 1993, J BIOL CHEM, V268, P15689; KIM KS, 1995, GENE PROBES, V2, P151; KONRADI C, 1994, J NEUROSCI, V14, P5623; KONRADI C, 1993, P NATL ACAD SCI USA, V90, P7005, DOI 10.1073/pnas.90.15.7005; KONRADI C, 1995, NEUROSCIENCE, V65, P1051, DOI 10.1016/0306-4522(94)00546-H; KVETNANS.R, 1971, ENDOCRINOLOGY, V89, P46, DOI 10.1210/endo-89-1-46; LAZAROFF M, 1995, J BIOL CHEM, V270, P21579, DOI 10.1074/jbc.270.37.21579; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEWIS EJ, 1983, J BIOL CHEM, V258, P4632; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MIN N, 1994, MOL BRAIN RES, V27, P281, DOI 10.1016/0169-328X(94)90011-6; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MUELLER RA, 1969, J PHARMACOL EXP THER, V169, P74; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; REIS DJ, 1974, BRAIN RES, V81, P380, DOI 10.1016/0006-8993(74)90956-1; RICHARD F, 1989, NEUROCHEM INT, V14, P199, DOI 10.1016/0197-0186(89)90122-8; ROSS RA, 1981, CELL MOL NEUROBIOL, V1, P301, DOI 10.1007/BF00710685; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHORT JM, 1986, J BIOL CHEM, V261, P9721; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; SURI C, 1993, J NEUROSCI, V13, P1280; TANK AW, 1986, MOL PHARMACOL, V30, P497; THOENEN H, 1969, J PHARMACOL EXP THER, V169, P249; THOENEN H, 1970, NATURE, V228, P861, DOI 10.1038/228861a0; THOENEN H, 1969, NATURE, V221, P1264, DOI 10.1038/2211264a0; VYAS S, 1990, EMBO J, V9, P3707, DOI 10.1002/j.1460-2075.1990.tb07583.x; WALKER WH, 1994, P NATL ACAD SCI USA, V91, P12423, DOI 10.1073/pnas.91.26.12423; WESSEL TC, 1992, MOL BRAIN RES, V15, P349, DOI 10.1016/0169-328X(92)90128-X; WONG SC, 1994, J NEUROCHEM, V62, P1691; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	68	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25375	25381		10.1074/jbc.271.41.25375	http://dx.doi.org/10.1074/jbc.271.41.25375			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810303	hybrid			2022-12-27	WOS:A1996VL69300047
J	Bradrick, TD; Shattuck, C; Strader, MB; Wicker, C; Eisenstein, E; Howell, EE				Bradrick, TD; Shattuck, C; Strader, MB; Wicker, C; Eisenstein, E; Howell, EE			Redesigning the quaternary structure of R67 dihydrofolate reductase - Creation of an active monomer from a tetrameric protein by quadruplication of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; LIGAND-BINDING; PLASMID R67; CONSTRUCTION; EQUILIBRIUM; ASYMMETRY; STABILITY; SUBUNITS	R67 dihydrofolate reductase (DHFR) provides resistance to the antibacterial drug trimethoprim. This R-plasmid-encoded enzyme does not share any homology with chromosomal DHFR. A recent crystal structure of active, homotetrameric R67 DHFR (Narayana, N., Matthews, D. A., Howell, E. E., and Xuong, N.-H. (1995) Nat. Struct. Biol. 2, 1018-1025) indicates that a single active site pore traverses the length of the molecule. Since the center of the pore possesses exact 222 symmetry, site-directed mutagenesis of residues in the pore will produce four mutations/active site. To break this inevitable symmetry, four copies of the gene have been linked in frame to create an active monomer possessing the essential tertiary structure of native tetrameric R67 DHFR. The protein product, quadruple R67 DHFR, is 4 times the molecular mass of native R67 DHFR in SDS-polyacrylamide gel electrophoresis and is monomeric under nondenaturing conditions as measured by sedimentation equilibrium experiments. The catalytic activity of quadruple R67 DHFR is decreased only slightly when compared with native R67 DHFR, Folding of quadruple R67 DHFR is completely reversible at pH 5. However, at pH 8, folding is not fully reversible; this is likely due to a competition between productive intramolecular versus nonproductive intermolecular domain association. The production of a fully active, monomeric R67 DHFR variant will enable the design of more meaningful site directed mutants where single substitutions per active site pore can be generated.	UNIV TENNESSEE,DEPT BIOCHEM CELL & MOL BIOL,KNOXVILLE,TN 37996; MYCOGEN CORP,SAN DIEGO,CA 92121; CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850; UNIV MARYLAND,DEPT CHEM & BIOCHEM,BALTIMORE,MD 21229	University of Tennessee System; University of Tennessee Knoxville; University System of Maryland; University of Maryland Baltimore				Howell, Elizabeth/0000-0001-6157-433X	NIGMS NIH HHS [GM35308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM035308, R01GM035308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON SA, 1980, BIOPOLYMERS, V19, P1475, DOI 10.1002/bip.1980.360190805; BABE LM, 1992, PROTEIN SCI, V1, P1244, DOI 10.1002/pro.5560011003; BACCANARI D, 1975, BIOCHEMISTRY-US, V14, P5267, DOI 10.1021/bi00695a006; BLAKLEY RL, 1960, NATURE, V188, P231, DOI 10.1038/188231a0; BORCHERT TV, 1993, STRUCTURE, V1, P205, DOI 10.1016/0969-2126(93)90021-8; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; Bradrick TD, 1996, BIOCHEMISTRY-US, V35, P11414, DOI 10.1021/bi960205d; BRADSHAW TP, 1993, BIOCHEMISTRY-US, V32, P12774, DOI 10.1021/bi00210a029; BREITER DR, 1994, PROTEIN SCI, V3, P2023, DOI 10.1002/pro.5560031115; BRISSON N, 1984, GENE, V28, P271, DOI 10.1016/0378-1119(84)90266-X; Cantor C. R., 1980, BIOPHYSICAL CHEM 2, P560; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; DAY PJ, 1995, BIOCHEMISTRY-US, V34, P6416, DOI 10.1021/bi00019a022; DILANNI C L, 1990, Journal of Biological Chemistry, V265, P17348; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; GRAHAM GJ, 1992, BIOTECHNIQUES, V13, P780; HALLEWELL RA, 1989, J BIOL CHEM, V264, P5260; HORECKER BL, 1948, J BIOL CHEM, V175, P385; HOWELL EE, 1987, BIOCHEMISTRY-US, V26, P8591, DOI 10.1021/bi00400a015; IWAKURA M, 1992, PROTEIN ENG, V5, P791, DOI 10.1093/protein/5.8.791; KUCHINKE W, 1985, EMBO J, V4, P1067, DOI 10.1002/j.1460-2075.1985.tb03740.x; LIANG H, 1993, P NATL ACAD SCI USA, V90, P7010, DOI 10.1073/pnas.90.15.7010; MATTHEWS DA, 1986, BIOCHEMISTRY-US, V25, P4194, DOI 10.1021/bi00363a005; NARAYANA N, 1995, NAT STRUCT BIOL, V2, P1018, DOI 10.1038/nsb1195-1018; NICHOLS R, 1993, BIOCHEMISTRY-US, V32, P1695, DOI 10.1021/bi00058a002; PREDKI PF, 1995, BIOCHEMISTRY-US, V34, P9834, DOI 10.1021/bi00031a003; REECE LJ, 1991, BIOCHEMISTRY-US, V30, P10895, DOI 10.1021/bi00109a013; Robinson CR, 1996, BIOCHEMISTRY-US, V35, P109, DOI 10.1021/bi9521194; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SMYTHE JA, 1994, PROTEIN ENG, V7, P145, DOI 10.1093/protein/7.2.145; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; WARD WHJ, 1988, BIOCHEMISTRY-US, V27, P1041, DOI 10.1021/bi00403a029; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; ZHUANG P, 1993, J BIOL CHEM, V268, P22672	36	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28031	28037		10.1074/jbc.271.45.28031	http://dx.doi.org/10.1074/jbc.271.45.28031			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910413	hybrid			2022-12-27	WOS:A1996VU03300013
J	Jeneson, JAL; Wiseman, RW; Westerhoff, HV; Kushmerick, MJ				Jeneson, JAL; Wiseman, RW; Westerhoff, HV; Kushmerick, MJ			The signal transduction function for oxidative phosphorylation is at least second order in ADP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; HUMAN SKELETAL-MUSCLE; ATP SYNTHESIS; RESPIRATORY CONTROL; CARRIER; METABOLISM; MECHANISM	To maintain ATP constant in the cell, mitochondria must sense cellular ATP utilization and transduce this demand to F-0-F-1-ATPase. In spite of a considerable research effort over the past three decades, no combination of signal(s) and kinetic function has emerged with the power to explain ATP homeostasis in all mammalian cells. We studied this signal transduction problem in intact human muscle using P-31 NMR spectroscopy. We find that the apparent kinetic order of the transduction function of the signal cytosolic ADP concentration ([ADP]) is at least second order and not first order as has been assumed. We show that amplified mitochondrial sensitivity to cytosolic [ADP] harmonizes with in vitro kinetics of [ADP] stimulation of respiration and explains ATP homeostasis also in mouse liver and canine heart. This result may well be generalizable to all mammalian cells.	UNIV WASHINGTON,SCH MED,DEPT RADIOL,NMR RES LAB,SEATTLE,WA 98195; FREE UNIV AMSTERDAM,FAC BIOL,DEPT MICROBIAL PHYSIOL,NL-1081 HV AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,BIOCTR,EC SLATER INST,NL-1018 TV AMSTERDAM,NETHERLANDS; UNIV WASHINGTON,SCH MED,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,CTR BIOENGN,SEATTLE,WA 98185	University of Washington; University of Washington Seattle; Vrije Universiteit Amsterdam; University of Amsterdam; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Westerhoff, Hans V/I-5762-2012	Westerhoff, Hans V/0000-0002-0443-6114	NIAMS NIH HHS [AR36281, AR41793, AR41928] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041928, R29AR041793, R01AR036281] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BERKICH DA, 1991, J BIOL CHEM, V266, P123; BISELL CC, 1994, CONTROL ENG, P1; BLEI ML, 1993, J PHYSIOL-LONDON, V465, P203, DOI 10.1113/jphysiol.1993.sp019673; BRANDOLIN G, 1993, J BIOENERG BIOMEMBR, V25, P459, DOI 10.1007/BF01108403; BYGRAVE FL, 1967, P NATL ACAD SCI USA, V57, P1409, DOI 10.1073/pnas.57.5.1409; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; CHANCE B, 1965, J GEN PHYSIOL, V49, P163, DOI 10.1085/jgp.49.1.163; DEMARTINO C, 1979, CELL TISSUE RES, V196, P1; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; DUYCKAERTS C, 1980, EUR J BIOCHEM, V106, P1; Hill A.V., 1910, J PHYSIOL-LONDON, V40, piv; HUANG AH, 1988, CIRC RES, V62, P286, DOI 10.1161/01.RES.62.2.286; JACOBUS WE, 1982, J BIOL CHEM, V257, P2397; JENESON JAL, 1995, AM J PHYSIOL-CELL PH, V268, pC1474, DOI 10.1152/ajpcell.1995.268.6.C1474; JENESON JAL, 1996, IN PRESS MOL CELL BI; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KORETSKY AP, 1995, PHYSIOL REV, V75, P667, DOI 10.1152/physrev.1995.75.4.667; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LANOUE KF, 1986, BIOCHEMISTRY-US, V25, P7667, DOI 10.1021/bi00371a058; LANOUE KF, 1995, ADV MOL CEL, V11, P207; LIGETI E, 1985, BIOCHEMISTRY-US, V24, P4423, DOI 10.1021/bi00337a025; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; MCCORMACK JG, 1986, TRENDS BIOCHEM SCI, V9, P71; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P525, DOI 10.1007/BF01108409; PFAFF E, 1969, EUR J BIOCHEM, V10, P484, DOI 10.1111/j.1432-1033.1969.tb00715.x; ROSING J, 1972, BIOCHIM BIOPHYS ACTA, V267, P275, DOI 10.1016/0005-2728(72)90116-8; ROTTENBERG H, 1973, BIOPHYS J, V13, P503, DOI 10.1016/S0006-3495(73)86004-7; Segel IH, 1975, ENZYME KINETICS, P346; SLUSEGOFFART CM, 1996, BIOTHERMOKINETICS LI, P218; SOUVERIJN JH, 1973, BIOCHIM BIOPHYS ACTA, V305, P185, DOI 10.1016/0005-2728(73)90168-0; VANDAM K, 1987, THERMODYNAMICS CONTR, P228	33	138	139	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27995	27998		10.1074/jbc.271.45.27995	http://dx.doi.org/10.1074/jbc.271.45.27995			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910406	Green Published, hybrid			2022-12-27	WOS:A1996VU03300006
J	Kawashima, H; Sequeira, DJ; Nelson, DR; Strobel, HW				Kawashima, H; Sequeira, DJ; Nelson, DR; Strobel, HW			Genomic cloning and protein expression of a novel rat brain cytochrome P-450 CYP2D18 catalyzing imipramine N-demethylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION OXIDASE SYSTEM; C6 CELL-LINE; PARKINSONS-DISEASE; GENE-EXPRESSION; SUBFAMILY; IDENTIFICATION; DEBRISOQUINE; METABOLISM; P450; 4-HYDROXYLATION	We have previously reported the isolation of two cDNA clones, designated 2d-29 and 2d-35, which have identical open reading frames and code for a novel brain cytochrome P-450 (P-450) belonging to the CYP2D subfamily, and noted that the mRNA of clone 2d-35 seems to be expressed in the brain but not in the liver (1). Although the deduced amino acid sequence of these clones differs from that of the liver CYP2D4 by only 5 amino acids distributed in the C-terminal region, this new P-450 cDNA clone contained st unique 5'-extension, and we posit in this report by analysis of a genomic clone that this 5'-untranslated sequence is derived from a gene distinct from that of CYP2D4. Thus, this novel P-450 was named P-450 2D18 according to the recommended nomenclature (2), The expressibility of this cDNA was confirmed by in vitro translation using a reticulocyte system, and protein expression was performed using COS-M6 cells. Immunoblot analysis showed a cross-reacting band of the predicted size range with anti-P-450 2D6 antiserum, which was not seen in control cells. Furthermore, the CYP2D18-expressed COS cell lysate showed N-demethylation activity toward imipramine, whereas another brain P-450 CYP4F6-expressed COS cell lysate showed 10-hydroxylation activity. This is the first report that associates an individual P-450 isozyme in brain with a particular metabolic alteration of the antidepressant imipramine.	UNIV TEXAS,SCH MED,DEPT BIOCHEM & MOL BIOL,HOUSTON,TX 77225; UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Texas System; University of Tennessee System; University of Tennessee Health Science Center				Nelson, David/0000-0003-0583-5421	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044923] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 44923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARBEAU A, 1985, LANCET, V2, P1213; BERGH AF, 1992, J NEUROCHEM, V59, P575, DOI 10.1111/j.1471-4159.1992.tb09408.x; BROSEN K, 1991, CLIN PHARMACOL THER, V49, P609, DOI 10.1038/clpt.1991.77; GENG J, 1993, BIOCHEM BIOPH RES CO, V197, P1179, DOI 10.1006/bbrc.1993.2601; GENG J, 1995, J NEUROCHEM, V65, P554; GONZALEZ F J, 1988, Genomics, V2, P174, DOI 10.1016/0888-7543(88)90100-0; GONZALEZ FJ, 1988, NATURE, V331, P442, DOI 10.1038/331442a0; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HODGSON AV, 1993, MOL CELL BIOCHEM, V120, P171, DOI 10.1007/BF00926090; HONDA S, 1994, BIOCHEM BIOPH RES CO, V198, P1153, DOI 10.1006/bbrc.1994.1163; ISHIDA N, 1988, BIOCHEM BIOPH RES CO, V156, P681, DOI 10.1016/S0006-291X(88)80896-9; JOHANSSON I, 1994, MOL PHARMACOL, V46, P452; KAWASHIMA H, 1995, BIOCHEM BIOPH RES CO, V209, P535, DOI 10.1006/bbrc.1995.1534; Kawashima H, 1995, BIOCHEM BIOPH RES CO, V217, P1137, DOI 10.1006/bbrc.1995.2887; KOMORI M, 1993, BIOCHEM BIOPH RES CO, V196, P721, DOI 10.1006/bbrc.1993.2309; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MATSUNAGA E, 1990, J MOL EVOL, V30, P155, DOI 10.1007/BF02099942; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; SEQUEIRA DJ, 1995, J CHROMATOGR B, V673, P251, DOI 10.1016/0378-4347(95)00274-X; SEQUEIRA DJ, 1996, IN PRESS BRAIN RES; STROBEL HW, 1989, PHARMACOL RES, V21, P169, DOI 10.1016/1043-6618(89)90235-1; SUZUKI T, 1992, FASEB J, V6, P771, DOI 10.1096/fasebj.6.2.1537468; TODA K, 1995, EUR J BIOCHEM, V231, P292, DOI 10.1111/j.1432-1033.1995.tb20699.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUNEOKA Y, 1993, J BIOCHEM, V114, P263, DOI 10.1093/oxfordjournals.jbchem.a124164; WYSS A, 1995, MOL PHARMACOL, V47, P1148	29	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28176	28180		10.1074/jbc.271.45.28176	http://dx.doi.org/10.1074/jbc.271.45.28176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910433	hybrid			2022-12-27	WOS:A1996VU03300033
J	Singh, J; Su, L; Snow, ET				Singh, J; Su, L; Snow, ET			Replication across O6-methylguanine by human DNA polymerase beta in vitro - Insights into the futile cytotoxic repair and mutagenesis of O6-methylguanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-CELLS; IN-VITRO; BASE SUBSTITUTION; ESCHERICHIA-COLI; HUMAN-TUMOR; O-6-METHYLGUANINE; GENE; OLIGONUCLEOTIDE; EXCISION; RESIDUES	Replication in vivo across unrepaired O-6-methylguanine (m(6)dG) lesions by mammalian DNA polymerase beta (pol beta) during short patch repair may contribute to the cytotoxicity and mutagenesis of m(6)dG. We have employed in vitro steady state kinetic analysis to investigate the replication of oligonucleotide templates containing site-specific m(6)dG by human pol beta. Our results show that m(6)dG is a strong but not absolute block to replication by pol beta. pol beta exhibits mixed kinetic discrimination during overall replication across dG and m(6)dG. pol beta preferentially inserts dTMP rather than dCMP opposite m(6)dG. However, pol beta extends from the dC-m(6)dG base pair more efficiently than from the dT-m(6)dG base pair. This is in strong contrast to other polymerases such as the exonuclease-deficient Klenow fragment of Escherichia coli DNA polymerase I (exo(-)KF) that preferentially extends dT-m(6)dG by a factor of 10 over dC-m(6)dG. When both insertion and extension are considered, pol beta has a 15-fold overall preference for incorporation of the mutagenic substrate dTTP rather than the nonmutagenic substrate dCTP during replication across m(6)dG. This suggests that pol beta, in concert with the T:G-specific thymine DNA glycosylase, may be intricately involved in the futile cytotoxic repair induced by m(6)dG. Our results also suggest that replication across m(6)dG by pol beta may contribute to m(6)dG-induced G --> A transition mutations.	NYU, MED CTR, NELSON INST ENVIRONM MED, TUXEDO PK, NY 10987 USA	New York University			Snow, Elizabeth T/J-7394-2014	Snow, Elizabeth T/0000-0002-9363-5130	NCI NIH HHS [CA13343] Funding Source: Medline; NIEHS NIH HHS [ES064983, ES001248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES001248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BHANOT OS, 1986, P NATL ACAD SCI USA, V83, P7348, DOI 10.1073/pnas.83.19.7348; BOOSALIS MS, 1989, J BIOL CHEM, V264, P11360; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DEVEREUX TR, 1993, MOL CARCINOGEN, V8, P177, DOI 10.1002/mc.2940080308; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DOBASHI Y, 1994, CANCER RES, V54, P2827; DOSANJH MK, 1991, BIOCHEMISTRY-US, V30, P11595, DOI 10.1021/bi00113a015; DOSANJH MK, 1993, P NATL ACAD SCI USA, V90, P3983, DOI 10.1073/pnas.90.9.3983; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; DUGGLEBY RG, 1981, ANAL BIOCHEM, V110, P9, DOI 10.1016/0003-2697(81)90104-4; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GOTH R, 1974, Z KREBSFORSCH KLIN O, V82, P37, DOI 10.1007/BF00304382; Grunberger D., 1983, MOL BIOL MUTAGENS CA, P55; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; KALNIK MW, 1989, BIOCHEMISTRY-US, V28, P6170, DOI 10.1021/bi00441a008; KAMIYA H, 1991, JPN J CANCER RES, V82, P997, DOI 10.1111/j.1349-7006.1991.tb01934.x; KAMIYA H, 1993, NUCLEIC ACIDS RES, V21, P2355, DOI 10.1093/nar/21.10.2355; KARRAN P, 1993, J BIOL CHEM, V268, P15878; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Korn D, 1983, NEW APPROACHES EUKAR, P17; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; KUNKEL TA, 1983, BIOCHEMISTRY-US, V22, P2387; LOECHLER EL, 1984, P NATL ACAD SCI-BIOL, V81, P6271, DOI 10.1073/pnas.81.20.6271; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1989, MOL CELL BIOL, V9, P3750, DOI 10.1128/MCB.9.9.3750; MENICHINI P, 1994, MUTAT RES, V307, P53, DOI 10.1016/0027-5107(94)90277-1; MOSBAUGH DW, 1980, J BIOL CHEM, V255, P239; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; PAINTER RB, 1980, MUTAT RES, V70, P337, DOI 10.1016/0027-5107(80)90023-8; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PATEL DJ, 1986, BIOCHEMISTRY-US, V25, P1027, DOI 10.1021/bi00353a012; PEGG AE, 1990, CANCER RES, V50, P6119; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PERRINO FW, 1990, MUTAT RES, V236, P289, DOI 10.1016/0921-8777(90)90012-T; RANDAHL H, 1988, J BIOL CHEM, V263, P12228; SAMBROOK J, 1989, MOL CLONING LAB MAN, V3; SCANLON KJ, 1991, P NATL ACAD SCI USA, V88, P10591, DOI 10.1073/pnas.88.23.10591; SIBGHATULLAH, 1995, BIOCHEMISTRY-US, V34, P6869, DOI 10.1021/bi00020a034; SIBGHATULLAH, 1993, NUCLEIC ACIDS RES, V21, P1281, DOI 10.1093/nar/21.5.1281; SINGER B, 1989, P NATL ACAD SCI USA, V86, P8271, DOI 10.1073/pnas.86.21.8271; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; SNOW ET, 1984, J BIOL CHEM, V259, P8095; ULLAH S, 1992, BIOCHEMISTRY-US, V31, P7998; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; WANG LM, 1992, CANCER RES, V52, P4824; Werneburg BG, 1996, BIOCHEMISTRY-US, V35, P7041, DOI 10.1021/bi9527202; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAROSH DB, 1984, MUTAT RES, V131, P27, DOI 10.1016/0167-8817(84)90044-0; YAROSH DB, 1983, CARCINOGENESIS, V4, P199, DOI 10.1093/carcin/4.2.199; ZAIDI NH, 1995, CARCINOGENESIS, V16, P461, DOI 10.1093/carcin/16.3.461	56	38	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28391	28398		10.1074/jbc.271.45.28391	http://dx.doi.org/10.1074/jbc.271.45.28391			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910463	hybrid			2022-12-27	WOS:A1996VU03300063
J	Escola, JM; Deleuil, F; Stang, E; Boretto, J; Chavrier, P; Gorvel, JP				Escola, JM; Deleuil, F; Stang, E; Boretto, J; Chavrier, P; Gorvel, JP			Characterization of a lysozyme major histocompatibility complex class II molecule-loading compartment as a specialized recycling endosome in murine B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; RECEPTOR-MEDIATED ENDOCYTOSIS; INVARIANT-CHAIN; IMMUNOELECTRON MICROSCOPY; INTRACELLULAR-TRANSPORT; CARCINOMA A431-CELLS; TRANSFERRIN RECEPTOR; SURFACE EXPRESSION; CARRIER VESICLES; FUSION INVITRO	We have previously identified an intracellular compartment involved in the association between processed lysozyme and IA(k) major histocompatibility complex class II molecules (called the lysozyme-loading compartment (LLC)), Here, we show that She LLC polypeptide composition analyzed by two-dimensional gel electrophoresis shares similarities with that of early endosomes, but not with that of late endosomes, The transferrin receptor, a well known marker for both early and recycling endosomes, colocalizes with IA(k) molecules in LLC. Moreover, both transferrin and fluid-phase markers have access to LLC after 15 min of internalization. In the presence of concanamycin B, SDS-stable dimer formation and transport of class II molecules out of LLC are impaired, In contrast, nocodazole treatment has no effect. These results suggest that LLC is a specialized compartment of the recycling pathway involved in lysozyme loading and in the targeting of lysozyme-major histocompatibility class II complexes toward the cell surface.	CNRS, INSERM, CTR IMMUNOL, F-13288 MARSEILLE 09, FRANCE; UNIV OSLO, DEPT BIOL, ELECTRON MICROSCOPY UNIT BIOL SCI, N-0316 OSLO, NORWAY	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of Oslo			CHAVRIER, Philippe/AAG-2645-2020; CHAVRIER, Philippe/B-4707-2010; Gorvel, Jean-Pierre/O-1332-2018	CHAVRIER, Philippe/0000-0002-7351-733X; CHAVRIER, Philippe/0000-0002-7351-733X; Gorvel, Jean-Pierre/0000-0002-2829-9804				AMIGORENA S, 1995, J EXP MED, V181, P1729, DOI 10.1084/jem.181.5.1729; AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BENAROCH P, 1995, EMBO J, V14, P37, DOI 10.1002/j.1460-2075.1995.tb06973.x; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CALAFAT J, 1994, J CELL BIOL, V126, P967, DOI 10.1083/jcb.126.4.967; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DABORA SL, 1988, CELL, V54, P27, DOI 10.1016/0092-8674(88)90176-6; DEBRABANDER M, 1988, CELL MOTIL CYTOSKEL, V9, P30, DOI 10.1002/cm.970090105; ESCOLA JM, 1995, J CELL SCI, V108, P2337; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GHOSH RN, 1994, J CELL SCI, V107, P2177; GRIFFITHS G, 1983, METHOD ENZYMOL, V96, P466; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1983, CELL, V35, P321, DOI 10.1016/0092-8674(83)90235-0; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KLIONSKY DJ, 1992, J BIOL CHEM, V267, P3416; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LIN J, 1988, J MOL CELL IMMUNOL, V3, P321; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARIC MA, 1994, P NATL ACAD SCI USA, V91, P2171, DOI 10.1073/pnas.91.6.2171; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MERESSE S, 1995, J CELL SCI, V108, P3349; MORIYAMA Y, 1989, J BIOL CHEM, V264, P3577; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; PARTON RG, 1989, J CELL BIOL, V109, P3259, DOI 10.1083/jcb.109.6.3259; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Robinson MS, 1996, CELL, V84, P13, DOI 10.1016/S0092-8674(00)80988-5; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; RUDENSKY AY, 1994, IMMUNITY, V1, P585, DOI 10.1016/1074-7613(94)90048-5; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; SUNG E, 1981, MOL IMMUNOL, V18, P899, DOI 10.1016/0161-5890(81)90013-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707; ZACHGO S, 1992, J CELL SCI, V103, P811	60	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27360	27365		10.1074/jbc.271.44.27360	http://dx.doi.org/10.1074/jbc.271.44.27360			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910313	hybrid			2022-12-27	WOS:A1996VQ67900031
J	Pathan, NI; Geahlen, RL; Harrison, ML				Pathan, NI; Geahlen, RL; Harrison, ML			The protein-tyrosine kinase Lck associates with and is phosphorylated by Cdc2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL-RECEPTOR; CYCLIN-DEPENDENT KINASES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; CROSS-LINKING; LYMPHOCYTES-T; B-LYMPHOCYTES; CD4 RECEPTOR; SH2 DOMAIN; C-SRC	The protein-tyrosine kinase Lck is essential for signaling through the T-cell antigen receptor, Treatment of T-cells with a variety of extracellular stimuli increases the phosphorylation of Lck on serine residues, This results in shifts in the apparent molecular weight of Lck to forms that exhibit reduced electrophoretic mobility on SDS-polyacrylamide gels, We found that as a result of arresting cells in mitosis, forms of Lck were generated that migrated with slower mobilities on SDS-polyacrylamide gels, This suggested that a serine/threonine kinase, active at mitosis, was phosphorylating Lck, Using antibodies to Lck and to the cyclin-dependent serine kinase, Cdc2, as well as the cyclin-dependent kinase affinity resin, Suc1-agarose, we detected a stable interaction between Lck and Cdc2, The interaction was mediated through the Src homology 3 domain of Lck and was selective, as only the active form of Cdc2 was found to associate with Lck, Moreover, Cdc2 was able to phosphorylate Lck in vitro and shift its electrophoretic mobility to a more slowly migrating form, An association between active Cdc2 and the Src-related kinases Lyn and Fyn was also demonstrated, although Cdc2 was not found associated with the tyrosine kinases, Csk and Syk, These results demonstrate that at mitosis, Cdc2 associates with and phosphorylates Lck.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; BOLEN JB, 1995, CURR OPIN IMMUNOL, V7, P306, DOI 10.1016/0952-7915(95)80103-0; CARRERA AC, 1995, J BIOL CHEM, V270, P3385, DOI 10.1074/jbc.270.7.3385; CASNELLIE JE, 1986, J BIOL CHEM, V261, P4921; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P552; CHURCHER Y, 1993, J BIOL CHEM, V268, P26144; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; EINSPAHR KJ, 1990, J IMMUNOL, V145, P1490; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FORD CE, 1994, J BIOL CHEM, V269, P30378; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1994, J IMMUNOL, V153, P2369; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HOWE LR, 1995, TRENDS BIOCHEM SCI, V20, P59, DOI 10.1016/S0968-0004(00)88958-6; HURLEY TR, 1989, ONCOGENE, V4, P265; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KIM YH, 1992, J IMMUNOL, V149, P17; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; LUO K, 1990, ONCOGENE, V5, P803; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARIECARDINE A, 1994, EUR J IMMUNOL, V24, P1255, DOI 10.1002/eji.1830240603; MARTH JD, 1989, J IMMUNOL, V142, P2430; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAIGE LA, 1993, J BIOL CHEM, V268, P8669; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PERI KG, 1993, ONCOGENE, V8, P2765; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SEFTON BM, 1991, ONCOGENE, V6, P683; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOULA M, 1993, J BIOL CHEM, V268, P27420; SRINIVAS PR, 1991, ALLERGY IMMUNOL, V10, P61; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; WANG QM, 1991, BIOCHEM J, V279, P567, DOI 10.1042/bj2790567; WATTS JD, 1993, J BIOL CHEM, V268, P23275; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WINKLER DG, 1993, P NATL ACAD SCI USA, V90, P5176, DOI 10.1073/pnas.90.11.5176; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195	66	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27517	27523		10.1074/jbc.271.44.27517	http://dx.doi.org/10.1074/jbc.271.44.27517			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910336	hybrid			2022-12-27	WOS:A1996VQ67900054
J	Reynolds, JE; Eastman, A				Reynolds, JE; Eastman, A			Intracellular calcium stores are not required for Bcl-2-mediated protection from apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; ENDONUCLEASE ACTIVATION; C-MYC; DNA FRAGMENTATION; IN-VITRO; BCL-2; CA-2+; THYMOCYTES; PROTEIN; OXYGEN	The ability of Bcl-2 to inhibit cell death is well documented but its mechanism of action remains elusive. Recent reports have suggested that Bcl-2 prevents apoptosis by inhibiting the release of Ca2+ from the thapsigargin-sensitive Ca2+ store. The mobilization of Ca2+ from this store has been implicated as a signal regulating apoptotic cell death induced by glucocorticoids and by interleukin-3 withdrawal, The present study was designed to determine if Bcl-2 would still inhibit apoptosis after depletion of intracellular Ca2+ stores. We compared the response of two Chinese hamster ovary cell lines (5AHSmyc and 5A300bcl-2.2) following incubation with the calcium ionophore ionomycin to deplete intracellular Ca2+ stores. Continued incubation of 5AHSmyc cells in calcium-free media induced substantial apoptotic DNA fragmentation within 4 h and >95% loss of viability within 48 h. However, 5A300bcl-2.2 cells showed no evidence of DNA fragmentation or loss of viability over the same time period. Intracellular Ca2+ was analyzed with the Ca2+-sensitive fluorescent dye INDO-1 and confirmed that ionomycin was capable of releasing Ca2+ from intracellular stores in both cell lines. These results show that depletion of intracellular Ca2+ stores induces apoptosis and that these Ca2+ stores are not required for the protection afforded by Bcl-2.	DARTMOUTH COLL SCH MED,DEPT PHARMACOL,HANOVER,NH 03755	Dartmouth College					NCI NIH HHS [CA23108, CA50224] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA050224, R01CA050224, P30CA023108] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BARRY MA, 1993, CANCER RES, V53, P2349; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BISONETTE RP, 1992, NATURE, V359, P552; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1984, J IMMUNOL, V132, P38; Distelhorst CW, 1996, ONCOGENE, V12, P2051; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; EASTMAN A, 1993, TOXICOL APPL PHARM, V121, P160, DOI 10.1006/taap.1993.1141; EASTMAN A, 1992, CANCER INVEST, V10, P229, DOI 10.3109/07357909209032765; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; EASTMAN A, 1995, SEMIN CANCER BIOL, V6, P45, DOI 10.1006/scbi.1995.0006; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DP, 1989, J BIOL CHEM, V264, P6398; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANEKO Y, 1994, CANCER LETT, V97, P147; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KLUCK RM, 1994, BBA-MOL CELL RES, V1223, P247, DOI 10.1016/0167-4889(94)90233-X; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; MARTIN SJ, 1995, CELL, V82, P348; MASON MJ, 1993, BIOCHEM J, V296, P33, DOI 10.1042/bj2960033; MCCONKEY DJ, 1988, SCIENCE, V242, P256, DOI 10.1126/science.3262923; MCCONKEY DJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P365, DOI 10.1016/0003-9861(89)90119-7; MCCONKEY DJ, 1990, FASEB J, V4, P2661, DOI 10.1096/fasebj.4.9.2347464; Morana SJ, 1996, J BIOL CHEM, V271, P18263, DOI 10.1074/jbc.271.30.18263; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NIKONOVA LV, 1982, BIOCHIM BIOPHYS ACTA, V699, P281, DOI 10.1016/0167-4781(82)90118-X; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STBIRD GJ, 1992, J BIOL CHEM, V267, P18382; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WANG HG, 1994, ONCOGENE, V9, P2751; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176	52	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27739	27743		10.1074/jbc.271.44.27739	http://dx.doi.org/10.1074/jbc.271.44.27739			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910367	hybrid			2022-12-27	WOS:A1996VQ67900085
J	VanCriekinge, W; Beyaert, R; VandeCraen, M; Vandenabeele, P; Schotte, P; DeValck, D; Fiers, W				VanCriekinge, W; Beyaert, R; VandeCraen, M; Vandenabeele, P; Schotte, P; DeValck, D; Fiers, W			Functional characterization of the prodomain of interleukin-1 beta-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CONVERTING-ENZYME; IL-1-BETA-CONVERTING ENZYME; CYSTEINE PROTEASE; MAMMALIAN HOMOLOG; MICE DEFICIENT; GENE CED-3; APOPTOSIS; IL-1-BETA; ICE	Interleukin 1 beta-converting enzyme (ICE) has been identified as the main protease responsible for maturation of the prodomain of interleukin-1 beta. Recently, it was shown to belong to a larger gene family, members of which play an important role in programmed cell death. A common feature of the ICE family proteases is the presence of a prodomain that has been hypothesized to keep the enzyme in an inactive form. Expression analysis in yeast revealed autocatalytic degradation of p45ICE, but not of p30ICE lacking a prodomain. We further demonstrate that p45ICE, in which the critical cysteine has been mutated, is still able to dimerize in vivo, Dimerization requires the prodomain and occurs prior to autoprocessing. These results provide evidence for a regulatory role of the prodomain of ICE.	FLANDERS INTERUNIV INST BIOTECHNOL,MOL BIOL LAB,B-9000 GHENT,BELGIUM; STATE UNIV GHENT,B-9000 GHENT,BELGIUM	Ghent University			Beyaert, Rudi/B-2589-2009; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022	Vandenabeele, Peter/0000-0002-6669-8822; Beyaert, Rudi/0000-0002-5704-582X				Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BLACK RA, 1988, J BIOL CHEM, V263, P9437; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; DINARELLO CA, 1994, EUR CYTOKINE NETW, V5, P517; DUAN H, 1996, J BIOL CHEM, V271, P35013; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1991, YEAST, V7, P253, DOI 10.1002/yea.320070307; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AD, 1995, J IMMUNOL, V154, P2321; JACOBSON MD, 1994, CURR BIOL, V4, P337, DOI 10.1016/S0960-9822(00)00073-7; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MILLER DK, 1993, J BIOL CHEM, V268, P18062; Miossec C, 1996, EUR J IMMUNOL, V26, P1032, DOI 10.1002/eji.1830260512; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NALIN CM, 1995, STRUCTURE, V3, P143, DOI 10.1016/S0969-2126(01)00144-7; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331	40	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27245	27248		10.1074/jbc.271.44.27245	http://dx.doi.org/10.1074/jbc.271.44.27245			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910297	hybrid			2022-12-27	WOS:A1996VQ67900015
J	Weinstein, J; Sundaram, S; Wang, XH; Delgado, D; Basu, R; Stanley, P				Weinstein, J; Sundaram, S; Wang, XH; Delgado, D; Basu, R; Stanley, P			A point mutation causes mistargeting of Golgi GlcNAc-TV in the Lec4A Chinese hamster ovary glycosylation mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; NH2-TERMINAL SIGNAL ANCHOR; LINKED OLIGOSACCHARIDES; ENDOPLASMIC-RETICULUM; CELL-SURFACE; CHO CELLS; PROTEIN; GLYCOSYLTRANSFERASES; EXPRESSION; GENE	The Lec4A and Lec4 Chinese hamster ovary glycosylation mutants lack N-linked glycans with GlcNAc beta-(1,6)Man alpha(1,6) branches that are initiated by the transferase termed GlcNAc-TV. Detergent extracts of Lec4 cells have no detectable GlcNAc-TV activity, but Lec4A extracts have activity equivalent to that of parental Chinese hamster ovary cells. This discrepancy occurs because Lec4A GlcNAc-TV activity co-localizes with membranes of the endoplasmic reticulum (ER) instead of with Golgi membranes (Chaney, W., Sundaram, S,, Friedman, N,, and Stanley, P, (1989) J, Cell, Biol, 109, 2089-2096), cDNAs from the coding region of the GlcNAc-TV gene have now been isolated from each mutant line. Lec4 GlcNAc-TV cDNA was found to possess two insertions, the first of which shifts the open reading frame and codes for a truncated transferase missing 585 amino acids from the catalytic domain. By contrast, Lec4A GlcNAc-TV cDNA possesses a single point mutation from T to G, which results in a change from Leu to Arg at position 188. When transfected into Lec4 cells, both cDNAs gave the appropriate phenotype; Lec4 cDNA was unable to restore GlcNAc-TV activity, whereas Lec4A cDNA converted Lec4 cells to the Lec4A. phenotype, with an active GlcNAc-TV mislocalized to ER membranes. Moreover Lec4A cDNA cured of its mutation restored a functional, Golgi-localized GlcNAc-TV to Lec4 cells. The results demonstrate that a single change in the 740 amino acids of GlcNAc-TV serves to functionally inactivate the transferase in an intact cell by causing it to localize to the En instead of the Golgi compartment. The mislocalized transferase retains full enzyme activity, showing that it is well folded and stable and suggesting that the L188R mutation either prevents association with exit complexes from the ER or causes retrograde transport from a Golgi compartment.	AMGEN INC, THOUSAND OAKS, CA 91320 USA; ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, NEW YORK, NY 10461 USA	Amgen; Yeshiva University				Stanley, Pamela/0000-0001-5704-3747	PHS HHS [R01 36434, R01 13330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHANEY W, 1989, J CELL BIOL, V109, P2089, DOI 10.1083/jcb.109.5.2089; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; CORNIL I, 1990, J CELL BIOL, V111, P773, DOI 10.1083/jcb.111.2.773; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GLEESON PA, 1994, GLYCOCONJUGATE J, V11, P381, DOI 10.1007/BF00731273; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KAHN SH, 1993, J BIOL CHEM, V268, P2468; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KUMAR R, 1990, MOL CELL BIOL, V10, P3857; KUMAR R, 1989, MOL CELL BIOL, V9, P5713, DOI 10.1128/MCB.9.12.5713; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PELTOLA M, 1994, HUM MOL GENET, V3, P2237, DOI 10.1093/hmg/3.12.2237; PERNG GS, 1994, GLYCOBIOLOGY, V4, P867, DOI 10.1093/glycob/4.6.867; RACCHI M, 1993, J BIOL CHEM, V268, P5735; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHOREIBAH M, 1993, J BIOL CHEM, V268, P15381; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STANLEY P, 1975, CELL, V6, P121, DOI 10.1016/0092-8674(75)90002-1; STANLEY P, 1983, METHOD ENZYMOL, V96, P157; STANLEY P, 1981, CELL, V23, P763, DOI 10.1016/0092-8674(81)90440-2; STANLEY P, 1982, ARCH BIOCHEM BIOPHYS, V219, P128, DOI 10.1016/0003-9861(82)90141-2; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963	36	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27462	27469		10.1074/jbc.271.44.27462	http://dx.doi.org/10.1074/jbc.271.44.27462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910328	hybrid			2022-12-27	WOS:A1996VQ67900046
J	Brzeska, H; Szczepanowska, J; Hoey, J; Korn, ED				Brzeska, H; Szczepanowska, J; Hoey, J; Korn, ED			The catalytic domain of Acanthamoeba myosin I heavy chain kinase .2. Expression of active catalytic domain and sequence homology to p21-activated kinase (PAK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYLATION SITES; CRYSTAL-STRUCTURE; AMINO-ACID; MAP KINASE; ACTIVATION; AUTOPHOSPHORYLATION; SUBUNIT; CDC42; LOCALIZATION	Acanthamoeba myosin I heavy chain (MIHC) kinase is a monomeric 97-kDa protein that is activated by binding to acidic phospholipids or by autophosphorylation. Activation by phospholipids is inhibited by Ca2+-calmodulin. In the accompanying paper (Brzeska, H., Martin, B., and Korn, E. D. (1996) J. Biol. Chem. 271, 27049-27055), we identified the catalytic domain as the COOH-terminal 35 kDa produced by trypsin digestion of phosphorylated MIHC kinase, In this paper, we report the cloning and sequencing of the corresponding cDNA and expression of fully active catalytic domain. The expressed catalytic domain has substrate specificity similar to that of native kinase and resistance to trypsin similar to that of fully phosphorylated MIHC kinase, MIHC kinase catalytic domain has only 25% sequence identity to the catalytic domain of protein kinase A and similarly low sequence identity to the catalytic domains of protein kinase C- and calmodulin-dependent kinases, but 50% sequence identity and 70% similarity to the p21-activated kinase (PAK) and STE20 family of kinases. This suggests that MIHC kinase is (at least) evolutionarily related to the PAK family, whose activities are regulated by small GTP-binding proteins, The homology includes the presence of a potential MIHC kinase autophosphorylation site as well as conserved Tyr and Ser/Thr residues in the region corresponding to the P+1 loop of protein kinase A. A synthetic peptide corresponding to this region of MIHC kinase is phosphorylated by both the expressed catalytic domain and native MIHC kinase.	NHLBI,NIH,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Korn, Edward D/F-9929-2012	Szczepanowska, Joanna/0000-0002-0434-1262; Korn, Edward/0000-0003-3867-6295				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BRZESKA H, 1989, J BIOL CHEM, V264, P19340; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; BRZESKA H, 1992, J BIOL CHEM, V267, P23870; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1996, J BIOL CHEM, V271, P16983, DOI 10.1074/jbc.271.29.16983; BRZESKA H, 1992, J BIOL CHEM, V267, P4949; Brzeska H, 1996, J BIOL CHEM, V271, P27049, DOI 10.1074/jbc.271.43.27049; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HAMMER JA, 1984, J BIOL CHEM, V259, P3224; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Higuchi R., 1989, PCR TECHNOLOGY, P61; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee S. F., 1995, Molecular Biology of the Cell, V6, p149A; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LYNCH TJ, 1989, J BIOL CHEM, V264, P19333; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Masaracchia R, 1996, FASEB J, V10, P1538; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; SHOJI S, 1979, J BIOL CHEM, V254, P6211; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WANG ZY, 1995, J BIOL CHEM, V270, P27969, DOI 10.1074/jbc.270.46.27969; YONEMOTO W, 1993, J BIOL CHEM, V268, P18626; ZHANG B, 1991, J BIOL CHEM, V266, P990; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0	43	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27056	27062		10.1074/jbc.271.43.27056	http://dx.doi.org/10.1074/jbc.271.43.27056			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900196				2022-12-27	WOS:A1996VP23300090
J	Kumble, KD; Kornberg, A				Kumble, KD; Kornberg, A			Endopolyphosphatases for long chain inorganic polyphosphate in yeast and mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; PROPIONIBACTERIUM-SHERMANII; EXOPOLYPHOSPHATASE; PURIFICATION; KINASE; GENE; GLUCOKINASE; MECHANISM; PROTEIN	Whereas exopolyphosphatases have been purified from yeast and a variety of bacteria, this is the first report characterizing endopolyphosphatases that act on long chain inorganic polyphosphate (polyP). The activity from Saccharomyces cerevisiae, localized in vacuoles, has been purified to homogeneity from a strain that possesses vacuolar proteases. The endopolyphosphatase is a dimer of 35-kDa subunits. Distributive action on polyP(750) produces shorter chains to a limit of about polyP(60), as well as the more abundant release of polyP(3); the K-m for polyP(750) is 185 nM. Endopolyphosphatases have been identified in a wide variety of sources, except for most eubacteria tested. The activity has been partially purified from rat and bovine brain where its abundance is about 10 times higher than in other tissues but less than 1/10 that of yeast; the limit product of digestion of the partially purified brain enzyme is polyP(3).	STANFORD UNIV, SCH MED, BECKMAN CTR, DEPT BIOCHEM, STANFORD, CA 94305 USA	Stanford University								AHN KH, 1990, J BIOL CHEM, V265, P11734; AKIYAMA M, 1993, J BIOL CHEM, V268, P633; AKIYAMA M, 1992, J BIOL CHEM, V267, P22556; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; GABEL N W, 1990, Evolutionary Theory, V9, P181; INGELMAN B, 1947, ACTA CHEM SCAND, V1, P422, DOI 10.3891/acta.chem.scand.01-0422; JAZWINSKI SM, 1990, METHOD ENZYMOL, V182, P154; KEASLING JD, 1993, P NATL ACAD SCI USA, V90, P7029, DOI 10.1073/pnas.90.15.7029; KORNBERG A, 1995, J BACTERIOL, V177, P491, DOI 10.1128/jb.177.3.491-496.1995; KORNBERG SR, 1956, J BIOL CHEM, V218, P23; KOWALCZYK TH, 1993, ANAL BIOCHEM, V212, P194, DOI 10.1006/abio.1993.1312; KOWALCZYK TH, 1991, FASEB J, V5, P288; KRISHNAN PS, 1952, ARCH BIOCHEM BIOPHYS, V37, P224, DOI 10.1016/0003-9861(52)90180-X; KRITSKII MS, 1972, BIOCHEMISTRY-US, V37, P822; KULAEV I S, 1971, Biochemistry (Moscow), V36, P356; Kulaev IS, 1979, BIOCH INORGANIC POLY; KUMBLE KD, 1995, J BIOL CHEM, V270, P5818, DOI 10.1074/jbc.270.11.5818; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGEN P, 1958, BIOCHEM Z, V330, P455; LORENZ B, 1994, J BIOL CHEM, V269, P22198; MATTENHEIMER H, 1956, HOPPESEYLER Z PHYSL, V303, P11; MERRIL CR, 1990, METHOD ENZYMOL, V182, P477; MUHAMMED A, 1959, J GEN MICROBIOL, V20, P482, DOI 10.1099/00221287-20-3-482; MURATA K, 1980, AGR BIOL CHEM TOKYO, V44, P61, DOI 10.1080/00021369.1980.10863915; PEPIN CA, 1986, J BIOL CHEM, V261, P4476; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROBINSON NA, 1986, J BIOL CHEM, V261, P4481; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; TINSLEY CR, 1993, INFECT IMMUN, V61, P3703, DOI 10.1128/IAI.61.9.3703-3710.1993; URECH K, 1978, ARCH MICROBIOL, V116, P275, DOI 10.1007/BF00417851; VANGROENESTIJN JW, 1987, ARCH MICROBIOL, V148, P14, DOI 10.1007/BF00429640; WIECKOWSKI EU, 1991, FASEB J, V5, P290; WURST H, 1994, J BIOL CHEM, V269, P10996; WURST H, 1995, J BACTERIOL, V177, P898, DOI 10.1128/jb.177.4.898-906.1995	34	92	101	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27146	27151		10.1074/jbc.271.43.27146	http://dx.doi.org/10.1074/jbc.271.43.27146			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900207	hybrid			2022-12-27	WOS:A1996VP23300101
J	Towner, JS; Ho, TV; Semler, BL				Towner, JS; Ho, TV; Semler, BL			Determinants of membrane association for poliovirus protein RAB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RNA REPLICATION; CYTOPLASMIC MEMBRANES; MICROSOMAL-MEMBRANES; VIRAL REPLICATION; 3AB; CYTOCHROME-B5; TOPOGRAPHY; EXPRESSION; POLYMERASE	Poliovirus protein 3AB may serve as the lipophilic carrier of a, protein primer (VPg or 3B) used for the initiation of genomic viral RNA synthesis, Tn order to study the membrane-protein interactions of 3AB required for its role in poliovirus RNA replication, we have developed an in vitro a membrane association assay capable of distinguishing membrane-bound from nonmembrane-bound proteins that are cotranslated together in the presence of canine microsomal membranes. This assay utilizes equilibrium sedimentation analysis in high density sucrose gradients to measure membrane association of both wild type and mutated Terms of 3AB, Using this assay and other biochemical assays, we have identified the following properties of the 3AB-membrane interaction: (a) 3AB is able to post-translationally associate with microsomal membraues, (b) 3AB is able to associate with membranes in a manner consistent with that of an integral membrane protein, (c) 3AB contains a critical hydrophobic sequence within the carboxyl-terminal half of the protein that is required for membrane association, and (d) the introduction of charged residues into this hydrophobic sequence disrupts the 3AB membrane-protein interaction, Taken together, these studies indicate that poliovirus protein 3AB associates tightly with biological membranes de novo in a manner that would allow it to serve as a lipophilic anchor for the assembly of the poliovirus RNA replication complex.	UNIV CALIF IRVINE,COLL MED,DEPT MICROBIOL & MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine			Semler, Bert/AAV-8795-2020; Towner, Jonathan/ABC-3780-2020	Semler, Bert/0000-0002-2424-5155; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022693] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22693, R01 AI022693] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DJ, 1983, P NATL ACAD SCI-BIOL, V80, P7249, DOI 10.1073/pnas.80.23.7249; ARINC E, 1987, J BIOL CHEM, V262, P15563; BIENZ K, 1992, J VIROL, V66, P2740, DOI 10.1128/JVI.66.5.2740-2747.1992; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1990, J VIROL, V64, P1156, DOI 10.1128/JVI.64.3.1156-1163.1990; CALIGUIRI LA, 1970, VIROLOGY, V42, P100, DOI 10.1016/0042-6822(70)90242-4; CALIGUIRI LA, 1970, VIROLOGY, V42, P112, DOI 10.1016/0042-6822(70)90243-6; CALIGUIRI LA, 1969, SCIENCE, V166, P885, DOI 10.1126/science.166.3907.885; CHARINI WA, 1991, J VIROL, V65, P2655, DOI 10.1128/JVI.65.5.2655-2665.1991; DAILEY HA, 1981, J BIOL CHEM, V256, P3951; DATTA U, 1994, J VIROL, V68, P4468, DOI 10.1128/JVI.68.7.4468-4477.1994; ECHEVERRI AC, 1995, VIROLOGY, V208, P540, DOI 10.1006/viro.1995.1185; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FROSHAUER S, 1988, J CELL BIOL, V107, P2075, DOI 10.1083/jcb.107.6.2075; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GIACHETTI C, 1991, J VIROL, V65, P2647, DOI 10.1128/JVI.65.5.2647-2654.1991; GIACHETTI C, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P83; GIACHETTI C, 1992, J VIROL, V66, P6045, DOI 10.1128/JVI.66.10.6045-6057.1992; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; JENNINGS ML, 1989, ANNU REV BIOCHEM, V58, P999; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1994, J BIOL CHEM, V269, P66; LAMA J, 1992, J BIOL CHEM, V267, P15932; LAMA J, 1995, J BIOL CHEM, V270, P14430, DOI 10.1074/jbc.270.24.14430; LI SC, 1992, FEBS LETT, V311, P217, DOI 10.1016/0014-5793(92)81106-V; LI SC, 1994, NAT STRUCT BIOL, V1, P558; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; PAUL AV, 1994, VIROLOGY, V199, P188, DOI 10.1006/viro.1994.1111; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2633, DOI 10.1021/bi00357a052; RESTREPOHARTWIG MA, 1994, J VIROL, V68, P2388, DOI 10.1128/JVI.68.4.2388-2397.1994; Sankaram M.B., 1993, NEW COMPREHENSIVE BI, VVolume 25, P127; SEMLER BL, 1982, CELL, V28, P405, DOI 10.1016/0092-8674(82)90358-0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; Singer S. J., 1971, STRUCTURE FUNCTION B, P145; STECK T L, 1973, Journal of Supramolecular Structure, V1, P220, DOI 10.1002/jss.400010307; TAKEGAMI T, 1983, VIROLOGY, V128, P33, DOI 10.1016/0042-6822(83)90316-1; TERSHAK DR, 1984, J VIROL, V52, P777, DOI 10.1128/JVI.52.3.777-783.1984; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Whitley P, 1996, J BIOL CHEM, V271, P7583, DOI 10.1074/jbc.271.13.7583; XIANG WK, 1995, J VIROL, V69, P3658, DOI 10.1128/JVI.69.6.3658-3667.1995; Xiang WK, 1995, RNA, V1, P892; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	45	123	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26810	26818		10.1074/jbc.271.43.26810	http://dx.doi.org/10.1074/jbc.271.43.26810			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900162	hybrid			2022-12-27	WOS:A1996VP23300056
J	Weng, GZ; Li, JR; Dingus, J; Hildebrandt, JD; Weinstein, H; Iyengar, R				Weng, GZ; Li, JR; Dingus, J; Hildebrandt, JD; Weinstein, H; Iyengar, R			G beta subunit interacts with a peptide encoding region 956-982 of adenylyl cyclase 2 - Cross-linking of the peptide to free G beta gamma but not the heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; SIGNALS; ALPHA	The region encoded by amino acids 956-982 of adenylyl cyclase 2 is important for G beta gamma stimulation. Interactions of a peptide encoding the 956-982 region of adenylyl cyclase 2 (QEHAQEPERQYMHIGTMVEFAYALVGK (QEHA peptide)) with G beta gamma subunits were studied, QEHA peptide was covalently attached to beta subunit of free G beta gamma by the cross-linker N-succinimidyl(4-iodoacetyl)aminobenzoate. Cross-linking was proportional to the amount of QEHA peptide added; other control peptides crosslinked minimally. When G(o) was used, very little crosslinking was observed with GDP and EDTA, but upon activation by guanosine 5'-3-O-(thio)triphosphate and Mg2+, specific cross-linking of the QEHA peptide to G beta was observed. We conclude that beta subunits of G proteins contain effector interaction domains that are occluded by G alpha subunits in the heterotrimer. Molecular modeling studies used to dock the QEHA peptide on to G beta indicate that amino acids 75-165 of G beta may be involved in effector interactions.	CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; MED UNIV S CAROLINA,DEPT PHARMACOL,CHARLESTON,SC 29425	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Medical University of South Carolina	Weng, GZ (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,BOX 1215,NEW YORK,NY 10029, USA.		WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818	NIDDK NIH HHS [DK37219, DK38761] Funding Source: Medline; NIGMS NIH HHS [GM54508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038761, R01DK037219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DINGUS J, 1994, METHOD ENZYMOL, V238, P457; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; LAMBRIGHT DG, 1996, NATURE, V379, P369; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PRONIN AN, 1994, METHOD ENZYMOL, V237, P482; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SONDEK J, 1996, NATURE, V379, P311; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597	20	46	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26445	26448		10.1074/jbc.271.43.26445	http://dx.doi.org/10.1074/jbc.271.43.26445			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900107	hybrid			2022-12-27	WOS:A1996VP23300001
J	Cook, PF; Tai, CH; Hwang, CC; Woehl, EU; Dunn, MF; Schnackerz, KD				Cook, PF; Tai, CH; Hwang, CC; Woehl, EU; Dunn, MF; Schnackerz, KD			Substitution of pyridoxal 5'-phosphate in the O-acetylserine sulfhydrylase from Salmonella typhimurium by cofactor analogs provides a test of the mechanism proposed for formation of the alpha-aminoacrylate intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE-AMINOTRANSFERASE; P-31 NMR; PHOSPHATE; SERINE; LT-2; ACID; SITE; PH	O-Acetylserine sulfhydrylase (OASS) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the final step in the de novo synthesis of L-cysteine in Salmonella typhimurium. Complementary cofactor mutagenesis in which the active site PLP is substituted with cofactor analogs is used to test the mechanism proposed for the OASS, Data obtained with the pyridoxal 5'-deoxymethylenephosphonate-substituted enzyme suggest that the binding of OAS as it forms the external Schiff base is such that the acetate side chain is properly positioned for elimination (orthogonal to the developing alpha,beta-double bond) only about 1% of the time, Data support the assignment of an enzyme group with a pK of 6.7 that interacts with the acetyl side chain, maintaining it orthogonal to the developing alpha,beta-double bond, Similar studies of the 2'-methylpyridoxal 5'-phosphate-substituted enzyme suggest that, although the mechanism is identical to that catalyzed by native OASS, the reaction coordinate for alpha-proton abstraction may be decreased compared with that observed for the native enzyme.	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; UNIV WURZBURG,BIOZENTRUM,THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY	University of California System; University of California Riverside; University of Wurzburg	Cook, PF (corresponding author), UNIV N TEXAS,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,FT WORTH,TX 76107, USA.		Hwang, Chi-Ching/K-7933-2012	Hwang, Chi-Ching/0000-0002-8328-674X; Weber-Ban, Eilika/0000-0002-5773-9274				BECKER MA, 1969, J BIOL CHEM, V244, P2418; Cleland W W, 1979, Methods Enzymol, V63, P103; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; COOK PF, 1981, BIOCHEMISTRY-US, V20, P1790, DOI 10.1021/bi00510a013; COOK PF, 1976, J BIOL CHEM, V251, P2023; ELLMANN GL, 1958, ARCH BIOCHEM BIOPHYS, V82, P70; Gorenstein D.G., 1984, PHOSPHORUS 31 NMR PR, P7; GROMAN E, 1972, P NATL ACAD SCI USA, V69, P3297, DOI 10.1073/pnas.69.11.3297; HARA S, 1990, Protein Expression and Purification, V1, P70, DOI 10.1016/1046-5928(90)90048-4; Hwang CC, 1996, BIOCHEMISTRY-US, V35, P6358, DOI 10.1021/bi9602472; KING EL, 1956, J PHYS CHEM-US, V60, P1375, DOI 10.1021/j150544a010; KREDICH NM, 1966, J BIOL CHEM, V241, P4955; KUPFER A, 1977, BIOCHEM BIOPH RES CO, V79, P1004, DOI 10.1016/0006-291X(77)91209-8; MCCLURE GD, 1994, BIOCHEMISTRY-US, V33, P1674, DOI 10.1021/bi00173a009; MERKL L, 1981, Z NATURFORSCH, V36, P778; MIURA R, 1989, ARCH BIOCHEM BIOPHYS, V270, P526, DOI 10.1016/0003-9861(89)90535-3; NORTHROP DB, 1975, BIOCHEMISTRY-US, V14, P2644, DOI 10.1021/bi00683a013; Parkin D., 1991, METHODS DETERMINATIO, P269; SCHIRCH V, 1978, BIOCHEM BIOPH RES CO, V85, P99; Schnackerz KD, 1995, ARCH BIOCHEM BIOPHYS, V324, P71, DOI 10.1006/abbi.1995.9927; SCHNACKERZ KD, 1989, EUR J BIOCHEM, V185, P525, DOI 10.1111/j.1432-1033.1989.tb15145.x; SCHNACKERZ KD, 1980, BIOCHEM BIOPH RES CO, V95, P1832, DOI 10.1016/S0006-291X(80)80112-4; SCHNACKERZ KD, 1986, VITAMIN B6 PYRIDOX A, P245; SCHNACKERZ KD, 1995, BIOCHEM BIOPH RES CO, V324, P71; SCHNACKERZ KD, 1995, BIOCHEMISTRY-US, V34, P12125; SHIMOMURA S, 1978, BIOCHEMISTRY-US, V17, P5359, DOI 10.1021/bi00618a006; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Strambini GB, 1996, BIOCHEMISTRY-US, V35, P8392, DOI 10.1021/bi952919e; TAI CH, 1995, BIOCHEMISTRY-US, V34, P12311, DOI 10.1021/bi00038a027; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; Woehl EU, 1996, BIOCHEMISTRY-US, V35, P4776, DOI 10.1021/bi952938o	31	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25842	25849		10.1074/jbc.271.42.25842	http://dx.doi.org/10.1074/jbc.271.42.25842			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824215				2022-12-27	WOS:A1996VN18000021
J	Wajant, H; Pfizenmaier, K				Wajant, H; Pfizenmaier, K			Identification of potential active-site residues in the hydroxynitrile Lyase from Manihot esculenta by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE CARBOXYPEPTIDASE-II; ENZYME-CATALYZED SYNTHESIS; POLYACRYLAMIDE GELS; SORGHUM-BICOLOR; PURIFICATION; PROTEINS; CLONING; (S)-CYANOHYDRINS; RESOLUTION; CASSAVA	The hydroxynitrile lyase from cassava (Manihot esculenta Crantz) (EC 4.1.2.37) catalyzes the decomposition of the achiral alpha-hydroxynitrile acetone cyanohydrin into HCN and acetone during cyanogenesis of damaged plants, This enzyme can also be used for stereoselective synthesis of a wide array of (S)-cyanohydrins by addition of HCN to aldehydes or ketones, Optically active cyanohydrins are interesting intermediates for the synthesis of alpha-hydroxy acids, alpha-hydroxy ketones, or beta-ethanolamines, all of which are important building blocks in organic synthesis, Inhibition of hydroxynitrile lyase from M. esculenta (MeHNL) by serine- and histidine-modifying reagents suggests involvement of active site seryl and histidyl residues. Furthermore, serine 80 of MeHNL is part of the active site motif Gly-X-Ser-X-Gly/Ala, often considered as the hallmark of catalytic triads having independently evolved in four groups of enzymes: the alpha/beta hydrolase fold enzymes, subtilisins, the cysteine proteases, and the eukaryotic serine proteases, By site-directed mutagenesis, three residues critical for enzyme activity have been identified: serine 80, aspartic acid 208, and histidine 236. These residues may be directly involved in MeHNL-catalyzed decomposition of cyanohydrins, providing evidence for a catalytical triad in HNLs, too. The order of the catalytic triad residues in the primary sequence of MeHNL is nucleophile-histidine-acid, suggesting that MeHNL belongs to the alpha/beta hydrolase fold group of enzymes, In contrast to all other enzymes having a catalytical triad, HNLs catalyze no net hydrolytic reactions.			Wajant, H (corresponding author), UNIV STUTTGART,INST CELL BIOL & IMMUNOL,ALLMANDRING 31,D-70569 STUTTGART,GERMANY.		Wajant, Harald/A-3020-2017	Wajant, Harald/0000-0002-2005-3949				ALBRECHT J, 1993, BIOTECHNOL APPL BIOC, V17, P191; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOVE C, 1961, J BIOL CHEM, V236, P207; CHENG IP, 1993, PLANT CELL PHYSIOL, V34, P1139; EFFENBERGER F, 1987, ANGEW CHEM INT EDIT, V26, P458, DOI 10.1002/anie.198704581; EFFENBERGER F, 1990, TETRAHEDRON LETT, V31, P1249, DOI 10.1016/S0040-4039(00)88777-8; HUGHES J, 1994, ARCH BIOCHEM BIOPHYS, V311, P496, DOI 10.1006/abbi.1994.1267; KLEMPIER N, 1993, TETRAHEDRON LETT, V34, P4769, DOI 10.1016/S0040-4039(00)74084-6; KUROKI GW, 1989, P NATL ACAD SCI USA, V86, P6978, DOI 10.1073/pnas.86.18.6978; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; POULTON JE, 1988, CIBA F SYMP, V140, P67; REIMMANN C, 1995, PHYSIOL MOL PLANT P, V46, P71, DOI 10.1006/pmpp.1995.1006; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Seigler D. S., 1991, HERBIVORES THEIR INT, VI, P35; SELMAR D, 1987, ANAL BIOCHEM, V166, P208, DOI 10.1016/0003-2697(87)90565-3; SMITSKAMPWILMS E, 1991, RECL TRAV CHIM PAY B, V110, P209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAJANT H, 1993, PLANT SCI, V89, P127, DOI 10.1016/0168-9452(93)90120-O; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758; WAJANT H, 1995, PLANT SCI, V108, P1, DOI 10.1016/0168-9452(95)04118-E; WAJANT H, 1995, PLANT PHYSIOL, V109, P1231, DOI 10.1104/pp.109.4.1231	25	54	60	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25830	25834		10.1074/jbc.271.42.25830	http://dx.doi.org/10.1074/jbc.271.42.25830			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824213	hybrid			2022-12-27	WOS:A1996VN18000019
J	Cox, GW; Taylor, LS; Willis, JD; Melillo, G; White, RL; Anderson, SK; Lin, JJ				Cox, GW; Taylor, LS; Willis, JD; Melillo, G; White, RL; Anderson, SK; Lin, JJ			Molecular cloning and characterization of a novel mouse macrophage gene that encodes a nuclear protein comprising polyglutamine repeats and interspersing histidines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC MESSENGER-RNAS; BULBAR MUSCULAR-ATROPHY; 3' UNTRANSLATED REGION; LARGE-T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; NUCLEOTIDE-SEQUENCE; ANDROGEN RECEPTOR; TRIPLET REPEAT; DNA-BINDING; NEURODEGENERATIVE DISEASES	Simple tandem repeats of the trinucleotide sequence CAG encode homopolymeric stretches of glutamine. Although polyglutamine has been identified in diverse proteins, it is present predominantly in transcription factors, We observed that oncogene-immortalized mouse macrophages express several genes that contain a CAG repeat motif. Therefore, we attempted to clone a novel gene that contains a CAG repeat and is associated with cytokine activation of macrophages. Screening of a mouse macrophage cDNA library with a probe comprising 12 consecutive CAG triplets identified at least one unique clone. The cDNA encodes a protein (named GRP-1 or glutamine repeat protein-1) with 171 amino acids, a calculated molecular mass of 21.6 kDa, and a predicted pI of 10.67. Greater than two-thirds of GRP-1 are only two amino acids, namely glutamine (50%) and histidine (18%). There are four polyglutamine motifs interspersed with histidine-rich regions. There is also a putative nuclear localization signal flanked by sites for possible serine phosphorylation. GRP-1 mRNA was expressed constitutively in some macrophage cell lines and B and T cell lines. Interferon-gamma or lipopolysaccharide augmented GRP-1 mRNA expression in the mouse macrophage cell line ANA-1. Western blot analyses using an antipeptide serum revealed that GRP-1 was localized in the nucleus of ANA-1 macrophages and transfected 3T3 fibroblasts. Overexpression of GRP-1 decreased Sp1-driven chloramphenicol acetyltransferase gene expression in transient cotransfection experiments. Because polyglutamine motifs can cause protein oligomerization and can function as transcriptional activation domains, we suggest that GRP-1 may be a transcription factor associated with interferon-gamma- or lipopolysaccharide-induced activation of macrophages.	SCI APPLICAT INT CORP,EXPT IMMUNOL LAB,FREDERICK,MD; SCI APPLICAT INT CORP,BIOCHEM PHYSIOL LAB,DIV BASIC SCI,FREDERICK,MD; SCI APPLICAT INT CORP,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD; NCI,FREDERICK CANC RES & DEV CTR,NATL INST HLTH,FREDERICK,MD 21702	Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); Science Applications International Corporation (SAIC); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Anderson, Stephen K/B-1727-2012	Anderson, Stephen K/0000-0002-7856-4266; White, Robert/0000-0003-2769-4340				BHAT BM, 1985, MOL CELL BIOL, V5, P3183, DOI 10.1128/MCB.5.11.3183; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BLASI E, 1987, EUR J IMMUNOL, V17, P1491, DOI 10.1002/eji.1830171016; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENDEL V, 1989, P NATL ACAD SCI USA, V86, P5698, DOI 10.1073/pnas.86.15.5698; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CHANG CS, 1988, P NATL ACAD SCI USA, V85, P7211, DOI 10.1073/pnas.85.19.7211; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Chomczynski P, 1993, BIOTECHNIQUES, V15, P536; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COX GW, 1992, J IMMUNOL, V149, P3290; COX GW, 1990, J IMMUNOL, V145, P1719; COX GW, 1989, J NATL CANCER I, V81, P1492, DOI 10.1093/jnci/81.19.1492; DANIELSEN M, 1986, EMBO J, V5, P2513, DOI 10.1002/j.1460-2075.1986.tb04529.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; DOYLE MV, 1985, J BIOL RESP MODIF, V4, P96; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; DUBOULE D, 1987, MOL CELL BIOL, V7, P2003, DOI 10.1128/MCB.7.5.2003; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYNES SR, 1989, DEV BIOL, V134, P246, DOI 10.1016/0012-1606(89)90094-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KARLIN S, 1989, J MOL BIOL, V205, P165, DOI 10.1016/0022-2836(89)90373-2; KASHIMA N, 1985, NATURE, V313, P402, DOI 10.1038/313402a0; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP, P239; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MHATRE AN, 1993, NAT GENET, V5, P184, DOI 10.1038/ng1093-184; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NEWFELD SJ, 1991, J MOL EVOL, V32, P415, DOI 10.1007/BF02101281; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STOTT K, 1995, P NATL ACAD SCI USA, V92, P6509, DOI 10.1073/pnas.92.14.6509; SUTHERLAND GR, 1995, P NATL ACAD SCI USA, V92, P3636, DOI 10.1073/pnas.92.9.3636; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG A, 1984, SCIENCE, V224, P1431, DOI 10.1126/science.6427925; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILTROUT RH, 1990, IMMUNOPHYSIOLOGY, P365; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x; YOKOTA T, 1985, P NATL ACAD SCI USA, V82, P68, DOI 10.1073/pnas.82.1.68; 1993, CELL, V72, P971	83	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25515	25523		10.1074/jbc.271.41.25515	http://dx.doi.org/10.1074/jbc.271.41.25515			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810323	hybrid			2022-12-27	WOS:A1996VL69300067
J	Charpentier, S; Jarvie, KR; Severynse, DM; Caron, MG; Tiberi, M				Charpentier, S; Jarvie, KR; Severynse, DM; Caron, MG; Tiberi, M			Silencing of the constitutive activity of the dopamine D1B receptor - Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; PRECOCIOUS PUBERTY; BETA(2)-ADRENERGIC RECEPTOR; NIGHT BLINDNESS; GENE; RHODOPSIN; EXPRESSION; CLONING; MUTANT; RESPONSIVENESS	Recently, we have shown that the dopamine D1B/D5 receptor displays binding and coupling properties that are reminiscent of those of the constitutively activated G protein-coupled receptors when compared with the related D1A/D1 receptor subtype (Tiberi, M., and Caron, M. G. (1994) J. Biol. Chem. 269, 27925-27931). The carboxyl-terminal region of the third cytoplasmic loop of several G protein coupled receptors has been demonstrated to be important for the regulation of the equilibrium between inactive and active receptor conformations. In this cytoplasmic region, the primary structure of dopamine D1A and D1B receptors differs by only two residues: Phe(264)/Arg(266) present in D1A receptor compared with Ile(288)/Lys(290) in the D1B receptor. To investigate whether these structural differences could account for the distinct binding and coupling properties of these dopamine receptor subtypes, we swapped the variant residues located in the carboxyl-terminal region by site-directed mutagenesis. The exchange of the D1A receptor residue Phe(264) by the D1B receptor counterpart isoleucine led to a D1A receptor mutant exhibiting D1B-like constitutive properties. In contrast, substitution of D1B receptor Ile(288) by the D1A receptor counterpart phenylalanine resulted in a loss of constitutive activation of the D1B receptor with binding and coupling properties similar to the D1A receptor. The Arg/Lys substitution had no effect on the function of either receptor. These results demonstrate that the carboxyl-terminal region, and in particular residue Ile(288), is a major determinant of the constitutive activity of the dopamine D1B receptor. Moreover, these results establish that not only can agonist-independent activity of a receptor be induced, but when given the appropriate mutation, it can be re versed or silenced.	DUKE UNIV, MED CTR, DEPT CELL BIOL, HOWARD HUGHES MED INST LABS, DURHAM, NC 27710 USA	Duke University								Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DRYJA TP, 1993, NAT GENET, V4, P280, DOI 10.1038/ng0793-280; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; GINGRICH JA, 1993, ANNU REV NEUROSCI, V16, P299, DOI 10.1146/annurev.ne.16.030193.001503; GRANDY DK, 1991, P NATL ACAD SCI USA, V88, P9175, DOI 10.1073/pnas.88.20.9175; HOGGER P, 1995, J BIOL CHEM, V270, P7405; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KREMER H, 1993, HUM MOL GENET, V2, P1779, DOI 10.1093/hmg/2.11.1779; LATRONICO AC, 1995, J CLIN ENDOCR METAB, V80, P2490, DOI 10.1210/jc.80.8.2490; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MILANO CA, 1994, P NATL ACAD SCI USA, V91, P10109, DOI 10.1073/pnas.91.21.10109; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PEI G, 1994, P NATL ACAD SCI USA, V91, P2699, DOI 10.1073/pnas.91.7.2699; Perez DM, 1996, MOL PHARMACOL, V49, P112; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; REN Q, 1993, J BIOL CHEM, V268, P16483; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SOKOLOFF P, 1995, TRENDS PHARMACOL SCI, V16, P270, DOI 10.1016/S0165-6147(00)89044-6; Spalding TA, 1995, J PHARMACOL EXP THER, V275, P1274; SUNAHARA RK, 1991, NATURE, V350, P614, DOI 10.1038/350614a0; TIBERI M, 1994, J BIOL CHEM, V269, P27925; TIBERI M, 1991, P NATL ACAD SCI USA, V88, P7491, DOI 10.1073/pnas.88.17.7491; WEISHANK RL, 1991, J BIOL CHEM, V266, P22427	36	49	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28071	28076		10.1074/jbc.271.45.28071	http://dx.doi.org/10.1074/jbc.271.45.28071			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910419	hybrid			2022-12-27	WOS:A1996VU03300019
J	Ried, C; Wahl, C; Miethke, T; Wellnhofer, G; Landgraf, C; SchneiderMergener, J; Hoess, A				Ried, C; Wahl, C; Miethke, T; Wellnhofer, G; Landgraf, C; SchneiderMergener, J; Hoess, A			High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI SEPSIS; ANTILIPOPOLYSACCHARIDE FACTOR; HORSESHOE-CRAB; SYNTHETIC PEPTIDES; IMPROVES SURVIVAL; SEPTIC SHOCK; LPS FACTOR; PROTEIN; BACTERIAL; SITE	Lipid A, the conserved portion of endotoxin or lipopolysaccharide, is the major mediator of septic shock, and therefore endotoxin-neutralizing molecules could have important clinical applications. The crystal structure of recombinant Limulus anti-lipopolysaccharide factor (rLALF) (Hoess, A., Watson, S., Siber, G. R., and Liddington, R. (1993) EMBO J. 12, 3351-3356), has been used to design synthetic peptides comprising different parts of the exposed amphipathic loop in the proposed endotoxin-binding domain of rLALF. We investigated the minimal requirements of rLALF for endotoxin and lipid A binding with linear 10-mer peptides. Only one Linear peptide, corresponding to amino acids 36-45 of rLALF, was able to bind lipid A and endotoxin above background levels. Cyclic peptides, however, bind lipid A and endotoxin with high affinity, presumably by mimicking the three dimensional characteristics of the exposed hairpin loop. The cyclic peptide including amino acids 36-47, LALF-14, has a Lipid A binding activity comparable to the high affinity endotoxin-binding peptide polymyxin B. LALF-14 has an improved serum half-life compared with its linear counterpart, and it is not toxic for cultured human monocytes or red blood cells. In mice, it blocks tumor necrosis factor-alpha induction after endotoxin challenge. The characterization of the minimal endotoxin-binding domain of rLALF and, importantly, its structure provided a basis for designing small molecules that could have prophylactic and/or therapeutic properties in humans for the management of septic shock.	MORPHOSYS GMBH, D-80807 MUNICH, GERMANY; TECH UNIV MUNICH, INST MED MICROBIOL & HYG, D-81675 MUNICH, GERMANY; HUMBOLDT UNIV BERLIN, INST MED IMMUNOL, D-10098 BERLIN, GERMANY	MorphoSys; Technical University of Munich; Humboldt University of Berlin								AKETAGAWA J, 1986, J BIOL CHEM, V261, P7357; ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; ALPERT G, 1992, J INFECT DIS, V165, P494, DOI 10.1093/infdis/165.3.494; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; CALANDRA T, 1991, PROG CLIN BIOL RES, V367, P141; DESCH CE, 1989, INFECT IMMUN, V57, P1612, DOI 10.1128/IAI.57.5.1612-1614.1989; GALLAY P, 1993, P NATL ACAD SCI USA, V90, P9935, DOI 10.1073/pnas.90.21.9935; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; Hirata M, 1994, Prog Clin Biol Res, V388, P147; Hoess A, 1995, Prog Clin Biol Res, V392, P327; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; IWANAGA S, 1986, J PROTEIN CHEM, V5, P255, DOI 10.1007/BF01025424; KLOCZEWIAK M, 1994, J INFECT DIS, V170, P1490, DOI 10.1093/infdis/170.6.1490; LARRICK JW, 1994, J IMMUNOL, V152, P231; LEVIN J, 1964, B JOHNS HOPKINS HOSP, V115, P265; LITTLE RG, 1994, J BIOL CHEM, V269, P1865; MARASTONI M, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1073; MORITA T, 1985, J BIOCHEM, V97, P1611, DOI 10.1093/oxfordjournals.jbchem.a135218; MORRISON DC, 1976, IMMUNOCHEMISTRY, V13, P813, DOI 10.1016/0019-2791(76)90181-6; MORRISON DC, 1993, IMMUNOBIOLOGY, V187, P212, DOI 10.1016/S0171-2985(11)80340-2; MUTA T, 1987, J BIOCHEM-TOKYO, V101, P1321, DOI 10.1093/oxfordjournals.jbchem.a121999; NACHUM R, 1979, J INVERTEBR PATHOL, V33, P290, DOI 10.1016/0022-2011(79)90029-6; NELSON D, 1995, CRIT CARE MED, V23, P92, DOI 10.1097/00003246-199501000-00017; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; RUSTICI A, 1993, SCIENCE, V259, P361, DOI 10.1126/science.8420003; SALADINO R, 1994, CIRC SHOCK, V42, P104; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; TAYLOR AH, 1995, J BIOL CHEM, V270, P17934, DOI 10.1074/jbc.270.30.17934; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; TSCHOPP JF, 1993, CORONARY ARTERY DIS, V4, P809, DOI 10.1097/00019501-199309000-00008; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WAINWRIGHT NR, 1990, INT CONGR SER, V923, P315; WARREN HS, 1992, INFECT IMMUN, V60, P2506, DOI 10.1128/IAI.60.6.2506-2513.1992; WONG YN, 1994, BIOPHARM DRUG DISPOS, V15, P535, DOI 10.1002/bdd.2510150702; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719	38	109	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28120	28127		10.1074/jbc.271.45.28120	http://dx.doi.org/10.1074/jbc.271.45.28120			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910426	hybrid			2022-12-27	WOS:A1996VU03300026
J	Yorita, K; Aki, K; OhkumaSoyejima, T; Kokubo, T; Misaki, H; Massey, V				Yorita, K; Aki, K; OhkumaSoyejima, T; Kokubo, T; Misaki, H; Massey, V			Conversion of L-lactate oxidase to a long chain alpha-hydroxyacid oxidase by site-directed mutagenesis of alanine 95 to glycine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINACH GLYCOLATE OXIDASE; RAT-KIDNEY; (S)-MANDELATE DEHYDROGENASE; PSEUDOMONAS-PUTIDA; BAKERS-YEAST; ACID OXIDASE; FLAVOCYTOCHROME-B2; RESOLUTION; SEQUENCE	A mutant form of L-lactate oxidase (LOX) from Aerococcus viridans in which alanine 95 was replaced by glycine was constructed as a mimic of L-lactate monooxygenase but proved instead to be a mimic of the long chain alpha-hydroxyacid oxidase from rat kidney. A95G-LOX keeps oxidase activity with L-lactate at the same level as wild type LOX but has much enhanced oxidase activity with longer chain L-alpha-hydroxyacids, alpha-hydroxy-n-butyric acid, alpha-hydroxy-n-valeric acid, etc., and also the aromatic alpha-hydroxyacid, L-mandelic acid. Kinetic analysis of the activity with these substrates indicates that the reduction of the enzyme bound flavin by substrates is the rate-limiting step in A95G-LOX. The affinity of pyruvate for the reduced enzyme is increased, and sulfite binding to the oxidized enzyme is weaker in A95G-LOX than in native enzyme. Wild type LOX stabilizes both the neutral and anionic flavin semiquinones with a pK(a) of 6.1, but A95G LOX stabilizes only the anionic semiquinone form. These results strongly suggest that the environment around the N5-C4a region of the flavin isoalloxazine ring is changed by this mutation.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; CIBA GEIGY JAPAN,TAKARAZUKA,HYOGO 665,JAPAN; ASAHI CHEM IND CO LTD,OHITO DIAGNOST PLANT,SHIZUOKA 41023,JAPAN	University of Michigan System; University of Michigan; Tokushima University					NIGMS NIH HHS [GM11106] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM011106, R37GM011106] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chance B, 1943, J BIOL CHEM, V151, P553; CROMARTIE TH, 1975, BIOCHEMISTRY-US, V14, P2588, DOI 10.1021/bi00683a005; Ghisla S., 1991, CHEM BIOCH FLAVOENZY, P243; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LE KHD, 1991, J BIOL CHEM, V266, P20877; LEDERER F, 1991, CHEM BIOCH FLAVOENZY, V2, P153; LINDQVIST Y, 1989, J MOL BIOL, V209, P151, DOI 10.1016/0022-2836(89)90178-2; LINDQVIST Y, 1989, J BIOL CHEM, V264, P3624; LOCKRIDGE O, 1972, J BIOL CHEM, V247, P8097; MAEDAYORITA K, 1995, BIOCHIMIE, V77, P631, DOI 10.1016/0300-9084(96)88178-8; MASSEY V, 1969, J BIOL CHEM, V244, P3999; MITRA B, 1993, BIOCHEMISTRY-US, V32, P12959, DOI 10.1021/bi00211a003; SMEKAL O, 1993, BIOCHEM J, V290, P103, DOI 10.1042/bj2900103; Sun WM, 1996, J BIOL CHEM, V271, P17226, DOI 10.1074/jbc.271.29.17226; TSOU AY, 1990, BIOCHEMISTRY-US, V29, P9856, DOI 10.1021/bi00494a015; URBAN P, 1988, BIOCHEMISTRY-US, V27, P7365, DOI 10.1021/bi00419a029; XIA ZX, 1990, J MOL BIOL, V212, P837, DOI 10.1016/0022-2836(90)90240-M; XIA ZX, 1987, P NATL ACAD SCI USA, V84, P2629, DOI 10.1073/pnas.84.9.2629	19	32	33	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28300	28305		10.1074/jbc.271.45.28300	http://dx.doi.org/10.1074/jbc.271.45.28300			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910450	hybrid			2022-12-27	WOS:A1996VU03300050
J	Biemann, HP; Harmer, SL; Koshland, DE				Biemann, HP; Harmer, SL; Koshland, DE			An aspartate insulin receptor chimera mitogenically activates fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; LIGAND-BINDING DOMAIN; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; BETA-SUBUNIT; CHEMOTAXIS; ALPHA; CHEMORECEPTOR; EXPRESSION	A gene encoding the ligand-binding domain of the Escherichia coli aspartate receptor fused to the cytoplasmic domain of the insulin receptor tyrosine kinase to produce the chimeric aspartate insulin receptor (AIR) was expressed in mammalian cells. A murine fibroblast transfectant line designated CA3 was generated that stably expressed the AIR receptor. This 70,000 M(r) receptor containing the tyrosine kinase of the insulin receptor was recognized by aspartate receptor-specific antisera. When isolated in cellular membrane preparations, AIR was found to be capable of autophosphorylation and phosphorylation of histone H2B on tyrosine. The receptor was found to be predominately cytoplasmic and to be situated in the endoplasmic reticulum and Golgi membranes by immunofluorescence imaging of CA3 cells. Mitogenic effects of AIR were observed; CA3 cells continued DNA synthesis under serum deprivation conditions that prevented parental cells from cycling. These results demonstrate that a chimeric receptor containing procaryotic transmembrane sequences is expressed by a eucaryotic cell in intracellular membranes and functionally couples to cellular signaling pathways.	UNIV CALIF BERKELEY,DEPT MOL & CELLULAR BIOL,BERKELEY,CA 94720; GENZYME CORP,DEPT CELL BIOL,CAMBRIDGE,MA 02139; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143	University of California System; University of California Berkeley; Sanofi-Aventis; Genzyme Corporation; University of California System; University of California San Francisco			Harmer, Sarah/G-5572-2016	Harmer, Sarah/0000-0002-5627-5500; Harmer, Stacey/0000-0001-6813-6682	PHS HHS [9765] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; CELIS JE, 1994, CELL BIOL LAB HDB, V1, P297; DANIELSON MA, 1994, BIOCHEMISTRY-US, V33, P6100, DOI 10.1021/bi00186a009; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; DINTZIS SM, 1994, J BIOL CHEM, V269, P12159; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; ELLIS L, 1986, P NATL ACAD SCI USA, V83, P8137, DOI 10.1073/pnas.83.21.8137; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARUTA T, 1995, BIOCHEM J, V305, P599, DOI 10.1042/bj3050599; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LANKFORD SP, 1993, J BIOL CHEM, V268, P4814; LEBWOHL DE, 1991, J BIOL CHEM, V266, P386; LEE J, 1994, AM J PHYSIOL, V94, pC319; LEE JS, 1993, J BIOL CHEM, V268, P4092; Mares J, 1992, GROWTH FACTORS, V6, P93, DOI 10.3109/08977199209011013; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; MILLIGAN DL, 1993, J BIOL CHEM, V268, P19991; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; SHOELSON SE, 1988, J BIOL CHEM, V263, P4852; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	29	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27927	27930		10.1074/jbc.271.44.27927	http://dx.doi.org/10.1074/jbc.271.44.27927			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910393	hybrid			2022-12-27	WOS:A1996VQ67900111
J	Blake, DA; Chakrabarti, P; Khosraviani, M; Hatcher, FM; Westhoff, CM; Goebel, P; Wylie, DE; Blake, RC				Blake, DA; Chakrabarti, P; Khosraviani, M; Hatcher, FM; Westhoff, CM; Goebel, P; Wylie, DE; Blake, RC			Metal binding properties of a monoclonal antibody directed toward metal-chelate complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MERCURIC IONS; PROTEINS	A monoclonal antibody that recognizes cadmium-EDTA complexes has been produced by the injection of BALB/c mice with a metal-chelate complex covalently coupled to a carrier protein, The ability of purified antibody to recognize 16 different metal-EDTA complexes was assessed by measuring equilibrium binding constants using a KinExA(TM) immunoassay instrument, The antibody bound to cadmium- and mercury-EDTA complexes with equilibrium dissociation constants of 21 and 26 nm, respectively, All other metal EDTA complexes tested, including those of Mn(II), In(III), Ni(II), Zn(II), Ga(III), Mg(II), and AI(III) bound with affinities from 20- to 40,000-fold less than that determined for the cadmium-EDTA complex, With the exception of mercury and magnesium, the binding of divalent metal-chelate complexes was well-correlated with the size of the metal ion, The amino acid sequences of the heavy and light chain variable regions were deduced from polymerase chain reaction-amplified regions of the corresponding genes and subsequently used to construct molecular models of the antigen binding region, The key residue for cadmium binding in the model for 2A81G5 appeared to be histidine 96 in the heavy chain.	MEHARRY MED COLL,DEPT MICROBIOL,NASHVILLE,TN 37208; UNIV NEBRASKA,DEPT BIOL,LINCOLN,NE 68588; XAVIER UNIV,DEPT BASIC PHARMACEUT SCI,NEW ORLEANS,LA 70125	Meharry Medical College; University of Nebraska System; University of Nebraska Lincoln; Xavier University of Louisiana	Blake, DA (corresponding author), TULANE UNIV,SCH MED,DEPT OPHTHALMOL,1430 TULANE AVE,NEW ORLEANS,LA 70112, USA.							ANDERSON WHK, 1992, HYBRIDOMA, V12, P677; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERA L, 1994, J NUCL MED, V35, P882; CHAKRABARTI P, 1994, ANAL BIOCHEM, V217, P70, DOI 10.1006/abio.1994.1084; CHOTHIA C, 1987, J MOL BIOL, V196, P901, DOI 10.1016/0022-2836(87)90412-8; GANSOW OA, 1991, NUCL MED BIOL, V18, P369, DOI 10.1016/0883-2897(91)90063-Q; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GILLETTE RW, 1989, J IMMUNOL METHODS, V124, P277, DOI 10.1016/0022-1759(89)90364-5; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; Kabat EA, 1991, SEQUENCES PROTEINS I; KOZAK RW, 1989, CANCER RES, V49, P2639; KRUCK TPA, 1976, CAN J CHEM, V8, P1300; Lide D. R., 1995, CRC HDB CHEM PHYS, P12; LIND MD, 1964, INORG CHEM, V3, P34, DOI 10.1021/ic50011a007; LOVE RA, 1993, BIOCHEMISTRY-US, V32, P10950, DOI 10.1021/bi00092a004; Meyer DL, 1990, BIOCONJUGATE CHEM, V1, P278, DOI 10.1021/bc00004a009; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; QUICHO FA, 1971, ADV PROTEIN CHEM, V25, P1; REARDAN DT, 1985, NATURE, V316, P265, DOI 10.1038/316265a0; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; THIERS R E, 1957, Methods Biochem Anal, V5, P273; TOMA S, 1991, BIOCHEMISTRY-US, V30, P97, DOI 10.1021/bi00215a015; WYLIE DE, 1991, ANAL BIOCHEM, V194, P381, DOI 10.1016/0003-2697(91)90245-O; WYLIE DE, 1992, P NATL ACAD SCI USA, V89, P4104, DOI 10.1073/pnas.89.9.4104	24	143	172	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27677	27685		10.1074/jbc.271.44.27677	http://dx.doi.org/10.1074/jbc.271.44.27677			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910359	hybrid			2022-12-27	WOS:A1996VQ67900077
J	Glaven, JA; Whitehead, IP; Nomanbhoy, T; Kay, R; Cerione, RA				Glaven, JA; Whitehead, IP; Nomanbhoy, T; Kay, R; Cerione, RA			Lfc and Lsc oncoproteins represent two new guanine nucleotide exchange factors for the Rho GTP-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; SEQUENCE SIMILARITY; EXPRESSION CLONING; CDC42 GTPASES; RAC; HOMOLOGY; ENCODES; KINASE; GENE	Lfc and Lsc are two recently identified oncoproteins that contain a Dbl homology domain in tandem with a pleckstrin homology domain and thus share sequence similarity with a number of other growth regulatory proteins including Dbl, Tiam-1, and Lbc. We show here that Lfc and Lsc, like their closest relative Lbc, are highly specific guanine nucleotide exchange factors (GEFs) for Rho, causing a > 10-fold stimulation of [H-3]GDP dissociation from Rho and a marked stimulation of GDP-[S-35]GTP gamma s (guanosine 5'-O-(3-thiotriphosphate) exchange, All three proteins (Lbc, Lfc, and Lsc) are able to act catalytically in stimulating the guanine nucleotide exchange activity, such Chat a single molecule of each of these oncoproteins can activate a number of molecules of Rho, Neither Lfc nor ise shows any ability to stimulate GDP dissociation from other related GTP-binding proteins ouch as Rac, Cdc42, or Res, Thus Lbc, Lfc, and Lsc appear to represent a subgroup of Dbl-related proteins that function as highly specific GEFs toward Rho and can be distinguished from Dbl, Ost, and Dbs which are less specific and show GEF activity toward both Rho and Cdc42, Consistent with these results, Lbc, Lfc, and Lsc each form tight complexes with the guanine nucleotide depleted form of Rho and bind weakly to the GDP- and GTP gamma S-bound states. None of these oncoproteins are able to form complexes with Cdc42 or Ras, However, Lfc (but not Lbc nor Lsc) can bind to Rac, and this binding occurs equally well when Rac is nucleotide-depleted or is in the GDP- or GTP gamma S-bound state, These findings raise the possibility that in addition to acting directly as a GEF for BI-ro, Lfc may play other roles that influence the signaling activities of Rac and/or coordinate the activities of the Rac and Rho proteins.	CORNELL UNIV,DEPT PHARMACOL,ITHACA,NY 14853; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; BRITISH COLUMBIA CANC AGCY,TERRY FOX LAB,VANCOUVER,BC V5Z 4E6,CANADA	Cornell University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; British Columbia Cancer Agency					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008210, R01GM047458] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM08210, GM47458] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CHAN AML, 1994, ONCOGENE, V9, P1057; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PASTERIS NG, 1994, CELL, V79, P669; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TOKSOZ D, 1994, ONCOGENE, V9, P621; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	35	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27374	27381		10.1074/jbc.271.44.27374	http://dx.doi.org/10.1074/jbc.271.44.27374			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910315	Green Published, hybrid			2022-12-27	WOS:A1996VQ67900033
J	Skouteris, GG; Schroder, CH				Skouteris, GG; Schroder, CH			The hepatocyte growth factor receptor kinase-mediated phosphorylation of lipocortin-1 transduces the proliferating signal of the hepatocyte growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCATTER FACTOR-RECEPTOR; C-MYC EXPRESSION; DEPENDENT PHOSPHORYLATION; CELL-LINE; ANNEXIN-I; PROTEIN; MITOGEN; PHOSPHOLIPASE-A2; EGF; TRANSFORMATION	Hepatocyte growth factor (HGF), which is identical to scatter factor (SF) through coupling to its receptor the product of c-met oncogene, was found to induce proliferation of A549 lung carcinoma cell line, accompanied by release of prostaglandin E(2) (PGE(2)), This activity was sensitive to 0.1-100 mu m indomethacin and to 5-50 nM of verapamil. Lipocortin-1, a dexamethasone-inducible inhibitor of phospholipase A(2), was shown to be phosphorylated on tyrosine 10 min upon addition of HGF and to translocate 60 the membrane fraction for up to 6 h upon ligand stimulation, Lipocortin-l was found to associate in vivo with the HGP receptor species, and this association was independent of the phosphorylation state of the beta-subunit of the HGF receptor (p145 beta(MET). ImmobiLized HGF receptor kinase species associated and phosphorylated in vitro lipocortin-1, thus providing evidence that lipocortin-l is directly phosphorylated by the p145 beta(MET). Incubation of A549 cells with antisense 21-mer lipocortin-1 oligonucleotides reduced the synthesis and the HGF-stimulated phosphorylation of lipocortin-1 as well as the HGF-stimulated cell proliferation, In processes where the HGF receptor tyrosine kinase is activated, phosphorylation of lipocortin-1 may function as a ''signal amplifier'' promoting the release of intercellular messengers (PGE(2)) with pluripotent roles in cell proliferation, chemotaxis, and vascular remodeling.			Skouteris, GG (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM, RES PROGRAM APPL TUMOR VIROL, DIV VIRUS HOST INTERACT, D-69120 HEIDELBERG, GERMANY.							ADACHI T, 1995, HEPATOLOGY, V21, P1668; BARDELLI A, 1992, ONCOGENE, V7, P1973; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CROXTALL JD, 1993, INT J CANCER, V54, P153, DOI 10.1002/ijc.2910540124; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; GANDINO G, 1994, EMBO J, V13, P3524; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GHERARDI E, 1989, P NATL ACAD SCI USA, V86, P5844, DOI 10.1073/pnas.86.15.5844; GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HAYASHI J, 1993, BIOCHEM MOL BIOL INT, V31, P143; HIRATA F, 1984, P NATL ACAD SCI-BIOL, V81, P4717, DOI 10.1073/pnas.81.15.4717; HUANG KS, 1986, CELL, V46, P191, DOI 10.1016/0092-8674(86)90736-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MASAKI T, 1994, HEPATOLOGY, V20, P425, DOI 10.1002/hep.1840200224; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; PALIOGIANNI F, 1995, J IMMUNOL, V155, P1809; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SAKATA T, 1988, NUCLEIC ACIDS RES, V16, P11818, DOI 10.1093/nar/16.24.11818; SKOUTERIS GG, 1992, BIOCHEM J, V281, P729, DOI 10.1042/bj2810729; SKOUTERIS GG, 1988, J CELL PHYSIOL, V135, P516, DOI 10.1002/jcp.1041350321; SKOUTERIS GG, 1991, BIOCHEM BIOPH RES CO, V178, P1240, DOI 10.1016/0006-291X(91)91026-9; SOLITO E, 1994, BRIT J PHARMACOL, V112, P347, DOI 10.1111/j.1476-5381.1994.tb13075.x; WEIDNER KM, 1990, J CELL BIOL, V111, P1815; ZARNEGAR R, 1989, CANCER RES, V49, P3314	37	69	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27266	27273		10.1074/jbc.271.44.27266	http://dx.doi.org/10.1074/jbc.271.44.27266			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910300	hybrid			2022-12-27	WOS:A1996VQ67900018
J	Teramoto, H; Coso, OA; Miyata, H; Igishi, T; Miki, T; Gutkind, JS				Teramoto, H; Coso, OA; Miyata, H; Igishi, T; Miki, T; Gutkind, JS			Signaling from the small GTP-binding proteins Rac1 and Cdc42 to the c-Jun N-terminal kinase stress-activated protein kinase pathway - A role for mixed lineage kinase 3 protein-tyrosine kinase 1, a novel member of the mixed lineage kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAIN; IDENTIFICATION; CLONING; SUBFAMILY; CASCADE; BEARING; BRAIN	Certain small GTP-binding proteins control the enzymatic activity of a family of closely related serine-threonine kinases known as mitogen-activated protein kinases (MAPKs), In turn, these MAPKs, such as p44(mapk) and p42(mapk), referred to herein as MAPKs, and stress activated protein kinases, also termed c-Jun N-terminal kinases (JNKs), phosphorylate and regulate the activity of key molecules that ultimately control the expression of genes essential for many cellular processes, Whereas Ras controls the activation of MAPK, we and others have recently observed that two members of the Rho family of small GTP-binding proteins, Rad and Cdc42, regulate the activity of JNKs. The identity of molecules communicating Rad and Cdc42 to JNK is still poorly understood. It has been suggested that Pak1 is the most upstream kinase connecting these GTPases to JNK; however, we have observed that coexpression of Pak1 with activated forms of Cdc42 or Rad diminishes rather than enhances JNK activation. This prompted us to explore the possibility that kinases other than Pak might participate in signaling from GTP binding proteins to JNK, In this regard, a computer-assisted search for proteins containing areas of homology to that in Pak1 that is involved in binding to Rad and Cdc42 led to the identification of mixed lineage kinase 3 (MLK3), also known as protein-tyrosine kinase 1, as a potential candidate for this function, In this study, we found that MLK3 overexpression is sufficient to activate JNK po tently without affecting the phosphorylating activity of MAPK or p38. Furthermore, we present evidence that MLK3 binds the GTP-binding proteins Cdc42 and Rad in vivo and that MLK3 mediates activation of MEKK-SEK-JNK kinase cascade by Rad and Cdc42. Taken together, these findings strongly suggest that members of the novel MLK family of highly related kinases link small GTP-binding proteins to the JNK signaling pathway.	NIDR,CELLULAR DEV & ONCOL LAB,MOL SIGNALING UNIT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; EZOE K, 1994, ONCOGENE, V9, P935; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; GALLO KA, 1994, J BIOL CHEM, V269, P15092; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; ING YL, 1994, ONCOGENE, V9, P1745; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KATOH M, 1995, ONCOGENE, V10, P1447; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER C, 1994, SCIENCE, V260, P315; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LIM PS, 1990, J INFECT DIS, V162, P1263, DOI 10.1093/infdis/162.6.1263; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	25	312	321	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27225	27228		10.1074/jbc.271.44.27225	http://dx.doi.org/10.1074/jbc.271.44.27225			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910292	hybrid			2022-12-27	WOS:A1996VQ67900010
J	Zhang, X; Vuolteenaho, R; Tryggvason, K				Zhang, X; Vuolteenaho, R; Tryggvason, K			Structure of the human laminin alpha 2-chain gene (LAMA2), which is affected in congenital muscular dystrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHAIN; CHROMOSOMAL ASSIGNMENT; BETA-SARCOGLYCAN; IV COLLAGEN; B2 CHAIN; EXPRESSION; MUTATIONS; MEROSIN; PROTEIN; CLONING	We have determined the structure and complete exon size pattern of the human laminin alpha 2-chain gene (LAMA2), which has been shown to be affected in congenital muscular dystrophy (Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Cruaud, C., Tesson, F., Weissenbach, J., Tome, F. M. S., Schwartz, IT,, Fardeau, M., Tryggvason, K., and Guicheney, P. (1995) Nat. Genet. 11, 216-218). The gene is over 260,000 base pairs and contains 64 exons. The sequence of all exon-intron borders was determined. Two of the exons, i.e. exons 43 and 52, are extremely small in size, 6 and 12 base pairs, respectively. Comparison of the exon pattern of the human LAMA2 gene with that of the Drosophila LAMA gene revealed that only 2 of 63 intron locations in the 5'-end of the human gene match the intron locations in the Drosophila gene, which contains 14 introns.	KAROLINSKA INST, DIV MATRIX BIOL, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN; UNIV OULU, BIOCTR, FIN-90570 OULU, FINLAND; UNIV OULU, DEPT BIOCHEM, FIN-90570 OULU, FINLAND	Karolinska Institutet; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu								Airenne T, 1996, GENOMICS, V32, P54, DOI 10.1006/geno.1996.0076; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; ENGEL J, 1992, BIOCHEMISTRY-US, V31, P10643, DOI 10.1021/bi00159a001; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; FUKUSHIMA Y, 1988, CYTOGENET CELL GENET, V48, P137, DOI 10.1159/000132610; GERECKE DR, 1994, J BIOL CHEM, V269, P11073; HAPARANTA T, 1991, MATRIX BIOL, V11, P151; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HSIAO LL, 1993, LAB INVEST, V68, P100; IIVANAINEN A, 1995, FEBS LETT, V365, P183, DOI 10.1016/0014-5793(95)00462-I; IIVANAINEN A, 1995, MATRIX BIOL, V14, P489, DOI 10.1016/0945-053X(95)90006-3; KALLUNKI P, 1992, J CELL BIOL, V119, P679, DOI 10.1083/jcb.119.3.679; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; KUSCHEGULLBERG M, 1992, EMBO J, V11, P4519, DOI 10.1002/j.1460-2075.1992.tb05553.x; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; NAGAYOSHI T, 1989, GENOMICS, V5, P932, DOI 10.1016/0888-7543(89)90136-5; NISSINEN M, 1991, BIOCHEM J, V276, P369, DOI 10.1042/bj2760369; Nissinen M, 1996, AM J HUM GENET, V58, P1177; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; PICCOLO F, 1995, NAT GENET, V10, P243, DOI 10.1038/ng0695-243; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; RICHARDS AJ, 1994, GENOMICS, V22, P237, DOI 10.1006/geno.1994.1372; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; RYAN MC, 1994, J BIOL CHEM, V269, P22779; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SOININEN R, 1989, J BIOL CHEM, V264, P13565; SRIVASTAVA AK, 1995, GENOMICS, V26, P502, DOI 10.1016/0888-7543(95)80168-L; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Tryggvason K, 1993, CURR OPIN CELL BIOL, V5, P877, DOI 10.1016/0955-0674(93)90038-R; VAILLY J, 1994, GENOMICS, V21, P286, DOI 10.1006/geno.1994.1263; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; WEWER UM, 1994, GENOMICS, V24, P243, DOI 10.1006/geno.1994.1612; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; Zhang X, 1996, GENOMICS, V33, P473, DOI 10.1006/geno.1996.0222; ZHOU J, 1994, J BIOL CHEM, V269, P6608	45	46	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27664	27669		10.1074/jbc.271.44.27664	http://dx.doi.org/10.1074/jbc.271.44.27664			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910357	hybrid			2022-12-27	WOS:A1996VQ67900075
J	Ihn, H; Ohnishi, K; Tamaki, T; LeRoy, EC; Trojanowska, M				Ihn, H; Ohnishi, K; Tamaki, T; LeRoy, EC; Trojanowska, M			Transcriptional regulation of the human alpha 2(I) collagen gene - Combined action of upstream stimulatory and inhibitory cis-acting elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; CCAAT-BINDING-FACTOR; DNA-BINDING; PRO-ALPHA-2(I) COLLAGEN; FUNCTIONAL-ANALYSIS; PROMOTER; ACTIVATION; ALPHA-1(I); PURIFICATION; EXPRESSION	This study identifies three regions of the human alpha 2(I) collagen promoter involved in the binding of nuclear factors. These regions include sequences from -173 to -155 (footprint I), -133 to -119 (footprint II), and -101 to -72 (footprint III). A novel positive cis-element containing a TCCTCC motif was identified within footprint II. In addition, we demonstrated that a pyrimidine-rich region within footprint I is a binding site for a transcriptional repressor, and a CCAAT motif within footprint III is a binding site for a transcriptional activator, Comparative functional analysis of the cis-acting elements within the proximal 350 base pairs of this promoter, including previously characterized Sp1 binding sites at -300, indicates that constitutive activity of this promoter is regulated equivalently by the three positive cis-acting elements at -300, -125, and -80. Mutations in the repressor site at -160 increase constitutive activity by 4-6 fold. However, simultaneous mutations of the repressor site and the cis-regulatory element at either the -300 or -125 sites result in no increase in constitutive transcription activity suggesting interaction between the activators and repressor elements, In contrast, simultaneous mutation of the CCAAT motif and the repressor site results in about a 4-fold increase, suggesting that activation via the CCAAT motif may be independent of this repressor.	MED UNIV S CAROLINA,DEPT MED,DIV RHEUMATOL,CHARLESTON,SC 29425	Medical University of South Carolina				Trojanowska, Maria/0000-0001-9550-7178	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042334] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42334] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BOAST S, 1990, J BIOL CHEM, V265, P13351; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; CHANG E, 1995, J BIOL CHEM, V270, P4473, DOI 10.1074/jbc.270.9.4473; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DICKSON LA, 1985, NUCLEIC ACIDS RES, V13, P3427, DOI 10.1093/nar/13.10.3427; HATAMOCHI A, 1993, FEBS LETT, V327, P325, DOI 10.1016/0014-5793(93)81014-Q; HATAMOCHI A, 1988, J BIOL CHEM, V263, P5940; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; IBARAKI K, 1993, GENE, V130, P225, DOI 10.1016/0378-1119(93)90423-Z; INAGAKI Y, 1995, J BIOL CHEM, V270, P3353, DOI 10.1074/jbc.270.7.3353; INAGAKI Y, 1994, J BIOL CHEM, V269, P14828; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KARSENTY G, 1991, J BIOL CHEM, V266, P24842; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KARSENTY G, 1991, BIOCHEM BIOPH RES CO, V177, P538, DOI 10.1016/0006-291X(91)92017-E; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; RAMIREZ F, 1990, FASEB J, V4, P1616, DOI 10.1096/fasebj.4.6.2180769; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; TAMAKI T, 1995, J BIOL CHEM, V270, P4299, DOI 10.1074/jbc.270.9.4299; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201	23	114	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26717	26723		10.1074/jbc.271.43.26717	http://dx.doi.org/10.1074/jbc.271.43.26717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900150	hybrid			2022-12-27	WOS:A1996VP23300044
J	Negrescu, EV; Siess, W				Negrescu, EV; Siess, W			Dissociation of the alpha(IIb)beta(3)-Integrin by EGTA stimulates the tyrosine kinase pp72(syk) without inducing platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; INTEGRIN CYTOPLASMIC DOMAINS; MEMBRANE GLYCOPROTEIN-IIB; OUT SIGNAL-TRANSDUCTION; FOCAL ADHESION KINASE; MONOCLONAL-ANTIBODIES; CALCIUM DEPRIVATION; DIVALENT-CATIONS; LIGAND-BINDING; PHOSPHORYLATION	Incubation of human platelets with EG;TA under conditions that dissociate the alpha(IIb)beta(3)-integrin stimulated tyrosine phosphorylation of pp72(syk) (6.8-fold) and of pro teins of 62 (2.2-fold), 68 (2.5-fold) and 130 kDa (1.4-fold), Stimulation of tyrosine phosphorylation of pp72(syk) was associated with an increase of pp72(syk) kinase activity, In contrast to pp72(syk), tyrosine phosphorylation of the fo cal adhesion kinase pp125(FAK) was not stimulated by EGTA. Preincubation of platelets with the monoclonal antibody P2, which binds to the alpha(IIb)beta(3) complex and thus stabilizes it, strongly reduced the increase of tyrosine phosphorylation of pp72(syk), p62, and p68 induced by EGTA, The Y2/51 monoclonal antibody, which recog nizes only the beta(3) glycoprotein, did not inhibit the stimulation of protein tyrosine phosphorylation evoked by EGTA, Stimulation of tyrosine phosphorylation of pp72(syk), p62, p68, and p130 induced by EGTA was not observed in thrombasthenic platelets, which lack the alpha(IIb)beta(3)-integrin. The results indicate that the dissociation of the alpha(IIb)beta(3) complex in intact platelets activates pp72(syk). The mechanism of activation was found to be insensitive to inhibition by cAMP and cGMP and only partially dependent on cytosolic Ca2+, suggesting a close functional coupling of alpha(IIb)beta(3)-integrin and pp72(syk). Since platelets retain their discoid shape after EG;TA treatment, we further conclude that pp72(syk) stimulation alone is not sufficient for platelet activation.	UNIV MUNICH,INST PROPHYLASE & EPIDEMIOL,KREISLAUFKRANKHEITEN,D-80336 MUNICH,GERMANY	University of Munich			Siess, Wolfgang/A-6430-2009	Siess, Wolfgang/0000-0003-0698-6416				BRASS LF, 1985, J BIOL CHEM, V260, P7875; BRASS LF, 1985, J BIOL CHEM, V260, P2231; BRASS LF, 1984, J CLIN INVEST, V73, P626, DOI 10.1172/JCI111252; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHAPPELL LT, 1993, J ADV MED, V6, P139; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FALET H, 1994, FEBS LETT, V345, P87, DOI 10.1016/0014-5793(94)00414-5; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FUJII C, 1994, EUR J BIOCHEM, V226, P243, DOI 10.1111/j.1432-1033.1994.tb20047.x; GACHET C, 1993, J CELL BIOL, V120, P1021, DOI 10.1083/jcb.120.4.1021; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; GOGSTAD GO, 1982, BIOCHIM BIOPHYS ACTA, V689, P21, DOI 10.1016/0005-2736(82)90184-5; GOGSTAD GO, 1982, BLOOD, V60, P663; HAGEN I, 1982, BIOCHIM BIOPHYS ACTA, V701, P1, DOI 10.1016/0167-4838(82)90303-X; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; KUNICKI TJ, 1981, BLOOD, V58, P268; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MCGREGOR JL, 1986, EUR J BIOCHEM, V159, P443, DOI 10.1111/j.1432-1033.1986.tb09906.x; NEGRESCU EV, 1995, J BIOL CHEM, V270, P1057, DOI 10.1074/jbc.270.3.1057; NOMURA S, 1987, THROMB RES, V47, P47, DOI 10.1016/0049-3848(87)90239-8; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PEERSCHKE EI, 1980, BRIT J HAEMATOL, V46, P247, DOI 10.1111/j.1365-2141.1980.tb05963.x; PIDARD D, 1986, BLOOD, V67, P604; PIDARD D, 1983, J BIOL CHEM, V258, P2582; SARGEANT P, 1994, EXP PHYSIOL, V79, P269, DOI 10.1113/expphysiol.1994.sp003762; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHATTIL SJ, 1992, J BIOL CHEM, V267, P18424; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SIESS W, 1990, ADV EXP MED BIOL, V273, P119; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; VANRIJ AM, 1994, CIRCULATION, V90, P1194, DOI 10.1161/01.CIR.90.3.1194; VOSTAL JG, 1991, J BIOL CHEM, V266, P16911; WHITE JG, 1968, SCAND J HAEMATOL, V5, P241; YANAGA F, 1995, BIOCHEM J, V311, P471, DOI 10.1042/bj3110471; ZUCKER MB, 1954, BLOOD, V9, P602, DOI 10.1182/blood.V9.6.602.602; ZUCKER MB, 1978, BLOOD, V52, P505	48	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26547	26553		10.1074/jbc.271.43.26547	http://dx.doi.org/10.1074/jbc.271.43.26547			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900125	hybrid			2022-12-27	WOS:A1996VP23300019
J	ODonohue, MJ; Beaumont, A				ODonohue, MJ; Beaumont, A			The roles of the prosequence of thermolysin in enzyme inhibition and folding in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA ELASTASE; SITE-DIRECTED MUTAGENESIS; PROTEASE PRO-REGION; IN-VIVO FORMATION; NEUTRAL PROTEASE; BACILLUS-SUBTILIS; CARBOXYPEPTIDASE-Y; ESCHERICHIA-COLI; DENATURED SUBTILISIN; CATALYTIC ACTIVITY	The zinc endopeptidase thermolysin (EC 3.4.24.27), an extracellular enzyme from Bacillus thermoproteolyticus, is synthesized as a preproprotein, with the prosequence (204 residues) being two thirds the size of the mature enzyme (316 residues). This prosequence, expressed in and purified from Escherichia coli, inhibited thermolysin in vitro with an IC50 value of 14 nM. It also inhibited a closely related enzyme produced by Bacillus stearothermophillus, albeit with a 16-fold higher IC50 value (220 nM). The IC50 value for thermolysin inhibition was also increased 15-fold (210 nm) by a monoclonal antibody that recognizes an epitope close to, but not forming a part of, the active site. At a prosequence concentration of 5 mu M a mammalian, thermolysin-like enzyme, neutral endopeptidase 24.11, was not inhibited. The prosequence appeared to act as a mixed, noncompetitive inhibitor of thermolysin activity, with a K-i value of 6 nM for its interaction with the enzyme alone and a K-i' value of 20 nM for its interaction with the enzyme substrate complex. In addition, when thermolysin was denatured in 6 M guanidinium hydrochloride at acid pH and then brought to neutral pH by rapid dilution, the prosequence was found to facilitate the recovery of active enzyme in a stoichiometric manner.	UNIV PARIS 05, CNRS,UNITE RECH ASSOCIEE D1500, DEPT PHARMACOCHIM MOL & STRUCT,INSERM, U266, F-75270 PARIS 06, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			O'Donohue, Michael/ABD-9239-2021; O'Donohue, Michael J/E-9183-2013	O'Donohue, Michael/0000-0003-4246-3938; O'Donohue, Michael J/0000-0003-4246-3938				AUBRY M, 1987, BIOCHEM CELL BIOL, V65, P398, DOI 10.1139/o87-050; BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BEAUMONT A, 1995, J BIOL CHEM, V270, P16803, DOI 10.1074/jbc.270.28.16803; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun P, 1996, MOL MICROBIOL, V19, P297, DOI 10.1046/j.1365-2958.1996.381908.x; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; CHANG SC, 1994, J BIOL CHEM, V269, P3548; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; IKEMURA H, 1987, J BIOL CHEM, V262, P7859; KAWAMOTO S, 1993, INFECT IMMUN, V61, P1400, DOI 10.1128/IAI.61.4.1400-1405.1993; KESSLER E, 1994, J BIOL CHEM, V269, P22726; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; MCIVER K, 1991, J BACTERIOL, V173, P7781, DOI 10.1128/jb.173.24.7781-7789.1991; MELCHIORI A, 1992, CANCER RES, V52, P2353; ODONOHUE MJ, 1994, BIOCHEM J, V300, P599, DOI 10.1042/bj3000599; OHTA Y, 1991, MOL MICROBIOL, V5, P1507, DOI 10.1111/j.1365-2958.1991.tb00797.x; RAMOS C, 1994, J BIOL CHEM, V269, P7006; ROQUES BP, 1993, PHARMACOL REV, V45, P87; Sambrook J, 1989, MOL CLONING LAB MANU, P1; SANSEGUNDO B, 1982, BIOCHIM BIOPHYS ACTA, V707, P74, DOI 10.1016/0167-4838(82)90398-3; SCHECHTER I, 1968, BIOCHEM BIOPH RES CO, V32, P898, DOI 10.1016/0006-291X(68)90326-4; SIGNOR G, 1990, EUR J BIOCHEM, V189, P221, DOI 10.1111/j.1432-1033.1990.tb15480.x; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; SMITH SM, 1989, J BIOL CHEM, V264, P20487; STARK W, 1992, EUR J BIOCHEM, V207, P781, DOI 10.1111/j.1432-1033.1992.tb17109.x; STRAUSBERG S, 1993, BIOCHEMISTRY-US, V32, P8112, DOI 10.1021/bi00083a009; TAYLOR M, 1995, PROTEIN ENG, V15, P59; THAYER MM, 1991, J BIOL CHEM, V266, P2864; TOMA S, 1989, PROTEIN ENG, V2, P359, DOI 10.1093/protein/2.5.359; TSURU D, 1993, J BIOCHEM-TOKYO, V113, P101, DOI 10.1093/oxfordjournals.jbchem.a123991; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VOGEL Z, 1977, FEBS LETT, V80, P332, DOI 10.1016/0014-5793(77)80469-9; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; WETMORE DR, 1992, MOL MICROBIOL, V6, P1593, DOI 10.1111/j.1365-2958.1992.tb00884.x; WETMORE DR, 1994, MOL MICROBIOL, V12, P747, DOI 10.1111/j.1365-2958.1994.tb01062.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330; WINTHER JR, 1994, J BIOL CHEM, V269, P22007; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	43	50	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26477	26481		10.1074/jbc.271.43.26477	http://dx.doi.org/10.1074/jbc.271.43.26477			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900115	Green Published, hybrid			2022-12-27	WOS:A1996VP23300009
J	Betting, J; Seufert, W				Betting, J; Seufert, W			A yeast Ubc9 mutant protein with temperature-sensitive in vivo function is subject to conditional proteolysis by a ubiquitin- and proteasome-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; SACCHAROMYCES-CEREVISIAE; CONJUGATING ENZYMES; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; 20S PROTEASOME; PEP4 GENE; S-PHASE; DEGRADATION; ENCODES	The UBC9 gene of the yeast Saccharomyces cerevisiae is essential for cell viability and encodes a soluble protein of the nucleus that is metabolically stable. Products of mutant alleles selected to confer temperature-sensitive in vivo function were found to be extremely short-lived at the restrictive but long-lived at the permissive condition. An extragenic suppressor mutation was isolated which increased thermoresistance of a ubc9-1 strain. This suppressor turned out to stabilize the mutated gene product, indicating that the physiological activity of ubc9-1 protein is primarily controlled by conditional proteolysis. The labile ubc9-1 protein appears to be a substrate for ubiquitination, and its turnover was substantially reduced by expression of a ubiquitin derivative that interferes with formation of multi-ubiquitin chains. Stabilization resulted also from competitive inhibition of Ubc4-related ubiquitin conjugating enzymes. Activity of the proteasome complex was crucial to rapid breakdown, whereas vacuolar proteases were dispensable. Thus, the heat-denatured ubc9-1 protein is targeted for proteolysis by the ubiquitin-proteasome pathway and may serve as a useful tool to further define the process by which a misfolded polypeptide is recognized.	UNIV MUNICH, INST GENET & MIKROBIOL, D-80638 MUNICH, GERMANY	University of Munich			Seufert, Wolfgang/F-7136-2019	Seufert, Wolfgang/0000-0001-8938-9064				ACHSTETTER T, 1984, J BIOL CHEM, V259, P3334; Alberts B., 1994, MOL BIOL CELL; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; Ausubel FM, 1994, CURRENT PROTOCOLS MO; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; CHIANG HL, 1994, NATURE, V369, P284, DOI 10.1038/369284a0; CHIANG HL, 1991, NATURE, V350, P313, DOI 10.1038/350313a0; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; ELLISON KS, 1991, J BIOL CHEM, V266, P24116; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HILT W, 1993, J BIOL CHEM, V268, P3479; HODGINS RRW, 1992, J BIOL CHEM, V267, P8807; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEWIN B, 1994, GENES, V5; MAICAS E, 1988, MOL CELL BIOL, V8, P169, DOI 10.1128/MCB.8.1.169; MCCUSKER JH, 1991, MOL CELL BIOL, V11, P746, DOI 10.1128/MCB.11.2.746; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURRAY A, 1993, CELL CYCLE; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHORK SM, 1994, NATURE, V369, P283, DOI 10.1038/369283a0; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SHARROCKS AD, 1992, NUCLEIC ACIDS RES, V20, P1147, DOI 10.1093/nar/20.5.1147; SHERMAN MY, 1992, EMBO J, V11, P71; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	65	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25790	25796		10.1074/jbc.271.42.25790	http://dx.doi.org/10.1074/jbc.271.42.25790			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824207	hybrid			2022-12-27	WOS:A1996VN18000013
J	Geider, S; Baronnet, A; Cerini, C; Nitsche, S; Astier, JP; Michel, R; Verdier, JM				Geider, S; Baronnet, A; Cerini, C; Nitsche, S; Astier, JP; Michel, R; Verdier, JM			Pancreatic lithostathine as a calcite habit modifier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STONE PROTEIN; CRYSTAL-GROWTH; CARBONATE; PHOSPHOPROTEIN; PRECIPITATION; SEQUENCE	Most biological fluids are supersaturated with calcium salts, A mechanism controlling crystal growth is therefore necessary to prevent excessive precipitation and development of a lithiasis. In pancreatic juice, calcite precipitation is prevented by lithostathine, a glycoprotein that inhibits calcite crystal growth, We describe here the interaction of lithostathine with calcite crystals, Without lithostathine, calcite crystals grew as rhombohedra showing six {10(1) over bar 4} faces. At low concentration (1 mu M), lithostathine already altered crystal growth by generating new {11(2) over bar 0} faces. At physiological concentrations (3-10 mu M), adsorption resulted in a transition from rhombohedral to sub cubic habits, Immunochemical localization demonstrated that, although all {10(1) over bar 4} faces are equivalent, lithostathine binding was restricted to the face edges distal to the c axis. Scanning electron microscopy showed that, at the site of lithostathine binding, spreading of new CaCO3 layers during crystal growth was arrested before reaching the crystal diad axis-bearing edges. The successive kinks generated during crystal growth formed the new, striated {11(2) over bar 0} faces. Similar modifications were observed with the N-terminal undecapeptide of lithostathine that bears the inhibitory activity. With 100 mu M lithostathine, {11(2) over bar 0} faces could reach the c axis outcrop of the former rhombohedron, resulting in an olive shaped crystal. Finally, the number of crystals increased and their average size decreased when lithostathine concentration increased from 0.1 to 100 mu M. Decreased Ca2+ concentration during crystal growth was delayed in the presence of lithostathine. It was concluded that lithostathine controls lithogenesis 1) by triggering germination of numerous calcite crystals and 2) by inhibiting the rate of Ca2+ ion apposition on the nuclei and therefore interfering with the apposition of new layers on calcite. Formation of smaller crystals, whose elimination is easier, is thereby favored.	INSERM,U315,UNITE RECH PHYSIOL & PATHOL DIGEST,F-13258 MARSEILLE 09,FRANCE; CNRS,CTR RECH MECANISMES CROISSANCE CRISTALLINE,MARSEILLE,FRANCE; HOP ST MARGUERITE,SERV NEPHROL & HEMODIALYSE,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille				VERDIER, Jean-Michel/0000-0002-7252-1556				ABBONA F, 1979, J CRYST GROWTH, V46, P339, DOI 10.1016/0022-0248(79)90082-4; ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; BERNARD JP, 1991, PANCREAS, V6, P162, DOI 10.1097/00006676-199103000-00006; BERNARD JP, 1992, GASTROENTEROLOGY, V103, P1277, DOI 10.1016/0016-5085(92)91516-7; Boistelle R., 1982, Interfacial Aspects of Phase Transformations. Proceedings of the NATO Advanced Study Institute, P621; BOISTELLE R, 1981, J CRYST GROWTH, V54, P275, DOI 10.1016/0022-0248(81)90472-3; DAGORN JC, 1993, PANCREAS BIOL PATHOB, P263; DECARO A, 1984, BIOCHEM J, V222, P669, DOI 10.1042/bj2220669; EDMONDSON HA, 1950, AM J PATHOL, V26, P37; GIORGI D, 1989, J CLIN INVEST, V84, P100, DOI 10.1172/JCI114128; GRUZENSKY PM, 1967, J PHYS CHEM SOLIDS S, V1, P365; HAY DI, 1973, ARCH ORAL BIOL, V18, P1531, DOI 10.1016/0003-9969(73)90128-3; HAY DI, 1979, INORG PERSPECT BIOL, V2, P271; MONTALTO G, 1986, BIOCHEM J, V238, P227, DOI 10.1042/bj2380227; MULTIGNER L, 1983, BIOCHEM BIOPH RES CO, V110, P69, DOI 10.1016/0006-291X(83)91261-5; NAKAGAWA Y, 1983, J BIOL CHEM, V258, P2594; PAQUETTE J, 1995, GEOCHIM COSMOCHIM AC, V59, P735, DOI 10.1016/0016-7037(95)00004-J; SHIMIZU S, 1989, J CLIN INVEST, V84, P1990, DOI 10.1172/JCI114389; STAUDT WJ, 1994, GEOCHIM COSMOCHIM AC, V58, P2087, DOI 10.1016/0016-7037(94)90287-9	19	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26302	26306		10.1074/jbc.271.42.26302	http://dx.doi.org/10.1074/jbc.271.42.26302			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824282	hybrid			2022-12-27	WOS:A1996VN18000088
J	Song, XL; Mott, JD; vonKampen, J; Pramanik, B; Tanaka, K; Slaughter, CA; DeMartino, GN				Song, XL; Mott, JD; vonKampen, J; Pramanik, B; Tanaka, K; Slaughter, CA; DeMartino, GN			A model for the quaternary structure of the proteasome activator PA28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT ACTIVATOR; MULTICATALYTIC PROTEINASE; 20S PROTEASOME; HOMOLOGOUS SUBUNITS; 20-S PROTEASOME; 11-S REGULATOR; PURIFICATION; COMPLEX; ACIDOPHILUM; CLONING	PA28 is a protein activator of the 20S proteasome. It has a native molecular weight of approximately 200,000 and is composed of six 28,000 dalton subunits arranged in a ring-shaped complex, Purified preparations of PA28 contain two polypeptides, alpha and beta, which are about 50% identical in primary structure. It has been unclear whether native PA28 consists of two distinct homohexameric proteins or of a single protein containing both alpha and beta subunits, To distinguish between these possibilities, we prepared antibodies that reacted specifically with either the alpha or beta subunit and used these subunit-specific antibodies in two types of experiments designed to elucidate PA28 quaternary structure. In the first experiment, the alpha and beta subunits were completely co-immunoprecipitated by each subunit-specific antibody, indicating that both subunits were part of a single protein complex, In the second experiment, PA28 was chemically cross-linked using bis(sulfosuccinimidyl)suberate. When the cross-linked products were immunoblotted after SDS-polyacrylamide gel electrophoresis, indistinguishable patterns were obtained with each subunit-specific antibody, These results confirm that the alpha and beta subunits were part of the same protein complex, The pattern of cross linked products also provided insight as to the relative abundance and arrangement of the subunits within the PA28 complex and indicated that the ring-shaped PA28 hexamer may be composed of alternating alpha and beta subunits with a stoichiometry of (alpha beta)(3). PA28 was inactivated by treatment with carboxypeptidase Y, which cleaved Tyr and Ile residues from the carboxyl terminus of the alpha subunit but had very little effect on the beta subunit, This selective and limited proteolysis prevented binding of both alpha and beta subunits to the proteasome and therefore provides additional evidence of the heterodimeric nature of PA28, These results indicate that a short carboxyl-terminal sequence of the alpha subunit is critical for binding of native PA28 to the proteasome. To learn about the relative functions of the alpha and beta subunits, PA28 alpha was expressed in Escherichia coli and purified to homogeneity. Purified PA28 alpha stimulated proteasome activity but required 5-10-fold greater concentrations than the heterodimeric PA28 to achieve a given level of activity. These results suggest that the heterodimeric structure of PA28 is required for maximal proteasome activation.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tokyo Metropolitan Institute of Medical Science					NHLBI NIH HHS [HL06296] Funding Source: Medline; NIDDK NIH HHS [DK46181] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046181, R01DK046181] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; CHUPING M, 1993, J BIOL CHEM, V268, P22514; DAHLMANN B, 1989, FEBS LETT, V251, P125, DOI 10.1016/0014-5793(89)81441-3; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GRZIWA A, 1991, FEBS LETT, V290, P186, DOI 10.1016/0014-5793(91)81256-8; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MOTT JD, 1994, J BIOL CHEM, V269, P31466; MUMBY SM, 1991, METHOD ENZYMOL, V195, P215; NIKAIDO T, 1990, CLIN EXP IMMUNOL, V79, P209; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; REALINI C, 1994, J BIOL CHEM, V269, P20727; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1992, NEW BIOL, V4, P173; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	28	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26410	26417		10.1074/jbc.271.42.26410	http://dx.doi.org/10.1074/jbc.271.42.26410			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824298	hybrid			2022-12-27	WOS:A1996VN18000104
J	Mason, MM; Grasso, JA; Gavrilova, O; Reitman, M				Mason, MM; Grasso, JA; Gavrilova, O; Reitman, M			Identification of functional elements of the chicken epsilon-globin promoter involved in stage-specific interaction with the beta/epsilon enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUS-CONTROL REGION; HUMAN GAMMA-GLOBIN; CORRECT DEVELOPMENTAL EXPRESSION; KRUPPEL-LIKE FACTOR; BETA-GLOBIN; TRANSCRIPTION FACTOR; GENE-EXPRESSION; TRANSGENIC MICE; SELECTOR ELEMENT; ERYTHROID-CELLS	Expression of the chicken globin genes is regulated in part by competition between the beta(A)-globin and epsilon-globin promoters for the enhancer found between the genes. To understand the determinants of the enhancer-promoter interaction in stage-specific regulation, the functional elements of the embryonic chicken epsilon-globin promoter were characterized. In vitro assays demonstrated that: (a) the TATA motif at -30 bound GATA-1, (b) Sp1 bound to an element centered at -54, and (c) both Sp1 and another factor, designated CACCC (which appears related to erythroid Kruppel-like factor, EKLF) bound in the -120 to -128 region. The functions of these motifs were tested using transient expression in embryonic erythroid cells, In the absence of the enhancer, promoter point mutants showed that the TATA, Sp1, and CCAAT motifs (but not the CACCC motif) contributed to promoter activity. In contrast, in the presence of the enhancer, all four motifs (including the CACCC motif) contributed to transcription. Developmental regulation of the enhancer activity was observed, with enhance ment decreasing sharply from 185-fold at 4 days (cells expressing epsilon-globin) to 16-fold at 10 days (when epsilon-globin is no longer expressed). Taken together, the data suggest that multiple transcription factors contribute to promoter-enhancer interaction and the developmental regulation of epsilon-globin expression, with EKLF-like factors having an especially important role. Regulation of stage specificity occurs at the level of enhancer/epsilon-promoter interaction, even in the absence of competition, and is not simply a property of the enhancer or promoter in isolation.	NIDDK,NIH,DIABET BRANCH,BETHESDA,MD 20892; NIDDK,NIH,MOL BIOL LAB,BETHESDA,MD 20892; UNIV CONNECTICUT,CTR HLTH,DEPT ANAT,FARMINGTON,CT 06030	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Connecticut			Reitman, Marc/B-4448-2013	Reitman, Marc/0000-0002-0426-9475				BARTON MC, 1993, GENE DEV, V7, P1796, DOI 10.1101/gad.7.9.1796; BRUNS GAP, 1973, PHILOS T ROY SOC B, V266, P225, DOI 10.1098/rstb.1973.0050; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CHOI OR, 1986, NATURE, V323, P731, DOI 10.1038/323731a0; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; CZELUSNIAK J, 1982, NATURE, V298, P297, DOI 10.1038/298297a0; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DODGSON JB, 1983, J BIOL CHEM, V258, P2685; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; FOLEY KP, 1992, GENE DEV, V6, P730, DOI 10.1101/gad.6.5.730; FONG TC, 1992, GENE DEV, V6, P521, DOI 10.1101/gad.6.4.521; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HANSCOMBE O, 1991, GENE DEV, V5, P1387, DOI 10.1101/gad.5.8.1387; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HESSE JE, 1986, P NATL ACAD SCI USA, V83, P4312, DOI 10.1073/pnas.83.12.4312; JACKSON PD, 1989, GENE DEV, V3, P1860, DOI 10.1101/gad.3.12a.1860; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KIM CG, 1992, GENE DEV, V6, P928, DOI 10.1101/gad.6.6.928; LIEHER MR, 1987, J CELL BIOL, V105, P1055; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MASON MM, 1995, MOL CELL BIOL, V15, P407, DOI 10.1128/MCB.15.1.407; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MINIE ME, 1992, DEVELOPMENT, V115, P1149; Moore DD, 1995, GLOB MOB SURV; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PERKINS AC, 1995, NATURE, V375, P318; PETERSON KR, 1993, MOL CELL BIOL, V13, P4836, DOI 10.1128/MCB.13.8.4836; REITMAN M, 1990, NATURE, V348, P749, DOI 10.1038/348749a0; REITMAN M, 1993, MOL CELL BIOL, V13, P3990, DOI 10.1128/MCB.13.7.3990; REITMAN M, 1993, GENOMICS, V18, P616, DOI 10.1016/S0888-7543(05)80364-7; RONINSON IB, 1982, CELL, V28, P515, DOI 10.1016/0092-8674(82)90206-9; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; YANG Z, 1995, J BIOL CHEM, V269, P10079	53	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25459	25467		10.1074/jbc.271.41.25459	http://dx.doi.org/10.1074/jbc.271.41.25459			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810316	hybrid			2022-12-27	WOS:A1996VL69300060
J	Pipe, SW; Kaufman, RJ				Pipe, SW; Kaufman, RJ			Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; COAGULATION-FACTOR-VIII; CELL ANTIGEN RECEPTOR; VONWILLEBRAND-FACTOR; ENDOPLASMIC-RETICULUM; HEMOPHILIA-A; LIGHT CHAIN; INTRACELLULAR DEGRADATION; MAMMALIAN-CELLS; PRE-GOLGI	The half-life of coagulation factor VIII (FVIII) in plasma is prolonged by noncovalent interaction with von Willebrand factor (vWF), Antibody inhibition data indicate that epitopes within the carboxyl terminus of the FVIII light chain play a role in vWF binding. Analysis of hemophilia A patient DNA samples have identified missense mutations within this carboxyl terminus of the FVIII light chain at amino acid 2307 in which arginine is replaced with either glutamine or leucine. Patients with these mutations have reduced FVIII activity proportional to reduced cross-reacting material in their plasma, It was hypothesized that the reduced levels of FVIII in plasma due to these mutations may be related to a defect in VWF binding with resultant plasma instability, Wild-type and mutant FVIII cDNA expression vectors were prepared and expressed in COS-1 monkey cells by transient DNA transfection. FVIII mutants R2307Q and R2307L were synthesized at equal rates compared to FVIII wild-type but had greater than 10-fold reduced accumulation of antigen and activity levels in the conditioned medium, An additional mutation, Y2305F, also displayed a similar defect in protein accumulation, whereas Y2332F was secreted similarly to wild-type. The specific activity of immunoaffinity purified R2307Q was mildly reduced compared to FVIII wildtype, whereas vWF binding properties were retained. Inhibition of intracellular cysteine proteases resulted in intracellular accumulation of R2307Q protein, suggesting that the mechanism leading to hemophilia A is related to a block in secretion and subsequent degradation within the secretory pathway rather than extracellular instability.	UNIV MICHIGAN,MED CTR,DEPT PEDIAT,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Pipe, Steven W./ABC-3843-2020	Pipe, Steven W./0000-0003-2558-2089	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; ANTONARAKIS SE, 1995, HUM MUTAT, V5, P1, DOI 10.1002/humu.1380050102; ARAI M, 1989, J CLIN INVEST, V83, P1978, DOI 10.1172/JCI114107; BACHHAWAT AK, 1991, J CELL BIOL, V115, P619, DOI 10.1083/jcb.115.3.619; BONIFACINO JS, 1994, CELLULAR PROTEOLYTIC; BRINKHOUS KM, 1985, P NATL ACAD SCI USA, V82, P8752, DOI 10.1073/pnas.82.24.8752; CASULA L, 1990, BLOOD, V75, P662; CHEN C, 1988, J CELL BIOL, V107, P2149, DOI 10.1083/jcb.107.6.2149; COTNER T, 1995, J BIOL CHEM, V270, P2379, DOI 10.1074/jbc.270.5.2379; DIXON JL, 1991, J BIOL CHEM, V266, P5080; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ELIASSON E, 1992, J BIOL CHEM, V267, P15765; Erlich H.A., 1989, PCR TECHNOLOGY PRINC; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; GILBERT GE, 1993, BLOOD, V82, pA59; GIRMA JP, 1987, BLOOD, V70, P605; GITSCHIER J, 1986, SCIENCE, V232, P1415, DOI 10.1126/science.3012775; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; INABA H, 1989, HUM GENET, V81, P335, DOI 10.1007/BF00283686; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; KOEDAM JA, 1990, EUR J BIOCHEM, V189, P229, DOI 10.1111/j.1432-1033.1990.tb15481.x; LE AQ, 1992, J BIOL CHEM, V267, P1072; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1991, J BIOL CHEM, V266, P740; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; MOORE SEH, 1993, J BIOL CHEM, V268, P3809; NESHEIM M, 1991, J BIOL CHEM, V266, P17815; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; OVER J, 1978, J CLIN INVEST, V62, P223, DOI 10.1172/JCI109120; PITTMAN DD, 1989, THROMB HAEMOSTASIS, V61, P161; PITTMAN DD, 1993, METHOD ENZYMOL, V222, P236; RICK ME, 1990, J LAB CLIN MED, V115, P415; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROTUNDO RL, 1989, J BIOL CHEM, V264, P3146; ROY S, 1992, J BIOL CHEM, V267, P23151; SAENKO EL, 1994, J BIOL CHEM, V269, P11601; SCHWAAB R, 1993, BRIT J HAEMATOL, V83, P450, DOI 10.1111/j.1365-2141.1993.tb04670.x; SHIMA M, 1991, INT J HEMATOL, V54, P515; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; STUBBS JD, 1990, P NATL ACAD SCI USA, V87, P8417, DOI 10.1073/pnas.87.21.8417; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TOKUNAGA F, 1995, BIOCHEMISTRY-US, V34, P1163, DOI 10.1021/bi00004a009; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1982, BRIT J HAEMATOL, V52, P259, DOI 10.1111/j.1365-2141.1982.tb03888.x; TULEY EA, 1991, P NATL ACAD SCI USA, V88, P6377, DOI 10.1073/pnas.88.14.6377; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WEISS HJ, 1977, J CLIN INVEST, V60, P390, DOI 10.1172/JCI108788; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILEMAN T, 1990, INT IMMUNOL, V2, P743, DOI 10.1093/intimm/2.8.743; WILEMAN T, 1993, J CELL BIOL, V122, P67, DOI 10.1083/jcb.122.1.67; WISE RJ, 1991, J BIOL CHEM, V266, P21948; ZATLOUKAL K, 1994, P NATL ACAD SCI USA, V91, P5148, DOI 10.1073/pnas.91.11.5148; ZIMMERMAN TS, 1985, CLIN HAEMATOL, V14, P343	65	40	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25671	25676		10.1074/jbc.271.41.25671	http://dx.doi.org/10.1074/jbc.271.41.25671			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810344	hybrid			2022-12-27	WOS:A1996VL69300088
J	Wilkinson, BM; Critchley, AJ; Stirling, CJ				Wilkinson, BM; Critchley, AJ; Stirling, CJ			Determination of the transmembrane topology of yeast Sec61p, an essential component of the endoplasmic reticulum translocation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PROTEIN TRANSLOCATION; HUMAN P-GLYCOPROTEIN; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; LACTOSE PERMEASE; SIGNAL SEQUENCE; SHUTTLE VECTORS; ER MEMBRANE; INSERTION	Sec61p is a highly conserved integral membrane protein that plays a role in the formation of a protein-conducting channel required for the translocation of polypeptides into, and across, the membrane of the endoplasmic reticulum. As a major step toward elucidating the structure of the endoplasmic reticulum translocation apparatus, we have determined the transmembrane topology of Sec61p using a combination of C-terminal reporter-domain fusions and the in situ digestion of specifically inserted factor Xa protease cleavage sites. Our data indicate the presence of 10 transmembrane domains, including several with surprisingly limited hydrophobicity. Furthermore, we provide evidence for complex intramolecular interactions in which these weakly hydrophobic domains require C-terminal sequences for their correct topogenesis, The incorporation of sequences with limited hydrophobicity into the bilayer may play a vital role in the formation of an aqueous membrane channel required for the translocation of hydrophilic polypeptide chains.	UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND	University of Manchester								AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; GREEN GN, 1989, J CELL SCI, P109; GREEN N, 1992, J CELL BIOL, V116, P597, DOI 10.1083/jcb.116.3.597; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIGH S, 1993, J CELL BIOL, V121, P743, DOI 10.1083/jcb.121.4.743; HIGH S, 1992, Current Opinion in Cell Biology, V4, P581, DOI 10.1016/0955-0674(92)90075-N; HOFFMANN W, 1987, MOL GEN GENET, V210, P277, DOI 10.1007/BF00325694; HUFFAKER TC, 1983, P NATL ACAD SCI-BIOL, V80, P7466, DOI 10.1073/pnas.80.24.7466; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; Martoglio B, 1996, TRENDS CELL BIOL, V6, P142, DOI 10.1016/0962-8924(96)10001-5; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; NAGAI K, 1984, NATURE, V309, P810, DOI 10.1038/309810a0; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SAHINTOTH M, 1995, BIOCHEMISTRY-US, V34, P1107, DOI 10.1021/bi00004a001; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; Sherman F, 1986, LAB COURSE MANUAL ME; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1993, J BIOL CHEM, V268, P23552; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STIRLING CJ, 1993, NATO ASI SERIES H, V71, P293; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035	60	126	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25590	25597		10.1074/jbc.271.41.25590	http://dx.doi.org/10.1074/jbc.271.41.25590			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810333	hybrid			2022-12-27	WOS:A1996VL69300077
J	Cheung, HS; Kurup, IV; Sallis, JD; Ryan, LM				Cheung, HS; Kurup, IV; Sallis, JD; Ryan, LM			Inhibition of calcium pyrophosphate dihydrate crystal formation in articular cartilage vesicles and cartilage by phosphocitrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NTP PYROPHOSPHOHYDROLASE; INORGANIC PYROPHOSPHATE; IN-VITRO; CITRATE; HYDROXYAPATITE; DISEASE; GROWTH; ATP	Articular cartilage vesicles (ACV), isolated by differential centrifugation of adult hyaline articular cartilage collagenase digests, mineralized in the presence of calcium and ATP. Mineral analysis by microscopy, chemical analysis, energy-dispersive analysis, and infrared spectroscopy revealed crystals resembling calcium pyrophosphate dihydrate (CPPD). Adult articular cartilage also underwent ATP-dependent mineralization, supporting the contention that vesicles in situ fostered adult articular cartilage mineralization. Phosphocitrate (PC) is a recognized in vitro inhibitor of hydroxyapatite and calcium oxalate monohydrate crystal formation, but it is not known whether PC can similarly restrict CPPD crystal development. In the present study we examine the effect of PC, citrate, and n-sulfo-2-amino-tricarballylate (SAT, a PC analogue) on the ATP-induced CPPD crystal formation in both ACV and articular cartilage models. Only PC (10-1000 mu M) blocked both the ATP-dependent and -independent mineralization in ACV in a dose-dependent fashion, At 1 mM, SAT and citrate blocked the ATP-independent mineralization. Similarly, only PC blocked both the ATP- and non-ATP-dependent mineralization in native articular cartilage slices, PC, SAT, and citrate had no effect on ACV nucleoside triphosphate pyrophosphohydrolase activity, suggesting that none of these agents blocked mineralization through the inhibition of nucleoside triphosphate pyrophosphohydrolase activity, which generates inorganic pyrophosphate from ATP.	UNIV TASMANIA, DEPT BIOCHEM, HOBART, TAS 7001, AUSTRALIA	University of Tasmania	Cheung, HS (corresponding author), MED COLL WISCONSIN, DIV RHEUMATOL, MILWAUKEE, WI 53226 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421, R01AR038656] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38421-06, AR38656-07] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN MR, 1985, UROLITHIASIS RELATED, P891; CHEUNG HS, 1990, BIOCHEM BIOPH RES CO, V171, P20, DOI 10.1016/0006-291X(90)91350-2; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; CHEUNG HS, 1993, JOINT CARTILAGE DEGR, P209; CHEUNG HS, 1994, REV BRAS REUMATOL, V34, pS117; DERFUS B, 1995, J RHEUMATOL, V22, P1514; DERFUS BA, 1992, ARTHRITIS RHEUM, V35, P231, DOI 10.1002/art.1780350218; DERFUS BA, 1994, ARTHRITIS RHEUM, V37, pS142; HALVERSON PB, 1992, ARTHRITIS ALLIED CON, P1857; HOWARD JE, 1976, JOHNS HOPKINS MED J, V139, P239; HOWELL DS, 1984, ARTHRITIS RHEUM, V27, P193, DOI 10.1002/art.1780270211; JOHNSSON M, 1991, CALCIFIED TISSUE INT, V49, P134, DOI 10.1007/BF02565136; KRANENDONK S, 1994, J BONE JT SURG ORTHO, V18, P502; KRUG HE, 1993, ARTHRITIS RHEUM, V36, P1603, DOI 10.1002/art.1780361116; MASUDA I, 1995, J CLIN INVEST, V95, P699, DOI 10.1172/JCI117716; PANKOWSKI AH, 1994, TETRAHEDRON LETT, V35, P927, DOI 10.1016/S0040-4039(00)76002-3; RACHOW JW, 1988, ARTHRITIS RHEUM, V31, P408, DOI 10.1002/art.1780310313; RYAN LM, 1992, ARTHRITIS RHEUM, V35, P1520, DOI 10.1002/art.1780351216; RYAN LM, 1991, J RHEUMATOL, V18, P716; RYAN LM, 1984, ARTHRITIS RHEUM, V27, P404, DOI 10.1002/art.1780270407; RYAN LM, 1992, ARTHRITIS ALLIED CON, P1835; SALLIS JD, 1995, SCANNING MICROSCOPY, V9, P127; SALLIS JD, 1991, ACS SYM SER, V444, P149; SALLIS JD, 1995, SURFACE REACTIVE PEP, P87; SHANKAR R, 1985, ATHEROSCLEROSIS, V50, P191; SIEGEL SA, 1983, J BIOL CHEM, V258, P8601; SUGINO Y, 1964, J BIOL CHEM, V239, P2360; TENENBAUM J, 1981, ARTHRITIS RHEUM, V24, P492, DOI 10.1002/art.1780240307; TEW WP, 1981, P NATL ACAD SCI-BIOL, V78, P5528, DOI 10.1073/pnas.78.9.5528; WARD LC, 1987, ATHEROSCLEROSIS, V65, P117, DOI 10.1016/0021-9150(87)90013-X; WIERZBICKI A, 1995, CALCIFIED TISSUE INT, V56, P297, DOI 10.1007/BF00318050; WILLIAMS G, 1982, CALCIFIED TISSUE INT, V34, P169, DOI 10.1007/BF02411229	32	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28082	28085		10.1074/jbc.271.45.28082	http://dx.doi.org/10.1074/jbc.271.45.28082			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910421	hybrid			2022-12-27	WOS:A1996VU03300021
J	Feldmann, H; Driller, L; Meier, B; Mages, G; Kellermann, J; Winnacker, EL				Feldmann, H; Driller, L; Meier, B; Mages, G; Kellermann, J; Winnacker, EL			HDF2, the second subunit of the Ku homologue from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HUMAN AUTOANTIGEN KU; DOUBLE-STRAND BREAKS; HIGHER EUKARYOTES; DNA-DAMAGE; ANTIGEN; RECOMBINATION; YEAST; GENE; CDNA	The high affinity DNA binding factor (HDF) protein of Saccharomyces cerevisiae is composed of two subunits and specifically binds ends of double-stranded DNA, The 70-kDa subunit, HDF1, shows significant homology with the 70-kDa subunit of the human Ku protein, Like the Ku protein, HDF1 has been shown to be involved in recombination and double stranded DNA break repair, We have purified and cloned HDF2, the second subunit of the HDF protein, The amino acid sequence of HDF2 shows a 45.6% homology with the 80-kDa subunit of the Ku protein. HDF1 by itself does not bind DNA, while HDF2 protein on its own seems to displays DNA binding activity. Targeted disruption of the HDF2 gene causes a temperature sensitive phenotype for growth comparable to the phenotype of hdf1(-) strains. The human Ku protein cannot complement this temperature-sensitive phenotype, hdf2(-) strains are sensitive to bleomycin and methyl methanesulfonate, but this sensitivity is reduced in comparison with hdf1(-) strains.	UNIV MUNICH,INST BIOCHEM,D-81377 MUNICH,GERMANY; MAX PLANCK INST BIOCHEM,D-82152 MARTINSRIED,GERMANY	University of Munich; Max Planck Society								ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Beall EL, 1996, GENE DEV, V10, P921, DOI 10.1101/gad.10.8.921; BEALL EL, 1994, P NATL ACAD SCI USA, V91, P12681, DOI 10.1073/pnas.91.26.12681; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BLIER PR, 1993, J BIOL CHEM, V268, P7594; CARR AM, 1995, TRENDS CELL BIOL, V5, P32, DOI 10.1016/S0962-8924(00)88934-5; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FALZON M, 1993, J BIOL CHEM, V268, P10546; FELDMANN H, 1993, J BIOL CHEM, V268, P12895; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; FRIEDBERG EC, 1995, DNA REPAIR; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P1; HWANG PI, 1995, FASEB J, V9, pA1398; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KESZENMAN DJ, 1992, J BACTERIOL, V174, P3125, DOI 10.1128/jb.174.10.3125-3132.1992; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Mages GJ, 1996, J BIOL CHEM, V271, P7910, DOI 10.1074/jbc.271.14.7910; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; Porter SE, 1996, NUCLEIC ACIDS RES, V24, P582, DOI 10.1093/nar/24.4.582; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; Siede W, 1996, GENETICS, V142, P91; SIKORSKI RS, 1989, GENETICS, V122, P19; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; STEIGHNER RJ, 1990, P NATL ACAD SCI USA, V87, P8350, DOI 10.1073/pnas.87.21.8350; Tsukamoto Y, 1996, NUCLEIC ACIDS RES, V24, P2067, DOI 10.1093/nar/24.11.2067; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; YANEVA M, 1989, J BIOL CHEM, V264, P13407	44	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27765	27769		10.1074/jbc.271.44.27765	http://dx.doi.org/10.1074/jbc.271.44.27765			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910371	hybrid			2022-12-27	WOS:A1996VQ67900089
J	Hinder, B; Schellenberg, M; Rodon, S; Ginsburg, S; Vogt, E; Martinoia, E; Matile, P; Hortensteiner, S				Hinder, B; Schellenberg, M; Rodon, S; Ginsburg, S; Vogt, E; Martinoia, E; Matile, P; Hortensteiner, S			How plants dispose of chlorophyll catabolites - Directly energized uptake of tetrapyrrolic breakdown products into isolated vacuoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENESCENT BARLEY LEAVES; REDUCED FERREDOXIN; IN-VITRO; RAPE; CONSTITUTION; REQUIREMENT; PROTOPLASTS; COTYLEDONS; PORPHYRIN; CLEAVAGE	During the yellowing of leaves the porphyrin moiety of chlorophyll is cleaved into colorless linear tetrapyrrolic catabolites, which eventually are deposited in the central vacuoles of mesophyll cells, In senescent cotyledons of rape, Brassica napus, three nonfluorescent chlorophyll catabolites (NCCs), accounting for practically all the chlorophyll broken down, were found to be located in the vacuoles (vacuoplasts) prepared from protoplasts, Transport of catabolites across the tonoplast was studied with vacuoles isolated from barley mesophyll protoplasts in conjunction with a radiolabeled NCC, Bn-NCC-1, prepared from senescent rape cotyledons, The uptake of Bn-NCC-1 into vacuoles was against a concentration gradient and strictly dependent on MgATP and it followed saturation kinetics with a K-m of approximately 100 mu M. Although the hydrolysis of ATP was required, transport was apparently independent of the vacuolar proton pumps: accumulation of the NCC occurred both in the presence of the H+-ATPase inhibitor bafilomycin and after destroying the Delta pH between the vacuolar sap and the medium, ATP could be replaced by GTP or UTP, and the transport was inhibited in the presence of vanadate, Chlorophyll catabolites isolated from senescent barley leaves competed with the rape-specific substrate for uptake into the vacuoles, Compounds such as the glutathione conjugate of N-ethylmaleimide and taurocholate, which are known to be transported across the tonoplast in a primary active mode, did not significantly inhibit uptake of Bn-NCC-1, Although the heme catabolites biliverdin and bilirubin inhibited the uptake of the NCC, this effect is caused by unspecific binding to the vacuolar membrane rather than to the specific inhibition of carrier-mediated transport, Taken together, the results demonstrate that barley mesophyll vacuoles are constitutively equipped with a directly energized carrier that transports tetrapyrrolic catabolites of chlorophyll into the vacuole.	UNIV ZURICH,DEPT PLANT BIOL,CH-8008 ZURICH,SWITZERLAND; ETH ZURICH,INST PLANT SCI,CH-8092 ZURICH,SWITZERLAND; UNIV POITIERS,INST BIOL VEGETAL,F-86022 POITIERS,FRANCE	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Universite de Poitiers			Martinoia, Enrico/AAH-8712-2021					BALZI E, 1994, BBA-BIOENERGETICS, V1187, P152, DOI 10.1016/0005-2728(94)90102-3; BORTLIK K, 1990, J PLANT PHYSIOL, V136, P161, DOI 10.1016/S0176-1617(11)81659-7; BORTLIK KH, 1990, THESIS U ZURICH; DUGGELIN T, 1988, J PLANT PHYSIOL, V133, P492; GINSBURG S, 1993, PLANT PHYSIOL, V102, P521, DOI 10.1104/pp.102.2.521; GINSBURG S, 1994, PLANT PHYSIOL, V105, P545, DOI 10.1104/pp.105.2.545; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HORTENSTEINER S, 1995, NEW PHYTOL, V129, P237, DOI 10.1111/j.1469-8137.1995.tb04293.x; HORTENSTEINER S, 1992, PLANTA, V187, P113, DOI 10.1007/BF00201632; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18466; KAISER G, 1986, PLANTA, V169, P345, DOI 10.1007/BF00392130; KRAUTLER B, 1992, PLANT PHYSIOL BIOCH, V30, P333; KRAUTLER B, 1991, ANGEW CHEM INT EDIT, V30, P1315, DOI 10.1002/anie.199113151; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MATILE P, 1992, PLANTA, V187, P230, DOI 10.1007/BF00201944; MATILE P, 1984, NATURWISSENSCHAFTEN, V71, P18, DOI 10.1007/BF00365975; MATILE P, 1988, P NATL ACAD SCI USA, V85, P9529, DOI 10.1073/pnas.85.24.9529; Matile P., 1992, CHLOROPLAST SENESCEN, P413; Muhlecker W, 1996, PLANT PHYSIOL BIOCH, V34, P61; MUHLECKER W, 1993, HELV CHIM ACTA, V76, P2976, DOI 10.1002/hlca.19930760822; PEISKER C, 1990, J PLANT PHYSIOL, V136, P544, DOI 10.1016/S0176-1617(11)80211-7; PEISKER C, 1991, THESIS U ZURICH; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; SCHELLENBERG M, 1993, PLANTA, V191, P417, DOI 10.1007/BF00195702; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743	26	87	95	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27233	27236		10.1074/jbc.271.44.27233	http://dx.doi.org/10.1074/jbc.271.44.27233			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910294	hybrid			2022-12-27	WOS:A1996VQ67900012
J	Verchere, CB; Paoletta, M; NeermanArbez, M; Rose, K; Irminger, JC; Gingerick, RL; Kahn, SE; Halban, PA				Verchere, CB; Paoletta, M; NeermanArbez, M; Rose, K; Irminger, JC; Gingerick, RL; Kahn, SE; Halban, PA			Des-(27-31)C-peptide - A novel secretory product of the rat pancreatic beta cell produced by truncation of proinsulin connecting peptide in secretory granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-PEPTIDE; INTRACELLULAR DEGRADATION; INSULIN CONVERSION; B-CELL; CLEAVAGE; ISLETS; SEQUENCE	Insulin and connecting peptide (C-peptide) are produced in equimolar amounts during proinsulin conversion in the pancreatic beta cell secretory granule, To determine whether insulin and C-peptide are equally stable in beta cell granules (and thus secreted in equimolar amounts), neonatal and adult rat beta cells were pulse chased, and radiolabeled insulin and C-peptide analyzed by high performance liquid chromatography, A novel truncated C-peptide was identified and shown by mass spectrometry to be des-(27-31)C-peptide (loss of 5 C-terminal amino acids), Des-(27-31)C peptide is a major beta cell secretory product, accounting for 37.4 +/- 1.6% (neonatal) and 8.5 +/- 0.6% (adult) of total labeled C-peptide in secretory granules after 10 h of chase, Des-(27-31)C-peptide is also secreted in a glucose-sensitive manner from the perfused adult rat pancreas, accounting for similar to 10% of total C-peptide immunoreactivity secreted, Human C-peptide is also a substrate for truncation in granules, Thus, when human proinsulin was expressed (infection with recombinant adenovirus) in transformed (INS) rat beta cells, human des-(27-31)C-peptide was secreted along with the intact human peptide and both intact and truncated rat C-peptide, In addition to truncation, 33.1 +/- 1.2% of C-peptide in neonatal but not adult rat beta cell granules was further degraded, Such degradation was completely inhibited by ammonium chloride (known to neutralize intra-granular pH), whereas truncation was only partially inhibited by similar to 50%, In conclusion, a novel beta cell secretory product, des-(27-31)C-peptide, has been identified and should be considered as a potential bioactive peptide, Both truncation and degradation of C-peptide are responsible for non-equimolar secretion of insulin and C-peptide in rat beta cells.	UNIV WASHINGTON, SEATTLE, WA 98108 USA; UNIV GENEVA, MED CTR, LOUIS JEANTET RES LABS, CH-1211 GENEVA 4, SWITZERLAND; UNIV GENEVA, MED CTR, DEPT BIOCHEM MED, CH-1211 GENEVA 4, SWITZERLAND; LINCO RES INC, ST CHARLES, MO 63304 USA	University of Washington; University of Washington Seattle; University of Geneva; University of Geneva	Verchere, CB (corresponding author), VET ADM MED CTR, DEPT MED, DIV METAB ENDOCRINOL & NUTR, 1660 S COLUMBIAN WAY, SEATTLE, WA 98108 USA.			Neerman-Arbez, Marguerite/0000-0002-9351-4195; Kahn, Steven/0000-0001-7307-9002	NIDDK NIH HHS [DK017047, DK-12829] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK017047, R01DK012829] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKPAN JO, 1993, INT J PANCREATOL, V13, P87; ARVAN P, 1991, J BIOL CHEM, V266, P14171; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BECKER TC, 1994, USE RECOMBINANT ADEN, P161; BLOCK MB, 1973, NEW ENGL J MED, V288, P1144, DOI 10.1056/NEJM197305312882202; CAHILL GF, 1973, NEW ENGL J MED, V288, P1181, DOI 10.1056/NEJM197305312882210; CONLON JM, 1995, PANCREAS, V10, P167, DOI 10.1097/00006676-199503000-00010; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; EDMONDS CG, 1990, METHOD ENZYMOL, V193, P412, DOI 10.1016/0076-6879(90)93430-S; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GROSS DJ, 1989, J BIOL CHEM, V264, P21486; HALBAN PA, 1991, DIABETOLOGIA, V34, P767, DOI 10.1007/BF00408349; HALBAN PA, 1983, DIABETES, V32, P254, DOI 10.2337/diabetes.32.3.254; HALBAN PA, 1987, DIABETOLOGIA, V30, P348, DOI 10.1007/BF00299029; HALBAN PA, 1986, DIABETOLOGIA, V29, P893, DOI 10.1007/BF00870146; HENRY JS, 1993, GEN COMP ENDOCR, V89, P299, DOI 10.1006/gcen.1993.1036; HUGHES GJ, 1987, J CHROMATOGR, V389, P327, DOI 10.1016/S0021-9673(01)94443-7; KAHN SE, 1990, DIABETES, V39, P634, DOI 10.2337/diabetes.39.5.634; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; KULIAWAT R, 1992, J CELL BIOL, V118, P521, DOI 10.1083/jcb.118.3.521; KWOK SCM, 1983, J BIOL CHEM, V258, P2357; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MICHAEL J, 1987, J BIOL CHEM, V262, P16531; NEERMANARBEZ M, 1993, J BIOL CHEM, V268, P16248; ORCI L, 1985, DIABETOLOGIA, V28, P528, DOI 10.1007/BF00281987; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; ORCI L, 1994, J CELL BIOL, V126, P1149, DOI 10.1083/jcb.126.5.1149; ORCI L, 1984, J CELL BIOL, V98, P222, DOI 10.1083/jcb.98.1.222; OYER PE, 1971, J BIOL CHEM, V246, P1375; POLONSKY KS, 1995, DIABETES, V44, P705, DOI 10.2337/diabetes.44.6.705; RHODES CJ, 1987, J BIOL CHEM, V262, P10712; RHODES CJ, 1988, BIOCHEM J, V251, P23, DOI 10.1042/bj2510023; ROUILLER DG, 1990, EXP CELL RES, V191, P305, DOI 10.1016/0014-4827(90)90019-7; SMITH RE, 1966, J CELL BIOL, V31, P319, DOI 10.1083/jcb.31.2.319; TAGER HS, 1973, J BIOL CHEM, V248, P3476; VERCHERE CB, 1995, DIABETOLOGIA, V38, pA65; VERCHERE CB, 1993, PHARMACOLOGY, V46, P50; WAHREN J, 1994, DIABETOLOGIA, V37, pS99, DOI 10.1007/BF00400832	38	23	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27475	27481		10.1074/jbc.271.44.27475	http://dx.doi.org/10.1074/jbc.271.44.27475			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910330	hybrid			2022-12-27	WOS:A1996VQ67900048
J	Zamir, LO; Nikolakakis, A; Devor, KA; Sauriol, F				Zamir, LO; Nikolakakis, A; Devor, KA; Sauriol, F			Biosynthesis of the trichothecene 3-acetyldeoxynivalenol - Is isotrichodermin a biosynthetic precursor?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-CULMORUM; METABOLITES	3-Acetyldeoxynivalenol is the major trichothecene produced by the fungus Fusarium culmorum, The first proven tricyclic intermediate in the biosynthesis of 3-acetyldeoxynivalenol has been shown by in vivo studies to be isotrichodermin, a natural metabolite of F. culmorum, Indeed, the feeding of ring-deuterated isotrichodermin resulted in ring-deuterated 3-acetyldeoxynivalenol as shown by NMR studies, In this work, we have shown that the 3-acetyl group of isotrichodermin is mostly lost in its metabolism to 3-acetyldeoxynivalenol. We have shown by two different approaches that the deacetylation occurs at an early step after the first oxygenation step at C-15, Derivatives of isotrichodermin lacking the 3-acetyl such as 3-deacetyl isotrichodermin or 3-oxo-12, 13-epoxytrichothec-9-ene are not precursors to 3-acetyldeoxynivalenol. The role of this acetyl exchange mechanism is not clear presently.	MCGILL UNIV,DEPT CHEM,MONTREAL,PQ H3Z 2K6,CANADA	McGill University	Zamir, LO (corresponding author), UNIV QUEBEC,INST ARMAND FRAPPIER,CTR RECH MICROBIOL APPL,531 BLVD PRAIRIES,LAVAL,PQ H7V 1B7,CANADA.							GLEDHILL L, 1991, FEMS MICROBIOL LETT, V81, P241, DOI 10.1111/j.1574-6968.1991.tb04765.x; GREENHALGH R, 1984, J AGR FOOD CHEM, V32, P945, DOI 10.1021/jf00124a060; GREENHALGH R, 1986, J AGR FOOD CHEM, V34, P98, DOI 10.1021/jf00067a027; HOHN TM, 1995, MOL GEN GENET, V248, P95, DOI 10.1007/BF02456618; MOHR P, 1984, HELV CHIM ACTA, V67, P406, DOI 10.1002/hlca.19840670208; Schenkman J B, 1978, Methods Enzymol, V52, P83; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; ZAMIR LO, 1991, J BIOL CHEM, V266, P14992; ZAMIR LO, 1990, J BIOL CHEM, V265, P6713; ZAMIR LO, 1987, J BIOL CHEM, V262, P15348; Zamir LO, 1996, CAN J MICROBIOL, V42, P828, DOI 10.1139/m96-104	11	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27353	27359		10.1074/jbc.271.44.27353	http://dx.doi.org/10.1074/jbc.271.44.27353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910312	hybrid			2022-12-27	WOS:A1996VQ67900030
J	Trifillis, P; Adachi, K; Yamaguchi, T; Schwartz, E; Surrey, S				Trifillis, P; Adachi, K; Yamaguchi, T; Schwartz, E; Surrey, S			Expression studies of delta-globin gene alleles associated with reduced hemoglobin A(2) levels in Greek cypriots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCEPTOR SPLICE SITE; BETA-THALASSEMIA; SEQUENCE-ANALYSIS; NUCLEOTIDE SUBSTITUTION; MOLECULAR-BASIS; AMPLIFIED DNA; RNA; KNOSSOS; MUTATIONS; VARIANT	We previously identified five delta-globin gene alleles associated with reduced hemoglobin (Hb) A(2) (Trifillis, P., Ioannou, P., Schwartz, E., and Surrey, S. (1991) Blood 78, 3298-3305). We have now evaluated functional consequences of the changes after expression in COS-1 cells to monitor effects on RNA splicing. In addition, variant Hb A(2) tetramers were expressed in yeast to assess effects of amino acid changes on oxygen binding and stability to heat and mechanical agitation. The G --> T change at codon 27 and the A --> G change in IVS-2 both affect RNA splicing, whereas the C --> T change at codon 97 and the AT deletion in IVS-2 have no effect. Oxygen equilibrium curves of the Hb A(2) variants expressed in yeast were similar to that of wild type Hb A(2). None of the three variant Hb A(2) tetramers (Thr --> Ile at codon 4 (Hb delta T4I), Ala --> Ser at codon 27 (Hb delta A27S), and Arg --> Cys at codon 116 (Hb delta R116C)) showed decreased heat stability compared with Hb A(2), whereas the Hb delta T4I variant showed highest instability to mechanical agitation, Coexpression in yeast of alpha-globin chain and the delta-chain variant containing a Leu --> Pro change at codon 141 yielded no identifiable tetramers, suggesting lack of assembly or severe tetramer instability, These studies show the probable cause for decreased Hb A(2) for two alleles is due to defective splicing, whereas decreased protein stability, increased tetramer association with red cell membranes, increased interdisulfide bond formation of delta-chains, which inhibits assembly with alpha-chains, and/or reduced assembly is suggested for the other three alleles.	CHILDRENS HOSP PHILADELPHIA,ABRAMSON PEDIAT RES CTR,DIV HEMATOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Childrens Hospital of Philadelphia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016691] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38632] Funding Source: Medline; NIDDK NIH HHS [DK 16691] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI K, 1993, J BIOL CHEM, V268, P21650; ADACHI K, 1978, J BIOL CHEM, V253, P382; ADACHI K, 1993, FEBS LETT, V315, P47, DOI 10.1016/0014-5793(93)81130-R; ADACHI K, 1992, PROTEIN ENG, V5, P807, DOI 10.1093/protein/5.8.807; ANTONARAKIS SE, 1984, P NATL ACAD SCI-BIOL, V81, P1154, DOI 10.1073/pnas.81.4.1154; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; AROUS N, 1982, FEBS LETT, V147, P247, DOI 10.1016/0014-5793(82)81052-1; ASAKURA T, 1974, BIOCHEM BIOPH RES CO, V57, P780, DOI 10.1016/0006-291X(74)90614-7; ASAKURA T, 1974, P NATL ACAD SCI USA, V71, P1594, DOI 10.1073/pnas.71.5.1594; ATWEH GF, 1985, NUCLEIC ACIDS RES, V13, P777, DOI 10.1093/nar/13.3.777; BLACKWELL RQ, 1971, BIOCHIM BIOPHYS ACTA, V243, P467; *BOLT BER NEWM LAB, EMBL GENB DAT; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CODRINGTON JF, 1989, BIOCHIM BIOPHYS ACTA, V1009, P87, DOI 10.1016/0167-4781(89)90083-3; DELANO JJM, 1993, P NATL ACAD SCI USA, V90, P918; FESTA RS, 1979, TRANSFUSION, V19, P107, DOI 10.1046/j.1537-2995.1979.19279160278.x; GALANELLO R, 1990, BLOOD, V75, P1747; GARCIA CR, 1983, HEMOGLOBIN, V7, P435, DOI 10.3109/03630268309038412; GOLDSMITH ME, 1983, P NATL ACAD SCI-BIOL, V80, P2318, DOI 10.1073/pnas.80.8.2318; HAYASHI A, 1971, NATURE-NEW BIOL, V230, P264, DOI 10.1038/newbio230264a0; HIRANO M, 1981, BLOOD, V57, P697; HUISMAN THJ, 1993, HEMOGLOBIN, V17, P89; INGRAM VM, 1959, BIOCHIM BIOPHYS ACTA, V36, P402, DOI 10.1016/0006-3002(59)90183-0; KELLER MA, 1993, PCR METH APPL, V3, P32; KLEIHAUER EF, 1968, BIOCHIM BIOPHYS ACTA, V154, P220, DOI 10.1016/0005-2795(68)90274-2; KLIPSTEIN FA, 1960, J CLIN INVEST, V39, P1894, DOI 10.1172/JCI104213; KULOZIK AE, 1988, BLOOD, V71, P457; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORKIN PA, 1975, BIOCHIM BIOPHYS ACTA, V386, P256, DOI 10.1016/0005-2795(75)90266-4; LORROWMURRAY D, 1991, FOCUS, V13, P65; LOSEKOOT M, 1989, HUM GENET, V83, P75, DOI 10.1007/BF00274153; LOUDIANOS G, 1991, BLOOD, V77, P2087; MATSUDA M, 1992, BLOOD, V80, P1347; MOI P, 1988, BLOOD, V72, P530; NAGEL RL, 1995, BLOOD S, V86, P251; NAKAMURA T, 1987, BLOOD, V70, P809; OLDS RJ, 1991, BRIT J HAEMATOL, V78, P430, DOI 10.1111/j.1365-2141.1991.tb04460.x; ORKIN SH, 1984, BLOOD, V64, P311; ORKIN SH, 1982, NATURE, V300, P768, DOI 10.1038/300768a0; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; PERUTZ MF, 1968, NATURE, V219, P131, DOI 10.1038/219131a0; PERUTZ MF, 1965, J MOL BIOL, V13, P646, DOI 10.1016/S0022-2836(65)80133-4; PIRASTU M, 1983, BLOOD, V62, P341; PIRASTU M, 1990, ANN NY ACAD SCI, V612, P90; PONCZ M, 1983, J BIOL CHEM, V258, P1599; Shackleton CHL, 1994, MASS SPECTROMETRY CL, V2, P135; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STEINBERG MH, 1991, BLOOD, V78, P2165; TONDO C, 1974, BIOCHIM BIOPHYS ACTA, V342, P15, DOI 10.1016/0005-2795(74)90101-9; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TRIFILLIS P, 1993, BLOOD, V82, P1647, DOI 10.1182/blood.V82.5.1647.bloodjournal8251647; TRIFILLIS P, 1991, BLOOD, V78, P3298; WAGENBACH M, 1991, BIO-TECHNOL, V9, P57, DOI 10.1038/nbt0191-57; WILLIAMSON D, 1993, BLOOD REV, V7, P146, DOI 10.1016/0268-960X(93)90002-L	54	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26931	26938		10.1074/jbc.271.43.26931	http://dx.doi.org/10.1074/jbc.271.43.26931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900178				2022-12-27	WOS:A1996VP23300072
J	Chen, P; Lee, P; Otto, L; Abrams, J				Chen, P; Lee, P; Otto, L; Abrams, J			Apoptotic activity of REAPER is distinct from signaling by the tumor necrosis factor receptor 1 death domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; DROSOPHILA-MELANOGASTER; TNF RECEPTOR; FAS; PROTEIN; CYTOTOXICITY; GENE	REAPER (RPR) is a 65-amino acid protein that is critical activator of programmed cell death in Drosophila. On the basis of sequence alignment data, it was recently proposed that RPR might represent an ancestral molecule from which the death domain in a number of proteins may have evolved, We tested this idea by examining the activity of mutations in RPR that parallel inactivation mutations of the tumor necrosis factor receptor 1 death domain. The RPR mutants retained potent apoptotic function, suggesting that cell death activity mediated by RPR is distinct from signaling by the tumor necrosis factor receptor 1 death domain.			Chen, P (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.				NIA NIH HHS [AG12466] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRAMS JM, 1996, APOPTOSIS NORMAL DEV, P171; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; GOLSTEIN P, 1995, IMMUNOL REV, V146, P45, DOI 10.1111/j.1600-065X.1995.tb00683.x; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; NORDSTROM W, IN PRESS DEV BIOL; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; STELLER H, 1994, PHILOS T ROY SOC B, V345, P247, DOI 10.1098/rstb.1994.0101; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VANDERSTRATEN A, 1989, CURR METHODS MOL BIO, V1, P1; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	25	37	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25735	25737		10.1074/jbc.271.42.25735	http://dx.doi.org/10.1074/jbc.271.42.25735			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824198				2022-12-27	WOS:A1996VN18000004
J	Chen, YH; Tukey, RH				Chen, YH; Tukey, RH			Protein kinase C modulates regulation of the CYP1A1 gene by the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; DNA-BINDING ACTIVITY; AH DIOXIN RECEPTOR; TRANSCRIPTIONAL ACTIVATION; DEPENDENT ACTIVATION; HEPATOMA-CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPRESSION; RAT; REPRESSION	Transcriptional activation of the human CYP1A1 gene by halogenated and polycyclic aromatic hydrocarbons is mediated by the aryl hydrocarbon receptor (AhR) complex, a ligand-dependent transcription factor. A competent AhR comprises at least two components following nuclear translocation and DNA binding, the AhR and the AhR nuclear translocator (Arnt) protein, whose combined action on human CYP1A1 gene transcription is shown to be dependent upon functional protein kinase C (PKC). In the present study, we examined the effects of phorbol 12-myristate 13-acetate, a potent PKC activator, on the ligand-induced transcriptional activation of the CYP1A1 gene and cellular function of the AhR in human HepG2 101L cells. The 101L cells carry a stable transgene consisting of 1800 bases of 5'-flanking DNA and the promoter of the human CYP1A1 gene linked to the firefly luciferase structural gene (Postlind, H., Vu, T. P., Tukey, R. H. & Quattrochi, L. C. (1993) Toxicol. Appl. Pharmacol, 118, 255-262). Pretreatment of cells with 12-myristate 13-acetate enhanced ligand-induced CYP1A1 gene expression 2-3-fold, Inhibition of PKC activity blocked directly the transcriptional activation and the transactivation of the CYP1A1 gene, indicating a role for PKC in the AhR-mediated transcriptional activation process. However, the DNA binding activities of the in vitro activated and the induced nuclear AhR as measured by electrophoretic mobility shift analysis were not affected when CYP1A1 transcription was inhibited, indicating the actions of PKC to be a nuclear event that works in concert with or precedes AhR binding to the gene. These results illustrate that PRC is absolutely essential for the cellular and molecular events that control induction of CYP1A1 gene transcription.	UNIV CALIF SAN DIEGO, UCSD CANC CTR, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego					NIGMS NIH HHS [GM36590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGHARD A, 1993, MOL CELL BIOL, V13, P677, DOI 10.1128/MCB.13.1.677; BOISJOYEUX B, 1995, J BIOL CHEM, V270, P10204, DOI 10.1074/jbc.270.17.10204; BOMBICK DW, 1985, BIOCHEM BIOPH RES CO, V127, P296, DOI 10.1016/S0006-291X(85)80158-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CORSARO CM, 1981, SOMAT CELL GENET, V7, P603, DOI 10.1007/BF01549662; DENIS M, 1988, BIOCHEM BIOPH RES CO, V155, P801, DOI 10.1016/S0006-291X(88)80566-7; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DENISON MS, 1988, J BIOL CHEM, V263, P17221; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GRADIN K, 1994, J BIOL CHEM, V269, P23800; Harlow GR, 1996, ARCH BIOCHEM BIOPHYS, V326, P85, DOI 10.1006/abbi.1996.0050; HARPER PA, 1991, ARCH BIOCHEM BIOPHYS, V290, P27, DOI 10.1016/0003-9861(91)90587-9; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Ko HSP, 1996, MOL CELL BIOL, V16, P430; LIN A, 1993, ADV SEC MESS PHOSPH, V28, P255; MAHON MJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P166, DOI 10.1006/abbi.1995.1217; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; MILLER AG, 1983, J BIOL CHEM, V258, P3523; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; OKINO ST, 1992, J BIOL CHEM, V267, P6991; PASANEN M, 1988, CHEM-BIOL INTERACT, V66, P223, DOI 10.1016/0009-2797(88)90073-7; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; PONGRATZ I, 1991, J BIOL CHEM, V266, P16813; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; SAFE S, 1990, CRIT REV TOXICOL, V21, P51, DOI 10.3109/10408449009089873; SCHAFER MW, 1993, ARCH BIOCHEM BIOPHYS, V307, P267, DOI 10.1006/abbi.1993.1589; SINGH SS, 1993, ARCH BIOCHEM BIOPHYS, V305, P170, DOI 10.1006/abbi.1993.1407; STRAVITZ RT, 1995, J LIPID RES, V36, P1359; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; WEBER TJ, 1994, J BIOCHEM TOXICOL, V9, P113, DOI 10.1002/jbt.2570090302; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333; WU L, 1993, NUCLEIC ACIDS RES, V21, P119, DOI 10.1093/nar/21.1.119; YEN HFY, 1990, CELL, V62, P1205	44	114	115	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26261	26266		10.1074/jbc.271.42.26261	http://dx.doi.org/10.1074/jbc.271.42.26261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824276	hybrid			2022-12-27	WOS:A1996VN18000082
J	Griffon, N; Badens, C; LenaRusso, D; Kister, J; Bardakdjian, J; Wajcman, H; Marden, MC; Poyart, C				Griffon, N; Badens, C; LenaRusso, D; Kister, J; Bardakdjian, J; Wajcman, H; Marden, MC; Poyart, C			Hb Bruxelles, deletion of Phe(beta 42), shows a low oxygen affinity and low cooperativity of ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-HEMOGLOBIN; FUNCTIONAL-PROPERTIES; UNSTABLE HEMOGLOBIN; VARIANT; CYANOSIS; HYBRIDS; DEOXY	Functional studies of partially purified hemoglobin (Hb) Bruxelles, phe(beta 42) (CD1) --> 0 indicate a major shift in the allosteric equilibrium toward the deoxy (T state) conformation. While Hb A shows a roughly symmetrical oxygenation curve with maximum cooperativity near half-saturation, Hb Bruxelles shows mainly properties of the low affinity (T state) form, The oxygen equilibrium curves for purified (> 80%) Hb Bruxelles show little cooperativity and a P-50 (without 2,3-diphosphoglycerate) about twice that of Hb A. The low cooperativity for Hb Bruxelles is partially compensated by an increase in oxygen affinity of the deoxy conformation and a lower 2,3-diphosphoglycerate effect. The beta chains of normal Hb have consecutive phenylalanine residues at positions 41 and 42. DNA sequencing studies of Db Bruxelles showed a deletion of the codon TTT, which corresponds to residue Phe(42). The CO rebinding kinetics after flash photolysis show mainly the slow phase, characteristic of CO binding to the deoxy conformation, In phosphate buffer at pH 7, the slow phase dominates even at low photolysis levels, where the main reaction is ligand binding to the triply liganded form, This indicates a switchover point, from the deoxy to oxy conformation, occurring beyond three ligands for Hb Bruxelles, There are few natural mutants that show a change in the oxygen affinity and cooperativity as large as that observed for Hb Bruxelles.	FAC MED MARSEILLE,CTR EMSEIGNEMENT & RECH GENET,INSERM,U406,F-13385 MARSEILLE 5,FRANCE; HOP HENRI MONDOR,INSERM,U91,F-94010 CRETEIL,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Griffon, N (corresponding author), HOP BICETRE,INSERM,U299,F-94275 LE KREMLIN BICETR,FRANCE.		Marden, Michael/AAA-5923-2020; Marden, Michael C/G-3139-2012; Badens, Catherine/J-8727-2016	Marden, Michael C/0000-0002-5254-6385; Badens, Catherine/0000-0001-9024-310X				ABRAHAM DJ, 1995, J MOL BIOL, V248, P845, DOI 10.1006/jmbi.1995.0265; ANDERSON L, 1975, J MOL BIOL, V94, P33, DOI 10.1016/0022-2836(75)90403-9; BAUDIN V, 1992, BIOCHIM BIOPHYS ACTA, V1159, P223, DOI 10.1016/0167-4838(92)90029-D; BLOUQUIT Y, 1989, HEMOGLOBIN, V13, P465, DOI 10.3109/03630268908998085; BOYIRI T, 1995, BIOCHEMISTRY-US, V34, P15021, DOI 10.1021/bi00046a008; BRANTLEY RE, 1993, J BIOL CHEM, V268, P6995; BRATU V, 1971, BIOCHIM BIOPHYS ACTA, V251, P1, DOI 10.1016/0005-2795(71)90051-1; Bunn HF, 1986, HEMOGLOBIN MOL GENET; BURKERT LB, 1976, BLOOD, V48, P645; CHEN LT, 1973, BLOOD, V41, P529, DOI 10.1182/blood.V41.4.529.529; DACIE JV, 1967, NATURE, V216, P663, DOI 10.1038/216663a0; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; HONIG GR, 1989, AM J HEMATOL, V32, P36, DOI 10.1002/ajh.2830320108; HONIG GR, 1990, J BIOL CHEM, V265, P126; HONIG GR, 1988, BLOOD, V72, P63; KIGER L, 1993, BIOPHYS J, V65, P1050, DOI 10.1016/S0006-3495(93)81164-0; KISTER J, 1987, BIOPHYS J, V52, P527, DOI 10.1016/S0006-3495(87)83242-3; KISTER J, 1989, NOUV REV FR HEMATOL, V31, P54; KOHLIKUMAR M, 1995, AM J HEMATOL, V49, P43, DOI 10.1002/ajh.2830490108; KRAWCZAK M, 1991, HUM GENET, V86, P425; LEE AWM, 1988, BIOCHEMISTRY-US, V27, P1285, DOI 10.1021/bi00404a031; LEONE L, 1985, J CHROMATOGR, V321, P407, DOI 10.1016/S0021-9673(01)90459-5; LICATA VJ, 1990, BIOCHEMISTRY-US, V29, P9771, DOI 10.1021/bi00494a003; MARDEN MC, 1987, EUR J BIOCHEM, V169, P611, DOI 10.1111/j.1432-1033.1987.tb13652.x; OGATA K, 1986, HEMOGLOBIN, V10, P469, DOI 10.3109/03630268609014132; OHBA Y, 1975, ACTA HAEMATOL JAPON, V38, P53; PRAXEDES H, 1972, P 14 INT C HEM SAO P; STABLER S, 1993, BLOOD, V82, P222; STABLER SP, 1994, MAYO CLIN PROC, V69, P237, DOI 10.1016/S0025-6196(12)61062-3; SUGAWARA Y, 1993, JPN J PHYSIOL, V43, P21, DOI 10.2170/jjphysiol.43.21; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303; WAJCMAN H, 1973, BIOCHIMIE, V55, P119, DOI 10.1016/S0300-9084(73)80383-9; YANASE H, 1995, PROTEIN SCI, V4, P21	33	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25916	25920		10.1074/jbc.271.42.25916	http://dx.doi.org/10.1074/jbc.271.42.25916			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824225	hybrid			2022-12-27	WOS:A1996VN18000031
J	Prigent, SA; Nagane, M; Lin, H; Huvar, I; Boss, GR; Feramisco, JR; Cavenee, WK; Huang, HJS				Prigent, SA; Nagane, M; Lin, H; Huvar, I; Boss, GR; Feramisco, JR; Cavenee, WK; Huang, HJS			Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERED AUTOPHOSPHORYLATION SITES; PROTEIN-TYROSINE KINASE; EGF-RECEPTOR; BINDING-SITES; LUNG CARCINOMAS; INTACT-CELLS; SHC PROTEINS; DOMAIN; RAS; GRB2	A mutant epidermal growth factor receptor (Delta EGFR) containing a deletion of 267 amino acids from the extracellular domain is common in human glioblastomas. We have previously shown that the mutant receptor fails to bind EGF, is constitutively phosphorylated, and confers upon U87MG glioblastoma cells expressing it (U87MG.Delta EGFR), an increased ability to form tumors in mice. Here we demonstrate that the constitutively phosphorylated Delta EGFR enhances growth of glioblastoma cells through increased activity of Ras: 1) there was an increase in the proportion of Ras present in the GTP-bound form, and 2) introduction of neutralizing anti-has 259 antibodies into U87MG and U87MG.Delta EGFR cells by microinjection inhibited DNA synthesis to the same low level in both cell populations, We also show that the truncated EGF receptor constitutively associates with the adapter proteins Shc and Grb2 which are involved in the recruitment of Ras to activated receptors, Several derivatives of Delta EGFR containing single, or multiple mutations at critical autophosphorylation sites were constructed and used to demonstrate that the major She binding site is Tyr-1148, and that Grb2 association occurs primarily through Tyr-1068, We conclude that the increased tumorigenic potential of glioblastoma cells expressing the truncated EGF receptor is due at least in part to has activation presumably involving the Shc and Grb2 adapter proteins.	UNIV CALIF SAN DIEGO, LUDWIG INST CANC RES, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR GENET MOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego				Boss, Gerry/0000-0002-9758-8714	NIGMS NIH HHS [GM49360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU T, 1994, ONCOGENE, V9, P3483; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Gotoh N, 1995, ONCOGENE, V11, P2525; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LI NX, 1994, ONCOGENE, V9, P3457; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	145	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25639	25645		10.1074/jbc.271.41.25639	http://dx.doi.org/10.1074/jbc.271.41.25639			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810340	hybrid			2022-12-27	WOS:A1996VL69300084
J	Sun, XL; Antony, AC				Sun, XL; Antony, AC			Evidence that a specific interaction between an 18-base cis-element in the 5'-untranslated region of human folate receptor-alpha mRNA and a 46-kDa cytosolic trans-factor is critical for translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; IRON-RESPONSIVE ELEMENTS; INITIATION-FACTOR EIF-4A; AMINO-ACID SEQUENCE; HUMAN KB-CELLS; BINDING-PROTEIN; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; IN-VIVO	Folate receptors (FR) are inversely regulated by the extracellular folate concentration at the translational level in cervical carcinoma cells. Accordingly, the potential for interaction of cis-elements in FR-alpha mRNA and trans-factors in these cells was determined. Gel-shift assays identified two signals that were specifically derived from the interaction of cytosolic proteins with the 5'-untranslated region of FR-alpha mRNA. RNase T1 mapping revealed that the RNA sequences interacting with these proteins were located between nucleotides -133 to -116 (18 bases) and -158 to -116 (43-bases), upstream of the translation start site. However, selective RNase H cleavage indicated that the 18-base RNA sequence was the cis-element. The RNA-protein interaction was competed by poly(C), but not by poly(U), homopolymers. UV cross-linking and Northwestern blot analysis confirmed that the trans-factors were 46-kDa proteins. An 18-base antisense oligodeoxynucleotide complementary to the cis-element specifically quenched the RNA-protein interaction and also completely inhibited translation of FR-ru mRNA without changing its stability. Thus, the interaction of the 18-base cis-element and the 46-kDa trans-factors likely have an important role in translational regulation of FR. In addition, because the 46-kDa proteins were widely distributed in cells expressing little to no FR-alpha, these species probably have additional functions that are unrelated to translation of FR.	INDIANA UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; RICHARD L ROUDEBUSH VET AFFAIRS MED CTR, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center					NATIONAL CANCER INSTITUTE [R01CA058919] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58919] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONY AC, 1992, BLOOD, V79, P2807; Antony AC, 1996, ANNU REV NUTR, V16, P501, DOI 10.1146/annurev.nu.16.070196.002441; BOTTERO F, 1993, CANCER RES, V53, P5791; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHAKRABARTI R, 1993, J BIOL CHEM, V268, P1298; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; CONEY LR, 1991, CANCER RES, V51, P6125; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DIXON KH, 1994, J BIOL CHEM, V269, P17; DODSON RE, 1994, MOL CELL BIOL, V14, P3130, DOI 10.1128/MCB.14.5.3130; ELWOOD PC, 1989, J BIOL CHEM, V264, P14893; FLEMING J, 1989, GENE, V79, P181, DOI 10.1016/0378-1119(89)90103-0; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HAILE DJ, 1989, MOL CELL BIOL, V9, P5055, DOI 10.1128/MCB.9.11.5055; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON GI, 1995, J LAB CLIN MED, V126, P184; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HSUCH CT, 1994, BIOCHEM PHARMACOL, V47, P1019; HSUEH CT, 1993, BIOCHEM PHARMACOL, V45, P2537; HUANG LY, 1993, J BIOL CHEM, V268, P25769; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KANE MA, 1988, J CLIN INVEST, V81, P1398, DOI 10.1172/JCI113469; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; KLETT C, 1994, HYPERTENSION, V23, pI120, DOI 10.1161/01.HYP.23.1_Suppl.I120; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li QJ, 1996, J INVEST MED, V44, pA203; LUHRS CA, 1992, J CLIN INVEST, V90, P840, DOI 10.1172/JCI115959; MADER S, 1995, MOL CELL BIOL, V15, P4990; MASCOTTI DP, 1995, ANNU REV NUTR, V15, P239, DOI 10.1146/annurev.nu.15.070195.001323; MATSUE H, 1992, P NATL ACAD SCI USA, V89, P6006, DOI 10.1073/pnas.89.13.6006; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MCHUGH M, 1979, J BIOL CHEM, V254, P1312; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MORRIS DR, 1993, BIOCHEMISTRY-US, V32, P2931, DOI 10.1021/bi00063a001; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PAUSE A, 1994, EMBO J, V13, P1205, DOI 10.1002/j.1460-2075.1994.tb06370.x; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; RATNASABAPATHY R, 1990, J BIOL CHEM, V265, P14050; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SADASIVAN E, 1994, J BIOL CHEM, V269, P4725; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; SUN XL, 1995, J CLIN INVEST, V96, P1535, DOI 10.1172/JCI118192; Sun XL, 1996, J INVEST MED, V44, pA203; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TIAN Y, 1995, RNA, V1, P317; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; VERMA RS, 1992, J BIOL CHEM, V267, P4119; WANG XM, 1995, MOL CELL BIOL, V15, P1769; WRESCHNER DH, 1988, EUR J BIOCHEM, V172, P333, DOI 10.1111/j.1432-1033.1988.tb13891.x; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24007	63	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25539	25547						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810326				2022-12-27	WOS:A1996VL69300070
J	Johnson, RE; Kovvali, GK; Guzder, SN; Amin, NS; Holm, C; Habraken, Y; Sung, P; Prakash, L; Prakash, S				Johnson, RE; Kovvali, GK; Guzder, SN; Amin, NS; Holm, C; Habraken, Y; Sung, P; Prakash, L; Prakash, S			Evidence for involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMPLE REPETITIVE DNA; MICROSATELLITE INSTABILITY; SACCHAROMYCES-CEREVISIAE; GASTRIC-CANCER; MUTATIONS; GENE; REPLICATION; EXTRACTS; TRACTS	DNA mismatch repair plays a key role in the maintenance of genetic fidelity. Mutations in the human mismatch repair genes hMSH2, hMLR1, hPMS1, and hPMS2 are associated with hereditary nonpolyposis colorectal cancer. The proliferating cell nuclear antigen (PCNA) is essential for DNA replication, where it acts as a processivity factor. Here, we identify a point mutation, pol30-104, in the Saccharomyces cerevisiae POL30 gene encoding PCNA that increases the rate of instability of simple repetitive DNA sequences and raises the rate of spontaneous forward mutation. Epistasis analyses with mutations in mismatch repair genes MSH2, MLH1, and PMS1 suggest that the pol30-104 mutation impairs MSH2/ MLH1/PMS1-dependent mismatch repair, consistent with the hypothesis that PCNA functions in mismatch repair. MSH2 functions in mismatch repair with either MSH3 or MSH6, and the MSH2 MSH3 and MSH2-MSH6 heterodimers have a role in the recognition of DNA mismatches. Consistent with the genetic data, we find specific interaction of PCNA with the MSH2-MSH3 heterodimer.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of Texas System; University of Texas Medical Branch Galveston; University of California System; University of California San Diego			Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NCI NIH HHS [CA41261] Funding Source: Medline; NIGMS NIH HHS [GM36510, GM19261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041261, R37CA041261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036510, R01GM019261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; GLEBOV OK, 1994, CANCER RES, V54, P3703; Habraken Y, 1996, CURR BIOL, V6, P1185, DOI 10.1016/S0960-9822(02)70686-6; HAN HJ, 1993, CANCER RES, V53, P5087; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; STRAND M, 1995, P NATL ACAD SCI USA, V92, P10418, DOI 10.1073/pnas.92.22.10418; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x	22	175	177	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27987	27990		10.1074/jbc.271.45.27987	http://dx.doi.org/10.1074/jbc.271.45.27987			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910404	hybrid			2022-12-27	WOS:A1996VU03300004
J	Pshezhetsky, AV; Potier, M				Pshezhetsky, AV; Potier, M			Association of N-acetylgalactosamine-6-sulfate sulfatase with the multienzyme lysosomal complex of beta-galactosidase, cathepsin A, and neuraminidase - Possible implication for intralysosomal catabolism of keratan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORQUIO-DISEASE; HUMAN-PLACENTA; DEFICIENCY; PROTEIN; ENZYME; ORGANIZATION; PURIFICATION; DIAGNOSIS; BINDING; ASSAY	N-Acetylgalactosamine-6-sulfate sulfatase (GALNS) catalyzes the first step of intralysosomal keratan sulfate (HS) catabolism. In Morquio type A syndrome GALNS deficiency causes the accumulation of HS in tissues and results in generalized skeletal dysplasia in affected patients. We show that in normal cells GALNS is in a 1.27 MDa complex with three other lysosomal hydrolases: beta-galactosidase, alpha-neuraminidase, and cathepsin A (protective protein). GALNS copurifies with the complex by different chromatography techniques: affinity chromatography on both cathepsin A-binding and beta-galactosidase-binding columns, gel filtration, and chromatofocusing. Anti-human cathepsin A rabbit antiserum coprecipitates GALNS together with cathepsin A, beta-galactosidase, and Lu-neuraminidase in both a purified preparation of the 1.27-MDa complex and crude glycoprotein fraction from human placenta extract. Gel filtration analysis of fibroblast extracts of patients deficient in either beta-galactosidase (beta-galactosidosis) or cathepsin A (galactosialidosis), which accumulate KS, demonstrates that the 1.27-MDa complex is disrupted and that GALNS is present only in free homodimeric form. The GALNS activity and cross-reacting material are reduced in the fibroblasts of patients affected with galactosialidosis, indicating that the complex with cathepsin A may protect GALNS in the lysosome. We suggest that the 1.27-MDa complex of lysosomal hydrolases is essential for RS catabolism and that the disruption of this complex may be responsible for the KS accumulation in beta-galactosidosis and galactosialidosis patients.	UNIV MONTREAL,FAC MED,DEPT PEDIAT,MONTREAL,PQ H3T 1C5,CANADA	Universite de Montreal	Pshezhetsky, AV (corresponding author), HOP ST JUSTINE,SERV GENET MED,3175 COTE ST CATHERINE,MONTREAL,PQ H3T 1C5,CANADA.			A, Pshezhetsky/0000-0002-6612-1062				ARBISSER AI, 1977, AM J MED GENET, V1, P195, DOI 10.1002/ajmg.1320010205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; FUKUDA S, 1992, J CLIN INVEST, V90, P1049, DOI 10.1172/JCI115919; GLOSSL J, 1978, CLIN CHIM ACTA, V88, P111, DOI 10.1016/0009-8981(78)90157-2; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUE M, 1991, J BIOCHEM-TOKYO, V110, P965, DOI 10.1093/oxfordjournals.jbchem.a123697; Matalon R, 1974, BIOCHEM BIOPH RES CO, V61, P709; MORREAU H, 1989, J BIOL CHEM, V264, P20655; Neufeld E. F., 1995, METABOLIC MOL BASES, V2; OKADA S, 1968, SCIENCE, V160, P1002, DOI 10.1126/science.160.3831.1002; OKAMURAOHO Y, 1996, BIOCHEMISTRY J, V313, P78; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; PSHEZHETSKY AV, 1995, BIOCHEMISTRY-US, V34, P2431, DOI 10.1021/bi00008a005; PSHEZHETSKY AV, 1994, ARCH BIOCHEM BIOPHYS, V313, P64, DOI 10.1006/abbi.1994.1359; PSHEZHETSKY AV, 1993, BIOCHEM BIOPH RES CO, V195, P354, DOI 10.1006/bbrc.1993.2051; ROBINSON JB, 1985, J BIOL CHEM, V260, P800; ROME LH, 1979, CELL, V17, P143, DOI 10.1016/0092-8674(79)90302-7; SINGH J, 1976, J CLIN INVEST, V57, P1036, DOI 10.1172/JCI108345; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; Suzuki Y., 1995, METABOLIC MOL BASES, VII; THOMAS GH, 1995, METABOLIC MOL BASES, V2; TOMATSU S, 1991, BIOCHEM BIOPH RES CO, V181, P677, DOI 10.1016/0006-291X(91)91244-7; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDERHORST GTJ, 1993, THESIS; VANDIGGELEN OP, 1990, CLIN CHIM ACTA, V187, P131, DOI 10.1016/0009-8981(90)90339-T	28	69	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28359	28365		10.1074/jbc.271.45.28359	http://dx.doi.org/10.1074/jbc.271.45.28359			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910459	hybrid			2022-12-27	WOS:A1996VU03300059
J	Zerangue, N; Kavanaugh, MP				Zerangue, N; Kavanaugh, MP			ASCT-1 is a neutral amino acid exchanger with chloride channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORT-SYSTEM ASC; GLUTAMATE TRANSPORTER; GLIAL-CELLS; ION FLUXES; EXPRESSION; POTASSIUM; SODIUM; ERYTHROCYTES; CLONING; FAMILY	The ubiquitous transport activity known as system ASC is characterized by a preference for small neutral amino acids including alanine, serine, and cysteine. ASCT-1 and ASCT-2, recently cloned transporters exhibiting system ASC-like selectivity, are members of a major amino acid transporter family that includes a number of glutamate transporters. Here we show that ASCT1 functions as an electroneutral exchanger that mediates negligible net amino acid flux. The electrical currents previously shown to be associated with ASCT1-mediated transport result from activation of a thermodynamically uncoupled chloride conductance with permeation properties similar to those described for the glutamate transporter subfamily. Like glutamate transporters, ASCT1 activity requires extracellular Na+. However, unlike glutamate transporters, which mediate net flux and complete a transport cycle by countertransport of K+, ASCT-1 mediates only homo- and heteroexchange of amino acids and is insensitive to K+. The properties of ASCT-1 suggest that it may function to equilibrate different pools of neutral amino acids and provide a mechanism to link amino acid concentration gradients.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201	Oregon Health & Science University					NIGMS NIH HHS [GM 48709] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048709] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSALEH EA, 1982, BIOCHIM BIOPHYS ACTA, V684, P157, DOI 10.1016/0005-2736(82)90001-3; AMATO A, 1994, J PHYSIOL-LONDON, V479, P371, DOI 10.1113/jphysiol.1994.sp020302; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1982, PHYSIOL REV, V62, P1193, DOI 10.1152/physrev.1982.62.4.1193; CHRISTENSEN HN, 1972, NA LINKED TRANSPORT, P161; Eliasof S, 1996, P NATL ACAD SCI USA, V93, P4153, DOI 10.1073/pnas.93.9.4153; ELWYN DH, 1966, FED PROC, V25, P854; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; KAVANAUGH MP, 1996, IN PRESS J BIOL CHEM, V271; Larsson HP, 1996, BIOPHYS J, V70, P733, DOI 10.1016/S0006-3495(96)79613-3; LIAO K, 1995, BIOCHEM BIOPH RES CO, V208, P1008, DOI 10.1006/bbrc.1995.1434; MAENZ DD, 1992, J BIOL CHEM, V267, P1510; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; SEPULVEDA FV, 1978, J PHYSIOL-LONDON, V282, P73, DOI 10.1113/jphysiol.1978.sp012449; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; STALLCUP WB, 1979, J NEUROCHEM, V32, P57, DOI 10.1111/j.1471-4159.1979.tb04509.x; Tamarappoo BK, 1996, BBA-BIOMEMBRANES, V1279, P131, DOI 10.1016/0005-2736(95)00259-6; UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VALDEOLMILLOS M, 1986, BIOCHIM BIOPHYS ACTA, V858, P181, DOI 10.1016/0005-2736(86)90304-4; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; YOUNG JD, 1980, PROC R SOC SER B-BIO, V209, P355, DOI 10.1098/rspb.1980.0100; Zerangue N, 1996, J PHYSIOL-LONDON, V493, P419, DOI 10.1113/jphysiol.1996.sp021393; ZERANGUE N, 1996, IN PRESS NATURE	34	133	140	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27991	27994		10.1074/jbc.271.45.27991	http://dx.doi.org/10.1074/jbc.271.45.27991			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910405	Green Published, hybrid			2022-12-27	WOS:A1996VU03300005
J	Borgne, A; Meijer, L				Borgne, A; Meijer, L			Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; MATURATION-PROMOTING FACTOR; XENOPUS CDC25 PHOSPHATASE; P34CDC2 KINASE ACTIVATION; WEE1 PROTEIN-KINASE; FISSION YEAST CDC2; M-PHASE; TYROSINE PHOSPHORYLATION; DEPENDENT KINASES; MEIOTIC MATURATION	The G(2)-M transition of the cell cycle is triggered by the p34(cdc2)/cyclin B kinase. During the prophase/metaphase transition, the inactive, Thr-14/Tyr-15 phosphorylated form of p34(cdc2) (T-P-Y-P) is modified to an active, Thr-14/Tyr-15 dephosphorylated form (T-Y) by the cdc25 dual-specificity phosphatase. Using highly synchronized starfish oocytes as a cellular model, we show that dephosphorylation in vivo and in vitro occurs in two steps: Thr-14 dephosphorylation precedes Tyr-15 dephosphorylation. The transient intermediate form (T-Y-P), which can be obtained in vitro by treatment of T-P-Y-P by protein phosphatase 2A, displays low but significant kinase activity. These results raise the possibility that the intermediate form T-Y-P may be involved in the autocatalytic amplification of the p34(cdc2)/cyclin B complex through phosphorylation/activation of the cdc25 phosphatase and phosphorylation/inactivation of the wee1 kinase.			Borgne, A (corresponding author), CNRS, BIOL STN, BP 74, F-29682 ROSCOFF, FRANCE.			, laurent/0000-0003-3511-4916				AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; AOKI F, 1992, DEV BIOL, V154, P66, DOI 10.1016/0012-1606(92)90048-L; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; AZZI L, 1994, J BIOL CHEM, V269, P13279; BARATTE B, 1992, ANTICANCER RES, V12, P873; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CAYLA X, 1994, J BIOL CHEM, V269, P15668; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENHAESE GJ, 1995, MOL BIOL CELL, V6, P371, DOI 10.1091/mbc.6.4.371; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ENDICOTT JA, 1994, PROTEIN ENG, V7, P243, DOI 10.1093/protein/7.2.243; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, EMBO J, V10, P177, DOI 10.1002/j.1460-2075.1991.tb07934.x; GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HONDA R, 1995, CHROMOSOME RES, V3, P300, DOI 10.1007/BF00713068; HONDA R, 1993, FEBS LETT, V318, P331, DOI 10.1016/0014-5793(93)80540-B; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; IZUMI T, 1995, MOL BIOL CELL, V6, P215, DOI 10.1091/mbc.6.2.215; IZUMI T, 1992, MOL BIOL CELL, V3, P927, DOI 10.1091/mbc.3.8.927; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KERNS J, 1995, BIOORG CHEM, V23, P101, DOI 10.1006/bioo.1995.1008; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUANG J, 1994, MOL BIOL CELL, V5, P135, DOI 10.1091/mbc.5.2.135; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MS, 1994, J BIOL CHEM, V269, P30530; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LOCK RB, 1992, CANCER RES, V52, P1817; LUKAS J, 1992, EUR J BIOCHEM, V207, P169, DOI 10.1111/j.1432-1033.1992.tb17034.x; LUNGREN K, 1991, CELL, V64, P1111; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; Meijer L., 1995, PROGR CELL CYCLE RES, V1; Meijer Laurent, 1994, Seminars in Developmental Biology, V5, P165, DOI 10.1006/sedb.1994.1022; MILLAR JBA, 1992, EMBO J, V11, P4933, DOI 10.1002/j.1460-2075.1992.tb05600.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NAGATA A, 1991, NEW BIOL, V3, P959; NAITO K, 1995, DEV BIOL, V168, P627, DOI 10.1006/dbio.1995.1107; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; OGG S, 1994, J BIOL CHEM, V269, P30461; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; OOKATA K, 1995, J CELL BIOL, V128, P849, DOI 10.1083/jcb.128.5.849; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PAULES RS, 1995, CANCER RES, V55, P1763; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; RIME H, 1991, EXP CELL RES, V196, P241, DOI 10.1016/0014-4827(91)90257-U; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHULZEGAHMEN U, 1995, PROTEINS, V22, P378, DOI 10.1002/prot.340220408; SCHUTTLEWORTH J, 1995, PROG CELL CYCLE RES, V1, P229; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Shapiro H, 1941, J CELL COMPAR PHYSL, V18, P61, DOI 10.1002/jcp.1030180108; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VANHOOF C, 1994, EUR J BIOCHEM, V226, P899; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x; YAMASHITA M, 1991, DEV GROWTH DIFFER, V33, P617	91	125	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27847	27854		10.1074/jbc.271.44.27847	http://dx.doi.org/10.1074/jbc.271.44.27847			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910383	hybrid			2022-12-27	WOS:A1996VQ67900101
J	Kimura, T; Kihara, H; Bhattacharyya, S; Sakamoto, H; Appella, E; Siraganian, RP				Kimura, T; Kihara, H; Bhattacharyya, S; Sakamoto, H; Appella, E; Siraganian, RP			Downstream signaling molecules bind to different phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) peptides of the high affinity IgE receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; BASOPHILIC LEUKEMIA-CELLS; PHOSPHOTYROSINE-CONTAINING PEPTIDES; IMMUNOGLOBULIN-E RECEPTOR; T-CELL; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; MAST-CELLS; ZETA-CHAIN; RBL-2H3 CELLS	The cytoplasmic tails of both the beta and gamma subunits of the high affinity IgE receptor (Fc epsilon RI) contain a consensus sequence termed the immunoreceptor tyrosine-based activation motif (ITAM). This motif plays a critical role in receptor-mediated signal transduction. Synthetic peptides based on the ITAM sequences of the beta and gamma subunits of Fc epsilon RI were used to investigate which proteins associate with these motifs. Tyrosine-phosphorylated beta and gamma ITAM peptides immobilized on beads precipitated Syk, Lyn, Shc, Grb2, and phospholipase C-gamma 1 from lysates of rat basophilic leukemia RBL-2H3 cells. Syk was precipitated predominantly by the tyrosine-diphosphorylated gamma ITAM peptide, but much less by the diphosphorylated beta ITAM peptide or by the monophosphorylated peptides. Phospholipase C-gamma 1, Shc, and Grb2 were precipitated only by the diphosphorylated beta ITAM peptide. Non-phosphorylated ITAM peptides did not precipitate these proteins. In membrane binding assays, fusion proteins containing the Src homology 2 domains of phospholipase C-gamma 1, Shc, Syk, and Lyn directly bound the tyrosine-phosphorylated ITAM peptides. Although the ITAM sequences of the beta and gamma subunits of Fc epsilon RI are similar, once they are tyrosine-phosphorylated they preferentially bind different downstream signaling molecules. Tyrosine phosphorylation of the ITAM of the gamma subunit recruits and activates Syk, whereas the beta subunit may be important for the Ras signaling pathway.	NCI,CELL BIOL LAB,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kimura, T (corresponding author), NIDR,IMMUNOL LAB,NATL INST HLTH,BLDG 10,RM 1N106,BETHESDA,MD 20892, USA.		Sakamoto, Hiroshi/A-3181-2011					ALBER G, 1991, J BIOL CHEM, V266, P22613; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ATKINSON TP, 1992, J IMMUNOL, V148, P2194; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Busse WW, 1993, ALLERGY PRINCIPLES P, P105; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; DASGUPTA JD, 1992, J EXP MED, V175, P285, DOI 10.1084/jem.175.1.285; EISEMAN E, 1992, J BIOL CHEM, V267, P21027; EISEMAN E, 1992, NATURE, V355, P78; FUKAMACHI H, 1992, P NATL ACAD SCI USA, V89, P9524, DOI 10.1073/pnas.89.20.9524; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HAMAWY MM, 1995, CELL SIGNAL, V7, P535, DOI 10.1016/0898-6568(95)00024-J; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JOHNSON SA, 1995, J IMMUNOL, V155, P4596; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, MOL CELL BIOL, V16, P1471; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SILLMAN AL, 1995, J BIOL CHEM, V270, P11806, DOI 10.1074/jbc.270.20.11806; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHAN V, 1992, J BIOL CHEM, V267, P5434; TAYLOR JA, 1995, MOL CELL BIOL, V15, P4149; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251	62	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27962	27968		10.1074/jbc.271.44.27962	http://dx.doi.org/10.1074/jbc.271.44.27962			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910399	hybrid			2022-12-27	WOS:A1996VQ67900117
J	Mazumder, A; Neamati, N; Pilon, AA; Sunder, S; Pommier, Y				Mazumder, A; Neamati, N; Pilon, AA; Sunder, S; Pommier, Y			Chemical trapping of ternary complexes of human immunodeficiency virus type I integrase, divalent metal, and DNA substrates containing an abasic site - Implications for the role of lysine 136 in DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 INTEGRASE; VIRAL-DNA; STABLE COMPLEX; PROTEIN; CLEAVAGE; SEQUENCE; REGION; VITRO; IDENTIFICATION; HETERODUPLEXES	We report a novel assay for monitoring the DNA binding of human immunodeficiency virus type 1 (HIV-1) integrase and the effect of cofactors and inhibitors. The assay uses depurinated oligonucleotides that can form a Schiff base between the aldehydic abasic site and a nearby enzyme lysine epsilon-amino group which can subsequently be trapped by reduction with sodium borohydride. Chemically depurinated duplex substrates representing the U5 end of the HIV-1 DNA were initially used. We next substituted an enzymatically generated abasic site for each of 10 nucleotides normally present in a 21-mer duplex oligonucleotide representing the U5 end of the HIV-1 DNA. Using HIV-1, HIV-2, or simian immunodeficiency virus integrases, the amount of covalent enzyme-DNA complex trapped decreased as the abasic site was moved away from the conserved CA dinucleotide. The enzyme-DNA complexes formed in the presence of manganese were not reversed by subsequent addition of EDTA, indicating that the divalent metal required for integrase catalysis is tightly bound in a ternary enzyme-metal-DNA complex. Both the N- and C-terminal domains of integrase contributed to efficient DNA binding, and mutation of Lys-136 significantly reduced Schiff base formation, implicating this residue in viral DNA binding.	NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; CUNIASSE P, 1987, NUCLEIC ACIDS RES, V15, P8003, DOI 10.1093/nar/15.19.8003; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ELLISON V, 1995, J BIOL CHEM, V270, P3320, DOI 10.1074/jbc.270.7.3320; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1995, J VIROL, V69, P5908, DOI 10.1128/JVI.69.9.5908-5911.1995; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; GRANDGENETT DP, 1978, VIROLOGY, V89, P119, DOI 10.1016/0042-6822(78)90046-6; HOHENEGGER M, 1994, J BIOL CHEM, V269, P32008; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; LEAVITT AD, 1992, J VIROL, V66, P2359, DOI 10.1128/JVI.66.4.2359-2368.1992; LEE SP, 1995, BIOCHEMISTRY-US, V34, P10215, DOI 10.1021/bi00032a015; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPFORD JR, 1994, J ACQ IMMUN DEF SYND, V7, P1215; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; MANOHARAN M, 1988, J AM CHEM SOC, V110, P1620, DOI 10.1021/ja00213a044; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P2865, DOI 10.1093/nar/23.15.2865; Mazumder A, 1996, J MED CHEM, V39, P2472, DOI 10.1021/jm960074e; Mazumder A, 1996, MOL PHARMACOL, V49, P621; OJWANG JO, 1995, ANTIMICROB AGENTS CH, V39, P2426, DOI 10.1128/AAC.39.11.2426; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; PRUSS D, 1995, NUCLEUS, V1, P3; ROTH MJ, 1988, J MOL BIOL, V203, P131, DOI 10.1016/0022-2836(88)90097-6; SCHAUER M, 1992, BIOCHEM BIOPH RES CO, V185, P874, DOI 10.1016/0006-291X(92)91708-X; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; VANDENENT FMI, 1994, J VIROL, V68, P7825, DOI 10.1128/JVI.68.12.7825-7832.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1991, NUCLEIC ACIDS RES, V19, P3821, DOI 10.1093/nar/19.14.3821; VARSHNEY U, 1991, BIOCHEMISTRY-US, V30, P4055, DOI 10.1021/bi00230a033; VINK C, 1994, NUCLEIC ACIDS RES, V22, P4103, DOI 10.1093/nar/22.20.4103; VINK C, 1991, J VIROL, V65, P4636, DOI 10.1128/JVI.65.9.4636-4644.1991; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; VINK C, 1993, TRENDS GENET, V9, P433, DOI 10.1016/0168-9525(93)90107-S; WILDE JA, 1989, J AM CHEM SOC, V111, P1894, DOI 10.1021/ja00187a062; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473; WITHKA JM, 1991, BIOCHEMISTRY-US, V30, P9931, DOI 10.1021/bi00105a017; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P297, DOI 10.1089/aid.1992.8.297; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507; Wolfe AL, 1996, J VIROL, V70, P1424, DOI 10.1128/JVI.70.3.1424-1432.1996; YOSHINAGA T, 1994, J VIROL, V68, P5690, DOI 10.1128/JVI.68.9.5690-5697.1994	47	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27330	27338		10.1074/jbc.271.44.27330	http://dx.doi.org/10.1074/jbc.271.44.27330			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910309	hybrid			2022-12-27	WOS:A1996VQ67900027
J	Trotta, E; DAmbrosio, E; Ravagnan, G; Paci, M				Trotta, E; DAmbrosio, E; Ravagnan, G; Paci, M			Simultaneous and different binding mechanisms of 4',6-diamidino-2-phenylindole to DNA hexamer (d(CGATCG))(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINOR-GROOVE BINDING; DIMENSIONAL NMR-SPECTROSCOPY; SEQUENTIAL RESONANCE ASSIGNMENTS; H-1-NMR SPECTRA; NUCLEIC-ACIDS; PROTON RESONANCES; AQUEOUS-SOLUTION; DAPI; INTERCALATION; DRUGS	The solution structure of the complex between 4',6-diamidino-2-phenylindole (DAPI) and DNA oligomer (d(CGATCG))(2) at a 2:1 drug/duplex ratio has been characterized by combined use of proton one- and two-dimensional NMR spectroscopy, molecular mechanics, and molecular dynamics computations. Intermolecular nuclear Overhauser effects (NOEs), DNA structure perturbations, and resonance shifts induced by binding provide evidence that DAPI interacts with DNA hexamer by two different binding mechanisms, in fast exchange on the NMR. time scale, without any significant distortion of the B-type conformation of DNA hexamer, The results indicate that the ligand binds into the minor groove of the central 5'-ATC-3' region of the hexamer and on the outside of the oligomer by a pi pi-stacking interaction with the terminal C1:G6 base pairs, A model for both binding mechanisms that accounts for all experimental data was generated by molecular mechanics and dynamics calculations based on experimental NOEs, In the minor groove binding, N2 amino group of G2 precludes a deep insertion of phenyl ring of DAPI into the groove, Position and orientation of the drug in the external stacking interaction resemble those suggested for intercalation of DAPI between C:G base pairs.	CNR,IST MED SPERIMENTALE,I-00137 ROME,ITALY; UNIV ROMA TOR VERGATA,DIPARTIMENTO SCI & TECNOL CHIM,I-00133 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Rome Tor Vergata			Trotta, Edoardo/AAW-4697-2020	Trotta, Edoardo/0000-0002-1417-9238				ALTONA C, 1982, RECL TRAV CHIM PAY B, V101, P413; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOELENS R, 1985, J MAGN RESON, V62, P378, DOI 10.1016/0022-2364(85)90207-0; BOELENS R, 1990, SOFTWARE PROCESSING; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; CHIANG SY, 1994, BIOCHEMISTRY-US, V33, P7033, DOI 10.1021/bi00189a003; CLORE GM, 1985, FEBS LETT, V179, P187, DOI 10.1016/0014-5793(85)80516-0; CONTE MR, 1995, EUR J BIOCHEM, V229, P443; DAVIES DB, 1978, PROG NUCL MAG RES SP, V12, P135, DOI 10.1016/0079-6565(78)80006-5; ERIKSSON S, 1993, BIOCHEMISTRY-US, V32, P2987, DOI 10.1021/bi00063a009; FEIGON J, 1984, J MED CHEM, V27, P450, DOI 10.1021/jm00370a007; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HOSUR RV, 1988, MAGN RESON CHEM, V26, P927, DOI 10.1002/mrc.1260261019; HOSUR RV, 1985, MAGNETIC RESONANCE B, P243; JANSEN K, 1993, J AM CHEM SOC, V115, P10527, DOI 10.1021/ja00076a009; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; KAPUSCINSKI J, 1979, NUCLEIC ACIDS RES, V6, P3519, DOI 10.1093/nar/6.11.3519; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KASTRUP RV, 1978, BIOCHEMISTRY-US, V17, P4855, DOI 10.1021/bi00616a002; KIM SK, 1993, J AM CHEM SOC, V115, P3441, DOI 10.1021/ja00062a006; KUBISTA M, 1987, BIOCHEMISTRY-US, V26, P4545, DOI 10.1021/bi00388a057; LARSEN TA, 1989, J BIOMOL STRUCT DYN, V7, P477, DOI 10.1080/07391102.1989.10508505; LOONTIENS FG, 1991, BIOCHEMISTRY-US, V30, P182, DOI 10.1021/bi00215a027; LOWN JW, 1984, NUCLEIC ACIDS RES, V12, P2519, DOI 10.1093/nar/12.5.2519; MANZINI G, 1983, NUCLEIC ACIDS RES, V11, P8861, DOI 10.1093/nar/11.24.8861; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MOHAN S, 1994, J BIOMOL STRUCT DYN, V11, P849, DOI 10.1080/07391102.1994.10508037; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; PALU G, 1987, BIOCHEM BIOPH RES CO, V145, P40, DOI 10.1016/0006-291X(87)91284-8; PAROLIN C, 1990, FEMS MICROBIOL LETT, V68, P341, DOI 10.1016/S0378-1097(05)80065-5; PAROLIN C, 1995, BIOCHEM BIOPH RES CO, V208, P332, DOI 10.1006/bbrc.1995.1342; PATEL DJ, 1987, Q REV BIOPHYS, V20, P35, DOI 10.1017/S0033583500004224; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; REID DG, 1983, BIOCHEMISTRY-US, V22, P2019, DOI 10.1021/bi00277a044; Samuelson Per, 1994, Journal of Molecular Recognition, V7, P233, DOI 10.1002/jmr.300070313; SCHEEK RM, 1984, BIOCHEMISTRY-US, V23, P1371, DOI 10.1021/bi00302a006; SCHEEK RM, 1983, J AM CHEM SOC, V105, P2914, DOI 10.1021/ja00347a075; SEHLSTEDT U, 1993, J AM CHEM SOC, V115, P12258, DOI 10.1021/ja00079a004; SKLENAR V, 1987, J MAGN RESON, V74, P469, DOI 10.1016/0022-2364(87)90269-1; STORL K, 1993, FEBS LETT, V317, P157, DOI 10.1016/0014-5793(93)81513-Y; STRANEY DC, 1987, BIOCHEMISTRY-US, V26, P1987, DOI 10.1021/bi00381a031; TANIOUS FA, 1994, J BIOMOL STRUCT DYN, V11, P1063, DOI 10.1080/07391102.1994.10508053; TANIOUS FA, 1992, BIOCHEMISTRY-US, V31, P3103, DOI 10.1021/bi00127a010; TROTTA E, 1995, NUCLEIC ACIDS RES, V23, P1333, DOI 10.1093/nar/23.8.1333; TROTTA E, 1993, J BIOL CHEM, V268, P3944; WELCH JJ, 1994, J BIOL CHEM, V269, P31051; WILSON WD, 1989, J AM CHEM SOC, V111, P5008, DOI 10.1021/ja00195a080; WILSON WD, 1990, ANTI-CANCER DRUG DES, V5, P31; WILSON WD, 1990, BIOCHEMISTRY-US, V29, P8452, DOI 10.1021/bi00488a036; [No title captured]	50	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27608	27614		10.1074/jbc.271.44.27608	http://dx.doi.org/10.1074/jbc.271.44.27608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910349	hybrid			2022-12-27	WOS:A1996VQ67900067
J	Yamazaki, H; Johnson, WW; Ueng, YF; Shimada, T; Guengerich, FP				Yamazaki, H; Johnson, WW; Ueng, YF; Shimada, T; Guengerich, FP			Lack of electron transfer from cytochrome b(5) in stimulation of catalytic activities of cytochrome P450 3A4 - Characterization of a reconstituted cytochrome P450 3A4 NADPH-cytochrome P450 reductase system and studies with apo-cytochrome b(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; OXIDATIVE DRUG-METABOLISM; GENETIC-POLYMORPHISM; ESCHERICHIA-COLI; N-DEMETHYLATION; FUSION PROTEIN; PURIFICATION; MECHANISM; ENZYMES; LM2	Many catalytic activities of cytochrome P450 (P450) 3A4, the major human liver P450 enzyme, require cytochrome b(5) (b(5)) for optimal rates, The stimulatory effect of b(5) on P450 reactions has generally been thought to be due to transfer of electrons from ferrous b(5) to the ferrous P-450-O-2-substrate complex. We found that apo-b(5), devoid of heme, could substitute for b(5) in stimulating two prototypic activities, testosterone 6 beta hydroxylation and nifedipine oxidation. The stimulatory effect was not seen with albumin, hemoglobin, catalase, or cytochrome c. Apo-b(5) could not substitute for b(5) in a testosterone 6 beta hydroxylation system composed of NADH-b(5) reductase and P450 3A4. Rates of electron transfer from NADPH-P450 reductase to ferric P450 3A4 were too slow (<2 min(-1)) to support testosterone 6 beta hydroxylation (similar to 14 min(-1)) unless b(5) or apo-b(5) was present, when rates of similar to 700 min(-1) were measured. The oxidation-reduction potential (E(m,7)) of the ferric/ferrous couple of P450 3A4 was unchanged (similar to-310 mV) under different conditions in which the kinetics of reduction vp ere altered by the addition of substrate and/or apo-b(5). Rapid reduction of P450 3A4 required substrate and a preformed complex of P450 3A4, NADPH-P450 reductase, and b(5); the rates of binding of the proteins to each other were 2-3 orders of magnitude less than reduction rates. We conclude that b(5) can facilitate some P450 3A4-catalyzed oxidations by complexing with P450 3A4 and enhancing its reduction by NADPH-P450 reductase, without directly transferrin,b electrons to P450.	OSAKA PREFECTURAL INST PUBL HLTH, OSAKA 537, JAPAN; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, CTR MOL TOXICOL, NASHVILLE, TN 37232 USA	Osaka Prefectural Institute of Public Health; Vanderbilt University; Vanderbilt University			Yamazaki, Hiroshi/A-6081-2011	Yamazaki, Hiroshi/0000-0002-1068-4261; Shimada, Tsutomu/0000-0003-2552-4348	NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, F32ES005663] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA44353] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267, F32 ES05663] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1988, J BIOL CHEM, V263, P247; BACKES WL, 1980, BIOCHEM BIOPH RES CO, V97, P860, DOI 10.1016/0006-291X(80)91456-4; Bell LC, 1996, FASEB J, V10, P2872; BONFILS C, 1981, J BIOL CHEM, V256, P9457; BRIAN WR, 1990, BIOCHEMISTRY-US, V29, P11280, DOI 10.1021/bi00503a018; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CAWLEY GF, 1995, BIOCHEMISTRY-US, V34, P1244, DOI 10.1021/bi00004a018; CHIANG JYL, 1983, BIOCHIM BIOPHYS ACTA, V750, P291, DOI 10.1016/0005-2760(83)90031-0; Chun YJ, 1996, ARCH BIOCHEM BIOPHYS, V330, P48, DOI 10.1006/abbi.1996.0224; CINTI DL, 1975, BIOCHIM BIOPHYS ACTA, V410, P32, DOI 10.1016/0005-2744(75)90205-3; Clark W. M., 1960, OXIDATION REDUCTION; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DIEHL H, 1970, H-S Z PHYSIOL CHEM, V351, P1359, DOI 10.1515/bchm2.1970.351.2.1359; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; GIGON PL, 1969, MOL PHARMACOL, V5, P109; GILLAM EMJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P123, DOI 10.1006/abbi.1993.1401; GOLLY I, 1988, ARCH BIOCHEM BIOPHYS, V260, P232, DOI 10.1016/0003-9861(88)90445-6; Guengerich F. P., 1995, CYTOCHROME P, P473; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P21, DOI 10.1021/tx00013a004; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; GUENGERICH FP, 1983, BIOCHEMISTRY-US, V22, P2811, DOI 10.1021/bi00281a007; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUENGERICH FP, 1990, CHEM RES TOXICOL, V3, P363, DOI 10.1021/tx00016a015; GUENGERICH FP, 1994, ADV DRUG METABOLISM, P179; GUENGERICH FP, 1994, SCHERING FDN WORKSHO, V13, P161; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; HUANG YY, 1986, BIOCHEMISTRY-US, V25, P1390, DOI 10.1021/bi00354a030; IMAOKA S, 1992, BIOCHEMISTRY-US, V31, P6063, DOI 10.1021/bi00141a015; IngelmanSundberg M, 1996, BIOCHEM BIOPH RES CO, V221, P318, DOI 10.1006/bbrc.1996.0593; JANSSON I, 1987, DRUG METAB DISPOS, V15, P344; KAMINSKY LS, 1985, EUR J BIOCHEM, V149, P479, DOI 10.1111/j.1432-1033.1985.tb08950.x; KERR BM, 1994, BIOCHEM PHARMACOL, V47, P1969, DOI 10.1016/0006-2952(94)90071-X; KOLARS JC, 1991, LANCET, V338, P1488, DOI 10.1016/0140-6736(91)92302-I; LIPKA JJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P152, DOI 10.1016/0003-9861(89)90576-6; MIHARA K, 1975, J BIOCHEM-TOKYO, V78, P1057, DOI 10.1093/oxfordjournals.jbchem.a130983; MORGAN ET, 1984, DRUG METAB DISPOS, V12, P358; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; PALMER G, 1992, J BIOL CHEM, V267, P665; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; Peterson JA, 1986, CYTOCHROME P 450 STR, P89; POMPON D, 1987, BIOCHEMISTRY-US, V26, P6429, DOI 10.1021/bi00394a020; POMPON D, 1984, J BIOL CHEM, V259, P5377; PORTER TD, 1991, J BIOL CHEM, V266, P13469; SANDHU P, 1994, ARCH BIOCHEM BIOPHYS, V309, P168, DOI 10.1006/abbi.1994.1099; SCHENKMAN JB, 1994, ARCH BIOCHEM BIOPHYS, V314, P234, DOI 10.1006/abbi.1994.1435; SCHMIDER J, 1995, J PHARMACOL EXP THER, V275, P592; SHET MS, 1993, P NATL ACAD SCI USA, V90, P11748, DOI 10.1073/pnas.90.24.11748; SHET MS, 1995, ARCH BIOCHEM BIOPHYS, V318, P314, DOI 10.1006/abbi.1995.1235; SHIMADA T, 1986, J BIOL CHEM, V261, P909; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Strittmatter P, 1978, Methods Enzymol, V52, P97; UENG YF, 1995, CHEM RES TOXICOL, V8, P218, DOI 10.1021/tx00044a006; VELICK SF, 1956, J BIOL CHEM, V221, P265; WISLOCKI PG, 1980, ENZYMATIC BASIS DETO, V1, P135; WRIGHTON SA, 1992, CRIT REV TOXICOL, V22, P1, DOI 10.3109/10408449209145319; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki H, 1996, ARCH BIOCHEM BIOPHYS, V325, P174, DOI 10.1006/abbi.1996.0022; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	62	171	172	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27438	27444		10.1074/jbc.271.44.27438	http://dx.doi.org/10.1074/jbc.271.44.27438			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910324	hybrid			2022-12-27	WOS:A1996VQ67900042
J	Zeng, L; An, SZ; Goetzl, EJ				Zeng, L; An, SZ; Goetzl, EJ			Regulation of expression of matrix metalloproteinase-9 in early human T cells of the HSB.2 cultured line by the EP(3) subtype of prostaglandin E(2) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; IV COLLAGENASE; HUMAN MONOCYTES; H SYNTHASE-2; EP2 SUBTYPE; CA2+ STORES; CLONING; INHIBITION; SPECIFICITY; STIMULATION	The expression by T lymphocytes (T cells) of more than one of the functionally distinct subtypes of prostaglandin E(2) (PGE(2)) receptors (Rs), designated EP(1), EP(2), EP(3), and EP(4) RS, is a principal determinant of specificity and diversity of the immune effects of PGE(2). The cultured line of human leukemic T cells, termed HSB.2, co-expresses a total of 7282 +/- 1805 EP(3), EP(4), and EP(2) Rs per cell with a K-d of 3.7 +/- 1.4 nM (mean +/- S.E., n = 9), The EP(3)/EP(1) R-selective agonist sulprostone, EP(3)/EP(2)/EP(4) R-selective agonists M&B 28767 and misoprostol, and EP(2) R-selective agonist butaprost but not the EP(1) R-selective antagonist SC-19220 competitively inhibited the binding of [H-3]PGE(2) to HSB.2 cells, Stimulation of increases in the intracellular concentration of cyclic AMP ([cAMP](i)) by PGE(2), misoprostol, and butaprost and of increases in the intracellular concentration of calcium ([Ca2+](i)) by PGE(2) and sulprostone demonstrated the respective involvement of EP(2)/EP(4) Rs and EP(3) Rs in transduction of biochemical signals, Matrix metalloproteinase (MMP)-9 was identified by zymography and Western blots as the principal MMP secreted by HSB.2 cells, The cytosolic level and secretion of MMP-9 were increased maximally after 24 h of incubation of HSB.2 cells with 10(-8)-10(-6) M PGE(2), sulprostone, M&B 28767, and misoprostol but not with 10(-6) M PGF(2 alpha), PGD(2), PGI(2), or butaprost, suggesting a principal dependence on EP(3) Rs. That stimulation of MMP-9 secretion by PGE(2) was not diminished in Ca2+-free medium but was suppressed significantly and dose-dependently by thapsigargin, an inhibitor of endomembrane Ca2+-ATPase, suggested that MMP-9 expression by HSB.2 cells is mediated by increases in [Ca2+](i) attributable to release of Ca2+ from intracellular stores, The lack of effect of dibutyryl cAMP, forskolin, and SQ 22536, an adenylyl cyclase inhibitor, on MMP-9 secretion by HSB.2 cells argued against any role for cAMP-dependent mechanisms linked to EP(2)/EP(4) Rs, Cycloheximide and actinomycin D, which respectively inhibited protein and RNA synthesis, suppressed basal and PGE(2) induction of MMP-9 production by HSB.2 cells, Northern analysis indicated that PGE(2) and sulprostone time-dependently increased expression of MMP-9 mRNA, Thus, stimulation of MMP-9 in HSB.2 T cells by PGE(2) is attributable to [Ca2+](i)-dependent EP(3) R-mediation of increases in message transcription.	UNIV CALIF SAN FRANCISCO, DEPT MED, MED CTR, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT IMMUNOL MICROBIOL, MED CTR, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 31809] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RA, 1970, EXP CELL RES, V62, P5, DOI 10.1016/0014-4827(79)90504-4; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; AN SZ, 1993, BIOCHEM BIOPH RES CO, V197, P263, DOI 10.1006/bbrc.1993.2470; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; Coleman RA, 1990, COMPREHENSIVE MED CH, P643; CORCORAN ML, 1994, ARCH BIOCHEM BIOPHYS, V310, P481, DOI 10.1006/abbi.1994.1196; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; Goetzl EJ, 1996, J IMMUNOL, V156, P1; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; GOUY H, 1990, EUR J IMMUNOL, V20, P2269, DOI 10.1002/eji.1830201016; HARA J, 1988, J CLIN INVEST, V81, P989, DOI 10.1172/JCI113453; HONDA A, 1993, J BIOL CHEM, V268, P7759; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; LEPPERT D, 1995, FASEB J, V9, P1473, DOI 10.1096/fasebj.9.14.7589989; MCCARTHY JB, 1980, J IMMUNOL, V124, P2405; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MISSIAEN L, 1992, J BIOL CHEM, V267, P22961; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; PREMACK BA, 1994, J IMMUNOL, V152, P5226; REGAN JW, 1994, MOL PHARMACOL, V46, P213; ROPER RL, 1992, J IMMUNOL, V149, P2984; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO H, 1993, J BIOL CHEM, V268, P23460; WATABE A, 1993, J BIOL CHEM, V268, P20175; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; XIE B, 1994, J IMMUNOL, V152, P3637; Zeng L, 1995, IMMUNOLOGY, V86, P620; ZHOU H, 1993, BIOCHIM BIOPHYS ACTA, V1177, P174, DOI 10.1016/0167-4889(93)90037-P	30	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27744	27750		10.1074/jbc.271.44.27744	http://dx.doi.org/10.1074/jbc.271.44.27744			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910368	hybrid			2022-12-27	WOS:A1996VQ67900086
J	Andralojc, PJ; Keys, AJ; Martindale, W; Dawson, GW; Parry, MAJ				Andralojc, PJ; Keys, AJ; Martindale, W; Dawson, GW; Parry, MAJ			Conversion of D-hamamelose into 2-carboxy-D-arabinitol and 2-carboxy-D-arabinitol 1-phosphate in leaves of Phaseolus vulgaris L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BISPHOSPHATE CARBOXYLASE ACTIVITY; 2-CARBOXYARABINITOL 1-PHOSPHATE; NOCTURNAL INHIBITOR; RUBISCO; 2'-CARBOXYARABINITOL; PHOSPHATASE; IDENTIFICATION; OXYGENASE; CARBON	[1-C-14]Hamamelose (2-hydroxymethyl-D-ribose) was synthesized by reaction of ribulose B-phosphate with potassium [C-14]cyanide, catalytic hydrogenation of the resulting cyanohydrin, and dephosphorylation of the product, Its identity was established by a chromatographic comparison with hamamelose isolated from the bark of witch hazel (Hamamelis virginiana L.). Following vacuum infiltration of the [1-C-14]hamamelose into leaf discs from Phaseolus vulgaris L., C-14-labeled 2-carboxy-D-arabinitol (CA) and 2-carboxy-D-arabinitol 1-phosphate (CA1P) were formed, in the dark. Conversion of hamamelose to both CA and CA1P in the leaf discs was inhibited by dithiothreitol and sodium fluoride, although at high concentrations of these inhibitors conversion into CA was still evident when conversion into CA1P was totally inhibited. Wheat (Triticum aestivum L.) leaves converted hamamelose into CA without formation of CA1P, Leaves from P. vulgaris contained 68 nmol . g(-1) fresh weight of hamamelose in the light and 35 nmol . g(-1) fresh weight in the dark, A pathway for the biosynthesis of CA1P from Calvin cycle intermediates is proposed which includes the sequence: hamamelose --> CA --> CA1P.	IACR ROTHAMSTED, DEPT BIOL & ECOL CHEM, HARPENDEN AL5 2JQ, HERTS, ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Andralojc, PJ (corresponding author), IACR ROTHAMSTED, DEPT BIOCHEM & PHYSIOL, HARPENDEN AL5 2JQ, HERTS, ENGLAND.		Martindale, Wayne/R-8135-2017	Martindale, Wayne/0000-0003-0117-1875; Parry, Martin/0000-0002-4477-672X				ANDRALOJC PJ, 1994, BIOCHEM J, V304, P781, DOI 10.1042/bj3040781; BECK E, 1989, PLANT PHYSIOL, V90, P13, DOI 10.1104/pp.90.1.13; Beck E., 1982, Encyclopedia of plant physiology. New series. Volume 13 A. Plant carbohydrates.I. Intracellular carbohydrates [Loewus, R.A.; Tanner, W. (Editors)], P124; BERRY JA, 1987, P NATL ACAD SCI USA, V84, P734, DOI 10.1073/pnas.84.3.734; BILCK H, 1975, CARBOHYD RES, V39, P160; DEMOORE B, 1991, PLANT PHYSIOL, V96, P208, DOI 10.1104/pp.96.1.208; GILCK H, 1974, Z PFLANZENPHYSIOL, V72, P395, DOI 10.1016/S0044-328X(74)80061-9; GUTTERIDGE S, 1986, NATURE, V324, P274, DOI 10.1038/324274a0; GUTTERIDGE S, 1989, FEBS LETT, V254, P225, DOI 10.1016/0014-5793(89)81044-0; HOLBROOK GP, 1989, PLANT PHYSIOL, V90, P673, DOI 10.1104/pp.90.2.673; KEYS AJ, 1995, J EXP BOT, V46, P1245, DOI 10.1093/jxb/46.special_issue.1245; KINGSTONSMITH AH, 1992, BIOCHEM J, V287, P821, DOI 10.1042/bj2870821; LEE YC, 1990, ANAL BIOCHEM, V189, P151, DOI 10.1016/0003-2697(90)90099-U; MCFADDEN BA, 1986, PHOTOSYNTH RES, V8, P53, DOI 10.1007/BF00028476; MOORE B, 1992, PLANT PHYSIOL, V99, P1551, DOI 10.1104/pp.99.4.1551; MOORE BD, 1992, PLANT PHYSIOL, V99, P1546, DOI 10.1104/pp.99.4.1546; Moore BD, 1995, PHOTOSYNTH RES, V45, P219, DOI 10.1007/BF00015562; ROBINSON SP, 1988, FEBS LETT, V233, P413, DOI 10.1016/0014-5793(88)80473-3; SASSENRATHCOLE GF, 1994, PLANT PHYSIOL, V105, P1115, DOI 10.1104/pp.105.4.1115; SCHILLING G, 1977, LIEBIGS ANN CHEM, P1475; SEEMANN JR, 1985, P NATL ACAD SCI USA, V82, P8024, DOI 10.1073/pnas.82.23.8024; SELLMAIR J, 1977, PHYTOCHEMISTRY, V16, P1201, DOI 10.1016/S0031-9422(00)94360-7; SERIANNI AS, 1982, METHOD ENZYMOL, V89, P73; SERVAITES JC, 1986, PLANT PHYSIOL, V82, P1161, DOI 10.1104/pp.82.4.1161; SHAFIZADEH F, 1956, ADV CARBOHYD CHEM, V11, P263	25	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26803	26809		10.1074/jbc.271.43.26803	http://dx.doi.org/10.1074/jbc.271.43.26803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900161	hybrid			2022-12-27	WOS:A1996VP23300055
J	Chamberlain, NL; Whitacre, DC; Miesfeld, RL				Chamberlain, NL; Whitacre, DC; Miesfeld, RL			Delineation of two distinct type I activation functions in the androgen receptor amino-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; STEROID-BINDING; GENE-EXPRESSION; RETINOIC ACID; TRANSACTIVATION; PROTEINS; VP16; IDENTIFICATION	Based on the finding that some transcription factors contain multiple transcriptional regulatory activities, we constructed a panel of rat androgen receptor (AR) mutants containing small internal deletions and point mutations within the amino-terminal region of the receptor. Trans-activation assays in CV-1 cells using AR-responsive reporter genes were performed and led to the identification of two noncontiguous trans-activation regions in the AR amino terminus, One of these regions, termed activator function 1a (AF-1a) is a highly-conserved 14-amino acid segment that is predicted to form a beta-turn followed by an acidic amphipathic alpha-helix. Point mutagenesis within AF-1a revealed that two adjacent hydrophobic residues were required for full AR transactivation function, as arginine substitutions resulted in a 60% reduction in transcriptional activity. A second amino-terminal region was also identified and has been designated AF-1b. Deletion of the 65-amino acid AF-1b segment, which contains numerous glutamate and aspartate residues, caused a 55% decrease in trans-activation function, An AF-1a/AF-1b double mutant retains less than 10% trans-activation function compared, with wild-type AR, suggesting that AF-1a and AF-1b may each contribute separately to maximal AR activity, To determine whether AF-1a and AF-1b play a role in AR-mediated trans-repression of AP-1 function, we tested single and double AF-1a/AF-1b mutants in a transient trans-repression assay, Our results showed that neither AF-1a nor AF-1b was required for AP-1 trans-repression, demonstrating that AR-mediated trans-repression and trans-activation are discrete functions.	UNIV ARIZONA,DEPT BIOCHEM,TUCSON,AZ 85721; UNIV ARIZONA,DEPT MOL & CELLULAR BIOL,TUCSON,AZ 85721	University of Arizona; University of Arizona					NCI NIH HHS [CA 09213] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Blau J, 1996, MOL CELL BIOL, V16, P2044; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DAHLMANWRIGHT K, 1994, P NATL ACAD SCI USA, V91, P1619, DOI 10.1073/pnas.91.5.1619; DIEKEN ES, 1992, MOL CELL BIOL, V12, P589, DOI 10.1128/MCB.12.2.589; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GORDON DA, 1995, EXP CELL RES, V217, P368, DOI 10.1006/excr.1995.1099; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KUPFER SR, 1994, J BIOL CHEM, V269, P20622; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Massari ME, 1996, MOL CELL BIOL, V16, P121; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MIESFELD RL, 1989, CRIT REV BIOCHEM MOL, V24, P101, DOI 10.3109/10409238909086395; Moore DD, 1995, GLOB MOB SURV; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; RUNDLETT SE, 1992, EXP CELL RES, V203, P214, DOI 10.1016/0014-4827(92)90057-F; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WONG CI, 1993, J BIOL CHEM, V268, P19004; ZANDI E, 1993, J MOL BIOL, V230, P124, DOI 10.1006/jmbi.1993.1130; ZOPPI S, 1993, J CLIN INVEST, V91, P1105, DOI 10.1172/JCI116269	34	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26772	26778		10.1074/jbc.271.43.26772	http://dx.doi.org/10.1074/jbc.271.43.26772			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900157	hybrid			2022-12-27	WOS:A1996VP23300051
J	Shibata, N; Inoue, T; Fukuhara, K; Nagara, Y; Kitagawa, R; Harada, S; Kasai, N; Uemura, K; Kato, K; Yokota, A; Kai, Y				Shibata, N; Inoue, T; Fukuhara, K; Nagara, Y; Kitagawa, R; Harada, S; Kasai, N; Uemura, K; Kato, K; Yokota, A; Kai, Y			Orderly disposition of heterogeneous small subunits in D-ribulose-1,5-bisphosphate carboxylase/oxygenase from spinach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; CRYSTAL-STRUCTURE; PLANT RUBISCO; X-RAY; OXYGENASE; BISPHOSPHATE; RESOLUTION; EXPRESSION; REFINEMENT	We determined the crystal structure of spinach ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco) by x-ray diffraction at 1.8-Angstrom resolution and found that the enzyme contained two kinds of S, S-I and S-II, present in equal number and disposed in an orderly way within the Rubisco holoenzyme. The electron density maps suggested that leucine was at residue 56 in S-I, although histidine was at that position in S-II. There were other residue differences. Thus, spinach Rubisco has a L(8)S(4)(I)S(II)4 subunit structure. The orderly disposition of the heterogeneous small subunits in the Rubisco holoenzyme provides accounts of a multigene family of S in plants.	OSAKA UNIV,FAC ENGN,DEPT APPL CHEM,SUITA,OSAKA 565,JAPAN; RES INST INNOVAT TECHNOL EARTH,PLANT MOL PHYSIOL LAB,KYOTO 61902,JAPAN	Osaka University; Research Institute of Innovative Technology for the Earth			Shibata, Naoki/AFK-9971-2022	Shibata, Naoki/0000-0002-5096-1104				AKAZAWA T, 1979, ENCY PLANT PHYSL, V6, P208; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1984, J MOL BIOL, V172, P363, DOI 10.1016/S0022-2836(84)80033-9; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CURMI PMG, 1992, J BIOL CHEM, V267, P16980; DEAN C, 1987, TAILORING GENES CROP, P59; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; JOHNS TA, 1985, METHOD ENZYMOL, V115, P157; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; MANZARA T, 1988, PHOTOSYNTH RES, V16, P117, DOI 10.1007/BF00039489; MARTIN PG, 1979, AUST J PLANT PHYSIOL, V6, P401; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MEIER I, 1995, PLANT PHYSIOL, V107, P1105, DOI 10.1104/pp.107.4.1105; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NEWMAN J, 1993, J BIOL CHEM, V268, P25876; NEWMAN J, 1993, ACTA CRYSTALLOGR D, V49, P548, DOI 10.1107/S090744499300530X; REN L, 1991, PLANT SCI, V74, P1, DOI 10.1016/0168-9452(91)90249-8; SAKABE N, 1983, J APPL CRYSTALLOGR, V16, P542, DOI 10.1107/S0021889883010973; SCHREUDER HA, 1993, PROTEIN SCI, V2, P1136, DOI 10.1002/pro.5560020708; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; WASMANN CC, 1989, P NATL ACAD SCI USA, V86, P1198, DOI 10.1073/pnas.86.4.1198; Yokota A, 1996, J BIOCHEM-TOKYO, V119, P487; YOKOTA A, 1994, PLANT CELL PHYSIOL, V35, P317; YOKOTA A, 1991, J BIOCHEM-TOKYO, V110, P246, DOI 10.1093/oxfordjournals.jbchem.a123565; YOKOTA A, 1991, J BIOCHEM-TOKYO, V110, P253, DOI 10.1093/oxfordjournals.jbchem.a123566; ZURAWSKI G, 1981, NUCLEIC ACIDS RES, V9, P3251, DOI 10.1093/nar/9.14.3251	30	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26449	26452		10.1074/jbc.271.43.26449	http://dx.doi.org/10.1074/jbc.271.43.26449			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900108	hybrid			2022-12-27	WOS:A1996VP23300002
J	Gemmill, TR; Trimble, RB				Gemmill, TR; Trimble, RB			Schizosaccharomyces pombe produces novel pyruvate-containing N-linked oligosaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSE; MUTANTS; YEAST	The large N-linked oligosaccharides released by endo-beta-N-acetylglucosaminidase H from Schizosaccharomyces pombe glycoproteins were analyzed for the presence of noncarbohydrate functional groups. No phosphate, sulfate, or acetate could be detected; however, approximately six molecules of pyruvic acid/molecule were found on 98% of the oligosaccharides. Pyruvate moieties were acetal (ketal)-linked to galactose residues in the R configuration to carbons 4 and 6. This is the first report of pyruvate functional groups being attached to N-linked oligosaccharides in yeast and appears only to be the second documentation of this sugar modification in eukaryotes.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,ALBANY,NY 12201; SUNY ALBANY,SCH PUBL HLTH,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023900] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23900] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; ARAKI S, 1989, J BIOL CHEM, V264, P19922; BALLOU CE, 1990, METHOD ENZYMOL, V185, P440; BALLOU L, 1995, P NATL ACAD SCI USA, V92, P2790, DOI 10.1073/pnas.92.7.2790; BYRD JC, 1982, J BIOL CHEM, V257, P4657; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; Downs F., 1976, METHODS CARBOHYDRATE, V7, P241; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FRIEDEMANN TE, 1957, METHOD ENZYMOL, V3, P414, DOI 10.1016/S0076-6879(57)03406-0; GORIN PA, 1961, CAN J CHEM, V39, P2274, DOI 10.1139/v61-301; GORIN PAJ, 1966, CAN J CHEM, V45, P521; HIND CRK, 1984, J EXP MED, V159, P1058, DOI 10.1084/jem.159.4.1058; KOBATA A, 1993, GLYCOBIOLOGY PRACTIC, P79; Manzi A, 1993, GLYCOBIOLOGY PRACTIC, P27; MASOUD H, 1994, CARBOHYD RES, V252, P223; SAHA SK, 1994, CARBOHYD RES, V254, P157; Schauer R, 1978, Methods Enzymol, V50, P374; Schauer R, 1978, Methods Enzymol, V50, P64; SILVESTRI LJ, 1982, ANAL BIOCHEM, V123, P303, DOI 10.1016/0003-2697(82)90450-X; SPILLMANN D, 1993, J BIOL CHEM, V268, P13378; TRUMBLY RJ, 1985, J BIOL CHEM, V260, P5683; ZEIGLER FD, 1994, J BIOL CHEM, V269, P12527	22	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25945	25949		10.1074/jbc.271.42.25945	http://dx.doi.org/10.1074/jbc.271.42.25945			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824229	hybrid			2022-12-27	WOS:A1996VN18000035
J	Liu, B; Maul, RS; Kaetzel, DM				Liu, B; Maul, RS; Kaetzel, DM			Repression of platelet-derived growth factor A-chain gene transcription by an upstream silencer element - Participation by sequence-specific single-stranded DNA-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATORY REGIONS; NUCLEASE-SENSITIVE REGION; PROMOTER REGION; S1 NUCLEASE; RESPONSIVE ELEMENT; VIMENTIN PROMOTER; ESTROGEN-RECEPTOR; CDNA SEQUENCE; CELL-LINES; IDENTIFICATION	Platelet-derived growth factor A-chain is a potent mitogen expressed in a restricted number of normal and transformed cells. Transient transfection and deletion analysis in BSC-1 (African green monkey, renal epithelial) cells revealed that the -1680 to -1374 region of the A-chain gene repressed homologous and heterologous promoter activities by 60-80%. An S1 nuclease-hypersensitive region (5'SHS) was identified within this region (-1418 to -1388) that exhibited transcriptional silencer activity in BSC-1 and a variety of human tumor cell lines (U87, HepG2, and HeLa). Electrophoretic mobility shift assays conducted with 5'SHS oligodeoxynucleotide probes revealed several binding protein complexes that displayed unique preferences for binding to sense, antisense, and double-stranded forms of the element. Southwestern blot analysis revealed that the antisense strand of 5'SHS binds to nuclear proteins of molecular mass 97, 87, 44, and 17 kDa, whereas the double-stranded form of 5'SHS is recognized by a 70-kDa factor. Mutations within 5'SHS element indicated the necessity of a central 5'-GGGGAGGGGG-3' motif for protein binding and silencer function, while nucleotides Banking both sides of the motif were also critical for repression, These results support a model in which silencer function of 5'SHS is mediated by antisense strand binding proteins, possibly by stabilizing single-stranded DNA conformations required for interaction with enhancer sequences in the proximal promoter region of the A-chain gene.	UNIV KENTUCKY, CHANDLER MED CTR, DEPT PHARMACOL, LEXINGTON, KY 40536 USA	University of Kentucky					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK045518] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45518] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTIOK S, 1993, MOL CELL BIOL, V13, P7303, DOI 10.1128/MCB.13.12.7303; BARTRAM CR, 1984, BLOOD, V63, P223; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BONTHRON DT, 1988, P NATL ACAD SCI USA, V85, P1492, DOI 10.1073/pnas.85.5.1492; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; COOKE NE, 1982, NATURE, V297, P603, DOI 10.1038/297603a0; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; FARRELL FX, 1990, MOL CELL BIOL, V10, P2349, DOI 10.1128/MCB.10.5.2349; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GARZON RJ, 1994, MOL CELL BIOL, V14, P934, DOI 10.1128/MCB.14.2.934; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIMALDI P, 1993, MOL ENDOCRINOL, V7, P1217, DOI 10.1210/me.7.9.1217; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; GUSTAFSON TA, 1989, P NATL ACAD SCI USA, V86, P2162, DOI 10.1073/pnas.86.7.2162; HAAS S, 1995, J BIOL CHEM, V270, P12503, DOI 10.1074/jbc.270.21.12503; HATA A, 1989, J BIOL CHEM, V264, P6404; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERMANSON M, 1992, CANCER RES, V52, P3213; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P5, DOI 10.1093/nar/19.1.5; JOHNSON R, 1992, KIDNEY INT, V41, P590, DOI 10.1038/ki.1992.88; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAETZEL DM, 1993, BIOFACTORS, V4, P71; KAETZEL DM, 1994, BIOCHEM J, V301, P321, DOI 10.1042/bj3010321; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KISS I, 1990, MOL CELL BIOL, V10, P2432, DOI 10.1128/MCB.10.5.2432; KOLLURI R, 1991, NUCLEIC ACIDS RES, V19, P4771, DOI 10.1093/nar/19.17.4771; LANNIGAN DA, 1989, P NATL ACAD SCI USA, V86, P863, DOI 10.1073/pnas.86.3.863; LEVEEN P, 1990, INT J CANCER, V46, P1066, DOI 10.1002/ijc.2910460620; LIN XH, 1992, J BIOL CHEM, V267, P25614; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; MIN LW, 1992, J IMMUNOL, V148, P1913; MIZUNO K, 1992, GENE, V119, P293, DOI 10.1016/0378-1119(92)90286-X; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; Potapova O, 1996, CANCER RES, V56, P280; PROST E, 1986, GENE, V45, P107, DOI 10.1016/0378-1119(86)90138-1; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RYDER K, 1986, CELL, V44, P719, DOI 10.1016/0092-8674(86)90838-X; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SILVER BJ, 1992, BIOFACTORS, V3, P217; SMITH KP, 1995, J BIOL CHEM, V270, P4484, DOI 10.1074/jbc.270.9.4484; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; STOVER DM, 1994, CANCER RES, V54, P3092; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; SWAN DC, 1982, P NATL ACAD SCI-BIOL, V79, P4691, DOI 10.1073/pnas.79.15.4691; TAKIMOTO Y, 1993, JPN J CANCER RES, V84, P1268, DOI 10.1111/j.1349-7006.1993.tb02833.x; TANUMA Y, 1995, MOL CELL BIOL, V15, P517, DOI 10.1128/MCB.15.1.517; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANDEKLUNDERT FAJM, 1992, GENE, V122, P337, DOI 10.1016/0378-1119(92)90223-C; VERRIJZER CP, 1991, EMBO J, V10, P3007, DOI 10.1002/j.1460-2075.1991.tb07851.x; WANG ZY, 1993, J BIOL CHEM, V268, P10681; WANG ZY, 1992, J BIOL CHEM, V267, P17022; WANG ZY, 1994, NUCLEIC ACIDS RES, V22, P457, DOI 10.1093/nar/22.3.457; WESTERMARK B, 1990, ACTA ENDOCRINOL-COP, V123, P131, DOI 10.1530/acta.0.1230131; WILKISON WO, 1990, J BIOL CHEM, V265, P477; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K	68	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26281	26290		10.1074/jbc.271.42.26281	http://dx.doi.org/10.1074/jbc.271.42.26281			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824279	hybrid			2022-12-27	WOS:A1996VN18000085
J	Weiss, RH; Fretland, DJ; Baron, DA; Ryan, US; Riley, DP				Weiss, RH; Fretland, DJ; Baron, DA; Ryan, US; Riley, DP			Manganese-based superoxide dismutase mimetics inhibit neutrophil infiltration in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY BOWEL-DISEASE; FREE-RADICALS; MYELOPEROXIDASE ACTIVITY; INTESTINAL ISCHEMIA; MYOCARDIAL INJURY; REPERFUSION; MIMICS; ACTIVATION; COMPLEXES; OXIDASE	In a previous study (Hardy et al, (1994) J, Biol, Chem, 269, 18535-18540), we observed that the manganese-based superoxide dismutase mimetic Mn(II)-dichloro(1,4,7,10,13-pentaazacyclopentadecane) (MnPAM) inhibited neutrophil-mediated cell injury in vitro, We have extended these studies with the low molecular weight superoxide dismutase mimic to evaluate the role of superoxide in neutrophil-mediated tissue injury in vivo, In a dose-dependent manner, MnPAM inhibited colonic tissue injury and neutrophil accumulation into the colonic tissue induced by the intracolonic instillation of dilute aqueous acetic acid in mice, Tissue injury was assessed by visual and histological analysis, Neutrophil infiltration was determined by tissue myeloperoxidase activity and confirmed by histological analysis, Two novel Mn(II) dichloro complexes of the carbon-substituted macrocycles 2-methyl-1,4,7,10,13-pentaazacyclopentadecane (MnMAM) and 2-(2-methylpropyl)1,4,7,10,13-pentaazacyclopentadecane (MnBAM) effectively catalyzed the dismutation of superoxide with catalytic rate constants (k(cat)) of 3.31 x 10(7) M(-1) s(-1) and 1.91 x 10(7) M(-1) s(-1), respectively, as determined by stopped-flow kinetic analysis at pH 8.1 and 21 degrees C. The superoxide dismutase mimetics MnMAM and MnBAM also attenuated dilute aqueous acetic acid-induced tissue injury and neutrophil infiltration into colonic tissue; however, two Mn(II) complexes that had little or no detectable SOD activity (k(cat) less than or equal to 0.1 x 10(7) M(-1) s(-1)), specifically the Mn(II) dichloro complexes of 1,4,7,10,13-pentaazacyclohexadecane and 1,4,7,11,14-pentaazacycloheptadecane, failed to inhibit the colonic tissue injury or infiltration of neutrophils in mice treated intracolonically with dilute aqueous acetic acid, These results are consistent with a proinflammatory role for superoxide in the mediation of neutrophil infiltration in vivo.	SEARLE RES & DEV, SKOKIE, IL 60077 USA	Pfizer	Weiss, RH (corresponding author), MONSANTO CO, 800 N LINDBERGH BLVD, MAIL ZONE Q3C, ST LOUIS, MO 63167 USA.							BABIOR BM, 1988, J BIOL CHEM, V263, P1713; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344, DOI 10.1152/ajpheart.1989.256.5.H1344; BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; CHEN LY, 1995, AM HEART J, V129, P211, DOI 10.1016/0002-8703(95)90000-4; DARR D, 1987, ARCH BIOCHEM BIOPHYS, V258, P351, DOI 10.1016/0003-9861(87)90354-7; DOWLING EJ, 1993, FREE RADICAL RES COM, V18, P291, DOI 10.3109/10715769309147496; FAULKNER KM, 1994, ARCH BIOCHEM BIOPHYS, V310, P341, DOI 10.1006/abbi.1994.1176; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; FRETLAND DJ, 1995, INFLAMMATION, V19, P503, DOI 10.1007/BF01539131; FRETLAND DJ, 1989, AGENTS ACTIONS, V27, P395, DOI 10.1007/BF01972832; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GOLDSTEIN S, 1988, FREE RADICAL BIO MED, V4, P295, DOI 10.1016/0891-5849(88)90050-0; GOLDSTEIN S, 1991, FREE RADICAL RES COM, V12-3, P5, DOI 10.3109/10715769109145761; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567, DOI 10.1152/ajpgi.1986.251.4.G567; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HARDY MM, 1994, J BIOL CHEM, V269, P18535; HORTON JW, 1993, J SURG RES, V55, P282, DOI 10.1006/jsre.1993.1141; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; Jadot G, 1986, Free Radic Res Commun, V2, P19, DOI 10.3109/10715768609088052; KILGORE KS, 1993, CLIN BIOCHEM, V26, P359, DOI 10.1016/0009-9120(93)90112-J; KITAJIMA N, 1993, INORG CHEM, V32, P1879, DOI 10.1021/ic00062a001; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; MACPHERSON BR, 1978, DIGESTION, V17, P135, DOI 10.1159/000198104; McCord J M, 1993, New Horiz, V1, P70; MCCORD J M, 1986, Journal of Free Radicals in Biology and Medicine, V2, P307; MCCORD JM, 1979, ADV INFLAMMAT RES, V1, P273; Michelson A M, 1986, Free Radic Res Commun, V2, P43, DOI 10.3109/10715768609088054; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; NAGANO T, 1989, J BIOL CHEM, V264, P9243; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; OMAR BA, 1991, J MOL CELL CARDIOL, V23, P149, DOI 10.1016/0022-2828(91)90102-R; OOIWA H, 1991, J MOL CELL CARDIOL, V23, P119, DOI 10.1016/0022-2828(91)90099-8; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; RICHARD VJ, 1988, CIRCULATION, V78, P473, DOI 10.1161/01.CIR.78.2.473; RILEY DP, 1994, J AM CHEM SOC, V116, P387, DOI 10.1021/ja00080a051; RILEY DP, 1991, ANAL BIOCHEM, V196, P344, DOI 10.1016/0003-2697(91)90476-A; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; RYAN US, 1988, OXYGEN RADICALS BIOL, P963; SAMUNI A, 1988, J BIOL CHEM, V263, P17921; SELLKE FW, 1993, CIRCULATION, V88, P395; SORENSON JRJ, 1984, J MED CHEM, V27, P1747, DOI 10.1021/jm00378a040; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; WADA K, 1994, ARCH BIOCHEM BIOPHYS, V310, P1, DOI 10.1006/abbi.1994.1132; WEISS RH, 1993, J BIOL CHEM, V268, P23049; WEISS RH, 1995, OXYGEN PARADOX, P641; WERNS SW, 1988, J CARDIOVASC PHARM, V11, P36, DOI 10.1097/00005344-198801000-00006	48	40	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26149	26156		10.1074/jbc.271.42.26149	http://dx.doi.org/10.1074/jbc.271.42.26149			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824260	hybrid			2022-12-27	WOS:A1996VN18000066
J	Yao, CC; Ziober, BL; Squillace, RM; Kramer, RH				Yao, CC; Ziober, BL; Squillace, RM; Kramer, RH			alpha 7 integrin mediates cell adhesion and migration on specific laminin isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAINS; ALPHA-6-BETA-1 INTEGRIN; SKELETAL-MUSCLE; RECEPTOR; EXPRESSION; VARIANTS; SUBUNIT; BINDING; PHOSPHORYLATION; ALPHA-6A-BETA-1	The laminin-binding alpha 7 beta 1 integrin receptor is expressed at high levels by skeletal and cardiac muscles and by certain melanocytic cells. We have assessed the potential role of the alpha 7A/B integrin isoforms in mediating cell adhesion and motility and determined the laminin isoform specificity of this integrin. When MCF-7 breast carcinoma cells, normally nonadherent to laminin 1, were stably transfected with cDNA for mouse alpha 7, they adhered with high efficiency and migrated on laminin 1 substrates. Function-perturbing monoclonal antibodies generated to mouse alpha 7 subunit blocked both adhesion and migration of alpha 7 transfectants on laminin 1 substrates. Additional studies with MCF-7 transfectants revealed that alpha 7 beta 1 binds well to laminin 1 and to a mixture of laminin 2 and 4 but not to laminin 5. Importantly, alpha 7 beta 1 was capable of promoting motility on both laminin 1 and laminin 2/4 substrates, However, MCF-7 cells transfected with cDNA for either alpha 7A or alpha 7B showed no significant differences in cell adhesion or motility on laminin 1 substrates. Although the role for the alternatively spliced cytoplasmic variants of alpha 7 remains unknown, the results establish that alpha 7 beta 1 mediates cell adhesive activities on a restricted number of laminin isoforms.	UNIV CALIF SAN FRANCISCO,DEPT STOMATOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH DENT,DEPT ANAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Yao, Chung-Chen/D-1470-2018	YAO, JANE CHUNG-CHEN/0000-0002-2293-7000	NATIONAL CANCER INSTITUTE [R01CA033834] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA33834] Funding Source: Medline; NIDCR NIH HHS [R01 DE10306] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAUER JS, 1992, J CELL BIOL, V116, P477, DOI 10.1083/jcb.116.2.477; COLLO G, 1993, J BIOL CHEM, V268, P19019; COOPER HM, 1991, J CELL BIOL, V115, P843, DOI 10.1083/jcb.115.3.843; COOPMAN P, 1991, CLIN EXP METASTAS, V9, P469, DOI 10.1007/BF01785532; DELWEL GO, 1993, J BIOL CHEM, V268, P25865; DELWEL GO, 1995, ADHESION RECEPTORS T; DEWEL GO, 1994, MOL BIOL CELL, V5, P203; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; ENGVALL E, 1990, CELL REGUL, V1, P731, DOI 10.1091/mbc.1.10.731; HOGERVORST F, 1993, J CELL BIOL, V121, P179, DOI 10.1083/jcb.121.1.179; HOGERVORST F, 1991, EUR J BIOCHEM, V199, P425, DOI 10.1111/j.1432-1033.1991.tb16140.x; HOGERVORST F, 1993, J BIOL CHEM, V268, P18427; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MUNAUT C, 1991, CELL BIOL INT REP, V15, P49; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; ROSEN EM, 1991, CANCER RES, V51, P5315; SCHWARTZ MA, 1995, ANN REV CELL DEV BIO, V11, P594; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SHAW LM, 1994, MOL BIOL CELL, V5, P679, DOI 10.1091/mbc.5.6.679; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; TAMURA RN, 1990, J CELL BIOL, V111, P1593, DOI 10.1083/jcb.111.4.1593; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; VANKOOYK Y, 1993, J EXP MED, V177, P185, DOI 10.1084/jem.177.1.185; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; Ziober BL, 1996, SEMIN CANCER BIOL, V7, P119, DOI 10.1006/scbi.1996.0017; ZIOBER BL, 1993, J BIOL CHEM, V268, P26733	34	99	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25598	25603		10.1074/jbc.271.41.25598	http://dx.doi.org/10.1074/jbc.271.41.25598			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810334	hybrid			2022-12-27	WOS:A1996VL69300078
J	Watson, AJ; Aragay, AM; Slepak, VZ; Simon, MI				Watson, AJ; Aragay, AM; Slepak, VZ; Simon, MI			A novel form of the G protein beta subunit G beta(5) is specifically expressed in the vertebrate retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; ALPHA-SUBUNIT; SIGNAL TRANSDUCTION; FAMILY; RECEPTORS; DIVERSITY; BRAIN	The G protein beta subunit, G beta(5), is predominantly expressed in the central nervous system. In rodent brain, G beta(5) is expressed as a protein with an apparent molecular mass of 39,000 daltons (39 kDa). We have identified an additional G beta(5) immunoreactive protein of apparent size 44 kDa in the vertebrate retina, Molecular cloning and sequencing of polymerase chain reaction products revealed that the cDNA encoding the larger species of G beta(5) (G beta(5L)) was identical to the shorter form with the addition of 126 base pairs of 5' DNA sequence potentially encoding an in-frame 42-amino acid extension. Sequencing of mouse G beta(5) genomic clones demonstrated that the 126-base pair of retinal-specific coding material is derived hom a hitherto undetected 5' exon. During sucrose density gradient fractionation of bovine retinas, the 44-kDa G beta(5L) protein co-purified with rod outer segment membranes. Incubation of rod outer segment membranes with the nonhydrolyzable guanine nucleotide, GTP gamma S (guanosine 5'-3-O-(thio)triphosphate), which released the G beta subunit of transducin (G beta(1)), failed to remove G beta(5L). The 39-kDa G beta(5) protein displayed differential association with retinal and brain membranes. In the retina, G beta(5) was present as a soluble protein and was undetectable in the membrane fraction, whereas in the brain approximately 70% of G beta(5) was associated with cellular membranes. In transient COS-7 cell expression experiments, G beta(5L) formed functional G beta gamma dimers and G alpha beta gamma heterotrimers, and activated phosphoinositide-specific phospholipase C beta(2) in a manner indistinguishable from the 39-kDa G beta(2) protein. The cloning of the retinal-specific G beta(5L) cDNA suggests the existence of potentially novel G protein-mediated signaling cascades in photoreception.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology			Aragay, Anna M/K-3813-2014	Aragay, Anna M/0000-0002-8240-4126	NIGMS NIH HHS [GM34236] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034236, R37GM034236] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1994, NATURE, V368, P474, DOI 10.1038/368474a0; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHANG H, 1995, BIOCHEMISTRY-US, V34, P16662; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GHALAYINI AJ, 1991, J NEUROCHEM, V57, P1405, DOI 10.1111/j.1471-4159.1991.tb08307.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KALYANARAMAN S, 1995, BIOCHEM BIOPH RES CO, V216, P126, DOI 10.1006/bbrc.1995.2600; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KEHLENBACH RH, 1994, NATURE, V372, P804; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; ONG OC, 1995, J BIOL CHEM, V270, P8495, DOI 10.1074/jbc.270.15.8495; PENG YW, 1992, P NATL ACAD SCI USA, V89, P10882, DOI 10.1073/pnas.89.22.10882; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Sambrook J., 2002, MOL CLONING LAB MANU; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WATSON JB, 1994, J NEUROSCI RES, V39, P108, DOI 10.1002/jnr.490390113; Watson S., 1994, G PROTEIN LINKED REC; WENSEL TG, 1988, ENZYME DYNAMICS REGU, P102; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WRIGHT AF, 1992, TRENDS GENET, V8, P85, DOI 10.1016/0168-9525(92)90195-A; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141	35	127	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28154	28160		10.1074/jbc.271.45.28154	http://dx.doi.org/10.1074/jbc.271.45.28154			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910430	hybrid			2022-12-27	WOS:A1996VU03300030
J	Guengerich, FP; Yun, CH; Macdonald, TL				Guengerich, FP; Yun, CH; Macdonald, TL			Evidence for a 1-electron oxidation mechanism in N-dealkylation of N,N-dialkylanilines by cytochrome P450 2B1 - Kinetic hydrogen isotope effects, linear free energy relationships, comparisons with horseradish peroxidase, and studies with oxygen surrogates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MICROSOMAL CYTOCHROME-P-450; ENZYMATIC S-OXYGENATION; ELECTRON-TRANSFER; SUBSTITUTED N,N-DIMETHYLANILINES; PURIFIED CYTOCHROME-P-450; ELECTROORGANIC CHEMISTRY; CONTAINING MONOOXYGENASE; RECONSTITUTED SYSTEM; ANODIC-OXIDATION; AMINE OXIDATIONS	Many enzymes catalyze N-dealkylations of alkylamines, including cytochrome P450 (P450) and peroxidase enzymes, Peroxidases, exemplified by horseradish peroxidase (HRP), are generally accepted to catalyze N-dealkylations via 1-electron transfer processes, Several lines of evidence also support a 1-electron mechanism for many P450 reactions, although this view has been questioned in light of reported trends for kinetic hydrogen isotope effects for N-demethylation with a series of 4-substituted N,N-dimethylanilines. No continuous trend for an increase of isotope effects with the electronic parameters of para-substitution was seen for the P450 2B1-catalyzed reactions in this study, The larger value seen with the 4-nitro derivative is consistent with a shift in mechanism due to either a reversible electron transfer step preceding deprotonation or to a hydrogen atom abstraction mechanism, With HRP, the trend is to lower isotope effects with para electron-withdrawing substituents, due to an apparent shift in rate-limiting steps, Biomimetic model high-valent porphyrins showed reduction rates with variously 4-substituted N,N-dialkylanilines that were consistent with a positively charged intermediate; such relationships were not seen for anisole O-demethylation with P450 2B1, In contrast to the case with the NADPH-supported P450 reactions, high deuterium isotope effects (similar to 7) were seen in the N-dealkylations supported by the oxygen surrogate iodosylbenzene. With iodosylbenzene, colored aminium radicals were observed in the oxidations of aminopyrine, N,N-dimethyl-4-aminothioanisole, and 4-methoxy-N,N dimethylaniline. With the latter compound, a substantial intermolecular deuterium isotope effect was observed for N-demethylation. In the N-dealkylation of N-ethyl,N-methylaniline by P450 2B1 (NADPH-supported), the ratio of N-demethylation to N-deethylation was 16, Although it is probably possible for P450s to catalyze amine N-dealkylations via hydrogen atom abstraction when such a course is electronically or sterically favored, we interpret the evidence to favor a 1-electron pathway with N,N-dialkylamines with P450 2B1 as well as HRP and several biomimetic models.	VANDERBILT UNIV,SCH MED,CTR MOL TOXICOL,NASHVILLE,TN 37232; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	Vanderbilt University; University of Virginia	Guengerich, FP (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,221 KIRKLAND HALL,NASHVILLE,TN 37232, USA.			Yun, Chul-Ho/0000-0003-2685-2968	NATIONAL CANCER INSTITUTE [R35CA044353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [CA44353] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABDELMONEM MM, 1975, J MED CHEM, V18, P427, DOI 10.1021/jm00238a021; ASHLEY PL, 1981, MOL PHARMACOL, V19, P146; ATOR MA, 1987, J BIOL CHEM, V262, P1542; AUGUSTO O, 1982, J BIOL CHEM, V257, P1288; BACIOCCHI E, 1990, J CHEM SOC CHEM COMM, P687, DOI 10.1039/c39900000687; BACIOCCHI E, 1994, 4 N AM M INT SOC STU, P264; BERG A, 1979, J BIOL CHEM, V254, P5264; BIEMANN K, 1962, MASS SPECTROMETRY OR, P222; BLAKE RC, 1989, J BIOL CHEM, V264, P3694; BONDON A, 1989, J BIOL CHEM, V264, P1988; BOYD JW, 1980, J AM CHEM SOC, V102, P3856, DOI 10.1021/ja00531a030; Budavari S., 1996, MERCK INDEX, P1132; BURKA LT, 1985, J AM CHEM SOC, V107, P2549, DOI 10.1021/ja00294a057; CASHMAN JR, 1989, MOL PHARMACOL, V36, P497; Chang MS, 1996, BIOCHEMISTRY-US, V35, P464, DOI 10.1021/bi952081v; CORDIS GA, 1994, J CHROMATOGR A, V661, P181, DOI 10.1016/0021-9673(94)85189-1; CORREIA MA, 1995, ARCH BIOCHEM BIOPHYS, V317, P471, DOI 10.1006/abbi.1995.1190; DAVIDSON RS, 1972, J CHEM SOC PERK T 2, P2355, DOI 10.1039/p29720002355; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; DEMONTELLANO PRO, 1989, DRUG METAB REV, V20, P183, DOI 10.3109/03602538909103535; DEMONTELLANO PRO, 1987, ACCOUNTS CHEM RES, V20, P289; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DINNOCENZO JP, 1993, J AM CHEM SOC, V115, P7111, DOI 10.1021/ja00069a007; DUNFORD HB, 1995, XENOBIOTICA, V25, P725, DOI 10.3109/00498259509061888; EKSTROM G, 1987, BIOCHEMISTRY-US, V26, P7348, DOI 10.1021/bi00397a023; Everse J., 1991, PEROXIDASES CHEM BIO, V2; Everse J.E.K.E., 1991, PEROXIDASES CHEM BIO, VI; FLEISCHER EB, 1971, J AM CHEM SOC, V93, P3162, DOI 10.1021/ja00742a012; Furniss B.S., 1978, VOGELS TXB PRACTICAL; GRIFFIN BW, 1980, ARCH BIOCHEM BIOPHYS, V205, P543, DOI 10.1016/0003-9861(80)90137-X; GRIFFIN BW, 1978, BIOCHEMISTRY-US, V17, P2206, DOI 10.1021/bi00604a029; GRILLER D, 1981, J AM CHEM SOC, V103, P619, DOI 10.1021/ja00393a020; GROVES JT, 1980, J AM CHEM SOC, V102, P6375, DOI 10.1021/ja00540a050; Guengerich F. Peter, 1994, P1259; GUENGERICH FP, 1984, J MED CHEM, V27, P1101, DOI 10.1021/jm00375a002; GUENGERICH FP, 1987, J BIOL CHEM, V262, P8459; GUENGERICH FP, 1980, ARCH BIOCHEM BIOPHYS, V205, P365, DOI 10.1016/0003-9861(80)90119-8; GUENGERICH FP, 1990, CRIT REV BIOCHEM MOL, V25, P97; GUENGERICH FP, 1991, J MED CHEM, V34, P1838, DOI 10.1021/jm00110a012; GUENGERICH FP, 1995, BIOCHIMIE, V77, P573, DOI 10.1016/0300-9084(96)88173-9; GUENGERICH FP, 1982, BIOCHEMISTRY-US, V21, P6019, DOI 10.1021/bi00266a045; GUENGERICH FP, 1995, XENOBIOTICA, V25, P689, DOI 10.3109/00498259509061886; GUENGERICH FP, 1984, ACCOUNTS CHEM RES, V17, P9, DOI 10.1021/ar00097a002; GUENGERICH FP, 1990, FASEB J, V4, P2453, DOI 10.1096/fasebj.4.8.2185971; GUSTAFSSON JA, 1979, BIOCHEMISTRY-US, V18, P865, DOI 10.1021/bi00572a020; HALL LR, 1990, J BIOL CHEM, V265, P12349; HANZLIK RP, 1982, J AM CHEM SOC, V104, P2048, DOI 10.1021/ja00371a055; HARADA N, 1984, J BIOL CHEM, V259, P3005; HAWKINS BK, 1992, J AM CHEM SOC, V114, P3547, DOI 10.1021/ja00035a059; HEIMBROOK DC, 1981, BIOCHEM BIOPH RES CO, V99, P530, DOI 10.1016/0006-291X(81)91777-0; HLAVICA P, 1979, BIOCHEM J, V182, P109, DOI 10.1042/bj1820109; HULL LA, 1967, J AM CHEM SOC, V89, P1163, DOI 10.1021/ja00981a023; KADIN SB, 1973, J ORG CHEM, V38, P1348, DOI 10.1021/jo00947a021; KARKI SB, 1995, J AM CHEM SOC, V117, P3657, DOI 10.1021/ja00118a001; KARKI SB, 1995, XENOBIOTICA, V25, P711, DOI 10.3109/00498259509061887; KEDDERIS GL, 1984, J BIOL CHEM, V259, P3663; KENNEDY CH, 1990, J BIOL CHEM, V265, P11425; LEWIS FD, 1980, J AM CHEM SOC, V102, P1751, DOI 10.1021/ja00525a061; LICHTENBERGER F, 1976, BIOCHEM BIOPH RES CO, V70, P939, DOI 10.1016/0006-291X(76)90682-3; Lindsay-Smith J. R., 1976, J CHEM SOC P2, P47; Lindsay-Smith J. R., 1973, J CHEM SOC P2, P206; MACDONALD TL, 1989, BIOCHEMISTRY-US, V28, P2071, DOI 10.1021/bi00431a016; MACDONALD TL, 1982, BIOCHEM BIOPH RES CO, V104, P620, DOI 10.1016/0006-291X(82)90682-9; MACDONALD TL, 1982, J AM CHEM SOC, V104, P2050, DOI 10.1021/ja00371a056; MANSUY D, 1982, TETRAHEDRON LETT, V23, P2781, DOI 10.1016/S0040-4039(00)87457-2; Mariano P, 1993, ADV ELECT T, V3, P191; Marnett L.J., 1986, CYTOCHROME P 450 STR, P29; Marnett Lawrence J., 1995, P49; MCGOWAN JC, 1959, J CHEM SOC, P3103, DOI 10.1039/jr9590003103; MCKILLOP A, 1974, TETRAHEDRON, V30, P1379, DOI 10.1016/S0040-4020(01)97250-3; MCMAHON RE, 1969, J AM CHEM SOC, V91, P3389, DOI 10.1021/ja01040a060; McMurry T. J., 1986, CYTOCHROME P450 STRU, P1; MIWA GT, 1984, J BIOL CHEM, V259, P3000; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; NIWA GT, 1983, J BIOL CHEM, V258, P14445; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; OAE S, 1963, TETRAHEDRON, V19, P1783, DOI 10.1016/S0040-4020(01)99252-X; OAE S, 1985, BIOCHEM BIOPH RES CO, V131, P567, DOI 10.1016/0006-291X(85)91274-4; OKAZAKI O, 1993, J BIOL CHEM, V268, P1546; Ortiz de Montellano PR, 1986, CYTOCHROME P450 STRU, P217; PALMER G, 1992, J BIOL CHEM, V267, P665; PARKER VD, 1991, J AM CHEM SOC, V113, P8778, DOI 10.1021/ja00023a026; ROSENBLATT DH, 1967, J AM CHEM SOC, V89, P1158, DOI 10.1021/ja00981a022; Saltzman H., 1973, ORG SYNTH, P658; SETO Y, 1993, J BIOL CHEM, V268, P9986; SHEA JP, 1983, J AM CHEM SOC, V105, P5451, DOI 10.1021/ja00354a044; SHONO T, 1982, J AM CHEM SOC, V104, P2639, DOI 10.1021/ja00373a053; SHONO T, 1975, J AM CHEM SOC, V97, P4264, DOI 10.1021/ja00848a020; SHRINER RL, 1965, SYSTEMATIC IDENTIFIC, P253; SMYSER BP, 1986, BIOCHEM PHARMACOL, V35, P1719, DOI 10.1016/0006-2952(86)90329-1; STEARNS RA, 1985, J AM CHEM SOC, V107, P4081, DOI 10.1021/ja00299a056; Ullrich V, 1979, Top Curr Chem, V83, P67; WALSH CT, 1979, ENZYMATIC REACTION M; WATANABE Y, 1982, TETRAHEDRON LETT, V23, P533, DOI 10.1016/S0040-4039(00)86881-1; WATANABE Y, 1982, B CHEM SOC JPN, V55, P188, DOI 10.1246/bcsj.55.188; WATANABE Y, 1980, TETRAHEDRON LETT, V21, P3685, DOI 10.1016/S0040-4039(00)78745-4; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZIEGLER DM, 1964, BIOCHEM BIOPH RES CO, V15, P188, DOI 10.1016/0006-291X(64)90322-5	99	138	140	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27321	27329		10.1074/jbc.271.44.27321	http://dx.doi.org/10.1074/jbc.271.44.27321			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910308	hybrid			2022-12-27	WOS:A1996VQ67900026
J	Kritharides, L; Kus, M; Brown, AJ; Jessup, W; Dean, RT				Kritharides, L; Kus, M; Brown, AJ; Jessup, W; Dean, RT			Hydroxypropyl-beta-cyclodextrin-mediated efflux of 7-ketocholesterol from macrophage foam cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CELLULAR CHOLESTEROL EFFLUX; SMOOTH-MUSCLE CELLS; UNESTERIFIED CHOLESTEROL; TRANSPORT; LDL; 25-HYDROXYCHOLESTEROL; ATHEROSCLEROSIS; ESTER; HPLC	Atherosclerosis involves the arterial accumulation of lipid-laden ''foam cells'' containing oxidized and unoxidized sterols and their esters (Mattsson-Hulten, L., Lindmark, H., Diczfalusy, U., Bjorkhem, I., Ottosson, M., Liu, Y., Bondjers, G., and Wiklund, O, (1996) J, Clin, Invest, 97, 461-8), Oxidized sterols are probably critical to atherogenesis because they inhibit cholesterol removal from cells and are cytotoxic. We recently reported that there is deficient induction of cellular cholesterol efflux by apolipoprotein A-I, the main initial acceptor of cellular cholesterol from macrophages loaded in vitro with oxidized low density lipoprotein (Kritharides, L., Jessup, W., Mander, E., and Dean, R. T. (1995) Arterioscler. Thromb. 15, 276-289). There was an even more marked impairment of the release of 7-ketocholesterol which is a major oxysterol in these cells and in human atherosclerotic lesions. Here we show that hydroxypropyl-beta-cyclodextrin can induce selective efflux of 7-ketocholesterol. Efflux of 7-ketocholesterol was time and concentration dependent, and the rate of its removal was 50-fold greater for hydroxypropyl-beta-cyclodextrin than for apolipoprotein A-I. Over a defined range of concentrations (0-5 mg/ml), efflux of 7-ketocholesterol was preferred over that of cholesterol and occurred without cell toxicity. Efflux of free 7-ketocholesterol was associated with decreased intracellular free and esterified 7-ketocholesterol, Hydroxypropyl-beta-cyclodextrin also enhanced efflux of other oxysterols. The physical solubilization of 7-ketocholesterol by the cyclodextrin was much greater than that of cholesterol, in accordance with its differential effects on efflux, These data highlight the importance of extracellular sterol solubilization in the efflux of cellular oxysterols and the mobilization of intracellular free and esterified oxysterol pools in macrophages loaded with oxidized low density lipoprotein. Synthetic sterol-solubilizing agents such as hydroxypropyl-beta-cyclodextrin are thus potential prototypes for the further development of oxysterol-removing agents.			Kritharides, L (corresponding author), HEART RES INST,CELL BIOL UNIT,SYDNEY,NSW,AUSTRALIA.		Kritharides, Leonard/AAQ-2720-2020; Kuś, Marek/V-2023-2019	Kuś, Marek/0000-0002-2767-3251; Dean, Roger Thornton/0000-0002-8859-8902				BARCZA L, 1989, CARBOHYD RES, V192, P103, DOI 10.1016/0008-6215(89)85170-5; Bender M. L., 1978, CYCLODEXTRIN CHEM; BREWSTER ME, 1989, J PARENT SCI TECHN, V43, P231; BROOKS CJW, 1966, BIOCHIM BIOPHYS ACTA, V125, P620, DOI 10.1016/0005-2760(66)90055-5; Brown AJ, 1996, J LIPID RES, V37, P320; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; CLAUDY P, 1991, J THERM ANAL, V37, P2497; FIELDING CJ, 1995, J LIPID RES, V36, P211; FROMMING KH, 1993, EUR J PHARM BIOPHARM, V39, P148; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; GUYTON JR, 1990, AM J PATHOL, V137, P125; HARA H, 1991, J BIOL CHEM, V266, P3080; HODIS HN, 1994, J LIPID RES, V35, P669; HUGHES H, 1994, ARTERIOSCLER THROMB, V14, P1177, DOI 10.1161/01.ATV.14.7.1177; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; JIALAL I, 1991, ARTERIOSCLER THROMB, V11, P482, DOI 10.1161/01.ATV.11.3.482; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAN CC, 1992, BIOCHEMISTRY-US, V31, P1866, DOI 10.1021/bi00121a040; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KILSDONK EPC, 1995, J LIPID RES, V36, P505; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; KRITHARIDES L, 1994, THESIS U SYDNEY; LANGE Y, 1995, J LIPID RES, V36, P1092; LISCUM L, 1992, J LIPID RES, V33, P1239; MAOR I, 1994, J LIPID RES, V35, P803; MATTSSONHULTEN L, 1996, J CLIN INVEST, V97, P461; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; ORAM JF, 1983, J CLIN INVEST, V72, P1611, DOI 10.1172/JCI111120; PETRACK B, 1993, J LIPID RES, V34, P643; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RYE KA, 1990, BIOCHIM BIOPHYS ACTA, V1042, P227, DOI 10.1016/0005-2760(90)90013-N; SHARMA A, 1991, CLIN CHIM ACTA, V199, P129, DOI 10.1016/0009-8981(91)90104-K; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUGIYAMA S, 1995, ARTERIOSCL THROM VAS, V15, P1968, DOI 10.1161/01.ATV.15.11.1968; ZHANG HF, 1990, J LIPID RES, V31, P1361	37	55	57	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27450	27455		10.1074/jbc.271.44.27450	http://dx.doi.org/10.1074/jbc.271.44.27450			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910326	hybrid, Green Submitted			2022-12-27	WOS:A1996VQ67900044
J	Hsu, HHT; Anderson, HC				Hsu, HHT; Anderson, HC			Evidence of the presence of a specific ATPase responsible for ATP-initiated calcification by matrix vesicles isolated from cartilage and bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; CALCIUM DEPOSITION; CA DEPOSITION; GROWTH-PLATE; IN-VITRO; INHIBITION; INVITRO; PROTEINS; MINERALIZATION; MEMBRANE	Accumulating evidence indicates that calcification by isolated mammalian matrix vesicles (MVs) can be initiated by ATP, Since ATP can be hydrolyzed by either a specific ATPase or by nonspecific alkaline phosphatase (ALP), it remains to be established whether ATPase or ALP mediates ATP-initiated Ca and P-i deposition. To support the hypothesis that specific ATPase is responsible for ATP-initiated calcification by MVs isolated from mammalian cartilage and bone, the effects of ATP analogs, ALP substrates, and specific inhibitors on ATP hydrolysis and ATP-initiated calcification were compared between intact MVs and monoclonal antibody affinity-purified MV ALP, ATP analogs such as ADP and AMP exerted marked inhibitory effects on both [gamma-P-32]ATP hydrolysis and ATP-initiated calcification by intact MVs, whereas phosphomonoesters such as beta-glycerophosphate or phosphoethanolamine had no effect, In contrast to intact MVs, purified MV ALP failed to calcify, and its [gamma-P-32]ATP hydrolytic activity was readily inhibited by phosphomonoesters. Additionally, [gamma-P-32]ATP hydrolysis by purified ALP in contrast to that by intact vesicles was completely inhibited by l-tetramisole, a specific inhibitor of ALP, suggesting a loss of specific ATPase during purification. Vanadate inhibition of ATP hydrolysis by purified ALP can be decreased by increasing ATP concentrations, On the contrary, ATP concentrations did not affect vanadate inhibition of ATP hydrolysis by intact MVs if ALP activity was blocked by l-tetramisole, These observations, therefore, suggest that: 1) a portion of [gamma-P-32]ATP hydrolysis by MVs is attributable to a specific ATPase, whereas the remaining activity is due to ALP; and 2) a specific ATPase, but not ALP, is responsible for ATP-dependent Ca- and P-i-depositing activity of MVs isolated from bone or cartilage.			Hsu, HHT (corresponding author), UNIV KANSAS,MED CTR,DEPT LAB MED & PATHOL,3901 RAINBOW BLVD,KANSAS CITY,KS 66160, USA.				NIDCR NIH HHS [DE05262] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005262] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKISAKA T, 1985, J HISTOCHEM CYTOCHEM, V33, P925, DOI 10.1177/33.9.3160764; ALI SY, 1973, BIOCHEM J, V134, P647, DOI 10.1042/bj1340647; ANDERSON HC, 1975, AM J PATHOL, V79, P237; Anderson HC, 1993, HDB EXPT PHARM, P267, DOI DOI 10.1007/978-3-642-77991-6_8; BOSKEY AL, 1994, MICROSC RES TECHNIQ, V28, P492, DOI 10.1002/jemt.1070280605; Bowness J M, 1968, Clin Orthop Relat Res, V59, P233; CARTIER P, 1955, B SOC CHIM BIOL, V37, P1159; CARTIER P, 1955, B SOC CHIM BIOL, V37, P485; CECIL RNA, 1978, METAB BONE DIS RELAT, V1, P89, DOI 10.1016/0221-8747(78)90043-7; CHAUDRY IH, 1982, YALE J BIOL MED, V55, P1; CUERVO LA, 1973, CALC TISS RES, V13, P1, DOI 10.1007/BF02015390; FALLON MD, 1980, LAB INVEST, V43, P489; FARLEY JR, 1982, MINER ELECTROL METAB, V7, P316; GLIMCHER MJ, 1989, ANAT REC, V224, P139, DOI 10.1002/ar.1092240205; HATORI M, 1995, J CELL PHYSIOL, V165, P468, DOI 10.1002/jcp.1041650304; HAUSCHKA PV, 1989, PHYSIOL REV, V69, P990, DOI 10.1152/physrev.1989.69.3.990; HONG KC, 1978, CALC TISS RES, V25, P241, DOI 10.1007/BF02010776; HOWELL DS, 1968, J CLIN INVEST, V47, P1121, DOI 10.1172/JCI105801; HSU HHT, 1992, BIOCHIM BIOPHYS ACTA, V1116, P227, DOI 10.1016/0304-4165(92)90015-M; HSU HHT, 1994, INT J BIOCHEM, V26, P1351, DOI 10.1016/0020-711X(94)90177-5; HSU HHT, 1983, J BIOL CHEM, V258, P3463; HSU HHT, 1993, INT J BIOCHEM, V25, P1737, DOI 10.1016/0020-711X(88)90301-1; HSU HHT, 1992, BONE MINER, V17, P279, DOI 10.1016/0169-6009(92)90751-X; HSU HHT, 1978, P NATL ACAD SCI USA, V75, P3805, DOI 10.1073/pnas.75.8.3805; HSU HHT, 1977, BIOCHIM BIOPHYS ACTA, V500, P162, DOI 10.1016/0304-4165(77)90056-3; HSU HHT, 1988, INT J BIOCHEM, V20, P1285, DOI 10.1016/0020-711X(88)90233-9; KRAUSFRIEDMANN N, 1982, EUR J BIOCHEM, V129, P7, DOI 10.1111/j.1432-1033.1982.tb07014.x; KRISHNA G, 1968, J PHARMACOL EXP THER, V163, P379; LIN SH, 1985, J BIOL CHEM, V260, P7850; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBEN RA, 1976, ENDOCRINOLOGY, V99, P526, DOI 10.1210/endo-99-2-526; MARTIN JB, 1949, ANAL CHEM, V21, P965, DOI 10.1021/ac60032a024; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; POLLESELLO P, 1991, BIOCHEM BIOPH RES CO, V180, P216, DOI 10.1016/S0006-291X(05)81279-3; Rapoport S, 1938, J BIOL CHEM, V126, P749; Robison R, 1923, BIOCHEM J, V17, P286, DOI 10.1042/bj0170286; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; SKILLEN AW, 1980, CALCIFIED TISSUE INT, V30, P67, DOI 10.1007/BF02408608; VANBELLE H, 1972, BIOCHIM BIOPHYS ACTA, V289, P158, DOI 10.1016/0005-2744(72)90118-0	39	49	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26383	26388		10.1074/jbc.271.42.26383	http://dx.doi.org/10.1074/jbc.271.42.26383			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824294	hybrid			2022-12-27	WOS:A1996VN18000100
J	Hu, YH; Bloomquist, BT; Cornfield, LJ; DeCarr, LB; FloresRiveros, JR; Friedman, L; Jiang, PL; LewisHiggins, L; Sadlowski, Y; Schaefer, J; Velazquez, N; McCaleb, ML				Hu, YH; Bloomquist, BT; Cornfield, LJ; DeCarr, LB; FloresRiveros, JR; Friedman, L; Jiang, PL; LewisHiggins, L; Sadlowski, Y; Schaefer, J; Velazquez, N; McCaleb, ML			Identification of a novel hypothalamic neuropeptide Y receptor associated with feeding behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PEPTIDE-YY; PANCREATIC-POLYPEPTIDE; CHOLECYSTOKININ RECEPTOR; PARAVENTRICULAR NUCLEUS; MOLECULAR-CLONING; FOOD-INTAKE; NPY; STIMULATION; Y1-RECEPTOR	Neuropeptide Y (NPY) plays important roles in the central control of appetite and energy balance, but the receptor subtype responsible for this function has not been cloned. Here we report the cloning by expression of a novel NPY receptor subtype from a rat hypothalamus cDNA library. The novel receptor, referred to as the NPY Y5 receptor, has a transcript of approximately 2.6 kilobases with an open reading frame of 1335 base pairs that encodes a 445-amino acid protein. The amino acid sequence deduced from the rat Y5 cDNA clone shows only 30-33% identity to other NPY receptors, including Y1, Y2, and Y4/PP1, Using the rat Y5 receptor cDNA probe, the human homologue was obtained by low stringency hybridization. The human Y5 amino acid sequence has 88% identity to the rat Y5 receptor. Importantly, pharmacological analysis shows that the rat and human Y5 receptors have high affinity for the peptides that elicit feeding (e.g, NPY, PYY, (2-36)NPY, and (LP)NPY) and low affinity for nonstimulating peptides (e.g. (13-36)NPY and rat PP), suggesting that it is the NPY feeding receptor subtype.			Hu, YH (corresponding author), BAYERS CORP,INST METAB DISORDERS,W HAVEN,CT 06516, USA.							AICHER SA, 1991, NEUROSCI LETT, V130, P32, DOI 10.1016/0304-3940(91)90220-N; BALASUBRAMANIAM A, 1994, J MED CHEM, V37, P811, DOI 10.1021/jm00032a015; BALL HJ, 1995, J BIOL CHEM, V270, P27272, DOI 10.1074/jbc.270.45.27272; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; Gregor P, 1996, FEBS LETT, V381, P58, DOI 10.1016/0014-5793(96)00067-1; Grundemar L., 1993, BIOL NEUROPEPTIDE RE, P197, DOI [10.1007/978-1-59259-465-8_5, DOI 10.1007/978-1-59259-465-8_5]; JOLICOEUR FB, 1991, BRAIN RES BULL, V26, P309, DOI 10.1016/0361-9230(91)90243-D; KALRA SP, 1991, PHYSIOL BEHAV, V50, P5, DOI 10.1016/0031-9384(91)90490-F; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEIBOWITZ SF, 1991, PEPTIDES, V12, P1251, DOI 10.1016/0196-9781(91)90203-2; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; Lundell I, 1996, P NATL ACAD SCI USA, V93, P5111, DOI 10.1073/pnas.93.10.5111; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; MCCARTHY HD, 1991, LIFE SCI, V49, P1491, DOI 10.1016/0024-3205(91)90049-H; MCLAUGHLIN CL, 1991, PHYSIOL BEHAV, V49, P521, DOI 10.1016/0031-9384(91)90274-R; NAKAJIMA M, 1994, J PHARMACOL EXP THER, V268, P1010; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; RUDOLF K, 1994, EUR J PHARMACOL, V271, pR11, DOI 10.1016/0014-2999(94)90822-2; Stanley B.G., 1993, BIOL NEUROPEPTIDE RE, P457, DOI [10.1007/978-1-59259-465-8_11, DOI 10.1007/978-1-59259-465-8_11]; STANLEY BG, 1985, PEPTIDES, V6, P1205, DOI 10.1016/0196-9781(85)90452-8; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; STANLEY BG, 1984, LIFE SCI, V35, P2635, DOI 10.1016/0024-3205(84)90032-8; WAHLESTEDT C, 1993, SCIENCE, V259, P528, DOI 10.1126/science.8380941; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; Yan H, 1996, P NATL ACAD SCI USA, V93, P4661, DOI 10.1073/pnas.93.10.4661	31	211	231	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26315	26319		10.1074/jbc.271.42.26315	http://dx.doi.org/10.1074/jbc.271.42.26315			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824284	hybrid			2022-12-27	WOS:A1996VN18000090
J	Kobayashi, J; ApplebaumBowden, D; Dugi, KA; Brown, DR; Kashyap, VS; Parrott, C; Duarte, C; Maeda, N; SantamarinaFojo, S				Kobayashi, J; ApplebaumBowden, D; Dugi, KA; Brown, DR; Kashyap, VS; Parrott, C; Duarte, C; Maeda, N; SantamarinaFojo, S			Analysis of protein structure-function in vivo - Adenovirus-mediated transfer of lipase lid mutants in hepatic lipase-deficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LIPOPROTEIN-LIPASE; HIGH-DENSITY-LIPOPROTEIN; SITE-DIRECTED MUTAGENESIS; PANCREATIC LIPASE; HUMAN-PLASMA; INTERFACIAL ACTIVATION; TRIGLYCERIDE LIPASE; CATALYTIC SITE; GENE; SEQUENCE	Hepatic lipase (HL) and lipoprotein lipase (LPL) are key enzymes involved in the hydrolysis of triglycerides and phospholipids present in circulating plasma lipoproteins. Despite their similarities, the role that each of these two lipases play in the metabolism of triglyceride-rich lipoproteins and high density lipoproteins is distinct. In order to identify structural domains that may confer the different substrate specificities between HL and LPL, we have utilized a novel approach for performing structure-function analysis of a protein, in vivo, by using recombinant adenovirus vectors to express native and mutant enzymes in an animal model for a human genetic deficiency, HL-deficient mice (n = 19) characterized by increased plasma cholesterol and phospholipid concentrations were injected with adenovirus expressing luciferase (rLucif-AdV), native hepatic (rHL-AdV), and lipoprotein lipase (rLPL-AdV) or lipase mutants in which the lid covering the catalytic site of either enzyme was exchanged (rHL+LPL lid-AdV and rLPL+HL lid-AdV). Mice injected with rLucif-AdV had no changes in post-heparin HL and LPL activities (217 +/- 29 and 7 +/- 2 nmol/min/ml, respectively) as well as plasma lipids. Despite expression of similar levels of post-heparin plasma lipase activity on day 5 post-adenovirus infusion (9806 +/- 915 and 9677 +/- 2033 nmol/min/ml, respectively) mice injected with rHL-AdV or rHL+LPL lid-AdV demonstrated marked differences in the reduction of plasma phospholipids (70% and 32%, respectively, p < 0.005), Similarly, despite post-heparin plasma lipolytic activities of 4495 +/- 534 and 4844 +/- 1336 nmol/min/ml, injection of rLPL-AdV or rLPL+HL lid-AdV resulted in phospholipid reductions of 31% and 81% (p < 0.005). Exchange of the lipase lid did not significantly alter plasma triglyceride concentrations. Thus, preferential in vivo hydrolysis of phospholipids was demonstrated in animals expressing lipases containing the HL lid but not the LPL lid. These studies identify the lipase lid as a major structural motif responsible for conferring the different in vivo phospholipase activities between HL and LPL, a function which may modulate the distinct physiological roles of these two similar lipolytic enzymes in lipoprotein metabolism. The use of recombinant adenovirus to express mutant proteins in animal models for human genetic deficiencies represents a powerful, new approach for performing structure-function analysis of proteins in vivo.	NHLBI,MOL DIS BRANCH,NIH,BETHESDA,MD 20892; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27599	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Kashyap, Vikram/0000-0003-1780-979X				ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; BOURNE Y, 1994, J MOL BIOL, V238, P709, DOI 10.1006/jmbi.1994.1331; BREWER HB, 1995, ENDOCRINOLOGY, P2731; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; BRZOZOWSKI AM, 1991, NATURE, V351, P491, DOI 10.1038/351491a0; BURSTEIN M, 1970, J LIPID RES, V11, P583; DATTA S, 1988, J BIOL CHEM, V263, P1107; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DAVIS RC, 1990, J BIOL CHEM, V265, P6291; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; DEMANT T, 1988, J LIPID RES, V29, P1603; DEREWENDA U, 1992, BIOCHEMISTRY-US, V31, P1532, DOI 10.1021/bi00120a034; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; DUGI KA, 1992, J BIOL CHEM, V267, P25086; EHNHOLM C, 1975, J BIOL CHEM, V250, P6756; EMMERICH J, 1992, J BIOL CHEM, V267, P4161; FAUSTINELLA F, 1991, J BIOL CHEM, V266, P9481; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; GLOMSET JA, 1968, J LIPID RES, V9, P155; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HIDE WA, 1992, J LIPID RES, V33, P167; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KOPFLER WP, 1994, CIRCULATION, V90, P1319, DOI 10.1161/01.CIR.90.3.1319; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; NICOLL A, 1980, EUR J CLIN INVEST, V10, P487, DOI 10.1111/j.1365-2362.1980.tb02090.x; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; Santamarina-Fojo S., 1992, CURR OPIN LIPIDOL, V3, P186; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; TALL AR, 1993, J LIPID RES, V34, P1255; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTOL A, 1980, BIOCHEM BIOPH RES CO, V94, P101, DOI 10.1016/S0006-291X(80)80193-8; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907	44	30	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26296	26301		10.1074/jbc.271.42.26296	http://dx.doi.org/10.1074/jbc.271.42.26296			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824281				2022-12-27	WOS:A1996VN18000087
J	Offermanns, S; Hu, YH; Simon, MI				Offermanns, S; Hu, YH; Simon, MI			G alpha(12) and G alpha(13) are phosphorylated during platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HETEROTRIMERIC G-PROTEINS; SIGNAL TRANSDUCTION; ALPHA-SUBUNITS; ADENYLATE-CYCLASE; CELLS; PURIFICATION; SPECIFICITY; INHIBITION; ISOENZYMES	The ubiquitously expressed G-proteins G(12) and G(13) whose function is currently not clear have been shown to be activated in platelet membranes through receptors that stimulate platelet aggregation. We used intact human platelets to determine whether alpha subunits of both G-proteins can be phosphorylated under physiological conditions, Activation of human platelets by thrombin and the thromboxane A(2) receptor agonist U46619 lead to phosphorylation of G alpha(12) and G alpha(13). Phosphorylation occurred rapidly after addition of thrombin and was not mediated by glycoprotein IIb/IIIa (integrin alpha(IIb)beta(3)) activation, Phosphorylation of G alpha(12) and G alpha(13) could be mimicked by phorbol 12-myristate 13-acetate, and thrombin-induced phosphorylation was inhibited by the protein kinase C inhibitor calphostin C indicating an involvement of protein kinase C in G alpha(12/13) phosphorylation in duced by thrombin in human platelets, The phosphorylation of both G protein alpha subunits was reconstituted in COS-7 cells cotransfected with G alpha(12) or G alpha(12) and different protein kinase C isoforms, Among the protein knase C isoforms tested, protein kinase C beta, delta, and epsilon were most effective in promoting phosphorylation of G alpha(12) and G alpha(13) in a phorbol 12-myristate 13-acetate-dependent maimer. These data demonstrate that G alpha(12) and G alpha(13) are phosphorylated under in vivo conditions and that this phosphorylation involves protein kinase C.	CALTECH,DEPT BIOL 14775,PASADENA,CA 91125	California Institute of Technology			Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805				BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; GRABAREK J, 1992, J BIOL CHEM, V267, P10011; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HOUSLAY MD, 1991, CELL SIGNAL, V3, P1, DOI 10.1016/0898-6568(91)90002-C; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KHAN WA, 1993, J BIOL CHEM, V268, P5063; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LOUNSBURY KM, 1991, J BIOL CHEM, V266, P22051; LOUNSBURY KM, 1993, J BIOL CHEM, V268, P3494; MORII N, 1992, J BIOL CHEM, V267, P20921; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; PFEIFER A, 1995, J BIOL CHEM, V270, P9052, DOI 10.1074/jbc.270.16.9052; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SCHUBERT R, 1990, COMPUT METH PROG BIO, V33, P93, DOI 10.1016/0169-2607(90)90065-H; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SINGER WD, 1994, J BIOL CHEM, V269, P19796; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STRASSHEIM D, 1994, J BIOL CHEM, V269, P14307; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WU DQ, 1992, J BIOL CHEM, V267, P25798	33	38	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26044	26048		10.1074/jbc.271.42.26044	http://dx.doi.org/10.1074/jbc.271.42.26044			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824244	hybrid			2022-12-27	WOS:A1996VN18000050
J	Kotanides, H; Reich, NC				Kotanides, H; Reich, NC			Interleukin-4-induced STAT6 recognizes and activates a target site in the promoter of the interleukin-4 receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JAK-3 JANUS KINASE; GAMMA-CHAIN; TRANSCRIPTION FACTOR; IL-2 RECEPTOR; DNA-BINDING; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; FUNCTIONAL-ANALYSIS; INTERFERON-GAMMA; CELLS	This study addresses the function of STAT6 in interleukin-4-stimulated gene expression. A specific STAT6 DNA-binding target site has been identified in the promoter of the interleukin-4 receptor gene, and STAT6 is shown to be involved in mediating activation of gene expression via this site. STAT6 can mediate transcription of a heterologous reporter gene construct containing the interleukin-4 receptor STAT6 binding site. In addition, evidence is provided that demonstrates a distinct effect of STAT6 DNA binding specificity on transcriptional regulation since transcription was not stimulated from a competent but different DNA binding site. To confirm the role of STAT6 in gene activation, STAT6 mutant proteins were generated and analyzed for their ability to function in interleukin-4-induced transcription. Although the interleukin-2 gamma chain receptor subunit has been demonstrated to be a component of the interleukin-4 receptor, it is not required for specific gene activation.	SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, GRAD PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA050773, R29CA050773] Funding Source: NIH RePORTER; NCI NIH HHS [CA50773] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHT B, 1994, INT IMMUNOL, V6, P1143, DOI 10.1093/intimm/6.8.1143; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DALY C, 1994, TRENDS ENDOCRIN MET, V5, P159, DOI 10.1016/1043-2760(94)90013-2; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; DEWIT H, 1994, BLOOD, V84, P608; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOKTER WHA, 1992, BLOOD, V80, P2721; GILMOUR KC, 1995, GENE EXPRESSION, V5, P1; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GUTCH MJ, 1993, THESIS STATE U NEW Y; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOWARD M, 1982, J EXP MED, V155, P914, DOI 10.1084/jem.155.3.914; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOND JJ, 1986, J IMMUNOL, V137, P3534; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; OHARA J, 1988, P NATL ACAD SCI USA, V85, P8221, DOI 10.1073/pnas.85.21.8221; PAUL WE, 1991, BLOOD, V77, P1859; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; PURKERSON J, 1992, FASEB J, V6, P3245, DOI 10.1096/fasebj.6.14.1385241; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SUTER U, 1989, J IMMUNOL, V143, P3087; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VELDE AAT, 1990, J IMMUNOL, V144, P3046; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	59	92	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25555	25561		10.1074/jbc.271.41.25555	http://dx.doi.org/10.1074/jbc.271.41.25555			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810328	hybrid			2022-12-27	WOS:A1996VL69300072
J	Patel, RC; Stanton, P; Sen, GC				Patel, RC; Stanton, P; Sen, GC			Specific mutations near the amino terminus of double-stranded RNA-dependent protein kinase (PKR) differentially affect its double-stranded RNA binding and dimerization properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION-FACTOR EIF-2; NF-KAPPA-B; INTERFERON ACTION; MESSENGER-RNAS; ALPHA-SUBUNIT; REV PROTEIN; P68 KINASE; FACTOR-II; IN-VIVO; DOMAIN	The amino-terminal region of the double-stranded (ds) RNA-dependent protein kinase, PKR, has been shown to mediate both dsRNA binding and protein dimerization, To critically examine if PKR dimerization is dependent on dsRNA binding, we generated a series of mutants that are incapable of binding dsRNA. Some, but not all, of these mutants retained the ability to dimerize, as shown by a two-hybrid transcriptional activation assay in vivo and a chemical cross-linking assay in vitro. These mutants were used further to demonstrate that the translational inhibitory activity of PKR in vivo requires dsRNA binding; PKR mutants that dimerized but did not bind dsRNA could not inhibit the translation of a transfected reporter gene.	CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Patel, Rekha/M-7123-2015	Patel, Rekha/0000-0001-9434-4880	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NCI NIH HHS [CA-68782, CA-62220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBER GN, 1992, VIROLOGY, V191, P670, DOI 10.1016/0042-6822(92)90242-H; BISCHOFF JR, 1985, J BIOL CHEM, V260, P8237; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COLTHURST DR, 1987, EUR J BIOCHEM, V166, P357, DOI 10.1111/j.1432-1033.1987.tb13523.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1987, EUR J BIOCHEM, V167, P467, DOI 10.1111/j.1432-1033.1987.tb13360.x; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; JUDAWARE R, 1991, MOL CELL BIOL, V11, P3259; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; KATZE MG, 1992, J INTERFERON RES, V12, P241, DOI 10.1089/jir.1992.12.241; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; OLSEN HS, 1990, GENE DEV, V4, P1357, DOI 10.1101/gad.4.8.1357; Ortega LG, 1996, VIROLOGY, V215, P31, DOI 10.1006/viro.1996.0004; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1994, J BIOL CHEM, V269, P18593; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SONENBERG N, 1990, New Biologist, V2, P402; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; ZAPP ML, 1991, P NATL ACAD SCI USA, V88, P7734, DOI 10.1073/pnas.88.17.7734; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	49	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25657	25663		10.1074/jbc.271.41.25657	http://dx.doi.org/10.1074/jbc.271.41.25657			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810342	hybrid			2022-12-27	WOS:A1996VL69300086
J	Slater, JE; Vedvick, T; ArthurSmith, A; Trybul, DE; Kekwick, RGO				Slater, JE; Vedvick, T; ArthurSmith, A; Trybul, DE; Kekwick, RGO			Identification, cloning, and sequence of a major allergen (Hev b 5) from natural rubber latex (Hevea brasiliensis)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEALTH-CARE WORKERS; ELONGATION-FACTOR; CROSS-REACTIVITY; SPINA-BIFIDA; PROTEINS; ANTIGENS; HYPERSENSITIVITY; PURIFICATION; IGE; PROPHYLAXIS	Proteins in commercial latex products, derived from the rubber tree Hevea brasiliensis, cause anaphylaxis in susceptible individuals, especially health care workers and children with spina bifida. To identify latex allergens, we utilized IgE from the serum of a latex-allergic health care worker to screen a cDNA Library from Hevea latex. The identified cDNA clone, cDNA Hev b 5, encodes an open reading frame of 163 peptide residues. Hybridization analysis of cDNA Hev b 5 with RNA extracted from Hevea tissue indicates that the full-length transcript is about 1000 bases. The nucleotide and deduced protein sequences have significant homology to sequences from kiwi and potato, which are known to cause allergic reactions in some latex-allergic patients. Fifty-six percent of spina bifida patients and 924 of health care workers with latex allergy have IgE specific to the protein encoded by cDNA Rev b 5. A monoclonal antibody raised from a mouse immunized with Hev b 5 binds to a protein in Hevea latex with an M(r) identical to that of the expressed and cleaved recombinant protein. Taken together, these results establish that the antigen Hev b 5 contains a major epitope for IgE-mediated reactions to H. brasiliensis latex products.	CORIXA CORP,SEATTLE,WA 98104; UNIV BIRMINGHAM,SCH BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Corixa; University of Birmingham	Slater, JE (corresponding author), CHILDRENS NATL MED CTR,CHILDRENS RES INST,CTR MOL MECH DIS RES,111 MICHIGAN AVE,NW,WASHINGTON,DC 20010, USA.				NIAID NIH HHS [AI 29428] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI029428] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKASAWA A, 1995, J ALLERGY CLIN IMMUN, V95, P1196, DOI 10.1016/S0091-6749(95)70076-5; Akasawa A, 1996, J ALLERGY CLIN IMMUN, V97, P1116, DOI 10.1016/S0091-6749(96)70266-X; ALENIUS H, 1994, J ALLERGY CLIN IMMUN, V93, P859, DOI 10.1016/0091-6749(94)90378-6; ALENIUS H, 1993, INT ARCH ALLERGY IMM, V102, P61, DOI 10.1159/000236551; ALENIUS H, 1995, INT ARCH ALLERGY IMM, V106, P258, DOI 10.1159/000236851; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; ATTANYAKA DPSTG, 1991, PLANT MOL BIOL, V16, P1079, DOI 10.1007/BF00016080; AUBERTFOUCHER E, 1992, J BIOL CHEM, V267, P15759; BEEZHOLD DH, 1994, CLIN EXP IMMUNOL, V98, P408; Beezhold DH, 1996, CLIN EXP ALLERGY, V26, P416, DOI 10.1046/j.1365-2222.1996.d01-334.x; BEUERS U, 1990, LANCET, V335, P1095, DOI 10.1016/0140-6736(90)92664-4; BLANCO C, 1994, ANN ALLERGY, V73, P309; BONNEKOH B, 1992, JAMA-J AM MED ASSOC, V267, P2603, DOI 10.1001/jama.267.19.2603; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CZUPPON AB, 1993, J ALLERGY CLIN IMMUN, V92, P690, DOI 10.1016/0091-6749(93)90012-5; DENNIS MS, 1989, J BIOL CHEM, V264, P18618; Dillard SF, 1992, INT LATEX C SENSITIV, P23; DOMPMARTIN A, 1994, CONTACT DERMATITIS, V30, P250, DOI 10.1111/j.1600-0536.1994.tb00662.x; GELB L, 1991, FDA MED ALERT MDA, V91, P1; HELFMAN DM, 1983, P NATL ACAD SCI-BIOL, V80, P31, DOI 10.1073/pnas.80.1.31; JEKEL PA, 1991, EUR J BIOCHEM, V200, P123, DOI 10.1111/j.1432-1033.1991.tb21057.x; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P9627, DOI 10.1093/nar/15.23.9627; Kekwick RGO, 1989, PHYSL RUBBER TREE LA, P145; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KURUP VP, 1993, J ALLERGY CLIN IMMUN, V91, P1128, DOI 10.1016/0091-6749(93)90314-6; KWITTKEN PL, 1992, ALLERGY PROC, V13, P123, DOI 10.2500/108854192778878782; LEDGER SE, 1994, PLANT MOL BIOL, V25, P877, DOI 10.1007/BF00028882; LEE H, 1991, J BIOL CHEM, V266, P15944; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; LU LJ, 1995, ALLERGY, V50, P545, DOI 10.1111/j.1398-9995.1995.tb01197.x; MAKINENKILJUNEN S, 1992, J ALLERGY CLIN IMMUN, V90, P230, DOI 10.1016/0091-6749(92)90076-E; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Rasmussen H B, 1993, APMIS Suppl, V39, P1; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Schultz D. J., 1994, Plant Molecular Biology Reporter, V12, P310, DOI 10.1007/BF02669273; SETLOCK MA, 1993, ANESTH ANALG, V76, P650; Shi Q., 1990, GEL ELECTROPHORESIS; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SLATER JE, 1989, NEW ENGL J MED, V320, P1126, DOI 10.1056/NEJM198904273201707; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V94, P139, DOI 10.1016/0091-6749(94)90031-0; SLATER JE, 1994, J ALLERGY CLIN IMMUN, V93, P644, DOI 10.1016/S0091-6749(94)70076-1; SLATER JE, 1995, J ALLERGY CLIN IMMUN, V95, P157; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; STCYR DR, 1992, ENCY CHEM TECHNOLOGY, P468; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; YEANG HY, 1996, IN PRESS J ALLERGY C	52	101	103	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25394	25399		10.1074/jbc.271.41.25394	http://dx.doi.org/10.1074/jbc.271.41.25394			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810306	hybrid			2022-12-27	WOS:A1996VL69300050
J	Sharma, S; Gopinathan, KP				Sharma, S; Gopinathan, KP			Transcriptional silencing of a tRNA(1)(Gly) copy from within a multigene family is modulated by distal cia elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENE; STABLE COMPLEX-FORMATION; 5' FLANKING REGION; 5'-FLANKING SEQUENCES; INVITRO TRANSCRIPTION; BOMBYX-MORI; POLYMERASE-III; EXPRESSION; SILKWORM; UPSTREAM	Individual copies of tRNA(1)(Gly) from within the multigene family in Bombyx mori could be classified based on in vitro transcription in homologous nuclear extracts into three categories of highly, moderately, or weakly transcribed genes, Segregation of the poorly transcribed gene copies 6 and 7, which are clustered in tandem within 425 base pairs, resulted in enhancement of their individual transcription levels, but the linkage itself had little influence on the transcriptional status, For these gene copies, when fused together generating a single coding region, transcription was barely detectable, which suggested the presence of negatively regulating elements located in the far flanking sequences. They exerted the silencing effect on transcription overriding the activity of positive regulatory elements. Systematic analysis of deletion, chimeric, and mutant constructs revealed the presence of a sequence element TATATAA located beyond 800 nucleotides upstream to the coding region acting as negative modulator, which when mutated resulted in high level transcription. Conversely, a TATATAA motif reintroduced at either far upstream or far downstream flanking regions exerted a negative effect on transcription. The location of cis-regulatory sequences at such farther distances from the coding region and the behavior of TATATAA element as negative regulator reported here are novel. These element(s) could play significant roles in activation or silencing of genes from within a multigene family, by recruitment or sequestration of transcription factors.	INDIAN INST SCI,DEPT MICROBIOL & CELL BIOL,BANGALORE 560012,KARNATAKA,INDIA; INDIAN INST SCI,CTR GENET ENGN,BANGALORE 560012,KARNATAKA,INDIA	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore								ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; ARNOLD GJ, 1988, DNA-J MOLEC CELL BIO, V7, P87, DOI 10.1089/dna.1988.7.87; CARBON P, 1991, EMBO J, V10, P599, DOI 10.1002/j.1460-2075.1991.tb07987.x; DEFRANCO D, 1981, J BIOL CHEM, V256, P2424; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; FOURNIER A, 1979, BIOCHIMIE, V61, P283, DOI 10.1016/S0300-9084(79)80073-5; FOURNIER A, 1993, GENE, V134, P183, DOI 10.1016/0378-1119(93)90092-H; GALLI G, 1981, NATURE, V294, P626, DOI 10.1038/294626a0; GAREL JP, 1976, NATURE, V260, P805, DOI 10.1038/260805a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; HIPSKIND RA, 1983, CELL, V34, P881, DOI 10.1016/0092-8674(83)90545-7; HOFSTETTER H, 1981, CELL, V24, P573, DOI 10.1016/0092-8674(81)90348-2; HUIBREGTSE JM, 1989, MOL CELL BIOL, V9, P3244, DOI 10.1128/MCB.9.8.3244; JOHNSON JD, 1984, J BIOL CHEM, V259, P5990; LARSON D, 1983, P NATL ACAD SCI-BIOL, V80, P3416, DOI 10.1073/pnas.80.11.3416; LEVEILLARD T, 1993, J BIOL CHEM, V268, P3594; MORRY MJ, 1986, MOL CELL BIOL, V6, P105, DOI 10.1128/MCB.6.1.105; PATEL CV, 1991, INDIAN J BIOCHEM BIO, V28, P521; RAYMOND KC, 1985, EMBO J, V4, P2649, DOI 10.1002/j.1460-2075.1985.tb03983.x; ROONEY RJ, 1988, NUCLEIC ACIDS RES, V16, P2509, DOI 10.1093/nar/16.6.2509; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAACK J, 1984, J BIOL CHEM, V259, P1461; SCHMUTZLER C, 1990, NUCLEIC ACIDS RES, V18, P5001, DOI 10.1093/nar/18.17.5001; Sharma S, 1996, J MOL BIOL, V262, P396, DOI 10.1006/jmbi.1996.0523; SHAW KJ, 1984, MOL CELL BIOL, V4, P657, DOI 10.1128/MCB.4.4.657; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; TANEJA R, 1992, P NATL ACAD SCI USA, V89, P1070, DOI 10.1073/pnas.89.3.1070; TAPPING RI, 1993, NUCLEIC ACIDS RES, V21, P4476, DOI 10.1093/nar/21.19.4476; WHITE RJ, 1994, RNA POLYMERASE 3 TRA; YOUNG LS, 1986, P NATL ACAD SCI USA, V83, P374, DOI 10.1073/pnas.83.2.374	30	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28146	28153		10.1074/jbc.271.45.28146	http://dx.doi.org/10.1074/jbc.271.45.28146			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910429	hybrid			2022-12-27	WOS:A1996VU03300029
J	Gregor, P; Feng, Y; DeCarr, LB; Cornfield, LJ; McCaleb, ML				Gregor, P; Feng, Y; DeCarr, LB; Cornfield, LJ; McCaleb, ML			Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-Y RECEPTOR; PROTEIN-COUPLED RECEPTOR; PEPTIDE-YY; FUNCTIONAL EXPRESSION; PLASMA-MEMBRANE; CLONING; BINDING; GLUCAGON; SUBTYPE; FAMILY	The family of mammalian neuropeptide Y (NPY)/peptide YY (PW)/pancreatic polypeptide (PP) receptors comprises several G protein-coupled receptors, i.e. Y1, Y2, and Y4/PP1. We now report cloning of a novel member of this family named PP2, The coding region of the mouse PP2 gene reveals no introns and predicts a seven transmembrane domain (TM) receptor of 371 amino acids, Percent identities of the mouse PP2 to mouse Y1, mouse Y4/PP1 and human Y2 receptors are 53, 42, and 31, respectively, The mouse PP2 receptor expressed in COS cells binds rat I-125-PP With high affinity, i.e. IC50 = 65 pM. Pharmacological characterization of I-125-PP binding shows a rank order of potency of PP much greater than PYY greater than or equal to NPY, which is similar to that of the mouse Y4/PP1 receptor. Mouse PP2 transcripts were not detectable by Northern analysis ill adult tissues and in 11-, 15-, and 17-day-old embryos. However, a 9.8-kb PP2 transcript was detectable in 7-day-old mouse embryo, i.e. prior to the organogenesis of pancreas and the onset of PP production. We have also cloned the human homologue of PP2, which is a single copy gene and maps to human chromosome 5q31. Surprisingly, the human PP2 cDNAs and gene sequences display a single base deletion in the coding region. This frameshifting mutation predicts a truncated receptor of 290 amino acids without TM7. Transfection of COS-7 cells with several different human PP2 expression constructs failed to confirm any specific binding of I-125-PP, I-125-PYY, Or I-125-NPY to cell membranes. These data suggest that in mouse there are at least tyro PP receptors, Y4/PP1 and PP2, whereas in humans, PP2 is either functionally inactive or it has acquired a PP-independent function.			Gregor, P (corresponding author), BAYER CORP,DIV PHARMACEUT,METAB DISORDERS RES,B-24,400 MORGAN LANE,W HAVEN,CT 06516, USA.							BALLANTYNE GH, 1993, AM J PHYSIOL, V264, pG848, DOI 10.1152/ajpgi.1993.264.5.G848; BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; COX H, 1993, BIOL NEUROPEPTIDE Y, P197; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DUMONT Y, 1992, PROG NEUROBIOL, V38, P125, DOI 10.1016/0301-0082(92)90038-G; EVA C, 1990, FEBS LETT, V271, P80; Gehlert DR, 1996, MOL PHARMACOL, V49, P224; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; Gregor P, 1996, FEBS LETT, V381, P58, DOI 10.1016/0014-5793(96)00067-1; Grundemar L., 1993, BIOL NEUROPEPTIDE RE, P197, DOI [10.1007/978-1-59259-465-8_5, DOI 10.1007/978-1-59259-465-8_5]; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HAZELWOOD RL, 1993, P SOC EXP BIOL MED, V202, P44; HERRERA PL, 1994, P NATL ACAD SCI USA, V91, P12999, DOI 10.1073/pnas.91.26.12999; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LI XJ, 1992, J BIOL CHEM, V267, P9; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; Maniatis T, 1989, DECONTAMINATION DILU; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NGUYEN TD, 1995, AM J PHYSIOL-GASTR L, V268, pG215, DOI 10.1152/ajpgi.1995.268.2.G215; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OKUMURA T, 1995, GASTROENTEROLOGY, V108, P1517, DOI 10.1016/0016-5085(95)90702-5; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; Rimland JM, 1996, MOL PHARMACOL, V49, P387; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; SCHONEBERG T, 1995, J BIOL CHEM, V270, P18000; Sundler F., 1993, BIOL NEUROPEPTIDE Y, P157, DOI [10.1007/978-1-59259-465-8, DOI 10.1007/978-1-59259-465-8]; TEITELMAN G, 1993, DEVELOPMENT, V118, P1031; UNSON CG, 1995, J BIOL CHEM, V270, P27720, DOI 10.1074/jbc.270.46.27720; UPCHURCH BH, 1994, DEVELOPMENT, V120, P245; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; WHITCOMB DC, 1990, AM J PHYSIOL, V259, pG687, DOI 10.1152/ajpgi.1990.259.4.G687; Yan H, 1996, P NATL ACAD SCI USA, V93, P4661, DOI 10.1073/pnas.93.10.4661	34	149	154	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27776	27781		10.1074/jbc.271.44.27776	http://dx.doi.org/10.1074/jbc.271.44.27776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910373	hybrid			2022-12-27	WOS:A1996VQ67900091
J	Huang, SM; Cao, ZY; Chung, DW; Davie, EW				Huang, SM; Cao, ZY; Chung, DW; Davie, EW			The role of beta gamma and alpha gamma complexes in the assembly of human fibrinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; RECOMBINANT HUMAN FIBRINOGEN; CELL-LINES; CHAIN; HEPATOCYTES; SECRETION; BIOSYNTHESIS; PROTEINS; SUBUNIT	The role of alpha gamma and beta gamma dimers as intermediates in the assembly of fibrinogen was examined in cell fusion experiments using stably transfected baby hamster kidney cell lines expressing one or combinations of fibrinogen chains. Fibrinogen was readily formed and secreted into the culture media when cells co-expressing beta and gamma chains and generating beta gamma complexes were fused with cells expressing only the alpha chain. Likewise, when cells co-expressing alpha and gamma chains and generating alpha gamma complexes were fused with cells expressing only the beta chain, fibrinogen was also formed and secreted. The relative amounts of alpha gamma or beta gamma intermediates observed during fibrinogen biosynthesis were determined by the levels of the component chains; i.e. when the beta chain was limiting the alpha gamma dimer was the predominant intermediate; likewise, when the alpha chain was limiting, the beta gamma complex was the predominant intermediate. The incorporation of preformed alpha gamma and beta gamma complexes into secreted fibrinogen did not require concurrent protein synthesis, as shown by experiments employing cycloheximide. These data strongly support the role of alpha gamma and beta gamma complexes as functional intermediates in the assembly of fibrinogen.			Huang, SM (corresponding author), UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98195 USA.		Sessum, Rachel/F-7312-2015	Sessum, Rachel/0000-0002-2444-7056	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016919] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16919] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALVING BM, 1982, ARCH BIOCHEM BIOPHYS, V217, P1, DOI 10.1016/0003-9861(82)90472-6; CHUNG DW, 1990, ADV EXP MED BIOL, V281, P39; DAVIDSON JM, 1977, EUR J BIOCHEM, V81, P349, DOI 10.1111/j.1432-1033.1977.tb11958.x; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DOOLITTLE RF, 1978, J MOL BIOL, V120, P311, DOI 10.1016/0022-2836(78)90070-0; DOOLITTLE RF, 1979, NATURE, V280, P464, DOI 10.1038/280464a0; ERICKSON HP, 1983, ANN NY ACAD SCI, V408, P146, DOI 10.1111/j.1749-6632.1983.tb23242.x; FARRELL DH, 1991, BIOCHEMISTRY-US, V30, P9414, DOI 10.1021/bi00103a004; FORMAN WB, 1964, JAMA-J AM MED ASSOC, V187, P128; FU YP, 1992, BIOCHEMISTRY-US, V31, P11968, DOI 10.1021/bi00163a002; GRIENINGER G, 1984, J BIOL CHEM, V259, P4973; HALL CE, 1959, J BIOPHYS BIOCHEM CY, V5, P11, DOI 10.1083/jcb.5.1.11; HANTGAN RR, 1987, BIOCHIM BIOPHYS ACTA, V927, P55, DOI 10.1016/0167-4889(87)90065-6; HARTWIG R, 1991, J BIOL CHEM, V266, P6578; HENSCHEN A, 1977, H-S Z PHYSIOL CHEM, V358, P1643; HENSCHEN A, 1979, H-S Z PHYSIOL CHEM, V360, P1951; HIROSE S, 1988, BIOCHEM J, V251, P373, DOI 10.1042/bj2510373; HUANG SM, 1993, J BIOL CHEM, V268, P8919; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTTSPEICH F, 1977, HOPPESEYLERS Z PHYSL, V358, P3787; MCKEE PA, 1966, ARCH BIOCHEM BIOPHYS, V116, P271, DOI 10.1016/0003-9861(66)90033-6; MULVIHILL E, 1988, Patent No. 39944; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; PLANT PW, 1986, J BIOL CHEM, V261, P2331; ROY SN, 1991, J BIOL CHEM, V266, P4758; WATT KWK, 1979, BIOCHEMISTRY-US, V18, P68, DOI 10.1021/bi00568a011; YU S, 1984, J BIOL CHEM, V259, P574; YU S, 1983, J BIOL CHEM, V258, P3407	30	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27942	27947		10.1074/jbc.271.44.27942	http://dx.doi.org/10.1074/jbc.271.44.27942			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910396	hybrid			2022-12-27	WOS:A1996VQ67900114
J	Riederer, B; Han, M; Keller, U				Riederer, B; Han, M; Keller, U			D-lysergyl peptide synthetase from the ergot fungus Claviceps purpurea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; POLYACRYLAMIDE GELS; BIOSYNTHESIS; ACTINOMYCIN; PROTEINS; PROTOPLASTS; BINDING; ENZYMES	The ergot fungus Claviceps pzrrpurea produces She medically important ergopeptines, which consist of a cyclol-structured tripeptide and D-lysergic acid linked by an amide bond, Az enzyme activity capable of nonribosomal synthesis of D-lysergyl-L-alanyl-L-phenylalanyl-L-proline lactam, the non-cyclol precursor of the ergopeptine ergotamine, has been purified about 18-fold from the ergotamine-producing C. purpurea strain D1. Analysis of radioactively labeled enzyme-substrate complexes revealed a 370-kDa lysergyl peptide synthetase 1 (LPS 1) carrying the amino acid activation domains for alanine, phenylalanine, and proline. The activation of D-lysergic acid is catalyzed by a 140-kDa peptide synthetase (LPS 2) copurifyimg with LPS 1, LPS 1 and LPS 2 contain 4'-phosphopantetheine and bind their substrates covalently by thioester linkage, Kinetic analysis of the synthesis reaction revealed a K-m of similar to 1.4 mu M for both D-lysergic acid and its structural homolog dihydrolysergic acid, which is one to two orders of magnitude lower than the K-m values for the other amino acids involved, The K-m values for the amino acids reflect their relative concentrations in the cellular pool of C, purpurea, This may indicate that in in vivo conditions D-lysergyl peptide formation is limited by the n-lysergic acid concentration in the cell, lit vitro, the multienzyme preparation catalyzes the formation of several different D-lysergyl peptide lactams according to the amino acids supplied. Specific antiserum was used to detect LPS 1 in various C. pupurea strains, In C, purpurea wild type, the enzyme was expressed at all. stages of cultivation and in different media, suggesting that it is produced constitutively.	TECH UNIV BERLIN,INST BIOCHEM & MOL BIOL,D-10587 BERLIN,GERMANY	Technical University of Berlin								AMICI AM, 1969, APPL MICROBIOL, V18, P464, DOI 10.1128/AEM.18.3.464-468.1969; AMICI AM, 1966, EXPERIENTIA, V22, P415, DOI 10.1007/BF01901174; ANDERSON JA, 1979, J NAT PROD, V42, P271, DOI 10.1021/np50003a004; BASSETT RA, 1973, BIOCHEM J, V134, P1; BELZECKI CM, 1980, J ORG CHEM, V45, P2215, DOI 10.1021/jo01299a035; BILLICH A, 1988, APPL ENVIRON MICROB, V54, P2504, DOI 10.1128/AEM.54.10.2504-2509.1988; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIERKES W, 1993, APPL ENVIRON MICROB, V59, P2029, DOI 10.1128/AEM.59.7.2029-2033.1993; HAESE A, 1993, MOL MICROBIOL, V7, P905, DOI 10.1111/j.1365-2958.1993.tb01181.x; HOFMANN A, 1963, HELV CHIM ACTA, V46, P2306, DOI 10.1002/hlca.19630460650; HOFMANN A, 1963, MUTTERKORNALKALOIDE, P35; KELLER U, 1984, BIOCHEM J, V218, P857, DOI 10.1042/bj2180857; KELLER U, 1987, J BIOL CHEM, V262, P5852; KELLER U, 1980, J GEN MICROBIOL, V118, P485; KELLER U, 1988, BIOCHEMISTRY-US, V27, P6164, DOI 10.1021/bi00416a051; KELLER U, 1983, APPL ENVIRON MICROB, V46, P580, DOI 10.1128/AEM.46.3.580-584.1983; KELLER U, 1984, APPL ENVIRON MICROB, V47, P710, DOI 10.1128/AEM.47.4.710-714.1984; KELLER U, 1992, J BIOL CHEM, V267, P11745; KELLER U, 1995, GENETICS BIOCH ANTIB, P71; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; Kobel H, 1986, BIOTECHNOLOGY, P569, DOI Weinheim; KOBEL H, 1976, Patent No. 577556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lipmann F, 1980, Adv Microb Physiol, V21, P227; PUGH EL, 1965, J BIOL CHEM, V240, P4727; QUIGLEY FR, 1981, J ORG CHEM, V46, P464, DOI 10.1021/jo00315a051; REHACEK Z, 1991, FOLIA MICROBIOL, V36, P323, DOI 10.1007/BF02814505; ROBBERS JE, 1972, J BACTERIOL, V112, P791, DOI 10.1128/JB.112.2.791-796.1972; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; SCOTTCRAIG JS, 1992, J BIOL CHEM, V267, P26044; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; Stadler P. A., 1984, NATURAL PRODUCTS DRU, P463; STADLER PA, 1982, PLANTA MED, V46, P131, DOI 10.1055/s-2007-970038; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; STINDL A, 1994, BIOCHEMISTRY-US, V33, P9358, DOI 10.1021/bi00197a041; STINDL A, 1993, J BIOL CHEM, V268, P10612; STINDL A, 1993, THESIS TU BERLIN BER; Stoll A., 1943, HELVETICA CHIM ACTA, V26, P1602, DOI 10.1002/hlca.19430260523; STUTZ P, 1973, EXPERIENTIA, V29, P936, DOI 10.1007/BF01930383; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VOGEL HJ, 1964, AM NAT, V98, P435, DOI 10.1086/282338; WEBER G, 1994, CURR GENET, V26, P120, DOI 10.1007/BF00313798; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P44	46	57	62	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27524	27530		10.1074/jbc.271.44.27524	http://dx.doi.org/10.1074/jbc.271.44.27524			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910337	hybrid			2022-12-27	WOS:A1996VQ67900055
J	Rojas, M; Yao, SY; Lin, YZ				Rojas, M; Yao, SY; Lin, YZ			Controlling epidermal growth factor (EGF)-stimulated ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASE; SIGNAL-TRANSDUCTION; SH2 DOMAINS; SH2-CONTAINING PROTEINS; ADAPTER PROTEIN; GRB2; BINDS; SOS; ASSOCIATION	Epidermal growth factor (EGF)-stimulated Ras activation involves specific interactions between the EGF receptor (EGFR), the adaptor proteins Grb2 and She, and the nucleotide exchange factor Sos-1. Study and control of these protein-protein interactions in vivo can be greatly promoted by introducing intracellular reagents that mimic EGFR functions, Here, we showed that a synthetic phosphopeptide encompassing the autophosphorylation site 1068 of EGFR formed a complex with endogenous Grb2 after this peptide was delivered into intact cells by a cell-permeable peptide import technique, Consequently, this intracellular peptide inhibited EGF-induced EGFR/Grb2 associations but not EGFR/Shc or Shc/GFb2 associations. Peptide-mediated disruption of the EGF/Grb2/Sos-1 cascade led to reduced Ras activation and mitogen-activated protein kinase activation. These results indicate that the binding of Grb2 to the phosphorylated Tyr-1068 of EGFR is crucial to the EGF-induced Ras/mitogen-activated protein kinase signaling pathway. The application of cell-permeable peptides to this study demonstrates a useful biochemical tool to probe and control various intracellular processes involved in signal transduction and gene transcription.	VANDERBILT UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA	Vanderbilt University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052500] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	211	241	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27456	27461		10.1074/jbc.271.44.27456	http://dx.doi.org/10.1074/jbc.271.44.27456			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910327	hybrid			2022-12-27	WOS:A1996VQ67900045
J	Steinberg, RA; Symcox, MM; Sollid, S; Ogreid, D				Steinberg, RA; Symcox, MM; Sollid, S; Ogreid, D			Arginine 210 is not a critical residue for the allosteric interactions mediated by binding of cyclic AMP to site A of regulatory (RI alpha) subunit of cyclic AMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE LYMPHOMA-CELLS; NUCLEOTIDE BINDING; CATALYTIC SUBUNIT; CAMP; MUTATIONS; ACTIVATION; DERIVATIVES; AFFINITY; ANALOGS; DOMAINS	The guanidinium groups of conserved arginines in the two intrachain cAMP-binding sites of regulatory (R) subunit of cAMP-dependent protein kinase have been implicated in the allosteric interactions by which cAMP binding leads to kinase activation, We have investigated the functional role of Arg-210, the conserved arginine in site A of murine type I alpha R subunit, by analyzing the effects of nine different substitutions at this residue on cAMP binding and allosteric properties of bacterially expressed RI alpha subunits, All substitutions reduced the cAMP binding affinity of site A, but the magnitude of reduction varied from several hundredfold to 10(6)-fold, The differential effects of the different substitutions could not easily be rationalized by interactions with cAMP and might, in part, reflect interactions with other residues in She unoccupied cAMP-binding pocket, None of the Arg-210 substitutions appeared to disrupt the allosteric interaction by which occupation of site a slows dissociation of cAMP from site B, although the effect was difficult to elicit in full with mutations that had strong effects on cAMP binding, The two weakest substitutions, Arg-210 --> Ile and Arg-210 --> Thr, could be shown to have: essentially no effect on the allosteric interaction by which occupation of site A reduces the affinity of R subunit for the catalytic subunit, The weaker mutations had a smaller effect on kinase activation by the suboptimal activator R(p)-adenosine cyclic 3',5'-phosphorothioate than by cAMP, suggesting that the analog largely bypasses interactions with the guanidinium group of Arg-210.	UNIV BERGEN,CTR MOL MED,HAUKELAND HOSP,N-5021 BERGEN,NORWAY	University of Bergen	Steinberg, RA (corresponding author), UNIV OKLAHOMA,CTR HLTH SCI,DEPT BIOCHEM & MOL BIOL,BMSB-853,POB 26901,OKLAHOMA CITY,OK 73190, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037583, R55DK037583] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37583] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOTELHO LHP, 1988, J BIOL CHEM, V263, P5301; BUBIS J, 1988, J BIOL CHEM, V263, P9668; CAUTHRON RD, 1995, J CELL PHYSIOL, V165, P376, DOI 10.1002/jcp.1041650219; DEWIT RJW, 1982, EUR J BIOCHEM, V122, P95; DEWIT RJW, 1984, EUR J BIOCHEM, V142, P255; DILLS WL, 1975, BIOCHEM BIOPH RES CO, V62, P70, DOI 10.1016/S0006-291X(75)80406-2; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; DOSTMANN WRG, 1991, BIOCHEMISTRY-US, V30, P8710, DOI 10.1021/bi00099a032; DOSTMANN WRG, 1990, J BIOL CHEM, V265, P10484; GORMAN KB, 1994, SOMAT CELL MOLEC GEN, V20, P801; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; HOUGE G, 1990, J BIOL CHEM, V265, P19507; JASTORFF B, 1979, EUR J BIOCHEM, V101, P555, DOI 10.1111/j.1432-1033.1979.tb19750.x; NEITZEL JJ, 1991, BIOCHEMISTRY-US, V30, P733, DOI 10.1021/bi00217a023; OBRIAN CA, 1982, BIOCHEMISTRY-US, V21, P4371, DOI 10.1021/bi00261a028; OGREID D, 1989, EUR J BIOCHEM, V181, P19; OGREID D, 1988, J BIOL CHEM, V263, P17397; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STEINBERG RA, 1994, ANAL BIOCHEM, V219, P155, DOI 10.1006/abio.1994.1246; STEINBERG RA, 1991, J BIOL CHEM, V266, P3547; STEINBERG RA, 1992, MOL CELL BIOL, V12, P767, DOI 10.1128/MCB.12.2.767; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; SYMCOX MM, 1994, J BIOL CHEM, V269, P23025; WEBER IT, 1987, BIOCHEMISTRY-US, V26, P343, DOI 10.1021/bi00376a003; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	28	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27630	27636		10.1074/jbc.271.44.27630	http://dx.doi.org/10.1074/jbc.271.44.27630			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910352	hybrid			2022-12-27	WOS:A1996VQ67900070
J	deChateau, M; Holst, E; Bjorck, L				deChateau, M; Holst, E; Bjorck, L			Protein PAB, an albumin-binding bacterial surface protein promoting growth and virulence.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGG-BINDING; STREPTOCOCCUS-PYOGENES; GEL ELECTROPHORESIS; ESCHERICHIA-COLI; CELL-WALL; RECEPTOR; M1-PROTEIN; REGIONS; MAGNUS; MODULE	The anaerobic bacterium Peptostreptococcus magnus is a human commensal and pathogen, Previous work has shown that strains of P. magnus isolated from patients with gynecological disease (vaginosis) frequently express an immunoglobulin (Ig) light chain-binding protein called protein L. Here we report that strains isolated from localized suppurative infections bind human serum albumin (HSA), whereas commensal isolates bind neither Ig nor HSA. The HSA-binding protein PAB was extracted from the bacterial surface or isolated from the culture supernatant of the P. magnus strain ALB8. Protein PAB was shown to have two homologous HSA binding domains, GA and uGA. GA is absent in the sequence of a related protein from another P. magnus strain and shows a high degree of homology to the HSA-binding domains of streptococcal protein G. Therefore GA is believed to have recently been shuffled as a module from genes of other bacterial species into the protein PAB gene, This GA module was shown to exhibit a much higher affinity for HSA than uGA and was also found to be present in all of the isolates tested from localized suppurative infections, indicating a role in virulence, Moreover, when peptostreptococci or streptococci expressing the GA module were grown in the presence of HSA, the growth rate was substantially increased. Thus, the HSA binding activity of the GA module adds selective advantages to the bacteria, which increases their virulence in the case of P. magnus strains.	LUND UNIV,DEPT MED MICROBIOL,S-22100 LUND,SWEDEN	Lund University	deChateau, M (corresponding author), LUND UNIV,DEPT CELL & MOL BIOL,POB 94,S-22100 LUND,SWEDEN.							AKERSTROM B, 1989, J BIOL CHEM, V264, P19740; AKERSTROM B, 1987, J BIOL CHEM, V262, P13388; AKESSON P, 1994, BIOCHEM J, V300, P877, DOI 10.1042/bj3000877; BJORCK L, 1988, J IMMUNOL, V140, P1194; BJORCK L, 1987, MOL IMMUNOL, V24, P1113, DOI 10.1016/0161-5890(87)90080-0; BJORCK L, 1984, J IMMUNOL, V133, P969; BOURGAULT AM, 1980, ANN INTERN MED, V93, P244, DOI 10.7326/0003-4819-93-2-244; BROOK I, 1985, CAN J MICROBIOL, V31, P176, DOI 10.1139/m85-033; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; deChateau M, 1996, P NATL ACAD SCI USA, V93, P8490, DOI 10.1073/pnas.93.16.8490; DECHATEAU M, 1994, J BIOL CHEM, V269, P12147; DECHATEAU M, 1993, SCAND J IMMUNOL, V37, P399; Ezaki T, 1992, PROKARYOTES, V2, P1879; FAHNESTOCK SR, 1986, J BACTERIOL, V167, P870, DOI 10.1128/jb.167.3.870-880.1986; FINEGOLD SM, 1995, ANAEROBE, V1, P3, DOI 10.1016/S1075-9964(95)80340-8; FISCHETTI VA, 1989, CLIN MICROBIOL REV, V2, P285, DOI 10.1128/CMR.2.3.285-314.1989; FORSGREN A, 1966, J IMMUNOL, V97, P822; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; GUSS B, 1986, EMBO J, V5, P1567, DOI 10.1002/j.1460-2075.1986.tb04398.x; JOHANSSON BG, 1972, SCAND J CLIN LAB INV, V29, P7, DOI 10.3109/00365517209102747; JOHANSSON MU, 1995, FEBS LETT, V374, P257, DOI 10.1016/0014-5793(95)01121-T; JONSSON H, 1994, GENE, V143, P85, DOI 10.1016/0378-1119(94)90609-2; JONSSON H, 1995, INFECT IMMUN, V63, P2968, DOI 10.1128/IAI.63.8.2968-2975.1995; KASTERN W, 1992, J BIOL CHEM, V267, P12820; KASTERN W, 1990, INFECT IMMUN, V58, P1217, DOI 10.1128/IAI.58.5.1217-1222.1990; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; Kraulis PJ, 1996, FEBS LETT, V378, P190, DOI 10.1016/0014-5793(95)01452-7; KREPEL CJ, 1992, J CLIN MICROBIOL, V30, P2330, DOI 10.1128/JCM.30.9.2330-2334.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moore LVH, 1977, VPI ANAEROBE LAB MAN; MURPHY JP, 1994, MOL MICROBIOL, V12, P911, DOI 10.1111/j.1365-2958.1994.tb01079.x; OCKNER RK, 1983, AM J PHYSIOL, V245, pG13, DOI 10.1152/ajpgi.1983.245.1.G13; PATELLA V, 1990, J IMMUNOL, V145, P3054; READER R, 1993, INFECT IMMUN, V61, P3696; REIS KJ, 1984, J IMMUNOL, V132, P3091; RETNONINGRUM DS, 1994, INFECT IMMUN, V62, P2387, DOI 10.1128/IAI.62.6.2387-2394.1994; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT KH, 1990, ZBL BAKT-INT J MED M, V273, P216; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SJOBRING U, 1992, INFECT IMMUN, V60, P3601; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	41	44	51	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26609	26615		10.1074/jbc.271.43.26609	http://dx.doi.org/10.1074/jbc.271.43.26609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900134	hybrid			2022-12-27	WOS:A1996VP23300028
J	Nornes, S; Mikkola, I; Krauss, S; Delghandi, M; Perander, M; Johansen, T				Nornes, S; Mikkola, I; Krauss, S; Delghandi, M; Perander, M; Johansen, T			Zebrafish Pax9 encodes two proteins with distinct C-terminal transactivating domains of different potency negatively regulated by adjacent N-terminal sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR BSAP; B-CELL DIFFERENTIATION; PAIRED BOX GENE; SONIC-HEDGEHOG; ALVEOLAR RHABDOMYOSARCOMA; POLARIZING ACTIVITY; EXPRESSION PATTERN; NERVOUS-SYSTEM; DEVELOPING CNS; EYELESS GENE	We describe the isolation of cDNA clones for zebrafish Pax9. Pax9 expression was initiated at the end of the segmentation period in mesenchymal sclerotome cells on both sides of the notochord similarly to the corresponding mouse and chick genes. Two transcripts, Pax9a and -b, are generated by alternative splicing. The gene contains 4 exons with exon 3 being included in the Pax9a transcript and spliced out in the Pax9b transcript. The Pax9a and -b proteins are identical for 212 amino acids from the N terminus but contain distinct C-terminal regions of 131 and 58 amino acids, respectively. The paired domain of Pax9 displayed a binding-site specificity distinct from Pax6 but similar to Pax1 and -2. Both Pax9a and -b activated a promoter containing a paired domain binding site. However, this activation was observed when low amounts of Pax9 expression vectors were used. Higher amounts led to a sharp decrease in the activation and even turned into repression. Both the distinct C-terminal regions of Pax9a and -b harbored transcriptional activating domains of different potency not revealed in the context of the full-length proteins due to a negative influence of the N-terminal region including the paired domain.	UNIV TROMSO, INST MED BIOL, DEPT BIOCHEM, N-9037 TROMSO, NORWAY; UNIV TROMSO, INST MED BIOL, DEPT MOL GENET, N-9037 TROMSO, NORWAY	UiT The Arctic University of Tromso; UiT The Arctic University of Tromso			Johansen, Terje/AAY-1753-2021; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Perander, Maria/0000-0002-1177-2407; Krauss, Stefan/0000-0001-6992-8091; Mikkola, Ingvild/0000-0001-6442-7626				ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; Affolter M, 1990, CURR OPIN CELL BIOL, V2, P485, DOI 10.1016/0955-0674(90)90132-X; BJORKOY G, 1995, J BIOL CHEM, V270, P21299; BOPP D, 1989, EMBO J, V8, P3447, DOI 10.1002/j.1460-2075.1989.tb08509.x; BURRI M, 1989, EMBO J, V8, P1183, DOI 10.1002/j.1460-2075.1989.tb03490.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CARRUTH LM, 1994, J VIROL, V68, P6137, DOI 10.1128/JVI.68.10.6137-6146.1994; CERNY T, 1995, MOL CELL BIOL, V15, P2858; CHALEPAKIS G, 1991, CELL, V66, P873, DOI 10.1016/0092-8674(91)90434-Z; CHALEPAKIS G, 1993, J NEUROBIOL, V24, P1367, DOI 10.1002/neu.480241009; CVEKL A, 1995, MOL CELL BIOL, V15, P653; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DAVIS RJ, 1994, CANCER RES, V54, P2869; DEUTSCH U, 1988, CELL, V53, P617, DOI 10.1016/0092-8674(88)90577-6; DEUTSCH U, 1991, SEMIN DEV BIOL, V2, P413; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FICKENSCHER HR, 1993, DNA CELL BIOL, V12, P381, DOI 10.1089/dna.1993.12.381; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HEIN J, 1990, METHOD ENZYMOL, V183, P626; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLST BD, 1994, J BIOL CHEM, V269, P22245; HOOK AG, 1988, J BIOL CHEM, V263, P2337; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; KHORANA S, 1994, NUCLEIC ACIDS RES, V22, P3425, DOI 10.1093/nar/22.16.3425; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KOZMIK Z, 1993, MOL CELL BIOL, V13, P6024, DOI 10.1128/MCB.13.10.6024; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; KRAUSS S, 1991, EMBO J, V10, P3609, DOI 10.1002/j.1460-2075.1991.tb04927.x; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; KRAUSS S, 1992, NATURE, V360, P87, DOI 10.1038/360087a0; KRAUSS S, 1991, NATURE, V353, P267, DOI 10.1038/353267a0; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARTIN P, 1992, ONCOGENE, V7, P1721; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; NORTON PA, 1994, J CELL SCI, V107, P1; OKAJIMA T, 1993, ANAL BIOCHEM, V211, P293, DOI 10.1006/abio.1993.1272; PETERS H, 1995, DEV DYNAM, V203, P1, DOI 10.1002/aja.1002030102; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PUSCHEL AW, 1992, DEVELOPMENT, V114, P643; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAFER BW, 1994, NUCLEIC ACIDS RES, V22, P4574, DOI 10.1093/nar/22.22.4574; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; STRACHAN T, 1994, CURR OPIN GENE DEV, V4, P427; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; TSUKAMOTO K, 1994, HUM GENET, V93, P270, DOI 10.1007/BF00212021; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VULLIET PR, 1989, J BIOL CHEM, V264, P16292; WALLIN J, 1993, MAMM GENOME, V4, P354, DOI 10.1007/BF00360584; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WARD TA, 1994, CELL GROWTH DIFFER, V5, P1015; WISBART DS, 1994, COMPUT APPL BIOSCI, V10, P121; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	84	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26914	26923		10.1074/jbc.271.43.26914	http://dx.doi.org/10.1074/jbc.271.43.26914			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900176	hybrid			2022-12-27	WOS:A1996VP23300070
J	Tao, JS; Sanghera, JS; Pelech, SL; Wong, G; Levy, JG				Tao, JS; Sanghera, JS; Pelech, SL; Wong, G; Levy, JG			Stimulation of stress-activated protein kinase and p38 HOG1 kinase in murine keratinocytes following photodynamic therapy with benzoporphyrin derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; C-JUN; PORPHYRIN PHOTOSENSITIZATION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS; MAPKAP KINASE-2; PHOSPHORYLATION; TRANSCRIPTION; INDUCTION	The activation state of the members of the mitogen-activated protein kinase family following photodynamic therapy (PDT) with benzoporphyrin derivative monoacid ring A was investigated using a naturally transformed murine keratinocyte cell line, Pam 212. PDT involves the use of photosensitizer molecules and a specific wavelength of visible light. The process of PDT generates singlet oxygen and other reactive oxygen intermediates (ROIs), and the cytotoxic effect of these ROIs is the basis for the use of PDT to treat cancer and psoriasis. PDT caused a strong dose- and time-dependent activation of both stress-activated protein kinase (SAPK) and p38 HOG1. The maximum activation of SAPK and p38 HOG1 occurred between 20 and 30 min following PDT treatment with 200 ng/ml benzoporphyrin derivative monoacid ring A and 2 J/cm(2) of red light at 690 nm. In our system, PDT did not cause significant activation of extracellularly regulated kinase (ERK) 1 and ERK2. Under the same experimental conditions, ultraviolet light irradiation caused strong activation of SAPK and p38 HOG1 and minimum activation of ERK1 and ERK2 in Pam212 cells. A number of ROI scavengers were tested for their effect on PDT-induced SAPK and p38 HOG1 activation. Both L-histidine and N-acetyl-L-cysteine showed a significant inhibitory effect on PDT-induced SAPK and p38 HOG1 activation. This indicated that PDT-induced SAPK and p38 HOG1 activation may be partially mediated by ROI.	UNIV BRITISH COLUMBIA, DEPT MED, VANCOUVER, BC V6T 1Z3, CANADA; UNIV BRITISH COLUMBIA, DEPT MICROBIOL & IMMUNOL, VANCOUVER, BC V6T 1Z3, CANADA; QLT PHOTOTHERAPEUT INC, VANCOUVER, BC V5Z 4H5, CANADA; KINETEK PHARMACEUT INC, VANCOUVER, BC V5Z 1A1, CANADA; STRESSGEN BIOTECHNOL CORP, VICTORIA, BC V8Z 4B9, CANADA	University of British Columbia; University of British Columbia								AGARWAL ML, 1993, CANCER RES, V53, P5897; AGARWAL ML, 1991, CANCER RES, V51, P5993; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CURRY PM, 1993, PHOTOCHEM PHOTOBIOL, V58, P374, DOI 10.1111/j.1751-1097.1993.tb09577.x; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EVANS S, 1990, J NATL CANCER I, V82, P34, DOI 10.1093/jnci/82.1.34; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GIROTTI A, 1990, PHOTODYNAMIC THERAPY, V1, P229; GOMER CJ, 1991, CANCER RES, V51, P6574; GOMER CJ, 1991, PHOTOCHEM PHOTOBIOL, V53, P275, DOI 10.1111/j.1751-1097.1991.tb03934.x; GOMER GJ, 1988, LASER SURG MED, V8, P450, DOI 10.1002/lsm.1900080503; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HALLIWELL B, 1989, PROTECTION OXIDANTS, P86; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HENDERSON BW, 1989, CANCER RES, V49, P6896; Karin M, 1991, CURR OPIN CELL BIOL, V3, P467, DOI 10.1016/0955-0674(91)90075-A; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRUTMANN J, 1989, J BIOL CHEM, V264, P11407; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEGRANDPOELS S, 1995, J BIOL CHEM, V270, P6925, DOI 10.1074/jbc.270.12.6925; LUNA MC, 1994, CANCER RES, V54, P1374; MAI S, 1989, J CELL SCI, V94, P609; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NICKOLOFF BJ, 1993, AM J PATHOL, V143, P325; PELECH SL, 1995, PROTEIN KINASE CIRCU; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RYTER SW, 1993, PHOTOCHEM PHOTOBIOL, V58, P753, DOI 10.1111/j.1751-1097.1993.tb04964.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND CL, 1996, IN PRESS J IMMUNOL; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	43	97	98	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27107	27115		10.1074/jbc.271.43.27107	http://dx.doi.org/10.1074/jbc.271.43.27107			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900202	hybrid			2022-12-27	WOS:A1996VP23300096
J	Yamashita, M; Ojima, N; Sakamoto, T				Yamashita, M; Ojima, N; Sakamoto, T			Molecular cloning and cold-inducible gene expression of ferritin H subunit isoforms in rainbow trout cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN; TRANSCRIPTIONAL REGULATION; TRANSFERRIN RECEPTOR; MESSENGER-RNAS; PROTEINS; IRON; IDENTIFICATION; MECHANISM; FIBROBLASTS; HIBERNATION	Cold acclimation of rainbow trout cells is considered to be mediated by alterations in the mRNAs and proteins present in cold-treated cells. A subtracted cDNA library from cold-treated rainbow trout RTG-2 cells was constructed and screened to isolate cDNA induced in the cold-treated cells in order to elucidate which genes are induced by cold acclimation. A set of cDNA clones encoding three members of ferritin H isoforms was isolated as cold-inducible genes, Northern blot analysis and nuclear run-on transcription assay showed that the transcription and accumulation of the ferritin H isoforms mRNA were enhanced by cold acclimation, Furthermore, the ferritin level in the trout cells increased on cold acclimation in response to a temperature shift from 22 degrees C to 4 degrees C. When the trout cells were subjected to 4 degrees C under the condition of a decreased ferritin H level obtained by the addition of an antisense oligonucleotide, cell growth was apparently inhibited. These findings indicate an association between the induction of ferritin H and cellular mechanisms during cold acclimation of trout cells.			Yamashita, M (corresponding author), NATL RES INST FISHERIES SCI, KANAZAWA KU, FUKUURA, YOKOHAMA, KANAGAWA 236, JAPAN.		Ojima, Nobuhiko/I-5377-2016					ANDREWS SC, 1992, J INORG BIOCHEM, V47, P161, DOI 10.1016/0162-0134(92)84062-R; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BARRESI R, 1994, GENE, V140, P195, DOI 10.1016/0378-1119(94)90544-4; BEAUMONT C, 1994, J BIOL CHEM, V269, P20281; BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; BEVILACQUA MA, 1992, GENE, V111, P255, DOI 10.1016/0378-1119(92)90696-M; BOYD D, 1984, P NATL ACAD SCI-BIOL, V81, P4751, DOI 10.1073/pnas.81.15.4751; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; COULSON RMR, 1993, P NATL ACAD SCI USA, V90, P7613, DOI 10.1073/pnas.90.16.7613; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DUMAN J, 1983, ANNU REV PHYSIOL, V45, P261, DOI 10.1146/annurev.ph.45.030183.001401; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HIROSE S, 1985, J BIOL CHEM, V260, P557; JOHNSTON IA, 1990, PHILOS T R SOC B, V326, P655, DOI 10.1098/rstb.1990.0037; KONDO N, 1992, J BIOL CHEM, V267, P473; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; LEVI S, 1988, J BIOL CHEM, V263, P18086; MICHOT B, 1990, EUR J BIOCHEM, V188, P219, DOI 10.1111/j.1432-1033.1990.tb15393.x; MOSSER DD, 1986, J CELL PHYSIOL, V128, P432, DOI 10.1002/jcp.1041280312; MOSSER DD, 1987, J CELL PHYSIOL, V132, P155, DOI 10.1002/jcp.1041320122; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MUNDY J, 1988, EMBO J, V7, P2279, DOI 10.1002/j.1460-2075.1988.tb03070.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; RAO K, 1986, MOL CELL BIOL, V6, P236, DOI 10.1128/MCB.6.1.236; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; TENEA AL, 1991, P NATL ACAD SCI USA, V88, P10907; THEIL EC, 1990, J BIOL CHEM, V265, P4771; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TREFFRY A, 1992, FEBS LETT, V302, P108, DOI 10.1016/0014-5793(92)80417-F; Yamashita M, 1996, FEBS LETT, V382, P261, DOI 10.1016/0014-5793(96)00172-X; ZAHRINGER J, 1976, P NATL ACAD SCI USA, V73, P857, DOI 10.1073/pnas.73.3.857	38	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26908	26913		10.1074/jbc.271.43.26908	http://dx.doi.org/10.1074/jbc.271.43.26908			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900175	hybrid			2022-12-27	WOS:A1996VP23300069
J	Beatch, M; Jesaitis, LA; Gallin, WJ; Goodenough, DA; Stevenson, BR				Beatch, M; Jesaitis, LA; Gallin, WJ; Goodenough, DA; Stevenson, BR			The tight junction protein ZO-2 contains three PDZ ((P)under-barSD-95/(d)under-bariscs-large/(Z)under-barO-1) domains and an alternatively spliced region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; EPITHELIAL-CELLS; SEPTATE JUNCTIONS; GUANYLATE KINASES; MEMBRANE-PROTEIN; IDENTIFICATION; LOCALIZATION; POLYPEPTIDE; CINGULIN; OCCLUDIN	The complete cDNA sequence for canine ZO-2, a tight junction-specific protein, is presented, A single open reading frame encodes a polypeptide of 1,174 amino acids with a predicted molecular mass of 132,085 daltons, As noted previously (1), ZO-2 is a member of the membrane-associated guanylate kinase-containing (MAGUK) protein family, a family which includes an additional tight junction-associated protein, ZO-1. These proteins contain a region homologous to guanylate kinase, an SH3 domain, and variable numbers of PSD-95/discs-large/ZO-1 (PDZ) domains, shown to be involved in protein-protein interactions, ZO-2 and ZO-1 contain three PDZ domains in the N-terminal half of the molecule. Between the first and second PDZ domains, ZO-2 displays a basic region (pI = 10.27) containing 22% arginine residues. Both ZO-1 and ZO-2 have proline-rich C-terminal regions that are not homologous to other MAGUK family members. Sequence analysis of multiple ZO-2 cDNAs reveals a 36-amino acid domain in this C-terminal region present in only some of the cDNAs. Overall, ZO-2 is highly homologous to ZO-1, showing 51% amino acid identity; however, the C-terminal ends of the molecules show only 25% amino acid identity. This suggests that the C-terminal ends of ZO-1 and ZO-2 have different functions.	UNIV ALBERTA,DEPT ANAT & CELL BIOL,EDMONTON,AB T6G 2H7,CANADA; UNIV ALBERTA,DEPT BIOL SCI,EDMONTON,AB T6G 2H7,CANADA; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	University of Alberta; University of Alberta; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028932, R01GM018974, R37GM018974] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28932, GM18974] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDA MS, 1993, AM J PHYSIOL, V264, pC918, DOI 10.1152/ajpcell.1993.264.4.C918; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CITI S, 1988, NATURE, V333, P272, DOI 10.1038/333272a0; DUCLOS F, 1994, HUM MOL GENET, V3, P909, DOI 10.1093/hmg/3.6.909; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; GUMBINER B, 1991, P NATL ACAD SCI USA, V88, P3460, DOI 10.1073/pnas.88.8.3460; ITOH M, 1991, J CELL BIOL, V115, P1449, DOI 10.1083/jcb.115.5.1449; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KURIHARA H, 1992, P NATL ACAD SCI USA, V89, P7075, DOI 10.1073/pnas.89.15.7075; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZAHRAOUI A, 1994, J CELL BIOL, V124, P101, DOI 10.1083/jcb.124.1.101; ZHONG Y, 1993, J CELL BIOL, V120, P477, DOI 10.1083/jcb.120.2.477	29	90	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25723	25726		10.1074/jbc.271.42.25723	http://dx.doi.org/10.1074/jbc.271.42.25723			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824195	hybrid			2022-12-27	WOS:A1996VN18000001
J	Denker, BM; Saha, C; Khawaja, S; Nigam, SK				Denker, BM; Saha, C; Khawaja, S; Nigam, SK			Involvement of a heterotrimeric G protein alpha subunit in tight junction biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; INTRACELLULAR CALCIUM; LOCALIZATION; CALMODULIN; MEMBRANE; NEPHRON; GAP-43; CELLS	The tight junction (TJ) of polarized epithelial cells is critical for maintaining an impermeant barrier and epithelial cell polarity. The signaling events important for TJ assembly require regulated calcium stores and protein kinase C (PKC), but the earliest signaling events in the cascade have not been well defined. We now show that G alpha(i2) in Madin Darby canine kidney (MDCK) cells localizes to a region overlapping with the TJ. To further analyze the localization of G alpha subunits in epithelial cells, rat G alpha(o), Q205L alpha(o) (G alpha(o) ''activated'' by point mutation) and plasmid without insert (PC) were transfected into MDCK cells and localized by immunofluorescence and confocal microscopy, Similar to endogenous G alpha(i2), G alpha(o)-MDCK cells localize G alpha(o), (84% similar to G alpha(i2)) in the subapical region overlapping with ZO-1 (zona occludens-I), a key component of the TJ, PC-MDCK cells have no detectable G alpha(o). In Ga alpha(o)-MDCK cells, a physical association of G alpha(o) with components of the TJ was detectable by immunoprecipitation of ZO-1. Immunoprecipitates of ZO-1 from G alpha(o)-MDCK cells consistently coprecipitated G alpha(o). Constitutively active Q205LG alpha(o) localized to the subapical lateral membrane similar to wild-type G alpha(o). To determine if constitutively activated G alpha subunits can affect TJ biogenesis, the formation of tight junctions in PC, G alpha(o), and Q205L alpha(o)-MDCK cells was followed by measurement of transepithelial resistance (TER) during the Ca2+ switch, a model widely used to study mechanisms of junctional assembly, Baseline and post Ca2+ switch TER values did not differ among the cell lines, However, constitutively activated Q205L alpha(o)-MDCK, cells developed TER significantly faster than PC and G alpha(o) cells in the early phase (0-4 h) (54 +/- 4 versus 23 +/- 3 (PC); 12 +/- 1 (G alpha(o)) Ohm . m(2)/h) and late phase (4-h peak) (117 +/- 10 versus 45 +/- 5 (PC); 66 +/- 7 (G alpha(o)) Ohm . cm(2)/h) after Ca2+ switch, Peak TER values were significantly higher in Q205L alpha(o)-MDCK cells (1168 +/- 107 versus 437 +/- 37 (PC); 548 +/- 54 (G alpha(o)) Ohm . cm(2)). These results indicate that G alpha(o) and Q205L alpha(o) expressed in MDCK cells are localized near the junctional complex, associate with at least one TJ protein, and that activated G alpha(o) accelerates TJ biogenesis without significantly affecting the maintenance of the TJ, Together, these results suggest an important role for heterotrimeric G proteins in TJ assembly.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	Denker, BM (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV RENAL, 75 FRANCIS ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002110] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02110] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDA MS, 1991, J MEMBRANE BIOL, V122, P193, DOI 10.1007/BF01871420; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BRUNSKILL N, 1991, KIDNEY INT, V40, P997, DOI 10.1038/ki.1991.307; CEREIJIDO M, 1993, J CELL SCI, P127; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEALMEIDA JB, 1994, J CELL SCI, V107, P507; DENKER BM, 1991, FEBS LETT, V279, P98, DOI 10.1016/0014-5793(91)80260-A; DENKER BM, 1992, J BIOL CHEM, V267, P6272; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; ENDOU M, 1994, J PHARMACOL EXP THER, V269, P221; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; NEER EJ, 1992, TRENDS CARDIOVAS MED, V2, P6, DOI 10.1016/1050-1738(92)90037-S; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STOW JL, 1991, AM J PHYSIOL, V261, pF831, DOI 10.1152/ajprenal.1991.261.5.F831; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; STRITTMATTER SM, 1995, CELL, V80, P445, DOI 10.1016/0092-8674(95)90495-6; Stuart RO, 1996, J BIOL CHEM, V271, P13636, DOI 10.1074/jbc.271.23.13636; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, SEMIN NEPHROL, V15, P315; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; VANDENBERGHE N, 1991, BIOCHEM J, V278, P565, DOI 10.1042/bj2780565; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WU K, 1992, P NATL ACAD SCI USA, V89, P8686, DOI 10.1073/pnas.89.18.8686; XIE RP, 1995, DEV BRAIN RES, V87, P77, DOI 10.1016/0165-3806(95)00061-H	30	117	117	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25750	25753		10.1074/jbc.271.42.25750	http://dx.doi.org/10.1074/jbc.271.42.25750			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824202	hybrid			2022-12-27	WOS:A1996VN18000008
J	Donovan, JA; Ota, Y; Langdon, WY; Samelson, LE				Donovan, JA; Ota, Y; Langdon, WY; Samelson, LE			Regulation of the association of p120(cbl) with Grb2 in Jurkat T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-CBL PROTOONCOGENE; RECEPTOR SIGNAL TRANSDUCTION; ANTIGEN RECEPTOR; SH3 DOMAIN; ZETA-CHAIN; PHOSPHORYLATED PROTEIN; HEMATOPOIETIC-CELLS; EXCHANGE PROTEIN; V-CBL	The c-cbl protooncogene product (p120(cbl)) is a known substrate of multiple tyrosine kinases. It is found in complexes with critical signal transduction molecules, including the linker protein Grb2. Here, we demonstrate using an immobilized Grb2-binding peptide that the Grb2-p120(cbl) complex dissociates in vivo following engagement of the T-cell antigen receptor in Jurkat T-cells. The early kinetics of this dissociation correlate with the known time course of tyrosine phosphorylation of p120(cbl) and other substrates. This dissociation persists In vivo even when p120(cbl) becomes dephosphorylated to basal levels. However, this decreased association is not observed in protein overlay assays on nitrocellulose membranes in which a Grb2 fusion protein is used to detect p120(cbl) from stimulated or unstimulated cells. These data suggest that the tyrosine phosphorylation of p120(cbl) does not completely account for the regulation of its association with Grb2. Additionally, we used truncation mutations of p120(cbl) to map the p120(cbl)-Grb2 interaction to amino acids 481-528 of p120(cbl); this interaction is stronger in longer constructs that include additional proline-rich motifs. The in vivo regulation of the Grb2-p120(cbl) complex further supports the idea of a significant role for p120(cbl) in receptor-mediated signaling pathways.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; UNIV WESTERN AUSTRALIA, NEDLANDS, WA 6009, AUSTRALIA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Western Australia								ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EGERTON M, 1994, J BIOL CHEM, V269, P11435; EGERTON M, 1992, J IMMUNOL, V149, P1847; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; FUKAMACHI H, 1994, J IMMUNOL, V152, P642; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GURUPRASAD L, 1995, J MOL BIOL, V248, P856, DOI 10.1006/jmbi.1995.0266; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; REIF K, 1994, J BIOL CHEM, V269, P14081; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Sattler M, 1996, ONCOGENE, V12, P839; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOODROW MA, 1993, J IMMUNOL, V150, P3853; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	59	51	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26369	26374		10.1074/jbc.271.42.26369	http://dx.doi.org/10.1074/jbc.271.42.26369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824292	hybrid			2022-12-27	WOS:A1996VN18000098
J	He, K; He, YA; Szklarz, GD; Halpert, JR; Correia, MA				He, K; He, YA; Szklarz, GD; Halpert, JR; Correia, MA			Secobarbital-mediated inactivation of cytochrome P450 2B1 and its active site mutants - Partitioning between heme and protein alkylation and epoxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE RECOGNITION SITES; DIRECTED MUTAGENESIS; AMINO-ACID; INSITU REARRANGEMENT; IRON COMPLEXES; SPECIFICITY; RAT; PURIFICATION; METABOLISM; MECHANISM	Secobarbital (SE) is a relatively selective mechanism-based inactivator of cytochrome P450 2B1, that partitions between epoxidation and heme and protein modification during its enzyme inactivation, The SB-2B1 heme adduct formed in situ in a functionally reconstituted system has been spectrally documented and structurally characterized as N-(5-(2-hydroxypropyl)-5-(1-methylbutyl)barbituric acid)protoporphyrin M. The SB-protein modification has been localized to 2B1 peptide 277-323 corresponding to the active site helix I of cytochrome P450 101., The targeting of heme and this active site peptide suggests that the 2B1 active site topology could influence the course of its inactivation, To explore this possibility, the individual SE epoxidation, heme and protein modification, and corresponding molar partition ratios of the wild type and seven structural 2B1 mutants, site-directed at specific substrate recognition sites, and known to influence 2B1 catalysis were examined after Escherichia coli expression, These studies reveal that Thr-302 is critical for SE-mediated heme N-alkylation, whereas Val-367 is a critical determinant of 2B1 protein modification, and Val-363 is important for SE epoxidation. SE docking into a refined 2B1 homology model coupled with molecular dynamics analyses provide a logical rationale for these findings.	UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOL PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOPHARMACEUT SCI & PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR LIVER, SAN FRANCISCO, CA 94143 USA; UNIV ARIZONA, DEPT PHARMACOL & TOXICOL, TUCSON, AZ 85721 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Arizona					NIDDK NIH HHS [DK26506] Funding Source: Medline; NIEHS NIH HHS [ES06694, ES03619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026506, R56DK026506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003619, P30ES006694] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BORNHEIM LM, 1986, ARCH BIOCHEM BIOPHYS, V246, P63, DOI 10.1016/0003-9861(86)90449-2; DEMONTELLANO PRO, 1983, ANNU REV PHARMACOL, V23, P481; DEXTER AF, 1995, J AM CHEM SOC, V117, P817, DOI 10.1021/ja00107a026; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GOTOH O, 1992, J BIOL CHEM, V267, P83; GRAB LA, 1988, BIOCHEMISTRY-US, V27, P4805, DOI 10.1021/bi00413a034; HALPERT JR, 1993, J BIOL CHEM, V268, P4453; HARVEY DJ, 1977, DRUG METAB DISPOS, V5, P527; He K, 1996, CHEM RES TOXICOL, V9, P614, DOI 10.1021/tx950177k; HE YA, 1992, BIOCHEMISTRY-US, V31, P9220, DOI 10.1021/bi00153a015; HE YQ, 1995, CHEM RES TOXICOL, V8, P574, DOI 10.1021/tx00046a011; HSU MH, 1993, J BIOL CHEM, V268, P6939; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; JOHNSON EF, 1992, TRENDS PHARMACOL SCI, V13, P122, DOI 10.1016/0165-6147(92)90042-5; KOMIVES EA, 1987, J BIOL CHEM, V262, P9793; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LUKTON D, 1988, CHEM RES TOXICOL, V1, P208, DOI 10.1021/tx00004a004; LUNETTA JM, 1989, MOL PHARMACOL, V35, P10; Luo Zongshu, 1994, Archives of Biochemistry and Biophysics, V309, P52; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PAULSEN MD, 1992, J COMPUT AID MOL DES, V6, P449, DOI 10.1007/BF00130396; PAULSEN MD, 1991, PROTEINS, V11, P184, DOI 10.1002/prot.340110304; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SHEPHARD EA, 1983, ANAL BIOCHEM, V129, P430, DOI 10.1016/0003-2697(83)90573-0; SWANSON BA, 1991, J BIOL CHEM, V266, P19258; SZKLARZ GD, 1994, J BIOMOL STRUCT DYN, V12, P61, DOI 10.1080/07391102.1994.10508088; SZKLARZ GD, 1995, BIOCHEMISTRY-US, V34, P14312, DOI 10.1021/bi00044a008; TUCK SF, 1992, BIOCHEMISTRY-US, V31, P6911, DOI 10.1021/bi00145a007; Von Wachenfeldt Claes, 1995, P183; WALSH CT, 1984, ANNU REV BIOCHEM, V53, P493, DOI 10.1146/annurev.bi.53.070184.002425; WAXMAN DJ, 1982, J BIOL CHEM, V257, P446; ZVELEBIL MJJM, 1991, PROTEIN ENG, V4, P271, DOI 10.1093/protein/4.3.271	32	30	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25864	25872		10.1074/jbc.271.42.25864	http://dx.doi.org/10.1074/jbc.271.42.25864			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824218	hybrid			2022-12-27	WOS:A1996VN18000024
J	Somasundaram, B; MahautSmith, MP; Floto, RA				Somasundaram, B; MahautSmith, MP; Floto, RA			Temperature-dependent block of capacitative Ca2+ influx in the human leukemic cell line KU-812	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; RAT MEGAKARYOCYTES; MAST-CELLS; DEPLETION; TRANSPORT; MEMBRANE; PROTEIN; STORES; CHANNELS; ENTRY	The mechanism by which depletion of intracellular Ca2+ stores activates Ca2+ influx is not understood, We recently showed that primaquine, an inhibitor of vesicular transport, blocks the activation of the calcium release-activated calcium current (I-CRAC) in rat megakaryocytes (Somasundaram, B., Norman, J. C., and Mahaut-Smith, M. P. (1995) Biochem. J, 309, 725-729), Since it is well established that vesicular transport is temperature-sensitive, we have investigated the effect of temperature on both the activation and maintenance of store-mediated Ca2+ and Mn2+ influx in the human leukemic cell line KU-812 using a combination of whole cell I-CRAC recordings and measurements of Mn2+ photoquench of fura-2, Activation of I-CRAC was temperature-sensitive, showing a nonlinear reduction when the temperature was lowered from 27 to 17 degrees C with an abrupt change at 21-22 degrees C and complete inhibition at 17 degrees C, Once activated, I-CRAC also displayed an abrupt reduction at 21-22 degrees C but was not completely blocked even when the temperature was reduced to 14 degrees C, suggesting that at least one of the temperature-sensitive components is exclusively involved in I-CRAC activation, Activation of store mediated Mn2+ influx also showed similar nonlinear temperature sensitivity and complete inhibition at 19 degrees C. However, in contrast to Io measurements, lowering the temperature following maximal activation of the influx pathway at 37 degrees C did not result in any detectable residual Mn2+ entry below 19 degrees C. We conclude that the mechanism of store-mediated Ca2+ influx involves temperature-dependent steps in both its maintenance and activation, suggesting dependence on a lipid membrane environment.			Somasundaram, B (corresponding author), UNIV CAMBRIDGE,PHYSIOL LAB,DOWNING ST,CAMBRIDGE CB2 3EG,ENGLAND.							BAMBERG E, 1974, BIOCHIM BIOPHYS ACTA, V367, P127, DOI 10.1016/0005-2736(74)90037-6; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CAVALIE A, 1985, PFLUG ARCH EUR J PHY, V405, P294, DOI 10.1007/BF00582574; CHAPMAN D, 1975, Q REV BIOPHYS, V8, P185, DOI 10.1017/S0033583500001797; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; DEAN WL, 1978, BIOCHEMISTRY-US, V17, P1683, DOI 10.1021/bi00602a016; FASALATO C, 1993, J BIOL CHEM, V268, P20737; FASALATO C, 1994, TRENDS PHARMACOL SCI, V15, P77; FISCHBACH GD, 1978, J PHYSIOL-LONDON, V280, P527, DOI 10.1113/jphysiol.1978.sp012399; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOFFMANN W, 1979, P NATL ACAD SCI USA, V76, P3860, DOI 10.1073/pnas.76.8.3860; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; KIM HY, 1995, J BIOL CHEM, V270, P9706, DOI 10.1074/jbc.270.17.9706; LINDEN CD, 1973, P NATL ACAD SCI USA, V70, P2271, DOI 10.1073/pnas.70.8.2271; LOCKWICH TP, 1994, J MEMBRANE BIOL, V141, P289; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MARRIOTT I, 1995, AM J PHYSIOL-CELL PH, V269, pC766, DOI 10.1152/ajpcell.1995.269.3.C766; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MOREAU P, 1994, BBA-REV BIOMEMBRANES, V1197, P257; NAKAZAWA M, 1989, BLOOD, V73, P2003; NARAHASHI T, 1987, J PHYSIOL-LONDON, V383, P231; NOBILE M, 1990, PFLUG ARCH EUR J PHY, V415, P658, DOI 10.1007/BF02584002; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RAISON JK, 1972, J BIOENERGETICS, V275, P559; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REGA AF, 1986, CA2 PLUS PUMP PLASMA, P97; ROMEY G, 1980, BIOCHIM BIOPHYS ACTA, V602, P610, DOI 10.1016/0005-2736(80)90339-9; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SHUTTLEWORTH TJ, 1991, J BIOL CHEM, V266, P1410; SOMASUNDARAM B, 1995, BIOCHEM J, V309, P725, DOI 10.1042/bj3090725; SOMASUNDARAM B, 1994, J PHYSIOL-LONDON, V480, P225, DOI 10.1113/jphysiol.1994.sp020355; SONDERGAARD L, 1979, BIOCHIM BIOPHYS ACTA, V557, P208, DOI 10.1016/0005-2736(79)90103-2; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; WARREN GB, 1975, NATURE, V255, P684, DOI 10.1038/255684a0; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	45	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26096	26104		10.1074/jbc.271.42.26096	http://dx.doi.org/10.1074/jbc.271.42.26096			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824252	hybrid			2022-12-27	WOS:A1996VN18000058
J	Woodcock, JM; Bagley, CJ; Zacharakis, B; Lopez, AF				Woodcock, JM; Bagley, CJ; Zacharakis, B; Lopez, AF			A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE RECEPTOR; LEUKEMIA INHIBITORY FACTOR; GM-CSF RECEPTOR; GAMMA-CHAIN; ERYTHROPOIETIN RECEPTOR; PROLACTIN RECEPTOR; ALPHA-CHAIN; MOLECULAR-CLONING; FUNCTIONAL RECEPTORS; EXTRACELLULAR DOMAIN	The beta-chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and interleukin-5 (IL-5) receptors functions as a communal receptor subunit and is often referred to as beta common (beta(c)). Analogous to other shared receptor subunits including gp130 and the IL-2R gamma chain, beta(c) mediates high affinity binding and signal transduction of all of its Ligands. It is not clear, however, how these common receptor subunits can recognize several Ligands and indeed whether they exhibit a common binding pocket to accomplish this. We have performed molecular modeling of beta(c) based on the known structures of the growth hormone and prolactin receptors and targeted the putative F'-G' loop for mutagenesis. Substitution of this whole predicted loop region with alanines completely abrogated high affinity binding of GM-CSF, IL-3, and IL-5. Individual alanine substitutions across the loop revealed that a single residue, Tyr(421), is critical for high affinity binding of GM-CSF, IL-3, and IL-5, whereas alanine substitution of adjacent residues has little or no effect on high affinity binding. Significantly, reintroducing Tyr(421) into the polyalanine-substituted mutant restored high affinity ligand binding of GM-CSF, IL-3, and IL-5, indicating that within this region the tyrosine residue alone is sufficient for high affinity Ligand interaction. Functional studies measuring STAT5 activation revealed that alanine substitution of Tyr(421) severely impaired the ability of beta(c) to signal, These results show for the first time that a single residue in a shared receptor subunit acts as a binding determinant for different ligands and may have implications for other receptor systems where communal receptor subunits exhibit hydrophobic residues in their putative F'-G' loops. These results also raise the possibility that a single compound targeted to this region may simultaneously inhibit the binding and function of multiple cytokines.	INST MED & VET SCI,DIV HUMAN IMMUNOL,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA	Institute Medical & Veterinary Science Australia			Lopez, Angel F/E-2260-2011	Lopez, Angel F/0000-0001-7430-0135; Woodcock, Joanna/0000-0001-5127-9687				AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAGLEY CJ, 1995, J LEUKOCYTE BIOL, V57, P739, DOI 10.1002/jlb.57.5.739; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODALL GJ, 1993, GROWTH FACTORS, V8, P87, DOI 10.3109/08977199309046929; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LIU JW, 1992, J BIOL CHEM, V267, P16763; LOCK P, 1994, P NATL ACAD SCI USA, V91, P252, DOI 10.1073/pnas.91.1.252; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAMURA Y, 1992, SCIENCE, V257, P1138, DOI 10.1126/science.257.5073.1138; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SHANAFELT AB, 1992, J BIOL CHEM, V267, P25466; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	62	87	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25999	26006		10.1074/jbc.271.42.25999	http://dx.doi.org/10.1074/jbc.271.42.25999			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824238	hybrid			2022-12-27	WOS:A1996VN18000044
J	Catimel, B; Ritter, G; Welt, S; Old, LJ; Cohen, L; Nerrie, MA; White, SJ; Heath, JK; Demediuk, B; Domagala, T; Lee, FT; Scott, AM; Tu, GF; Ji, H; Moritz, RL; Simpson, RJ; Burgess, AW; Nice, EC				Catimel, B; Ritter, G; Welt, S; Old, LJ; Cohen, L; Nerrie, MA; White, SJ; Heath, JK; Demediuk, B; Domagala, T; Lee, FT; Scott, AM; Tu, GF; Ji, H; Moritz, RL; Simpson, RJ; Burgess, AW; Nice, EC			Purification and characterization of a novel restricted antigen expressed by normal and transformed human colonic epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; QUANTITATIVE-ANALYSIS; PROTEIN; CANCER; BIOSENSOR; A33	A cell surface antigen that is expressed by normal and 95% of transformed colonic epithelium and is recognized by the monoclonal antibody A33 (Welt, S., Divgi, C. R., Real F. X., Yeh, S. D., Garin-Chesa, P., Finstad, C. L., Sakamoto, J., Cohen, A., Sigurdson, E. R., Kemeny, N., Carswell, E. A., Oettgen, H. F., and Old, L. J. (1990) J. Clin. Oncol. 8, 1894-1906) has been purified to homogeneity from the human colonic carcinoma cell line LIM1215. The A33 protein was purified fi om Triton X-114 extracts of LIM1215 cells under nondenaturing conditions. These extracts were applied sequentially to Green-Sepharose HE-4BD, Mono-Q HR 10/10, Superose 12 HR 10/30, and micropreparative Brownlee Aquapore RP 300. The purification was monitored by biosensor analysis using surface plasmon resonance detection with a F(ab')(2) fragment of the humanized A33 monoclonal antibody immobilized on the sensor surface and Western blot analysis following SDS-polyacrylamide gel electrophoresis (PAGE) under nonreducing conditions using humanized A33 monoclonal antibody. The purified A33 antigen has a M(r) on SDS-PAGE of 43,000 under nonreducing conditions. By contrast, the purified protein displayed a M(r) of approximately 180,000 under native conditions on both size exclusion chromatography and native PAGE, possibly due to the formation of a homotetramer. N-terminal amino acid sequence analysis of the purified protein identified 34 amino acid residues of a unique sequence: ISVETPQDVLRASQGKSVTLPXTYHTSXXXREGLIQWD. A polyclonal antibody was raised against a synthetic peptide corresponding to residues 2-20 of this sequence. The antipeptide serum recognized the purified protein using Western blot analysis under both nonreducing (M(r) 43,000) and reducing (M(r) 49,000) conditions.	LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA; LUDWIG INST CANC RES, JOINT PROT STRUCT LAB, MELBOURNE, VIC 3050, AUSTRALIA; WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; LUDWIG INST CANC RES, JOINT ONCOL UNIT, HEIDELBERG, VIC 3084, AUSTRALIA; AUSTIN HOSP, HEIDELBERG, VIC 3084, AUSTRALIA; MEM SLOAN KETTERING CANC CTR, LUDWIG INST CANC RES, NEW YORK, NY 10021 USA	Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; Memorial Sloan Kettering Cancer Center			Heath, Joan/D-3054-2012; Nice, Edouard C/B-1026-2011; Moritz, Robert L/B-9222-2011	Heath, Joan/0000-0001-6955-232X; Scott, Andrew/0000-0002-6656-295X; CATIMEL, Bruno/0000-0002-4350-6875; Simpson, Richard/0000-0002-9834-0796				BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BRUSCA JS, 1994, METHOD ENZYMOL, V228, P182; CHAIKEN I, 1992, ANAL BIOCHEM, V201, P197, DOI 10.1016/0003-2697(92)90329-6; KING DJ, 1995, BRIT J CANCER, V72, P1364, DOI 10.1038/bjc.1995.516; LASKY M, 1978, ELECTROPHORESIS 78, P195; LIEDBERG B, 1983, SENSOR ACTUATOR, V4, P299, DOI 10.1016/0250-6874(83)85036-7; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; LOW MG, 1987, BIOCHEM J, V244, P1; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MOORE AE, 1955, CANCER RES, V15, P598; MORITZ RL, 1995, TECHNIQUES PROTEIN C, V4, P331; NICE E, 1994, J CHROMATOGR A, V660, P169, DOI 10.1016/0021-9673(94)85110-7; NICE E, 1993, J CHROMATOGR, V646, P159, DOI 10.1016/S0021-9673(99)87017-4; Nice EC, 1996, MOL IMMUNOL, V33, P659, DOI 10.1016/0161-5890(96)00016-8; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PARHAM P, 1983, J IMMUNOL, V131, P2895; REID GE, 1995, ELECTROPHORESIS, V16, P1120, DOI 10.1002/elps.11501601189; SCHMOLL HJ, 1994, ANN ONCOL, V5, pS115, DOI 10.1093/annonc/5.suppl_3.S115; Shapiro H. M., 1988, PRACTICAL FLOW CYTOM; SIMPSON RJ, 1989, ANAL BIOCHEM, V177, P221, DOI 10.1016/0003-2697(89)90044-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; UBRICH N, 1995, J MOL RECOGNIT, V8, P111, DOI 10.1002/jmr.300080120; WELT S, 1990, J CLIN ONCOL, V8, P1894, DOI 10.1200/JCO.1990.8.11.1894; WELT S, 1994, J CLIN ONCOL, V12, P1561, DOI 10.1200/JCO.1994.12.8.1561; Welt S, 1996, J CLIN ONCOL, V14, P1787, DOI 10.1200/JCO.1996.14.6.1787; WHITEHEAD RH, 1985, JNCI-J NATL CANCER I, V74, P759	27	50	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25664	25670		10.1074/jbc.271.41.25664	http://dx.doi.org/10.1074/jbc.271.41.25664			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810343	hybrid			2022-12-27	WOS:A1996VL69300087
J	Heymach, JV; Kruttgen, A; Suter, U; Shooter, EM				Heymach, JV; Kruttgen, A; Suter, U; Shooter, EM			The regulated secretion and vectorial targeting of neurotrophins in neuroendocrine and epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HIPPOCAMPAL-NEURONS; PC12 CELLS; EXOGENOUS PROTEINS; MAMMALIAN-CELLS; FACTOR NGF; RAT IRIS; A-CHAIN; EXPRESSION; BDNF	The varied roles that neurotrophins play in the development and activity-dependent plasticity of the nervous system presumably require that the sites and quantity of neurotrophin release be precisely regulated, As a step toward understanding how different neurotrophins are sorted and secreted by neurons, we expressed nerve growth factor (NGF), brain-derived neurotrophic factor, and neurotrophin-3 in cell lines used as models for neuronal protein sorting. All three-neurotrophins were secreted by a regulated pathway in transfected AtT-20 and PC12 neuroendocrine cells, with a 3-6-fold increase in neurotrophin release in response to 8-bromo-cAMP or depolarization, respectively. To determine if the propeptide directs the intracellular sorting of mature NGF, we examined mutants in which regions spanning the propeptide were deleted. These mutants underwent regulated release in every case in which expression could be detected. Similarly, NGF sorting was not significantly altered by mutations which specifically abolished N-glycosylation or proteolytic processing sites within the NGF precursor. Finally, we found that all three neurotrophins were secreted 65-75% basolaterally by polarized Madin-Darby canine kidney epithelial cells, These findings suggest that the determinants of regulated neurotrophin secretion lie within the mature neurotrophin moiety and that NGF, brain-derived neurotrophic factor, and neurotrophin-3 are likely to be sorted similarly and released in a regulated manner by neurons.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Heymach, John/AAG-2361-2019; Kruttgen, Alexander P/E-9232-2010; Suter, Ueli/A-1624-2010	Heymach, John/0000-0001-9068-8942; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07249] Funding Source: Medline; NINDS NIH HHS [NS04270, NS07158] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ACHESON A, 1995, NATURE, V374, P450, DOI 10.1038/374450a0; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSSON M, 1994, J BIOL CHEM, V269, P926; BARTH EM, 1984, J CELL BIOL, V99, P839, DOI 10.1083/jcb.99.3.839; BLOCHL A, 1995, EUR J NEUROSCI, V7, P1220, DOI 10.1111/j.1460-9568.1995.tb01112.x; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BRION C, 1992, J BIOL CHEM, V267, P1477; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHAVEZ RA, 1994, METHOD CELL BIOL, V43, P263; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; CUOZZO JW, 1995, J BIOL CHEM, V270, P15611, DOI 10.1074/jbc.270.26.15611; DAVIES AM, 1994, J NEUROBIOL, V25, P1334, DOI 10.1002/neu.480251103; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; DRINKWATER CC, 1993, J BIOL CHEM, V268, P23202; EBENDAL T, 1989, J NEUROSCI RES, V22, P223, DOI 10.1002/jnr.490220302; EDWARDS RH, 1986, NATURE, V319, P784, DOI 10.1038/319784a0; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; GONZALEZ A, 1987, P NATL ACAD SCI USA, V84, P3738, DOI 10.1073/pnas.84.11.3738; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; HOYLE GW, 1993, NEURON, V10, P1019, DOI 10.1016/0896-6273(93)90051-R; HUTTNER WB, 1995, CURR BIOL, V5, P242, DOI 10.1016/S0960-9822(95)00049-2; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; JONGSTRABILEN J, 1989, MOL BRAIN RES, V5, P159, DOI 10.1016/0169-328X(89)90007-7; JOURNET AM, 1993, EUR J CELL BIOL, V60, P31; JUNG LJ, 1991, SCIENCE, V251, P1330, DOI 10.1126/science.2003219; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; KELLY RB, 1993, ANNU REV NEUROSCI, V16, P95, DOI 10.1146/annurev.ne.16.030193.000523; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LO DC, 1995, NEURON, V15, P979, DOI 10.1016/0896-6273(95)90085-3; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; Martin Thomas F. J., 1994, Current Opinion in Neurobiology, V4, P626, DOI 10.1016/0959-4388(94)90002-7; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; NARHI LO, 1993, J BIOL CHEM, V268, P13309; NELSON WJ, 1987, J CELL BIOL, V104, P1527, DOI 10.1083/jcb.104.6.1527; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWEITZER ES, 1990, J CELL SCI, V96, P375; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; SHELTON DL, 1986, J CELL BIOL, V102, P1940, DOI 10.1083/jcb.102.5.1940; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; SURPRENANT A, 1982, J CELL BIOL, V95, P559, DOI 10.1083/jcb.95.2.559; SUTER U, 1991, EMBO J, V10, P2395, DOI 10.1002/j.1460-2075.1991.tb07778.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; TWISS JL, 1995, J NEUROCHEM, V64, P550; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; vonBartheld CS, 1996, NATURE, V379, P830, DOI 10.1038/379830a0; WETMORE C, 1994, J NEUROSCI, V14, P1688, DOI 10.1523/JNEUROSCI.14-03-01688.1994; WETMORE C, 1991, P NATL ACAD SCI USA, V88, P9843, DOI 10.1073/pnas.88.21.9843; WICK PF, 1993, J BIOL CHEM, V268, P10983	63	89	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25430	25437		10.1074/jbc.271.41.25430	http://dx.doi.org/10.1074/jbc.271.41.25430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810312	hybrid			2022-12-27	WOS:A1996VL69300056
J	Yan, C; Zhao, AZ; Bentley, JK; Beavo, JA				Yan, C; Zhao, AZ; Bentley, JK; Beavo, JA			The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue-specific manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 3' UNTRANSLATED REGION; MOLECULAR-CLONING; BOVINE BRAIN; STIMULATED PHOSPHODIESTERASE; EXPRESSION; SEQUENCE; 63-KDA; 61-KDA; PURIFICATION	We report here the identification of cDNAs for three new mouse PDE1C splice variants and the characterization of their kinetics, regulation by Ca2+, sensitivities to inhibitors, and tissue/cellular expression patterns. Sequence analysis indicated that these three cDNAs (PDE1C1, PDE1C4, and PDE1C5), together with our previously reported PDE1C2 and PDE1C3, are alternative splice products of the PDE1C gene. The results from RNase protection analysis and in situ hybridization indicated that the expression of the different PDE1C splice variants is differentially regulated in a tissue/cell-specific manner. Particularly, high levels of PDE1C mRNAs were found in the olfactory epithelium, testis, and several regions of mouse brain such as cerebellar granule cells, All of these splice variants have similar kinetic properties, showing high affinities and approximately the same relative V-max values for both cAMP and cGMP. However, they responded to Ca2+ stimulation differently, In addition, they show different sensitivities to the calmodulin-dependent phosphodiesterase inhibitors, KS505a and SCH51866. Substrate competition experiments suggested the presence of only one catalytic site on these PDE1C isozymes for both cAMP and cGMP. In summary, these findings suggest that the PDE1C gene undergoes tissue-specific alternative splicing that generates structurally and functionally diverse gene products.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle				Bentley, John Kelley/0000-0001-8865-7979; Yan, Chen/0000-0002-1397-6358	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44948] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAVO J, 1990, CYCLIC NUCLEOTIDE PH, V2, P19; BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BORISY FF, 1992, J NEUROSCI, V12, P915; BRAWERMAN G, 1987, CELL, V48, P5, DOI 10.1016/0092-8674(87)90346-1; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; DIDIER M, 1992, MOL BRAIN RES, V12, P249, DOI 10.1016/0169-328X(92)90091-O; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLIS P, 1991, J BIOL CHEM, V266, P3172; HAGIWARA M, 1984, BIOCHEM PHARMACOL, V33, P453, DOI 10.1016/0006-2952(84)90240-5; HANSEN RS, 1986, J BIOL CHEM, V261, P4636; HANSEN RS, 1982, P NATL ACAD SCI-BIOL, V79, P2788, DOI 10.1073/pnas.79.9.2788; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOUGHNEY K, 1994, FASEB J, V8, P469; MACFARLAND RT, 1991, J BIOL CHEM, V266, P136; MAYER B, 1992, J NEUROCHEM, V59, P2024; NAKANISHI S, 1992, J ANTIBIOT, V45, P341, DOI 10.7164/antibiotics.45.341; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; POLLI JW, 1992, P NATL ACAD SCI USA, V89, P11079, DOI 10.1073/pnas.89.22.11079; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROSSI P, 1988, J BIOL CHEM, V263, P15521; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARMA RK, 1991, BIOCHEMISTRY-US, V30, P5963, DOI 10.1021/bi00238a021; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; Sonnenburg WK, 1995, J BIOL CHEM, V270, P30989, DOI 10.1074/jbc.270.52.30989; VAN VBJ, 1989, J NEUROCHEM, V52, P1229; VANDERMEERS A, 1983, BIOCHEM J, V211, P341, DOI 10.1042/bj2110341; WATKINS RW, 1995, FASEB J, V9, P342; YAN C, 1994, J NEUROSCI, V14, P973; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677	35	124	128	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25699	25706		10.1074/jbc.271.41.25699	http://dx.doi.org/10.1074/jbc.271.41.25699			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810348	hybrid			2022-12-27	WOS:A1996VL69300092
J	Biessen, EAL; Noorman, F; vanTeijlingen, ME; Kuiper, J; BarrettBergshoeff, M; Bijsterbosch, MK; Rijken, DC; vanBerkel, TJC				Biessen, EAL; Noorman, F; vanTeijlingen, ME; Kuiper, J; BarrettBergshoeff, M; Bijsterbosch, MK; Rijken, DC; vanBerkel, TJC			Lysine-based cluster mannosides that inhibit ligand binding to the human mannose receptor at nanomolar concentration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION DOMAINS; RABBIT ALVEOLAR MACROPHAGES; HIGH-AFFINITY BINDING; PLASMINOGEN-ACTIVATOR; CELLS; ENDOCYTOSIS; LIVER; GLYCOPROTEINS; CLEARANCE; LECTINS	In search of synthetic high affinity ligands for the mannose receptor, we synthesized a series of lysine-based oligomannosides containing two (M(2)L) to six (M(6)L(5)) terminal alpha-D-mannose groups that are connected with the backbone by flexible elongated spacers (16 Angstrom). The synthesized cluster mannosides were all able to displace binding of biotinylated ribonuclease B and tissue-type plasminogen activator to isolated human mannose receptor, The affinity of these cluster mannosides for the mannose receptor was continuously enhanced from 18-23 mu M to 0.5-2.6 nM, with mannose valencies increasing from two to six. On average, expansion of the cluster mannoside with an additional alpha-D-mannose group resulted in a 10-fold increase in its affinity for the mannose receptor. M(3)L(2) to M(6)L(5) displayed negative cooperative inhibition of ligand binding to the mannose receptor, suggesting that binding of these mannosides involves multiple binding sites. The nanomolar affinity of the most potent ligand, the hexamannoside M(6)L(5) makes it the most potent synthetic cluster mannoside for the mannose receptor yet developed. As a result of its high affinity and accessible synthesis, M(6)L(5) not only is a powerful tool to study the mechanism of ligand binding by the mannose receptor, but it is also a promising targeting device to accomplish cell-specific delivery of genes and drugs to liver endothelial cells or macrophages in bone marrow, lungs, spleen, and atherosclerotic plaques.	TNO PREVENT & HLTH,GAUBIUS LAB,NL-2301 CE LEIDEN,NETHERLANDS	Netherlands Organization Applied Science Research	Biessen, EAL (corresponding author), LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,POB 9503,NL-2300 RA LEIDEN,NETHERLANDS.		Van Berkel, Theo/ABD-7677-2021	Noorman, Femke/0000-0002-4891-2047				BIESSEN EAL, 1994, BIOCHEM J, V299, P291, DOI 10.1042/bj2990291; BIESSEN EAL, 1995, J MED CHEM, V38, P1538, DOI 10.1021/jm00009a014; BIESSEN EAL, 1988, BIOCHEM PHARMACOL, V37, P3959, DOI 10.1016/0006-2952(88)90080-9; BIESSEN EAL, 1996, CIRCULATION, V92, P692; BRUNDA MJ, 1983, INT J CANCER, V31, P373, DOI 10.1002/ijc.2910310319; DERIJKE YB, 1992, J LIPID RES, V33, P1315; DERRIEN D, 1989, GLYCOCONJUGATE J, V6, P241, DOI 10.1007/BF01050652; EZEKOWITZ RAB, 1991, NATURE, V351, P155, DOI 10.1038/351155a0; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HOPPE CA, 1984, BIOCHEMISTRY-US, V23, P1723, DOI 10.1021/bi00303a022; HOPPE CA, 1983, J BIOL CHEM, V258, P4193; JANSEN RW, 1991, J BIOL CHEM, V266, P3343; KATAOKA M, 1984, J HISTOCHEM CYTOCHEM, V32, P1091, DOI 10.1177/32.10.6434628; KERY V, 1992, ARCH BIOCHEM BIOPHYS, V298, P49, DOI 10.1016/0003-9861(92)90092-B; LEE RT, 1991, J BIOL CHEM, V266, P4810; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; MAIHOTRA R, 1995, NAT MED, V1, P237; MAYNARD Y, 1981, J BIOL CHEM, V256, P8063; MONSIGNY M, 1983, BIOL CELL, V47, P95; OSHIMI Y, 1988, ARCH BIOCHEM BIOPHYS, V260, P241; OTTER M, 1992, ANN NY ACAD SCI, V667, P431, DOI 10.1111/j.1749-6632.1992.tb51645.x; OTTER M, 1992, HEPATOLOGY, V16, P54, DOI 10.1002/hep.1840160111; OTTER M, 1991, J BIOL CHEM, V266, P13931; OTTER M, 1992, BIOCHEM J, V284, P545, DOI 10.1042/bj2840545; ROBBINS JC, 1981, P NATL ACAD SCI-BIOL, V78, P7294, DOI 10.1073/pnas.78.12.7294; SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345; STAHL PD, 1990, AM J RESP CELL MOL, V2, P317, DOI 10.1165/ajrcmb/2.4.317; STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; TAYLOR ME, 1993, J BIOL CHEM, V268, P399; TAYLOR ME, 1993, BIOCHEM SOC T, V21, P468, DOI 10.1042/bst0210468	33	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28024	28030		10.1074/jbc.271.45.28024	http://dx.doi.org/10.1074/jbc.271.45.28024			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910412	Green Published, hybrid			2022-12-27	WOS:A1996VU03300012
J	Gurnett, CA; Campbell, KP				Gurnett, CA; Campbell, KP			Transmembrane auxiliary subunits of voltage-dependent ion channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SENSITIVE CALCIUM-CHANNEL; CA2+-ACTIVATED K+ CHANNEL; SODIUM-CHANNEL; SKELETAL-MUSCLE; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; POTASSIUM CHANNELS; SAXITOXIN BINDING; GAMMA-SUBUNIT; CELL LINE		UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa; University of Iowa				Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889				Bangalore R, 1996, AM J PHYSIOL-HEART C, V270, pH1521, DOI 10.1152/ajpheart.1996.270.5.H1521; BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BenEfraim I, 1996, J BIOL CHEM, V271, P8768, DOI 10.1074/jbc.271.15.8768; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BROWN EM, 1993, NATURE, V366, P373; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; Chen CF, 1995, PFLUG ARCH EUR J PHY, V431, P186, DOI 10.1007/BF00410190; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; ESGUERRA M, 1994, NATURE, V369, P563, DOI 10.1038/369563a0; FENG GP, 1995, CELL, V82, P1001, DOI 10.1016/0092-8674(95)90279-1; FOLANDER K, 1995, SOC NEUR ABSTR, P1326; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GILAD B, 1995, NEUROSCI LETT, V193, P157, DOI 10.1016/0304-3940(95)11689-T; GODINOT N, 1995, SOC NEUR ABSTR, P1326; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; ILES DE, 1994, HUM MOL GENET, V3, P969, DOI 10.1093/hmg/3.6.969; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; JACKSON FR, 1986, J NEUROGENET, V3, P1, DOI 10.3109/01677068609106891; JAY SD, 1990, SCIENCE, V248, P490, DOI 10.1126/science.2158672; KNAUS HG, 1994, J BIOL CHEM, V269, P23336; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; MCCLATCHEY AI, 1993, HUM MOL GENET, V2, P745, DOI 10.1093/hmg/2.6.745; MCCOBB DP, 1995, AM J PHYSIOL-HEART C, V269, pH767, DOI 10.1152/ajpheart.1995.269.3.H767; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; MCMANUS OB, 1995, NEURON, V14, P645, DOI 10.1016/0896-6273(95)90321-6; MESSNER DJ, 1986, J BIOL CHEM, V261, P211; MORTON ME, 1994, FASEB J, V8, P884, DOI 10.1096/fasebj.8.11.8070639; ODOWD DK, 1988, J NEUROSCI, V8, P3633; POWERS PA, 1993, J BIOL CHEM, V268, P9275; RECIOPINTO E, 1990, NEURON, V5, P675, DOI 10.1016/0896-6273(90)90221-Z; ROCK DM, 1993, EPILEPSY RES, V16, P89, DOI 10.1016/0920-1211(93)90023-Z; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; SCHEINMAN RI, 1989, J BIOL CHEM, V264, P10660; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SHISTIK E, 1995, J PHYSIOL-LONDON, V489, P55, DOI 10.1113/jphysiol.1995.sp021029; SMITH RG, 1992, NEW ENGL J MED, V327, P1721, DOI 10.1056/NEJM199212103272405; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; STRUBE C, 1996, IN PRESS BIOPHYS J; TAKUMI T, 1991, J BIOL CHEM, V266, P22192; TOKUMARU H, 1995, J NEUROCHEM, V65, P831; WEI A, 1994, NEURON, V13, P671, DOI 10.1016/0896-6273(94)90034-5; WEI XY, 1995, J BIOL CHEM, V270, P27106, DOI 10.1074/jbc.270.45.27106; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; Wiser O, 1996, FEBS LETT, V379, P15, DOI 10.1016/0014-5793(95)01475-6	52	59	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27975	27978		10.1074/jbc.271.45.27975	http://dx.doi.org/10.1074/jbc.271.45.27975			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910401	hybrid			2022-12-27	WOS:A1996VU03300001
J	Lin, HC; Gilman, AG				Lin, HC; Gilman, AG			Regulation of dynamin I GTPase activity by G protein beta gamma subunits and phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAINS; CLATHRIN-COATED VESICLES; HIGH-AFFINITY BINDING; MECHANOCHEMICAL ENZYME; PH DOMAIN; MICROTUBULES; ACTIVATION; KINASE; ENDOCYTOSIS; SHIBIRE	Dynamin I is a 100-kDa GTPase that plays an important role in the recycling of synaptic vesicles. Hydrolysis of GTP by dynamin is thought to be a critical step in fission of coated pits to form coated vesicles. We report that the heterotrimeric G protein beta gamma subunit complex (G(beta gamma)) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) are negative and positive regulators of dynamin GTPase activity, respectively. Furthermore, the apparent affinity of dynamin for G(beta gamma) is substantially enhanced by PtdIns(4,5)P-2. However, the GTPase activity of oligomeric dynamin is unaffected by G(beta gamma). The effects of heterotrimeric G proteins on endocytosis may thus be mediated directly and not involve more remote aspects of their signaling properties.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CHERKSEY B, 1994, NEUROCHEM RES, V19, P1101, DOI 10.1007/BF00968722; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; LIU JP, 1994, J BIOL CHEM, V269, P21043; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SILVA WI, 1991, JPN J PHARMACOL, V56, P97, DOI 10.1254/jjp.56.97; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	28	79	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27979	27982		10.1074/jbc.271.45.27979	http://dx.doi.org/10.1074/jbc.271.45.27979			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910402	hybrid			2022-12-27	WOS:A1996VU03300002
J	Rostovtseva, T; Colombini, M				Rostovtseva, T; Colombini, M			ATP flux is controlled by a voltage-gated channel from the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC POLYANION; NEUROSPORA-CRASSA; VDAC CHANNEL; PORIN; PERMEABILITY; CALCIUM; PROTEIN; MODE	A voltage-gated channel, called VDAC (mitochondrial porin) is known to be responsible for most of the metabolite flux across the mitochondrial outer membrane. Here, direct measurements of ATP flux through VDAC channels reconstituted into planar phospholipid membranes establish that VDAC is sufficient to provide passage for ATP efflux from mitochondria. Further, the gating of the channel can shut down ATP flux completely while, simultaneously, allowing the flow of small ions. Thus, these channels are ideally suited to control ATP flux through the mitochondrial outer membrane and, consequently, mitochondrial function. The block to ATP flow through the closed state is likely to be not steric but electrostatic.	UNIV MARYLAND,DEPT ZOOL,CELL BIOL LABS,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014					BENZ R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P311, DOI 10.1016/0005-2736(90)90279-W; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BRDICZKA D, 1994, NATO ASI SERIES H, V83, P297; CHAPPELL JB, 1964, BIOCHEM J, V90, P237, DOI 10.1042/bj0900237; Colombini M, 1980, Ann N Y Acad Sci, V341, P552, DOI 10.1111/j.1749-6632.1980.tb47198.x; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1994, CURR TOP MEMBR, V42, P73, DOI 10.1016/S0070-2161(08)60819-9; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; FEIN A, 1988, NATURE, V331, P437, DOI 10.1038/331437a0; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; INOUE I, 1991, NATURE, V352, P244, DOI 10.1038/352244a0; LEE AC, 1994, J BIOL CHEM, V269, P30974; LINDEN M, 1984, BIOCHIM BIOPHYS ACTA, V770, P93, DOI 10.1016/0005-2736(84)90077-4; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MANNELLA CA, 1990, BIOPHYS J, V57, P23, DOI 10.1016/S0006-3495(90)82503-0; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; SORGATO MC, 1987, NATURE, V330, P498, DOI 10.1038/330498a0; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; ZAMBROWICZ EB, 1993, BIOPHYS J, V65, P1093, DOI 10.1016/S0006-3495(93)81148-2; ZIZI M, 1994, J BIOL CHEM, V269, P1614	27	200	204	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28006	28008		10.1074/jbc.271.45.28006	http://dx.doi.org/10.1074/jbc.271.45.28006			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910409	hybrid			2022-12-27	WOS:A1996VU03300009
J	Verdot, L; Lalmanach, G; Vercruysse, V; Hartmann, S; Lucius, R; Hoebeke, J; Gauthier, F; Vray, B				Verdot, L; Lalmanach, G; Vercruysse, V; Hartmann, S; Lucius, R; Hoebeke, J; Gauthier, F; Vray, B			Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGG-WHITE CYSTATIN; TRYPANOSOMA-CRUZI; CYSTEINE PROTEINASES; ALVEOLAR MACROPHAGES; RESPIRATORY BURST; CHICKEN CYSTATIN; CHAGAS-DISEASE; SYNTHASE GENE; T-KININOGEN; INHIBITORS	Up-regulation of nitric oxide (NO) production by activated murine macrophages was observed during infection by Trypanosoma cruzi, the etiological agent of Chagas' disease. Cell infection by T. cruzi depends at least in part on cruzipain, a membrane-associated papain-related proteinase which is sensitive to inhibition by synthetic inhibitors of cysteine proteinases. Using the natural cysteine proteinase inhibitor chicken cystatin, a representative member of cystatin family 2, to investigate the effect of cruzipain on macrophage infection and NO release, we found that the inhibitor alone up-regulated NO release from interferon-gamma-activated macrophages. A 12-fold increase in NO production was observed in the presence of 1 mu M chicken cystatin. This overproduction was concentration-dependent and could be detected at concentrations as low as 10 nM and remained in the presence of polymyxin B. Representative members of the other cystatin families, i.e. stefin B (family 1), T-kininogen, and its inhibitory domains (family 3), were also able to enhance NO production from interferon-gamma-activated macrophages. Neither E64, an irreversible inhibitor of cysteine proteinases, nor inhibitors of aspartyl and serine proteinases (aprotinin, pepstatin, and soybean trypsin inhibitor) enhanced NO production. Upon complexation with saturating amounts of reduced-alkylated papain, cystatins still remained active in increasing NO production, suggesting that the cystatin inhibitory site was not involved in the mechanism. The results demonstrate that members of all 3 cystatin families share another common property unrelated to their function of cysteine proteinase inhibitors, i.e. upregulation of NO production, which biological significance remains to be elucidated.	FREE UNIV BRUSSELS, FAC MED, EXPT IMMUNOL LAB, B-1070 BRUSSELS, BELGIUM; UNIV TOURS, LAB ENZYMOL & CHIM PROT, F-37032 TOURS, FRANCE; HUMBOLDT UNIV BERLIN, INST BIOL, BERLIN, GERMANY	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite de Tours; Humboldt University of Berlin			Hartmann, Susanne/M-9154-2016	Lalmanach, Gilles/0000-0001-8562-4821				ARAUJO-JORGE T C D, 1989, Memorias do Instituto Oswaldo Cruz, V84, P441; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BJORK I, 1989, BIOCHEM J, V260, P61; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BOGLE RG, 1991, BIOCHEM BIOPH RES CO, V180, P926, DOI 10.1016/S0006-291X(05)81154-4; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; CAZULLO JJ, 1990, BIOCHIM BIOPHYS ACTA, V1037, P186; CAZULLO JJ, 1989, MOL BIOCHEM PARASIT, V33, P33; CHESROWN SE, 1994, BIOCHEM BIOPH RES CO, V200, P126, DOI 10.1006/bbrc.1994.1424; DENG WL, 1993, J IMMUNOL, V151, P322; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682, DOI 10.1002/jlb.55.5.682; EAKIN AE, 1992, J BIOL CHEM, V267, P7411; ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUTMAN N, 1988, EUR J BIOCHEM, V171, P577, DOI 10.1111/j.1432-1033.1988.tb13827.x; HARTH G, 1993, MOL BIOCHEM PARASIT, V58, P17, DOI 10.1016/0166-6851(93)90086-D; JORENS PG, 1992, AGENTS ACTIONS, V36, P243; JORENS PG, 1992, BIOCHEM PHARMACOL, V44, P387, DOI 10.1016/0006-2952(92)90025-E; KILBOURN R, 1990, J IMMUNOL, V144, P1042; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LEUNGTACK J, 1990, EXP CELL RES, V188, P16, DOI 10.1016/0014-4827(90)90272-C; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; MEIRELLES MNL, 1992, MOL BIOCHEM PARASIT, V52, P175, DOI 10.1016/0166-6851(92)90050-T; METZ G, 1993, PARASITE IMMUNOL, V15, P693, DOI 10.1111/j.1365-3024.1993.tb00584.x; MOREAU T, 1989, J BIOL CHEM, V264, P4298; MURTA ACM, 1990, MOL BIOCHEM PARASIT, V43, P27, DOI 10.1016/0166-6851(90)90127-8; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OSWALD IP, 1994, COMP BIOCHEM PHYS C, V108, P11, DOI 10.1016/1367-8280(94)90083-3; PETRAY P, 1994, PARASITE IMMUNOL, V16, P193, DOI 10.1111/j.1365-3024.1994.tb00340.x; SAKURADA JK, 1992, RES IMMUNOL, V143, P157, DOI 10.1016/S0923-2494(92)80158-H; SCHARFSTEIN J, 1986, J IMMUNOL, V137, P1336; SCHARFSTEIN J, 1995, J IMMUNOL METHODS, V182, P63, DOI 10.1016/0022-1759(95)00023-4; SOUTOPADRON T, 1990, J CELL SCI, V96, P485; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TANOWITZ HB, 1992, CLIN MICROBIOL REV, V5, P400, DOI 10.1128/CMR.5.4.400-419.1992; TIFFANY CW, 1989, FEBS LETT, V247, P189, DOI 10.1016/0014-5793(89)81331-6; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VESPA GNR, 1994, INFECT IMMUN, V62, P5177, DOI 10.1128/IAI.62.11.5177-5182.1994; WEISZ A, 1994, J BIOL CHEM, V269, P8324; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	44	98	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28077	28081		10.1074/jbc.271.45.28077	http://dx.doi.org/10.1074/jbc.271.45.28077			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910420	hybrid			2022-12-27	WOS:A1996VU03300020
J	Iwasaki, T; Imai, T; Urushiyama, A; Oshima, T				Iwasaki, T; Imai, T; Urushiyama, A; Oshima, T			Redox-linked ionization of Sulredoxin, an archaeal Rieske-type [2Fe-2S] protein from Sulfolobus sp strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; RESONANCE RAMAN-SPECTROSCOPY; MAGNETIC CIRCULAR-DICHROISM; THERMOACIDOPHILIC ARCHAEON; PHTHALATE DIOXYGENASE; ACIDOTHERMOPHILIC ARCHAEBACTERIUM; CYTOCHROME-BC1 COMPLEXES; 2 HISTIDINES; FES CENTER; ACIDOCALDARIUS	''Sulredoxin'' of Sulfolobus sp. strain 7 is an archaeal soluble Rieske-type [2Fe-2S] protein and was initially characterized by several spectroscopic techniques (Iwasaki, T., Isogai, T., Iizuka, T., and Oshima, T. (1995) J. Bacteriol. 177, 2576-2582), It appears to have tightly linked ionization affecting the redox properties of the protein, which is characteristic of the Rieske FeS proteins found as part of the respiratory chain, Sulredoxin had an E(m)(low pH) value of +188 +/- 9 mV, and the slope of pH dependence of the midpoint redox potential indicated two ionization equilibria in the oxidized form with pK(a(ox1)) of 6.23 +/- 0.22 and pK(a(ox2)) of 8.57 +/- 0.20, The absorption, CD, and resonance Raman spectra of oxidized sulredoxin are consistent with the proposed (S2FeS2Fe)-Fe-t-Fe-b[N(His)](t)(2) core structure, and deprotonation of one of the two putative coordinated histidine imidazoles, having the pK(a(ox2)) of 8.57 +/- 0.20, causes a decrease in the midpoint redox potential, the change in the optical and CD spectra, and the appearance of a new Raman transition at 278 cm(-1), without major structural rearrangement of the [2Fe-2S] cluster as well as the overall protein conformation, The redox-linked ionization of sulredoxin is also contributed by local changes involving another ionizable group having the pK(a(ox1)) of 6.23 +/- 0.22, which is probably attributed to a certain positively charged amino acid residue that may not be a ligand by itself but located very close to the cluster. We suggest that sulredoxin provides a new tractable model of the membrane-bound homologue of the respiratory chain, the Rieske FeS proteins of the cytochrome bc(1)-b(6)f complexes.	TOKYO INST TECHNOL, DEPT LIFE SCI, YOKOHAMA, KANAGAWA 226, JAPAN; RIKKYO UNIV, DEPT CHEM, TOSHIMA KU, TOKYO 171, JAPAN; TOKYO UNIV PHARM & LIFE SCI, DEPT MOL BIOL, HACHIOJI, TOKYO 19203, JAPAN	Tokyo Institute of Technology; Rikkyo University; Tokyo University of Pharmacy & Life Sciences	Iwasaki, T (corresponding author), NIPPON MED COLL, DEPT BIOCHEM & MOL BIOL, BUNKYO KU, 1-1-5 SENDAGI, TOKYO 113, JAPAN.			Iwasaki, Toshio/0000-0001-9562-4649				ANEMULLER S, 1994, BIOCHEM BIOPH RES CO, V202, P252, DOI 10.1006/bbrc.1994.1920; ANEMULLER S, 1993, FEBS LETT, V318, P61, DOI 10.1016/0014-5793(93)81328-W; BRITT RD, 1991, BIOCHEMISTRY-US, V30, P1892, DOI 10.1021/bi00221a023; Clark W. M., 1960, OXIDATION REDUCTION; CLINE JF, 1985, J BIOL CHEM, V260, P3251; DAVIDSON E, 1992, BIOCHEMISTRY-US, V31, P3342, DOI 10.1021/bi00128a006; DENDA K, 1990, J BIOL CHEM, V265, P21509; FEE JA, 1984, J BIOL CHEM, V259, P124; FEE JA, 1986, BIOCHIM BIOPHYS ACTA, V853, P153, DOI 10.1016/0304-4173(86)90009-1; FU WG, 1992, J BIOL CHEM, V267, P15502; GURBIEL RJ, 1989, BIOCHEMISTRY-US, V28, P4861, DOI 10.1021/bi00437a051; GURBIEL RJ, 1991, BIOCHEMISTRY-US, V30, P11579, DOI 10.1021/bi00113a013; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; IMAI T, 1995, FEBS LETT, V368, P23, DOI 10.1016/0014-5793(95)00601-5; IWASAKI T, 1995, J BACTERIOL, V177, P2576, DOI 10.1128/jb.177.9.2576-2582.1995; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; IWASAKI T, 1994, J BIOL CHEM, V269, P29444; IWASAKI T, 1995, J BIOL CHEM, V270, P17878, DOI 10.1074/jbc.270.30.17878; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; KNAFF DB, 1976, BIOCHIM BIOPHYS ACTA, V430, P244, DOI 10.1016/0005-2728(76)90082-7; KONISHI J, 1987, J BIOCHEM, V102, P1379, DOI 10.1093/oxfordjournals.jbchem.a122184; KUILA D, 1987, J AM CHEM SOC, V109, P1559, DOI 10.1021/ja00239a041; KUILA D, 1992, BIOCHIM BIOPHYS ACTA, V1140, P175, DOI 10.1016/0005-2728(92)90007-O; KUILA D, 1986, J BIOL CHEM, V261, P2768; LIEBL U, 1992, J BIOL CHEM, V267, P14068; LINK TA, 1992, EUR J BIOCHEM, V208, P685, DOI 10.1111/j.1432-1033.1992.tb17235.x; LUBBEN M, 1994, EUR J BIOCHEM, V224, P151, DOI 10.1111/j.1432-1033.1994.tb20006.x; MASON JR, 1992, ANNU REV MICROBIOL, V46, P277, DOI 10.1146/annurev.mi.46.100192.001425; MEYER J, 1992, ADV INORG CHEM, V38, P73, DOI 10.1016/S0898-8838(08)60062-8; MEYER J, 1986, BIOCHIM BIOPHYS ACTA, V873, P108, DOI 10.1016/0167-4838(86)90196-2; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PRINCE RC, 1976, FEBS LETT, V65, P117, DOI 10.1016/0014-5793(76)80634-5; SCHMIDT CL, 1995, FEBS LETT, V359, P239, DOI 10.1016/0014-5793(94)00052-W; SPIRO TG, 1995, METHODS ENZYMOL, V246, P416; STEPHENS PJ, 1978, BIOCHEMISTRY-US, V17, P4770, DOI 10.1021/bi00615a026; TRUMPOWER BL, 1990, MICROBIOL REV, V54, P101, DOI 10.1128/MMBR.54.2.101-129.1990; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; WAKAGI T, 1986, SYST APPL MICROBIOL, V7, P342; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Zhang Q, 1996, J BIOCHEM-TOKYO, V120, P587	43	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27659	27663		10.1074/jbc.271.44.27659	http://dx.doi.org/10.1074/jbc.271.44.27659			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910356	hybrid			2022-12-27	WOS:A1996VQ67900074
J	Johanning, K; Mathis, JP; Lindberg, I				Johanning, K; Mathis, JP; Lindberg, I			Processing site blockade results in more efficient conversion of proenkephalin to active opioid peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SPINAL-CORD; MESSENGER-RNA; ATT-20 CELLS; PROHORMONE CONVERTASE-1; DIRECTED MUTAGENESIS; CHROMAFFIN CELLS; BETA-ENDORPHIN; CLEAVAGE; PROOPIOMELANOCORTIN; BIOSYNTHESIS	Prohormones are known to be processed at various cleavage sites in a defined temporal order, suggesting the possibility of sequential unfolding of processing sites. In order to investigate whether sequential processing at predefined sites is in fact required for proper processing, site-directed mutagenesis was performed to block known initial cleavage sites within proenkephalin. Pulse-chase/immunoprecipitation experiments were employed to analyze the fate of mutant and native proenkephalins in stably transfected AtT-20 cells. While processing did not occur at blockaded sites, surprisingly, overall processing of mutant proenkephalins proceeded efficiently, and alternative sites were chosen. When compared with native proenkephalin, processing of mutant proenkephalins occurred more slowly at early stages and more quickly at later stages. Experiments employing endoglycosidase H indicated that the early slow processing of mutant proenkephalins may be due to delays in intracellular transport. Metabolic labeling studies showed that more efficient production of bioactive opioids occurred in all processing site blockade mutants examined; these results were confirmed using several different radioimmunoassays of stored peptide products. We conclude that efficient processing of prohormone precursors does not require a specific temporal order of processing events. The fact that mutant proenkephalins were more fully processed than native proenkephalin may provide a route for more efficient production of opioid peptides in applications for chronic pain treatment.	LOUISIANA STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,NEW ORLEANS,LA 70112	Louisiana State University System			Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA005084, R56 DA005084] Funding Source: Medline; PHS HHS [5084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRAKCH N, 1993, BIOCHEMISTRY-US, V32, P4925, DOI 10.1021/bi00069a029; CHRISTIE DL, 1991, J BIOL CHEM, V266, P15679; DAY NC, 1993, NEUROPEPTIDES, V24, P253, DOI 10.1016/0143-4179(93)90013-Z; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; DOCHERTY K, 1989, J BIOL CHEM, V264, P18335; DUGUAY SJ, 1995, J BIOL CHEM, V270, P17566, DOI 10.1074/jbc.270.29.17566; GILES N, 1991, MOL ENDOCRINOL, V5, P404; GIRAUD P, 1981, NEUROPEPTIDES, V1, P237, DOI 10.1016/0143-4179(81)90002-0; HAMA AT, 1994, BRAIN RES, V651, P183, DOI 10.1016/0006-8993(94)90696-3; Johanning K, 1996, J NEUROCHEM, V66, P898; JUNG LJ, 1993, J CELL BIOL, V121, P11, DOI 10.1083/jcb.121.1.11; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LINDBERG I, 1984, BRAIN RES, V299, P73, DOI 10.1016/0006-8993(84)90789-3; LINDBERG I, 1991, ENDOCRINOLOGY, V128, P1849, DOI 10.1210/endo-128-4-1849; LINDBERG I, 1994, MOL CELL NEUROSCI, V5, P263, DOI 10.1006/mcne.1994.1030; LINDBERG I, 1986, J BIOL CHEM, V261, P6317; Lindberg I., 1995, METH NEUROSCI, V23, P94; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; MATHIS JP, 1992, ENDOCRINOLOGY, V131, P2287, DOI 10.1210/en.131.5.2287; MILGRAM SL, 1994, J CELL SCI, V107, P737; MOCCHETI I, 1994, EUR J PHARMACOL, V106, P427; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROSTOVTSEV AP, 1994, MOL CELL ENDOCRINOL, V101, P267; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P1; SAGEN J, 1986, P NATL ACAD SCI USA, V83, P7522, DOI 10.1073/pnas.83.19.7522; SAGEN J, 1986, BRAIN RES, V384, P189, DOI 10.1016/0006-8993(86)91238-2; SAITOH Y, 1995, CELL TRANSPLANT, V4, pS13, DOI 10.1016/0963-6897(94)00072-R; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILLER MR, 1995, BIOCHEMISTRY-US, V34, P7988, DOI 10.1021/bi00025a004; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; TAKAHASHI KI, 1995, PEPTIDES, V16, P93; THORNE BA, 1989, J BIOL CHEM, V264, P3545; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; Wilson S. P., 1995, Society for Neuroscience Abstracts, V21, P1847; WILSON SP, 1991, J NEUROCHEM, V57, P876, DOI 10.1111/j.1471-4159.1991.tb08232.x; WU HH, 1994, J NEUROSCI, V14, P4806; YOSHIKAWA K, 1984, J BIOL CHEM, V259, P4301; ZHOU A, 1994, J BIOL CHEM, V269, P17440; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU Y, 1994, J BIOL CHEM, V269, P18408	45	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27871	27878		10.1074/jbc.271.44.27871	http://dx.doi.org/10.1074/jbc.271.44.27871			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910386	hybrid			2022-12-27	WOS:A1996VQ67900104
J	Lee, DH; Goldberg, AL				Lee, DH; Goldberg, AL			Selective inhibitors of the proteasome-dependent and vacuolar pathways of protein degradation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC PATHWAY; UBIQUITIN; YEAST; LACTACYSTIN; CELLS; CFTR	We have studied whether various agents that inhibit purified yeast and mammalian 26 S proteasome can suppress the breakdown of different classes of proteins in Saccharomyces cerevisiae. The degradation of short-lived proteins was inhibited reversibly by peptide aldehyde inhibitors of proteasomes, carbobenzoxyl-leucinyl-leucinyl-leucinal (MG132) and carbobenzoxyl-leucinyl-leucinyl-norvalinal (MG115), in a yeast mutant with enhanced permeability, but not irt wild-type strains, Lactacystin, an irreversible proteasome inhibitor, had no effect, but the beta-lactone derivative of lactacystin, which directly reacts with proteasomes, inhibited the degradation of short-lived proteins, These inhibitors also blocked the rapid ubiquitin-dependent breakdown of a beta-galactosidase fusion protein and caused accumulation of enzymatically active molecules in cells, The degradation of the bulk of cell proteins, which are long-lived molecules, was not blocked by proteasome inhibitors, but could be blocked by phenylmethylsulfonyl fluoride, This agent, which inhibits multiple vacuolar proteases, did not affect the proteasome or breakdown of short-lived proteins, These two classes of inhibitors can thus be. used to distinguish the cytosolic and vacuolar proteolytic pathways and to increase the cellular content of short-lived proteins.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School								AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1994, BIOL HEAT SHOCK PROT, P137; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GRAHAM TR, 1993, EMBO J, V12, P869, DOI 10.1002/j.1460-2075.1993.tb05727.x; GRONOSTAJSKI RM, 1985, J BIOL CHEM, V260, P3344; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Lee DH, 1996, MOL CELL BIOL, V16, P4773; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; OMURA S, 1991, J ANTIBIOT, V44, P117, DOI 10.7164/antibiotics.44.117; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tawa Nicholas T. Jr., 1995, Surgical Forum, V46, P12; VANDERREST ME, 1995, MICROBIOL REV, V59, P304, DOI 10.1128/MMBR.59.2.304-322.1995; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6	33	340	348	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27280	27284		10.1074/jbc.271.44.27280	http://dx.doi.org/10.1074/jbc.271.44.27280			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910302	hybrid			2022-12-27	WOS:A1996VQ67900020
J	Retzler, C; Gohring, W; Rauch, U				Retzler, C; Gohring, W; Rauch, U			Analysis of neurocan structures interacting with the neural cell adhesion molecule N-CAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; PROTEIN-TYROSINE-PHOSPHATASE; BRAIN; RECEPTOR; SELECTIN; CLONING; BINDING; LIGAND	Neurocan is a brain-specific chondroitin sulfate proteoglycan, which has been shown to bind to the neural cell adhesion molecule N-CAM and to inhibit its homophilic interaction, To study in more detail the structures of neurocan responsible for this interaction, various recombinant neurocan fragments were generated, The ability of these fragments to interact with N-CAM was investigated in several different in vitro assay systems, enzyme-linked immunosorbent assay-type binding assays, Covasphere-aggregation assays, and assays based on an optical biosensor (BIA-core(TM)) system, The analysis of the hamophilic N-CAM interaction in the BLAcore system revealed a K-D of 64 nM. This homophilic interaction could be reduced by preincubation of soluble N-CAM with neurocan. Direct binding of N-CAM to immobilized neurocan care protein and recombinant neurocan fragments could also be demonstrated, and K-D values behveen 25 and 100 nM were obtained. in addition, direct binding of N-CAM to chondroitin sulfate could be demonstrated Binding of N-CAM to the immobilized neurocan core protein could be inhibited with all recombinant fragments containing chondroitin sulfate or major parts of the mucin-like central region of neurocan. For the inhibition of homophilic N-CAM interactions, however, a combination of globular and extended structures was required.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY	Max Planck Society								BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; COLE GJ, 1986, NATURE, V320, P445, DOI 10.1038/320445a0; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; GRUMET M, 1993, J CELL BIOL, V120, P815, DOI 10.1083/jcb.120.3.815; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAUREL P, 1994, P NATL ACAD SCI USA, V91, P2512, DOI 10.1073/pnas.91.7.2512; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MILEV P, 1994, J CELL BIOL, V127, P1703, DOI 10.1083/jcb.127.6.1703; RAO Y, 1993, J BIOL CHEM, V268, P20630; RAUCH U, 1992, J BIOL CHEM, V267, P19536; RAUCH U, 1991, J BIOL CHEM, V266, P14785; Retzler C, 1996, J BIOL CHEM, V271, P17107, DOI 10.1074/jbc.271.29.17107; RUTISHAUSER U, 1985, J CELL BIOL, V101, P1842, DOI 10.1083/jcb.101.5.1842; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Storms SD, 1996, EXP CELL RES, V223, P385, DOI 10.1006/excr.1996.0093; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354	21	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27304	27310		10.1074/jbc.271.44.27304	http://dx.doi.org/10.1074/jbc.271.44.27304			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910306	hybrid			2022-12-27	WOS:A1996VQ67900024
J	Belden, WJ; Barlowe, C				Belden, WJ; Barlowe, C			Erv25p, a component of COPII-coated vesicles, forms a complex with Emp24p that is required for efficient endoplasmic reticulum to Golgi transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; PROTEIN-TRANSPORT; MEMBRANE-PROTEIN; PLASMA-MEMBRANE; SHUTTLE VECTORS; SEC PROTEINS; HOST STRAINS; GENE	COPII-coated endoplasmic reticulum (ER)-derived transport vesicles contain a distinct set of membrane-bound polypeptides. We have obtained the NH2-terminal amino acid sequence of polypeptide constituents found on purified vesicles and in this report investigate the 24- and 25-kDa species. The 24-kDa protein is identical to Emp24p, a type I transmembrane protein that is required for transport of a subset of secretory proteins from the ER to the Golgi complex (Schimmoller, F., Singer-Kruger, B., Schroder, S., Kruger, U., Barlowe, C., and Riezman, H. (1995) EMBO J, 14, 1329-1339). The 25-kDa protein, termed Erv25p (ER vesicle protein of 25 kDa), corresponds to an open reading frame found on chromosome XIII of Saccharomyces cerevisiae, Erv25p shares overall sequence identity with Emp24p, but the two proteins are not functionally interchangeable. Antibodies directed against Erv25p reveal that Emp24p and Erv25p depend on each other for stability and form a protein complex that can be isolated after chemical cross-linking. Yeast strains lacking Erv25p (erv25 Delta) are viable and display the same selective defect in transport of secretory proteins from the ER to Golgi complex as an emp24 Delta strain. A cell-free assay that measures vesicle formation from ER membranes demonstrates that Erv25p and Emp24p are incorporated equally into ER-derived vesicles when COPII-coated budding is reconstituted. Vesicle formation from an erv25 Delta strain, an emp24 Delta strain and a double erv25 Delta emp24 Delta strain proceed at wild-type levels; however, incorporation of the Erv25p or the Emp24p protein into COPII-coated vesicles requires expression of both subunits, A potential model for transport of the Erv25p-Emp24p complex between the ER and Golgi compartments is discussed.	DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College					NIGMS NIH HHS [GM52549] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM052549, R01GM052549] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARRELL BG, 1995, Z49810; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FRANKHAUSER C, 1991, EUR J BIOCHEM, V195, P439; HARLOW E, 1988, ANTIBODIES LABORATOR, P312; HOLTHUIS JCM, 1995, BIOCHEM J, V312, P205, DOI 10.1042/bj3120205; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; QUINN P, 1984, J CELL BIOL, V98, P2142, DOI 10.1083/jcb.98.6.2142; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROTHBLATT JA, 1989, J CELL BIOL, V109, P2641, DOI 10.1083/jcb.109.6.2641; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1993, J BIOL CHEM, V268, P14376; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STERLING CJ, 1992, MOL BIOL CELL, V3, P129; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WADA I, 1991, J BIOL CHEM, V266, P19599; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WOODCOCK DM, 1989, NUCLEIC ACIDS RES, V17, P3469, DOI 10.1093/nar/17.9.3469; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567	50	170	173	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26939	26946		10.1074/jbc.271.43.26939	http://dx.doi.org/10.1074/jbc.271.43.26939			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900179	hybrid			2022-12-27	WOS:A1996VP23300073
J	Beltman, J; McCormick, F; Cook, SJ				Beltman, J; McCormick, F; Cook, SJ			The selective protein kinase C inhibitor, Ro-31-8220, inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, induces c-Jun expression, and activates Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; CELL-LINE; GROWTH-FACTORS; PHOSPHORYLATION; SPECIFICITY; DOMAIN; FOS; IDENTIFICATION; FIBROBLASTS; INDUCTION	The role of protein kinase C (PKC) in inflammation, mitogenesis, and differentiation has been deduced in part through the use of a variety of PKC inhibitors. Two widely used inhibitors are the structurally related compounds GF109203X and Ro-31-8220, both of which potently inhibit PKC activity and are believed to be highly selective. While using GF109203X and Ro-31-8220 to address the role of PKC in immediate early gene expression, we observed striking differential effects by each of these two compounds. Growth factors induce the expression of the immediate early gene products MAP kinase phosphatase-1 (MKP-1), c-Fos and c-Jun. Ro-31-8220 inhibits growth factor-stimulated expression of MKP-1 and c-Fos but strongly stimulated c-Jun expression, even in the absence of growth factors, GF109203X displays none of these properties. These data suggest that Ro-31-8220 may have other pharmacological actions in addition to PKC inhibition, Indeed, Ro-31-8220 strongly stimulates the stress-activated protein kinase, JNK1. Furthermore, Ro-31-8220 apparently activates JNK in a PKC-independent manner. Neither the down-regulation of PKC by phorbol esters nor the inhibition of PKC by GF109203X affected the ability of Ro-31-8220 to activate JNK1, These data suggest that, in addition to potently inhibiting PKC, Ro-31-8220 exhibits novel pharmacological properties which are independent of its ability to inhibit PKC.			Beltman, J (corresponding author), ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806, USA.				NIGMS NIH HHS [GM16575] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BRADSHAW D, 1993, AGENTS ACTIONS, V38, P135, DOI 10.1007/BF02027225; BUDWORTH J, 1995, FEBS LETT, V362, P139, DOI 10.1016/0014-5793(95)00227-Z; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHARLES CH, 1992, ONCOGENE, V7, P187; Chen RH, 1996, ONCOGENE, V12, P1493; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COOK SJ, 1991, BIOCHEM J, V280, P431, DOI 10.1042/bj2800431; COOK SJ, 1996, IN PRESS BIOCH J; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JOHNSON MS, 1993, FEBS LETT, V333, P67, DOI 10.1016/0014-5793(93)80376-6; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MCLEES A, 1995, BIOCHEM J, V307, P743, DOI 10.1042/bj3070743; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MUKAI H, 1995, BBA-GENE STRUCT EXPR, V1261, P296, DOI 10.1016/0167-4781(95)00030-K; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SAMPSON LE, 1993, BIOCHEM J, V292, P289, DOI 10.1042/bj2920289; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; STANWELL C, 1994, INT J CANCER, V56, P585; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	43	166	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27018	27024		10.1074/jbc.271.43.27018	http://dx.doi.org/10.1074/jbc.271.43.27018			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900190	hybrid			2022-12-27	WOS:A1996VP23300084
J	Doerrler, WT; Ye, JH; Falck, JR; Lehrman, MA				Doerrler, WT; Ye, JH; Falck, JR; Lehrman, MA			Acylation of glucosaminyl phosphatidylinositol revisited - Palmitoyl-CoA dependent palmitoylation of the inositol residue of a synthetic dioctanoyl glucosaminyl phosphatidylinositol by hamster membranes permits efficient mannosylation of the glucosamine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; TRYPANOSOMA-BRUCEI; GLYCOSYL-PHOSPHATIDYLINOSITOL; MAMMALIAN-CELLS; COENZYME-A; BIOSYNTHESIS; GLYCOSYLPHOSPHATIDYLINOSITOL; ANCHOR; PURIFICATION; GLYCOLIPIDS	Two critical steps in the assembly of yeast and mammalian glycosylphosphatidylinositol (GPI) anchor precursors are palmitoylation of the inositol residue and mannosylation of the glucosamine residue of the glucosaminyl phosphatidylinositol (GlcN alpha-PI) intermediate. Palmitoylation has been reported to be acyl-CoA dependent in yeast membranes (Costello, L. C., and Orlean, P. (1992) J. Biol. Chem. 267, 8599-8603) but strictly acyl-CoA independent in rodent membranes (Stevens, V. L., and Zhang, H. (1994) J. Biol. Chem. 269, 31397-31403), and thus poorly conserved. In addition, it was suggested that acylation must precede mannosylation in both yeast (Costello, L. C., and Orlean, P. (1992) J. Biol. Chem. 276, 8599-8603) and rodent (Urakaze, M., Kamitani, T., DeGasperi, R., Sugiyama, E., Chang, H.-M., Warren, C. D., and Yeh, E. T. H. (1992) J. Biol. Chem. 267, 6459-6462) cells because GlcN alpha-acyl-PI accumulates in vivo when mannosylation is blocked. However, GlcN alpha-acyl-PI accumulation would also be expected if mannosylation and acylation were independent of each other. These issues were addressed by the use of a synthetic dioctanoyl GlcN alpha-PI analogue (GlcN alpha-PI(C8)) as an in vitro substrate for GPI-synthesizing enzymes in Chinese hamster ovary cell membranes. GlcN alpha-PI(C8) was acylated in an manner requiring acyl-CoA. Thus, the process involving acyl-CoA reported for yeast has been conserved in mammals. Furthermore, both GlcN alpha-PI(C8) and GlcN alpha-acyl-PI(C8) could be mannosylated in vitro, but mannosylation of the latter was significantly more efficient. This provides direct support for the earlier suggestion that acylation precedes mannosylation in rodents cells. A similar result was also observed with the Saccharomyces cerevisiae mannosyltransferase. In contrast, it has been reported that mannosylation of endogenous GlcN alpha-PI by Trypansoma brucei membranes occurs without prior acylation. The same result was obtained with GlcN alpha-PI(C8), confirming that the mannosyltransferase of trypanosomes is divergent from those in yeasts and rodents.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MOL GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT CELL REGULAT GRAD PROGRAM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278, R01GM038545, R56GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545, GM31278] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMAN RA, 1985, J BIOL CHEM, V260, P6966; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; CAMP LA, 1993, J BIOL CHEM, V268, P6721; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DAVITZ MA, 1989, J BIOL CHEM, V264, P13760; DELUCA AW, 1994, GLYCOBIOLOGY, V4, P909, DOI 10.1093/glycob/4.6.909; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1993, LIPID MODIFICATIONS, P191; FIELD MC, 1991, EMBO J, V10, P2731, DOI 10.1002/j.1460-2075.1991.tb07821.x; GARIGAPATI VR, 1993, TETRAHEDRON LETT, V34, P769, DOI 10.1016/0040-4039(93)89007-D; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LIU YC, 1989, TETRAHEDRON LETT, V30, P1617, DOI 10.1016/S0040-4039(00)99535-2; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1991, CELL BIOL INT REP, V15, P1007; PENKETH PG, 1991, J PROTOZOOL, V38, P172, DOI 10.1111/j.1550-7408.1991.tb04425.x; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; STEVENS VL, 1994, J BIOL CHEM, V269, P31397; TAYLOR DC, 1990, ANAL BIOCHEM, V184, P311, DOI 10.1016/0003-2697(90)90686-4; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; Ye JH, 1996, BIOORG MED CHEM LETT, V6, P1715	30	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27031	27038		10.1074/jbc.271.43.27031	http://dx.doi.org/10.1074/jbc.271.43.27031			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900192				2022-12-27	WOS:A1996VP23300086
J	Fuller, CM; Ismailov, II; Berdiev, BK; Shlyonsky, VG; Benos, DJ				Fuller, CM; Ismailov, II; Berdiev, BK; Shlyonsky, VG; Benos, DJ			Kinetic interconversion of rat and bovine homologs of the alpha subunit of an amiloride-sensitive Na+ channel by C-terminal truncation of the bovine subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; MOLECULAR-CLONING; EXPRESSION; PROTEINS	We have recently cloned the a subunit of a bovine amiloride-sensitive Na+ channel (alpha bENaC). This subunit shares extensive homology with both rat and human alpha ENaC subunits but shows marked divergence at the C terminus beginning at amino acid 584 of the 697-residue sequence, When incorporated into planar lipid bilayers, alpha bENaC almost exclusively exhibits a main transition to 39 picosiemens (pS) with very rare 13 pS step transitions to one of two subconductance states (26 and 13 pS), In contrast, the alpha subunit of the rat renal homolog of ENaC (alpha rENaC) has a main transition step to 13 pS that is almost constituitively open, with a second stepwise transition of 26 to 39 pS, A deletion mutant of alpha bENaC, encompassing the entire C-terminal region (R567X), converts the kinetic behavior of alpha bENaC to that of alpha rENaC, i.e. a transition to 13 pS followed by a second 26 pS transition to 39 pS, Chemical cross-linking of R567X restores the wild-type alpha bENaC gating pattern, whereas treatment with the reducing agent dithiothreitol produced only 13 pS transitions, In contrast, an equivalent C-terminal truncation of alpha rENaC (R613X) had no effect on the gating pattern of alpha rENaC. These results are consistent with the hypothesis that interactions between the C termini of alpha bENaC account for the different kinetic behavior of this member of the ENaC family of Na+ channels.			Fuller, CM (corresponding author), UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BHSB 735, UNIV STN, BIRMINGHAM, AL 35294 USA.		Fuller, Cathy/B-4046-2011	Shlyonsky, Vadim/0000-0003-2999-6553	NIDDK NIH HHS [DK37206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BRADFORD AL, 1995, AM J PHYSIOL-CELL PH, V269, pC601, DOI 10.1152/ajpcell.1995.269.3.C601; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P27411, DOI 10.1074/jbc.270.46.27411	18	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26602	26608		10.1074/jbc.271.43.26602	http://dx.doi.org/10.1074/jbc.271.43.26602			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900133	hybrid			2022-12-27	WOS:A1996VP23300027
J	Mu, J; Cheng, C; Roach, PJ				Mu, J; Cheng, C; Roach, PJ			Initiation of glycogen synthesis in yeast - Requirement of multiple tyrosine residues for function of the self-glucosylating Glg proteins in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-D-MALTOSIDE; SACCHAROMYCES-CEREVISIAE; BRANCHING ENZYME; XYLOSYL TRANSFER; BIOGENESIS; SYNTHASE; ACCUMULATION; MECHANISM; MUSCLE	The self-glucosylating proteins, G1g1p and G1g2p, are required for glycogen synthesis in Saccharomyces cerevisiae (Cheng, C., Mu., J., Farkas, I., Huang., If,, Goebl M. G., and Roach, P. J. (1995) Mol. Cell. Biol. 15, 6632-6640). G1g2p was shown to be associated with carbohydrate in vivo and was released from the high molecular weight glycogen fraction by treatment with alpha-amylase. In addition, some G1g2p exists as a protein of M(r) similar to 43,000, whose proportion is increased in cells lacking glycogen synthase, Unlike the. mammalian counterpart, glycogenin, the yeast GIg proteins appear to require multiple Tyr residues for functionality. In G1g2p, mutation of both Tyr(230) and Tyr(232) is necessary to suppress self-glucosylation of purified protein in vitro. The mutant protein is still capable of transferring glucose to an exogeneous acceptor, rt-dodecyl beta-D-maltoside. A small COOH-terminal region, conserved between G1g1p and G1g2p, is also important for function; mutation of Tyr(367) Or truncation at:residue 362 impairs the ability of primed G1g2p to be elongated by glycogen synthase. Complete suppression of glycogen accumulation in vivo requires mutation of all three Tyr residues. In G1g1p, two Tyr residues are implicated, Tyr(232), and Tyr(600), mutation of both being required to eliminate glycogen accumulation in vivo.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis				Mu, James/0000-0001-8081-2401	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042576] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42576] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALONSO MD, 1994, FEBS LETT, V342, P38, DOI 10.1016/0014-5793(94)80580-6; ALONSO MD, 1995, FEBS LETT, V359, P110, DOI 10.1016/0014-5793(95)00018-5; ALONSO MD, 1995, FASEB J, V9, P1126, DOI 10.1096/fasebj.9.12.7672505; ALONSO MD, 1995, J BIOL CHEM, V270, P15315, DOI 10.1074/jbc.270.25.15315; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO YJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P293, DOI 10.1006/abbi.1995.1295; CAO YJ, 1993, J BIOL CHEM, V268, P14687; CHENG C, 1995, MOL CELL BIOL, V15, P6632; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; EIBLE R, 1992, BIOTECHNIQUES, V13, P18; FARKAS I, 1991, J BIOL CHEM, V266, P15602; FARKAS I, 1990, J BIOL CHEM, V265, P20879; Gu J, 1994, BIOTECHNIQUES, V17, P260; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMAKO J, 1988, FASEB J, V2, P3097, DOI 10.1096/fasebj.2.15.2973423; MANZELLA S, 1995, ARCH BIOCHEM BIOPHYS, V320, P361, DOI 10.1016/0003-9861(95)90020-9; MANZELLA SM, 1995, GLYCOBIOLOGY, V5, P263, DOI 10.1093/glycob/5.2.263; MANZELLA SM, 1994, ANAL BIOCHEM, V216, P383, DOI 10.1006/abio.1994.1056; PITCHER J, 1988, EUR J BIOCHEM, V176, P391, DOI 10.1111/j.1432-1033.1988.tb14294.x; RODRIGUEZ IR, 1988, ARCH BIOCHEM BIOPHYS, V260, P628, DOI 10.1016/0003-9861(88)90491-2; Rose MD., 1990, METHODS YEAST GENETI; ROWEN DW, 1992, MOL CELL BIOL, V12, P22, DOI 10.1128/MCB.12.1.22; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE C, 1991, EUR J BIOCHEM, V200, P625, DOI 10.1111/j.1432-1033.1991.tb16225.x; SMYTHE C, 1988, EMBO J, V7, P2681, DOI 10.1002/j.1460-2075.1988.tb03121.x; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THON VJ, 1992, J BIOL CHEM, V267, P15224	30	22	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26554	26560		10.1074/jbc.271.43.26554	http://dx.doi.org/10.1074/jbc.271.43.26554			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900126	hybrid			2022-12-27	WOS:A1996VP23300020
J	Takahashi, M; Ilan, Y; Chowdhury, NR; Guida, J; Horwitz, M; Chowdhury, JR				Takahashi, M; Ilan, Y; Chowdhury, NR; Guida, J; Horwitz, M; Chowdhury, JR			Long term correction of bilirubin-UDP-glucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-II ALLOANTIGENS; GENE-TRANSFER; CELLULAR MECHANISMS; INDUCED TOLERANCE; T-CELLS; EXPRESSION; INDUCTION; COMPLEX; VECTORS; INVIVO	Injection of a recombinant adenovirus expressing human bilirubin-UGT(1) (Ad-hBUGT(1)) (3 x 10(9) plaque-forming units (pfu) intravenously) in adult bilirubin-UDP-glucuronosyltransferase-1 (BUGT(1))-deficient Gunn rats resulted in biliary excretion of bilirubin glucuronides and a 70% reduction of serum bilirubin levels. However, the effect was transient, and. host humoral and cellular immune response prevented transgene expression after subsequent injections. To determine whether injection during the neonatal period would tolerize the host to the recombinant virus, we injected 1 x 10(8) pfu of Ad-hBUGT(1) or Ad-LacZ (a recombinant adenovirus expressing Escherichia coli beta-galactosidase) into 1-3-day-old Gunn rats, Two subsequent injections (3 x 10(9) pfu) were given 56 and 112 days after the initial injection, Injection of Ad-BUGT(1), but not Ad-LacZ, reduced serum bilirubin by 70-76% of the levels in untreated pups (9 +/- 1.3 mg/dl), followed by a gradual increase to 3.25 +/- 0.3 mg/dl in 56 days; similar or greater reductions occurred after the second and third injection. Serum neutralizing antibody titer and cytotoxic lymphocyte activity against adenovirus-infected hepatocytes were low or undetectable. Thus, tolerization by injection of the virus during the neonatal period permits long term gene therapy by repeated injection of the virus.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, DEPT MED & MOL GENET, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041296, R01DK046057, R01DK039137] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30-DK 41296, R01-DK 39137, R01-DK 46057] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BETT AJ, 1993, J VIROL, V67, P5911, DOI 10.1128/JVI.67.10.5911-5921.1993; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; CHOWDHURY J R, 1981, Hepatology, V1, P622; CHOWDHURY R, 1993, ANIMAL MODELS LIVER, P150; DAI YF, 1995, P NATL ACAD SCI USA, V92, P1401, DOI 10.1073/pnas.92.5.1401; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; EMI Y, 1995, J BIOCHEM, V117, P392, DOI 10.1093/jb/117.2.392; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; HORWITZ MS, 1990, VIROLOGY, P01679; JAFFE HA, 1992, NAT GENET, V1, P372, DOI 10.1038/ng0892-372; Jansen P L, 1995, Prog Liver Dis, V13, P125; Jendrassik L, 1938, BIOCHEM Z, V297, P81; KASSEISLER A, 1994, GENE THER, V1, P395; MATRIANO JA, 1994, J IMMUNOL, V153, P1515; MATRIANO JA, 1994, J IMMUNOL, V153, P1505; MOHLER KM, 1989, TRANSPLANTATION, V47, P633, DOI 10.1097/00007890-198904000-00014; POWELL TJ, 1990, J IMMUNOL, V144, P854; POWELL TJ, 1991, TRANSPLANTATION, V52, P383; PREVEC L, 1989, J GEN VIROL, V70, P429, DOI 10.1099/0022-1317-70-2-429; Raper S E, 1995, Prog Liver Dis, V13, P201; RITTER JK, 1992, J BIOL CHEM, V267, P3257; SENGUPTA K, 1994, HEPATOLOGY, V13, pA320; TAKAHASHI M, 1995, HEPATOLOGY, V22, P453; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WOOD PJ, 1987, J IMMUNOL, V138, P3661; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, J VIROL, V69, P2004, DOI 10.1128/JVI.69.4.2004-2015.1995	27	100	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26536	26542		10.1074/jbc.271.43.26536	http://dx.doi.org/10.1074/jbc.271.43.26536			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900123	hybrid			2022-12-27	WOS:A1996VP23300017
J	Zhang, X; Chen, ZQ; Wang, ZW; Mohan, W; Tam, SP				Zhang, X; Chen, ZQ; Wang, ZW; Mohan, W; Tam, SP			Protein-DNA interactions at a drug-responsive element of the human apolipoprotein A-I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; HIGH-DENSITY LIPOPROTEIN; TRANSCRIPTION FACTOR AP-2; CHOLESTEROL-FED RATS; HEPATOMA-CELL LINES; PEROXISOME PROLIFERATORS; GEMFIBROZIL TREATMENT; CONTROL EXPRESSION; NUCLEAR RECEPTOR; TRANSGENIC MICE	Previously, we demonstrated that when two human hepatoma cell lines, Hep3B and HepG2, were exposed to gemfibrozil, a hypolipidemic drug, a 2-fold induction in apolipoprotein A-I (apoA-I) mRNA levels resulted, To determine if mRNA stabilization Nas responsible for the changes in apoA-I mRNA levels, the half-lives for apoA-I mRNA were measured in the presence of actinomycin D with and without gemfibrozil. These experiments revealed no differences in stability, However, nuclear runoff assays indicated that the transcription rate of the apoA-I gene was increased 2-fold in gemfibrozil-treated cells, Transient transfection experiments also indicated that the induction of apoA-I mRNA level in response to gemfibrozil is mediated at the transcriptional level, We have identified two copies of the ''drug-responsive element'' (DRE) in the apoA-I promoter region that may be responsible for the increase in apoA-I transcriptional activity by gemfibrozil, Using gel mobility shift assays with a synthetic DRE oligonucleotide, we have demonstrated that exposure of Hep3B and HepG2 cells to gem fibrozil resulted in strong induction of a protein-DNA complex, The formation of this complex is highly sequence-specific as indicated by the DNA competition experiments, The drug-inducible nuclear proteins bind to the DRE of the human apoA-I gene with an apparent K-d of 4.1 nM. Methylation interference experiments have localized the contact sites of nuclear factors to the DRE region, Southwestern blot analyses have identified two groups of drug-inducible nuclear proteins with molecular masses of approximately 30 and 15 kDa. When a copy of synthetic DRE oligonucleotide was inserted upstream of the thymidine kinase promoter and luciferase reporter construct, a significant 2-fold induction in luciferase activity was observed in the presence of gemfibrozil following transient transfection of two human hepatoma cell lines, HepG2 and Hep3B, However, a plasmid containing one copy of mutated apoA-I-DRE oligomer did not confer responsiveness to gemfibrozil treatment, Furthermore, pGL2 (apoA-I -250 mutant DRE), which carried an internal mutation of the DRE in the human apoA-I proximal promoter region, showed no increase in luciferase activity in response to gemfibrozil, These results implicate protein-DNA interactions at the DRE region in the transcriptional induction of human apoA-I gene expression by gemfibrozil.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada			Zhang, Xia/B-8152-2008	Zhang, Xia/0000-0002-9040-1486				ALVARES K, 1994, CANCER RES, V54, P2303; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALFOUR JA, 1990, DRUGS, V40, P260, DOI 10.2165/00003495-199040020-00007; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; BARTALENA L, 1992, MOL ENDOCRINOL, V6, P935, DOI 10.1210/me.6.6.935; BROWN WV, 1987, AM J MED, V84, P85; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; CHEN D, 1994, J BIOL CHEM, V269, P5420; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; DELAIGLESIA FA, 1982, ATHEROSCLEROSIS, V43, P19, DOI 10.1016/0021-9150(82)90096-X; DENG TL, 1992, P NATL ACAD SCI USA, V89, P8572, DOI 10.1073/pnas.89.18.8572; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRICK MH, 1987, NEW ENGL J MED, V34, P74; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; Glomset J A, 1980, Adv Intern Med, V25, P91; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1992, BIOCHEM PHARMACOL, V43, P393, DOI 10.1016/0006-2952(92)90554-V; GRUNDY SM, 1987, AM J MED, V83, P9, DOI 10.1016/0002-9343(87)90866-7; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; HAMSTEN A, 1986, ATHEROSCLEROSIS, V60, P199, DOI 10.1016/0021-9150(86)90166-8; HAPGOOD J, 1991, MOL CELL BIOL, V11, P4314, DOI 10.1128/MCB.11.9.4314; INNIS MA, 1990, PCR PROTOCOLS, P13; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; KRAUSE BR, 1986, ATHEROSCLEROSIS, V59, P95, DOI 10.1016/0021-9150(86)90036-5; KRAUSE BR, 1986, ATHEROSCLEROSIS, V61, P245, DOI 10.1016/0021-9150(86)90145-0; KUUSI T, 1987, ARTERIOSCLEROSIS, V7, P421, DOI 10.1161/01.ATV.7.4.421; LARSEN ML, 1993, CURR OPIN LIPIDOL, V4, P34, DOI 10.1097/00041433-199302000-00007; LEIGHTON JK, 1984, J BIOL CHEM, V259, P1165; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; MILLER NE, 1985, NATURE, V314, P109, DOI 10.1038/314109a0; MOLL PP, 1989, AM J HUM GENET, V44, P124; MORRISON HG, 1993, BIOTECHNIQUES, V14, P454; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; ORTON TC, 1982, DRUG METAB DISPOS, V10, P110; PAGANI F, 1990, J LIPID RES, V31, P1371; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; *PROM, 1991, GEN PLASM TECHN MAN, P1; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SAKU K, 1985, J CLIN INVEST, V75, P1702, DOI 10.1172/JCI111879; Sambrook J., 2002, MOL CLONING LAB MANU; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; SIGURDSSON G, 1992, ARTERIOSCLER THROMB, V12, P1017, DOI 10.1161/01.ATV.12.9.1017; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SIRTORI CR, 1988, PHARMACOL THERAPEUT, V37, P167, DOI 10.1016/0163-7258(88)90024-1; SMITH JD, 1992, J CLIN INVEST, V89, P1796, DOI 10.1172/JCI115783; SOGAWA K, 1986, P NATL ACAD SCI USA, V83, P8044, DOI 10.1073/pnas.83.21.8044; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; TAM SP, 1992, ALCOHOL CLIN EXP RES, V16, P1021, DOI 10.1111/j.1530-0277.1992.tb00693.x; TAM SP, 1991, ATHEROSCLEROSIS, V91, P51, DOI 10.1016/0021-9150(91)90186-7; TAM SP, 1994, ATHEROSCLEROSIS, V105, P235, DOI 10.1016/0021-9150(94)90054-X; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VANDENBROUCK Y, 1995, EUR J BIOCHEM, V231, P126, DOI 10.1111/j.1432-1033.1995.tb20678.x; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHAO SP, 1994, AM J MED, V96, P49, DOI 10.1016/0002-9343(94)90115-5; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	75	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27152	27160		10.1074/jbc.271.43.27152	http://dx.doi.org/10.1074/jbc.271.43.27152			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900208	hybrid			2022-12-27	WOS:A1996VP23300102
J	Bouzat, C; Barrantes, FJ				Bouzat, C; Barrantes, FJ			Modulation of muscle nicotinic acetylcholine receptors by the glucocorticoid hydrocortisone - Possible allosteric mechanism of channel blockade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSILON-SUBUNIT; STEROIDS; PROTEIN; IDENTIFICATION; KINETICS; MODIFY; FETAL	Mechanisms of ion channel blockade by noncompetitive inhibitors of the nicotinic acetylcholine receptor (AChR) have been particularly difficult to elucidate, We have combined here transient expression of embryonic, adult, and a mutated adult muscle AChR associated with a slow channel syndrome (Ohno, K., Hutchinson, D. O. Milone, M., Brengman, J. M., Bouzat, C., Sine, S., and Engel, A. (1995) Proc. Natl. Acad, Sci, U. S. A, 92, 758-762) with single channel recordings to determine subunit specificity and mechanisms of action of the prototype glucocorticoid hydrocortisone (HC), HC affected in a similar manner the gating kinetics of all types of muscle AChR, producing briefer openings with normal amplitudes, We postulate that this steroid acts as a noncompetitive inhibitor of the AChR and that its mechanism of action can be interpreted in terms of blocking models, The forward rate constant for the blocking process was also similar for all channel types, indicating that the structural differences between them are not responsible for the effect, The reduction in the channel open time was not dependent on agonist concentration; it was slightly voltage dependent, suggesting that HC binds to a site located inside the membrane that senses the electric field, Recordings at high acetylcholine concentration in the presence of HC showed a reduced number of openings per activation period and the long closed times typically observed in the desensitization phenomenon, In competition studies with the classical open channel blocker QX-222, HC induced an early termination of the burst, suggesting that the two act at different sites, Taken together the results support the existence of specific sites sensed by the membrane field, different from those of open channel blockers and probably located at the lipid-protein interface, From this site(s), glucocorticoids and other hydrophobic noncompetitive inhibitors could allosterically mediate channel blockade.	INST INVEST BIOQUIM,RA-8000 BAHIA BLANCA,ARGENTINA				Barrantes, Francisco J./HCH-0258-2022	Barrantes, Francisco J./0000-0002-4745-681X				ADAMS PR, 1977, J PHYSIOL-LONDON, V268, P291, DOI 10.1113/jphysiol.1977.sp011858; AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; Barann M., 1996, Biophysical Journal, V70, pA76; BARRANTES FJ, 1989, CRIT REV BIOCHEM MOL, V24, P457; BARRY MA, 1993, MICROSC RES TECHNIQ, V26, P231, DOI 10.1002/jemt.1070260306; BENOIT P, 1993, NEUROSCI LETT, V160, P81, DOI 10.1016/0304-3940(93)90918-B; BERTRAND D, 1991, NEUROREPORT, V2, P277, DOI 10.1097/00001756-199105000-00016; BERTRAND D, 1995, NEUROSCIENCES, V7, P75; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; BOUZAT C, 1994, NEURON, V13, P1395, DOI 10.1016/0896-6273(94)90424-3; BOUZAT C, 1993, NEUROREPORT, V4, P143, DOI 10.1097/00001756-199302000-00007; Bouzat Cecilia B., 1993, Molecular Neuropharmacology, V3, P109; CHARNET P, 1990, NEURON, V2, P87; DILGER JP, 1992, MOL PHARMACOL, V41, P127; ELLENA JF, 1983, BIOCHEMISTRY-US, V22, P5523, DOI 10.1021/bi00293a012; Engel A., 1994, MYOLOGY; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B, 1984, IONIC CHANNELS EXCIT; MCEWEN BS, 1991, TRENDS PHARMACOL SCI, V12, P141, DOI 10.1016/0165-6147(91)90531-V; MIDDLEMAS DS, 1987, BIOCHEMISTRY-US, V26, P1219, DOI 10.1021/bi00379a003; MILLER KW, 1991, ANN NY ACAD SCI, V625, P600, DOI 10.1111/j.1749-6632.1991.tb33895.x; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MURRAY N, 1995, NEURON, V14, P865, DOI 10.1016/0896-6273(95)90230-9; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; NEHER E, 1978, J PHYSIOL-LONDON, V277, P153, DOI 10.1113/jphysiol.1978.sp012267; OHNO K, 1995, P NATL ACAD SCI USA, V92, P758, DOI 10.1073/pnas.92.3.758; PAPKE RL, 1993, PROG NEUROBIOL, V41, P509, DOI 10.1016/0301-0082(93)90028-Q; RAINES DE, 1995, ANESTHESIOLOGY, V82, P276, DOI 10.1097/00000542-199501000-00033; SIGWORTH FJ, 1987, BIOPHYS J, V52, P1047, DOI 10.1016/S0006-3495(87)83298-8; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; UEDA I, 1994, ANESTH ANALG, V78, P718; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; VALERA S, 1992, P NATL ACAD SCI USA, V89, P9949, DOI 10.1073/pnas.89.20.9949	34	80	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25835	25841		10.1074/jbc.271.42.25835	http://dx.doi.org/10.1074/jbc.271.42.25835			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824214	hybrid			2022-12-27	WOS:A1996VN18000020
J	Dotson, SB; Smith, CE; Ling, CS; Barry, GF; Kishore, GM				Dotson, SB; Smith, CE; Ling, CS; Barry, GF; Kishore, GM			Identification, characterization, and cloning of a phosphonate monoester hydrolase from Burkholderia caryophilli PG2982	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PSEUDOMONAS SP; DNA FRAGMENTS; ENZYME; GLYPHOSATE; EXPRESSION; SEQUENCES; SITE	The glyphosate degrading bacterium, Burkholderia caryophilli PG2982, was observed to utilize glyceryl glyphosate as a sole phosphorus source. The hydrolysis of glyceryl glyphosate to glyphosate by a phosphonate ester hydrolase (PEH) was identified as the first metabolic step in the mineralization pathway, This observation provides the first biological role for a phosphonate ester hydrolase activity, Purified PEH enzyme hydrolyzed several phosphonate esters including p-nitrophenyl phenylphosphonate, beta-naphthyl phenylphosphonate, and 5-bromo-4-chloro-3-indolyl phenylphosphonate, The purified PEH also hydrolyzed some phosphodiesters including p-nitrophenyl 5'-thymidine monophosphate and p-nitrophenyl phosphorylcholine. The most catalytically efficient substrate identified was bis-(p-nitrophenyl) phosphate with a K-m of 0.9 mM and a k(cat) of 6.2 x 10(2) min(-1), suggesting that the enzyme may also function in vice as a phosphodiesterase. The native enzyme was a homotetramer of 58-kDa subunits and exhibited a pi of 4.2. The enzyme activity had a pH activity optimum of 9.0 and was stimulated 14-fold by Mn2+ ions, but a metal cofactor was not essential for activity, N-terminal and tryptic fragment amino acid sequences were obtained from the purified PEH protein and used to clone the B. caryophilli PG2982 gene, designated pehA. The unique substrate specificity of the enzyme and potential use as a novel conditional lethal gene in plants are discussed.	GD SEARLE & CO,PROT BIOCHEM GRP,CHESTERFIELD,MO 63198; MONSANTO CORP RES,ANALYT SCI CTR,ST LOUIS,MO 63167; CEREGEN,CHESTERFIELD,MO 63198	Monsanto	Dotson, SB (corresponding author), MONSANTO CO,GD SEARLE & CO,GLYCOBIOL GRP,MAIL ZONE T3M,800 N LINDBERGH BLVD,ST LOUIS,MO 63167, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dhingra OP, 1988, United States Patent, Patent No. [4,735,649, 4735649]; Dotson SB, 1996, PLANT J, V10, P383, DOI 10.1046/j.1365-313X.1996.10020383.x; DWORKIN M, 1958, J BACTERIOL, V75, P592, DOI 10.1128/JB.75.5.592-603.1958; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FITZGIBBON J, 1988, APPL ENVIRON MICROB, V54, P1886, DOI 10.1128/AEM.54.7.1886-1888.1988; HAMES BD, 1985, GEL ELECTROPHORESIS, P1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOHN B, 1980, GENE, V11, P291, DOI 10.1016/0378-1119(80)90069-4; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; HYNIE I, 1970, CAN J BIOCHEM CELL B, V48, P1141, DOI 10.1139/o70-178; KELLY SJ, 1975, BIOCHEM BIOPH RES CO, V66, P316, DOI 10.1016/S0006-291X(75)80330-5; KELLY SJ, 1975, BIOCHEMISTRY-US, V14, P4983, DOI 10.1021/bi00693a030; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; KUNITZ M, 1950, J GEN PHYSIOL, V33, P349, DOI 10.1085/jgp.33.4.349; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEATHERBARROW RJ, 1992, ENZFITTER; LIAO TH, 1988, BIOCHEM J, V255, P781, DOI 10.1042/bj2550781; LITALIEN JJ, 1986, METHODS PROTEIN MICR, P279; MOORE JK, 1983, APPL ENVIRON MICROB, V46, P316, DOI 10.1128/AEM.46.2.316-320.1983; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; OLINS PO, 1988, GENE, V73, P227, DOI 10.1016/0378-1119(88)90329-0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILLING RJ, 1994, ANAL BIOCHEM, V216, P154, DOI 10.1006/abio.1994.1019; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; WILLADSEN P, 1989, BIOCHEM J, V258, P79, DOI 10.1042/bj2580079; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZANKOWALCZEWSKA M, 1987, BIOCHEMISTRY-US, V26, P1194, DOI 10.1021/bi00378a030	30	32	37	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25754	25761		10.1074/jbc.271.42.25754	http://dx.doi.org/10.1074/jbc.271.42.25754			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824203	hybrid			2022-12-27	WOS:A1996VN18000009
J	Herbert, JM; Clowes, M; Lea, HJ; Pascal, M; Clowes, AW				Herbert, JM; Clowes, M; Lea, HJ; Pascal, M; Clowes, AW			Protein kinase C alpha expression is required for heparin inhibition of rat smooth muscle cell proliferation in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYC MESSENGER-RNA; PHORBOL ESTERS; DNA-SYNTHESIS; 3T3 CELLS; FOS; TRANSCRIPTION; MECHANISM; GROWTH; FIBROBLASTS; PROGRESSION	Heparin is a complex glycosaminoglycan that inhibits vascular smooth muscle cell (SMC) growth in vitro and in vivo. To define the mechanism by which heparin exerts its antiproliferative effects, we asked whether heparin interferes with the activity of intracellular protein kinase C (PKC). The membrane-associated intracellular PKC activity increased following stimulation of cultured rat SMCs with fetal calf serum and was suppressed by heparin in a time- and dose-dependent manner, Heparin acted through a selective inhibition of the PKC-alpha since preincubation of the cells with a 20-mer phosphorothioate PKC-alpha antisense oligodeoxynucleotide (ODN) eliminated the heparin effect. In vivo, following balloon injury of the rat carotid artery, particulate fraction PKC content increased with a time course and to an extent comparable with the observed changes in vitro. Heparin, administered at the time of injury or shortly thereafter, inhibited the activity of the particulate PKC and suppressed the in situ phosphorylation of an 80-kDa myristoylated alanine-rich protein kinase C substrate (MARCKS), a substrate of PKC, The topical application of the phosphorothioate antisense ODN selectively suppressed the expression of the PKC-alpha isoenzyme in vivo but did not affect injury-induced myointimal proliferation. Topical application of the ODN also eliminated the antiproliferative activity of heparin. These results therefore suggest that heparin might block SMC proliferation by interfering with the PKC pathway through a selective direct inhibition of the PKC-alpha isoenzyme.	UNIV WASHINGTON,DEPT SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Herbert, JM (corresponding author), SANOFI RECH,HEMOBIOL RES DEPT,195 ROUTE DESPAGNE,F-31036 TOULOUSE,FRANCE.							ANDREA JE, 1992, HYPERTENSION, V20, P585, DOI 10.1161/01.HYP.20.5.585; AU YPT, 1992, J BIOL CHEM, V267, P3438; AU YPT, 1992, CIRC RES, V70, P1062, DOI 10.1161/01.RES.70.5.1062; AUSTIN GE, 1985, J AM COLL CARDIOL, V6, P365; BUSCH SJ, 1992, J CELL BIOL, V116, P31, DOI 10.1083/jcb.116.1.31; CAMPISI J, 1982, EXP CELL RES, V140, P389, DOI 10.1016/0014-4827(82)90128-8; CASTELLOT JJ, 1987, SEMIN THROMB HEMOST, V13, P489, DOI 10.1055/s-2007-1003525; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; DAMON DH, 1992, EXP CELL RES, V201, P154, DOI 10.1016/0014-4827(92)90359-G; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; GOUELI SA, 1991, FEBS LETT, V282, P445, DOI 10.1016/0014-5793(91)80533-9; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HERBERT JM, 1991, BIOCHIM BIOPHYS ACTA, V1091, P432; HERBERT JM, 1990, BIOCHEM PHARMACOL, V9, P201; KARIYA K, 1987, EXP CELL RES, V173, P504, DOI 10.1016/0014-4827(87)90290-4; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; PUKAC LA, 1990, CELL REGUL, V1, P435, DOI 10.1091/mbc.1.5.435; PUKAC LA, 1992, J BIOL CHEM, V267, P3707; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; REILLY CF, 1989, J BIOL CHEM, V264, P6990; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; ROSS R, 1986, NEW ENGL J MED, V314, P448; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; ROZENGURT E, 1984, P NATL ACAD SCI-BIOL, V81, P5748, DOI 10.1073/pnas.81.18.5748; SASAGURI T, 1993, EXP CELL RES, V208, P311, DOI 10.1006/excr.1993.1251; SKOGLUND G, 1985, EUR J BIOCHEM, V148, P407, DOI 10.1111/j.1432-1033.1985.tb08854.x; SMITH CD, 1992, BIOCHEM J, V281, P803, DOI 10.1042/bj2810803; STAUBLE B, 1993, BIOCHEM MOL BIOL INT, V29, P203; URATSUJI Y, 1988, J CELL PHYSIOL, V136, P431, DOI 10.1002/jcp.1041360306; WRIGHT TC, 1989, P NATL ACAD SCI USA, V86, P3199, DOI 10.1073/pnas.86.9.3199; WRIGHT TN, 1989, AM REV RESPIR DIS, V140, P1132	41	196	207	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25928	25935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824227				2022-12-27	WOS:A1996VN18000033
J	Hoffmann, KF; Strand, M				Hoffmann, KF; Strand, M			Molecular identification of a Schistosoma mansoni tegumental protein with similarity to cytoplasmic dynein light chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-ARM DYNEIN; SURFACE-ANTIGEN; MICE; PHOSPHORYLATION; GLYCOPROTEINS; FLAGELLA; CALNEXIN; CLONING; SMIRV1; SERA	The tegument of Schistosoma mansoni contains a number of proteins that presumably function in its maintenance and/or repair against damage incurred from host-mediated humoral immune responses. Here, we show that the schistosome antigen identified by monoclonal antibody 709A2/2 is a cytoplasmic dynein light chain, Dynein light chains are components of dynein, an enzyme complex involved in various aspects of microtubule-based motility. Monoclonal antibody 709A2/2 recognizes two polypeptides, one of 8.9 kDa and a second of 7.6 kDa, as determined by SDS-polyacrylamide gel electrophoresis. me find that expression of S. mansoni dynein light chain is developmentally regulated and localized to the tegument in the schistosomula, lung stage worms, and adult worms, but is not present in the cercariae or ciliated miracidia. By Northern blot analysis of adult worm RNA, S. mansoni dynein light chain is encoded by a single message of similar to 600 base pairs. A cDNA encoding this polypeptide contains an open reading frame of 89 amino acids with a deduced molecular mass of 10.4 kDa. Coprecipitation of an apparent 18.4-kDa antigen with S. mansoni dynein light chain by monoclonal antibody 709A2/2 illustrates that this molecule has an affinity for other proteins. Such interactions may play a role in S. mansoni dynein Light chain participation in organelle trafficking in S. mansoni.	JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOL SCI, CTR MONOCLONAL STUDIES, BALTIMORE, MD 21205 USA	Johns Hopkins University				Hoffmann, Karl/0000-0002-3932-5502	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI019217, R37AI019217] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19217, AI-55270] Funding Source: Medline; NIGMS NIH HHS [5732 GM07626] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; BARKALOW K, 1994, J CELL BIOL, V126, P727, DOI 10.1083/jcb.126.3.727; BERGQUIST NR, 1995, PARASITOL TODAY, V11, P191, DOI 10.1016/0169-4758(95)80157-X; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUTTERWORTH AE, 1987, PARASITOL TODAY, V3, P11, DOI 10.1016/0169-4758(87)90091-3; CIANFRIGLIA M, 1983, HYBRIDOMA, V2, P451, DOI 10.1089/hyb.1983.2.451; DALTON JP, 1986, J IMMUNOL, V136, P4689; DALTON JP, 1987, P NATL ACAD SCI USA, V84, P4268, DOI 10.1073/pnas.84.12.4268; Dick T, 1996, MOL GEN GENET, V251, P38; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Harlow E., 1989, ANTIBODIES LAB MANUA; HAWN TR, 1993, J BIOL CHEM, V268, P7692; HAWN TR, 1994, J BIOL CHEM, V269, P20083; Hockley D.J., 1973, Advances Parasit, V11, P233, DOI 10.1016/S0065-308X(08)60188-8; HOCKLEY D J, 1973, International Journal for Parasitology, V3, P13, DOI 10.1016/0020-7519(73)90004-0; Holzbaur Erika L. F., 1994, V13, P251; KING SM, 1990, CELL MOTIL CYTOSKEL, V16, P266, DOI 10.1002/cm.970160406; KING SM, 1995, J BIOL CHEM, V270, P11445, DOI 10.1074/jbc.270.19.11445; KOSTER B, 1994, PARASITOLOGY, V108, P433, DOI 10.1017/S0031182000075995; KOSTER B, 1994, ARCH BIOCHEM BIOPHYS, V310, P108, DOI 10.1006/abbi.1994.1146; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P2662, DOI 10.1073/pnas.92.7.2662; LEWIS SA, 1988, THESIS J HOPKINS U; MONELL CR, 1992, THESIS J HOPKINS U; NORDEN AP, 1985, AM J TROP MED HYG, V34, P495, DOI 10.4269/ajtmh.1985.34.495; OAKS JA, 1981, J PARASITOL, V67, P761, DOI 10.2307/3280697; REYNOLDS SR, 1994, J IMMUNOL, V152, P193; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATIR P, 1995, BIOPHYS J, V68, pS222; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; STEPHENS RE, 1992, J CELL SCI, V103, P999; Stirewalt M.A., 1974, Advances Parasit, V12, P115, DOI 10.1016/S0065-308X(08)60388-7; STRAND M, 1982, EXP PARASITOL, V54, P145, DOI 10.1016/0014-4894(82)90121-7; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; VALLEE R, 1993, P NATL ACAD SCI USA, V90, P8769, DOI 10.1073/pnas.90.19.8769; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WITMAN G B, 1992, Current Opinion in Cell Biology, V4, P74; Witman George B., 1994, V13, P229	40	47	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26117	26123		10.1074/jbc.271.42.26117	http://dx.doi.org/10.1074/jbc.271.42.26117			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824255	hybrid			2022-12-27	WOS:A1996VN18000061
J	Ricketts, WA; Rose, DW; Shoelson, S; Olefsky, JM				Ricketts, WA; Rose, DW; Shoelson, S; Olefsky, JM			Functional roles of the Shc phosphotyrosine binding and Src homology 2 domains in insulin and epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PROTEIN SHC; PTB DOMAIN; NPXY MOTIF; ASSOCIATION; ACTIVATION; PATHWAY; SITES; RAS	Shc is involved in the activation of Ras in response to many growth factors. Shc contains two phosphotyrosine binding domains, an Src homology 2 (SH2) domain in the carboxyl terminus of the protein and a phosphotyrosine binding (PTB) domain in the amino terminus. Since functional roles for these two domains have not been established, we microinjected glutathione S-transferase fusion proteins of either the Shc PTB or SH2 domains into fibroblasts expressing insulin and epidermal growth factor receptors and measured their effects on DNA synthesis. We found that the Shc PTB was necessary for insulin-induced mitogenic signaling, whereas the SH2 domain was not. In contrast, for epidermal growth factor signaling, the Shc SH2 was functionally more important. These differential modes of signal transduction may be an important factor in determining the specificity of the response of a cell to external stimuli.	UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM RES SERV,SAN DIEGO,CA; UNIV CALIF SAN DIEGO,BIOMED SCI GRAD PROGRAM,SAN DIEGO,CA 92103; WHITTIER DIABET PROGRAM,LA JOLLA,CA 92093; JOSLIN DIABET CTR,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	University of California System; University of California San Diego; University of California System; University of California San Diego; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARUTA T, 1995, J BIOL CHEM, V270, P27991; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; KABURAGI Y, 1995, ENDOCRINOLOGY, V136, P3437, DOI 10.1210/en.136.8.3437; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Morris AJ, 1996, P NATL ACAD SCI USA, V93, P8401, DOI 10.1073/pnas.93.16.8401; OKADA S, 1995, J BIOL CHEM, V270, P20737, DOI 10.1074/jbc.270.35.20737; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; THIES RA, 1990, J BIOL CHEM, V265, P1032; TRUB T, 1995, J BIOL CHEM, V270, P18205; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085	28	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26165	26169		10.1074/jbc.271.42.26165	http://dx.doi.org/10.1074/jbc.271.42.26165			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824262	hybrid			2022-12-27	WOS:A1996VN18000068
J	Scholl, D; Nixon, BT				Scholl, D; Nixon, BT			Cooperative binding of DctD to the dctA upstream activation sequence of Rhizobium meliloti is enhanced in a constitutively active truncated mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; SIGMA(54)-DEPENDENT TRANSCRIPTIONAL ACTIVATOR; C-4-DICARBOXYLATE TRANSPORT GENES; DICARBOXYLIC-ACID TRANSPORT; NITROGEN REGULATOR-I; CI-REPRESSOR; ENVIRONMENTAL STIMULI; BACTERIOPHAGE-LAMBDA; PARAMETER-ESTIMATION; SIGNAL-TRANSDUCTION	DctD, a sigma(54)-dependent, two-component regulator, binds to promoter distal (A) and promoter proximal (B) sites in an activation sequence located upstream of the dctA promoter. We report gel filtration and quantitative DNase I footprint experiments supporting a model in which DctD(2) binds to these sites cooperatively, The global analysis of upstream activation sequences containing sites A and B, A and B one-half helical turn out of phase, and only B yielded values for the intrinsic and cooperative binding free energies of Delta G(A)(0) = -9.5 +/- 0.3, Delta G(B)(0) = -11.2 +/- 0.2, and Delta G(AB)(0) = -2.5 +/- 0.5. A separate analysis of data from upstream activation sequences containing site A and a point mutant of site B, and site A and mutant site B one-half helical turn out of phase confirmed the estimate of cooperativity, yielding free energy values of Delta G(A)(0) = -9.4 +/- 0.2, Delta G(B(G-->C))(0) = -10.0 +/- 0.2, and Delta G(AB(G-->C))(0) = -2.2 +/- 0.4. We previously showed that removing the two-component receiver domain from DctD, making DctD(Delta(1-142)), yields a constitutively active truncated protein. Global analysis of binding data for DctD(Delta(1-142)) showed that this constitutively active mutant has intrinsic binding energies equal to that of the inactive DctD protein, but that it displays significantly higher cooperativity (Delta G(A)(0) = -9.4 +/- 0.6, Delta G(B)(0) = -11.1 +/- 0.3, and Delta G(AB)(0) = -3.8 +/- 0.6.).	PENN STATE UNIV,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM40404] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040404, R55GM040404] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ARWAS R, 1985, J GEN MICROBIOL, V131, P2059; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BOLTON E, 1986, ARCH MICROBIOL, V144, P142, DOI 10.1007/BF00414724; BRENOWITZ M, 1989, NUCLEIC ACIDS RES, V17, P3747, DOI 10.1093/nar/17.10.3747; CHEN P, 1995, J BACTERIOL, V177, P2490, DOI 10.1128/jb.177.9.2490-2496.1995; ENGELKE T, 1989, J BACTERIOL, V171, P5551, DOI 10.1128/jb.171.10.5551-5560.1989; ENGELKE T, 1987, J GEN MICROBIOL, V133, P3019; FIEDLER U, 1995, EMBO J, V14, P3696, DOI 10.1002/j.1460-2075.1995.tb00039.x; FINAN TM, 1988, J BACTERIOL, V170, P3396, DOI 10.1128/jb.170.8.3396-3403.1988; GIBLIN L, 1995, FEMS MICROBIOL LETT, V126, P25, DOI 10.1016/0378-1097(94)00520-2; GU BH, 1994, MOL MICROBIOL, V13, P51, DOI 10.1111/j.1365-2958.1994.tb00401.x; HUALA E, 1992, J BACTERIOL, V174, P1428, DOI 10.1128/jb.174.4.1428-1431.1992; JIANG J, 1989, J BACTERIOL, V171, P5244, DOI 10.1128/jb.171.10.5244-5253.1989; JOHNSON ML, 1992, METHOD ENZYMOL, V210, P1; KOBLAN KS, 1992, METHOD ENZYMOL, V210, P405; LABES M, 1993, J BACTERIOL, V175, P2674, DOI 10.1128/JB.175.9.2674-2681.1993; LEDEBUR H, 1990, J BACTERIOL, V172, P3888, DOI 10.1128/jb.172.7.3888-3897.1990; LEDEBUR H, 1992, MOL MICROBIOL, V6, P3479, DOI 10.1111/j.1365-2958.1992.tb01783.x; LEE JH, 1995, P NATL ACAD SCI USA, V92, P9702, DOI 10.1073/pnas.92.21.9702; LEE JH, 1994, J BIOL CHEM, V269, P20401; Maniatis T., 1982, MOL CLONING LABORATO, P86; MERABET E, 1995, BIOCHEMISTRY-US, V34, P8554, DOI 10.1021/bi00027a005; METTKE I, 1995, J BACTERIOL, V177, P5056, DOI 10.1128/jb.177.17.5056-5061.1995; NIXON BT, 1986, P NATL ACAD SCI USA, V83, P7850, DOI 10.1073/pnas.83.20.7850; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PORTER SC, 1993, GENE DEV, V7, P2258, DOI 10.1101/gad.7.11.2258; Ronson C. W., 1985, Nitrogen fixation research progress. Proceedings of the 6th International Symposium on Nitrogen Fixation, Corvallis, OR, USA, August 4-10. 1985., P201; RONSON CW, 1987, J BACTERIOL, V169, P2424, DOI 10.1128/jb.169.6.2424-2431.1987; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; RONSON CW, 1981, P NATL ACAD SCI-BIOL, V78, P4284, DOI 10.1073/pnas.78.7.4284; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SAROFF HA, 1993, BIOPOLYMERS, V33, P1327, DOI 10.1002/bip.360330903; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SENEAR DF, 1992, METHOD ENZYMOL, V210, P463; SENEAR DF, 1986, BIOCHEMISTRY-US, V25, P7344, DOI 10.1021/bi00371a016; SENEAR DF, 1993, BIOCHEMISTRY-US, V32, P6179, DOI 10.1021/bi00075a010; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; STRAHS D, 1994, J MOL BIOL, V244, P494, DOI 10.1006/jmbi.1994.1748; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WANG YP, 1989, GENE, V85, P135, DOI 10.1016/0378-1119(89)90473-3; WATSON RJ, 1990, MOL PLANT MICROBE IN, V3, P174, DOI 10.1094/MPMI-3-174; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N; WEISS V, 1992, P NATL ACAD SCI USA, V89, P5088, DOI 10.1073/pnas.89.11.5088; YAROSH OK, 1989, MOL MICROBIOL, V3, P813, DOI 10.1111/j.1365-2958.1989.tb00230.x	46	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26435	26442		10.1074/jbc.271.42.26435	http://dx.doi.org/10.1074/jbc.271.42.26435			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824302	hybrid			2022-12-27	WOS:A1996VN18000108
J	Wimalasena, K; Dharmasena, S; Wimalasena, DS; HughbanksWheaton, DK				Wimalasena, K; Dharmasena, S; Wimalasena, DS; HughbanksWheaton, DK			Reduction of dopamine beta-monooxygenase - A unified model for apparent negative cooperativity and fumarate activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMAFFIN-GRANULE GHOSTS; REDUCING EQUIVALENTS; ADRENAL-MEDULLA; ASCORBATE; MEMBRANE; MECHANISM; HYDROXYLASE; COPPER; ACID	The interactions of reductants with dopamine beta-monooxygenase (D beta M) were examined using two novel classes of reductants. The steady-state kinetics of the previously characterized D beta M reductant, N,N-dimethyl-1,4-p-phenylenediamine (DMPD), were parallel to the ascorbic acid-supported reaction with respect to pH dependence and fumarate activation, DMPD also displayed pH and fumarate-dependent apparent negative cooperativity demonstrating that the previously reported cooperative behavior of D beta M toward the reductant is not unique to ascorbic acid, The 6-OH phenyl and alkylphenyl-substituted ascorbic acid derivatives were more efficient reductants for the enzyme than ascorbic acid. Kinetic studies suggested that these derivatives behave as pseudo bisubstrates with respect to ascorbic acid and the amine substrate, The lack of apparent cooperative behavior with these derivatives suggests that this behavior of D beta M is not common for all the reductants, Based on these findings and additional kinetic evidence, the proposal that the apparent negative cooperativity in the interaction of ascorbic acid with D beta M was due to the presence of a distinct allosteric regulatory site has been ruled out, In contrast to previous models, where fumarate was proposed to interact with a distinct anion binding site, the effect of fumarate on the steady state kinetics of these novel reductants suggests that fumarate and the reductant may interact with the same site of the enzyme, In accordance with these observations and mathematical analysis of the experimental data, a unified model for the apparent negative cooperativity and fumarate activation of D beta M in which both fumarate and the reductant interact with the same site of all forms of the enzyme with varying affinities under steady state turnover conditions has been proposed.			Wimalasena, K (corresponding author), WICHITA STATE UNIV,DEPT CHEM,WICHITA,KS 67260, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045026, R01GM045026] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45026] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN N, 1983, BIOCHEMISTRY-US, V22, P3096, DOI 10.1021/bi00282a012; ALBERTY RA, 1954, J AM CHEM SOC, V76, P2485, DOI 10.1021/ja01638a053; BEERS MF, 1986, J BIOL CHEM, V261, P2529; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; Cleland W W, 1979, Methods Enzymol, V63, P103; CRAINE JE, 1973, J BIOL CHEM, V248, P7838; FERSHT A, 1984, ENZYME STRUCTURE MEC, P263; GOLDSTEIN M, 1968, BIOCHEMISTRY-US, V7, P2724, DOI 10.1021/bi00848a005; HUYGHE BG, 1991, J BIOL CHEM, V266, P11544; INGEBRETSEN OC, 1980, BIOCHIM BIOPHYS ACTA, V628, P182, DOI 10.1016/0304-4165(80)90365-7; KELLEY DM, 1986, J BIOL CHEM, V261, P6429; KIRSHNER N, 1962, J BIOL CHEM, V237, P2311; LEVIN EY, 1960, J BIOL CHEM, V235, P2080; LJONES T, 1976, EUR J BIOCHEM, V6, P525; LJONES T, 1984, COPPER PROTEINS COPP, V2, P131; Michaelis L., 1939, J AM CHEM SOC, V61, P1981; NJUS D, 1983, J BIOL CHEM, V258, P27; NJUS D, 1979, BIOCHEM J, V180, P579, DOI 10.1042/bj1800579; PHILLIPS JH, 1982, NEUROSCIENCE, V7, P1595, DOI 10.1016/0306-4522(82)90017-3; RAO PS, 1975, J PHYS CHEM-US, V79, P1063, DOI 10.1021/j100578a005; SABBAN EL, 1983, J BIOL CHEM, V258, P7812; SKOTLAND T, 1979, INORG PERSPECT BIOL, V2, P151; SLATER EP, 1981, ARCH BIOCHEM BIOPHYS, V211, P288, DOI 10.1016/0003-9861(81)90456-2; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STEWART LC, 1991, J BIOL CHEM, V266, P11537; VILLAFRANCA JJ, 1981, METAL IONS BIOL, V3, P263; WAKEFIELD LM, 1986, J BIOL CHEM, V261, P9739; WIMALASENA K, 1994, BIOCHEM BIOPH RES CO, V200, P113, DOI 10.1006/bbrc.1994.1422; WIMALASENA K, 1991, BIOCHEM BIOPH RES CO, V175, P920, DOI 10.1016/0006-291X(91)91653-T; WIMALASENA K, 1991, ANAL BIOCHEM, V197, P353, DOI 10.1016/0003-2697(91)90404-H; WIMALASENA K, 1995, J BIOL CHEM, V270, P27516, DOI 10.1074/jbc.270.46.27516; WINKLER H, 1970, BIOCHEM J, V118, P303, DOI 10.1042/bj1180303	32	10	10	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26032	26043		10.1074/jbc.271.42.26032	http://dx.doi.org/10.1074/jbc.271.42.26032			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824243	Green Submitted, hybrid			2022-12-27	WOS:A1996VN18000049
J	vanGeest, M; Lolkema, JS				vanGeest, M; Lolkema, JS			Membrane topology of the sodium ion-dependent citrate carrier of Klebsiella pneumoniae - Evidence for a new structural class of secondary transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LACTOSE PERMEASE; GENE FUSIONS; PROTEIN; SEQUENCE; EXPRESSION; PHOA; INSERTION; BACTERIA	The predicted secondary structure model of the sodium ion-dependent citrate carrier of Klebsiella pneumoniae (CitS) presents the la-transmembrane helix motif observed for many secondary transporters, Biochemical evidence presented in this paper is not consistent with this model. N-terminal and C-terminal fusions of CitS with the biotin acceptor domain of the oxaloacetate decarboxylase of K. pneumoniae catalyze citrate transport, showing the correct folding of the CitS part of the fusion proteins in the membrane. Proteolysis experiments with these fusion proteins revealed that the N terminus of CitS is located in the cytoplasm, while the C terminus faces the periplasm, The membrane topology was studied further by constructing a set of 20 different fusions of N-terminal fragments of the citrate transporter with the reporter enzyme alkaline phosphatase (CitS-PhoA fusions), Most fusion points were selected in hydrophilic areas flanking the putative transmembrane-spanning domains in CitS that are predicted from the hydropathy profile of the primary sequence, The alkaline phosphatase activities of cells expressing the CitS-PhoA fusions suggest that the polypeptide traverses the membrane nine times and that the C-terminal half of the protein is characterized by two large hydrophobic periplasmic loops and two large hydrophilic cytoplasmic loops. CitS belongs to the family of the 2-hydroxycarboxylate transporters in which also the citrate carriers, CitPs, of lactic acid bacteria and the malate transporter, MleP, of Lactococcus lactis are found. Since the hydrophobicity profile of CitS is very similar to the hydrophobicity profiles of CitP and MleP, it is most likely that the new structural motif of nine transmembrane segments is shared within this new transporter family.	UNIV GRONINGEN,DEPT MICROBIOL,GRONINGEN BIOTECHNOL & BIOMOL SCI INST,NL-9751 NN HAREN,NETHERLANDS	University of Groningen								CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CONSLER TG, 1993, P NATL ACAD SCI USA, V90, P6934, DOI 10.1073/pnas.90.15.6934; DAVID S, 1990, J BACTERIOL, V172, P5789, DOI 10.1128/jb.172.10.5789-5794.1990; DIMROTH P, 1986, BIOL CHEM H-S, V367, P813, DOI 10.1515/bchm3.1986.367.2.813; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GOTT P, 1988, MOL MICROBIOL, V2, P655, DOI 10.1111/j.1365-2958.1988.tb00074.x; GUTIERREZ C, 1989, NUCLEIC ACIDS RES, V17, P3999, DOI 10.1093/nar/17.10.3999; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; Jander G, 1996, J BACTERIOL, V178, P3049, DOI 10.1128/jb.178.11.3049-3058.1996; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P625; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LLOYD AD, 1990, J BACTERIOL, V172, P1688, DOI 10.1128/jb.172.4.1688-1693.1990; LOLKEMA JS, 1994, BBA-BIOENERGETICS, V1187, P211, DOI 10.1016/0005-2728(94)90113-9; LOLKEMA JS, 1994, EUR J BIOCHEM, V220, P469, DOI 10.1111/j.1432-1033.1994.tb18645.x; LOLKEMA JS, 1996, HDB BIOL PHYS, V2, P229; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; MartyTeysset C, 1996, J BACTERIOL, V178, P2178, DOI 10.1128/jb.178.8.2178-2185.1996; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; PONGS O, 1993, J MEMBRANE BIOL, V136, P1; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POOMAN B, 1992, J BACTERIOL, V173, P6030; POS MK, 1996, BIOCHEMISTRY-US, V35, P1018; POS MK, 1995, FEBS LETT, V374, P37; Pourcher T, 1996, BIOCHEMISTRY-US, V35, P4161, DOI 10.1021/bi9527496; REED KE, 1991, J BIOL CHEM, V266, P11425; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARZ E, 1985, EMBO J, V4, P1599, DOI 10.1002/j.1460-2075.1985.tb03823.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UJWAL ML, 1995, BIOCHEMISTRY-US, V34, P14909, DOI 10.1021/bi00045a036; VANDERREST ME, 1992, J BIOL CHEM, V267, P8791; VANDERREST ME, 1992, J BACTERIOL, V174, P4892; VAUGHAN EE, 1995, APPL ENVIRON MICROB, V61, P3172, DOI 10.1128/AEM.61.8.3172-3176.1995; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YUN CH, 1991, J BIOL CHEM, V266, P10967; ZEN KH, 1995, BIOCHEMISTRY-US, V34, P3430, DOI 10.1021/bi00010a035	38	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25582	25589		10.1074/jbc.271.41.25582	http://dx.doi.org/10.1074/jbc.271.41.25582			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810332	hybrid, Green Published			2022-12-27	WOS:A1996VL69300076
J	Liao, YF; Lal, A; Moremen, KW				Liao, YF; Lal, A; Moremen, KW			Cloning, expression, purification, and characterization of the human broad specificity lysosomal acid alpha-mannosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLYCOPROTEIN-BIOSYNTHESIS; DICTYOSTELIUM-DISCOIDEUM; SACCHAROMYCES-CEREVISIAE; SUBSTRATE-SPECIFICITY; MOLECULAR-CLONING; PICHIA-PASTORIS; COMPLEX GLYCANS; GOLGI; GENE	We have cloned and expressed two cDNAs encoding the human lysosomal alpha-mannosidase (EC 3.2.1.24) by RT-PCB of human spleen mRNk This enzyme is required for the degradation of N-Linked carbohydrates during glycoprotein catabolism in eucaryotic cells, The shorter of the two cDNAs (3 kilobases (kb)) was found to encode an open reading frame of 2964 base pairs and, when expressed in Pichia pastoris, was found to encode an enzyme that could cleave high mannose oligosaccharides, oligosaccharides isolated from alpha-mannosidosis fibroblasts, and p-nitrophenyl-alpha-D-mannopyranoside substrates, In addition, the Pichia-expressed enzyme was inhibited by swainsonine, and had a pH optimum, K-m, and V-max characteristic of the enzyme purified previously from human liver. The second, larger RT-PCR product (3.6 kb) was found to contain an insertion and a deletion relative to the 3-kb spleen amplimer and encoded a truncated coding region, indicating that it resulted from alternate transcript splicing, No alpha-mannosidase activity could be detected in Pichia transformants containing this coding region, indicating that it did not encode a functional enzyme, Antiserum raised to the recombinant product of the 3-kb alpha-mannosidase cDNA immunoprecipitated lysosomal alpha-mannosidase activity from human fibroblast extracts, Northern blots identified a 3-kb RNA transcript in all human tissues tested, including alpha-mannosidosis fibroblasts, while minor transcripts of 3.6 kb were also present in several adult tissues, Human chromosome mapping of the mannosidase gene confirmed that the functional gene maps to the MANB locus on chromosome 19, Sequence comparisons were made to preciously published human cDNA sequences encoding a putative lysosomal alpha-mannosidase (Nebes, V, L., and Schmidt, M. C. (1994) Biochem. Biophys. Res, Commun. 200, 289-245) and several differences were found relative to the functional lysosomal alpha-mannosidase encoded by the 3-kb spleen cDNA.	UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30602; UNIV GEORGIA,COMPLEX CARBOHYDRATE RES CTR,ATHENS,GA 30602	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia			Moremen, Kelley/AAD-4661-2019; Liao, Yung-Feng/A-9761-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047533] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05351] Funding Source: Medline; NIGMS NIH HHS [GM47533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDAHER S, 1991, BIOCHEM J, V277, P743, DOI 10.1042/bj2770743; ARONSON NN, 1989, FASEB J, V3, P2615, DOI 10.1096/fasebj.3.14.2531691; BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; BENNET JK, 1995, AM J MED GENET, V55, P21, DOI 10.1002/ajmg.1320550108; BISCHOFF J, 1990, J BIOL CHEM, V265, P17110; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CARROLL M, 1972, BIOCHEM BIOPH RES CO, V49, P579, DOI 10.1016/0006-291X(72)90450-0; CHAMPION MJ, 1978, CYTOGENET CELL GENET, V22, P186, DOI 10.1159/000130932; CHAMPION MJ, 1977, P NATL ACAD SCI USA, V74, P2968, DOI 10.1073/pnas.74.7.2968; CHENG SH, 1986, BIOCHEM J, V233, P65, DOI 10.1042/bj2330065; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DANIEL PF, 1992, GLYCOBIOLOGY, V2, P327, DOI 10.1093/glycob/2.4.327; DEGASPERI R, 1991, J BIOL CHEM, V266, P16556; DEGASPERI R, 1992, J BIOL CHEM, V267, P9706; Desnick R J, 1976, Adv Exp Med Biol, V68, P277; DESNICK RJ, 1976, PEDIATR RES, V10, P985, DOI 10.1203/00006450-197612000-00008; EMILIANI C, 1995, BIOCHEM J, V305, P363, DOI 10.1042/bj3050363; HASE S, 1994, METHOD ENZYMOL, V230, P225; HASE S, 1988, J CHROMATOGR-BIOMED, V434, P51, DOI 10.1016/0378-4347(88)80061-6; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; INGRAM PH, 1977, BIOCHEM GENET, V15, P455, DOI 10.1007/BF00520191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIS H, 1966, J BIOL CHEM, V241, P684; MARTINIUK F, 1985, HUM GENET, V69, P109, DOI 10.1007/BF00293278; MERKLE RK, 1994, GLYCOBIOLOGY, V4, P734; MICHALSKI JC, 1990, EUR J BIOCHEM, V189, P369, DOI 10.1111/j.1432-1033.1990.tb15498.x; MIERENDORF RC, 1983, J BIOL CHEM, V258, P5878; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NEBES VL, 1994, BIOCHEM BIOPH RES CO, V200, P239, DOI 10.1006/bbrc.1994.1440; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; OKUMURA T, 1973, J BIOCHEM, V73, P131; OPHEIM DJ, 1978, J BIOL CHEM, V253, P1017; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PHILLIPS NC, 1976, BIOCHEM J, V153, P579, DOI 10.1042/bj1530579; PHILLIPS NC, 1977, BIOCHEM J, V163, P269, DOI 10.1042/bj1630269; POHLMANN R, 1983, BIOCHEM BIOPH RES CO, V115, P1083, DOI 10.1016/S0006-291X(83)80046-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZLE J, 1992, J BIOL CHEM, V267, P4000; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; STADEN R, 1987, NUCLEIC ACID PROTEIN, P173; TAYLOR HA, 1975, CLIN CHIM ACTA, V59, P93, DOI 10.1016/0009-8981(75)90223-5; TSAY GC, 1975, J CLIN INVEST, V56, P711, DOI 10.1172/JCI108142; Tschopp J F, 1991, Biotechnology, V18, P305; TSCHOPP JF, 1987, NUCLEIC ACIDS RES, V15, P3859, DOI 10.1093/nar/15.9.3859; TULSIANI DRP, 1989, J CELL BIOL, V109, P1257, DOI 10.1083/jcb.109.3.1257; TULSIANI DRP, 1995, DEV BIOL, V167, P584, DOI 10.1006/dbio.1995.1050; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YAMASHITA K, 1980, J BIOL CHEM, V255, P5126	55	104	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28348	28358		10.1074/jbc.271.45.28348	http://dx.doi.org/10.1074/jbc.271.45.28348			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910458	hybrid			2022-12-27	WOS:A1996VU03300058
J	Louie, DF; Resing, KA; Lewis, TS; Ahn, NG				Louie, DF; Resing, KA; Lewis, TS; Ahn, NG			Mass spectrometric analysis of 40 S ribosomal proteins from rat-1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLISION-INDUCED DISSOCIATION; MAP KINASE KINASE; ELECTROSPRAY-IONIZATION; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLATION SITES; LOCALIZATION; RNA; LIVER; NUCLEOLIN; PEPTIDES	Although sequences of most mammalian ribosomal proteins are available, little is known about the posttranslational processing of ribosomal proteins. To exam ine their post-translational modifications, 40 S subunit proteins purified from Rat-1 fibroblasts and their peptides were analyzed by Liquid chromatography coupled with electrospray mass spectrometry. Of 41 proteins observed, 36 corresponded to the 32 rat 40 S ribosomal proteins with known sequences (S3, S5, S7, and S24 presented in two forms). The observed masses of S4, S6-S8, S13, S15a, S16, S17, S19, S27a, S29, and S30 matched those predicted. Sa, S3a, S5, S11, S15, S18, S20, S21, S24, S26-S28, and an 57 variant showed changes in mass that were consistent with N-terminal demethionylation and/or acetylation (S5 and S27 also appeared to be internally formylated and acetylated, respectively). S23 appeared to be internally hydroxylated or methylated. S2, S3, S9, S10, S12, S14, and S25 showed changes in mass inconsistent with known covalent modifications (+220, -75, +86, +56, -100, -117, and -103 Da, respectively), possibly representing novel post-translational modifications or allelic sequence variation. Five unidentified proteins (12,084, 13,706, 13,741, 13,884, and 34,987 Da) were observed; for one, a sequence tag (PPGPPP), absent in any known ribosomal proteins, was determined, suggesting that it is a previously undescribed ribosome-associated protein. This study establishes a powerful method to rapidly analyze protein components of large biological complexes and their covalent modifications.	UNIV COLORADO,HOWARD HUGHES MED INST,BOULDER,CO 80309	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Louie, DF (corresponding author), UNIV COLORADO,DEPT CHEM & BIOCHEM,CAMPUS BOX 215,BOULDER,CO 80309, USA.				NIAMS NIH HHS [AR39730] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR039730] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARFIN SM, 1988, BIOCHEMISTRY-US, V27, P7979, DOI 10.1021/bi00421a001; ASHTON DS, 1994, FEBS LETT, V342, P1, DOI 10.1016/0014-5793(94)80572-5; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BURLINGAME AL, 1994, ANAL CHEM, V66, pR634; CHAN YL, 1993, BIOCHEM BIOPH RES CO, V193, P106, DOI 10.1006/bbrc.1993.1596; CHAN YL, 1994, BIOCHEM BIOPH RES CO, V200, P1498, DOI 10.1006/bbrc.1994.1620; CHAN YL, 1990, FEBS LETT, V263, P85, DOI 10.1016/0014-5793(90)80711-Q; CHAN YL, 1995, BIOCHEM BIOPH RES CO, V215, P682, DOI 10.1006/bbrc.1995.2518; CHAN YL, 1987, NUCLEIC ACIDS RES, V15, P9451, DOI 10.1093/nar/15.22.9451; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; CHAN YL, 1988, J BIOL CHEM, V263, P2891; Cooks R.G., 1978, COLLISION SPECTROSCO; CREANCIER L, 1993, MOL BIOL CELL, V4, P1239, DOI 10.1091/mbc.4.12.1239; DEVI KRG, 1989, BIOCHIM BIOPHYS ACTA, V1008, P258; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; HILL WE, 1990, RIBOSOMES STRUCTURE; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; ITOH T, 1985, BIOCHEMISTRY-US, V24, P7418, DOI 10.1021/bi00346a058; JACKSON R, 1970, NATURE, V227, P672, DOI 10.1038/227672a0; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KATTA V, 1991, ANAL CHEM, V63, P174, DOI 10.1021/ac00002a016; KITAGAWA M, 1991, FEBS LETT, V283, P210, DOI 10.1016/0014-5793(91)80590-Y; KITAOKA Y, 1994, BIOCHEM BIOPH RES CO, V202, P314, DOI 10.1006/bbrc.1994.1929; KRISHNA RG, 1993, ADV ENZYMOL RAMB, V67, P265; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LOO JA, 1993, ANAL CHEM, V65, P425, DOI 10.1021/ac00052a020; LUTSCH G, 1979, MOL GEN GENET, V176, P281, DOI 10.1007/BF00273223; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MANN M, 1995, TRENDS BIOCHEM SCI, V20, P219, DOI 10.1016/S0968-0004(00)89019-2; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MUSATOV A, 1994, BIOCHEMISTRY-US, V33, P10561, DOI 10.1021/bi00201a001; NAKANISHI O, 1985, GENE, V35, P289; OLVERA J, 1993, J BIOL CHEM, V268, P17967; PALMITER RD, 1978, P NATL ACAD SCI USA, V75, P94, DOI 10.1073/pnas.75.1.94; RESING KA, 1993, BIOCHEMISTRY-US, V32, P10036, DOI 10.1021/bi00089a020; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SHERTON CC, 1972, J BIOL CHEM, V247, P4460; STEWART MJ, 1994, BIOESSAYS, V16, P809, DOI 10.1002/bies.950161107; SUZUKI K, 1990, FEBS LETT, V271, P51, DOI 10.1016/0014-5793(90)80369-T; SUZUKI K, 1990, BIOCHIMIE, V72, P299, DOI 10.1016/0300-9084(90)90088-X; SUZUKI K, 1991, J BIOL CHEM, V266, P20007; SUZUKI K, 1990, BIOCHEM BIOPH RES CO, V117, P519; TERAO K, 1970, BIOCHEM BIOPH RES CO, V38, P80, DOI 10.1016/0006-291X(70)91086-7; WAGNER R, 1994, ARCH MICROBIOL, V161, P100, DOI 10.1007/s002030050028; WEIR MS, 1994, TECHNIQUES PROTEIN C, V5, P115; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; Wool IG, 1995, BIOCHEM CELL BIOL, V73, P933, DOI 10.1139/o95-101	53	48	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28189	28198		10.1074/jbc.271.45.28189	http://dx.doi.org/10.1074/jbc.271.45.28189			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910435	hybrid			2022-12-27	WOS:A1996VU03300035
J	Wang, YY; Rasnick, D; Klaus, J; Payan, D; Bromme, D; Anderson, DC				Wang, YY; Rasnick, D; Klaus, J; Payan, D; Bromme, D; Anderson, DC			Nucleophile labeling of cysteine and serine protease substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; SPECIFICITY; INHIBITORS; AMINOLYSIS; SURFACE	Dipeptides containing fluorescein or biotin have been incorporated into proteolytic substrate cleavage products of bovine serum albumin generated by human cathepsin S or neutrophil elastase and into a fragment of the 31-kDa interleukin 1 beta precursor by human interleukin 1 beta-converting enzyme, Incorporation of the nucleophile is blocked by prior inhibition of the enzymes, and is not seen when proteolysis occurs in the absence of label, and the protease is then inhibited before the addition of label, Labeling is dependent on the pH, the time of reaction, and the concentrations of the nucleophile and substrate. Labeling of proteins can be readily detected by SDS-polyacrylamide gel electrophoresis. The pattern of elastase-labeled bovine serum albumin bands differs among P-1' Phe, Ala, and Gly, suggesting that nucleophilic attack on acyl enzyme intermediates derived from a large protein may differ from attack on small intermediates, The only observed labeled fragment catalyzed by interleukin 1 beta-converting enzyme is fragment 28-116 from the interleukin 1 beta precursor, suggesting that the cleavage between residues 27 and 28 is at least as efficient as between residues 116 and 117, This labeling method does not require organic solvent or nonphysiological pH values and thus may be useful for the discovery of novel protease substrates in cells or other in vivo systems or for diagnostic applications.	KHEPRI PHARMACEUT, San Francisco, CA 94080 USA									BROMME D, 1993, FEBS LETT, V322, P211, DOI 10.1016/0014-5793(93)81571-G; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; FOX JEB, 1994, BLOOD COAGUL FIBRIN, V5, P291, DOI 10.1097/00001721-199404000-00020; GROMOV PS, 1989, INT J BIOCHEM, V21, P941, DOI 10.1016/0020-711X(89)90296-6; HOOK VYH, 1994, FASEB J, V8, P1269, DOI 10.1096/fasebj.8.15.8001739; Klenk Hans-Dieter, 1994, Trends in Microbiology, V2, P39, DOI 10.1016/0966-842X(94)90123-6; Knop M, 1993, CURR OPIN CELL BIOL, V5, P990, DOI 10.1016/0955-0674(93)90082-2; KRUFT V, 1991, BIOCHEMISTRY-US, V30, P11781, DOI 10.1021/bi00115a007; KULLMAN W, 1987, ENZYMATIC PEPTIDE SY; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MENARD R, 1993, FEBS LETT, V328, P107, DOI 10.1016/0014-5793(93)80975-Z; SCHELLENBERGER V, 1993, BIOCHEMISTRY-US, V32, P4349, DOI 10.1021/bi00067a026; SCHUSTER M, 1992, BIOCHIM BIOPHYS ACTA, V1121, P207, DOI 10.1016/0167-4838(92)90356-I; SMEEKENS SP, 1993, BIO-TECHNOL, V11, P182, DOI 10.1038/nbt0293-182; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; SORENSEN SB, 1995, J AM CHEM SOC, V117, P5944, DOI 10.1021/ja00127a006; STEIN RL, 1987, BIOCHEMISTRY-US, V26, P2238, DOI 10.1021/bi00382a025; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615	21	0	0	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28399	28406		10.1074/jbc.271.45.28399	http://dx.doi.org/10.1074/jbc.271.45.28399			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910464	hybrid			2022-12-27	WOS:A1996VU03300064
J	Yuan, CS; AultRiche, DB; Borchardt, RT				Yuan, CS; AultRiche, DB; Borchardt, RT			Chemical modification and site-directed mutagenesis of cysteine residues in human placental S-adenosylhomocysteine hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-HOMOCYSTEINE; AMINO-ACID SEQUENCE; RAT-LIVER; ANTIVIRAL AGENTS; CDNA SEQUENCE; INACTIVATION; MECHANISM; TARGET; CHEMOTHERAPY; SYNTHETASE	Human placental S-adenosylhomocysteine (AdoHcy) hydrolase (EC 3.3.1.1) was inactivated by 5',5-dithio-bis(2-nitrobenzoic acid) following pseudo first-order kinetics. Modification of three of the 10 cysteine residues per enzyme subunit resulted in complete inactivation of the enzyme, The three modified cysteine residues were identified as Cys(113), Cys(195), and Cys(421), respectively by protein sequencing after modification with [1-C-14]iodoacetamide. Of the three modifiable cysteines, Cys(113) and Cys(195) could be protected from modification in the presence of the substrate adenosine (Ado), which also protected the enzyme from inactivation. On the other hand, Cys(421) was not protected by Ado, and modification of Cys(421) alone did not affect the enzyme activity. To verify whether some of these cysteine residues are important for the enzyme catalysis, these three cysteine residues were replaced by either serine or aspartic acid using site-directed mutagenesis. Mutants of both Cys(113) (C113S and C113D) and Cys(421) (C421S and C421D) had enzyme activities similar to that of the wild type enzyme, and only slight changes were observed in the steady-state kinetics measured in both the synthetic and hydrolytic directions. However, mutants of Cys(195) (C195D and C195S) displayed drastically reduced enzyme activities, and k(cat) values were only 7 and 12% of that of the wild-type enzyme, respectively, resulting in a calculated loss in binding energy (Delta Delta G) of approximate 1 Kcal/mol. The Cys(195) mutants were capable of catalyzing both the 3'-oxidative and 5'-hydrolytic reactions, as evidenced by the reduction of E . NAD(+) to NADH and formation of the 5'-hydrolytic product when incubated with (E)-5',6'-didehydro-6'-deoxy-6'-chlorohomoadenosine at rates comparable with those catalyzed by the wild-type enzyme. However, mutations of the Cys(195) Severely altered the 3'-reduction potential as evidenced by the drastic reduction in the rate of [2,8-H-3]Ado release from the E(-NADH).[2,8-H-3]3'-keto-Ado complex. Circular dichroism studies of the Cys(195) mutants confirmed that the observed effects are not due to changes in secondary structure, These results suggested that the Cys(195) is involved in the catalytic center and may play an important role in maintaining the 3'-reduction potential for effective release of the reaction products and regeneration of the active form (NAD(+) form) of the enzyme; the Cys(113) is located in or near the substrate binding site, but plays no role beneficial to the catalysis; and the Cys(421) is a nonessential residue, which also explains why Cys(421) does not occur in any other known AdoHcy hydrolases.	UNIV KANSAS, DEPT BIOCHEM, LAWRENCE, KS 66047 USA	University of Kansas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKSAMIT RR, 1994, J BIOL CHEM, V269, P4084; AULTRICHE DB, 1994, J BIOL CHEM, V269, P31472; AULTRICHE DB, 1993, MOL PHARMACOL, V43, P989; BITONTI AJ, 1990, BIOCHEM PHARMACOL, V40, P601, DOI 10.1016/0006-2952(90)90562-Y; BORCHARDT RT, 1980, J MED CHEM, V23, P347, DOI 10.1021/jm00178a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COULTERKARIS DE, 1989, ANN HUM GENET, V53, P169, DOI 10.1111/j.1469-1809.1989.tb01781.x; CREEDON KA, 1994, J BIOL CHEM, V269, P16364; DECLERCQ E, 1987, BIOCHEM PHARMACOL, V36, P2567, DOI 10.1016/0006-2952(87)90533-8; DELAHABA G, 1959, J BIOL CHEM, V234, P603; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREY MN, 1973, ACTA CRYSTALLOGR B, VB 29, P876, DOI 10.1107/S0567740873003481; GOMI T, 1986, J BIOL CHEM, V261, P3422; GOMI T, 1982, BIOCHEMISTRY-US, V21, P4171, DOI 10.1021/bi00260a039; GOMI T, 1985, J BIOL CHEM, V260, P2789; GOMI T, 1983, BIOCHEMISTRY-US, V22, P137, DOI 10.1021/bi00270a020; GUPTA RA, 1995, ARCH BIOCHEM BIOPHYS, V319, P365, DOI 10.1006/abbi.1995.1306; HENDERSON DM, 1992, MOL BIOCHEM PARASIT, V53, P169, DOI 10.1016/0166-6851(92)90019-G; KASIR J, 1988, BIOCHEM BIOPH RES CO, V153, P359, DOI 10.1016/S0006-291X(88)81231-2; KAWALLECK P, 1992, P NATL ACAD SCI USA, V89, P4713, DOI 10.1073/pnas.89.10.4713; KELER BT, 1988, ANTIVIRAL DRUG DEV, P123; KERR KA, 1975, ACTA CRYSTALLOGR B, V31, P2022, DOI 10.1107/S0567740875006772; LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H; OGAWA H, 1987, P NATL ACAD SCI USA, V84, P719, DOI 10.1073/pnas.84.3.719; PALMER JL, 1979, J BIOL CHEM, V254, P1217; PORTER DJT, 1992, J BIOL CHEM, V267, P3205; PRASAD SS, 1993, GENOME, V36, P57, DOI 10.1139/g93-008; SGANGA MW, 1992, P NATL ACAD SCI USA, V89, P6328, DOI 10.1073/pnas.89.14.6328; TAKATA Y, 1983, J BIOL CHEM, V258, P7374; TAKATA Y, 1985, ARCH BIOCHEM BIOPHYS, V240, P827, DOI 10.1016/0003-9861(85)90092-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WOLFE MS, 1991, J MED CHEM, V34, P1521, DOI 10.1021/jm00109a001; WOLOS JA, 1993, J IMMUNOL, V151, P526; YUAN CS, 1995, J BIOL CHEM, V270, P16140, DOI 10.1074/jbc.270.27.16140; YUAN CS, 1993, J BIOL CHEM, V268, P17030; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P3758, DOI 10.1021/bi00178a036; YUAN CS, 1994, BIOCHEMISTRY-US, V33, P12305, DOI 10.1021/bi00206a038	38	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28009	28016		10.1074/jbc.271.45.28009	http://dx.doi.org/10.1074/jbc.271.45.28009			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910410	hybrid			2022-12-27	WOS:A1996VU03300010
J	Hoehler, D; Marquardt, RR; McIntosh, AR; Xiao, H				Hoehler, D; Marquardt, RR; McIntosh, AR; Xiao, H			Free radical generation as induced by ochratoxin A and its analogs in bacteria (Bacillus brevis)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED LIPID-PEROXIDATION; INNER MITOCHONDRIAL-MEMBRANE; BALKAN ENDEMIC NEPHROPATHY; PLUS PROOXIDANTS; PERMEABILIZATION; TOXICITY; LIVER; FOODSTUFFS; MECHANISM; CA-2+	Lipid peroxidation is considered as one of the manifestations of cellular damage in the toxicity of ochratoxin A (OA), OA; its three natural analogs, OB, OC, and O alpha; and four synthetic analogs, d-OA, the ethylamide of OA (OE-OA), O-methylated OA (OM-OA), and the lactone-opened OA (OP-OA) were used to study free radical generation in bacteria with Bacillus brevis as a model system. The uptake of the different ochratoxins by E. brevis varied substantially depending on the molecular structures, Electron paramagnetic resonance spectroscopy using alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone as a spin trapping agent showed an enhanced free radical generation due to the addition of OA and most of the analogs. The EPR signals could be further enhanced by the addition of Ca2+, a calcium ionophore and an ATPase uncoupler, whereas they were eliminated by incubating the growing cells with vitamin E. The spin adduct hyperfine splitting constants indicate the presence of alpha-hydroxyethyl radicals resulting from generated hydroxyl radicals, which are trapped by alpha-(4-pyridyl-1-oxide)-N-tert-butyl nitrone. The results further suggest that OA induces free radical production in this model system by enhancing the permeability of the cellular membrane to Ca2+.	UNIV MANITOBA,DEPT ANIM SCI,WINNIPEG,MB R3T 2N2,CANADA; UNIV MANITOBA,FAC PHARM,WINNIPEG,MB R3T 2N2,CANADA	University of Manitoba; University of Manitoba								ALEO MD, 1991, TOXICOL APPL PHARM, V107, P73, DOI 10.1016/0041-008X(91)90332-9; AUGUSTO O, 1986, ARCH BIOCHEM BIOPHYS, V244, P147, DOI 10.1016/0003-9861(86)90103-7; BOSE S, 1994, FOOD CHEM TOXICOL, V32, P533, DOI 10.1016/0278-6915(94)90110-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTILHO RF, 1995, FREE RADICAL BIO MED, V18, P479, DOI 10.1016/0891-5849(94)00166-H; CHU FS, 1972, LIFE SCI, V11, P503, DOI 10.1016/0024-3205(72)90200-7; Cole RJ, 1981, HDB TOXIC FUNGAL MET; FAGIAN MM, 1990, J BIOL CHEM, V265, P19955; FINKELSTEIN E, 1982, MOL PHARMACOL, V21, P262; HASINOFF BB, 1990, BIOCHIM BIOPHYS ACTA, V1032, P78; KAKUDA Y, 1981, J AM OIL CHEM SOC, V58, P773, DOI 10.1007/BF02887320; KHAN S, 1989, BIOCHEM PHARMACOL, V38, P67, DOI 10.1016/0006-2952(89)90150-0; KROGH P, 1977, ACTA PATH MICRO IM B, V85, P238; KROGH P, 1982, ENV CARCINOGENS SELE, V5; Kuiper-Goodman T, 1989, Biomed Environ Sci, V2, P179; MADHYASTHA MS, 1994, J FOOD PROTECT, V57, P48, DOI 10.4315/0362-028X-57.1.48; MALAVEILLE C, 1994, MUTAT RES, V307, P141, DOI 10.1016/0027-5107(94)90286-0; MARQUARDT RR, 1992, J ANIM SCI, V70, P3968, DOI 10.2527/1992.70123968x; MEISNER H, 1976, ARCH BIOCHEM BIOPHYS, V173, P132, DOI 10.1016/0003-9861(76)90243-5; MERRYFIELD ML, 1982, J BIOL CHEM, V257, P3628; NAKAMURA H, 1991, J CLIN INVEST, V87, P1810, DOI 10.1172/JCI115202; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; OMAR RF, 1990, BIOCHEM PHARMACOL, V40, P1183, DOI 10.1016/0006-2952(90)90382-U; OMAR RF, 1991, J BIOCHEM TOXICOL, V6, P203, DOI 10.1002/jbt.2570060306; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PAVLOVIC M, 1979, ACTA PATH MICRO IM B, V87, P243; POU S, 1994, ANAL BIOCHEM, V217, P76, DOI 10.1006/abio.1994.1085; RAHIMTULA AD, 1988, BIOCHEM PHARMACOL, V37, P4469, DOI 10.1016/0006-2952(88)90662-4; ROSCHENTHALER R, 1984, J TOXICOL-TOXIN REV, V3, P53; SQUIRES EJ, 1990, POULTRY SCI, V69, P1371, DOI 10.3382/ps.0691371; TURRENS JF, 1991, FREE RADIC RES COMM, V12, P661; VALLE VGR, 1993, ARCH BIOCHEM BIOPHYS, V307, P1, DOI 10.1006/abbi.1993.1551; VANDERME.KJ, 1965, NATURE, V205, P1112, DOI 10.1038/2051112a0; VANDERMERWE KJ, 1965, J CHEM SOC, V20, P7083; VERCESI AF, 1993, METHODS TOXICOLOGY, V2; Xiao H, 1996, TOXICOL APPL PHARM, V137, P182, DOI 10.1006/taap.1996.0071; XIAO H, 1995, J AGR FOOD CHEM, V43, P524, DOI 10.1021/jf00050a050	37	56	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27388	27394		10.1074/jbc.271.44.27388	http://dx.doi.org/10.1074/jbc.271.44.27388			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910317	hybrid			2022-12-27	WOS:A1996VQ67900035
J	Lin, HH; Tu, ZJ; Ann, DK				Lin, HH; Tu, ZJ; Ann, DK			Involvement of nuclear orphan receptor NGFI-B in transcriptional activation of salivary-specific R15 gene by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLINE-RICH PROTEIN; PAROTID-GLANDS; BINDING PROTEINS; TRANSGENIC MICE; DNA-BINDING; MULTIGENE FAMILY; CONTROL REGION; AMYLASE GENES; RP4 GENE; EXPRESSION	Proline rich proteins (PRPs) are selectively expressed in the acinar cells of the salivary glands and are inducible by beta-agonist isoproterenol and dietary tannins, In the previous studies of rat PRP gene, R15, the 5'-flanking region up to -1.7 kilobase pairs (kb), which was thought to contain the necessary proximal regulatory elements, failed to confer the catecholamine isoproterenol and dietary tannin inducibility to the transgene expression in the salivary glands of transgenic mice, Here we analyzed distal 5'-flanking region of R15 in order to understand the mechanisms of tissue-specific and inducible gene regulation, An upstream regulatory region located between -2.4 and -1.7 kb of the R15 5'-flanking region is demonstrated to be indispensable for the salivary-specific and inducible reporter gene expression in vivo, by transgenic approach, Element(s) within the 0.7-kb (-2.4 to -1.7) region that is able to cis-activate the expression of a heterologous reporter gene expression is further elucidated by transient transfection assays in vitro. Three distinct nuclear orphan receptor NGFI-B regulatory sequences are identified within a 184-base pair (bp) minimal control region extended from -1995 to -1812 nucleotides relative to the transcription start site. When reporter gene containing this 184-bp control region and heterologous promoter was cotransfected with the NGFI-B expression construct, a transactivation that mimics the effect of cAMP is observed in the parotid cells, Finally, mutations on all three identified NGFI-B binding sites and coexpression of a dominant negative mutant construct, pCMV-NGFI-B(Delta 25-195), abolish this transactivation mediated by NGFI-B. In summary, these data suggest that the inducible nuclear orphan receptor NGFI-B may participate in the regulation of salivary acinar cell-specific and inducible expression of the rat R15 gene via three distinct distal NGFI-B sites.	UNIV SO CALIF,DEPT MOL PHARMACOL & TOXICOL,LOS ANGELES,CA 90033	University of Southern California					NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE10742] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ANN DK, 1987, J BIOL CHEM, V262, P899; ANN DK, 1985, J BIOL CHEM, V260, P5863; BEIMLING P, 1992, ONCOGENE, V7, P257; CRAWFORD PA, 1995, MOL CELL BIOL, V15, P4331; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOUSVELARI E, 1996, STUDIES STOMATOLOGY, P85; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAYFIELD R, 1992, EUR J BIOCHEM, V204, P591, DOI 10.1111/j.1432-1033.1992.tb16672.x; LAZOWSKI KW, 1992, DIFFERENTIATION, V51, P225, DOI 10.1111/j.1432-0436.1992.tb00700.x; Lin H. Helen, 1992, Gene Expression, V2, P365; LIN HH, 1991, GENOMICS, V10, P102, DOI 10.1016/0888-7543(91)90490-6; LIN HH, 1991, GENE, V104, P219, DOI 10.1016/0378-1119(91)90253-8; LIN HH, 1993, J BIOL CHEM, V268, P10214; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEHANSHO H, 1983, P NATL ACAD SCI-BIOL, V80, P3948, DOI 10.1073/pnas.80.13.3948; MEHANSHO H, 1987, J BIOL CHEM, V262, P12344; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUENZER J, 1979, J BIOL CHEM, V254, P5623; ONATE SA, 1995, SCIENCE, V270, P1354; PACKAGE WSA, 1995, RELEASE 8; PAULSEN RE, 1992, J BIOL CHEM, V267, P16491; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; REDMAN R S, 1987, P1; ROBERTS SGE, 1991, NUCLEIC ACIDS RES, V19, P5205, DOI 10.1093/nar/19.19.5205; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Tu Zheng-Jin, 1993, Gene Expression, V3, P289; WILKIE TM, 1986, DEV BIOL, V118, P9, DOI 10.1016/0012-1606(86)90068-0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WRIGHT PS, 1990, J MOL ENDOCRINOL, V4, P81, DOI 10.1677/jme.0.0040081; WRIGHT PS, 1988, FASEB J, V2, P3104, DOI 10.1096/fasebj.2.15.2847950; YAN C, 1995, J BIOL CHEM, V270, P24852, DOI 10.1074/jbc.270.42.24852	43	24	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27637	27644		10.1074/jbc.271.44.27637	http://dx.doi.org/10.1074/jbc.271.44.27637			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910353	hybrid			2022-12-27	WOS:A1996VQ67900071
J	VanMelderen, L; Thi, MHD; Lecchi, P; Gottesman, S; Couturier, M; Maurizi, MR				VanMelderen, L; Thi, MHD; Lecchi, P; Gottesman, S; Couturier, M; Maurizi, MR			ATP-dependent degradation of CcdA by Lon protease - Effects of secondary structure and heterologous subunit interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; F-PLASMID; AMINO-ACID; HOST-CELL; PROTEOLYSIS; PROTEINS; DNA; SEQUENCE; LA; PURIFICATION	CcdA, the antidote protein of the ccd post-segregational killing system carried by the F plasmid, was degraded in vitro by purified Lon protease from Escherichia coli. CcdA had a low affinity for Lon (K-m greater than or equal to 200 mu M), and the peptide bond turnover number was similar to 10 min(-1). CcdA formed tight complexes with purified CcdB, the killer protein encoded in the ccd operon, and fluorescence and hydrodynamic measurements suggested that interaction with CcdB converted CcdA to a more compact conformation. CcdB prevented CcdA degradation by Lon and blocked the ability of CcdA to activate the ATPase activity of Lon, suggesting that Lon may recognize bonding domains of proteins exposed when their partners are absent. Degradation of CcdA required ATP hydrolysis; however, CcdA41, consisting of the carboxyl-terminal 41 amino acids of CcdA and lacking the alpha-helical secondary structure present in CcdA, was degraded without ATP hydrolysis. Lon cleaved CcdA primarily between aliphatic and hydrophilic residues, and CcdA41 was cleaved at the same peptide bonds, indicating that ATP hydrolysis does not affect cleavage specificity, CcdA lost alpha-helical structure at elevated temperatures (T-m similar to 50 degrees C), and its degradation became independent of ATP hydrolysis at this temperature, ATP hydrolysis may be needed to disrupt interactions that stabilize the secondary structure of proteins allowing the disordered protein greater access to the proteolytic active sites.	NCI,CELL BIOL LAB,BETHESDA,MD 20892; NCI,MOL BIOL LAB,BETHESDA,MD 20892; FREE UNIV BRUSSELS,DEPT BIOL MOL,GENET LAB,B-1640 RHODE ST GENESE,BELGIUM; FREE UNIV BRUSSELS,INST MOL BIOL,B-1640 RHODE ST GENESE,BELGIUM; NIDDK,ANALYT CHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Van Melderen, Laurence/0000-0002-7778-1736				BERNARD P, 1992, J MOL BIOL, V226, P735, DOI 10.1016/0022-2836(92)90629-X; BERNARD P, 1993, J MOL BIOL, V234, P534, DOI 10.1006/jmbi.1993.1609; BERNARD P, 1991, MOL GEN GENET, V226, P297, DOI 10.1007/BF00273616; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; DEPAUW E, 1990, METHOD ENZYMOL, V193, P201, DOI 10.1016/0076-6879(90)93416-I; GERDES K, 1990, New Biologist, V2, P946; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOLUB EI, 1988, MOL GEN GENET, V214, P353, DOI 10.1007/BF00337735; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P327, DOI 10.1093/nar/14.1.327; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; INOUE I, 1994, J BIOL CHEM, V269, P29241; JAFFE A, 1985, J BACTERIOL, V163, P841; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; JUBETE Y, 1996, IN PRESS J BIOL CHEM, V271; KAROUI H, 1983, EMBO J, V2, P1863, DOI 10.1002/j.1460-2075.1983.tb01672.x; LECCHI P, 1996, NEW METHODS PEPTIDE, P219; LOH SM, 1988, GENE, V66, P259, DOI 10.1016/0378-1119(88)90362-9; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P14921; MIKI T, 1992, J MOL BIOL, V225, P39, DOI 10.1016/0022-2836(92)91024-J; MIKI T, 1984, J MOL BIOL, V174, P605, DOI 10.1016/0022-2836(84)90086-X; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; SALMON MA, 1994, MOL GEN GENET, V244, P530, DOI 10.1007/BF00583904; SHERMAN MY, 1992, EMBO J, V11, P71; SONEZAKI S, 1995, APPL MICROBIOL BIOT, V43, P304; STEYAERT J, 1993, J MOL BIOL, V231, P513, DOI 10.1006/jmbi.1993.1301; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; ZAMYATNIN AA, 1984, ANNU REV BIOPHYS BIO, V13, P145, DOI 10.1146/annurev.bb.13.060184.001045	40	167	167	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27730	27738		10.1074/jbc.271.44.27730	http://dx.doi.org/10.1074/jbc.271.44.27730			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910366	hybrid			2022-12-27	WOS:A1996VQ67900084
J	Varoqui, H; Erickson, JD				Varoqui, H; Erickson, JD			Active transport of acetylcholine by the human vesicular acetylcholine transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO SYNAPTIC VESICLES; H-3 VESAMICOL BINDING; CLONAL CELL LINE; CHOLINE-ACETYLTRANSFERASE; CAENORHABDITIS-ELEGANS; MONOAMINE TRANSPORTER; FUNCTIONAL IDENTIFICATION; ALZHEIMERS-DISEASE; MOLECULAR-CLONING; RAT STRIATUM	The characteristics of ATP dependent transport of acetylcholine (ACh) in homogenates of pheochromocytoma (PC-12) cells stably transfected with the human vesicular acetylcholine transporter (VAChT) cDNA are described. The human VAChT protein was abundantly expressed in this line and appeared as a diffuse band with a molecular mass of similar to 75 kDa on Western blots, Vesicular [H-3]ACh accumulation increased similar to 20 times over levels attained by the endogenous rat VAChT, expressed at low levels in control PC-12 cells, The transport of [H-3]ACh by human VAChT was dependent upon the addition of exogenous ATP at 37 degrees C. Uptake was abolished by low temperature (4 degrees C), the proton ionophore carbonyl cyanide p-trifluoromethoxyphenylhydrazone (2.5 mu M) and bafilomycin A(1) (1 mu M), a specific inhibitor of the vesicular H+-ATPase, The kinetics of [H-3]ACh uptake by human VAChT were saturable, exhibiting an apparent K-m of 0.97 +/- 0.1 mM and V-max of 0.58 +/- 0.04 nmol/min/mg, Maximal steady-state levels of vesicular [H-3]ACh accumulation were directly proportional to the concentration of substrate present in the medium with saturation occurring at similar to 4 mM. Uptake was stereospecifically inhibited by L-vesamicol with an IC50 of 14.7 +/- 1.5 nM. The apparent affinity (K-d) of [H-3] vesamicol for human VAChT was 4.1 +/- 0.5 nM, and the B-max was 8.9 +/- 0.6 pmol/mg. The turnover (VmaxBmax) of the human VAChT was similar to 65/min. This expression system should prove useful for the structure/function analysis of VAChT.	NIMH, CELL BIOL LAB, MOL NEUROSCI SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ALFONSO A, 1994, J MOL BIOL, V241, P627, DOI 10.1006/jmbi.1994.1538; ALFONSO A, 1993, SCIENCE, V261, P617, DOI 10.1126/science.8342028; BAHR BA, 1986, P NATL ACAD SCI USA, V83, P2267, DOI 10.1073/pnas.83.7.2267; BAHR BA, 1986, J NEUROCHEM, V46, P1214, DOI 10.1111/j.1471-4159.1986.tb00640.x; BAUERFEIND R, 1993, NEURON, V11, P105, DOI 10.1016/0896-6273(93)90275-V; BEJANIN S, 1994, J BIOL CHEM, V269, P21944; BERRARD S, 1995, J NEUROCHEM, V65, P939; BERSE B, 1995, J BIOL CHEM, V270, P22101, DOI 10.1074/jbc.270.38.22101; BLUMBERG D, 1992, J NEUROCHEM, V58, P801, DOI 10.1111/j.1471-4159.1992.tb09328.x; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIEBLER MF, 1989, J NEUROCHEM, V52, P813, DOI 10.1111/j.1471-4159.1989.tb02526.x; ERICKSON JD, 1993, J NEUROCHEM, V61, P2314, DOI 10.1111/j.1471-4159.1993.tb07476.x; Erickson JD, 1996, P NATL ACAD SCI USA, V93, P5166, DOI 10.1073/pnas.93.10.5166; ERICKSON JD, 1990, BRAIN RES, V516, P155, DOI 10.1016/0006-8993(90)90912-U; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLAGHER M, 1995, CURR OPIN NEUROBIOL, V5, P161, DOI 10.1016/0959-4388(95)80022-0; Gilmor ML, 1996, J NEUROSCI, V16, P2179; GREENE LA, 1977, NATURE, V268, P349, DOI 10.1038/268349a0; GREENE LA, 1977, BRAIN RES, V129, P247, DOI 10.1016/0006-8993(77)90005-1; HAIGH JR, 1994, NEUROREPORT, V5, P773, DOI 10.1097/00001756-199403000-00009; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; KISH SJ, 1990, NEUROSCI LETT, V117, P347, DOI 10.1016/0304-3940(90)90689-7; KOSHIMURA K, 1990, J NEUROCHEM, V54, P533, DOI 10.1111/j.1471-4159.1990.tb01904.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MELEGA WP, 1981, BIOCHEMISTRY-US, V20, P4477, DOI 10.1021/bi00518a036; MISAWA H, 1995, NEUROREPORT, V6, P965, DOI 10.1097/00001756-199505090-00004; Misawa H., 1994, Society for Neuroscience Abstracts, V20, P890; PARSONS SM, 1993, INT REV NEUROBIOL, V35, P279, DOI 10.1016/S0074-7742(08)60572-3; PETER D, 1994, J BIOL CHEM, V269, P7231; REBOIS RV, 1980, BIOCHEMISTRY-US, V19, P1240, DOI 10.1021/bi00547a031; ROGHANI A, 1994, P NATL ACAD SCI USA, V91, P10620, DOI 10.1073/pnas.91.22.10620; RUBERG M, 1990, NEUROSCIENCE, V35, P327, DOI 10.1016/0306-4522(90)90086-J; SALVATERRA PM, 1989, INT REV NEUROBIOL, V31, P81; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schafer MKH, 1995, J MOL NEUROSCI, V6, P225, DOI 10.1007/BF02736782; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P5184, DOI 10.1073/pnas.74.11.5184; SLOTKIN TA, 1994, J CLIN INVEST, V94, P696, DOI 10.1172/JCI117387; STRADA O, 1992, P NATL ACAD SCI USA, V89, P9549, DOI 10.1073/pnas.89.20.9549; TABB JS, 1992, J BIOL CHEM, V267, P15412; TOLL L, 1980, J BIOL CHEM, V255, P1787; Tuek S., 1988, HDB EXPT PHARM, P125; USDIN TB, 1995, TRENDS NEUROSCI, V18, P218, DOI 10.1016/0166-2236(95)93906-E; VAROQUI H, 1994, FEBS LETT, V342, P97, DOI 10.1016/0014-5793(94)80592-X; Varoqui H, 1996, PROG BRAIN RES, V109, P83; WEIHE E, 1994, J MOL NEUROSCI, V5, P149, DOI 10.1007/BF02736730; Weihe E, 1996, P NATL ACAD SCI USA, V93, P3547, DOI 10.1073/pnas.93.8.3547; WHITTAKER VP, 1988, HDB EXP PHARM, V86, P3; WU DH, 1994, J NEUROCHEM, V62, P1653; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8	53	94	99	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27229	27232		10.1074/jbc.271.44.27229	http://dx.doi.org/10.1074/jbc.271.44.27229			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910293	hybrid			2022-12-27	WOS:A1996VQ67900011
J	Aparicio, JG; Applebury, ML				Aparicio, JG; Applebury, ML			The photoreceptor guanylate cyclase is an autophosphorylating protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; ROD OUTER SEGMENTS; CRYSTAL-STRUCTURE; ADENINE-NUCLEOTIDES; CATALYTIC SUBUNIT; ACTIVATION; PURIFICATION; CALCIUM; DOMAIN; FAMILY	The photoreceptor membrane guanylate cyclase is a member of a family of proteins with a set of four structural motifs: an extracellular ligand binding domain, a transmembrane domain, an intracellular protein kinase-like domain, and an intracellular catalytic domain. Purified preparations of the photoreceptor guanylate cyclase have allowed us to explore the function of the protein kinase-like domain. ATP enhances the guanylate cyclase activity 2-fold in membranes stripped of peripheral proteins, The stimulation can be mimicked by ATP gamma S (adenosine 5'-O-(3-thiotriphosphate)), AMPPNP (5'-adenylyl beta,gamma-imidodiphosphate), and ADP, but not AMP. While this effect is lost by solubilizing guanylate cyclase, ATP binds the purified, solubilized enzyme in a site distinct from the catalytic GTP site as shown by specific labeling with 8-N-3[alpha-P-32]ATP. The enzyme has a protein kinase activity that is Mg2+-dependent and autophosphorylates serine residues. Myelin basic protein serves as a substrate for the kinase and enables further characterization of the kinase properties. The K-m for ATP is 81 mu M. The kinase activity is unaffected by calcium, cyclic nucleotides, and phorbol 12-myristate 13-acetate/L-alpha-phosphatidylserine/Ca2+ and is inhibited by high concentrations of staurosporine. These properties are distinct from other Ser/Thr kinases identified in rod outer segment preparations including protein kinase A, protein kinase C, and rhodopsin kinase. The observations offer the first biochemical evidence that a member of the receptor guanylate cyclase family has intrinsic protein kinase activity.	UNIV CHICAGO, COMM NEUROBIOL, CHICAGO, IL 60637 USA	University of Chicago				Aparicio, Jennifer/0000-0002-6442-3032	NEI NIH HHS [EY04810] Funding Source: Medline; NIMH NIH HHS [MH1-164] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004810] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APARICIO JG, 1995, PROTEIN EXPRES PURIF, V6, P501, DOI 10.1006/prep.1995.1067; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANG CH, 1990, BIOCHIM BIOPHYS ACTA, V1052, P159, DOI 10.1016/0167-4889(90)90071-K; CHINKERS M, 1991, ANNU REV BIOCHEM, V60, P553, DOI 10.1146/annurev.bi.60.070191.003005; CHINKERS M, 1991, J BIOL CHEM, V266, P4088; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; Czarnecki J, 1979, Methods Enzymol, V56, P642; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; DUDA T, 1993, BIOCHEMISTRY-US, V32, P1391, DOI 10.1021/bi00057a001; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GAZZANO H, 1991, INFECT IMMUN, V59, P1552, DOI 10.1128/IAI.59.4.1552-1557.1991; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GORACZNIAK RM, 1994, BIOCHEM J, V302, P455, DOI 10.1042/bj3020455; GORCZYCA WA, 1994, BIOCHEMISTRY-US, V33, P3217, DOI 10.1021/bi00177a011; GORCZYCA WA, 1994, P NATL ACAD SCI USA, V91, P4014, DOI 10.1073/pnas.91.9.4014; HALEY BE, 1989, ICN BIOSCOPE, V1, P3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HEBDON GM, 1981, P NATL ACAD SCI-BIOL, V78, P120, DOI 10.1073/pnas.78.1.120; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOLLER KJ, 1992, MOL CELL BIOL, V12, P2581, DOI 10.1128/MCB.12.6.2581; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KUROSE H, 1987, FEBS LETT, V219, P375, DOI 10.1016/0014-5793(87)80256-9; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; POZDNYAKOV N, 1995, BIOCHEMISTRY-US, V34, P14279, DOI 10.1021/bi00044a002; SHICHI H, 1978, J BIOL CHEM, V253, P7040; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; SITARAMAYYA A, 1991, BIOCHEMISTRY-US, V30, P6742, DOI 10.1021/bi00241a016; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; WOLBRING G, 1995, BIOCHEMISTRY-US, V34, P4689, DOI 10.1021/bi00014a024; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YOUNT RG, 1971, BIOCHEMISTRY-US, V10, P2490, DOI 10.1021/bi00789a010; YUEN PST, 1992, ANNU REV NEUROSCI, V15, P193	49	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27083	27089		10.1074/jbc.271.43.27083	http://dx.doi.org/10.1074/jbc.271.43.27083			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900199	hybrid			2022-12-27	WOS:A1996VP23300093
J	Palmer, M; Saweljew, P; Vulicevic, I; Valeva, A; Kehoe, M; Bhakdi, S				Palmer, M; Saweljew, P; Vulicevic, I; Valeva, A; Kehoe, M; Bhakdi, S			Membrane-penetrating domain of streptolysin O identified by cysteine scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-ACTIVATED TOXIN; PNEUMOLYSIN; CYTOLYSIN; REQUIRE	Streptolysin O (SLO), a polypeptide of 571 amino acids, belongs to a family of highly homologous toxins that bind to cell membranes containing cholesterol and then polymerize to form large transmembrane pores. A conserved region close to the C terminus contains the single cysteine residue of SLO and has been implicated in membrane binding, which has been the only clear assignment of function to a part of the sequence. We have used a cysteine-less active mutant of SLO to introduce single cysteine residues at 19 positions distributed throughout the sequence. The cysteines were derivatized with the polarity-sensitive fluorophore acrylodan, and the fluorescence emission of the label was examined. at the different stages of SLO pore assembly. With several mutants, oligomerization on membranes was accompanied by emission blue-shifts, indicating movement of the label into a more hydrophobic environment, These effects were essentially confined to the range of amino acids 213-305. With oligomeric mutants L274C, S286C, and S305C, additional environmental alterations were induced when different nondenaturing detergents were used to dislodge the membrane lipids from the oligomers. The corresponding amino acid residues thus insert. into the lipid bilayer during pore formation. Conversely, the spectra of oligomeric mutants A213C and T245C were not affected by detergents, Devoid of contact with the lipid bilayer, these amino acid residues probably participate in the interaction of SLO molecules within the oligomer.	UNIV NEWCASTLE UPON TYNE, SCH MED, DEPT MICROBIOL, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND	Newcastle University - UK	Palmer, M (corresponding author), UNIV MAINZ, INST MED MICROBIOL, AUGUSTUSPL, D-55101 MAINZ, GERMANY.							Alouf JE, 1991, SOURCEBOOK BACTERIAL, P147; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; CORMACK B, 1987, CURRENT PROTOCOLS MO; DELOSTOYOS JR, 1996, INFECT IMMUN, V64, P40; DUNCAN JL, 1975, J CELL BIOL, V67, P160, DOI 10.1083/jcb.67.1.160; FUESSLE R, 1981, Journal of Cell Biology, V91, P83; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; HUGO F, 1986, INFECT IMMUN, V54, P641, DOI 10.1128/IAI.54.3.641-645.1986; IWAMOTO M, 1987, EUR J BIOCHEM, V167, P425, DOI 10.1111/j.1432-1033.1987.tb13355.x; KEHOE MA, 1987, INFECT IMMUN, V55, P3228, DOI 10.1128/IAI.55.12.3228-3232.1987; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; OHNOIWASHITA Y, 1991, J BIOCHEM-TOKYO, V110, P369, DOI 10.1093/oxfordjournals.jbchem.a123588; PALMER M, 1995, EUR J BIOCHEM, V231, P388, DOI 10.1111/j.1432-1033.1995.tb20711.x; PINKNEY M, 1989, INFECT IMMUN, V57, P2553, DOI 10.1128/IAI.57.8.2553-2558.1989; PINKNEY M, 1995, INFECT IMMUN, V63, P2776, DOI 10.1128/IAI.63.7.2776-2779.1995; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; SAUNDERS FK, 1989, INFECT IMMUN, V57, P2547, DOI 10.1128/IAI.57.8.2547-2552.1989; SEKIYA K, 1993, J BACTERIOL, V175, P5953, DOI 10.1128/JB.175.18.5953-5961.1993; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; Weller U, 1996, EUR J BIOCHEM, V236, P34, DOI 10.1111/j.1432-1033.1996.00034.x	22	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26664	26667		10.1074/jbc.271.43.26664	http://dx.doi.org/10.1074/jbc.271.43.26664			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900142	hybrid			2022-12-27	WOS:A1996VP23300036
J	Petrova, TV; Takagi, T; Cox, JA				Petrova, TV; Takagi, T; Cox, JA			Phosphorylation of the IQ domain regulates the interaction between Ca2+-vector protein and its target in amnphioxus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM VECTOR PROTEIN; LIGHT CHAIN KINASE; CALMODULIN-BINDING-PROTEIN; SKELETAL-MUSCLE; MYOSIN-BINDING; TROPONIN-C; IDENTIFICATION; AMPHIOXUS; PURIFICATION; NEUROMODULIN	Calcium vector protein target (CaVPT) a 26-kDa endogenous target of calcium vector protein from Amphioxus (CaVP), contains three distinct regions: a N-terminal Pro-Ala-Lys-rich motif segment 36-50 displaying sequence similarity to the calmodulin-binding site in neuromodulin and neurogranin where they are designated as the IQ domain; and two immunoglobulinlike folds. The phosphorylation by protein kinase C of Ser-43 in the IQ domain drastically decreases the affinity of CaVPT for CaVP and CaVP protects CaVPT from phosphorylation. Phosphorylation by the catalytic subunit of cyclic AMP-dependent protein kinase has a similar effect, but in addition to Ser 43 four other phosphorylated sites were identified. Removal of the Pro-Ala-Lys-rich region and the IQ domain in CaVPT by trypsin leads to the loss of binding to CaVP, whereas the chymotryptic fragment, containing these regions and first immunoglobulin-like domain, retained the ability to interact with CaVP. A synthetic IQ domain alone interacts strongly with calmodulin, but not with CaVP. Two main conclusions can be drawn from this study: 1) the regulation of interaction between CaVP and CaVPT is very similar to the mechanism observed in the complex between neuromodulin or neurogranin and calmodulin; 2) in spite of this similarity the entire CaVP-binding site is not restricted to the IQ domain; in addition the Pro-Ala-Lys-rich motif may he necessary for high affinity binding to CaVP.	UNIV GENEVA,DEPT BIOCHEM,CH-1211 GENEVA 4,SWITZERLAND; TOHOKU UNIV,FAC SCI,INST BIOL,SENDAI,MIYAGI 980,JAPAN	University of Geneva; Tohoku University								ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ALEXANDER KA, 1988, J BIOL CHEM, V263, P7544; APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; BRONSTEIN I, 1990, BIOTECHNIQUES, V8, P310; BUELT MK, 1994, J BIOL CHEM, V269, P29367; CHENEY RE, 1991, J CELL BIOL, V115, P432; COX JA, 1986, J BIOL CHEM, V261, P3173; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DURUSSEL I, 1993, BIOCHEMISTRY-US, V32, P2394, DOI 10.1021/bi00060a034; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FURST DO, 1992, J CELL SCI, V102, P769; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HEAD JF, 1974, BIOCHEM J, V137, P145, DOI 10.1042/bj1370145; HOLDEN HM, 1992, J MOL BIOL, V227, P840, DOI 10.1016/0022-2836(92)90226-A; ITO M, 1989, J BIOL CHEM, V264, P13971; LABEIT S, 1992, EMBO J, V11, P1711, DOI 10.1002/j.1460-2075.1992.tb05222.x; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NOGUCHI J, 1992, J BIOL CHEM, V267, P20302; OBERMANN WMJ, 1995, EUR J BIOCHEM, V233, P110, DOI 10.1111/j.1432-1033.1995.110_1.x; OLSON NJ, 1990, P NATL ACAD SCI USA, V87, P2284, DOI 10.1073/pnas.87.6.2284; PETROVA TV, 1995, BIOCHEMISTRY-US, V34, P312, DOI 10.1021/bi00001a038; PETROVA TV, 1995, 9 INT S CALC BIND PR; PFUHL M, 1995, J BIOMOL NMR, V6, P48, DOI 10.1007/BF00417491; ROSE K, 1994, J AM CHEM SOC, V116, P30, DOI 10.1021/ja00080a004; TAKAGI T, 1990, J BIOL CHEM, V265, P19721; TAKAGI T, 1994, EUR J BIOCHEM, V221, P537, DOI 10.1111/j.1432-1033.1994.tb18766.x; VALETTETALBI L, 1993, HISTOCHEMISTRY, V100, P73, DOI 10.1007/BF00268880; VAUGHAN KT, 1993, J BIOL CHEM, V268, P3670; VONDERHAAR F, 1976, BIOCHEM BIOPH RES CO, V70, P1009, DOI 10.1016/0006-291X(76)90692-6; WALSH DA, 1994, FASEB J, V8, P1227, DOI 10.1096/fasebj.8.15.8001734; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4	36	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26646	26652		10.1074/jbc.271.43.26646	http://dx.doi.org/10.1074/jbc.271.43.26646			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900139	hybrid			2022-12-27	WOS:A1996VP23300033
J	Watanabe, R; Kinoshita, T; Masaki, R; Yamamoto, A; Takeda, J; Inoue, N				Watanabe, R; Kinoshita, T; Masaki, R; Yamamoto, A; Takeda, J; Inoue, N			PIG-A and PIG-H, which participate in glycosylphosphatidylinositol anchor biosynthesis, from a protein complex in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GPI-ANCHOR; GENE; PHOSPHATIDYLINOSITOL; CLONING; IDENTIFICATION; EXPRESSION; COMPONENT; MUTATIONS; MUTANTS	Many eukaryotic cell surface proteins are bound to the membrane via a glycosylphosphatidylinositol (GPI) anchor. Assembly of the GPI anchor precursor is a sequential addition of components to phosphatidylinositol (PI) in the endoplasmic reticulum (ER). The first step is the transfer of N-acetylglucosamine (GlcNAc) to PI from UDB-GlcNAc to generate GlcNAc-PI. This simple step, however, is regulated by at least three genes because in both mammals and yeasts, there ape three mutants of different complementation classes. To clarify this complexity we analyzed the products of two cloned human genes, PIG-A and PIG-H. Here we demonstrate 1) that PIG-A is an ER transmembrane protein with a large cytoplasmic domain that has homology to a bacterial GlcNAc transferase and a small lumenal domain; 2) that PIG-H is a cytoplasmically oriented, ER-associated protein; and 3) that they form a protein complex. We also show that part of the small lumenal domain of PIG-A plays an essential functional role in targeting itself to the rough ER. Taken together with the cytoplasmic orientation of GlcNAc-PI, these results indicated that PIG-A and PIG-H are subunits of the GPI GlcNAc transferase that transfers GlcNAc to PI on the cytoplasmic side of the ER.	OSAKA UNIV, MICROBIAL DIS RES INST, DEPT IMMUNOREGULAT, SUITA, OSAKA 565, JAPAN; KANSAI MED UNIV, DEPT PHYSIOL, MORIGUCHI, OSAKA 570, JAPAN; KANSAI MED UNIV, LIVER RES CTR, DIV CELL BIOL, MORIGUCHI, OSAKA 570, JAPAN	Osaka University; Kansai Medical University; Kansai Medical University			Kinoshita, Taroh/C-7353-2009	Watanabe, Reika/0000-0002-7427-7702				BENGHEZAL M, 1995, J CELL BIOL, V130, P1333, DOI 10.1083/jcb.130.6.1333; BESSLER M, 1994, EMBO J, V13, P110, DOI 10.1002/j.1460-2075.1994.tb06240.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; HAMBURGER D, 1995, J CELL BIOL, V129, P629, DOI 10.1083/jcb.129.3.629; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; INOUE N, 1993, J BIOL CHEM, V268, P6882; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; Kinoshita T, 1995, ADV IMMUNOL, V60, P57, DOI 10.1016/S0065-2776(08)60584-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MOHNEY RP, 1994, J BIOL CHEM, V269, P6536; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; OSTENDORF T, 1995, BLOOD, V85, P1640, DOI 10.1182/blood.V85.6.1640.bloodjournal8561640; ROSSE WF, 1995, BLOOD, V86, P3277, DOI 10.1182/blood.V86.9.3277.bloodjournal8693277; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8	29	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26868	26875		10.1074/jbc.271.43.26868	http://dx.doi.org/10.1074/jbc.271.43.26868			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900170	hybrid			2022-12-27	WOS:A1996VP23300064
J	Cohen-Armon, M; Hammel, I; Anis, Y; Homburg, S; Dekel, N				Cohen-Armon, M; Hammel, I; Anis, Y; Homburg, S; Dekel, N			Evidence for endogenous ADP-ribosylation of GTP-binding proteins in neuronal cell nucleus - Possible induction by membrane depolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE SODIUM-CHANNELS; RAT-BRAIN; MUSCARINIC RECEPTORS; ADENYLATE-CYCLASE; CYSTEINE; RIBOSE; ALPHA	GTP-binding protein(s) recognized by antibodies against the alpha-subunits of G(i)- and G(o)-proteins were detected in crude nuclei isolated from rat brain stem and cortex. Immunohistochemical staining indicated that in the cortex these proteins are perinuclear, or are embedded in the nuclear membrane. Evidence is presented for an endogenous ADP-ribosylation of these proteins, which competes with their PTX-catalyzed ADP-ribosylation. The endogenous reaction has the characteristics of nonenzymatic ADP-ribosylation of cysteine residues, known to involve NAD-glycohydrolase activity. In vitro experiments showed that the alpha-subunit of G(o)-proteins in the cell membrane also acts as a substrate of this endogenous ADP-ribosylation. The in situ effect of membrane depolarization on the nuclear GTP-binding proteins may be attributable to their depolarization-induced endogenous ADP-ribosylation, suggesting a novel signaling mechanism in neuronal cells in the central nervous system.	TEL AVIV UNIV, SACKLER SCH MED, DEPT PATHOL, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine	Cohen-Armon, M (corresponding author), TEL AVIV UNIV, NEUFELD CARDIAC RES INST, DEPT PHYSIOL & PHARMACOL, IL-69978 TEL AVIV, ISRAEL.							ALTHAUS FR, 1987, MOL BIOL BIOCH BIOPH, V37, P140; Ausubel FM., 2006, ENZYMATIC MANIPULATI; COHEN-ARMON M, 1986, J BIOL CHEM, V261, P2498; COHEN-ARMON M, 1991, NEUROSCI LETT, V126, P87, DOI 10.1016/0304-3940(91)90378-7; COHEN-ARMON M, 1993, J BIOL CHEM, V268, P9824; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; COHEN-ARMON M, 1991, J BIOL CHEM, V266, P2595; CREVELING CR, 1983, MOL PHARMACOL, V23, P350; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; FERROLUZZI AG, 1976, BIOCHEMISTRY-US, V15, P617; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GUIDA L, 1992, BIOCHEM BIOPH RES CO, V188, P402, DOI 10.1016/0006-291X(92)92399-I; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; JACOBSON EL, 1994, MOL CELL BIOCHEM, V138, P207, DOI 10.1007/BF00928463; JACOBSON MK, 1990, J BIOL CHEM, V265, P10825; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUTIER D, 1993, MOL CELL BIOCHEM, V122, P171, DOI 10.1007/BF01076101; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONALD LJ, 1994, MOL CELL BIOCHEM, V138, P221, DOI 10.1007/BF00928465; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MCDONALD LJ, 1992, BIOCHEMISTRY-US, V31, P11881, DOI 10.1021/bi00162a029; MCNEAL ET, 1985, J MED CHEM, V28, P381, DOI 10.1021/jm00381a019; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OFFERMANS S, 1990, FEBS LETT, V260, P14, DOI 10.1016/0014-5793(90)80054-M; PFEUFFER T, 1977, J BIOL CHEM, V252, P7224; POLAK MJ, 1984, INTRO IMMUNOCYTOCHEM; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SNELTER CH, 1979, METHOD BIOCHEM ANAL, V24, P129; SPIEGEL AM, 1990, ADP RIBOSYLATION TOX, P207; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TANUMA S, 1988, J BIOL CHEM, V263, P5485; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDEA K, 1990, ADP RIBOSYLATING TOX, P525; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; ZANGERLE L, 1992, J NEUROCHEM, V59, P181, DOI 10.1111/j.1471-4159.1992.tb08889.x; ZUBIAUR M, 1993, J NEUROSCI RES, V35, P207, DOI 10.1002/jnr.490350212	41	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26200	26208		10.1074/jbc.271.42.26200	http://dx.doi.org/10.1074/jbc.271.42.26200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824268	hybrid			2022-12-27	WOS:A1996VN18000074
J	Hatch, GM; McClarty, G				Hatch, GM; McClarty, G			Regulation of cardiolipin biosynthesis in H9c2 cardiac myoblasts by cytidine 5'-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; CYCLOPENTENYL CYTOSINE; ESCHERICHIA-COLI; HELA-CELLS; CTP; SYNTHASE; HEART	The regulation of cardiolipin biosynthesis by CTP in H9c2 cardiac myoblasts was investigated. H9c2 cells were incubated in the presence of cyclopentenylcytosine which is converted to cyclopentenylcytosine triphosphate, a potent and specific inhibitor of CTP synthetase. Incubation of cells for 12 h with cyclopentenylcytosine reduced the cellular pool size of CTP to less than 10% of control cells but did not influence the pool size of other nucleotides. The de novo biosynthesis of phosphatidylcholine from [methyl-H-3]choline, phosphatidylethanolamine from [1-H-3]ethanolamine, and biosynthesis of all glycerol containing phospholipids from [U-C-14]glycerol or [1,3-H-3]glycerol were reduced approximately 50% after preincubation of the cells with cyclopentenylcytosine. In contrast, radioactive glycerol accumulated in phosphatidic acid, diacylglycerol, and triacylglycerol in cyclopentenylcytosine-treated cells compared with controls suggesting a re-routing of phospholipid biosynthesis away from CTP utilizing reactions toward neutral lipid synthesis. The de novo biosynthesis of all phospholipids was restored to control levels by addition of cytidine to the medium which elevated CTP levels. Cyclopentenylcytosine did not affect the in vitro enzyme activities involved in cardiolipin biosynthesis in these cells. In addition, the resynthesis of cardiolipin and most phospholipids from [1-C-14]linoleic acid was not affected by cyclopentenylcytosine. Our findings indicate that the cellular CTP level may regulate cardiolipin biosynthesis in H9c2 cardiac myoblasts and sup port the notion that the cellular CTP level may be a universal signal/switch for all phospholipid biosynthesis in eukaryotic cells.	UNIV MANITOBA,DEPT BIOCHEM & MOL BIOL,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG,MB R3E 0W3,CANADA; UNIV MANITOBA,DEPT MED MICROBIOL,WINNIPEG,MB R3E 0W3,CANADA	University of Manitoba; University of Manitoba; University of Manitoba	Hatch, GM (corresponding author), UNIV MANITOBA,FAC MED,DEPT PHARMACOL & THERAPEUT,RM 307,CHOWN BLDG,770 BANNATYNE AVE,WINNIPEG,MB R3E 0W3,CANADA.							Arita M., 1983, NUCLEIS ACID RES S S, V12, P25; ARVIDSON GA, 1968, EUR J BIOCHEM, V4, P478, DOI 10.1111/j.1432-1033.1968.tb00237.x; BLANEY SM, 1993, BIOCHEM PHARMACOL, V45, P1493, DOI 10.1016/0006-2952(93)90050-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley D. N., 1992, BIOCH LIPIDS LIPOPRO, P171; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARTER JR, 1966, J LIPID RES, V7, P678; CHENG P, 1995, LIPIDS, V30, P513, DOI 10.1007/BF02537025; CHOY PC, 1980, J BIOL CHEM, V255, P1070; GLAZER RI, 1985, BIOCHEM PHARMACOL, V24, P2535; GROENER JEM, 1977, BIOCHIM BIOPHYS ACTA, V487, P105, DOI 10.1016/0005-2760(77)90047-9; HATCH GM, 1994, BIOCHEM J, V297, P201, DOI 10.1042/bj2970201; HEACOCK PN, 1989, J BIOL CHEM, V264, P14972; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; HOSTETLER KY, 1971, BIOCHIM BIOPHYS ACTA, V239, P113, DOI 10.1016/0005-2760(71)90201-3; KANG GJ, 1989, J BIOL CHEM, V264, P713; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KHYM JX, 1978, J BIOL CHEM, V253, P8741; KIMES BW, 1976, EXP CELL RES, V98, P367, DOI 10.1016/0014-4827(76)90447-X; KIYASU JY, 1963, J BIOL CHEM, V238, P2293; LEELAVATHI DE, 1977, ANAL BIOCHEM, V83, P258, DOI 10.1016/0003-2697(77)90534-6; LIM MI, 1984, J MED CHEM, V27, P1536, DOI 10.1021/jm00378a002; LOPEZ G, 1992, J NEUROCHEM, V59, P338; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD PM, 1980, BIOCHIM BIOPHYS ACTA, V260, P80; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCMURRAY WC, 1978, CAN J BIOCHEM CELL B, V56, P414, DOI 10.1139/o78-065; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NISHIJIMA S, 1988, J BACTERIOL, V170, P775, DOI 10.1128/jb.170.2.775-780.1988; OHNO M, 1985, NUCLEOS NUCLEOT NUCL, V4, P21, DOI 10.1080/07328318508077828; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; POLITI PM, 1995, CANCER CHEMOTH PHARM, V36, P513, DOI 10.1007/BF00685802; POORTHUIS BJHM, 1976, J LIPID RES, V17, P433; RIJCKEN WRP, 1993, BIOCHEM J, V293, P207, DOI 10.1042/bj2930207; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; STOFFEL W, 1968, H-S Z PHYSIOL CHEM, V349, P1017, DOI 10.1515/bchm2.1968.349.2.1017; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; Vance D. E., 1996, BIOCH LIPIDS LIPOPRO; VANCE DE, 1980, J BIOL CHEM, V255, P1064; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; VANDENBOSCH H, 1972, PHYSIOL REV, V66, P14; VANWIJK GMT, 1991, BIOCHIM BIOPHYS ACTA, V1086, P99, DOI 10.1016/0005-2760(91)90160-J; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; WHITEHEAD FW, 1981, CAN J BIOCHEM CELL B, V59, P38, DOI 10.1139/o81-006; WU WI, 1994, J BIOL CHEM, V269, P29495; ZHANG H, 1993, CANCER RES, V53, P5714; 1993, BIOCHEM J, V289, P727	55	83	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25810	25816		10.1074/jbc.271.42.25810	http://dx.doi.org/10.1074/jbc.271.42.25810			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824210	hybrid			2022-12-27	WOS:A1996VN18000016
J	KowalskiChauvel, A; Pradayrol, L; Vaysse, N; Seva, C				KowalskiChauvel, A; Pradayrol, L; Vaysse, N; Seva, C			Gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 and its association with Grb2 and the phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE-EXTENDED PROGASTRIN; PDGF RECEPTOR; GROWTH-FACTOR; SIGNAL TRANSDUCTION; KINASE-ACTIVITY; DNA-SYNTHESIS; CELL LINE; ACTIVATION; PROTEIN; BINDING	The growth-promoting effects of gastrin on normal and neoplastic gastrointestinal tissues have been shown to be mediated by the gastrin/CCKB receptor, which belongs to the family of G protein-coupled receptors, However, the downstream signaling pathways activated by gastrin are not well characterized, In the present study, we demonstrate that gastrin stimulates tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1), the major cytoplasmic substrate of the insulin receptor, The gastrin induced phosphorylation of IRS-1 was rapid and transient, occurring within 30 s of treatment and diminishing thereafter, IRS-1 binds several proteins containing Src homology 2 domains through its multiple tyrosine phosphorylation sites. Following gastrin stimulation, we observed a time- and dose-dependent association of IRS-1 with the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase), Ln addition, activation of PI 3-kinase was detected in anti-IRS-1 immunoprecipitates from gastrin-treated cells, suggesting that tyrosine phosphorylation of IRS-1, which leads to the rapid recruitment of p85, might be one mechanism used by gastrin to activate PI 3-kinase. We have previously reported that tyrosine phosphorylation of Shc and its association with the Grb2-Sos complex may contribute to the activation of the mitogen-activated protein kinase pathway by gastrin, We report here that Grb2 also interacts with tyrosine-phosphorylated IRS-1 in response to gastrin. Taken together, our results suggest that IRS-1 may serve as a converging target in the signaling pathways stimulated by receptors that belong to different families, such as the gastrin/CCKB G protein coupled receptor and the insulin receptor.	CHU RANGUEIL,INSERM,U151,GRP RECH BIOL & PATHOL DIGEST,INST LOUIS BUGNARD,F-31054 TOULOUSE,FRANCE	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)			Kowalski-Chauvel, Aline/O-9212-2014; SEVA, Catherine/O-9166-2014	SEVA, Catherine/0000-0002-4265-7372				ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BERTRAND V, 1994, INT J CANCER, V56, P427, DOI 10.1002/ijc.2910560324; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN YH, 1994, J BIOL CHEM, V269, P27372; COUGHLIN SR, 1989, SCIENCE, V243, P1191; Edkins JS, 1905, P R SOC LOND B-CONTA, V76, P376, DOI 10.1098/rspb.1905.0029; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; FUKUI Y, 1989, ONCOGENE RES, V4, P283; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; ITO M, 1993, J BIOL CHEM, V268, P18300; JESSOP HW, 1980, IN VITRO, V16, P222; JOHNSON LR, 1977, ANNU REV PHYSIOL, V39, P135, DOI 10.1146/annurev.ph.39.030177.001031; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SAAD MJA, 1995, BIOCHEM J, V310, P741, DOI 10.1042/bj3100741; SALEEM A, 1995, J BIOL CHEM, V270, P10380, DOI 10.1074/jbc.270.18.10380; SETHI T, 1993, CANCER RES, V53, P5208; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Seva C, 1996, FEBS LETT, V378, P74, DOI 10.1016/0014-5793(95)01414-4; SEVA C, 1994, REGUL PEPTIDES, V52, P31, DOI 10.1016/0167-0115(94)90018-3; SEVA C, 1990, CANCER RES, V50, P5829; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1986, CANCER RES, V46, P1612; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; TANIGUCHI T, 1994, ONCOGENE, V9, P861; TODISCO A, 1995, J BIOL CHEM, V270, P28337; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VEMURI GS, 1994, BIOCHEM BIOPH RES CO, V202, P1619, DOI 10.1006/bbrc.1994.2118; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; WATSON SA, 1989, INT J CANCER, V43, P692, DOI 10.1002/ijc.2910430425; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; ZHANG J, 1993, J BIOL CHEM, V268, P22251	44	61	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26356	26361		10.1074/jbc.271.42.26356	http://dx.doi.org/10.1074/jbc.271.42.26356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824290	hybrid			2022-12-27	WOS:A1996VN18000096
J	Nelson, J; Scott, WN; Allen, WE; Wilson, DJ; Harriott, P; McFerran, NV; Walker, B				Nelson, J; Scott, WN; Allen, WE; Wilson, DJ; Harriott, P; McFerran, NV; Walker, B			Murine epidermal growth factor peptide (33-42) binds to a YIGSR-specific laminin receptor on both tumor and endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; PENTAPEPTIDE; FIBRONECTIN; PROTEIN; CHAIN; ANGIOGENESIS; INHIBITION; SEQUENCE; DOMAINS; INVITRO	A laminin-antagonist peptide, comprising amino acids 33-42 of murine epidermal growth factor (mEGF-(33-42)), interacts with a breast cancer- and endothelial cell-associated receptor, which is specific for the laminin B1 chain sequence, CDPGYIGSR-NH2 (Lam.B1-(925-933)), and is immunologically similar to a previously described 67-kDa laminin receptor. In whole cell receptor assays, mEGF-(33-42), Lam.B1-(925-933), and laminin all have IC50 values for displacement of 125(I)-laminin in the range 1-5 nM. Cell attachment to solid-phase laminin is also blocked by all three ligands, but in contrast to the receptor assays, mEGF-(33-42) or Lam.B1-(925-933), while equipotent with each other, were less effective than laminin. The concentrations of the peptides required to produce half-maximal inhibition of attachment were in the range 230-390 nM, but those for laminin were 1000-fold lower, in the range 0.2-0.3 nM. Like laminin, solid-phase mEGF-(33-42) supports cell attachment, and this ability is blocked by anti-67-kDa receptor antibodies. Modeling studies suggest that both peptides present a tyrosyl and an arginyl residue on the same face of a right-handed helical fold with elliptical cross-section.	QUEENS UNIV BELFAST,SCH BIOMED SCI,DEPT ANAT,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND	Queens University Belfast	Nelson, J (corresponding author), QUEENS UNIV BELFAST,SCH BIOL & BIOCHEM,CTR PEPTIDE & PROT ENGN,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.		Walker, Brian/C-5263-2008					ALBINI A, 1986, P NATL ACAD SCI USA, V83, P8182, DOI 10.1073/pnas.83.21.8182; ALLEN WE, 1994, J ANAT, V184, P194; BAILIE JR, 1989, BIOCHEM SOC T, V17, P409, DOI 10.1042/bst0170409; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERTHOD H, 1967, THEOR CHIM ACTA, V8, P212, DOI 10.1007/BF00527306; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P149, DOI 10.1007/BF01025085; CARPENTER G, 1992, HDB EXPT PHARM, P69; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; GRAF J, 1987, CELL, V48, P989, DOI 10.1016/0092-8674(87)90707-0; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; GULLICK WJ, 1984, ANAL BIOCHEM, V141, P253, DOI 10.1016/0003-2697(84)90454-8; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; KANAMURUU H, 1989, UROL RES, V25, P259; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; LANDOWSKI TH, 1995, CLIN EXP METASTAS, V13, P357; LAZAR E, 1989, MOL CELL BIOL, V9, P860, DOI 10.1128/MCB.9.2.860; LEATHERBARROW RJ, 1992, GRAFIT VERSION 3; LIOTTA LA, 1984, BASEMENT MEMBRANES C, P146; MARANO RPC, 1995, EXP EYE RES, V60, P5, DOI 10.1016/S0014-4835(05)80079-X; MASSIA SP, 1993, J BIOL CHEM, V268, P8053; MCCARTHY JB, 1985, CANCER METAST REV, V4, P125, DOI 10.1007/BF00050692; MCKELVEY DR, 1991, J PROTEIN CHEM, V10, P265, DOI 10.1007/BF01025625; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; NELSON J, 1995, CANCER RES, V55, P3772; OSTHEIMER GJ, 1992, J BIOL CHEM, V267, P25120; PANAYOTOU G, 1989, CELL, V56, P93, DOI 10.1016/0092-8674(89)90987-2; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; ROMANOV V, 1994, CELL ADHES COMMUN, V2, P201, DOI 10.3109/15419069409004438; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SAKAMOTO N, 1991, CANCER RES, V51, P903; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TERRANOVA VP, 1984, SCIENCE, V226, P982, DOI 10.1126/science.6505678; TERRANOVA VP, 1983, P NATL ACAD SCI-BIOL, V80, P444, DOI 10.1073/pnas.80.2.444; VUOLTEENAHO R, 1990, J BIOL CHEM, V265, P15611; WEWER UM, 1987, CANCER RES, V47, P5691; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; YURCHENCO PD, 1985, J BIOL CHEM, V260, P7636	39	16	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26179	26186		10.1074/jbc.271.42.26179	http://dx.doi.org/10.1074/jbc.271.42.26179			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824265	hybrid			2022-12-27	WOS:A1996VN18000071
J	Fushinobu, S; Kamata, K; Iwata, S; Sakai, H; Ohta, T; Matsuzawa, H				Fushinobu, S; Kamata, K; Iwata, S; Sakai, H; Ohta, T; Matsuzawa, H			Allosteric activation of L-lactate dehydrogenase analyzed by hybrid enzymes with effector-sensitive and -insensitive subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARTATE TRANSCARBAMOYLASE; BIFIDOBACTERIUM-LONGUM; DIFFERENT ARRANGEMENTS; CATALYTIC SUBUNITS; SITE; COMMUNICATION; BINDING; CHAINS; MUTAGENESIS; MOLECULES	Subunit-hybrid enzymes of mutant tetrameric L-lactate dehydrogenases from Bifidobacterium longum were studied in an examination of the mechanism of allosteric activation by fructose 1,6-bisphosphate. We earlier developed an in, vivo method for subunit hybridization in Escherichia coli and the hybrids formed were a mixture with different subunit compositions, The B. longum hybrids were separated by anion-exchange chromatography with a mutational tag, Hybrids formed between fructose 1,6-bisphosphate-desensitized subunits and wild-type subunits and also between fructose 1,6-bisphosphate-desensitized subunits and catalytically inactive subunits, Kinetic analyses of the hybrid enzymes showed that (i) those residues from two symmetrically related subunits that constituted the fructose 1,6-bisphosphate-binding site could bind fructose 1,6-bisphosphate and activate the enzyme only if intact, (ii) hybrids with only one functional fructose 1,6-bisphosphate-binding site were fully sensitive to fructose 1,6-bisphosphate, but the allosteric equilibrium had shifted partially, and (iii) activation by fructose 1,6-bisphosphate at the fructose 1,6-bisphosphate-binding site was transmitted to the active sites through a quaternary structural change, not through direct conformational change within a subunit, These results are evidence of the validity of the concerted allosteric model of this enzyme based on T- and R-state structures in the same crystal lattice proposed earlier.	UNIV TOKYO, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Wood, David W/B-2992-2012; Fushinobu, Shinya/E-4987-2011	Fushinobu, Shinya/0000-0003-1346-6435				ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; ADAMS MJ, 1973, J MOL BIOL, V76, P519, DOI 10.1016/0022-2836(73)90489-0; CALIGIURI MG, 1991, SCIENCE, V252, P1845, DOI 10.1126/science.2063197; CAMERON AD, 1994, J MOL BIOL, V238, P615, DOI 10.1006/jmbi.1994.1318; CHAN WWC, 1981, CAN J BIOCHEM CELL B, V59, P461, DOI 10.1139/o81-064; CLARKE AR, 1986, NATURE, V324, P699, DOI 10.1038/324699a0; Dixon M., 1979, ENZYMES, P400; EISENSTEIN E, 1992, J BIOL CHEM, V267, P22148; EVENTOFF W, 1977, P NATL ACAD SCI USA, V74, P2677, DOI 10.1073/pnas.74.7.2677; GARVIE EI, 1980, MICROBIOL REV, V44, P106, DOI 10.1128/MMBR.44.1.106-139.1980; GIBBONS I, 1976, BIOCHEMISTRY-US, V15, P1324, DOI 10.1021/bi00651a024; GOLDBERG E, 1965, ARCH BIOCHEM BIOPHYS, V109, P134, DOI 10.1016/0003-9861(65)90298-5; HERMANN R, 1982, H-S Z PHYSIOL CHEM, V363, P1259, DOI 10.1515/bchm2.1982.363.2.1259; Holbrook JJ., 1975, ENZYMES, P191; IWATA S, 1989, AGR BIOL CHEM TOKYO, V53, P3365, DOI 10.1080/00021369.1989.10869841; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; IWATA S, 1993, J MOL BIOL, V230, P21, DOI 10.1006/jmbi.1993.1122; IWATA S, 1989, J BIOCHEM-TOKYO, V106, P558, DOI 10.1093/oxfordjournals.jbchem.a122894; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; MARKERT CL, 1963, SCIENCE, V140, P1329, DOI 10.1126/science.140.3573.1329; MINOWA T, 1989, GENE, V85, P161, DOI 10.1016/0378-1119(89)90476-9; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHTA T, 1992, FARADAY DISCUSS, V93, P153, DOI 10.1039/fd9929300153; Perutz M.F., 1989, MECH COOPERATIVITY A; ROSSMANN MG, 1973, J MOL BIOL, V76, P533, DOI 10.1016/0022-2836(73)90491-9; SALTHE SN, 1965, NATURE, V207, P723, DOI 10.1038/207723a0; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG CM, 1981, J BIOL CHEM, V256, P7028; YANG YR, 1980, P NATL ACAD SCI-BIOL, V77, P5187, DOI 10.1073/pnas.77.9.5187; YANG YR, 1987, ANAL BIOCHEM, V163, P188, DOI 10.1016/0003-2697(87)90111-4	33	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25611	25616		10.1074/jbc.271.41.25611	http://dx.doi.org/10.1074/jbc.271.41.25611			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810336	hybrid			2022-12-27	WOS:A1996VL69300080
J	Magyar, A; Zhang, YD; Kohn, H; Widger, WR				Magyar, A; Zhang, YD; Kohn, H; Widger, WR			The antibiotic bicyclomycin affects the secondary RNA binding site of Escherichia coli transcription termination factor Rho	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-RHO; MUTANT-RHO; PHYSICAL-PROPERTIES; NUSG PROTEIN; SEQUENCE; HELICASE; DOMAIN; STABILIZATION; INHIBITION; ACTIVATION	The interaction of Rho and the antibiotic bicyclomycin was probed using in vitro transcription termination reactions, poly(C) binding assays, limited tryptic digestions, and the bicyclomycin inhibition kinetics of ATPase activity in the presence of poly(dC) and ribo(C)(10). The approximate I-50 value for the bicyclomycin inhibition of transcription termination at Rho-dependent sites within a modified trp operon template was 5 mu M. At antibiotic concentrations near the I-50 value, bicyclomycin inhibition of Rho-dependent transcripts was accompanied by the appearance of a new set of transcripts whose size was midway between the Rho-dependent transcripts and the readthrough transcripts, Bicyclomycin did not inhibit poly(C) binding to Rho, In the presence of poly(dC), bicyclomycin showed a reversible mixed inhibition of the ribo(C)(10)-stimulated ATPase activity, The extrapolated K-i for bicyclomycin was 2.8 mu M without ribo(C)(10) and increased to 26 mu M in the presence of ribo(C)(10). Correspondingly, the K-m(app) for ribo(C)(10) without bicyclomycin was 0.8 mu M and with bicyclomycin was 5 mu M at infinite inhibitor concentration, The data suggested that the antibiotic binds to Rho, influencing the secondary RNA binding (tracking) site on Rho and slows the tracking of Rho toward the bound RNA polymerase.	UNIV HOUSTON,DEPT BIOCHEM & BIOPHYS SCI,HOUSTON,TX 77204; UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204	University of Houston System; University of Houston; University of Houston System; University of Houston					NIGMS NIH HHS [GM 37934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUZAR S, 1989, J AM CHEM SOC, V111, P4895, DOI 10.1021/ja00195a049; ABUZAR S, 1990, J AM CHEM SOC, V112, P3114, DOI 10.1021/ja00164a036; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18802; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; DOMBROSKI AJ, 1988, J BIOL CHEM, V263, P18810; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; GEISELMANN J, 1993, P NATL ACAD SCI USA, V90, P7754, DOI 10.1073/pnas.90.16.7754; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P121, DOI 10.1021/bi00116a018; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAMIYA T, 1972, J ANTIBIOT, V25, P576, DOI 10.7164/antibiotics.25.576; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; MIYAMURA S, 1972, J ANTIBIOT TOKYO, V25, P39; MIYOSHI T, 1972, J ANTIBIOT, V25, P569, DOI 10.7164/antibiotics.25.569; MODRAK D, 1994, BIOCHEMISTRY-US, V33, P8292, DOI 10.1021/bi00193a016; MORI H, 1989, J MOL BIOL, V210, P39, DOI 10.1016/0022-2836(89)90289-1; MOTT JE, 1985, P NATL ACAD SCI USA, V82, P88, DOI 10.1073/pnas.82.1.88; NEHRKE KW, 1994, J MOL BIOL, V243, P830, DOI 10.1006/jmbi.1994.1685; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; PARK HG, 1995, ARCH BIOCHEM BIOPHYS, V323, P447, DOI 10.1006/abbi.1995.0066; PARK HG, 1995, STUDIES MECH ACTION; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; RICHARDSON JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P127, DOI 10.1016/0167-4781(90)90048-7; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5767; SULLIVAN SL, 1992, CELL, V68, P989, DOI 10.1016/0092-8674(92)90041-A; TSURUSHITA N, 1989, J MOL BIOL, V210, P23, DOI 10.1016/0022-2836(89)90288-X; WANG Y, 1993, J BIOL CHEM, V268, P13940; WILLIAMS RM, 1988, CHEM REV, V88, P511, DOI 10.1021/cr00085a004; WU AM, 1981, P NATL ACAD SCI-BIOL, V78, P2913, DOI 10.1073/pnas.78.5.2913; YANOFSKY C, 1995, J BACTERIOL, V177, P4451, DOI 10.1128/jb.177.15.4451-4456.1995; ZHENG CH, 1994, P NATL ACAD SCI USA, V91, P7543, DOI 10.1073/pnas.91.16.7543; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	46	53	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25369	25374		10.1074/jbc.271.41.25369	http://dx.doi.org/10.1074/jbc.271.41.25369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810302	hybrid			2022-12-27	WOS:A1996VL69300046
J	Zeilinger, S; Mach, RL; Schindler, M; Herzog, P; Kubicek, CP				Zeilinger, S; Mach, RL; Schindler, M; Herzog, P; Kubicek, CP			Different inducibility of expression of the two xylanase genes xyn1 and xyn2 in Trichoderma reesei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; CCAAT-BINDING; TRANSFORMATION SYSTEM; D-XYLOSE; CELLULASE; PROTEIN; INDUCTION; CLONING; ADJACENT; PROMOTER	Regulation of formation of the extracellular xylanase system of Trichoderma reesei QM 9414 during growth on xylan, cellulose, and replacement onto a number of soluble inducers was investigated by Northern analysis of xyn1 and xyn2 transcripts and by the use of the Escherichia coli hph (hygromycin B-phosphotransferase-encoding) gene as a reporter. Whereas the xyn1 promoter is active in the presence of xylan and xylose, and virtually silenced in the presence of glucose, the xyn2 promoter enables basal transcription at a low level, but is enhanced in the presence of xylan and xylobiose and also of sophorose or cellobiose. The respective regulatory nucleotide regions were localized on a 221-base pair fragment and a 55-base pair fragment of the xyn1 and zyn2 5'-upstream noncoding sequences, respectively. Electrophoretic mobility shift assays, using cell-free extracts, identified induction-specific protein-DNA complexes: one complex of high mobility was observed under basal, noninduced conditions (glucose) with xyn2, which was in part replaced by a slow-migrating complex upon induction by xylan or sophorose. Both complexes bound to a CCAAT box. With xyn1, the induced complex also binds to a CCAAT box, but this binding is not observed in the presence of the carbon catabolite repressor Cre1, which binds to a nearby located consensus motif.	VIENNA TECH UNIV, INST BIOCHEM TECHNOL & MIKROBIOL, MIKROBIELLE BIOCHEM ABT, A-1060 VIENNA, AUSTRIA	Technische Universitat Wien			Zeilinger, Susanne/AAX-6578-2020; Robert, Mach/AAU-8968-2020	Zeilinger, Susanne/0000-0003-3112-0948; Mach, Robert, L./0000-0003-2375-7244				ABRAHAONETO J, 1995, BIOCHEMISTRY-US, V34, P10456, DOI 10.1021/bi00033a018; ARAMAYO R, 1993, EMBO J, V12, P2039, DOI 10.1002/j.1460-2075.1993.tb05853.x; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BIELY P, 1994, FEBS LETT, V356, P137, DOI 10.1016/0014-5793(94)01248-2; BIELY P, 1991, EUR J BIOCHEM, V200, P157, DOI 10.1111/j.1432-1033.1991.tb21062.x; Biely P, 1993, TRICHODERMA CELLULAS, P125; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUBERO B, 1994, EMBO J, V13, P407, DOI 10.1002/j.1460-2075.1994.tb06275.x; DEGRAAFF L, 1993, MOL MICROBIOL, V12, P479; ELGOGARY S, 1989, P NATL ACAD SCI USA, V86, P6138, DOI 10.1073/pnas.86.16.6138; FORSBURG SL, 1989, GENE DEV, V3, P1166, DOI 10.1101/gad.3.8.1166; GRUBER F, 1990, CURR GENET, V18, P447, DOI 10.1007/BF00309915; GRUBER F, 1990, CURR GENET, V18, P71, DOI 10.1007/BF00321118; HRMOVA M, 1986, ARCH MICROBIOL, V144, P307, DOI 10.1007/BF00410968; KUBICEK CP, 1988, J GEN MICROBIOL, V134, P1215; MACH RL, 1994, CURR GENET, V25, P567, DOI 10.1007/BF00351679; MACH RL, 1996, IN PRESS MOL MICROBI; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MULDER W, 1994, MOL GEN GENET, V245, P96, DOI 10.1007/BF00279755; OLESEN JT, 1991, MOL CELL BIOL, V11, P611, DOI 10.1128/MCB.11.2.611; PAPAGIANNOPOULO.P, 1995, FUNGAL GENET NEWSL S, V42, P16; ROYER JC, 1990, APPL ENVIRON MICROB, V56, P2535, DOI 10.1128/AEM.56.8.2535-2539.1990; SAARELAINEN R, 1993, MOL GEN GENET, V241, P497, DOI 10.1007/BF00279891; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENIOR DJ, 1989, ACS SYM SER, V399, P641; STANGL H, 1993, CURR GENET, V23, P115, DOI 10.1007/BF00352009; STERNBERG D, 1979, J BACTERIOL, V139, P761, DOI 10.1128/JB.139.3.761-769.1979; STRAUSS J, 1995, FEBS LETT, V376, P103, DOI 10.1016/0014-5793(95)01255-5; TENKANEN M, 1992, ENZYME MICROB TECH, V14, P566, DOI 10.1016/0141-0229(92)90128-B; Timell T. E., 1965, ADV CARBOHYD CHEM, V20, P409, DOI DOI 10.1016/S0096-5332(08)60304-5; TORRONEN A, 1994, EMBO J, V13, P2493, DOI 10.1002/j.1460-2075.1994.tb06536.x; TORRONEN A, 1995, BIOCHEMISTRY-US, V34, P847, DOI 10.1021/bi00003a019; TORRONEN A, 1992, BIO-TECHNOL, V10, P1461, DOI 10.1038/nbt1192-1461; VANHEESWIJCK R, 1991, NUCLEIC ACIDS RES, V19, P2655, DOI 10.1093/nar/19.10.2655; VIIKARI L, 1994, FEMS MICROBIOL REV, V13, P335, DOI 10.1016/0168-6445(94)90090-6; WITTEVEEN CFB, 1989, J GEN MICROBIOL, V135, P2163; WONG KKY, 1988, MICROBIOL REV, V52, P305, DOI 10.1128/MMBR.52.3.305-317.1988	40	96	108	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25624	25629		10.1074/jbc.271.41.25624	http://dx.doi.org/10.1074/jbc.271.41.25624			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810338	hybrid			2022-12-27	WOS:A1996VL69300082
J	Habib, S; Hasnain, SE				Habib, S; Hasnain, SE			A 38-kDa host factor interacts with functionally important motifs within the Autographa californica multinucleocapsid nuclear polyhedrosis virus homologous region (hr1) DNA sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION FACTOR GENES; 30-KDA PROTEIN-BINDING; ENHANCER ELEMENTS; PUTATIVE ORIGINS; REPLICATION; TRANSCRIPTION; IE1; TRANSACTIVATOR; PROMOTER; REPEAT	We recently demonstrated that the Autographa californica multinucleocapsid nuclear polyhedrosis virus homologous region (hr1) enhances transcription from the viral polyhedrin promoter and also functions as a putative origin of replication (ori). Hr1, carrying five 28-base pair core palindrome units, has also been mapped with respect to its enhancer and ori functions (Habib, S., Pandey, S., Chatterji, U., Burma, S., Ahmad, R., Jain, A., and Hasnain, S. E. (1996) DNA Cell Biol. 15, 737-747). A 38-kDa host factor termed hr1-binding protein (hr1-BP) binds with high specificity and affinity (K-d similar to 6.5 x 10(-11) M) to functionally important motifs within hr1. The core palindrome as well as sequences immediately flanking it are required for this interaction. Divalent cations are not essential, and ionic interactions play only a minor role in complex formation. hr1-BP binds through the minor groove of the double helix to multiple sites within hr1, and binding occurs as a function of the number of modules within hr1. Phosphorylation of hr1-BP is important for host factor-hr1 interaction. Hr1-BP differs in several respects from the other host factor, polyhedrin promoter-binding protein described previously (Burma, S., Mukherjee, B., Jain, A., Habib, S., and Hasnain, S. E. (1994) J. Biol. Chem 269, 2750-2757). When hr1-BP was sequestered out, in vivo, by a plasmid carrying hr1 alone, the hr1-mediated enhancement of reporter expression was abolished, demonstrating that the binding of hr1-BP may be crucial for the enhancer activity of the dual function hr1 element.	NATL INST IMMUNOL,EUKARYOT GENE EXPRESS LAB,NEW DELHI 110067,INDIA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)			HASNAIN, SEYED/C-1492-2009	Hasnain, Seyed/0000-0002-2967-0791				AHRENS CH, 1996, IN PRESS DNA REPLICA; BURMA S, 1994, J BIOL CHEM, V269, P2750; CARSON DD, 1991, J VIROL, V65, P945, DOI 10.1128/JVI.65.2.945-951.1991; CHOI J, 1995, VIROLOGY, V209, P99, DOI 10.1006/viro.1995.1234; CHOI J, 1995, J VIROL, V69, P4548, DOI 10.1128/JVI.69.7.4548-4551.1995; COPENHAVER GP, 1994, NUCLEIC ACIDS RES, V22, P2651, DOI 10.1093/nar/22.13.2651; DAVID E, 1995, J BIOL CHEM, V270, P8353, DOI 10.1074/jbc.270.14.8353; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GUARINO LA, 1986, J VIROL, V60, P224, DOI 10.1128/JVI.60.1.224-229.1986; GUARINO LA, 1991, J VIROL, V65, P3676, DOI 10.1128/JVI.65.7.3676-3680.1991; GUARINO LA, 1986, J VIROL, V60, P215, DOI 10.1128/JVI.60.1.215-223.1986; GUARINO LA, 1994, VIROLOGY, V200, P328, DOI 10.1006/viro.1994.1197; Habib S, 1996, DNA CELL BIOL, V15, P737, DOI 10.1089/dna.1996.15.737; HASNAIN SE, 1995, METHODS ENZYMOLOGY R, P20; Jain A, 1996, EUR J BIOCHEM, V239, P384, DOI 10.1111/j.1432-1033.1996.0384u.x; KANDALA JC, 1994, VIROLOGY, V198, P514, DOI 10.1006/viro.1994.1062; KIM SK, 1993, FEBS LETT, V315, P61, DOI 10.1016/0014-5793(93)81133-K; KOOL M, 1993, J GEN VIROL, V74, P2661, DOI 10.1099/0022-1317-74-12-2661; KOOL M, 1993, VIROLOGY, V192, P94, DOI 10.1006/viro.1993.1011; KOOL M, 1995, J GEN VIROL, V76, P2103, DOI 10.1099/0022-1317-76-9-2103; LEISY DJ, 1995, VIROLOGY, V208, P742, DOI 10.1006/viro.1995.1206; LEISY DJ, 1993, VIROLOGY, V196, P722, DOI 10.1006/viro.1993.1529; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; LU A, 1995, J VIROL, V69, P975, DOI 10.1128/JVI.69.2.975-982.1995; LU A, 1995, J VIROL, V69, P6265, DOI 10.1128/JVI.69.10.6265-6272.1995; MUKHERJEE B, 1995, J BIOL CHEM, V270, P4405, DOI 10.1074/jbc.270.9.4405; OSTAPCHUK P, 1986, P NATL ACAD SCI USA, V83, P8550, DOI 10.1073/pnas.83.22.8550; PAPAVASSILIOU AG, 1992, ANAL BIOCHEM, V203, P302, DOI 10.1016/0003-2697(92)90317-Z; PARTHUN MR, 1992, MOL CELL BIOL, V12, P4981, DOI 10.1128/MCB.12.11.4981; PEARSON M, 1992, SCIENCE, V257, P1382, DOI 10.1126/science.1529337; RODEMS SM, 1995, J VIROL, V69, P5368, DOI 10.1128/JVI.69.9.5368-5375.1995; RYDEN TA, 1993, J VIROL, V67, P2862, DOI 10.1128/JVI.67.5.2862-2870.1993; SUMMERS MD, 1987, B TEXAS AGR EXPT STA, V1555, P10	35	25	26	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28250	28258		10.1074/jbc.271.45.28250	http://dx.doi.org/10.1074/jbc.271.45.28250			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910443	hybrid			2022-12-27	WOS:A1996VU03300043
J	Yang, YZ; BurgosTrinidad, M; Wu, YF; Koenig, RJ				Yang, YZ; BurgosTrinidad, M; Wu, YF; Koenig, RJ			Thyroid hormone receptor variant alpha 2 - Role of the ninth heptad in DNA binding, heterodimerization with retinoid X receptors, and dominant negative activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSE ELEMENTS; TARGET GENES; TRANS-ACTIVATION; DIRECT REPEAT; CO-REPRESSOR; VITAMIN-D; V-ERBA; DIMERIZATION; RESISTANCE; SEQUENCES	Thyroid hormone receptors bind DNA with highest affinity as heterodimers with retinoid X receptors, and such heterodimers generally are thought to be the biological mediators of thyroid hormone action. An alternative splice product of the thyroid hormone receptor cu gene, thyroid hormone receptor variant alpha 2, does not bind thyroid hormone and functions as a weak dominant negative inhibitor of thyroid hormone action, Thyroid hormone receptor variant alpha 2 is missing one-half of the ninth heptad, a region of the bona fide receptor thought to be important for heterodimerization with retinoid X receptors, The role of the ninth heptad in heterodimerization has been evaluated further, Thyroid hormone receptor variant alpha 2-retinoid X receptor heterodimers form on a subset of direct repeat response elements but not on palindromic or inverted palindromic elements, Restoration of the missing ninth heptad sequence is critical for restoring heterodimerization on the palindromic DNA, but either the ninth heptad amino acids or a stretch of alanines is equally able to restore heterodimerization on the inverted palindrome, Thus, the role of the ninth heptad in heterodimerization differs on direct repeat, palindromic, and inverted palindromic response elements, suggesting that the protein-protein interactions differ on each of these elements, The dominant negative activity of thyroid hormone receptor variant alpha 2 requires DNA binding, but the relatively weak nature of the dominant negative activity is only partially explained by the weak DNA binding.	UNIV MICHIGAN,MED CTR,DIV ENDOCRINOL & METAB,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BRENT GA, 1989, MOL ENDOCRINOL, V3, P1996, DOI 10.1210/mend-3-12-1996; CAI Z, 1990, BIOTECHNIQUES, V8, P528; CHATTERJEE VKK, 1991, J CLIN INVEST, V87, P1977; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; COLLINGWOOD TN, 1994, MOL ENDOCRINOL, V8, P1262, DOI 10.1210/me.8.9.1262; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; FARSETTI A, 1992, J BIOL CHEM, V267, P15784; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KATZ D, 1993, J BIOL CHEM, V268, P20904; KATZ D, 1992, MOL ENDOCRINOL, V6, P805, DOI 10.1210/me.6.5.805; KATZ D, 1995, MOL CELL BIOL, V15, P2341; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KATZ RW, 1994, J BIOL CHEM, V269, P9500; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LAZAR MA, 1988, MOL ENDOCRINOL, V2, P893, DOI 10.1210/mend-2-10-893; LAZAR MA, 1989, P NATL ACAD SCI USA, V86, P7771, DOI 10.1073/pnas.86.20.7771; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LIU RT, 1995, MOL ENDOCRINOL, V9, P86, DOI 10.1210/me.9.1.86; MOORE DD, 1986, GENE AMST, V45, P107; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NAGAYA T, 1992, J BIOL CHEM, V267, P13014; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; ODONNELL AL, 1990, MOL ENDOCRINOL, V4, P715, DOI 10.1210/mend-4-5-715; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PROST E, 1988, NUCLEIC ACIDS RES, V16, P6248, DOI 10.1093/nar/16.13.6248; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; ROSEN ED, 1993, J BIOL CHEM, V268, P11534; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUBAUSTE JS, 1995, J BIOL CHEM, V270, P7957, DOI 10.1074/jbc.270.14.7957; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E	42	41	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28235	28242		10.1074/jbc.271.45.28235	http://dx.doi.org/10.1074/jbc.271.45.28235			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910441	hybrid			2022-12-27	WOS:A1996VU03300041
J	Hawley, SA; Davison, M; Woods, A; Davies, SP; Beri, RK; Carling, D; Hardie, DG				Hawley, SA; Davison, M; Woods, A; Davies, SP; Beri, RK; Carling, D; Hardie, DG			Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; YEAST SNF1; SKELETAL-MUSCLE; PURIFICATION; REDUCTASE; GENE; PHOSPHATASE-1; HEPATOCYTES; SPECIFICITY; QUANTITIES	We have developed a sensitive assay for the AMP-activated protein kinase kinase, the upstream component in the AMP-activated protein kinase cascade. Phosphorylation and activation of the downstream kinase by the upstream kinase absolutely requires AMP and is antagonized by high (millimolar) concentrations of ATP. We have purified the upstream kinase >1000-fold from rat liver; a variety of evidence indicates that the catalytic subunit may be a polypeptide of 58 kDa. The physical properties of the downstream and upstream kinases, e.g. catalytic subunit masses (63 versus 58 kDa) and native molecular masses (190 versus 195 kDa), are very similar, However, unlike the downstream kinase, the upstream kinase is not inactivated by protein phosphatases. The upstream kinase phosphorylates the downstream kinase at a single major site on the a subunit, i.e. threonine 172, which lies in the ''activation segment'' between the DFG and APE motifs. This site aligns with activating phosphorylation sites on many other protein kinases, including Thr(177) on calmodulin-dependent protein kinase I. As well as suggesting a mechanism of activation of AMP-activated protein kinase, this finding is consistent with our recent report that the AMP-activated protein kinase kinase can slowly phosphorylate and activate calmodulin-dependent protein kinase I, at least in vitro (Hawley, S. A., Selbert, M. A., Goldstein, E. G., Edelman, A. M., Carling, D., and Hardie, D. G. (1995) J. Biol. Chem. 270, 27186-27191).	UNIV DUNDEE,DEPT BIOCHEM,DUNDEE DD1 4HN,SCOTLAND; ZENECA PHARMACEUT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,MRC,MOL MED GRP,LONDON W12 0NN,ENGLAND	University of Dundee; Imperial College London			Carling, David/F-1943-2014; Hardie, David/Z-1979-2019	Carling, David/0000-0002-2316-1830; Hardie, Grahame/0000-0002-8373-7379	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BERI RK, 1994, FEBS LETT, V356, P117, DOI 10.1016/0014-5793(94)01247-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1989, EUR J BIOCHEM, V186, P129, DOI 10.1111/j.1432-1033.1989.tb15186.x; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; COHEN P, 1988, METHOD ENZYMOL, V159, P390; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; COULL J M, 1990, Journal of Protein Chemistry, V9, P259; DALE S, 1995, FEBS LETT, V361, P191, DOI 10.1016/0014-5793(95)00172-6; Davies SP, 1995, FEBS LETT, V377, P421, DOI 10.1016/0014-5793(95)01368-7; DAVIES SP, 1994, EUR J BIOCHEM, V223, P351, DOI 10.1111/j.1432-1033.1994.tb19001.x; DAVIES SP, 1992, EUR J BIOCHEM, V203, P615, DOI 10.1111/j.1432-1033.1992.tb16591.x; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; ESTRUCH F, 1992, GENETICS, V132, P639; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; HANKS SK, 1995, PROTEIN KINASE FACTS, V1, P7; Hardie D. Grahame, 1994, Seminars in Cell Biology, V5, P409, DOI 10.1006/scel.1994.1048; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; HAYSTEAD CMM, 1993, EUR J BIOCHEM, V214, P459, DOI 10.1111/j.1432-1033.1993.tb17942.x; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MOORE F, 1991, EUR J BIOCHEM, V199, P691, DOI 10.1111/j.1432-1033.1991.tb16172.x; MUNDAY MR, 1988, EUR J BIOCHEM, V175, P331, DOI 10.1111/j.1432-1033.1988.tb14201.x; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; SIM ATR, 1988, FEBS LETT, V233, P294, DOI 10.1016/0014-5793(88)80445-9; Stapleton D, 1996, J BIOL CHEM, V271, P611, DOI 10.1074/jbc.271.2.611; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; STREULI M, 1988, J EXP MED, V168, P1553; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837	46	971	1004	2	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27879	27887		10.1074/jbc.271.44.27879	http://dx.doi.org/10.1074/jbc.271.44.27879			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910387	hybrid			2022-12-27	WOS:A1996VQ67900105
J	Severinov, K; Mustaev, A; Kukarin, A; Muzzin, O; Bass, I; Darst, SA; Goldfarb, A				Severinov, K; Mustaev, A; Kukarin, A; Muzzin, O; Bass, I; Darst, SA; Goldfarb, A			Structural modules of the large subunits of RNA polymerase - Introducing archaebacterial and chloroplast split sites in the beta and beta' subunits Escherichia coli RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOLYDIGIN-RESISTANT MUTANTS; ACTIVE-CENTER; 3-DIMENSIONAL STRUCTURE; RIFAMPICIN-RESISTANT; DNA-SEQUENCE; TRANSCRIPTION; PROMOTER; GENES; ENZYME; ELONGATION	The beta and beta' subunits of Escherichia coli DNA-dependent RNA polymerase are highly conserved throughout eubacterial and eukaryotic kingdoms. However, in some archaebacteria and chloroplasts, the corresponding sequences are ''split'' into smaller polypeptides that are encoded by separate genes. To test if such split sites can be accommodated into E. coli RNA polymerase, subunit fragments encoded by the segments of E. coli rpoB and rpoC genes corresponding to archaebacterial and chloroplast split subunits were individually overexpressed. The purified fragments, when mixed in vitro with complementing intact RNA polymerase subunits, yielded an active enzyme capable of catalyzing the phosphodiester bond formation. Thus, the large subunits of eubacteria and eukaryotes are composed of independent structural modules corresponding to the smaller subunits of archaebacteria and chloroplasts.	PUBL HLTH RES INST,NEW YORK,NY 10016; RUSSIAN ACAD SCI,INST MOL GENET,MOSCOW 123182,RUSSIA	Russian Academy of Sciences	Severinov, K (corresponding author), ROCKEFELLER UNIV,BOX 224,1230 YORK AVE,NEW YORK,NY 10021, USA.		Severinov, Konstantin/C-8545-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759, R01GM030717] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30717, GM53759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARMSTRONG VW, 1979, BIOCHEMISTRY-US, V18, P5117, DOI 10.1021/bi00590a014; BERGHOFER B, 1988, NUCLEIC ACIDS RES, V16, P8113, DOI 10.1093/nar/16.16.8113; BERGSLAND KJ, 1991, J BACTERIOL, V173, P3446, DOI 10.1128/jb.173.11.3446-3455.1991; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BOOR KJ, 1995, J BIOL CHEM, V270, P20329, DOI 10.1074/jbc.270.35.20329; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; DANILKOVICH AV, 1988, DOKL AKAD NAUK SSSR+, V303, P241; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; GRACHEV MA, 1986, BIOORG KHIM+, V12, P1678; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HEUMANN H, 1987, BIOCHIM BIOPHYS ACTA, V909, P126, DOI 10.1016/0167-4781(87)90034-0; HONORE N, 1993, MOL MICROBIOL, V7, P207, DOI 10.1111/j.1365-2958.1993.tb01112.x; HU J, 1990, P NATL ACAD SCI USA, V87, P1531, DOI 10.1073/pnas.87.4.1531; IGLOI GL, 1990, MOL GEN GENET, V221, P379, DOI 10.1007/BF00259403; Ishihama A, 1981, Adv Biophys, V14, P1; IWABE N, 1991, J MOL EVOL, V32, P70, DOI 10.1007/BF02099931; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; MUSTAEV A, 1994, P NATL ACAD SCI USA, V91, P12036, DOI 10.1073/pnas.91.25.12036; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; OHME M, 1986, FEBS LETT, V200, P87, DOI 10.1016/0014-5793(86)80516-6; OVCHINNIKOV YA, 1981, MOL GEN GENET, V184, P536, DOI 10.1007/BF00352535; PALM P, 1993, NUCLEIC ACIDS RES, V21, P4904, DOI 10.1093/nar/21.21.4904; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4569, DOI 10.1073/pnas.86.12.4569; REITER WD, 1990, P NATL ACAD SCI USA, V87, P9509, DOI 10.1073/pnas.87.24.9509; SCHNEIDER GJ, 1987, J BIOL CHEM, V262, P14633; SCHULTZ P, 1993, EMBO J, V12, P2601, DOI 10.1002/j.1460-2075.1993.tb05920.x; SCHYNS G, 1994, MOL MICROBIOL, V13, P887, DOI 10.1111/j.1365-2958.1994.tb00480.x; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, J BIOL CHEM, V270, P29428, DOI 10.1074/jbc.270.49.29428; SEVERINOV K, 1994, J BIOL CHEM, V269, P14254; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1994, MOL GEN GENET, V244, P120, DOI 10.1007/BF00283512; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; SEVERINOV K, 1994, J BIOL CHEM, V269, P31701; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; SHIMADA H, 1990, MOL GEN GENET, V221, P395, DOI 10.1007/BF00259404; SWOETSER D, 1987, P NATL ACAD SCI USA, V84, P1192; TANG H, 1995, P NATL ACAD SCI USA, V92, P4902, DOI 10.1073/pnas.92.11.4902; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; XIE WQ, 1989, J BACTERIOL, V171, P1967, DOI 10.1128/jb.171.4.1967-1973.1989; YANG XF, 1995, J BIOL CHEM, V270, P23930, DOI 10.1074/jbc.270.41.23930; ZILLIG W, 1986, RNA POLYMERASE REGUL, P17	57	69	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27969	27974		10.1074/jbc.271.44.27969	http://dx.doi.org/10.1074/jbc.271.44.27969			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910400	hybrid			2022-12-27	WOS:A1996VQ67900118
J	Kennedy, MT; Brockman, H; Rusnak, F				Kennedy, MT; Brockman, H; Rusnak, F			Contributions of myristoylation to calcineurin structure/function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NITRIC-OXIDE SYNTHASE; NH2-TERMINAL BLOCKING GROUP; SUBCELLULAR-LOCALIZATION; CATALYTIC SUBUNIT; PHOSPHOLIPID-VESICLES; TRANSFORMING PROTEIN; PHOSPHATASE-ACTIVITY; PHASE-TRANSITIONS; MEMBRANE-BINDING	Calcineurin is a serine/threonine protein phosphatase composed of a catalytic subunit, calcineurin A (58 kDa), and a NH2-terminal myristoylated regulatory subunit, calcineurin B (19 kDa). In order to study the effect of myristoylation on calcineurin structure/function, a dual plasmid transfection system was used to generate myristoylated and nonmyristoylated calcineurin B. Both metabolic labeling of calcineurin B with radiolabeled myristic acid and electrospray mass spectral analysis confirmed that myristic acid was covalently and stoichiometrically linked to calcineurin B, Myristoyl and non-myristoyl calcineurin B were reconstituted with recombinant calcineurin A to form native-like heterodimers, and the properties of the two calcineurin forms were examined. Myristoylation had no effect on enzymatic activity, calcineurin-immunosuppressant/immunophilin interactions, or Ca2+ binding, Surprisingly, myristoylation also had no effect on calcineurin heterodimer association with phospholipid monolayers. Fatty acylation, however, significantly influenced the thermal stability of calcineurin, with an approximate 10 degrees C increase in t(1/2) observed for myristoyl calcineurin when compared to the non-myristoyl form. Myristoylation of calcineurin B therefore appears to provide structural stability to the calcineurin heterodimer.	MAYO CLIN & MAYO FDN,HEMATOL RES SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	Mayo Clinic; Mayo Clinic; University of Minnesota System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046865] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49180] Funding Source: Medline; NIGMS NIH HHS [GM46865] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AITKEN A, 1982, FEBS LETT, V150, P314, DOI 10.1016/0014-5793(82)80759-X; ALEXANDER DR, 1988, BIOCHEM J, V256, P885, DOI 10.1042/bj2560885; ALLAND L, 1994, J BIOL CHEM, V269, P16701; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 1995, J BIOL CHEM, V270, P30909, DOI 10.1074/jbc.270.52.30909; APERIA A, 1992, P NATL ACAD SCI USA, V89, P7394, DOI 10.1073/pnas.89.16.7394; BLUME A, 1979, BIOCHIM BIOPHYS ACTA, V557, P32, DOI 10.1016/0005-2736(79)90087-7; BROCKMAN HL, 1984, J PHYS E SCI INSTRUM, V17, P351, DOI 10.1088/0022-3735/17/5/006; BUSCONI L, 1994, J BIOL CHEM, V269, P25016; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CALVERT PD, 1995, J BIOL CHEM, V270, P24127, DOI 10.1074/jbc.270.41.24127; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DEMEL RA, 1975, BIOCHIM BIOPHYS ACTA, V406, P97, DOI 10.1016/0005-2736(75)90045-0; DURONIO R J, 1990, Methods (Orlando), V1, P253, DOI 10.1016/S1046-2023(05)80325-1; GREENHUT SF, 1985, J BIOL CHEM, V260, P5883; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HAO R, 1993, PROTIEN SCI, V2, P122; HECKER M, 1994, J NEUROCHEM, V62, P1524; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; JONES MN, 1995, MICELLES MONOLAYERS, P59; JOSEPH M, 1995, J BIOL CHEM, V270, P16749, DOI 10.1074/jbc.270.28.16749; KAKALIS LT, 1995, FEBS LETT, V362, P55, DOI 10.1016/0014-5793(95)00207-P; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LUAN S, 1993, P NATL ACAD SCI USA, V90, P2202, DOI 10.1073/pnas.90.6.2202; MACDONALD RC, 1988, J BIOL CHEM, V263, P10052; MOMSEN WE, 1990, J COLLOID INTERF SCI, V135, P547, DOI 10.1016/0021-9797(90)90025-J; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; NAGLE JF, 1976, J MEMBRANE BIOL, V27, P233, DOI 10.1007/BF01869138; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; POLITINO M, 1990, J BIOL CHEM, V265, P7619; POLITINO M, 1987, J BIOL CHEM, V262, P10109; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SAITOH Y, 1991, BIOMED RES-TOKYO, V12, P215, DOI 10.2220/biomedres.12.215; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; SIGAL CT, 1994, P NATL ACAD SCI USA, V91, P12253, DOI 10.1073/pnas.91.25.12253; SIKKINK R, 1995, BIOCHEMISTRY-US, V34, P8348, DOI 10.1021/bi00026a016; TALLANT EA, 1983, BIOCHEMISTRY-US, V22, P3630, DOI 10.1021/bi00284a014; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	58	43	45	3	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26517	26521		10.1074/jbc.271.43.26517	http://dx.doi.org/10.1074/jbc.271.43.26517			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900120	hybrid			2022-12-27	WOS:A1996VP23300014
J	Kessler, MM; Zhao, J; Moore, CL				Kessler, MM; Zhao, J; Moore, CL			Purification of the Saccharomyces cerevisiae cleavage/polyadenylation factor I - Separation into two components that are required for both cleavage and polyadenylation of mRNA 3' ends	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; POLY(A) POLYMERASE; SPECIFICITY FACTOR; SUBUNIT; GENE; CLONING; PROTEIN; BINDING; SITE; EXPRESSION	The cleavage/polyadenylation factor I (CF I) is one of four factors required for mRNA 3' end formation in the yeast Saccharomyces cerevisiae, Here we describe the purification of CF I and its separation into two components, CF IA and CF IB, Both components are needed to reconstitute CF I activity in cleavage and poly(A) addition, CF IA consists of a complex of four polypeptides of 76, 70, 50, and 38 kDa, and CF IB is a single 73-kDa polypeptide. The 76- and 38-kDa subunits of CF IA correspond to the previously identified RNA14 and RNA15 proteins, The RNA14 protein, but not the 70- or 50-kDa proteins, coimmunoprecipitates with the RNA15 protein, indicating that RNA14 and RNA15 proteins exist in a tight complex, RNA15 is the only subunit of CF I that can be cross-linked to pre-mRNA.	TUFTS UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,BOSTON,MA 02111	Tufts University					NIGMS NIH HHS [R01 GM417S2] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1990, EMBO J, V9, P3691, DOI 10.1002/j.1460-2075.1990.tb07581.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; BONNEAUD N, 1994, J CELL SCI, V107, P913; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOTTLIEB M, 1987, ANAL BIOCHEM, V165, P33, DOI 10.1016/0003-2697(87)90197-7; GUO ZJ, 1995, MOL CELL BIOL, V15, P5983; Guo ZJ, 1996, MOL CELL BIOL, V16, P2772; Harlow E., 1988, ANTIBODIES LAB MANUA; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; JENNY A, 1995, NUCLEIC ACIDS RES, V23, P2629, DOI 10.1093/nar/23.14.2629; Jha PK, 1996, BIOCHEMISTRY-US, V35, P11026, DOI 10.1021/bi960406h; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KESSLER MM, 1995, BIOCHEMISTRY-US, V34, P1750, DOI 10.1021/bi00005a032; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGNER J, 1991, NATURE, V354, P496, DOI 10.1038/354496a0; LINGNER J, 1991, J BIOL CHEM, V266, P8741; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MANLEY JL, 1995, CURR OPIN GENET DEV, V5, P222, DOI 10.1016/0959-437X(95)80012-3; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; RUSSO P, 1993, MOL CELL BIOL, V13, P7836, DOI 10.1128/MCB.13.12.7836; Sambrook J., 2002, MOL CLONING LAB MANU; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1994, NATURE, V372, P471, DOI 10.1038/372471a0; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2; ZHELKOVSKY AM, 1995, J BIOL CHEM, V270, P26715, DOI 10.1074/jbc.270.44.26715	36	79	83	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27167	27175		10.1074/jbc.271.43.27167	http://dx.doi.org/10.1074/jbc.271.43.27167			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900210	hybrid			2022-12-27	WOS:A1996VP23300104
J	Kishi, K; Hayashi, H; Wang, LH; Kamohara, S; Tamaoka, K; Shimizu, T; Ushikubi, F; Narumiya, S; Ebina, Y				Kishi, K; Hayashi, H; Wang, LH; Kamohara, S; Tamaoka, K; Shimizu, T; Ushikubi, F; Narumiya, S; Ebina, Y			G(q)-coupled receptors transmit the signal for GLUT4 translocation via an insulin-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE-TRANSPORTER; ACTIVATING-FACTOR RECEPTOR; GROWTH-FACTOR TRIGGERS; RAT SKELETAL-MUSCLE; MOLECULAR-CLONING; PLASMA-MEMBRANE; PHOSPHOLIPASE-C; G-PROTEINS; FAT-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE	Guanosine 5'-O-(3-thiotriphosphate) (GTP gamma S) induces the translocation of glucose transporter type 4 (GLUT4) from an intracellular pool to the cell surface and increases glucose uptake in adipocytes. The GTP-binding protein(s) responsible for the translocation has remained to be identified. Using a sensitive and quantitative method to assess the translocation of c-MYC epitope tagged GLUT4, we obtained evidence that the activation of receptor-coupled G(q) (neither G(i) nor G(s)) triggered GLUT4 translocation In cells, independently of insulin signaling pathway(s). Platelet-activating factor (PAF) induced GLUT4 translocation in the cells expressing the Gi and G(q)-coupled PAF receptor, but the translocation was induced even after pretreatment with wortmannin, an islet-activating protein and phorbol 12,13-dibutyrate. Norepinephrine triggered GLUT4 translocation in cells expressing the G(q) coupled alpha(1)-adrenergic receptor, but prostaglandin E(2) did not cause GLUT4 translocation in cells expressing the G(s)-coupled EP4 receptor or the G(i)-coupled EP3 alpha receptor. The nor epinephrine-stimulated GLUT4 translocation and glucose uptake via G(q) may possibly contribute to the fuel supply required for thermogenesis in brown adipocytes and for the enhanced contractility in cardiomyocytes, both of which have an abundant endogenous GLUT4.	UNIV TOKUSHIMA,INST ENZYME RES,DEPT ENZYME GENET,TOKUSHIMA 770,JAPAN; AOBA OKA HOSP,TONDABAYASHI,OSAKA 584,JAPAN; UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN	Tokushima University; University of Tokyo; Kyoto University				Hayashi, Hideki/0000-0003-4585-6542; Kamohara, Seika/0000-0002-2482-6611				BALDINI G, 1991, J BIOL CHEM, V266, P4037; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BROZINICK JT, 1994, BIOCHEM J, V297, P539, DOI 10.1042/bj2970539; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; CORMONT M, 1991, ENDOCRINOLOGY, V129, P3343, DOI 10.1210/endo-129-6-3343; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DELISLE RC, 1986, ANNU REV PHYSIOL, V48, P225; Dietze GJ, 1996, DIABETES, V45, pS110, DOI 10.2337/diab.45.1.S110; DOUEN AG, 1990, J BIOL CHEM, V265, P13427; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; Fischer Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1204, DOI 10.1152/ajpcell.1996.270.4.C1204; GARFINKEL D, 1971, COMPUT BIOMED RES, V4, P1, DOI 10.1016/0010-4809(71)90044-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HONDA A, 1993, J BIOL CHEM, V268, P7759; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HORIE K, 1994, EUR J PHARM-MOLEC PH, V268, P399, DOI 10.1016/0922-4106(94)90065-5; ISHII K, 1994, BIOCHEM BIOPH RES CO, V205, P857, DOI 10.1006/bbrc.1994.2743; ISHII K, 1995, BIOCHEM J, V309, P813, DOI 10.1042/bj3090813; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KAMOHARA S, 1995, P NATL ACAD SCI USA, V92, P1077, DOI 10.1073/pnas.92.4.1077; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KANAI F, 1993, J BIOL CHEM, V268, P14523; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MUHLBACHER C, 1988, BIOCHEM J, V249, P865; NAKAMURA M, 1992, FEBS LETT, V314, P125, DOI 10.1016/0014-5793(92)80957-I; NAKAMURA M, 1991, J BIOL CHEM, V266, P20400; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OBERMAIERKUSSER B, 1988, BIOCHEM J, V256, P515, DOI 10.1042/bj2560515; OKADA T, 1994, J BIOL CHEM, V269, P3568; OMATSUKANBE M, 1992, FEBS LETT, V314, P246, DOI 10.1016/0014-5793(92)81481-Z; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUON MJ, 1994, P NATL ACAD SCI USA, V91, P5587, DOI 10.1073/pnas.91.12.5587; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHROER DW, 1986, BIOCHIM BIOPHYS ACTA, V885, P317, DOI 10.1016/0167-4889(86)90247-8; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SHIBATA K, 1995, MOL PHARMACOL, V48, P250; SHIMIZU Y, 1994, BIOCHEM BIOPH RES CO, V202, P660, DOI 10.1006/bbrc.1994.1981; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Todaka M, 1996, BIOCHEM J, V315, P875, DOI 10.1042/bj3150875; VILARO S, 1989, NATURE, V342, P798, DOI 10.1038/342798a0; VOGT B, 1991, BIOCHEM J, V275, P597, DOI 10.1042/bj2750597; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; WU DQ, 1992, J BIOL CHEM, V267, P25798; YEH JI, 1995, J BIOL CHEM, V270, P2107, DOI 10.1074/jbc.270.5.2107	64	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26561	26568		10.1074/jbc.271.43.26561	http://dx.doi.org/10.1074/jbc.271.43.26561			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900127	hybrid			2022-12-27	WOS:A1996VP23300021
J	Liu, J; Shworak, NW; Fritze, LMS; Edelberg, JM; Rosenberg, RD				Liu, J; Shworak, NW; Fritze, LMS; Edelberg, JM; Rosenberg, RD			Purification of heparan sulfate D-glucosaminyl 3-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-BINDING SEQUENCE; ENDOTHELIAL-CELLS; CHONDROITIN 6-SULFOTRANSFERASE; HEPARINLIKE MOLECULES; CULTURE-MEDIUM; HIGH-AFFINITY; BIOSYNTHESIS; SULFOTRANSFERASE; IDENTIFICATION; MASTOCYTOMA	The cellular generation of proteoglycans with anticoagulant heparan sulfate (HSPG(act)) is determined by microsomal ''HSact conversion activity'' that functions in concert with the sulfate doctor 3'-phosphoadenosine 5'phosphosulfate (PAPS) to convert nonanticoagulant heparan sulfate (HSinact) to anticoagulant heparan sulfate (HSact) (Shworak, N. W., Fritze, L. M., S., Liu, J., Butler, L. D., and Rosenberg, R. D. (1996) J. Biol. Chem. 271, 27063-27071), Suspension cultures of L-33(+) cells in serum-free medium produce HSPG(act) and secrete HSact conversion activity, The secreted protein exhibiting HSact conversion activity was isolated by subjecting large volumes of conditioned suspension culture medium to heparin-AF Toyopearl affinity chromatography, Mono Q-FPLC, TSK SW3000-HPLC, and 3',5'-ADP-agarose affinity chromatography. The final product was purified similar to 700,000-fold relative to cellular material with a 5% overall recovery of HSact conversion activity, The isolated protein migrated. on SDS-polyacrylamide gel electrophoresis as a broad band of M(r) = 46,000 and co-migrated on nondenaturing acidic pH gel electrophoresis with HSact conversion activity, The purified component was identified as heparan sulfate D-glucosaminyl 3-O-sulfotransferase because it transferred sulfate from [S-35]PAPS to the 3-O-position of D-glucosamine and D-glucosamine 6-O-sulfate of HSact precursor and HSinact precursor to produce nearly equivalent amounts of labeled HSact and HSinact. The exhaustive modification of wild-type LTA cell [S-35]HS with either microsomal HSact conversion activity or purified enzyme increased HSact content from 9 to similar to 36%, which indicates that microsomal HSact conversion activity predominantly reflects the level of a 3-O-sulfotransferase that converts HSact precursor into HSact, The kinetic parameters of purified 3-O-sulfotransferase were determined for modification of HSact precursor and HSinact precursor, The apparent K*(M)--- and V*(max)---, with respect to PAPS concentration for sulfation of HSact precursor and HSinact precursor were 2.4 mu M and 23 fmol of sulfate/min/ng of enzyme and 2.1 mu M and 38 fmol of sulfate/min/ng of enzyme, respectively, There was substrate inhibition of the sulfation reaction at elevated HS concentration, The apparent K*(M)--- and V*(max)--- with respect to GAG concentration or sulfation of HSact precursor and HSinact precursor were 16 nM and 120 fmol of sulfate/min/ng of enzyme and 17 nM and 240 fmol of sulfate/min/ng of enzyme, respectively The observation that purified 3-O-sulfotransferase catalyzes sulfation of HSact precursor and HSinact precursor in conjunction with a documented discordant regulation of 3-O-sulfate content in HSinact and HSact suggests that two discrete forms of the enzyme may exist.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,BOSTON,MA 02215	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School			Shworak, Nicholas/AAJ-6770-2020	Shworak, Nicholas/0000-0001-7783-4634	NHLBI NIH HHS [HL-41484, HL-33014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041484, P01HL033014] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; ATHA DH, 1984, BIOCHEMISTRY-US, V23, P5801, DOI 10.1021/bi00319a020; ATHA DH, 1987, BIOCHEMISTRY-US, V26, P6454, DOI 10.1021/bi00394a024; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; CHOAY J, 1980, THROMB RES, V18, P573, DOI 10.1016/0049-3848(80)90356-4; CLELAND WW, 1970, ENZYMES, V2, P35; CLEVELAND WL, 1983, J IMMUNOL METHODS, V56, P221; COLLIECJOUAULT S, 1994, J BIOL CHEM, V269, P24953; DAMUS PS, 1973, NATURE, V246, P355, DOI 10.1038/246355a0; DANISHEFSKY I, 1969, J BIOL CHEM, V244, P1741; DELANEY SR, 1980, ANAL BIOCHEM, V100, P253; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HAMILTON W, 1977, IN VITRO, V9, P537; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; KOJIMA T, 1992, J BIOL CHEM, V267, P4859; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; LAM LH, 1976, BIOCHEM BIOPH RES CO, V69, P570, DOI 10.1016/0006-291X(76)90558-1; LEDER IG, 1980, BIOCHEM BIOPH RES CO, V94, P1183, DOI 10.1016/0006-291X(80)90544-6; LIND T, 1993, J BIOL CHEM, V268, P20705; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; MARCUM JA, 1985, BIOCHEM BIOPH RES CO, V126, P365, DOI 10.1016/0006-291X(85)90615-1; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; MARCUM JA, 1986, AM J PHYSIOL, V250, pH879, DOI 10.1152/ajpheart.1986.250.5.H879; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MONTGOMERY RI, 1992, P NATL ACAD SCI USA, V89, P11327, DOI 10.1073/pnas.89.23.11327; MORAWITZ P, 1959, CHEM BLOOD COAGULATI; OOSTA GM, 1981, P NATL ACAD SCI-BIOL, V78, P829, DOI 10.1073/pnas.78.2.829; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; RAZI N, 1995, J BIOL CHEM, V270, P11267, DOI 10.1074/jbc.270.19.11267; ROSENBERG RD, 1979, P NATL ACAD SCI USA, V76, P1218, DOI 10.1073/pnas.76.3.1218; ROSENBERG RD, 1978, P NATL ACAD SCI USA, V75, P3065, DOI 10.1073/pnas.75.7.3065; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Shworak NW, 1996, J BIOL CHEM, V271, P27063, DOI 10.1074/jbc.271.43.27063; STONE AL, 1982, P NATL ACAD SCI-BIOL, V79, P7190, DOI 10.1073/pnas.79.23.7190; SUGUMARAN G, 1995, J BIOL CHEM, V270, P22483, DOI 10.1074/jbc.270.38.22483; WLAD H, 1994, J BIOL CHEM, V269, P24538	47	101	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27072	27082		10.1074/jbc.271.43.27072	http://dx.doi.org/10.1074/jbc.271.43.27072			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900198	hybrid			2022-12-27	WOS:A1996VP23300092
J	Nett, JH; Trumpower, BL				Nett, JH; Trumpower, BL			Dissociation of import of the Rieske iron-sulfur protein into Saccharomyces cerevisiae mitochondria from proteolytic processing of the presequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST MITOCHONDRIA; MUTATIONAL ANALYSIS; COMPLEX; PEPTIDASE; PRECURSOR; CLEAVAGE	The correlation between the import of the Rieske iron-sulfur protein into the mitochondrial matrix and processing of the precursor protein by matrix processing peptidase was investigated using high concentrations of metal chelators and iron sulfur protein in which the recognition site for the matrix processing peptidase was destroyed by site-directed mutagenesis. High concentrations of EDTA and o-phenanthroline inhibit import of iron-sulfur protein into the matrix. The non-chelating structural isomers m-phenanthroline and p-phenan-throline inhibit import similar to o-phenanthroline, indicating that inhibition of import is mainly independent of the metal chelating ability of the compounds. Iron-sulfur protein in which the recognition site for the matrix processing peptidase had been destroyed by a point mutation was efficiently imported into the matrix space. Import of this mutant iron-sulfur protein was inhibited by the same concentrations of EDTA and o-phenanthroline which inhibit import of the wild-type protein. These results indicate that import of the iron-sulfur protein into the mitochondrial matrix is independent of proteolytic processing of the presequence, and that o-phenanthroline together with EDTA inhibits import of iron-sulfur protein into the matrix space of mitochondria by inhibiting a step other than proteolysis of the presequence.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College					NIGMS NIH HHS [GM 20379] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020379, R01GM020379] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRETZ M, 1994, J BIOL CHEM, V269, P4959; FU W, 1991, J BIOL CHEM, V266, P16212; FU W, 1990, J BIOL CHEM, V265, P16541; GRAHAM LA, 1993, J BIOENERG BIOMEMBR, V25, P245, DOI 10.1007/BF00762586; GRAHAM LA, 1991, J BIOL CHEM, V266, P22485; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P631; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HORWICH AL, 1986, CELL, V44, P451, DOI 10.1016/0092-8674(86)90466-6; KALOUSEK F, 1992, EMBO J, V11, P2803, DOI 10.1002/j.1460-2075.1992.tb05347.x; MCADA PC, 1982, J BIOL CHEM, V257, P3177; RAMABADRAN RS, 1992, ARCH BIOCHEM BIOPHYS, V296, P279, DOI 10.1016/0003-9861(92)90573-F; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535	15	12	12	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26713	26716		10.1074/jbc.271.43.26713	http://dx.doi.org/10.1074/jbc.271.43.26713			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900149	hybrid			2022-12-27	WOS:A1996VP23300043
J	Washington, MT; Rosenberg, AH; Griffin, K; Studier, FW; Patel, SS				Washington, MT; Rosenberg, AH; Griffin, K; Studier, FW; Patel, SS			Biochemical analysis of mutant T7 primase/helicase proteins defective in DNA binding, nucleotide hydrolysis, and the coupling of hydrolysis with DNA unwinding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; SINGLE-STRANDED-DNA; COLI RECA PROTEIN; BACTERIOPHAGE-T7 DEOXYRIBONUCLEIC-ACID; PRIMASE-HELICASE PROTEIN; GENE-4 PROTEIN; RNA-POLYMERASE; CLONED GENES; REPLICATION; SEQUENCE	We characterized nine helicase-deficient mutants of bacteriophage T7 helicase-primase protein (4A') prepared by random mutagenesis as reported in the accompanying paper (Rosenberg, A, H., Griffin, K., Washington, A. T., Patel, S. S., and Studier, F. W. (1996) J. Biol. Chem. 271, 26819-26824). Mutants were selected from each of the helicase-conserved motifs for detailed analysis to understand better their function. In agreement with the in vivo results, the mutants were defective in helicase activity but were active in primase function, dTTP hydrolysis, DNA binding, and hexamer formation were examined, Three classes of defective mutants were observed, Group A mutants (E348K, D424N, and S496F), defective in dTTP hydrolysis, lie in motifs 1a, 2, and 4 and are possibly involved in NTP binding/hydrolysis, Group B mutants (R487C and G488D), defective in DNA binding, lie in motif 4 and are responsible directly or indirectly for DNA binding, Group C mutants (G116D, A257T, S345F, and G451E) were not defective in any of the activities except the helicase function, These mutants, scattered throughout the protein, appear defective in coupling dTTPase activity to helicase function, Secondary structural predictions of 4A' and DnaB helicases resemble the known structures of RecA and F-1-ATPase enzymes, Alignment shows a striking correlation in the positions of the amino acids that interact with NTP and DNA.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	University System of Ohio; Ohio State University; United States Department of Energy (DOE); Brookhaven National Laboratory				Washington, Todd/0000-0001-8680-2992				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BERNSTEIN JA, 1988, P NATL ACAD SCI USA, V85, P396, DOI 10.1073/pnas.85.2.396; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DUNN JJ, 1981, J MOL BIOL, V148, P303, DOI 10.1016/0022-2836(81)90178-9; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FULLER CW, 1985, J BIOL CHEM, V260, P3185; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GEOURJON C, 1995, IN PRESS COMP APPL B; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KOLODNER R, 1978, J BIOL CHEM, V253, P566; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MENDELMAN LV, 1991, J BIOL CHEM, V266, P23240; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MIWA Y, 1995, J MOL BIOL, V254, P816; NAKAI H, 1986, J BIOL CHEM, V261, P5208; NAKAI H, 1988, J BIOL CHEM, V263, P9818; NOTARNICOLA SM, 1993, J BIOL CHEM, V268, P27198; NOTARNICOLA SM, 1995, J BIOL CHEM, V270, P20215, DOI 10.1074/jbc.270.34.20215; PATEL SS, 1992, J BIOL CHEM, V267, P15013; PATEL SS, 1993, J BIOL CHEM, V268, P10668; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Pereira S, 1995, J BIOL CHEM, V270, P30401, DOI 10.1074/jbc.270.51.30401; Rosenberg AH, 1996, J BIOL CHEM, V271, P26819, DOI 10.1074/jbc.271.43.26819; ROSENBERG AH, 1992, J BIOL CHEM, V267, P15005; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Sambrook J., 2002, MOL CLONING LAB MANU; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x	42	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26825	26834		10.1074/jbc.271.43.26825	http://dx.doi.org/10.1074/jbc.271.43.26825			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900164	hybrid			2022-12-27	WOS:A1996VP23300058
J	Zimmermann, G; Taussig, R				Zimmermann, G; Taussig, R			Protein kinase C alters the responsiveness of adenylyl cyclases to G protein alpha and beta gamma subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BOVINE BRAIN; RAT-BRAIN; EXPRESSION; STIMULATION; PURIFICATION; INHIBITION; ACTIVATION; CLONING; CELLS	The ability of protein kinase C (PKC) to regulate the responsiveness of adenylyl cyclase to different activators was assessed, Membranes prepared from Sf9 cells infected with recombinant baculoviruses encoding either type II or IV adenylyl cyclase were incubated with recombinant PKC alpha (purified from Sf9 cells), and the effects on adenylyl cyclase activity were measured after reconstitution with G(s alpha), G beta gamma, or forskolin, PKC alpha treatment of type II adenylyl cyclase leads to increases in basal, forskolin-stimulated, and beta gamma-stimulated activities and greater sensitivity to stimulation by G(s alpha). Paradoxically, most of the beta gamma potentiation of G(s alpha)-stimulated activity is eliminated by pretreatment with PKC alpha, By contrast, treatment of type IV adenylyl cyclase with PKC alpha has little effect on the basal, forskolin-stimulated, or beta gamma-stimulated activities but markedly reduces the G(s alpha)-stimulated and beta gamma-potentiated activity of this isoform. These studies demonstrate that protein kinases can alter both the activity of adenylyl cyclase isoforms and their responsiveness to G protein regulation, thereby altering the ability of adenylyl cyclases to integrate signals derived from multiple hormonal inputs.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [5 P60 DK20572-19, P30 DK34933] Funding Source: Medline; NIGMS NIH HHS [GM53645-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, P30DK034933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053645] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GIRARD PR, 1985, P NATL ACAD SCI USA, V82, P3030, DOI 10.1073/pnas.82.9.3030; Gorman R R, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17B, P963; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GUSOVSKY F, 1991, MOL PHARMACOL, V39, P124; HANNUN YA, 1985, J BIOL CHEM, V260, P39; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JACOBOWITZ O, 1993, J BIOL CHEM, V268, P3829; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; LEE E, 1994, METHOD ENZYMOL, V237, P146; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; SUMMERS MD, 1987, TEX AGR EXP STN B, V155, P1; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, METHOD ENZYMOL, V238, P95; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Tsu RC, 1996, J NEUROSCI, V16, P1317; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YEAGER RE, 1985, J NEUROCHEM, V44, P818, DOI 10.1111/j.1471-4159.1985.tb12889.x; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	39	116	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27161	27166		10.1074/jbc.271.43.27161	http://dx.doi.org/10.1074/jbc.271.43.27161			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900209	hybrid			2022-12-27	WOS:A1996VP23300103
J	Li, N; Jiang, XN; Cai, GP; Yang, SF				Li, N; Jiang, XN; Cai, GP; Yang, SF			A novel bifunctional fusion enzyme catalyzing ethylene synthesis via 1-aminocyclopropane 1-carboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCURONIDASE; ESCHERICHIA-COLI; KEY ENZYME; HORMONE ETHYLENE; FORMING ENZYME; HIGHER-PLANTS; GENE FUSION; SYNTHASE; BIOSYNTHESIS; EXPRESSION	A C terminus truncated soybean 1-aminocyclopropane-1-carboxylic acid (ACC) synthase (466 aa) was fused to an N terminus truncated tomato ACC oxidase (312 aa) to create a 778-amino acid fusion polypeptide, This ACC synthase-ACC oxidase fusion enzyme (ACSO) was expressed in a heterologous prokaryotic Escherichia coli system, which is capable of converting endogenous S-adenosyl-L-methionine (AdoMet) to ethylene, The molecular weight of the fusion enzyme, ACSO, as determined by sodium dodecyl sulfate-polyacryl amide gel electrophoresis, was 90 +/- 3 kDa. Gel filtration analysis indicates that the native ACSO is oligomeric and is capable of converting exogenously supplied AdoMet to ethylene, The ethylene production rate of ACSO fusion enzyme was determined to be 6.0 nmol h(-1) mg(-1) under our assaying conditions using the partially purified enzyme extract, In the enzyme reaction mixture, an increase in ethylene production catalyzed by the bifunctional ACSO was accompanied by a decrease in ACC accumulation. Similarly, in E. coli cells, the level of ACC, produced as an intermediate during the sequential reactions from AdoMet to ethylene, was also found to arise earlier than that of ethylene, Because ACSO could produce ethylene from the ubiquitous AdoMet in living cell and the method commonly used to measure gaseous ethylene is simple, fast, and sensitive, we anticipate this bifunctional fusion enzyme to be useful as a reporter and for research in molecular biology, developmental biology, fermentation, and genetic engineering.			Li, N (corresponding author), HONG KONG UNIV SCI & TECHNOL, DEPT BIOL, CLEAR WATER BAY, HONG KONG, HONG KONG.							Abeles F, 1992, ETHYLENE PLANT BIOL; ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; BOLLER T, 1979, PLANTA, V145, P293, DOI 10.1007/BF00454455; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULOW L, 1991, TRENDS BIOTECHNOL, V9, P226, DOI 10.1016/0167-7799(91)90075-S; CHAMPE SP, 1962, J MOL BIOL, V4, P288, DOI 10.1016/S0022-2836(62)80006-0; DATLA RSS, 1991, GENE, V101, P239, DOI 10.1016/0378-1119(91)90417-A; DONG JG, 1992, P NATL ACAD SCI USA, V89, P9789, DOI 10.1073/pnas.89.20.9789; ELMAYAN T, 1994, PLANT J, V6, P433, DOI 10.1046/j.1365-313X.1994.06030433.x; HAMILTON AJ, 1991, P NATL ACAD SCI USA, V88, P7434, DOI 10.1073/pnas.88.16.7434; HAMILTON AJ, 1990, NATURE, V346, P284, DOI 10.1038/346284a0; HOHENESTER E, 1994, J MOL BIOL, V243, P947, DOI 10.1006/jmbi.1994.1695; JEFFERSON RA, 1987, EMBO J, V6, P3901; KENDE H, 1993, ANNU REV PLANT PHYS, V44, P283, DOI 10.1146/annurev.pp.44.060193.001435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li N, 1996, FEBS LETT, V378, P286, DOI 10.1016/0014-5793(95)01464-0; LI N, 1992, FEBS LETT, V306, P103, DOI 10.1016/0014-5793(92)80978-P; LI N, 1994, J BIOL CHEM, V269, P6908; LIEBERMAN M, 1979, ANNU REV PLANT PHYS, V30, P533, DOI 10.1146/annurev.pp.30.060179.002533; LIU DR, 1993, PLANT CELL PHYSIOL, V34, P1151; LIZADA MCC, 1979, ANAL BIOCHEM, V100, P140, DOI 10.1016/0003-2697(79)90123-4; MAYNARD JA, 1963, AUST J CHEM, V16, P596, DOI 10.1071/CH9630596; NAKAJIMA N, 1990, PLANT CELL PHYSIOL, V31, P1021; OWENS LD, 1971, PLANT PHYSIOL, V48, P1, DOI 10.1104/pp.48.1.1; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; SATO T, 1989, P NATL ACAD SCI USA, V86, P6621, DOI 10.1073/pnas.86.17.6621; SATOH S, 1993, PLANT CELL PHYSIOL, V34, P753, DOI 10.1093/oxfordjournals.pcp.a078479; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; SMITH MC, 1988, J BIOL CHEM, V263, P7211; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VAN DER STRAETEN D, 1990, P NATL ACAD SCI USA, V87, P4859, DOI 10.1073/pnas.87.12.4859; VERVERIDIS P, 1991, PHYTOCHEMISTRY, V30, P725, DOI 10.1016/0031-9422(91)85241-Q; WHITE MF, 1994, P NATL ACAD SCI USA, V91, P12428, DOI 10.1073/pnas.91.26.12428; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YANG SF, 1984, ANNU REV PLANT PHYS, V35, P155, DOI 10.1146/annurev.pp.35.060184.001103; YIP WK, 1991, PLANT PHYSIOL, V95, P251, DOI 10.1104/pp.95.1.251; YU YB, 1979, ARCH BIOCHEM BIOPHYS, V198, P280, DOI 10.1016/0003-9861(79)90420-X; ZHANG ZH, 1995, BIOCHEM J, V307, P77, DOI 10.1042/bj3070077	38	18	19	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25738	25741		10.1074/jbc.271.42.25738	http://dx.doi.org/10.1074/jbc.271.42.25738			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824199	hybrid			2022-12-27	WOS:A1996VN18000005
J	Schultz, TF; Spiker, S; Quatrano, RS				Schultz, TF; Spiker, S; Quatrano, RS			Histone H1 enhances the DNA binding activity of the transcription factor EmBP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSCISIC-ACID; RESPONSE ELEMENTS; RECEPTOR-BINDING; PROTEIN; WHEAT; GENE; IDENTIFICATION; RECOGNIZES; SEQUENCES; PROMOTER	Previous work indicated that nuclear extracts isolated from embryogenic rice suspension cells treated with the phytohormone abscisic acid (ABA) have enhanced binding activity to an ABA response element (Emla) in the promoter of the Em gene from wheat, We identified an activity in wheat and maize nuclear extracts that enhances binding of the recombinant transcription factor EmBP-1 to Emla by 80-fold. Fractionation of nuclear extracts led us to identify histone H1 and HMGb (but not HMGc or -d) as two factors that can enhance the ability of EmBP-1 to bind to Emla and account for at least a part of this activity of nuclear extracts. Our results, which indicate for the first time that histone ill possesses this type of activity, lend further support to the model that positively charged proteins can drastically affect the DNA binding activity of specific transcription factors. Furthermore, our study points to these chromosomal proteins as potential targets of an ABA-mediated modification (e.g. acetylation) that could affect the regulation of Em gene expression.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; N CAROLINA STATE UNIV,DEPT GENET,RALEIGH,NC 27695	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University				Schultz, Thomas/0000-0001-9694-9920	NIGMS NIH HHS [GM44288] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; CAVANAUGH AH, 1990, BIOCHEMISTRY-US, V29, P989, DOI 10.1021/bi00456a022; CROTHERS DM, 1994, SCIENCE, V266, P1819, DOI 10.1126/science.7997876; FINKELSTEIN RR, 1993, MOL GEN GENET, V238, P401, DOI 10.1007/BF00291999; GRANELLIPIPERNO A, 1991, P NATL ACAD SCI USA, V88, P11431, DOI 10.1073/pnas.88.24.11431; GRASSER KD, 1994, PLANT J, V6, P351, DOI 10.1046/j.1365-313X.1994.06030351.x; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GUILTINAN MJ, 1990, SCIENCE, V250, P267, DOI 10.1126/science.2145628; Hill A, 1996, J BIOL CHEM, V271, P3366, DOI 10.1074/jbc.271.7.3366; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; MARCOTTE WR, 1988, NATURE, V335, P454, DOI 10.1038/335454a0; MARCOTTE WR, 1989, PLANT CELL, V1, P969, DOI 10.2307/3868997; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; ONATE SA, 1994, MOL CELL BIOL, V14, P3376, DOI 10.1128/MCB.14.5.3376; SPIKER S, 1982, J BIOL CHEM, V257, P4250; SPIKER S, 1984, J BIOL CHEM, V259, P2007; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZLATANOVA J, 1991, DNA CELL BIOL, V10, P239, DOI 10.1089/dna.1991.10.239	24	45	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25742	25745		10.1074/jbc.271.42.25742	http://dx.doi.org/10.1074/jbc.271.42.25742			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824200	hybrid, Green Published			2022-12-27	WOS:A1996VN18000006
J	AratoOshima, T; Matsui, H; Wakizaka, A; Homareda, H				AratoOshima, T; Matsui, H; Wakizaka, A; Homareda, H			Mechanism responsible for oligomycin-induced occlusion of Na+ within Na/K-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; NA,K-ATPASE ALPHA-SUBUNIT; POTASSIUM-IONS; ADENOSINE-TRIPHOSPHATASE; SODIUM-PUMP; BETA-SUBUNIT; BOUND FORMS; NA+,K+-ATPASE; K+; TRANSPORT	The mechanism whereby oligomycin occludes Na+ within Na/K-ATPase was investigated to study Na+ and K+ transport mechanisms. Oligomycin stimulated Na+ binding to Na/K-ATPase but inhibited Na-H and Na-Na exchange. The oligomycin concentration required to stimulate Na+ binding to half-maximal was 4.5 mu M, which was close to the concentration that reduced Na-Na and Na-K exchange and ATPase activity to half-maximal, suggesting that Na/K-ATPase possesses an oligomycin binding site responsible for stimulating Na+ binding and reducing ion exchange and ATPase activity. In contrast, neither K+ binding nor K+ transport was affected by oligomycin. Limited tryptic digestion of Na/K-ATPase showed that, unlike Na+, K+, and ouabain, oligomycin treatment did not result in a specific digestion pattern. Oligomycin appeared to inhibit ouabain binding in a noncompetitive manner, whereas it did not affect ATP binding. Na/K-ATPase isoforms with low and high sensitivities to ouabain were equally sensitive to oligomycin. These results suggest that the oligomycin binding site is located on the extracellular side of Na/K-ATPase, at a different position from the ouabain binding site, and this antibiotic did not induce a conformational change of Na/K-ATPase. We propose that oligomycin interacts with the Na+ occlusion site from the extracellular side of Na/K-ATPase, which delays Na+ release to the extracellular side without inducing a conformational change, suggesting that the pathways responsible for Na+ and K+ transport differ.	KYORIN UNIV, SCH MED, DEPT BIOCHEM 2, MITAKA, TOKYO 181, JAPAN; KYORIN UNIV, SCH MED, DEPT BIOCHEM 1, MITAKA, TOKYO 181, JAPAN	Kyorin University; Kyorin University								ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ASKARI A, 1968, BIOCHEM BIOPH RES CO, V32, P227, DOI 10.1016/0006-291X(68)90373-2; BLOSTEIN R, 1970, J BIOL CHEM, V245, P270; CHANDLER HD, 1978, BIOCHEM J, V169, P559, DOI 10.1042/bj1690559; CORNELIUS F, 1985, BIOCHIM BIOPHYS ACTA, V818, P211, DOI 10.1016/0005-2736(85)90572-3; ESMANN M, 1991, BIOCHIM BIOPHYS ACTA, V1064, P31, DOI 10.1016/0005-2736(91)90408-Z; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; FAHN S, 1966, J BIOL CHEM, V241, P1882; FAHN S, 1968, J BIOL CHEM, V243, P1993; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORTES PAG, 1984, J BIOL CHEM, V259, P1176; GARRAHAN PJ, 1967, J PHYSIOL-LONDON, V192, P217, DOI 10.1113/jphysiol.1967.sp008297; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; HALPERIN JA, 1991, BIOCHIM BIOPHYS ACTA, V1070, P497, DOI 10.1016/0005-2736(91)90092-M; HAYASHI Y, 1977, BIOCHIM BIOPHYS ACTA, V482, P185, DOI 10.1016/0005-2744(77)90365-5; HEGYVARY C, 1976, BIOCHIM BIOPHYS ACTA, V422, P365, DOI 10.1016/0005-2744(76)90148-0; HOMAREDA H, 1982, J BIOCHEM, V92, P219, DOI 10.1093/oxfordjournals.jbchem.a133917; HOMAREDA H, 1991, J BIOCHEM-TOKYO, V109, P70; INTURRISI CE, 1968, MOL PHARMACOL, V4, P591; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; ISHII T, 1995, SEIKAGAKU, V67, P816; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; JORGENSEN PL, 1986, BIOCHIM BIOPHYS ACTA, V139, P450; KAPLAN JH, 1991, SOC GEN PHY, V46, P117; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V525, P252, DOI 10.1016/0005-2744(78)90219-X; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN WH, 1994, P NATL ACAD SCI USA, V91, P9881, DOI 10.1073/pnas.91.21.9881; MATSUI H, 1982, J BIOCHEM-TOKYO, V92, P193, DOI 10.1093/oxfordjournals.jbchem.a133916; MATSUI H, 1988, METHOD ENZYMOL, V156, P29; NAGAMATSU S, 1986, ACTA ENDOCRINOL-COP, V111, P69, DOI 10.1530/acta.0.1110069; NOGUCHI S, 1990, J BIOL CHEM, V265, P15991; POST RL, 1979, CATION FLUX BIOMEMBR, P3; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; ROBINSON JD, 1971, MOL PHARMACOL, V7, P238; SACHS JR, 1980, J PHYSIOL-LONDON, V302, P219; SCHWARTZ A, 1975, PHARMACOL REV, V27, P3; SIMONS TJB, 1974, J PHYSIOL-LONDON, V237, P123, DOI 10.1113/jphysiol.1974.sp010474; SKOU JC, 1980, BIOCHIM BIOPHYS ACTA, V601, P386, DOI 10.1016/0005-2736(80)90543-X; TANIGUCHI K, 1975, J BIOL CHEM, V250, P3010; TANIGUCHI K, 1991, J BIOCHEM-TOKYO, V109, P299; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; von Glehn M, 1972, FEBS Lett, V20, P267, DOI 10.1016/0014-5793(72)80083-8; WHITTAM R, 1964, NATURE, V203, P720, DOI 10.1038/203720a0; YODA A, 1982, MOL PHARMACOL, V22, P693	52	25	25	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25604	25610						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810335				2022-12-27	WOS:A1996VL69300079
J	Panariello, L; Quadro, L; Trematerra, S; Colantuoni, V				Panariello, L; Quadro, L; Trematerra, S; Colantuoni, V			Identification of a novel retinoic acid response element in the promoter region of the retinol-binding protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE; TRANSCRIPTIONAL REGULATION; VITAMIN-A; SIGNALING PATHWAYS; LIGAND SENSITIVITY; NUCLEAR RECEPTOR; DIRECT REPEATS; CELL LINES; RXR-BETA; EXPRESSION	We have previously demonstrated that the retinol-binding protein (REP) gene is induced by retinoids in hepatoma cells. In this report, we define in greater detail the region that mediates the retinoic acid response of the gene. It consists of two degenerate retinoic acid response elements, separated by 30 nucleotides that encompass a GC-rich Sp1 consensus-like sequence. We demonstrate that the entire region, as well as each element taken singly, can bind the retinoic acid receptors as homo- and heterodimers with low affinity. However, only the entire region is able to confer retinoic acid inducibility to a heterologous promoter. We also show that the correct phasing of the DNA segment is necessary to achieve full responsiveness. Site-directed mutants in each element retained partial induction after transfection, while the double mutant was no longer responsive, suggesting that the two elements act synergistically. Mutational analysis of the Spl binding site and cotransfection experiments revealed that Spl or a related protein plays an important role in the transcription of the gene. Thus, the retinoic acid induction of the REP gene is mediated by a novel and complex responsive unit formed by two distinct elements located in a specific sequence context and the interplay of the retinoid receptors with Spl is required for induction.	UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOCHIM & BIOTECNOL MED,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC FARM,I-88100 CATANZARO,ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria								ADAN RAH, 1993, MOL ENDOCRINOL, V7, P47, DOI 10.1210/me.7.1.47; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENSHUSHAN E, 1995, MOL CELL BIOL, V15, P1034; BLOMHOFF R, 1992, ANNU REV NUTR, V12, P37, DOI 10.1146/annurev.nu.12.070192.000345; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; COLANTUONI V, 1987, EMBO J, V6, P631, DOI 10.1002/j.1460-2075.1987.tb04801.x; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1989, EMBO J, V8, P429, DOI 10.1002/j.1460-2075.1989.tb03394.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIXON JL, 1987, J CELL PHYSIOL, V130, P14, DOI 10.1002/jcp.1041300104; DONOFRIO C, 1985, EMBO J, V4, P1981, DOI 10.1002/j.1460-2075.1985.tb03881.x; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; DYAN WS, 1983, CELL, V35, P79; FLINK IL, 1990, J BIOL CHEM, V265, P11233; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Higuchi R., 1989, PCR TECHNOLOGY, P61; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEHMANN JM, 1992, MOL CELL BIOL, V12, P2976, DOI 10.1128/MCB.12.7.2976; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUCAS PC, 1991, P NATL ACAD SCI USA, V88, P2184, DOI 10.1073/pnas.88.6.2184; MAJELLO B, 1995, ONCOGENE, V10, P1841; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARINARI L, 1987, J LIPID RES, V28, P941; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MOUREY MS, 1994, J CELL PHYSIOL, V160, P596, DOI 10.1002/jcp.1041600323; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; PIKARSKY E, 1994, MOL CELL BIOL, V14, P1026, DOI 10.1128/MCB.14.2.1026; RONNE H, 1983, J CELL BIOL, V96, P907, DOI 10.1083/jcb.96.3.907; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHOORLEMMER J, 1994, MOL CELL BIOL, V14, P1122, DOI 10.1128/MCB.14.2.1122; SCHRADER M, 1995, MOL CELL BIOL, V15, P1154; SCHRADER M, 1994, NATURE, V370, P382, DOI 10.1038/370382a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SMITH JE, 1978, CELL, V15, P865, DOI 10.1016/0092-8674(78)90271-4; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; Soprano Dianne Robert, 1994, P257; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	56	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25524	25532		10.1074/jbc.271.41.25524	http://dx.doi.org/10.1074/jbc.271.41.25524			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810324	hybrid			2022-12-27	WOS:A1996VL69300068
J	Chandrasekaran, C; Coopersmith, CM; Gordon, JI				Chandrasekaran, C; Coopersmith, CM; Gordon, JI			Use of normal and transgenic mice to examine the relationship between terminal differentiation of intestinal epithelial cells and accumulation of their cell cycle regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SMALL INTESTINE; RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN-DIPLOID FIBROBLASTS; SV40 T-ANTIGEN; G(1) CYCLINS; IN-VIVO; S-PHASE; PROTEIN; EXPRESSION; DNA	A spatially well organized continuum of proliferation, differentiation, and death is displayed along crypt-villus units in the adult mouse small intestine, This continuum provides an opportunity to examine in vivo the mechanisms by which proliferative status changes as a function of cellular differentiation. Immunohistochemical studies of normal FVB/N mice revealed that as epithelial cells complete their terminal differentiation during a 48-72-h migration up villi, there is a marked and rapid fall in the levels of two important regulators of the G(1)/S transition, cyclin D-1 and cyclin-dependent kinase (cdk) 2, However, cellular levels of their partners, cdk4 and cyclin E, remain unchanged as does the level of pRB, Adult FVB/N transgenic mice were studied that contained an intestinal fatty acid binding protein gene promoter (Fabpi) linked to wild type Simian virus 40 large T antigen (SV40 TAgWt) or a mutant TAg with Lys for Glu substitutions at residues 107 and 108 (SV40 TAgK107/8) that fails to bind pRB and related pocket proteins, Both transgenes are expressed only in villus enterocytes, SV40 TAgWt causes these terminally differentiated cells to re-enter the cycle, Re-entry is accompanied by a reduction in un/hypophosphorylated pRB, an induction of cyclin D-1 and cdk2, but no change in cdk4, cyclin E, or E2F-1. In contrast, SV40 TAgK107/8 fails to induce reentry and does not produce changes in un/hypophosphorylated pRB, cyclin D-1, or cdk2 accumulation, These results suggest that un/hypophosphorylated pRB is an important mediator of the cell cycle arrest that normally occurs as enterocytes exit the crypt and complete their differentiation. Fabpi-directed expression of E2F-1 does not cause villus enterocytes to return to the cell cycle, alter their suppression of cyclin D-1 or cdk2, or affect their state of differentiation emphasizing the insensitivity of these cells to the effects of E2F-1, Analyses of p53(-/-) and p58(+/+) mice containing Fabpi-SV40 TAgWt and Fabpi-SV40 TAgK107/8 established that the proliferation induced by SV40 TAgWt does not require p53 and is associated with increased (p53-independent) apoptosis, The presence of cyclin E and cdk4 in differentiating villus enterocytes emphasizes that these cells retain part of their proliferative heritage expressed 24-72 h earlier in the crypt, The data suggest that down-regulation of cdk2 and/or cyclin D-1 expression may be important for control of proliferative status and/or execution of terminal differentiation.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT SURG,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NIDDK NIH HHS [DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030292, R37DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BATES S, 1994, ONCOGENE, V9, P1633; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRY L, 1994, P NATL ACAD SCI USA, V91, P10335, DOI 10.1073/pnas.91.22.10335; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CHENG H, 1974, AM J ANAT, V141, P481, DOI 10.1002/aja.1001410404; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; CHENG H, 1974, AM J ANAT, V141, P521, DOI 10.1002/aja.1001410406; COHN SM, 1984, J BIOL CHEM, V259, P2456; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; COOPER JA, 1989, CELL, V58, P1009, DOI 10.1016/0092-8674(89)90495-9; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Fromm L, 1996, ONCOGENE, V12, P69; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HAGEMANN RF, 1970, AM J ANAT, V129, P41, DOI 10.1002/aja.1001290104; HALL PA, 1994, J CELL SCI, V107, P3569; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAUFT SM, 1992, J CELL BIOL, V117, P825, DOI 10.1083/jcb.117.4.825; Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HOGAN B, 1986, MANIPULATING MOUSE E; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KIM SH, 1993, J CELL BIOL, V123, P877, DOI 10.1083/jcb.123.4.877; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, TRENDS BIOL SCI, V19, P443; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; MITTNACHT S, 1994, EMBO J, V13, P118, DOI 10.1002/j.1460-2075.1994.tb06241.x; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; Sambrook J., 2002, MOL CLONING LAB MANU; SEEBURG PH, 1982, DNA-J MOLEC CELL BIO, V1, P239, DOI 10.1089/dna.1.1982.1.239; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; WICE BM, 1992, J CELL BIOL, V116, P405, DOI 10.1083/jcb.116.2.405; WIMAN KG, 1993, FASEB J, V7, P841, DOI 10.1096/fasebj.7.10.8393817; WRIGHT NA, 1982, P NATL ACAD SCI USA, V91, P3602; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	70	67	70	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28414	28421		10.1074/jbc.271.45.28414	http://dx.doi.org/10.1074/jbc.271.45.28414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910466	hybrid			2022-12-27	WOS:A1996VU03300066
J	ElMezgueldi, M; Marston, SB				ElMezgueldi, M; Marston, SB			The effects of smooth muscle calponin on the strong and weak myosin binding sites of F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITRO MOTILITY ANALYSIS; ATPASE ACTIVITY; TROPONIN-TROPOMYOSIN; HEAVY-MEROMYOSIN; SKELETAL-MUSCLE; IN-VITRO; ACTOMYOSIN MGATPASE; THIN-FILAMENTS; CALDESMON; INHIBITION	We have investigated the mechanism of inhibition of the actomyosin MgATPase by the smooth muscle protein calponin. We have shown previously the specific interaction of calponin with Glu(334) of actin (EL-Mezgueldi, M., Fattoum, A., Derancourt, J., and Hassab, R. (1992) J. Biol. Chem. 267, 15943-15951). This residue is within the sequence 332-334, which has been proposed to be an important part of the strong myosin binding site (Rayment, L., Holden, H. M., Whittaker, M., Yohn, C. B., Lorenz, M., Holmes, K. C., and Milligan, R. A. (1993) Science 261, 58-65), Therefore, we suggested that calponin will affect the strong binding actin-myosin interaction, To test this hypothesis we have investigated the effect of calponin on the strong binding of S-1 . MgAMP-PNP (5'-adenylyl imidodiphosphate) and on the weak binding of S-1 . MgADP . P-i to actin, We found that an inhibitory concentration of calponin decreased the binding of S-1 . MgAMP-PNP to actin but had no effect on the binding of S-1 . MgADP . P-i. Similar results were obtained with skeletal muscle and smooth muscle S-1. In competition experiments calponin was found to displace S-1 . MgAMP-PNP and S-1 . MgADP but not S-1 . MgADP . P-i from the actin filament, S-1 displaced calponin from actin in the rigor state, in the presence of MgADP, and in the presence of MgAMP-PNP. We conclude that calponin inhibits the actin activated S-1 ATPase by blocking a strong S-1 binding site on actin and does not block the weak binding site.			ElMezgueldi, M (corresponding author), NATL HEART & LUNG INST,UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SCH MED,DEPT CARDIAC MED,LONDON SW3 6LY,ENGLAND.			Marston, Steven/0000-0001-6054-6070	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; BARANY M, 1991, BIOCH SMOOTH MUSCLE, P321; BERTRAND R, 1989, EUR J BIOCHEM, V181, P747, DOI 10.1111/j.1432-1033.1989.tb14787.x; BONETKERRACHE A, 1995, BIOCHEM BIOPH RES CO, V206, P127, DOI 10.1006/bbrc.1995.1018; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; ELMEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; ELMEZGUELDI M, 1996, BIOCHEMISTRY-US, V35, P365; ELMEZGUELDI M, 1995, J BIOL CHEM, V270, P8867; FRASER IDC, 1995, J BIOL CHEM, V270, P19688, DOI 10.1074/jbc.270.34.19688; FRASER IDC, 1995, J BIOL CHEM, V270, P7836, DOI 10.1074/jbc.270.14.7836; GREENE L, 1982, J BIOL CHEM, V257, P3993; GREENE LE, 1983, BIOCHEMISTRY-US, V22, P530, DOI 10.1021/bi00272a002; HOLMES KC, 1995, BIOPHYS J, V68, pS2; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; JAWOROWSKI A, 1995, FEBS LETT, V365, P167, DOI 10.1016/0014-5793(95)00451-E; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KING RT, 1985, BIOCHEMISTRY-US, V24, P7009, DOI 10.1021/bi00345a039; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; LASH JA, 1986, J BIOL CHEM, V261, P6155; LU FWM, 1995, BIOCHEMISTRY-US, V34, P11864, DOI 10.1021/bi00037a026; Mabuchi K, 1996, J MUSCLE RES CELL M, V17, P243, DOI 10.1007/BF00124246; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON S, 1975, BIOCHEMISTRY-US, V14, P3868, DOI 10.1021/bi00688a021; MARSTON S, 1995, INT J BIOCHEM CELL B, V27, P97, DOI 10.1016/1357-2725(94)00080-U; MARSTON SB, 1991, FEBS LETT, V292, P179, DOI 10.1016/0014-5793(91)80862-W; MARSTON SB, 1994, J BIOL CHEM, V269, P32104; MARSTON SB, 1992, J BIOL CHEM, V267, P16796; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1993, J BIOL CHEM, V268, P12317; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MARSTON SB, 1976, J MOL BIOL, V104, P263, DOI 10.1016/0022-2836(76)90012-7; MIKI M, 1992, BIOCHEM BIOPH RES CO, V187, P867, DOI 10.1016/0006-291X(92)91277-W; Milligan RA, 1996, P NATL ACAD SCI USA, V93, P21, DOI 10.1073/pnas.93.1.21; NORTH AJ, 1994, J CELL SCI, V107, P437; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SCHWYTER D, 1989, BIOCHEMISTRY-US, V28, P5889, DOI 10.1021/bi00440a027; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; Straub F.B., 1942, STUDIES I MED CHEM U, P3; SZYMANSKI PT, 1993, FEBS LETT, V331, P256, DOI 10.1016/0014-5793(93)80348-X; TAKAHASHI K, 1988, HYPERTENSION, V11, P620, DOI 10.1161/01.HYP.11.6.620; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WILLS FL, 1993, BIOCHEMISTRY-US, V32, P2321, DOI 10.1021/bi00060a025; WILLS FL, 1994, BIOCHEMISTRY-US, V33, P5562, DOI 10.1021/bi00184a027; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1992, JPN J PHARMACOL, V58, pP29; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	52	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28161	28167		10.1074/jbc.271.45.28161	http://dx.doi.org/10.1074/jbc.271.45.28161			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910431	hybrid			2022-12-27	WOS:A1996VU03300031
J	Nicholson, AC; Nachman, RL; Altieri, DC; Summers, BD; Ruf, W; Edgington, TS; Hajjar, DP				Nicholson, AC; Nachman, RL; Altieri, DC; Summers, BD; Ruf, W; Edgington, TS; Hajjar, DP			Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VEIN ENDOTHELIAL-CELLS; TISSUE-PLASMINOGEN ACTIVATOR; SMOOTH-MUSCLE; FACTOR-VA; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; COS-1 CELLS; FACTOR VIIA; ANNEXIN-II; THROMBIN	The binding and assembly of the coagulation proteases on the endothelial cell surface are important steps not only in the generation of thrombin and thrombogenesis, but also in vascular cell signaling. Effector cell protease receptor (EPR-1) was identified as a novel leukocyte cell surface receptor recognizing the coagulation serine protease Factor Xa but not the precursor Factor X. We now demonstrate that EPR-1 is expressed on vascular endothelial cells and smooth muscle cells. Northern blots of endothelial and smooth muscle cells demonstrated three abundant mRNA bands of 3.0, 1.8, and 1.3 kDa. I-125-Labeled Factor Xa bound to endothelial cells in a dose-dependent saturable manner, and the binding was inhibited by antibody to EPR-1. No specific binding was observed with a recombinant mutant Factor X in which the activation site was substituted by Arg(196) --> Gln to prevent the proteolytic conversion to Xa. EPR-1 was identified immunohistochemically on microvascular endothelial and smooth muscle cells. Functionally, exposure of smooth muscle cells or endothelial cells to Factor Xa induced a 3-fold and a 8-fold increase in [H-3]thymidine uptake, respectively. However, receptor occupancy alone is insufficient for mitogenic signaling because the active site of the enzyme is required for mitogenesis. Thus, EPR-1 represents a site of specific protease-receptor complex assembly, which during local initiation of the coagulation cascade could mediate cellular signaling and responses of the vessel wall.	CORNELL UNIV, COLL MED, DEPT BIOCHEM A626, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT PATHOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA	Cornell University; Cornell University; Cornell University; Scripps Research Institute; Yale University					NHLBI NIH HHS [HL 46403, HL-18828, HL-43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773, P50HL018828, P01HL046403] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1988, P NATL ACAD SCI USA, V85, P7462, DOI 10.1073/pnas.85.20.7462; Ambrosini G, 1996, J BIOL CHEM, V271, P1243, DOI 10.1074/jbc.271.2.1243; ANNAMALAI AE, 1986, ARTERIOSCLEROSIS, V6, P196, DOI 10.1161/01.ATV.6.2.196; BARSHAVIT R, 1983, SCIENCE, V220, P728, DOI 10.1126/science.6836310; BOUCHARD B, 1995, BLOOD S, V86, P450; CERVENY TJ, 1984, BLOOD, V63, P1467; CESARMAN GM, 1994, J BIOL CHEM, V269, P21198; CHEN LB, 1976, EXP CELL RES, V101, P41, DOI 10.1016/0014-4827(76)90409-2; CHEN LB, 1975, P NATL ACAD SCI USA, V72, P131, DOI 10.1073/pnas.72.1.131; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DOI T, 1993, J BIOL CHEM, V268, P2126; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAIR DS, 1979, J CLIN INVEST, V64, P884, DOI 10.1172/JCI109554; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; HAJJAR KA, 1994, J BIOL CHEM, V269, P21191; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MARMUR JD, 1993, J CLIN INVEST, V91, P2253, DOI 10.1172/JCI116452; MARUYAMA I, 1984, J CLIN INVEST, V74, P224, DOI 10.1172/JCI111405; MESSIER TL, 1991, GENE, V99, P291, DOI 10.1016/0378-1119(91)90141-W; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MULLER WA, 1992, J EXP MED, V175, P1401, DOI 10.1084/jem.175.5.1401; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; RODGERS GM, 1985, BIOCHIM BIOPHYS ACTA, V844, P320, DOI 10.1016/0167-4889(85)90133-8; ROTTINGEN JA, 1995, J BIOL CHEM, V270, P4650, DOI 10.1074/jbc.270.9.4650; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1991, THROMB HAEMOSTASIS, V66, P529; RUF W, 1991, J BIOL CHEM, V266, P2158; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SAKAI T, 1990, J BIOL CHEM, V265, P9105; STERN DM, 1984, J CLIN INVEST, V74, P1910, DOI 10.1172/JCI111611; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUGO T, 1995, J BIOCHEM-TOKYO, V117, P244, DOI 10.1093/jb/117.2.244; TRACY PB, 1992, METHOD ENZYMOL, V215, P329; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V	46	76	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28407	28413		10.1074/jbc.271.45.28407	http://dx.doi.org/10.1074/jbc.271.45.28407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910465	hybrid			2022-12-27	WOS:A1996VU03300065
J	Tang, WM; Wo, YYP; Stewart, J; Hawkins, AL; Griffin, CA; Sutter, TR; Greenlee, WF				Tang, WM; Wo, YYP; Stewart, J; Hawkins, AL; Griffin, CA; Sutter, TR; Greenlee, WF			Isolation and characterization of the human cytochrome p450 CYP1B1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AROMATIC HYDROCARBON METABOLISM; PHENOL-CHLOROFORM EXTRACTION; DIOXIN-RESPONSIVE ENHANCER; PROTEIN-DNA INTERACTIONS; SINGLE-STEP METHOD; AH-RECEPTOR; MESSENGER-RNA; ADRENAL CYTOCHROME-P450; INSITU HYBRIDIZATION; RAT CYP1B1	Previously, we identified a novel human cytochrome P450 cDNA that is inducible by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and represents the first member of a new subfamily designated cytochrome P4501B1 (CYP1B1; Sutter, T. R.,, Tang, Y. M., Hayes, C. L., Wo, Y. P., Jabs, E. W., Li, X., Yin, H., Cody, C. W., and Greenlee, W. F. (1994) J. Biol. Chem 269, 13092-13099). Here, we report on the isolation and initial characterization of the CYP1B1 gene. The CYP1B1 gene maps to human chromosome 2 at 2p21-22 and contains three exons and two introns. The putative open reading frame starts in the second exon and is 1629 base pairs in length. Southern analysis using DNA probes directed to each of the three exons confirmed that CYP1B1 is a single copy gene, Human CYP1B1 differs from its two most closely related members of the cytochrome P450 superfamily, CYP1A1 and CYP1A2, in the number of exons (3 versus 7) and chromosome location (2 versus 15). A single transcription initiation site was identified by primer extension analysis and S1 nuclease mapping, Based on nucleotide sequence analysis, the CYP1B1 gene lacks a consensus TATA box in the promoter region and contains nine TCDD-responsive enhancer core binding motifs (5'-GCGTG-3') located within a 2,5-kilobase pair genomic fragment 5'-ward of the transcription initiation start site, Deletion analysis of chloramphenicol acetyltransferase reporter gene constructs containing 5' CYP1B1 genomic fragments indicates that a region from -1022 to -835 containing three of the nine core binding moths contributes to the TCDD-inducible expression of CYP1B1.	UNIV MASSACHUSETTS,MED CTR,DEPT PHARMACOL & MOL TOXICOL,WORCESTER,MA 01655; PURDUE UNIV,DEPT PHARMACOL & TOXICOL,W LAFAYETTE,IN 47907; JOHNS HOPKINS MED INST,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT ENVIRONM HLTH SCI,BALTIMORE,MD 21205	University of Massachusetts System; University of Massachusetts Worcester; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007009, P30ES003819, R29ES006071] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES06071, ES07009, ES03819] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BHATTACHARYYA KK, 1995, J BIOL CHEM, V270, P11595, DOI 10.1074/jbc.270.19.11595; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; FISHER JM, 1990, J BIOL CHEM, V265, P9676; GONZALEZ FJ, 1990, PHARMACOL THERAPEUT, V45, P1, DOI 10.1016/0163-7258(90)90006-N; GONZALEZ FJ, 1989, PHARMACOL REV, V40, P243; GREENLEE WF, 1994, PROG CLIN BIOL RES, V387, P47; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KELLER W, 1984, CELL, V39, P423, DOI 10.1016/0092-8674(84)90449-5; KELLY RB, 1970, J BIOL CHEM, V245, P39; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; LANG D, 1992, NUCLEIC ACIDS RES, V20, P3287, DOI 10.1093/nar/20.13.3287; LEWIN B, 1980, CELL, V22, P324, DOI 10.1016/0092-8674(80)90340-2; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUSSKA A, 1993, J BIOL CHEM, V268, P6575; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; NELSON DR, 1987, MOL BIOL EVOL, V4, P572; OTTO S, 1992, ENDOCRINOLOGY, V131, P3067, DOI 10.1210/en.131.6.3067; OTTO S, 1991, ENDOCRINOLOGY, V129, P970, DOI 10.1210/endo-129-2-970; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; QUATTROCHI LC, 1986, P NATL ACAD SCI USA, V83, P6731, DOI 10.1073/pnas.83.18.6731; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; REZNIKOFF WS, 1985, ANNU REV GENET, V19, P335; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROUET P, 1992, BIOTECHNIQUES, V13, P700; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHEN ZY, 1993, P NATL ACAD SCI USA, V90, P11483, DOI 10.1073/pnas.90.24.11483; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SPINK DC, 1994, J STEROID BIOCHEM, V51, P251, DOI 10.1016/0960-0760(94)90037-X; SPINK DC, 1990, P NATL ACAD SCI USA, V87, P6917, DOI 10.1073/pnas.87.17.6917; SUTTER TR, 1991, SCIENCE, V254, P415, DOI 10.1126/science.1925598; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; WALKER NJ, 1995, CARCINOGENESIS, V16, P1319, DOI 10.1093/carcin/16.6.1319; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	46	178	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28324	28330		10.1074/jbc.271.45.28324	http://dx.doi.org/10.1074/jbc.271.45.28324			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910454	hybrid			2022-12-27	WOS:A1996VU03300054
J	Goalstone, ML; Draznin, B				Goalstone, ML; Draznin, B			Effect of insulin on farnesyltransferase activity in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-PROTEIN TRANSFERASE; TGF-BETA-RECEPTOR; GROWTH-FACTOR; RAS PROTEINS; SELECTIVE-INHIBITION; P21RAS; ACTIVATION; EXPRESSION; P21(RAS); CELLS	Activation of p21(ras) by GTP loading is a critical step in a cascade of intracellular insulin signaling. Farnesylation of p21(ras) protein is an obligatory event that facilitates Ras migration to the plasma membrane and subsequent activation. Farnesyltransferase (FTase) is a ubiquitous enzyme that catalyzes the lipid modification of p21(ras) by the addition of farnesyl to the C-terminal ''CAAX'' motif. In vitro and in vivo FTase activities were studied in 3T3-L1 adipocytes in response to insulin challenge. Insulin exerted a biphasic stimulatory effect on FTase activity measured in vitro with a 31% increase at 5 min and a 130% increase at 60 min. Insulin-stimulated farnesylation of p21(ras) pools in vivo correlated with FTase activity seen in vitro by displaying an increase in farnesylated p21(ras) from 40% of total cellular Ras in control cells to 63% by 5 min and 80% by 60 min (p < 0.05) in insulin-treated cells. Insulin challenge of 3T3-L1 adipocytes increased incorporation of tritiated mevalonic acid in p21(ras) in a dose-dependent manner and stimulated a a-fold increase in phosphorylation of the alpha-subunit of FTase at 5 min and a 4-fold increase at 60 min.	VET AFFAIRS MED CTR,MED RES SERV,DENVER,CO; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO; UNIV COLORADO,CTR HLTH SCI,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; Bishop WR, 1995, J BIOL CHEM, V270, P30611, DOI 10.1074/jbc.270.51.30611; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Goalstone ML, 1996, BIOL REPROD, V54, P675, DOI 10.1095/biolreprod54.3.675; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MENDOLA CE, 1990, CELL GROWTH DIFFER, V1, P499; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NIGAM M, 1993, J BIOL CHEM, V268, P20695; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRENDERGAST GC, 1993, CELL GROWTH DIFFER, V4, P707; QIAN YM, 1994, J BIOL CHEM, V269, P12410; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	37	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27585	27589		10.1074/jbc.271.44.27585	http://dx.doi.org/10.1074/jbc.271.44.27585			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910345	hybrid			2022-12-27	WOS:A1996VQ67900063
J	Huber, M; Pelletier, JG; Torossian, K; Dionne, P; Gamache, I; CharestGaudreault, R; Audette, M; Poulin, R				Huber, M; Pelletier, JG; Torossian, K; Dionne, P; Gamache, I; CharestGaudreault, R; Audette, M; Poulin, R			2,2'-Dithiobis(N-ethyl-spermine-5-carboxamide) is a high affinity, membrane-impermeant antagonist of the mammalian polyamine transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; L1210 LEUKEMIA-CELLS; GLUCOSE-TRANSPORTER; ORNITHINE DECARBOXYLASE; BIOLOGICAL PROPERTIES; SPERMINE SYNTHASE; TUMOR-GROWTH; AMINO-ACIDS; BINDING; PROTEIN	We have synthesized 2,2'-dithiobis(N-ethyl-spermine-5-carboxamide) (DESC), its thiol monomer (MESC), and the mixed MESC-cysteamine disulfide (DEASC) as potential inhibitors of polyamine transport in mammalian cells, DESC was the most potent antagonist; of spermine transport in ZR-75-1 human breast cancer cells, with K-i values of 5.0 +/- 0.7, 80 +/- 31, and 16 +/- 3 mu m for DESC, MESC, and DEASC, respectively. DESC also strongly blocked putrescine and spermidine uptake in ZR-75-1 cells (K-i = 1.6 +/- 0.5 and 2.7 +/- 1.1 mu M, respectively). While DESC and MESC were purely competitive inhibitors of putrescine transport, DEASC was a mixed competitive/ noncompetitive antagonist, Remarkably, DESC was virtually impermeant in ZR-75-1 cells despite its low K-i toward polyamine transport, The marked difference in affinity between DESC and MESC was essentially due to the tail-to-tail juxtaposition of two spermine-like structures, suggesting that dimeric ligands of the polyamine transporter might simultaneously interact with more than one binding site. While DESC strongly decreased the initial rate of [H-3]spermidine transport, even a 40-fold molar excess of antagonist could not completely abolish intracellular spermidine accumulation Moreover, as little as 0.3 mu M spermidine fully restored growth in ZR-75-1 cells treated with an inhibitor of polyamine biosynthesis in the presence of 50 mu M DESC, thus emphasizing the importance of uptake of trace amounts of exogenous polyamines. Thus, reducing the exogenous supply of polyamines with a patent competitive inhibitor mag be kinetically inadequate to block; replenishment of the polyamine pool in polyamine-depleted tumor cells that display high transport capacity. These results demonstrate that polyamine analogues cross-linked into a dimeric structure such as DESC interact with high affinity with the mammalian polyamine carrier without being used as substrates. These novel properties provide a framework for the design of specific irreversible inhibitors of the polyamine transporter, which should present advantages over competitive antagonists for an efficient blockade of polyamine transport in tumor cells.	UNIV LAVAL,MED RES CTR,MOL ENDOCRINOL LAB,ST FOY,PQ G1V 4G2,CANADA; HOP ST FRANCOIS ASSISE,RES CTR,QUEBEC CITY,PQ G1L 3L5,CANADA	Laval University; Laval University								ASK A, 1992, CANCER LETT, V66, P29, DOI 10.1016/0304-3835(92)90276-2; AZIZ SM, 1995, J PHARMACOL EXP THER, V274, P181; BACHRACH U, 1989, PHYSL POLYAMINES, V2, P235; BASU HS, 1989, CANCER RES, V49, P5591; BEHR JP, 1989, J CHEM SOC CHEM COMM, P101, DOI 10.1039/c39890000101; BERGERON RJ, 1986, BIOORG CHEM, V14, P345, DOI 10.1016/0045-2068(86)90001-5; BERGERON RJ, 1984, SYNTHESIS-STUTTGART, P782; BLASCHKO H, 1959, J PHYSIOL-LONDON, V145, P124, DOI 10.1113/jphysiol.1959.sp006132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNE B, 1991, EXP CELL RES, V195, P323, DOI 10.1016/0014-4827(91)90380-D; BRUNTON VG, 1990, BIOCHEM PHARMACOL, V40, P1893, DOI 10.1016/0006-2952(90)90371-Q; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CAVALLINI D, 1956, EXPERIENTIA, V12, P377, DOI 10.1007/BF02157276; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; Dixon M., 1976, ENZYMES; FELSCHOW DM, 1995, J BIOL CHEM, V270, P28705, DOI 10.1074/jbc.270.48.28705; GORDONSMITH RH, 1983, BIOCHEM PHARMACOL, V32, P3701, DOI 10.1016/0006-2952(83)90138-7; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; HESSELS J, 1989, INT J CANCER, V43, P1115; HOLLEY JL, 1992, CANCER RES, V52, P4190; HUBER M, 1995, CANCER RES, V55, P934; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAWASE M, 1982, BIOCHEM PHARMACOL, V31, P2983, DOI 10.1016/0006-2952(82)90273-8; LESSARD M, 1995, J BIOL CHEM, V270, P1685, DOI 10.1074/jbc.270.4.1685; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MINCHIN RF, 1989, BIOCHEM J, V262, P391, DOI 10.1042/bj2620391; MITCHELL JLA, 1992, BIOCHEM BIOPH RES CO, V186, P81, DOI 10.1016/S0006-291X(05)80778-8; Morgan D. M., 1989, PHYSL POLYAMINES, V1, P203; MOULINOUX JP, 1991, CELL MOL BIOL, V37, P773; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PEGG AE, 1989, BIOCHEMISTRY-US, V28, P8446, DOI 10.1021/bi00447a026; PEGG AE, 1988, CANCER RES, V48, P759; PEGG AE, 1982, AM J PHYSIOL, V243, pC212, DOI 10.1152/ajpcell.1982.243.5.C212; PEGG AE, 1991, BIOCHEM J, V274, P167, DOI 10.1042/bj2740167; PEGG AE, 1989, J BIOL CHEM, V264, P11744; PERSSON L, 1988, CANCER RES, V48, P4807; PONNUSAMY E, 1986, SYNTHESIS-STUTTGART, P48; PORTER CW, 1985, CANCER RES, V45, P2050; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1982, CANCER RES, V42, P4072; PORTER CW, 1983, SCIENCE, V219, P1083, DOI 10.1126/science.6823570; POULIN R, 1992, J BIOL CHEM, V267, P150; RANNELS DE, 1985, AM J PHYSIOL, V249, pE506, DOI 10.1152/ajpendo.1985.249.5.E506; REMY JS, 1995, P NATL ACAD SCI USA, V92, P1744, DOI 10.1073/pnas.92.5.1744; SARHAN S, 1989, ANTICANCER RES, V9, P215; SCALABRINO G, 1981, ADV CANCER RES, V36, P1; SEILER N, 1990, CANCER RES, V50, P5077; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; Seiler N., 1987, INHIBITION POLYAMINE, P49; SIMARD J, 1990, ENDOCRINOLOGY, V126, P3223, DOI 10.1210/endo-126-6-3223; SMITH LL, 1981, BIOCHEM PHARMACOL, V30, P1053, DOI 10.1016/0006-2952(81)90441-X; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Torossian K, 1996, BIOCHEM J, V319, P21, DOI 10.1042/bj3190021; [No title captured]	59	28	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27556	27563		10.1074/jbc.271.44.27556	http://dx.doi.org/10.1074/jbc.271.44.27556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910341	hybrid			2022-12-27	WOS:A1996VQ67900059
J	Uozumi, N; Yanagidani, S; Miyoshi, E; Ihara, Y; Sakuma, T; Gao, CX; Teshima, T; Fujii, S; Shiba, T; Taniguchi, N				Uozumi, N; Yanagidani, S; Miyoshi, E; Ihara, Y; Sakuma, T; Gao, CX; Teshima, T; Fujii, S; Shiba, T; Taniguchi, N			Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha 1->6fucasyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HAMSTER-KIDNEY CELLS; SIALYL-LEWIS-X; ALPHA-FETOPROTEIN; MOLECULAR-CLONING; ACETYLGLUCOSAMINYLTRANSFERASE-V; GENE FAMILY; HEPATOCELLULAR-CARCINOMA; MEMBRANE-GLYCOPROTEINS; ENZYMATIC BASIS	GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha 1 --> 6fucosyl-transferase (alpha 1-6FucT; EC 2.4.1.68), which catalyzes the transfer of fucose from GDP-Fuc to N-linked type complex glycopeptides, was purified from a Triton X-100 extract of porcine brain microsomes. The purification procedures included sequential affinity chromatographies on GlcNAc beta 1-2Man alpha 1-6(GlcNAc beta 1-2Man alpha 1-2)-Man beta 1-4GlcNAc beta 1-4GlcNAc-Asn-Sepharose 4B and synthetic GDP-hexanolamine-Sepharose 4B columns. The enzyme was recovered in a 12% final yield with a 440,000-fold increase in specific activity. SDS-polyacrylamide gel electrophoresis of the purified enzyme gave a major band corresponding to an apparent molecular mass of 58 kDa, The alpha 1-6FucT has 575 amino acids and no putative N-glycosylation sites. The cDNA was cloned in to pSVK3 and was then transiently transfected into COS-l cells. alpha 1-6FucT activity was found to be high in the transfected cells, as compared with non- or mock-transfected cells. Northern blotting analyses of rat adult tissues showed that alpha 1-6FucT was highly expressed in brain. No sequence homology was found with other previously cloned fucosyltransferases, but the enzyme appears to be a type II transmembrane protein like the other glycosyltransferases.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; KANSAI MED UNIV,CHEM LAB,HIRAKATA,OSAKA 573,JAPAN; PROT RES FDN,PEPTIDE INST,OSAKA 562,JAPAN	Osaka University; Kansai Medical University			Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968; Sakuma, Takahiko/0000-0002-9477-2196				AOYAGI Y, 1993, CANCER-AM CANCER SOC, V72, P615, DOI 10.1002/1097-0142(19930715)72:2<615::AID-CNCR2820720246>3.0.CO;2-T; AOYAGI Y, 1985, BIOCHIM BIOPHYS ACTA, V830, P217, DOI 10.1016/0167-4838(85)90277-8; ARAR C, 1995, J BIOL CHEM, V270, P3551, DOI 10.1074/jbc.270.8.3551; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BOLSCHER JGM, 1986, CANCER RES, V46, P4080; BOLSCHER JGM, 1988, EMBO J, V7, P3361, DOI 10.1002/j.1460-2075.1988.tb03208.x; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; CUMMINGS RD, 1988, J BIOL CHEM, V263, P511; DESOUSA CBP, 1993, ACTA TROP, V53, P59, DOI DOI 10.1016/0001-706X(93)90006-W; EASTON EW, 1991, J BIOL CHEM, V266, P21674; FENDERSON BA, 1986, DEV BIOL, V114, P12, DOI 10.1016/0012-1606(86)90379-9; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; GUY RA, 1993, INFECT IMMUN, V61, P1553, DOI 10.1128/IAI.61.4.1553-1558.1993; HAGEN FK, 1993, J BIOL CHEM, V268, P18963; HALL SE, 1994, J IMMUNOL, V153, P3218; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HUBBARD SC, 1987, J BIOL CHEM, V262, P16403; HUCHINSON WL, 1991, HEPATOLOGY, V13, P683; KAPADIA A, 1981, EXP CELL RES, V131, P185, DOI 10.1016/0014-4827(81)90418-3; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOSCIELAK J, 1987, GLYCOCONJUGATE J, V4, P43, DOI 10.1007/BF01048443; Koscielak Jerzy, 1995, Acta Biochimica Polonica, V42, P35; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RT, 1994, J BIOL CHEM, V269, P19617; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7412; LIN AI, 1994, GLYCOBIOLOGY, V4, P895, DOI 10.1093/glycob/4.6.895; LONGMORE GD, 1982, CARBOHYD RES, V100, P365, DOI 10.1016/S0008-6215(00)81049-6; MIYOSHI E, 1995, J BIOL CHEM, V270, P6216, DOI 10.1074/jbc.270.11.6216; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; NUNEZ HA, 1981, CAN J CHEM, V59, P2086, DOI 10.1139/v81-304; OHNO M, 1992, INT J CANCER, V51, P315, DOI 10.1002/ijc.2910510223; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PIERCE M, 1986, J BIOL CHEM, V261, P772; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; SANTER UV, 1984, CANCER RES, V44, P3730; SANTER UV, 1987, BIOCHEMISTRY-US, V18, P2533; SCHACHTER H, 1983, CAN J BIOCHEM CELL B, V61, P1049, DOI 10.1139/o83-134; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SHINLER R, 1993, EUR J CELL BIOL, V61, P1; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STAHL P, 1982, J CELL BIOL, V93, P49, DOI 10.1083/jcb.93.1.49; TAKETA K, 1990, GASTROENTEROLOGY, V99, P508, DOI 10.1016/0016-5085(90)91034-4; TAKETA K, 1990, HEPATOLOGY, V12, P1420, DOI 10.1002/hep.1840120625; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; Uozumi N, 1996, J BIOCHEM, V120, P385; VANBEEK WP, 1977, BRIT J CANCER, V36, P157, DOI 10.1038/bjc.1977.172; VOYNOW JA, 1991, J BIOL CHEM, V266, P21572; VOYNOW JA, 1988, ANAL BIOCHEM, V169, P367; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WESTON BW, 1992, J BIOL CHEM, V267, P24575; WILSON JR, 1976, BIOCHEM BIOPH RES CO, V72, P909, DOI 10.1016/S0006-291X(76)80218-5; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; YAMASHITA K, 1984, J BIOL CHEM, V259, P834	58	159	170	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27810	27817		10.1074/jbc.271.44.27810	http://dx.doi.org/10.1074/jbc.271.44.27810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910378	hybrid			2022-12-27	WOS:A1996VQ67900096
J	Sugahara, K; Tanaka, Y; Yamada, S; Seno, N; Kitagawa, H; Haslam, SM; Morris, HR; Dell, A				Sugahara, K; Tanaka, Y; Yamada, S; Seno, N; Kitagawa, H; Haslam, SM; Morris, HR; Dell, A			Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic acid from king crab cartilage chondroitin sulfate K - Unexpected degradation by chondroitinase ABC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNANCEJA-HORRIDA VENOM; HNK-1 EPITOPE; IGM PARAPROTEINS; HEPARAN-SULFATE; PROTEOGLYCANS; GLYCOLIPIDS; TETRASACCHARIDES; HYALURONIDASE; CARBOHYDRATE; NEUROPATHY	We prepared a series of oligosaccharides from king crab cartilage chondroitin sulfate K after exhaustive digestion with testicular hyaluronidase, and determined the structures of four tetrasaccharides and a pentasaccharide by fast atom bombardment mass spectrometry, high performance liquid chromatography analysis of chondroitinase AC-II digests, and 500-MHz H-1 NMR spectroscopy. The tetrasaccharides shared the common core structure GlcA beta 1-3GalNAc beta 1-4GlcA beta 1-3GalNAc with various sulfation profiles. One structure was GlcA beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S), whereas three of them have the following hitherto unreported structures including a novel glucuronate 3-O-sulfate: GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA beta 1-3GalNAc(4S), GlcA beta 1-3GalNAc(4S)beta 1-4GlcA(3S)beta 1-3GalNAc(4S), and GlcA (3S)beta 1-3GalNAc(4S)beta 1-4GlcA(3S)beta 1-3GalNAc(4S) where 3S or 4S represents 3-O- or 4-O-sulfate, respectively. The structure of the pentasaccharide was determined as GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA(3S)beta 1-3GalNAc(4S)beta 1-4GlcA. Chondroitinase ABC digestion of the tetrasaccharides with GlcA(3S) at the internal position destroyed the disaccharide unit containing GlcA(3S) derived from the reducing side and resulted in only the disaccharide unit from the non-reducing side. In contrast, these tetrasaccharides remained totally resistant to chondroitinase AC-II. The results indicated that it is necessary to reevaluate the disaccharide composition of chondroitin sulfate poly- or oligosaccharides purified from various biological sources, since they were usually determined after chondroitinase ABC digestion, It is probable that the structures containing GlcA(3S) would not have been detected.	OCHANOMIZU UNIV, DEPT CHEM, TOKYO 112, JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND	Ochanomizu University; Imperial College London	Sugahara, K (corresponding author), KOBE PHARMACEUT UNIV, DEPT BIOCHEM, HIGASHINADA KU, KOBE 658, JAPAN.		Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIGA T, 1987, J BIOL CHEM, V262, P848; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1991, J NEUROCHEM, V57, P852, DOI 10.1111/j.1471-4159.1991.tb08229.x; DIFERRANTE N, 1956, J BIOL CHEM, V220, P303; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; GOTO F, 1994, BIOORG MED CHEM LETT, V4, P619, DOI 10.1016/S0960-894X(01)80166-9; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; HARRIS MJ, 1970, CARBOHYD RES, V15, P57, DOI 10.1016/S0008-6215(00)80294-3; ILYAS AA, 1986, BRAIN RES, V385, P1, DOI 10.1016/0006-8993(86)91540-4; KARAMANOS NK, 1994, BIOCHIMIE, V76, P79, DOI 10.1016/0300-9084(94)90066-3; KRESSE H, 1987, ADV ENZYMOL RAMB, V60, P217; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MEYER K, 1958, FED PROC, V17, P1075; Meyer K., 1971, ENZYMES, V5, P307; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; POH CH, 1992, COMP BIOCHEM PHYS B, V101, P159, DOI 10.1016/0305-0491(92)90172-N; POOLE AR, 1986, BIOCHEM J, V236, P1; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; SENO N, 1974, BIOCHIM BIOPHYS ACTA, V343, P423, DOI 10.1016/0304-4165(74)90107-X; SENO N, 1982, CARBOHYD RES, V103, P190; SENO N, 1974, BIOCHIM BIOPHYS ACTA, V362, P290, DOI 10.1016/0304-4165(74)90221-9; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1992, BIOCHEM J, V283, P99, DOI 10.1042/bj2830099; SUGAHARA K, 1994, CARBOHYD RES, V255, P145, DOI 10.1016/S0008-6215(00)90976-5; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; SUGAHARA K, 1994, INT S CART MET NOV 1, P12; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; SUZUKI S, 1960, J BIOL CHEM, V235, P3580; VIEIRA RP, 1991, J BIOL CHEM, V266, P13530; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WEISSMANN B, 1955, J BIOL CHEM, V216, P783; YAMADA S, 1992, J BIOCHEM-TOKYO, V112, P440, DOI 10.1093/oxfordjournals.jbchem.a123919; YAMADA SH, 1993, J BIOL CHEM, V268, P4780	38	92	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26745	26754		10.1074/jbc.271.43.26745	http://dx.doi.org/10.1074/jbc.271.43.26745			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900154	hybrid			2022-12-27	WOS:A1996VP23300048
J	Sugiyama, N; Boyd, AE; Taylor, P				Sugiyama, N; Boyd, AE; Taylor, P			Anionic residue in the alpha-subunit of the nicotinic acetylcholine receptor contributing to subunit assembly and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; AMINO-ACID-RESIDUES; MOLECULAR DISSECTION; DELTA-SUBUNIT; IDENTIFICATION; AFFINITY; SNAKE; DETERMINANTS; ANTAGONISTS; SELECTIVITY	To ascertain the anionic sites on the nicotinic receptor to which acetylcholine and other quaternary ammonium ligands bind, we have examined the role of an aspartyl residue (Asp-152) in the alpha-subunit. Prior photolytic labeling with agonist analogues of the neighboring residues Trp-149 and Try-151 suggests that their side chains reside on the binding face (also termed the (+)- or counterclockwise face) of the alpha-subunit. Asp-152 presents an anionic charge in the vicinity of these aromatic residues. Modification of the aspartate to asparagine (D152N) creates a glycosylation signal (Asn-152-Gly-Ser), and we find, on the basis of altered electrophoretic migration, that glycosylation occurs at this position upon cotransfection of the mutant alpha-subunit with beta-, gamma-, and delta-subunits. Glycosylation results in a reduction in the capacity of the receptor to assemble; this reduction is manifest in the initial step of dimer formation between the alpha gamma- and alpha delta-subunits. The alpha-subunit mutant receptor reaching the assembled pentamer exhibits an altered selectivity for certain ligands, Little reduction in alpha-bungarotoxin binding is observed, whereas affinities for agonists and competitive alkaloid antagonists are reduced substantially. Separation of the contributions of charge removal and glycosylation addition shows that both factors affect agonist affinity, with the charge influence being far more predominant. These findings raise the possibility that a component of the coulombic attraction stabilizing the binding of agonists comes from the aspartyl residue at position 152 in the alpha-subunit.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NIGMS NIH HHS [GM18360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018360, R01GM018360] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON SN, 1991, J MED CHEM, V34, P1798, DOI 10.1021/jm00110a007; ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AMRTIN M, 1996, J BIOL CHEM, V271, P13497; BARCHAN D, 1992, P NATL ACAD SCI USA, V89, P7717, DOI 10.1073/pnas.89.16.7717; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BULLER AL, 1994, MOL PHARMACOL, V46, P858; CHIARA D C, 1992, Biophysical Journal, V61, pA106; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; CRAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KELLER SH, 1995, J BIOL CHEM, V270, P4165, DOI 10.1074/jbc.270.8.4165; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NEUMANN D, 1989, P NATL ACAD SCI USA, V86, P7255, DOI 10.1073/pnas.86.18.7255; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1995, NEURON, V15, P229, DOI 10.1016/0896-6273(95)90080-2; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362	43	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26575	26581		10.1074/jbc.271.43.26575	http://dx.doi.org/10.1074/jbc.271.43.26575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900129	hybrid			2022-12-27	WOS:A1996VP23300023
J	Bingham, CO; Murakami, M; Fujishima, H; Hunt, JE; Austen, KF; Arm, JP				Bingham, CO; Murakami, M; Fujishima, H; Hunt, JE; Austen, KF; Arm, JP			A heparin-sensitive phospholipase A(2) and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin D-2 generation in mouse bone marrow-derived mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ARACHIDONIC-ACID; II PHOSPHOLIPASE-A(2); CYTOPLASMIC PHOSPHOLIPASE-A(2); SULFATE PROTEOGLYCAN; HUMAN NEUTROPHILS; EXPRESSION; CLONING; CYCLOOXYGENASE; TRANSLOCATION	BALB/cJ mouse bone marrow-derived mast cells (BMMC) developed with interleukin (IL)-3 can be stimulated by c-kit ligand (KL) in the presence of IL-10 and IL-1 beta for sequential immediate and delayed generation of prostaglandin (PG) D-2 through utilization of constitutive prostaglandin endoperoxide synthase (PGHS) -1 and induced PGHS-2, respectively (Murakami, M., Matsumoto, R., Austen, K, F., and Arm, J. P. (1994) J. Biol, Chem, 269, 22269-22275), We now report that BALB/cJ BMMC stimulated with KL + IL-10 + IL-1 beta also exhibit the biphasic release of [H-3]arachidonic acid with an immediate phase over the first 10 min followed by a delayed phase from 2 to 7 h, The delayed phase of arachidonic acid release and of PGD(2) generation was inhibited by heparin, which concomitantly released a phospholipase (PL) A(2) from the cells into the supernatant. Both dexamethasone and a type II PLA(2) inhibitor, 12-epi-scalaradial, suppressed delayed-phase PGD(2) generation at concentrations that did not affect immediate eicosanoid generation, Transcripts for type IIA PLA(2), as assessed by reverse transcription-polymerase chain reaction, were progressively induced in BALB/cJ BMMC treated for 2 to 7 h with KL + IL-10 + IL-1 beta; the induction of these transcripts was down-regulated by 10(-6) M dexa methasone. The expression of steady-state transcripts and protein for cytosolic PLA(2) (cPLA(2)) did not change, PGHS-2-dependent delayed-phase PGD(2) generation elicited by IgE-dependent activation of BALB/cJ BMMC primed with KL + IL-10 was also accompanied by the induction of type IIA PLA(2) transcripts and was suppressed by heparin, with concomitant release of PLA(2) into the supernatant, However, both the direct, cytokine stimulated and the cytokine primed, IgE-dependent, delayed phase PGD(2) generation occurred in BMMC from C57BL/6J mice, which have a natural disruption of the type IIA PLA(2) gene. Thus, kinetic, pharmacologic, and genetic analyses suggest that an inducible, heparin-sensitive PLA(2), rather than cPLA(2), provides arachidonic acid to concomitantly induced PGHS-2 for delayed phase PGD(2) biosynthesis in activated BMMC, Further more, this heparin-sensitive PLA(2) likely represents a novel PLA(2) or a new function for a known low molecular weight PLA(2).	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	Bingham, CO (corresponding author), BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,DEPT MED,SEELEY G MUDD BLDG,RM 628,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI22531, AI07306, AI31599] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022531, R37AI022531, T32AI007306, U01AI031599, U19AI031599] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL J, 1994, EUR J BIOCHEM, V226, P125, DOI 10.1111/j.1432-1033.1994.tb20033.x; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DOLE VP, 1960, J BIOL CHEM, V235, P2595; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; FONTEH AN, 1995, J CLIN INVEST, V96, P1432, DOI 10.1172/JCI118179; FONTEH AN, 1994, J IMMUNOL, V152, P5438; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HARA T, 1995, BLOOD, V85, P2332; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; HULKOWER KI, 1992, BIOCHEM BIOPH RES CO, V184, P712, DOI 10.1016/0006-291X(92)90648-5; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P709; MCNISH RW, 1993, BIOCHEM BIOPH RES CO, V196, P147; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; MULHERKAR R, 1993, BIOCHEM BIOPH RES CO, V195, P1254, DOI 10.1006/bbrc.1993.2179; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1995, P NATL ACAD SCI USA, V92, P6107, DOI 10.1073/pnas.92.13.6107; MURAKAMI M, 1992, J BIOCHEM-TOKYO, V111, P175, DOI 10.1093/oxfordjournals.jbchem.a123733; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, BIOCHIM BIOPHYS ACTA, V1043, P34, DOI 10.1016/0005-2760(90)90107-9; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OTTO JC, 1994, J BIOL CHEM, V269, P19868; RAZIN E, 1982, J BIOL CHEM, V257, P7229; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; Tischfield JA, 1996, GENOMICS, V32, P328, DOI 10.1006/geno.1996.0126; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; XU XX, 1994, J BIOL CHEM, V269, P31693; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	53	94	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25936	25944		10.1074/jbc.271.42.25936	http://dx.doi.org/10.1074/jbc.271.42.25936			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824228	hybrid			2022-12-27	WOS:A1996VN18000034
J	Hawes, JW; Jaskiewicz, J; Shimomura, Y; Huang, BL; Bunting, J; Harper, ET; Harris, RA				Hawes, JW; Jaskiewicz, J; Shimomura, Y; Huang, BL; Bunting, J; Harper, ET; Harris, RA			Primary structure and tissue-specific expression of human beta-hydroxyisobutyryl-coenzyme A hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCES; FORM	beta-Hydroxyisobutyryl-CoA (HIBYL-CoA) hydrolase is responsible for the specific hydrolysis of HIBYL-CoA, a saline catabolite, as well as the hydrolysis of beta-hydroxypropionyl-CoA, an intermediate in a minor path way of propionate metabolism, We have obtained the amino acid sequences of several tryptic peptides derived from purified rat liver HIBYL-CoA hydrolase, and the NH2-terminal peptize sequence was matched to the translated sequence of a human expressed sequence tag present in the data base of the IMAGE Consortium (Lawrence Livermore National Laboratory, Livermore, CA), The complete nucleotide sequence and the deduced amino acid sequence showed no similarity to the sequences of well known thioesterases but showed significant homology to the enoyl-CoA hydratase/isomerase enzyme family, The cDNA fragment corresponding to the mature (processed) protein was expressed in Escherichia coli, The purified recombinant enzyme displayed substrate specificity very similar to that of the rat enzyme and was specifically bound by polyclonal antibodies raised against purified rat liver HIBYL-CoA hydrolase, Northern and Western blot analyses with various human tissues indicated predominant expression in liver, heart, and kidney, with discrepancies occurring in the amounts of HIBYL-CoA hydrolase mRNA compared to stably expressed protein in several tissues.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040441] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40441] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Broustas CG, 1996, J BIOL CHEM, V271, P10470, DOI 10.1074/jbc.271.18.10470; DRISCOLL JR, 1992, J BACTERIOL, V174, P5063, DOI 10.1128/JB.174.15.5063-5071.1992; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; LETTO J, 1986, BIOCHEM J, V240, P909, DOI 10.1042/bj2400909; MULLERNEWEN G, 1995, EUR J BIOCHEM, V228, P68, DOI 10.1111/j.1432-1033.1995.tb20230.x; RENDINA G, 1957, J BIOL CHEM, V225, P523; SHIMOMURA Y, 1994, J BIOL CHEM, V269, P14248; TAI MH, 1993, P NATL ACAD SCI USA, V90, P1852, DOI 10.1073/pnas.90.5.1852; VIJAYAKUMAR EKS, 1984, BIOPOLYMERS, V23, P877, DOI 10.1002/bip.360230505; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x	11	38	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26430	26434		10.1074/jbc.271.42.26430	http://dx.doi.org/10.1074/jbc.271.42.26430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824301				2022-12-27	WOS:A1996VN18000107
J	Shida, T; Iwasaki, H; Saito, A; Kyogoku, Y; Shinagawa, H				Shida, T; Iwasaki, H; Saito, A; Kyogoku, Y; Shinagawa, H			Analysis of substrate specificity of the RuvC Holliday junction resolvase with synthetic Holliday junctions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-WAY DNA JUNCTION; ESCHERICHIA-COLI; RESOLUTION; RECOMBINATION; CLEAVAGE; PROTEIN; ENDONUCLEASE; GEOMETRY	The Escherichia coli RuvC protein endonucleolytically resolves Holliday junctions, which are formed as intermediates during genetic recombination and recombination repair. Previous studies using model Holliday junctions suggested that a certain size of central core of homology and a specific sequence in the junction were required for efficient cleavage by RuvC, although not for binding. To determine the minimum length of sequence homology required for RuvC cleavage, we made a series of synthetic Holliday junctions with various lengths of homologous sequence in the core region. It was demonstrated that a monomobile junction possessing only 2 base pairs of the homology core was efficiently cleaved by RuvC. To study the sequence specificity for cleavage, we made 16 bimobile junctions, which differed only in the homologous core sequence. Among them, 6 junctions were efficiently cleaved. Cleavage occurred by introduction of nicks symmetrically at the 3'-side of thymine in all cases. However, the nucleotide bases at the 3'-side of the thymines were not always identical between the two strands nicked. These results suggest that RuvC recognizes mainly topological symmetry of the Holliday junction but not the sequence symmetry per se, that the thymine residue at the cleavage site plays an important role for RuvC-mediated resolution, and that a long homologous core sequence is not essential for cleavage.	OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SHINSHU UNIV,FAC TEXT SCI & TECHNOL,DEPT APPL BIOL,UEDA,NAGANO 386,JAPAN; OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN	Osaka University; Shinshu University; Osaka University			Iwasaki, Hiroshi/Y-7946-2018	Iwasaki, Hiroshi/0000-0002-0153-6873				ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, P NATL ACAD SCI USA, V92, P5635, DOI 10.1073/pnas.92.12.5635; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; CHURCHILL MEA, 1988, P NATL ACAD SCI USA, V85, P4653, DOI 10.1073/pnas.85.13.4653; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; COOPER JP, 1989, P NATL ACAD SCI USA, V86, P7336, DOI 10.1073/pnas.86.19.7336; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; MURCHIE AIH, 1989, NATURE, V341, P763, DOI 10.1038/341763a0; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SHAH R, 1994, CELL, V79, P853, DOI 10.1016/0092-8674(94)90074-4; Shida T, 1996, J BIOCHEM-TOKYO, V119, P653; Shinagawa H, 1996, TRENDS BIOCHEM SCI, V21, P107, DOI 10.1016/0968-0004(96)10014-1; TAKAHAGI M, 1994, J BIOL CHEM, V269, P15132; VONKITZING E, 1990, NUCLEIC ACIDS RES, V18, P2671, DOI 10.1093/nar/18.9.2671	18	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26105	26109		10.1074/jbc.271.42.26105	http://dx.doi.org/10.1074/jbc.271.42.26105			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824253	hybrid			2022-12-27	WOS:A1996VN18000059
J	Friedlander, P; Legros, Y; Soussi, T; Prives, C				Friedlander, P; Legros, Y; Soussi, T; Prives, C			Regulation of mutant p53 temperature-sensitive DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; MONOCLONAL-ANTIBODY; CELL-LINES; TRANSCRIPTIONAL ACTIVATION; PROTEINS BIND; HOT-SPOT; MUTATIONS; SEQUENCE; GENE	We have examined in detail the DNA binding properties of several immunopurified tumor-derived mutant p53 proteins (Val-143 --> Ala, Arg-175 --> His, Arg-248 --> Trp, Arg-249 --> Ser, and Arg-273 --> His). While all mutants were defective for binding to DNA at 37 degrees C, each bound specifically to several cognate p53 binding sites at sub-physiological temperatures (25-33 degrees C), and several mutants activated transcription from a p53-responsive promoter at 26 degrees C in transfected H1299 cells. Heating mutant p53 proteins at 37 degrees C irreversibly destroyed their ability to subsequently bind at 25 degrees C. However, several different monoclonal antibodies that each share the ability to recognize an epitope encompassing amino acids 46-55 markedly stabilized binding by mutant p53 proteins at 37 degrees C. Both intact antibody and FAb fragments allowed mutant p53 to bind to DNA. By contrast, antibodies that recognize epitopes located elsewhere within p53 stabilized mutant p53 binding significantly less effectively. Our data show that the major hot-spot p53 mutants have the intrinsic ability to bind to DNA and that a unique region within the N terminus of p53 may be critical for rescuing them from loss of binding at physiological temperatures. This suggests the possibility of developing small molecules that can stabilize mutant p53 proteins under physiological conditions.	COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; INST GENET MOL,INSERM,U301,F-75010 PARIS,FRANCE	Columbia University; Institut National de la Sante et de la Recherche Medicale (Inserm)				soussi, thierry/0000-0001-8184-3293				ABARZUA P, 1995, CANCER RES, V55, P3490; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILLER CW, 1993, ONCOGENE, V8, P1815; MIYASHITA T, 1995, CELL, V80, P293; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PETERSON MG, 1990, SCIENCE, V248, P1626; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; ROTH RA, 1983, J BIOL CHEM, V258, P2094; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1993, ONCOGENE, V8, P2555; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	64	92	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25468	25478		10.1074/jbc.271.41.25468	http://dx.doi.org/10.1074/jbc.271.41.25468			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810317	hybrid			2022-12-27	WOS:A1996VL69300061
J	Hofer, G; Grimmer, C; Sukhatme, VP; Sterzel, RB; Rupprecht, HD				Hofer, G; Grimmer, C; Sukhatme, VP; Sterzel, RB; Rupprecht, HD			Transcription factor Egr-1 regulates glomerular mesangial cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE ELEMENTS; ZINC FINGER PROTEIN; C-FOS; ANTISENSE OLIGONUCLEOTIDES; GROWTH-FACTOR; EPITHELIAL-CELL; 3T3 CELLS; GENE; EXPRESSION; DIFFERENTIATION	Increase of glomerular mesangial cells (MCs) is a prominent histopathological finding in many types of glomerulonephritis. We have shown previously that expression of the zinc-finger transcription factor, early growth response gene-1 (egr-1), is closely correlated with the proliferation of cultured MCs. To elucidate whether Egr-1 is required for MC proliferation, we inhibited serum-induced Egr-1 expression by phosphothioate-modified antisense oligonucleotides (ODNs), Uptake of antisense ODNs into ASCs was demonstrated, and five different egr-1 antisense ODNs were tested for their impact on serum-induced egr-1 mRNA and protein levels and on MC growth. The most potent egr-1 antisense ODN inhibited serum-induced egr-1 mRNA by 68%, protein induction by 58%, and MC replication as measured by [H-3]thymidine uptake and cell counts by 78 and 46%, respectively. The effects of antisense ODNs on MC growth correlated closely with their ability to inhibit Egr-1 protein, ODNs acted in a dose-dependent manner, the minimal effective concentration being 1 mu M. Control ODNs had no significant effects. In addition, antisense ODNs against egr-1 potently inhibited endothelin-1-induced Egr-1 expression and MC growth, Heparin, a known inhibitor of MC growth, suppressed serum-induced [H-3]thymidine uptake by 39% and egr-1 mRNA expression by 44%. We conclude that Egr-1 is an essential part of the mitogenic signal transduction cascade in cultured MCs.	BETH ISRAEL HOSP,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Hofer, G (corresponding author), UNIV ERLANGEN NURNBERG,MED KLIN 4,NEPHROL FORSCHUNGSLAB,LOSCHGESTR 8,D-91054 ERLANGEN,GERMANY.		Sukhatme, Vikas/W-2776-2019					ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; AKAI Y, 1994, AM J PHYSIOL, V267, pC482, DOI 10.1152/ajpcell.1994.267.2.C482; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CASTELLOT JJ, 1985, AM J PATHOL, V120, P427; CHENG T, 1994, J BIOL CHEM, V269, P30848; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUPTA MP, 1991, J BIOL CHEM, V266, P12813; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; HALLAHAN DE, 1991, P NATL ACAD SCI USA, V88, P2156, DOI 10.1073/pnas.88.6.2156; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; HUANG RP, 1994, ONCOGENE, V9, P1367; KINANE TB, 1994, J BIOL CHEM, V269, P27503; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEREZCASTILLO A, 1993, J BIOL CHEM, V268, P19445; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; RICKER RD, 1992, FEBS LETT, V309, P363, DOI 10.1016/0014-5793(92)80808-T; RUPPRECHT HD, 1992, AM J PHYSIOL, V263, pF623, DOI 10.1152/ajprenal.1992.263.4.F623; RUPPRECHT HD, 1993, AM J PHYSIOL, V265, pF351, DOI 10.1152/ajprenal.1993.265.3.F351; RUPPRECHT HD, 1994, J CELL PHYSIOL, V159, P311, DOI 10.1002/jcp.1041590214; SANKAR S, 1989, EUR J BIOCHEM, V184, P39, DOI 10.1111/j.1432-1033.1989.tb14987.x; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0	40	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28306	28310		10.1074/jbc.271.45.28306	http://dx.doi.org/10.1074/jbc.271.45.28306			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910451	hybrid			2022-12-27	WOS:A1996VU03300051
J	Jimenez, EC; Olivera, BM; Gray, WR; Cruz, LJ				Jimenez, EC; Olivera, BM; Gray, WR; Cruz, LJ			Contryphan is a D-tryptophan-containing Conus peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-AMINO-ACID; ACHATINA-FULICA; AMPHIBIAN SKIN; D-SERINE; RESIDUE; DERMORPHIN; NEUROPEPTIDE; PRECURSOR; SEQUENCE; AFFINITY	In this report, we document for the first time the occurrence of D-tryptophan in a normally translated polypeptide, contryphan. The peptide, isolated from the venom of the fish-hunting marine snail Conus radiatus, produces the ''stiff-tail'' syndrome in mice. Characterization of the octapeptide gave the following sequence, Gly-Cys-Hyp-D-Trp-Glu-Pro-Trp-Cys-NH2 SEQUENCE 1 where Hyp = 4-trans-hydroxyproline. The presence of D-tryptophan in position 4 of contryphan was confirmed by chemical synthesis. The posttranslational epimerization in all other D-amino acid-containing small peptides characterized previously from vertebrates and molluscan systems is in position 2.	UNIV UTAH,DEPT BIOL,SALT LAKE CITY,UT 84112; UNIV PHILIPPINES,INST MARINE SCI,QUEZON 1101,PHILIPPINES	Utah System of Higher Education; University of Utah; University of the Philippines System; University of the Philippines Diliman			Jimenez, Elsie/AAA-7347-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CRUZ L J, 1976, Veliger, V18, P302; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; FUJISAWA Y, 1992, COMP BIOCHEM PHYS C, V102, P91, DOI 10.1016/0742-8413(92)90049-D; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Heck SD, 1996, P NATL ACAD SCI USA, V93, P4036, DOI 10.1073/pnas.93.9.4036; HECK SD, 1994, J AM CHEM SOC, V116, P10426, DOI 10.1021/ja00102a009; HECK SD, 1994, SCIENCE, V266, P1065, DOI 10.1126/science.7973665; HOCHLOWSKI JE, 1994, J ANTIBIOT, V47, P528, DOI 10.7164/antibiotics.47.528; KAMATANI Y, 1989, BIOCHEM BIOPH RES CO, V160, P1015, DOI 10.1016/S0006-291X(89)80103-2; KREIL G, 1994, J BIOL CHEM, V269, P10967; KREIL G, 1989, EUR J PHARMACOL, V162, P123, DOI 10.1016/0014-2999(89)90611-0; KUWADA M, 1994, MOL PHARMACOL, V46, P587; MONTECUCCHI PC, 1981, INT J PEPT PROT RES, V17, P275; MOR A, 1989, FEBS LETT, V255, P269, DOI 10.1016/0014-5793(89)81104-4; OHTA N, 1991, BIOCHEM BIOPH RES CO, V178, P486, DOI 10.1016/0006-291X(91)90133-R; RICHTER K, 1990, P NATL ACAD SCI USA, V87, P4836, DOI 10.1073/pnas.87.12.4836; RICHTER K, 1987, SCIENCE, V238, P200, DOI 10.1126/science.3659910; SHIKATA Y, 1995, J BIOL CHEM, V270, P16719, DOI 10.1074/jbc.270.28.16719; SOYEZ D, 1994, J BIOL CHEM, V269, P18295; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0; YASUDAKAMATANI Y, 1995, J NEUROCHEM, V64, P2248	21	125	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28002	28005		10.1074/jbc.271.45.28002	http://dx.doi.org/10.1074/jbc.271.45.28002			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910408	hybrid			2022-12-27	WOS:A1996VU03300008
J	Paulssen, RH; Woodson, J; Liu, Z; Ross, EM				Paulssen, RH; Woodson, J; Liu, Z; Ross, EM			Carboxyl-terminal fragments of phospholipase C-beta 1 with intrinsic G(q) GTPase-activating protein (GAP) activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; GUANINE-NUCLEOTIDE-BINDING; ALPHA-SUBUNIT; DEPENDENT ACTIVATION; C ISOZYMES; GQ-ALPHA; PURIFICATION; STIMULATION; RECEPTORS; CLONING	Fragments of the similar to 50 kDa COOH-terminal region of phospholipase C-beta 1 (PLC-beta 1(1)), ranging in size from 14 to 38 kDa, were expressed in Escherichia coli, purified, and tested for their regulatory activities. As expected, none of the fragments had phospholipase activity, Several fragments, referred to as PLC tails, displayed GTPase-activating protein (GAP) activity for G(q), the G protein class that stimulates the PLC-beta s in response to receptors, G(q) GAP activity is characteristic of intact PLC-beta s. In reconstituted phospholipid vesicles that contained purified G(q) and m1 muscarinic cholinergic receptors, the most active tails increased agonist-stimulated, steady-state GTPase activity over 4-fold. Stimulation of steady-state GTPase by the tails depended on receptors for facilitation of GDP-GTP exchange, suggesting that the tails act by accelerating hydrolysis of bound GTP, In addition to intrinsic GAP activity, one tail with high GAP activity and others with low or minimal activity potentiated the GAP activity of intact PLC-beta 1. Other tails inhibited PLC-beta 1s GAP effect, Both intrinsic GAP activity and potentiation of the PLC-beta 1 GAP effect were often biphasic, with maxima as low as 100 nm tail and declining activities at higher concentrations, Several tails inhibited either the phospholipase activity of PLC-beta 1, beta 1, its stimulation by G(q), or both. The tails thus define the region of PLC-beta 1 that has G(q) GAP activity and suggest a mechanism of action in which the COOH terminus of PLC-beta s can interact with G(q) and with other PLC-beta 1 molecules.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM30355] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; BLANK JL, 1991, J BIOL CHEM, V266, P18206; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; Goo Rhee Sue, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P35; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; JHON DY, 1993, J BIOL CHEM, V268, P6654; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1994, J BIOL CHEM, V269, P25335; LEE E, 1994, METHOD ENZYMOL, V237, P146; MARTELL AE, 1952, CHEM METAL CHELATE C; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER EM, 1991, J BIOL CHEM, V266, P519; PATERSON A, 1995, CELL SIGNAL, V7, P709, DOI 10.1016/0898-6568(95)00039-R; PEDERSEN SE, 1985, J BIOL CHEM, V260, P4150; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; SUH PG, 1988, J BIOL CHEM, V263, P14497; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, J BIOL CHEM, V268, P3704	31	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26622	26629		10.1074/jbc.271.43.26622	http://dx.doi.org/10.1074/jbc.271.43.26622			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900136	hybrid			2022-12-27	WOS:A1996VP23300030
J	Somasundaram, R; Schuppan, D				Somasundaram, R; Schuppan, D			Type I, II, III, IV, V, and VI collagens serve as extracellular ligands for the isoforms of platelet-derived growth factor (AA, BB, and AB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; PLASMINOGEN-ACTIVATOR; MATRIX INTERACTIONS; BINDING DOMAINS; BODY-FLUIDS; PDGF; PROTEIN; TISSUE; CELLS; LIVER	The biological activities of several growth factors/cytokines have been shown to be modulated by binding to molecules of the extracellular matrix. Here, the interactions of PDGF (isoforms AA, BB, and AB), a potent mitogen for mesenchymal cells, with collagens were investigated. All radiolabeled PDGF isoforms specifically interacted with type I, II, III, IV, V, and VI collagens (preferential binding to types III, I, VI, and IV) and their constituent chains, either when immobilized on polystyrene or blotted to nitrocellulose. PDGF-collagen interactions were of medium affinity (K-D between 4 and 22 nM) and were inhibited by different soluble collagen chains suggesting a collagenous consensus binding site(s) for the PDGF isoforms investigated. Scatchard analysis revealed molar ratios of up to 3-4 PDGF molecules bound/triple-helical (native) collagen. Biological activity of collagen-bound PDGF was demonstrated by a 1.5-3-fold stimulation of proliferation of human fibroblasts and mouse 3T3 cells. Furthermore, a preferential association of PDGF with the collagenous extracellular matrix of cirrhotic liver could be shown by immunostaining. Our data are in accord with previous studies that localized PDGF in the extracellular matrix of fibroproliferative lesions and suggest that binding of PDGF to collagens may localize and modulate its biological activities.	FREE UNIV BERLIN, UNIV KLINIKUM BENJAMIN FRANKLIN, GASTROENTEROL & HEPATOL ABT, D-12200 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Somasundaram, Rajan/0000-0003-3461-3326				ABBOUD HE, 1992, KIDNEY INT, V41, P581, DOI 10.1038/ki.1992.86; ALON R, 1994, J IMMUNOL, V152, P1304; BECKER J, 1986, J HISTOCHEM CYTOCHEM, V34, P1417, DOI 10.1177/34.11.3772076; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; ELNAHAS AM, 1992, KIDNEY INT, V41, pS15; FLOEGE J, 1992, KIDNEY INT, V41, P297, DOI 10.1038/ki.1992.42; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; GAY S, 1989, J INVEST DERMATOL, V92, P301, DOI 10.1111/1523-1747.ep12276895; GAY S, 1992, ARTHRITIS RHEUM, V35, P304, DOI 10.1002/art.1780350309; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GOSPODAROWICZ D, 1987, ENDOCR REV, V8, P95, DOI 10.1210/edrv-8-2-95; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HERSHKOVIZ R, 1994, J IMMUNOL, V153, P554; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KHAGIGIAN LM, 1994, PEPTIDES, V15, P133; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; LEVESQUE JP, 1991, IMMUNOL TODAY, V12, P258, DOI 10.1016/0167-5699(91)90122-A; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MILLER EJ, 1982, METHOD ENZYMOL, V82, P33; MOORADIAN DL, 1989, J CELL BIOCHEM, V41, P189, DOI 10.1002/jcb.240410404; MOSER TL, 1993, J BIOL CHEM, V268, P18917; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; NUGENT MA, 1989, J BIOL CHEM, V264, P18060; PARALKAR VM, 1991, DEV BIOL, V143, P303, DOI 10.1016/0012-1606(91)90081-D; PIERCE GF, 1991, J CELL BIOCHEM, V45, P319, DOI 10.1002/jcb.240450403; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; Pollock RA, 1992, GROWTH FACTORS, V7, P267, DOI 10.3109/08977199209046409; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; RAINES EW, 1992, J CELL BIOL, V116, P533, DOI 10.1083/jcb.116.2.533; RAINES EW, 1990, PEPTIDE GROWTH FACTO, V1, P173; RAMSDEN L, 1992, EUR J IMMUNOL, V22, P3027, DOI 10.1002/eji.1830221139; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUOSLAHTI E, 1992, BRIT J CANCER, V66, P239, DOI 10.1038/bjc.1992.250; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SALONEN EM, 1989, J BIOL CHEM, V264, P6339; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schubert D, 1992, Trends Cell Biol, V2, P63, DOI 10.1016/0962-8924(92)90057-T; SCHUPPAN D, 1990, J BIOL CHEM, V265, P8823; SCHUPPAN D, 1985, ANAL BIOCHEM, V149, P238, DOI 10.1016/0003-2697(85)90501-9; SCHUPPAN D, 1986, J CLIN INVEST, V78, P241, DOI 10.1172/JCI112557; SCHUPPAN D, 1986, CELL TISSUE RES, V243, P535; SOMASUNDARAM R, 1993, GASTROENTEROLOGY, V104, pA988; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WALZOG B, 1995, EXP CELL RES, V218, P28, DOI 10.1006/excr.1995.1127; WESTERMARK B, 1990, ACTA ENDOCRINOL-COP, V123, P131, DOI 10.1530/acta.0.1230131; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WILCOX JN, 1990, GROWTH FACTORS DIFFE, P305; WONG P, 1995, J BIOL CHEM, V270, P25805, DOI 10.1074/jbc.270.43.25805; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	58	99	110	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26884	26891		10.1074/jbc.271.43.26884	http://dx.doi.org/10.1074/jbc.271.43.26884			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900172	hybrid			2022-12-27	WOS:A1996VP23300066
J	Dalton, TP; Lio, QW; Bittel, D; Liang, LC; Andrews, GK				Dalton, TP; Lio, QW; Bittel, D; Liang, LC; Andrews, GK			Oxidative stress activates metal-responsive transcription factor-1 binding activity - Occupancy in vivo of metal response elements in the metallothionein-I gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; LIGATION-MEDIATED PCR; YA-SUBUNIT GENE; NF-KAPPA-B; FACTOR MTF-1; PHENOLIC ANTIOXIDANTS; INDUCIBLE EXPRESSION; HYDROXYL RADICALS; DNA INTERACTIONS; GROWTH-FACTOR	Oxidative stress (tert-butylhydroquinone) rapidly induced metallothionein-I gene expression in mouse Hepa cells, and this effect was mediated predominantly through metal response promoter elements in transient transfection assays. In vivo genomic footprinting of the mouse metallothionein-I promoter after treatment of Hepa cells with hydrogen peroxide, tert-butylhydroquinone, or zinc suggested a rapid increase in occupancy of the metal response elements. More subtle changes also occurred in the constitutive genomic footprint at the composite major late transcription factor/antioxidant response element. This element may, in part, mediate induction by hydrogen peroxide, Electrophoretic mobility shift assays demonstrated a rapid (30 min) increase in the DNA binding activity of metal-responsive transcription factor-1 in Hepa cells treated with any of these inducers, In control cells, upstream stimulatory factor binding with the major late transcription factor site, and a nuclear protein complex distinct from AP-I, but specific for the antioxidant response element, were detected, The amounts of these complexes were not altered after these treatments, These studies indicate that metal-responsive transcription factor-1 plays a role in activating mouse metallothionein-I gene transcription in response to reactive oxygen species.	UNIV KANSAS, MED CTR, DEPT BIOCHEM & MOL BIOL, KANSAS CITY, KS 66160 USA	University of Kansas; University of Kansas Medical Center					NATIONAL CANCER INSTITUTE [R01CA061262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005704] Funding Source: NIH RePORTER; NCI NIH HHS [CA-61262] Funding Source: Medline; NIEHS NIH HHS [ES-05704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANDREWS GK, 1990, PROG FOOD NUTR SCI, V14, P193; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAUMAN JW, 1991, TOXICOL APPL PHARM, V110, P347, DOI 10.1016/S0041-008X(05)80017-1; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BERGELSON S, 1994, ONCOGENE, V9, P565; BERGMANN B, 1992, TOXICOLOGY, V74, P127, DOI 10.1016/0300-483X(92)90133-Y; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUGNERA E, 1994, NUCLEIC ACIDS RES, V22, P3167, DOI 10.1093/nar/22.15.3167; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; Dalton T, 1996, J NUTR, V126, P825, DOI 10.1093/jn/126.4.825; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DALTON T, 1994, BIOL REPROD, V51, P597, DOI 10.1095/biolreprod51.4.597; DE SK, 1990, J BIOL CHEM, V265, P15267; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HEUCHEL R, 1994, EMBO J, V13, P2870, DOI 10.1002/j.1460-2075.1994.tb06581.x; HORNSTRA IK, 1993, ANAL BIOCHEM, V213, P179, DOI 10.1006/abio.1993.1407; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KNIGHT JA, 1995, ANN CLIN LAB SCI, V25, P111; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee DK, 1996, MOL REPROD DEV, V43, P158, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;158::AID-MRD4&gt;3.0.CO;2-Q; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; MARET W, 1995, NEUROCHEM INT, V27, P111, DOI 10.1016/0197-0186(94)00173-R; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Palmiter R D, 1987, Experientia Suppl, V52, P63; PALMITER RD, 1994, P NATL ACAD SCI USA, V91, P1219, DOI 10.1073/pnas.91.4.1219; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RADTKE F, 1995, NUCLEIC ACIDS RES, V23, P2277, DOI 10.1093/nar/23.12.2277; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHILDERMAN PAEL, 1993, CARCINOGENESIS, V14, P347, DOI 10.1093/carcin/14.3.347; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; TAMAI KT, 1993, P NATL ACAD SCI USA, V90, P8013, DOI 10.1073/pnas.90.17.8013; TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YIANGOU M, 1991, BIOCHEMISTRY-US, V30, P3798; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	60	205	213	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26233	26241		10.1074/jbc.271.42.26233	http://dx.doi.org/10.1074/jbc.271.42.26233			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824273	hybrid			2022-12-27	WOS:A1996VN18000079
J	FranchiGazzola, R; Visigalli, R; Bussolati, O; Gazzola, GC				FranchiGazzola, R; Visigalli, R; Bussolati, O; Gazzola, GC			Involvement of protein kinase C epsilon in the stimulation of anionic amino acid transport in cultured human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-DEPENDENT TRANSPORT; HUMAN SKIN FIBROBLASTS; HIGH-AFFINITY UPTAKE; RAT-BRAIN; DIFFERENTIAL REGULATION; GLUTAMATE TRANSPORTERS; PHORBOL ESTERS; EXPRESSION; CELLS; PHOSPHORYLATION	Protein kinase C (PKC) activation stimulates transport system X(AG)(-) for anionic amino acids in cultured human fibroblasts (Franchi-Gazzola, R., Visigalli, R., Bussolati, O., and Gazzola, G. C. (1994) FEBS Lett. 352, 109-112), To identify which PKC isoform is responsible for this effect, aspartate transport through system X(AG)(-), PKC activity, and the subcellular distribution of PKC isoforms have been studied before and after treatment with phorbol 12,13-dibutyrate (PDBu) in fibroblasts maintained at low serum for 1 (control cells) or 7 days (quiescent cells), In control cells aspartate transport and PKC activity in the particulate fraction were stimulated by short term PDBu treatment; both stimulatory effects were down-regulated by a prolonged exposure to the phorbol. In contrast, in quiescent cells aspartate transport and particulate PKC activity were higher than control under basal conditions, unaffected by a short term PDBu treatment, and lowered by a prolonged incubation with the phorbol, In both control and quiescent cells a short term PDBu treatment modified PKC alpha distribution, increasing its membrane associated fraction. PKC delta was mostly in the soluble fraction and scarcely sensitive to PDBu. A brief exposure to PDBu increased membrane-associated PKC epsilon in control but not in quiescent cells, In these cells epsilon isoform was found exclusively in the particulate fraction even in PDBu-untreated cells. A prolonged PDBu treatment caused a partial down-regulation of membrane-associated PKC epsilon in control cells and its marked decrease in quiescent cells, It is concluded that PKC-dependent changes in system Ii,, activity parallel the behavior of PKC epsilon, thus suggesting a specific role for this isoform in system X(AG)(-) regulation.	UNIV PARMA,IST PATOL GEN,I-43100 PARMA,ITALY	University of Parma			Bussolati, Ovidio/B-7589-2013	Bussolati, Ovidio/0000-0002-4301-2939				ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BALCAR VJ, 1992, FEBS LETT, V300, P203, DOI 10.1016/0014-5793(92)80846-9; BUSSOLATI O, 1993, BIOCHIM BIOPHYS ACTA, V1151, P153, DOI 10.1016/0005-2736(93)90099-L; CASADO M, 1991, J NEUROCHEM, V57, P1185, DOI 10.1111/j.1471-4159.1991.tb08278.x; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHEN CC, 1995, NEUROCHEM INT, V26, P455, DOI 10.1016/0197-0186(94)00157-P; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FRANCHIGAZZOLA R, 1990, BIOCHEM BIOPH RES CO, V173, P1304, DOI 10.1016/S0006-291X(05)80929-5; FRANCHIGAZZOLA R, 1994, FEBS LETT, V352, P109, DOI 10.1016/0014-5793(94)00929-5; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GONZALEZ A, 1993, ANAL BIOCHEM, V215, P184, DOI 10.1006/abio.1993.1574; GOODE N, 1992, J BIOL CHEM, V267, P16878; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANAI Y, 1994, FASEB J, V8, P1450; KANNER BI, 1993, FEBS LETT, V325, P95, DOI 10.1016/0014-5793(93)81421-U; KARIM Z, 1995, AM J PHYSIOL-CELL PH, V269, pC134, DOI 10.1152/ajpcell.1995.269.1.C134; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEHEL C, 1994, J BIOL CHEM, V269, P4761; MCDERMOTT RH, 1993, J CELL SCI, V104, P51; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; PONZONI M, 1993, FEBS LETT, V322, P120, DOI 10.1016/0014-5793(93)81550-J; RACCHI M, 1994, ARCH BIOCHEM BIOPHYS, V314, P107, DOI 10.1006/abbi.1994.1417; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; ZHANG QY, 1992, J IMMUNOL, V149, P1402	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26124	26130		10.1074/jbc.271.42.26124	http://dx.doi.org/10.1074/jbc.271.42.26124			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824256	hybrid			2022-12-27	WOS:A1996VN18000062
J	Lee, HS; Aumais, J; White, JH				Lee, HS; Aumais, J; White, JH			Hormone-dependent transactivation by estrogen receptor chimeras that do not interact with hsp90 - Evidence for transcriptional repressors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-90; NUCLEAR RECEPTORS; STEROID-RECEPTORS; THYROID-HORMONE; BINDING-PROPERTIES; RETINOIC ACID; CO-REPRESSOR; IN-VIVO; ACTIVATION; SUPERFAMILY	The ligand-free estrogen receptor (ER), like other steroid receptors, interacts with the 90-kDa heat shock protein hsp90 in vitro. Analysis of the effect of potential ER-hsp90 interactions in vivo on receptor function is complicated by the fact that hsp90 binds to ER domains required for hormone binding and stable DNA binding, ER chimeras were therefore created by replacing the ER DNA binding domain with that of GAL4. In addition, the N-terminal-AF-1 domain of the ER was replaced with the strong constitutive activation domain of VP16 to create VP16-GAL-ERs. These chimeras bind DNA in a ligand-independent manner, but, importantly, are ligand-dependent transactivators, unlike VP16-GAL, which displays strong constitutive activity under the same conditions. Hormone induces transactivation by VP16-GAL-ERs to levels similar to the constitutive activity of VP16-GAL. Glycerol gradient and coimmunoprecipitation experiments showed that, unlike the wild-type ER, VP1G-GAL-ER chimeras do not interact with hsp90. Deletion analyses indicate that a region of the ER, primarily between amino acids 370 and 470, is responsible for repressed transcription. Our results suggest that interaction with hsp90 is not necessary for controlling dependent transcription by the ER and provide evidence for repressor factors that interact with the N-terminal portion of the receptor's ligand binding domain in the absence of hormone.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	McGill University			white, john h/N-9782-2013	white, john h/0000-0002-4785-2687				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHAMBRAUD B, 1990, J BIOL CHEM, V265, P20686; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; DALMAN FC, 1991, BIOCHEMISTRY-US, V30, P5605, DOI 10.1021/bi00236a038; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FERRARA J, 1994, J BIOL CHEM, V269, P2971; FUXE K, 1987, J STEROID BIOCHEM, V27, P159, DOI 10.1016/0022-4731(87)90306-2; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P389; GREENE GL, 1986, J STEROID BIOCHEM, V26, P1; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ISHIBASHI T, 1989, BIOL REPROD, V40, P1275; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; LANDEL CC, 1994, MOL ENDOCRINOL, V8, P1407, DOI 10.1210/me.8.10.1407; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MADER S, 1993, NUCLEIC ACIDS RES, V21, P1125, DOI 10.1093/nar/21.5.1125; MCDONNELL DP, 1992, P NATL ACAD SCI USA, V89, P10563, DOI 10.1073/pnas.89.22.10563; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; ONATE SA, 1995, SCIENCE, V270, P1354; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRESS MF, 1985, J HISTOCHEM CYTOCHEM, V33, P915, DOI 10.1177/33.9.4020102; SCHERRER LC, 1993, BIOCHEMISTRY-US, V32, P5381, DOI 10.1021/bi00071a013; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TZUKERMAN M, 1990, New Biologist, V2, P613; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457	37	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25727	25730		10.1074/jbc.271.42.25727	http://dx.doi.org/10.1074/jbc.271.42.25727			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824196	hybrid			2022-12-27	WOS:A1996VN18000002
J	Wang, Z; Chacko, S				Wang, Z; Chacko, S			Mutagenesis analysis of functionally important domains within the C-terminal end of smooth muscle caldesmon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING-SITES; ATPASE ACTIVITY; CALMODULIN-BINDING; HEAVY-MEROMYOSIN; MYOSIN SUBFRAGMENTS; F-ACTIN; TROPOMYOSIN; ACTOMYOSIN; PHOSPHORYLATION; EXPRESSION	The ability of chicken gizzard smooth muscle caldesmon (CaD) to inhibit actomyosin ATPase activity is due mainly to an inhibitory domain that resides within the C-terminal 67 amino acid residues of the CaD molecule. In the present study, a series of C-terminal truncation and internal deletion mutants of chicken gizzard smooth muscle CaD were systematically designed using a site-directed mutagenesis approach, and these mutant proteins were overexpressed in a baculovirus expression system. Analysis of actin binding and inhibition of actomyosin ATPase activity using these mutants identified a strong actin-binding motif of 6 amino acid residues (from Lys(718) to Glu(723)), which also form the core sequence for CaD-induced inhibition of actomyosin ATPase, However, maximal inhibition by CaD requires the presence of residues 728-731, which are not associated with actin binding, Our data provide direct evidence for the requirement of actin binding to a specific region in CaD for CaD-induced inhibition of actin activation of smooth muscle myosin ATPase. Furthermore, our findings also show that the region between residues 690 and 717 is responsible for the weak inhibition of actomyosin ATPase and reveal that the inhibitory determinants located in the regions between residues 690 and 717 and residues 718 and 756 can function independently.	UNIV PENN,SCH VET MED,DEPT PATHOBIOL,PHILADELPHIA,PA 19104; UNIV PENN,DIV UROL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039740, R01DK047514] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 39740, DK 47514] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; BARTEGI A, 1990, J BIOL CHEM, V265, P1521; CHACKO S, 1981, BIOCHEMISTRY-US, V20, P702, DOI 10.1021/bi00507a005; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHALOVICH JM, 1987, J BIOL CHEM, V262, P5711; CHILDS TJ, 1992, J BIOL CHEM, V267, P22853; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DOBROWOLSKI Z, 1988, BIOCHIM BIOPHYS ACTA, V956, P140, DOI 10.1016/0167-4838(88)90260-9; HEASLIP RJ, 1985, BIOCHEMISTRY-US, V24, P2731, DOI 10.1021/bi00332a020; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HORIUCHI KY, 1995, J MUSCLE RES CELL M, V16, P11, DOI 10.1007/BF00125306; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; IKEBE M, 1988, J BIOL CHEM, V263, P3055; ISHIKAWA R, 1992, CELL MOTIL CYTOSKEL, V23, P244, DOI 10.1002/cm.970230404; LASH JA, 1986, J BIOL CHEM, V261, P6155; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1991, BIOCHEM J, V279, P1; MARSTON SB, 1985, ADV PROTEIN PHOSPHAT, V2, P171; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGAI PK, 1984, J BIOL CHEM, V259, P3656; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; REDWOOD CS, 1993, FEBS LETT, V327, P85, DOI 10.1016/0014-5793(93)81045-2; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOBUE K, 1991, J BIOL CHEM, V266, P12115; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1990, J BIOL CHEM, V265, P2929; VELAZ L, 1989, J BIOL CHEM, V264, P9602; WANG CLA, 1991, J BIOL CHEM, V266, P9166; Wang Z, 1996, J BIOL CHEM, V271, P2234, DOI 10.1074/jbc.271.4.2234; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; ZHAN Q, 1991, J BIOL CHEM, V266, P21810; ZHUANG SB, 1995, J BIOL CHEM, V270, P19964, DOI 10.1074/jbc.270.34.19964	41	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25707	25714		10.1074/jbc.271.41.25707	http://dx.doi.org/10.1074/jbc.271.41.25707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810349	hybrid			2022-12-27	WOS:A1996VL69300093
J	Chen, CJ; Lin, TT; Shively, JE				Chen, CJ; Lin, TT; Shively, JE			Role of interferon regulatory factor-1 in the induction of biliary glycoprotein (cell CAM-1) by interferon-gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARCINOEMBRYONIC ANTIGEN CEA; CROSS-REACTING ANTIGEN; LIGATION-MEDIATED PCR; IFN-INDUCIBLE GENES; FACTOR-I IRF-1; NF-KAPPA-B; ADHESION MOLECULE; TRANSCRIPTION FACTOR; ESCHERICHIA-COLI; MONOCLONAL-ANTIBODIES	Biliary glycoprotein (BGP), also known as C-CAM-1, has been shown to be down-regulated in colon and prostate tumors. Previously, we demonstrated that BGP mRNA is up-regulated by interferon-gamma (IFN-gamma) in colon cancer cell lines (Takahashi, H., Okai, Y., Paxton, R. J., Hefta, L. J. F., and Shivery, J. E. (1993) Cancer Res. 53, 1612-1619). We now show that the BGP promoter contains an interferon-sensitive response element (ISRE) that is specifically protected in in vivo footprints. Interferon regulatory factor-1 (IRF-1) was identified as the ISRE-binding factor by electrophoretic mobility shift assays. The induction of IRF-1 mRNA by IFN-gamma in HT-29 cells reaches a maximum at 6 h and is superinduced by cycloheximide. Four mRNA species for BGP are induced by IFN-gamma, the major band of which is inhibited by cycleheximide. Transfection of HT-29 cells with an IRF-1 expression plasmid (pAct-1) transactivates a BGP promoter reporter gene containing wild-type (but not mutant) ISRE. Electrophoretic mobility shift assay analysis of a second footprint reveals the binding of Sp1, an Sp1-like protein, and upstream stimulatory factor. The Sp1-like complex wits also induced by IFN-gamma treatment of HT-29 cells and may be a second point of transcriptional control for the BGP gene.	BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NATIONAL CANCER INSTITUTE [R01CA037808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37808, CA 65767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARANOV V, 1994, CANCER RES, V54, P3305; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BRIKEN V, 1995, MOL CELL BIOL, V15, P975; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; CHEN CJ, 1995, CANCER RES, V55, P3873; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGMAN JD, 1983, METHOD ENZYMOL, V101, P582; DVESKSLER GS, 1993, J VIROL, V67, P1; FRANGSMYR L, 1995, CANCER RES, V55, P2963; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAO E, 1993, J BIOL CHEM, V268, P19697; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HIRADA H, 1990, CELL, V63, P303; HSEIH JT, 1995, CANCER RES, V55, P190; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KLEINERMAN DI, 1995, CANCER RES, V55, P2831; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; LEUSCH HG, 1990, FEBS LETT, V261, P405, DOI 10.1016/0014-5793(90)80603-G; MARGOLIS RN, 1990, BIOCHEM BIOPH RES CO, V166, P52; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P195; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MUELLER PR, 1994, CURRENT PROTOCOLS MO; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NAEVE GS, 1992, CELL GROWTH DIFFER, V3, P919; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QUERSHI SA, 1995, P NATL ACAD SCI USA, V92, P3829; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; ROSENBERG M, 1993, CANCER RES, V53, P4938; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; SAUTER SL, 1991, INFECT IMMUN, V59, P2485, DOI 10.1128/IAI.59.7.2485-2493.1991; SAUTER SL, 1993, J BIOL CHEM, V268, P15510; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SKUBITZ KM, 1992, J IMMUNOL, V148, P852; SVENBERG T, 1976, INT J CANCER, V17, P588, DOI 10.1002/ijc.2910170506; SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436; TAKAHASHI H, 1993, CANCER RES, V53, P1612; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TEGLUND S, 1994, GENOMICS, V23, P669, DOI 10.1006/geno.1994.1556; THOMPSON J, 1992, GENOMICS, V12, P761, DOI 10.1016/0888-7543(92)90307-E; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TURBIDE C, 1991, J BIOL CHEM, V266, P309; TYNAN K, 1992, NUCLEIC ACIDS RES, V20, P1629, DOI 10.1093/nar/20.7.1629; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421	57	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28181	28188		10.1074/jbc.271.45.28181	http://dx.doi.org/10.1074/jbc.271.45.28181			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910434	hybrid			2022-12-27	WOS:A1996VU03300034
J	Porter, JE; Hwa, J; Perez, DM				Porter, JE; Hwa, J; Perez, DM			Activation of the alpha(1b)-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1-ADRENERGIC RECEPTOR; LIGAND-BINDING; SITE; IDENTIFICATION; EXPRESSION; RHODOPSIN; SUBTYPES; MUTATION; CLONING; CDNA	Rhodopsin receptor activation in involves the disruption of a salt bridge constraint between glutamic acid 113 on transmembrane 3 and a lysine 296 in transmembrane 7, which forms a Schiffs base with retinal, Light-induced isomerization of cis-retinal to the all trans form breaks this rhodopsin salt bridge leading to receptor activation, The analogous residues in alpha(1b)-adrenergic receptors, aspartic acid 125 and lysine 331, also have the potential of forming a constraining salt bridge holding the receptor to an inactive protein configuration, This alpha(1b)-adrenergic receptor salt bridge constraint is then released upon binding by the receptor agonist. To test this hypothesis, site-directed mutagenesis was used to eliminate the positive charge at position 331 by substitution of an alanine, The expressed alpha(1b)-adrenergic receptor mutant demonstrated a 6-fold increased epinephrine binding affinity with no alterations of affinity values for selective adrenergic receptor antagonists, Furthermore, an increased epinephrine potency for total soluble inositol phosphate production along with an elevated basal inositol triphosphate level was observed in COS-1 cells transfected with mutant versus wild-type alpha(1b)-adrenergic receptors, Similar results were obtained for a lysine to a glutamic acid alpha(1b)-adrenergic receptor mutation. In addition, increased basal inositol triphosphate levels were also observed for two aspartic acid 125 alpha(1b)-adrenergic receptor mutations, consistent with this residue's role as the counterion of the salt bridge, Taken together, these alpha(1b)-adrenergic receptor mutations suggest a molecular mechanism by which the positively charged lysine 331 stabilizes the negatively charged aspartic acid 125 via a salt bridge constraint until bound by the receptor agonist.	CLEVELAND CLIN FDN,RES INST,DEPT MOL CARDIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [F32DE005646] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL52544] Funding Source: Medline; NIDCR NIH HHS [F32-DE05646] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABEL PW, 1995, PHARM COMMUN, V6, P29; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYLUND DB, 1992, FASEB J, V6, P832, DOI 10.1096/fasebj.6.3.1346768; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P8812, DOI 10.1021/bi00027a033; HO BY, 1992, FEBS LETT, V312, P259, DOI 10.1016/0014-5793(92)80948-G; Hwa J, 1996, J BIOL CHEM, V271, P7956, DOI 10.1074/jbc.271.14.7956; Hwa J, 1996, J BIOL CHEM, V271, P6322, DOI 10.1074/jbc.271.11.6322; HWA J, 1995, J BIOL CHEM, V270, P23189, DOI 10.1074/jbc.270.39.23189; HWA J, 1996, AUTONOMIC NERVOUS SY, V8, P49; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P188, DOI 10.1016/S0165-6147(00)89020-3; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; MULTULSKY HJ, 1987, FASEB J, V1, P365; Perez DM, 1996, MOL PHARMACOL, V49, P112; PEREZ DM, 1994, MOL PHARMACOL, V46, P823; PEREZ DM, 1991, MOL PHARMACOL, V40, P876; Piascik MT, 1995, J PHARMACOL EXP THER, V275, P1583; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; RUFFOLO RR, 1991, PHARMACOL REV, V43, P475; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sambrook J., 2002, MOL CLONING LAB MANU; STRADER CD, 1991, J BIOL CHEM, V266, P5; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; WANG CD, 1991, MOL PHARMACOL, V40, P168	25	107	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28318	28323		10.1074/jbc.271.45.28318	http://dx.doi.org/10.1074/jbc.271.45.28318			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910453	hybrid			2022-12-27	WOS:A1996VU03300053
J	Zhong, XT; Kolter, R; Tai, PC				Zhong, XT; Kolter, R; Tai, PC			Processing of colicin V-1, a secretable marker protein of a bacterial ATP binding cassette export system, requires membrane integrity, energy, and cytosolic factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; GENETIC-ANALYSIS; TRANSPORT PROTEINS; ABC TRANSPORTERS; OUTER-MEMBRANE; P-GLYCOPROTEIN; HEMOLYSIN; SECRETION	Extracellular secretion of the peptide antibiotic colicin V (ColV) in Escherichia coli is mediated by a dedicated exporter system consisting of host TolC protein and the products of two specific genes, cvaA and cvaB, the latter being a member of the ATP binding cassette (ABC) superfamily. An amino-terminal export signal of ColV is specific for the CvaA-CvaE-TolC exporter and is processed concomitant with secretion. In this study, we attempt to characterize this processing with a secretable marker protein, ColV-1, using a newly developed in vitro assay. Processing is found to be dependent on both CvaA-CvaB transporters and the TolC protein and to require membrane integrity. An additional cytoplasmic soluble factor(s) is also necessary for the processing. Although the sequence of the cleavage site suggests it could be a substrate, ColV-1 cannot be processed in vitro by the purified leader peptidase I. Moreover, ColV-1 processing is inhibited by antipain and N-ethylmaleimide. Furthermore, the processing requires energy in the form of nucleotide hydrolysis. These results indicate that the processing of ColV-1 is specific and more complex than expected, requiring the CvaA-CvaB-TolC transporter intact in the membrane, energy, and cytosolic factors for rapid cleavage.	GEORGIA STATE UNIV, DEPT BIOL, ATLANTA, GA 30303 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOL GENET, BOSTON, MA 02115 USA	University System of Georgia; Georgia State University; Harvard University; Harvard Medical School								AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; FATH MJ, 1994, BIOCHEMISTRY-US, V33, P6911, DOI 10.1021/bi00188a021; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FATH MJ, 1993, THESIS HARVARD U CAM; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; FELMLEE T, 1988, P NATL ACAD SCI USA, V85, P5269, DOI 10.1073/pnas.85.14.5269; GARRIDO MD, 1988, EMBO J, V7, P1853, DOI 10.1002/j.1460-2075.1988.tb03018.x; GERLACH JH, 1986, NATURE, V324, P485, DOI 10.1038/324485a0; Gething M, 1985, PROTEIN TRANSPORT SE, P103; GILSON L, 1987, J BACTERIOL, V169, P2466, DOI 10.1128/jb.169.6.2466-2470.1987; GILSON L, 1990, EMBO J, V9, P3875, DOI 10.1002/j.1460-2075.1990.tb07606.x; GLASER P, 1988, EMBO J, V7, P3997, DOI 10.1002/j.1460-2075.1988.tb03288.x; GRAY L, 1986, MOL GEN GENET, V205, P127, DOI 10.1007/BF02428042; GRAY L, 1989, J CELL SCI, P45; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAVARSTEIN LS, 1995, MOL MICROBIOL, V16, P229, DOI 10.1111/j.1365-2958.1995.tb02295.x; HAVARSTEIN LS, 1994, MICROBIOL-SGM, V140, P2383, DOI 10.1099/13500872-140-9-2383; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLAND IB, 1990, J BIOENERG BIOMEMBR, V22, P473, DOI 10.1007/BF00763178; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KANE SE, 1990, J BIOENERG BIOMEMBR, V22, P593, DOI 10.1007/BF00762963; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KLAENHAMMER TR, 1992, BACTERIOCINS MICROCI, P37; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KORONAKIS V, 1989, EMBO J, V8, P595, DOI 10.1002/j.1460-2075.1989.tb03414.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETOFFE S, 1990, EMBO J, V9, P1375, DOI 10.1002/j.1460-2075.1990.tb08252.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; OROPEZAWEKERLE RL, 1990, J BACTERIOL, V172, P3711, DOI 10.1128/jb.172.7.3711-3717.1990; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; TAI PC, 1991, METHOD CELL BIOL, V34, P167; TSCHANTZ WR, 1994, METHOD ENZYMOL, V244, P285; VENEMA K, 1995, MOL MICROBIOL, V17, P515, DOI 10.1111/j.1365-2958.1995.mmi_17030515.x; WAGNER W, 1983, J BACTERIOL, V154, P200, DOI 10.1128/JB.154.1.200-210.1983; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANDERSMAN C, 1990, P NATL ACAD SCI USA, V87, P4776, DOI 10.1073/pnas.87.12.4776; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; WATERS VL, 1991, MICROBIOL REV, V55, P437, DOI 10.1128/MMBR.55.3.437-450.1991; WOLIN SL, 1994, CELL, V77, P787, DOI 10.1016/0092-8674(94)90124-4; YANG CC, 1984, J BACTERIOL, V158, P757, DOI 10.1128/JB.158.2.757-759.1984; ZHANG LH, 1995, GENETICS, V141, P25; ZHONG X, UNPUB	51	24	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28057	28063		10.1074/jbc.271.45.28057	http://dx.doi.org/10.1074/jbc.271.45.28057			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910417	hybrid			2022-12-27	WOS:A1996VU03300017
J	Karsan, A; Yee, E; Harlan, JM				Karsan, A; Yee, E; Harlan, JM			Endothelial cell death induced by tumor necrosis factor-alpha is inhibited by the Bcl-2 family member, A1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-MEDIATED CYTOTOXICITY; CERAMIDE-INDUCED APOPTOSIS; GROWTH-FACTOR; RETROVIRAL VECTORS; GENE-TRANSFER; PROTEIN; EXPRESSION; INTERLEUKIN-1; ACTIVATION; RESISTANCE	Endothelial cells play a central role in the inflammatory process, Tumor necrosis factor-cy (TNF) is a multifunctional cytokine which elicits many of the inflammatory responses of endothelial cells, While TNF directly causes apoptosis of tumor cells and virally infected cells, normal cells are generally resistant. However, most resistant cells, including human endothelial cells, can be rendered susceptible to TNF by inhibiting RNA or protein synthesis. This finding suggests that TNF provides a cell survival signal in addition to a death signal. We have previously cloned a human Bcl-2 homologue, Al, and shown that it is specifically induced by proinflammatory cytokines but not by endothelial growth factors. In this study, we show that retroviral-mediated transfer of the Al cDNA to a human microvascular endothelial cell line provides protection against cell death initiated by TNF in the presence of actinomycin D. The induction of Al by TNF in this system is mediated via a protein kinase C pathway, Since TNF signaling has also been shown to proceed via ceramides, we tested whether exogenous ceramides could induce Al, Our findings indicate that ceramides do not induce Al but do up-regulate c-jun and induce endothelial death. Ceramide-activated endothelial death is also inhibited by Al, suggesting that TNF may initiate divergent survival and death pathways via separate lipid second messengers.			Karsan, A (corresponding author), UNIV WASHINGTON,DIV HEMATOL,BOX 357710,SEATTLE,WA 98195, USA.		Karsan, Aly/K-2067-2015		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; ARAKI S, 1990, BIOCHEM BIOPH RES CO, V168, P1194, DOI 10.1016/0006-291X(90)91155-L; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CARMICHAEL J, 1987, CANCER RES, V47, P943; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; FANG W, 1995, J IMMUNOL, V155, P66; HAIMOVITZFRIEDMAN A, 1994, CANCER RES, V54, P2591; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HENNET T, 1993, CANCER RES, V53, P1456; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAATTELA M, 1995, ONCOGENE, V10, P2297; JARVIS WD, 1994, J BIOL CHEM, V269, P31685; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; Karsan A, 1996, BLOOD, V87, P3089, DOI 10.1182/blood.V87.8.3089.bloodjournal8783089; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; KUMAR S, 1991, J BIOL CHEM, V266, P20960; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACIAG T, 1979, P NATL ACAD SCI USA, V76, P5674, DOI 10.1073/pnas.76.11.5674; Masamune A, 1996, J BIOL CHEM, V271, P9368, DOI 10.1074/jbc.271.16.9368; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAWAI H, 1995, J BIOL CHEM, V270, P27326, DOI 10.1074/jbc.270.45.27326; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wallach D, 1986, Interferon, V7, P89; WALLACH D, 1984, J IMMUNOL, V132, P2464; WEPSIC HT, 1989, IMMUNOPHARM IMMUNOT, V11, P81, DOI 10.3109/08923978909082144; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	51	207	214	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27201	27204		10.1074/jbc.271.44.27201	http://dx.doi.org/10.1074/jbc.271.44.27201			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910286	hybrid			2022-12-27	WOS:A1996VQ67900004
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			The minimum functional unit of human P-glycoprotein appears to be a monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATPASE ACTIVITY; NUCLEOTIDE-BINDING SITES; MEMBRANE-PROTEIN; CELLS; MUTANTS; GENE; RECONSTITUTION; PURIFICATION; MUTATIONS; TOPOLOGY	Several studies have demonstrated the presence of oligomers of P-glycoprotein in multidrug-resistant cells. The minimum functional unit of P-glycoprotein, however, is not known. In order to determine whether the functional unit is an oligomer, we tested for associations between P-glycoproteins containing either a histidine tag or the epitope tag for monoclonal antibody A52 at the COOH-terminal end of the molecule. Both tagged molecules were active and had indistinguishable drug resistance profiles. The tagged P-glycoprotin were expressed contemporaneously in HEK 293 cells, purified by nickel-chelate chromatography followed by immuno-blot analysis. We found that P-glycoprotein-A52 did not copurify with functionally active P-glycoprotein-(His)(10), even when the former was overexpressed relative to the histidine-tagged protein. Similar results were obtained with phosphorylation-deficient mutants of P-glycoprotein. By contrast, we could purify and reconstitute drug-stimulated ATPase activity when the half-molecules NH2-terminal half-(His)(10)/COOH-terminal half-A52 or NH2-terminal half-A52/COOH-terminal half-(His)(10) were coexpressed in HEK 293 cells. These results suggest that nickel-chelate chromatography may be a suitable method for studying protein-protein interactions in membrane proteins and that the minimal functional unit of P-glycoprotein is likely to be a monomer.	UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BOSCOBOINIK D, 1990, BIOCHIM BIOPHYS ACTA, V1027, P225, DOI 10.1016/0005-2736(90)90311-B; CASEY JR, 1993, BIOCHEMISTRY-US, V32, P1172, DOI 10.1021/bi00055a023; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Kast C, 1996, J BIOL CHEM, V271, P9240, DOI 10.1074/jbc.271.16.9240; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; LOO TW, 1994, J BIOL CHEM, V269, P28683; NAITO M, 1992, BIOCHEM BIOPH RES CO, V185, P284, DOI 10.1016/S0006-291X(05)80988-X; PORUCHYNSKY MS, 1994, BIOCHEMISTRY-US, V33, P4163, DOI 10.1021/bi00180a009; REITHMEIER RAF, 1994, CURR OPIN CELL BIOL, V6, P583, DOI 10.1016/0955-0674(94)90080-9; SCHINKEL AH, 1995, EUR J CANCER, V31A, P1295, DOI 10.1016/0959-8049(95)00130-B; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schuetz EG, 1996, P NATL ACAD SCI USA, V93, P4001, DOI 10.1073/pnas.93.9.4001; SEKLER I, 1995, J BIOL CHEM, V270, P21028, DOI 10.1074/jbc.270.36.21028; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	27	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27488	27492		10.1074/jbc.271.44.27488	http://dx.doi.org/10.1074/jbc.271.44.27488			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910332	hybrid			2022-12-27	WOS:A1996VQ67900050
J	Nakahara, H; Nomizu, M; Akiyama, SK; Yamada, Y; Yeh, YY; Chen, WT				Nakahara, H; Nomizu, M; Akiyama, SK; Yamada, Y; Yeh, YY; Chen, WT			A mechanism for regulation of melanoma invasion - Ligation of alpha(6)beta(1) integrin by laminin G peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-ADHESION; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; SYNTHETIC PEPTIDES; BETA-1 INTEGRINS; IV COLLAGENASE; SCATTER FACTOR; A CHAIN; FIBRONECTIN	Invasion of LOX human melanoma cells involves extracellular matrix (ECM) degradation and formation of cell surface invadopodia. Here we show that the ligation of alpha(6) beta(1) by two peptides derived from the COOH-terminal globular domain of laminin-1 alpha(1) chain (laminin G peptides), designated AG-10 (NPWHSIYITRFG) and AG-32 (TWYKIAFQRNRK), and antibodies against alpha(6) and beta(1) integrins promoted invasiveness. AG-10 and AG-SB inhibited cell adhesion on laminin, and the antibodies blocked cell adhesion on immobilized AG-10 and AG-32, suggesting that the peptides interact primarily with alpha(6) beta(1) integrin. These soluble peptides and integrin antibodies induced invasiveness by causing an 2-3-fold increase in ECM degradation and invadopodial activity independently of adhesion activity of integrins that were prebound to ECM. The induced ECM degradation and invasion was associated with an increased surface expression of the 170-kDa membrane-bound gelatinase, seprase, as well as its intense localization at invadopodia but not at focal adhesions. However, the total expression levels of seprase, gelatinase A and beta(1) integrins were not altered. We suggest that laminin G peptides act on the alpha(6) beta(1) integrin signaling of invasion by stimulating invadopodial activities, which is distinct from their direct effects on cell adhesion on immobilized ECM.	GEORGETOWN UNIV,MED CTR,LOMBARDI CANC CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT CELL BIOL,WASHINGTON,DC 20007; NIDR,DEV BIOL LAB,NIH,BETHESDA,MD 20892	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)					NCI NIH HHS [R01 CA-39077] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039077] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; CHEN WT, 1994, BREAST CANCER RES TR, V31, P217, DOI 10.1007/BF00666155; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; KELLY T, 1994, J CELL PHYSIOL, V158, P299, DOI 10.1002/jcp.1041580212; KIKKAWA Y, 1994, J BIOCHEM-TOKYO, V116, P862, DOI 10.1093/oxfordjournals.jbchem.a124608; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MACKAY AR, 1994, LAB INVEST, V70, P800; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; MONSKY WL, 1994, CANCER RES, V54, P5702; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; MUELLER SC, 1989, J CELL BIOL, V109, P3455, DOI 10.1083/jcb.109.6.3455; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; RAMOS DM, 1990, CANCER RES, V50, P728; SCHWARTZ MA, 1991, P NATL ACAD SCI USA, V88, P7849, DOI 10.1073/pnas.88.17.7849; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; SEFTOR REB, 1993, CANCER RES, V53, P3411; STACK MS, 1993, CANCER RES, V53, P1998; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TURPEENNIEMIHUJANEN T, 1986, J BIOL CHEM, V261, P1883; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMAMURA K, 1993, CANCER RES, V53, P423	30	102	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27221	27224		10.1074/jbc.271.44.27221	http://dx.doi.org/10.1074/jbc.271.44.27221			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910291	hybrid			2022-12-27	WOS:A1996VQ67900009
J	Saftig, P; Peters, C; vonFigura, K; Craessaerts, K; VanLeuven, F; DeStrooper, B				Saftig, P; Peters, C; vonFigura, K; Craessaerts, K; VanLeuven, F; DeStrooper, B			Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; CANINE KIDNEY-CELLS; BETA-PROTEIN; CLEAVAGE; MUTATION; PATHWAY; EXPRESSION; IDENTIFICATION; PROTEASES; FRAGMENTS	beta A4-Amyloid peptide, the main component of the amyloid plaques in the brain of Alzheimer's disease patients is produced from amyloid precursor protein (APP) by proteolytical processing. Several lines of evidence suggest a direct role for cathepsin D, the major endosomal/lysosomal aspartic endopeptidase, in beta A4-amyloid peptide generation, Here we tested this hypothesis using primary cultures of hippocampal neurons derived from cathepsin D-deficient (knock out) mice and expressing wild-type human APP and two clinical APP variants via recombinant Semliki Forest virus. We demonstrate APP secretory processing, production of carboxyl-terminal amyloid fragments, and secretion of the beta A4-amyloid peptide in the complete absence of cathepsin D. The results rule out cathepsin D as a critical component of alpha-, beta-, or gamma-secretase and therefore as a primary target for drugs aimed at decreasing the beta A4-amyloid peptide burden in Alzheimer's disease.	UNIV HOSP GASTHUISBERG,CTR HUMAN GENET,EXPT GENET GRP,B-3000 LOUVAIN,BELGIUM; UNIV GOTTINGEN,ZENTRUM BIOCHEM & MOL ZELLBIOL,BIOCHEM ABT 2,D-37073 GOTTINGEN,GERMANY	KU Leuven; University Hospital Leuven; University of Gottingen			de+Strooper, Bart/Z-1638-2019; De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010	De Strooper, Bart/0000-0001-5455-5819; 				CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1990, P NATL ACAD SCI USA, V87, P3861, DOI 10.1073/pnas.87.10.3861; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DESTROOPER B, 1993, J CELL BIOL, V121, P295, DOI 10.1083/jcb.121.2.295; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DIEDRICH JF, 1991, J VIROL, V65, P4759, DOI 10.1128/JVI.65.9.4759-4768.1991; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1985, J BIOL CHEM, V260, P5311; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goslin K., 1991, CULTURING NERVE CELL, P251; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KOHNKEN RE, 1995, EXP NEUROL, V133, P105, DOI 10.1006/exnr.1995.1013; KONIG G, 1992, J BIOL CHEM, V267, P10804; KOO EH, 1994, J BIOL CHEM, V269, P17386; KUENTZEL SL, 1993, BIOCHEM J, V295, P367, DOI 10.1042/bj2950367; LADROR US, 1994, J BIOL CHEM, V269, P18422; LO ACY, 1994, J BIOL CHEM, V269, P30966; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; REID WA, 1986, J CLIN PATHOL, V39, P1323, DOI 10.1136/jcp.39.12.1323; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; SCHWAGERL AL, 1995, J NEUROCHEM, V64, P443; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SIMAN R, 1993, J BIOL CHEM, V268, P16602; Simons M, 1996, J NEUROSCI, V16, P899; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; VANNOORT JM, 1994, EUR J IMMUNOL, V24, P2175, DOI 10.1002/eji.1830240936; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	45	77	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27241	27244		10.1074/jbc.271.44.27241	http://dx.doi.org/10.1074/jbc.271.44.27241			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910296	hybrid			2022-12-27	WOS:A1996VQ67900014
J	Singh, US; Cerione, RA				Singh, US; Cerione, RA			Biochemical effects of retinoic acid on GTP-binding protein transglutaminases in HeLa cells - Stimulation of GTP-binding and transglutaminase activity, membrane association, and phosphatidylinositol lipid turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; TISSUE TRANSGLUTAMINASE; KERATINOCYTE TRANSGLUTAMINASE; FACTOR-XIII; ALPHA-1-ADRENERGIC RECEPTOR; ANCHORAGE REGION; EPIDERMAL-CELLS; IDENTIFICATION; EXPRESSION; DIFFERENTIATION	Treatment of HeLa cells with retinoic acid (RA) gives rise to a marked stimulation in the incorporation of [alpha-P-32]GTP into an similar to 87-kDa cytosolic protein that cross reacts with a monoclonal antibody raised against tissue transglutaminases. In the absence of RA treatment, the transglutaminase immunoreactivity elutes from a gel filtration column with an apparent size of similar to 600 kDa (designated TGa), whereas following RA treatment, a second peak of transglutaminase immunoreactivity (described TGb) is detected with an apparent size of similar to 150 kDa, The TGa fractions show little or no GTP-binding or GTP hydrolytic activity and very little transglutaminase activity, However, the TGb fractions show all three activities. Retinoic acid treatment also promotes the association of the GTP-binding protein/transglutaminase with membrane fractions, as detected by Western blotting and photoaffinity cross-linking with [alpha-P-32]GTP. In addition, the TGb fraction shows a markedly enhanced ability (relative to TGa) to associate with membranes from control (non-RA-treated) cells. The ability of the GTP-binding protein/transglutaminase to bind to membranes is correlated with the stimulation of a membrane-associated phospholipase C activity, Thus, these findings indicate that RA treatment results ill a number of changes in the biochemical properties of a GTP-binding protein/transglutaminase which strongly enhance its ability to bind GTP, associate with plasma membranes, and stimulate phosphoinositide Lipid turnover.	CORNELL UNIV,CTR VET MED,DEPT PHARMACOL,ITHACA,NY 14853	Cornell University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; BERTRAM JS, 1983, CANCER SURV, V2, P243; CARIELLO L, 1984, BIOCHEMISTRY-US, V23, P6843, DOI 10.1021/bi00321a087; CERLONE RA, 1984, BIOCHEMISTRY-US, V23, P4519; CHAKRAVARTY R, 1990, BIOCHEM J, V271, P25, DOI 10.1042/bj2710025; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; CHEN R, 1970, P NATL ACAD SCI USA, V66, P472, DOI 10.1073/pnas.66.2.472; CHIOCCA EA, 1988, J BIOL CHEM, V263, P11584; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; DIVECHA N, 1993, BIOCHEM J, V289, P617, DOI 10.1042/bj2890617; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1983, ADV ENZYMOL RAMB, V54, P1; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P4633, DOI 10.1021/bi00364a027; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1990, J BIOL CHEM, V265, P18944; KIM HC, 1990, J BIOL CHEM, V265, P21971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; LICHTI U, 1985, J BIOL CHEM, V260, P1422; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; NARA K, 1989, J BIOL CHEM, V264, P19308; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; RAGSDALE CW, 1989, NATURE, V341, P654, DOI 10.1038/341654a0; RICE RH, 1990, BIOCHEM J, V265, P351, DOI 10.1042/bj2650351; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SPORN MB, 1983, CANCER RES, V43, P3034; TAKAGI T, 1974, BIOCHEMISTRY-US, V13, P750, DOI 10.1021/bi00701a018; THACHER SM, 1985, CELL, V40, P685, DOI 10.1016/0092-8674(85)90217-X; UUSPA SH, 1982, J BIOL CHEM, V257, P9906; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	36	39	39	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27292	27298		10.1074/jbc.271.44.27292	http://dx.doi.org/10.1074/jbc.271.44.27292			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910304	hybrid			2022-12-27	WOS:A1996VQ67900022
J	Takahashi, M; Hood, DA				Takahashi, M; Hood, DA			Protein import into subsarcolemmal and intermyofibrillar skeletal muscle mitochondria - Differential import regulation in distinct subcellular regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE TRANSCARBAMYLASE PRECURSOR; RAT CARDIAC-MUSCLE; MALATE-DEHYDROGENASE; INNER MEMBRANE; MAMMALIAN MITOCHONDRIA; INTERFIBRILLAR MITOCHONDRIA; OXIDATIVE-PHOSPHORYLATION; INTERMEMBRANE SPACE; YEAST MITOCHONDRIA; TRANSIT PEPTIDE	To date, no studies have described the import of proteins in mitochondria obtained from skeletal muscle. In this tissue, mitochondria consist of the functionally and biochemically distinct intermyofibrillar (IMF) and subsarcolemmal (SS) subfractions, which are localized in specialized cellular compartments, This mitochondrial heterogeneity in muscle could be due, in part, to differential rates of protein import, To evaluate this possibility, the import of precursor malate dehydrogenase and ornithine carbamyltransferase proteins was investigated in isolated IMF and SS mitochondria in vitro, Import of these was 3-4-fold greater in IMF compared with SS mitochondria as a function of time, This could account for the higher malate dehydrogenase enzyme activity in IMF mitochondria, Divergent import rates in IMF and SS mitochondria likely result from a differential reliance on various components of the import pathway, SS mitochondria possess a greater content of the molecular chaperones hsp60 and Grp75, yet import is lower than in IMF mitochondria, On the other hand, adriamycin inhibition studies illustrated a greater reliance on acidic phospholipids (i.e. cardiolipin) for the import process in SS mitochondria, Matrix ATP levels were 3-fold higher in IF mitochondria, but experiments in which ATP depletion was performed with atractyloside and oligomycin illustrated a dissociation between import rates and levels of ATP, In contrast, a close relationship was found between the rate of ATP production (i.e. mitochondrial respiration) and protein import, When respiratory rates in IMF and SS mitochondria were equalized, import rates in both subfractions were similar, These data indicate that 1) import rates are more closely related to the rate of ATP production than the steady state ATP level, 2) import into IMF and SS mitochondrial subfractions is regulated differently, and 3) mitochondrial heterogeneity within a cell type can be due to differences in the rates of protein import, suggesting that this step is a potentially regulatable event in determining the final mitochondrial phenotype.	YORK UNIV,DEPT BIOL,N YORK,ON M3J 1P3,CANADA; YORK UNIV,DEPT KINESIOL,N YORK,ON M3J 1P3,CANADA	York University - Canada; York University - Canada								ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BEASLEY E M, 1992, Current Opinion in Cell Biology, V4, P646, DOI 10.1016/0955-0674(92)90084-P; CASCARANO J, 1995, HEPATOLOGY, V22, P837, DOI 10.1016/0270-9139(95)90306-2; CHIEN SM, 1984, J BIOL CHEM, V259, P3633; CHU TW, 1987, J BIOL CHEM, V262, P12806; CHU TW, 1989, J BIOL CHEM, V264, P9552; COGSWELL AM, 1993, AM J PHYSIOL, V264, pC383, DOI 10.1152/ajpcell.1993.264.2.C383; CONBOY JG, 1982, BIOCHEM BIOPH RES CO, V105, P1, DOI 10.1016/S0006-291X(82)80002-8; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; COTE C, 1990, BIOCHEM BIOPH RES CO, V170, P1273, DOI 10.1016/0006-291X(90)90531-Q; DECERQUEIRA CM, 1995, ARCH BIOCHEM BIOPHYS, V324, P9; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DUAN JM, 1989, CAN J PHYSIOL PHARM, V67, P704, DOI 10.1139/y89-114; DUAN JM, 1989, MOL CELL BIOCHEM, V90, P47; EILERS M, 1989, J BIOL CHEM, V264, P2945; ELANDER A, 1985, CLIN SCI, V69, P153, DOI 10.1042/cs0690153; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; Essig D A, 1996, Exerc Sport Sci Rev, V24, P289; GILLESPIE LL, 1985, J BIOL CHEM, V260, P6045; GLICK BS, 1993, PROTEIN SCI, V2, P1901, DOI 10.1002/pro.5560021112; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; GOGLIA F, 1988, BIOCHEM BIOPH RES CO, V151, P1241, DOI 10.1016/S0006-291X(88)80499-6; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; HARTMANN CM, 1991, BIOCHEM BIOPH RES CO, V174, P1232, DOI 10.1016/0006-291X(91)91553-O; HOOD DA, 1989, FEBS LETT, V247, P471, DOI 10.1016/0014-5793(89)81393-6; HOOD DA, 1994, CAN J APPL PHYSIOL, V19, P12, DOI 10.1139/h94-002; HOOD DA, 1992, COMP BIOCHEM PHYS A, V101, P597, DOI 10.1016/0300-9629(92)90514-Q; HOPPEL CL, 1982, J BIOL CHEM, V257, P1540; HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248; Komiya T, 1996, EMBO J, V15, P399, DOI 10.1002/j.1460-2075.1996.tb00370.x; KONDO H, 1990, P SOC EXP BIOL MED, V196, P83; KRIEGER DA, 1980, J APPL PHYSIOL, V48, P23, DOI 10.1152/jappl.1980.48.1.23; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; Leenhouts JM, 1995, BIOCHEM SOC T, V23, P968, DOI 10.1042/bst0230968; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; LOPEZMEDIAVILLA C, 1989, FEBS LETT, V254, P115, DOI 10.1016/0014-5793(89)81020-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACLACHLAN LK, 1994, BIOCHEM J, V303, P657, DOI 10.1042/bj3030657; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P98, DOI 10.1139/y82-016; MANDIEAU V, 1995, FEBS LETT, V368, P15, DOI 10.1016/0014-5793(95)00577-V; MARTIN TP, 1987, COMP BIOCHEM PHYS B, V88, P273, DOI 10.1016/0305-0491(87)90113-1; MARTINUS RD, 1995, FASEB J, V9, P371, DOI 10.1096/fasebj.9.5.7896006; MCMILLINWOOD J, 1980, BIOCHIM BIOPHYS ACTA, V591, P251, DOI 10.1016/0005-2728(80)90157-7; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; NEUPERT NW, 1993, MOL CHAPERONES, P99; NGUYEN M, 1986, J BIOL CHEM, V261, P800; OGATA T, 1985, CELL TISSUE RES, V241, P251, DOI 10.1007/BF00217168; ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119; OU WJ, 1988, J BIOCHEM-TOKYO, V103, P589, DOI 10.1093/oxfordjournals.jbchem.a122312; PALMER JW, 1977, J BIOL CHEM, V252, P8731; PALMER JW, 1985, ARCH BIOCHEM BIOPHYS, V236, P691, DOI 10.1016/0003-9861(85)90675-7; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PINSKY WW, 1981, AM J PHYSIOL, V240, pH326, DOI 10.1152/ajpheart.1981.240.3.H326; RALSTON E, 1992, J CELL BIOL, V119, P1063, DOI 10.1083/jcb.119.5.1063; RILEY DA, 1990, FASEB J, V4, P84, DOI 10.1096/fasebj.4.1.2153085; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARZ E, 1994, BBA-BIOENERGETICS, V1187, P270, DOI 10.1016/0005-2728(94)90125-2; SHORE GC, 1983, METHOD ENZYMOL, V97, P396; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SKERJANC I, 1987, EMBO J, V6, P6117; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; SZTUL ES, 1989, J CELL SCI, V94, P695; SZTUL ES, 1987, J CELL BIOL, V105, P2631, DOI 10.1083/jcb.105.6.2631; TAKAHASHI M, 1993, J APPL PHYSIOL, V74, P934, DOI 10.1152/jappl.1993.74.2.934; TERADA K, 1995, MOL CELL BIOL, V15, P3708; THOMPSON LM, 1989, J BIOL CHEM, V264, P12091; VERNER K, 1987, EMBO J, V6, P2449, DOI 10.1002/j.1460-2075.1987.tb02524.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WANG Y, 1994, BIOCHEMISTRY-US, V33, P12860, DOI 10.1021/bi00209a018; WEBSTER TJ, 1994, DNA CELL BIOL, V13, P1213, DOI 10.1089/dna.1994.13.1213; WEINSTEIN ES, 1985, ARCH SURG-CHICAGO, V120, P332; WINDER W, 1980, PLASTICITY MUSCLE, P581; ZARA V, 1992, J BIOL CHEM, V267, P12077	77	102	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27285	27291		10.1074/jbc.271.44.27285	http://dx.doi.org/10.1074/jbc.271.44.27285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910303	hybrid			2022-12-27	WOS:A1996VQ67900021
J	Tsuboi, S; Isogai, Y; Hada, N; King, JK; Hindsgaul, O; Fukuda, M				Tsuboi, S; Isogai, Y; Hada, N; King, JK; Hindsgaul, O; Fukuda, M			6'-sulfo sialyl Le(x) but not 6-sulfo sialyl Le(x) expressed on the cell surface supports L-selectin-mediated adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT METASTATIC POTENTIALS; ENDOTHELIAL-DERIVED LIGAND; HAMSTER OVARY CELLS; MAJOR CAPPING GROUP; FUCOSYL-TRANSFERASE; LEWIS-X; O-GLYCANS; LINKED OLIGOSACCHARIDES; CARBOHYDRATE LIGAND; MOLECULAR-CLONING	In order to determine if a sulfated oligosaccharide on the cell surface can function as an L-selectin ligand, a novel approach for in vitro transfer of oligosaccharides was utilized (Srivastava, G., Kaun, K. J., Hindsgaul, O., and Palcic, M. M. (1992) J. Biol. Chem. 267, 22356-22361). CHO cells were incubated with synthetic 6'-sulfo sialyl Le(x), NeuNAc alpha 2-->3(sulfate-6)Gal beta 1-->4(Fuc alpha 1-->3)GlcNAc or 6-sulfo sialyl Le(x), NeuNAc alpha 2-->3Gal beta 1-->4[(Fuc-alpha 1-->3)sulfate-->6GlcNAc] oligosaccharide linked to C-6 of a fucose residue in GDP-fucose and a milk fucosyltransferase, The resultant CHO cells expressing 6'-sulfo sialyl Le(x) or 6-sulfo sialyl Le(x) on their cell surface were tested for adhesion to E-selectin and L-selectin chimeric proteins coated on plates, The results indicate that 6'-sulfo sialyl Le(x) supports L-selectin-mediated adhesion much better than sialyl Le(x) similarly tagged on the cell surface, In contrast, 6 sulfo sialyl Le(x) containing a sulfate group on the N-acetylglucosamine residue did not support adhesion with either selectin, These combined results suggest that 6'-sulfo sialyl Lex is a much better ligand than sialyl Le(x) oligosaccharide for L-selectin.	BURNHAM INST,LA JOLLA CANC RES CTR,GLYCOBIOL PROGRAM,LA JOLLA,CA 92037; UNIV ALBERTA,DEPT CHEM,EDMONTON,AB T6G 2G2,CANADA	Sanford Burnham Prebys Medical Discovery Institute; University of Alberta					NATIONAL CANCER INSTITUTE [P01CA071932, R01CA048737, R37CA033000] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA33000, P01 CA71932, R01 CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERTOZZI CR, 1995, BIOCHEMISTRY-US, V34, P14271, DOI 10.1021/bi00044a001; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HALLGREN C, 1995, J CARBOHYD CHEM, V14, P453, DOI 10.1080/07328309508005350; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HO MK, 1983, J BIOL CHEM, V258, P636; IMAI Y, 1993, NATURE, V361, P555; JAIN RK, 1994, J AM CHEM SOC, V116, P12123, DOI 10.1021/ja00105a091; JOHNSON PH, 1982, BIOCHEM SOC T, V10, P445; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; PRIEELS JP, 1981, J BIOL CHEM, V256, P456; ROSEN SD, 1985, SCIENCE, V228, P1005, DOI 10.1126/science.4001928; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SASAKI H, 1987, J BIOL CHEM, V262, P12059; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SAWADA R, 1994, J BIOL CHEM, V269, P1425; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SMITH DF, 1990, J BIOL CHEM, V265, P6225; SRIVASTAVA G, 1992, J BIOL CHEM, V267, P22356; STOOLMAN LM, 1984, J CELL BIOL, V99, P1535, DOI 10.1083/jcb.99.4.1535; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	43	80	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27213	27216		10.1074/jbc.271.44.27213	http://dx.doi.org/10.1074/jbc.271.44.27213			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910289	hybrid			2022-12-27	WOS:A1996VQ67900007
J	Anderson, MS; Lopes, JM				Anderson, MS; Lopes, JM			Carbon source regulation of PIS1 gene expression in Saccharomyces cerevisiae involves the MCM1 gene and the two-component regulatory gene, SLN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL SYNTHASE; 2-COMPONENT REGULATORS; STRUCTURAL GENE; INO1 PROMOTER; CELL-WALL; YEAST; INOSITOL; IDENTIFICATION	The Saccharomyces cerevisiae PISI gene encodes phosphatidylinositol synthase. The amount of phosphatidylinositol synthase is not affected by the presence of inositol and choline in the growth medium. This is unusual because the amounts and/or activities of other phospholipid biosynthetic enzymes are affected by these precursors, and the promoter of the PIS1 gene contains a sequence resembling the regulatory element that coordinates the inositol-mediated regulation (UAS(INO)). We found that transcription of the PIS1 gene was insensitive to inositol and choline and did not require the putative UAS(INO) regulatory sequence or the cognate regulatory genes (INO2 and OPI1). The PIS1 promoter includes sequences (MCEs) that hind the Mcm1 protein. Because the Mcm1 protein interacts with both the Sln1 and the Gal11 regulatory proteins, we examined the effect of mutant alleles of the MCMI and SLN1 genes and carbon source on expression of the PISI. gene. We found that expression of the PIS1 gene was reduced when cells were grown in a medium containing glycerol and increased when grown in a medium containing galactose relative to cells grown in a glucose medium. The glycerol-mediated repression of PIS1 gene expression required both the MCM1 gene and the MCEs, whereas the SLN1 gene was required for full galactose-mediated induction of a PIS1-lacZ reporter gene. Thus, PISI gene expression is unique among the phospholipid biosynthetic structural genes because it is uncoupled from the inositol response and regulated in response to the carbon source. This is the first example in yeast of a complete circuit linking a stimulus (carbon source) to gene regulation (PIS1) using a two-component regulator (SLN1).	LOYOLA UNIV,DEPT MOL & CELLULAR BIOL,PROGRAM MOL BIOL,MAYWOOD,IL 60153	Loyola University Chicago								AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BACCHAWAT N, 1995, J BIOL CHEM, V270, P25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BUTLER G, 1988, CURR GENET, V14, P405, DOI 10.1007/BF00521261; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CHAMBERS A, 1989, MOL CELL BIOL, V9, P5516, DOI 10.1128/MCB.9.12.5516; CULBERTSON MR, 1976, J BACTERIOL, V126, P232, DOI 10.1128/JB.126.1.232-242.1976; DENIS CL, 1983, J BIOL CHEM, V258, P1165; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; ELBLE R, 1991, P NATL ACAD SCI USA, V88, P10966, DOI 10.1073/pnas.88.23.10966; ELION EA, 1984, CELL, V39, P663, DOI 10.1016/0092-8674(84)90473-2; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, V2, P193; KELLY BL, 1990, BIOCHIM BIOPHYS ACTA, V1046, P144, DOI 10.1016/0005-2760(90)90181-V; KODAKI T, 1991, J BIOCHEM-TOKYO, V109, P276; KOIPALLY J, 1996, IN PRESS YEAST; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KUO MH, 1994, MOL CELL BIOL, V14, P348, DOI 10.1128/MCB.14.1.348; LAWTHER RP, 1990, J BACTERIOL, V172, P2320, DOI 10.1128/jb.172.5.2320-2327.1990; LI ZY, 1993, MOL GEN GENET, V241, P680, DOI 10.1007/BF00279911; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MEYERS AM, 1986, GENE, V45, P299; MORGAN BA, 1995, EMBO J, V14, P5679, DOI 10.1002/j.1460-2075.1995.tb00255.x; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; NIKAWA JI, 1988, J BACTERIOL, V170, P4727, DOI 10.1128/jb.170.10.4727-4731.1988; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PAPCIAK SM, 1992, MOL GEN GENET, V234, P22, DOI 10.1007/BF00272341; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SWIFT S, 1995, NUCLEIC ACIDS RES, V23, P1426, DOI 10.1093/nar/23.8.1426; WHITE MJ, 1991, J BIOL CHEM, V266, P863; YU GY, 1995, J BIOL CHEM, V270, P8739, DOI 10.1074/jbc.270.15.8739; YU GY, 1993, MOL CELL BIOL, V13, P63, DOI 10.1128/MCB.13.1.63	50	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26596	26601		10.1074/jbc.271.43.26596	http://dx.doi.org/10.1074/jbc.271.43.26596			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900132	hybrid			2022-12-27	WOS:A1996VP23300026
J	Hartland, RP; Fontaine, T; Debeaupuis, JP; Simenel, C; Delepierre, M; Latge, JP				Hartland, RP; Fontaine, T; Debeaupuis, JP; Simenel, C; Delepierre, M; Latge, JP			A novel beta-(1-3)-glucanosyltransferase from the cell wall of Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CANDIDA-ALBICANS; BETA-GLUCAN; ENZYMATIC-SYNTHESIS; BGL2 GENE; CHITIN; YEAST; TRANSGLYCOSYLATION; OLIGOSACCHARIDES; XYLOGLUCAN	Cell wall transferases utilizing beta-(1-3)-glucan chains as substrates may play important roles in cell wall assembly and rearrangement, as beta-(1-3)-glucan is a major structural component of the cell wall of many fungi, A novel beta-(1-3)-glucanosyltransferase was purified to apparent homogeneity from an autolysate of the cell wall of Aspergillus fumigatus. The enzyme had a molecular mass of 49 kDa and contained approximately 5 kDa of N-linked carbohydrate. The enzyme catalyzed an initial endo-type splitting of a beta-(1-3) glucan molecule, followed by linkage of the newly generated reducing end to the nonreducing end of another beta-(13)-glucan molecule, Laminarioligosaccharides of size G(10) and greater were donor substrates for the transferase, Laminarioligosaccharides of size G(5) and greater formed accepters. The enzyme was able to reuse initial transferase products as donors and accepters in extended incubations, resulting in the formation of increasingly larger transferase products until they became insoluble. The major initial products from an incubation of the transferase with borohydride-reduced G(11) (rG(11)) were rG(6) and rG(16). H-1 MMR analysis of the rG(16) transferase product showed it was a laminarioligosaccharide, indicating that the enzyme forms a beta-(1-3)-linkage during transfer. The enzyme may have a key function in vivo by allowing the integration of newly synthesized glucan into the wall and promoting cell wall expansion during cell growth.	INST PASTEUR, ASPERGILLUS LAB, F-75724 PARIS 15, FRANCE; INST PASTEUR, LAB NUCL MAGNET RESONANCE, F-75724 PARIS 15, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Fontaine, thierry/Q-2201-2018; Fontaine, Thierry/F-8227-2011; latge, jean paul/F-3581-2011; Latge, Jean Paul/C-9846-2014; Debeaupuis, Jean-Paul/A-2035-2012	Fontaine, thierry/0000-0002-8184-789X; 				Ashwell G., 1966, METHODS ENZYMOLOGY, V8, P85; CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CABIB E, 1988, MICROBIOL SCI, V5, P370; COEN ML, 1994, MICROBIOL-SGM, V140, P2229, DOI 10.1099/13500872-140-9-2229; Fleet G.H., 1991, YEASTS, VVol. 4, P199, DOI [10.1002/jobm.19720120411, DOI 10.1002/JOBM.19720120411]; FRY SC, 1992, BIOCHEM J, V282, P821, DOI 10.1042/bj2820821; FRY SC, 1989, PHYSIOL PLANTARUM, V75, P532, DOI 10.1111/j.1399-3054.1989.tb05620.x; FRY SC, 1989, J EXP BOT, V40, P1, DOI 10.1093/jxb/40.1.1; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; GOODAY GW, 1993, J APPL BACTERIOL, V74, pS12, DOI 10.1111/j.1365-2672.1993.tb04338.x; HARTLAND RP, 1991, P ROY SOC B-BIOL SCI, V246, P155, DOI 10.1098/rspb.1991.0138; HARTLAND RP, 1994, YEAST, V10, P1591, DOI 10.1002/yea.320101208; HEARN VM, 1994, MICROBIOL-UK, V140, P789, DOI 10.1099/00221287-140-4-789; KAPTEYN JC, 1995, J BACTERIOL, V177, P3788, DOI 10.1128/jb.177.13.3788-3792.1995; KLEBL F, 1989, J BACTERIOL, V171, P6259, DOI 10.1128/jb.171.11.6259-6264.1989; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; KOPECKA M, 1986, ARCH MICROBIOL, V143, P387, DOI 10.1007/BF00412807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATGE JP, 1994, INFECT IMMUN, V62, P5424; MATSUI I, 1991, BIOCHIM BIOPHYS ACTA, V1077, P416, DOI 10.1016/0167-4838(91)90560-M; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MRSA V, 1993, J BACTERIOL, V175, P2102, DOI 10.1128/JB.175.7.2102-2106.1993; NAKAMURA A, 1994, FEBS LETT, V337, P66, DOI 10.1016/0014-5793(94)80631-4; NILSSON KGI, 1988, TRENDS BIOTECHNOL, V6, P256, DOI 10.1016/0167-7799(88)90058-3; NISHITANI K, 1992, J BIOL CHEM, V267, P21058; Peberdy J., 1990, BIOCH CELL WALLS MEM, P5, DOI [10.1007/978-3-642-74215-6_2, DOI 10.1007/978-3-642-74215-6_2]; RAM SP, 1988, LIFE SCI ADV, V7, P379; RUIZHERRERA J, 1991, ANTON LEEUW INT J G, V60, P73, DOI 10.1007/BF00572695; SAITO H, 1990, BIOPOLYMERS, V29, P1689, DOI 10.1002/bip.360291402; SANZ P, 1985, J GEN MICROBIOL, V131, P2925; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; SIETSMA JH, 1979, J GEN MICROBIOL, V114, P99, DOI 10.1099/00221287-114-1-99; SINNOT ML, 1989, ENZYME MECH, P259; SMITH RC, 1991, BIOCHEM J, V279, P529, DOI 10.1042/bj2790529; STONE BA, 1992, CHEM BIOL 1 3 BETA G, P1; SULLIVAN PA, 1991, FEMS SYMP, V50, P35; SURARIT R, 1988, J GEN MICROBIOL, V134, P1723; USUI T, 1990, CARBOHYD RES, V203, P65, DOI 10.1016/0008-6215(90)80046-6; VANRINSUM J, 1991, YEAST, V7, P717, DOI 10.1002/yea.320070707; WESSELS JGH, 1990, TIP GROWTH PLANT FUN, P1; YU LP, 1993, J BIOMOL NMR, V3, P429	43	95	100	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26843	26849		10.1074/jbc.271.43.26843	http://dx.doi.org/10.1074/jbc.271.43.26843			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900166	hybrid			2022-12-27	WOS:A1996VP23300060
J	Li, WQ; Li, W; Chen, XH; Kelley, CA; Alimandi, M; Zhang, JC; Chen, Q; Bottaro, DP; Pierce, JH				Li, WQ; Li, W; Chen, XH; Kelley, CA; Alimandi, M; Zhang, JC; Chen, Q; Bottaro, DP; Pierce, JH			Identification of tyrosine 187 as a protein kinase C-delta phosphorylation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATION; ACTIVATION; PKC	Protein kinase C-delta (PKC-delta) has been demonstrated to be phosphorylated on tyrosine residue(s) in many different biological systems (Li, W., Yu, J.-C., Michieli, P., Beeler, J. F., Ellmore, N., Heidaran, M. A., and Pierce, J. H. (1994) Mol. Cell. Biol. 14, 6727-6735; Li, W., Mischak, H., Yu, J.-C., Wang, L.-M., Mushinski, J. F., Heidaran, M. A., and Pierce, J. H. (1994) J. Biol. Chem. 269, 2349-2352; Denning, M. F., Dlugosz, A. A., Howett, M. A., and Yuspa, S. H. (1993) J. Biol. Chem. 268, 26079-26081). Tyrosine phosphorylation of PKC-delta has also been shown to occur in vitro when purified PKC-delta is coincubated with different tyrosine kinase sources. However, the tyrosine phosphorylation site(s) is currently unknown and the exact effect of this phosphorylation on its serine/threonine kinase activity and biological functions is still controversial. To directly investigate the potential role of PKC-delta tyrosine phosphorylation, tyrosine 187 was converted to phenylalanine (PKC-delta Y187F) by site-directed mutagenesis, and expression vectors containing PKC-delta Y187F cDNAs were transfected into both 32D myeloid progenitor cells and NIH 3T3 fibroblasts. The results showed that tyrosine 187 of PKC-delta became phosphorylated in vivo in response to 12-O-tetradecanoylphorbol-13-acetate stimulation or platelet-derived growth factor receptor activation. In vivo labeling and subsequent two-dimensional phosphopeptide analysis demonstrated that one phosphopeptide was absent in PKC-delta Y187F when compared to wild type PKC-delta, further substantiating that tyrosine 187 of PKC-delta is phosphorylated in vivo. Although the phosphotyrosine content of PKC-delta Y187F was reduced compared with PKC-delta WT, the kinase activity of PKC-delta Y187F toward a PKC-delta substrate was not altered. Moreover, 12-O-tetradecanoylphorbol-13-acetate-mediated monocytic differentiation of 32D cells was not affected by expression of the PKC-delta Y187F mutant. Taken together, these results suggest that tyrosine phosphorylation of PKC-delta on 187 may not influence PKC-delta activation and known functions.	UNIV CHICAGO, BEN MAY INST CANC RES, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA; NHLBI, NATL INST HLTH, BETHESDA, MD 20892 USA	University of Chicago; University of Chicago; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Li, WQ (corresponding author), NCI, CELLULAR & MOL BIOL LAB, BLDG 37, RM 1E24, BETHESDA, MD 20892 USA.		Bottaro, Donald P/AAF-3853-2020; Alimandi, Maurizio/AAG-9246-2019; Bottaro, Donald P/F-8550-2010	Bottaro, Donald P/0000-0002-5057-5334; Alimandi, Maurizio/0000-0002-1409-6803; Bottaro, Donald P/0000-0002-5057-5334				DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Li W, 1996, CURR TOP MICROBIOL, V211, P55; Li WQ, 1996, ONCOGENE, V13, P731; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO S, 1991, ADV ENZYME REGUL, V31, P287, DOI 10.1016/0065-2571(91)90018-H; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH H, 1995, P NATL ACAD SCI USA, V92, P9112; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490	15	64	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26404	26409		10.1074/jbc.271.42.26404	http://dx.doi.org/10.1074/jbc.271.42.26404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824297	hybrid			2022-12-27	WOS:A1996VN18000103
J	Taupiac, MP; Alami, M; Beaumelle, B				Taupiac, MP; Alami, M; Beaumelle, B			Translocation of full-length Pseudomonas exotoxin from endosomes is driven by ATP hydrolysis but requires prior exposure to acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICIN-A CHAIN; PURIFIED ENDOSOMES; ENDOCYTIC PATHWAY; DIPHTHERIA-TOXIN; GOLGI-APPARATUS; MEMBRANE; PROTEIN; RECEPTOR; CELL; CYTOTOXICITY	We attached human transferrin to Pseudomonas exotoxin A (PE) to specifically localize this toxin to the endosomal compartment and study its translocation from purified endosomes using a cell-free assay, Transferrin was linked to PE via a disulfide bond, Chemical derivatization inactivated the PE cell-binding domain, and transferrin-PE was found to be endocytosed via the transferrin receptor only, Transferrin was also conjugated to a truncated PE with no receptor-binding domain (PE46). After labeling mouse lymphocytes with radiolabeled transferrin-PE or transferrin-PE46 and endosome isolation, selective translocation of the full-sized toxin portion of the conjugate was observed in a cell-free system, This translocation was strictly dependent upon ATP hydrolysis and was not affected when the acidity of the endosome lumen was neutralized using weak bases, protonophores, or bafilomycin A(1), Nevertheless, when present during cell labeling, inhibitors of endosome acidification prevented PE from acquiring translocation competence, Similar inhibition was observed when endocytosis was performed in the presence of brefeldin A, a drug known to interfere with the delivery of endocytic tracers to acidic endosomes, Our data indicate that full-length PE can be transferred to the cytosol directly from endosomes during intoxication by PE conjugates and that, although exposure to acidic pH is a prerequisite for translocation, ATP hydrolysis directly provides the energy required for PE translocation.	UNIV MONTPELLIER 2,CNRS,UMR 5539,DEPT BIOL SANTE,F-34095 MONTPELLIER 5,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier				Beaumelle, Bruno/0000-0002-4912-9134				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; BEAUMELLE B, 1993, J BIOL CHEM, V268, P23661; BEAUMELLE BD, 1989, BIOCHEM J, V264, P137, DOI 10.1042/bj2640137; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; DOMINGO DL, 1985, METHOD ENZYMOL, V112, P238; DOUGLAS CM, 1987, J BACTERIOL, V169, P4962, DOI 10.1128/jb.169.11.4962-4966.1987; FISHMAN A, 1994, BIOCHEMISTRY-US, V33, P6235, DOI 10.1021/bi00186a025; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HUDSON TH, 1987, J BIOL CHEM, V262, P16484; JIANG JX, 1990, J BIOL CHEM, V265, P8636; JINNO Y, 1988, J BIOL CHEM, V263, P13203; KONDO T, 1988, J BIOL CHEM, V263, P9470; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KREITMAN RJ, 1995, BIOCHEM J, V307, P29, DOI 10.1042/bj3070029; MARSH JW, 1988, J BIOL CHEM, V263, P15993; MELLBY EL, 1991, J CELL BIOCHEM, V47, P251; MORRIS RE, 1986, INFECT IMMUN, V52, P445, DOI 10.1128/IAI.52.2.445-453.1986; Olsnes S., 1988, IMMUNOTOXINS, P39; PASTAN I, 1992, ANNU REV BIOCHEM, V61, P331, DOI 10.1146/annurev.bi.61.070192.001555; RASO V, 1984, J BIOL CHEM, V259, P1143; ROBBINS AR, 1984, J CELL BIOL, V99, P1296, DOI 10.1083/jcb.99.4.1296; SEETHARAM S, 1991, J BIOL CHEM, V266, P17376; SIMMONS BM, 1986, J BIOL CHEM, V261, P7912; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; WHITNEY JA, 1995, CELL, V83, P703; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; YAZDI PT, 1994, CANCER RES, V54, P6387; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	32	9	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26170	26173		10.1074/jbc.271.42.26170	http://dx.doi.org/10.1074/jbc.271.42.26170			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824263	hybrid, Green Published			2022-12-27	WOS:A1996VN18000069
J	Vaziri, C; Schneider, A; Sherr, DH; Faller, DV				Vaziri, C; Schneider, A; Sherr, DH; Faller, DV			Expression of the aryl hydrocarbon receptor is regulated by serum and mitogenic growth factors in murine 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AH RECEPTOR; GENE-EXPRESSION; C-MYC; CELLS; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; TRANSCRIPTION; INHIBITION; MECHANISM; TCDD	The aryl-hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates biological responses to planar aromatic hydrocarbons such as benzo[a]pyrene. However, no endogenous physiological ligand for the AhR has been identified, Since the AhR regulates bioactivity to common environmental pollutants, and since it is predicted to play an important physiological function, we have investigated the expression of the AhR during the cell cycle of murine 3T3 fibroblasts. We show here that stimulation of growth-arrested 3T3 cells with serum results in increased expression of AhR protein, Serum-induced expression of AhR in synchronized, serum-stimulated cells occurs at the onset of DNA synthesis (S phase) and is maximal at time points corresponding to late S phase. Transient transfections with an AhR-promoter-luciferase construct demonstrate that reporter gene transcription from the AhR promoter is regulated in a serum-dependent manner. Serum-dependent induction of AhR expression is prevented by an inhibitor of tyrosine kinase activity, Ligand-activated growth factor receptors (platelet-derived growth factor receptor basic fibroblast growth factor receptor) as well as an ectopically expressed tyrosine kinase (the v-Src oncoprotein) induce AhR expression in the absence of serum, Therefore, tyrosine kinase signaling is both necessary and sufficient for induction of AhR expression. Studies with the G(1) blocker sodium butyrate show that the signal transduction pathways mediating serum-stimulated progression through the cell cycle are distinct from those that induce AhR expression. These data suggest that transcriptional regulation of the AhR is important in determining cellular sensitivity to the actions of AhR Ligand(s) and that the AhR may play a role during the cellular proliferative response.	BOSTON UNIV,SCH MED,SCH PUBL HLTH,BOSTON,MA 02118	Boston University	Vaziri, C (corresponding author), BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118, USA.			Sherr, David/0000-0003-3353-0553	NCI NIH HHS [CA 50459] Funding Source: Medline; NIEHS NIH HHS [1P42ES 07381, R01-ES06086] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006086, P42ES007381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTT BD, 1994, TOXICOL APPL PHARM, V126, P16, DOI 10.1006/taap.1994.1085; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; DEAN M, 1986, J BIOL CHEM, V261, P9161; DENISON MS, 1995, J BIOL CHEM, V270, P18175, DOI 10.1074/jbc.270.31.18175; DOLWICK KM, 1993, P NATL ACAD SCI USA, V90, P8566, DOI 10.1073/pnas.90.18.8566; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KRISHNAN V, 1995, MOL CELL BIOL, V15, P6710; LAU LF, 1991, MOL ASPECTS CELLULAR, V6, P257; McDonnell WM, 1996, SCIENCE, V271, P223; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS JM, 1995, TOXICOL APPL PHARM, V134, P214, DOI 10.1006/taap.1995.1186; PHILLIPS M, 1995, J CELL SCI, V108, P395; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; ROLLINS BJ, 1987, SCIENCE, V238, P1269, DOI 10.1126/science.3685976; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SALGUERO PF, 1995, SCIENCE, V268, P722; SCHMIDT JV, 1993, J BIOL CHEM, V268, P22203; SWANSON HI, 1993, ARCH BIOCHEM BIOPHYS, V302, P167, DOI 10.1006/abbi.1993.1195; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251	24	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25921	25927		10.1074/jbc.271.42.25921	http://dx.doi.org/10.1074/jbc.271.42.25921			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824226				2022-12-27	WOS:A1996VN18000032
J	Bolgar, MS; Yang, CY; Gaskell, SJ				Bolgar, MS; Yang, CY; Gaskell, SJ			First direct evidence for lipid/protein conjugation in oxidized human low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; MASS-SPECTROMETRY; PROTEIN ADDUCTS; OXIDATION; SEQUENCE; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; ALDEHYDES; RESIDUES; DOMAINS; LYSINE	It has been postulated that lipids incorporated in atherosclerotic plaques are derived from the uptake of oxidized low density lipoprotein (LDL) by a macrophage-bound receptor. In vitro studies of LDL oxidation have established that reactive lipids are formed and that the exposure of native LDL to these products leads to modified protein with physical properties similar to oxidized LDL. Here we describe the application of highly specific tandem mass spectrometric techniques to the first characterization of lipid modified LDL by demonstrating the addition of 4-hydroxy-2-nonenal to histidine residues of apolipoprotein B-100, following oxidation of LDL. The modified residues have been assigned to specific locations that have been previously shown to reside on the surface of the LDL particle.	UNIV MANCHESTER,INST SCI & TECHNOL,MICHAEL BARBER CTR MASS SPECT,MANCHESTER M60 1QD,LANCS,ENGLAND; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	University of Manchester; Baylor College of Medicine								BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; Bolgar MS, 1996, ANAL CHEM, V68, P2325, DOI 10.1021/ac9601021; BRUENNER BA, 1995, CHEM RES TOXICOL, V8, P552, DOI 10.1021/tx00046a009; CHEN SH, 1986, J BIOL CHEM, V261, P2918; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1987, J LIPID RES, V28, P495; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; SZWEDA LI, 1993, J BIOL CHEM, V268, P3342; UCHIDA K, 1992, P NATL ACAD SCI USA, V89, P4544, DOI 10.1073/pnas.89.10.4544; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96	19	61	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					27999	28001		10.1074/jbc.271.45.27999	http://dx.doi.org/10.1074/jbc.271.45.27999			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910407	hybrid			2022-12-27	WOS:A1996VU03300007
J	Swope, DL; Mueller, CL; Chrivia, JC				Swope, DL; Mueller, CL; Chrivia, JC			CREB-binding protein activates transcription through multiple domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; TRANSACTIVATION DOMAIN; SOMATOSTATIN GENE; ADENOVIRUS E1A; CAMP; PHOSPHORYLATION; ELEMENT; CBP; INTERACTS; P300	CREB-binding protein (CBP) functions as a coactivator molecule for a number of transcription factors including CREB, c-Fos, c-Jun, c-Myb, and several nuclear receptors. Although binding sites for these factors within CBP have been identified, the regions of CBP responsible for transcriptional activation are unknown. In this report, we show that the N-terminal half of CBP is sufficient for activation of CREB-mediated transcription and that this region contains a strong transcriptional activation domain (TAD). Both deletion of this TAD or sequestering of factors that the TAD binds using a squelching assay were found to greatly decrease the ability of CBP to activate CREB-mediated transcription, In vivo studies by others have shown that p300/CBP associates with TBP; using an in vitro approach, we show the N-terminal TAD binds TBP. We also examined the ability of the C terminus of CBP to activate transcription using GAL-CBP chimeras, With this approach, we identified two C-terminal TADs located adjacent to the c-Fos binding site, In previous studies, cAMP-dependent protein kinase A (PKA) increased the transcriptional activity of a GAL full-length CBP chimera in F9 cells, and of the C terminus in PC-12 cells. Here, we demonstrate that PKA also increased the ability of the N-terminal TADs of CBP to activate transcription in PC-12 but not F9 or COS-7 cells, suggesting that this PKA-responsiveness is cell type-specific.	ST LOUIS UNIV,SCH MED,DEPT PHARMACOL & PHYSIOL SCI,ST LOUIS,MO 63104	Saint Louis University								ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ADLER V, 1992, J BIOL CHEM, V267, P17001; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BANNISTER AJ, 1996, ONCOGENE, V11, P2510; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COMB M, 1986, NATURE, V323, P353, DOI 10.1038/323353a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HOEFFLER JP, 1988, SCIENCE, V242, P1428; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KEEGAN L, 1986, SCIENCE, V231, P669; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LUNDBLAD JR, 1995, NATURE, V374, P77; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUN PQ, 1995, J BIOL CHEM, V270, P7041, DOI 10.1074/jbc.270.13.7041; WALTON KM, 1992, MOL NEUROBIOL, V4, P197; XING LP, 1995, J BIOL CHEM, V270, P17488, DOI 10.1074/jbc.270.29.17488	46	153	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28138	28145		10.1074/jbc.271.45.28138	http://dx.doi.org/10.1074/jbc.271.45.28138			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910428	hybrid			2022-12-27	WOS:A1996VU03300028
J	Berman, DM; Kozasa, T; Gilman, AG				Berman, DM; Kozasa, T; Gilman, AG			The GTPase-activating protein RGS4 stabilizes the transition state for nucleotide hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; HUMAN GENE; G1 ARREST; SF9 CELLS; A-FACTOR; SUBUNITS; TRANSDUCIN; PHOSPHODIESTERASE	RGS proteins constitute a newly appreciated group of negative regulators of G protein Signaling. Discovered by genetic screens in yeast, worms, and other organisms, two mammalian RGS proteins, RGS4 and GAIP, act as GTPase-activating proteins for members of the G(i) family of G protein alpha subunits. We have purified recombinant RGS4 to homogeneity and demonstrate that it acts catalytically to stimulate GTP hydrolysis by G(i) proteins. Furthermore, RGS4 stabilizes the transition state for GTP hydrolysis, as evidenced by its high affinity for the GDP-AlF4--bound forms of G(o alpha) and G(i alpha) and its relatively low affinity for the GTP gamma S- and GDP-bound forms of these proteins. Consequently, RGS4 is most likely not a downstream effector for activated G(alpha) subunits. All members of the G(i) subfamily of proteins tested are substrates for RGS4 (including G(t alpha) and G(z alpha)); the protein has lower affinity for G(q alpha), and it does not stimulate the GTPase activity of G(s alpha) or G(12 alpha).	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07062, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HONG JX, 1993, J IMMUNOL, V150, P3895; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEE E, 1994, METHOD ENZYMOL, V237, P146; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; PAGES F, 1993, J BIOL CHEM, V268, P26358; ROSS EM, 1995, RECENT PROG HORM RES, V50, P207; Roush W, 1996, SCIENCE, V271, P1056, DOI 10.1126/science.271.5252.1056; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207	29	293	296	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27209	27212		10.1074/jbc.271.44.27209	http://dx.doi.org/10.1074/jbc.271.44.27209			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910288	hybrid			2022-12-27	WOS:A1996VQ67900006
J	Esposito, C; Pucci, P; Amoresano, A; Marino, G; Cozzolino, A; Porta, R				Esposito, C; Pucci, P; Amoresano, A; Marino, G; Cozzolino, A; Porta, R			Transglutaminase from rat coagulating gland secretion - Post-translational modifications and activation by phosphatidic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DORSAL PROSTATE; MASS-SPECTROMETRY; CDNA CLONES; PROTEIN; SEQUENCE; PURIFICATION; FLUIDS; MOUSE; SEMEN	Structural and biochemical characteristics of transglutaminase purified by a rapid chromatographic procedure from the rat coagulating gland (anterior prostate) secretion are reported. Fast atom bombardment mapping and automated Edman degradation experiments allowed us to verify that at least 85% of the entire transglutaminase amino acid sequence is identical to that derived from the cDNA of the major androgen-dependent rat prostate protein called DP1, The enzyme was found NH2 terminally blocked and largely posttranslationally modified, since the presence of N-linked oligosaccharides, as well as of complex lipidic structures, was observed, Mass spectral analysis showed that Asn-408 and -488 are the glycosylated sites, the N-linked structures identified belonging to both high-mannose and complex type glycans. The presence of myo-inositol, of glycerol bound fatty acids, and the high content of mannose residues, are in agreement with previous observations suggesting, that a Lipid anchor is bound to coagulating gland secretion transglutaminase, Furthermore, two tightly bound calcium ions per molecule of enzyme were detected, Finally, a strong stimulation of the enzyme activity in vitro by both SDS and a variety of phosphatidic acids was observed. The reported structural and functional peculiarities should definitively lead to consider She prostate enzyme as a new member (type IV) of the transglutaminase family.	UNIV NAPLES 2,DEPT BIOCHEM & BIOPHYS,I-80138 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DEPT ORGAN & BIOL CHEM,I-80134 NAPLES,ITALY; CNR,MASS SPECTROMETRY SERV,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,INTERDEPT CTR RES BIOACT PEPTIDES,I-80134 NAPLES,ITALY	Universita della Campania Vanvitelli; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II				AMORESANO, Angela/0000-0002-8386-655X; PUCCI, Pietro/0000-0002-5885-1495; Porta, Raffaele/0000-0003-4455-0664				AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BEIL RE, 1973, BIOL REPROD, V8, P613, DOI 10.1093/biolreprod/8.5.613; CAMUS L, 1896, COMPT REND SOC BIOL, V48, P787; CHAKRAVARTY R, 1989, J BIOL CHEM, V264, P625; DELL A, 1990, METHOD ENZYMOL, V193, P647, DOI 10.1016/0076-6879(90)93443-O; Ferguson MAJ, 1991, CURR OPIN STRUC BIOL, V1, P522, DOI 10.1016/S0959-440X(05)80072-7; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOTTERER GS, 1957, P SOC EXP BIOL MED, V94, P60, DOI 10.3181/00379727-94-22855; HARSFALVI J, 1987, BIOCHIM BIOPHYS ACTA, V923, P42, DOI 10.1016/0304-4165(87)90123-1; HO KC, 1992, J BIOL CHEM, V267, P12660; ICHINOSE A, 1990, J BIOL CHEM, V265, P13411; IKURA K, 1988, BIOCHEMISTRY-US, V27, P2898, DOI 10.1021/bi00408a035; IYER RN, 1971, ARCH BIOCHEM BIOPHYS, V142, P101, DOI 10.1016/0003-9861(71)90263-3; KIM HC, 1991, J BIOL CHEM, V266, P536; KIM IG, 1993, J BIOL CHEM, V268, P12682; LAEMMLI UK, 1970, NATURE, V309, P116; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; LORAND L, 1987, ACTA BIOCHIM BIOPHYS, V22, P337; NITTI G, 1995, EUR J BIOCHEM, V228, P250, DOI 10.1111/j.1432-1033.1995.tb20257.x; PAONESSA G, 1984, SCIENCE, V226, P852, DOI 10.1126/science.6149619; PORTA R, 1990, INT J PEPT PROT RES, V35, P117; PORTA R, 1991, BIOCHEMISTRY-US, V30, P3114, DOI 10.1021/bi00226a019; PORTA R, 1986, BIOL REPROD, V35, P965, DOI 10.1095/biolreprod35.4.965; PUCCI P, 1988, BIOMED ENVIRON MASS, V17, P287, DOI 10.1002/bms.1200170410; PUCCI P, 1985, BIOCHEM BIOPH RES CO, V130, P84, DOI 10.1016/0006-291X(85)90385-7; SEITZ J, 1990, HISTOCHEMISTRY, V93, P525, DOI 10.1007/BF00266412; SEITZ J, 1991, BIOCHIM BIOPHYS ACTA, V1078, P139, DOI 10.1016/0167-4838(91)99002-A; STEINHOFF M, 1994, EUR J CELL BIOL, V65, P49; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WILLIAMSASHMAN HG, 1977, BIOCHEM BIOPH RES CO, V79, P1192, DOI 10.1016/0006-291X(77)91132-9; WILLIAMSASHMAN HG, 1984, MOL CELL BIOCHEM, V58, P51, DOI 10.1007/BF00240604; WILSON EM, 1980, J BIOL CHEM, V255, P946	33	41	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27416	27423		10.1074/jbc.271.44.27416	http://dx.doi.org/10.1074/jbc.271.44.27416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910321	hybrid			2022-12-27	WOS:A1996VQ67900039
J	Gottlin, EB; Xu, X; Epstein, DM; Burke, SP; Eckstein, JW; Ballou, DP; Dixon, JE				Gottlin, EB; Xu, X; Epstein, DM; Burke, SP; Eckstein, JW; Ballou, DP; Dixon, JE			Kinetic analysis of the catalytic domain of human Cdc25B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; ACTIVATES P34CDC2; PURIFICATION; MECHANISM; INDUCER	The Cdc25 cell cycle regulator is a member of the dual-specificity class of protein-tyrosine phosphatases that hydrolyze phosphotyrosine- and phosphothreonine-containing substrates, To study the mechanism of Cdc25B, we have overexpressed and purified the catalytic domain of human Cdc25B (Xu, X., and Burke, S, P, (1996) J, Biol, Chem, 271, 5118-5124), In the present work, we have analyzed the kinetic properties of the Cdc25B catalytic domain using the artificial substrate 3-O-methylfluorescein phosphate (OMFP), Steady-state kinetic analysis indicated that the k(cat)/K-m for OMFP hydrolysis is almost 3 orders of magnitude greater than that for p-nitrophenyl phosphate hydrolysis, Like other dual-specificity phosphatases, Cdc25 exhibits a two-step catalytic mechanism, characterized by formation and breakdown of a phosphoenzyme intermediate, Presteady-state kinetic analysis of OMFP hydrolysis indicated that formation of the phosphoenzyme intermediate is similar to 20 times faster than subsequent phosphoenzyme breakdown, The resulting burst pattern of product formation allowed us to derive rate constants for enzyme phosphorylation (26 s(-1)) and dephosphorylation (1.5 s(-1)) as well as the dissociation constant for OMFP (0.3 mM). Calculations suggest that OMFP binds with higher affinity and reacts faster with Cdc25B than does p-nitrophenyl phosphate, OMFP is a highly efficient substrate for the dual-specificity protein-tyrosine phosphatases VHR and rVH6, but not for two protein-tyrosine phosphatases, PTP1 and YOP, The ability to observe distinct phases of the reaction mechanism during OMFP hydrolysis will facilitate future analysis of critical catalytic residues in Cdc25 and other dual-specificity phosphatases.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109; MITOTIX INC,CAMBRIDGE,MA 02139	University of Michigan System; University of Michigan			dballou@umich.edu, David P/A-1298-2007	Gottlin, Elizabeth/0000-0003-0886-0024	NIGMS NIH HHS [GM20877] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020877, R37GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; DAVIS RL, 1988, J BIOENERG BIOMEMBR, V20, P571, DOI 10.1007/BF00768920; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; HILL HD, 1968, ANAL BIOCHEM, V24, P9, DOI 10.1016/0003-2697(68)90054-7; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KWAK SP, 1994, J BIOL CHEM, V269, P3596; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Montserat J, 1996, J BIOL CHEM, V271, P7868, DOI 10.1074/jbc.271.13.7868; POT DA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P35, DOI 10.1016/0167-4889(92)90082-M; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; WALSH CT, 1979, ENZYMATIC REACTION M; Xu X, 1996, J BIOL CHEM, V271, P5118; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007	27	77	78	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27445	27449		10.1074/jbc.271.44.27445	http://dx.doi.org/10.1074/jbc.271.44.27445			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910325	hybrid			2022-12-27	WOS:A1996VQ67900043
J	Heath, RJ; Rock, CO				Heath, RJ; Rock, CO			Roles of the FabA and FabZ beta-hydroxyacyl-acyl carrier protein dehydratases in Escherichia coli fatty acid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYDECANOYL THIOESTER DEHYDRASE; THIOL ESTER DEHYDRASE; SYNTHETASE; INVIVO	There are two genes, fabA and fabZ, encoding beta-hydroxyacyl-acyl carrier protein (ACP) dehydratases that function in the dissociated, type II fatty acid synthase system of Escherichia coli. We have investigated their roles in fatty acid synthesis by purifying the two proteins and reconstituting cycles of fatty acid synthesis in vitro using five other purified proteins. FabA and FabZ exhibited broad, overlapping chain length specificities, The FabZ dehydratase efficiently catalyzed the dehydration of short chain beta-hydroxyacyl-ACPs and long chain saturated and unsaturated beta-hydroxyacyl-ACPs. FabA was most active on intermediate chain length beta-hydroxyacyl-ACPs and also possessed significant activity toward both short and long chain saturated beta-hydroxyacyl-ACPs. Significantly, FabA was virtually inactive in the dehydration of long chain unsaturated beta-hydroxyacyl-ACP. The introduction of the double bond at the 10-carbon stage of fatty acid synthesis by FabA was only detected in the presence of beta-ketoacyl-ACP synthase I (FabB). A yeast two-hybrid analysis failed to detect an interaction between FabA and FabB, therefore the channeling of intermediates toward unsaturated fatty acid synthesis by FabB was attributed to the affinity of the condensing enzyme for cis-decenoyl-ACP. The broad substrate specificity of FabZ coupled with the inactivity of FabA toward a long chain unsaturated p hydroxyacyl-ACP provides a biochemical explanation for the phenotypes of cells with genetically altered levels of the two dehydratases.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AW, 1972, J BIOL CHEM, V247, P3190; ANNAND RR, 1993, J AM CHEM SOC, V115, P1088, DOI 10.1021/ja00056a038; BIRGE CH, 1972, J BIOL CHEM, V247, P4930; BIRGE CH, 1967, BIOCHEM BIOPH RES CO, V26, P808; BLOCH K, 1971, ENZYMES, P441; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK DJH, 1967, J BIOL CHEM, V242, P4432; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; CRONAN JE, 1988, J BIOL CHEM, V263, P4641; CRONAN JE, 1973, J BIOL CHEM, V248, P1188; CRONAN JE, 1969, J BACTERIOL, V100, P601, DOI 10.1128/JB.100.2.601-604.1969; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; ENDO K, 1970, J BIOL CHEM, V245, P4293; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; GUERRA DJ, 1990, ARCH BIOCHEM BIOPHYS, V280, P336, DOI 10.1016/0003-9861(90)90339-Z; Heath RJ, 1996, J BIOL CHEM, V271, P1833, DOI 10.1074/jbc.271.4.1833; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; HELMKAMP GM, 1969, J BIOL CHEM, V244, P6014; HELMKAMP GM, 1968, J BIOL CHEM, V243, P3229; JACKOWSKI S, 1992, METHOD ENZYMOL, V209, P111; KASS LR, 1967, J BIOL CHEM, V242, P4418; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MORISAKI M, 1971, Bioorganic Chemistry, V1, P188, DOI 10.1016/0045-2068(71)90015-0; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; OHLROGGE JB, 1982, TRENDS BIOCHEM SCI, V7, P386, DOI 10.1016/0968-0004(82)90176-1; PETTY KJ, 1994, CURRENT PROTOCOLS MO; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RANDO RR, 1968, J BIOL CHEM, V243, P5627; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; ROSENFELD IS, 1973, J BIOL CHEM, V248, P2452; SCHWAB JM, 1985, ANAL BIOCHEM, V150, P121, DOI 10.1016/0003-2697(85)90449-X; SCHWAB JM, 1986, J AM CHEM SOC, V108, P5304, DOI 10.1021/ja00277a040; SCHWAB JM, 1984, J AM CHEM SOC, V106, P7217, DOI 10.1021/ja00335a060; SHARMA A, 1990, J BIOL CHEM, V265, P5110; SILBERT DF, 1967, P NATL ACAD SCI USA, V58, P1579, DOI 10.1073/pnas.58.4.1579; TOOMEY RE, 1966, BIOCHIM BIOPHYS ACTA, V116, P189, DOI 10.1016/0005-2760(66)90001-4; VALLARI DS, 1987, J BIOL CHEM, V262, P2468	45	196	231	5	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27795	27801		10.1074/jbc.271.44.27795	http://dx.doi.org/10.1074/jbc.271.44.27795			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910376	hybrid			2022-12-27	WOS:A1996VQ67900094
J	McHugh, TE; Atkins, WM; Racha, JK; Kunze, KL; Eaton, DL				McHugh, TE; Atkins, WM; Racha, JK; Kunze, KL; Eaton, DL			Binding of the aflatoxin-glutathione conjugate to mouse glutathione S-transferase A3-3 is saturated at only one ligand per dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; HEPATIC GLUTATHIONE; COMPLEX; RAT; RESOLUTION; PRODUCT; MECHANISM; SUBUNITS; SITE; DNA	The binding of two different reaction products (p-nitrobenzyl glutathione and the aflatoxin-glutathione conjugate) to mouse glutathione S-transferase A3-3 (mGSTA3-3) has been measured using equilibrium dialysis and a direct fluorescence quenching technique, As expected, p-nitrobenzyl glutathione was found to bind with a stoichiometry of 2.24 +/- 0.17 mol/mol of dimeric enzyme. However, the much larger aflatoxin-glutathione conjugate, 8,9-dihydro-S-(S-glutathionyl)-9-hydroxyl-aflatoxin B-1 (AFB-GSH), was found to bind with a stoichiometry of 1.12 +/- 0.08 mol/mol of dimeric enzyme. p-Nitrobenzyl glutathione bound mGSTA3-3 with a dissociation constant (K-d) of 59 +/- 17 mu M while the aflatoxin-glutathione conjugate bound the enzyme with a K-d of 0.86 +/- 0.19 mu M. Glutathione competitively inhibited binding of AFB-GSH to mGSTA3-3 with a K-i of 1.5 mM, suggesting that AFB-GSH was binding to the enzyme active site. Although AFB-GSH bound to mGSTA3-3 with a stoichiometry of 1 mol/mol of dimeric enzyme, AFB-GSH completely inhibited activity toward 1-chloro-2,4-dinitrobenzene, indicating that AFB-GSH binding to one active site alters affinity for 1-chloro-2,4-dinitrobenzene ill the active site of the other subunit. To our knowledge, this is the first report of a glutathione S-transferase reaction product which binds to the enzyme with a stoichiometry of 1 mol/mol of dimer.	UNIV WASHINGTON,CTR ECOGENET & ENVIRONM HLTH,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98105; UNIV WASHINGTON,DEPT ENVIRONM HLTH,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98105; UNIV WASHINGTON,SCH PHARM,DEPT MED CHEM,SEATTLE,WA 98105	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Eaton, David/AAO-1832-2020		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, R01ES005780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048750] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES-05780, P30 ES-07033] Funding Source: Medline; NIGMS NIH HHS [GM 48750] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENSON AM, 1978, CANCER RES, V38, P4486; BUETLER TM, 1992, CANCER RES, V52, P314; BUETLER TM, 1992, BIOCHEM BIOPH RES CO, V188, P597, DOI 10.1016/0006-291X(92)91098-B; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; Habig W H, 1981, Methods Enzymol, V77, P398; Hall A. J., 1994, TOXICOLOGY AFLATOXIN, P233; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1981, BIOCHEM J, V197, P491, DOI 10.1042/bj1970491; IVANETICH KM, 1990, BIOCHEM PHARMACOL, V39, P1999, DOI 10.1016/0006-2952(90)90621-Q; JAKOBSON I, 1979, J BIOL CHEM, V254, P7085; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KITAHARA A, 1981, BIOCHEM BIOPH RES CO, V103, P943, DOI 10.1016/0006-291X(81)90901-3; KLOTZ IM, 1990, PROTEIN FUNCTION PRA, P25; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P342; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MCTIGUE MA, 1995, J MOL BIOL, V246, P21, DOI 10.1006/jmbi.1994.0061; MONROE DH, 1988, TOXICOL APPL PHARM, V94, P118, DOI 10.1016/0041-008X(88)90342-0; MOSS EJ, 1983, BIOCHEM J, V210, P227, DOI 10.1042/bj2100227; RANEY KD, 1992, CHEM RES TOXICOL, V5, P333, DOI 10.1021/tx00027a002; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRAMM VL, 1984, J BIOL CHEM, V259, P714; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; VANDERJAGT DL, 1982, J BIOL CHEM, V257, P1997; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27470	27474		10.1074/jbc.271.44.27470	http://dx.doi.org/10.1074/jbc.271.44.27470			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910329	hybrid			2022-12-27	WOS:A1996VQ67900047
J	Ohyama, T				Ohyama, T			Bent DNA in the human adenovirus type 2 E1A enhancer is an architectural element for transcription stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI PROMOTER; CURVED DNA; INVITRO TRANSCRIPTION; UPSTREAM ACTIVATION; INTRINSIC CURVATURE; BACILLUS-SUBTILIS; SEQUENCES; BINDING; REGIONS; INITIATION	The upstream half of the human adenovirus type 2 enhancer adopts a curved DNA structure. Most of the enhancer elements are within the curvature, suggesting that this unusual structure is linked to enhancer function. To verify this experimentally, I constructed in vitro transcription assay systems which could distinguish any effects generated by conformational changes in a DNA template, The curved DNA conformation in the enhancer clearly affected the extent of the stimulation of the E1A gene transcription: assays using the wildtype DNA template showed that the moderately curved enhancer was superior to the highly curved enhancer in transcriptional stimulation. In additional experiments, the enhancer region was substituted with a curved DNA derived from the bacteriophage lambda origin of replication, Assays using this mutant revealed that this curved segment could also act as an enhancer when it had the proper conformation. Consequently, DNA conformation may play a general role in transcriptional stimulation.	MEIJI INST HLTH SCI,DIV MOL BIOL,ODAWARA 250,JAPAN; RES INST INNOVAT TECHNOL EARTH,ODAWARA 250,JAPAN	Research Institute of Innovative Technology for the Earth								AUGEREAU P, 1986, EMBO J, V5, P1791, DOI 10.1002/j.1460-2075.1986.tb04428.x; BOSSI L, 1984, CELL, V39, P643, DOI 10.1016/0092-8674(84)90471-9; BRACCO L, 1989, EMBO J, V8, P4289, DOI 10.1002/j.1460-2075.1989.tb08615.x; CALLADINE CR, 1988, J MOL BIOL, V201, P127, DOI 10.1016/0022-2836(88)90444-5; COLLIS CM, 1989, NUCLEIC ACIDS RES, V17, P9447, DOI 10.1093/nar/17.22.9447; DIEKMANN S, 1987, NUCLEIC ACIDS RES, V15, P247, DOI 10.1093/nar/15.1.247; ESPINOSAURGEL M, 1993, NUCLEIC ACIDS RES, V21, P3667; GARTENBERG MR, 1991, J MOL BIOL, V219, P217, DOI 10.1016/0022-2836(91)90563-L; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; HEARING P, 1986, CELL, V45, P229, DOI 10.1016/0092-8674(86)90387-9; HIROTA Y, 1995, J MOL BIOL, V254, P566, DOI 10.1006/jmbi.1995.0639; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; INOKUCHI K, 1988, NUCLEIC ACIDS RES, V16, P6693, DOI 10.1093/nar/16.14.6693; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KIM J, 1995, J BIOL CHEM, V270, P1282, DOI 10.1074/jbc.270.3.1282; LAVIGNE M, 1992, J MOL BIOL, V224, P293, DOI 10.1016/0022-2836(92)90995-V; LOZINSKI T, 1991, NUCLEIC ACIDS RES, V19, P2947, DOI 10.1093/nar/19.11.2947; MCALLISTER CF, 1988, J BIOL CHEM, V263, P11743; MCALLISTER CF, 1989, J BIOL CHEM, V264, P10451; MIZUNO T, 1987, GENE, V54, P57, DOI 10.1016/0378-1119(87)90347-7; OHYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1617, DOI 10.1093/nar/20.7.1617; OHYAMA T, 1989, NUCLEIC ACIDS RES, V17, P3845, DOI 10.1093/nar/17.10.3845; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1984, P NATL ACAD SCI-BIOL, V81, P308, DOI 10.1073/pnas.81.2.308; SCHOLER HR, 1985, EMBO J, V4, P3005, DOI 10.1002/j.1460-2075.1985.tb04036.x; SCHROTH GP, 1992, J BIOL CHEM, V267, P9958; TRAVERS A, 1989, NATURE, V341, P184, DOI 10.1038/341184a0; WILDEMAN AG, 1984, EMBO J, V3, P3129, DOI 10.1002/j.1460-2075.1984.tb02269.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAHN K, 1985, NATURE, V317, P451, DOI 10.1038/317451a0	32	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27823	27828						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910380				2022-12-27	WOS:A1996VQ67900098
J	Wang, WH; Duan, JX; Vu, TH; Hoffman, AR				Wang, WH; Duan, JX; Vu, TH; Hoffman, AR			Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN H19 GENE; HUMAN EMBRYOGENESIS; IGF2; CANCER; LOCUS; CHROMOSOME-11; RELAXATION; SUSCEPTIBILITY; METHYLATION; ACTIVATION	Loss of imprinting of insulin-like growth factor-II gene (IGF2) and/or loss of heterozygosity at the 11p15 loci have been postulated to be responsible for IGF2 overexpression in Wilms' tumor. In order to delineate the mechanism of IGF2 overexpression in Wilms' tumors, we have genotyped the 11p15-11p13 chromosomal region and determined allelic expression of IGF2 and H19 in both tumor tissue and in normal adjacent kidney tissue from 40 patients with Wilms' tumor. In five of the eight subjects informative for the ApaI IGF2 polymorphism, loss of imprinting of IGF2 was observed in both normal and tumor tissues. A significant increase (>5-fold) in IGF2 expression in tumor tissues compared to the normal adjacent kidney tissue was observed regardless of the IGF2 imprinting or the chromosome 11p15 heterozygosity status. In each case, the overexpression of IGF2 in the tumors was accompanied by activation of all four IGF2 promoters. Our data indicate that alterations of IGF2 imprinting occurred in normal adjacent kidney tissue before tumorigenesis and that the IGF2 overexpression in Wilms' tumor tissue occurs through a loss of heterozygosity- or loss of imprinting-independent process.	VET AFFAIRS MED CTR,MED SERV 111,PALO ALTO,CA 94304; VET AFFAIRS MED CTR,GRECC,PALO ALTO,CA 94304; STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	US Department of Veterans Affairs; Veterans Health Administration (VHA); Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK36054] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DAUGHADAY WH, 1990, ENDOCRINOLOGY, V127, P1; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; GOSHEN R, 1993, MOL REPROD DEV, V34, P374, DOI 10.1002/mrd.1080340405; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOBAN PR, 1990, NUCLEIC ACIDS RES, V19, P1164; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUNIEN C, 1994, KIDNEY INT, V46, P1264, DOI 10.1038/ki.1994.394; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LITTLE MH, 1991, NATURE, V7, P635; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; MANNENS M, 1990, CANCER RES, V50, P3279; Morison IM, 1996, NAT MED, V2, P311, DOI 10.1038/nm0396-311; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1994, DEVELOPMENT, V120, P361; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; PritchardJones K, 1995, EUR J CANCER, V31A, P2138, DOI 10.1016/0959-8049(95)00558-7; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7280; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TANIGUCHI T, 1995, ONCOGENE, V11, P751; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; Yballe CM, 1996, J CLIN ENDOCR METAB, V81, P1607, DOI 10.1210/jc.81.4.1607; ZHAN SL, 1995, J BIOL CHEM, V270, P27983; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang LJ, 1996, CANCER RES, V56, P1367; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	51	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27863	27870		10.1074/jbc.271.44.27863	http://dx.doi.org/10.1074/jbc.271.44.27863			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910385	hybrid			2022-12-27	WOS:A1996VQ67900103
J	Xiang, BS; Markham, GD				Xiang, BS; Markham, GD			The conformation of inosine 5'-monophosphate (IMP) bound to IMP dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE CONFORMATIONS; MYCOPHENOLIC-ACID; KINASE COMPLEXES; ACTIVE-SITE; INHIBITOR; PURIFICATION; ENHANCEMENT; TIAZOFURIN; SYNTHETASE; MECHANISM	IMP dehydrogenase (IMPDH) catalyzes the NAD-dependent synthesis of xanthosine 5'-monophosphate which is the rate-limiting step in guanine nucleotide biosynthesis. Although IMPDH is the target of numerous chemotherapeutic agents, nothing has been known about the conformation of the enzyme-bound substrates. The conformation of IMP bound to human type II IMP dehydrogenase has been determined by two-dimensional transferred nuclear Overhauser effect NMR spectroscopy at 600 MHz. NOE buildup rates were determined by recording NOESY spectra at numerous mixing times. The cross-relaxation rates determined from the initial NOE build-up rates were used to calculate interproton distances of bound IMP. The conformation of the enzyme-bound IMP was obtained by molecular modeling with energy minimization using the experimentally determined inter-proton distance constraints. The glycosidic torsion angle of the bound nucleotide is anti and the sugar is in the C-2-endo-conformation. This conformation places H-2 of IMP, which is transferred to NAD in the reaction, in a position clear of the rest of the molecule in order to facilitate the reaction.	FOX CHASE CANC CTR, CANC RES INST, PHILADELPHIA, PA 19111 USA	Fox Chase Cancer Center					NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-51481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1760, DOI 10.1021/bi00173a019; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1753, DOI 10.1021/bi00173a018; BALZARINI J, 1993, J BIOL CHEM, V268, P24591; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5183, DOI 10.1021/bi00183a023; CAMPBELL AP, 1993, ANNU REV BIOPH BIOM, V22, P99, DOI 10.1146/annurev.bb.22.060193.000531; CARR SF, 1993, J BIOL CHEM, V268, P27286; CLORE GM, 1983, J MAGN RESON, V53, P423, DOI 10.1016/0022-2364(83)90215-9; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; EHRLICH RS, 1990, BIOCHEMISTRY-US, V29, P5179, DOI 10.1021/bi00473a026; FRANCHETTI P, 1995, J MED CHEM, V38, P3829, DOI 10.1021/jm00019a013; GHAREHBAGHI K, 1994, INT J CANCER, V56, P892, DOI 10.1002/ijc.2910560623; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; JACKSON RC, 1977, BIOCHEM J, V166, P1; JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0; JARORI GK, 1995, EUR J BIOCHEM, V230, P517; JARORI GK, 1994, BIOCHEMISTRY-US, V33, P6784, DOI 10.1021/bi00188a006; KOBLAN KS, 1995, PROTEIN SCI, V4, P681; LANGMAN LJ, 1995, CLIN CHEM, V41, P295; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MAGASANIK B, 1957, J BIOL CHEM, V226, P339; MATSUNAGA TO, 1993, BIOCHEMISTRY-US, V32, P13180, DOI 10.1021/bi00211a029; MURALI N, 1993, BIOCHEMISTRY-US, V32, P12941, DOI 10.1021/bi00210a049; MURALI N, 1994, BIOCHEMISTRY-US, V33, P14227, DOI 10.1021/bi00251a035; NI F, 1994, PROG NUCL MAG RES SP, V26, P517, DOI 10.1016/0079-6565(94)90000-0; OKADA A, 1994, BIOCHEMISTRY-US, V33, P9438, DOI 10.1021/bi00198a009; OTTING G, 1986, J MAGN RESON, V66, P187, DOI 10.1016/0022-2364(86)90122-8; PERLMAN ME, 1994, BIOCHEMISTRY-US, V33, P7547, DOI 10.1021/bi00190a007; PLESNIAK LA, 1995, BIOCHEMISTRY-US, V34, P4943, DOI 10.1021/bi00015a005; ROSEVEAR PR, 1989, METHOD ENZYMOL, V177, P333; ROSEVEAR PR, 1983, BIOCHEMISTRY-US, V22, P3439, DOI 10.1021/bi00283a021; Saenger W., 1984, PRINCIPLES NUCLEIC A, P9; SEELIG GF, 1995, J BIOL CHEM, V270, P9241, DOI 10.1074/jbc.270.16.9241; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; SONG S, 1994, BIOCHEMISTRY-US, V33, P693, DOI 10.1021/bi00169a010; STEWART JMM, 1989, BIOCHEMISTRY-US, V28, P4695, DOI 10.1021/bi00437a028; STREETER DG, 1973, P NATL ACAD SCI USA, V70, P1174, DOI 10.1073/pnas.70.4.1174; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WANG ZL, 1993, BIOCHEMISTRY-US, V32, P13991, DOI 10.1021/bi00213a032; Whitby FG, 1995, PROTEINS, V23, P598, DOI 10.1002/prot.340230417; WU JC, 1995, FASEB J, V9, pA1337; Xiang BS, 1996, J BIOL CHEM, V271, P1435, DOI 10.1074/jbc.271.3.1435; YAMADA Y, 1988, BIOCHEMISTRY-US, V27, P2193, DOI 10.1021/bi00406a057; 1983, EUR J BIOCHEM, V131, P9	47	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27531	27535		10.1074/jbc.271.44.27531	http://dx.doi.org/10.1074/jbc.271.44.27531			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910338	hybrid			2022-12-27	WOS:A1996VQ67900056
J	Eissa, NT; Strauss, AJ; Haggerty, CM; Choo, EK; Chu, SC; Moss, J				Eissa, NT; Strauss, AJ; Haggerty, CM; Choo, EK; Chu, SC; Moss, J			Alternative splicing of human inducible nitric-oxide synthase mRNA - Tissue-specific regulation and induction by cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DIVERSITY; MOLECULAR-CLONING; MESSENGER-RNA; GENE; EXPRESSION; CALMODULIN; BINDING; TETRAHYDROBIOPTERIN; MACROPHAGES; EPITHELIUM	Human inducible nitric-oxide synthase (iNOS) is responsible for nitric oxide synthesis in response to inflammatory mediators. The human iNOS gene, containing 26 exons, encodes a protein of 131 kDa. This study was aimed at investigating the presence of alternative splicing of human iNOS mRNA. Total RNA from human alveolar macrophages, nasal and bronchial epithelial cells, and several human tissues was transcribed to cDNA and analyzed using polymerase chain reaction with specific primers for segmental analysis of the iNOS gene, Four sites of alternative splicing were identified by sequence analysis; these included deletion of: (i) exon 5; (ii) exons 8 and 9; (iii) exons 9, 10, and 11; and (iv) exons 15 and 16. The deduced amino acid sequences of the novel iNOS cDNAs predict one truncated protein (resulting from exon 5 deletion) and three iNOS proteins with in-frame deletions, Southern analyses of polymerase chain reaction products were consistent with tissue-specific regulation of alternative splicing, In cultured cells, iNOS induction by cytokines and lipopolysaccharide was associated with an increase in alternatively spliced mRNA transcripts, Because iNOS is active as a dimer, the novel forms of alternatively spliced iNOS may be involved in regulation of nitric oxide synthesis.			Eissa, NT (corresponding author), NHLBI,NIH,PULM CRIT CARE MED BRANCH,10 CTR DR,MSC 1590,RM 6D03,BLDG 10,BETHESDA,MD 20892, USA.			Haggerty, Cynthia/0000-0002-6019-2724; Choo, Esther/0000-0001-8847-5745				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; CHU SC, 1995, J BIOL CHEM, V270, P10625, DOI 10.1074/jbc.270.18.10625; EISSA NT, 1994, HUM GENE THER, V5, P1105, DOI 10.1089/hum.1994.5.9-1105; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HALL AV, 1994, J BIOL CHEM, V269, P33082; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; MEDFORD RM, 1984, CELL, V38, P409, DOI 10.1016/0092-8674(84)90496-3; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; SALTINI C, 1984, AM REV RESPIR DIS, V130, P650; Skerjanc IS, 1996, J BIOL CHEM, V271, P3555, DOI 10.1074/jbc.271.7.3555; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; XIE QW, 1994, J BIOL CHEM, V269, P28500; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	23	91	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27184	27187		10.1074/jbc.271.43.27184	http://dx.doi.org/10.1074/jbc.271.43.27184			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900212	hybrid			2022-12-27	WOS:A1996VP23300106
J	Li, YK; Davis, KL; Sytkowski, AJ				Li, YK; Davis, KL; Sytkowski, AJ			Protein kinase C-epsilon is necessary for erythropoietin's up-regulation of c-myc and for factor-dependent DNA synthesis - Evidence for discrete signals for growth and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; ERYTHROID-DIFFERENTIATION; PHOSPHATIDYLINOSITOL 3-KINASE; MESSENGER-RNA; EXPRESSION; RECEPTOR; ACTIVATION; PHOSPHORYLATION; ASSOCIATION; RAUSCHER	Erythropoietin regulates the transcription of the protooncogenes c-myc and c-myb by discrete protein kinase C (PKC)-dependent and protein serine/threonine phosphatase-dependent pathways, respectively (Spangler, R., Bailey, S. C., and Sytkowski, A. J. (1991) J. Biol. Chem. 266, 681-684; Patel H. R. Choi H.-S, and Sytkowski A. J. (1992) J. Biol. Chem. 267, 21300-21302), In the present study we demonstrate that up-regulation of c-myc requires the PKC-epsilon isoform and that this pathway is required for erythropoietin-induced DNA synthesis (growth) but apparently not for beta-globin expression (differentiation), Treatment of Rauscher murine erythroleukemia cells resulted in phosphorylation of phospholipase C-gamma 1 and activation of PKC-epsilon as evidenced by its translocation from soluble to particulate subcellular fractions, Artificial down-regulation of PKC-epsilon with anti-sense oligodeoxynucleotides blocked erythropoietin's up-regulation of c-myc in a concentration-dependent manner, In contrast, antisense oligodeoxynucleotides to PKC-alpha, -beta, -gamma, -delta, and -zeta had no effect, Although down-regulation of PKC-epsilon blocked the increase in c-myc expression, it did not inhibit erythropoietin induction of beta-globin expression, a marker of erythroid differentiation, However, down-regulation of PKC-epsilon did block factor-dependent DNA synthesis quantified by measurement of [H-3]thymidine incorporation into newly synthesized DNA of normal murine erythroid cells, The results are consistent with discrete intracellular signals regulating erythroid cell growth and differentiation.	HARVARD UNIV,NEW ENGLAND DEACONESS HOSP,SCH MED,DEPT MED,DIV HEMATOL & ONCOL,BOSTON,MA 02215	Harvard University; Harvard Medical School					NIDDK NIH HHS [1 F32 DK09118, DK38841] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009118, R01DK038841] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY SC, 1991, J BIOL CHEM, V266, P24121; BECKMAN BS, 1992, EXP HEMATOL, V20, P324; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CHALLBERG MD, 1979, P NATL ACAD SCI USA, V76, P655, DOI 10.1073/pnas.76.2.655; CHERN Y, 1991, BLOOD, V78, P1; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CHOI HS, 1987, J BIOL CHEM, V262, P2933; CHOI HS, 1990, J BIOL CHEM, V265, P4143; CLARK KJ, 1995, J BIOL CHEM, V270, P7097, DOI 10.1074/jbc.270.13.7097; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAMEN JE, 1993, BLOOD, V81, P3204; DANDREA A, 1990, NATURE, V343, P762; de Both N J, 1978, Nature, V272, P626, DOI 10.1038/272626a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LENG L, 1993, CANCER RES, V53, P5554; MAY WS, 1994, J BIOL CHEM, V269, P26865; MAYEUX P, 1993, EUR J BIOCHEM, V216, P821, DOI 10.1111/j.1432-1033.1993.tb18203.x; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIURA O, 1994, J BIOL CHEM, V269, P614; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; PATEL HR, 1992, J BIOL CHEM, V267, P21300; POWELL CT, 1992, P NATL ACAD SCI USA, V89, P147, DOI 10.1073/pnas.89.1.147; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; REN HY, 1994, J BIOL CHEM, V269, P19633; Sambrook J., 2002, MOL CLONING LAB MANU; SPANGLER R, 1991, J BIOL CHEM, V266, P681; SPANGLER R, 1992, BLOOD, V79, P52; SPIVAK JL, 1991, BLOOD, V77, P1228; SYTKOWSKI AJ, 1980, SCIENCE, V210, P74, DOI 10.1126/science.6932101; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	41	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27025	27030		10.1074/jbc.271.43.27025	http://dx.doi.org/10.1074/jbc.271.43.27025			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900191	hybrid			2022-12-27	WOS:A1996VP23300085
J	Tsygankov, AY; Mahajan, S; Fincke, JE; Bolen, JB				Tsygankov, AY; Mahajan, S; Fincke, JE; Bolen, JB			Specific association of tyrosine-phosphorylated c-Cbl with Fyn tyrosine kinase in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC SIGNAL-TRANSDUCTION; ANTIGEN RECEPTOR; SRC FAMILY; SH3 DOMAIN; PROTEIN-KINASES; IN-VIVO; PROTOONCOGENE PRODUCT; CROSS-LINKING; JURKAT CELLS; V-CBL	Fyn is a Src family protein tyrosine kinase functionally associated with the T-cell antigen receptor (TcR)/CD3 receptor complex. We have demonstrated earlier that the TcR/CD3-induced activation of Fyn results in tyrosine phosphorylation of several Fyn-associated proteins, including a protein of 116 kDa. In this resort, we identify the Fyn-associated 116-kDa phosphoprotein (p116) as c-Cbl. The identity of p116 has been demonstrated by its specific reactivity with anti-Cbl and similarity of phosphopeptides generated by V8 proteolysis of phospho-Cbl and p116. We demonstrate here that the association of Fyn and c-Cbl is direct and does not require the presence of other proteins. We also demonstrate that Fyn is the Src family kinase that preferentially inter acts with c-Cbl in T cells. The fraction of c-Cbl capable of coprecipitating with Fyn is increased by TcR/CD3 ligation. This increase is likely due to the involvement of Fyn SH2 in the interactions between Fyn and tyrosine-phosphorylated c-Cbl.	UNIV MINNESOTA,SCH MED,BIOTHERAPY PROGRAM,ROSEVILLE,MN 55113; DNAX RES INST MOL & CELLULAR BIOL INC,PALO ALTO,CA 94304	University of Minnesota System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Tsygankov, AY (corresponding author), TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,KRESGE BLDG,RM 506,3400 BROAD ST,PHILADELPHIA,PA 19140, USA.		Tsygankov, Alexander Y/K-6205-2017					ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DASILVA AJ, 1993, J EXP MED, V178, P2107, DOI 10.1084/jem.178.6.2107; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DESEAU V, 1987, J CELL BIOCHEM, V35, P113, DOI 10.1002/jcb.240350205; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Fusaki N, 1996, J IMMUNOL, V156, P1369; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TSYGANKOV AY, 1994, J LEUKOCYTE BIOL, V55, P289, DOI 10.1002/jlb.55.3.289; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; TSYGANKOV AY, 1992, CELL IMMUNOL, V140, P97, DOI 10.1016/0008-8749(92)90179-S; TSYGANKOV AY, 1993, STEM CELLS, V11, P371, DOI 10.1002/stem.5530110504; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791	45	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27130	27137		10.1074/jbc.271.43.27130	http://dx.doi.org/10.1074/jbc.271.43.27130			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900205	hybrid			2022-12-27	WOS:A1996VP23300099
J	Wang, XD; Russell, RM; Liu, C; Stickel, F; Smith, DE; Krinsky, NI				Wang, XD; Russell, RM; Liu, C; Stickel, F; Smith, DE; Krinsky, NI			beta-oxidation in rabbit liver in vitro and in the perfused ferret liver contributes to retinoic acid biosynthesis from beta-apacarotenoic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-MERCAPTOPROPIONIC ACID; ENZYMATIC CONVERSION; 9-CIS-RETINOIC ACID; INTESTINAL-MUCOSA; VITAMIN-A; RAT-LIVER; CAROTENE; METABOLISM; ABSORPTION; 9-CIS-BETA-CAROTENE	The biosynthesis of retinoic acid from beta-apocarotenoic acids was examined for a beta-oxidation-like process using both rabbit liver mitochondrial fractions with various beta-apocarotenoic acids (beta-apo-14'-, beta-apo-12'-, and beta-apo-8'-carotenoic acid) and perfusion in ferret liver through the portal vein with beta-apo-8'-carotenoic acid. The in vitro incubation of beta-apo-8', beta-apo-12'-, and beta-apo-14'-carotenoic acids gave rise Co shorter chain beta-apocarotenoic acids as well as retinoic acid, The rate of retinoic acid synthesis from 10 mu M beta-apo-8', beta-apo-12'-, and beta-apo-14'-carotenoic acids was 11 +/- 2, IS +/- 3, and 30 +/- 7 pmol/h/mg of protein, respectively, The stepwise oxidation of beta-apocarotenoic acid in mitochondria was dose-related to both protein concentration and substrate concentration beta-Apocarotenoic acid oxidation was inhibited in a dose dependent manlier when it was co-incubated with oleoyl CoA. The in vivo perfusion of ferret liver with beta-apo-8'-carotenoic acid resulted in a linear increase in the retinoic acid concentration of bile, which was completely abolished by co-perfusion of 3-mercaptopropionic acid, an inhibitor of long chain acyl-CoA dehydrogenase, and partially inhibited by 2-tetradecylglycidic acid, an inhibitor of carnitine-palmitoyl-CoA transferase I. However, the formation of retinoic acid from the beta-apocarotenoic acids was not inhibited, either in vitro or in vivo, by citral, an inhibitor of retinal oxidase. Thus, the formation of retinoic acid was not occurring by the central cleavage pathway. These data suggest that the oxidation of intermediate compounds between beta-carotene and retinoic acid may undergo a type of beta-oxidative process to form retinoic acid, which is reminiscent of mitochondrial fatty acid beta-oxidation. This pathway may play an important role in the biosynthesis of retinoic acid from beta-carotene.	TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA	Tufts University	Wang, XD (corresponding author), TUFTS UNIV, USDA, HUMAN NUTR RES CTR AGING, GASTROINTESTINAL NUTR LAB, 711 WASHINGTON ST, BOSTON, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA049195] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA49195-04A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baginski ES, 1974, METH ENZYMOL; BARUA AB, 1990, METHOD ENZYMOL, V189, P136; BARUA AB, 1969, BIOCHEM J, V113, P447, DOI 10.1042/bj1130447; CONNOR MJ, 1987, BIOCHEM J, V244, P489, DOI 10.1042/bj2440489; CRAIN FD, 1967, J LIPID RES, V8, P249; DMITROVSKI AA, 1991, NEW TRENDS BIOL CHEM, P297; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; FOX JG, 1992, BIOL DIS FERRET, P1; FRITZ IB, 1967, PERSPECT BIOL MED, V10, P643; Ganguly J., 1985, World Review of Nutrition and Dietetics, V45, P198; GLOVER J, 1960, VITAM HORM, V18, P371; GOODMAN DS, 1965, SCIENCE, V149, P879, DOI 10.1126/science.149.3686.879; HEBUTERNE X, 1995, J LIPID RES, V36, P1264; Hebuterne X, 1996, J LIPID RES, V37, P482; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KIORPES TC, 1984, J BIOL CHEM, V259, P9750; LAKSHMAN MR, 1989, P NATL ACAD SCI USA, V86, P9124, DOI 10.1073/pnas.86.23.9124; LAKSHMAN.MR, 1972, J LIPID RES, V13, P477; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; OLSON JA, 1969, AM J CLIN NUTR, V22, P953; PETKOVICH M, 1992, ANNU REV NUTR, V12, P443, DOI 10.1146/annurev.nu.12.070192.002303; SABBAGH E, 1985, J BIOL CHEM, V260, P7337; SHARMA RV, 1976, BIOCHEM J, V158, P377, DOI 10.1042/bj1580377; SHARMA RV, 1977, BIOCHIM BIOPHYS ACTA, V486, P183, DOI 10.1016/0005-2760(77)90083-2; SILVA DP, 1982, BIOCHEM J, V206, P33, DOI 10.1042/bj2060033; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; TANG GW, 1991, BIOCHEMISTRY-US, V30, P9829, DOI 10.1021/bi00105a003; WANG XD, 1994, ARCH BIOCHEM BIOPHYS, V313, P150, DOI 10.1006/abbi.1994.1371; WANG XD, 1992, ARCH BIOCHEM BIOPHYS, V293, P298, DOI 10.1016/0003-9861(92)90399-H; WANG XD, 1991, ARCH BIOCHEM BIOPHYS, V285, P8, DOI 10.1016/0003-9861(91)90322-A; WANG XD, 1993, BIOCHIM BIOPHYS ACTA, V1167, P159, DOI 10.1016/0005-2760(93)90157-5; WANG XD, 1992, AM J PHYSIOL, V263, pG480, DOI 10.1152/ajpgi.1992.263.4.G480; WANG XD, 1994, J AM COLL NUTR, V13, P314, DOI 10.1080/07315724.1994.10718416; YAMAMOTO M, 1994, GASTROENTEROLOGY, V107, P517, DOI 10.1016/0016-5085(94)90179-1; YEUM KJ, 1995, ARCH BIOCHEM BIOPHYS, V321, P167, DOI 10.1006/abbi.1995.1382; ZENG SH, 1992, AM J CLIN NUTR, V56, P433, DOI 10.1093/ajcn/56.2.433	38	83	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26490	26498		10.1074/jbc.271.43.26490	http://dx.doi.org/10.1074/jbc.271.43.26490			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900117	hybrid			2022-12-27	WOS:A1996VP23300011
J	Chen, WN; Chen, S; Yap, SF; Lim, L				Chen, WN; Chen, S; Yap, SF; Lim, L			The Caenorhabditis elegans p21-activated kinase (CePAK) colocalizes with CeRac1 and CDC42Ce at hypodermal cell boundaries during embryo elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN STRESS FIBERS; PROTEIN-KINASE; MOLECULAR-CLONING; RAC1; RAS; AUTOPHOSPHORYLATION; IDENTIFICATION; DROSOPHILA; EXPRESSION; FILOPODIA	The p21-activated kinase (PAK) is a downstream target of Rac and CDC42, members of the Ras-related Rho subfamily, that mediates signaling pathway leading to cytoskeletal reorganization. To investigate its function in Caenorhabditis elegans development, we have isolated the cDNA coding for the p21-activated kinase homologue (CePAK) from a C. elegarts embryonic cDNA library, This 2.35-kilobase pair cDNA encodes a polypeptide of 572 amino acid residues, with the highly conserved N-terminal p21-binding and the C-terminal kinase domains, Similar to its mammalian and Drosophila counterparts, the CePAK protein expressed in E. coli exhibits binding activity toward GTP-bound CeRac1 and CDC42Ce. Polyclonal antibodies raised against the recombinant CePAK recognize a specific 70-kDa protein from embryonic extracts that displays CeRac1/CDC42Ce-binding and kinase activities, Immunofluorescence analysis indicates that CePAK is specifically expressed at the hypodermal cell boundaries during embryonic body elongation, which involves dramatic cytoskeletal reorganization. Interestingly, CeRac1 and CDC42Ce are found at the same location, which might point to their common involvement in hypodermal cell fusion, a crucial morphogenetic event for nematode development.	INST NEUROL, LONDON WC1N 1PJ, ENGLAND; NATL UNIV SINGAPORE, INST MOL & CELL BIOL, GLAXO IMCB GRP, SINGAPORE 119260, SINGAPORE	University of London; University College London; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; National University of Singapore				, Yang/0000-0002-6620-8897				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BENNER GE, 1995, J BIOL CHEM, V270, P21121, DOI 10.1074/jbc.270.36.21121; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEN WI, 1993, J BIOL CHEM, V268, P320; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CHEN WN, 1994, J BIOL CHEM, V269, P32394; CHEN WN, 1994, J BIOL CHEM, V269, P820; COUSUHRESKO M, 1994, J CELL BIOL, V124, P491; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; Harden N, 1996, MOL CELL BIOL, V16, P1896; HARDEN N, 1995, DEVELOPMENT, V121, P903; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lloyd CW, 1989, CURR OPIN CELL BIOL, V1, P30, DOI 10.1016/S0955-0674(89)80033-X; LU XY, 1990, J BIOL CHEM, V265, P3293; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Miller DM, 1995, METHOD CELL BIOL, V48, P365; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; PODBILEWICZ B, 1994, DEV BIOL, V161, P408, DOI 10.1006/dbio.1994.1041; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sardet Christian, 1994, Trends in Cell Biology, V4, P166, DOI 10.1016/0962-8924(94)90201-1; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TUCKER JB, 1976, J CELL BIOL, V71, P207, DOI 10.1083/jcb.71.1.207; Wood WB, 1988, NEMATODE CAENORHABDI, P587	34	44	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26362	26368		10.1074/jbc.271.42.26362	http://dx.doi.org/10.1074/jbc.271.42.26362			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824291	hybrid			2022-12-27	WOS:A1996VN18000097
J	Crute, BE; Lewis, AF; Wu, ZN; Bushweller, JH; Speck, NA				Crute, BE; Lewis, AF; Wu, ZN; Bushweller, JH; Speck, NA			Biochemical and biophysical properties of the core-binding factor alpha 2 (AML1) DNA-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN SECONDARY STRUCTURE; CRYSTAL-STRUCTURE; RUNT DOMAIN; P-LOOP; CIRCULAR-DICHROISM; ESCHERICHIA-COLI; GENE RUNT; EXPRESSION	The Runt domain is the DNA-binding domain defining a small family of transcription factors that are involved in important developmental processes. Developmental pathways controlled by Runt domain proteins include sex determination, neurogenesis, segmentation, and eye development in Drosophila and hematopoiesis in mammals. In addition to binding DNA, the Runt domain also mediates heterodimerization with another subunit called the core-binding factor beta (CBF beta) subunit. In this study we overexpress the Runt domain from the mouse CBF alpha 2 (AML1) protein in Escherichia coli, and purify it from the insoluble fraction. We determine the equilibrium constants for Runt domain binding to two different DNA sequences by surface plasmon resonance technology. Circular dichroism spectroscopy demonstrates that the Runt domain is a folded beta-domain with essentially no alpha-helical content. The single tryptophan residue in the CBF alpha 2 Runt domain at amino acid 79 is shown by tryptophan fluorescence spectroscopy to reside in a polar environment. Finally, we demonstrate that ATP can be UV cross-linked to the Runt domain and that ATP binding is sensitive to an amino acid substitution in the putative Kinase-1a motif (P-loop).	DARTMOUTH COLL,SCH MED,DEPT CHEM,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,DEPT BIOCHEM,HANOVER,NH 03755; DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755	Dartmouth College; Dartmouth College; Dartmouth College				Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [CA09658, CA58343] Funding Source: Medline; NIAID NIH HHS [AI07363] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343, T32CA009658] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; BITTER MA, 1987, HUM PATHOL, V18, P211, DOI 10.1016/S0046-8177(87)80002-3; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; ETFINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Hall DR, 1996, ANAL BIOCHEM, V235, P175, DOI 10.1006/abio.1996.0109; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; INGHAM P, 1988, DEVELOPMENT, V104, P51; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOCABIVIK S, 1994, INT J BIOCHEM, V26, P61, DOI 10.1016/0020-711X(94)90196-1; Lakowicz JR, 1983, PRINCIPLES FLUORESCE, P187, DOI 10.1007/978-1-4615-7658-7_7; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; NUCIFORA G, 1995, BLOOD, V86, P1; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Pace C N, 1986, Methods Enzymol, V131, P266; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; SANCHEZ L, 1983, EMBO J, V2, P485, DOI 10.1002/j.1460-2075.1983.tb01451.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SHIRAKIHARA Y, 1988, J MOL BIOL, V204, P973, DOI 10.1016/0022-2836(88)90056-3; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; YANKIE L, 1995, BIOCHEMISTRY-US, V34, P2188, DOI 10.1021/bi00007a012	57	52	53	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26251	26260		10.1074/jbc.271.42.26251	http://dx.doi.org/10.1074/jbc.271.42.26251			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824275	hybrid			2022-12-27	WOS:A1996VN18000081
J	Takagi, Y; Conaway, RC; Conaway, JW				Takagi, Y; Conaway, RC; Conaway, JW			Characterization of Elongin C functional domains required for interaction with Elongin B and activation of Elongin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-SIII; TUMOR-SUPPRESSOR PROTEIN; MYELOID-LEUKEMIA; LEUCINE ZIPPER; FACTOR-EPSILON; ELONGATION; CLONING; BINDING; T(11-19)(Q23-P13.1)	The Elongin (SIII) complex stimulates the rate of elongation by RNA polymerase II by suppressing transient pausing by polymerase at many sites along DNA templates. The Elongin (SIII) complex is composed of a transcriptionally active A subunit, a chaperone-like B subunit, which promotes assembly and enhances stability of the Elongin (SIII) complex, and a regulatory C subunit, which (i) functions as a potent activator of Elongin A transcriptional activity, (ii) interacts specifically with Elongin B to form an isolable Elongin BC complex, and (iii) is bound and negatively regulated in vitro by the product of the von Hippel-Lindau tumor suppressor gene. As part of our effort to understand how Elongin C regulates the activity of the Elongin (SIII) complex, we are characterizing Elongin C functional domains. In this report, we identify Elongin C mutants that fall into multiple functional classes based on their abilities to bind Elongin B and to bind and activate Elongin A under our assay conditions. Characterization of these mutants suggests that Elongin C is composed of multiple overlapping regions that mediate functional interactions with Elongin A and B.	OKLAHOMA MED RES FDN,PROGRAM MOL & CELL BIOL,OKLAHOMA CITY,OK 73104; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,OKLAHOMA CITY,OK 73190	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center				Conaway, Joan/0000-0002-2786-0663	NIGMS NIH HHS [GM41628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041628, R01GM041628] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; BRADSHER JN, 1993, J BIOL CHEM, V268, P25594; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CONAWAY JW, 1990, SCIENCE, V248, P1550, DOI 10.1126/science.2193400; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY JW, 1991, J BIOL CHEM, V266, P7804; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GARRETT KP, 1994, P NATL ACAD SCI USA, V91, P5237, DOI 10.1073/pnas.91.12.5237; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; Kane C. M., 1994, TRANSCRIPTION MECH R, P279; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PETERSON MG, 1991, NATURE, V354, P369; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; REINES D, 1994, TRANSCRIPTION MECHAN, P263; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; TAN SY, 1994, BIOTECHNIQUES, V16, P824; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TSUBOI A, 1992, NUCLEIC ACIDS RES, V20, P3250, DOI 10.1093/nar/20.12.3250	34	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25562	25568		10.1074/jbc.271.41.25562	http://dx.doi.org/10.1074/jbc.271.41.25562			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810329	hybrid			2022-12-27	WOS:A1996VL69300073
J	Ryuto, M; Ono, M; Izumi, H; Yoshida, S; Weich, HA; Kohno, K; Kuwano, M				Ryuto, M; Ono, M; Izumi, H; Yoshida, S; Weich, HA; Kohno, K; Kuwano, M			Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells - Possible roles of SP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; HUMAN CANCER-CELLS; PERMEABILITY FACTOR; TRANSCRIPTION FACTOR; GENE-EXPRESSION; GLIOBLASTOMA-MULTIFORME; LESS PROMOTER; JUN ENCODES; KAPPA-B; ANGIOGENESIS	The expression of vascular endothelial growth factor (VEGF) has been implicated in brain tumor angiogenesis, and the promoter region for the VEGF gene contains several SP-1 and AP-1 (c-Fos and c-Jun) binding motifs. Among eight human glioma cell lines, cellular mRNA levels of transcription factors SP-T and AP-1 (c-Fos and c-Jun) were found to be closely correlated with those of VEGF. VEGF expression appears to be highly susceptible to hypoxia or exogenous cytokines and growth factors. Of various cytokines and growth factors, basic fibroblast growth factor (bFGF), tumor necrosis factor alpha (TNF-alpha), and interleukin 1 most potently enhanced VEGF mRNA levels of a glioma cell line, U251, Incubation of the glioma cells with bFGF or TNF-alpha increased both VEGF and SP-1 mRNA at 30 min and c-Fos mRNA at 1-3 h, over 5-fold. Nuclear run-on assays showed an apparent increase of the transcription of the VEGF gene as well as the SP-1 gene by bFGF or TNF-alpha. Gel mobility shift assays demonstrated that only SP-1 binding activity was increased 1 h after exposure to bFGF or TNF-alpha, and also that AP-1, but not SP-1, activity was significantly activated by hypoxia. Mithramycin, an inhibitor of SP-1, at 1-10 nM inhibited activation of the VEGF gene by bFGF or TNF-alpha but not that by hypoxia. Western blot analysis also demonstrated an increase in cellular amounts of VEGF by TNF-alpha and a decrease by co-administration with mithramycin. The promoter activity of the VEGF gene, which contains five SP-1 binding sites and one AP-1 binding site but not hypoxia regulatory elements, was enhanced by bFGF or TNF-alpha but not by hypoxia. The chloramphenicol acetyltransferase assay with VEGF promoter deletion constructs demonstrated that four clusterized SP-1 binding sites in the proximal promoter were essential for the basal transcription and the TNF-alpha-dependent activation. These data indicated that the expression of the VEGF gene enhanced by bFGF or TNF-alpha appeared to be mediated in part through the transcription factor SP-1, suggesting a different mechanism from that for hypoxia-induced activation of the VEGF gene.	KYUSHU UNIV,SCH MED,DEPT BIOCHEM,FUKUOKA 81282,JAPAN; NATL BIOTECHNOL RES CTR,DEPT GENE EXPRESS,D-318124 BRAUNSCHWEIG,GERMANY; UNIV OCCUPAT & ENVIRONM HLTH,DEPT MOL BIOL,KITAKYUSHU,FUKUOKA 807,JAPAN	Kyushu University; University of Occupational & Environmental Health - Japan				Yoshida, Shigeo/0000-0003-1049-8909				ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; ABE T, 1994, CLIN EXP METASTAS, V12, P296, DOI 10.1007/BF01753836; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASAKUNO K, 1995, BRAIN RES, V702, P23, DOI 10.1016/0006-8993(95)00880-8; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Brandford M.M., 1976, ANAL BIOCHEM, V72, P248; CHEN XR, 1992, ONCOGENE, V7, P1805; CLAFFEY KP, 1992, J BIOL CHEM, V267, P16317; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DOLECKI GJ, 1991, BIOCHEM BIOPH RES CO, V180, P572, DOI 10.1016/S0006-291X(05)81103-9; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FIEDLER IJ, 1994, CELL, V79, P185; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HARDENBOL P, 1992, BIOCHEM BIOPH RES CO, V185, P553, DOI 10.1016/0006-291X(92)91660-I; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; IZUMI H, 1994, EXP CELL RES, V214, P654, DOI 10.1006/excr.1994.1303; JOLLIFF K, 1991, NUCLEIC ACIDS RES, V19, P2267, DOI 10.1093/nar/19.9.2267; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; KOHNO K, 1993, EXP CELL RES, V208, P498, DOI 10.1006/excr.1993.1272; KOHNO K, 1994, J BIOL CHEM, V269, P20503; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; KOONG AC, 1994, CANCER RES, V54, P1425; KUBO T, 1995, CANCER RES, V55, P3860; KUWANO M, 1994, GANN MONOGR CANC RES, V42, P113; LEE JK, 1992, J BIOL CHEM, V267, P4638; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MA L, 1992, NUCLEIC ACIDS RES, V20, P217, DOI 10.1093/nar/20.2.217; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; OKAMURA K, 1991, J BIOL CHEM, V266, P19162; Okimoto T, 1996, ONCOGENE, V12, P1625; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SAMOTO K, 1995, CANCER RES, V55, P1189; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SHIBUYA M, 1990, ONCOGENE, V5, P519; Shono T, 1996, MOL CELL BIOL, V16, P4231; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEFANIK DF, 1991, CANCER RES, V51, P5760; Stoltz RA, 1996, P NATL ACAD SCI USA, V93, P2832, DOI 10.1073/pnas.93.7.2832; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VRIES CD, 1992, SCIENCE, V255, P989; WAKABAYASHI M, 1995, JPN J CANC RES, V86, P1189; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; YAMANE A, 1994, ONCOGENE, V9, P2683; YAO KS, 1994, MOL CELL BIOL, V14, P5997, DOI 10.1128/MCB.14.9.5997; YOKOMIZO A, 1995, J BIOL CHEM, V270, P19451, DOI 10.1074/jbc.270.33.19451; ZAGZAG D, 1990, CANCER RES, V50, P7393	72	421	440	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28220	28228		10.1074/jbc.271.45.28220	http://dx.doi.org/10.1074/jbc.271.45.28220			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910439	hybrid			2022-12-27	WOS:A1996VU03300039
J	Calsou, P; Frit, P; Salles, B				Calsou, P; Frit, P; Salles, B			Double strand breaks in DNA inhibit nucleotide excision repair in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; XENOPUS-LAEVIS OOCYTES; CELL-FREE-EXTRACTS; V(D)J RECOMBINATION; SACCHAROMYCES-CEREVISIAE; POLYMERASE-EPSILON; IONIZING-RADIATION; MAMMALIAN-CELLS; SCID MUTATION; KU	Nucleotide excision repair (NER) was measured in human cell extracts incubated with either supercoiled or linearized damaged plasmid DNA as repair substrate, NER, as quantified by the extent of repair synthesis activity, was reduced by up to 80% in the case of linearized plasmid DNA when compared with supercoiled DNA. An excess of undamaged linearized plasmid in the repair mixture did not interfere with DNA repair synthesis activity on a supercoiled damaged plasmid, indicating a cis-acting inhibiting effect. In contrast, gaps on circular or linearized plasmids were filled in identically by the DNA polymerases operating in the extracts, When the extent of damage-dependent incision activity was measured, a similar to 70% reduction of repair incision activity by human cell extract was observed on linearized damaged plasmids, Recessed, protruding, or blunt ends were similarly inhibitory. NER activity was partly restored when the extracts were preincubated with autoimmune human sera containing antibodies against the nuclear DNA end binding heterodimer Ku, In addition, the inhibition of repair activity on linear damaged plasmids was released in extracts from rodent cells deficient in Ku activity but not in extracts from murine scid cells devoid of Ku-associated DNA dependent kinase activity.			Calsou, P (corresponding author), INST PHARMACOL & BIOL STRUCT, CNRS, UPR 9062, 205 ROUTE NARBONNE, F-31077 TOULOUSE, FRANCE.		salles, bernard/B-8531-2008; calsou, patrick/AAB-5123-2020	Calsou, Patrick/0000-0001-7951-9806				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ANDERSON CW, 1994, J PROTEIN CHEM, V13, P500; BARRET JM, 1995, CARCINOGENESIS, V16, P1611, DOI 10.1093/carcin/16.7.1611; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BIGGERSTAFF M, 1991, MUTAT RES, V254, P217, DOI 10.1016/0921-8777(91)90059-X; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; CALSOU P, 1994, NUCLEIC ACIDS RES, V22, P4937, DOI 10.1093/nar/22.23.4937; CALSOU P, 1994, BIOCHEM BIOPH RES CO, V202, P788, DOI 10.1006/bbrc.1994.1999; CHU G, 1994, J BIOL CHEM, V269, P787; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; FALZON M, 1993, J BIOL CHEM, V268, P10546; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HANSSON J, 1989, NUCLEIC ACIDS RES, V17, P8073, DOI 10.1093/nar/17.20.8073; HOEIJMAKERS JHJ, 1990, MUTAT RES, V236, P223, DOI 10.1016/0921-8777(90)90007-R; HUANG JC, 1994, J BIOL CHEM, V269, P19034; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; JESSBERGER R, 1991, MOL CELL BIOL, V11, P445, DOI 10.1128/MCB.11.1.445; LEGERSKI RJ, 1987, MOL CELL BIOL, V7, P4317, DOI 10.1128/MCB.7.12.4317; MA LB, 1995, BBA-REV CANCER, V1242, P137, DOI 10.1016/0304-419X(95)00008-4; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MIMORI T, 1981, J CLIN INVEST, V68, P611, DOI 10.1172/JCI110295; MIMORI T, 1986, J BIOL CHEM, V261, P375; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NICOLAS AL, 1994, MOL CELL BIOL, V14, P170, DOI 10.1128/MCB.14.1.170; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SAGE E, 1987, BIOCHEMISTRY-US, V26, P3307, DOI 10.1021/bi00386a010; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; STRATHERN JN, 1995, GENETICS, V140, P965; SVOBODA DL, 1993, J BIOL CHEM, V268, P1931; SZYMKOWSKI DE, 1993, P NATL ACAD SCI USA, V90, P9823, DOI 10.1073/pnas.90.21.9823; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; WOOD RD, 1995, PHILOS T ROY SOC B, V347, P69, DOI 10.1098/rstb.1995.0011; ZENG XR, 1994, J BIOL CHEM, V269, P13748	47	23	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27601	27607		10.1074/jbc.271.44.27601	http://dx.doi.org/10.1074/jbc.271.44.27601			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910348	hybrid			2022-12-27	WOS:A1996VQ67900066
J	Chun, RF; Jeang, KT				Chun, RF; Jeang, KT			Requirements for RNA polymerase II carboxyl-terminal domain for activated transcription of human retroviruses human T-cell lymphotropic virus I and HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; MAJOR LATE PROMOTER; LARGEST SUBUNIT; MAMMALIAN-CELLS; NONPHOSPHORYLATED FORM; PREINITIATION COMPLEX; TRANS-ACTIVATION; TAX PROTEIN; PHOSPHORYLATION; ENHANCER	The carboxyl-terminal domain (CTD) of RNA polymerase (RNAP) II contains multiple repeats with a heptapeptide consensus: Tyr-Ser-Pro-Thr-Ser-Pro-Ser. It has been proposed that phosphorylation of this CTD facilitates clearance and elongation of transcription complexes initiated at the promoters. However, not all transcribed promoters require RNAP II with full-length CTD. Furthermore, different activators can promote capably the transcriptional activity of polymerase II mutants deleted in the CTD. Thus, the role of the RNAP II CTD in transcription and in response to activators remains incompletely understood. To study the role of CTD in the regulated transcription of human retroviruses human-T cell lymphotropic virus I and human immunodeficiency virus 1, we used an alpha-amanitin-resistant system developed previously (Gerber, H. P., Hagmann, M., Seipel, K., Georgiev, O., West, M. A., Litingtung, Y., Schaffner, W., and Corden, J. L. (1995) Nature 374, 660-662). We found that transcription directed by the human T-cell lymphotropic virus I activator protein Tax was strongly promoted by CTD-deficient RNA polymerase II. By contrast, the human immunodeficiency virus 1 activator Tat, which is recruited to the promoter by tethering to a nascent leader RNA, requires CTD-containing polymerase II for transcriptional activity. Biochemically, we characterized that Tat associated with a cellular CTD kinase activity, whereas Tax did not. Concordantly, we found that cellular transcription factor Sp1, which can activate CTD-deficient polymerase II with an efficiency similar to Tax, also failed to bind a CTD kinase. Taken together, these observations address mechanistic corollaries between activators with(out) a linked CTD kinase and regulated transcription by RNA polymerase II moieties with(out) a CTD.	NIAID,MOL VIROL SECT,MOL MICROBIOL LAB,NATL INST HLTH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Jeang, Kuan-Teh/A-2424-2008; Chun, Rene/A-9415-2010	Chun, Rene/0000-0002-0190-0807				BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BERAUD C, 1991, EMBO J, V10, P3795, DOI 10.1002/j.1460-2075.1991.tb04949.x; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Franklin Audrey A., 1995, Journal of Biomedical Science, V2, P17, DOI 10.1007/BF02257921; FUJII M, 1991, ONCOGENE, V6, P2349; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GERBER HP, 1995, NATURE, V374, P660, DOI 10.1038/374660a0; GOREN I, 1995, J VIROL, V69, P5806, DOI 10.1128/JVI.69.9.5806-5811.1995; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Jeang K T, 1991, AIDS, V5 Suppl 2, pS3, DOI 10.1097/00002030-199101001-00002; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; JEANG KT, 1992, J BIOL CHEM, V267, P17891; JEANG KT, 1988, P NATL ACAD SCI USA, V85, P8291, DOI 10.1073/pnas.85.21.8291; JEANG KT, 1991, VIROLOGY, V181, P218, DOI 10.1016/0042-6822(91)90487-V; JEANG KT, 1994, HUMAN RETROVIRUSES A; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; LIS J, 1993, CELL, V74, P1, DOI 10.1016/0092-8674(93)90286-Y; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MCMILLAN NAJ, 1995, VIROLOGY, V213, P413, DOI 10.1006/viro.1995.0014; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; ROY R, 1994, J BIOL CHEM, V269, P9826; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5606; SEMMES OJ, 1995, J VIROL, V69, P1827, DOI 10.1128/JVI.69.3.1827-1833.1995; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZEHRING WA, 1990, J BIOL CHEM, V265, P8351; ZHANG J, 1991, J BIOL CHEM, V266, P2297; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	64	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27888	27894		10.1074/jbc.271.44.27888	http://dx.doi.org/10.1074/jbc.271.44.27888			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910388	hybrid			2022-12-27	WOS:A1996VQ67900106
J	Gao, M; Loe, DW; Grant, CE; Cole, SPC; Deeley, RG				Gao, M; Loe, DW; Grant, CE; Cole, SPC; Deeley, RG			Reconstitution of ATP-dependent leukotriene C-4 transport by co-expression of both half-molecules of human multidrug resistance protein in insect cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMAN TUMOR-CELLS; CYSTIC-FIBROSIS; P-GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; GENE OVEREXPRESSION; TOPOISOMERASE-II; DRUG-EFFLUX; MRP	Multidrug resistance protein (MRP) confers a multidrug resistance phenotype similar to that associated with overexpression of P-glycoprotein. Unlike P-glycoprotein, MRP has also been shown to be a primary active ATP-dependent transporter of conjugated organic anions, The mechanism(s) by which MRP transports these compounds and increases resistance to natural product drugs is unknown, To facilitate studies on the structure and function of MRP, we have determined whether a baculovirus expression system can be used to produce active protein, Full-length MRP as well as molecules corresponding to either the NH2- or COOH-proximal halves of the protein were expressed individually and in combination in Spodoptera frugiperda Sf21 cells, High levels of intact and half-length proteins were detected in membrane vesicles from infected cells. Although underglycosylated, the full-length protein transported leukotriene C-4 (LTC(4)) with kinetic parameters very similar to those of MRP produced in transfected HeLa cells, Neither half-molecule was able to transport LTC(4). However, a functional transporter with characteristics similar to those ofintact protein could be reconstituted vvhen both half-molecules were co expressed. Transport of LTC(4) by Sf21 membrane vesicles containing either intact or reconstituted MRP was competitively inhibited by both S-decylglutathione and 17 beta-estradiol 17-(beta-a-glucuronide), with K-i values similar to those reported previously for MRP expressed in HeLa cells (Loe, D. W., Almquist, K. C., Deeley, R. G., and Cole, S. P. C. (1996) J. Biol. Chem. 271, 9675-9682; Loe, D. W., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (1996) J. Biol. Chem. 271, 9683-9689), These studies demonstrate that human MRP produced in insect cells can function as an active transporter of LTC(4) and that the NH2- and COOH-proximal halves of the protein can assemble efficiently to form a transporter with functional characteristics similar to those of the intact protein.	QUEENS UNIV, CANC RES LABS, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT PATHOL, KINGSTON, ON K7L 3N6, CANADA	Queens University - Canada; Queens University - Canada			Deeley, Roger/J-4828-2012; Cole, Susan P.C./I-6389-2017	Cole, Susan P.C./0000-0001-6571-6884				AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; ALMQUIST KC, 1995, CANCER RES, V55, P102; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BINASCHI M, 1995, INT J CANCER, V62, P84, DOI 10.1002/ijc.2910620116; BREUNINGER LM, 1995, CANCER RES, V55, P5342; BROCK I, 1995, CANCER RES, V55, P459; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; COLEY HM, 1991, BRIT J CANCER, V63, P351, DOI 10.1038/bjc.1991.84; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FLENS MJ, 1994, CANCER RES, V54, P4557; Gartner J, 1993, Semin Cell Biol, V4, P45, DOI 10.1006/scel.1993.1006; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRANT CE, 1994, CANCER RES, V54, P357; HASEGAWA S, 1995, BRIT J CANCER, V71, P907, DOI 10.1038/bjc.1995.177; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1996, CANCER RES, V56, P3307; HIPFNER DR, 1994, CANCER RES, V54, P5788; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KARTNER N, 1991, CELL, V64, P681, DOI 10.1016/0092-8674(91)90498-N; Koronakis V, 1993, Semin Cell Biol, V4, P7, DOI 10.1006/scel.1993.1002; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; LI CH, 1993, NAT GENET, V3, P311, DOI 10.1038/ng0493-311; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MARSH W, 1986, CANCER RES, V46, P4053; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; PIND S, 1994, J BIOL CHEM, V269, P12784; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SCHNEIDER E, 1994, CANCER RES, V54, P152; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SLAPAK CA, 1994, BLOOD, V84, P3113, DOI 10.1182/blood.V84.9.3113.bloodjournal8493113; Stride BD, 1996, MOL PHARMACOL, V49, P962; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; vanKuijck MA, 1996, P NATL ACAD SCI USA, V93, P5401, DOI 10.1073/pnas.93.11.5401; WARD CL, 1994, J BIOL CHEM, V269, P25710; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822	54	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27782	27787		10.1074/jbc.271.44.27782	http://dx.doi.org/10.1074/jbc.271.44.27782			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910374	hybrid			2022-12-27	WOS:A1996VQ67900092
J	Lipari, F; Herscovics, A				Lipari, F; Herscovics, A			Role of the cysteine residues in the alpha 1,2-mannosidase involved in N-glycan biosynthesis in Saccharomyces cerevisiae - The conserved Cys(340) and Cys(385) residues form an essential disulfide bond	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PROCESSING ALPHA-MANNOSIDASE; MOLECULAR-CLONING; 1,2-ALPHA-D-MANNOSIDASE GENE; GLYCOPROTEIN-BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; PROTEINS; PURIFICATION; YEAST; POLYPEPTIDES	The Saccharomyces cerevisiae alpha 1,2-mannosidase, which removes one specific mannose residue from Man(9)GlcNAc(2) to form Man(8)GlcNAc(2), is a member of a family of alpha 1,2-mannosidases with similar amino acid sequences. The yeast alpha 1,2-mannosidase contains five cysteine residues, three of which are conserved, Recombinant yeast alpha 1,2-mannosidase, produced as the soluble catalytic domain, was shown to contain two disulfide bonds and one free thiol group using 2-nitro-5-thiosulfobenzoate and 5,5'-dithiobis(2-nitrobenzoate), respectively, Cys485 contains the free thiol group, as demonstrated by sequencing of labeled peptides following modification with [H-3]ICH2COOH and by high performance liquid chromatography/mass spectrometry tryptic peptide mapping, A Cys(340)-Cys(385) disulfide was demonstrated by sequencing a purified peptide containing this disulfide and by tryptic peptide mapping, Cys(468) and Cys(471) were not labeled with [H-3]ICH2COOH and a peptide containing these two residues was identified in the tryptic peptide map, showing that Cys468 and Cys471 form the second disulfide bond, The alpha 1,alpha-mannosidase loses its activity in the presence of dithiothreitol with first order kinetics, suggesting that at least one disulfide bond is essential for activity, Mutagenesis of each cysteine residue to serine showed that Cys(340) and Cys(385) are essential for production of recombinant enzyme, whereas Cys468, Cys(471), and Cys485 are not re quired for production and enzyme activity, These results indicate that the sensitivity to dithiothreitol is due to reduction of the Cys(340)-Cys(385) disulfide, Since Cys(340) and Cys(385) are conserved residues, it is likely that this disulfide bond is important to maintain the correct structure in the other members of the alpha 1,2-mannosidase family.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA	McGill University					NIGMS NIH HHS [GM 31265] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUSE E, 1993, EUR J BIOCHEM, V217, P535, DOI 10.1111/j.1432-1033.1993.tb18274.x; Burke J, 1996, EUR J CELL BIOL, V70, P298; CAMIRAND A, 1991, J BIOL CHEM, V266, P15120; CARR SA, 1990, METHOD ENZYMOL, V193, P508; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; GRONDIN B, 1992, GLYCOBIOLOGY, V2, P369, DOI 10.1093/glycob/2.4.369; Gros E., 1967, METHOD ENZYMOL, V11, P238; HERSCOVICS A, 1994, J BIOL CHEM, V269, P9864; INOUE T, 1995, BBA-PROTEIN STRUCT M, V1253, P141, DOI 10.1016/0167-4838(95)00195-6; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JELINEKKELLY S, 1985, J BIOL CHEM, V260, P2253; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P44; KERSCHER S, 1995, DEV BIOL, V168, P613, DOI 10.1006/dbio.1995.1106; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAL A, 1994, J BIOL CHEM, V269, P9872; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Markwell M A, 1981, Methods Enzymol, V72, P296; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; ROBERTSON JG, 1994, BIOCHEMISTRY-US, V33, P11563, DOI 10.1021/bi00204a019; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Scaman CH, 1996, GLYCOBIOLOGY, V6, P265, DOI 10.1093/glycob/6.3.265; SCHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484, DOI 10.1006/abbi.1993.1243; SORENSEN SB, 1991, FEBS LETT, V294, P195, DOI 10.1016/0014-5793(91)80667-R; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; VILLA S, 1989, ANAL BIOCHEM, V177, P161, DOI 10.1016/0003-2697(89)90032-8; WANG QP, 1994, J AM CHEM SOC, V116, P11594, DOI 10.1021/ja00104a060; YOSHIDA T, 1995, BBA-GENE STRUCT EXPR, V1263, P159, DOI 10.1016/0167-4781(95)00101-L; ZIEGLER F D, 1991, Glycobiology, V1, P605, DOI 10.1093/glycob/1.6.605	31	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27615	27622		10.1074/jbc.271.44.27615	http://dx.doi.org/10.1074/jbc.271.44.27615			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910350	hybrid			2022-12-27	WOS:A1996VQ67900068
J	Rajaraman, K; Raman, B; Rao, CM				Rajaraman, K; Raman, B; Rao, CM			Molten-globule state of carbonic anhydrase binds to the chaperone-like alpha-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; B-CRYSTALLIN; MOLECULAR CHAPERONE; STRUCTURAL CHARACTERIZATION; INTERMEDIATE; LYSOZYME; LACTALBUMIN; EXPRESSION; LENS; DENATURATION	alpha-Crystallin, a multimeric protein, exhibits chaperone-like activity in preventing aggregation of several proteins, We have studied the chaperone-like activity of alpha-crystallin toward heat-induced aggregation of bovine and human carbonic anhydrase, Human carbonic anhydrase aggregates at 60 degrees C, while bovine carbonic anhydrase does not aggregate significantly at this temperature, Removal of the enzyme-bound metal ion, Zn2+, by EDTA modulates the aggregation behavior of bovine carbonic anhydrase, Fluorescence and circular dichroism studies show that removal of the metal ion from the bovine carbonic anhydrase by a chelator such as EDTA enhances the propensity of the enzyme to adopt the molten-globule state, alpha-Crystallin binds to this state of the enzyme and prevents aggregation, Fluorescence and circular dichroism studies on the alpha-crystallin enzyme complexes show that the enzymes in the complex are in the molten-globule state, These results are of relevance to the interaction of chaperones with the partially unfolded states of target proteins.	CTR CELLULAR & MOL BIOL, HYDERABAD 500007, ANDHRA PRADESH, INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Krishnan, Rajaraman/0000-0002-5189-4097				AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; BALDWIN RL, 1993, CURR OPIN STRUC BIOL, V3, P84, DOI 10.1016/0959-440X(93)90206-Z; BARRICK D, 1994, J MOL BIOL, V237, P588, DOI 10.1006/jmbi.1994.1257; BARRICK D, 1993, PROTEIN SCI, V2, P869, DOI 10.1002/pro.5560020601; BOYLE D, 1993, BIOCHEM BIOPH RES CO, V192, P1147, DOI 10.1006/bbrc.1993.1536; BUCK M, 1993, BIOCHEMISTRY-US, V32, P669, DOI 10.1021/bi00053a036; BYCHKOVA VE, 1988, FEBS LETT, V238, P231, DOI 10.1016/0014-5793(88)80485-X; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391; DAS KP, 1995, BIOCHEM J, V311, P367, DOI 10.1042/bj3110367; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; DUBIN RA, 1989, MOL CELL BIOL, V9, P1083, DOI 10.1128/MCB.9.3.1083; FARAHBAKHSH ZT, 1995, BIOCHEMISTRY-US, V34, P509, DOI 10.1021/bi00002a015; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; GROENEN PJTA, 1994, EUR J BIOCHEM, V225, P1, DOI 10.1111/j.1432-1033.1994.00001.x; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; IKEGUCHI M, 1986, J BIOCHEM-TOKYO, V99, P1191, DOI 10.1093/oxfordjournals.jbchem.a135582; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; IWAKI T, 1989, CELL, V57, P71, DOI 10.1016/0092-8674(89)90173-6; JAGANNADHAM MV, 1985, FEBS LETT, V188, P326, DOI 10.1016/0014-5793(85)80396-3; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1080, P173, DOI 10.1016/0167-4838(91)90146-Q; KELLEY MJ, 1993, J BIOL CHEM, V268, P18844; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KUWAJIMA K, 1986, INT J PEPT PROT RES, V27, P18; KUWAJIMA K, 1985, BIOCHEMISTRY-US, V24, P874, DOI 10.1021/bi00325a010; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MERCK KB, 1993, J BIOL CHEM, V268, P1046; MULDERS JWM, 1985, EUR J BIOCHEM, V152, P721, DOI 10.1111/j.1432-1033.1985.tb09253.x; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NYMAN PO, 1968, EUR J BIOCHEM, V6, P172, DOI 10.1111/j.1432-1033.1968.tb00435.x; PARDON E, 1995, J BIOL CHEM, V270, P10514, DOI 10.1074/jbc.270.18.10514; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Raman B, 1996, J BIOL CHEM, V271, P17067, DOI 10.1074/jbc.271.29.17067; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; RAMAN B, 1994, J BIOL CHEM, V269, P27264; RAMAN B, 1995, J BIOL CHEM, V270, P19888, DOI 10.1074/jbc.270.34.19888; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SUNDARI CS, 1991, BIOCHIM BIOPHYS ACTA, V1065, P35; VANDAEL H, 1993, BIOCHEMISTRY-US, V32, P11886, DOI 10.1021/bi00095a018; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; WANG KY, 1994, J BIOL CHEM, V269, P13601; WARD RL, 1970, BIOCHEMISTRY-US, V9, P2447, DOI 10.1021/bi00814a009; WHITNEY PL, 1967, J BIOL CHEM, V242, P4206; WONG KP, 1973, J BIOL CHEM, V248, P8518	54	93	93	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27595	27600		10.1074/jbc.271.44.27595	http://dx.doi.org/10.1074/jbc.271.44.27595			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910347	hybrid			2022-12-27	WOS:A1996VQ67900065
J	Wang, ZZ; Hardy, SF; Hall, ZW				Wang, ZZ; Hardy, SF; Hall, ZW			Assembly of the nicotinic acetylcholine receptor - The first transmembrane domains of truncated alpha and delta subunits are required for heterodimer formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFECTED COS CELLS; ENDOPLASMIC-RETICULUM; BINDING-SITES; TERMINAL DOMAINS; EPSILON SUBUNIT; ION CHANNELS; MUSCLE-CELLS; MOUSE; PROTEIN; IDENTIFICATION	To investigate the mechanism of assembly of the mouse muscle acetylcholine receptor, we have expressed truncated N-terminal fragments of the alpha and delta subunits in COS cells and have examined their ability to fold, to associate into heterodimers, and to form a ligand-binding site, Truncated fragments of the alpha subunit that include all, part, or none of the first transmembrane domain (M1) folded to acquire cu-bungarotoxin binding activity, Neither the full-length alpha subunit nor any of the fragments were expressed on the cell surface, although the shortest folded fragment lacking a transmembrane domain was secreted into the medium, When coexpressed with the delta subunit, the alpha subunit fragment possessing M1 formed a heterodimer containing a ligand-binding site, but shorter fragments, which lack transmembrane segments, did not associate with the delta subunit, N-terminal delta subunit fragments gave similar results. An N-terminal delta subunit fragment that contains M1 associated with the alpha subunit to form a heterodimer, while a fragment lacking M1 did not. These results show that a complete M1 domain is necessary for association of truncated N-terminal alpha and delta subunits into a heterodimer with high affinity ligand binding activity.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; NIMH, CELL BIOL LAB, BETHESDA, MD 20892 USA	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)								ANDERSON DJ, 1981, P NATL ACAD SCI-BIOL, V78, P5598, DOI 10.1073/pnas.78.9.5598; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BUONANNO A, 1986, J BIOL CHEM, V261, P6451; CARLIN BE, 1987, PROTEIN COMPARTMENTA, P71; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; FORSAYETH JR, 1992, J CELL BIOL, V117, P841, DOI 10.1083/jcb.117.4.841; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; FROEHNER SC, 1983, J BIOL CHEM, V258, P7112; FU DX, 1994, J BIOL CHEM, V269, P26152; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GUILLICK W, 1983, BICOHEMISTRY, V22, P3312; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; KARLIN A, 1991, HARVEY LECT, V85, P71; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; MERLIE JP, 1982, J BIOL CHEM, V257, P2694; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; NOMOTO H, 1986, EUR J BIOCHEM, V157, P233, DOI 10.1111/j.1432-1033.1986.tb09661.x; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; Shtrom SS, 1996, J BIOL CHEM, V271, P25506, DOI 10.1074/jbc.271.41.25506; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SMITH MM, 1987, J BIOL CHEM, V262, P4367; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WILSON PT, 1988, MOL PHARMACOL, V34, P643; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; YU XM, 1994, MOL PHARMACOL, V46, P964	52	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27575	27584		10.1074/jbc.271.44.27575	http://dx.doi.org/10.1074/jbc.271.44.27575			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910344	hybrid			2022-12-27	WOS:A1996VQ67900062
J	Yamaguchi, Y; Ikenaka, K; Niinobe, M; Yamada, H; Mikoshiba, K				Yamaguchi, Y; Ikenaka, K; Niinobe, M; Yamada, H; Mikoshiba, K			Myelin proteolipid protein (PLP), but not DM-20, is an inositol hexakisphosphate-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVOUS-SYSTEM MYELIN; JIMPY MUTANT MOUSE; RAT-BRAIN; POLYPHOSPHATE RECEPTOR; SYNAPTIC FUNCTION; CLATHRIN BINDING; GOLGI-APPARATUS; MESSENGER-RNAS; GENE FAMILY; CNS MYELIN	Myelin proteolipid protein (PLP) and its alternatively spliced isoform, DM-20, are the major integral membrane proteins of central nervous system myelin. It is known that PLP and DM-20 are delivered to myelin by a finely regulated vesicular transport system in oligodendrocytes. Evolutionarily, it is believed that ancestral DM-20 acquired a PLP-specific exon to create PLP, after which PLP/DM-20 became a major component of central nervous system myelin. We purified PLP as an inositol 1,3,4,5-tetrakisphosphate-binding protein after solubilization in a non-organic solvent. However, under the Isotonic condition, PLP binds inositol hexakisphosphate (InsP(6)) significantly, not inositol 1,3,4,5-tetrakisphosphate. Most of the InsP(6)-binding proteins are involved in vesicular transport, suggesting the involvement of PLP in vesicular transport. We separated DM-20 from PLP by CM-52 chromatography and showed that DM-20 has no InsP(6) binding activity. These findings indicate that the PLP-specific domain confers the InsP(6) binding activity and this interaction may be important for directing PLP transport to central nervous system myelin.	OKAZAKI NATL RES INST,NATL INST PHYSIOL SCI,LAB NEURAL INFORMAT,OKAZAKI,AICHI 444,JAPAN; OSAKA UNIV,INST PROT RES,DIV REGULAT MACROMOL FUNCT,SUITA,OSAKA 565,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL NEUROBIOL LAB,TSUKUBA,IBARAKI 305,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOL NEUROBIOL,MINATO KU,TOKYO 108,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); Osaka University; RIKEN; University of Tokyo			Mikoshiba, Katsuhiko/N-7943-2015	Yamaguchi, Yoshihide/0000-0002-5686-9325				BECK KA, 1991, J BIOL CHEM, V266, P4442; BENJAMINS JA, 1978, J NEUROCHEM, V31, P1077, DOI 10.1111/j.1471-4159.1978.tb00150.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; CHADWICK CC, 1992, J BIOL CHEM, V267, P3473; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; DIEHL HJ, 1986, P NATL ACAD SCI USA, V83, P9807, DOI 10.1073/pnas.83.24.9807; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GARDINIER MV, 1986, MOL CELL BIOL, V6, P3755, DOI 10.1128/MCB.6.11.3755; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HUDSON LD, 1987, P NATL ACAD SCI USA, V84, P1454, DOI 10.1073/pnas.84.5.1454; Hudson Lynn D., 1992, P677; IKENAKA K, 1988, J MOL BIOL, V199, P587, DOI 10.1016/0022-2836(88)90303-8; KAGAWA T, 1994, NEURON, V13, P427, DOI 10.1016/0896-6273(94)90358-1; KITAGAWA K, 1993, NEURON, V11, P433, DOI 10.1016/0896-6273(93)90148-K; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lees Marjorie B., 1992, P237; LUCAS AH, 1994, FEBS LETT, V347, P273; MACKLIN WB, 1987, J NEUROSCI RES, V18, P383, DOI 10.1002/jnr.490180302; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1993, EMBO J, V12, P667, DOI 10.1002/j.1460-2075.1993.tb05700.x; NAISMITH AL, 1985, NUCLEIC ACIDS RES, V13, P7413, DOI 10.1093/nar/13.20.7413; NAKAO J, 1995, J NEUROCHEM, V64, P2396; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; NAVE KA, 1986, P NATL ACAD SCI USA, V83, P9264, DOI 10.1073/pnas.83.23.9264; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NUSSBAUM JL, 1983, CELL TISSUE RES, V234, P547; PERIN MS, 1991, J BIOL CHEM, V266, P615; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; PUCKETT C, 1987, J NEUROSCI RES, V18, P511, DOI 10.1002/jnr.490180402; READHEAD C, 1994, NEURON, V12, P583, DOI 10.1016/0896-6273(94)90214-3; ROUSSEL G, 1987, J NEUROCYTOL, V16, P195, DOI 10.1007/BF01795303; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SASAKAWA N, 1995, BIOCHEM PHARMACOL, V50, P137, DOI 10.1016/0006-2952(95)00059-9; SCHWOB VS, 1985, J NEUROCHEM, V45, P559, DOI 10.1111/j.1471-4159.1985.tb04024.x; Skoff Robert P., 1992, P653; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STOFFEL W, 1984, P NATL ACAD SCI-BIOL, V81, P5012, DOI 10.1073/pnas.81.16.5012; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; THEIBERT AB, 1991, P NATL ACAD SCI USA, V88, P3165, DOI 10.1073/pnas.88.8.3165; TIMERMAN AP, 1992, P NATL ACAD SCI USA, V89, P8976, DOI 10.1073/pnas.89.19.8976; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; WEIMBS T, 1992, BIOCHEMISTRY-US, V31, P12289, DOI 10.1021/bi00164a002; WENDLAND B, 1991, NEURON, V6, P993, DOI 10.1016/0896-6273(91)90239-V; YAMAMURA T, 1991, J NEUROCHEM, V57, P1671, DOI 10.1111/j.1471-4159.1991.tb06367.x; YE WL, 1995, J BIOL CHEM, V270, P10933, DOI 10.1074/jbc.270.18.10933; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	57	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27838	27846		10.1074/jbc.271.44.27838	http://dx.doi.org/10.1074/jbc.271.44.27838			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910382	hybrid			2022-12-27	WOS:A1996VQ67900100
J	Erickson, JW; Zhang, CJ; Kahn, RA; Evans, T; Cerione, RA				Erickson, JW; Zhang, CJ; Kahn, RA; Evans, T; Cerione, RA			Mammalian Cdc42 is a brefeldin A-sensitive component of the Golgi apparatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; SACCHAROMYCES-CEREVISIAE GENE; ADP-RIBOSYLATION FACTOR; DBL ONCOGENE PRODUCT; ACTIN STRESS FIBERS; CELL POLARITY; MONOCLONAL-ANTIBODY; MEMBRANE-PROTEIN; PHOSPHOLIPASE-D	In this study, we have used immunocytochemical and fractionation approaches to provide a description oft he localization of the mammalian Cdc42 protein (designated Cdc42Hs) in vivo. A specific anti-peptide antibody was generated against the C-terminal region of Cdc42Hs. Using affinity-purified preparations of this antibody in indirect immunofluorescence experiments, Cdc42Hs was found to be localized to the Golgi apparatus, Similar to the well-characterized non-clathrin coat proteins ADP-ribosylation factor (ARF) and beta-COP, the perinuclear clustering of Cdc42Hs is rapidly dispersed upon exposure of the cells to the drug brefeldin A, suggesting that it too may play a role in the processes of intracellular lipid and protein transport, Employing cell lines possessing inducible forms of ARF, we demonstrate here a tight coupling of the nucleotide bound state of ARF and the subcellular localization of Cdc42Hs. Specifically, the expression of wild-type ARF had no effect on the brefeldin A sensitivity of Cdc42Hs while, as is the case for ARF and P-COP, expression of a GTPase-deficient form of ARF (ArF(Q71L)) renders these Golgi-localized proteins resistant to brefeldin A treatment (Teal et al., 1994; Zhang et al,, 1994). Moreover, the induced expression of a mutant form of ARF with a low affinity for nucleotide resulted in constitutive redistribution of Cdc42Hs in the absence of brefeldin A treatment. These results suggest that Cdc42Hs may play a role in cell morphogenesis by acting on targets in the Golgi that direct polarized growth at the plasma membrane.	NCI,BIOL CHEM LAB,DEV THERAPEUT PROGRAM,DIV CANC TREATMENT,NIH,BETHESDA,MD 20892; ONYX PHARMACEUT,RICHMOND,CA 94806	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Erickson, JW (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NIGMS NIH HHS [GM47458] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047458] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BARON MD, 1990, J BIOL CHEM, V265, P19928; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KTISTAKIS NT, 1991, J CELL BIOL, V113, P1009, DOI 10.1083/jcb.113.5.1009; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ORCI L, 1991, CELL, V64, P1183; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; TEAL SB, 1994, J BIOL CHEM, V269, P3135; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	41	165	170	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26850	26854		10.1074/jbc.271.43.26850	http://dx.doi.org/10.1074/jbc.271.43.26850			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900167	hybrid			2022-12-27	WOS:A1996VP23300061
J	Lee, AC; Xu, XF; Colombini, M				Lee, AC; Xu, XF; Colombini, M			The role of pyridine dinucleotides in regulating the permeability of the mitochondrial outer membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-MITOCHONDRIA; NAD(P)H DEHYDROGENASES; SYNTHETIC POLYANION; INTERMEMBRANE SPACE; RAT-HEART; CHANNEL; VDAC; PROTEIN; MUSCLE; NUCLEOTIDES	Both NADH and NADPH reduce the permeability of the mitochondrial outer membrane to ADP. This is specific for the outer membrane and uncorrelated with the respiratory control ratio, This could result in a 7-fold difference between the concentration of ADP in the intermembrane space and that in the external environment, (at 5 mu M ADP). in both cases the permeability declines by a factor of 5, but NADH is more potent: K-D = 86 mu M for NADH versus 580 mu M for NADPH. The lower apparent affinity for NADPH is partly explained by Mg2+-NADPH being the active species, and under our conditions only 30% of the NADPH is in this form. The corrected K-D is 184 mu M. Free NADH has the same charge as the Mg2+-NADPH complex, and thus both likely bind to the same site, The ability of NADH and NADPH to induce the closure of reconstituted VDAC channels is consistent with VDAC being the main pathway for metabolite flow across the outer membrane, Oncotic pressure, effective at inducing VDAC closure, also decreases the enter membrane permeability. Thus, in the presence of cytosolic colloidal osmotic pressure NAD(P)H may inhibit mitochondrial catabolic pathways and divert reducing equivalents to anabolic pathways.	UNIV MARYLAND, DEPT ZOOL, CELL BIOL LABS, COLLEGE PK, MD 20742 USA	University System of Maryland; University of Maryland College Park			Colombini, Marco/A-1540-2014		NIGMS NIH HHS [GM 35759] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPS DK, 1973, BIOCHIM BIOPHYS ACTA, V320, P379, DOI 10.1016/0304-4165(73)90319-X; ARRON GP, 1980, PLANT PHYSIOL, V65, P591, DOI 10.1104/pp.65.4.591; BELL CF, 1977, OXFORD CHEM SERIES, P86; BENZ R, 1988, FEBS LETT, V231, P75, DOI 10.1016/0014-5793(88)80706-3; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRINDLE KM, 1989, BIOCHEMISTRY-US, V28, P4887, DOI 10.1021/bi00437a054; CANEPA L, 1991, BIOCHIM BIOPHYS ACTA, V1074, P101, DOI 10.1016/0304-4165(91)90046-J; COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; COLOMBINI M, 1987, BIOCHIM BIOPHYS ACTA, V905, P279, DOI 10.1016/0005-2736(87)90456-1; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; FREITAG H, 1983, METHOD ENZYMOL, V97, P286; GELLERICH FN, 1993, BIOCHIM BIOPHYS ACTA, V1142, P217, DOI 10.1016/0005-2728(93)90150-E; GELLERICH FN, 1987, BIOCHIM BIOPHYS ACTA, V890, P117, DOI 10.1016/0005-2728(87)90012-0; GELLERICH FN, 1989, ANION CARRIERS OF MITOCHONDRIAL MEMBRANES, P349; GOTTSCHALK ME, 1981, BIOCHEMISTRY-US, V20, P2245, DOI 10.1021/bi00511a027; HARVEY AE, 1953, ANAL CHEM, V25, P498, DOI 10.1021/ac60075a031; HOLDEN MJ, 1993, BIOCHIM BIOPHYS ACTA, V1144, P396, DOI 10.1016/0005-2728(93)90126-Z; HOLDEN MJ, 1988, FEBS LETT, V241, P105, DOI 10.1016/0014-5793(88)81040-8; INCE C, 1992, OXYGEN TRANSPORT TIS, V14; LEE AC, 1994, J BIOL CHEM, V269, P30974; LIU MY, 1992, BIOCHIM BIOPHYS ACTA, V1098, P255, DOI 10.1016/S0005-2728(05)80344-5; MOLLER IM, 1986, ANNU REV PLANT PHYS, V37, P309, DOI 10.1146/annurev.arplant.37.1.309; MOLLER IM, 1993, J BIOENERG BIOMEMBR, V25, P377, DOI 10.1007/BF00762463; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; NUUTINEN EM, 1984, BASIC RES CARDIOL, V79, P49, DOI 10.1007/BF01935806; PALMER JM, 1982, TRENDS BIOCHEM SCI, V7, P258, DOI 10.1016/0968-0004(82)90039-1; Parsegian VA, 1995, METHOD ENZYMOL, V259, P43; PROUTY MS, 1985, J MOL BIOL, V184, P517, DOI 10.1016/0022-2836(85)90298-0; ROTH K, 1991, MAGNET RESON MED, V22, P505, DOI 10.1002/mrm.1910220258; SCHWITZGUEBEL JP, 1984, PLANT PHYSIOL, V75, P670, DOI 10.1104/pp.75.3.670; Song JM, 1996, J BIOENERG BIOMEMBR, V28, P153, DOI 10.1007/BF02110646; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; VELOSO D, 1973, J BIOL CHEM, V248, P4811; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WAN B, 1993, AM J PHYSIOL, V265, pH453, DOI 10.1152/ajpheart.1993.265.2.H453; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; YOUNG A, 1955, ANAL CHEM, V27, P418, DOI 10.1021/ac60099a026; ZIMMERBERG J, 1986, NATURE, V323, P36, DOI 10.1038/323036a0; ZIZI M, 1994, J BIOL CHEM, V269, P1614	40	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26724	26731		10.1074/jbc.271.43.26724	http://dx.doi.org/10.1074/jbc.271.43.26724			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900151	hybrid			2022-12-27	WOS:A1996VP23300045
J	Pahwa, GS; Maher, LJ; Hollingsworth, MA				Pahwa, GS; Maher, LJ; Hollingsworth, MA			A potential H-DNA element in the MUC1 promoter does not influence transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR GENE; UPSTREAM	A purine/pyrimidine mirror repeat element (M-PMR3) in the MUC1 promoter has been shown to form H-DNA under in vitro conditions, We investigated this element for biological function in the regulation of transcription of this gene. Chloramphenicol acetyltransferase reporter-promoter constructs were prepared in which the mirror repeat element (PMR3) was intact, deleted, or modified, and their activities were evaluated by transient transfection assays into the cell lines Capan-2, PANC1, and HT-29. Deletion or modification of M-PMR3 increased expression of chloramphenicol acetyltransferase activity in MUC1-expressing cells; however, a role for an H-DNA structure in this activity was not supported by the results.	UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC & ALLIED DIS, OMAHA, NE 68198 USA; MAYO CLIN & MAYO FDN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN 55905 USA	University of Nebraska System; University of Nebraska Medical Center; Mayo Clinic					NATIONAL CANCER INSTITUTE [R01CA057362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046589, R01DK044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA57362] Funding Source: Medline; NIDDK NIH HHS [DK46589, DK44762] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; AUSUBEL MF, 1992, SHORT PROTOCOLS MOL; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; HOLLINGSWORTH MA, 1994, NUCLEIC ACIDS RES, V22, P1138, DOI 10.1093/nar/22.7.1138; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MAXWELL IH, 1993, HUM GENE THER, V4, P441, DOI 10.1089/hum.1993.4.4-441; MCDONALD CD, 1994, GENE, V150, P267, DOI 10.1016/0378-1119(94)90436-7; Nelson KL, 1996, J BIOL CHEM, V271, P18061, DOI 10.1074/jbc.271.30.18061; PEAT N, 1992, CANCER RES, V52, P1954; RAGHU G, 1994, NUCLEIC ACIDS RES, V22, P3271, DOI 10.1093/nar/22.16.3271; WYNSHAW-BORIS A, 1986, Biotechniques, V4, P104; XU L, 1993, VIROLOGY, V194, P10	14	10	10	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26543	26546		10.1074/jbc.271.43.26543	http://dx.doi.org/10.1074/jbc.271.43.26543			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900124	hybrid			2022-12-27	WOS:A1996VP23300018
J	Waldburger, CD; Sauer, RT				Waldburger, CD; Sauer, RT			Signal detection by the PhoQ sensor-transmitter - Characterization of the sensor domain and a response-impaired mutant that identfies ligand-binding determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ASPARTATE RECEPTOR; MOLECULAR ANALYSIS; DNA-BINDING; TRANSDUCTION; GENE; REPRESSOR; INHIBITION; PROTEINS	The PhoP-PhoQ two-component system is required for virulence and/or regulatory stress responses in enteric bacteria, The PhoQ protein responds to low concentrations of extracellular divalent cations by activating PhoP mediated transcription of a set of genes. PhoQ is a member of a family of transmembrane proteins that contain a periplasmic sensor domain coupled to a cytoplasmic transmitter domain. Here, we describe the cloning, purification, and properties of a fragment of Escherichia coli PhoQ corresponding to the sensor domain, This fragment is monomeric in solution and has a circular dichroism spectrum indicative of a mixture of alpha-helix and beta-sheet. Divalent cations do not affect the oligomeric state, circular dichroism spectrum, or fluorescence spectrum of the sensor domain but do stabilize this domain to denaturation in a fashion expected for a direct binding model. We have also constructed a mutant in which a cluster of acidic amino acids (ED-DDDAE) in the sensor domain is replaced with conservative, uncharged residues (QNNNNAQ). The mutant sensor domain is indistinguishable from wild type in terms of oligomeric form and spectral properties but. differs in being substantially more stable to urea denaturation, showing no additional stabilization in the presence of divalent, cations, and showing little activation of PhoP-mediated transcription in response to divalent-cation starvation in vivo. These data are consistent with a model in which divalent cations bind to the acidic cluster of the wild-type sensor domain and stabilize a conformation that; is inactive in signaling, Substituting uncharged residues for the acidic cluster appears to mimic the effect of divalent-cation binding by stabilizing the inactive conformation.			Waldburger, CD (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Sauer, Robert/0000-0002-1719-5399	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-16892] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADES SE, 1994, BIOCHEMISTRY-US, V33, P9187, DOI 10.1021/bi00197a022; ALBRIGHT LM, 1989, ANNU REV GENET, V23, P311, DOI 10.1146/annurev.ge.23.120189.001523; AMMAN E, 1983, GENE, V25, P167; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRENSTEIN RJ, 1989, ROBELKO SOFTWARE VER; CHURCHWARD G, 1984, GENE, V31, P165, DOI 10.1016/0378-1119(84)90207-5; DELORENZO V, 1990, J BACTERIOL, V172, P6568, DOI 10.1128/jb.172.11.6568-6572.1990; Doty SL, 1996, J BACTERIOL, V178, P961, DOI 10.1128/jb.178.4.961-970.1996; DZIEJMAN M, 1995, 2 COMPONENT SIGNAL T, P305; Eisenhaber F, 1996, PROTEINS, V25, P157, DOI 10.1002/(SICI)1097-0134(199606)25:2<157::AID-PROT2>3.0.CO;2-F; FASMAN GD, 1975, HDB BIOCH MOL BIOL, V1, P187; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOHNSON BH, 1994, BIO-TECHNOL, V12, P1357, DOI 10.1038/nbt1294-1357; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KASAHARA M, 1991, J BACTERIOL, V173, P6760, DOI 10.1128/jb.173.21.6760-6765.1991; KASAHARA M, 1992, J BACTERIOL, V174, P492, DOI 10.1128/jb.174.2.492-498.1992; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Miller J. H, 1972, EXPT MOL GENETICS; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NELSON DL, 1971, J BIOL CHEM, V246, P3042; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PAN SQ, 1993, P NATL ACAD SCI USA, V90, P9939, DOI 10.1073/pnas.90.21.9939; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; ROBINSON CR, 1996, IN PRESS BIOCHEMISTR; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SUSSKIND MM, 1980, J MOL BIOL, V138, P685, DOI 10.1016/0022-2836(80)90060-1; TEALE FWJ, 1960, BIOCHEM J, V76, P381, DOI 10.1042/bj0760381; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; WALDBURGER CD, 1995, BIOCHEMISTRY-US, V34, P13109, DOI 10.1021/bi00040a023; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	38	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26630	26636		10.1074/jbc.271.43.26630	http://dx.doi.org/10.1074/jbc.271.43.26630			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900137	hybrid			2022-12-27	WOS:A1996VP23300031
J	Bartsevich, VV; Pakrasi, HB				Bartsevich, VV; Pakrasi, HB			Manganese transport in the cyanobacterium Synechocystis sp PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CADMIUM; MAGNESIUM; SYSTEMS; MUTANT	We have inactivated the genes encoding components of MntABC, an ABC (ATP binding cassette) transporter system for manganese in the cyanobacterium Synechocystis sp, PCC 6803. The growth rates of these mutant strains were significantly lower in a manganese-deficient medium and were restored to near normal levels upon addition of micromolar concentrations of Mn2+, indicating the presence of a second transport system for manganese in this organism, Mn-54(2+) uptake experiments indicated that the MntABC transporter was induced under manganese starvation conditions, whereas the second transporter system was induced in the presence of micromolar levels of manganese, Both of these systems were nonfunctional at low temperatures and could transport trace levels of Mn-54(2+), reflecting high affinity active transport, The initial rates of Mn2+ uptake for cells grown with or without manganese exhibited biphasic saturation kinetics, suggesting that Mn2+ can also be accumulated by a low affinity system in these bacteria. The kinetic parameters for the MntABC transporter system are K-m = 1-3 mu M and V-max = 3-8 pmol/min . 10(8) cells, Accumulation of manganese by this system was competitively inhibited by Cd2+ (K-i = 4-8 mu M), Co2+ and Zn2+ (K-i = 8-15 mu M). In contrast, the second high affinity system was highly specific for manganese and was not inhibited by any tested metal ion. We have also demonstrated that in this organism, photosynthetic electron transport is necessary for optimal rates of manganese uptake.	WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA	Washington University (WUSTL)								ALLEN MM, 1968, J PHYCOL, V4, P1, DOI 10.1111/j.1529-8817.1968.tb04667.x; ARCHIBALD FS, 1984, J BACTERIOL, V158, P1; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; CHENIAE GM, 1969, PLANT PHYSIOL, V44, P351, DOI 10.1104/pp.44.3.351; DIXON M, 1964, ENZYMES, P327; EISENSTADT E, 1973, J BACTERIOL, V113, P1363, DOI 10.1128/JB.113.3.1363-1372.1973; JASPER P, 1978, J BACTERIOL, V133, P1323, DOI 10.1128/JB.133.3.1323-1328.1978; LADDAGA RA, 1985, J BACTERIOL, V162, P1100, DOI 10.1128/JB.162.3.1100-1105.1985; LADDAGA RA, 1985, J BACTERIOL, V162, P1106, DOI 10.1128/JB.162.3.1106-1110.1985; PARK MH, 1976, J BACTERIOL, V126, P1096, DOI 10.1128/JB.126.3.1096-1103.1976; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SILVER S, 1970, J BACTERIOL, V104, P1299, DOI 10.1128/JB.104.3.1299-1306.1970; SILVER S, 1977, MICROORGANISMS MINER, P105; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; WEISS AA, 1978, ANTIMICROB AGENTS CH, V14, P856, DOI 10.1128/AAC.14.6.856; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766	16	84	88	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26057	26061		10.1074/jbc.271.42.26057	http://dx.doi.org/10.1074/jbc.271.42.26057			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824246	hybrid			2022-12-27	WOS:A1996VN18000052
J	Fink, M; Duprat, F; Lesage, F; Heurteaux, C; Romey, G; Barhanin, J; Lazdunski, M				Fink, M; Duprat, F; Lesage, F; Heurteaux, C; Romey, G; Barhanin, J; Lazdunski, M			A new K+ channel beta subunit to specifically enhance Kv2.2 (CDRK) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED ION CHANNELS; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; RAT-BRAIN; MOLECULAR-CLONING; DENDROTOXIN-I; MAMMALIAN BRAIN; XENOPUS-OOCYTES; INACTIVATION; LOCALIZATIONS	Cloned K+ channel beta subunits are hydrophilic proteins which associate to pore-forming alpha subunits of the Shaker subfamily. The resulting alpha beta heteromultimers K+ channels have inactivation kinetics significantly more rapid than those of the corresponding alpha homomultimers. This paper reports the cloning and the brain localization of mKv beta(4) (m for mouse), a new beta subunit. This new beta subunit is highly expressed in the nervous system but is also present in other tissues such as kidney. In contrast with other beta subunits, coexpression of the mKv beta(4) subunit with alpha subunits of Shaker-type K+ channel does not modify the kinetic properties or voltage-dependence of these channels in Xenopus oocytes. Instead, mKv beta(4) associates to Kv2.2 (CDRK), a Shab K+ channel, to specifically enhance (a factor of up to 6) its expression level without changing its elementary conductance or kinetics. It is without effect on another closely related Shab K+ channel Kv2.1 (DRK1). Chimeras between Kv2.1 and Kv2.2 indicate that the COOH-terminal end of the Kv2.2 protein is essential for its mKv beta(4) sensitivity. The functional results associated with the observation of the co-localization of mKv beta(4) and Kv2.2 transcripts in most brain areas strongly suggest that both subunits interact in vivo to form a slowly-inactivating K+ channel. A chaperone-like effect of mKv beta(4) seems to permit the integration of a larger number of Kv2.2 channels at the plasma membrane.	CNRS,INST PHARMACOL MOL & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Lesage, Florian/D-5097-2011; HEURTEAUX, Catherine/M-4947-2016; Duprat, Fabrice/D-1221-2013; Lesage, Florian/P-9780-2019	Lesage, Florian/0000-0002-4406-7106; HEURTEAUX, Catherine/0000-0002-9741-9777; Duprat, Fabrice/0000-0001-8774-1220; Lesage, Florian/0000-0002-4406-7106				ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; ALDRICH RW, 1994, CURR BIOL, V4, P839, DOI 10.1016/S0960-9822(00)00187-1; ATTALI B, 1992, J BIOL CHEM, V267, P8650; ATTALI B, 1993, J BIOL CHEM, V268, P24283; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BIDARD JN, 1987, BIOCHEM BIOPH RES CO, V143, P383, DOI 10.1016/0006-291X(87)90677-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS2; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GUILLEMARE E, 1992, BIOCHEMISTRY-US, V31, P12463, DOI 10.1021/bi00164a024; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HWANG PM, 1993, J NEUROSCI, V13, P1569; HWANG PM, 1993, NEUROSCIENCE, V55, P613, DOI 10.1016/0306-4522(93)90427-H; HWANG PM, 1992, NEURON, V8, P473, DOI 10.1016/0896-6273(92)90275-I; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LESAGE F, 1993, RECEPTOR CHANNEL, V1, P143; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; PAK MD, 1991, P NATL ACAD SCI USA, V88, P4386, DOI 10.1073/pnas.88.10.4386; PONGS O, 1995, SEMIN NEUROSCI, V7, P137, DOI 10.1006/smns.1995.0015; REHM H, 1988, BIOCHEMISTRY-US, V27, P1827, DOI 10.1021/bi00406a005; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RENARD S, 1995, PFLUG ARCH EUR J PHY, V430, P299, DOI 10.1007/BF00373903; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SCHROTER KH, 1991, FEBS LETT, V278, P211, DOI 10.1016/0014-5793(91)80119-N; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	45	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26341	26348		10.1074/jbc.271.42.26341	http://dx.doi.org/10.1074/jbc.271.42.26341			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824288	hybrid			2022-12-27	WOS:A1996VN18000094
J	Inoue, Y; Kimura, A				Inoue, Y; Kimura, A			Identification of the structural gene for glyoxalase I from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PUTIDA; HANSENULA-MRAKII; METHYLGLYOXAL REDUCTASE; ESCHERICHIA-COLI; YEAST GLYOXALASE; PURIFICATION; METABOLISM; CLONING; GLUTATHIONE; CATABOLISM	The structural gene for glyoxalase I (GLO1) of Saccharomyces cerevisiae was identified, The GLO1 gene contained an open reading frame with 326 amino acids, and the molecular weight of the gene product (Glo1p) deduced from the DNA sequence was calculated to be 37,207.06. Glyoxalase I activity increased approximately 95-fold when the GLO1 gene was introduced into the yeast cell with a multicopy plasmid, and the resultant transformant showed the increased resistance against methylglyoxal, Since the knockout mutant of the GLO1 gene of haploid strain of S. cerevisiae was still viable, the GLO1 gene was thought to be unnecessary for growth of the yeast, The GLO1 gene was overexpressed in two kinds of glutathione-deficient mutants, gamma-glutamylcysteine synthetase-deficient (gsh1(-)) and glutathione synthetase-deficient (gsh2(-)), respectively, and the sensitivites to methylglyoxal mere compared, The gsh1-deficient mutant, which could not produce glutathione at all, was hypersensitive to methylglyoxal, and overproduction of the Glo1p did not restore the growth arrest caused by exogenously added methylglyoxal. The gsh2-deficient mutant, which accumulates gamma-glutamylcysteine (an intermediate of glutathione biosynthesis), was also sensitive to methylglyoxal compared with the isogenic wild type strain, although the growth arrest caused by methylglyoxal was partially restored by overexpression of the GLO1 gene. Purified glyoxalase I from yeast could use gamma-glutamylcysteine as a substrate (k(cat)/K-m = 1.89 x 10(7) m(-1)s(-1), glutathione; 3.47 x 10(4) M(-1) s(-1), gamma-glutamylcysteine).			Inoue, Y (corresponding author), KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN.		kimura, akira/D-1215-2010					BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; COOPER RA, 1974, EUR J BIOCHEM, V44, P81, DOI 10.1111/j.1432-1033.1974.tb03459.x; COOPER RA, 1984, ANNU REV MICROBIOL, V38, P49, DOI 10.1146/annurev.mi.38.100184.000405; COOPER RA, 1970, FEBS LETT, V11, P273, DOI 10.1016/0014-5793(70)80546-4; Cryer D R, 1975, Methods Cell Biol, V12, P39; Dakin HD, 1913, J BIOL CHEM, V14, P155; DOUGLAS KT, 1986, INT J BIOCHEM, V18, P549, DOI 10.1016/0020-711X(86)90167-9; EGYUD LG, 1966, P NATL ACAD SCI USA, V56, P203, DOI 10.1073/pnas.56.1.203; FODOR G, 1967, P NATL ACAD SCI USA, V57, P1644, DOI 10.1073/pnas.57.6.1644; HIGGINS IJ, 1969, BIOCHIM BIOPHYS ACTA, V184, P464, DOI 10.1016/0304-4165(69)90052-X; HOPPER DJ, 1971, FEBS LETT, V13, P213, DOI 10.1016/0014-5793(71)80538-0; HOPPER DJ, 1972, BIOCHEM J, V128, P321, DOI 10.1042/bj1280321; Inoue Y, 1995, Adv Microb Physiol, V37, P177, DOI 10.1016/S0065-2911(08)60146-0; INOUE Y, 1987, J BIOCHEM-TOKYO, V102, P583, DOI 10.1093/oxfordjournals.jbchem.a122091; INOUE Y, 1985, EUR J BIOCHEM, V153, P243, DOI 10.1111/j.1432-1033.1985.tb09293.x; INOUE Y, 1991, J FERMENT BIOENG, V71, P131, DOI 10.1016/0922-338X(91)90239-D; INOUE Y, 1994, J FERMENT BIOENG, V77, P557, DOI 10.1016/0922-338X(94)90129-5; INOUE Y, 1990, J BIOCHEM-TOKYO, V108, P4, DOI 10.1093/oxfordjournals.jbchem.a123159; INOUE Y, 1992, J FERMENT BIOENG, V74, P46, DOI 10.1016/0922-338X(92)90266-W; INOUE Y, 1991, BIOTECHNOL APPL BIOC, V14, P391; INOUE Y, 1991, J FERMENT BIOENG, V71, P134, DOI 10.1016/0922-338X(91)90240-H; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; KIM NS, 1993, J BIOL CHEM, V268, P11217; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LU TF, 1994, GENE, V150, P93, DOI 10.1016/0378-1119(94)90864-8; MARMSTAL E, 1979, BIOCHEM J, V183, P23, DOI 10.1042/bj1830023; MURATA K, 1986, J FERMENT BIOENG, V64, P1, DOI 10.1016/0385-6380(86)90049-X; MURATA K, 1985, EUR J BIOCHEM, V151, P631, DOI 10.1111/j.1432-1033.1985.tb09151.x; MURATA K, 1985, BIOCHEM BIOPH RES CO, V131, P190, DOI 10.1016/0006-291X(85)91788-7; Neuberg C, 1913, BIOCHEM Z, V49, P502; OHTAKE Y, 1990, AGR BIOL CHEM TOKYO, V54, P3145, DOI 10.1080/00021369.1990.10870487; PENNINCKX MJ, 1983, J BIOL CHEM, V258, P6030; RANGANATHAN S, 1993, J BIOL CHEM, V268, P5661; RHEE H, 1986, BIOCHEM BIOPH RES CO, V141, P993, DOI 10.1016/S0006-291X(86)80142-5; RHEE H, 1987, AGR BIOL CHEM TOKYO, V51, P1059, DOI 10.1080/00021369.1987.10868174; RHEE HI, 1988, AGR BIOL CHEM TOKYO, V52, P2243; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; SZENTGYO.A, 1967, SCIENCE, V155, P539, DOI 10.1126/science.155.3762.539; TAYLOR DG, 1980, J GEN MICROBIOL, V118, P159; TSAI PK, 1976, J BIOL CHEM, V251, P364; VANDERJAGT DL, 1992, J BIOL CHEM, V267, P4364; WILLETTS AJ, 1970, BIOCHIM BIOPHYS ACTA, V222, P668, DOI 10.1016/0304-4165(70)90195-9; Woodward GE, 1942, J BIOL CHEM, V145, P471; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	70	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25958	25965		10.1074/jbc.271.42.25958	http://dx.doi.org/10.1074/jbc.271.42.25958			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824231	hybrid			2022-12-27	WOS:A1996VN18000037
J	Watts, SD; Tang, CL; Capaldi, RA				Watts, SD; Tang, CL; Capaldi, RA			The stalk region of the Escherichia coli ATP synthase - Tyrosine 205 of the gamma subunit is in the interface between the F-1 and F-0 parts and can interact with both the epsilon and c oligomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; CATALYTIC SITES; MONOCLONAL-ANTIBODIES; ELECTRON-MICROSCOPY; CYSTEINE RESIDUES; LOOP REGION; POLAR LOOP; F1-ATPASE; BINDING	The soluble portion of the Escherichia coli F1F0 ATP synthase (ECF(1)) and E. coli F1F0 ATP synthase (ECF(1)F(0)) have been isolated hom a novel mutant gamma Y205C. ECF(1) isolated from this mutant had an ATPase activity 3.5-fold higher than that of wild-type enzyme and could be activated further by maleimide modification of the introduced cysteine. This effect was not seen in ECF(1)F(0). The mutation partly disrupts the F-1 to F-0 interaction, as indicated by a reduced efficiency of proton pumping, ECF(1) containing the mutation gamma Y205C was bound to the membrane-bound portion of the E. coli F1F0 ATP synthase (ECF(0)) isolated from mutants cA39C, cQ42C, cP43C, and cD44C to reconstitute hybrid enzymes, Cu2+ treatment or reaction with 5,5'-dithio-bis(2-nitro-benzoic acid) induced disulfide bond formation between the Cys at gamma position 205 and a Cys residue at positions 42, 43, or 44 in the c subunit but not at position 39, Using Cu2+ treatment, this covalent cross-linking was obtained in yields as high as 95% in the hybrid ECF(1) gamma Y205C/cQ42C and in ECF(1)F(0) isolated from the double mutant of the same composition, The covalent linkage of the gamma to a c subunit had little effect on ATPase activity, However, ATP hydrolysis linked proton translocation was lost, by modification of both gamma Cys-205 and c Cys-42 by bulky reagents such as 5,5'-dithio-bis (2 nitro-benzoic acid) or benzophenone-4-maleimide. In both ECF(1) and ECF(1)F(0) containing a Cys at gamma 205 and a Cys in the epsilon subunit (at position 38 or 43), cross linking of the gamma to the epsilon subunit was induced in high yield by Cu2+, NO cross-linking was observed in hybrid enzymes in which the Cys was at position 10, 65, or 108 of the epsilon subunit, Cross-linking of gamma to epsilon had only a minimal effect on ATP hydrolysis, The reactivity of the Cys at gamma 205 showed a nucleotide dependence of reactivity to maleimides in both ECF(1) and ECF(1)F(0), which was lost in ECF(1) when the epsilon subunit was removed, Our results show that there is close interaction of the gamma and a subunits for the full-length of the stalk region in ECF(1)F(0). We argue that this interaction controls the coupling between nucleotide binding sites and the proton channel in ECF(1)F(0).	UNIV OREGON,INST MOL BIOL,EUGENE,OR 97403	University of Oregon					NHLBI NIH HHS [HL 24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1990, BIOCHEMISTRY-US, V29, P10387, DOI 10.1021/bi00497a013; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1992, J BIOL CHEM, V267, P21355; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Feng ZY, 1996, J BIOL CHEM, V271, P17986, DOI 10.1074/jbc.271.30.17986; GIRVIN ME, 1989, BIOCHEMISTRY-US, V28, P4340, DOI 10.1021/bi00436a032; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; LUNSDORF H, 1984, J MOL BIOL, V173, P131, DOI 10.1016/0022-2836(84)90408-X; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TANG CL, 1994, J BIOL CHEM, V269, P4467; TURINA P, 1994, J BIOL CHEM, V269, P13465; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; WISE JG, 1981, J BIOL CHEM, V256, P383; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; ZHANG Y, 1994, J BIOL CHEM, V269, P10221	36	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28341	28347		10.1074/jbc.271.45.28341	http://dx.doi.org/10.1074/jbc.271.45.28341			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910457	hybrid			2022-12-27	WOS:A1996VU03300057
J	Denisenko, ON; ONeill, B; Ostrowski, J; VanSeuningen, I; Bomsztyk, K				Denisenko, ON; ONeill, B; Ostrowski, J; VanSeuningen, I; Bomsztyk, K			Zik1, a transcriptional repressor that interacts with the heterogeneous nuclear ribonucleoprotein particle K protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEINS; MAMMALIAN-CELLS; IL-1-RESPONSIVE KINASE; IN-VITRO; EXPRESSION; DOMAIN; DNA; IDENTIFICATION; COMPLEX; INVITRO	The heterogeneous nuclear ribonucleoprotein particle (hnRNP) K protein is comprised of multiple modular domains that serve to engage a diverse group of molecular partners including DNA, RNA, the product of the proto-oncogene vav, and tyrosine and serine/threonine kinases. To identify additional K protein molecular partners and to further understand its function, we used a fragment of K protein as a bait in the yeast two-hybrid screen. The deduced primary structure of one of the positive clones revealed a novel zinc finger protein, hereby denoted as Zik1. In addition to the nine contiguous zinc fingers in the C terminus, Zik1 contains a KRAB-A domain thought to be involved in transcriptional repression, Zik1 and K protein bound in vitro and co-immunoprecipitated from cell extracts indicating that in vivo their interaction is direct. Expression of Gal4 DNA-binding domain-Zik1 fusion protein repressed a gene promoter bearing Gal4-binding elements, indicating that from cognate DNA elements Zik1 is a transcriptional repressor. The known diverse nature of K protein molecular interactions and now the identification of a K protein partner that is a transcriptional repressor lends support to the notion that K protein is a remarkably versatile molecule that may be acting as a docking platform to facilitate communication among molecules involved in signal transduction and gene expression.	INST PROT RES,PUSHCHINO 142292,RUSSIA		Denisenko, ON (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.		VAN SEUNINGEN, Isabelle/N-6176-2016	VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Ostrowski, Jerzy/0000-0003-1363-3766	NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134, GM42508] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045978, R01DK045978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045134, P01GM042508] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALLARD DW, 1988, J BIOL CHEM, V263, P8450; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BIRD TA, 1989, J IMMUNOL, V142, P126; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAILLARD C, 1994, NUCLEIC ACIDS RES, V22, P4183, DOI 10.1093/nar/22.20.4183; GAILLARD C, 1990, J MOL BIOL, V215, P245, DOI 10.1016/S0022-2836(05)80343-2; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HOBERT O, 1994, J BIOL CHEM, V269, P20225; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; Lee MH, 1996, J BIOL CHEM, V271, P3420; MATUNIS MJ, 1994, NUCLEIC ACIDS RES, V22, P1059, DOI 10.1093/nar/22.6.1059; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; OSTROWSKI J, 1994, J BIOL CHEM, V269, P17626; OSTROWSKI J, 1991, J BIOL CHEM, V266, P12722; PAIGE CJ, 1978, J IMMUNOL, V121, P641; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; Sambrook J., 2002, MOL CLONING LAB MANU; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; THIESEN H-J, 1990, New Biologist, V2, P363; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; VANSEUNINGEN I, 1994, J AM SOC NEPHROL, V5, P735; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514	37	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27701	27706		10.1074/jbc.271.44.27701	http://dx.doi.org/10.1074/jbc.271.44.27701			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910362	hybrid			2022-12-27	WOS:A1996VQ67900080
J	Muda, M; Theodosiou, A; Rodrigues, N; Boschert, U; Camps, M; Gillieron, C; Davies, K; Ashworth, A; Arkinstall, S				Muda, M; Theodosiou, A; Rodrigues, N; Boschert, U; Camps, M; Gillieron, C; Davies, K; Ashworth, A; Arkinstall, S			The dual specificity phosphatases M3/6 and MKP-3 are highly selective for inactivation of distinct mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; IMMEDIATE-EARLY GENE; MAP KINASE; HEAT-SHOCK; TYROSINE-PHOSPHATASE; MAMMALIAN-CELLS; RAS; STRESS; TRANSFORMATION; EXPRESSION	The mitogen-activated protein (MAP) kinase family includes extracellular signal regulated kinase (ERK), c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) and p38/RK/CSBP (p38) as structurally and functionally distinct enzyme classes. Here we describe two new dual specificity phosphatases of the CL100/MKP-1 family that are selective for inactivating ERK or JNK/SAPK and p38 MAP kinases when expressed in COS-7 cells. M3/6 is the first phosphatase of this family to display highly specific inactivation of JNK/SAPK and p38 MAP kinases. Although stress-induced activation of p54 SAPK beta, p46 SAPK gamma (JNK1) or p38 MAP kinases is abolished upon co-transfection with increasing amounts of M3/6 plasmid, epidermal growth factor-stimulated ERK1 is remarkably insensitive even to the highest levels of M3/6 expression obtained. In contrast to M3/6, the dual specificity phosphatase MKP-3 is selective for inactivation of ERK family MAP kinases. Low level expression of MKP-3 blocks totally epidermal growth factor-stimulated ERK1, whereas stress-induced activation of p54 SAPK beta and p38 MAP kinases is inhibited only partially under identical conditions. Selective regulation by M3/6 and MKP-3 was also observed upon chronic MAP kinase activation by constitutive p21(ras) GTPases. Hence, although M3/6 expression effectively blocked p54 SAPK beta activation by p21(rac) (G12V), ERK1 activated by p21(ras) (G12V) was insensitive to this phosphatase. ERK1 activation by oncogenic p21(ras) was, however, blocked totally by co-expression of MKP-3. This is the first report demonstrating reciprocally selective inhibition of different MAP kinases by two distinct dual specificity phosphatases.	GLAXO WELLCOME RES & DEV LTD,GENEVA BIOMED RES INST,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND; UNIV OXFORD,DEPT BIOCHEM,GENET LAB,OXFORD OX1 3QU,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,CANC RES CAMPAIGN,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	GlaxoSmithKline; University of Oxford; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Camps, Montserrat/0000-0002-9849-8657	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1993, ONCOGENE, V8, P2015; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THEODOSIOU AM, 1996, HUM MOL GENET, V96, P675; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; XIA A, 1996, SCIENCE, V270, P1326; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	49	312	319	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27205	27208		10.1074/jbc.271.44.27205	http://dx.doi.org/10.1074/jbc.271.44.27205			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910287	hybrid			2022-12-27	WOS:A1996VQ67900005
J	Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Riordan, JR; Clarke, DM				Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Riordan, JR; Clarke, DM			Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CL CHANNEL; ATP HYDROLYSIS; CFTR GENE; R-DOMAIN; PHOSPHORYLATION; MUTATIONS; IDENTIFICATION; BINDING; CELLS; DYSFUNCTION	To examine the contribution of the large cytoplasmic loops of the cystic fibrosis transmembrane conductance regulator (CFTR) to channel activity, the three point-mutations (S945L, H949Y, G970R) were characterized that have been detected in the third cytoplasmic loop (CL3, residues 933-990) in patients with cystic fibrosis, Chinese hamster ovary cell lines stably expressing wildtype CFTR or mutant G970R-CFTR yielded polypeptides with apparent masses of 170 kDa as the major products, whereas the major products of mutants S945L-CFTR and H949Y-CFTR had apparent masses of 150 kDa. The 150-kDa forms of CFTR were sensitive to endoglycosidase H digestion, indicating that these mutations interfered with maturation of the protein, Increased levels of mature CFTR (170 kDa) could be obtained for mutant H949Y when cells were grown at a lower temperature (26 degrees C) or incubated in the presence of 10% glycerol, For all mutants, the open probability (P-0) of the CFTR channels was significantly altered, S945L-CFTR and G970R-CFTR showed a severe reduction in the P-0, whereas the H949Y mutation doubled the P-0 relative to wild type. The changes in P-0 predominantly resulted from an alteration of the mean burst durations which suggests that CL3 is involved in obtaining and/or maintaining stability of the open state. In addition, mutants S945L and G970R had current-voltage relationships that were not completely linear over the range +/-80 mV, but showed slight outward rectification, The fact that CL3 mutations can have subtle effects on channel conductance indicates that this region may be physically close to the inner mouth of the pore.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MAYO CLIN SCOTTSDALE,SC JOHNSON MED RES CTR,MAYO GRAD SCH MED,SCOTTSDALE,AZ 85259; MAYO CLIN SCOTTSDALE,SC JOHNSON MED RES CTR,DEPT BIOCHEM & MOL BIOL,SCOTTSDALE,AZ 85259	University of Toronto; McGill University; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Seibert, FS (corresponding author), UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA.		Clarke, David M./A-1112-2008; Hanrahan, John/AGG-1926-2022	Clarke, David M./0000-0003-4335-7184; Hanrahan, John/0000-0001-9080-2039; Loo, Tip W/0000-0003-2108-0188; Linsdell, Paul/0000-0001-6257-6273				ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BAYER EA, 1988, ANAL BIOCHEM, V170, P271, DOI 10.1016/0003-2697(88)90631-8; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CARSON MR, 1995, J BIOL CHEM, V270, P1711, DOI 10.1074/jbc.270.4.1711; Carson MR, 1995, BIOPHYS J, V69, P2443, DOI 10.1016/S0006-3495(95)80113-X; CHAMPIGNY G, 1995, EMBO J, V14, P2417, DOI 10.1002/j.1460-2075.1995.tb07239.x; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CLAUSTRES M, 1993, HUM MOL GENET, V2, P1209, DOI 10.1093/hmg/2.8.1209; CUPPENS H, 1993, GENOMICS, V18, P693, DOI 10.1016/S0888-7543(05)80376-3; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOO TW, 1994, J BIOL CHEM, V269, P28683; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; PRINCE LS, 1994, P NATL ACAD SCI USA, V91, P5192, DOI 10.1073/pnas.91.11.5192; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROSENFELD MA, 1994, HUM GENE THER, V5, P1121, DOI 10.1089/hum.1994.5.9-1121; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Seibert FS, 1996, J BIOL CHEM, V271, P15139, DOI 10.1074/jbc.271.25.15139; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; TABCHARANI JA, 1992, BIOPHYS J, V62, P1, DOI 10.1016/S0006-3495(92)81759-9; Tao T, 1996, BIOPHYS J, V70, P743, DOI 10.1016/S0006-3495(96)79614-5; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; Wilkinson DJ, 1996, J GEN PHYSIOL, V107, P103, DOI 10.1085/jgp.107.1.103; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; XIE JX, 1995, J BIOL CHEM, V270, P28084	41	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27493	27499		10.1074/jbc.271.44.27493	http://dx.doi.org/10.1074/jbc.271.44.27493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910333	hybrid			2022-12-27	WOS:A1996VQ67900051
J	Yruela, I; Pueyo, JJ; Alonso, PJ; Picorel, R				Yruela, I; Pueyo, JJ; Alonso, PJ; Picorel, R			Photoinhibition of photosystem II from higher plants - Effect of copper inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CU(II)-INHIBITORY BINDING-SITE; SINGLET OXYGEN PRODUCTION; REACTION CENTERS; EPR SPECTROSCOPY; DONOR-SIDE; THYLAKOID MEMBRANES; ELECTRON-TRANSPORT; LIPID-PEROXIDATION; 2 SITES; DEGRADATION	Strong illumination of Cu(II)-inhibited photosystem II membranes resulted in a faster loss of oxygen evolution activity compared with that of the intact samples. The phenomenon was oxygen- and temperature-dependent, However, D1 protein degradation rate was similar in both preparations and slower than that found in non-oxygen evolving PSII particles (i.e., Mn-depleted photosystem II), These results seem to indicate that during illumination Cu(II)-inhibited samples do not behave as a typical non-oxygen evolving photosystem II, Cytochrome b(559) was functional in the presence of Cu(II). The effect of Cu(II) inhibition decreased the amount of photoreduced cytochrome b(559) and slowed down the rate of its photoreduction, The presence of Cu(II) during illumination seems to protect P680 against photodamage as occurs in photosystem II reaction centers when the acceptor side is protected, The data were consistent with the finding that production of singlet oxygen was highly reduced in the preparations treated with Cu(II). EPR. spin trapping experiments showed that inactivation of Cu(II)-treated samples was dominated by hydroxyl radical, and the loss of oxygen evolution activity was diminished by the presence of superoxide dismutase and catalase, These results indicate that the rapid loss of oxygen evolution activity in the presence of Cu(II) is mainly due to the formation of (OH)-O-. radicals from superoxide ion via a Cu(II)-catalyzed Haber-Weiss mechanism, Considering that this inactivation process was oxygen-dependent, we propose that the formation of superoxide occurs in the acceptor side of photosystem II by interaction of molecular oxygen with reduced electron acceptor species, and thus, the primarily Cu(II)inhibitory site in photosystem II is on the acceptor side.	CSIC, ESTAC EXPT AULA DEI, E-50080 ZARAGOZA, SPAIN; UNIV ZARAGOZA, CSIC, INST CIENCIA MAT ARAGON, ZARAGOZA 50009, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Aula Dei (EEAD); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC - Instituto de Ciencia de Materiales de Aragon (ICMA); University of Zaragoza			Alonso, Pablo J/L-2759-2014; PICOREL, RAFAEL/K-7930-2014; Pueyo, José J./D-8993-2016; Yruela, Inmaculada/A-9330-2015; Yruela, Inmaculada/T-1239-2019	Alonso, Pablo J/0000-0003-3449-4929; PICOREL, RAFAEL/0000-0003-3791-129X; Pueyo, José J./0000-0003-0337-4078; Yruela, Inmaculada/0000-0003-3608-4720; Yruela, Inmaculada/0000-0003-3608-4720				ALFONSO M, 1994, BIOCHEMISTRY-US, V33, P10494, DOI 10.1021/bi00200a034; ALLAKHVERDIEV SI, 1994, BIOCHEMISTRY-US, V33, P12210, DOI 10.1021/bi00206a025; ANDERSON IC, 1960, PLANT PHYSIOL, V35, P531, DOI 10.1104/pp.35.4.531; ANDERSSON B., 1991, CURR TOP BIOENERG, V16, P1; AOSHIMA H, 1986, AGR BIOL CHEM TOKYO, V50, P1777, DOI 10.1080/00021369.1986.10867648; ARELLANO JB, 1995, PHOTOSYNTH RES, V45, P127, DOI 10.1007/BF00032584; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ASADA K, 1987, TOPICS PHOTOSYNTHESI, V9, P227; BARBER J, 1987, FEBS LETT, V220, P67, DOI 10.1016/0014-5793(87)80877-3; BARBER J, 1992, TRENDS BIOCHEM SCI, V17, P61, DOI 10.1016/0968-0004(92)90503-2; BARENYI B, 1985, PLANTA, V163, P218, DOI 10.1007/BF00393510; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BUSER CA, 1992, BIOCHEMISTRY-US, V31, P11449, DOI 10.1021/bi00161a025; CHAMULITRAT W, 1991, ARCH BIOCHEM BIOPHYS, V290, P153, DOI 10.1016/0003-9861(91)90601-E; CHEN GX, 1992, BIOCHEMISTRY-US, V31, P11072, DOI 10.1021/bi00160a017; COGDELL RJ, 1987, BIOCHIM BIOPHYS ACTA, V895, P63, DOI 10.1016/S0304-4173(87)80008-3; DAVIES MJ, 1987, BIOCHEM J, V245, P167, DOI 10.1042/bj2450167; DELASRIVAS J, 1992, FEBS LETT, V301, P246, DOI 10.1016/0014-5793(92)80250-K; DURRANT JR, 1990, BIOCHIM BIOPHYS ACTA, V1017, P167, DOI 10.1016/0005-2728(90)90148-W; ECKERT HJ, 1991, PHOTOSYNTH RES, V27, P97, DOI 10.1007/BF00033249; ELSTNER EF, 1982, ANNU REV PLANT PHYS, V33, P73, DOI 10.1146/annurev.pp.33.060182.000445; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; GRIFFITHS M, 1955, NATURE, V176, P1211, DOI 10.1038/1761211a0; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIDEG E, 1994, PHOTOSYNTH RES, V39, P191, DOI 10.1007/BF00029386; HIDEG E, 1994, BBA-BIOENERGETICS, V1186, P143, DOI 10.1016/0005-2728(94)90173-2; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JEGERSCHOLD C, 1995, BIOCHEMISTRY-US, V34, P12747, DOI 10.1021/bi00039a034; JEGERSCHOLD C, 1991, FEBS LETT, V280, P87, DOI 10.1016/0014-5793(91)80210-T; JEGERSCHOLD C, 1990, BIOCHEMISTRY-US, V29, P6179, DOI 10.1021/bi00478a010; KIRILOVSKY D, 1994, BIOCHEMISTRY-US, V33, P3087, DOI 10.1021/bi00176a043; KIRILOVSKY DL, 1990, BIOCHEMISTRY-US, V29, P8100, DOI 10.1021/bi00487a016; KLIMOV VV, 1990, PHOTOSYNTH RES, V23, P59, DOI 10.1007/BF00030063; KOKA P, 1978, PHOTOCHEM PHOTOBIOL, V28, P509, DOI 10.1111/j.1751-1097.1978.tb06959.x; KYLE DJ, 1987, TOPICS PHOTOSYNTHESI, V9, P196; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LION Y, 1976, NATURE, V263, P442, DOI 10.1038/263442a0; MACPHERSON AN, 1993, BIOCHIM BIOPHYS ACTA, V1143, P301, DOI 10.1016/0005-2728(93)90201-P; MATHEWS MM, 1964, NATURE, V20, P1092; MISHRA NP, 1994, BBA-BIOENERGETICS, V1186, P81, DOI 10.1016/0005-2728(94)90138-4; MISHRA NP, 1993, J PHOTOCH PHOTOBIO B, V19, P19, DOI 10.1016/1011-1344(93)80088-Q; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; RENGER G, 1992, TOPICS PHOTOSYNTHESI, V11, P45; SAGER R, 1958, NATURE, V182, P98, DOI 10.1038/182098a0; SANDMANN G, 1980, PLANT PHYSIOL, V66, P797, DOI 10.1104/pp.66.5.797; SCHRODER WP, 1994, J BIOL CHEM, V269, P32865; SHIPTON CA, 1991, P NATL ACAD SCI USA, V88, P6691, DOI 10.1073/pnas.88.15.6691; TAOKA S, 1993, PHOTOSYNTH RES, V38, P425, DOI 10.1007/BF00046770; TELFER A, 1991, BIOCHIM BIOPHYS ACTA, V1060, P106, DOI 10.1016/S0005-2728(05)80125-2; TELFER A, 1989, FEBS LETT, V246, P223, DOI 10.1016/0014-5793(89)80287-X; TELFER A, 1990, BIOCHIM BIOPHYS ACTA, V1017, P143, DOI 10.1016/0005-2728(90)90145-T; TELFER A, 1994, J BIOL CHEM, V266, P1; TOMASI A, 1993, BIOL MAGN RESON, V13, P353; VASS I, 1993, BIOCHIM BIOPHYS ACTA, V1183, P388, DOI 10.1016/0005-2728(93)90244-A; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; YRUELA I, 1992, PHOTOSYNTH RES, V33, P227, DOI 10.1007/BF00030033; YRUELA I, 1991, J BIOL CHEM, V266, P22847; Yruela I, 1996, BIOCHEMISTRY-US, V35, P9469, DOI 10.1021/bi951667e; YRUELA I, 1993, J BIOL CHEM, V268, P1684; [No title captured]	61	89	93	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27408	27415		10.1074/jbc.271.44.27408	http://dx.doi.org/10.1074/jbc.271.44.27408			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910320	hybrid			2022-12-27	WOS:A1996VQ67900038
J	Eliasson, R; Pontis, E; Jordan, A; Reichard, P				Eliasson, R; Pontis, E; Jordan, A; Reichard, P			Allosteric regulation of the third ribonucleotide reductase (NrdEF enzyme) from enterobacteriaceae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CLONING; EXPRESSION	Enterobacteriaceae contain genes for three separate ribonucleotide reductases: nrdAB code for a class Ia enzyme, active during aerobiosis, nrdDG for a class III enzyme, active during anaerobiosis, and nrdEF for a cryptic class Ib enzyme. The NrdEF enzyme provides the active reductase in other, widely different bacteria. Here, we describe the allosteric regulation of the Salmonella, typhimurium NrdEF enzyme. It consists of two tightly bound homodimeric proteins, R1E and R2F. Nucleoside triphosphates (ATP, dATP, dGTP, and dTTP) regulate the substrate specificity by binding to a single site af the R1E protein (one nucleotide per polypeptide). Regulation is similar to that of the NrdAB enzyme, with one major exception: dATP stimulates reduction of CDP (and UDP) under conditions when dATP strongly inhibits all activity of the NrdAB enzyme. The nrdA-coded RI protein contains a second binding site for dATP (and ATP) that controls general enzyme activity. All known R1E proteins lack the 50 N-terminal amino acids of R1, and we propose that the activity site is located in this area of the protein. The more sophisticated regulation of NrdAB enzymes of eukaryotes provides protection against the possibly harmful overproduction of dNTPs.	KAROLINSKA INST, DEPT BIOCHEM 1, MED NOBEL INST, MBB, S-17177 STOCKHOLM, SWEDEN; AUTONOMOUS UNIV BARCELONA, DEPT GENET & MICROBIOL, FAC SCI, BELLATERRA 08193, BARCELONA, SPAIN	Karolinska Institutet; Autonomous University of Barcelona			jordan, albert/K-4678-2014; jordan, albert/ABC-8229-2020	jordan, albert/0000-0002-3970-8693; jordan, albert/0000-0002-3970-8693				ABERG A, 1989, J BIOL CHEM, V264, P12249; BLAKLEY RL, 1964, BIOCHEM BIOPH RES CO, V16, P391, DOI 10.1016/0006-291X(64)90363-8; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN NC, 1969, J MOL BIOL, V46, P25, DOI 10.1016/0022-2836(69)90055-2; BROWN NC, 1969, J MOL BIOL, V46, P39, DOI 10.1016/0022-2836(69)90056-4; CARAS IW, 1988, MOL CELL BIOL, V8, P2698, DOI 10.1128/MCB.8.7.2698; CHEN AK, 1974, BIOCHEMISTRY-US, V13, P654, DOI 10.1021/bi00701a004; ELIASSON R, 1994, J BIOL CHEM, V269, P26052; FONTECAVE M, 1992, ADV ENZYMOL RAMB, V65, P147; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Jordan A, 1996, J BIOL CHEM, V271, P8779, DOI 10.1074/jbc.271.15.8779; JORDAN A, 1994, J BACTERIOL, V176, P3420, DOI 10.1128/jb.176.11.3420-3427.1994; JORDAN A, 1994, P NATL ACAD SCI USA, V91, P12892, DOI 10.1073/pnas.91.26.12892; KIM JJ, 1977, ARCH BIOCHEM BIOPHYS, V182, P674, DOI 10.1016/0003-9861(77)90548-3; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; Ollagnier S, 1996, J BIOL CHEM, V271, P9410, DOI 10.1074/jbc.271.16.9410; ORMO M, 1990, ANAL BIOCHEM, V182, P674; REICHARD P, 1993, J BIOL CHEM, V268, P8383; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; YANG FD, 1994, J BACTERIOL, V176, P6738, DOI 10.1128/JB.176.21.6738-6743.1994	24	41	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26582	26587		10.1074/jbc.271.43.26582	http://dx.doi.org/10.1074/jbc.271.43.26582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900130	hybrid			2022-12-27	WOS:A1996VP23300024
J	Liang, YL; Ackerman, SH				Liang, YL; Ackerman, SH			Characterization of mutations in the beta subunit of the mitochondrial F-1-ATPase that produce defects in enzyme catalysis and assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BOVINE HEART-MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; ATP-SYNTHASE; DIRECTED MUTAGENESIS; SHUTTLE VECTORS; H+-ATPASE; YEAST; GENES; SEQUENCE	The ATP2 gene, coding for the beta subunit of the mitochondrial F-1-ATPase, was cloned from nine independent isolates of chemically mutagenized yeast. Seven different mutant alleles were identified. In one case the mutation occurs in the mitochondrial targeting sequence (M1I). The remaining six mutations map to the mature part of the beta subunit protein and alter amino acids that are conserved in the bovine heart mitochondrial and Escherichia coli beta subunit proteins. Biochemical analysis of the yeast atp2 mutants identified two different phenotypes. The G133D, P179L, and G227D mutations correlate with an assembly-defective phenotype that is characterized by the accumulation of the F-1 alpha and beta subunits in large protein aggregates. Strains harboring the A192V, E222K, or R293K mutations assemble an F-1 of normal size that is none-the-less catalytically inactive. The effect of the atp2 mutations was also analyzed in diploids formed by Grossing the mutants to wild type yeast. Hybrid enzymes formed with beta subunits containing either the G133D, E222K, or R293K mutations are compromised for steady-state ATPase activity. The display of partial dominance confirms the importance of Gly(133) for structural stability and of Glu(222) and Arg(293) for catalytic cooperativity.	WAYNE STATE UNIV, SCH MED, DEPT SURG, DETROIT, MI 48201 USA; WAYNE STATE UNIV, SCH MED, DEPT BIOCHEM & MOL BIOL, DETROIT, MI 48201 USA	Wayne State University; Wayne State University					NIGMS NIH HHS [GM48157] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048157] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1987, J BIOL CHEM, V262, P13765; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALSHAWI MK, 1989, J BIOL CHEM, V264, P15376; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FUTAI M, 1988, J BIOENERG BIOMEMBR, V20, P41, DOI 10.1007/BF00762137; FUTAI M, 1983, MICROBIOL REV, V47, P285, DOI 10.1128/MMBR.47.3.285-312.1983; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GRUNSTEIN M, 1975, P NATL ACAD SCI USA, V72, P3961, DOI 10.1073/pnas.72.10.3961; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HSU SY, 1987, FEBS LETT, V218, P222, DOI 10.1016/0014-5793(87)81050-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MUELLER DM, 1989, BIOCHEM BIOPH RES CO, V164, P381, DOI 10.1016/0006-291X(89)91730-0; MUELLER DM, 1988, J BIOL CHEM, V263, P5634; MUELLER DM, 1989, J BIOL CHEM, V264, P16552; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; NOUMI T, 1986, J BIOL CHEM, V261, P9196; PARSONAGE D, 1988, ARCH BIOCHEM BIOPHYS, V261, P222, DOI 10.1016/0003-9861(88)90121-X; PARSONAGE D, 1987, J BIOL CHEM, V262, P6301; PENEFSKY HS, 1991, ADV ENZYMOL RAMB, V64, P173; RAO R, 1987, J BIOL CHEM, V262, P17450; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; SHEN HG, 1994, J BIOL CHEM, V269, P9424; SIKORSKI RS, 1989, GENETICS, V122, P19; TAKEDA M, 1994, YEAST, V10, P1531, DOI 10.1002/yea.320101118; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; WALKER JE, 1984, BIOCHIM BIOPHYS ACTA, V768, P164, DOI 10.1016/0304-4173(84)90003-X; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WALPOLE RE, 1978, PROBABILITY STAT ENG, P12; Wang ZG, 1996, J BIOL CHEM, V271, P4887	45	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26522	26528		10.1074/jbc.271.43.26522	http://dx.doi.org/10.1074/jbc.271.43.26522			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900121				2022-12-27	WOS:A1996VP23300015
J	Liu, Y; Arshavsky, VY; Ruoho, AE				Liu, Y; Arshavsky, VY; Ruoho, AE			Interaction sites of the COOH-terminal region of the gamma subunit of cGMP phosphodiesterase with the GTP-bound alpha subunit of transducin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; AMINO-ACID-SEQUENCE; G-PROTEIN; INHIBITORY SUBUNIT; SYNTHETIC PEPTIDES; BINDING PROTEIN; ACTIVATION MECHANISM; STRUCTURAL-ANALYSIS; CATALYTIC SUBUNITS	In photoreceptor cells, visual transduction occurs through photoexcitation of rhodopsin, GTP activation of the alpha subunit of transducin, and interaction between GTP-bound transducin alpha subunit and the inhibitory gamma subunit of phosphodiesterase. The gamma subunit of phosphodiesterase, in turn, accelerates the hydrolysis of GTP on the alpha subunit if transducin. Within the COOH-terminal residues (46-87) of the phosphodiesterase gamma subunit, Trp-70 has been implicated in phosphodiesterase activation, transducin alpha subunit-phosphodiesterase gamma subunit, interaction, and the GTP hydrolysis accelerating activity. We have derivatized the phosphodiesterase gamma subunit with a reversible photoactivatable reagent, [I-125]N-[(3-iodo-4-azidophenylpropionamido-S-(2-thiopyridyl)] cysteine ([I-125]ACTP), at cysteine (Cys-68). A light-dependent, cross-linked complex of guanosine 5'-(gamma-thio)-triphosphate-bound transducin alpha subunit and ACTP-derivatized phosphodiesterase gamma subunit formed after photolysis of a 1:1 stoichiometric complex of the two proteins. The specificity of complex formation between the transducin alpha subunit and the phosphodiesterase gamma subunit was demonstrated by specific protection by the C68A mutant of the phosphodiesterase gamma subunit. The cross-linked complex was treated with beta-mercaptoethanol to transfer the I-125 photomoiety from the phosphodiesterase gamma subunit to the transducin alpha subunit. Combined techniques involving electrophoresis, chemical and enzymatic cleavage, and chemical and radiosequencing were based to identify photoinsertion sites on the alpha(3) and alpha(4)/beta(6) regions of the transducin alpha subunit. Three photo-labeled residues, His-244 (alpha(3) helix), Met-308, and Arg-310 (alpha(4)/beta(6) interface), were specifically identified as photoinsertion sites. Utilizing the crystal structure coordinates of the GTP-bound transducin alpha subunit and molecular modeling, we conclude that Cys-68 of the phosphodiesterase gamma subunit is located at a position between the exposed face of the alpha(3) and alpha(4), helices of the transducin alpha subunit. We propose that the phosphodiesterase gamma subunit interacts with GTP-bound transducin alpha subunit at multiple sites in which the cysteine 68 to tryptophan 70 sequence of the phosphodiesterase gamma subunit, which is critical for GTP hydrolysis accelerating activity, interacts in the alpha(3)/alpha(4)/beta(6) region of GTP-bound transducin alpha subunit.	UNIV WISCONSIN, SCH MED, DEPT PHARMACOL, MADISON, WI 53706 USA; HARVARD UNIV, MASSACHUSETTS EYE & EAR INFIRM, SCH MED, BOSTON, MA 02114 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary					NATIONAL EYE INSTITUTE [R01EY010336] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033138] Funding Source: NIH RePORTER; NEI NIH HHS [EY-10336] Funding Source: Medline; NIGMS NIH HHS [GM33138] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKINSTALL S, 1995, FEBS LETT, V364, P45, DOI 10.1016/0014-5793(95)00351-9; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; ARTEMYEV NO, 1992, J BIOL CHEM, V267, P25067; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BENNETT N, 1989, BIOCHEMISTRY-US, V28, P7418, DOI 10.1021/bi00444a040; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BORNSTEIN P, 1977, METHOD ENZYMOL, V47, P133; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; BROWN RL, 1989, P NATL ACAD SCI USA, V86, P4922, DOI 10.1073/pnas.86.13.4922; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CRIMMINS DL, 1990, ANAL BIOCHEM, V187, P27, DOI 10.1016/0003-2697(90)90412-3; CUNNICK J, 1994, BIOCHEM J, V297, P87, DOI 10.1042/bj2970087; DETERRE P, 1986, Proteins Structure Function and Genetics, V1, P188, DOI 10.1002/prot.340010210; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DHANASEKARAN N, 1988, J BIOL CHEM, V263, P17942; ERICKSON JW, 1995, BIOCHEMISTRY-US, V34, P8693, DOI 10.1021/bi00027a019; Fontana A, 1972, Methods Enzymol, V25, P419, DOI 10.1016/S0076-6879(72)25037-6; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1983, J BIOL CHEM, V258, P503; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; JOHNSON GL, 1991, J CELL BIOCHEM, V47, P136, DOI 10.1002/jcb.240470207; KROLL S, 1989, J BIOL CHEM, V264, P4490; KUTUZOV M, 1994, EUR J BIOCHEM, V220, P963, DOI 10.1111/j.1432-1033.1994.tb18700.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Mitchell W M, 1977, Methods Enzymol, V47, P165; MORRISON DF, 1989, J BIOL CHEM, V264, P11671; MORRISON DF, 1987, FEBS LETT, V222, P266, DOI 10.1016/0014-5793(87)80383-6; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OPPERT B, 1991, BIOCHEM BIOPH RES CO, V181, P306, DOI 10.1016/S0006-291X(05)81418-4; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKIBA NP, 1995, J BIOL CHEM, V270, P13210, DOI 10.1074/jbc.270.22.13210; Skiba NP, 1996, J BIOL CHEM, V271, P413, DOI 10.1074/jbc.271.1.413; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SPICKOFSKY N, 1994, NAT STRUCT BIOL, V1, P771, DOI 10.1038/nsb1194-771; STEINMAN HM, 1974, J BIOL CHEM, V249, P7326; STRYER L, 1991, J BIOL CHEM, V266, P10711; TAKEMOTO DJ, 1992, BIOCHEM J, V281, P637, DOI 10.1042/bj2810637; VAILLANCOURT RR, 1995, BIOCHEM J, V311, P987, DOI 10.1042/bj3110987; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316	56	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26900	26907		10.1074/jbc.271.43.26900	http://dx.doi.org/10.1074/jbc.271.43.26900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900174	hybrid			2022-12-27	WOS:A1996VP23300068
J	Marshall, NF; Peng, JM; Xie, Z; Price, DH				Marshall, NF; Peng, JM; Xie, Z; Price, DH			Control of RNA polymerase II elongation potential by a novel carboxyl-terminal domain kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; TRANSCRIPTION FACTOR TFIIH; ADENOSINE-DEAMINASE GENE; LARGEST SUBUNIT; PROTEIN-KINASE; MESSENGER-RNA; REPEAT DOMAIN; XENOPUS-OOCYTES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER	The entry of RNA polymerase II into a productive mode of elongation is controlled, in part, by the postinitiation activity of positive transcription elongation factor b (P-TEFb) (Marshall, N.F., and Price, D.H. (1995) J. Biol. Chem. 270, 12335-12338). We report here that removal of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II abolishes productive elongation. Correspondingly, we found that P-TEFb can phosphorylate the CTD of pure RNA polymerase II. Furthermore, P-TEFb can phosphorylate the CTD of RNA polymerase II when the polymerase is in an early elongation complex. Both the function and kinase activity of P-TEFb are blocked by the drugs 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) and H-8. P-TEFb is distinct from transcription factor IIH (TFIIH) because the two factors have no subunits in common, P-TEFb is more sensitive to DRB than is TFIIH, and most importantly, TFIIH cannot substitute functionally for P-TEFb. We propose that phosphorylation of the CTD by P-TEFb controls the transition from abortive into productive elongation mode.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa			Peng, Junmin/N-2614-2018; Price, David H/F-6173-2010	Peng, Junmin/0000-0003-0472-7648; Price, David/0000-0002-5597-385X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; Austin RJ, 1996, P NATL ACAD SCI USA, V93, P5788, DOI 10.1073/pnas.93.12.5788; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BRICKEY WJ, 1995, GENETICS, V140, P599; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; COLLART MA, 1991, MOL CELL BIOL, V11, P2826, DOI 10.1128/MCB.11.5.2826; DAHMUS ME, 1994, PROG NUCLEIC ACID RE, V48, P143, DOI 10.1016/S0079-6603(08)60855-7; DAHMUS ME, 1995, BBA-GENE STRUCT EXPR, V1261, P171, DOI 10.1016/0167-4781(94)00233-S; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Egyhazi E, 1996, CHROMOSOMA, V104, P422, DOI 10.1007/s004120050134; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; HAIR A, 1993, MOL CELL BIOL, V13, P7925, DOI 10.1128/MCB.13.12.7925; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; KANG ME, 1993, J BIOL CHEM, V268, P25033; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KESSLER M, 1989, J BIOL CHEM, V264, P9785; KESSLER M, 1991, J BIOL CHEM, V266, P13019; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KRAUSKOPF A, 1991, MOL CELL BIOL, V11, P3515, DOI 10.1128/MCB.11.7.3515; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; MEULIA T, 1993, MOL CELL BIOL, V13, P5647, DOI 10.1128/MCB.13.9.5647; MIDDLETON KM, 1990, MOL CELL BIOL, V10, P727, DOI 10.1128/MCB.10.2.727; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; RASMUSSEN EB, 1995, J MOL BIOL, V252, P522, DOI 10.1006/jmbi.1995.0517; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SPENCER CA, 1990, ONCOGENE, V5, P777; STONE N, 1992, J BIOL CHEM, V267, P6353; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; WRIGHT S, 1993, MOL BIOL CELL, V4, P661, DOI 10.1091/mbc.4.7.661; Xie Z, 1996, J BIOL CHEM, V271, P11043, DOI 10.1074/jbc.271.19.11043; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZANDOMENI R, 1986, J BIOL CHEM, V261, P3414; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x	70	514	525	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					27176	27183		10.1074/jbc.271.43.27176	http://dx.doi.org/10.1074/jbc.271.43.27176			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900211	hybrid			2022-12-27	WOS:A1996VP23300105
J	McLaurin, J; Chakrabartty, A				McLaurin, J; Chakrabartty, A			Membrane disruption by Alzheimer beta-amyloid peptides mediated through specific finding to either phospholipids or gangliosides - Implications for neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN A-BETA; PRECURSOR PROTEIN; CIRCULAR-DICHROISM; DISEASE; A-BETA-42(43); CONFORMATION; DEPOSITION; PLAQUES; BRAIN; CELLS	Increasing evidence implicates A beta peptides as neurotoxic agents in Alzheimer's disease. We investigated one possible mechanism of neurotoxicity, namely A beta-membrane lipid interactions, We find that A beta disruption membranes containing acidic phospholipids. This disruption is greater at slightly acidic pH (characteristic of endosomes) than at neutral pH (characteristic of the extracellular space). This pH dependence suggests that A beta has the capacity to disrupt endosomal and plasma membranes, and this disruption could account, at least in part, for the observed neurotoxic effects of the peptide. We also find that gangliosides induce A beta to adopt a novel alpha/beta conformation at neutral pH.	UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto				Chakrabartty, Avi/0000-0001-7002-8381				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Cataldo AM, 1996, J NEUROSCI, V16, P186; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; FRASER PE, 1991, BIOPHYS J, V60, P1190, DOI 10.1016/S0006-3495(91)82154-3; Fukumoto H, 1996, AM J PATHOL, V148, P259; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GRAVINA SA, 1995, J BIOL CHEM, V270, P7013, DOI 10.1074/jbc.270.13.7013; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KEMPF C, 1982, J BIOL CHEM, V257, P2469; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEYLAHUD E, 1995, SCIENCE, V269, P9770; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; SELKOE DJ, 1995, NAT MED, V1, P998, DOI 10.1038/nm1095-998; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SEUBERT P, 1992, NATURE, V359, P268; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TERZI E, 1995, J MOL BIOL, V252, P633, DOI 10.1006/jmbi.1995.0525; TERZI E, 1994, BIOCHEMISTRY-US, V33, P7434, DOI 10.1021/bi00189a051; WANG D, 1995, J NEUROPATH EXP NEUR, V54, P548, DOI 10.1097/00005072-199507000-00009; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062; YANG JT, 1986, METHOD ENZYMOL, V130, P208; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	40	282	291	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26482	26489		10.1074/jbc.271.43.26482	http://dx.doi.org/10.1074/jbc.271.43.26482			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900116	hybrid			2022-12-27	WOS:A1996VP23300010
J	Glaser, M; Wanaski, S; Buser, CA; Boguslavsky, V; Rashidzada, W; Morris, A; Rebecchi, M; Scarlata, SF; Runnels, LW; Prestwich, GD; Chen, J; Aderem, A; Ahn, J; McLaughlin, S				Glaser, M; Wanaski, S; Buser, CA; Boguslavsky, V; Rashidzada, W; Morris, A; Rebecchi, M; Scarlata, SF; Runnels, LW; Prestwich, GD; Chen, J; Aderem, A; Ahn, J; McLaughlin, S			Myristoylated alanine-rich C kinase substrate (MARCKS) produces reversible inhibition of phospholipase C by sequestering phosphatidylinositol 4,5-bisphosphate in lateral domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ASSOCIATION; CA2+-ACTIVATED SECRETION; MEDIATED PHAGOCYTOSIS; QUANTITATIVE-ANALYSIS; HUMAN-MONOCYTES; HIGH-AFFINITY; PROTEIN; BINDING; PHOSPHORYLATION; PEPTIDES	The myristoylated alanine-rich protein kinase C substrate (MARCKS) is a major protein kinase C (PRC) substrate in many different cell types. MARCKS is bound to the plasma membrane, and several recent studies suggest that this binding requires both hydrophobic insertion of its myristate chain into the bilayer and electrostatic interaction of its cluster of basic residues with acidic lipids. Phosphorylation of MARCKS by PKC introduces negative charges into the basic cluster, reducing its electrostatic interaction with acidic lipids and producing translocation of MARCKS from membrane to cytoplasm. The present study shows that physiological concentrations of MARCKS (<10 mu M) inhibit phospholipase C (PLC)-catalyzed hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) in phospholipid vesicles. A peptide corresponding to the basic cluster, MARCKS(151-175), produces a similar inhibition, which was observed with both PLC-delta(1) and -beta(1). Direct fluorescence microscopy observations demonstrate that the MARCKS peptide forms lateral domains enriched in the acidic lipids phosphatidylserine and PIP2 but not PLC, which accounts for the observed inhibition of PIP2 hydrolysis. Phosphorylation of MARCKS(151-175) by PKC releases the inhibition and allows PLC to produce a burst of inositol 1,4,5-trisphosphate and diacylglycerol.	SUNY STONY BROOK, HLTH SCI CTR, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA; UNIV ILLINOIS, DEPT BIOCHEM, URBANA, IL 61801 USA; SUNY STONY BROOK, DEPT CHEM, STONY BROOK, NY 11794 USA; ROCKEFELLER UNIV, LAB SIGNAL TRANSDUCT, NEW YORK, NY 10021 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Illinois System; University of Illinois Urbana-Champaign; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Rockefeller University				Runnels, Loren/0000-0002-2537-7360				ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; CEVC G, 1987, PHOSPHOLIPID BILAYER, P348; Chen J, 1996, J ORG CHEM, V61, P6305, DOI 10.1021/jo960895r; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; DAS S, 1986, BIOCHEMISTRY-US, V25, P2882, DOI 10.1021/bi00358a022; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DEER JLR, 1995, J BIOL CHEM, V270, P12623, DOI 10.1074/jbc.270.21.12623; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; EVANS EA, 1980, MECHANICS THERMODYNA, P85; EXTON JH, 1990, J BIOL CHEM, V265, P1; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FROMHERZ P, 1975, REV SCI INSTRUM, V46, P1380, DOI 10.1063/1.1134025; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GEORGE DJ, 1992, J BIOL CHEM, V267, P24879; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GONI FM, 1994, BIOCHEM SOC T, V22, P839, DOI 10.1042/bst0220839; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HELM CA, 1992, BIOCHEMISTRY-US, V31, P1794, DOI 10.1021/bi00121a030; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1994, J BIOL CHEM, V269, P28214; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MOSIOR M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P185, DOI 10.1016/0005-2736(92)90178-O; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1992, J BIOL CHEM, V267, P15263; OSTRANDER DB, 1995, J BIOL CHEM, V270, P27045, DOI 10.1074/jbc.270.45.27045; PAP EHW, 1995, BIOCHEMISTRY-US, V34, P9118, DOI 10.1021/bi00028a022; Ponting CP, 1996, PROTEIN SCI, V5, P162; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; RAND RP, 1986, ANNU REV PHYSIOL, V48, P201; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RHEE SG, 1991, METHOD ENZYMOL, V197, P502; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; RYU SH, 1990, J BIOL CHEM, V265, P17941; SANCHEZMIGALLON MP, 1994, ARCH BIOCHEM BIOPHYS, V314, P205, DOI 10.1006/abbi.1994.1431; SEELIG A, 1992, BIOCHEMISTRY-US, V31, P2897, DOI 10.1021/bi00126a008; SEELIG A, 1987, BIOCHIM BIOPHYS ACTA, V899, P196, DOI 10.1016/0005-2736(87)90400-7; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWIERCZYNSKI SL, 1995, J BIOL CHEM, V270, P13436, DOI 10.1074/jbc.270.22.13436; TAMM LK, 1991, BIOCHIM BIOPHYS ACTA, V1071, P123, DOI 10.1016/0304-4157(91)90021-N; TANIGUCHI H, 1993, J BIOL CHEM, V268, P9960; Thorgeirsson TE, 1996, BIOCHEMISTRY-US, V35, P1803, DOI 10.1021/bi952300c; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WERNER MH, 1992, MOL PHARMACOL, V41, P382; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YANG L, 1995, BIOCHEMISTRY-US, V34, P1500, DOI 10.1021/bi00005a005; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042	68	203	208	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26187	26193		10.1074/jbc.271.42.26187	http://dx.doi.org/10.1074/jbc.271.42.26187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824266	hybrid			2022-12-27	WOS:A1996VN18000072
J	Hogg, PJ; Jackson, CM; Labanowski, JK; Bock, PE				Hogg, PJ; Jackson, CM; Labanowski, JK; Bock, PE			Finding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; BLOOD-COAGULATION PROTEINASES; PEPTIDE CHLOROMETHYL KETONES; ANTITHROMBIN-III; ACTIVE-SITE; QUANTITATIVE CHARACTERIZATION; FLUORESCENCE PROBES; BINDING EXOSITE; INACTIVATION; SPECIFICITY	Interaction of the blood clotting proteinase, thrombin, with fibrin monomer and heparin to form a thrombin fibrin monomer heparin ternary complex is accompanied by a change in thrombin catalytic specificity, Equilibrium binding interactions in the assembly of the ternary complex were characterized quantitatively using thrombin labeled at the active site with a fluorescent probe and related to changes in thrombin specificity toward exosite I-dependent binding of hirudin and cleavage of fibrinogen, Changes in the active site environment accompanying binding of heparin or fibrin to thrombin in binary complexes were reported by fluorescence enhancements which contributed additively to the perturbation accompanying formation of the ternary complex, Quantitative analysis of the interactions supports a preferentially ordered path of ternary complex assembly, in which initial binding of heparin to thrombin facilitates binding of fibrin monomer with an similar to 40-fold increased affinity, Binding of fibrin monomer in the ternary complex decreased the affinity of native thrombin for hirudin by > 100-fold and inhibited cleavage of fibrinogen, but this inhibition was overcome when fibrin(ogen)-fibrin interactions occurred, These results support a ternary complex model in which heparin binding through exosite II of thrombin facilitates fibrin monomer binding via exosite I, with accompanying changes in thrombin catalytic specificity resulting from perturbations in the active site and reduced accessibility of exosite I to hirudin and fibrinogen.	OHIO SUPERCOMP CTR,COLUMBUS,OH 43212; VANDERBILT UNIV,SCH MED,DEPT PATHOL,NASHVILLE,TN 37232; AMER RED CROSS,BLOOD SERV,SE MICHIGAN REG,DETROIT,MI 48232	Vanderbilt University; American Red Cross	Hogg, PJ (corresponding author), UNIV NEW S WALES,SCH PATHOL,CTR THROMBOSIS & VASC RES,SYDNEY,NSW 2052,AUSTRALIA.		Jackson, Craig M/AAC-6338-2020	Jackson, Craig/0000-0001-9484-4420; Hogg, Philip/0000-0001-6486-2863	NHLBI NIH HHS [HL-38779, HL-02832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038779, R01HL038779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BLOOD, V81, P3186; BJORK I, 1989, HEPARIN CHEM BIOL PR, P229; BOCK PE, 1992, J BIOL CHEM, V267, P14963; BOCK PE, 1992, J BIOL CHEM, V267, P14974; BODE W, 1992, PROTEIN SCI, V1, P426; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; DECRISTOFARO R, 1991, J PROTEIN CHEM, V10, P455, DOI 10.1007/BF01025473; DUGGLEBY RG, 1977, BIOCHIM BIOPHYS ACTA, P297; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; FENTON JW, 1988, BIOCHEMISTRY-US, V27, P7106, DOI 10.1021/bi00418a066; GAN ZR, 1994, J BIOL CHEM, V269, P1301; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HOFSTEENGE J, 1986, BIOCHEM J, V237, P243, DOI 10.1042/bj2370243; HOGG PJ, 1990, J BIOL CHEM, V265, P248; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HOTCHKISS KA, 1994, BLOOD, V84, P498; JACKMAN MP, 1992, J BIOL CHEM, V267, P15375; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; KAMINSKI M, 1983, J BIOL CHEM, V258, P530; LATALLO ZS, 1986, THROMB RES, V43, P507, DOI 10.1016/0049-3848(86)90071-X; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LEWIS SD, 1985, BIOCHEMISTRY-US, V24, P6772, DOI 10.1021/bi00345a007; LIU CY, 1979, J BIOL CHEM, V254, P421; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P539, DOI 10.1016/0167-4838(83)90272-8; MIHALYI E, 1988, BIOCHEMISTRY-US, V27, P976, DOI 10.1021/bi00403a021; NASKI MC, 1993, THROMB RES, V69, P453, DOI 10.1016/0049-3848(93)90234-F; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NASKI MC, 1991, BIOCHEMISTRY-US, V30, P934, DOI 10.1021/bi00218a008; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SACHE E, 1982, THROMB RES, V25, P443, DOI 10.1016/0049-3848(82)90086-X; SCULLEY MJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P44, DOI 10.1016/0167-4838(86)90100-7; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; STONE SR, 1995, TRENDS CARDIOVAS MED, V5, P134, DOI 10.1016/1050-1738(95)00049-F; STONE SR, 1987, EUR J BIOCHEM, V169, P373, DOI 10.1111/j.1432-1033.1987.tb13622.x; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; STONE SR, 1993, METHOD ENZYMOL, V223, P312; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; WEITZ J, 1993, J LAB CLIN MED, V122, P364; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; WEITZ JI, 1995, AM J CARDIOL, V75, pB18, DOI 10.1016/0002-9149(95)80005-D	48	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26088	26095		10.1074/jbc.271.42.26088	http://dx.doi.org/10.1074/jbc.271.42.26088			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824251	hybrid			2022-12-27	WOS:A1996VN18000057
J	Krishna, MC; Samuni, A; Taira, J; Goldstein, S; Mitchell, JB; Russo, A				Krishna, MC; Samuni, A; Taira, J; Goldstein, S; Mitchell, JB; Russo, A			Stimulation by nitroxides of catalase-like activity of hemeproteins - Kinetics and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; HYDROGEN-PEROXIDE; FREE-RADICALS; SUPEROXIDE; OXIDATION; FERRYLMYOGLOBIN; EPOXIDATION; HEMOGLOBIN; REDUCTION; STYRENE	The ability of stable nitroxide radicals to detoxify hypervalent heme proteins such as ferrylmyoglobin (MbFe(IV)) produced in the reaction of metmyoglobin (MbFe(III)) and H2O2 was evaluated by monitoring O-2 evolution, H2O2 depletion, and redox changes of the heme prosthetic group, The rate of H2O2 depletion and O-2 evolution catalyzed by MbFe(III) was enhanced by stable nitroxides such as 4-OH-2,2,6,6-tetramethyl-piperidinoxyl (TPL) in a catalytic fashion, The reduction of MbFe(IV) to MbFe(III) was the rate-limiting step, Excess TPL over MbFe(III) enhanced catalase-like activity more than 4-fold. During dismutation of H2O2, [TPL] and [MbFe(IV)] remained constant, NADH caused: (a) inhibition of H2O2 decay; (b) progressive reduction of TPL to its respective hydroxylamine TPL-H; and (c) arrest/inhibition of oxygen evolution or elicit consumption of O-2. Following depletion of NADH the evolution of O-2 resumed, and the initial concentration of TPL was re stored, Kinetic analysis showed that two distinct forms of MbFe(IV) might be involved in the process, In summary, by shuttling between two oxidation states, namely nitroxide and oxoammonium cation, stable nitroxides enhance the catalase mimic activity of MbFe(III), thus facilitating H2O2 dismutation accompanied by O-2 evolution and providing protection against hypervalent heme proteins.	HEBREW UNIV JERUSALEM,SCH MED,DEPT BIOL MOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem	Krishna, MC (corresponding author), NCI,RADIAT BIOL BRANCH,NIH,BLDG 10,RM B3-B69,BETHESDA,MD 20892, USA.			Taira, Junsei/0000-0003-0431-3242				ABUGO OO, 1994, J BIOL CHEM, V269, P24845; ARDUINI A, 1990, ARCH BIOCHEM BIOPHYS, V281, P41, DOI 10.1016/0003-9861(90)90410-Z; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; CHANCE M, 1986, BIOCHEMISTRY-US, V25, P1259, DOI 10.1021/bi00354a010; CHOE YS, 1994, ARCH BIOCHEM BIOPHYS, V314, P126, DOI 10.1006/abbi.1994.1420; DAVIES MJ, 1991, BIOCHIM BIOPHYS ACTA, V1077, P86, DOI 10.1016/0167-4838(91)90529-9; DEBONO D, 1994, FREE RADICAL RES, V20, P327, DOI 10.3109/10715769409145632; DEGRAFF W, 1994, BIOCHEM PHARMACOL, V48, P1427, DOI 10.1016/0006-2952(94)90567-3; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; FISH JR, 1988, J PHYS CHEM-US, V92, P3745, DOI 10.1021/j100324a012; GALARIS D, 1989, BIOCHEM BIOPH RES CO, V160, P1162, DOI 10.1016/S0006-291X(89)80125-1; GELVAN D, 1991, P NATL ACAD SCI USA, V88, P4680, DOI 10.1073/pnas.88.11.4680; GIULIVI C, 1992, ARCH BIOCHEM BIOPHYS, V299, P302, DOI 10.1016/0003-9861(92)90279-6; GIULIVI C, 1994, METHOD ENZYMOL, V233, P189; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; HAHN SM, 1992, CANCER RES, V52, P1750; HOCHANADEL CJ, 1952, J PHYS CHEM-US, V56, P587, DOI 10.1021/j150497a008; KALYANARAMAN B, 1983, J BIOL CHEM, V258, P3855; KARMELI F, 1995, GUT, V37, P386, DOI 10.1136/gut.37.3.386; KEILIN D, 1950, NATURE, V166, P513, DOI 10.1038/166513a0; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; Kocherginski N., 1995, NITROXIDE SPIN LABEL; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; LARANJINHA J, 1995, FREE RADICAL BIO MED, V19, P329, DOI 10.1016/0891-5849(95)00039-Z; LIEBMANN J, 1994, LIFE SCI, V54, P503; MEHLHORN RJ, 1992, FREE RADICAL RES COM, V17, P157, DOI 10.3109/10715769209068163; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MITCHELL JB, 1991, ARCH BIOCHEM BIOPHYS, V289, P62, DOI 10.1016/0003-9861(91)90442-L; NILSSON UA, 1989, J BIOL CHEM, V264, P11131; OSAWA Y, 1991, P NATL ACAD SCI USA, V88, P7081, DOI 10.1073/pnas.88.16.7081; RAO SI, 1994, J BIOL CHEM, V269, P7210; RAO SI, 1993, J BIOL CHEM, V268, P803; SAMUNI A, 1990, FREE RADICAL RES COM, V9, P241, DOI 10.3109/10715769009145682; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; TAJIMA G, 1987, J BIOL CHEM, V262, P12603; TEW D, 1988, J BIOL CHEM, V263, P17880; TURNER JJO, 1991, BIOCHEM J, V277, P833, DOI 10.1042/bj2770833; UYEDA M, 1981, BIOCHEMISTRY-US, V20, P2028, DOI 10.1021/bi00510a045; WHITBURN KD, 1982, J BIOL CHEM, V257, P1860; YAMAGUCHI T, 1984, BIOCHEM BIOPH RES CO, V120, P534, DOI 10.1016/0006-291X(84)91287-7; YONETANI T, 1967, J BIOL CHEM, V242, P1974	42	159	164	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26018	26025		10.1074/jbc.271.42.26018	http://dx.doi.org/10.1074/jbc.271.42.26018			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824241	hybrid			2022-12-27	WOS:A1996VN18000047
J	Murante, RS; Rumbaugh, JA; Barnes, CJ; Norton, JR; Bambara, RA				Murante, RS; Rumbaugh, JA; Barnes, CJ; Norton, JR; Bambara, RA			Calf RTH-1 nuclease can remove the initiator RNAs of Okazaki fragments by endonuclease activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND DNA-REPLICATION; ESCHERICHIA-COLI; CLEAVAGE; 5'-EXONUCLEASE; 3'-EXONUCLEASE; COMPLETION; CHROMOSOME; PROTEINS; ORIGIN; GENE	In eukaryotes, the endonucleolytic activity of the calf RTH-1 class 5'- to 3'-exo/endonuclease can function without RNase H1 to remove initiator RNA from Okazaki fragments, Cleavage requires that the RNA be displaced to form an unannealed single-stranded 5'-tail or flap structure, On substrates with RNA-initiated primers, DNA oligomers that competed with the RNA for template binding simulated strand displacement syn thesis from an upstream Okazaki fragment, This allowed cutting of displaced RNA segments by RTH-1 nuclease, Requirements for the reaction also were examined on substrates in which the tail was unannealed because it was intentionally mispaired. On both types of substrate, the nuclease slides over the RNA region from the 5'-end and cleaves at the beginning of the annealed region, irrespective of whether ribo- or deoxyribonucleotides are at the cleavage site. Presence of a triphosphate or a 7-methyl 3'G5' ppp5' G cap structure at the 5'-end of the RNA does not affect cleavage, The previously reported stimulation of the nuclease by an upstream primer was not always observed, suggesting that not every site in the downstream Okazaki fragment is equally susceptible to cleavage during displacement synthesis in vice, The biological role of the endonuclease activity of RTH-1 nuclease in Okazaki fragment processing is discussed.	UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007102, R13GM073536, R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM073536, T32-GM07102, GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; FUNNELL BE, 1986, J BIOL CHEM, V261, P5616; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; HUANG L, 1994, J BIOL CHEM, V269, P25922; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; OGAWA T, 1984, MOL GEN GENET, V193, P231, DOI 10.1007/BF00330673; ROBINS P, 1994, J BIOL CHEM, V269, P28535; SAMBROOK J, 1989, MOL CLONING LAB MANU, P636; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; WAGA S, 1994, J BIOL CHEM, V269, P10923; WANG TSF, 1984, J BIOL CHEM, V259, P1854	21	54	54	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25888	25897		10.1074/jbc.271.42.25888	http://dx.doi.org/10.1074/jbc.271.42.25888			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824221	hybrid			2022-12-27	WOS:A1996VN18000027
J	Gan, QF; Browner, MF; Sloane, DL; Sigal, E				Gan, QF; Browner, MF; Sloane, DL; Sigal, E			Defining the arachidonic acid binding site of human 15-lipoxygenase - Molecular modeling and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; LOW-DENSITY-LIPOPROTEIN; ALL-TRANS-RETINOL; SOYBEAN LIPOXYGENASE; POSITIONAL SPECIFICITY; ESCHERICHIA-COLI; LINOLEIC ACID; ACTIVE-SITE; PROTEIN; 12-LIPOXYGENASE	Mammalian lipoxygenases have been implicated in the pathogenesis of several inflammatory disorders and are, therefore, important targets for drug discovery, Both plant and mammalian lipoxygenases catalyze the dioxygenation of polyunsaturated fatty acids, which contain one or more 1,4-cis,cis-pentadiene units to yield hydroperoxide products. At the time this study was initiated, soybean lipoxygenase-1 was the only lipoxygenase for which an atomic resolution structure had been determined, No structure of lipoxygenase with substrate or inhibitor bound is currently available, A model of arachidonic acid docked into the proposed substrate binding site in the soybean structure is presented here. Analysis of this model suggested two residues, an aromatic residue and a positively charged residue, could be critical for substrate binding, Validation of this model is provided by site-directed mutagenesis of human 15-lipoxygenase, despite the low amino acid sequence identity between the soybean and mammalian enzymes, Both a positively charged amino acid residue (Arg(402)) and an aromatic amino acid residue (Phe(414)) are identified as critical for the binding of fatty acid substrates in human 15-lipoxygenase. Thus, binding determinants shown to be characteristic of non-enzymatic fatty acid-binding proteins are now implicated in the substrate binding pocket of lipoxygenases.	MERCATOR GENET,MENLO PK,CA 94025; ROCHE BIOSCI,PALO ALTO,CA 94304; TARGETED GENET,SEATTLE,WA 98108	Roche Holding					NHLBI NIH HHS [HL48591] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048591] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; CHEN XS, 1993, FASEB J, V7, P694, DOI 10.1096/fasebj.7.8.8500694; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; EGMOND MR, 1973, BIOCHEM BIOPH RES CO, V54, P1178, DOI 10.1016/0006-291X(73)90816-4; GAN QF, 1995, BIOCHEMISTRY-US, V34, P7069, DOI 10.1021/bi00021a019; GIBIAN MJ, 1987, ANAL BIOCHEM, V163, P343, DOI 10.1016/0003-2697(87)90234-X; GLICKMAN MH, 1994, J AM CHEM SOC, V116, P793, DOI 10.1021/ja00081a060; GUND P, 1977, J MED CHEM, V20, P1146, DOI 10.1021/jm00219a007; HAMBERG M, 1967, J BIOL CHEM, V242, P5329; HAMBERG M, 1965, BIOCHEM BIOPH RES CO, V21, P531, DOI 10.1016/0006-291X(65)90517-6; HWANG CC, 1994, J AM CHEM SOC, V116, P795, DOI 10.1021/ja00081a061; KUHN H, 1986, ADV ENZYMOL RAMB, V58, P273; KUHN H, 1990, J BIOL CHEM, V265, P16300; KUHN H, 1993, BIOCHIM BIOPHYS ACTA, V1169, P80, DOI 10.1016/0005-2760(93)90085-N; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; LI E, 1991, J BIOL CHEM, V266, P3622; LI E, 1990, J BIOL CHEM, V265, P11549; MINOR W, 1993, BIOCHEMISTRY-US, V32, P6320, DOI 10.1021/bi00076a003; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; ORENGO CA, 1994, NATURE, V372, P631, DOI 10.1038/372631a0; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; PERCIVAL MD, 1991, J BIOL CHEM, V266, P10058; PETERSSON L, 1987, BIOCHIM BIOPHYS ACTA, V913, P228, DOI 10.1016/0167-4838(87)90334-7; PISTORIUS EK, 1974, J BIOL CHEM, V249, P3183; Prigge ST, 1996, PROTEINS, V24, P275; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SLOANE DL, 1995, PROTEIN ENG, V8, P275, DOI 10.1093/protein/8.3.275; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SUZUKI H, 1994, BBA-LIPID LIPID MET, V1210, P308, DOI 10.1016/0005-2760(94)90234-8; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	35	89	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25412	25418		10.1074/jbc.271.41.25412	http://dx.doi.org/10.1074/jbc.271.41.25412			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810309	hybrid			2022-12-27	WOS:A1996VL69300053
J	Green, SP; Chuntharapai, A; Curnutte, JT				Green, SP; Chuntharapai, A; Curnutte, JT			Interleukin-8 (IL-8), melanoma growth-stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil NADPH oxidase through the type A or type B IL-8 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SUPEROXIDE ANION PRODUCTION; SIGNAL-TRANSDUCTION; RESPIRATORY BURST; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; PHAGOCYTIC-CELLS; BINDING-PROTEINS; OXIDATIVE BURST; CHEMOKINES	The capacity of neutrophils to generate superoxide (O-2(T)) can be enhanced by prior exposure to ''priming'' agents such as interleukin-8 (IL-8), melanoma growth-stimulatory activity (MGSA), and neutrophil-activating peptide (ENA-78). The biological effects of these chemokines are mediated by at least two distinct receptors: type A (IL-8-RA) and type B (IL-8-RB). Using neutralizing monoclonal antibodies to ILS-RA and IL-8-RB, we have investigated the contribution each receptor makes to the priming response, Preincubation with IL-8, MGSA, or ENA-78 enhanced the ability of neutrophils to generate O-2(T) following stimulation with the bacterial peptide formyl-Met-Leu-Phe. The priming effect of IL-8 was eliminated by an anti-IL-8 monoclonal antibody (mAb) that is known to bind IL-8 with high affinity and prevent receptor occupancy. Incubation of neutrophils with a neutralizing mAb specific for IL-8-RA blocked IL-8-induced priming but had no effect on priming by MGSA or ENA-78. In contrast, treatment with a neutralizing mAb specific for IL-8-RB faded to inhibit the priming effect of IL-8 but blocked both MGSA and ENA-78-induced priming. These observations indicate that the priming effect of IL-8 on the neutrophil respiratory burst is predominantly mediated via IL-8-RA whereas priming by MGSA and ENA-78 is mediated by IL-8-RB.	GENENTECH INC,DEPT BIOANAL TECHNOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech	Green, SP (corresponding author), GENENTECH INC,DEPT IMMUNOL,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D; BADWEY JA, 1982, BIOCHEM BIOPH RES CO, V106, P170, DOI 10.1016/0006-291X(82)92073-3; Baggiolini M, 1992, Cytokines, V4, P1; BAJAJ MS, 1992, INFLAMMATION, V16, P241, DOI 10.1007/BF00918813; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BENBARUCH A, 1995, J BIOL CHEM, V270, P9121, DOI 10.1074/jbc.270.16.9121; BOKOCH GM, 1995, TRENDS CELL BIOL, V5, P109, DOI 10.1016/S0962-8924(00)88960-6; BROADDUS VC, 1995, CRC HDB CHEMOATTRACT; CHUNTHARAPAI A, 1995, J IMMUNOL, V155, P2587; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; CHUNTHARAPAI A, 1994, J IMMUNOL, V152, P1783; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; DANIELS RH, 1994, IMMUNOLOGY, V82, P465; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; ELBIM C, 1994, INFECT IMMUN, V62, P2195, DOI 10.1128/IAI.62.6.2195-2201.1994; GUDEWICZ PW, 1994, BIOCHEM BIOPH RES CO, V205, P706, DOI 10.1006/bbrc.1994.2723; HALLETT MB, 1995, IMMUNOL TODAY, V16, P2654; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1992, CELLULAR MOL MECHANI, V4, P43; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; JESAITIS AJ, 1995, J IMMUNOL, V155, P3286; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; LEE J, 1992, J BIOL CHEM, V267, P16283; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEPIDI H, 1995, J CELL SCI, V108, P1771; LHEUREUX GP, 1995, BLOOD, V85, P522, DOI 10.1182/blood.V85.2.522.bloodjournal852522; LLOYDS D, 1995, IMMUNOLOGY, V84, P220; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MCCOLL SR, 1990, J IMMUNOL, V145, P3047; MCCOLL SR, 1989, BLOOD, V73, P588; METZNER B, 1995, J INVEST DERMATOL, V104, P789, DOI 10.1111/1523-1747.ep12606993; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MOSER B, 1990, J EXP MED, V171, P1797, DOI 10.1084/jem.171.5.1797; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARBOOSINGH JS, 1995, ARCH NEUROL-CHICAGO, V52, P1160, DOI 10.1001/archneur.1995.00540360038013; Quan JM, 1996, BIOCHEM BIOPH RES CO, V219, P405, DOI 10.1006/bbrc.1996.0246; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RICHARD S, 1994, J IMMUNOL, V152, P2479; ROBERTS PJ, 1993, BRIT J HAEMATOL, V84, P586, DOI 10.1111/j.1365-2141.1993.tb03132.x; SHAPIRA L, 1995, INFLAMMATION, V19, P289, DOI 10.1007/BF01534388; SMITH RJ, 1992, J LEUKOCYTE BIOL, V52, P17, DOI 10.1002/jlb.52.1.17; WALZ A, 1991, J EXP MED, V174, P1355, DOI 10.1084/jem.174.6.1355; WALZ A, 1993, ADV EXP MED BIOL, V351, P129; WOZNIAK A, 1993, IMMUNOLOGY, V79, P608; YUO A, 1991, BLOOD, V78, P2708	50	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25400	25405		10.1074/jbc.271.41.25400	http://dx.doi.org/10.1074/jbc.271.41.25400			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810307	hybrid			2022-12-27	WOS:A1996VL69300051
J	Hammani, K; Blakis, A; Morsette, D; Bowcock, AM; Schmutte, C; Henriet, P; DeClerck, YA				Hammani, K; Blakis, A; Morsette, D; Bowcock, AM; Schmutte, C; Henriet, P; DeClerck, YA			Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-POTENTIATING ACTIVITY; TUMOR-CELL-LINES; TIMP GENE; MATRIX METALLOPROTEINASES; DNA METHYLATION; BINDING-SITES; EXPRESSION; TRANSCRIPTION; PROMOTER; COLLAGENASE	We report here the characterization of the human tissue inhibitor of metalloproteinases-2 (TIMP-2) gene. The gene is 83 kilobase pairs (kb) long with exon-intron splicing sites located in preserved positions among the three members of the TIMP family. A 2.6-kb genomic DNA fragment flanking the 5'-end of the gene contains several regulatory elements including five Sp1, two AP-2, one AP-1, and three PEA-3 binding sites, Despite the presence of a complete AP-1 consensus at position -281, the promoter did not respond to 12-O-tetradecanoylphorbol-13-acetate treatment; However, 12-O-tetradecanoylphorbol-13-acetate response was generated by insertion of a similar AP-1 consensus at position -71, indicating the importance of the positioning of this motif. The promoter contains a typical CpG island; however, methylation of this island did not seem to influence gene expression. Analysis of the 3'-end of the gene revealed that the two mRNAs for TIMP-2 (1.2 and 3.8 kb) differ by the selection of their polyadenylation signal sites, but selection of these sites does not affect RNA stability. In summary, the TIMP-2 gene has several features observed in housekeeping genes, and differs significantly from TIMP-1 and TIMP-3 genes. These differences are likely to explain the specific roles that these inhibitors play in the regulation of matrix metalloproteinases.	CHILDRENS HOSP LOS ANGELES,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90054; UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV SO CALIF,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Southern California			Hammani, khalil/GSD-7743-2022	Bowcock, Anne/0000-0001-8691-9090; Hammani, Khalil/0000-0002-4005-4244; Henriet, Patrick/0000-0003-4602-8888; DeClerck, Yves/0000-0002-3688-0113	NATIONAL CANCER INSTITUTE [R01CA042919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043177] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 42919] Funding Source: Medline; NIAMS NIH HHS [AR 43177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AHLERING TE, 1987, CANCER RES, V47, P6660; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APTE SS, 1994, DEV DYNAM, V200, P177, DOI 10.1002/aja.1002000302; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHANDLER LA, 1986, CANCER RES, V46, P2944; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; COUCH FJ, 1995, GENOMICS, V25, P264, DOI 10.1016/0888-7543(95)80134-8; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; D'ORAZI G, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P316; DECLERCK Y, 1992, GENOMICS, V14, P782, DOI 10.1016/S0888-7543(05)80186-7; DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6; DETWET JR, 1987, MOL CELL BIOL, V7, P725; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hammani K, 1996, GENE, V170, P287, DOI 10.1016/0378-1119(95)00864-0; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SHAPIRO SD, 1992, J BIOL CHEM, V267, P13890; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; SUN Y, 1995, J BIOL CHEM, V270, P19312, DOI 10.1074/jbc.270.33.19312; TANAKA K, 1995, CANCER RES, V55, P2927; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WAHL GM, 1987, P NATL ACAD SCI USA, V84, P2160, DOI 10.1073/pnas.84.8.2160; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WICK M, 1995, BIOCHEM J, V311, P549, DOI 10.1042/bj3110549; WILLIARD H F, 1989, Human Genetics, V81, P235; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	50	101	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25498	25505		10.1074/jbc.271.41.25498	http://dx.doi.org/10.1074/jbc.271.41.25498			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810321	hybrid			2022-12-27	WOS:A1996VL69300065
J	McGee, TP; Cheng, RH; Kumagai, H; Omura, S; Simoni, RD				McGee, TP; Cheng, RH; Kumagai, H; Omura, S; Simoni, RD			Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; UBIQUITIN-PROTEASOME PATHWAY; HMG COA REDUCTASE; REGULATED DEGRADATION; ORNITHINE DECARBOXYLASE; PROTEIN-DEGRADATION; CELLS; MEVALONATE; ENZYME; INHIBITION	The endoplasmic reticulum (ER) membrane protein 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is subject to regulated degradation when cells are presented with an excess of sterols or mevalonate, In this report, we demonstrate the degradation of HMG-CoA reductase in ER membranes prepared from cells which have been pretreated with mevalonate or sterols prior to membrane purification, Degradation of HMG-CoA reductase in membranes prepared from pretreated cells is more rapid than in membranes prepared from cells which have received no regulatory molecules, In vitro degradation is blocked by protease inhibitors previously shown to inhibit reductase degradation in vivo and is specific for intact HMG-CoA reductase, The lumenal contents of the ER membranes are dispensible for the regulated proteolysis and the proteases responsible for reductase degradation are stably associated with the ER membrane, Regulated proteolysis of HMG-CoA reductase is inhibited by lactacystin, a newly defined inhibitor of the multicatalytic protease, the proteasome, and in vitro degradation of reductase correlates with the presence of proteasome subunits in purified ER membranes, The ubiquitin system for protein degradation, which has recently been shown to be required for the degradation of several ER membrane proteins, is not required for the degradation of HMG-CoA reductase. Finally, we conclude that the regulated proteolysis of HMG-CoA reductase in response to regulatory molecules such as mevalonate or sterols is mediated by increased susceptibility of the reductase to ER proteases, rather than the induction of a new proteolytic activity.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; KITASATO INST,BIOL FUNCT RES CTR,TOKYO 108,JAPAN	Stanford University; Kitasato University			Cheng, Holland/A-8973-2008	McGee, Todd/0000-0002-3901-1001	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017363] Funding Source: NIH RePORTER; NIGMS NIH HHS [1 F32 GM17363-01] Funding Source: Medline; OHS HRSA HHS [ST32 CA09302] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; BONAFACINO JS, 1994, CELLULAR PROTEOLYTIC, P137; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORRELL CC, 1994, J BIOL CHEM, V269, P633; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GIBSON DM, 1987, ENZYMES, V88, P179; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GROPPER R, 1991, J BIOL CHEM, V266, P3602; HARDEMAN EC, 1984, ARCH BIOCHEM BIOPHYS, V232, P549, DOI 10.1016/0003-9861(84)90572-1; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; INOUE S, 1991, J BIOL CHEM, V266, P13311; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LAING JG, 1995, J BIOL CHEM, V270, P26399, DOI 10.1074/jbc.270.44.26399; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; LISCUM L, 1985, J BIOL CHEM, V260, P522; MEIGS TE, 1992, J BIOL CHEM, V267, P13547; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; ORCI L, 1984, CELL, V36, P835, DOI 10.1016/0092-8674(84)90033-3; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; PEFFLEY DM, 1992, SOMAT CELL MOLEC GEN, V18, P19, DOI 10.1007/BF01233446; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RIVETT AJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1165, DOI 10.1177/40.8.1619280; ROITELMAN J, 1992, J CELL BIOL, V117, P959, DOI 10.1083/jcb.117.5.959; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; ROITELMAN J, 1991, J BIOL CHEM, V266, P16085; ROSENBERGHASSON Y, 1989, EUR J BIOCHEM, V185, P469, DOI 10.1111/j.1432-1033.1989.tb15138.x; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991; TANAKA RD, 1986, J LIPID RES, V27, P261; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; URADE R, 1993, J BIOL CHEM, V268, P22004; URBANI L, 1990, J BIOL CHEM, V265, P1919; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; WILCOX CA, 1991, J CELL BIOL, V115, P297, DOI 10.1083/jcb.115.2.297; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	43	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	1996	271	41					25630	25638		10.1074/jbc.271.41.25630	http://dx.doi.org/10.1074/jbc.271.41.25630			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VL693	8810339	hybrid			2022-12-27	WOS:A1996VL69300083
J	Mehta, A; Banerjee, S; Driscoll, DM				Mehta, A; Banerjee, S; Driscoll, DM			Apobec-1 interacts with a 65-kDa complementing protein to edit apolipoprotein-B mRNA in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMMERHEAD RIBOZYME CATALYSIS; RNA-BINDING PROTEINS; MESSENGER-RNA; CYTIDINE DEAMINASE; MOLECULAR-CLONING; ENZYME; SITE; SUBUNIT; EXPRESSION; SEQUENCES	The editing of apolipoprotein-B (apoB) mRNA involves the deamination of cytidine at nucleotide 6666 to uridine, The catalytic subunit of the editing enzyme, apobec-1, is a cytidine deaminase that requires other unidentified proteins to edit apoB mRNA in vitro. We partially purified an activity from baboon kidney that functionally complements apobec-1, The complementing activity was protease-sensitive and micrococcal nuclease-resistant, had a native molecular mass of 65 +/- 10 kDa on size exclusion chromatography, and sedimented at 4.5 S in glycerol gradients, Purified recombinant His,tagged apobec-1 immobilized on beads depleted >90% of the complementing activity hom partially purified extracts, These beads edited apoB mRNA in vitro in the absence of exogenous apobec-1 or complementing activity, A functional holoenzyme containing apobec-1 and the complementing activity was eluted from the apobec-1-affinity resin using 0.5 nn imidazole, whereas buffer containing 0.4 M KCl eluted only the complementing activity, The carboxyl-terminal 59 amino acids of apobec-1 were not required for interaction with the complementing activity in vitro. Our results demonstrate that the complementing protein interacts directly with apobec-1 in the absence of apoB mRNA.	CLEVELAND CLIN FDN, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045478, R29HL045478] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45478] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANT S, 1995, J BIOL CHEM, V270, P14762, DOI 10.1074/jbc.270.24.14762; BACKUS JW, 1994, BBA-GENE STRUCT EXPR, V1217, P65; BACKUS JW, 1992, NUCLEIC ACIDS RES, V20, P6007, DOI 10.1093/nar/20.22.6007; BACKUS JW, 1991, NUCLEIC ACIDS RES, V19, P6781, DOI 10.1093/nar/19.24.6781; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1993, MOL CELL BIOL, V13, P7288, DOI 10.1128/MCB.13.12.7288; DRISCOLL DM, 1990, J BIOL CHEM, V265, P21401; GARCIA ZC, 1992, ARTERIOSCLER THROMB, V12, P172, DOI 10.1161/01.ATV.12.2.172; GIANNONI F, 1994, J BIOL CHEM, V269, P5932; GREEVE J, 1991, NUCLEIC ACIDS RES, V19, P3569, DOI 10.1093/nar/19.13.3569; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; Harlow E., 1988, ANTIBODIES LAB MANUA; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HODGES P, 1992, TRENDS BIOCHEM SCI, V17, P77, DOI 10.1016/0968-0004(92)90506-5; JOHNSON DF, 1993, BIOCHEM BIOPH RES CO, V195, P1204, DOI 10.1006/bbrc.1993.2172; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; NAVARATNAM N, 1995, CELL, V81, P187, DOI 10.1016/0092-8674(95)90328-3; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; SHAH RR, 1991, J BIOL CHEM, V266, P16301; SMITH HC, 1991, P NATL ACAD SCI USA, V88, P1489, DOI 10.1073/pnas.88.4.1489; TENG BB, 1990, J BIOL CHEM, V265, P20616; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAMANAKA S, 1995, CIRCULATION, V92, P788; Yang Y, 1996, BIOCHEM BIOPH RES CO, V218, P797, DOI 10.1006/bbrc.1996.0142	41	34	34	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28294	28299		10.1074/jbc.271.45.28294	http://dx.doi.org/10.1074/jbc.271.45.28294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910449	hybrid			2022-12-27	WOS:A1996VU03300049
J	Leidich, SD; Orlean, P				Leidich, SD; Orlean, P			Gpi1, a Saccharomyces cerevisiae protein that participates in the first step in glycosylphosphatidylinositol anchor synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PIG-A GENE; CELL-SURFACE; GLYCOSYL-PHOSPHATIDYLINOSITOL; ALPHA-AGGLUTININ; MEMBRANE-PROTEINS; CHITIN SYNTHESIS; SHUTTLE VECTORS; APPLE MACINTOSH; SPT14 GENE	The temperature-sensitive Saccharomyces cerevisiae gpi1 mutant is blocked in [H-3]inositol incorporation into protein and defective in the synthesis of N-acetylglucosaminylphosphatidylinositol, the first step in glycosylphosphatidylinositol (GPI) anchor assembly (Leidich, S, D., Drapp, D, A, and Orlean, P, (1994) J, Biol, Chem. 269, 10193-10196). The GPI1 gene, which encodes a 609-amino acid membrane protein, was cloned by complementation of the temperature sensitivity of gpi1 and corrects the mutant's [H-3]inositol labeling and enzymatic defects, Disruption of GPI1 yields viable haploid cells that are temperature-sensitive for growth, for [H-3]inositol incorporation into protein, and for GPI anchor dependent processing of the Gas1/Ggp1 protein and that lack in vitro N-acetylglucosaminylphosphatidylinositol synthetic activity, The Gpi1 protein thus participates in GPI synthesis and is required for growth at 37 degrees C. When grown at a semipermissive temperature of 30 degrees C, gpi1 cells and gpi1::URA3 disruptants form large, round, multiply budded cells with a separation defect, Homozygous gpi1/gpi1, gpi1::URA3/gpi1::URA3, gpi2/gpi2, and gpi3/gpi3 diploids undergo meiosis, but are defective in ascospore wall maturation for they fail to give the fluorescence due to the dityrosine-containing layer in the ascospore wall, These findings indicate that GPIs have key roles in the morphogenesis and development of S, cerevisiae.	UNIV ILLINOIS, DEPT BIOCHEM, ROGER ADAMS LAB 309, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046220] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46220] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; BALLARD MJ, 1991, EMBO J, V10, P3753, DOI 10.1002/j.1460-2075.1991.tb04944.x; BRIZA P, 1986, J BIOL CHEM, V261, P4288; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; BRIZA P, 1994, P NATL ACAD SCI USA, V91, P4524, DOI 10.1073/pnas.91.10.4524; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; BULAWA CE, 1993, ANNU REV MICROBIOL, V47, P505, DOI 10.1146/annurev.micro.47.1.505; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; CONZELMANN A, 1990, EMBO J, V9, P653, DOI 10.1002/j.1460-2075.1990.tb08157.x; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; DAUM G, 1982, J BIOL CHEM, V257, P3028; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FASSLER JS, 1991, MOL GEN GENET, V230, P310, DOI 10.1007/BF00290682; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FREIFELDER D, 1960, J BACTERIOL, V80, P567, DOI 10.1128/JB.80.4.567-568.1960; FUCHS R, 1991, COMPUT APPL BIOSCI, V7, P105; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HIROSE S, 1992, J BIOL CHEM, V267, P5272; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HYMAN R, 1988, TRENDS GENET, V4, P5, DOI 10.1016/0168-9525(88)90120-5; KAMITANI T, 1993, J BIOL CHEM, V268, P20733; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; KIM YJ, 1994, J CELL BIOL, V127, P1381, DOI 10.1083/jcb.127.5.1381; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIDICH SD, 1995, METHOD ENZYMOL, V250, P560; LEIDICH SD, 1994, J BIOL CHEM, V269, P10193; LEIDICH SD, 1995, J BIOL CHEM, V270, P13029, DOI 10.1074/jbc.270.22.13029; LIPKE PN, 1989, MOL CELL BIOL, V9, P3155, DOI 10.1128/MCB.9.8.3155; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LU CF, 1994, MOL CELL BIOL, V14, P4825, DOI 10.1128/MCB.14.7.4825; MARCK C, 1988, NUCLEIC ACIDS RES, V16, P1829, DOI 10.1093/nar/16.5.1829; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; MULLER G, 1992, J BIOL CHEM, V267, P25337; NUOFFER C, 1993, J BIOL CHEM, V268, P10558; PAMMER M, 1992, YEAST, V8, P1089, DOI 10.1002/yea.320081211; POPOLO L, 1988, EUR J CELL BIOL, V47, P173; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; PUOTI A, 1991, J BIOL CHEM, V266, P21051; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; ROSE MD, 1990, METHODS YEAST GENETI, P122; ROY A, 1991, MOL CELL BIOL, V11, P4196, DOI 10.1128/MCB.11.8.4196; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHONBACHLER M, 1995, EMBO J, V14, P1637, DOI 10.1002/j.1460-2075.1995.tb07152.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SNYDER M, 1989, J CELL BIOL, V108, P1419, DOI 10.1083/jcb.108.4.1419; STEVENS VL, 1991, J BIOL CHEM, V266, P10039; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TAKEDAJ, 1995, TRENDS BIOCHEM SCI, V20, P367; VOSSEN JH, 1995, BBA-GEN SUBJECTS, V1243, P549, DOI 10.1016/0304-4165(95)00002-S; WEINSTOCK KG, 1987, J BACTERIOL, V169, P4384, DOI 10.1128/jb.169.9.4384-4387.1987; WHELAN WL, 1975, J BACTERIOL, V124, P1545, DOI 10.1128/JB.124.3.1545-1557.1975; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; WILSON RB, 1991, MOL CELL BIOL, V11, P3369, DOI 10.1128/MCB.11.6.3369; WOJCIECHOWICZ D, 1993, MOL CELL BIOL, V13, P2554, DOI 10.1128/MCB.13.4.2554; YEH ETH, 1988, CELL, V52, P665, DOI 10.1016/0092-8674(88)90404-7	67	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27829	27837		10.1074/jbc.271.44.27829	http://dx.doi.org/10.1074/jbc.271.44.27829			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910381	hybrid			2022-12-27	WOS:A1996VQ67900099
J	Neyroz, P; Menna, C; Polverini, E; Masotti, L				Neyroz, P; Menna, C; Polverini, E; Masotti, L			Intrinsic fluorescence properties and structural analysis of p13(suc1) from Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; CELL-CYCLE CONTROL; CDC2 PROTEIN-KINASE; HISTONE H-1 KINASE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ALCOHOL-DEHYDROGENASE; SECONDARY STRUCTURE; CIRCULAR-DICHROISM; DIVISION CYCLE	p(13suc1) acts in the fission yeast cell division cycle as a component of p34(cdc2). I, the present work, structural information contained in the intrinsic fluorescence of p13(suc1) has been extracted by steady-state and time-resolved fluorescence techniques. In its native form, the steady-state emission spectrum of p13(suc1) is centered at 336 nm. Upon denaturation by guanidine HCl (4.0 M), the emission spectrum is shifted to 355-360 nm and the fluorescence intensity decreases 70%. The same changes are not obtained with p(13suc1) at 56 degrees C or after incubation at 100 degrees C, and the protein appears to be substantially temperature-stable. The fluorescence decay of p(13suc1) is best described by three discrete lifetimes of 0.6 ns (tau(1)), 2.9 ns (tau(2)), and 6.1 ns (tau(3)), with amplitudes that are dependent on the native or unfolded state of the protein. Under native conditions, the two predominant decay-associated spectra, DAS-tau(2), (lambda(max), = 332 nm) and DAS-tau(3) (lambda(max) = 340 nm), derive from two different excitation DAS. Moreover distinct quenching mechanisms and collisional accessibilities (k(q)(tau(2))much greater than k(q)(tau(3))) are resolved for each lifetime. An interpretation in terms of specific tryptophan residue (or protein conformer)-lifetime as signments is presented. The decay of the fluorescence anisotropy of native p13(suc1) is best described by a double exponential decay. The longer correlation time recovered (9 ns less than or equal to phi(2) less than or equal to 15ns) can be associated with the rotational motion of the protein as a whole and a Stokes radius of 21.2 Angstrom has been calculated for p13(suc1). Anisotropy measurements obtained as a function of temperature indicate that, in solution, the protein exists exclusively as a prolate monomer. In 1 mM zinc, changes of the anisotropy decay parameters are compatible with subunits oligomerization.			Neyroz, P (corresponding author), UNIV BOLOGNA, DIPARTIMENTO BIOCHIM G MORUZZI, SEZ BIOCHIM FARMACEUT, VIA SAN DONATO 19-2, I-40127 BOLOGNA, ITALY.			Polverini, Eugenia/0000-0003-1665-2129; NEYROZ, PAOLO/0000-0002-9790-4027				AMELOOT M, 1984, BIOPHYS J, V46, P525, DOI 10.1016/S0006-3495(84)84050-3; ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; AZUMI T, 1962, J CHEM PHYS, V37, P2413, DOI 10.1063/1.1733019; Badea M G, 1979, Methods Enzymol, V61, P378; BEECHEM JM, 1985, ANAL INSTRUM, V14, P379; BEECHEM JM, 1985, ANNU REV BIOCHEM, V54, P43, DOI 10.1146/annurev.biochem.54.1.43; BENFENATI F, 1990, J BIOL CHEM, V265, P12584; Bevington P. R, 1969, DATA REDUCTION ERROR; BIRCK C, 1995, FEBS LETT, V363, P145, DOI 10.1016/0014-5793(95)00300-X; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CROSS AJ, 1984, BIOPHYS J, V46, P45, DOI 10.1016/S0006-3495(84)83997-1; DAHMS TES, 1995, BIOPHYS J, V69, P569, DOI 10.1016/S0006-3495(95)79930-1; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GAVIN AC, 1992, MOL REPROD DEV, V33, P287, DOI 10.1002/mrd.1080330309; Gilbert C. W., 1983, TIME RESOLVED FLUORE, P605; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; HARRIS DL, 1990, BIOCHEMISTRY-US, V29, P5276, DOI 10.1021/bi00474a009; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HINDLEY J, 1987, MOL CELL BIOL, V7, P504, DOI 10.1128/MCB.7.1.504; JOHNSON ML, 1983, BIOPHYS J, V44, P101, DOI 10.1016/S0006-3495(83)84281-7; KNIGHT AEW, 1971, CHEM PHYS LETT, V10, P43, DOI 10.1016/0009-2614(71)80152-5; KNUTSON JR, 1992, METHOD ENZYMOL, V210, P357; KNUTSON JR, 1982, BIOCHEMISTRY-US, V21, P4671, DOI 10.1021/bi00262a024; KNUTSON JR, 1983, CHEM PHYS LETT, V102, P501, DOI 10.1016/0009-2614(83)87454-5; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Lakowicz JR., 1992, TOPICS FLUORESCENCE, V2; LAWS WR, 1992, METHOD ENZYMOL, V210, P448; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEW J, 1992, J BIOL CHEM, V267, P13383; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MEIJER L, 1991, EMBO J, V10, P1545, DOI 10.1002/j.1460-2075.1991.tb07674.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NEYROZ P, 1987, J BIOL CHEM, V262, P15900; O'Connor D. V., 1984, TIME CORRELATED SING; PAOLETTI J, 1969, ANAL BIOCHEM, V31, P33, DOI 10.1016/0003-2697(69)90238-3; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4369, DOI 10.1021/bi00518a021; ROYER CA, 1990, BIOPHYS J, V58, P363, DOI 10.1016/S0006-3495(90)82383-3; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SZABO AG, 1980, J AM CHEM SOC, V102, P554, DOI 10.1021/ja00522a020; TAO T, 1969, BIOPOLYMERS, V8, P609, DOI 10.1002/bip.1969.360080505; WAHL P, 1969, BIOCHIM BIOPHYS ACTA, V175, P55, DOI 10.1016/0005-2795(69)90145-7; WAHL P, 1974, REV SCI INSTRUM, V45, P28, DOI 10.1063/1.1686442	66	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27249	27258		10.1074/jbc.271.44.27249	http://dx.doi.org/10.1074/jbc.271.44.27249			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910298	hybrid			2022-12-27	WOS:A1996VQ67900016
J	Moriguchi, T; Toyoshima, F; Gotoh, Y; Iwamatsu, A; Irie, K; Mori, E; Kuroyanagi, N; Hagiwara, M; Matsumoto, K; Nishida, E				Moriguchi, T; Toyoshima, F; Gotoh, Y; Iwamatsu, A; Irie, K; Mori, E; Kuroyanagi, N; Hagiwara, M; Matsumoto, K; Nishida, E			Purification and identification of a major activator for p38 from osmotically shocked cells - Activation of mitogen-activated protein kinase 6 by osmotic shock, tumor necrosis factor-alpha, and H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-JUN; MAMMALIAN-CELLS; HEAT-SHOCK; STRESS; PHOSPHORYLATION; YEAST; CASCADE; THREONINE; TYROSINE	A stress-activated, serine/threonine kinase, p38 (also known as HOG1 or MPK2) belongs to a subgroup of mitogen-activated protein kinase (MAPK) superfamily molecules, An activity to activate p38 (p38 activator activity) as well as p38 activity itself were greatly stimulated by hyperosmolar media in mouse lymphoma L5178Y cells, The activator activity has been purified by sequential chromatography. A 36-kDa polypeptide that was coeluted with the activity in the final chromatography step was identified as MAPK kinase 6 (MAPKK6) by protein microsequencing analysis, Monoclonal and polyclonal antibodies raised against recombinant MAPKK6 recognized specifically the 36-kDa MAPKK6 protein but did not cross react with MKK3 proteins. The use of these anti-MAPKK6 antibodies revealed that two major peaks of the p38 activator activity in the first chromatography step reside in the activated MAPKK6, Using a genetic screen in yeast, we isolated MKK3b, an alternatively spliced form of MKK3. Like MKK3 and MAPKK6, MKK3b was shown to be a specific activator for p38 and was activated by osmotic shock when expressed in COS7 cells, Immunoblotting analysis revealed that MAPKK6 is expressed highly in HeLa and KB cells and scarcely in PC12 cells, whereas MKK3 and MKK3b are expressed in all cells examined, Immunodepletion of MAPKK6 from the extracts obtained from L5178Y cells and KB cells exposed to hyperosmolar media depleted them of almost all of the p38 activator activity, indicating that MAPKK6 is a major activator for p38 in an osmosensing pathway in these cells. In addition, MAPKK6 was activated strongly by tumor necrosis factor-alpha, H2O2, and okadaic acid and moderately by cycloheximide in KB cells. Thus, there are at least three members of p38 activator, MKK3, MKK3b, and MAPKK6, and MAPKK6 may function as a major activator for p38 when expressed.	KYOTO UNIV,INST VIRUS RES,DEPT MOL BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOL BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Kyoto University; Kirin Brewery Company Limited; Nagoya University; Nagoya University			Moriguchi, Tetsuo/D-7061-2012	Moriguchi, Tetsuo/0000-0002-9598-4991				AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1996, J BIOL CHEM, V271, P28886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MEIER R, 1996, EUR J BIOCHEM, V236, P769; MERCURIO F, 1995, SCIENCE, V268, P286; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	36	149	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26981	26988		10.1074/jbc.271.43.26981	http://dx.doi.org/10.1074/jbc.271.43.26981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900184	hybrid			2022-12-27	WOS:A1996VP23300078
J	Narayanaswami, V; Wang, JJ; Kay, CM; Scraba, DG; Ryan, RO				Narayanaswami, V; Wang, JJ; Kay, CM; Scraba, DG; Ryan, RO			Disulfide bond engineering to monitor conformational opening of apolipophorin III during lipid binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL ACYLTRANSFERASE ACTIVATION; MANDUCA-SEXTA; INSECT LIPOPROTEIN; TRANSFER PARTICLE; STRUCTURAL MOTIF; APOLIPOPROTEIN-E; PHOSPHOLIPASE-C; STABILITY; DIACYLGLYCEROL	Apolipophorin III (apoLp-III) from the Sphinx moth, Manduca sexta, is an exchangeable, amphipathic apolipoprotein that alternately exists in water-soluble and lipid-bound forms. It is organized as a five-helix bundle in solution, which has been postulated to open at putative hinge domains to expose the hydrophobic interior, thereby facilitating interaction with the lipoprotein surface (Breiter, D. R., Kanost, M. R., Benning, M. M., Wesenberg, G., Law, J. H., Wells, M. A., Rayment, I., and Holden, H. M. (1991) Biochemistry 30, 603-608). To test this hypothesis, we engineered two cysteine residues in apoLp-III, which otherwise lacks cysteine, by site-directed mutagenesis at Asn-40 and Leu-90. Under oxidizing conditions the two cysteines spontaneously form a disulfide bond, which should tether the helix bundle and thereby prevent opening and concomitant lipid interaction. N40C/L90C apoLp-III was overexpressed in Escherichia coli and characterized for disulfide bond formation, secondary structure content, and stability, under both oxidizing and reducing conditions. Functional characterization was carried out by comparing the abilities of the oxidized and reduced protein to associate with modified lipoproteins in vitro, While the reduced form behaved like wild type apoLp-III, the oxidized form was unable to associate with lipoproteins. These results suggest that opening of the helix bundle is required for interaction with lipoproteins and provide a molecular basis for the dual existence of water-soluble and lipid-bound forms of apoLp-III, However, in phospholipid bilayer association assays, wild type, reduced, and oxidized N40C/L90C apoLp-III exhibited similar abilities to transform dimyristoylphosphatidylcholine multilamellar vesicles to disclike complexes, as judged by electron microscopy. These data emphasize that underlying differences exist in initiating or maintaining a stable interaction of apoLp-III with phospholipid disc complexes versus spherical lipoprotein surfaces.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 252,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 252,CANADA; UNIV ALBERTA,PROT ENGN NETWORK CTR EXCELLENCE,EDMONTON,AB T6G 252,CANADA	University of Alberta; University of Alberta; University of Alberta				Narayanaswami, Vasanthy/0000-0001-7088-4057				BAILEY CJ, 1982, BIOCHEM J, V203, P775, DOI 10.1042/bj2030775; BEENAKKERS AMT, 1985, PEPTIDES, V6, P437, DOI 10.1016/0196-9781(85)90411-5; BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; CARDAMONE M, 1995, BIOCHEMISTRY-US, V34, P5773, DOI 10.1021/bi00017a009; CHANG YY, 1995, J BIOL CHEM, V270, P7896, DOI 10.1074/jbc.270.14.7896; COLE KD, 1987, J BIOL CHEM, V262, P11794; DEPAUW M, 1995, BIOCHEMISTRY-US, V34, P10953, DOI 10.1021/bi00034a030; DUCHE D, 1994, J BIOL CHEM, V269, P6332; EDELSTEIN C, 1980, J BIOL CHEM, V255, P5747; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; EPAND RM, 1987, J BIOL CHEM, V262, P9389; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JIRGENSONS B, 1976, BIOCHIM BIOPHYS ACTA, V434, P58, DOI 10.1016/0005-2795(76)90035-0; KAWOOYA JK, 1986, J BIOL CHEM, V261, P3588; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; MATSUMURA M, 1989, NATURE, V342, P291, DOI 10.1038/342291a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; NARAYANASWAMI V, 1995, BIOCHEMISTRY-US, V34, P11822, DOI 10.1021/bi00037a021; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; RYAN RO, 1990, J BIOL CHEM, V265, P10551; RYAN RO, 1995, J LIPID RES, V36, P1066; RYAN RO, 1993, J BIOL CHEM, V268, P1525; RYAN RO, 1988, J BIOL CHEM, V263, P14140; SAMBROOK J, 1989, MOL CLONINB LAB MANU, V3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SINGH TKA, 1992, J BIOL CHEM, V267, P9275; SINGH TKA, 1994, J LIPID RES, V35, P1561; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 1996, BIOCHEMISTRY-US, V35, P5191, DOI 10.1021/bi952794d; SOULAGES JL, 1995, P NATL ACAD SCI USA, V92, P5650, DOI 10.1073/pnas.92.12.5650; SOULAGES JL, 1994, BIOCHEMISTRY-US, V33, P2356, DOI 10.1021/bi00175a002; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; UPADHYAYA M, 1995, ARCH INSECT BIOCHEM, V30, P211, DOI 10.1002/arch.940300210; VANDERHORST DJ, 1988, J BIOL CHEM, V263, P2027; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; WANG JJ, 1992, BIOCHEMISTRY-US, V31, P8706, DOI 10.1021/bi00152a004; WEERS PMM, 1994, BIOCHEMISTRY-US, V33, P3617, DOI 10.1021/bi00178a019; WEINBERG RB, 1985, J BIOL CHEM, V260, P4914; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WELLS MA, 1987, J BIOL CHEM, V262, P4172; WETZEL R, 1988, P NATL ACAD SCI USA, V85, P401, DOI 10.1073/pnas.85.2.401; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; WolffLong VL, 1995, J BIOL CHEM, V270, P31111, DOI 10.1074/jbc.270.52.31111; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P3942, DOI 10.1021/bi00066a014	50	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26855	26862		10.1074/jbc.271.43.26855	http://dx.doi.org/10.1074/jbc.271.43.26855			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900168	hybrid			2022-12-27	WOS:A1996VP23300062
J	Auguste, P; Robledo, O; Olivier, C; Froger, J; Praloran, V; PouplardBarthelaix, A; Gascan, H				Auguste, P; Robledo, O; Olivier, C; Froger, J; Praloran, V; PouplardBarthelaix, A; Gascan, H			Alanine substitution for Thr(268) and Asp(269) of soluble ciliary neurotrophic factor (CNTF) receptor alpha component defines a specific antagonist for the CNTF response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; HUMAN GROWTH-HORMONE; ONCOSTATIN-M; MOLECULAR-CLONING; SYMPATHETIC NEURONS; REACTIVE GLIOSIS; GP130; BINDING; EXPRESSION	Ciliary neurotrophic factor (CNTF) associates with an cu subunit (CNTFR alpha) of the receptor complex to initiate signal transduction by facilitating heterodimerization of the gp130 transducing protein and the leukemia inhibitory factor receptor (LIFR) beta. CNTFR alpha is anchored to the membrane by a glycosylphosphatidylinositol Linkage; however, a soluble form of the alpha subunit can still bind CNTF to recruit the signal transducing components of the receptor complex. In the present study me show that alanine substitution for residues Thr(268) and Asp(269) of the CNTFR alpha subunit results in a mutated receptor subunit (R3), which can bind CNTF with an affinity similar to that of the wild type CNTFR alpha but, when expressed as a soluble receptor subunit, lowers the binding of CNTF to its tripartite receptor. In addition, CNTFR3 alpha inhibits the proliferation of the TF1 hematopoietic cell line triggered by CNTF plus soluble wild type CNTFR alpha but not by IL-6 or oncostatin M. Similarly, CNTFR3 alpha specifically antagonizes the induction of gp130 and LIFR beta tyrosine phosphorylation observed in response to CNTF and wild type soluble CNTFR alpha in the HepG2 hepatoma cell line, as well as the subsequent events leading to haptoglobin synthesis. Positions 268 and 269 of CNTFR alpha appear to be critical for its interaction with gp130 and LIFR beta, whereby alanine substitution of the residues at these positions results in antagonism of the CNTF-induced response.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE; CHU LIMOGES,HEMATOL LAB,F-87025 LIMOGES,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Limoges			OLIVIER, Christophe/L-1598-2015	Auguste, Patrick/0000-0003-1485-0295				ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CHEREL M, 1995, BLOOD, V86, P2534; Chevalier S, 1996, J BIOL CHEM, V271, P14764, DOI 10.1074/jbc.271.25.14764; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUQUESNOY P, 1994, EMBO J, V13, P1386, DOI 10.1002/j.1460-2075.1994.tb06392.x; EDDELSTON M, 1993, NEUROSCIENCE, V54, P15; ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P465; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Robledo O, 1996, J NEUROCHEM, V66, P1391; SAGGIO I, 1995, EMBO J, V14, P3045, DOI 10.1002/j.1460-2075.1995.tb07307.x; SALVATI AL, 1995, J BIOL CHEM, V270, P12242, DOI 10.1074/jbc.270.20.12242; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YIN TG, 1993, J IMMUNOL, V151, P2555	50	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					26049	26056		10.1074/jbc.271.42.26049	http://dx.doi.org/10.1074/jbc.271.42.26049			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824245	hybrid			2022-12-27	WOS:A1996VN18000051
J	Prince, RJ; Sine, SM				Prince, RJ; Sine, SM			Molecular dissection of subunit interfaces in the acetylcholine receptor - Identification of residues that determine agonist selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BINDING; MOUSE; ACTIVATION; CONTRIBUTE; KINETICS; CELLS	Agonists and antagonists select between the alpha gamma and alpha delta binding sites of the fetal muscle acetylcholine receptor owing to different contributions by the gamma and delta subunits, To identify determinants of selectivity for agonists, we constructed a panel of gamma-delta subunit chimeras, co-expressed them with the alpha subunit in 293 HEK cells, and measured carbamylcholine binding affinity of intracellular complexes, Wild-type alpha delta complexes bind carbamyl choline about 30-fold more tightly than alpha gamma complexes. This degree of selectivity is similar to that of the resting state of the receptor determined by kinetic analysis of single-channel events, We identify a primary set of determinants of selectivity, Lys(gamma 34)/Ser(delta 36) and phe(gamma 172)/Ile(delta 178), and a secondary set, Glu(gamma 57)/Asp(delta 59) and Cys(gamma 115)/Tyr(delta 117). The contributions of all four determinants are subunit-dependent and are modified by interaction with one another, Coexpression of point mutant subunits with complementary wild-type subunits to form cell surface pentamers shows that Lys(gamma 34)/Ser(delta 36) and phe(gamma 172)/Ile(delta 178) contribute in a manner consistent with affecting selectivity of the resting state of the receptor, while Glu(gamma 57) appears to contribute to the affinity of the desensitized state. The four determinants either coincide with or are close to residues known to contribute to the acetylcholine binding site. These results suggest that a minimum of four loops in the gamma and delta subunits contribute to the agonist binding site.			Prince, RJ (corresponding author), MAYO CLIN & MAYO FDN,DEPT PHYSIOL & BIOPHYS,RECEPTOR BIOL LAB,ROCHESTER,MN 55905, USA.							BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23028; CHIARA D C, 1992, Biophysical Journal, V61, pA106; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; FIGL A, 1992, FEBS LETT, V308, P245, DOI 10.1016/0014-5793(92)81284-S; FU DX, 1994, J BIOL CHEM, V269, P26152; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; JACKSON MB, 1989, P NATL ACAD SCI USA, V86, P2199, DOI 10.1073/pnas.86.7.2199; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; SINE S, 1979, J BIOL CHEM, V254, P3315; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; SINE SM, 1995, NEURON, V15, P205, DOI 10.1016/0896-6273(95)90077-2; ZHANG YN, 1995, J PHYSIOL-LONDON, V486, P189, DOI 10.1113/jphysiol.1995.sp020802	16	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25770	25777		10.1074/jbc.271.42.25770	http://dx.doi.org/10.1074/jbc.271.42.25770			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824205				2022-12-27	WOS:A1996VN18000011
J	Sorensen, PG; Lutkenhaus, J; Young, K; Eveland, SS; Anderson, MS; Raetz, CRH				Sorensen, PG; Lutkenhaus, J; Young, K; Eveland, SS; Anderson, MS; Raetz, CRH			Regulation of UDP-3-0-[R-3-hydroxymyristoyl]-N-acetylglucosamine deacetylase in Escherichia coli - The second enzymatic step of lipid a biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; SALMONELLA-TYPHIMURIUM; ENDOTOXIN BIOSYNTHESIS; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; LIPOPOLYSACCHARIDE BIOSYNTHESIS; SIGNAL-TRANSDUCTION; DEFICIENT MUTANT; 1ST STEP; PROTEIN	The first enzyme of lipid A assembly in Escherichia coli is an acyltransferase that attaches an R-3-hydroxy-myristoyl moiety to UDP-GlcNAc at the GlcNAc 3-OH. This reaction is reversible and thermodynamically unfavorable. The subsequent deacetylation of the product, UDP-3-O-[R-3-hydroxymyristoyl]-GlcNAc, is therefore the first committed step of lipid A biosynthesis. We now demonstrate that inhibition of either the acyltransferase or the deacetylase in living cells results in a 5-10-fold increase in the specific activity of the deacetylase in extracts prepared from such cells. Five other enzymes of the lipid A pathway are not affected. The elevated specific activity of deacetylase observed in extracts of lipid A-depleted cells is not accompanied by a significant change in the K-m for the substrate, but is mainly an effect on V-max. Western blots demonstrate that more deacetylase protein is indeed made. However, deacetylase messenger RNA levels are not significantly altered. Inhibition of lipid A biosynthesis must either stimulate bit the translation of available mRNA or slow the turnover of pre-existing deacetylase. In contrast, inhibition of 3-deoxy-D-manno-octulosonic acid (Kdo) biosynthesis has no effect on deacetylase specific activity. The under-acylated lipid A-like disaccharide precursors that accumulate during inhibition of Kdo formation may be sufficient to exert normal feedback control.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV KANSAS,MED CTR,DEPT MICROBIOL,KANSAS CITY,KS 66103; MERCK RES LABS,DEPT ANTIBIOT DISCOVERY & DEV,RAHWAY,NJ 07065; MERCK RES LABS,DEPT ENZYMOL,RAHWAY,NJ 07065	Duke University; University of Kansas; University of Kansas Medical Center; Merck & Company; Merck & Company					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051310, T32GM007754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-51310, 5T32GM-07754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON MS, 1993, J BIOL CHEM, V268, P19858; ARMSTRONG KA, 1984, J MOL BIOL, V175, P331, DOI 10.1016/0022-2836(84)90352-8; Ausubel FM, 1989, CURRENT PROTOCOLS MO, V1-3; BEALL B, 1987, J BACTERIOL, V169, P5408, DOI 10.1128/jb.169.12.5408-5415.1987; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; GOLDMAN R, 1987, NATURE, V329, P162, DOI 10.1038/329162a0; GOLDMAN RC, 1988, J BACTERIOL, V170, P2185, DOI 10.1128/jb.170.5.2185-2191.1988; HAMMOND SM, 1987, NATURE, V327, P730, DOI 10.1038/327730a0; HAMPTON RY, 1992, METHOD ENZYMOL, V209, P466; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HELLINGWERF KJ, 1995, FEMS MICROBIOL REV, V16, P309; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; KELLY TM, 1993, J BIOL CHEM, V268, P19866; KENNEDY EP, 1987, ESCHERICHIA COLI SAL, V1, P672; KUMAGAI H, 1995, J BIOL CHEM, V270, P19107, DOI 10.1074/jbc.270.32.19107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIVE L, 1974, ANN NY ACAD SCI, V235, P109, DOI 10.1111/j.1749-6632.1974.tb43261.x; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; Miller J.H., 1972, EXPT MOL GENETICS; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MUTA T, 1991, J BIOL CHEM, V266, P6554; NIKAIDO H, 1987, ESCHERICHIA COLI SAL, V1, P7; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1981, J BIOL CHEM, V256, P690; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; Osborn MJ., 1979, BACTERIAL OUTER MEMB, P15; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RADIKA K, 1988, J BIOL CHEM, V263, P14859; Raetz C. R. H., 1996, ESCHERICHIA COLI SAL, V1, P1035; RAETZ CRH, 1993, J BACTERIOL, V175, P5745, DOI 10.1128/JB.175.18.5745-5753.1993; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAETZ CRH, 1981, J BIOL CHEM, V256, P2109; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1990, J BIOL CHEM, V265, P1285; RAY BL, 1987, J BIOL CHEM, V262, P1122; RICK PD, 1977, J BIOL CHEM, V252, P4904; RICK PD, 1987, ESCHERICHIA COLI SAL, V1, P648; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; Russo F D, 1993, Trends Microbiol, V1, P306, DOI 10.1016/0966-842X(93)90007-E; SATO R, 1993, P NATL ACAD SCI USA, V90, P9261, DOI 10.1073/pnas.90.20.9261; SATO R, 1994, J BIOL CHEM, V269, P17267; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SHIBUYA I, 1992, PROG LIPID RES, V31, P245, DOI 10.1016/0163-7827(92)90010-G; SPARROW CP, 1983, J BIOL CHEM, V258, P9963; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; WILLIAMSON JM, 1991, J BACTERIOL, V173, P3591, DOI 10.1128/jb.173.11.3591-3596.1991; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384	63	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25898	25905		10.1074/jbc.271.42.25898	http://dx.doi.org/10.1074/jbc.271.42.25898			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824222	hybrid			2022-12-27	WOS:A1996VN18000028
J	Calaycay, JR; Kelly, TM; MacNaul, KL; McCauley, ED; Qi, HB; Grant, SK; Griffin, PR; Klatt, T; Raju, SM; Nussler, AK; Shah, S; Weidner, JR; Williams, HR; Wolfe, GC; Geller, DA; Billiar, TR; MacCoss, M; Mumford, RA; Tocci, MJ; Schmidt, JA; Wong, KK; Hutchinson, NI				Calaycay, JR; Kelly, TM; MacNaul, KL; McCauley, ED; Qi, HB; Grant, SK; Griffin, PR; Klatt, T; Raju, SM; Nussler, AK; Shah, S; Weidner, JR; Williams, HR; Wolfe, GC; Geller, DA; Billiar, TR; MacCoss, M; Mumford, RA; Tocci, MJ; Schmidt, JA; Wong, KK; Hutchinson, NI			Expression and immunoaffinity purification of human inducible nitric-oxide synthase - Inhibition studies with 2-amino-5,6-dihydro-4H-1,3-thiazine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; L-ARGININE; STRUCTURAL-ANALYSIS; MASS-SPECTROMETRY; MAMMALIAN-CELLS; MACROPHAGE; BRAIN; CALMODULIN; CLONING; TETRAHYDROBIOPTERIN	Recombinant human inducible nitric-oxide synthase (rH-iNOS) was expressed in the baculovirus system and purified by a novel immunoaffinity column. rH-iNOS and its native counterpart from cytokine-stimulated primary hepatocytes exhibited similar molecular mass of 130 kDa on SDS-polyacrylamide gel electrophoresis, recognition by antipeptide antibodies, specific activities, and IC50 values for inhibitors. The active dimeric form exhibited a specific activity range of 114-260 nmol/min/mg at 37 degrees C and contained 1.15 +/- 0.04 mol of calmedulin/monomer. The enzyme exhibited a Soret lambda(max) at 396 nm with a shoulder at 460 nm and contained 0.28-0.64 mel of heme/monomer. Dithionite reduction under CO yielded an absorbance maximum at 446 nm, indicating a P-450-type heme. Imidazole induced a type II difference spectrum, reversible by L-Arg. 2-Amino-5,6-dihydro-4H-1,3-thiazine (ADT) was competitive versus L-Arg (K-i = 22.6 +/- 1.9 nM), reversed the type II difference spectrum induced by imidazole (K-d = 17.7 nM), and altered the GO-ferrous absorbance of rH-iNOS. L-Arg did not perturb the CO-ferrous adduct directly, but it partially reversed the ADT-induced absorbance shift, indicating that both bind similarly to the protein but interact differently with the heme.	MERCK RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065; MERCK RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065; MERCK RES LABS,DEPT MED CHEM,RAHWAY,NJ 07065; UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15261	Merck & Company; Merck & Company; Merck & Company; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Calaycay, JR (corresponding author), MERCK RES LABS,DEPT MOL DESIGN & DIVERS,MAIL DROP RY80-A23,POB 2000,RAHWAY,NJ 07065, USA.		Nussler, Andreas/H-3557-2019	Nussler, Andreas/0000-0002-6666-6791				ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; AITHAL HN, 1988, J IMMUNOL METHODS, V112, P63, DOI 10.1016/0022-1759(88)90034-8; ANAGLI J, 1995, EUR J BIOCHEM, V233, P701, DOI 10.1111/j.1432-1033.1995.701_3.x; ATKINS WM, 1990, BIOCHEMISTRY-US, V29, P1271, DOI 10.1021/bi00457a024; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHARLES IG, 1993, P NATL ACAD SCI USA, V90, P11419, DOI 10.1073/pnas.90.23.11419; CHENAIS B, 1991, J CHROMATOGR, V539, P433, DOI 10.1016/S0021-9673(01)83952-2; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; FELDMAN PL, 1993, J MED CHEM, V36, P491, DOI 10.1021/jm00056a009; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GRIFFIN PR, 1991, INT J MASS SPECTROM, V111, P131, DOI 10.1016/0168-1176(91)85052-N; GROSS SS, 1992, J BIOL CHEM, V267, P25722; JANSSENS SP, 1992, J BIOL CHEM, V267, P22694; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; KEWIN JF, 1995, J MED CHEM, V38, P4343; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; KLATT P, 1993, J BIOL CHEM, V268, P14781; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laubach VE, 1996, BIOCHEM BIOPH RES CO, V218, P802, DOI 10.1006/bbrc.1996.0143; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCLUCKEY SA, 1991, ANAL CHEM, V63, P375, DOI 10.1021/ac00004a015; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1995, MOL PHARMACOL, V47, P831; NAKANE M, 1995, BIOCHEM BIOPH RES CO, V206, P511, DOI 10.1006/bbrc.1995.1073; NARAYANAN K, 1994, J MED CHEM, V37, P885, DOI 10.1021/jm00033a004; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; OLKEN NM, 1992, J MED CHEM, V35, P1137, DOI 10.1021/jm00084a020; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P128; Rieske JS, 1967, METHOD ENZYMOL, V10, P488, DOI DOI 10.1016/0076-6879(67)10081-5; ROBERTSON CA, 1993, BIOCHEM BIOPH RES CO, V197, P523, DOI 10.1006/bbrc.1993.2510; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SALTZMAN BE, 1954, ANAL CHEM, V26, P1949, DOI 10.1021/ac60096a025; SCHOBERL A, 1958, LIEBIGS ANN CHEM, V614, P83; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WANG JL, 1993, J BIOL CHEM, V268, P22255; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V15, P3335, DOI 10.1093/nar/15.8.3335	54	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28212	28219		10.1074/jbc.271.45.28212	http://dx.doi.org/10.1074/jbc.271.45.28212			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910438	hybrid			2022-12-27	WOS:A1996VU03300038
J	Chen, GL; Wang, LJ; Liu, SJ; Chuang, C; Roche, TE				Chen, GL; Wang, LJ; Liu, SJ; Chuang, C; Roche, TE			Activated function of the pyruvate dehydrogenase phosphatase through Ca2+-facilitated binding to the inner lipoyl domain of the dihydrolipoyl acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-X COMPONENT; BOVINE KIDNEY; CALCIUM-IONS; TRANSACETYLASE COMPONENT; SACCHAROMYCES-CEREVISIAE; ADENINE-NUCLEOTIDES; ALPHA-KETOGLUTARATE; B PHOSPHATASE; COMPLEX; PURIFICATION	Micromolar Ca2+ facilitates similar to 10-fold enhancement of pyruvate dehydrogenase phosphatase (PDP) activity by aiding the association of PDP with the dihydrolipoyl acetyltransferase (E2) component, Connected by linker regions, E2 consists of two lipoyl domains, the NH2-lipoyl domain (L1) and the interior lipoyl domain (L2), and a pyruvate dehydrogenase component binding domain surrounding a 60-mer inner core. Using recombinant constructs of L1 or L2, E2-enhanced PDP activity was markedly decreased by L2 but not by L1, effectively competing with intact E2 in Ca2+-dependent binding of PDP (half-maximal reduction at 2.0 mu M L2 versus 6.7 mu M E2 subunit). Using L2 fused to glutathione S-transferase resulted in direct Ca2+-dependent binding of PDP to L2 (K-d similar to 1.7 mu M L2). Affinity-bound glutathione S-transferase-L2 was used to purify PDP to homogeneity by selective binding and elution by Ca2+ chelation. The large activity enhancement of PDP by E2 was eliminated by enzymatic removal of lipoates from E2 and restored by their enzymatic reintroduction. The critical role of the L2 lipoate is not in binding of PDP to E2, since PDP was still bound by delipoylated L2, and delipoylated L2 inhibited E2-enhanced PDP activity, although lipoylated L2 was more effective in each of these tests, Thus, pyruvate dehydrogenase complex activity is increased by enhanced availability of PDP to its E2-bound, phosphorylated pyruvate dehydrogenase substrate as a consequence of the Ca2+-facilitated interchange of PDP among the mobile L2 domains and an essential (undetermined) step engaging the L2 lipoate.	KANSAS STATE UNIV,DEPT BIOCHEM,MANHATTAN,KS 66506	Kansas State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R55DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DAMUNI Z, 1984, BIOCHEM BIOPH RES CO, V124, P95, DOI 10.1016/0006-291X(84)90921-5; DAMUNI Z, 1987, J BIOL CHEM, V262, P5133; DAVIS PF, 1977, BIOCHEM BIOPH RES CO, V75, P541, DOI 10.1016/0006-291X(77)91506-6; DENTON RM, 1972, BIOCHEM J, V128, P161, DOI 10.1042/bj1280161; DENTON RM, 1978, BIOCHEM J, V176, P894; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; Hansford R.G., 1980, CURR TOP BIOENERG, VVolume 10, P217, DOI 10.1016/B978-0-12-152510-1.50012-2; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLIS VB, 1981, BIOCHEMISTRY-US, V20, P2512, DOI 10.1021/bi00512a023; LAWLIS VB, 1981, BIOCHEMISTRY-US, V20, P2519, DOI 10.1021/bi00512a024; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LAWSON JE, 1991, BIOCHEMISTRY-US, V30, P2834, DOI 10.1021/bi00225a015; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LINN TC, 1969, P NATL ACAD SCI USA, V62, P227; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; Maeng CY, 1996, BIOCHEMISTRY-US, V35, P5879, DOI 10.1021/bi9600254; MCCORMACK JG, 1993, BIOCHEM SOC T, V21, P793, DOI 10.1042/bst0210793; MCCORMACK JG, 1979, BIOCHEM J, V180, P533, DOI 10.1042/bj1800533; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2; PRATT ML, 1982, EUR J BIOCHEM, V125, P349, DOI 10.1111/j.1432-1033.1982.tb06690.x; RAHMATULLAH M, 1986, J BIOL CHEM, V261, P6515; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1988, J BIOL CHEM, V263, P8106; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1996, ALPHA KETO ACID DEHY, P131; REED LJ, 1987, ADV PROT PHOSPHATASE, V4, P59; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; ROCHE TE, 1996, ALPHA KETO ACID DEHY, P33; SUZUKI K, 1963, J BIOL CHEM, V238, P4021; TEAGUE WM, 1982, BIOCHEMISTRY-US, V21, P5585, DOI 10.1021/bi00265a031; THOMAS AP, 1986, BIOCHEM J, V238, P83, DOI 10.1042/bj2380083; THOMAS AP, 1986, BIOCHEM J, V238, P93, DOI 10.1042/bj2380093; WAGENKNECHT T, 1991, J BIOL CHEM, V266, P24650; Yan JG, 1996, P NATL ACAD SCI USA, V93, P4953, DOI 10.1073/pnas.93.10.4953	43	35	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	1996	271	45					28064	28070		10.1074/jbc.271.45.28064	http://dx.doi.org/10.1074/jbc.271.45.28064			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VU033	8910418	hybrid			2022-12-27	WOS:A1996VU03300018
J	Brown, TJ; Shuford, WW; Wang, WC; Nadler, SG; Bailey, TS; Marquardt, H; Mittler, RS				Brown, TJ; Shuford, WW; Wang, WC; Nadler, SG; Bailey, TS; Marquardt, H; Mittler, RS			Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; O-LINKED OLIGOSACCHARIDES; FAS-INDUCED APOPTOSIS; PROTEIN KINASE-C; MAJOR SIALOGLYCOPROTEIN; AFFINITY-CHROMATOGRAPHY; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEINS; SIALOPHORIN CD43	The monoclonal antibody (mAb) J393 induces apoptosis in Jurkat T-cells, NH2-terminal amino acid sequence analysis identified the 140-kDa surface antigen for mAb J393 as CD43/leukosialin, the major sialoglycoprotein of leukocytes, While Jurkat cells co-expressed two discrete cell-surface isoforms of CD43, recognized by mAb J393 and mAb G10-2, respectively, only J393/CD43 signaled apoptosis. J393/CD43 was found to be hyposialylated, bearing predominantly O-linked monosaccharide glycans, whereas G10-2/CD43 bore complex sialylated tetra- and hexasaccharide chains, Treatment with soluble, bivalent mAb J393 killed 25-50% of the cell population, while concomitant engagement of either the CD3 . TcR complex or the integrins CD18 and CD29 significantly potentiated this effect, Treatment of Jurkat cells with mAb J393 induced tyrosine phosphorylation of specific protein substrates that underwent hyperphosphorylation upon antigen receptor costimulation. Tyrosine kinase inhibition by herbimycin A diminished J393/CD43-mediated apoptosis, whereas inhibition of phosphotyrosine phosphatase activity by bis(maltolato) oxovanadium-IV enhanced cell death, Signal transduction through tyrosine kinase activation may lead to altered gene expression, as J393/CD43 ligation prompted decreases ill the nuclear Localization of the transcriptional regulatory protein NF-kappa B and proteins binding the interferon-inducible regulatory element, Since peripheral blood T-lymphocytes express cryptic epitopes for mAb J393, these findings demonstrate the existence of a tightly regulated CD43-mediated pathway for inducing apoptosis in human T-cell lineages.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb								ALVARADO M, 1995, EUR J IMMUNOL, V25, P1051, DOI 10.1002/eji.1830250429; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; AXELSSON B, 1988, J IMMUNOL, V141, P2912; AXELSSON B, 1989, SCAND J IMMUNOL, V30, P539, DOI 10.1111/j.1365-3083.1989.tb02461.x; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BAZIL V, 1995, BLOOD, V86, P502, DOI 10.1182/blood.V86.2.502.bloodjournal862502; BERGER EG, 1994, TRANSFUS CLIN BIOL, V1, P103, DOI 10.1016/S1246-7820(94)80004-9; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BROWN WRA, 1981, NATURE, V289, P456, DOI 10.1038/289456a0; CARLSSON SR, 1986, J BIOL CHEM, V261, P12878; CHATILA TA, 1988, J IMMUNOL, V140, P4308; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; CYSTER J, 1990, EUR J IMMUNOL, V20, P875, DOI 10.1002/eji.1830200424; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; DAKOUR J, 1987, ANAL BIOCHEM, V161, P140, DOI 10.1016/0003-2697(87)90663-4; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DINGHAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ELLIES LG, 1994, GLYCOBIOLOGY, V4, P885, DOI 10.1093/glycob/4.6.885; FOX RI, 1983, J IMMUNOL, V131, P762; FUKUDA M, 1986, MED BIOL, V64, P335; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hayden M S, 1994, Ther Immunol, V1, P3; HernandezCaselles T, 1996, J IMMUNOL, V156, P3668; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; INOUE M, 1994, CANCER RES, V54, P85; JONES AT, 1994, J IMMUNOL, V153, P3426; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KENNEY D, 1986, BLOOD, V68, P1329; KOJIMA N, 1994, EXP CELL RES, V214, P537, DOI 10.1006/excr.1994.1291; LEE N, 1990, J BIOL CHEM, V265, P20476; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MANJUNATH N, 1995, NATURE, V377, P535, DOI 10.1038/377535a0; MARESH GA, 1994, ARCH BIOCHEM BIOPHYS, V311, P95, DOI 10.1006/abbi.1994.1213; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MITTLER RS, 1983, J EXP MED, V158, P99, DOI 10.1084/jem.158.1.99; NAKADA H, 1991, BIOCHEM BIOPH RES CO, V179, P762, DOI 10.1016/0006-291X(91)91882-D; OHLSON S, 1988, ANAL BIOCHEM, V169, P204, DOI 10.1016/0003-2697(88)90275-8; PALLANT A, 1989, P NATL ACAD SCI USA, V86, P1328, DOI 10.1073/pnas.86.4.1328; PARKMAN R, 1981, LANCET, V2, P1387; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PILLER V, 1989, J BIOL CHEM, V264, P18824; PILLER V, 1990, J BIOL CHEM, V265, P9264; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROSENSTEIN Y, 1991, NATURE, V354, P233, DOI 10.1038/354233a0; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SAITOH O, 1991, BLOOD, V77, P1491; SCHIEVEN GL, 1995, J BIOL CHEM, V270, P20824, DOI 10.1074/jbc.270.35.20824; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SHELLEY CS, 1990, BIOCHEM J, V270, P569, DOI 10.1042/bj2700569; SILVERMAN LB, 1989, J IMMUNOL, V142, P4194; Siminovitch K A, 1993, Immunodeficiency, V4, P99; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPERLING AI, 1995, J EXP MED, V182, P139, DOI 10.1084/jem.182.1.139; SPORTSMAN JR, 1985, J IMMUNOL, V135, P158; TAKAHASHI T, 1994, INT IMMUNOL, V6, P1567, DOI 10.1093/intimm/6.10.1567; TEPPER MA, 1995, J IMMUNOL, V155, P2427; THOMAS ML, 1995, IMMUNOLOGY, V7, P279; THUNHER M, 1993, J CLIN INVEST, V91, P2103; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WANG WC, 1988, ANAL BIOCHEM, V175, P390, DOI 10.1016/0003-2697(88)90562-3; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG RCK, 1990, J IMMUNOL, V144, P1455	72	52	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27686	27695		10.1074/jbc.271.44.27686	http://dx.doi.org/10.1074/jbc.271.44.27686			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910360	hybrid			2022-12-27	WOS:A1996VQ67900078
J	Matsumoto, M; Nomura, T; Momose, K; Ikeda, Y; Kondou, Y; Akiho, H; Togami, J; Kimura, Y; Okada, M; Yamaguchi, T				Matsumoto, M; Nomura, T; Momose, K; Ikeda, Y; Kondou, Y; Akiho, H; Togami, J; Kimura, Y; Okada, M; Yamaguchi, T			Inactivation of a novel neuropeptide Y peptide YY receptor gene in primate species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE D4 RECEPTOR; FUNCTIONAL EXPRESSION; PANCREATIC-POLYPEPTIDE; NONSENSE MUTATIONS; CLONING; SUBTYPES	Neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP) belong to a family of structurally related peptides which have numerous functions in both neural and endocrine signaling, By homology screening, we cloned a novel gene sharing the highest homology with the NPY Y1 receptor gene from humans, rabbits, and several other species. This novel gene of rabbit encodes a functional NPY/PYY receptor, designated Y2b, which prefers NPY13-36 rather than [Leu(31,)Pro(34)]NPY despite its higher identity with the Y1 receptor. Although, at low levels, mRNA was detected in the tissues and brain regions, including hypothalamus. Further, sequence data revealed that this gene is the orthologue of the recently cloned mouse novel NPY receptor, Y5. However, our study demonstrates that the receptor function of this gene has been inactivated in primates by a frameshift mutation occurring early in primate evolution. This novel NPY receptor represents the first neuro transmitter receptor identified that has universally lost its receptor function in primate species. Interestingly, despite its inactivation in humans, the transcripts were abundantly detected in the heart and skeletal muscle, suggesting a novel function of the human gene.	YAMANOUCHI PHARMACEUT CO LTD,INST DRUG DISCOVERY RES,MOL MED RES LAB,TSUKUBA,IBARAKI 305,JAPAN; YAMANOUCHI PHARMACEUT CO LTD,INST DRUG DISCOVERY RES,CLIN PHARMACOL RES LAB,TSUKUBA,IBARAKI 305,JAPAN	Astellas Pharmaceuticals; Astellas Pharmaceuticals	Matsumoto, M (corresponding author), YAMANOUCHI PHARMACEUT CO LTD,INST DRUG DISCOVERY RES,NEUROSCI & GASTROINTESTINAL RES LAB,TSUKUBA,IBARAKI 305,JAPAN.		Matsumoto, Mitsuyuki/G-3207-2012	Matsumoto, Mitsuyuki/0000-0002-1172-2354				BARD JA, 1995, J BIOL CHEM, V270, P26762, DOI 10.1074/jbc.270.45.26762; BASERGA SJ, 1988, P NATL ACAD SCI USA, V85, P2056, DOI 10.1073/pnas.85.7.2056; GEHLERT DR, 1994, LIFE SCI, V55, P551, DOI 10.1016/0024-3205(94)00481-1; GERALD C, 1995, J BIOL CHEM, V270, P26758, DOI 10.1074/jbc.270.45.26758; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; HAAG F, 1994, J MOL BIOL, V243, P537, DOI 10.1006/jmbi.1994.1680; HERZOG H, 1992, P NATL ACAD SCI USA, V89, P5794, DOI 10.1073/pnas.89.13.5794; Hidaka K, 1996, BRIT J PHARMACOL, V117, P1625, DOI 10.1111/j.1476-5381.1996.tb15332.x; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LUNDELL I, 1995, J BIOL CHEM, V270, P29123, DOI 10.1074/jbc.270.49.29123; Matsumoto M, 1996, J NEUROCHEM, V66, P915; MATSUMOTO M, 1995, BIOCHEM BIOPH RES CO, V207, P467, DOI 10.1006/bbrc.1995.1211; MATSUMOTO M, 1995, MOL BRAIN RES, V29, P157, DOI 10.1016/0169-328X(94)00245-A; MICHEL MC, 1991, TRENDS PHARMACOL SCI, V12, P389, DOI 10.1016/0165-6147(91)90610-5; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; ROSE PM, 1995, J BIOL CHEM, V270, P22661, DOI 10.1074/jbc.270.39.22661; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WAHLESTEDT C, 1993, ANN REV PHARM TOXICO, V32, P309; Weinberg DH, 1996, J BIOL CHEM, V271, P16435, DOI 10.1074/jbc.271.28.16435; WU XW, 1992, J MOL EVOL, V34, P78, DOI 10.1007/BF00163854	20	127	133	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27217	27220		10.1074/jbc.271.44.27217	http://dx.doi.org/10.1074/jbc.271.44.27217			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910290	hybrid			2022-12-27	WOS:A1996VQ67900008
J	Sakai, M; Miyazaki, A; Hakamata, H; Kodama, T; Suzuki, H; Kobori, S; Shichiri, M; Horiuchi, S				Sakai, M; Miyazaki, A; Hakamata, H; Kodama, T; Suzuki, H; Kobori, S; Shichiri, M; Horiuchi, S			The scavenger receptor serves as a route for internalization of lysophosphatidylcholine in oxidized low density lipoprotein-induced macrophage proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MOUSE PERITONEAL-MACROPHAGES; ENDOTHELIAL-CELLS; CHOLESTEROL ACYLTRANSFERASE; ATHEROSCLEROTIC LESIONS; MONOCYTE MACROPHAGES; MEDIATED RECOGNITION; CULTURED HUMAN; GROWTH-FACTOR; DNA-SYNTHESIS	We have recently demonstrated that the growth of murine macrophages is induced by oxidized low density lipoprotein (OY-LDL) and that lysophosphatidylcholine (lyse-PC), a major phospholipid component of Ox-LDL, plays an essential role in its mitogenic effect, The present study was undertaken to further characterize the role of the macrophage scavenger receptor (MSR) in Ox-LDL-induced macrophage growth. The growth-stimulating effect of Ox-LDL on murine resident peritoneal macrophages was inhibited by maleylated bovine serum albumin (maleyl-BSA), a non-lipoprotein ligand for MSR but a poor carrier of lyse-PC, while maleyl-BSA itself failed to induce macrophage growth even in the presence of lyso-PC. Moreover, it competitively inhibited the endocytic uptake of I-125-Ox-LDL and the specific uptake of lyse-PC by MSR, whereas nonspecific lyse-PC transfer to cells was not affected. Furthermore, the Ox-LDL-induced cell growth of peritoneal macrophages obtained from MSR knockout mice was significantly weaker than that of macrophages obtained from their wild-type Littermates. Our results suggest that the MSR is an important and efficient internalization pathway for lyse-PC in Ox-LDL-induced macrophage growth.	KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,KUMAMOTO 860,JAPAN; UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	Kumamoto University; University of Tokyo								ACTON SL, 1994, J BIOL CHEM, V269, P21003; ALBERS JJ, 1984, ARTERIOSCLEROSIS, V4, P49, DOI 10.1161/01.ATV.4.1.49; ARAI H, 1989, BIOCHEM BIOPH RES CO, V159, P1375, DOI 10.1016/0006-291X(89)92262-6; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; DERIJKE YB, 1994, J BIOL CHEM, V269, P824; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; HABERLAND ME, 1985, P NATL ACAD SCI USA, V82, P2693, DOI 10.1073/pnas.82.9.2693; HAKAMATA H, 1995, FEBS LETT, V363, P29, DOI 10.1016/0014-5793(95)00273-C; HAMILTON JA, 1983, J CELL PHYSIOL, V115, P67, DOI 10.1002/jcp.1041150111; HAMILTON JA, 1981, J CELL PHYSIOL, V106, P445, DOI 10.1002/jcp.1041060314; HARA H, 1991, J BIOL CHEM, V266, P3080; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUGIYAMA K, 1993, CIRC RES, V73, P335, DOI 10.1161/01.RES.73.2.335; KUGIYAMA K, 1990, NATURE, V344, P160, DOI 10.1038/344160a0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; KUME N, 1994, J CLIN INVEST, V93, P907, DOI 10.1172/JCI117047; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; KURIHARA Y, 1992, CIRCULATION, V86, P471; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MELKKO J, 1994, J EXP MED, V179, P405, DOI 10.1084/jem.179.2.405; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MURAKAMI M, 1987, J BIOCHEM-TOKYO, V101, P729, DOI 10.1093/jb/101.3.729; MURATA Y, 1988, BIOCHIM BIOPHYS ACTA, V972, P17, DOI 10.1016/S0005-2728(88)80087-2; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2085; RESINK TJ, 1992, ARTERIOSCLER THROMB, V12, P278, DOI 10.1161/01.ATV.12.3.278; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAI M, 1994, J BIOL CHEM, V269, P31430; SAKAI M, 1992, FEBS LETT, V314, P199, DOI 10.1016/0014-5793(92)80974-L; Sakai M, 1996, ARTERIOSCL THROM VAS, V16, P600, DOI 10.1161/01.ATV.16.4.600; SAMBRANO GR, 1995, P NATL ACAD SCI USA, V92, P1396, DOI 10.1073/pnas.92.5.1396; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SHINOHARA M, 1992, J BIOL CHEM, V267, P1603; SPAGNOLI LG, 1991, ATHEROSCLEROSIS, V88, P87, DOI 10.1016/0021-9150(91)90260-A; STANTON LW, 1992, J BIOL CHEM, V267, P22446; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; TAKATA K, 1989, BIOCHIM BIOPHYS ACTA, V984, P273, DOI 10.1016/0005-2736(89)90293-9; VANBERKEL TJC, 1991, J BIOL CHEM, V266, P2282; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YUI S, 1986, J IMMUNOL, V136, P1334; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331	46	89	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	1996	271	44					27346	27352		10.1074/jbc.271.44.27346	http://dx.doi.org/10.1074/jbc.271.44.27346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VQ679	8910311	hybrid			2022-12-27	WOS:A1996VQ67900029
J	Greene, JAL; Leytze, GM; Emswiler, J; Peach, R; Bajorath, J; Cosand, W; Linsley, PS				Greene, JAL; Leytze, GM; Emswiler, J; Peach, R; Bajorath, J; Cosand, W; Linsley, PS			Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE-PLASMON RESONANCE; BINDING STOICHIOMETRY; LYMPHOCYTES-T; CD28 RECEPTOR; CTLA-4; ACTIVATION; ANTIGEN; B7-1; IMMOBILIZATION; SPECIFICITY	T lymphocyte receptors CD28 and CTLA-4 bind costimulatory molecules CD80 (B7-1) and CD86 (B7-2) on antigen presenting cells and regulate T cell activation, While distinct functional roles have been ascribed to each of these molecules, little is known about how they interact, To better characterize these interactions, we have used surface plasmon resonance to perform equilibrium and kinetic binding analyses of extracellular fragments of CD28/CTLA-4/CD80/CD86. We show that CTLA-4 and CD28 binding are both characterized by rapid kinetic on-rates and rapid dissociation rates, Native disulfide-linked homodimers of CD28 and CTLA-4 bound with two kinetically distinct binding sites, one of high avidity and slow dissociation and one of low avidity and more rapid dissociation, Monomeric CTLA-4 bound only with low affinity and rapid dissociation, Therefore, covalent dimerization of CTLA-4 is required for its high avidity binding. Oligomerization of CD80/CD86 is also required for high avidity CTLA-4 binding since CTLA-4 bound with low avidity to monomeric CD86, This contrasts with the ability of CD80/CD86 on antigen presenting cells to bind CTLA4Ig with high avidity and predicts their organization as oligomers or clusters that permit multivalent binding. Thus, covalent receptor dimerization and ligand oligomerization are two key features of the CD28/CTLA-4/CD80/CD86 receptor System that control ligand binding and may regulate signal transduction by controlling the duration of receptor occupancy.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb			Bajorath, Jürgen/F-7493-2014					ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; GRIBBEN JG, 1995, P NATL ACAD SCI USA, V92, P811, DOI 10.1073/pnas.92.3.811; GUINAN EC, 1994, BLOOD, V84, P3261; Hollenbaugh D, 1995, J IMMUNOL METHODS, V188, P1, DOI 10.1016/0022-1759(95)00194-8; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KHILKO SN, 1993, J BIOL CHEM, V268, P15425; KRUMMEL MF, 1995, J EXP MED, V182, P459, DOI 10.1084/jem.182.2.459; KUCHROO VK, 1995, CELL, V80, P1; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1995, J BIOL CHEM, V270, P15417, DOI 10.1074/jbc.270.25.15417; LINSLEY PS, 1995, RES IMMUNOL, V146, P130, DOI 10.1016/0923-2494(96)80246-X; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1995, J EXP MED, V182, P289, DOI 10.1084/jem.182.2.289; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, J EXP MED, V176, P1595, DOI 10.1084/jem.176.6.1595; Morton PA, 1996, J IMMUNOL, V156, P1047; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; PEACH RJ, 1994, J EXP MED, V180, P2049, DOI 10.1084/jem.180.6.2049; Schuck P, 1996, BIOPHYS J, V70, P1230, DOI 10.1016/S0006-3495(96)79681-9; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SYMINGTON FW, 1993, J IMMUNOL, V150, P1286; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985	31	175	195	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26762	26771		10.1074/jbc.271.43.26762	http://dx.doi.org/10.1074/jbc.271.43.26762			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900156	hybrid			2022-12-27	WOS:A1996VP23300050
J	Grimaldi, ME; Adamo, HP; Rega, AF; Penniston, JT				Grimaldi, ME; Adamo, HP; Rega, AF; Penniston, JT			Deletion of amino acid residues 18-75 inactivates the plasma membrane Ca2+ pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; ERYTHROCYTE-MEMBRANE; PROTEOLYSIS; MUTANTS; ATPASE; CELLS; SITE; CA2+-ATPASE; EXPRESSION; SEQUENCE	A mutant of the plasma membrane Ca2+ pump hPMCA4b(d18-75)(ct120) containing a deletion of the N-terminal amino acid residues 18-75 and lacking the C-terminal 120 amino acid residues was expressed in COS-1 cells, The deletion in the N-terminal region did not significantly affect the level of expression of the Ca2+ pump. Tryptic digestion of the hPMCA4b(d18-75)(ct120) mutant resulted in the appearance of the same fragments obtained by proteolysis of the hPMCA4b(ct120) enzyme, suggesting that deletion of residues 18-75 neither impeded the insertion in the membrane nor extensively affected the folding of the mutant protein. The functional competence of the hPMCA4b(d18-75)(ct120) enzyme was examined by measuring the Ca2+ transport and the Ca2+ ATPase activity of COS-1 cell microsomes expressing the mutant protein. Both tests proved the mutant to be inactive, Under conditions in which hPMCA4b(ct120) becomes phosphorylated, hPMCA4b(d18-75)(ct120) was incapable of reacting with ATP and Ca2+ to form the phosphoenzyme. Taken together these results suggest that the segment of amino acids 18-75 is essential for the activity of the plasma membrane Ca2+ pump.	UNIV BUENOS AIRES,FAC FARM & BIOQUIM,INST QUIM & FISICOQUIM BIOL,RA-1113 BUENOS AIRES,DF,ARGENTINA; MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	University of Buenos Aires; Mayo Clinic			Adamo, Hugo Pedro/ABB-8338-2021	Adamo, Hugo Pedro/0000-0002-1712-8049	NIGMS NIH HHS [GM28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ADAMO HP, 1995, J BIOL CHEM, V270, P30111; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FILOTEO AG, 1987, J BIOL CHEM, V262, P6526; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HEIM R, 1992, J BIOL CHEM, V267, P24476; JAMES P, 1988, J BIOL CHEM, V263, P2905; JAMES P, 1987, BIOCHEM BIOPH RES CO, V149, P7, DOI 10.1016/0006-291X(87)91597-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTERBACHER S, 1983, EXPERIENTIA, V39, P311, DOI 10.1007/BF01955322; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; SARKADI B, 1986, J BIOL CHEM, V261, P9552; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	18	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26995	26997		10.1074/jbc.271.43.26995	http://dx.doi.org/10.1074/jbc.271.43.26995			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900186	hybrid			2022-12-27	WOS:A1996VP23300080
J	Jensen, PH; Jensen, TG; Laug, WE; Hager, H; Gliemann, J; Pepinsky, B				Jensen, PH; Jensen, TG; Laug, WE; Hager, H; Gliemann, J; Pepinsky, B			The Exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLACENTA; BIOLOGICAL FUNCTION; CROSS-LINKING; LIPOCORTIN-I; TYPE-2; CELLS; VITRONECTIN; OVALBUMIN; RECEPTOR; TRANSGLUTAMINASE	We have used a combination of biochemical and immunological methods to probe for proteins that interact with the cytoplasmic form of plasminogen activator inhibitor 2 (PAI-2) and to identify the structure in PAI-2 that mediates the binding, By affinity chromatography on immobilized PAI-2, we purified a collection of PAI-2-binding proteins. These proteins bound I-125-labeled PAI-2 in vitro (IC50, similar to 10-100 nM) in a calcium-imdependent reaction that did not abrogate the proteinase inhibitory function of PAI-2. Annexin I was identified among the eluted proteins, and purified annexins I, II, IV, and V, but not III and VI, possessed I-125-labeled PAI-2 binding activity, Immune precipitation by anti-PAI-2 monoclonal and polyclonal antibodies of metabolically labeled melanoma cells treated with a cleavable cross-linker prior to analysis revealed three prominent proteins with apparent masses of 100, 70, and 50 kDa. We localized the protein binding domain in PAI-2 between amino acid residues 66 and 98, as determined by using a PAI-2 mutant lacking this domain and a synthetic peptide spanning this region, This region of PAI-2 corresponds to exon 3 of the gene sequence thought to be critical for PAI-2 functions.	AARHUS UNIV,DEPT HUMAN GENET,DK-8000 AARHUS C,DENMARK; CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,LOS ANGELES,CA 90027; BIOGEN INC,CAMBRIDGE,MA 02142	Aarhus University; Children's Hospital Los Angeles; Biogen	Jensen, PH (corresponding author), AARHUS UNIV,DEPT MED BIOCHEM,DK-8000 AARHUS C,DENMARK.			Jensen, Poul Henning/0000-0002-4439-9020				ANTALIS TM, P NATL ACAD SCI USA, V85, P985; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; CELIS JE, 1994, ELECTROPHORESIS, V15, P1349, DOI 10.1002/elps.11501501208; COUGHLIN P, 1993, P NATL ACAD SCI USA, V90, P9417, DOI 10.1073/pnas.90.20.9417; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894, DOI 10.1074/jbc.270.46.27894; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JENSEN PH, 1994, J BIOL CHEM, V269, P15394; JENSEN PH, 1994, BRIT J CANCER, V70, P834, DOI 10.1038/bjc.1994.407; JENSEN PH, 1993, EUR J BIOCHEM, V214, P141, DOI 10.1111/j.1432-1033.1993.tb17906.x; JENSEN PH, 1990, CELL REGUL, V1, P1043, DOI 10.1091/mbc.1.13.1043; JENSEN PH, 1989, BIOCHIM BIOPHYS ACTA, V986, P135, DOI 10.1016/0005-2736(89)90282-4; JENSEN PJ, 1995, EXP CELL RES, V217, P65, DOI 10.1006/excr.1995.1064; JOHNSON MD, 1990, HUM PATHOL, V21, P182, DOI 10.1016/0046-8177(90)90127-Q; KEIJER J, 1991, BLOOD, V78, P1254; KRUITHOF EKO, 1995, BLOOD, V86, P4007, DOI 10.1182/blood.V86.11.4007.bloodjournal86114007; KUHN LA, 1990, P NATL ACAD SCI USA, V87, P8506, DOI 10.1073/pnas.87.21.8506; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; PEPINSKY RB, 1990, FEBS LETT, V261, P247, DOI 10.1016/0014-5793(90)80564-Y; PRATT CW, 1992, J BIOL CHEM, V267, P8789; RADTKE KP, 1990, BIOL CHEM H-S, V371, P1119, DOI 10.1515/bchm3.1990.371.2.1119; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; REMOLDODONNELL E, 1993, FEBS LETT, V315, P105, DOI 10.1016/0014-5793(93)81143-N; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; STONE SR, 1994, BIOCHEMISTRY-US, V33, P7731, DOI 10.1021/bi00190a028; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; VARTICOVSKI L, 1988, BIOCHEMISTRY-US, V27, P3682, DOI 10.1021/bi00410a024; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; WUN TC, 1987, J BIOL CHEM, V262, P3646; YE RD, 1987, J BIOL CHEM, V262, P3718; YE RD, 1989, J BIOL CHEM, V264, P5495; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	36	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26892	26899		10.1074/jbc.271.43.26892	http://dx.doi.org/10.1074/jbc.271.43.26892			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900173	hybrid			2022-12-27	WOS:A1996VP23300067
J	Kamatkar, S; Radha, V; Nambirajan, S; Reddy, RS; Swarup, G				Kamatkar, S; Radha, V; Nambirajan, S; Reddy, RS; Swarup, G			Two splice variants of a tyrosine phosphatase differ in substrate specificity, DNA binding, and subcellular location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE PHOSPHATASES; ENHANCED EXPRESSION; TERMINAL SEQUENCE; PROTEIN-KINASE; HOMOLOGY; CLONING; CDNA; LOCALIZATION; PTP-1B; LIVER	Four different forms of a non-receptor type protein-tyrosine phosphatase are generated by alternative splicing; two of these forms (PTP-S2 and PTP-S4) are major forms, which are expressed in rat as well as human cells. Here we report that PTP-S2 binds to nonspecific DNA in vitro and localizes in the nucleus upon transfection in HeLa cells. PTP-S4 does not bind to nonspecific DNA and shows perinuclear and cytoplasmic localization. Removal of the C-terminal 34 amino acids of PTP-S4 gives rise to a truncated protein, which binds to nonspecific DNA and localizes to the nucleus, PTP-S4, but not PTP-S2, interacts strongly with the isolated nuclear matrix, The two forms of this tyrosine phosphatase show different substrate specificity in vitro, a feature novel to splice variants of tyrosine phosphatases, Mitogenic stimulation induces mRNAs for PTP-S2 as well as for PTP-S4 in the G(1) phase during liver regeneration, These results suggest that alternative splicing gives rise to two protein-tyrosine phosphatases with distinct substrate specificities and subcellular locations, The 34 amino acids at the C terminus of PTP-S4 play a critical role in determining substrate specificity, subcellular location, and interaction with nuclear matrix and DNA.	CTR CELLULAR & MOL BIOL,HYDERABAD 500007,ANDHRA PRADESH,INDIA	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)				Swarup, Ghanshyam/0000-0002-8098-0509				BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P1203; COOL DE, 1989, P NATL ACAD SCI USA, V86, P5257, DOI 10.1073/pnas.86.14.5257; DIAMOND RH, 1994, MOL CELL BIOL, V14, P3752, DOI 10.1128/MCB.14.6.3752; FAURE R, 1993, GLIA, V9, P311, DOI 10.1002/glia.440090409; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; LORENZEN JA, 1995, J CELL BIOL, V131, P631, DOI 10.1083/jcb.131.3.631; LOYER P, 1994, J BIOL CHEM, V269, P2491; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; NAMBIRAJAN S, 1995, J BIOSCIENCE, V20, P461, DOI 10.1007/BF02703529; PIENTA KJ, 1989, CANCER RES, V49, P2525; RADHA V, 1994, BIOCHEM J, V299, P41, DOI 10.1042/bj2990041; RADHA V, 1993, BIOCHEMISTRY-US, V32, P2194, DOI 10.1021/bi00060a010; Radha V, 1996, EUR J BIOCHEM, V236, P352, DOI 10.1111/j.1432-1033.1996.00352.x; RAJENDRAKUMAR GV, 1993, BIOCHIM BIOPHYS ACTA, V1216, P205, DOI 10.1016/0167-4781(93)90146-5; Reddy RS, 1995, DNA CELL BIOL, V14, P1007, DOI 10.1089/dna.1995.14.1007; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAITO H, 1991, CELL GROWTH DIFFER, V2, P59; SHIFRIN VI, 1993, J BIOL CHEM, V268, P25376; STONE RL, 1994, J BIOL CHEM, V269, P31323; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; SWARUP G, 1991, FEBS LETT, V280, P65, DOI 10.1016/0014-5793(91)80205-H; SWARUP G, 1992, CURR SCI INDIA, V62, P462; SWARUP G, 1989, J BIOL CHEM, V264, P7801; TILLMANN U, 1994, MOL CELL BIOL, V14, P3030, DOI 10.1128/MCB.14.5.3030; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YANG Q, 1993, J BIOL CHEM, V268, P6622; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	38	50	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26755	26761		10.1074/jbc.271.43.26755	http://dx.doi.org/10.1074/jbc.271.43.26755			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900155	hybrid			2022-12-27	WOS:A1996VP23300049
J	SchulzeMuth, P; Irmler, S; Schroder, G; Schroder, J				SchulzeMuth, P; Irmler, S; Schroder, G; Schroder, J			Novel type of receptor-like protein kinase from a higher plant (Catharanthus roseus) - cDNA, gene intramolecular autophosphorylation, and identification of a threonine important for auto- and substrate phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; ARABIDOPSIS-THALIANA; BRASSICA-OLERACEA; DISEASE RESISTANCE; MOLECULAR ANALYSIS; LOCUS; EXPRESSION; SENSITIVITY; TOMATO; SUPERFAMILY	We characterize CrRLK1, a novel type of receptor-like kinase (RLK), from the plant Catharanthus roseus (Madagascar periwinkle). The protein (90.2 kDa) deduced from the complete genomic and cDNA sequences is a RLK by predicting a N-terminal signal peptide, a large extracytoplasmic domain, a membrane-spanning hydrophobic region followed by a transfer-stop signal, and a C-terminal cytoplasmic protein kinase with all 11 conserved subdomains, It is a novel RLK type because the predicted extracytoplasmic region shares no similarity with other RLKs, The autophosphorylation was investigated with affinity-purified proteins expressed in Escherichia coli, The activity was higher with Mn2+ than with Mg2+ and achieved half-maximal rates at 2-2.5 mu M ATP. The phosphorylation was predominantly on Thr, less on Ser, and not on Tyr, In contrast to other plant RLK, the kinase used an intra- rather than an intermolecular phosphorylation mechanism, After protein cleavage with formic acid, most of the radioactivity Tvas in a 14.1-kDa peptide located at the end of the kinase domain, Mutagenesis of the four Thr residues in this peptide identified Thr-720 in the subdomain XI as important for autophosphorylation and for phosphorylation of beta-casein. This Thr is conserved in other related kinases, suggesting a subfamily sharing common autophosphorylation mechanisms.	UNIV FREIBURG, INST BIOL 2, D-79104 FREIBURG, GERMANY	University of Freiburg								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON PJ, 1985, ANAL BIOCHEM, V148, P105, DOI 10.1016/0003-2697(85)90634-7; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CROWE J, 1992, QIAEXPRESSIONIST; DWYER KG, 1994, PLANT CELL, V6, P1829, DOI 10.1105/tpc.6.12.1829; GORING DR, 1992, PLANT CELL, V4, P1273, DOI 10.1105/tpc.4.10.1273; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HammondKosack KE, 1996, NEW PHYTOL, V133, P11, DOI 10.1111/j.1469-8137.1996.tb04338.x; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HENGEN PN, 1995, TRENDS BIOCHEM SCI, V20, P372, DOI 10.1016/S0968-0004(00)89079-9; HORN MA, 1994, BBA-PROTEIN STRUCT M, V1208, P65, DOI 10.1016/0167-4838(94)90160-0; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KNOBLOCH KH, 1980, Z NATURFORSCH C, V35, P551; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Landon, 1977, Methods Enzymol, V47, P145; LOH YT, 1995, PLANT PHYSIOL, V108, P1735, DOI 10.1104/pp.108.4.1735; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MARTIN GB, 1994, PLANT CELL, V6, P1543, DOI 10.1105/tpc.6.11.1543; MARUYAMA IN, 1995, NUCLEIC ACIDS RES, V23, P3796, DOI 10.1093/nar/23.18.3796; MU JH, 1994, PLANT CELL, V6, P709, DOI 10.1105/tpc.6.5.709; NASRALLAH JB, 1994, PLANT J, V5, P373, DOI 10.1111/j.1365-313X.1994.00373.x; NEUFELD E, 1989, ANAL BIOCHEM, V177, P138, DOI 10.1016/0003-2697(89)90028-6; ROMMENS CMT, 1995, PLANT CELL, V7, P249, DOI 10.1105/tpc.7.3.249; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHALLER GE, 1993, FEBS LETT, V333, P306, DOI 10.1016/0014-5793(93)80676-L; SCHIEL O, 1987, Z NATURFORSCH C, V42, P1075; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STEIN JC, 1993, PLANT PHYSIOL, V101, P1103, DOI 10.1104/pp.101.3.1103; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; STREBEL K, 1986, J VIROL, V57, P983, DOI 10.1128/JVI.57.3.983-991.1986; SWARUP R, 1996, PLANT PHYSL; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; Torii KU, 1996, PLANT CELL, V8, P735, DOI 10.1105/tpc.8.4.735; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VETTER HP, 1992, PLANT PHYSIOL, V100, P998, DOI 10.1104/pp.100.2.998; VONLINTIG J, 1991, MOL PLANT MICROBE IN, V4, P370, DOI 10.1094/MPMI-4-370; Wang XQ, 1996, P NATL ACAD SCI USA, V93, P2598, DOI 10.1073/pnas.93.6.2598; ZHANG R, 1993, PLANT MOL BIOL, V21, P1171, DOI 10.1007/BF00023612	44	88	90	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26684	26689		10.1074/jbc.271.43.26684	http://dx.doi.org/10.1074/jbc.271.43.26684			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900145	hybrid			2022-12-27	WOS:A1996VP23300039
J	Schussler, O; Lantoine, F; Devynck, MA; Glotz, D; DavidDufilho, M				Schussler, O; Lantoine, F; Devynck, MA; Glotz, D; DavidDufilho, M			Human immunoglobulins inhibit thrombin-induced Ca2+ movements and nitric oxide production in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISCORDANT XENOGRAFT REJECTION; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; RELEASE; PROSTACYCLIN; BRADYKININ; ACTIVATION; MECHANISM; RECEPTOR; EDRF	Binding of natural antibodies to endothelial cell plays an important role in hyperacute xenograft rejection be tween discordant species. Human intravenous immunoglobulins (IVIg) delay this hyperacute rejection, but their mechanisms of action on endothelial cells have to be defined. Here we demonstrate that IVIg dose-dependently prevent thrombin from eliciting cytosolic Ca2+ movements and nitric oxide (NO) production in aortic endothelial cells from guinea pig. The Ca2+ response to thrombin was similarly affected by IVIg whether they were removed or not from the incubation medium before stimulation. Pretreatment by rat natural antibodies also suppress the thrombin-induced Ca2+ peak corresponding to Ca2+ release from intracellular stores but stimulate the subsequent sustained increase in [Ca2+](i) and the release of NO. The action of human intravenous immunoglobulins seems to be selective for the thrombin receptor because they do not affect [Ca2+](i) and NO responses to endothelin-l or thapsigargin. However, these antibodies also suppress the first phase of the cytosolic Ca2+ response to ATP, which does not release NO under our experimental conditions. These observations raise the possibility that IVIg selectively interact with targets localized on plasma membrane of endothelial cells for controlling receptor-activated Ca2+ pathways and NO release.	UNIV PARIS 05,NECKER UNIV SCH MED,DEPT PHARMACOL,CNRS,URA 1482,F-75015 PARIS,FRANCE; ECOLE NATL SUPER CHIM PARIS,LAB ELECTROCHIM & CHIM ANALYT,CNRS,URA 216,F-75231 PARIS 05,FRANCE; HOP BROUSSAIS,INSERM,U430,LAB IMMUNOL PATHOL HUMAINE,F-75674 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Glotz, Denis/F-7881-2011	Glotz, Denis/0000-0001-5258-4237; DAVID-DUFILHO, Monique/0000-0002-7479-075X				ANTOINE F, 1995, BIOCHEM BIOPH RES CO, V215, P842; ASTARIE C, 1992, AM J HYPERTENS, V5, P281, DOI 10.1093/ajh/5.5.281; BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BAZIN H, 1974, EUR J IMMUNOL, V4, P44, DOI 10.1002/eji.1830040112; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAKELY ML, 1994, TRANSPLANTATION, V58, P1059, DOI 10.1097/00007890-199411270-00001; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; COHEN RA, 1995, CIRCULATION, V92, P3337, DOI 10.1161/01.CIR.92.11.3337; DOLOR RJ, 1992, AM J PHYSIOL, V262, pC171, DOI 10.1152/ajpcell.1992.262.1.C171; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; GOSINK EC, 1993, AM J PHYSIOL, V265, pC1620, DOI 10.1152/ajpcell.1993.265.6.C1620; GROSCHNER K, 1994, CIRC RES, V75, P304, DOI 10.1161/01.RES.75.2.304; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIRATA Y, 1993, J CLIN INVEST, V91, P1367, DOI 10.1172/JCI116338; INAGAMI T, 1995, ANNU REV PHYSIOL, V57, P171; IOUZALEN L, 1995, EUR J PHARM-MOLEC PH, V289, P189, DOI 10.1016/0922-4106(95)90094-2; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KORENAGA R, 1993, CELL STRUCT FUNCT, V18, P95, DOI 10.1247/csf.18.95; LANTOINE F, 1995, J ELECTROANAL CHEM, V392, P85, DOI 10.1016/0022-0728(95)04042-M; LATREMOUILLE C, 1994, TRANSPLANT P, V26, P1285; LEVENTHAL JR, 1993, TRANSPLANTATION, V56, P1, DOI 10.1097/00007890-199307000-00001; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; Magee J C, 1994, Ther Immunol, V1, P45; MAGEE JC, 1995, TRANSPLANT P, V27, P271; MIYAGAWA S, 1988, TRANSPLANTATION, V46, P825, DOI 10.1097/00007890-198812000-00007; MONCADA S, 1991, PHARMACOL REV, V43, P109; NEWBY AC, 1990, ANNU REV PHYSIOL, V52, P661; RYAN US, 1986, J TISSUE CULTURE MET, V10, P3; TRACEY WR, 1993, J VASC RES, V30, P68; TSUKAHARA H, 1994, J BIOL CHEM, V269, P21778; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; Wang YP, 1996, J BIOL CHEM, V271, P5647, DOI 10.1074/jbc.271.10.5647	34	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	1996	271	43					26473	26476		10.1074/jbc.271.43.26473	http://dx.doi.org/10.1074/jbc.271.43.26473			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VP233	8900114	hybrid			2022-12-27	WOS:A1996VP23300008
J	Caulfield, JL; Singh, SP; Wishnok, JS; Deen, WM; Tannenbaum, SR				Caulfield, JL; Singh, SP; Wishnok, JS; Deen, WM; Tannenbaum, SR			Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXYNITRITE; SUPEROXIDE; KINETICS; OXIDATION; LUMINOL; DAMAGE; DNA	N-Nitrosation in oxygenated nitric oxide (NO.) solutions was previously shown to be significantly inhibited by phosphate and chloride presumably by anion scavenging of the nitrosating agent nitrous anhydride, N-2O3 (Lewis, R. S., Tannenbaum, S, R., and Deen, W. M. (1995) J. Am. Chem. Sec. 117, 3933-3939), Here, bicarbonate is shown to exhibit this same inhibitory effect, Rate constants for reaction of morpholine, phosphate, and bicarbonate with N2O3 relative to N2O3 hydrolysis at pH 8.9 were determined to be (3.7 +/- 0.2) x 10(4) M(-1), (4.0 +/- 0.9) x 10(2) M(-1), and (9.3 +/- 1.5) x 10(2) M(-1), respectively, The morpholine and phosphate rate constants at pH 8.9 are similar to those reported at pH 7.4 assuring that these results are relevant to physiological conditions, The rate constant for this previously unrecognized reaction of bicarbonate with N2O3 suggests the strong scavenging ability of bicarbonate; accordingly, bicarbonate may contribute to reducing deleterious effects of N2O3, This is biologically important due to substantial bicarbonate concentrations in vivo, approximately 30 mM. Bicarbonate was previously shown to alter peroxynitrite reactivity; however, carbon dioxide is the probable reactive species, Bicarbonate is therefore potentially important in determining the fate of two reactive species generated from nitric oxide, N2O3 and ONOO-, and may thus act as a regulator of NO.-induced toxicity.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; MIT,DIV TOXICOL,CAMBRIDGE,MA 02139; MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Wishnok, John S./A-3173-2009		NATIONAL CANCER INSTITUTE [P01CA026731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES004675] Funding Source: NIH RePORTER; NCI NIH HHS [CA26731, CA09112] Funding Source: Medline; NIEHS NIH HHS [ES04675] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carola R., 1990, HUMAN ANATOMY PHYSL; DEROJASWALKER T, 1995, CHEM RES TOXICOL, V8, P473, DOI 10.1021/tx00045a020; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KEITH WG, 1969, J CHEM SOC, pA90; LEWIS RS, 1995, J BIOL CHEM, V270, P29350, DOI 10.1074/jbc.270.49.29350; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LEWIS RS, 1995, J AM CHEM SOC, V117, P3933, DOI 10.1021/ja00119a006; LYMAR SV, 1995, J AM CHEM SOC, V117, P8867, DOI 10.1021/ja00139a027; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MICHELSON AM, 1983, BIOCHIMIE, V65, P95, DOI 10.1016/S0300-9084(83)80179-5; MONCADA S, 1991, PHARMACOL REV, V43, P109; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; RADI R, 1993, BIOCHEM J, V290, P51, DOI 10.1042/bj2900051; TREININ A, 1970, J AM CHEM SOC, V92, P5821, DOI 10.1021/ja00723a001; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; ZHU L, 1992, ARCH BIOCHEM BIOPHYS, V298, P452, DOI 10.1016/0003-9861(92)90434-X	18	90	92	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	1996	271	42					25859	25863		10.1074/jbc.271.42.25859	http://dx.doi.org/10.1074/jbc.271.42.25859			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VN180	8824217	hybrid			2022-12-27	WOS:A1996VN18000023
